<SEC-DOCUMENT>0000950170-24-027178.txt : 20240306
<SEC-HEADER>0000950170-24-027178.hdr.sgml : 20240306
<ACCEPTANCE-DATETIME>20240306162331
ACCESSION NUMBER:		0000950170-24-027178
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		110
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240306
DATE AS OF CHANGE:		20240306

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PepGen Inc.
		CENTRAL INDEX KEY:			0001835597
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41374
		FILM NUMBER:		24726232

	BUSINESS ADDRESS:	
		STREET 1:		1 MARINA PARK DRIVE, SUITE 900
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		703-456-8000

	MAIL ADDRESS:	
		STREET 1:		1 MARINA PARK DRIVE, SUITE 900
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>pepg-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:pepg="http://pepgen.com/20231231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_0f24035f-4dc0-4b99-b2f1-f911e6a219c0" name="dei:DocumentFiscalPeriodFocus" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9">FY</ix:nonNumeric><ix:nonNumeric id="F_059c4de9-7310-475c-9025-ab308539e75e" name="dei:AmendmentFlag" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_0ec7a155-894a-4a3e-b2c1-5b0559562c05" name="dei:EntityCentralIndexKey" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9">0001835597</ix:nonNumeric><ix:nonFraction id="F_0d70d773-c0e8-4741-991d-30b53e69f2b9" name="us-gaap:PreferredStockValue" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_103f5d8d-8f9e-4d7e-a3c7-dd555847280a" name="us-gaap:PreferredStockValue" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_0e60f457-09a0-4d36-973d-dc52a1d8e6c2" name="us-gaap:RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric id="F_82e8c746-990f-4d25-9100-51e93f9ca429" name="us-gaap:RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonFraction id="F_11100503-2fd3-4c49-87ab-244664e4d838" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_5ce499b8-803d-4c0a-b7dc-bd9d43f1ccdf" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">0.982</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="pepg-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="C_de36be0e-422a-44fa-b610-cce5387a9700"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:ServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:CarnotPharmaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e714e23e-c60b-4649-bcf1-f9525f905459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:TechnologyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-31</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a41894a-8ad8-4c44-9399-b1722da555e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa6a276c-2e4d-4050-a264-a051017ad010"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1b4f98a-2717-48fb-ae1c-8c5f9097d55f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_896cd8db-b4db-45ff-915a-26b26be0959d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pepg:StockRestrictionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd645434-03f7-4e7a-9254-fc4113a4fc17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed06b17b-3586-4df6-a87e-12566f6bab76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8e10c34-dfed-494a-8b1a-5d7203d659eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pepg:UsTreasuryBackedMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_220d4a87-56e9-4b2f-88b9-0f2f98c86ac0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pepg:LaboratoryAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ff7e6d1-9dc6-4e1d-af82-7945a62662d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pepg:HarrisonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b88145a-4875-4cd0-a443-e63d1611c62d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9fc357d1-aca9-4939-8508-2e6b6c2e1aef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9444a584-901b-44fb-95ce-d2000dc58dd6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a903df65-a661-4f64-9e9c-45d340ce2506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pepg:AtTheMarketEquityOfferingSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-05</xbrli:startDate><xbrli:endDate>2024-02-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6da8e9ac-df70-4c39-a066-f43de00ad6c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a6bbe33-4c45-482c-ac03-94f727c30255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pepg:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56d10337-c99d-4729-a0be-2f97270f71c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_48802948-74ba-4e4c-bd84-6de3c161ffbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pepg:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c12cd4a1-d2bb-4e7d-be33-635f490062b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:RaCapitalManagementLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:ServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_16414ef5-2d6c-482f-bb76-768259311b2c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pepg:StockRestrictionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cc8621bc-02a4-40ab-b23b-4c8af4926152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1cd4d63-b40b-4d86-834f-9218d8c92734"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pepg:TwoThousandTwentyTwoEquityIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a02d2713-9447-4f0e-94e0-cac5b3c390f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_efb79f6f-7f45-4f73-8424-9da26d4e839d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cab43832-788b-441d-b9a4-b33219debd4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pepg:StockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d913f63c-8af0-45d4-9fb8-34b4620d0aa9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pepg:HarrisonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0686ad9d-2e32-4f08-a030-a696dc15aec5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pepg:TwoThousandTwentyTwoEquityIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74f25be0-4a88-4a9d-915a-d6fbbd72d532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a65d95cd-5bc9-4e3d-baa3-39ba00afc7f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f5fe547c-69eb-4ca8-ab02-fd92fb002da6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c3ab2e29-df24-48f1-bf82-ebac3d3a83b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:TechnologyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9262d869-15f9-481b-9005-cda8096e70c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ace6a7aa-5e97-4501-8932-98392f77ce72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e0c2b471-faa6-4641-8385-0e58de723dee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:ServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:CarnotPharmaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d3eca86e-4d27-4894-81cf-8b20a08cff1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b497aad-3cba-4deb-9dd2-e0a9d56f3614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:TechnologyLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_37a6b7a6-092b-457c-bee8-fde979f4e845"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e5fff44b-bbb8-4123-aa83-3f024c4f13f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pepg:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76920238-6f16-4c2c-b840-91aee4e50447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:TechnologyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c802d06c-99b8-4fc0-8210-d04f7dc4782d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a065b967-ade2-4903-9ca0-ebd7ce31343d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_580f0221-c422-43d6-9cb9-c47b83af1d6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pepg:HarrisonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0917bb69-33a3-4140-b895-0b204ca96986"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7fb2ae36-5ee1-44d5-910b-7802e0cbbbc7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:ServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:CarnotPharmaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8318feed-c68a-4d65-a6b4-50a029944a36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pepg:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_098c1eb1-fac5-4644-b049-d1ecd9083a38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pepg:TenantImprovementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_abeb202e-1d0f-4fd4-950d-779ee59e02dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb8cf3d7-367c-4f24-aa0c-6cc587368dd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae4f1a1a-7f76-43a6-b05d-f7cb7ac0bb50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c24a5f2f-a1e3-4f88-98c5-79645a25bbbf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ce499b8-803d-4c0a-b7dc-bd9d43f1ccdf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-29</xbrli:startDate><xbrli:endDate>2022-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9cb04199-144a-4871-b5ab-87a87eb6a48d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pepg:StockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_42e30e60-16d0-4ac2-909d-87e5b27fbd3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f9f5a3b-bb7f-443b-98eb-04f3e2b9c50d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pepg:StockRestrictionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4470897-58c2-4502-9300-1a8a6d7d7faf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:TechnologyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_030a5a87-1169-4748-9cd4-a4a73f0d0618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:TechnologyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f09d803-162d-4289-ba95-128a23f2de31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pepg:StockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_620ef023-203d-4a5a-845f-4edc70fd7788"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c59812be-057a-482f-bae8-fa2c033d1afd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e7e9bfb4-48e5-4056-bafa-50d040cb558e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pepg:FollowOnOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-09</xbrli:startDate><xbrli:endDate>2024-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59392f99-502b-454a-8db2-aeb447f458ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:TechnologyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-31</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b8a0d2c-51ea-4fba-866a-5ab866ff3776"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:TechnologyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f58e97f2-94c9-4dc7-ac7d-e3f44208d56a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pepg:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_887c0bf2-95aa-4fe1-afb6-f5b7822e931f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a035c4f4-0bbe-47a2-a989-557b4c88dd4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_111dcd21-eeba-473b-9067-9dc4b9836ccf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pepg:UsTreasuryBackedMoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a76bcc79-0abb-40aa-b47b-a2d80c882380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pepg:UsTreasuryBackedMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f91c8a3a-fd8f-4f54-b410-a52327d04868"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pepg:SharesSalesAgreementAndFollowOnOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-09</xbrli:startDate><xbrli:endDate>2024-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b89ce0c5-83ee-4433-97d2-dc32416736cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_298b30ab-8f35-409c-81dc-e0ab49287a93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f589bb63-125f-4e69-a1dc-e5029e610005"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pepg:UsTreasuryBackedMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ddcf7e0e-5706-4523-945c-daec00947c1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe73f47a-1a8a-4c3f-bc3a-56c5282d62d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc45efd8-3a91-4f49-a118-89ede6cb57a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:TechnologyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:OxfordScienceEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_740f6998-3da5-4c11-9020-117389e3b4ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23a4b3c2-3578-4710-8ebf-43d479465cfb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff132215-5434-4c88-b5f1-c47dfe048266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f814e08d-65a5-4cb9-880c-4b1766772c26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:ServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:CarnotPharmaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e9bca87a-c16a-42e1-91d3-d72a8f122225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pepg:ClassAAndClassBCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pepg:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5bca00da-1c31-464f-a7f2-5cd7315f851e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-16</xbrli:startDate><xbrli:endDate>2022-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4800734-4394-4f05-a937-22e162de9696"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6eb59534-d6e4-4470-9e92-dc335995eadd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pepg:NewtonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0eec95c7-6d1e-4442-a8e7-29920d1d09af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e4cd814-3cb3-4300-b818-efc911437b4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pepg:UndesignatedPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_240e4da2-412b-4131-b975-ff30d06f0d88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c4ecf543-b902-40c7-b9ae-990d6d5dc573"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pepg:SeriesBStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pepg:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_063bd5cf-7893-460d-a103-34991df7eaa2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pepg:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_479f1274-d273-4c6d-b379-65dc65120fec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-04</xbrli:startDate><xbrli:endDate>2022-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_15495aa7-f537-415e-97da-a0992d3b9cb6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0cb40be6-2cf0-473a-a7d2-976e96f36428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">pepg:UkTaxAuthoritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_369017c2-22f5-42b3-85de-349e0de7ffa4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_452249ff-841b-462f-a646-241176965c50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pepg:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ed7174f-94bd-4691-abc3-6e866114de8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pepg:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba1eafbf-79c8-4ea9-b601-011eeea8dba7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e00b2f45-4b2c-4c07-b7e3-9f43f7606c50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_24eafb5a-baba-449c-8e96-c46f37a25e6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:RaCapitalManagementLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:ServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4665c752-93dc-481c-88bb-900dcc8ff971"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pepg:UsTreasuryBackedMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30c84240-eef7-4c05-8cf3-d66492402ca5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:TechnologyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6aa00088-cf17-4c43-988e-abab7676b8a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8dfabb69-ba07-4d32-a14c-6d3c76995bf3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77094e71-f93f-47be-9749-eda2c5ae4461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be762841-9478-40d4-a7e8-487a90f06ec8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pepg:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_48600fa6-eba6-438a-9b5f-dff15a734745"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pepg:HarrisonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_585c525a-f403-4998-a8ec-14fc01861152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pepg:StockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0719f76-c7a1-4758-8910-36fbdccb7a19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pepg:StockRestrictionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1b696bc0-9c03-4cef-975e-0195f8d44c1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9262d127-7f2e-41a9-86ad-3e2211e86b50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pepg:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pepg:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-24</xbrli:startDate><xbrli:endDate>2020-11-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d325b41-5448-4a9d-a322-34100e9ca687"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6da82c22-e37a-42bc-980f-059274a23288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_941e7577-cf0a-4629-9509-58cf297868bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pepg:HarrisonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-28</xbrli:startDate><xbrli:endDate>2022-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_30fabfc5-c97f-4da0-9e33-dae485ef6dee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_36f077db-3490-4321-ac37-fd742c52e7c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7f2ab9a-431e-4fa5-8e9c-4fbda0da11cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pepg:AuthorizedForFutureStockAwardsOrOptionGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce675452-0281-4938-89df-5ecb187847bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pepg:SeriesBStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pepg:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2b7323c-10fa-445b-aaed-2945a4bc04a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pepg:AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_09aa4d44-be62-4c19-89e9-09be49174654"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pepg:SeriesA2PreferredStockWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4a43b6a-4e2b-469c-a21b-5b9a3de9dfc0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e8c98aaa-dcdb-45ee-9cad-d9b7440c3550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pepg:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2fed675d-4772-487a-92d4-4d992856e675"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_85e7bad8-943c-4a0e-ad95-12e210a9becd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:TechnologyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_472ca393-199b-4e03-9b1a-59688620fedb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pepg:CambridgeMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6be9b902-7f6b-479b-bfa6-7743f9105ed0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pepg:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pepg:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_99f0f78d-bedd-484e-bfa2-ac51788e3369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pepg:AuthorizedForFutureStockAwardsOrOptionGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cce7a15c-5959-4b95-821c-ff224707de79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d198184c-cc7e-4c68-a75d-06a166129ca1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_83c51675-48f0-45b3-8010-597a2244a8c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pepg:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_084747ab-da2f-409a-8832-1a799b9b3b81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pepg:SeriesA2PreferredStockWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d0b0ba5-3b8a-4068-b299-799ed4f36e53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad331ffb-3ca8-41af-9e8c-a5d2e3f07401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:TechnologyLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:OxfordScienceEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4284776a-c9e1-4a96-bba1-46cb3d689de2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_79b1260c-c408-4a48-8c54-3595577f6b00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pepg:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79566393-e152-4220-b13f-d5411f25b12a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pepg:AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18a316cc-fb97-4041-99e0-a3525fa31567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pepg:HarrisonLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1609515-c590-4eef-875c-348138380b4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001835597</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pepg:SharesSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-05</xbrli:startDate><xbrli:endDate>2024-02-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_EUR"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="U_Vote"><xbrli:measure>pepg:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_GBP"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>pepg:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Stockholder"><xbrli:measure>pepg:Stockholder</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="min-height:0.5in;"></div>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e22f8158-0d4d-48fd-8bce-c12baf35c603" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_18a0601a-fcd3-48c6-b129-27187c5af6b7" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d0ef6b71-4bf2-4518-997c-c08d9ec7c53e" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cc16d6a1-c3fa-4bdd-8de3-b89685950296" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fe5b54d5-16ac-4369-9a4c-96a4eb54114c" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">OR</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_0503dc94-8fea-4bac-94c0-73ee77c2c9cd" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _____________________ TO _____________________</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_87a0825f-ba7e-4a13-978d-75405d665a1c" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">001-41374</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:20pt;font-family:Times New Roman;"><ix:nonNumeric id="F_014e4562-7d1b-4bf9-9e66-13f2c35b40e0" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;min-width:fit-content;">PEPGEN INC.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a41aa5cc-5c1c-4124-9868-30f4dd7beafb" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_4ef73132-b11d-4417-913b-efae7e42503b" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">85-3819886</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_88a48cc3-bdce-471c-922b-f11ae0ee7008" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">321 Harrison Avenue</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_0b95432a-261b-4aa1-9472-cb1c650b5e9a" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Boston</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_d48ab339-0c21-4754-84b3-8db15bb9e731" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">MA</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ad3f89df-3769-40ba-bb7a-e91604532939" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">02118</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_75095398-7977-4577-91bd-b336b60fd18b" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">781</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e2a5c51b-e4d9-447f-b57f-52b5ac1d47ae" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">797-0979</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:38%;"/>
    <td style="width:1%;"/>
    <td style="width:15%;"/>
    <td style="width:1%;"/>
    <td style="width:45%;"/>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_e06cf49f-18bc-49b7-9dc1-cb14dfa22cc3" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_093c68ea-0c10-4e90-ae4c-386acb22f2c1" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">PEPG</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_d2d70e6d-73fc-4329-bf7c-85265ca3b808" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">None</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744;     </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0ec5a3b6-e453-4224-91de-d407dd438995" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  Yes &#9744;      </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_969065d1-da0f-4e80-bf30-7e61685e0ddb" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a843bca2-19d7-42b0-a3fe-e5d0e2277eb4" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;     No &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_059908e7-491d-40a9-a34a-3e6178825da7" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;     No &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.9%;"/>
    <td style="width:1%;"/>
    <td style="width:55.84%;"/>
    <td style="width:1.06%;"/>
    <td style="width:20.1%;"/>
    <td style="width:1%;"/>
    <td style="width:2.1%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:7.5pt;"><ix:nonNumeric id="F_97efa1c3-360b-47e4-ad87-a5ae76e2ea20" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_44f7e075-bd77-46f9-8bce-f788480d89f2" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_ddf3d04f-32f2-4219-be7a-f4f57de12c20" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c45a61bd-8f22-4648-8c2f-35b3fa29295c" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b2c6132-9399-4acf-9c43-6a200dcde57f" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_55f6606e-ca38-431b-a9d9-a9a44d07f180" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive o&#64259;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes &#9744;     No </span><span style="font-size:7.5pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c0cc3f36-be6b-4625-8b5c-f6df783d77fc" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on Nasdaq Global Select Market on June 30, 2023, was $</span><span style="font-size:7.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f265073-8bc8-4b6d-8dd2-77c465111532" contextRef="C_42e30e60-16d0-4ac2-909d-87e5b27fbd3e" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">97.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"> million. The number of shares of Registrant&#8217;s Common Stock outstanding as of March 1, 2024 was </span><span style="font-size:7.5pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_194b0c13-bc22-4ccf-a4a9-4867c7bfc842" contextRef="C_9262d869-15f9-481b-9005-cda8096e70c3" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">32,354,495</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div><ix:nonNumeric id="F_6d6b40f6-8682-49a8-8758-19a73502e250" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Portions of the registrant&#8217;s Definitive Proxy Statement relating to its 2024 Annual Meeting of Stockholders to be filed hereafter are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.26%;"/>
    <td style="width:16.66%;"/>
    <td style="width:12.2%;"/>
    <td style="width:20%;"/>
    <td style="width:13.34%;"/>
    <td style="width:25.54%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Auditor Firm Id:</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_f79dc2bf-6f22-4293-98a4-a8a96246e865" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">185</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Auditor Name:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_f7f7d3ce-72d7-48af-808f-77186ba65297" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">KPMG LLP</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Auditor Location:</span></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_4f4a75e9-1ca6-41dc-8838-2abf4ae6806f" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Phoenix, AZ, USA</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11%;"/>
    <td style="width:82%;"/>
    <td style="width:7%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART I</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">107</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">107</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART II</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrant_common"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">109</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_reserved"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">109</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_management_discussion_and_analysi"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">110</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_qualitative_discol"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statement_and_suppleme"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_and_disagreement"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">118</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">119</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">119</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART III</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_officers"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_of_certain"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_and_relate"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">121</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 16.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summa"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">124</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">i</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K, or 10-K, contains express or implied forward-looking statements that are based on our management&#8217;s belief and assumptions and on information currently available to our management and that are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, or the or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this 10-K include, but are not limited to, statements about:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, and the period during which the results of our clinical trials will become available;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to efficiently develop our existing product candidates and discover new product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to successfully manufacture our investigational drug substances and drug product for preclinical use, for clinical trials and on a larger scale for commercial use, if our investigational drug candidates are approved;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain and maintain regulatory approval of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to commercialize our product candidates, if approved;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the pricing and reimbursement of our product candidates, if approved;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the implementation of our business model, and strategic plans for our business and product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our technology platform;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">estimates of our future expenses, revenues, capital requirements, and our needs for additional financing;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the size and growth potential of the markets for our product candidates, and our ability to serve those markets;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our financial performance;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the rate and degree of market acceptance of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory developments in the United States, or U.S., and foreign countries;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to produce our products or product candidates with advantages in turnaround times or manufacturing cost;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success of competing therapies that are or may become available;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to attract and retain key research and development or management personnel;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of laws and regulations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developments relating to our competitors and our industry;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effects of the COVID-19 pandemic, or any future pandemics, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our preclinical studies and clinical trials and any future studies or trials; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">other risks and uncertainties, including those listed under the caption &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.&#8221;</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions, and are subject to change due to known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">may cause actual results to differ materially from current expectations include, among other things, those listed under the section titled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; and elsewhere in this 10-K. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. You should read this 10-K and the documents that we reference in this 10-K and have filed with the Securities and Exchange Commission, or the SEC, completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The forward-looking statements in this 10-K represent our views as of the date of this 10-K. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This 10-K also contains estimates, projections and other information concerning our industry, our business and the markets for our programs and product candidates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from our own internal estimates and research as well as from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we are not aware of any misstatements regarding any third-party information presented in this 10-K, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties and are subject to change based on various factors, including those discussed under the section titled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; and elsewhere in this 10-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TRADEMARKS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This 10-K contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to, including logos, artwork and other visual displays, may appear without the &#174; or TM symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SUMMARY OF RISK FACTORS</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business is subject to numerous risks and uncertainties that you should be aware of in evaluating our business. These risks include, but are not limited to, the following:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred significant losses since our inception, have no products approved for sale and we expect to incur losses for the foreseeable future.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will need to raise substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, scale back, or discontinue our product development programs or future commercialization efforts.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are early in our development efforts. We have only completed a Phase 1 clinical trial for our lead product candidate and initiated a Phase 1 clinical trial of a second product candidate as well as Phase 2 clinical trials of</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our lead product candidate, and as a result it will be years before we commercialize a product candidate, if ever. If we are unable to advance our product candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them, or experience significant delays in doing so, our business will be materially harmed.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business is highly dependent on the clinical advancement of our programs and modalities and is especially dependent on the success of our lead product candidates, PGN-EDO51 and PGN-EDODM1. Delay or failure to advance programs or modalities, including PGN-EDO51 and PGN-EDODM1, could adversely impact our business.  </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preclinical and clinical development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical and clinical studies, including studies of PGN-EDO51, PGN-EDODM1 and PGN-EDO53, are not necessarily predictive of the results of later preclinical studies and any clinical trials of our product candidates. Our product candidates may not have favorable results in clinical trials, if any, or receive regulatory approval on a timely basis, if at all.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Substantial delays in the commencement, enrollment or completion of our clinical trials and advancement of our clinical trials, or failure to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities could prevent us from commercializing product candidates we determine to develop on a timely basis, if at all.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely, and expect to continue to rely, on third parties to conduct some or all aspects of our product manufacturing, research, preclinical and clinical testing, and these third parties may not perform satisfactorily.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face significant competition, and if our competitors develop technologies or product candidates more rapidly than we do or their technologies or product candidates are more effective or have more favorable safety or tolerability profiles, our business and our ability to develop and successfully commercialize products may be adversely affected.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to obtain and maintain patent protection for our Enhanced Delivery Oligonucleotide platform, therapeutic development candidates or programs and/or other proprietary technologies we develop, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our therapeutic product candidates or programs and other proprietary technologies we may develop may be adversely affected.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to expand our headcount to support our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The price of our common stock is volatile and fluctuates substantially, which could result in substantial losses for holders of our common stock. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The summary risk factors described above should be read together with the text of the full risk factors below in the section titled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; in Part I, Item 1.A. and the other information set forth in this 10-K, as well as in other documents that we file with the SEC. The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not precisely known to us, or that we currently deem to be immaterial, may also materially adversely affect our business, financial condition, results of operations and future growth prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">P</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ART I</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1. B</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">usiness.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PepGen Inc. (also referred to as &#8220;PepGen,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221;) is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Our proprietary Enhanced Delivery Oligonucleotide, or EDO, platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Our EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery, and in preclinical studies we have observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle. We have demonstrated robust delivery and activity of oligonucleotides to skeletal muscle in a clinical trial. Furthermore, the high levels of pharmacological activity observed in preclinical and clinical studies support our belief that our EDO platform technology has the potential to deliver therapeutic agents to the nucleus of the target cells. Using these EDO peptides, we are generating a pipeline of oligonucleotide product candidates that target the root cause of serious diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are initially focused on addressing the underlying cause of Duchenne muscular dystrophy, or DMD, and myotonic dystrophy type 1, or DM1, that have high unmet need. Our current pipeline depicted below consists of two clinical stage programs - PGN-EDO51 for DMD patients who are amenable to exon 51-skipping and PGN-EDODM1 for DM1 patients, and three additional preclinical stage programs. We anticipate expanding this pipeline over time to include other neuromuscular targets as well as potential opportunities in neurologic diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_0.jpg" alt="img224999359_0.jpg" style="width:720px;height:312px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PGN-EDO51</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We completed a first-in-human Phase 1 clinical trial in healthy volunteers, or HVs, with our lead product candidate, PGN-EDO51, in the third quarter of 2022. We are developing PGN-EDO51 to treat DMD patients whose mutations are amenable to an exon 51-skipping approach. In the Phase 1 clinical trial in HVs, treatment with PGN-EDO51 resulted in the highest levels of mean exon skipping</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in humans following a single dose compared to publicly available data for a single dose of other DMD exon 51-skipping approaches that are approved or in clinical development.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our clinical development program for PGN-EDO51 comprises two parallel Phase 2 studies of PGN-EDO51 in DMD patients whose mutations are amenable to an exon 51-skipping approach. The first study, CONNECT1-EDO51, or CONNECT1, is an ongoing open-label, multiple ascending dose, or MAD, Phase 2 study in boys and young men living with DMD being conducted in Canada. We initiated dosing patients in CONNECT1 in January 2024 and have fully enrolled the first cohort at the 5 mg/kg PGN-EDO51 dose level. We anticipate initial proof-of-concept data, that would include safety, exon skipping and dystrophin production for this cohort in mid-2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, we received clearance from the Medicines and Healthcare products Regulatory Agency, or MHRA, to initiate the second study, CONNECT2-EDO51, or CONNECT2, a Phase 2, multinational, randomized, double-blind, placebo-controlled MAD study. The results from the initial cohorts of the CONNECT1 study will inform the conduct of the CONNECT2 study, which is designed to support a potential accelerated approval pathway for PGN-EDO51, subject to alignment with regulatory authorities. Building on the high levels of exon skipping of PGN-EDO51 observed in our preclinical studies and Phase 1 trial in HVs, we believe that repeat dosing of PGN-EDO51 may lead to therapeutically relevant accumulation of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMD </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">exon 51-skipped transcript and an</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">associated increase in dystrophin protein in patients, which may in turn drive meaningful clinical benefit for those who live with this devastating, progressive, life-shortening disease.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PGN-EDODM1</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also developing PGN-EDODM1 for the treatment of DM1 and are utilizing what we believe to be a unique mechanism of action and a different delivery approach compared to other approaches in more advanced stages of clinical development. The therapeutic oligonucleotide component of PGN-EDODM1 is engineered to bind to the pathogenic cytosine-uracil-guanine, or CUG repeat expansion present in the myotonic dystrophy protein kinase, or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, messenger RNA, or mRNA, of DM1 patients, thus reducing the ability of these expanded trinucleotide repeats to bind and sequester RNA binding proteins including MBNL1, a critical RNA splicing factor. The liberation of MBNL1 in turn leads to the correction of downstream mis-splicing events that drive the pathology of DM1. We believe this approach, which is not designed to knock down or degrade </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">transcript, has the potential to selectively and directly address the underlying genetic defect central to this disease. In a DM1 mouse model, the HSA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">LR </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mouse, following single and repeat dosing of PGN-EDODM1 every four weeks, we demonstrated robust correction of mis-splicing and resolution of myotonia.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These preclinical data with PGN-EDODM1 form the basis of our clinical development plan for PGN-EDODM1. In May 2023, we announced that we received a clinical hold notice from the U.S. Food and Drug Administration, or FDA, regarding our investigational new drug, or IND, application to initiate our first in-human Phase 1 FREEDOM-DM1, or FREEDOM, study in DMI patients. In September 2023, we announced that Health Canada had cleared our Clinical Trial Application, or CTA, for the FREEDOM study in Canada. In October 2023, we announced that the FDA lifted the clinical hold on the FREEDOM study, allowing this study to proceed in the U.S. In December 2023, we announced that the MHRA had cleared our CTA for the FREEDOM study in the United Kingdon, or the U.K. FREEDOM is a multinational, randomized, double-blind, placebo-controlled, single ascending dose, or SAD, study, designed to assess PGN-EDODM1's safety, splicing correction, and functional outcome measures in DM1 patients. We expect to report preliminary data from this study in the second half of 2024. In February 2024, we announced that PGN-EDODM1 received Fast Track designation from the FDA for the treatment of DM1. We also expect to open the FREEDOM2-DM1 Phase 2 randomized, double blind, placebo-controlled MAD study in DM1 patients in the second half of 2024.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional Development Programs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to these lead clinical stage programs, we are developing EDO candidates for additional DMD sub-populations amenable to skipping of other exons, including exon 53, 45 and 44. We have previously reported robust exon 53-skipping levels following either a single dose or multiple doses in non-human primates, or NHPs, for our PGN-EDO53 program. We anticipate advancing PGN-EDO53, our DMD exon 53-skipping candidate, into CTA and/or IND-enabling preclinical studies in 2024. We have also initiated research efforts for additional indications, including neuromuscular diseases and neurologic disorders.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our EDO Platform</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Background on Oligonucleotide Therapeutics</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Oligonucleotide therapeutics consist of small single or double stranded segments of deoxyribonucleic acid, or DNA, or ribonucleic acid, or RNA, molecules that are made up of nucleotides that bind to their targets via complementary Watson-Crick base pairing thereby modulating the expression of their target DNA or RNA sequence, thereby addressing the root cause of many diseases. Upon binding to their target sequence, oligonucleotides can modulate function through the modulation of RNA expression and processing. The mechanisms of action of these medicines include interference with gene expression; degradation of toxic RNA species; alteration of gene translation; interference with interactions between RNA and other nucleic acids or proteins; endogenous human adenosine deaminase acting on RNA, or ADAR; site-directed RNA editing; and modulation of the splicing of transcripts. Each of these approaches can lead to profound biological effects. The development of oligonucleotide therapeutics has enabled the targeting of a diverse set of diseases that have proven difficult to treat through other approaches due to their high degree of specificity to target pathogenic mutations, which is otherwise difficult using conventional drugs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Oligonucleotide therapeutics have demonstrated clinical benefit and been approved for the treatment of multiple diseases, such as spinal muscular atrophy, DMD, familial hypercholesterolemia and hereditary transthyretin-mediated amyloidosis. These approved drugs span two classes &#8211; ASOs, which are short, synthetic, single-stranded oligonucleotides, and small interfering RNAs, or siRNAs, which are double-stranded oligonucleotides. ASOs and siRNAs both bind their target mRNAs or pre-mRNAs but differ in their respective modes of action. ASOs are designed to either (i) degrade target RNA species through an RNAse-H-mediated process, or (ii) modulate RNA-RNA and/or RNA-protein interactions through a steric blocking mechanism. In contrast, siRNAs are designed to silence or knockdown a particular mRNA through the RNA interference, or RNAi, pathway.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASOs are typically synthetic molecules that may contain modified nucleotide bases, sugars and phosphate linkages designed to overcome the historical limitations of unmodified oligonucleotides, including instability, immunogenicity and a poor pharmacological profile. Many approved oligonucleotides incorporate a modified oligonucleotide backbone in which the phosphate and ribose sugars are replaced by phosphorodiamidate morpholino groups, or PMOs. The resulting PMOs are resistant to multiple hydrolases in serum, while their uncharged nature ensures that they do not interact strongly with proteins in a nonspecific way. PMOs have shown promising results in early-stage preclinical studies and have become marketed products for the treatment of a host of diseases. For example, EXONDYS 51</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(eteplirsen), marketed by Sarepta Therapeutics, Inc., or Sarepta, is a PMO that was approved in 2016 for individuals with DMD who are amenable to exon 51-skipping but has left much room for improvement given its relatively low tissue and cell penetration and minimal induction of dystrophin production.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Challenge of Oligonucleotide Delivery</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order for oligonucleotide therapeutics to exert their intended effect, they must first gain access to the nucleus where mRNAs are synthesized and processed. Historically, the delivery of oligonucleotides to the interior of the cell proved challenging due to their high molecular weight and the lack of a specific mechanism to facilitate their transport across the cell membrane and escape the endosome to enter the cytoplasm and nucleus. Several methods have been developed to increase the cellular uptake of oligonucleotides, the most clinically advanced of which is the covalent attachment of cell-penetrating peptides, or CPPs. CPPs are designed to facilitate the transport of oligonucleotides across the plasma membrane, thus allowing these cargo species to reach their eventual site of action in the nucleus. We believe that these capabilities are critical in enabling oligonucleotides to exert their intended therapeutic effect within the cell. Early research into CPPs showed that simple peptides consisting primarily of multiple arginine residues could increase the cellular uptake of oligonucleotides and increase their activity in modulating RNA splicing. However, a considerable number of these early CPPs were found to be highly toxic in animal models, and in many instances, there existed a direct correlation between toxicity and activity, which limited the clinical translation and development of these first-generation delivery vectors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Approach: A Solution for the Oligonucleotide Delivery Challenge</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img224999359_1.jpg" alt="img224999359_1.jpg" style="width:720px;height:296px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our EDO platform is based on novel CPP technology. We engineered our proprietary EDO technology to optimize tissue penetration, cellular uptake and nuclear delivery, which we believe may enhance therapeutic activity and improve the tolerability of oligonucleotide therapeutics. This technology is founded on over a decade of research and development conducted in the academic laboratories of our founders Michael Gait, Ph.D. at the Medical Research Council Laboratory of Molecular Biology in Cambridge, United Kingdom, or MRC, and Professor Matthew Wood, M.D., Ph.D. at the University of Oxford, United Kingdom. Drs. Gait and Wood developed a new generation of CPPs focused on oligonucleotide delivery, and optimized these peptides for tissue penetration, cellular uptake and nuclear delivery, along with improved tolerability in animal models.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our EDO platform peptides possess the following key structural characteristics:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Two positively charged, arginine-rich regions, one at the N-terminus and the other at the C-terminus interspersed with non-natural amino acids to confer greater peptide stability;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A central core rich in hydrophobic residues that separates the arginine-rich regions and contributes to endosomal escape&#8203;; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A linear peptide sequence with a length of less than 20 amino acids designed to be non-immunogenic&#8203;.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our EDO peptides were developed through an iterative optimization process that selected simultaneously for: biodistribution to key muscle targets, including cardiac tissue; high cellular uptake; endosomal escape, where the therapeutic agent is released from the endosomes, a sub-cellular organelle, in a functional form and delivered to the cell nucleus; and acceptable tolerability. We utilize PMOs in our approach, and these therapeutic cargos are conjugated to one of our optimized, proprietary, novel EDO peptides to generate our lead EDO product candidates - peptide conjugated PMOs, or PPMOs. We intend to continue to build and develop this platform technology to enable us to expand into new therapeutic areas.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that our therapeutic candidates may offer the following advantages with the goal of enabling the safe and efficient delivery of oligonucleotide cargos:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Enhanced delivery to skeletal muscle, diaphragm and cardiac muscle.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We have observed in preclinical and clinical studies that our peptides delivered their cargo oligonucleotide therapeutics to different muscle tissues, allowing us to address multiple disease pathologies in multi-systemic indications such as DMD and DM1. This differentiating feature of our EDO platform has been observed in mice and NHPs across multiple tissue types, including those critical to neuromuscular indications &#8211; skeletal, smooth and cardiac muscle. Furthermore, we believe our EDO peptides support the ability to promote endosomal escape and facilitate the robust delivery of cargo oligonucleotides to the cell nucleus. We have now shown in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and in NHP models that the EDO technology can mediate higher uptake of oligonucleotide in the nucleus.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, EDO peptide conjugated to a PMO (EDO23) resulted in up to 25-fold higher cellular uptake and nuclear delivery of oligonucleotide into myotubes compared to naked PMO. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In NHPs, EDO peptide conjugated to a PMO (PMO51) led to high levels of oligonucleotide in the muscle nuclei.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_2.jpg" alt="img224999359_2.jpg" style="width:499px;height:269px;"/><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In murine myotubes, EDO23 resulted in up to 25-fold higher uptake of EDO23 compared to naked PMO23</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">. In vitro staining image with 10&#181;M conc. of EDO or naked PMO; green= actin, red= EDO or naked PMO and blue= nuclei.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img224999359_3.jpg" alt="img224999359_3.jpg" style="width:624px;height:187px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In NHPs, IV dosing of EDO conjugated to PMO51 resulted in 72% of muscle cells with uptake of PMO in the nuclei</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">. RNAScope was performed; red=PMO and blue (DAPI)=nuclei. Cells with PMO signal were quantified; n=3 (&#177; SD)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Improved activity in skeletal muscle and tolerable safety profile was observed in a Phase 1 clinical study, in NHPs and in </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">mdx</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice, with robust levels of activity observed in skeletal and other muscle types.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In our Phase 1 clinical study of PGN-EDO51 in HVs, we observed the highest levels of mean exon skipping in humans following a single dose when compared to publicly available single dose data for other </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMD</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> exon 51-skipping approaches.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In NHPs, a dose of 30 mg/kg of PGN-EDO51 achieved over 70% exon 51 skipping in skeletal muscle, including diaphragm, which we believe is the highest level of exon 51 skipping reported for any approved therapeutic or </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">known development candidate at tolerable target dose levels based on cross-trial comparison of publicly available data.</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">mdx </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mice, we observed the highest level of dystrophin production following a single dose when compared to &#8220;murine analogues&#8221; of other clinical-stage DMD therapeutic candidates.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Enhanced balance between activity and tolerability, which is designed to afford our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">platform a wider therapeutic index.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our delivery peptides have been specifically engineered to achieve a wider therapeutic index, and we have observed robust activity and an improved tolerability profile in NHPs and humans when compared to data published on previous CPPs. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In a Phase 1 clinical study in HVs, PGN-EDO51, our lead EDO candidate, was found to be generally well-tolerated at therapeutically relevant dose levels. We believe this characteristic is a promising step-change over the narrow therapeutic index observed for previous generations of CPPs. </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Robust, scalable and cost-efficient manufacturing that does not require cell-based processes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We have developed a modular manufacturing process that is highly scalable, easily characterizable, and utilizes readily available building blocks. This process is fully synthetic in nature and does not rely on microbial fermentation, thus substantially reducing the risk of introducing microbial DNA or protein into our product candidates. </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accelerated and efficient development of pipeline therapeutic candidates enabled by use of a single EDO peptide across all our initial programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We currently utilize the same EDO delivery peptide across all of our programs. We intend to apply our knowledge and learnings from our current lead programs in order to efficiently pursue our future programs, and we will additionally aim to take advantage of economies of scale in our manufacturing processes. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comparison with Other Oligonucleotide Delivery Technologies in Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other CPP-PMO or PPMO Approaches</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are a number of other peptide-mediated approaches that are currently being developed for the delivery of oligonucleotide therapeutics. Of these, we have, through an extensive review of publicly available presentations and patent applications, hypothesized that the most clinically advanced peptide-based delivery approach for oligonucleotides utilizes the cell-penetrating properties of a hexa-arginine sequence with an additional glycine residue. We refer to this CPP as R</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">G herein and have conducted extensive head-to-head preclinical studies to compare the biodistribution and activity of our model of this moiety with our novel EDO peptides.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have observed robust </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> activity of our EDO technology in a number of animal models, with this activity being significantly higher when compared to our model of the competing R</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">G approach. In one such study, we compared our EDO-conjugated PMO to an R</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">G peptide which we believe is structurally equivalent to the peptide component of SRP-5051, conjugated to the same murine exon 23-skipping PMO. SRP-5051 is the most clinically advanced peptide-ASO conjugate in development by Sarepta. In this single dose study, we administered 10 mg/kg of PGN-EDO23 or R</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">G-PMO23 to wild type, or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">WT</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice, intravenously followed by tissue collection one week after dosing. In the biceps, PGN-EDO23 resulted in 51.7% exon skipping versus 0.46% exon skipping with R</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">G-PMO23 as assessed by RT-PCR, demonstrating that PGN-EDO23 is more potent than R</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">G-PMO23. In line with high levels of exon skipping in biceps, we observed 62.5% exon skipping in quadriceps with PGN-EDO23 versus 2.0% exon skipping with R</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">G-PMO23.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_4.jpg" alt="img224999359_4.jpg" style="width:519px;height:243px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Robust exon skipping was observed with single dose of PGN-EDO23 compared to R</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">G-PMO23 in </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">WT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Graph plotted as mean &#177; SD; n = 5 for each group.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our EDO technology has shown enhanced delivery of PMO to additional tissues that remain challenging to penetrate with existing technologies. In a repeat-dose preclinical study in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">WT </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mice, three 30 mg/kg intravenous doses of our EDO conjugate every</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">two weeks resulted in exon skipping levels in the heart that were 7-fold higher than those of the R</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">G conjugate, when measured by RT-PCR seven days after the last dose. We believe the higher level of exon skipping achieved in this study supports the ability of our EDO technology to successfully deliver oligonucleotides to cardiac tissue furthering the potential of EDO technology to address cardio-respiratory failure, the primary cause of death in DMD patients.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_5.jpg" alt="img224999359_5.jpg" style="width:342px;height:257px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Multiple doses of PGN-EDO23 in </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">WT </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mice led to increased exon skipping in heart compared to R</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">G-PMO23. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Graphs plotted as mean &#177; SEM; **** denotes extremely significant, p &lt; 0.0001; n = 5 per group for single dose activity, n = 8 per group for repeat dose activity.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Antibody-oligonucleotide Approaches</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the CPP-PMO approaches described above, a number of groups are developing antibody-oligonucleotide conjugates with the aim of enhancing the delivery and activity of their cargo therapeutics. These groups utilize both antigen-binding fragments, or Fabs, and monoclonal antibodies, or mAbs, as delivery vectors, to target specific cell surface receptors. We believe our EDO platform offers significant potential benefits over such approaches, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">More efficient tissue penetration due to the small size of our EDO delivery peptides relative to a mAb or Fab; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Superior nuclear delivery with the combination of poly-Arg sequences and hydrophobic core;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Limited immunogenicity or risk of complement activation due to the considerably lower protein load associated with our EDO peptides; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A scalable, facile, fully-synthetic manufacturing process with no cell-based steps that is supported by a readily-characterizable drug product. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe these benefits support further development and clinical translation of our suite of EDO product candidates and underpin the potential for our robust competitive position in the neuromuscular and neurologic disease space.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Strategy</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our goal is to become a leading biopharmaceutical company focused on the development and commercialization of oligonucleotide therapies to transform the lives of patients with severe neuromuscular and neurologic diseases. We aim to accomplish this goal by implementing the following strategies:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Advance our lead product candidate, PGN-EDO51, through clinical trials and potential regulatory approval</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We are developing PGN-EDO51, an EDO peptide conjugated to a PMO therapeutic cargo to treat DMD patients whose mutations are amenable to an exon 51-skipping approach. There is no cure for DMD and approved exon-skipping therapies or advanced stage exon-skipping investigational candidates for patients who are amenable to exon 51 skipping are thought to have limited impact on disease progression due to low levels (&lt;5%) of dystrophin production. In a Phase 1 clinical trial of PGN-EDO51 in HVs, we observed the highest levels of mean exon skipping in humans following a single dose when compared to publicly available single dose data for other exon 51-skipping approaches. We began dosing patients in a Phase 2 clinical trial in January 2024 and have completed enrollment of the first cohort at the 5 mg/kg dose.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Advance PGN-EDODM1 through clinical trials and potential regulatory approval</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We are developing PGN-EDODM1 (which utilizes the same EDO peptide as PGN-EDO51) conjugated to a PMO therapeutic cargo to treat DM1 patients and have observed robust pharmacological activity in preclinical models with both long and short cytosine-thymine-guanine, or </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CTG repeats. We began dosing patients in a Phase 1 clinical trial in December 2023 and announced Fast Track Designation for PGN-EDODM1 in February 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Advance and expand our pipeline of oligonucleotide therapeutic candidates for the treatment of additional DMD patient populations. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are expanding our portfolio by pursuing additional programs where our EDO technology could address areas of unmet need. We are employing the same EDO technology used in PGN-EDO51 and PGN-EDODM1 for PGN-EDO53, our exon-skipping product candidate for the treatment of individuals with DMD whose mutations are amenable to treatment with an exon 53-skipping approach. We have observed high levels of exon skipping in NHPs for PGN-EDO53 and we plan to progress this program into IND/CTA enabling studies in 2024.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leverage the full potential of our EDO technology to expand into other neuromuscular and neurological disease areas.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Given the potential of the EDO technology to efficiently deliver nucleic acid payloads such as PMOs to skeletal muscle, cardiac tissue and diaphragm, we are looking to develop disease-modifying peptide-conjugated oligonucleotide candidates for the potential treatment of other neuromuscular and neurological indications.  </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Utilize the modular nature of our EDO platform to evaluate new cargos and peptide technologies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We believe that our EDO technology has the potential to facilitate the delivery of multiple classes of nucleic acid payloads, including other oligonucleotide therapeutics, and we intend to expand the scope of the cargos that can be delivered by our EDO platform as part of our ongoing platform development work.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Maximize the value of our pipeline and our EDO platform by selectively exploring strategic collaborations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We have a disciplined strategy to maximize the value of our pipeline and currently have worldwide development and commercial rights to all of our product candidates. Given the potential of our EDO platform, we may opportunistically enter into strategic collaborations around certain geographies, targets or programs. We may seek to build such relationships where we believe the resources and expertise of a third-party pharmaceutical or biotechnology company could be beneficial to the development or commercialization of our product candidates or to the expansion of our platform capabilities. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Portfolio</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are harnessing the power of our EDO platform to generate a pipeline of oligonucleotide therapeutic candidates. Our EDO conjugates have been engineered to successfully target the root cause of serious diseases while maintaining a tolerability profile that is acceptable for clinical use. We are initially focused on addressing neuromuscular indications and are building a portfolio of therapeutic candidates to address the underlying genetic mutations found in DMD and DM1, with our current pipeline being comprised of five programs, two clinical and three preclinical.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the future, we anticipate expanding this pipeline to include other neuromuscular targets, along with potential opportunities in neurologic indications, and we will seek to leverage the modular, scalable nature of our EDO technology to support our expansion into these new therapeutic areas. We have worldwide development and commercialization rights to all our programs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">PGN-EDO51</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our initial product candidate is PGN-EDO51, an EDO peptide conjugated to a PMO, that we are developing for the treatment of DMD patients with mutations amenable to an exon 51-skipping approach. An exon is a segment of a gene that, together with other exons, contains the genetic code that is translated into a protein. Exon skipping is a therapeutic mechanism that enables mutations in the gene to be bypassed, thereby repairing this code or reading frame and enabling production of a truncated, yet functional version of the target protein. PGN-EDO51 is designed to splice out exon 51 and potentially additional exons depending on the mutation of the dystrophin pre-mRNA, resulting in the restoration of the open reading frame of the dystrophin transcript and production of an internally deleted, yet functional dystrophin protein. In a Phase 1 clinical trial of PGN-EDO51 in HVs, we observed the highest levels of mean exon skipping in humans following a single dose in a cross-trial comparison with publicly available Phase 1 HV data following a single dose of vesleteplirsen (SRP-5051 or R</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">G conjugated exon 51 PMO) and eteplirsen. In NHP studies, at tolerable doses, we have observed what we believe is the highest rate of exon 51 skipping in skeletal muscles, including diaphragm, based on cross-trial comparisons with publicly available data for any approved therapeutic or known developmental candidate for the exon-51 skipping amenable DMD patient population. Furthermore, in head-to-head studies conducted in NHPs, we found that PGN-EDO51 had greater activity than R</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">G-PMO at the same dose level, a comparator compound which we believe to be structurally equivalent to Sarepta&#8217;s SRP-5051, the most clinically advanced PPMO. Our Phase 1 clinical trial also indicated that PGN-EDO51 was generally well-tolerated at pharmacologically relevant dose levels. We opened CONNECT1, an open-label MAD study in DMD patients amenable to an exon 51-skipping approach in Canada and began dosing patients in January 2024. We have fully enrolled the 5 mg/kg dose cohort and expect to report preliminary safety, exon skipping and dystrophin production data from this cohort in mid-2024. In February 2024, we received clearance from the MHRA to initiate CONNECT2 in the U.K.  CONNECT2 is a multinational, randomized, placebo-controlled MAD clinical trial designed to potentially support a future accelerated approval pathway, subject to alignment with regulatory authorities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disease Background and Prevalence</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DMD is a debilitating X-linked recessive, progressive, muscle-wasting disease that predominantly affects boys. It is one of the most prevalent rare genetic diseases globally, with an incidence of up to 1 in 3,500 to 5,000 live male births, and it is invariably fatal by young adulthood. There are up to 15,000 DMD patients in the U.S., approximately 25,000 DMD patients in Europe and approximately 5,000 in Japan. DMD is caused by mutations in the gene encoding dystrophin, a protein necessary for normal muscle function. The primary role of dystrophin is as a shock absorber, and this protein allows muscle cells to retain their structural integrity while under mechanical stress. In the absence of dystrophin, muscle fibers are no longer protected from the mechanical forces of contraction, which leads to cell death, fibrotic tissue formation and muscle degeneration resulting in loss of ambulation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Early symptoms of disease include difficulty walking or jumping, loss of balance, and increased fatigue when compared to healthy peers. By their mid-teenage years, most DMD patients will need to use a wheelchair on a regular basis. As the disease progresses, life-threatening heart and respiratory conditions become common. Dilated cardiomyopathy &#8211; a condition where the cardiac muscle becomes weakened and the chambers of the heart are enlarged &#8211; often arises, and heart failure is a leading cause of death in DMD patients. Pulmonary function also becomes progressively impaired as the dystrophic process affects respiratory muscles, including the diaphragm, leading to significant morbidity and mortality. DMD patients ultimately succumb to cardiac and respiratory failure in early adulthood, with a mean lifespan of approximately 25 years. Therefore, the restoration of dystrophin is a compelling therapeutic strategy, and a number of therapeutic modalities have been explored with this goal in mind. However, the nature of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMD </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">gene, the range of mutations implicated in DMD, and the large size of the dystrophin protein itself provide considerable obstacles to this approach.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMD</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> gene, at 2.1 million base pairs and 79 exons, is one of the largest in the human genome. Over 6,000 mutations are known, and the gene has a relatively high natural mutation rate, with approximately 1 in 3 DMD cases arising due to a </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">de novo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mutation. There is no one mutation that is highly prevalent, and this factor provides a considerable challenge for therapeutics looking to target the root genetic cause of this debilitating disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">That said, mutations in the dystrophin gene are not random, with hotspots of mutations existing between exons 45-53 and to a lesser extent between exons 2-20. It is thought that 13% of patients with DMD have mutations that are amenable to treatment with an exon 51-skipping approach, and thus the estimated exon 51 patient population is approximately 2,000 in the U.S., 3,200 in Europe and 700 in Japan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_6.jpg" alt="img224999359_6.jpg" style="width:267px;height:267px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Breakdown of DMD population by amenability to treatment with exon skipping therapeutics.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Current Approaches and Unmet Needs</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is no cure for DMD and approved exon-skipping therapies or advanced stage exon-skipping investigational candidates for patients who are amenable to exon 51 skipping are thought to have limited impact on disease progression due to low levels (&lt;5%) of dystrophin production. Corticosteroids are the mainstay of pharmacologic treatment for DMD as they have been shown to temporarily improve muscle strength, prolong the period of ambulation and slow the progression of this disease. However, glucocorticoid use is associated with well-known adverse effects, such as weight gain, stunted growth, weakening of bone structure, high blood pressure, diabetes, psychological effects, skin thinning and an increased risk of infection.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Several approaches have been taken to address groups of mutations in the dystrophin gene, one of which is to alter the processing of the dystrophin mRNA. A number of DMD patients suffer from mutations that result in the disruption of the reading frame of the DMD transcript, which in turn leads to an absence of the dystrophin protein. Using an ASO, the mRNA splicing process in the nucleus can be altered to skip over a select exon, allowing the open reading frame to be restored. This exon skipping approach results in the subsequent generation of dystrophin protein isoform which, although internally deleted, retains much of its function and can thus protect muscle tissue against further contraction-induced damage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Several unconjugated, or &#8220;naked&#8221; ASOs have been approved to treat DMD, including eteplirsen, marketed as EXONDYS 51 by Sarepta for the treatment of mutations amenable to an exon 51-skipping approach. This drug received accelerated approval from the FDA on the basis of an increase of less than 1% in the expression of dystrophin, with this readout being considered a valid surrogate endpoint under the accelerated approval regulatory pathway. Published observational studies of small numbers of patients on EXONDYS 51 appear to show somewhat slower disease progression than historical controls. However, at this level of dystrophin, this therapeutic has yet to formally establish evidence of clinical benefit through rigorously powered and adequately controlled clinical trials with functional endpoints. EXONDYS 51 has not been approved in Europe, or in Japan on the basis of this minimal degree of dystrophin restoration as a surrogate endpoint.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, several companies are developing gene therapies to treat DMD, including Pfizer Inc. (PF-06939926), which is currently being assessed in a Phase 3 clinical trial, Sarepta (SRP-9001 and Galgt2 gene therapy program), the former of which was approved by the FDA in June 2023 for treatment of ambulatory pediatric patients aged 4 through 5 years with DMD with a confirmed mutation in the DMD gene and is marketed as ELEVIDYS.  Sarepta has recently filed an efficacy supplement to its biologics license application, or BLA, to expand the indication for ELEVIDYS to encompass &#8220;treatment of DMD patients with a confirmed mutation in the DMD gene.&#8221; The FDA accepted the filing of the efficacy supplement and has given the application priority review with a review goal date of June 21, 2024. There are additional investigational gene therapy programs in different stages of development to treat DMD. It is important to note that adeno-associated virus, or AAV-based gene replacement approaches deliver a significantly truncated dystrophin (micro-dystrophin) which we believe has the potential to limit the therapeutic efficacy of the approved and clinical stage AAV-based pipeline candidates. In addition, there are gene editing treatments that are in preclinical development. Exon skipping does not face some of the inherent challenges associated with gene therapy modalities, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Limited packaging size of AAV vectors, resulting in the need to employ truncated &#8216;micro-dystrophin&#8217; genes with an unclear functional benefit, where &gt;70% of the dystrophin gene is omitted, including regions that correspond to key structural and binding domains;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Increased safety concerns with high-dose AAV-based gene therapies (e.g. complement activation); </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Immunogenicity of AAV, resulting in:</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Up to half of all patients possessing antibodies against the most commonly used recombinant AAV vector serotypes, precluding their eligibility for treatment; </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Production of anti-AAV antibodies in treated patients, resulting in an inability to re-dose; and</span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Loss of gene copies over time as patients mature and their cells divide, reducing the durability of therapeutic effect;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Complexity and challenges inherent to manufacturing of AAV-based therapies. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also aware of several companies targeting non-dystrophin mechanisms for the treatment of DMD, including Edgewise Therapeutics, Inc., or Edgewise, with EDG-5506, a muscle stabilizer that is currently in clinical development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that an exon skipping approach aimed at producing functional, truncated dystrophin will be a cornerstone approach to effectively treat patients with DMD.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Approach</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are developing a portfolio of product candidates for the treatment of DMD in which exon skipping PMOs are conjugated to our EDO peptide in order to enhance their delivery to muscle cells. Our initial product candidate is PGN-EDO51, an investigational EDO peptide-conjugated exon 51-skipping ASO with a proposed mechanism of action we believe to be identical to that of eteplirsen.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_7.jpg" alt="img224999359_7.jpg" style="width:624px;height:273px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PGN-EDO51 is designed to facilitate the skipping of exon 51, allowing the synthesis of a shortened, but functional, dystrophin.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The key differentiator between PGN-EDO51 and other exon 51-skipping approaches is the greater exon skipping activity observed with PGN-EDO51 in HVs and in preclinical models. We believe the higher levels of exon skipping observed with PGN-EDO51 in HVs and in NHPs when compared to publicly available data and head-to-head data, respectively, from other therapies is directly related to the potential of our EDO platform to drive tissue penetration, cellular uptake and nuclear delivery of the PMO cargo therapeutic resulting in exon skipping of the defective dystrophin mRNA.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Preclinical Data</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have evaluated the pharmacology of PGN-EDO51 in a number of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preclinical studies and have observed robust activity in every model system evaluated. In DMD patient cells, treatment with PGN-EDO51 resulted in high levels of exon 51 skipping and dystrophin production.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">mdx</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mouse, a well-characterized model of DMD, PGN-EDO23, a murine analogue of PGN-EDO51, resulted in high levels of exon skipping and dystrophin production. In the skeletal muscle, a single dose of PGN-EDO23 at 60 mg/kg resulted in 86.3% to 93.1% exon skipping and 90.4% to 99.7% dystrophin restoration. In the diaphragm, this dosing regimen afforded an exon skipping rate of 76.6% and dystrophin restoration levels of 80.6%, while in the heart it resulted in 62.3% exon skipping and 25.7% dystrophin restoration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_8.jpg" alt="img224999359_8.jpg" style="width:624px;height:221px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Robust dose-dependent increase in exon skipping and dystrophin protein production was observed following a single dose of PGN-EDO23 in </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">mdx </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mice.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Graphs plotted as mean &#177; SD. Dystrophin protein results are expressed as a percentage of WT dystrophin.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In accordance with the pharmacology, we observed significant reduction in creatine kinase, or CK, which is a critical biomarker of muscle damage, with this enzyme being elevated in DMD patients from birth. In the absence of dystrophin, the structural integrity of the sarcolemma, or muscle cell membrane, is disrupted, leading to the release of CK into the blood. Following intravenous administration of a single, generally well-tolerated dose of 30 mg/kg or 60 mg/kg of PGN-EDO23, we observed normalization of serum CK to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">WT</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> levels in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">mdx</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice seven days post-dose. The normalization of CK levels observed in this study suggest that PGN-EDO23 may restore muscle cell integrity and prevent further damage in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">mdx </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mice under a single dose regimen, and we believe that this outcome supports the potential therapeutic utility of PGN-EDO51 in the treatment of DMD patients.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_9.jpg" alt="img224999359_9.jpg" style="width:359px;height:254px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A single dose of PGN-EDO23, the murine analogue of PGN-EDO51, was observed to normalize creatine kinase, a marker of muscle damage in </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">mdx</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Graph plotted as mean &#177; SEM; **** = p &#8804; 0.0001, ns = p &#8805; 0.05; n = 3 for control groups, n = 5 for treated group.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We subsequently conducted a repeat-dose study where we dosed </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">mdx </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mice with 30 mg/kg of PGN-EDO23 every four weeks, with up to four doses, with tissue collection and analysis four weeks following the final dose. In the biceps, the level of exon skipping was observed to be 91.5% after four doses when measured by RT-PCR, a value that was 1.7 times higher than that observed following a single dose (52.5%). Dystrophin production was measured by western blot and was observed to reach a level of 82.2% in the same tissue after four doses in comparison to a level of 22.5% obtained after a single dose. We believe this marked increase of 3.7 times between the level of dystrophin obtained following one dose, and the level obtained following four doses supports the clinical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential of a once-every-four-week dosing regimen for PGN-EDO51 and serves to highlight our belief that dystrophin production is likely to increase with subsequent doses in DMD patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_10.jpg" alt="img224999359_10.jpg" style="width:720px;height:335px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Robust exon skipping and dystrophin restoration was observed with repeat dosing of PGN-EDO23 in </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">mdx </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mice. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Graph plotted as mean &#177; SD; n = 4-5 for each group; grey band represents dystrophin LLOQ (2.5%).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in this repeat dosing study in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">mdx</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice, dystrophin protein localization and the percent dystrophin positive fibers, or PDPF, were evaluated by immunofluorescence microscopy. Importantly, this orthogonal assessment of dystrophin demonstrated that dystrophin protein was uniformly distributed across the skeletal muscle sarcolemma and found 97.1% of biceps muscle fibers were dystrophin positive following four doses of PGN-EDO23 administered once every four weeks, which was close to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">WT</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> dystrophin levels (&gt;99%).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_11.jpg" alt="img224999359_11.jpg" style="width:720px;height:332px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dystrophin levels and distribution in skeletal muscle with repeat dosing of PGN-EDO23 in </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">mdx</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Dystrophin protein evaluation by western blot and immunofluorescence (IF). Graph is presented as mean &#177; SD; n = 4-5 per cohort; grey band is dystrophin LLOQ (2.5%).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have also conducted a number of studies in NHPs and have observed the robust </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> activity of PGN-EDO51 in this higher order animal model. There is complete homology of the oligonucleotide binding site between the DMD gene in humans and the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DMD gene in NHPs for an exon 51-skipping therapeutic, thus allowing the activity of our clinical candidate to be assessed in this species.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We observed that seven days following a single dose of PGN-EDO51 in NHPs, high rates of exon 51 skipping were observed in the tibialis anterior, or TA, diaphragm and heart. In the TA, diaphragm and heart, exon skipping levels of 57.6%, 70.7% and 18.6%, respectively, were observed by RT-PCR following single doses of 20mg/kg.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_12.jpg" alt="img224999359_12.jpg" style="width:403px;height:228px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Single doses of PGN-EDO51 led to high rates of exon 51 skipping in a preclinical NHP study. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Graph plotted as mean &#177; SEM; n = 2 per group.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to benchmark the ability of our lead EDO peptide to improve the tissue penetration, cellular uptake and nuclear delivery of oligonucleotide therapeutics, we carried out a study comparing our EDO-conjugated PMO to an R</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">G peptide conjugated to the same PMO. We have conducted a considerable number of benchmarking studies of PGN-EDO51 against this conjugate, and we believe, based on publicly available information, that R</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">G-PMO is structurally equivalent to SRP-5051, Sarepta&#8217;s CPP-PMO product candidate that is currently in clinical development for the treatment of DMD patients who are amenable to an exon 51-skipping approach. In this preclinical study, NHPs were dosed intravenously with either PGN-EDO51, R</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">G-PMO or a saline control three times with an interval of two weeks between doses. Biopsies of the biceps and quadriceps were collected seven days after the first and second dose, and tissues were harvested seven days after the final dose.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Through RT-PCR analysis of key skeletal muscles collected by biopsy seven days after the first dose, we observed markedly higher exon skipping levels for PGN-EDO51 when compared to R</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">G-PMO. At 30 mg/kg, a single dose of PGN-EDO51 afforded an</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">exon 51-skipping level of 43.6% in the biceps, which was eight times higher than the level of 5.5% observed for R</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">G-PMO. In the quadriceps, this differential was 10 times, with 44.9% exon 51 skipping observed for PGN-EDO51, and just 4.5% for R</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">G-PMO.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_13.jpg" alt="img224999359_13.jpg" style="width:393px;height:280px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Single dose administration of PGN-EDO51 in NHPs yielded considerably higher exon skipping levels than R</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">G-PMO. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Graph plotted as mean &#177; SD; n = 3 per group; study was not powered for statistical significance.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following three bi-weekly doses of 30 mg/kg, we observed robust exon skipping activity for PGN-EDO51, with levels of greater than 70% obtained in key skeletal muscles following analysis by RT-PCR seven days after the final dose. In biceps, an exon 51 skipping level of 77.5% was obtained; and in quadriceps, 73.4%. We observed exon 51 skipping levels of over 20% in the left ventricle for PGN-EDO51, and 75.9% in the diaphragm, and we believe that these results highlight the potential of our lead candidate to address the key cardio-respiratory morbidities affecting multiple organs observed in DMD.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_14.jpg" alt="img224999359_14.jpg" style="width:426px;height:273px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Repeat dose administration of PGN-EDO51 in NHPs yielded high exon skipping rates in the key skeletal muscles, including the diaphragm, and in the cardiac left ventricle. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Graph plotted as mean &#177; SD; n = 3 per group; study was not powered for statistical significance.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to understand the potential accumulation of exon 51-skipped transcripts under a four-weekly, or Q4W, repeat dose regimen, we assessed NHP tissue samples of the biceps collected seven days following a single administration of PGN-EDO51, and compared these with samples of the biceps collected seven days following four administrations of PGN-EDO51 once every four weeks. The levels of exon 51 skipping of the DMD transcript were assayed via a droplet digital PCR, or ddPCR, protocol. The results obtained showed a robust accumulation in the levels of the exon 51-skipped transcript between one dose and four doses. Following four doses of 20 and 30 mg/kg, exon 51 skipping levels were 34.9% and 37.6%, respectively, which were 14 times and 3.4 times higher than for a single dose. We believe this accumulative effect suggests that the activity of PGN-EDO51 is likely to increase with</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">chronic dosing in DMD patients, which we believe further supports the clinical potential of our lead candidate in this devastating disease. Our ongoing CONNECT1 study will determine the level of exon skipping and dystrophin production in biceps in DMD patients following four monthly doses of PGN-EDO51.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_15.jpg" alt="img224999359_15.jpg" style="width:405px;height:420px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exon skipped transcripts in the biceps accumulated under a preclinical repeat-dose regimen of PGN-EDO51 when assessed by ddPCR. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Graph plotted as mean &#177; SD; n = 3-8 per group; study was not powered for statistical significance.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In conclusion, we demonstrated 14 times higher levels of exon 51 skipping in NHPs following four doses of PGN-EDO51 compared to a single dose. This 14-fold increase in exon-skipped transcript can be ascribed to the accumulation of PGN-EDO51 oligonucleotide in the muscle and the accumulation of exon 51-skipped transcript with repeat dosing shown in NHP studies. In HVs, following a single 10 mg/kg dose of PGN-EDO51, we observed 1.4% exon skipping 28 days following dosing, and similar to our observations in NHPs, we anticipate seeing meaningfully higher levels of exon 51-skipped transcript following four doses. Higher levels of exon-skipped transcript have been shown to produce higher levels of dystrophin in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">mdx </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mice and in DMD patients.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PGN-EDO51 was generally well-tolerated in single-dose, 28-day Good Laboratory Practice, or GLP, toxicity studies in mice and NHPs; no treatment-related mortality and no serious adverse events were observed through the therapeutic dose range. There were no adverse microscopic observations and no adverse impacts on clinical chemistry markers at clinically relevant dose levels.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> T cell stimulation assay conducted with peripheral blood mononuclear cells from healthy donors indicated that PGN-EDO51 has a very low immunotoxicity risk. This is further supported by data showing that the pharmacokinetic, or PK, profile of PGN-EDO51 was similar following the first and third dose, suggesting no significant neutralizing anti-drug antibody responses were present after a three-dose regimen in NHPs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have also conducted several repeat dose NHP studies to assess the safety and tolerability of PGN-EDO51. In one such study, we administered 11 doses of PGN-EDO51 intravenously to NHPs at 45 mg/kg over 60 minutes every 28 days over 39 weeks, and serum chemistry markers were assessed. Following the first administration, an elevation in serum creatinine was observed at day two; this elevation was completely resolved by day eight. Importantly, there were no adverse findings in the kidney even after 11 doses and there were no notable hematologic, cardiovascular or hepatic effects in this study. Additionally, following subsequent administrations, the day two elevations seen after the first dose were of lower magnitude. We believe these data support an acceptable tolerability profile for the ongoing CONNECT1 and planned CONNECT2 clinical studies since the planned therapeutic dose, as described below, is significantly under 45 mg/kg.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_16.jpg" alt="img224999359_16.jpg" style="width:584px;height:360px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In NHPs, an amelioration of elevations in serum creatinine was observed with repeat dosing of PGN-EDO51 at 45 mg/kg. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Graph plotted as mean &#177; SD; n = 12; grey bar shows normal range.</span><span style="color:#035491;white-space:pre-wrap;font-size:8pt;font-family:Arial;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">* Samples were not collected for these time points. PD= Pre-dose</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 1 HV Study</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2022, we completed a first-in-human, Phase 1, single-center, randomized, double-blind, placebo-controlled, SAD clinical trial to assess the target engagement (exon skipping), pharmacokinetics (oligonucleotide tissue concentration), safety and tolerability of PGN-EDO51 administered intravenously to 32 healthy adult male volunteers. Following administration, safety data were evaluated by a safety review committee prior to progressing to the next dose level. Volunteers were dosed with either 1, 5, 10 or 15 mg/kg of PGN-EDO51 or placebo. Oligonucleotide tissue concentration and exon skipping were assessed from needle biopsies of biceps muscle taken on Days 10 and 28, with the latter being measured by a ddPCR assay.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A dose dependent increase in mean exon skipping was observed in biceps, with the levels obtained being the highest observed in humans following a single dose, based on cross-trial comparisons with publicly available data for other exon 51-skipping approaches.</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the 10 mg/kg dose cohort, PGN-EDO51 exhibited mean exon skipping of 1.4% in biceps biopsies taken at Day 28 (n=6).</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the 15 mg/kg dose cohort, PGN-EDO51 exhibited mean exon skipping of 2.0% in biceps biopsies taken at Day 28 (n=6).</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_17.jpg" alt="img224999359_17.jpg" style="width:323px;height:267px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We observed the highest levels of mean exon skipping in humans following a single dose based on cross-trial comparisons with publicly available data for other exon 51-skipping approaches. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Data is shown as mean &#177; SD; n = 6 for PGN-EDO51 (n = 5 for D10 at 15 mg/kg), n = 8 for placebo. Asterisks indicate values that were under the lower level of quantification.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A dose-dependent increase in PGN-EDO51 tissue concentration was observed in biceps, with the levels obtained being the highest observed in humans for a DMD therapeutic following a single dose, based on cross-trial comparisons with publicly available data for other exon 51 skipping approaches.</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the 10 mg/kg dose cohort, PGN-EDO51 exhibited mean oligonucleotide tissue concentrations of 11 nM in biceps biopsies taken at Day 28 (n=6).</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the 15 mg/kg dose cohort, PGN-EDO51 exhibited mean oligonucleotide tissue concentrations of 50 nM in biceps biopsies taken at Day 28 (n=6).</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_18.jpg" alt="img224999359_18.jpg" style="width:331px;height:246px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">High, persistent tissue concentrations of oligonucleotide were observed. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Data is shown as mean &#177; SD; n = 6 for PGN-EDO51 (n = 5 for D10 at 15 mg/kg), n = 8 for placebo. Asterixis indicate values that were under the lower level of quantification.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In summary, we have demonstrated six times higher exon skipping after a single 10 mg/kg dose of PGN-EDO51 compared to SRP-5051 dosed at 20 mg/kg, based on cross-trial comparison of publicly available data from a Phase 1 HV study following a single dose of SRP-5051. We believe that the exon skipping data obtained from HVs in this clinical trial indicate the potential for clinically meaningful accumulation of exon 51-skipped transcripts and dystrophin in patient tissue with repeated doses of PGN-EDO51. Accumulation of exon skipped transcripts is further supported by the preclinical data from NHPs that demonstrated repeat dosing of PGN-EDO51 at 20 mg/kg resulted in 14 times greater exon skipping compared to a single dose. Thus, based on these data, we anticipate that the exon skipping rates afforded by PGN-EDO51 when administered to patients have the potential to exceed the rates observed when administered to HVs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Phase 1 trial met its primary endpoint, providing evidence that PGN-EDO51 was generally well tolerated at clinically relevant doses. By way of example, at a dose of 10 mg/kg:</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All participants completed the study with no discontinuations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All related treatment-emergent adverse events, or TEAEs, including transient, reversible changes in kidney biomarkers, were assessed as mild and resolved without any intervention;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Serum cystatin C, the recommended biomarker to assess renal function in DMD, did not change; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There was no evidence of hypomagnesemia.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At 15 mg/kg there was one non-life threatening serious adverse event, or SAE, related to changes in kidney biomarkers that were transient and reversible. This HV was admitted to the hospital for less than 24 hours, received hydration and then was re-admitted to the Phase 1 unit and completed the study. There were no clinical symptoms of acute kidney injury in any of the subjects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the tissue concentration and exon skipping observed in this Phase 1 study, alongside PK and pharmacodynamic, or PD, prediction models informed by preclinical data from </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">mdx </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mice and NHPs, we are expecting our target therapeutic dose in CONNECT1 and CONNECT2 studies to be lower than 15 mg/kg and at these doses, we expect a favorable safety profile.  Additionally, in support of the expected tolerability profile for PGN-EDO51, as mentioned above, we have demonstrated in NHPs that 11 doses of PGN-EDO51 administered intravenously at 45 mg/kg every 28 days resulted in elevation in serum creatinine at day two post dose, but this elevation was completely resolved by day eight. At target therapeutic doses in our CONNECT1 study and CONNECT2 study, we may see changes in kidney biomarkers at 10 mg/kg or higher doses but expect these will be transient and reversible.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also observed transient mild (Grade 1) hypomagnesemia in one participant and moderate (Grade 2) hypomagnesemia in one participant at the 15 mg/kg dose that did not require any intervention. We note that &#8805; Grade 3 hypomagnesemia was a SAE observed with repeat dosing of SRP-5051 at the 20 mg/kg and 30 mg/kg doses in the MOMENTUM study and that Sarepta amended the protocol to include magnesium supplementation in the pivotal Phase 2 MOMENTUM, Part B study. The Phase 2 MOMENTUM Part A and Part B safety and tolerability data shows that the severity of hypomagnesemia is dose dependent. Based on the safety and tolerability data of PGN-EDO51 to date, and the expected higher potency of PGN-EDO51 compared to SRP-5051, we believe PGN-EDO51 has the potential for a wider therapeutic index enabling desirable efficacy at a lower dose without &#8805; Grade 3 hypomagnesemia and without the need for prophylactic magnesium supplementation. It is possible that we may observe mild to</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">moderate hypomagnesemia following repeat-dose administration of PGN-EDO51 in our clinical trials, and we are carefully monitoring serum magnesium levels in our ongoing CONNECT1 clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Phase 1 protocol for PGN-EDO51, any non-life-threatening SAE was considered a dose-limiting toxicity, or DLT, however the study was not halted by the safety review committee, nor was it put on hold by Health Canada. In light of higher than anticipated oligonucleotide levels and exon skipping levels in muscle observed at 5 mg/kg and 10 mg/kg, we determined that further dose escalation in the Phase 1 study was not necessary.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TEAEs were mild and resolved without intervention at clinically relevant doses. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Asterisk denotes that no Grade 4 or 5 TEAEs were recorded.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_19.jpg" alt="img224999359_19.jpg" style="width:720px;height:306px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONNECT1 and CONNECT2 Phase 2 MAD Studies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The results from our Phase 1 HV clinical trial, together with the experience and expertise of our clinical development team and scientific advisory board, as well as learnings from previous clinical studies conducted in exon 51 skipping-amenable DMD patients,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">have guided the design, parameters and objectives of our planned Phase 2 clinical trials of PGN-EDO51 in DMD patients amenable to an exon 51-skipping approach.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Phase 2 clinical development plan for PGN-EDO51 consists of two studies conducted in parallel; a smaller open label MAD study, CONNECT1, is being conducted in Canada. A larger, multinational, randomized, double-blind placebo-controlled MAD study, CONNECT2, was recently authorized by the MHRA for initiation in the U.K. In the CONNECT1 study, participants will be administered PGN-EDO51 once every four weeks at 5 mg/kg, 10 mg/kg or potentially a higher dose (if needed) for 12 weeks. Dose escalation is based on data review by the data safety monitoring board, or DSMB. We will conduct muscle biopsies at baseline and week 13. In addition to assessing safety and tolerability, we are measuring exon skipping and dystrophin expression in CONNECT1. We began dosing patients in our CONNECT1 study in early 2024 and have fully enrolled the 5 mg/kg dose cohort. We anticipate reporting preliminary data from this cohort in mid-2024, including safety, exon skipping and dystrophin production.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As noted above, in February 2024, we received clearance from the MHRA to initiate CONNECT2 in the U.K. The CONNECT2 will enroll approximately 20 ambulatory and non-ambulatory boys and young men living with DMD amenable to exon 51-skipping, who are at least six years of age. Participants will receive seven doses of either PGN-EDO51 or placebo at approximately four-week intervals for 24 weeks. The starting dose will escalate from 5 mg/kg to 10 mg/kg, and potentially higher (if needed); the same dose levels are being evaluated in the CONNECT1 trial. Dose escalation will be determined based on data review by the DSMB. We will conduct muscle biopsies at baseline and at week 25. We will assess safety, tolerability, exon skipping, dystrophin production and functional outcome measures in this study.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that this clinical development plan may enable us to pursue an accelerated approval pathway for PGN-EDO51 with the FDA. In the DMD space, the FDA has approved four drugs under the accelerated approval pathway since 2016. If we receive positive results from our Phase 2 trials for PGN-EDO51 that show an acceptable emerging safety profile; a clinically meaningful increase in dystrophin levels, a surrogate endpoint in the biceps of DMD patients; and robust exon skipping levels in the same tissue; we intend to pursue discussions with the FDA for a potential accelerated approval pathway.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">PGN-EDODM1</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are developing PGN-EDODM1, an EDO peptide-conjugated PMO, for the treatment of DM1, a debilitating genetic disease with no approved therapies. PGN-EDODM1 leverages the same EDO peptide as PGN-EDO51 to deliver a PMO into muscle cells that binds to the pathogenic CUG trinucleotide repeat expansion present in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mRNA, thus reducing the ability of these trinucleotide repeats to sequester RNA binding proteins like MBNL1, a critical RNA processing protein. This approach, which is not designed to knock down </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, directly addresses the underlying genetic defect of this disease, and we have observed robust levels of activity in preclinical models with both long and short CTG repeats. In DM1 patient cells, we observed that treatment with PGN-EDODM1 led to a reduction in toxic nuclear foci, and liberated bound MBNL1 which mediated robust correction of mis-splicing. In preclinical studies in the mouse HSA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">LR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> DM1 model, a single dose of PGN-EDODM1 was observed to correct the molecular and functional deficits, including correcting &gt;65% of transcript mis-splicing events and reversing &gt;70% of myotonia. Multiple monthly doses of PGN-EDODM1 corrected 99% of transcript mis-splicing and myotonia. This correction of mis-splicing following a single dose of PGN-EDODM1 was observed to persist for up to six months. Furthermore, the muscle concentrations of PGN-EDODM1 oligonucleotide that mediated these effects in the HSA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">LR </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mouse model were similar to those observed 28 days following a single dose of 10 mg/kg of PGN-EDO51 in human muscle in our Phase 1 HV clinical trial. Given the molecular overlaps of PGN-EDO51 and PGN-EDODM1, we believe this supports the potential of a single 10 mg/kg dose of PGN-EDODM1 to achieve therapeutic muscle levels of oligonucleotide in DM1 patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We opened our FREEDOM Phase 1, randomized, placebo-controlled SAD clinical trial of PGN-EDODM1 in DM1 patients in the second half of 2023 in Canada, followed by the U.S. and U.K. and began dosing patients in December 2023. We expect to report preliminary data from this study, including safety, splicing correction and functional outcome measures in the second half of 2024. We also expect to open the FREEDOM2-DM1 Phase 2 randomized, double blind, placebo-controlled MAD study in DM1 patients in the second half of 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">    </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disease Background and Prevalence</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DM1 is a monogenic, autosomal dominant, progressive disorder that primarily affects skeletal, cardiac and smooth muscles, with central nervous system, or CNS, symptoms also being evident. Globally, the prevalence of DM1 is estimated to be 1 in 8,000 people, with approximately 40,000 patients in the U.S., 75,000 patients in Europe and 15,000 patients in Japan. However, under- and misdiagnosis is believed to be widespread, and genetic screening studies for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> triplet repeats have suggested that the prevalence of DM1 may be as high as 1 in 2,100 people.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DM1 patients can suffer from various manifestations of disease including myotonia, or a temporary rigidity due to the inability to relax muscles, muscle weakness, cardiac abnormalities, respiratory problems, fatigue, gastrointestinal complications, early cataracts, and cognitive and behavioral impairments. For patients with more severe forms of DM1, life expectancy is reduced due to increased mortality rates resulting from pulmonary and cardiac complications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The broad spectrum of pathologies associated with DM1 arise due to genetic changes in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">gene. Specifically, DM1 is caused by an expansion in the number of CTG triplet repeats that are present in the non-coding region of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> gene, and following transcription this mutant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> gene yields an mRNA product with an expanded CUG repeat region. Healthy,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">asymptomatic individuals possess between 5 and 37 such repeats, but in DM1 patients the number of repeats can be in the thousands. These highly repetitive sequences form stable hairpin structures in the nucleus of cells and sequester critical RNA splicing proteins, such as MBNL1, leading to the formation of nuclear foci. The sequestration of MBNL1 prevents this key protein from performing its normal function of processing RNA molecules before they are exported from the nucleus, leading to downstream mis-splicing events in a number of other transcripts. The mis-splicing of these transcripts results in the dysregulation of a broad set of downstream proteins, which in turn leads to in the multi-systemic pathologies that are associated with DM1, which include:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Musculoskeletal: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Myotonia (a temporary inability to relax a muscle after contraction), muscle weakness &amp; wasting.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cardiac:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Conduction defects.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Respiratory:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Breathing difficulties, sleep apnea.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gastrointestinal: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dysphagia (difficulty swallowing), constipation, Irritable Bowel Syndrome.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CNS:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Cognitive impairments, behavioral / psychologic disorders, excessive daytime sleepiness.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vision:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Early-onset cataracts, retinal damage.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Endocrine:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Thyroid dysfunction, diabetes.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other pathologies: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Skin, immune system and reproductive pathologies, increased cancer risk.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is a general correlation between the number of CTG repeats in the aberrant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> gene and the severity of disease. Individuals with 50 to 150 repeats are prone to development of mild myotonia and cataracts, but typically have a normal lifespan. Individuals with up to approximately 1,000 repeats typically have muscle weakness and cardiac arrhythmia, with an average lifespan of 48 to 55 years. The most serious cases of DM1 are generally observed in individuals with more than 1,000 repeats, and these patients are likely to also suffer from respiratory defects and intellectual disability, with a shortened lifespan of approximately 45 years. Genetic anticipation is also observed, whereby the age of onset decreases in subsequent generations due to expansion of the CTG repeat between generations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Current Approaches and Limitations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are no approved therapies to treat DM1, with current standards of care being medicines that are used off-label for symptom management. Previously, a phosphorothioate ASO designed to cause degradation of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">transcript was clinically assessed as a therapeutic for DM1. However, this therapeutic approach was restricted by the inefficiency of ASO delivery into target tissues and cells, thus limiting the effective clinical translation of this product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are several clinical-stage approaches leveraging antibody-oligonucleotide conjugate, or AOC, technologies, that are currently in development for the treatment of DM1. These approaches utilize mAbs and Fabs that target the transferrin receptor 1, or TfR1, in order to deliver cargo oligonucleotides that are designed to knockdown or degrade </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Such knockdown or degradation approaches cannot differentiate between expanded and non-expanded transcripts. In contrast to knockdown or degradation of overall </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">levels, our approach is more targeted as PGN-EDODM1 is designed to disrupt the binding of MBNL1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">transcript.  This approach maintains overall </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> levels and thereby averts any potential for haploinsufficiency, a condition where a copy of the gene is deleted or mutated and the remaining copy is unable to produce sufficient protein for normal function. Furthermore, the correlation between the level of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> knockdown and the level of splicing correction required for therapeutic benefit is currently unclear, a consideration that may confound clinical development of these approaches. Therefore, we believe that PGN-EDODM1 is differentiated relative to the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">knockdown approaches in development for DM1 given its mechanism of action that is intended to bind </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, allowing release of MBNL1 to restore splicing and downstream functional effects. In addition, in preclinical studies, the EDO platform has shown successful delivery of therapeutic PMOs to the nucleus, which we believe is critical to drive the anticipated therapeutic benefit of PGN-EDODM1.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also aware of VX-670, another cell-penetrating peptide approach conjugated to a PMO that is designed to block the CUG repeats in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">transcript that has recently entered clinical development for the treatment of DM1.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Approach</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidate for the treatment of DM1, PGN-EDODM1, consists of our lead EDO CPP conjugated to an ASO that binds to the pathogenic CUG repeat expansion in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mRNA. We are employing the same EDO peptide in PGN-EDO51 and PGN-EDODM1. PGN-EDODM1 is designed to directly address the deleterious effects of genetic alteration in DM1, specifically the sequestration of MBNL1 due to the high number of CUG repeat expansion in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> transcript.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that this innovative therapeutic approach has considerable advantages over oligonucleotide modalities that rely on knockdown or degradation of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">transcript. PGN-EDODM1 disrupts the binding between the CUG repeat expansion and MBNL1, an approach which we believe will allow the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">transcript to continue performing its normal function within the cell,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">while also liberating MBNL1 to correct downstream mis-splicing events. We believe that this therapeutic strategy positions us to potentially provide clinically meaningful benefits for DM1 patients while mitigating the risk of potential deleterious outcomes.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img224999359_20.jpg" alt="img224999359_20.jpg" style="width:720px;height:341px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PGN-EDODM1 is designed to bind to the CUG repeats in </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RNA and liberate MBNL1 to restore physiological splicing, in contrast to modalities that indiscriminately target both normal and pathogenic </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for degradation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preclinical Data</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">study utilizing DM1 patient cells with approximately 2,600 CTG repeats in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> gene, we observed a robust reduction in nuclear foci, liberation of MBNL1 from foci and the correction of downstream transcript mis-splicing pathologies. In this study, immortalized myoblasts from a DM1 patient were differentiated for four days, and then treated for 24 hours with PGN-EDODM1 at a range of concentrations from 0 &#181;M to 20 &#181;M. Myoblasts from a healthy individual were utilized as a control, and the unconjugated PMO was also assessed at a concentration of 20 &#181;M in this study in order to demonstrate the critical role that our EDO platform plays in driving efficient cell uptake of this therapeutic cargo.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A characteristic feature of DM1 is the accumulation of nuclear foci, or myonuclear aggregates of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mRNA bearing the pathogenic CUG repeat expansion. These foci sequester MBNL1, a critical modulator of transcript splicing, and thus play a key role in the downstream spliceopathies that are observed in this multi-systemic disorder. We assessed the impact of PGN-EDODM1 treatment on the presence of nuclear foci in DM1 cells through visualization with fluorescence </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in situ </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hybridization, or FISH, and immunofluorescence co-staining, and we observed that treatment led to a robust reduction of 54% in the number of these toxic aggregates. In contrast, treatment with the unconjugated PMO cargo did not yield a reduction in nuclear foci, an observation which we</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">believe supports the potential utility of our EDO platform in driving the successful delivery of therapeutic agents to their nuclear site of action.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_21.jpg" alt="img224999359_21.jpg" style="width:564px;height:288px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In a preclinical study conducted in DM1 patient cells, PGN-EDODM1 treatment supported the reduction of pathogenic nuclear foci in a dose-dependent fashion. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Graph plotted as mean &#177; SD; n = 3-4 per group.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In this same </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> study, we also assessed the impact of PGN-EDODM1 treatment on the sequestration of MBNL1. Following treatment and visualization, we observed a reduction in the amount of foci-bound MBNL1, indicating that that this critical splicing factor is liberated upon treatment with our DM1 product candidate. We believe these results provide additional support for the proposed mechanism of action of PGN-EDODM1, suggesting that &#8211; once delivered to the cell nucleus &#8211; our therapeutic cargo may</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">bind to the CUG repeat expansion present in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">transcript, resulting in a reduction in the number of nuclear foci and the liberation of MBNL1.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img224999359_22.jpg" alt="img224999359_22.jpg" style="width:720px;height:403px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PGN-EDODM1 treatment resulted in the liberation of MBNL1 from DPMK</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foci.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Treatment of DM1 patient cells with PGN-EDODM1 led to robust correction of downstream mis-spliced transcripts associated with key disease pathologies in a dose-dependent fashion. At the highest dose assessed, 20 &#181;M, PGN-EDODM1 treatment resulted in robust mis-splicing correction, resulting in exon inclusion or exclusion rates of approximately 70% of healthy control levels in these transcripts. This observation supports our therapeutic hypothesis that treatment with PGN-EDODM1 may restore the altered global spliceopathy profiles seen in DM1 patients, thus ameliorating the key pathologies that are the hallmark of this devastating disease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_23.jpg" alt="img224999359_23.jpg" style="width:325px;height:274px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In an </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">study, PGN-EDODM1 treatment resulted in correction of mis-splicing pathologies to around 70% of healthy control levels. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Graph plotted as mean &#177; SD; n = 5 per group.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Building on the encouraging positive data from our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> studies, we utilized the HSA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">LR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mouse model of DM1 to assess the activity of PGN-EDODM1. This transgenic mouse model contains between 220 and 250 CTG trinucleotide repeats in the inserted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">human skeletal actin</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">HSA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, gene, and exhibits molecular and functional pathologies that are very similar to those seen in human DM1 patients. The CUG repeat expansion present in the HSA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">LR </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mouse model, and the subsequent sequestration of MBNL1, leads to downstream defects in the normal mRNA splicing patterns for a number of transcripts, resulting in aberrant inclusions or exclusions of exons.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sequestration of MBNL1 in the HSA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">LR </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mouse model causes mis-splicing of multiple RNAs including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clcn1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Atp2a1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, both of which are involved in the regulation of muscle movement. This mis-splicing causes the mice to exhibit myotonia, effectively recapitulating the classic symptom of disease that is observed in DM1 patients. Mis-splicing of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Atp2a1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> manifests as a lack of exon 22 inclusion in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Atp2a1 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mRNA when compared to wild-type splicing patterns, while mis-splicing of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clcn1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> manifests as an increase in exon 7a inclusion in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clcn1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mRNA when compared to wild-type splicing patterns. Following a single intravenous administration of PGN-EDODM1, we observed dose-dependent normalization of the splicing of these genes in the quadriceps and gastrocnemius muscles two weeks after dosing. At a dose of 30 mg/kg, we achieved 91% correction of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Atp2a1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mis-splicing and 68% correction of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clcn1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mis-splicing, highlighting the potential of our product candidate to address such downstream pathologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_24.jpg" alt="img224999359_24.jpg" style="width:480px;height:280px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PGN-EDODM1 led to a dose-dependent normalization of the splicing of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Atp2a1 </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clcn1</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> transcripts in preclinical study in quadriceps muscles in HSA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">LR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Graph plotted as mean &#177; SEM; n = 8 for PGN-EDODM1 group, n = 16 for HSA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">LR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> saline control, n = 8 for WT saline control; **** = p&#8804;0.0001.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consistent with the reversal of mis-splicing events, treatment with a single dose of PGN-EDODM1 also led to a complete reversal of myotonia phenotype in HSA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">LR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice as assessed by electromyography, with a dose of 30 mg/kg showing complete normalization two weeks after administration. In observational studies we noted quantitative amelioration of myotonia, where treated mice were able to ambulate normally following the inducement of this functional phenotype of disease by hindlimb pinching. In</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">contrast, untreated HSA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">LR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice were unable to efficiently use their hind legs and dragged them behind following the same myotonic inducement event.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_25.jpg" alt="img224999359_25.jpg" style="width:478px;height:386px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PGN-EDODM1 led to a complete amelioration of myotonia in a preclinical study after a single administration. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Graph plotted as min to max; n = 8 for PGN-EDODM1 group, n = 16 for HSA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">LR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> saline control, n = 8 for WT saline control; *** = p&#8804;0.001.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, the pharmacologic effects of PGN-EDODM1 were observed to be highly durable. In a duration of effect study, again in the HSA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">LR </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mouse model, amelioration of the pathogenic splicing patterns of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Atp2a1 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clcn1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> transcripts in the gastrocnemius and quadriceps persisted for at least 24 weeks following a single 30 mg/kg intravenous administration of PGN-EDODM1.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_26.jpg" alt="img224999359_26.jpg" style="width:624px;height:247px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PGN-EDODM1 led to durable improvements in mRNA splicing through 24 weeks post-dose in the HSA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">LR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mouse model. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Graph plotted as mean &#177;SEM; n = 7 for 0 timepoint, 8 for 2- and 12-week timepoints; 5 for 24-week timepoint.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In another study in the HSA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">LR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mouse model, multiple doses of PGN-EDODM1 at 30 mg/kg given once every four weeks were evaluated. While a single dose corrected 68% of transcript mis-splicing and 76% of myotonia, as measured using the pinch test, four repeat doses produced 99% correction of mis-splicing and 99% correction of the myotonia.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><img src="img224999359_27.jpg" alt="img224999359_27.jpg" style="width:668px;height:394px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PGN-EDODM1 led to a normalization of splicing and near complete correction of myotonia in a repeat dosing preclinical study in skeletal muscles in HSA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">LR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Mis-splicing analysis considers multiple transcripts. Graph is presented as mean &#177; SD; n = 8-12 per cohort per transcript. Myotonia pinch test was performed four weeks post-final dose. Grade 3 = Clear sign of myotonia strong AND reproducible, Grade 2 = Clear sign of myotonia, strong OR reproducible, Grade 1 = Clear sign of myotonia but non reproducible, Grade 0 = No sign of myotonia. Graph is presented as mean &#177; SD; n = 12-43 per cohort.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to understand the PK/PD relationship for PGN-EDODM1 to inform the clinical development strategy for PGN-EDODM1, we also quantified the concentration of PGN-EDODM1 in the muscle tissue in HSA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">LR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mouse model. Following PGN-EDODM1 administration in HSA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">LR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice, we observed mean tissue concentrations of 6 nM at 28 days post single dose and 13 nM at 28 days post four doses. Furthermore, the clinical PK/PD relationship for PGN-EDO51 demonstrated that PGN-EDO51 at 10 mg/kg resulted in exon skipping activity in HVs while achieving muscle PMO concentration in the range of concentration similar to PGN-EDODM1 in HSA</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">lr</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mice, as indicated below. Therefore, given that the EDO delivery peptide is identical for both programs and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">based on PGN-EDODM1 HSA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">LR </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mouse PK/PD relationship and PGN-EDO51 human PK/PD relationship, we believe that PGN-EDODM1 has the potential to demonstrate improvement in splicing with a single dose in our ongoing FREEDOM trial.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_28.jpg" alt="img224999359_28.jpg" style="width:573px;height:335px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tissue concentrations of PGN-EDODM1 28 days post dose in HSA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">LR </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mice and tissue concentrations of PGN-EDO51 28 days post single dose (as shown in Phase 1 HV study results included above)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Graph plotted as mean &#177; SEM; n = 8 for PGN-EDODM1 group, n = 8 for WT saline control; n = 6 for PGN-EDO51 data.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In summary, based on our preclinical data from the HSA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">LR </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mouse model along with the expected PK/PD relationship from PGN-EDO51, we have designed a clinical development plan that we believe has the potential to translate the robust impact of PGN-EDODM1 on splicing and functional outcomes observed in the HSA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">LR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> mouse model to patients.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unlike several other approaches currently in clinical development, PGN-EDODM1&#8217;s mechanism of action does not target </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> transcript for degradation. In both DM1 patient cells and in NHPs, mean </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">transcript levels remained unchanged relative to an untreated control following exposure to PGN-EDODM1.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To elaborate on these studies, in an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> study, immortalized myoblasts from a DM1 patient with 2,600 CTG repeats were differentiated for four days to myotubes and treated for 24 hours with PGN-EDODM1 at a range of concentrations between 1 and 20 &#181;M. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> transcript levels were evaluated by qPCR and normalized to ribosomal protein P0, or</span><span style="color:#4d5156;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">RPLP0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In NHPs, three doses of 10, 30 or 60 mg/kg of PGN-EDODM1 were administered every two weeks. One week following the final dose, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">transcript levels were evaluated by RT-PCR and normalized to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">RPLP0. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mean </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">transcript levels remained unchanged relative to an untreated control following exposure to PGN-EDODM1.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_29.jpg" alt="img224999359_29.jpg" style="width:624px;height:340px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No significant changes in mean </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> transcript levels were observed in DM1 patient cells or in NHPs. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Graphs plotted as mean &#177; SEM; n = 4 for patient cell data, n = 3-4 for NHP data.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Thus, we believe this unique mechanism of action design may offer a potential safety benefit, as we believe such an approach does not carry the risk of possible </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">haploinsufficiency.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have completed a number of GLP studies that support a generally well-tolerated safety profile for PGN-EDODM1. In a four dose, 12-week sub-chronic toxicology study in NHPs, PGN-EDODM1 was observed to be generally well-tolerated through 60 mg/kg. While we observed transient increases in serum creatinine that resolve within a week post dose&#8203;, importantly, we did not see any adverse findings in the kidney through 60 mg/kg. Furthermore, there were no noteworthy hematologic, cardiovascular or hepatic effects observed.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_30.jpg" alt="img224999359_30.jpg" style="width:515px;height:263px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PGN-EDODM1 administration in NHPs led to a transient increase in serum creatinine followed by reduction in serum creatinine to baseline levels by day 8. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">NHPs were dosed intravenously four times once every 28 days at 60 mg/kg over 60 min (n=6 males; n=6 females). Data shown as mean &#177; SD.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that the totality of the data obtained from the safety/toxicology studies that have enabled IND/CTA filings highlight a potentially favorable safety profile for PGN-EDODM1.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In summary, based on PGN-EDODM1&#8217;s improvement of mis-splicing and myotonia in HSA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">LR </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mouse model, the favorable safety profile observed in toxicology studies, and the ability of the EDO technology to achieve pharmacologically active levels of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PMO in skeletal muscle, as seen in the PGN-EDO51 Phase 1 HV data, we believe that PGN-EDODM1 has the potential to be a meaningful therapy for patients with DM1.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Development</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are currently enrolling patients with DM1 in the FREEDOM study, a randomized, double-blind placebo-controlled Phase 1 study. In this study, we intend to enroll approximately 24 adult patients with DM1 in multiple geographies including the U.S., U.K. and Canada, to evaluate the safety and tolerability of PGN-EDODM1. Per the protocol, PGN-EDODM1 will be administered at the starting dose of 5 mg/kg and subsequently at 10 mg/kg and 20 mg/kg. Dose escalation to the higher dose will be determined based upon evaluation of safety data from the prior dose cohort(s). We will conduct muscle biopsies at baseline, at day 28 and at week 16. In addition to safety and tolerability, we plan to assess oligonucleotide muscle concentrations, splicing correction and functional outcome measures at day 28 and at week 16 following a single dose of PGN-EDODM1. We anticipate reporting preliminary data, including safety, correction of splicing and functional outcome measures, in the second half of 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The safety data from the initial cohorts of the FREEDOM trial will inform the design of the planned FREEDOM2-DM1 trial, which will be a Phase 2 randomized, double blind, placebo-controlled MAD study in DM1 patients, which we anticipate opening in the second half of 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on preclinical data, emerging safety profile and translatability of our EDO platform from preclinical species to humans as observed with PGN-EDO51, we believe that PGN-EDODM1 has the potential to be disease-modifying and could improve outcomes for patients living with DM1. Notably, the FDA has recently granted Fast Track designation to PGN-EDODM1.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PGN-EDO53</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also developing EDO therapeutics for additional DMD patient population, including PGN-EDO53, for patients who are amenable to exon 53 skipping, representing approximately 8% of DMD patients. PGN-EDO53 utilizes the same EDO CPP as our exon 51-skipping product candidate, PGN-EDO51, which we believe will allow us to leverage our drug development experience in DMD to rapidly drive this candidate to the clinic. In a NHP study of PGN-EDO53, we observed single-dose exon skipping levels that were almost seven times higher than those observed for R</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">G-PMO53, a relevant comparator peptide-PMO conjugate approach. We intend to progress the selected candidate for PGN-EDO53 into IND/CTA enabling studies in 2024.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Current Approaches and Unmet Needs</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Two unconjugated ASOs leveraging PMO chemistry have been approved for the treatment of individuals with DMD who are amenable to an exon 53-skipping approach &#8211; golodirsen, marketed as VYONDYS 53</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> by Sarepta and viltolarsen, marketed as VILTEPSO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> by NS Pharma, Inc. in the U.S.. These drugs were approved in the U.S. through the accelerated approval regulatory pathway based on an increased expression of dystrophin, which is considered to be a surrogate endpoint for this indication. Both golodirsen and viltolarsen have yet to establish a clinical benefit for DMD patients through a confirmatory trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Approach for Preclinical Development</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are developing PGN-EDO53, a peptide-conjugated ASO designed to skip exon 53 of the dystrophin transcript in DMD patients who are amenable to such a therapeutic approach. We have completed a preclinical </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> screen of a number of candidate ASO sequences utilizing the established PMO chemistry. We synthesized several exon 53-skipping PMOs conjugated to our lead EDO peptide and assessed the activity of these in human-derived myoblasts carrying mutations that are amenable to treatment with an exon 53-skipping approach. Based on the data obtained from this </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">screen, we have subsequently assessed several development candidates in a repeat-dose NHP study, where these PPMOs were assessed alongside a relevant comparator, R</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">G-PMO53. Three doses of each PPMO were administered intravenously over 60 minutes every four weeks, with biopsies of the biceps collected five to seven days after the first and second administrations, and terminal samples collected seven days after the final dose. Exon 53 skipping was assessed by RT-PCR.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notably, the single-dose exon skipping levels of 36.4% obtained for the selected PGN-EDO53 candidate were almost seven times higher than those observed for the R</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">G-PMO53 comparator at 5.4%. Furthermore, exon 53 skipped transcripts accumulated with repeat dosing of PGN-EDO53. Following the third and final dose of PGN-EDO53, mean exon skipping levels were observed to be 57.2%, a level that was nearly three times higher than the mean exon skipping levels of 20.8% that were observed for the R</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">G-PMO53 comparator. We believe that this accumulation in skipped transcript is indicative of the potential of the EDO platform to drive</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinically meaningful levels of exon skipping, and ultimately dystrophin production, in DMD patients. We are initiating IND/CTA enabling studies for PGN-EDO53 in 2024.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img224999359_31.jpg" alt="img224999359_31.jpg" style="width:367px;height:326px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Treatment with PGN-EDO53 afforded single-dose exon skipping levels almost seven times higher than for a comparator PPMO. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Graphs plotted as mean &#177; SD; n = 3 per group; study was not powered for statistical significance.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expanding the Application and Scope of Our EDO Platform</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New Indications with PMO Therapeutics</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the future, we intend to apply our deep understanding of our EDO platform and PMO therapeutics to the development of additional product candidates in other indications. Based on extensive preclinical data we have generated, we believe that the ability of our EDO peptides to deliver exon skipping and RNA blocking therapeutics to muscle cells and other target tissues positions us to develop additional product candidates in other neuromuscular indications as well as in potentially neurologic indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New Cargos</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that our EDO technology has the potential to facilitate the delivery of multiple types of oligonucleotide therapeutics. To date, our efforts have primarily focused on the delivery of PMOs, but we also intend to pursue the expansion of our cargo scope to other nucleic acid species.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New Peptide Technologies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We intend to further establish our expertise and competitive position in the field of oligonucleotide delivery through the ongoing research and development of new peptides. In connection with these efforts, we intend to leverage our deep expertise in this field to design new peptides that target specific tissue types, and to seek to further optimize the tissue and cellular delivery of our EDO platform.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our manufacturing process is modular in nature. The peptide and oligonucleotide components are assembled using readily available building blocks and are subsequently conjugated using well-established methodologies. This process is fully synthetic and does not rely on microbial fermentation, thus substantially reducing the risk of introducing microbial DNA or protein into our product candidates. Furthermore, our manufacturing process is highly scalable and easily characterizable &#8211; attributes that we intend to leverage to support the rapid development and clinical translation of our EDO conjugate therapeutics. We have produced, manufactured and released multiple batches under current Good Manufacturing Practice, or cGMP, and have successfully utilized this material in a Phase 1 clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not own or operate manufacturing facilities, and currently rely on third-party contract development manufacturing organizations, or CDMOs, and suppliers for the cell-penetrating peptide, linker and oligonucleotide components that comprise our EDOs, and for the conjugation of our product candidates as well as for the manufacturing of the finished dosage form (sterile injectable drug product). We anticipate that we will continue to utilize third-party CDMOs and suppliers to support our ongoing and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">future preclinical, clinical and commercial activities, and our intention is to build this network of organizations as we scale our manufacturing requirements. Long-term, we may also decide to establish internal manufacturing of our drugs or selected intermediates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that there are multiple sources for all raw materials employed in the manufacturing of our EDO therapeutics, and we believe that several CDMOs are able to assemble either the peptide intermediate, the linker, and the oligonucleotide as well as the final API.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are extensive regulations that govern the manufacturing of biopharmaceutical products, and the third-party manufacturing organizations we work with are required to adhere to these regulations. Our CDMOs are required to manufacture our product candidates under cGMP requirements, alongside other applicable laws and regulations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competition</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The biopharmaceutical industry is characterized by the rapid evolution and development of new technologies, leading to an environment that is intensely competitive in nature and thus supports the robust protection and defense of intellectual property. Any EDO product candidates that we successfully develop and commercialize will compete both with existing therapeutics, and with new approaches that may arise in the future. While we believe that our unique EDO platform and extensive expertise in oligonucleotide delivery may provide us with a differentiated position in the neuromuscular and neurologic spaces, such competing technologies may arise from many different sources, including large biopharmaceutical organizations, specialty pharmaceutical and biotechnology companies, academic institutions, government agencies, and public and private research organizations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to face competition from existing products and product candidates in development for each of our programs. Currently, patients with DMD are treated with corticosteroids to manage the inflammatory component of the disease. EMFLAZA (deflazacort) is an FDA-approved corticosteroid marketed by PTC Therapeutics, Inc., or PTC. Individuals with DMD also use prednisone or prednisolone off-label. In addition, there are several FDA-approved exon skipping drugs: EXONDYS 51 and VYONDYS 53, which are naked PMOs approved for the treatment of DMD patients amenable to exon 51 and exon 53 skipping, respectively, marketed by Sarepta; and VILTEPSO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, a naked PMO approved for the treatment of DMD patients amenable to exon 53 skipping, which is marketed in the U.S. by NS Pharma, Inc. Companies focused on developing treatments for DMD that target increased dystrophin expression, as our DMD program does, include Sarepta with SRP-5051, a peptide-linked PMO currently being evaluated in a Phase 2b clinical trial for patients amenable to exon 51 skipping, Dyne Therapeutics, Inc., or Dyne, with DYNE-251, an antibody-conjugated PMO that targets exon 51 skipping in a Phase 1/2 clinical trial; BioMarin Pharmaceutical Inc., or BioMarin, with BMN-351,a phosphorothioate oligonucleotide that targets exon 51 skipping currently in preclinical development; and Wave Life Sciences Ltd., or Wave, with WVE-N531, a stereopure oligonucleotide in a Phase 1/2 clinical trial for patients amenable to exon 53 skipping.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, several companies are developing gene therapies to treat DMD. These include Sarepta&#8217;s ELEVIDYS (SRP-9001) which was approved in June 2023 for treatment of ambulatory pediatric patients aged 4 through 5 years with DMD with a confirmed mutation in the DMD gene. In an interim readout of a recent Phase 3 EMBARK trial, which is still ongoing, patients with DMD between ages 4 through 7 years treated with ELEVIDYS did not show statistically significant benefit on the North Star Ambulatory Assessment, which was the primary endpoint. ELEVIDYS showed statistically significant results on all key pre-specified secondary endpoints, time to rise and 10-meter walk/run test. Based on the interim read out from EMBARK, Sarepta has filed an efficacy supplement to its BLA to encompass &#8220;treatment of DMD patients with a confirmed mutation in the DMD gene.&#8221; The FDA accepted the filing of the efficacy supplement and has given the application priority review with a review goal date of June 21, 2024. In addition, several other companies are developing investigational gene therapies to treat DMD, including Pfizer Inc.&#8217;s PF-06939926, fordadistrogene movaparvovec, which is currently being assessed in a Phase 3 clinical trial, and Sarepta&#8217;s Galgt2 gene therapy program, Solid Biosciences Inc.&#8217;s SGT-003 and REGENXBIO Inc.&#8217;s RGX-202, currently in clinical development. Gene editing treatments that are in preclinical development are also being pursued by Vertex Pharmaceuticals, Inc., or Vertex, and Sarepta.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also aware of several companies targeting non-dystrophin mechanisms for the treatment of DMD, including Edgewise with EDG-5506, a muscle stabilizer that is currently in clinical development and </span><span style="color:#1f1f1f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">givinostat</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, a</span><span style="color:#1f1f1f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> histone deacetylase, or HDAC, inhibitor,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> that reduces fibrosis in patients with DMD and is currently under review by the FDA and EMA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For DM1, there are currently no approved therapies to treat the underlying cause of the disease. Product candidates currently in clinical development to treat DM1 include several approaches that target </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RNA. These include AOC 1001, an antibody linked siRNA in Phase 1/2 clinical development with a global Phase 3 study planned for initiation in the second quarter of 2024 by Avidity Biosciences, Inc., or Avidity; DYNE-101, an antibody conjugated antisense oligonucleotide in clinical development by Dyne; and VX-670, a peptide conjugated PMO in Phase 1 by Entrada Therapeutics, Inc., or Entrada, and Vertex. There are additional approaches under development such as ATX-01, a micro RNA that modulates the expression of MBNL1 by Arthex Biotech S.L. that recently received IND clearance. Another small molecule, tideglusib, which is a GSK3-&#223; inhibitor is in clinical development by AMO Pharma Ltd. for the congenital phenotype of DM1, recently failed to meet primary endpoint in a pivotal study.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Several gene editing treatments are in preclinical development by Vertex; an artificial site-specific RNA endonuclease gene therapy is being developed by Enzerna Biosciences Inc., or Enzerna; Design Therapeutics, Inc. is developing an approach to prevent formation of CUG hairpins; Expansion Therapeutics, Inc. is developing an approach utilizing the interaction of small molecules with RNA in preclinical development; and therapeutics based on biomolecular condensate biology are in preclinical development by Dewpoint Therapeutics, Inc., or Dewpoint, and Pfizer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">     </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will also compete more generally with other companies developing alternative scientific and technological approaches, including companies working to develop conjugates with oligonucleotides for extra-hepatic delivery, including Alnylam Pharmaceuticals, Inc., or Alnylam, Aro Biotherapeutics Co., or Aro, Arrowhead Pharmaceuticals, Inc., or Arrowhead, Avidity, Dicerna Pharmaceuticals, Inc. (acquired by Novo Nordisk), or Dicerna, Dyne, Entrada, Ionis Pharmaceuticals, Inc., or Ionis. NeuBase Therapeutics, Inc., or NeuBase, PYC Therapeutics Limited, or PYC, and Sarepta, as well as gene therapy and gene editing approaches.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of the companies which we compete with or may compete with in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Accordingly, our competitors may be more successful than us in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining approval for treatments and achieving widespread market acceptance, rendering our treatments obsolete or non-competitive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any of our products, if approved. Competitive products or technological approaches may make any products we develop, or our EDO platform, obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products, if approved, could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales and Marketing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently do not have a commercial infrastructure in any geography. As we progress our programs through development, we may build a commercial infrastructure in the U.S. and selected other territories to support the commercialization of each of our product candidates when we believe a regulatory approval in a particular territory is likely. We intend to conduct market research in connection with designing our commercialization strategy for each of our product candidates, which strategy may depend on the size and geographic dispersion of the target patient population and the characteristics of the prescribing audience for our products, if approved. For example, with respect to certain of our product candidates that target diseases with a limited patient population, a concentrated prescribing audience and a small number of key opinion leaders who influence the treatments prescribed for the relevant patient population, we may address each such market using our own targeted, specialty sales and marketing organization supported by internal sales personnel, an internal marketing group and distribution support. For other product candidates, we may establish a larger and more dispersed sales force, or seek strategic collaborations to support our commercialization efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We intend to evaluate our commercialization strategy as we advance each product candidate through clinical development. In any core markets outside of the U.S. that we may identify, where appropriate, we may utilize strategic partners, distributors or contract sales forces to expand the commercial availability of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Material Contracts</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License of Technology Agreement with Oxford University Innovation Limited and Medical Research Council as Part of United Kingdom Research and Innovation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 26, 2018, we, through our wholly-owned subsidiary PepGen Limited, entered into a license agreement, or the OUI/MRC License, with Oxford University Innovation Limited, or OUI, and MRC. We amended the OUI/MRC License on December 21, 2018, and subsequently amended and restated it on November 23, 2020.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the OUI/MRC License, we obtained from OUI and MRC an exclusive, royalty-bearing, sublicensable with consent (through one tier) license under certain patent rights, or the OUI/MRC Patents, and data, or the OUI/MRC Licensed Technology, and a nonexclusive, royalty-bearing, sublicensable (through one tier) license under certain know-how, or the OUI/MRC Know-How, for certain biological and chemical compounds, including compounds that comprise amino acids and/or nucleic acids relating to our EDO peptides, proprietary linkers and the resulting EDO conjugates. The Licensed Technology is incorporated in our product candidates PGN-EDO51, PGN-EDODM1, PGN-EDO53, PGN-EDO45 and PGN-EDO44, and will likely be utilized in future discovery programs. Under such licenses, we have the right to make, have made, import, use, sell, offer for sale, market, research, develop, trial, register, modify, enhance, improve, manufacture, have manufactured, hold, keep, formulate, optimize, have used, export, transfer, distribute, promote, have sold, dispose of, offer to dispose of or otherwise exploit in all fields of use on a worldwide basis any products or services that incorporate or otherwise utilize the OUI/MRC Licensed Technology or, in each such case, an OUI/MRC Licensed Product. We granted OUI, and those persons who at any time work or have worked on the OUI/MRC Licensed Technology and OUI/MRC Know-How, and MRC an irrevocable, perpetual, royalty-free, sublicensable license under the OUI/MRC Licensed Technology and OUI/MRC Know-How to use the OUI/MRC Licensed Technology and OUI/MRC Know-How for non-commercial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical, research, teaching, publication, or other scholarly purposes, or Non-Commercial Purposes. MRC also retained the right to grant sublicenses under our rights in the OUI/MRC Licensed Technology and OUI/MRC Know-How for Non-Commercial Purposes to any person at MRC or any academic or not-for-profit institutions who have worked or collaborated on, or otherwise funded, the OUI/MRC Licensed Technology or OUI/MRC Know-How. Further, OUI, MRC and the Chancellor, Masters and Scholars of the University of Oxford retained the right to freely use, publish (subject to certain obligations) or grant licenses under the OUI/MRC Know-How.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The OUI/MRC License requires us to use commercially reasonable efforts to exploit the OUI/MRC Licensed Technology and to achieve certain development milestones in accordance with a development plan and commercialize the OUI/MRC Licensed Products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In consideration for the rights conveyed by OUI and MRC under the OUI/MRC License, we were obligated to pay, and have paid, to OUI certain up-front fees in an aggregate amount of approximately &#163;80,000 in connection with the execution of each of the original OUI/MRC License and the amended and restated OUI/MRC License. In addition, we are obligated to pay to OUI sub-single to low, single-digit percentage royalties, or the Royalty Rate, on net sales of any OUI/MRC Licensed Products in excess of a threshold amount between &#163;20 million and &#163;30 million that are commercialized by us. The royalty rate for a given OUI/MRC Licensed Product will decrease a certain percentage following expiration or revocation of the last valid claim of the OUI/MRC Patents covering such OUI/MRC Licensed Product and where there is a product sold by a third party that competes with such OUI/MRC Licensed Product on a country-by-country basis. If we receive any non-royalty payments and royalties in connection with sublicenses or other contracts relating to the OUI/MRC Licensed Technology or OUI/MRC Know-How, we are obligated to pay to OUI, in each instance, a sublicense fee that is from mid-single digit to mid teen percentage depending on the license year in which we execute the sublicense or contract. We are also required to pay certain milestone payments to OUI upon the achievement by us or our sublicensees of specified commercial milestones in an aggregate amount of &#163;100,000 for each OUI/MRC Licensed Product and specified patent procurement milestones in an aggregate amount of &#163;10,000.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon completion of our initial public offering, or IPO, in May 2022, we paid an exit fee of $1.4 million to OUI during the second quarter of 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unless earlier terminated, the OUI/MRC License will terminate in its entirety upon the later of (a) the date on which all patents and patent applications licensed to us under the OUI/MRC License have been abandoned or allowed to lapse or expired or been rejected or revoked without a right of further appeal in a relevant country or territory or (b) March 26, 2038. The last-to-expire licensed patent under the OUI/MRC License is set to expire on February 11, 2042. We may terminate the OUI/MRC License in its entirety at any time for convenience upon providing OUI and MRC with written notice. Either party may terminate the OUI/MRC License in its entirety for the other party&#8217;s uncured material breach after an opportunity for the other party to cure such material breach. OUI and MRC may terminate the OUI/MRC License for our (a) insolvency or if we challenge the validity of the licensed patents, (b) breach our obligation to develop and exploit the technology in accordance with the development plan and subsequent failure to take remedial action reasonably requested by OUI and/or MRC or (c) failure to pay the Exit Fee or Exit Buy Out Fee. If the OUI/MRC License is terminated by either party for any reason, the OUI/MRC Licenses will terminate and all rights thereunder will revert to OUI and MRC, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intellectual Property</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We seek to protect the intellectual property, or IP, and proprietary technology that we consider important to our business, including by pursuing patent applications that cover our product candidates and methods of using the same, as well as any other relevant inventions and improvements that are considered commercially important to the development of our business. We likewise seek to protect the IP to which we obtain rights through licenses and sublicenses (e.g., from universities and research institutions) and work collaboratively with our licensors to ensure (and if possible be the driver of) patent prosecution and protection. We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and IP positions. Our commercial success depends, in part, on our ability to obtain, maintain, enforce and protect our intellectual property and other proprietary rights for the technology, inventions and improvements we consider important to our business, and to defend any patents we may own or in-license in the future, prevent others from infringing any patents we may own or in-license in the future, preserve the confidentiality of our trade secrets, and operate without infringing, misappropriating or otherwise violating the valid and enforceable patents and proprietary rights of third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As with other biotechnology and pharmaceutical companies, our ability to maintain and solidify our proprietary and intellectual property position(s) for our product candidates and technologies will depend on our success in obtaining effective patent claims and enforcing those claims if granted. However, our pending patent applications, and any patent applications that we may in the future file or license from third parties, may not result in the issuance of patents and any issued patents we may obtain do not guarantee us the right to protect our technology in relation to the commercialization of our products. We also cannot predict the breadth of claims that may be allowed or enforced in any patents we may own or in-license in the future. Notwithstanding the scope of the patent protection available to us, a competitor could develop competitive products that are not covered by our intellectual property, and we may be unable to stop such competitor from commercializing such products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any issued patents that we may own or in-license in the future may be challenged, invalidated, circumvented or have the scope of their claims narrowed. Because patent applications can take many years to issue, there may be applications unknown to us, which applications may later result in issued patents that our existing or future products or technologies may be alleged to infringe. Additionally, we cannot be certain of the priority of inventions covered by pending third-party patent applications. If third parties prepare and file patent applications in the U.S. that also claim technology or therapeutics to which we have rights, we may have to participate in interference proceedings in the U.S. Patent and Trademark Office, or USPTO, to determine priority of invention, which is highly unpredictable and which could result in substantial costs, even if the eventual outcome is favorable to us. We are aware of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">certain patents in the U.S. and other jurisdictions owned by third parties that claim subject matter that relates to our product candidates and the EDO platform. In addition, because of the extensive time required for clinical development and regulatory review of a product candidate we may develop, it is possible that, before any of our product candidates can be commercialized, any patent covering a certain product may expire or remain in force for only a short period following commercialization, thereby limiting the protection such patent would afford the respective product and any competitive advantage such patent may provide.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of individual patents depends upon the date of filing of the patent application, the date of patent issuance and the legal term of patents in the countries in which they are obtained. In most countries, including the U.S., the patent term is 20 years from the earliest filing date of a non-provisional patent application. In the U.S., a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent or may be shortened if a patent is terminally disclaimed over an earlier expiring patent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of a patent claiming a new drug product may also be eligible for a limited patent term extension when FDA approval is granted, provided statutory and regulatory requirements are met. The restoration period granted on a patent covering a product is typically one-half the time between the effective date of a clinical investigation involving human beings is begun and the submission date of an application, plus the time between the submission date of an application and the ultimate approval date. The restoration period cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following FDA approval. Only one patent applicable to an approved product is eligible for the extension, and only those claims covering the approved product, a method for using it, or a method for manufacturing it may be extended. Additionally, the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent term extension or restoration in consultation with the FDA. In the future, if our product candidates receive approval by the FDA, we expect to apply for patent term extensions on any issued patents covering those products, depending upon the length of the clinical studies for each product and other factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There can be no assurance that our pending patent applications will issue or that we will benefit from any patent term extension or favorable adjustments to the terms of any patents we may own or in-license in the future. In addition, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. Patent term may be inadequate to protect our competitive position on our products for an adequate amount of time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the future, we may need to engage in litigation to enforce patents issued or licensed to us, to protect our trade secrets or know-how or to defend against claims of infringement of the rights of others. Litigation could be costly and could divert our attention from other functions and responsibilities. Furthermore, even if our patents are found to be valid and infringed, a court may refuse to grant injunctive relief against the infringer and instead grant us monetary damages and/or ongoing royalties. Such monetary compensation may be insufficient to adequately offset the damage to our business caused by the infringer&#8217;s competition in the market. Adverse determinations in litigation could subject us to significant liabilities to third parties, could require us to seek licenses from third parties and pay significant royalties to such third parties and could prevent us from manufacturing, selling or using our product or techniques, any of which could severely harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we owned two pending U.S. patent applications and one pending Patent Cooperation Treaty, or PCT, international application, and exclusively licensed one issued patent (a European patent validated in France, Germany, Italy, Spain, and Great Britain) and 74 pending patent applications under our OUI/MRC License. For more information regarding our OUI/MRC License, see the section titled &#8220;Business&#8212;Material Contracts&#8212;License of Technology Agreement with Oxford University Innovation Limited and Medical Research Council as Part of United Kingdom Research and Innovation.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The issued patent and patent applications that cover our product candidates and technology, as of December 31, 2023, include:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With respect to PGN-EDO51, we owned applications pending in the U.S., Europe and Japan that cover methods of use and exclusively licensed 47 pending patent applications under the OUI/MRC License that cover compositions of matter and methods of use, including applications in Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, India, Japan, South Korea, Mexico, the Russian Federation, Saudi Arabia, and the U.S. Any patents issuing from the patent applications would have expiration dates ranging from 2039 to 2042, without accounting for any available patent term adjustments or extensions. </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With respect to PGN-EDODM1, we owned applications pending in the U.S., Canada, China, Europe and Japan that cover methods of use and exclusively licensed 45 pending patent applications under the OUI/MRC License that cover compositions of matter and methods of use, including applications in Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, India, Japan, South Korea, Mexico, the Russian Federation, Saudi Arabia, and the U.S. Any patents issuing from the patent applications would have expiration dates ranging from 2039 to 2042, without accounting for any available patent term adjustments or extensions. </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With respect to PGN-EDO53, PGN-EDO45 and PGN-EDO44, we exclusively licensed 30 pending patent applications under the OUI/MRC License that cover compositions of matter and methods of use, including applications in Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, India, Japan, South Korea, Mexico, the Russian Federation, Saudi Arabia, and the U.S. Any patents issuing from these patent applications would expire in 2039, without accounting for any available patent term adjustments or extensions. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With respect to our EDO platform, we owned one pending PCT international patent application and exclusively licensed one issued European patent and 41 pending patent applications under the OUI/MRC License that cover compositions of matter and methods of use, including applications in Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, India, Japan, South Korea, Mexico, the Russian Federation, Saudi Arabia, and the U.S. The issued European patent is expected to expire in 2035, without accounting for any available patent term adjustments or extensions. The issued European patent was validated in France, Germany, Italy, Spain, and Great Britain, and it relates to certain compositions of matter and uses that may be utilized during future platform development activities. Any patents issuing from the patent applications would have expiration dates ranging from 2035 to 2043, without accounting for any available patent term adjustments or extensions. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose requirements upon companies involved in the clinical development, manufacture, marketing and distribution of drugs, such as those we are developing. These agencies and other federal, state and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling and export and import of drugs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Government Regulation of Drug Products</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S., the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending New Drug Applications, or NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The process required by the FDA before a drug may be marketed in the U.S. generally involves the following:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s GLP regulations; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Submission to the FDA of an IND, which must become effective before human clinical trials may begin; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Performance of adequate and well-controlled human clinical trials in accordance with Good Clinical Practices, or GCP, requirements to establish the safety and efficacy of the proposed drug product for each proposed indication; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Submission to the FDA of an NDA after completion of all pivotal trials, together with the payment of application user fees, as applicable; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A determination by the FDA within 60 days of its receipt of an NDA to accept the marketing application for review; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Satisfactory completion of an FDA advisory committee review, if applicable; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA review and approval of the NDA. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preclinical Studies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before testing any drug product candidate, including our product candidates, in humans, the product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as in vitro and animal studies to assess potential safety and efficacy. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to beginning the first clinical trial with a product candidate in the U.S., we must submit an IND to the FDA. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data and any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin. Some preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue even after</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to initiate. For example, in May 2023, we announced that we received a clinical hold notice from the FDA regarding our IND application to initiate our Phase 1 FREEDOM study, and in June 2023, we provided an update on our plans with respect to this program. In October 2023, we announced that the FDA lifted the clinical hold on our Phase 1 FREEDOM study, allowing this study to proceed in the U.S.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Trials</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it is initiated at that institution. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also must review and approve the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a DSMB, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on their www.clinicaltrials.gov website. Information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. Although sponsors are obligated to disclose the results of their clinical trials after completion, disclosure of the results can be delayed in some cases for some time. Failure to timely register a covered clinical study or to submit study results as provided for in the law can give rise to civil monetary penalties and also prevent the non-compliant party from receiving future grant funds from the federal government.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness. </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. Generally, two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of an NDA. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval on an NDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if SAEs occur. Written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies or animal or in vitro testing that suggest a significant risk for human subjects and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">NDA Submission and FDA Review and Approval</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. Data may come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and effectiveness of the investigational drug product for the proposed indication to the satisfaction of the FDA. In most cases, the submission of an NDA is subject to a substantial application user fee; a waiver of such fees may be obtained under certain limited circumstances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA, for a new molecular entity to review and act on the submission, and six months from the filing date of a new molecular entity NDA with priority review. Accordingly, this review process typically takes 12 months and eight months, respectively from the date the NDA is submitted to the FDA. The FDA does not always meet its PDUFA goal dates for standard or priority NDAs, and the review process is often extended by FDA requests for additional information or clarification. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, under the Pediatric Research Equity Act of 2003, or PREA, as amended, certain NDAs or supplements to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. A sponsor who is planning to submit a marketing application for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration must submit an initial Pediatric Study Plan, or PSP, within 60 days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before initiation of the Phase 3 or Phase 2/3 study. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials and/or other clinical development programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may refer an application for a novel drug or a drug that presents difficult questions of safety or efficacy to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA also may require the submission of a Risk Evaluation and Mitigation Strategy, or REMS, if it determines that a REMS is necessary to ensure that the benefits of the drug outweigh its risks and to assure the safe use of the drug. A REMS may include one or more elements, including medication guides, physician communication plans, patient package insert and/or elements to assure safe use, such as restricted distribution methods, patient registries or other risk minimization tools. The FDA determines the requirement for a REMS, as well as the specific REMS provisions, on a case-by-case basis. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without a REMS, if required.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a Complete Response Letter. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter generally outlines the deficiencies in the submission and contains a statement of specific conditions that must be met in order to secure final approval of the NDA; it may require additional clinical or preclinical testing in order for FDA to reconsider the application. If a Complete Response Letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Orphan Drug Designation and Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug product intended to treat a rare disease or condition, which is generally a disease or condition that affects either (i) fewer than 200,000 individuals in the U.S., or (ii) more than 200,000 individuals in the U.S. and for which there is no reasonable expectation that the cost of developing and making the product available in the U.S. for this type of disease or condition will be recovered from sales of the product. A company must request orphan drug designation before submitting an NDA. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product is entitled to orphan product exclusivity. Orphan product exclusivity means that the FDA may not approve any other applications to market the same product for the same indication for seven years, except in certain limited circumstances. Orphan exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same active ingredient for the same indication is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. Further, the FDA may approve more than one product for the same orphan indication or disease as long as the products contain different active ingredients. Moreover, competitors may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan drug has exclusivity. Other benefits of orphan drug designation include tax credits for certain research and waiver from the NDA application fee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A designated orphan drug many not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the U.S. may be lost if the FDA later determines that the request for designation was materially defective or, as noted above, if a second applicant demonstrates that its product is clinically superior to the approved product with orphan exclusivity or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expedited Development and Review Programs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA maintains several programs intended to facilitate and expedite development and review of new drugs to address unmet medical needs in the treatment of serious or life-threatening diseases or conditions. These programs include Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval, and the purpose of these programs is to either expedite the development or review of important new drugs to get them to patients earlier than under standard FDA development and review procedures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA has a Fast Track designation program that is intended to expedite or facilitate the process for reviewing new drugs that meet certain criteria. Specifically, new drugs are eligible for Fast Track designation if they are intended to treat a serious or life threatening condition and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to both the product and the specific indication for which it is being studied. The sponsor can request that the FDA grant the product Fast Track designation any time before receiving NDA approval, but ideally no later than the pre-NDA meeting. Fast Track designation provides increased opportunities for sponsor interactions with the FDA review team to expedite development and review of the product. The FDA may also review sections of the NDA for a Fast Track designated-product on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application. Fast Track designation may be lost if the designation is no longer supported by data emerging in the clinical trial process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, a drug may be eligible for designation as a breakthrough therapy if the product is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life- threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. The benefits of Breakthrough Therapy designation include the same benefits as Fast Track designation, plus intensive guidance from the FDA to ensure an efficient drug development program. Breakthrough therapy designation comes with all of the benefits of Fast Track designation, which means that the sponsor may file sections of the NDA for review on a rolling basis if certain conditions are satisfied, including an agreement with the FDA on the proposed schedule for submission of portions of the application and the payment of applicable user fees before the FDA may initiate a review.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A product may also be eligible for priority review if it treats a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. The FDA determines at the time that the marketing application is submitted, on a case-by-case basis, whether the proposed drug represents a significant improvement in treatment, prevention or diagnosis of disease when compared with other available therapies. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications and to shorten the FDA&#8217;s goal for taking action on a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">marketing application from ten months to six months for an NDA for a new molecular entity from the date of filing. If criteria are not met for priority review, the application for a new molecular entity is subject to the standard FDA review period of ten months after FDA accepts the application for filing. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A product may also be eligible for accelerated approval if it treats a serious or life-threatening disease or condition, generally provides a meaningful advantage over available therapies and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA generally requires that a sponsor perform adequate and well-controlled post-marketing clinical trials to verify and describe the product&#8217;s clinical benefit. These confirmatory trials must be completed with due diligence, and, under the Food and Drug Omnibus Reform Act of 2022, or FDORA, the FDA is now permitted to require, as appropriate, that such trials be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. Under FDORA, the FDA has increased authority for expedited procedures to withdraw the product from the market (and withdraw its approval). In addition, for products being considered for accelerated approval, the FDA generally requires, unless otherwise informed by the agency, pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Fast Track designation, Breakthrough Therapy designation, priority review and accelerated approval do not change the standards for approval and may not ultimately expedite the development or approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Non-Patent Exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market exclusivity provisions under the FDCA can delay the submission or the approval of certain follow-on applications. The FDCA provides a five-year period of data exclusivity within the U.S. to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an Abbreviated New Drug Application, or ANDA, for a generic version of the drug or a 505(b)(2) NDA for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, such a follow-on application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDCA also provides three years of market exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity period covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving follow-on applications that do not reference the protected clinical data. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pediatric exclusivity is another type of regulatory market exclusivity in the U.S. Pediatric exclusivity, if granted, adds six months to existing regulatory exclusivity periods fo</span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">r</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> all formulations, dosage forms, and indications of the active moiety and listed patent terms. This six-month exclusivity may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#8220;Written Request&#8221; for such a trial, provided that at the time pediatric exclusivity is granted there is not less than nine months of term remaining. The issuance of a Written Request does not require the sponsor to undertake the described clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Post-approval Requirements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There are continuing, annual user fee requirements for any marketed products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA regulations require that products be manufactured in specific facilities and in accordance with cGMP regulations which require, among other things, quality control and quality assurance, the maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs and those supplying products, ingredients, and components of them are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Manufacturers and other parties involved in the drug supply chain for prescription drug products must also comply with product tracking and tracing requirements and for notifying FDA of counterfeit, diverted, stolen and intentionally adulterated products or products that are otherwise unfit for distribution in the U.S. Changes to the manufacturing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. Manufacturers and other parties involved in the drug supply chain for prescription drug products must also comply with product tracking and tracing requirements and for notifying FDA of counterfeit, diverted, stolen and intentionally adulterated products or products that are otherwise unfit for distribution in the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Once an approval of a drug is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Other potential consequences include, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fines, warning letters or clinical holds on post-approval clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or withdrawal of product approvals; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Product seizure or detention, or refusal to permit the import or export of products; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mandated modification of promotional materials and labeling and the issuance of corrective information; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted by a manufacturer and any third parties acting on behalf of a manufacturer only for the approved indications and in a manner consistent with the approved label for the product. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined companies from engaging in off-label promotion. The FDA and other regulatory agencies have also required that companies enter into consent decrees and/or imposed permanent injunctions under which specified promotional conduct is changed or curtailed. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA-approved labeling.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Coverage and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales of any product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. These third-party payors are increasingly reducing coverage and reimbursement for medical products, drugs and services. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The U.S. government, state legislatures and foreign governments have also continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product and also have a material adverse effect on sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Healthcare Laws</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business that may constrain the financial arrangements and relationships through which we research, as well as sell, market and distribute any products for which we obtain marketing authorization. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, and transparency laws and regulations related to drug pricing and payments and other transfers of value made to physicians and other healthcare providers. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply, we may be subject to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting obligations, exclusion from participation in federal and state healthcare programs and responsible individuals may be subject to imprisonment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare Reform and Legislative Updates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S., in 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, each as amended, collectively known as the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly affected the pharmaceutical industry. The ACA contained a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement adjustments and changes to fraud and abuse laws. For example, the ACA:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">required collection of rebates for drugs paid by Medicaid managed care organizations; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">required manufacturers to participate in a coverage gap discount program, under which they must agree to offer 70 percent point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell &#8220;branded prescription drugs&#8221; to specified federal government programs. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since its enactment, there have also been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA. Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year to 2031, unless additional Congressional action is taken. The U.S. American Taxpayer Relief Act of 2012 further reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. On March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. Due to the Statutory Pay-As-You-Go Act of 2010, estimated budget deficit increases resulting from the American Rescue Plan Act of 2021, and subsequent legislation, Medicare payments to providers will be further reduced starting in 2025 absent further legislation.&#8239; These laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There has been increasing legislative and enforcement interest in the U.S. with respect to drug pricing practices. Specifically, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and review the relationship between pricing and manufacturer patient programs. The Inflation Reduction Act of 2022 (IRA) includes several provisions that may impact our business to varying degrees, including provisions that reduce the out-of-pocket spending cap for Medicare Part D beneficiaries from $7,050 to $2,000 starting in 2025, thereby effectively eliminating the coverage gap; impose new manufacturer financial liability on certain drugs under Medicare Part D, allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs and biologics without generic or biosimilar competition; require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation; and delay until January 1, 2032 the implementation of the HHS rebate rule that would have limited the fees that pharmacy benefit managers can charge. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one orphan designation and for which the only approved indication is for that disease or condition.  If a product receives multiple orphan designations or has multiple approved indications, it may not qualify for the orphan drug exemption. The implementation of the IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA&#8217;s Medicare drug price negotiation program. The implementation of the IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA&#8217;s Medicare drug price negotiation program. The effects of the IRA on our business and the healthcare industry in general is not yet known.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries, proposed and enacted legislation and executive orders designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Individual states in the U.S. have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could impact the amounts that federal and state governments and other third-party payors will pay for healthcare products and services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Data Privacy and Security</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Numerous state, federal and foreign laws, regulations and standards govern the collection, use, access to, confidentiality and security of health-related and other personal information, and could apply now or in the future to our operations or the operations of our partners. In the U.S., numerous federal and state laws and regulations, including data breach notification laws, health information privacy and security laws and consumer protection laws and regulations govern the collection, use, disclosure, and protection of health-related and other personal information. In addition, certain foreign laws govern the privacy and security of personal data, including health-related data. For example, European Union General Data Protection Regulation (EU) 2016/679, or the GDPR imposes strict requirements for processing the personal data of individuals within the European Economic Area, or EEA, including requirements relating to processing health-related and other sensitive data, establishing a legal basis for processing such as obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, imposing limitations on retention of personal data; maintaining a record of data processing, complying with the principal of accountability and the obligation to demonstrate compliance through policies, procedures, training and audit and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA to countries that the European Union, or EU does not consider to have in place adequate data protection legislation, including the U.S. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the non-compliant company, whichever is greater. Further, from January 1, 2021, companies have had to comply with the GDPR and also the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in the U.K., or UK national law. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Regulation and Procedures Governing Approval of Medicinal Products Outside the United States</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, an applicant will need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. For example, the process governing approval of medicinal products in the EU generally follows the same lines as in the United States. It entails satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication. It also requires the submission to the relevant competent authorities of a marketing authorization application, and granting of a marketing authorization by these authorities before the product can be marketed and sold in the EU.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">European Union Drug Development and Approval</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Trial Approval</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2014, the EU adopted the Clinical Trials Regulation (EU) No 536/2014, or CTR, which repealed and replaced the previous Clinical Trials Directive (2001/20/EC) on January 31, 2022. The transitory provisions of the CTR provide that all ongoing clinical trials must have transitioned to the CTR by January 31, 2025. The CTR overhauls the previous system of approvals for clinical trials in the EU. Specifically, the CTR, which is directly applicable in all EU Member States (meaning no national implementing legislation in each Member State is required), aims at simplifying and streamlining the approval of clinical trials in the EU, simplifying adverse-event reporting procedures, improving the supervision of clinical trials and increasing their transparency. The main characteristics of the CTR include: a streamlined application procedure via a single-entry point through the Clinical Trials Information System, or CTIS; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials. The role of the relevant ethics committees in the assessment procedure continues to be governed by the national law of the applicable Member State, however overall related timelines are defined by the CTR.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Marketing Authorization</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To obtain a marketing authorization for a product in the EU, an applicant must submit a marketing authorization application, either under a centralized procedure administered by the EMA or one of the procedures administered by competent authorities in EU Member States (decentralized procedure, national procedure, or mutual recognition procedure). A marketing authorization may be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">granted only to an applicant established in the EU or the additional Member States of the European Economic Area (Norway, Iceland and Liechtenstein), or EEA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all EU Member States, as well as the additional Member States of the EEA. Pursuant to Regulation (EC) No. 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products (gene-therapy, somatic cell-therapy or tissue-engineered medicines) and products with a new active substance indicated for the treatment of cancer, HIV, AIDS, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions or viral diseases. The centralized procedure is optional for products containing a new active substance not yet authorized in the EU, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the centralized procedure, the Committee for Medicinal Products for Human Use, or CHMP, established at the EMA is responsible for conducting an initial assessment of a product. The maximum timeframe for the evaluation of a marketing authorization application is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Clock stops may extend the timeframe of evaluation of an application considerably beyond 210 days. Where the CHMP gives a positive opinion, the EMA provides the opinion together with supporting documentation to the European Commission, who makes the final decision to grant a marketing authorization, which is issued within 67 days of receipt of the EMA&#8217;s recommendation. Accelerated evaluation may be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the viewpoint of public health and, in particular, therapeutic innovation. If the CHMP accepts such a request, the time limit of 210 days will be reduced to 150 days, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that it is no longer appropriate to conduct an accelerated assessment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">National marketing authorizations, which are issued by the competent authorities of the Member States of the EU and only cover their respective territory, are available for products not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in a Member State of the EU, this national authorization can be recognized in other Member States through the mutual recognition procedure. If the product has not received a national authorization in any Member State at the time of application, it can be approved simultaneously in various Member States through the decentralized procedure.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Data and Market Exclusivity in the European Union</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, new chemical entities (including both small molecules and biological medicinal products) approved on the basis of a complete and independent data package qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. Data exclusivity, if granted, prevents generic or biosimilar applicants from referencing the innovator&#8217;s pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization, for a period of eight years from the date on which the reference product was first authorized in the EU. During the additional two-year period of market exclusivity, a generic or biosimilar marketing authorization application can be submitted, and the innovator&#8217;s data may be referenced, but no medicinal product can be marketed until the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to authorization, is held to bring a significant clinical benefit in comparison with currently approved therapies. There is no guarantee that a product will be considered by the EMA to be a new chemical entity, and products may not qualify for data exclusivity.  Even if a product is considered to be a new chemical entity so that the innovator gains the prescribed period of data exclusivity, another company could nevertheless also market another version of the product if such company obtained marketing authorization based on a marketing authorization application with a complete and independent data package of pharmaceutical tests, preclinical tests and clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Orphan Designation and Exclusivity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulation (EC) No 141/2000 and Regulation (EC) No. 847/2000 provide that a product can be designated as an orphan medicinal product by the European Commission if its sponsor can establish that: (1) the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition, (2) either (i) such condition affects no more than five in ten thousand persons in the EU when the application is made, or (ii) without the benefits derived from orphan status, it is unlikely that the marketing of the product in the EU would generate sufficient return to justify the necessary investment in its development; (3)  there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the product would be of significant benefit to those affected by that condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An orphan designation provides a number of benefits, including fee reductions, regulatory assistance and the possibility to apply for a centralized EU marketing authorization. Marketing authorization for an orphan medicinal product leads to a ten-year period of market exclusivity being granted following marketing approval of the orphan product. During this market exclusivity period, the EMA, the European Commission or the competent authorities of the EU Member States may only grant marketing authorization to a &#8220;similar medicinal product&#8221; for the same therapeutic indication if: (i) a second applicant can establish that its product, although similar to the authorized product, is safer, more effective or otherwise clinically superior; (ii) the marketing authorization holder for the authorized product consents to a second orphan medicinal product application; or (iii) the marketing authorization holder for the authorized product cannot supply enough orphan medicinal product. A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic indication may, however, be reduced to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation because, for example, the product is sufficiently profitable not to justify market exclusivity. Orphan designation must be requested before submitting an application for marketing approval. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aforementioned EU rules are generally applicable in the EEA.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reform of the Regulatory Framework in the European Union</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The European Commission introduced legislative proposals in April 2023 that, if implemented, will replace the current regulatory framework in the EU for all medicines (including those for rare diseases and for children). The European Commission has provided the legislative proposals to the European Parliament and the European Council for their review and approval. In October 2023, the European Parliament published draft reports proposing amendments to the legislative proposals, which will be debated by the European Parliament. Once the European Commission&#8217;s legislative proposals are approved (with or without amendment), they will be adopted into EU law.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Brexit and the Regulatory Framework in the United Kingdom</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The U.K. formally left the EU on January 31, 2020, and the EU and the U.K. have concluded a trade and cooperation agreement, or TCA, which was provisionally applicable since January 1, 2021 and has been formally applicable since May 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of cGMP, inspections of manufacturing facilities for medicinal products and cGMP documents issued, but does not provide for wholesale mutual recognition of United Kingdom and EU pharmaceutical regulations. At present, EU laws which have been transposed into U.K. law through secondary legislation continue to be applicable as &#8220;retained EU law&#8221;. However, legislation such as the EU Clinical Trials Regulation or in relation to orphan medicinal products are not applicable. The U.K. government has passed the Medicines and Medical Devices Act 2021, which introduced delegated powers in favor of the Secretary of State (or for Northern Ireland, the Department of Health in Northern Ireland) to amend or supplement existing regulations in the area of medicinal products and medical devices. This allows new rules to be introduced in the future by way of secondary legislation, which aims to allow flexibility in addressing regulatory gaps and future changes in the fields of human medicines, clinical trials and medical devices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of January 1, 2021, the MHRA is the U.K.&#8217;s standalone medicines and medical devices regulator. As a result of the Northern Ireland protocol, different rules apply in Northern Ireland than in England, Wales, and Scotland (together, Great Britain, or GB); broadly, Northern Ireland currently continues to follow the EU regulatory regime, but its national competent authority will remain the MHRA. On February 27, 2023, the U.K. government and the European Commission announced a political agreement in principle to replace the Northern Ireland Protocol with a new set of arrangements, known as the &#8220;Windsor Framework&#8221;. This new framework fundamentally changes the existing system under the Northern Ireland Protocol, including with respect to the regulation of medicinal products in the U.K.. In particular, the MHRA will be responsible for approving all medicinal products destined for the U.K. market (i.e., Great Britain and Northern Ireland), and the EMA will no longer have any role in approving medicinal products destined for Northern Ireland. A single U.K.-wide marketing authorization will be granted by the MHRA for all medicinal products to be sold in the U.K., enabling products to be sold in a single pack and under a single authorization throughout the U.K.. The Windsor Framework was approved by the EU-U.K. Joint Committee on March 24, 2023, so the U.K. government and the EU will enact legislative measures to bring it into law. On June 9, 2023, the MHRA announced that the medicines aspects of the Windsor Framework will apply from January 1, 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The MHRA has introduced changes to national licensing procedures, including procedures to prioritize access to new medicines that will benefit patients, including a 150-day assessment and a rolling review procedure. All existing EU marketing authorizations for centrally authorized products were automatically converted or grandfathered into U.K. marketing authorizations, effective in Great Britain (only), free of charge on January 1, 2021, unless the marketing authorization holder chose to opt-out. In order to use the centralized procedure to obtain a marketing authorization that will be valid throughout the EEA, companies must be established in the EEA. Therefore, since Brexit, companies established in the U.K. can no longer use the centralized procedure and instead an EEA entity must hold any centralized marketing authorizations. In order to obtain a U.K. marketing authorization to commercialize products in the U.K., an applicant must be established in the U.K. or EEA and must follow one of the U.K. national authorization procedures. On January 1, 2024, a new international recognition framework was put in place, which will have regard to decisions on the approval of marketing authorizations made by the European Medicines Agency and certain other regulators when determining an application for a GB authorization. The MHRA also has the power to have regard to marketing authorizations approved in EU Member States (or Iceland, Liechtenstein, Norway) through decentralized or mutual recognition procedures when determining an application for a GB authorization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is no longer pre-marketing authorization orphan designation in GB. Instead, the MHRA reviews applications for orphan designation in parallel to the corresponding marketing authorization application. The criteria are essentially the same, but have been tailored for the market, i.e., the prevalence of the condition in GB, rather than the EU, must not be more than five in 10,000. Should an orphan designation be granted, the period or market exclusivity will be set from the date of first approval of the product in GB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pricing Decisions for Approved Products</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. For example, EU Member States have the option to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the EU have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage health care expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the EU. The downward pressure on health care costs in general, particularly prescription products, has become intense.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States, and parallel trade, i.e., arbitrage between low-priced and high-priced EU Member States, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rest of the World Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For other countries outside of Canada, the EU and the U.S., such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. Additionally, the clinical trials must be conducted in accordance with GCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employees and Human Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had 64 full-time employees, of whom 24</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">have Ph.D. degrees, and several part-time employees employed on a co-op or internship basis. Within our workforce, 52</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">employees are engaged in research and development and 12</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">are engaged in business development, finance, legal, and general management and administration. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity incentive plans are to attract, retain and reward personnel through the granting of equity-based compensation awards in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Facilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2023, we primarily operated out of 31,668 square feet of office and laboratory space at 321 Harrison Street, Boston, Massachusetts 02118. The lease was signed on December 1, 2021 and the lease term commenced on December 29, 2022. The term of the lease is 110 months from the commencement date, expiring in May 2032, with an option to extend the lease for one successive five-year term.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that our facilities are adequate for our current needs and for the foreseeable future. To meet the future needs of our business, we may lease additional or alternate space. We believe that suitable additional or substitute space at commercially reasonable terms will be available as needed to accommodate any future expansion of our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Culture and Team</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our mission is to deliver transformative therapeutics to those in need, and we believe our innovative EDO technology is well-positioned to effect this change for patients, families and the broader healthcare community. As a company, we value:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: We are a data-driven scientific company at heart, and we approach our work with an evidence-based mindset; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Innovation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: We are always exploring new ways to learn, build and improve across all facets of our company; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Integrity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: We act ethically and honestly in both our scientific and business conduct; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Responsibility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: As a therapeutic company, we appreciate the impact our work has on patients and their families. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In support of our mission, we have assembled a leadership team with deep experience in research and development, clinical translation, regulatory affairs, corporate development and compliance. Our Chief Executive Officer, James McArthur, Ph.D., brings over 25 years of industry experience to the company, including senior leadership and Board roles at Imara Inc., Cydan LLC and Nightstar Therapeutics plc, with a specific focus on rare disease therapeutics. Dr. McArthur is ably supported by Noel Donnelly, M.B.A., our Chief Financial Officer, who has over 25 years of experience in financial planning and analysis, business analytics and portfolio management and has held roles at EIP Pharma Inc., Takeda Pharmaceuticals, Inc., and Shire HGT; Mary Beth DeLena, our General Counsel and Secretary, who has over 20 years of experience advising life sciences companies in a broad range of strategic, transactional, and corporate matters, spanning early research and development to commercial launch and execution, and has held roles at Alnylam Pharmaceuticals, Praecis Pharmaceuticals, Inc. and Skadden, Arps, Slate, Meagher &amp; Flom LLP; Michelle L. Mellion, M.D., our Senior Vice President, Clinical Development, who is double Board-certified in neurology and clinical neurophysiology and has held roles at Fulcrum Therapeutics, Inc., Vertex Pharmaceuticals, Inc., and Biogen Inc; and Niels Svenstrup, Ph.D., our Senior Vice President of Chemistry, Manufacturing and Control, who has extensive experience in the manufacturing and release of peptide drugs for late-stage clinical programs and has held roles at Ascendis Pharma A/S, Cydan LLC, and Lundbeck A/S, amongst others. We have established a strong scientific advisory board, with members who bring a wealth of expertise from both the indication and therapeutic modality perspectives in their roles as academics, clinicians and drug developers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We were founded in 2018 with technology spun out from the University of Oxford and MRC to further develop and commercialize this novel peptide delivery approach. This technology was created and refined over a decade by Michael Gait, Ph.D. and Professor Matthew Wood, M.D., Ph.D. We have exclusively licensed the patents, patent applications and know-how associated with this technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1A. Risk Factors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing in our common stock involves a high degree of risk. You should carefully read and consider all of the risks described below, as well as the other information in this 10-K, including our financial statements and the related notes and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and in other documents we file with the SEC when evaluating our business. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. Unless otherwise indicated, references to our business being harmed in these risk factors will include harm to our business, reputation, financial condition, results of operations and future prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. The risks described below are not intended to be exhaustive and are not the only risks that we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations and the market price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Financial Position and Need for Additional Capital</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have incurred significant losses since our inception, have no products approved for sale and we expect to incur losses for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since inception, we have incurred significant operating losses. Our net losses were $78.6 million and $69.1 million for the years ended December 31, 2023 and December 31, 2022, respectively. As of December 31, 2023, we had an accumulated deficit of $181.5 million. To date, we have financed our operations primarily with the proceeds raised from the sale of our convertible preferred stock in private placements and common stock in our IPO and our equity offerings in early 2024, described below. We have devoted substantially all of our financial resources and efforts to research and development activities, business planning, establishing and maintaining our intellectual property portfolio, acquiring and developing product and technology rights, hiring personnel, leasing premises and associated capital expenditures, raising capital, and providing general and administrative support for these operations. We are still in the early stages of development of our programs and have only advanced two product candidates into clinical development. We expect to continue to incur significant expenses and operating losses for the foreseeable future. Our operating expenses and net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">complete preclinical activities for our programs in DMD and DM1 and continue to advance them into and through clinical development; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">advance any additional product candidates we identify through our research programs into IND- or CTA-enabling studies and clinical trials following regulatory clearance to commence clinical research; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue to develop and expand the capabilities of our proprietary EDO platform; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish manufacturing sources for our product candidates and secure supply chain capacity to provide sufficient quantities for preclinical and clinical development and commercial supply;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek marketing approvals for any product candidates that successfully complete pivotal clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain, expand, maintain, defend and enforce our intellectual property portfolio; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hire additional clinical, regulatory and scientific personnel; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ultimately establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">add operational, legal, compliance, financial and management information systems and personnel to support our research, product development and future commercialization efforts, as well as to support our operations as a public company. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we obtain regulatory approval of, and are successful in commercializing, one or more of our product candidates, we will continue to incur substantial research and development and other costs to develop and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have never generated revenue from product sales and may never achieve or maintain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we have completed our Phase 1 clinical trial for PGN-EDO51 and initiated a Phase 2 clinical trial for PGN-EDO51 and our Phase 1 clinical trial for PGN-EDODM1, we expect that it will be many years, if ever, before we have a product candidate ready for commercialization. To become and remain profitable, we must succeed in developing, obtaining the necessary regulatory</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approvals for and eventually commercializing a product or products that generate significant revenue. The ability to achieve this success will require us to be effective in a range of challenging activities, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identifying product candidates and completing preclinical development of our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining regulatory authorization to commence clinical trials and initiating and successfully completing such trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining marketing approval for our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing (or securing third-party manufacturers to manufacture), marketing and selling any products for which we may obtain regulatory approval; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">achieving market acceptance of any products for which we obtain regulatory approval as a viable treatment option; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfying any post-marketing requirements. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. We completed a Phase 1 clinical trial for our first product candidate, PGN-EDO51 and initiated a Phase 2 clinical trial for PGN-EDO51 as well as a Phase 1 clinical trial for PGN-EDODM1. Because of the numerous risks and uncertainties associated with product development, we are unable to accurately estimate or know the nature, timing or costs of the efforts that will be necessary to complete the preclinical and clinical development and commercialization of our product candidates or when, or if, we will be able to generate revenues or achieve profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are successful in obtaining regulatory approval to market one or more of our product candidates, our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement, and whether we own the commercial rights for that territory. If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable could impair our ability to raise capital, maintain our research and development efforts, expand our business or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will need to raise substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, scale back or discontinue our product development programs or future commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we identify, continue the research and development of, continue preclinical testing and initiate clinical trials of, arrange for the manufacturing of, and potentially seek marketing approval for any product candidates that successfully completes clinical testing. To date, we have only completed a Phase 1 clinical trial for our first product candidate, PGN-EDO51 and initiated Phase 2 clinical trials for PGN-EDO51 as well as a Phase 1 clinical trial for our second product candidate, PGN-EDODM1. In addition, if we obtain marketing approval for any product candidate, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Furthermore, we expect to continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed, on attractive terms or at all, we may be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had cash, cash equivalents, and marketable securities of $110.4 million. In July 2021, we raised aggregate gross proceeds of $21.0 million from the final milestone closing of our Series A-2 convertible preferred stock and aggregate gross proceeds of $112.5 million from the private placement of our Series B convertible preferred stock. In addition, in May 2022, we raised aggregate gross proceeds of $122.9 million from our IPO.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 5, 2024, we sold shares under our at-the-market offering program, or ATM program, pursuant to an At-the-Market Equity Offering Sales Agreement, or Sales Agreement, with Stifel, Nicolaus &amp; Company, Incorporated, resulting in net proceeds of $9.9 million. On February 9, 2024, we sold shares in a follow-on offering, or the Follow-on Offering, resulting in net proceeds of $76.9 million after deducting underwriters' fees of $3.2 million. Net proceeds from the ATM program and Follow-on Offering, after deducting underwriters' fees and before deducting costs of the offerings, were $86.8 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on our current operating plans, we believe that our existing cash, cash equivalents, marketable securities, including proceeds from shares sold under our ATM program and in the Follow-on Offering, will be sufficient to fund our operations into 2026. However, we have based this estimate on assumptions that may prove to be wrong, and our operating plans may change as a result of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">many factors, including factors currently unknown to us. As a result, we could deplete our capital resources sooner than we currently expect and could be forced to seek additional funding sooner than planned.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future capital requirements will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, progress, costs and results of preclinical and clinical development for our product candidates and any additional product candidates we may develop or any new indications we may pursue; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, costs, timing and outcome of regulatory review of our product candidates and any additional product candidates we may develop or any new indications we may pursue; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost and timing of manufacturing activities; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the identification of additional research programs and product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and scope of the continued development of our EDO platform; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of preparing, filing and prosecuting applications for patents, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims, including claims of infringement, misappropriation or other violations of third-party intellectual property; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any product candidate that receives marketing approval; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of satisfying any post-marketing requirements; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the revenue, if any, received from commercial sales of our product candidates if marketing approval is received; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of operational, financial and management information systems and associated personnel; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the associated costs in connection with any acquisition of in-licensed products, intellectual property and technologies; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of operating as a public company. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, even if we successfully develop product candidates and those are approved, we may not achieve commercial success. Our commercial revenues, if any, may not be sufficient to sustain our operations. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our operations. We cannot be certain that additional funding will be available on acceptable terms, when needed or at all. We have no committed source of additional capital and, if we are unable to raise additional capital in sufficient amounts, when needed or on terms acceptable to us, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product candidate, or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations. We could be required to seek collaborators for product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to product candidates in markets where we otherwise would seek to pursue development or commercialization ourselves. Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We commenced operations in 2018, have no products approved for commercial sale and have not generated any revenue from product sales. To date, our operations have been limited to organizing and staffing our company, business planning, executing collaborations, raising capital, licensing, conducting research activities, conducting preclinical studies of our programs and clinical trials of our product candidates, filing and prosecuting patent applications and providing general and administrative support for these operations. One of our product candidates, PGN-EDO51, completed a Phase 1 clinical trial and we have initiated Phase 2 clinical trials of PGN-EDO51 in DMD patients amenable to exon 51 skipping, as well as a Phase 1 clinical trial for another product candidate, PGN-EDODM1, in DM1 patients. All of our other research programs are still in the research or preclinical stage of development, and their risk of failure is high. We have not yet demonstrated our ability to successfully complete clinical trials consistently, obtain marketing approvals, manufacture product on a commercial scale or arrange for a third party to do so on our behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions you make</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our limited operating history may make it difficult to evaluate our technology and industry and predict our future performance. Our limited history as an operating company makes any assessment of our future success or viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by early-stage companies in rapidly evolving fields. If we do not address these risks successfully, our business will suffer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, as our business grows, we may encounter unforeseen expenses, restrictions, difficulties, complications, delays and other known and unknown factors. We will need to continue to transition from a company with a research focus to a company capable of conducting development activities for multiple product candidates and then to a company supporting commercial activities. We may not be successful in such transitions. If we do not adequately address these risks and difficulties or successfully make such a transition, it could have a material adverse impact on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Discovery, Development, Preclinical and Clinical Testing</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are early in our development efforts. We have only completed a Phase 1 clinical trial for our lead product candidate and initiated a Phase 1 clinical trial of a second product candidate as well as Phase 2 clinical trials of our lead product candidate, and as a result it will be years before we commercialize a product candidate, if ever. If we are unable to advance our product candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them, or experience significant delays in doing so, our business will be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are early in our development efforts and have invested our research efforts to date in developing our EDO platform. We have a portfolio of research programs and we have two product candidates in clinical trials &#8212; PGN-EDO51 for DMD and PGN-EDODM1 for DM1. We have completed a Phase 1 clinical trial for our first product candidate, PGN-EDO51. We have initiated our Phase 2 CONNECT1 trial for PGN-EDO51 in Canada, and began dosing patients in January of 2024. We received clearance from the MHRA to initiate our multinational Phase 2 CONNECT2 trial for PGN-EDO51 in February 2024. We have initiated a Phase 1 clinical trial, designated FREEDOM, for our second product candidate, PGN-EDODM1, and began dosing patients in December 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not completed IND- or CTA-enabling activities for any of our other product candidates or advanced any of our other product candidates into clinical trials. Our ability to generate product revenue, which we do not expect will occur for many years, if ever, will depend heavily on the successful clinical development and eventual commercialization of our product candidates, which may never occur. We currently generate no revenue from sales of any product, and we may never be able to develop or commercialize a marketable product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commencing clinical trials in the U.S. is subject to authorization by the FDA, of an IND and finalizing the trial design based on discussions with the FDA and other regulatory authorities. In the event that the FDA requires us to complete additional preclinical studies or we are required to satisfy other FDA or other regulator requests prior to commencing clinical trials, the start of our clinical trials may be delayed. For example, in May 2023, we announced that FDA had placed a clinical hold on our planned Phase 1 FREEDOM clinical trial of PGN-EDODM1 in the U.S. We submitted a response to the FDA and in October 2023, we announced that the FDA had lifted the clinical hold, allowing us to initiate FREEDOM in the U.S. Even after initiating FREEDOM in the U.S., the FDA or other regulatory authorities could disagree that we have satisfied their requirements to commence any clinical trial, including with respect to PGN-EDODM1, or change their position on the acceptability of our trial design or the clinical endpoints selected, which may require us to complete additional preclinical studies or clinical trials or impose stricter approval conditions than we currently expect. There are equivalent processes and risks applicable to CTAs in other countries, including Canada and countries in Europe.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commercialization of our product candidates will require preclinical and clinical development; regulatory approval; manufacturing supply, capacity and expertise; a commercial organization; and significant marketing efforts. The success of our product candidates will depend on many factors, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">timely and successful completion of preclinical studies, including toxicology studies, biodistribution studies and minimally efficacious dose studies in animals, where applicable; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorization to initiate clinical trials under INDs, CTAs or comparable foreign applications that allow commencement of our planned clinical trials or future clinical trials for our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successful initiation, enrollment and completion of clinical trials, including under the FDA&#8217;s GCPs, GLPs, and any additional regulatory requirements from foreign regulatory authorities;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">positive results from our clinical trials that support a finding of safety and effectiveness and an acceptable risk-benefit profile in the intended populations to the satisfaction of the applicable regulatory authorities; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">receipt of marketing approvals from applicable regulatory authorities, including the completion of any required post-marketing studies or trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishment of arrangements through our own facilities or with third-party manufacturers for clinical supply and, where applicable, commercial manufacturing capabilities; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishment, maintenance, defense and enforcement of patent, trademark, trade secret and other intellectual property protection or regulatory exclusivity for our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">commercial launch of our product candidates, if approved, whether alone or in collaboration with others; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acceptance of the benefits and use of our product candidates, including method of administration, if and when approved, by patients, the medical community and third-party payors; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">effective competition with other therapies; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintenance of a continued acceptable safety, tolerability and efficacy profile of our product candidates following marketing approval, including acceptable results from any post-approval studies or clinical trials agreed to by us or required by FDA or other regulatory authorities; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishment and maintenance of healthcare coverage and adequate reimbursement by payors. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of these factors are beyond our control and if we do not succeed in one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize any product candidates, which would materially harm our business. If we are unable to advance our product candidates to clinical development or successfully complete clinical trials, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our approach to the discovery and development of product candidates based on our EDO platform is unproven, and we may not be successful in our efforts to identify, discover or develop potential product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The success of our business depends upon our ability to identify, develop and commercialize products based on our proprietary EDO platform. Our current product candidates that have been developed through our EDO platform are peptide-conjugated oligonucleotides designed to have a disease-modifying impact on degenerative neuromuscular diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our lead product candidates are currently in clinical-stage development, while our other product candidates are still in the research or preclinical stage of development and our approach to treating muscle disease is unproven. Our research programs may fail to identify potential product candidates for clinical development for a number of reasons. Our research methodology may be unsuccessful in identifying potential product candidates and our potential product candidates may be shown to have harmful side effects in preclinical in vitro experiments or in vivo animal model studies, or in future clinical studies. In addition, our potential product candidates may not show promising signals of therapeutic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable or unlikely to receive marketing approval. Further, because all of our development programs are based on our EDO platform, adverse developments with respect to one of our programs may have a significant adverse impact on the actual or perceived likelihood of success and value of our other programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have advanced our first two product candidates, PGN-EDO51 and PGN-EDODM1, into the clinic, and have completed a Phase 1 trial of PGN-EDO51 in HVs. However, the positive results we have observed in our preclinical studies and in the completed Phase 1 trial may not be repeated in future clinical trials, including in patients with DMD amenable to a DMD skipping approach, and regulatory authorities may disagree with the interpretation of data from our trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we are advancing our initial programs in DMD and DM1, our EDO platform may fail to yield additional product candidates for clinical development for a number of reasons, including those discussed in these risk factors. In addition:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not be able to assemble sufficient resources to acquire or discover product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">competitors may develop alternatives that render our potential product candidates obsolete or less attractive;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential product candidates we develop may be covered by third parties&#8217; patents or other intellectual property rights; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential product candidates may, on further study, be shown to have harmful side effects, toxicities or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential product candidates may not be effective in treating their targeted diseases or disorders; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the market for a potential product candidate may change so that the continued development of that product candidate is no longer reasonable; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a potential product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the regulatory pathway for a potential product candidate may be too complex and difficult to navigate successfully or economically. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to identify and discover suitable product candidates for clinical development, this would adversely impact our business strategy and our financial position and share price and could potentially cause us to cease operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Drug development is a lengthy and expensive process, and preclinical and clinical testing is uncertain as to the outcome. We may encounter substantial delays in the commencement, enrollment or completion of our clinical trials and may never advance to clinical trials, or we may fail to demonstrate safety and effectiveness to the satisfaction of applicable regulatory authorities, which could prevent us from advancing or commercializing our product candidates on a timely basis, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The risk of failure in developing product candidates is high. It is impossible to predict when or if any product candidate would prove effective or safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical development, obtain regulatory authorization to commence clinical trials, and then conduct extensive clinical trials to demonstrate the safety and efficacy of product candidates in humans. To date, we have only completed a Phase 1 clinical trial of PGN-EDO51 and initiated a Phase 1 clinical trial of PGN-EDODM1 and Phase 2 clinical trials of PGN-EDO51.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials may fail to demonstrate that our product candidates are safe for humans and effective for indicated uses, and earlier results, both preclinical and clinical, may not be indicative of future clinical trial results. Even if the clinical trials are successful, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance, varying interpretations of clinical data or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support clearance of our INDs, CTAs and other similar regulatory filings. We cannot be certain if the outcome of our preclinical studies and clinical trials will ultimately support further development of our product candidates or future programs. Although we have completed a Phase 1 study of our lead product candidate, PGN-EDO51, and initiated a Phase 1 clinical trial of our second candidate, PGN-EDODM1, we cannot be certain of the completion or outcome of our preclinical testing and studies for our other product candidates and cannot predict whether the FDA, EMA or comparable foreign regulatory authorities will accept our proposed clinical programs or whether the outcome of our preclinical testing and studies will ultimately support the further development of our other product candidates. Conducting preclinical testing is a lengthy, time-consuming and expensive process. The length of time may vary substantially according to the type, complexity and novelty of the program, and often can be several years or more per program. In addition, the progress and timing of our preclinical studies, including pharmacology and toxicology studies, may be impacted by the limited supply of NHPs needed for such studies. As a result, we cannot be sure that we will be able to submit INDs, CTAs and other similar regulatory filings for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of such regulatory filings will result in the FDA, EMA or comparable foreign regulatory authorities allowing clinical trials to begin. For example, in May 2023, we announced that we received a clinical hold notice from the FDA regarding our IND application to initiate our Phase 1 FREEDOM study, and in June 2023, we provided an update on our plans with respect to this program. In October 2023, we announced that the FDA lifted the clinical hold on our Phase 1 FREEDOM study, allowing this study to proceed in the U.S.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, product candidates are subject to continued preclinical safety studies, which may be conducted concurrently with our clinical testing. The outcomes of these safety studies may delay the launch of or enrollment in clinical trials and could impact our ability to continue to conduct our clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical testing is expensive, is difficult to design and implement, can take many years to complete and is uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, or at all. A failure of one or more clinical trials can occur at any stage of testing, which may result from a multitude of factors, including, but not limited to, flaws in trial design, dose selection issues, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other events that may prevent successful or timely completion of clinical development include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in reaching a consensus with regulatory authorities on trial design; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in reaching agreement on acceptable terms with prospective clinical research organizations, or CROs, and clinical trial sites; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in opening clinical trial sites or obtaining required IRB or independent ethics committee approval, or the equivalent review groups for sites outside the U.S., at each clinical trial site; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event or manufacturing concerns or after an inspection of our clinical trial operations or trial sites; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">negative or inconclusive results observed in clinical trials, including failure to demonstrate statistical significance, which could lead us, or cause regulators to require us, to conduct additional clinical trials or abandon product development programs; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure by us, any CROs we engage or any other third parties to adhere to clinical trial requirements; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to perform in accordance with the FDA&#8217;s GCPs or those of other regulatory authorities; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure by physicians to adhere to delivery protocols leading to variable results; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical sites, including delays by third parties with whom we have contracted to perform certain of those functions; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure of our third-party contractors to comply with regulatory requirements or to meet their contractual obligations to us in a timely manner, or at all; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inability to recruit patients to participate in a clinical trial, including as a result of competition with other pharmaceutical and biotechnology companies and the patient population size for our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in having patients complete participation in a clinical trial or return for post-treatment follow-up; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical trial sites or patients dropping out of a trial;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">occurrence of serious adverse events associated with a product candidate in development by another company, which are viewed to outweigh its potential benefits, and which may negatively impact the perception of our product due to a similarity in technology or approach; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the legal or regulatory regimes domestically or internationally related to patient rights and privacy; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">lack of adequate funding to continue the clinical trial; or</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">lack of diminished revenue potential of the program(s) due to competition.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials must be conducted in accordance with the FDA and other applicable regulatory authorities&#8217; legal requirements, regulations or guidelines, and are subject to oversight by these governmental agencies and IRBs or ethics committees at the medical institutions where the clinical trials are conducted. We could encounter delays if a clinical trial is suspended or terminated by us, by the data safety monitoring board for such trial or by the FDA or any other regulatory authority, or if the IRBs of the institutions in which such trials are being conducted suspend or terminate the participation of their clinical investigators and sites subject to their review. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, disruptions caused by the effects of the COVID-19 pandemic, or any future pandemics, may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any inability to successfully complete preclinical studies and clinical trials could result in additional costs to us or impair our ability to generate revenues from product sales, regulatory and commercialization milestones and royalties. In addition, if we make</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing or formulation changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, conducting clinical trials in foreign countries, as we plan to continue to do for our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, if the results of clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our product candidates, we may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be delayed in obtaining marketing approval for product candidates, if at all; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain approval for indications or patient populations that are not as broad as intended or desired; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be subject to changes in the way the product is administered; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution in the form of a REMS; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be subject to the addition of labeling statements, such as warnings or contraindications; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">be sued; or </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">experience damage to our reputation. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In particular, each of the conditions for which we plan to develop product candidates are rare genetic diseases with limited patient pools from which to draw for clinical trials. Further, because it can be difficult to diagnose these diseases in the absence of a genetic screen, we may have difficulty finding patients who are eligible to participate in our studies. The eligibility criteria of our clinical trials will further limit the pool of available study participants. Additionally, the process of finding and diagnosing patients may prove costly. The treating physicians in our clinical trials may also use their medical discretion in advising patients enrolled in our clinical trials to withdraw from our studies or to try alternative therapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The outcome of preclinical studies and earlier-stage clinical trials may not be predictive of future results or the success of later preclinical studies and clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are in the early stages of our programs and have successfully completed a Phase 1 clinical trial in Canada for our lead product candidate, PGN-EDO51, and have initiated a Phase 1 clinical trial for our PGN-EDODM1 product candidate, but we have not completed IND- or CTA-enabling activities for our other product candidates or advanced any other product candidates into clinical development. As a result, our belief in the capabilities of our platform is based on early research, preclinical studies and our completed Phase 1 clinical trial in HVs. However, the results of preclinical studies may not be predictive of the results of later preclinical studies or clinical trials, and the results of any early-stage clinical trials may not be predictive of the results of later clinical trials. For example, we may not see the same levels of exon skipping, oligonucleotide delivery or dystrophin production in DMD patients as was observed in our preclinical studies or, with respect to exon skipping, in our Phase 1 HV study of PGN-EDO51. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Our clinical trials may not ultimately be successful or support further clinical development of our product candidates. There is a high failure rate for product candidates proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving encouraging results in earlier studies. Any such setbacks in our clinical development could materially harm our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, our planned clinical trials may utilize an &#8220;open-label&#8221; trial design. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our product candidates when studied in a controlled environment with a placebo or active control.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our ability to complete clinical trials may be adversely impacted.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics, to complete our clinical trials in a timely manner. Patient enrollment and trial completion is affected by factors including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">perceived risks and benefits of novel unproven approaches; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">size of the patient population, in particular for rare diseases such as the diseases on which we are initially focused, and process for identifying patients; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">design of the trial protocol; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">eligibility and exclusion criteria; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">perceived risks and benefits of the product candidate under study; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">availability of competing therapies and clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">severity of the disease or disorder under investigation; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">proximity and availability of clinical trial sites for prospective patients; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ability to obtain and maintain patient consent; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">risk that enrolled patients will drop out before completion of the trial; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ability to recruit clinical trial investigators of appropriate competencies and experience; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patient referral practices of physicians; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ability to monitor patients adequately during and after treatment; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">other factors outside of our control, such as the potential effects of the COVID-19 pandemic or a future pandemic or health crisis. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our inability to enroll a sufficient number of patients for clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in these clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing. Furthermore, we rely on and expect to continue to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and we will have limited influence over their performance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining patients in our clinical trials. Many of the patients who end up receiving placebo may perceive that they are not receiving the product candidate being tested, and they may decide to withdraw from our clinical trials to pursue other alternative therapies rather than continue the trial with the perception that they are receiving placebo. If we have difficulty enrolling or maintaining a sufficient number of patients to conduct our clinical trials, we may need to delay, limit or terminate clinical trials, any of which would harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interim, initial, &#8220;topline&#8221;, and preliminary data from our preclinical studies or clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may publicly disclose preliminary or topline data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. For example, in September 2022, we announced results from our Phase 1 clinical trial of PGN-EDO51. The topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">being materially different from the preliminary data we previously published. As a result, topline data and preliminary results should be viewed with caution until the final data are available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data could result in volatility in the price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If any of our product candidates cause undesirable side effects or have other unexpected adverse properties, such side effects or properties could delay or prevent the initiation or completion of clinical trials, regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we have only completed dosing up to 15 mg/kg in a Phase 1 clinical trial of PGN-EDO51, in which PGN-EDO51 was generally well-tolerated at clinically active doses, there can be no assurance that our product candidates will not cause undesirable side effects in patients. For example, in preclinical toxicology studies of PGN-EDO51 in normal NHPs, we observed transient, clinical signs of hypotension in some animals treated at a dose level higher than that which we intend to evaluate in the clinic. In addition, in our Phase 1 clinical trial of PGN-EDO51, at 15 mg/kg, we observed mild, transient, reversible changes in kidney biomarkers that resolved without intervention in all but one participant who experienced a non-life threatening serious adverse event. While the trial was not halted by the safety review committee nor put on hold by Health Canada, under the protocol for this Phase 1 clinical trial, any non-life-threatening SAE was considered a dose-limiting toxicity. This participant was admitted to the hospital for less than 24 hours, received intravenous hydration, and then was re-admitted to the Phase 1 unit and completed the study. We also observed transient mild to moderate hypomagnesemia in two participants in the Phase 1 trial, which did not require intervention.  Based on published data and other publicly available information, such adverse events are consistent with the types of events reported with this class of oligonucleotides in general.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although other oligonucleotide therapeutics have received regulatory approval, ours is a novel approach to oligonucleotide therapy. As a result, there is uncertainty as to the safety profile of our product candidates compared to more well-established classes of therapies, or oligonucleotide therapeutics on their own. Moreover, there have been only a limited number of clinical trials involving the use of peptide conjugated oligonucleotide therapeutics and only one completed trial involving the proprietary technology used in our EDO platform.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite the outcome of our Phase 1 clinical trial of PGN-EDO51, results of our Phase 2 clinical trials for PGN-EDO51 or any other product candidate could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics than previously anticipated. If any product candidates we develop are associated with serious adverse events, undesirable side effects or unexpected characteristics, we may need to abandon their development or limit development to certain uses or subpopulations in which the serious adverse events, undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, any of which would have a material adverse effect on our business, financial condition, results of operations and prospects. In addition, regulatory authorities may draw different conclusions, require additional testing to confirm these determinations, require more restrictive labeling or deny regulatory approval of the product candidate. Many product candidates that initially showed promise in early-stage testing have later been found to cause side effects that prevented further clinical development of the product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is possible that, as we test our product candidates in larger, longer and more extensive clinical trials, including with different dosing regimens, or as the use of our product candidates becomes more widespread following any regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition, results of operations and prospects significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, if our product candidates receive marketing approval, and we or others later identify undesirable side effects caused by treatment with such drug, a number of potentially significant negative consequences could result, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may suspend, limit or withdraw approvals of such product, or seek an injunction against its manufacture or distribution; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to recall a product or change the way the drug is administered to patients; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may require additional warnings in the labeling, such as a contraindication or a boxed warning, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to change the way the product is administered or conduct additional clinical trials or post-approval studies; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to implement a REMS, or create a medication guide outlining the risks of such side effects for distribution to patients; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additional restrictions may be imposed on the marketing or promotion of the particular product or the manufacturing processes for the product or any component thereof; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be subject to fines, injunctions or the imposition of criminal penalties; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we could be sued and held liable for harm caused to patients; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the drug could become less competitive; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our reputation may suffer. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of our lead product candidate or our other product candidates, if approved, and could significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may expend our limited resources to pursue a particular program, product candidate or indication and fail to capitalize on programs, product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because we have limited financial and managerial resources, we focus on research programs and expect to focus on product candidates that we identify for specific indications among many potential options. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential, or we may choose to focus our efforts and resources on a potential product candidate that ultimately proves to be unsuccessful. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable medicines. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Any such event could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The increasing use of social media platforms presents new risks and challenges.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Social media is increasingly being used to communicate about pharmaceutical companies&#8217; clinical development activities, and we intend to utilize appropriate social media in connection with our development efforts. Additionally, patients may use social media channels to comment on their experience in an ongoing blinded clinical trial or to report an alleged adverse event. If such disclosures occur in the future in connection with any of our sponsored clinical trials, there is a risk that trial enrollment may be adversely impacted, that we may fail to monitor and comply with applicable adverse event reporting obligations or that we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our product candidates. There is also a risk of inappropriate disclosure of sensitive or confidential information or negative or inaccurate posts or comments about us on any social networking website. In addition, we may encounter attacks on social media regarding our company, management or our product candidates, and fraudsters could and have attempted to illegally use our name on social media platforms to defraud the public. If any of these events were to occur or we fail to comply with applicable regulations, we could incur liability, face regulatory actions or incur other harm to our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical trial and product liability lawsuits against us could divert our resources, could cause us to incur substantial liabilities and could limit commercialization of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will face an inherent risk of clinical trial and product liability exposure related to the testing of product candidates that proceed to clinical trials, and we will face an even greater risk if we commercially sell any products that receive marketing approval. While we currently have only two product candidates in clinical development and none that have been approved for commercial sale, the future use of product candidates by us in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies or others selling such products. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we may incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decreased demand for our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injury to our reputation and significant negative media attention; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of clinical trial participants; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">significant costs to defend any related litigation; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial monetary awards to trial participants or patients; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">loss of revenue; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduced resources of our management to pursue our business strategy; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to commercialize our product candidates. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have insurance coverage in place that we believe to be appropriate for our current phase of clinical development, but we may need to further increase this coverage for subsequent clinical trials, or if we commence commercialization of any product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If a successful clinical trial or product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We intend to conduct certain clinical trials for our product candidates outside of the U.S. However, the FDA and comparable foreign regulatory authorities may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our first clinical trial in Canada, and we intend to conduct one or more of our subsequent clinical trials for our product candidates outside the U.S., including our ongoing CONNECT1 trial in Canada, and our CONNECT2 trial and FREEDOM clinical trial, both of which will have sites in multiple countries outside of the U.S. Although the FDA may accept data from clinical trials conducted outside the U.S., acceptance of this data is subject to certain conditions imposed by the FDA. Where data from foreign clinical trials are intended to serve as the basis for marketing approval in the U.S., the FDA will not approve the application on the basis of foreign data alone unless those data are applicable to the U.S. population and U.S. medical practice; the studies were performed by clinical investigators of recognized competence; and the data are considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. For studies that are conducted only at sites outside of the U.S. and not subject to an IND, the FDA generally does not provide advance comment on the clinical protocols for the studies, and therefore there is an additional potential risk that the FDA could determine that the study design or protocol for a non-U.S. clinical trial was inadequate, which could require us to conduct additional clinical trials. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCP and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign regulatory authorities have similar approval requirements. There can be no assurance the FDA will accept data from clinical trials conducted outside of the U.S. If the FDA does not accept data from our clinical trials of our product candidates, it would likely result in the need for additional clinical trials, which would be costly and time consuming and delay or permanently halt our development of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Conducting clinical trials outside the U.S. also exposes us to additional risks, including risks associated with:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additional foreign regulatory requirements; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign exchange fluctuations; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with foreign manufacturing, customs, shipment and storage requirements; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cultural differences in medical practice and clinical research; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">diminished protection of intellectual property in some countries. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely, and expect to continue to rely, on third parties to conduct some or all aspects of our product manufacturing, research and preclinical and clinical testing, and these third parties may not perform satisfactorily.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not expect to independently conduct all aspects of our product manufacturing, research and preclinical and clinical testing. We currently rely, and expect to continue to rely, on third parties with respect to many of these items, including contract development manufacturing organizations, or CDMOs, for the manufacturing of any product candidates we test in preclinical or clinical development, as well as CROs for the conduct of our animal testing and research for the conduct of our current and planned clinical trials. Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it could delay our product development activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibility to ensure compliance with all required regulations and study protocols. For example, we will remain responsible for ensuring that each of our IND- and CTA-enabling studies and clinical trials are conducted in accordance with the study plan and protocols. Moreover, the FDA requires us to comply with GCPs for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. If we or any of our CROs or other third parties, including trial sites, fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under conditions that comply with the FDA&#8217;s current Good Manufacturing Practices, or cGMPs. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we intend to design the preclinical studies and clinical trials for our product candidates, CROs will conduct some or all of the preclinical studies and clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, will be outside of our direct control. Our reliance on third parties to conduct future preclinical studies and clinical trials will also result in less direct control over the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">have staffing difficulties; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fail to comply with contractual obligations; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">experience regulatory compliance issues; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">undergo changes in priorities or become financially distressed; or </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">form relationships with other entities, some of which may be our competitors. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These factors may materially adversely affect the willingness or ability of third parties to conduct our preclinical studies and clinical trials and may subject us to unexpected cost increases that are beyond our control. In addition, any third parties conducting our clinical trials will not be our employees, and except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our clinical programs. If the CROs and other third parties do not perform preclinical studies and clinical trials in a satisfactory manner, if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, or if they breach their obligations to us or fail to comply with regulatory requirements, the development, regulatory approval and commercialization of our product candidates may be delayed, we may not be able to obtain regulatory approval and commercialize our product candidates or our development programs may be materially and irreversibly harmed. If we are unable to rely on preclinical and clinical data collected by our CROs and other third parties, we could be required to repeat, extend the duration of or increase the size of any preclinical studies or clinical trials we conduct and this could significantly delay commercialization and require greater expenditures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, we will not be able to complete, or may be delayed in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">completing, the preclinical studies and clinical trials required to support future IND, CTA and other similar regulatory filings and potential approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, there are few CDMOs who have the capability to both, on the one hand, manufacture oligonucleotides and peptides, and, on the other hand, conjugate them, both of which processes are critical to the development and production of our product candidates. We are aware that one or more competitors have engaged many of these CDMOs, which may hinder our ability to also contract with those CDMOs. As a result, we may have difficulty finding and engaging sufficient third-party manufacturers to develop and manufacture our product candidates, which may affect our ability to conduct preclinical studies and clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We currently depend on a small number of third-party suppliers to supply the product candidates that we are evaluating in our research programs. The loss of these or future third-party suppliers, or their inability to provide us with sufficient supply, could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not own or operate manufacturing facilities and have no current plans to develop our own clinical or commercial-scale manufacturing capabilities. We rely on a small number of third-party suppliers for the manufacture of the product candidates that we are evaluating in our research programs. We expect to continue to depend on third-party suppliers for the manufacture of any product candidates we advance into preclinical and clinical development, as well as for commercial manufacture if those product candidates receive marketing approval. The facilities used by third-party manufacturers to manufacture our product candidates must be approved by the FDA, the EMA and any comparable foreign regulatory authority pursuant to inspections that will be conducted after we submit an NDA, to the FDA or any comparable filing to the EMA or other foreign regulatory authority. We do not control the manufacturing process of, and are completely dependent on, third-party manufacturers for compliance with cGMP requirements for the manufacture of products. If these third-party manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, the EMA or any comparable foreign regulatory authority, we may incur delays in our clinical trials or regulatory submissions and they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we have no control over the ability of third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA, the EMA or any comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also seek to eventually establish our own manufacturing facility for the long-term commercial supply of our product candidates for which receive regulatory approval, if any. If we determine to establish our own manufacturing facility and manufacture our products on our own, we will need to obtain the resources and expertise in order to build such manufacturing capabilities and to conduct such manufacturing operations. In addition, our conduct of such manufacturing operations will be subject to the extensive regulations and operational risks to which our third-party suppliers are subject. If we are not successful in building these capabilities or complying with the regulations or otherwise operating our manufacturing function, our commercial supply could be disrupted and our business could be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our or a third party&#8217;s failure to execute on our manufacturing requirements on commercially reasonable terms and in compliance with cGMP could adversely affect our business in a number of ways, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an inability to initiate or conduct preclinical studies or clinical trials of product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in initiating or completing preclinical studies or clinical trials of product candidates or in submitting regulatory applications, or receiving marketing approvals, for product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requirements to cease development or to recall batches of product candidates; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in the event of approval to market and commercialize any product, an inability to meet commercial demands for the product. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are party to manufacturing agreements with a number of third-party manufacturers. We may be unable to maintain these agreements or establish any additional agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to maintain or establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">breach of the manufacturing agreement by the third party; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to manufacture according to our specifications; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to manufacture according to our schedule or at all; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">misappropriation of our proprietary information, including our trade secrets and know-how; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may compete with third parties for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not currently have arrangements in place for redundant supply or a second source for all required raw materials. If our existing or future third-party manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them on a timely basis or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, if supply from one approved manufacturer is interrupted, there could be a significant disruption in supply. An alternative manufacturer would need to be qualified and authorized pursuant to a submission to our approved NDA or NDA supplement which could result in further delay. Further, we will also need to verify, such as through comparability or bridging studies, that any new or modified manufacturing processes will produce our product candidate according to the specifications previously submitted to the FDA, the EMA or comparable foreign regulatory authorities. The delays associated with the verification of a new third-party manufacturer could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. Furthermore, a third-party manufacturer may possess technology related to the manufacture of our product candidate that such third-party manufacturer owns independently. This would increase our reliance on such third-party manufacturer or require us to obtain a license from such third-party manufacturer in order to have another third-party manufacturer manufacture our product candidates. We may be unsuccessful in demonstrating the comparability of clinical supplies to those previously allowed into clinical development by the FDA, the EMA or comparable foreign regulatory authorities which could require the conduct of additional studies or clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. These factors could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our product candidates, cause us to incur higher costs and prevent us from commercializing our products successfully. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed or we could lose potential revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current and anticipated future dependence upon third parties for the manufacture of any product candidates we develop may adversely affect our development programs and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may from time to time be dependent on single-source suppliers for some of the components and materials used in our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we currently do not use any single-source supplier, we may from time to time depend on such suppliers for some of the components and materials used in our product candidates. We cannot ensure that these suppliers or service providers will remain in business, have sufficient capacity or supply to meet our needs or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our use of single-source suppliers of raw materials, components, key processes and finished goods could expose us to several risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components, materials and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single-source supplier or service provider could lead to supply delays or interruptions which would damage our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are required to switch to a replacement supplier, the manufacture and delivery of our product candidates could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers, if required, may not be accomplished quickly. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. In the event that we should depend on single-source suppliers, we would seek to maintain adequate inventory of the single source components and materials used</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in our products; however, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand for our investigational medicines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may enter into collaborations with third parties for the research, development and commercialization of certain of our product candidates. If any such collaborations are not successful, we may not be able to capitalize on the market potential of those product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may seek third-party collaborators for the research, development and commercialization of certain of our product candidates. If we enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of any product candidates we may seek to develop with them. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. We cannot predict the success of any collaboration that we enter into.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaborations involving our research programs or our product candidates pose numerous risks to us, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators would have significant discretion in determining the efforts and resources that they will apply to these collaborations; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may delay programs, preclinical studies or clinical trials, provide insufficient funding for programs, preclinical studies or clinical trials, stop a preclinical study or clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may be acquired by a third party having competitive products or different priorities, causing the emphasis on our product development or commercialization program under such collaboration to be delayed, diminished or terminated; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not properly obtain, maintain, enforce or defend our intellectual property or proprietary rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development, or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may lose certain valuable rights under certain circumstances, including if we undergo a change of control; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the affected product candidates; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our collaborations do not result in the successful development and commercialization of product candidates, or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of product candidates could be delayed, and we may need additional resources to develop product candidates. In addition, if one of our collaborators terminates its agreement with us, we may find it more difficult to find a suitable replacement collaborator or attract new collaborators, and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. All of the risks relating to product development, regulatory approval and commercialization described in this 10-K apply to the activities of our collaborators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These relationships, or those like them, may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. In addition, we could</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">face significant competition in seeking appropriate collaborators, and the negotiation process is time-consuming and complex. Our ability to reach a definitive collaboration agreement will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of several factors. If we license rights to any product candidates we or our collaborators may develop, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If conflicts arise between us and our potential collaborators, these parties may act in a manner adverse to us and could limit our ability to implement our strategies.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If conflicts arise between us and our potential collaborators, the other party may act in a manner adverse to us and could limit our ability to implement our strategies. Our collaborators may develop, either alone or with others, products in related fields that are competitive with our product candidates that are the subject of these collaborations with us. Competing products, either developed by the collaborators or to which the collaborators have rights, may result in the withdrawal of support for our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some of our future collaborators could also become our competitors. Our collaborators could develop competing products, preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, terminate their agreements with us prematurely, fail to devote sufficient resources to the development and commercialization of products, or merge with or be acquired by a third party who may do any of these things. Any of these developments could harm our product development efforts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product development and research programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. For some of our product candidates, we may decide to collaborate with other pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA, the EMA or comparable foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization, reduce the scope of any sales or marketing activities, or increase our own expenditures on the development of the product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are dependent on third-party vendors to provide certain licenses, products and services and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We engage a number of third-party suppliers and service providers to supply critical goods and services, such as contract research services, contract manufacturing services and IT services. Disruptions to the business, financial stability or operations of these suppliers and service providers, including due to strikes, labor disputes or other disruptions to the workforce, for instance, if, as a result of the COVID-19 pandemic or a similar pandemic or health epidemic, employees are not able to come to work, or to their willingness and ability to produce or deliver such products or provide such services in a manner that satisfies the requirements put forth by the authorities, or in a manner that satisfies our own requirements, could affect our ability to develop and market our future product candidates on a timely basis. If these suppliers and service providers were unable or unwilling to continue to provide their products or services in the manner expected, or at all, we could encounter difficulty finding alternative suppliers. Even if we are able to secure appropriate alternative suppliers in a timely manner, costs for such products or services could increase significantly. Any of these events could adversely affect our results of operations and our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Regulatory Approval and Other Regulatory and Legal Compliance Matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our lead product candidates are in clinical development, while all of our other product candidates are still in preclinical development. As an organization, we have only completed one clinical trial and initiated one other Phase 1 clinical trial and two Phase 2 clinical trials and may be unable to do so for any of our other product candidates nor carry out or complete further studies for our lead candidate.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we are currently in clinical development for two product candidates, we have no experience as a company in conducting, completing and managing the full suite of clinical trials necessary to obtain regulatory approvals, including approval by the FDA, the EMA or comparable foreign regulatory authorities, or in obtaining approval of any of our product candidates. We are early in our development efforts for our product candidates, and we have successfully completed a Phase 1 clinical trial and initiated Phase 2 trials for our lead product candidate, PGN-EDO51, and initiated a Phase 1 clinical trial for our second product candidate, PGN-EDODM1. We will need to successfully complete IND- or CTA-enabling activities, early-stage, later-stage and pivotal clinical trials, in order to obtain FDA, EMA or comparable foreign regulatory approval to market PGN-EDO51, PGN-EDODM1, and, if advanced, PGN-EDO53, PGN-EDO45, PGN-EDO44 and any future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Carrying out clinical trials and the submission of a successful NDA is a complicated process. We completed our first Phase 1 clinical trial for PGN-EDO51 in the third quarter of 2022, and we began dosing patients in CONNECT1 in Canada in January 2024. We received clearance from the MHRA to initiate CONNECT2 in the U.K. in February 2024 in boys and young men living with DMD.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the observed high levels of oligonucleotide delivery and exon skipping in muscle in our Phase 1 trial of PGN-EDO51, we believe that these results could signal the potential for the accumulation of exon 51 skipped transcript and dystrophin protein in muscle tissue with repeated doses of PGN-EDO51 in DMD patients. However, our belief based on the Phase 1 clinical trial with HVs may be erroneous. There can be no assurance that our expectations of higher exon skipping and dystrophin production will be reflected in clinical evaluation of PGN-EDO51 in DMD patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we completed a Phase 1 clinical trial for our lead product candidate, we have not completed any additional clinical trials, have limited experience as a company in preparing, submitting and prosecuting regulatory filings. In addition, we have had limited interactions with the FDA, the EMA and comparable foreign regulatory authorities and cannot be certain how many clinical trials of PGN-EDO51, PGN-EDODM1, PGN-EDO53, PGN-EDO45, PGN-EDO44 or any other product candidates will be required or how such trials should be designed. For example, the FDA has approved at least four drugs based on their minimal dystrophin production, and it is our belief that we may be able to pursue an accelerated approval pathway for PGN-EDO51 on that same basis. The FDA has provided feedback on our clinical trials for PGN-EDO51, and we are addressing their feedback in our clinical trial designs to support the potential for accelerated approval. We may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to regulatory submission and approval of any of our product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our current or planned clinical trials, could prevent us from or delay us in submitting NDAs for and commercializing our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of our product candidates. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other regulatory authorities in the U.S., the EMA and comparable authorities in other countries. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate in a given jurisdiction. We have not received approval to market any product candidates from regulatory authorities in any jurisdiction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have no experience as a company in submitting and supporting the applications necessary to gain marketing approvals and may need to rely on third parties to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and effectiveness. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities, or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The process of obtaining marketing approvals, both in the U.S. and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Of the large number of products in development, only a small percentage successfully complete the FDA, EMA or foreign regulatory approval processes and are commercialized. Even if our product candidates demonstrate safety and efficacy in clinical trials, the regulatory agencies may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. The FDA, the EMA and comparable foreign regulatory authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for those product candidates may be harmed, and our ability to generate revenues will be materially impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA also has substantial discretion in the approval process. The number and types of preclinical studies and clinical trials that will be required for NDA approval varies depending on the product candidate, the disease or the condition that the product candidate is designed to treat and the regulations applicable to any particular product candidate. Despite the time and expense associated with preclinical studies and clinical trials, failure can occur at any stage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trial failure may result from a multitude of factors including flaws in trial design, dose selection, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits, and failure in clinical trials can occur at any stage. Companies in the drug development industry frequently suffer setbacks in the advancement of clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Based upon negative or inconclusive results, we may decide, or regulators may require us, to conduct additional clinical trials or preclinical studies. In addition, data obtained from clinical trials is susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may further delay, limit or prevent marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA or any foreign regulatory authority could delay, limit or deny approval of a product candidate for many reasons, including because the FDA or such other regulatory authority:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">may disagree with the design or implementation of our trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">may not deem a product candidate to be safe or effective for its intended uses; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">determines that the product candidate does not have an acceptable benefit-risk profile; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">may not agree that the data collected from preclinical studies and clinical trials are acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval, and may impose requirements for additional preclinical studies or clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">may determine that adverse events experienced by participants in our clinical trials represent an unacceptable level of risk; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">may determine that the population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population for which we seek approval; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">may not accept clinical data from trials that are conducted at clinical facilities or in countries where the standard of care is potentially different from that of the U.S.; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">may disagree regarding the formulation, labeling and/or specifications; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">may not approve the manufacturing processes associated with a product candidate or may determine that a manufacturing facility does not have an acceptable compliance status; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">may change approval policies or adopt new regulations; or </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">may not file a submission due to, among other reasons, the content or formatting of the submission. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we eventually complete clinical testing and receive approval of an NDA or foreign marketing application for any product candidates, the FDA, EMA or applicable foreign regulatory authority may grant approval or other marketing authorization contingent on the performance of costly additional clinical trials, including post-market clinical trials. For example, we expect that the FDA will require a post-marketing confirmatory trial of PGN-EDO51, if it is approved under the accelerated approval regulations requiring applicants to demonstrate clinical benefit in post-approval studies. The FDA, EMA or the applicable foreign regulatory authority also may approve or authorize for marketing a product candidate for a more limited indication or patient population that we originally request, and the FDA, EMA or applicable foreign regulatory authority may not approve or authorize the labeling that we</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">believe is necessary or desirable for the successful commercialization of a product candidate. Any of these restrictions or commitments could render an approved product not commercially viable, which would materially adversely impact our business and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining marketing approval or commercialization of our product candidates in the U.S. does not mean that we will be successful in obtaining marketing approval of our product candidates in other jurisdictions. Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed in such jurisdictions, which, in turn, would materially impair our ability to generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to market and sell our product candidates in the EU and many other foreign jurisdictions, we or our collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the U.S. generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the U.S., it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We or these third parties may not obtain approvals from regulatory authorities outside the U.S. on a timely basis, if at all. Approval by the FDA does not ensure approval by the EMA or regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the U.S. does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. Furthermore, since the withdrawal of the U.K. from the EU, a separate authorization is needed to market medicinal products in Great Britain. We may not be able to file for marketing approvals and may not receive the necessary approvals to commercialize our medicines in any jurisdiction, which would materially impair our ability to generate revenue.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any delay in obtaining, or an inability to obtain, any marketing approvals would prevent us from commercializing any product candidates in the U.K. and/or the EU and/or other foreign jurisdictions and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the U.K. and/or the EU and/or other foreign jurisdictions for our product candidates, which could significantly and materially harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may attempt to seek approval from the FDA or comparable foreign regulatory authorities, where applicable, under the accelerated approval pathways. We may fail to obtain approval under such accelerated approval pathways. Moreover, these pathways may not lead to a faster development, regulatory review or approval process and do not increase the likelihood that our product candidates will receive marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may in the future seek accelerated approval, where applicable, under the FDA&#8217;s accelerated approval pathway. A product may be eligible for accelerated approval if it treats a serious or life-threatening condition, generally provides a meaningful advantage over available therapies, and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of accelerated approval, the FDA likely would require that we perform adequate and well-controlled post-marketing clinical trials to confirm the product&#8217;s clinical benefit. These confirmatory trials must be completed with due diligence. Under FDORA, the FDA is permitted to require, as appropriate, that a post-approval confirmatory study or studies be underway prior to approval or within a specified time period after the date of accelerated approval was granted. FDORA also requires sponsors to send updates to the FDA every 180 days on the status of such studies, including progress toward enrollment targets, and the FDA must promptly post this information publicly. FDORA also gives the FDA increased authority to withdraw approval of a drug or biologic granted accelerated approval on an expedited basis if the sponsor fails to conduct such studies in a timely manner, send the necessary updates to the FDA, or if such post-approval studies fail to verify the drug&#8217;s predicted clinical benefit. Under FDORA, the FDA is empowered to take action, such as issuing fines, against companies that fail to conduct with due diligence any post-approval confirmatory study or submit timely reports to the agency on their progress. If we receive positive results from our Phase 2 trials for PGN-EDO51 that show an acceptable safety and tolerability profile; a clinically meaningful increase in dystrophin levels, a surrogate endpoint, in the biceps of DMD patients; and robust exon skipping levels in the same tissue, we intend to pursue this accelerated approval pathway subject to discussions with the FDA. However, our Phase 2 clinical trial may fail to produce such data, and we may be unable to pursue the accelerated approval pathway as planned. In addition, the FDA currently requires, unless otherwise informed by the agency, pre-approval of promotional materials for products receiving accelerated approval, which could adversely impact the timing of the commercial launch of the product. Thus, even if we seek to utilize the accelerated approval pathway, we may not be able to obtain accelerated approval and, even if we do, we may not experience a faster development, regulatory review or approval process for that product. In addition, receiving accelerated approval does not assure that the product&#8217;s accelerated approval will eventually be converted to a full approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, under the centralized procedure, the EMA&#8217;s Committee for Medicinal Products for Human Use may perform an accelerated assessment of a marketing authorization application. Applicants requesting an accelerated assessment procedure must justify that the product candidate is expected to be of major public health interest, particularly from the point of view of therapeutic</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">innovation. Prior to seeking accelerated approval for any of our product candidates, we intend to seek feedback from the FDA or similar foreign regulatory authorities and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit an NDA or similar application for accelerated approval or any other form of expedited development or review. Similarly, there can be no assurance that after subsequent FDA or similar foreign regulatory authorities feedback we will continue to pursue or apply for accelerated approval or any other form of expedited development or review, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or other expedited development or review for our product candidates, there can be no assurance that such submission or application will be accepted or that any expedited development or review will be granted on a timely basis, or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development or review for our product candidate would result in a longer time period to commercialization of such product candidate, if any, could increase the cost of development of such product candidate, and could harm our competitive position in the marketplace.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may seek one or more designations or expedited programs for one or more of our product candidates, but we might not receive such designations or be allowed to proceed on expedited program pathways, and even if we do and proceed on such expedited program pathways in the future, such designations or expedited programs may not lead to a faster development or regulatory review or approval process, and each designation does not increase the likelihood that any of our product candidates will receive marketing approval in the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have received fast track designation for PGN-EDODM1 for the treatment of DM1 and may seek fast track designation for some of our other product candidates. If a drug is intended for the treatment of a serious or life-threatening condition and nonclinical or clinical data for the drug demonstrates the potential to address an unmet medical need for such a condition, the drug sponsor may apply for fast track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it for any of our other product candidates. Even with fast track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may seek a breakthrough therapy designation for some of our product candidates. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that such product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the FDA determines that a product candidate offers a treatment for a serious condition and, if approved, the product would provide a significant improvement in safety or effectiveness, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months. We may request priority review for our product candidates. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily result in an expedited regulatory review or approval process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may pursue orphan drug designation for certain of our product candidates, and we may not be able to obtain such designation, or obtain or maintain the benefits of such designation including orphan drug exclusivity, and even if we do, that exclusivity may not prevent regulatory authorities from approving other competing products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, the FDA granted Orphan Drug Designation to PGN-EDODM1 for the treatment of DM1. We intend to seek orphan drug designation for some of our product candidates; however, we may never receive such designations. Under the Orphan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Drug Act, the FDA may designate a product as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the U.S., or a patient population greater than 200,000 in the U.S. where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the U.S. Orphan drug designation must be requested before submitting an NDA. A similar regulatory scheme governs orphan products in the EU.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and application fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. In addition, if a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same product for the same therapeutic indication for seven years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different products can be approved for the same condition. In addition, even after an orphan drug is approved, the FDA can subsequently approve the same product for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity may also be lost if the FDA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of the patients with the rare disease or condition. Further, even if we obtain orphan drug designation, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may seek designation for our EDO platform as a designated platform technology, but we might not receive such designation, and even if we do, such designation may not lead to a faster regulatory review or approval process.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may seek designation for our EDO platform as a designated platform technology. Under FDORA, a platform technology incorporated within or utilized by a drug or biological product is eligible for designation as a designated platform technology if (1) the platform technology is incorporated in, or utilized by, a drug approved under an NDA; (2) preliminary evidence submitted by the sponsor of the approved or licensed drug, or a sponsor that has been granted a right of reference to data submitted in the application for such drug, demonstrates that the platform technology has the potential to be incorporated in, or utilized by, more than one drug without an adverse effect on quality, manufacturing, or safety; and (3) data or information submitted by the applicable person indicates that incorporation or utilization of the platform technology has a reasonable likelihood to bring significant efficiencies to the drug development or manufacturing process and to the review process. A sponsor may request the FDA to designate a platform technology as a designated platform technology concurrently with, or at any time after, submission of an IND application for a drug that incorporates or utilizes the platform technology that is the subject of the request. If so designated, the FDA may expedite the development and review of any subsequent original NDA for a drug that uses or incorporates the platform technology. Even if we believe our EDO platform meets the criteria for such designation, the FDA may disagree and instead determine not to grant such designation. In addition, the receipt of such designation for a platform technology does not ensure that a drug will be developed more quickly or receive FDA approval. Moreover, the FDA may revoke a designation if the FDA determines that a designated platform technology no longer meets the criteria for such designation.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to post-market study requirements, marketing and labeling restrictions, and even recall or market withdrawal if unanticipated safety issues are discovered following approval. In addition, we may be subject to penalties or other enforcement action if we fail to comply with regulatory requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA, the EMA or a comparable foreign regulatory authority may not approve any of our product candidates derived from our platform. However, if the FDA, EMA or comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, conformance with applicable product tracking and tracing requirements, establishment registration and listing, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing studies, and surveillance to monitor the safety and efficacy of the product. Additionally, under FDORA, sponsors of approved drugs and biologics must provide six months&#8217; notice to the FDA of any changes in marketing status, such as the withdrawal</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of a drug, and failure to do so could result in the FDA placing the product on a list of discontinued products, which would revoke the product&#8217;s ability to be marketed. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fines, warning letters or other regulatory enforcement action; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal by the FDA, the EMA or comparable foreign regulatory authorities to approve pending applications or supplements to approved applications filed by us; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the FDA&#8217;s, EMA&#8217;s and other foreign regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any product candidate for which we obtain marketing approval will be subject to restrictions, such as the laws and regulations prohibiting the promotion of off-label uses, or may need to be withdrawn from the market, and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our medicines, when and if any of them are approved.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA, EMA and other foreign regulatory authorities closely regulate the post-approval marketing and promotion of medicines to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA, EMA and other foreign regulatory authorities impose stringent restrictions on manufacturers&#8217; communications regarding off-label use. In particular, a product may not be promoted for uses that are not approved by the FDA, EMA and other foreign regulatory authorities as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may be subject to enforcement action for off-label marketing by the FDA and other federal and state enforcement agencies, including the Department of Justice. Violation of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription products may also lead to investigations or allegations of violations of federal and state healthcare fraud and abuse laws and state consumer protection laws. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The government has also required companies to enter into consent decrees and/or imposed permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, later discovery of previously unknown problems with our medicines, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on such medicines, manufacturers or manufacturing processes; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the labeling or marketing of a medicine; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the distribution or use of a medicine; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requirements to conduct post-marketing clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">receipt of warning or untitled letters; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of the medicines from the market; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal to approve pending applications or supplements to approved applications that we submit; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recall of medicines; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fines, restitution or disgorgement of profits or revenue; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspension or withdrawal of marketing approvals; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspension of any ongoing clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal to permit the import or export of our medicines; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizure; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize any product candidates we develop and adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, if any of our product candidates receive marketing approval, the FDA could require us to adopt a REMS to ensure that the benefits outweigh its risks, which may include, among other things, a medication guide outlining the risks of the product for distribution to patients and a communication plan to healthcare practitioners. Furthermore, if we or others later identify undesirable side effects caused by our product candidate, several potentially significant negative consequences could result, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may suspend or withdraw approvals of such product candidate; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may require additional warnings on the label; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to change the way a product candidate is administered or conduct additional clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we could be sued and held liable for harm caused to patients; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our reputation may suffer. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We and our contract manufacturers are subject to significant regulation. The manufacturing facilities on which we rely may not continue to meet regulatory requirements, which could materially harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All entities involved in the preparation of product candidates for clinical trials or commercial sale, including any contract manufacturers, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMP regulations. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturer must supply all necessary documentation in support of an NDA on a timely basis and must adhere to the FDA&#8217;s cGMP regulations enforced through its facilities inspection program. Our facilities and quality systems and the facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or our other potential products or the associated quality systems for compliance with the regulations applicable to the activities being conducted. If these facilities do not pass a pre-approval plant inspection, FDA approval of the products will not be granted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The regulatory authorities also may, at any time following approval of a product for sale, audit any of our future manufacturing facilities or those of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new product, or revocation of a pre-existing approval. Any such consequence would severely harm our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur significant costs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We and any contract manufacturers and suppliers we engage are subject to numerous federal, state and local environmental, health, and safety laws, regulations and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs relating to any contamination at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research and product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws, regulations and permitting requirements. These current or future laws, regulations and permitting requirements may impair our research, development or production efforts. Failure to comply with these laws, regulations and permitting requirements also may result in substantial fines, penalties or other sanctions or business disruption. Any third-party contract manufacturers and suppliers we engage will also be subject to these and other environmental, health and safety laws and regulations. Liabilities they incur pursuant to these laws and regulations could result in significant costs or an interruption in operations, which could in turn have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Shutdowns or disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the COVID-19 public health emergency, a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our relationships with healthcare providers, physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthcare providers, physicians and third-party payors play a primary role in the recommendation and prescription of any product candidates that we develop for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research, market, sell and distribute our medicines for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include, without</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">74</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limitation, the federal Anti-Kickback Statute, the federal civil and criminal False Claims Act and Physician Payments Sunshine Act and regulations. For more information, see &#8220;Business &#8211; Healthcare Regulation &#8211; Other Healthcare Laws&#8221; in this 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we are subject to state and foreign equivalents of each of these healthcare laws and regulations, among others, some of which may be broader in scope and may apply regardless of the payor. Many U.S. states have adopted laws similar to the federal Anti-Kickback Statute and False Claims Act, and may apply to our business practices, including, but not limited to, research, distribution, sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental payors, including private insurers. In addition, some states have passed laws that require pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers of America&#8217;s Code on Interactions with Healthcare Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state and require the registration of pharmaceutical sales representatives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the EU. The provision of benefits or advantages to induce or reward improper performance generally is typically governed by the national anti-bribery laws of European Union Member States, and the Bribery Act 2010 in the U.K. Infringement of these laws could result in substantial fines and imprisonment. EU Directive 2001/83/EC, which is the EU Directive governing medicinal products for human use, further provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to such persons unless they are inexpensive and relevant to the practice of medicine or pharmacy. This provision has been transposed into the Human Medicines Regulations 2012 and so remains applicable in the U.K. despite its departure from the EU.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The scope and enforcement of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. We have entered into consulting and scientific advisory board arrangements with physicians and other healthcare providers, including some who could influence the use of our product candidates, if approved. Compensation under some of these arrangements includes the provision of stock or stock options in addition to cash consideration. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs, reputational harm, and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Further, defending against any such actions can be costly and time consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and individual imprisonment. If any of the above occur, our ability to operate our business and our results of operations could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare legislative reform discourse and potential or enacted measures may increase the difficulty and cost for us and any future collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Payors, whether domestic or foreign, or governmental or private, are developing increasingly sophisticated methods of controlling healthcare costs and those methods are not always specifically adapted for new technologies such as gene therapy and therapies addressing rare diseases such as those we are developing. In both the U.S. and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our products profitably. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and in additional downward pressure on the price that we, or any collaborators, may receive for any approved products. For more information, see &#8220;Business &#8211; Healthcare Regulation &#8211; Healthcare Reform and Legislative Updates&#8221; in this 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">75</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the demand for our product candidates, if we obtain regulatory approval; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to set a price that we believe is fair for our products, if licensed; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to generate revenue and achieve or maintain profitability; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the level of taxes that we are required to pay; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of capital.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that other healthcare reform measures may be adopted in the future, which may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement, and new payment methodologies. This could lower the price that we receive for our products. Any denial in coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payors, which may prevent us from being able to generate sufficient revenue, attain profitability or commercialize our products. It is not clear how other future potential changes to the ACA will change the reimbursement model and market outlook for our current and future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees, consultants and partners, and in our clinical trials, our principal investigators. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the EU and other jurisdictions, provide accurate information to the FDA, the European Commission and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the U.S. and abroad, report financial information or data accurately, or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA, the European Commission and other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations and prospects, including the imposition of significant fines or other sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain product candidates outside of the U.S. and require us to develop and implement costly compliance programs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to numerous laws and regulations in each jurisdiction outside the United States in which we operate. The creation, implementation and maintenance of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Foreign Corrupt Practices Act (FCPA) prohibits any U.S. individual or business from paying, offering, or authorizing the provision of money or anything of value, directly or indirectly through parties, to any foreign official, official of a public international organization, or political party official or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the U.S. to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the Department of Justice. The SEC is involved with enforcement of the books and records provisions of the FCPA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compliance with the FCPA and other anti-corruption laws potentially applicable to our business is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, compliance with the FCPA and other anti-corruption laws presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Various U.S. export and sanctions laws, regulations and executive orders also restrict the use and dissemination outside of the U.S., or the sharing with certain non-U.S. nationals, of certain products and technical data relating to those products. Furthermore, such export and sanctions laws include restrictions or prohibitions on the sale or supply of certain products and services to U.S. embargoed countries or sanctioned countries, governments, persons and entities. Our expansion outside of the U.S. has required, and will continue to require, us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing or selling certain drugs and drug candidates outside of the U.S., which could limit our growth potential and increase our development costs. The failure to comply with laws governing international business practices may result in substantial penalties, including suspension or debarment from government contracting. Violation of the FCPA and export and sanctions laws can result in significant civil and criminal penalties, imprisonment, the loss of export or import privileges, debarment, breach of contract and fraud litigation, reputational harm, and other consequences. Indictment alone under the FCPA can lead to suspension of the right to do business with the U.S. government until the pending claims are resolved. Conviction of a violation of the FCPA can result in long-term disqualification as a government contractor. The termination of a government contract or relationship as a result of our failure to satisfy any of our obligations under laws governing international business practices would have a negative impact on our operations and harm our reputation and ability to procure government contracts. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to stringent data protection, privacy, and security laws, regulations, standards and contractual obligations and actual or perceived failure to comply with such requirements could have a material adverse effect on our business, financial condition, results of operations or prospects.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to data privacy and protection laws, regulations, policies, standards and contractual obligations that impose certain requirements relating to the collection, transmission, storage and use of personal information. The legislative and regulatory landscape for data privacy and protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues. Actual or perceived failure to comply with laws and regulations governing personal information could result in government investigations and enforcement actions against us, fines, claims for damages by affected third parties, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of personal information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which we must comply. For example, the collection, use, disclosure, transfer or other processing of personal data, including personal health data, of individuals in the European Economic Area, or EEA, is subject to the EU General Data Protection Regulation, or EU GDPR, as well as national data protection laws in effect in the member states of the EEA, and similar processing of personal data regarding individuals in the U.K. is governed by the U.K. General Data Protection Regulation, or U.K. GDPR and the U.K. Data Protection Act 2018. In this document, &#8220;GDPR&#8221; refers to both the EU GDPR and the U.K. GDPR, unless specified otherwise. The U.K. GDPR is currently largely in line with the EU GDPR, but the data protection regimes may diverge more in the future. The GDPR imposes stringent requirements on companies that process personal data, including requirements relating to processing health-related and other sensitive data, obtaining consent of the individuals to whom the personal data relates, establishing a legal basis for processing, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data that requires the adoption of administrative, physical and technical safeguards to protect such information, providing notification of data breaches to appropriate data protection authorities or data subjects, establishing means for data subjects to exercise rights in relation to their personal data and taking certain measures when engaging third-party processors. The GDPR's definition of personal data includes coded data and it imposes rules relating to informed consent practices and for clinical trials and notices for clinical trial subjects and investigators. Failure to comply with the requirements of the GDPR may result in warning letters, mandatory audits, orders to cease/change the use of data, and financial penalties, including fines, which can be up to 4% of global revenues or &#8364;20 million (&#163;17.5 million for the U.K.), whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">77</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Among other requirements, the GDPR includes restrictions on cross-border transfers of personal data subject to the GDPR to countries outside the EEA/U.K. that have not been found to provide adequate protection to such personal data (third countries), unless a valid GDPR transfer mechanism (for example, the European Commission approved Standard Contractual Clauses, or SCCs, certification to the EU-U.S. Data Privacy Framework (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the framework)  and the U.K. International Data Transfer Agreement/Addendum, or U.K. IDTA) has been put in place. Where relying on the SCCs /U.K. IDTA for data transfers, we may also be required to carry out transfer impact assessments to assess whether the recipient is subject to local laws which allow public authority access to personal data. The international transfer obligations under the EEA/U.K. data protection regimes will require significant effort and cost, and may result in us needing to make strategic considerations around where EEA/U.K. personal data is transferred and which service providers we can utilize for the processing of EEA/U.K. personal data. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results. Switzerland has also adopted similar restrictions on transfer of personal data outside of its borders. Although the U.K. is regarded as a third country under the EU&#8217;s GDPR, the European Commission has adopted an (adequacy decision) in favor of the U.K., a decision recognizing the U.K. as providing adequate protection under the EU GDPR and enabling data transfers from EU Member States to the U.K. without additional safeguards. However, the U.K. adequacy decision will automatically expire in June 2025 unless the European Commission re-assesses and renews or extends that decision and remains under review by the Commission during this period. The U.K. government has confirmed that personal data transfers from the U.K. to the EEA remain free flowing. The U.K. Government has also now introduced a Data Protection and Digital Information Bill (U.K. Bill) into the U.K. legislative process. The aim of the U.K. Bill is to reform the U.K.&#8217;s data protection regime following Brexit. If passed, the final version of the U.K. Bill may have the effect of further altering the similarities between the U.K. and EEA data protection regime and threaten the U.K. Adequacy Decision from the European Commission. This may lead to additional compliance costs and could increase our overall risk. It is unclear how U.K. data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the U.K. will be regulated in the long term.  Although the EU GDPR and the U.K. GDPR currently impose substantially similar obligations it is possible that over time the respective provisions, interpretations and enforcement of the EU GDPR and U.K. GDPR may further diverge in the future and create additional regulatory challenges and uncertainties. The lack of clarity on future U.K. laws and regulations and their interaction with EU laws and regulations could add legal risk, uncertainty, complexity and cost to our handling of U.K. and EEA personal data and our privacy and data security compliance programs, and could require us to implement different compliance measures for the U.K. and the EEA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to implement a valid solution for personal data transfers from the EEA, U.K. or Switzerland to the U.S. or other countries, we will face increased exposure to regulatory actions, substantial fines and injunctions against processing personal data in those jurisdictions. Inability to import personal data from the EEA, U.K. or Switzerland may also restrict our clinical trials activities in those jurisdictions; limit our ability to collaborate with contract research organizations as well as other service providers, contractors and other companies subject to data protection laws in those jurisdictions; and require us to increase our data processing capabilities in those jurisdictions at significant expense. Additionally, other countries outside of the EEA, U.K., and Switzerland have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Given the breadth and depth of applicable data protection obligations, preparing for and complying with the GDPR and similar laws&#8217; requirements are rigorous and time intensive and require significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data. The GDPR, and other laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from our clinical trials, could require us to change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and increase our cost of doing business, and could lead to government enforcement actions, private litigation and significant fines and penalties against us and could have a material adverse effect on our business, financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Similar privacy and data security requirements are either in place or underway in the U.S. There are numerous data protection laws that may be applicable to our activities, and a range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission and state Attorneys General are aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered or have been implemented at both the state and federal levels. For example, the California Consumer Privacy Act of 2018, or the CCPA, which became effective on January 1, 2020, requires companies that process information of California consumers (as defined under the CCPA) to provide disclosures to such consumers about their data collection, use and sharing practices, provides Californian consumers with new individual data privacy rights, imposes new operational requirements for covered businesses, provides a private right of action for data breaches and creates a statutory damages framework. Although there are limited exemptions for clinical trial data under the CCPA, the CCPA and other similar laws could impact our business activities depending on how such laws are interpreted. Additionally, effective starting on January 1, 2023, the California Privacy Rights Act, or CPRA will significantly</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">78</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">modify the CCPA, including by expanding consumers&#8217; rights with respect to certain sensitive personal information. The CPRA also creates a new state agency that will be vested with authority to implement and enforce the CCPA and the CPRA. Many other states are considering similar legislation, and a broad range of legislative measures also have been introduced at the federal level.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, regulations promulgated pursuant to HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and referred herein collectively as HIPAA, imposes privacy, security and breach notification obligations on health plans, healthcare clearinghouses and certain healthcare providers, known as covered entities, as well as their business associates that perform certain services that involve creating, receiving, maintaining or transmitting individually identifiable health information for or on behalf of such covered entities, and their covered subcontractors. HIPAA establishes privacy and security standards that limit the use and disclosure of protected health information, or PHI, and requires the implementation of administrative, physical and technological safeguards to protect the privacy of PHI and ensure the confidentiality, integrity and availability of electronic PHI. Most healthcare providers, including research institutions from which we obtain patient health information, are subject to HIPAA. We do not believe that we are currently acting as a covered entity or business associate under HIPAA and thus are not directly subject to its requirements. However, any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems. Further, any failure by our third-party collaborators, service providers, contractors or consultants to comply with applicable law, regulations or contractual obligations related to data privacy or security could result in proceedings against us by governmental entities or others.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also publish privacy policies and other documentation regarding our collection, processing, use and disclosure of personal information and/or other confidential information. Although we endeavor to comply with our published policies and other documentation, we may at times fail to do so or may be perceived to have failed to do so. Despite our efforts, we may not be successful in achieving compliance if our employees or vendors fail to comply with our published policies and documentation. Such failures can subject us to potential international, local, state and federal action if they are found to be deceptive, unfair, or misrepresentative of our actual practices. Claims that we have violated individuals&#8217; privacy rights or failed to comply with data protection laws or applicable privacy notices, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. We also face a threat of consumer class actions related to these laws and the overall protection of personal information. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business, financial condition, results of operations or prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If any of our product candidates obtains regulatory approval and does not receive appropriate periods of non-patent exclusivity, competitors could enter the market with generic versions of such products more quickly than we expect, which may result in a material decline in sales of our products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments to the FDCA, a company may file an abbreviated new drug application, or ANDA, seeking approval of a generic version of an approved innovator product. Under the Hatch-Waxman Amendments, a company may also submit an NDA under section 505(b)(2) of the FDCA that references the FDA&#8217;s prior approval of the innovator product. A 505(b)(2) NDA product may be for a new or improved version of the original innovator product. The Hatch-Waxman Amendments also provide for certain periods of regulatory exclusivity, which preclude FDA approval (or in some circumstances, FDA filing and review) of an ANDA or 505(b)(2) NDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S., once an NDA is approved, the product covered thereby becomes a &#8220;reference listed drug&#8221; in the FDA&#8217;s publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; or the Orange Book. Manufacturers may seek approval of generic versions of reference listed drugs through submission of abbreviated new drug applications, or ANDAs, in the U.S. In support of an ANDA, a generic manufacturer generally must show that its product has the same active ingredient(s), dosage form, strength, route of administration, and adequate labeling as the reference listed drug and that the generic version is bioequivalent to the reference listed drug, meaning, in part, that it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring to market than the reference listed drug and companies that produce generic products are generally able to offer them at lower prices. Moreover, many states allow or require substitution of therapeutically equivalent generic drugs at the pharmacy level even if the branded drug is prescribed. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference listed drug may be lost to the generic product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may not finally approve an ANDA for a generic product until any applicable period of non-patent exclusivity for the reference listed drug has expired. The FDCA provides a period of five years of non-patent exclusivity for a new drug containing a new chemical entity, or NCE. For the purposes of this provision, an NCE is a drug that contains no active moiety that has previously been</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">79</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approved by the FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance. Specifically, in cases where such exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a patent certification that a patent covering the listed drug is invalid unenforceable or will not be infringed by the generic product. In that case, the applicant may submit its application four years following approval of the listed drug and seek to launch its generic product even if we still have patent protection for our product unless an infringement suit is timely filed by the NDA or patent holder in which case the FDA cannot approve the ANDA for 30 months unless a court decision in favor of the generic manufacturer is issued earlier.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Three-year exclusivity is given to a drug if it contains an active moiety that has previously been approved, and the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the NDA. This form of marketing exclusivity is known as New Clinical Investigation, or NCI, exclusivity. If our product candidates are approved with only NCI exclusivity, generic manufacturers may file their ANDAs any time following approval of our product candidates and seek to launch their generic products following the expiration of the three year market exclusivity period, even if we still have patent protection for our product unless an infringement suit is timely filed triggering a 30 month stay on approval of the generic product (subject to the disposition of the patent litigation).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we believe that our product candidates may be new chemical entities in the U.S., the FDA may determine, however, that they are not eligible for NCE exclusivity but receive three years of NCI exclusivity instead, if and when FDA approves an NDA for the product. If any product we develop does not receive five years of NCE exclusivity, the FDA may approve generic versions of such product three years after its date of approval, subject to any patents exclusivity we may have. If an ANDA applicant certifies to the invalidity or non-infringement of listed patents and an infringement suit is timely filed by the NDA or patent holder, the FDA cannot finally approve the ANDA for 30 months unless a court decision in favor of the generic manufacturer is issued earlier.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, if any of our product candidates is approved, competitors could file ANDAs for generic versions of these products or 505(b)(2) NDAs that reference our product candidates. If there are patents listed for our product candidates in the Orange Book, any ANDA and 505(b)(2) NDA applicants would be required to include a certification as to each listed patent indicating whether the ANDA applicant does or does not intend to challenge the patent. FDORA also requires that the FDA consider therapeutic equivalence determinations for certain Section 505(b)(2) drugs that are pharmaceutical equivalents to listed drugs relied upon in an application either at the time of approval or up to 180 days post-approval, upon request of the sponsor. These therapeutic equivalence determinations could have an adverse effect on our business. Because we remain early in the research and preclinical development of our product candidates, we cannot predict which, if any, patents in our current portfolio or patents we may obtain in the future will be eligible for listing in the Orange Book, how any generic competitor would address such patents, whether we would sue on any such patents or the outcome of any such suit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be successful in securing or maintaining proprietary patent protection for products and technologies we develop or license, despite expending a significant amount of resources that could have been focused on other areas of our business. Moreover, if any of our owned or in-licensed patents that are listed in the Orange Book are successfully challenged by way of a patent certification and subsequent litigation, the affected product could immediately face generic competition and its sales would likely decline rapidly and materially.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Commercialization</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing products before us or more successfully than we do.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The development and commercialization of new drug products is highly competitive. We face competition with respect to our product candidates from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of many of the disorders for which we are conducting research programs. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach, and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than our product candidates or that would render our product candidates obsolete or non-competitive. Our competitors also may obtain FDA, EMA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to face competition from existing products and product candidates in development for each of our programs. Currently, patients with DMD are treated with corticosteroids to manage the inflammatory component of the disease. EMFLAZA is an FDA-approved corticosteroid marketed by PTC. Individuals with DMD also use prednisone or prednisolone off-label. In addition, there are several FDA-approved exon skipping drugs: EXONDYS 51 and VYONDYS 53, which are naked PMOs approved for the treatment of DMD patients amenable to exon 51 and exon 53 skipping, respectively, and are marketed by Sarepta; and VILTEPSO, a naked PMO approved for the treatment of DMD patients amenable to exon 53 skipping, which is marketed in the U.S. by NS Pharma, Inc. Companies focused on developing treatments for DMD that target dystrophin, as our DMD program does, include Sarepta with SRP-5051, a peptide-linked PMO currently being evaluated in a Phase 2b clinical trial for patients amenable to exon 51 skipping; Dyne with DYNE-251, an antibody-conjugated PMO that targets exon 51 skipping in a Phase 1/2 clinical trial; BioMarin with BMN-351, a phosphorothioate oligonucleotide that targets exon 51 skipping currently in preclinical development; and Wave with WVE-N531, a stereopure oligonucleotide in a Phase 1/2 clinical trial for patients amenable to exon 53 skipping.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, several companies are developing gene therapies to treat DMD. These include ELEVIDYS (SRP-9001) which was approved in June 2023 for treatment of ambulatory pediatric patients aged 4 through 5 years with DMD with a confirmed mutation in the DMD gene. In an interim readout of a recent Phase 3 trial (EMBARK), which is still ongoing, patients with DMD between ages 4 through 7 years treated with ELEVIDYS did not show statistically significant benefit on the North Star Ambulatory Assessment, which was the primary endpoint. ELEVIDYS showed statistically significant results on all key pre-specified secondary endpoints, time to rise and 10-meter walk/run test. Based on the interim read out from EMBARK, Sarepta has filed an efficacy supplement to its BLA to expand the label of ELEVIDYS to encompass &#8220;treatment of DMD patients with a confirmed mutation in the DMD gene.&#8221; The FDA accepted the filing of the efficacy supplement and has given the application priority review with a review goal date of June 21, 2024. In addition, several other companies are developing investigational gene therapies to treat DMD, including Pfizer Inc.&#8217;s PF-06939926, fordadistrogene movaparvovec, which is currently being assessed in a Phase 3 clinical trial, Sarepta&#8217;s Galgt2 gene therapy program, and Solid Biosciences Inc.&#8217;s SGT-003 and REGENXBIO Inc.&#8217;s RGX-202, currently in clinical development. Gene editing treatments that are in preclinical development are also being pursued by Vertex and Sarepta</span><span style="color:#000000;white-space:pre-wrap;text-decoration:line-through;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. We are also aware of several companies targeting non-dystrophin mechanisms for the treatment of DMD, including Edgewise with EDG-5506, a muscle stabilizer that is currently in clinical development and givinostat, a</span><span style="color:#1f1f1f;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> HDAC inhibitor,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> that reduces fibrosis in patients with DMD and is currently under review by the FDA and EMA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For DM1, there are currently no approved therapies to treat the underlying cause of the disease. Pipeline candidates currently in development to treat DM1 include several approaches that target </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">DMPK </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RNA. These include AOC 1001, an antibody linked siRNA in Phase 1/2 clinical development with a global Phase 3 study planned for initiation in the second quarter of 2024 by Avidity; DYNE-101, an antibody conjugated antisense oligonucleotide in clinical development by Dyne; and VX-670, a peptide conjugated PMO in Phase 1 by Entrada and Vertex. There are additional approaches under development such as ATX-01, a microRNA that modulates expression of MBNL1 by Arthex Biotech S.L., that recently received IND clearance.  Another small molecule, tideglusib, which is a GSK3-&#223; inhibitor is in clinical development by AMO Pharma Ltd. for the congenital phenotype of DM1, recently failed to meet primary endpoint in a pivotal study.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Several gene editing treatments are in preclinical development by Vertex; an artificial site-specific RNA endonuclease gene therapy is being developed by Enzerna; Design Therapeutics, Inc. is developing an approach to prevent formation of CUG hairpins; Expansion Therapeutics, Inc. is developing an approach utilizing the interaction of small molecules with RNA in preclinical development; and therapeutics based on biomolecular condensate biology in preclinical development by Dewpoint and Pfizer.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will also compete more generally with other companies developing alternative scientific and technological approaches, including other companies working to develop conjugates with oligonucleotides for extra-hepatic delivery, including Alnylam, Aro, Arrowhead, Avidity, Dicerna, Dyne, Entrada, Ionis, NeuBase, PYC and Sarepta, as well as gene therapy and gene editing approaches.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of the companies against which we compete or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Accordingly, our competitors may be more successful than us in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining approval for treatments and achieving widespread market acceptance, rendering our treatments obsolete or non-competitive.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any of our products, if approved. Competitive products or technological approaches may make any products we develop, or our EDO platform, obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products, if approved, could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if one or more of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of our product candidates progresses successfully through clinical development and receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. Sales of medical products depend in part on the willingness of physicians to prescribe the treatment, which is likely to be based on a determination by these physicians that the products are safe, therapeutically effective and cost-effective. In addition, the inclusion or exclusion of products from treatment guidelines established by various physician groups and the viewpoints of influential physicians can affect the willingness of other physicians to prescribe the treatment. We cannot predict whether physicians, physicians&#8217; organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that our product is safe, therapeutically effective and cost-effective as compared with competing treatments. Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the efficacy and safety of such product candidates as demonstrated in clinical trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential advantages and limitations compared to alternative treatments; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effectiveness of sales and marketing efforts; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of treatment in relation to alternative treatments; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the clinical indications for which the product is approved; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the convenience and ease of administration compared to alternative treatments; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the strength of marketing and distribution support; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of market introduction of competitive products; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of third-party coverage and adequate reimbursement; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the prevalence and severity of any side effects; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any restrictions on the use of our products, if approved, together with other medications. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If the market opportunities for any product candidates we develop are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer. Because the target patient populations of our programs are small, and the addressable patient population even smaller, we must be able to successfully identify patients and capture a significant market share to achieve profitability and growth.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We focus our research and product development on treatments for rare diseases. Given the small number of patients who have the diseases that we are targeting, it is critical to our ability to grow and become profitable that we continue to successfully identify patients with these rare diseases. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations or market research that we conducted, and may prove to be incorrect or contain errors. New studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. The effort to identify patients with diseases we seek to treat is in early stages, and we cannot accurately predict the number of patients for whom treatment might be possible. Additionally, the potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment with our product candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business. Further, even if we obtain significant market share for our product candidates, because the potential target populations are very small, we may never achieve profitability despite obtaining such significant market share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">82</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our target patient populations are relatively small, and as a result, the pricing and reimbursement of our product candidates, if approved, is uncertain, but must be adequate to support commercial infrastructure. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell product candidates will be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The estimates of market opportunity and forecasts of market growth included in this 10-K may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market opportunity estimates and growth forecasts included in this 10-K are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. The estimates and forecasts included in this 10-K relating to size and expected growth of our target market may prove to be inaccurate. Even if the markets in which we compete meet the size estimates and growth forecasts included in this 10-K, our business may not grow at similar rates, or at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many risks and uncertainties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The pricing and third-party payor coverage and reimbursement status of newly approved products are uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our future product candidates, if approved, could limit our ability to market those products and decrease our ability to generate product revenue.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S. and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Our ability to successfully commercialize our product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. For more information, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business &#8211; Healthcare Regulation &#8211; Coverage and Reimbursement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; in this 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the U.S., the decisions about coverage and reimbursement for new products under the Medicare program are made by the Centers for Medicare &amp; Medicaid Services, or CMS. Private payors tend to follow CMS to a substantial degree. However, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the drug product. Further, a payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Reimbursement agencies in the EU may be more conservative than CMS. Factors payors consider in determining reimbursement are based on whether the product is:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a covered benefit under its health plan; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">safe, effective and medically necessary;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">appropriate for the specific patient; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cost-effective; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">neither experimental nor investigational. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price, or ASP, and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outside the U.S., international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in the EU, the U.K., Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as our product candidates. In many countries, particularly the countries of the EU, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. As a result, we might obtain marketing approval for a product in a particular country, but then be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">83</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subject to price regulations that delay or might even prevent our commercial launch of the product, possibly for lengthy periods of time. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In general, the prices of products under such systems are substantially lower than in the U.S. Other countries allow companies to fix their own prices for products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for product candidates. Accordingly, in markets outside the U.S., the reimbursement for our product candidates may be reduced compared with the U.S. and may be insufficient to generate commercially reasonable revenues and profits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to establish sales, marketing and distribution capabilities or enter into sales, marketing and distribution agreements with third parties, we may not be successful in commercializing our product candidates if any are approved.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of pharmaceutical products. To achieve commercial success for any product for which we have obtained marketing approval, we will need to establish a sales, marketing and distribution organization, either ourselves or through collaborations or other arrangements with third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the future, we may build a sales and marketing infrastructure to market certain of our product candidates if they receive marketing approval. There are risks involved with establishing our own sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. These efforts may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Factors that may inhibit our efforts to commercialize our products on our own include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to recruit, train and retain adequate numbers of effective sales, marketing, coverage or reimbursement, customer service, medical affairs and other support personnel; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability of sales personnel to educate adequate numbers of physicians on the benefits of any future products; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement and other acceptance by payors; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to price our products at a sufficient price point to ensure an adequate and attractive level of profitability; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient population; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unforeseen costs and expenses associated with creating an independent sales and marketing organization. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to establish our own sales, marketing and distribution capabilities and we enter into arrangements with third parties to perform these services, our product revenues and our profitability, if any, are likely to be lower than if we were to market, sell and distribute any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell, market and distribute our product candidates or may be unable to do so on terms that are acceptable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we or our licensors are unable to obtain, maintain and defend patent and other intellectual property protection for any product candidates or technology, or if the scope of the patent or other intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully develop and commercialize our product candidates or our technology may be adversely affected due to such competition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends in large part on our and our licensors&#8217; ability to obtain and maintain patent and other intellectual property protection in the U.S. and other jurisdictions. We and our licensors have sought, and will seek, to protect our proprietary position by filing additional patent applications in the U.S. and abroad related to certain technologies and our platform that are important to our business. However, our patent portfolio is at an early stage; except for one issued patent and seven applications currently under</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">84</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">examination, which we in-licensed from Oxford University and the Medical Research Council of United Kingdom Research and Innovation, substantive examination of the currently pending patent applications we own or license has yet to begin. In addition, there can be no assurance as to whether or when our patent applications will issue as granted patents. Our ability to stop third parties from making, using, selling, marketing, offering to sell, importing and commercializing our product candidates and our technology is dependent upon the extent to which we have rights under valid and enforceable patents and other intellectual property that cover our platform and technology. If we are unable to secure, maintain, defend and enforce patents and other intellectual property with respect to our product candidates and our technology, it would have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our pending PCT patent applications are not eligible to become issued patents until, among other things, we file a national stage patent application within 30 to 32 months, depending on the jurisdiction, from such application&#8217;s priority date in the jurisdictions in which we are seeking patent protection. Similarly, our pending provisional patent applications are not eligible to become issued patents until, among other things, we file a non-provisional patent application within 12 months of such provisional patent application&#8217;s filing date. If we do not timely file such national stage patent applications or non-provisional patent applications, we may lose our priority date with respect to such PCT or provisional patent applications, respectively, and any patent protection on the inventions disclosed in such PCT or provisional patent applications, respectively. While we and our licensors intend to timely file national stage and non-provisional patent applications relating to our PCT and provisional patent applications, respectively, we cannot predict whether any such patent applications will result in the issuance of patents. If we or our licensors do not successfully obtain issued patents, or, if the scope of any patent protection we or our licensors obtain is not sufficiently broad, we will be unable to prevent others from using our product candidates or our technology or from developing or commercializing technology and products similar or identical to ours or other competing products and technologies. Any failure to obtain or maintain patent protection with respect to our product candidates or our EDO platform would have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent prosecution process is expensive, time-consuming and complex, and we and our licensors may not be able to file, prosecute, maintain, defend, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. We and our licensors may not be able to obtain, maintain or defend patents and patent applications due to the subject matter claimed in such patents and patent applications being in the public domain. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Consequently, we would not be able to prevent any third party from using any of our technology that is in the public domain to compete with our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of patent rights are highly uncertain. Our pending and future owned and licensed patent applications may not result in patents being issued which protect our technology or product candidates, effectively prevent others from commercializing competitive technologies and product or otherwise provide any competitive advantage. In fact, patent applications may not issue as patents at all, and even if such patent applications do issue as patents, they may not issue in a form, or with a scope of claims, that will provide us with any meaningful protection, prevent others from competing with us or otherwise provide us with any competitive advantage. In addition, the scope of claims of an issued patent can be reinterpreted after issuance, and changes in either the patent laws or interpretation of the patent laws in the U.S. and other jurisdictions may diminish the value of our patent rights or narrow the scope of our patent protection. Furthermore, our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third parties have developed technologies that may be related or competitive to our own technologies and product candidates and may have filed or may file patent applications, or may have obtained issued patents, claiming inventions that may overlap or conflict with those claimed in our owned or licensed patent applications or issued patents. We may not be aware of all third-party intellectual property rights potentially relating to our current and future product candidates and technology. Publications of discoveries in the scientific literature often lag the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot know for certain whether the inventors of our owned or licensed patents and patent applications were the first to make the inventions claimed in any owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. If a third party can establish that we or our licensors were not the first to make or the first to file for patent protection of such inventions, our owned or licensed patent applications may not issue as patents and even if issued, may be challenged and invalidated or ruled unenforceable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the U.S. and other jurisdictions. For example, we may be subject to a third-party submission of prior art to the USPTO, challenging the validity of one or more claims of our owned or licensed patents. Such</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">85</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submissions may also be made prior to a patent&#8217;s issuance, precluding the granting of a patent based on one of our owned or licensed pending patent applications. We may become involved in opposition, derivation, re-examination, inter partes review, post-grant review or interference proceedings and similar proceedings in foreign jurisdictions (for example, opposition proceedings) challenging our owned or licensed patent rights. In addition, a third party may claim that our owned or licensed patent rights are invalid or unenforceable in a litigation. An adverse result in any litigation or patent office proceeding could put one or more of our owned or licensed patents at risk of being invalidated, ruled unenforceable or interpreted narrowly and could allow third parties to commercialize products identical or similar to our product candidates and compete directly with us, without payment to us. Moreover, we, or one of our licensors, may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge priority of invention or other features of patentability. Such challenges and proceedings may result in loss of patent rights, exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and our product candidates. Such challenges and proceedings may also result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. Moreover, there could be public announcements of the results of hearings, motions or other interim proceedings or developments related to such challenges and proceedings. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, patents have a limited lifespan. In the U.S., the expiration of a patent is generally 20 years from the earliest date of filing of the first non-provisional patent application to which the patent claims priority. Patent term adjustments and extensions may be available; however, the overall term of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our owned and licensed patent and other intellectual property rights may not provide us with sufficient rights to exclude others from commercializing products similar or identical to our technology and our product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our rights to develop and commercialize any product candidates are subject and may in the future be subject, in part, to the terms and conditions of licenses granted to us by third parties. If we fail to comply with our obligations under our current or future intellectual property license agreements or otherwise experience disruptions to our business relationships with our current or any future licensors, we could lose intellectual property rights that are important to our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are and expect to continue to be reliant upon third-party licensors for certain patent and other intellectual property rights that are important or necessary to the development of our technology and product candidates. For example, we rely on a license from Oxford University Innovation Limited (OUI), and the Medical Research Council of United Kingdom Research and Innovation, or MRC, to certain patent rights and know-how of OUI and MRC, or the OUI/MRC License. The OUI/MRC License imposes, and we expect that any future license agreement will impose, specified diligence, milestone payment, fee payment, royalty, commercialization, development and other obligations on us and require us to meet development timelines, or to exercise diligent or commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, our licensors have, or may in the future have, the right to terminate a license if we materially breach the agreement and fail to cure such breach within a specified period or in the event we undergo certain bankruptcy events. In spite of our best efforts, our current or any future licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements. If our license agreements are terminated, we may lose our rights to develop and commercialize product candidates and technology, lose patent protection, experience significant delays in the development and commercialization of our product candidates and technology, and incur liability for damages. If these in-licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, our competitors or other third parties could have the freedom to seek regulatory approval of, and to market, products and technologies identical or competitive to ours and we may be required to cease our development and commercialization of certain of our product candidates and technology. In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing licenses in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties, including our competitors, to receive licenses to a portion of the intellectual property that is subject to our existing licenses and to compete with our product candidates and our technology. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disputes may arise regarding intellectual property subject to a licensing agreement, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our or our licensors&#8217; ability to obtain, maintain and defend intellectual property and to enforce intellectual property rights against third parties; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">86</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which our technology, product candidates and processes infringe, misappropriate or otherwise violate the intellectual property of the licensor that is not subject to the license agreement; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the sublicensing of patent and other intellectual property rights under our license agreements; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our diligence, development, regulatory, commercialization, financial or other obligations under the license agreement and what activities satisfy those diligence obligations; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our current or future licensors and us and our partners; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the priority of invention of patented technology. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the OUI/MRC License is, and future license agreements are likely to be, complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our diligence, development, regulatory, commercialization, financial or other obligations under the relevant agreement. In addition, if disputes over intellectual property that we have licensed or any other dispute related to our license agreements prevent or impair our ability to maintain our license agreements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates and technology. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While the OUI/MRC License grants certain exclusive patent and technology rights to us, license agreements we may enter into in the future may be non-exclusive. Accordingly, third parties may also obtain non-exclusive licenses from such licensors with respect to the intellectual property licensed to us under such license agreements. Accordingly, these license agreements may not provide us with exclusive rights to use such licensed patent and other intellectual property rights, or may not provide us with exclusive rights to use such patent and other intellectual property rights in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, some of our in-licensed patent and other intellectual property rights are, and may in the future be, subject to third party interests such as co-ownership. If we are unable to obtain an exclusive license to such third-party co-owners&#8217; interest, in such patent and other intellectual property rights, such third-party co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. We or our licensors may need the cooperation of any such co-owners of our licensed patent and other intellectual property rights in order to enforce them against third parties, and such cooperation may not be provided to us or our licensors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we may not have complete control over the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications that we license from third parties. It is possible that our licensors&#8217; filing, prosecution and maintenance of the licensed patents and patent applications, enforcement of patents against infringers or defense of such patents against challenges of validity or claims of enforceability may be less vigorous than if we had conducted them ourselves, and accordingly, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business. If our licensors fail to file, prosecute, maintain, enforce and defend such patents and patent applications, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, our right to develop and commercialize any of our technology and any product candidates we may develop that are the subject of such licensed rights could be adversely affected and we may not be able to prevent competitors or other third parties from making, using and selling competing products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, our owned and in-licensed patent rights may be subject to a reservation of rights by one or more third parties. When new technologies are developed with government funding, in order to secure ownership of patent rights related to the technologies, the recipient of such funding is required to comply with certain government regulations, including timely disclosing the inventions claimed in such patent rights to the U.S. or foreign government and timely electing title to such inventions. A failure to meet these obligations may lead to a loss of rights or the unenforceability of relevant patents or patent applications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Filing, prosecuting, maintaining, enforcing and defending patents and other intellectual property rights on our technology and our product candidates in all jurisdictions throughout the world would be prohibitively expensive, and accordingly, our intellectual property rights in some jurisdictions outside the U.S. could be less extensive than those in the U.S. In some cases, we or our licensors may not be able to obtain patent or other intellectual property protection for certain technology and product candidates outside the U.S. In addition, the laws of some foreign jurisdictions do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Consequently, we and our licensors may not be able to obtain issued patents or other intellectual property rights covering our product candidates and our technology in all jurisdictions outside the U.S. and, as a result, may not be able to prevent third parties from practicing our and our licensors&#8217; inventions in all countries outside the U.S., or from selling or importing products</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">87</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">made using our inventions in and into the U.S. or other jurisdictions. Third parties may use our technologies in jurisdictions where we and our licensors have not pursued and obtained patent or other intellectual property protection to develop their own products and, further, may export otherwise infringing, misappropriating or violating products to territories where we have patent or other intellectual property protection, but enforcement is not as strong as that in the U.S. These products may compete with our product candidates and our technology and our or our licensors&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain jurisdictions, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement, misappropriation or other violation of our patent and other intellectual property rights or marketing of competing products in violation of our intellectual property rights generally. For example, an April 2019 report from the Office of the U.S. Trade Representative identified a number of countries, including China, Russia, Argentina, Chile and India, where challenges to the procurement and enforcement of patent rights have been reported. Proceedings to enforce our or our licensors&#8217; patent and other intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patent and other intellectual property rights at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We or our licensors may not prevail in any lawsuits that we or our licensors initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many jurisdictions have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many jurisdictions limit the enforceability of patents against government agencies or government contractors. In these jurisdictions, the patent owner may have limited remedies, which could materially diminish the value of such patents. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents or other intellectual property or the intellectual property of our licensors, which could be expensive, time-consuming, and unsuccessful.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competitors may infringe our patents or other intellectual property or the intellectual property of our licensors. To cease such infringement or unauthorized use, we may be required to file patent infringement claims, which can be expensive and time-consuming and divert the time and attention of our management and scientific personnel. Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. In addition, in an infringement proceeding or a declaratory judgment action, a court may decide that one or more of our patents is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceeding could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in patent law in the U.S. or worldwide could diminish the value of patents in general, thereby impairing our ability to protect our product candidates and our technology.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in either the patent laws or interpretation of patent laws in the U.S. and worldwide, including patent reform legislation such as the Leahy-Smith America Invents Act (Leahy-Smith Act), could increase the uncertainties and costs surrounding the prosecution of any owned or in-licensed patent applications and the maintenance, enforcement or defense of any current in-licensed issued patents and issued patents we may own or in-license in the future. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Assuming that other requirements for patentability are met, prior to March 2013, in the U.S., the first to invent the claimed invention was entitled to the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">88</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patent, while outside the U.S., the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the U.S. transitioned to a first-to-file system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our in-licensed issued patents and issued patents we may own or in-license in the future, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Since patent applications in the U.S. and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim unpatentable even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to review patentability of our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. As one example, in the case Assoc. for Molecular Pathology v. Myriad Genetics, Inc., the U.S. Supreme Court held that certain claims to DNA molecules are not patentable simply because they have been isolated from surrounding material. Moreover, in 2012, the USPTO issued a guidance memo to patent examiners indicating that process claims directed to a law of nature, a natural phenomenon or a naturally occurring relation or correlation that do not include additional elements or steps that integrate the natural principle into the claimed invention such that the natural principle is practically applied and the claim amounts to significantly more than the natural principle itself should be rejected as directed to patent-ineligible subject matter. Accordingly, in view of the guidance memo, there can be no assurance that claims in our patent rights covering our product candidates or our technology will be held by the USPTO or equivalent foreign patent offices or by courts in the U.S. or in foreign jurisdictions to cover patentable subject matter. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or patent applications will be due to be paid to the USPTO and various government patent agencies outside of the U.S. over the lifetime of our owned or licensed patent rights. We rely on our outside counsel and other professionals or our licensing partners to pay these fees due to the USPTO and non-U.S. government patent agencies. The USPTO and various non-U.S. government patent agencies also require compliance with several procedural, documentary and other similar provisions during the patent application process. We rely on our outside counsel and other professionals to help us comply and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment, loss of priority or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be successful in obtaining necessary rights to our product candidates through acquisitions and in-licenses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently have rights to certain intellectual property through the OUI/MRC License. Because our programs may require the use of additional intellectual property rights held by third parties, the growth of our business likely will depend, in part, on our ability to acquire, in-license or use these intellectual property rights. In addition, with respect to any patent or other intellectual property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">89</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">rights that we co-own with third parties, we may require exclusive licenses to such co-owners&#8217; interest in such patent or other intellectual property rights. However, we may be unable to secure such licenses or otherwise acquire or in-license any intellectual property rights related to compositions, methods of use, processes or other components from third parties that we identify as necessary for our product candidates and our technology on commercially reasonable terms, or at all. Even if we are able to in-license any such necessary intellectual property, it could be on non-exclusive terms, thereby giving our competitors and other third parties access to the same intellectual property licensed to us, and the applicable licensors could require us to make substantial licensing and royalty payments. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We sometimes collaborate with non-profit and academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to third parties, potentially blocking our ability to pursue our research program and develop and commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have licensed, we may be required to expend significant time and resources to redesign our product candidates or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or before administrative bodies in the U.S. or abroad.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our owned and licensed patent rights may be subject to priority, validity, inventorship and enforceability disputes. If we or our licensors are unsuccessful in any of these proceedings, such patent rights may be narrowed, invalidated or held unenforceable, we may be required to obtain licenses from third parties, which may not be available on commercially reasonable terms or at all, or we may be required to cease the development, manufacture and commercialization of one or more of our product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we or one of our licensors initiate legal proceedings against a third party to enforce a patent covering our product candidates or our technology, the defendant could counterclaim that the patent covering the product candidate or technology is invalid or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, lack of written description or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include re-examination, interference proceedings, derivation proceedings, post grant review, inter partes review and equivalent proceedings such as opposition, invalidation and revocation proceedings in foreign jurisdictions. Such proceedings could result in the revocation or cancellation of or amendment to our patents in such a way that they no longer cover our product candidates or our technology or prevent third parties from competing with our product candidates or our technology. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which the patent examiner and we or our licensing partners were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection on one or more of our product candidates or technology. Such a loss of patent protection could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect and some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets. We seek to protect our proprietary technology and processes, in part, by</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">entering into confidentiality agreements with our employees, consultants, scientific advisors, contractors and other parties who have access to such technology and processes. However, we may not be able to prevent the unauthorized disclosure or use of our technical know-how or other trade secrets by the parties to these agreements. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the collaborators, scientific advisors, employees and consultants who are parties to these agreements breach or violate the terms of any of these agreements, we may not have adequate remedies for any such breach or violation. As a result, we could lose our trade secrets and third parties could use our trade secrets to compete with our product candidates and our technology. Additionally, we cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems; however, such systems and security measures may be breached, and we may not have adequate remedies for any breach.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our trade secrets may otherwise become known or be independently discovered by competitors or other third parties. Competitors or third parties could purchase our product candidates or our technology and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our intellectual property rights or develop their own competitive technologies that fall outside the scope of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate such trade secrets, from using that technology or information to compete with us. If our trade secrets are not adequately protected so as to protect our market against competitors&#8217; products, our business, financial condition, results of operations and prospects could be materially and adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends upon our ability and the ability of our collaborators, if any, to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. We may become party to, or be threatened with, adversarial proceedings or litigation in which third parties may assert infringement, misappropriation or other violation claims against us, alleging that our product candidates, manufacturing methods, formulations or administration methods are covered by their patents. Given the vast number of patents and other intellectual property in our field of technology, we cannot be certain or guarantee that we do not infringe, misappropriate or otherwise violate patents or other intellectual property. Other companies and institutions have filed, and continue to file, patent applications that may be related to our technology and, more broadly, to gene therapy and related manufacturing methods. Some of these patent applications have already been allowed or issued and others may issue in the future. Since this area is competitive and of strong interest to pharmaceutical and biotechnology companies, there will likely be additional patent applications filed and additional patents granted in the future, as well as additional research and development programs expected in the future. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that we may be subject to claims of infringement of the patent rights of third parties. If a patent holder believes the manufacture, use, sale or importation of our product candidates or our technology infringes its patent, the patent holder may sue us even if we have licensed other patent rights for our technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are aware of certain patents in the U.S. and other jurisdictions owned by third parties that claim subject matter that relates to our product candidates and the EDO platform. Such third parties may assert these patents against us in litigation in the U.S. or other jurisdictions. The outcome of any such litigation is uncertain and, even if we prevail, the costs of such litigation could have a material adverse effect on our financial position, result in disclosure of our trade secrets, distract key personnel from the continued development of our business, and adversely affect our ability to enter or maintain commercial relationships with collaborators, clients or customers. If we are unsuccessful in such litigation, we could be prevented from commercializing products or could be required to take licenses from such third parties which may not be available on commercially reasonable terms, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is also possible that we have failed to identify relevant third-party patents or applications. Because patent applications can take many years to issue, may be confidential for 18 months or more after filing and can be revised before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the manufacture, use, sale or importation of our product candidates or our technology and we may not be aware of such patents. Furthermore, applications filed before November 29, 2000 and certain applications filed after that date that will not be filed outside the U.S. may remain confidential until a patent issues. Moreover, it is difficult for industry participants, including us, to identify all third-party patent rights that may be relevant to our product candidates and our technologies because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We may fail to identify relevant patents or patent applications or may identify pending patent applications of potential interest but incorrectly predict the likelihood that such</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">91</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patent applications may issue with claims of relevance to our technology. In addition, we may incorrectly conclude that a third-party patent is invalid, unenforceable or not infringed by our activities. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our product candidates or the use of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could adversely affect our ability to commercialize our product candidates or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. If we are found to infringe a third party&#8217;s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing our product candidates and our technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidates. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us from manufacturing and commercializing our product candidates or force us to cease some of our business operations, which could harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual property litigation or other proceedings could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competitors may challenge the validity and enforceability of our patent rights or those of our licensing partners, infringe, misappropriate or otherwise violate our or our licensors&#8217; patent and other intellectual property rights, or we may be required to defend against claims of infringement, misappropriation or other violation. Litigation and other proceedings in connection with any of the foregoing claims can be unpredictable, expensive and time consuming. Even if resolved in our favor, litigation or other proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our scientific, technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors or other third parties may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could adversely affect our ability to compete in the marketplace and could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or be required to obtain licenses to such intellectual property rights, which may not be available on commercially reasonable terms or at all. An inability to incorporate such intellectual property rights would harm our business and may prevent us from successfully commercializing our product candidates. In addition, we may lose personnel as a result of such claims and any such litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent contractors. A loss of key personnel or their work product could hamper or prevent our ability to commercialize our product candidates and our technology, which would have a material adverse effect on our business, results of operations, financial condition and prospects. Even if we are successful in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">defending against such claims, litigation could result in substantial costs and be a distraction to our scientific and management personnel.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. Moreover, even when we obtain agreements assigning intellectual property to us, the assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Furthermore, individuals executing agreements with us may have pre-existing or competing obligations to a third party, such as an academic institution, and thus an agreement with us may be ineffective in perfecting ownership of inventions developed by that individual. Disputes about the ownership of intellectual property that we own may have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we or our licensors may in the future be subject to claims by former employees, consultants or other third parties asserting an ownership right in our owned or licensed patent rights. An adverse determination in any such submission or proceeding may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar technology and therapeutics, without payment to us, or could limit the duration of the patent protection covering our technology and our product candidates. Such challenges may also result in our inability to develop, manufacture or commercialize our technology and product candidates without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our owned or licensed patent rights are threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future technology and product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we do not obtain patent term extension for our product candidates, our business may be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments to the FDCA, a company may file an abbreviated new drug application, or ANDA, seeking approval of a generic version of an approved innovator product. Depending upon the timing, duration and specifics of any FDA marketing approval of our product candidates and our technology, one or more of our U.S. patents that we license or may own in the future may be eligible for limited patent term extension under Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved product, a method for using it or a method for manufacturing it may be extended. The application for the extension must be submitted prior to the expiration of the patent for which extension is sought. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. In addition, to the extent we wish to pursue patent term extension based on a patent that we in-license from a third party, we would need the cooperation of that third party. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our patent and other intellectual property rights.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patent rights, trade secrets or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates or technology. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or in-licensed patent rights, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of or right to use intellectual property that is important to our product candidates or our technology. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">93</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current and future trademark applications in the U.S. and other foreign jurisdictions may not be allowed or may be subsequently opposed. Once filed and registered, our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. As a means to enforce our trademark rights and prevent infringement, we may be required to file trademark claims against third parties or initiate trademark opposition proceedings. This can be expensive and time-consuming, particularly for a company of our size. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may be able to make products that are similar to our product candidates but that are not covered by the intellectual property, including the claims of the patents, that we own or license currently or in the future; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we, or our license partners or current or future collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or license currently or in the future;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we, or our license partners or current or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing, misappropriating or otherwise violating our owned or licensed intellectual property rights; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that our or our licensors&#8217; current or future pending patent applications will not lead to issued patents; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by third parties; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">third parties might conduct research and development activities in jurisdictions where we do not have patent or other intellectual property rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the patents or other intellectual property rights of others may have an adverse effect on our business; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may choose not to file a patent for certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor or other third party will discover our trade secrets or that our trade secrets will be misappropriated or disclosed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because we currently rely on certain third parties to manufacture all or part of our product candidates and to perform quality testing, and because we may need to collaborate with various third parties for the advancement of our product candidates and technology, we may be required to, at times, share our proprietary technology and confidential information, including trade secrets, with them. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements and, if applicable, material transfer agreements, collaboration agreements, services agreements, consulting agreements and other similar agreements prior to beginning research or disclosing any proprietary information to such third parties. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">94</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors or other third parties, are inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets. We may need to share our proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors. Further, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third-party, we would have no right to prevent them from using that technology or information to compete with us. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of these agreements, independent development or publication of information including our trade secrets by third parties. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s or other third party&#8217;s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure would impair our competitive position and may harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Employee Matters, Managing Growth and Other Operational Matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are highly dependent on the research and development, clinical, financial, operational and other business expertise of our executive officers, as well as the other principal members of our management, scientific and clinical teams. Although we have entered into employment offer letters with our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. Recruiting and retaining qualified scientific, clinical, manufacturing, accounting, legal and sales and marketing personnel will also be critical to our success.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. Our success as a public company also depends on implementing and maintaining internal controls and the accuracy and timeliness of our financial reporting. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We expect to expand our headcount to support our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had 64 full-time employees. As our development progresses, we expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, clinical, regulatory affairs and, if any product candidate receives marketing approval, sales, marketing, distribution and coverage and reimbursement capabilities. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a growing biotechnology company, we expect to pursue new platforms and product candidates in multiple therapeutic areas and across a wide range of diseases. Successfully developing product candidates for, and fully understanding the regulatory and manufacturing pathways to, each of these therapeutic areas and disease states requires a significant depth of talent, resources and corporate processes in order to allow simultaneous execution across multiple areas. Due to our limited resources, we may not be able to effectively manage this simultaneous execution and the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, give rise to operational mistakes, legal or regulatory compliance</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">95</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failures, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The physical expansion of our operations may lead to significant costs and may divert financial resources from other projects, such as the development of our product candidates. If our management is unable to effectively manage our expected development and expansion, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to compete effectively and commercialize our product candidates, if approved, will depend in part on our ability to effectively manage the future development and expansion of our company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our international activities subject us to various risks, and our failure to manage these risks could adversely affect our results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face significant operational risks as a result of doing business internationally, such as:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fluctuations in foreign currency exchange rates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">differing payor reimbursement regimes, governmental payors or patient self-pay systems and price controls;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potentially adverse and/or unexpected tax consequences, including penalties due to the challenge by tax authorities on our tax position; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential changes to the accounting standards, which may influence our financial situation and results; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with tax, employment, immigration and labor laws should we have any employees living or traveling abroad; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">becoming subject to the different, complex and changing laws, regulations and court systems of multiple jurisdictions and compliance with a wide variety of foreign laws, treaties; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduced protection of, or significant difficulties in enforcing, intellectual property rights, or increased risk of intellectual property disputes, in certain countries; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulties in attracting and retaining qualified consultants, contractors, and personnel; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions imposed by any applicable local labor practices and laws on our business and operations, including unilateral cancellation or modification of contracts; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">rapid changes in global government, economic and political policies and conditions, political or civil unrest or instability, terrorism or epidemics and other similar outbreaks or events, and potential failure in confidence of our suppliers or customers due to such changes or events; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">geopolitical tensions that affect our activities, operations and/or operations of our contractors, consultants, collaborators, vendors or partners; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tariffs, trade protection measures, import or export licensing requirements, trade embargoes and other trade barriers. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future acquisitions or strategic alliances could disrupt our business and harm our financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may acquire additional businesses, technologies or assets, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products or product candidates resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the transaction. The risks we face in connection with acquisitions, include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">diversion of management time and focus from operating our business to addressing acquisition integration challenges; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">coordination of research and development efforts; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">retention of key employees from the acquired company; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in relationships with collaborators as a result of product acquisitions or strategic positioning resulting from the acquisition; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cultural challenges associated with integrating employees from the acquired company into our organization; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">96</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the need to implement or improve controls, procedures and policies at a business that prior to the acquisition may have lacked sufficiently effective controls, procedures and policies; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">liability for activities of the acquired company before the acquisition, including intellectual property infringement claims, violation of laws, commercial disputes, tax liabilities and other known liabilities; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unanticipated write-offs or charges; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">litigation or other claims in connection with the acquired company, including claims from terminated employees, customers, former stockholders or other third parties. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our failure to address these risks or other problems encountered in connection with our past or future acquisitions or strategic alliances could cause us to fail to realize the anticipated benefits of these transactions, cause us to incur unanticipated liabilities and harm the business generally. There is also a risk that future acquisitions will result in the incurrence of debt, contingent liabilities, amortization expenses or incremental operating expenses, any of which could harm our financial condition or results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our internal information technology systems, or those of our vendors, collaborators or other contractors or consultants, may fail or suffer security breaches, loss or leakage of data and other disruptions or compromise, which could result in a material disruption of our product development programs, compromise sensitive information related to our business or prevent us from accessing critical information, or trigger contractual and legal obligations, potentially exposing us to liability, reputational harm or otherwise adversely affecting our business and financial results.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are increasingly dependent upon information technology systems and infrastructure to operate our business. In the ordinary course of business, we collect, store and transmit confidential information (including but not limited to intellectual property, proprietary business information and personal information). It is critical that we, our vendors, collaborators and other contractors or consultants, do so in a secure manner to maintain the availability, security, confidentiality, privacy and integrity of such confidential information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite the implementation of security measures, given the size and complexity of our internal information technology systems and those of our current and future vendors, collaborators and other contractors or consultants, and the increasing amounts of confidential information that we and our affiliated third parties maintain, such information technology systems are still vulnerable to damage or interruption from computer viruses, computer hackers, malicious code, employee error, theft or misuse, denial-of-service attacks, sophisticated nation-state and nation-state-supported actors, unauthorized access, natural disasters, terrorism, war, telecommunication and electrical failures or other compromise. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. As a result of the effects of a pandemic, such as the COVID-19 pandemic or other health crisis, we may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely for a portion of their time, which may create additional opportunities for cybercriminals to exploit vulnerabilities. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations or hostile foreign governments or agencies. As such, we may experience security breaches that may remain undetected for an extended period. We may be unable to anticipate all types of security threats, or implement preventive measures effective against all such security threats. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection and to remove or obfuscate forensic evidence.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We and certain of our service providers are from time to time subject to cyberattacks and security incidents. While we do not believe that we have experienced any significant system failure, accident or security breach to date, if such an event were to occur, it could result in a disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary or confidential information or other disruptions. For example, the loss of clinical trial data from clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. If we were to experience a significant cybersecurity breach of our information systems or data, the costs associated with the investigation, remediation and potential notification of the breach to counterparties, data subjects, regulators or others could be material. In addition, our remediation efforts may not be successful. Moreover, if the information technology systems of our vendors, collaborators and other contractors and consultants become subject to disruptions or security breaches, we may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring. If we do not allocate and effectively manage the resources necessary to build and sustain the proper technology and cybersecurity infrastructure, we could suffer significant business disruption, including transaction errors, supply chain or manufacturing interruptions, processing inefficiencies, data loss or the loss of or damage to intellectual property or other proprietary information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">97</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent that any disruption or security breach were to result in a loss of, or damage to, our or our vendors&#8217;, collaborators&#8217; or other contractors&#8217; or consultants&#8217; data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, including litigation exposure and penalties and fines. Any such event that leads to unauthorized access, use, or disclosure of personal information, including personal information regarding our customers or employees, could harm our reputation, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information. We could become the subject of regulatory action or investigation, and our competitive position and reputation could be harmed and the further development and commercialization of our product candidates could be delayed. As a result of such an event, we may also be in breach of our contractual obligations. Any of the above could have a material adverse effect on our business, financial condition, results of operations or prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The financial exposure from the events referenced above could either not be insured against or not be fully covered through any insurance that we maintain. In addition, we cannot be sure that our existing insurance coverage will continue to be available on acceptable terms or that our insurers will not deny coverage as to any future claim. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages as a result of the events referenced above.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our operations or those of the third parties upon whom we depend might be affected by the occurrence of a natural disaster, pandemic or other catastrophic event.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We depend on our employees, consultants, CDMOs and CROs, as well as regulatory agencies and other parties, for the continued operation of our business. While we maintain disaster recovery plans, they might not adequately protect us. Despite any precautions we take for natural disasters or other catastrophic events, these events, including terrorist attack, pandemics, hurricanes, fire, floods and ice and snowstorms, could result in significant disruptions to our research and development, preclinical studies, clinical trials, and, ultimately, commercialization of our products. Long-term disruptions in the infrastructure caused by events, such as natural disasters, the outbreak of war, the escalation of hostilities and acts of terrorism or other &#8220;acts of God,&#8221; particularly involving cities in which we have offices, manufacturing or clinical trial sites, could adversely affect our businesses. Although we carry business interruption insurance policies and typically have provisions in our contracts that protect us in certain events, our coverage might not respond or be adequate to compensate us for all losses that may occur. Any natural disaster or catastrophic event affecting us, our CDMOs, CROs, regulatory agencies or other parties with which we are engaged could have a significant negative impact on our operations and financial performance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and its financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. Although we are not a borrower or party to any such instruments with any financial institution that has experienced such events, if we were to borrow money in the future and if any of our lenders or counterparties to any such instruments were to be placed into receivership, we may be unable to access such funds. In addition, if any of our customers, suppliers or other parties with whom we conduct business are unable to access funds pursuant to such instruments or lending arrangements with such a financial institution, such parties&#8217; ability to pay or perform their obligations to us or to enter into new commercial arrangements requiring additional payments to us or additional funding could be adversely affected. In this regard, counterparties to credit agreements and arrangements with banks in receivership or other financial difficulty, and third parties such as beneficiaries of letters of credit (among others), may experience direct impacts from the closure or reorganization of such financial institutions and uncertainty remains over liquidity concerns in the broader financial services industry. Similar impacts have occurred in the past, such as during the 2008-2010 financial crisis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inflation and rapid increases in interest rates have led to a decline in the trading value of previously issued government securities with interest rates below current market interest rates. Although the U.S. Department of Treasury, FDIC and Federal Reserve Board have announced a program to provide up to $25 billion of loans to financial institutions secured by certain government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediate liquidity may exceed the capacity of such program. Additionally, there is no guarantee that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions in the future, or that they would do so in a timely fashion.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">98</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we assess our banking relationships as we believe necessary or appropriate, our access to funding sources in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial institutions with which we have financial arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all.  Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws.  Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity, our current and/or projected business operations, and financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The effects of the COVID-19 pandemic, or a future pandemic, epidemic or outbreak of an infectious or highly contagious disease, may materially and adversely affect our business and financial results and could cause a disruption in the development of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Public health crises such as pandemics, including the COVID-19 pandemic or similar outbreaks, could adversely impact our business. For example, in connection with COVID-19, we and our CDMOs and CROs have in the past experienced a reduction in the capacity to undertake research-scale production and to execute some preclinical studies, and we may face future similar disruptions that affect our ability to initiate and complete preclinical studies. We may also encounter disruptions in procuring items that are essential for our research and development activities, such as raw materials used in the manufacture of any product candidates, laboratory supplies used in our preclinical and clinical studies, or animals that are used for preclinical testing for which there are or may be shortages because of ongoing efforts to address COVID-19 or a future health pandemic. The ultimate extent to which COVID-19, or a future outbreak of other highly infectious or contagious diseases, impacts our operations or those of our third-party partners, including our preclinical studies or clinical trial operations, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the scope, severity and duration of an outbreak, actions taken to contain an outbreak or mitigate its impact, and the direct and indirect economic effects of an outbreak and containment measures, among other developments.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Ownership of Our Common Stock</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The stock price of our common stock has been and may continue to be volatile or may decline regardless of our operating performance and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">You may not be able to sell your shares quickly or at the market price if trading in shares of our common stock is not active. An active or liquid market in our common stock may not develop or, if it does develop, it may not be sustainable, and the prices at which shares of our common stock trade in the market have fluctuated and may fluctuate in the future considerably or decline or be quite volatile regardless of our operating performance and prospects. As a result of these and other factors, you may be unable to resell your shares of our common stock at or above the initial public offering price or the per share price you paid for your shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic collaborations or acquire companies or products by using our shares of common stock as consideration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. In February 2024, we sold shares under our ATM program and in the Follow-on Offering, receiving in aggregate net proceeds of $86.8 million after deducting underwriters' fees and before deducting costs of the offerings. Any debt financing or preferred equity financing, if available, may involve, agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making capital expenditures, declaring dividends or encumbering our assets to secure future indebtedness.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">99</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed or on terms acceptable to us, we may be required to delay, limit, reduce or eliminate some or all of our research and development programs, pipeline expansion or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If securities or industry analysts do not continue to publish research or reports or publish inaccurate or unfavorable research or reports about our business, our stock price and trading volume could decline.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. In the event one or more analysts downgrade our stock price or change their opinion of our stock price, our stock price would likely decline. In addition, if one or more analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our stock price or trading volume to decline.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The price of our common stock is volatile and fluctuates substantially, which could result in substantial losses for holders of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The stock market in general, and the market for smaller biopharmaceutical companies in particular, have experienced extreme price volatility and volume fluctuations that have often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at or above the price you paid for it. The market price for our common stock may be influenced by many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">timing and results of, or developments in, preclinical studies and clinical trials of our product candidates or those of our competitors or potential competitors; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse regulatory rulemaking, guidance or decisions, including failure to receive marketing approvals for our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our success in commercializing any product candidates that may be approved; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success of competitive products or technologies; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory or legal developments in the U.S. and other countries; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developments or disputes concerning patent applications, issued patents or other intellectual property or proprietary rights; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the recruitment or departure of key personnel; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the level of expenses related to our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the results of our efforts to discover, develop, acquire or in-license products, product candidates, technologies or data referencing rights, the costs of commercializing any such products and the costs of development of any such product candidates or technologies; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">actual or anticipated changes in estimates as to our financial condition or results, clinical outcomes, development timelines or recommendations by securities analysts; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">variations in our financial condition or results or the financial condition or results of companies that are perceived to be similar to us; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sales of our common stock by us, our executive officers, directors or principal stockholders or others; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the structure of healthcare payment systems; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">general economic, industry, political and market conditions, including conditions resulting from the effects of the COVID-19 pandemic, high inflation and capital market disruptions, and government macroeconomic policies; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the other factors described in this &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk factors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221; section. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of the factors listed above could materially adversely affect your investment in our common stock, and our common stock may trade at prices significantly below the price you paid for our stock, which could contribute to a loss of all or part of your investment. In such circumstances the trading price of our common stock may not recover and may experience a further decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class-action litigation has often been instituted against that company. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our offerings or business practices. Such litigation may also cause us to incur other substantial costs to defend such claims and maintain liability insurance coverages and may also result in the diversion of management&#8217;s attention and resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unfavorable global economic conditions could adversely affect our business, financial condition, stock price and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, the 2008 global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn resulting from the effects of the COVID-19 pandemic or future pandemic could result in a variety of risks to our business, including weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all. In addition, the current military conflict between Russia and Ukraine and armed conflict in Israel and the Gaza Strip could disrupt or otherwise adversely impact our operations and those of third parties upon which we rely. Related sanctions, export controls or other actions that have been or may be initiated by nations, including the U.S. or the EU, or actions taken by Russia (e.g., potential cyberattacks, disruption of energy flows, etc.) could adversely affect our business and/or our supply chain, our CROs, CDMOs and other third parties with which we conduct business. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could impair our ability to achieve our growth strategy, could harm our financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that our current or future service providers, manufacturers or other collaborators may not survive such difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget. We cannot anticipate all of the ways in which the current economic climate, including increasing interest rates and high inflation, and financial market conditions could adversely impact our business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our executive officers, directors and principal shareholders, if they choose to act together, will continue to have the ability to significantly influence all matters submitted to stockholders for approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based upon our common stock outstanding as of March 1, 2024, our executive officers, directors, greater than five percent shareholders and their affiliates beneficially own approximately 47.1% of our outstanding common stock. As a result, if these stockholders were to choose to act together, they would be able to significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs, even though some of these persons or entities may have interests that are different than those of yours. For example, these stockholders, if they choose to act together, could significantly influence the election of directors and approval of any merger, consolidation or sale of substantially all of our assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This concentration of ownership may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delay, defer or prevent a merger, consolidation or sale of all or substantially all of our assets that may be desired by other stockholders; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delay, defer or prevent a change in control transaction involving us that other stockholders may desire; or </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">entrench our management and board of directors. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The sale of a significant number of shares of our common stock, or the perception that such sales could occur, could cause the market price of our common stock to drop significantly, even if our business is doing well.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock, impair our ability to raise capital through the sale of additional equity securities, and make it more difficult for you to sell your common stock at a time and price that you deem appropriate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">101</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, holders of an aggregate of 8,778,170 shares of our common stock have rights, subject to specified conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We have also filed a registration statement on Form S-8 to register all of the shares of common stock that we are able to issue under our equity compensation plans. Shares registered under these registration statements on Form S-8 can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates, vesting arrangements, exercise of options and any contractual restrictions that may apply to such shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are an &#8220;emerging growth company,&#8221; or EGC, as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act. We may remain an EGC until the end of the year that is the fifth anniversary of the closing of our IPO, although if the market value of our common stock that is held by non-affiliates exceeds $700.0 million as of any June 30 before that time or if we have annual gross revenues of $1.235 billion or more in any fiscal year, we would cease to be an EGC as of December 31 of the applicable year. We also would cease to be an EGC if we issue more than $1.0 billion of non-convertible debt over a three-year period. For so long as we remain an EGC, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not EGCs. These exemptions include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduced disclosure obligations regarding executive compensation; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even after we no longer qualify as an EGC, we may continue to qualify as a smaller reporting company, which would allow us to take advantage of many of the same exemptions from disclosure requirements, including reduced disclosure obligations regarding executive compensation. In addition, if we are a smaller reporting company with less than $100 million in annual revenue, we would not be required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002 (Section 404). In reliance on these exemptions, we have taken advantage of reduced reporting obligations in this 10-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the JOBS Act permits an EGC to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected to take advantage of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either irrevocably elect to &#8220;opt out&#8221; of such extended transition period or no longer qualify as an EGC. We may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We incur substantial costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives and corporate governance practices.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a public company, and even more so after we are no longer an EGC or a smaller reporting company, we incur or will incur significant legal, accounting and other expenses. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Global Select Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote and will need to continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased and may continue to increase our legal and financial compliance costs, particularly as we hire additional financial and accounting employees to meet public company internal control and financial reporting requirements and have made and will make some activities more time-consuming and costly compared to when we were a private company. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, and we might be forced to accept reduced policy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">102</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified members of our board of directors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot predict or estimate the amount of additional costs we may incur as a public company or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 404, we are required to furnish a report by our management on our internal control over financial reporting beginning with this 10-K. However, while we remain an EGC or a smaller reporting company with less than $100 million in annual revenue, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we are engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, including through hiring additional financial and accounting personnel, engaging outside consultants and adopting a detailed work plan to assess and document the adequacy of internal control over financial reporting, continuing steps to improve control processes as appropriate, validating through testing that controls are functioning as documented and implementing a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses in our internal control over financial reporting, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements, particularly if such material weakness results in the necessity of a restatement of our historical financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, is designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could harm our business and have a negative effect on the trading price of our stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are required to disclose changes made in our internal controls and procedures on a quarterly basis and our management is required to assess the effectiveness of these controls annually. However, for as long as we are an EGC under the JOBS Act or a smaller reporting company with less than $100 million in annual revenue, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404. We could be an EGC for up to five fiscal years after our IPO, which occurred on May 6, 2022. An independent assessment of the effectiveness of our internal control over financial reporting could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal control over financial reporting could lead to financial statement restatements and require us to incur the expense of remediation, which could have a negative effect on the trading price of our stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Anti-takeover provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current directors and members of management.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Anti-takeover provisions in our amended and restated certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish a classified board of directors such that only one of three classes of directors is elected each year; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">103</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">allow the authorized number of our directors to be changed only by resolution of our board of directors; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limit the manner in which stockholders can remove directors from our board of directors; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limit who may call stockholder meetings; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require the approval of the holders of at least 66.7% of the votes that all our stockholders would be entitled to cast to amend or repeal specified provisions of our certificate of incorporation or bylaws. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law (DGCL), which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our amended and restated bylaws designate the Court of Chancery of the State of Delaware and the federal district courts of the United States of America as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers and employees.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware does not have jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any derivative action or proceeding brought on our behalf; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or stockholders to our company or our stockholders; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any action asserting a claim arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; or </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any action asserting a claim arising pursuant to any provision of our certificate of incorporation or bylaws (in each case, as they may be amended from time to time) or governed by the internal affairs doctrine. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These choice of forum provisions will not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and bylaws provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any claims arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated bylaws. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These exclusive forum provisions may limit the ability of our stockholders to bring a claim in a judicial forum that such stockholders find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees. If a court were to find the exclusive forum provision contained in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving such action in other jurisdictions, all of which could materially adversely affect our business, financial condition and operating results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to continue to satisfy listing requirements of the Nasdaq Global Select Market or maintain a listing of our common stock on the Nasdaq Global Select Market.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock is listed on the Nasdaq Global Select Market. We must meet certain financial and liquidity criteria to maintain such listing. If we violate or fail to meet any of the Nasdaq Global Select Market&#8216;s listing standards, our common stock may be delisted. In addition, our board of directors may determine that the cost of maintaining our listing on a national securities exchange outweighs the benefits of such listing. A delisting of our common stock from the Nasdaq Global Select Market may materially impair our stockholders&#8217; ability to buy and sell our common stock and could have an adverse effect on the market price of, and the efficiency of the trading market for, our common stock. The delisting of our common stock could significantly impair our ability to raise capital and the value of your investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in tax laws or regulations or in their implementation or interpretation may adversely affect our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business or financial condition. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. A number of other factors could materially adversely affect our business and financial condition including: tax policy initiatives and reforms under consideration (such as those related to the Organization for Economic Co-Operation and Development&#8217;s (OECD), Base Erosion and Profit Shifting (BEPS), Project, the European Commission&#8217;s state aid investigations and other initiatives), the practices of tax authorities in jurisdictions in which we operate; the resolution of issues arising from tax audits or examinations and any related interest or penalties. Such changes may include (but are not limited to) the taxation of operating income, investment income, dividends received or (in the specific context of withholding tax) dividends paid.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Organization for Economic Co-operation &amp; Development, or OECD, Pillar Two Model Rules established a minimum global effective tax rate of 15% on country-by-country basis. EU member states along with many other countries adopted or expected to adopt the OECD Pillar Two Model effective January 1, 2024 or thereafter. The OECD and other countries continue to publish guidelines and legislation which include transition and safe harbor rules. We continue to monitor new legislative changes and assess the global impact of the Pillar Two Model Rules. Based on our initial assessment, we anticipate Pillar Two top-up taxes to be immaterial.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The U.S. government may enact significant new changes to the taxation of business entities including, among others, an increase in the corporate income tax rate. Furthermore, the rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are unable to predict what tax reform may be proposed or enacted in the future or what effect such changes would have on our business, but such changes, to the extent they are brought into tax legislation, regulations, policies or practices in jurisdictions in which we operate, could increase the estimated tax liability that we have expensed to date and paid or accrued on our balance sheets, and otherwise affect our financial position, future results of operations, cash flows in a particular period and overall or effective tax rates in the future in countries where we have operations, reduce post-tax returns to our shareholders and increase the complexity, burden and cost of tax compliance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Tax authorities may disagree with our positions and conclusions regarding certain tax positions, or may apply existing rules in an unforeseen manner, resulting in unanticipated costs, taxes or non-realization of expected benefits.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A tax authority may disagree with tax positions that we take, which could result in increased tax liabilities. For example, His Majesty&#8217;s Revenue &amp; Customs, the IRS or another tax authority could challenge our allocation of income by tax jurisdiction and the amounts paid between our affiliated companies pursuant to our intercompany arrangements and transfer pricing policies, including amounts paid with respect to our intellectual property development. Similarly, a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection, often referred to as a &#8220;permanent establishment&#8221; under international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A tax authority may take the position that material income tax liabilities, interest and penalties are payable by us, in which case we expect that we might contest such assessment. Contesting such an assessment may be lengthy and costly and if we were unsuccessful in disputing the assessment, the implications could increase our anticipated effective tax rate, where applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">105</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be subject to limitations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have a history of cumulative losses and anticipate that we will continue to incur significant losses in the foreseeable future; thus, we do not know whether or when we will generate taxable income necessary to utilize our net operating losses, or NOLs, or research and development tax credit carryforwards. As of December 31, 2023, we had federal and state NOL carryforwards of $23.4 million. We did not generate U.K. NOLs in 2022 or 2023, and do not anticipate any going forward.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a company that carries out extensive research and development activities, we sought to benefit from the U.K. research and development tax relief programs, being the Small and Medium-sized Enterprises R&amp;D tax relief program (SME Program), and, to the extent that our projects are grant funded or relate to work subcontracted to the company by third parties, the Research and Development Expenditure Credit program (RDEC Program). Under the SME Program, we may be able to surrender the trading losses that arise from our qualifying research and development activities for a cash rebate of approximately 33.4% of the surrenderable losses. The majority of our research and development activities during 2021 were eligible for inclusion within these tax credit cash rebate claims. We may not be able to continue to claim payable research and development tax credits in the future if we cease to qualify as an SME, based on size criteria concerning employee headcount, turnover and gross assets or if we no longer conduct qualifying research and development activities through our wholly-owned subsidiary PepGen Limited. The U.K. Finance Act of 2021 introduced a cap on payable credit claims under the SME Program in excess of &#163;20,000 with effect from April 2021 by reference to, broadly, three times the total PAYE and NICs liability of the company, subject to an exception which prevents the cap from applying. That exception requires the company to be creating, taking steps to create or managing intellectual property, as well as having qualifying research and development expenditure in respect of connected parties which does not exceed 15% of the total qualifying expenditure. If such exception does not apply, this could restrict the amount of credit that we are able to claim. For the year ended December 31, 2023, our research and development tax credits from the U.K. government were not material as the intellectual property was transferred from our wholly-owned U.K. subsidiary, PepGen Limited, to the parent company, PepGen Inc. in January 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For U.S. federal income tax purposes, in general, under Sections 382 and 383 of the U.S. Internal Revenue Code of 1986, as amended, or the Code, and corresponding provisions of state law, a corporation that undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, is subject to limitations on its ability to utilize its pre-change NOLs and pre-change research and development tax credit carryforwards to offset post-change income or taxes. We have not conducted a study to assess whether any such ownership changes have occurred. We may experience such ownership changes in the future. As a result, if, and to the extent that, we earn net taxable income, our ability to use our NOL carryforwards and research and development tax credit carryforwards to offset such taxable income may be subject to limitations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the use of the U.K. NOL carryforwards could be restricted, under Part 14 of the Corporation Tax Act 2010, if a &#8220;change in ownership&#8221; of either PepGen Inc. or PepGen Limited were to occur and certain other conditions are met. A &#8220;change in ownership&#8221; is defined, broadly, as the acquisition by one or more persons of more than half of the ordinary share capital of a company. The use of the U.K. NOL carryforwards could be restricted if, within a certain period of a change in ownership, there is a major change in the conduct of PepGen Limited&#8217;s trade, PepGen Limited&#8217;s trading activities become small or negligible, or if certain other conditions are met.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any restructuring or change in the nature of our operations of our company may give rise to tax liabilities and/or restrictions in the amount and/or availability of tax attributes.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have undergone, and may in the future undertake, changes in the nature or conduct of our operations. For example, pursuant to an asset transfer agreement effective as of January 1, 2022, we effected a novation of all intellectual property assets of our wholly-owned U.K. subsidiary PepGen Limited to PepGen Inc., which resulted in the recording of a tax charge of $3.7 million, including $0.7 million related to an uncertain tax position. Any future actions regarding transfer of assets from our U.K. subsidiary or other international subsidiaries could give rise to tax liabilities for us and/or to the erosion of our tax attributes (such as net operating losses).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to certain reporting requirements of the Securities Exchange Act of 1934, as amended, (Exchange Act). Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">106</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">As a public company, we may be at an increased risk of securities class action litigation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Historically, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. If we were to be sued, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be exposed to significant foreign exchange risk.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We incur portions of our expenses, and may in the future derive revenues, in a variety of currencies. As a result, we are exposed to foreign currency exchange risk as our results of operations and cash flows are subject to fluctuations in foreign currency exchange rates. Fluctuations in currency exchange rates have had, and will continue to have, an impact on our results as expressed in U.S. dollars. We currently do not engage in hedging transactions to protect against uncertainty in future exchange rates between particular foreign currencies and the euro. We cannot predict the impact of foreign currency fluctuations, and foreign currency fluctuations in the future may adversely affect our financial condition, results of operations and cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1B. Unresolved S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">taff Comments.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1C. Cybersecurity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cyber Risk Management and Strategy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have processes for assessing, identifying, and managing cybersecurity risks, which are built into our information technology function and are designed to help protect our information assets and operations from internal and external cyber threats, protect employee and clinical trial information from unauthorized access or attack, as well as secure our networks and systems. Such processes include physical, procedural, and technical safeguards, and routine review of our policies and procedures in an effort to identify risks and refine our practices. We engage certain external parties, including a contracted information technology consultant who is dedicated to our organization, to enhance our cybersecurity oversight.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In an effort to deter and detect cyber threats, we perform annual phishing tests with employees. We also require annual cybersecurity and prevention training for employees, which may cover topics such as social engineering, phishing, password protection, confidential data protection, and mobile security, and is designed to educate employees on incident reporting. We also use technology-based tools, including third-party tools and solutions, designed to mitigate cybersecurity risks and to bolster our employee-based cybersecurity programs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not identified any cybersecurity incidents or threats that have materially affected us or are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition; however, like other companies in our industry, we and our third-party vendors may, from time to time, experience threats and security incidents relating to our and our third-party vendors&#8217; information systems. For more information, see &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Factors-Risks Related to Employee Matters, Managing Growth and Other Operational Matters -Our internal information technology systems, or those of our vendors, collaborators or other contractors or consultants, may fail or suffer security breaches, loss or leakage of data and other disruptions or compromise, which could result in a material disruption of our product development programs, compromise sensitive information related to our business or prevent us from accessing critical information, or trigger contractual and legal obligations, potentially exposing us to liability, reputational harm or otherwise adversely affecting our business and financial results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Governance Related to Cybersecurity Risks</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audit committee of the board of directors, or the Audit Committee, is responsible for overseeing cybersecurity risk, pursuant to the Audit Committee charter, and periodically updates our board of directors on such matters. The Audit Committee receives periodic updates from management and our contracted information technology consultant regarding cybersecurity matters.  We have a process for the Audit Committee to be notified between such updates in the event of any significant new cybersecurity threats or incidents.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management is responsible for, and is forming a committee tasked with, the operational oversight of company-wide cybersecurity strategy, policy, and standards across relevant departments to assess and help prepare us to address cybersecurity risks.  Our contracted information technology consultant, supported by management, oversees the day-to-day implementation and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">107</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">management of our cybersecurity program.  Our information technology consultant reports to the Senior Vice President, or SVP, of Chemistry and Manufacturing, who currently operates as our head of information technology. Our information technology consultant has approximately 20 years of experience in information technology, and also leverages the experience of a third-party managed systems provider. Our information technology consultant regularly reports to the SVP of Chemistry and Manufacturing as well as to other executive management on cyber matters, as appropriate.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Prop</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">erties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our principal facility is located at 321 Harrison Ave, Boston, Massachusetts, where we lease and occupy approximately 31,668 square feet of office and laboratory space. The lease was signed on December 1, 2021 and the lease term commenced on December 29, 2022. The current term of our lease expires in May 2032, with an option to extend the lease for one successive five-year term. We believe our facilities are adequate and suitable for our current needs and that should it be needed, suitable additional or alternative space will be available to accommodate our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Legal P</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">roceedings.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may be a party to litigation or subject to claims incident to the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, we currently believe that the final outcome of these ordinary course matters will not have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. As of December 31, 2023, we were not a party to any material legal proceedings.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Mine Safety D</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">isclosures.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">108</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">T II</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrant_common"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5. Market for Registran</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Market Information</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock has traded on the Nasdaq Global Select Market under the symbol &#8220;PEPG&#8221; since May 10, 2022. Prior to that date, there was no public trading market for our common stock.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Holders</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 1, 2024, we had 11</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">holders of record of our common stock. The actual number of stockholders is greater than the number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. The number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dividend Policy</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid cash dividends on our common stock since our inception. We currently intend to retain all available funds and any future earnings to fund the development and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to declare and pay dividends will be made at the discretion of our board of directors and will depend on then-existing conditions, including our results of operations, financial condition, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Securities Authorized for Issuance Under Equity Compensation Plans</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information about our equity compensation plans is incorporated by reference herein to Item 12 Part III of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unregistered Sales of Equity Securities</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Proceeds</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 10, 2022, we closed our IPO in which we sold an aggregate of 9,000,000 shares at a public offering price of $12.00 per share for gross proceeds of $108.0 million. In connection with the IPO, we granted the underwriters a 30-day option to purchase 1,350,000 additional shares of common stock. On May 16, 2022, the underwriters exercised the option in part and we issued 1,238,951 shares of our common stock for gross proceeds of $14.9 million. From the IPO and option exercise by the underwriters, we received approximately $122.9 million in gross proceeds and $110.2 million in net proceeds, after deducting underwriting discounts and estimated offering expenses payable by us. None of the underwriting discounts and commissions or offering expenses were incurred or paid, directly or indirectly, to any of our directors or officers or their associates or to persons owning 10% or more of our common stock or to any of our affiliates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The offer and sale of all of the shares of our common stock in our IPO were registered under the Securities Act pursuant to a registration statement on Form S-1, as amended (File No. 333- 264335), which was declared effective by the SEC on May 5, 2022. BofA Securities, Inc., SVB Securities LLC, Stifel, Nicolaus &amp; Company, Incorporated and Wedbush Securities Inc. acted as underwriters for the IPO.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_reserved"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 6. [Reserved].</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">109</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_management_discussion_and_analysi"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7. Management&#8217;s Discussio</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">n and Analysis of Financial Condition and Results of Operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes included elsewhere in this 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this 10-K, including information with respect to our plans, strategies, objectives, expectations and intentions for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this 10-K, our actual results could differ materially from the results described in or implied by these forward-looking statements. Please also see the section titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PepGen is a clinical-stage biotechnology company&#8239;advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. Our proprietary EDO platform is founded on over a decade of research and development and leverages CPPs to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are initially focused on addressing the underlying cause of DMD and DM1, that have high unmet need. Our current pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to exon 51 skipping and PGN-EDODM1 for DM1 patients, along with three additional preclinical stage programs. We anticipate expanding this pipeline over time to include other neuromuscular targets as well as potential opportunities in neurologic diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We completed a first-in-human Phase 1 HV clinical trial with our lead product candidate, PGN-EDO51, in the third quarter of 2022. In the Phase 1 clinical trial, treatment with PGN-EDO51 resulted in the highest levels of mean exon skipping</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in humans following a single dose compared to publicly available data for a single dose of other DMD exon 51-skipping approaches that are approved or in clinical development.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our clinical development program for PGN-EDO51 comprises two parallel Phase 2 studies of PGN-EDO51 in DMD patients whose mutations are amenable to an exon 51-skipping approach. The first study, CONNECT1, is an ongoing open-label, MAD Phase 2 study in boys and young men living with DMD being conducted in Canada. We initiated dosing patients in CONNECT1 in January 2024 and have fully enrolled the first cohort at the 5 mg/kg PGN-EDO51 dose level. We anticipate reporting initial proof-of-concept data, that would include safety, exon skipping and dystrophin production for this cohort in mid-2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, we received clearance from the MHRA to initiate the second study, CONNECT2, a Phase 2, multinational, randomized, double-blind, placebo-controlled MAD study, in the U.K. The CONNECT2 study will evaluate multiple dose cohorts and trial participants will be administered PGN-EDO51 once every four weeks for six months. We will assess safety, tolerability, exon skipping, dystrophin expression and functional outcomes in this study. The CONNECT2 study, together with data from the CONNECT1 study, is designed to support a potential accelerated approval pathway for PGN-EDO51, subject to alignment with regulatory authorities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also developing PGN-EDODM1 for the treatment of DM1 and are utilizing what we believe to be a unique mechanism of action and a different delivery approach compared to other approaches in more advanced stages of clinical development. We have conducted extensive preclinical studies of our product candidate, and these preclinical data form the basis of our clinical development plan for PGN-EDODM1. In May 2023, we announced that we received a clinical hold notice from the FDA regarding our IND application to initiate our first-in-human Phase 1 FREEDOM study. In September 2023, we announced that Health Canada had cleared our CTA for the FREEDOM study in Canada. In October 2023, we announced that the FDA lifted the clinical hold on the FREEDOM study, allowing this study to proceed in the U.S. In December 2023, we announced that the MHRA had cleared our CTA for the FREEDOM study in the U.K. and we began dosing patients in this study. FREEDOM is a multinational, randomized, double-blind, placebo-controlled, SAD study designed to assess PGN-EDODM1's safety and tolerability, splicing correction and functional outcome measures in DM1 patients. We expect to report preliminary data from this study in the second half of 2024. In February 2024, we announced that PGN-EDODM1 received Fast Track designation from the FDA for the treatment of DM1. We also expect to open the FREEDOM2-DM1 Phase 2 randomized, double blind, placebo-controlled MAD study in DM1 patients in the second half of 2024.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to these lead candidates, we are developing EDO candidates for additional DMD sub-populations amenable to skipping of other exons, including exon 53, 45 and 44. We have previously reported robust exon 53-skipping levels following either a single dose or multiple doses in NHPs for our PGN-EDO53 program. We anticipate advancing PGN-EDO53 into CTA and/or IND-enabling preclinical studies in 2024.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Initial Public Offering and Liquidity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 10, 2022, we closed our IPO in which we sold an aggregate of 9,000,000 shares at a public offering price of $12.00 per share for gross proceeds of $108.0 million. In connection with the IPO, we granted the underwriters a 30-day option to purchase</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">110</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,350,000 additional shares of common stock. On May 16, 2022, the underwriters exercised the option in part and we issued 1,238,951 shares of common stock for gross proceeds of $14.9 million. From the IPO and option exercise by the underwriters, we received approximately $122.9 million in gross proceeds and $110.2 million in net proceeds, after deducting underwriting discounts and offering expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Immediately prior to consummation of the IPO, all 12,546,805 outstanding shares of our redeemable convertible preferred stock, and 35,529 preferred stock warrants that were exercised on May 4, 2022, converted into 12,359,856 shares of common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 5, 2024, we issued and sold 1,000,000 shares at a purchase price of $10.00 per share under our ATM program, resulting in net proceeds of $9.9 million. On February 9, 2024, we issued and sold 7,530,000 shares at a purchase price of $10.635 per share, which was the closing sale price of our common stock on the Nasdaq Global Select Market on February 6, 2024 in a Follow-on Offering. The Follow-on Offering resulted in net proceeds of $76.9 million after deducting underwriters' fees of $3.2 million. Net proceeds from the ATM program and Follow-on Offering, after deducting underwriters' fees and before deducting costs of the offerings, were $86.8 million.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since our inception, we have not generated any revenue from product sales or other sources and have incurred significant operating losses and negative cash flows from our operations. Our primary uses of cash to date have been to fund our research and development activities, business planning, establishing and maintaining our intellectual property portfolio, acquiring and developing product and technology rights, hiring personnel, leasing premises and associated capital expenditures, raising capital, and providing general and administrative support for these operations. To date, we have funded our operations primarily through private placements of our convertible preferred stock and proceeds from our IPO, the ATM program and the Follow-on Offering.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred operating losses in each year since our inception. Our net losses were $78.3 million and $69.1 million for the years ended December 31, 2023 and December 31, 2022, respectively. As of December 31, 2023, we had cash, cash equivalents, and marketable securities of $110.4 million, excluding proceeds from the ATM program offering and the Follow-on Offering made subsequent to December 31, 2023. As of December 31, 2023, we had an accumulated deficit of $181.2 million. We expect our expenses and operating losses will continue as we conduct our ongoing preclinical studies and current and planned clinical trials, continue our research and development activities, utilize third parties to manufacture our product candidates and related raw materials, hire additional personnel, protect our intellectual property and incur additional costs associated with being a public company, including audit, legal, regulatory, and tax-related services associated with maintaining compliance with an exchange listing and SEC requirements, director and officer insurance premiums, and investor relations costs. In addition, we have several development, regulatory and commercial milestone payment obligations under our licensing arrangements. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our preclinical studies and current and planned clinical trials and our expenditures on other research and development activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on our current operating plans, we believe that our existing cash, cash equivalents, marketable securities, and proceeds from shares sold under our ATM program and in the Follow-on Offering will be sufficient to fund our operations into 2026. We do not expect to generate any revenues from product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates, which will not be for at least the next several years, if ever. If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Accordingly, until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements when needed would have a negative impact on our financial condition and could force us to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Corporate Reorganization</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We were initially formed as PepGen Limited on January 25, 2018, in the U.K. On November 9, 2020, PepGen Limited initiated a corporate reorganization, or the Reorganization. As part of the Reorganization, PepGen Limited formed PepGen Inc., a Delaware corporation with nominal assets and liabilities, for the purpose of consummating the Reorganization. In connection with the Reorganization, the existing shareholders of PepGen Limited exchanged each of their classes of shares of PepGen Limited for the same number and class of common stock of PepGen Inc. on a one-to-one basis. The newly issued stock of PepGen Inc. had substantially identical rights to the exchanged shares of PepGen Limited. As a result of the exchange, PepGen Inc. became the sole shareholder of PepGen Limited. Upon the completion of the Reorganization on November 23, 2020, the historical financial statements of PepGen Limited became the historical financial statements of PepGen Inc., as the Reorganization was deemed to be between entities under common control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">111</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After the Reorganization was completed, PepGen Limited began the process of transferring certain operations, including financial management functions, to PepGen Inc. pursuant to an intercompany services agreement, effective as of April 2021, and certain assets, including a novation of all intellectual property assets, pursuant to an asset transfer agreement, effective as of January 1, 2022. After the transfer of intellectual property and other assets from PepGen Limited to PepGen Inc., there were limited operations through the end of 2022 at PepGen Limited.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Components of Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, our research and development expenses have primarily consisted of external and internal costs associated with our research and development activities, including our discovery and research efforts, the development of our proprietary EDO platform, and the preclinical and clinical development of our product candidates. Our research and development expenses include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">external expenses, including expenses incurred under arrangements with third parties, such as CROs, CDMOs, consultants and our scientific advisors; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">personnel-related costs, including salaries, cash incentive compensation, payroll taxes, employee benefits, and stock-based compensation; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs for laboratory supplies and materials and reagents for chemical synthesis of product candidates; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">facility costs, depreciation, and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance, and other supplies. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development activities are recorded as prepaid expenses until the goods or services are received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table (in thousands) summarizes our research and development expenses for the years ended December 31, 2023 and December 31, 2022. The direct external development program expenses reflect external costs attributable to our clinical development candidates and preclinical candidates selected for further development. Our internal resources, personnel and infrastructure are not directly tied to any one research or drug discovery program and are typically deployed across multiple programs. As such, we do not track internal expenses on a program-specific basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">External expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">PGN-EDO51</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,369</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,089</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">PGN-EDODM1</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,486</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,853</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other programs and unallocated expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,762</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,296</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total external expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,617</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37,238</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Internal expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Personnel-related (including stock-based compensation)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,143</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,744</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Facilities and related costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,165</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,672</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,201</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,423</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,126</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,077</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our research and development expenses to increase in 2024 as we conduct our CONNECT1 and CONNECT2 Phase 2 clinical trials, our FREEDOM Phase 1 clinical trial, our planned FREEDOM2-DM1 Phase 2 clinical trial, and continue to conduct our ongoing research and development activities. The process of conducting preclinical studies, producing drug product supply, and completing clinical trials necessary to obtain regulatory approval is costly and time consuming. We may never succeed in achieving marketing approval for any of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The timelines and costs associated with research and development activities are uncertain and can vary significantly for each product candidate and development program due to the inherently unpredictable nature of preclinical and clinical development. We anticipate we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to preclinical and clinical results, regulatory developments, and ongoing assessments as to each program&#8217;s commercial potential. We will need to raise substantial additional capital in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">112</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future development costs may vary significantly based on factors such as:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the status of clinical trials, animal and other preclinical studies and IND- or CTA-enabling studies; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">per patient trial costs; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of trials required for approval; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of sites included in the trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the countries in which the trials are conducted; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the length of time required to enroll eligible patients; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of patients that participate in the trials; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of doses that patients receive; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the drop-out or discontinuation rates of patients; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the duration of patient participation in the trials and follow-up; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost and timing of manufacturing our product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the efficacy and safety profile of our product candidates; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintaining a continued acceptable safety profile of our products if any receive regulatory approval. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses consist primarily of personnel-related costs, including salaries, cash incentive compensation, payroll taxes, employee benefits, and stock-based compensation charges for those individuals in executive, finance, facility operations, and other administrative functions. Other significant costs include legal fees relating to intellectual property and corporate matters, professional fees for audit, accounting and consulting services, and insurance costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate that our general and administrative expenses will remain consistent in 2024 as compared to 2023 to support our public company operating expenses associated with audit, legal, regulatory, and tax-related services associated with maintaining compliance with our exchange listing and SEC requirements, director and officer insurance premiums, and investor relations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income (Expense), Net</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Income</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interest income consists of interest earned on our money market mutual funds and short-term U.S. treasury holdings.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income (expense)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We classified our outstanding warrants to purchase shares of our Series A-2 convertible preferred stock as liabilities on our consolidated balance sheets at their estimated fair value as the underlying convertible preferred stock was classified as temporary equity. At the end of each reporting period, changes in the estimated fair value during the period were recorded as a component of other income (expense), net. We recognized changes in the fair value of our warrant liability until the warrants were exercised on May 4, 2022, prior to the completion of our IPO.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other components of other income (expense) relate to realized and unrealized gains and losses on currency revaluation.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not recorded a U.S. provision for federal or state income taxes as we have no revenue and have incurred losses since inception. During the year ended December 31, 2022, we recorded a $3.7 million tax charge associated with the transfer of our intellectual property assets from our wholly owned subsidiary, PepGen Limited, to the parent company, PepGen Inc. (see Note 11 of Notes to the Consolidated Financial Statements). We had no material tax liability for the year ended December 31, 2023.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">113</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comparison of the Year Ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our results of operations for the years ended December 31, 2023 and 2022 (in thousands):</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
    <td style="width:1.399%;"/>
    <td style="width:1%;"/>
    <td style="width:10.776%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Period-to-</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Period Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,126</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">54,077</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,049</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,640</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,224</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,416</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">84,766</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,301</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,465</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(84,766</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(68,301</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,465</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,400</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,793</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,607</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(187</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">110</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(297</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other income (expense), net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,213</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,903</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,310</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss before income tax</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(78,553</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(65,398</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(13,155</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(73</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,706</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,633</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(78,626</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(69,104</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(9,522</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses increased by $14.0 million from $54.1 million for the year ended December 31, 2022, to $68.1 million for the year ended December 31, 2023. This increase was attributable to increased research and development activities related to the advancement of our pipeline programs, including a $2.7 million increase in preclinical and manufacturing costs, a $2.9 million increase in clinical costs due to our CONNECT1, CONNECT2 and FREEDOM trials, and a $5.4 million increase in personnel-related costs due to increased headcount, including an increase of $1.3 million in stock-based compensation expense. There was also an increase of $4.4 million in facility and office expenses related to rent and related expense on our principal facility lease and a $0.4 million increase in depreciation expense related to lab equipment in our new lab space. These increases were partially offset by a $1.5 million decrease in other research and development expense primarily related to the OUI exit fee that was expensed upon completion of our IPO and a $0.4 million decrease in consulting expense.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses increased by $2.4 million from $14.2 million for the year ended December 31, 2022, to $16.6 million for the year ended December 31, 2023. The increase was primarily driven by a $1.7 million increase in personnel-related costs due to increased headcount, including an increase of $1.0 million in stock-based compensation expense, an increase of $1.4 million in facility-related costs due to our expansion of operations in Boston, Massachusetts, and a $0.3 million increase in insurance expense associated with operating as a public company. These increases were partially offset by a $0.9 million decrease in consulting and legal expense.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income (Expense), Net</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income (expense), net was income of $6.2 million for the year ended December 31, 2023, compared to income of $2.9 million for the year ended December 31, 2022. The increase was primarily driven by interest earned from our money market fund and U.S. treasury holdings.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Tax Expense</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income tax expense decreased by $3.6 million from $3.7 million for the year ended December 31, 2022, to $0.1 million for the year ended December 31, 2023 due to a tax charge associated with the transfer of all intellectual property assets from PepGen Limited to the parent company, PepGen Inc., pursuant to an asset transfer agreement, in January 2022.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">114</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sources of Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From our inception in January 2018 through December 31, 2023, we have funded our operations primarily through the sale of our common stock and convertible preferred stock. We received aggregate gross proceeds of $163.9 million from these sales prior to our IPO. Additionally, in May 2022, we received gross proceeds from our IPO of $108.0 million, and $14.9 million when the underwriters partially exercised their option to purchase 1,350,000 additional shares of common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We filed a shelf registration statement on Form S-3 with the SEC, which covers the offering, issuance and sale of an amount up to $300.0 million in the aggregate of shares of our common stock, preferred stock, debt securities, warrants, and/or units or any combination thereof, which was declared effective on June 16, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 8, 2023, we filed a prospectus supplement and entered into a Sales Agreement with Stifel, Nicolaus &amp; Company, Incorporated, as sales agent, which provides for the issuance and sale by us of up to $100.0 million of shares of common stock from time to time under the ATM program. On February 5, 2024, we issued and sold 1,000,000 shares at a purchase price of $10.00 per share under the ATM program, resulting in net proceeds of $9.9 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 9, 2024, we issued and sold 7,530,000 shares in the Follow-on Offering at a purchase price of $10.635 per share, resulting in net proceeds of $76.9 million after deducting underwriters' fees of $3.2 million.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future Funding Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had cash, cash equivalents, and marketable securities in the amount of $110.4 million. On February 5, 2024, we issued and sold 1,000,000 shares at a purchase price of $10.00 per share under our ATM program, resulting in net proceeds of $9.9 million. On February 9, 2024, we issued and sold 7,530,000 shares at a purchase price of $10.635 per share, resulting in net proceeds of $76.9 million after deducting underwriting fees of $3.2 million in the Follow-on Offering. Based on our current operating plans, we believe that our existing cash, cash equivalents, marketable securities, together with proceeds from shares sold under our ATM Program and in the Follow-on Offering, will be sufficient to fund our operations into 2026. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. Additionally, the process of conducting preclinical studies and testing product candidates in clinical trials is costly, and the timing of progress and expenses in these studies and trials is uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future capital requirements will depend on many factors, including but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, progress, costs and results of preclinical and clinical development for our product candidates, any additional product candidates we may develop and any new indications we may pursue; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, costs, timing and outcome of regulatory review of our product candidates, any additional product candidates we may develop and any new indications we may pursue; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost and timing of manufacturing activities; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the identification of additional research programs and product candidates; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and scope of the continued development of our EDO platform; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of preparing, filing and prosecuting applications for patents, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims, including claims of infringement, misappropriation or other violations of third-party intellectual property; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any product candidate that receives marketing approval; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of satisfying any post-marketing requirements; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the revenue, if any, received from commercial sales of our product candidates if marketing approval is received; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of operational, financial and management information systems and associated personnel; </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the associated costs in connection with any acquisition of in-licensed products, intellectual property and technologies; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of operating as a public company. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">115</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenue to support our cost structure, we expect to finance our cash needs through equity offerings, debt financings, or other capital sources, potentially including collaborations, licenses, and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise funds through collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. Our failure to raise capital or enter into such other arrangements when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our drug candidates even if we would otherwise prefer to develop and market such drug candidates ourselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth a summary of the net cash flow activity for the years ended December 31, 2023 and December 31, 2022 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash (used in) provided by:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(68,997</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(59,265</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(32,003</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,755</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(189</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">112,193</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effect of exchange rate changes on cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">286</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(316</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net increase (decrease) in cash, cash equivalents and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(100,903</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">48,857</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023, net cash used in operating activities was $69.0 million resulting from our net loss of $78.6 million partially offset by cash provided by changes in our operating assets and liabilities of $2.0 million and non-cash charges of $7.7</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">million. The net changes in our operating assets and liabilities were primarily due to an increase in accrued expenses of $1.4 million and an increase in prepaids and other current assets of $2.0 million. These increases were partially offset by a $1.2 million decrease in operating lease liabilities related to cash paid towards tenant improvements on our new office and lab lease. Non-cash charges included $7.0 million in stock-based compensation expense and $1.2 million in depreciation expense.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2022, net cash used in operating activities was $59.3 million resulting from our net loss of $69.1 million partially offset by cash provided by changes in our operating assets and liabilities of $4.5 million and non-cash charges of $5.3 million. The net changes in our operating assets and liabilities were primarily due to an increase in accrued expenses of $5.5 million and receipt of $4.2 million associated with our U.K. R&amp;D tax credit in 2022, which is accounted for in other receivables. These increases were partially offset by a $2.0 million decrease in operating lease liabilities related to cash paid towards tenant improvements on our new office and lab lease. Non-cash charges included $4.8 million in stock-based compensation expense and $0.5 million in depreciation expense.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in investing activities was $32.0 million during the year ended December 31, 2023 as compared to $3.8 million during the year ended December 31, 2022. Cash used for investing activities was related to $29.4 million in purchases of marketable securities and $2.6 million in purchases of property and equipment during the year ended December 31, 2023. Cash used for investing activities related to $3.8 million in purchase of property and equipment during the year ended December 31, 2022.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in financing activities was $0.2 million for the year ended December 31, 2023, which was primarily the result of  $0.4 million in payments towards offering costs related to our Form S-3 and Sales Agreement filings in May and August 2023, respectively. These payments were partially offset by $0.3 million of proceeds from equity plans .</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">116</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash provided by financing activities was $112.2 million for the year ended December 31, 2022, which was primarily the result of $114.3 million in net proceeds from the IPO, after deducting the payment of $2.7 million in IPO-related costs made in 2022. In 2021, we made payments of $1.4 million in IPO-related costs. Total net proceeds from the IPO were $110.2 million. Additionally, we generated $0.4 million from the exercise of the A-2 preferred stock warrants and $0.2 million in proceeds from stock option exercises.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Polices and Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which are prepared in accordance with generally accepted accounting principles in the U.S., or GAAP. The preparation of our financial statements requires us to make estimates and management discussion assumptions that affect the reported amounts of assets, liabilities, costs, and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. We evaluate our estimates and judgments on an ongoing basis. We base our estimates and assumptions on historical experience, known trends and events, and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While our significant accounting policies are more fully described in Note 2, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#8220;Summary of Significant Accounting Policies&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to our consolidated financial statements appearing elsewhere in this 10-K, we believe that the following accounting policies are the most critical for fully understanding and evaluating our financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses and Accrued Research and Development Costs</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are required to estimate our expenses resulting from obligations under contracts with vendors, consultants, CDMOs, and CROs, in connection with conducting research and development activities. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. We reflect research and development expenses in our financial statements by matching those expenses with the period in which services and efforts are expended. We account for these expenses according to the progress of the applicable preclinical or clinical study as measured by the timing of various aspects of the study or related activities. We determine accrual estimates through review of the underlying contracts along with preparation of financial models taking into account discussions and confirmations with research and other key personnel and the third-party vendors as to the progress of studies, or other services being conducted. During the course of a study, we adjust our rate of expense recognition if actual results differ from our estimates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We account for all stock-based compensation awards granted as stock-based compensation expense at fair value in accordance with the Financial Accounting Standards Board ASC Topic 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation&#8212;Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Stock-based compensation expense represents the cost of the grant date fair value of equity awards recognized over the requisite service period of the awards (usually the vesting period) on a straight-line or accelerated basis. We estimate the fair value of stock option awards using the Black-Scholes option pricing model and recognize forfeitures as they occur.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Black-Scholes option pricing model requires the use of subjective assumptions, including the risk-free interest rate, the expected stock price volatility, the expected term of stock options, the expected dividend yield, and the fair value of the underlying common stock on the date of grant. Changes in the assumptions can materially affect the fair value and ultimately how much stock-based compensation expense is recognized. Prior to our IPO, there was no public market for our common stock, and consequently, the estimated fair value of our common stock was determined by our board of directors as of the date of each stock option grant, with input from management, considering third-party valuations of our common stock as well as our board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent third-party valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or Practice Aid. The Practice Aid identifies various available methods for allocating the enterprise value across classes of series of capital stock in determining the fair value of our common stock at each valuation date. Since our IPO, we have determined the fair market value of our common stock using the closing price of our common stock as reported on the Nasdaq Global Select Market.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Off-balance sheet arrangements</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">117</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_qualitative_discol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statement_and_suppleme"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8. Financial Statements and </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supplementary Data.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our consolidated financial statements, together with the reports of our independent registered public accounting firms, appear beginning on page F-1 of this Form 10-K</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_and_disagreement"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9. Changes in and Disagreements W</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ith Accountants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_and_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9A. Controls</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and Procedures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) that are designed to ensure that information required to be disclosed in reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms and (2) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. In designing and evaluating our disclosure controls and procedures, our management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer have concluded based upon the evaluation described above that, as of December 31, 2023, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act). Our internal control over financial reporting is a process designed under the supervision of our principal executive and principal financial officer to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Management assessed our internal control over financial reporting as of December 31, 2023. Management based its assessment on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on that evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Form 10-K does not include an attestation report of our independent registered public accounting firm due to an exemption established by the JOBS Act for &#8220;emerging growth companies.&#8221;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">118</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d&#8209;15(f) under the Exchange Act) that occurred during the quarter ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9B. Other Informat</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ion.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Director and Executive Officer Trading Arrangements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the fourth quarter of 2023, none of our directors or officers </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_69ed245d-75cd-4897-848a-e5fe9924d191" contextRef="C_6aa00088-cf17-4c43-988e-abab7676b8a0" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_135a0917-494e-4388-8d2c-d650a2b104fe" contextRef="C_6aa00088-cf17-4c43-988e-abab7676b8a0" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5110f7c3-ebe2-4cfd-be86-7e28d588d87d" contextRef="C_6aa00088-cf17-4c43-988e-abab7676b8a0" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_c4ff1a5a-ac63-4c7e-9f33-1c0607850d7a" contextRef="C_6aa00088-cf17-4c43-988e-abab7676b8a0" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> any contract, instruction or written plan for the purchase or sale of our securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any &#8220;non-Rule 10b5-1 trading arrangement&#8221; (as defined in Item 408(c) of Regulation S-K).</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_disclosure_regarding_foreign"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9C. Disclosure Rega</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">rding Foreign Jurisdictions that Prevent Inspections.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not Applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">119</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">T III</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_officers"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 10. Directors, Executive</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Officers and Corporate Governance.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required under this item is incorporated herein by reference to our definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the SEC not later than 120 days after the close of our fiscal year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 11. Executive Com</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pensation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required under this item is incorporated herein by reference to our definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the SEC not later than 120 days after the close of our fiscal year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership_of_certain"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 12. Security Ownership of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain Beneficial Owners and Management and Related Stockholder Matters.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required under this item is incorporated herein by reference to our definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the SEC not later than 120 days after the close of our fiscal year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_certain_relationships_and_relate"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 13. Certain Relationships </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and Related Transactions, and Director Independence.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required under this item is incorporated herein by reference to our definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the SEC not later than 120 days after the close of our fiscal year ended December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accounting_fees"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 14. Principal Accou</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nting Fees and Services.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required under this item is incorporated herein by reference to our definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the SEC not later than 120 days after the close of our fiscal year ended December 31, 2023.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">120</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> IV</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statement"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 15. Exhibits, Financial Statem</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ent Schedules.</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For a list of the financial statements included herein, see Index to the Consolidated Financial Statements on page F-1 of this Annual Report on Form 10-K, incorporated into this Item by reference.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">121</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.752626672113803%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibits:</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">122</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11%;"/>
    <td style="width:2%;"/>
    <td style="width:87%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1***</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835597/000095017022011719/pepg-ex3_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Third Amended and Restated Certificate of Incorporation (Incorporated by reference to Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q filed on June 16, 2022 (File No. 001-41374))</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2***</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835597/000095017022024186/pepg-ex3_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certificate of Correction to Third Amended and Restated Certificate of Incorporation (Incorporated by reference to Exhibit 3.2 to the Company's Quarterly Report on Form 10-Q filed on November 10, 2022 (File No. 001-41374)).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.3***</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835597/000095017022011719/pepg-ex3_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated By-laws (Incorporated by reference to Exhibit 3.2 to the Company's Quarterly Report on Form 10-Q filed on June 16, 2022 (File No. 001-41374)).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1***</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835597/000119312522106884/d235586dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Investors' Rights Agreement, dated July 30, 2021, among the Company and certain of its stockholders (Incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-1, as amended (File No. 333-264335)).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2***</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835597/000119312522135245/d235586dex42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Specimen Common Stock Certificate (Incorporated by reference to Exhibit 4.2 to the Company's Registration Statement on Form S-1, as amended (File No. 333-264335)).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3***</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835597/000095017023009500/pepg-ex4_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Description of Securities (Incorporated by reference to Exhibit 4.3 to the Company's Annual Report on Form 10-K filed on March 23, 2023 (File No. 001-41374))</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1***</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835597/000119312522106884/d235586dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2020 Stock Plan, as amended, and forms of award agreements thereunder (Incorporated by reference to Exhibit 10.1 to the Company's Registration Statement on Form S-1, as amended (File No. 333-264335)).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2***</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835597/000119312522135245/d235586dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2022 Stock Option and Incentive Plan, and forms of award agreements thereunder (Incorporated by reference to Exhibit 10.2 to the Company's Registration Statement on Form S-1, as amended (File No. 333-264335)).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.3***</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835597/000119312522135245/d235586dex103.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2022 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.3 to the Company's Registration Statement on Form S-1, as amended (File No. 333-264335)).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.4**</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835597/000119312522135245/d235586dex104.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Senior Executive Cash Incentive Bonus Plan (Incorporated by reference to Exhibit 10.4 to the Company's Registration Statement on Form S-1, as amended (File No. 333-264335)).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.5***</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835597/000095017022024186/pepg-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Non-Employee Director Compensation Policy (Incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on August 8, 2023 (File No. 001-41374)).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.6***</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835597/000119312522135245/d235586dex105.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Indemnification Agreement between the Company and each of its directors and executive officers (Incorporated by reference to Exhibit 10.5 to the Company's Registration Statement on Form S-1, as amended (File No. 333-264335)).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7***</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835597/000095017023009500/pepg-ex10_7.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated March 21, 2023, between James McArthur and the Company (Incorporated by reference to Exhibit 10.7 to the Company's Annual Report on Form 10-K filed on March 23, 2023 (File No. 001-41374))</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8***</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835597/000095017023009500/pepg-ex10_8.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated March 21, 2023, between Noel Donnelly and the Company (Incorporated by reference to Exhibit 10.8 to the Company's Annual Report on Form 10-K filed on March 23, 2023 (File No. 001-41374))</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9***</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835597/000095017023009500/pepg-ex10_9.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated March 21, 2023, between Jaya Goyal and the Company (Incorporated by reference to Exhibit 10.9 to the Company's Annual Report on Form 10-K filed on March 23, 2023 (File No. 001-41374)).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.10***</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835597/000095017023009500/pepg-ex10_10.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated March 21, 2023, between Michelle Mellion and the Company (Incorporated by reference to Exhibit 10.10 to the Company's Annual Report on Form 10-K filed on March 23, 2023 (File No. 001-41374)).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.11***</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835597/000095017023009500/pepg-ex10_11.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated March 21, 2023, between Niels Svenstrup and the Company (Incorporated by reference to Exhibit 10.11 to the Company's Annual Report on Form 10-K on March 23, 2023 (File No. 001-41374))</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.12&#134;***</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835597/000119312522106884/d235586dex1010.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">License of Technology, dated November 23, 2020, among Oxford University Limited, Medical Research Counsel as part of the United Kingdom Research and Innovation and PepGen Limited (Incorporated by reference to Exhibit 10.10 to the Company's Registration Statement on Form S-1, as amended (File No. 333-264335)).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.13***</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835597/000119312522106884/d235586dex1011.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Lease, dated December 1, 2021, between B9 LS Harrison &amp; Washington LLC and the Company (Incorporated by reference to Exhibit 10.11 to the Company's Registration Statement on Form S-1, as amended (File No. 333-264335)).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.14***</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835597/000095017023020829/pepg-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First  Lease Amendment, dated January 14, 2022, between B9 LS Harrison &amp; Washington LLC and the Company (Incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on May 11, 2023 (File No. 001-41374)).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.15***</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835597/000095017023020829/pepg-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Lease Amendment, dated March 29, 2023, between B9 LS Harrison &amp; Washington LLC and the Company (Incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on May 11, 2023 (File No. 001-41374)).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.16***</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835597/000095017023039392/pepg-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment No. 1 to the License of Technology Agreement, dated February 12, 2021, by and among Oxford University Innovation Limited, Medical Research Counsel as part of the United Kingdom Research and Innovation and PepGen Limited (Incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on August 8, 2023 (File No. 001-41374)).</span></a></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">123</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11%;"/>
    <td style="width:2%;"/>
    <td style="width:87%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.17***</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835597/000095017023039392/pepg-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Agreement for Contract Novation, dated January 1, 2022, by and among Oxford University Innovation Limited, United Kingdom Research and Innovation, PepGen Limited and PepGen Inc. (Incorporated by reference to Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q filed on August 8, 2023 (File No. 001-41374)).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18***</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835597/000119312523205630/d537671dex11.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">At-the-Market Equity Offering Sales Agreement, dated August 8, 2023, between Stifel, Nicolaus &amp; Company, Incorporated and the Company (Incorporated by reference to Exhibit 1.1 to the Company&#8217;s Current Report on Form 8-K filed on August 8, 2023 (File No. 001-41374))</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.19*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="pepg-ex10_19.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated December 6, 2023, between Mary Beth DeLena and the Company</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.1***</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1835597/000119312522106884/d235586dex211.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Subsidiaries of Registrant (Incorporated by reference to Exhibit 21.1 to the Company's Registration Statement on Form S-1, as amended (File No. 333-264335)).</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.1*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="pepg-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of KPMG, LLP, independent registered public accounting firm</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.1*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="pepg-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.2*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="pepg-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.1**</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="pepg-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.2**</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="pepg-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97*</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="pepg-ex97.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Compensation Recovery Policy</span></a></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.CAL</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.DEF</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.LAB</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.PRE</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:80%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">* Filed herewith.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">** Furnished herewith.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">*** Previously filed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#134; Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the SEC.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summa"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 16. Form 1</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0-K Summary.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">124</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized, on March 6, 2024.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.38%;"/>
    <td style="width:2.7%;"/>
    <td style="width:7%;"/>
    <td style="width:44.92%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">PEPGEN INC.</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ James McArthur</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">James McArthur</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated as of March 6, 2024.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:78.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:42.072%;"/>
    <td style="width:1.34%;"/>
    <td style="width:55.249%;"/>
    <td style="width:1.34%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ James McArthur</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">James McArthur, Ph. D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Noel Donnelly</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Noel Donnelly, M.B.A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Laurie B. Keating</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chairperson of the Board of Directors</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Laurie B. Keating, J.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Christopher Ashton</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Christopher Ashton, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Habib Joseph Dable</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Habib Joseph Dable</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Heidi Henson</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Heidi Henson</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Howard Mayer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Howard Mayer, M.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Joshua Resnick.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Joshua Resnick, M.D., M.B.A</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">125</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93%;"/>
    <td style="width:7%;"/>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.05555555555555555in;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.05555555555555555in;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_of_independent_registered"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID No. 185)</span></a></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.05555555555555555in;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Consolidated Financial Statements as of and for the Year Ended December 31, 2023 and 2022:</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.05555555555555555in;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.05555555555555555in;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.05555555555555555in;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidatedstatementsofoperation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Operations</span></a></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.05555555555555555in;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_comprehensive_loss"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Comprehensive Loss</span></a></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.05555555555555555in;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></a></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.05555555555555555in;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_cashflows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.05555555555555555in;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notestoconsolidatedfinancialstatements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_of_independent_registered"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Report of Independent Regi</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">stered Public Accounting Firm</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the Stockholders and Board of Directors<br/>PepGen Inc.:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Opinion on the Consolidated Financial Statements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of PepGen Inc. and subsidiaries (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations, comprehensive loss, convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows for each of the years in the two-year period ended December 31, 2023, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ KPMG LLP</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2021.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phoenix, Arizona<br/>March 6, 2024</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PEPGEN INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheets_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED BALANCE SHEETS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(IN THOUSANDS, EXCEPT SHARE AND PAR VALUE AMOUNTS)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fb3fa18-38e7-4caa-8e5a-a7f812d23808" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,774</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa2a3bdb-d224-4c27-98d0-7a589d70c65b" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">181,752</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable Securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_007461dc-e9bf-46e4-833d-4f5c16db53c9" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,633</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dedefbe3-a8ef-42f8-896c-b936397982e3" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,271</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b64d4e56-24cf-4131-8dcd-abdb80b9f1d2" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,331</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26a4cf99-11ca-4649-a758-229ba7f71d74" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112,678</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b5b91c4-6357-4331-8f29-c7d8c4e2bff5" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">186,083</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e003a75-c6cf-485e-87db-600c96d833d9" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,764</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aded7590-5088-4b37-8fc3-218937f2900b" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,335</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use asset</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a3b375d-5d97-459b-8d57-e631395c5393" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,620</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_100b9ad0-e352-4843-bb95-399252b8aaf1" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,549</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab12be16-a4ad-4aed-ac9e-5338b459d918" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,990</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e876dae-8eb0-483a-a1d1-68f805c7c649" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,473</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6af30fdf-faf7-4de5-a4d0-5e30a9b94934" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,052</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_efff4dde-cad4-4e7e-82f4-e55a13026167" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">217,440</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities, convertible preferred stock, and stockholders&#8217; equity (deficit)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b4ed28c-11ed-4daa-8c93-057b34def909" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,005</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_097d878d-5131-49a0-9259-48fcf831f3e4" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,362</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84fde079-2bfa-4d77-b754-24fca5aa9dbc" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,522</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b056f4f6-6cca-4586-857b-f6fda944b121" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,913</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00c37a73-e2dd-4e01-a591-28f06e027ecf" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,004</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fe3fc7e-d37d-462f-a043-ae1085d122f3" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,553</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_367c896d-dde4-4245-9ee9-e9a3afe4338e" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,531</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8265082-c77e-4cc6-9605-7b200eb2e1a8" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,828</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability, net of current portion</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4eb5678-2320-4402-91d3-38bb83136304" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,100</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e5dbc91-8320-4d1f-8a6a-2995875a4769" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,981</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0bcd5a3-2163-4ecf-acfc-fd7e0e1ac9c9" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,631</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ae19ea7-5fe0-44f6-9192-8eb1f582a6eb" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,809</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af6203f0-9ec8-4b0a-847a-c0c32cbe3aee" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c6553d22-293a-4417-8593-21a20ccf2cff" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0baf930b-0078-4143-8078-3b91dd498568" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c3954a80-b912-48c8-bb4a-145e8e0d9e17" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized<br/>&#160;&#160;&#160;at December 31, 2023 and 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_0d70d773-c0e8-4741-991d-30b53e69f2b9;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_103f5d8d-8f9e-4d7e-a3c7-dd555847280a;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b13658b0-fc00-4ca1-a633-a2471e84a4f1" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_535dc419-fb9b-4ad7-8c7f-5b03f14aa18c" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1426abf0-ceca-4447-b6d8-14227ba06466" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f98f8bea-09af-4d0d-8acf-22827206d560" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized<br/>&#160;&#160;&#160;as of December 31, 2023 and 2022, respectively; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b648f7c-26f5-40ca-86f7-50aee85f1b3d" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2bb839a2-bb4e-411d-ad1c-9a155cf03d8a" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">23,823,241</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab6fe3d3-c3c4-428e-ba0a-993b35f06d82" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2c2bda19-543c-41b3-982d-699f70388707" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">23,713,196</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares<br/>&#160;&#160;&#160;issued and outstanding as of December 31, 2023 and 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9aa5cb63-8902-46b6-b9c8-c8f9b29052d7" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ee33a4c-39c3-45db-8530-d6d172066fac" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2da41d3-6e91-43b6-addb-c7c2c52473d9" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">289,867</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13cc7409-d24e-4363-9967-65ea6fbeb931" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">282,566</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive income (loss)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97459db8-41df-4256-8b18-f68e569de05c" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab4355f7-4142-45e4-8569-03924cc06275" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">81</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_022a7048-5689-4400-bdcf-3d50f8b8b898" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">181,482</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9d917f0-7912-4fd4-8234-e672e09d4049" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">102,856</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#8217; equity (deficit)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79bb0dbd-0ca7-4e35-9f00-2805065db2b5" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,421</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d3addbe-f9d9-4227-b9da-208283c6c456" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">179,631</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities, convertible preferred stock, and stockholders&#8217; equity (deficit)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09ad027f-380f-44c4-9a71-3e1105d9cbff" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,052</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5733c431-a7f2-4079-9ebb-3d6e19897f31" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">217,440</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PEPGEN INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidatedstatementsofoperation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS OF OPERATIONS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04dc78ce-89fa-422b-adfc-7abef9197e4d" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,126</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dcc25330-fcc9-449e-94b2-8518aea4749a" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,077</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f87df946-6811-436c-b699-3ac981785d32" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,640</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3b19c6c-3d14-41d8-b0b3-890b9492b053" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,224</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edb486bc-89eb-4ac3-b024-15f2f3f065b9" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,766</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0fd14957-ca81-405f-9c0c-8faf0e8e158d" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,301</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1962a512-dc59-4344-8617-b06a46f6e118" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">84,766</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_353aa263-2d06-48db-8300-9c04960ff52f" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">68,301</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_adfc8d43-086f-4e38-aa75-8dc9265822ff" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,400</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0bc45c77-95e5-415c-a0cc-0e4826873e89" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,793</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_625c7a6c-0c72-4aac-aa5c-187a1f53b6eb" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">187</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_156dfb8e-184a-4024-9368-406bc63a720a" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">110</ix:nonFraction></span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77261c15-f332-4b05-b2d7-d325e8fa13ca" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,213</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6cfb22a7-1f22-46f3-a34c-843a3e1ed0e2" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,903</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss before income tax</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1fc3412-9757-4d69-bee9-5b4101af0d2a" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">78,553</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebf164ff-c255-4589-b692-4aa9f13d3299" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">65,398</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb81aa85-81ba-40c6-8c81-05790b530da7" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44368a02-94a0-4fc4-8de3-1c3c11f2c3ea" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,706</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a807111-03ca-4db0-a3b1-2645afddd9c9" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">78,626</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27931617-4bbc-410e-acae-8aee46bd11fc" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">69,104</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71a19b6f-e3ba-48fa-b9d8-8c4b1dcbb60d" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9b9f69f7-6be9-4d71-b31f-5e109f34f956" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">3.30</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96495e4f-e4a5-4ba0-b1f8-496730d4eca2" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c49c18c0-e043-4dc3-965b-f50d62ca749c" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">4.42</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average common shares outstanding, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68e1dc74-3411-4a2a-9cef-124528907ca2" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_fa8eee00-9035-494f-b911-9202699b7edf" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">23,796,000</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5248125c-0bfa-4aeb-9583-8316c6c8b873" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4a461a2d-7c04-4f77-b193-119a1afa21ab" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">15,639,728</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PEPGEN INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_comprehensive_loss"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> OF COMPREHENSIVE LOSS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(IN THOUSANDS)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91081160-7b58-4a80-b1ed-f4778ed3f513" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">78,626</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a5d6339-5450-4679-92ad-b9fde708b6a8" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">69,104</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cumulative translation adjustment arising during the period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c17c08e-8d48-4c45-b791-30b4034040ca" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_263b497e-3682-4291-978d-2c4685ceb662" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">98</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain on marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87aae7c4-4af1-4931-bbcb-68b5158a2043" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62ca795d-296c-449d-b43d-3dcbd2f5813d" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">78,511</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a8ddf99-4019-417b-bd98-51ba5bedd5fa" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">69,202</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PEPGEN INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(IN THOUSANDS, EXCEPT SHARE AMOUNTS)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:15.277%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.479%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.479%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.479%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.479%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.479%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:2.48%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.479%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.479%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:4.519%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.079%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.479%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.819%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Series A-1<br/>Convertible<br/>Preferred Stock</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Series A-2<br/>Convertible<br/>Preferred Stock</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Series B<br/>Convertible<br/>Preferred Stock</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>Paid-in<br/>Capital</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Deficit</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Stockholders&#8217;<br/>Equity<br/>(Deficit)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance as of December 31, 2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09722c04-48c8-466a-a34d-31fd6249eeb0" contextRef="C_f58e97f2-94c9-4dc7-ac7d-e3f44208d56a" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,372,970</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2ff7342-d237-48d0-a3d9-8aa5b2e68c01" contextRef="C_f58e97f2-94c9-4dc7-ac7d-e3f44208d56a" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,454</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88ede50f-2f04-4372-9488-98dbc6114492" contextRef="C_063bd5cf-7893-460d-a103-34991df7eaa2" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,939,069</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4832b1a0-2bbe-4234-9d73-4105cefab706" contextRef="C_063bd5cf-7893-460d-a103-34991df7eaa2" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,639</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_989f6651-2d91-4d4e-9472-5c39d4397d93" contextRef="C_48802948-74ba-4e4c-bd84-6de3c161ffbd" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,234,766</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a24b6518-4ebf-4ced-8267-34cf6a80e241" contextRef="C_48802948-74ba-4e4c-bd84-6de3c161ffbd" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112,083</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91f5ac71-5155-48ee-aee4-253db55e94ee" contextRef="C_9fc357d1-aca9-4939-8508-2e6b6c2e1aef" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">963,588</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8785bc8e-8a8f-4196-a99f-adb4c79c5b3e" contextRef="C_6da8e9ac-df70-4c39-a066-f43de00ad6c8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,653</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be6b0874-750d-4904-88df-3ff6a79ef0c7" contextRef="C_c802d06c-99b8-4fc0-8210-d04f7dc4782d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_251a2b60-8f6e-4fa3-9521-ed2c8acd0d7e" contextRef="C_a02d2713-9447-4f0e-94e0-cac5b3c390f0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">33,752</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c0ad6b9-bbec-427b-8456-5dc6374f192a" contextRef="C_1b696bc0-9c03-4cef-975e-0195f8d44c1a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">32,082</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:8pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of Series A-2 stock upon exercise of warrants</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ceed9cb8-3034-4cff-bbe5-85e402fe7f24" contextRef="C_e5fff44b-bbb8-4123-aa83-3f024c4f13f7" name="pepg:TemporaryEquityStockIssuedDuringPeriodSharesStockUponExerciseOfWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">35,529</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e088cc8-6ff2-434e-81d1-d1cc6ea27e08" contextRef="C_e5fff44b-bbb8-4123-aa83-3f024c4f13f7" name="pepg:TemporaryEquityStockIssuedDuringPeriodValueStockUponExerciseOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">574</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:8pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of convertible preferred stock upon IPO</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01900440-488a-4b2d-a46c-73b45da21d3a" contextRef="C_be762841-9478-40d4-a7e8-487a90f06ec8" name="pepg:TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering" unitRef="U_shares" decimals="INF" sign="-" format="ixt:num-dot-decimal">1,372,970</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b49aabf8-84ea-4b0b-884c-216ffd028cb3" contextRef="C_be762841-9478-40d4-a7e8-487a90f06ec8" name="pepg:TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,454</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9eac9a9a-cc27-430c-9b74-ccea8b719a54" contextRef="C_e5fff44b-bbb8-4123-aa83-3f024c4f13f7" name="pepg:TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering" unitRef="U_shares" decimals="INF" sign="-" format="ixt:num-dot-decimal">3,974,598</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_952022bd-39a3-4044-8209-9c83eb5abdd0" contextRef="C_e5fff44b-bbb8-4123-aa83-3f024c4f13f7" name="pepg:TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">45,213</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d256bda9-b6e3-4f14-bd97-372e85329c1f" contextRef="C_8318feed-c68a-4d65-a6b4-50a029944a36" name="pepg:TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering" unitRef="U_shares" decimals="INF" sign="-" format="ixt:num-dot-decimal">7,234,766</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_afe50dbc-ee15-416d-853b-2721d8c925f8" contextRef="C_8318feed-c68a-4d65-a6b4-50a029944a36" name="pepg:TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">112,083</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbd5b467-8d24-4c59-afb8-689bab989ada" contextRef="C_9444a584-901b-44fb-95ce-d2000dc58dd6" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,359,856</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4de4332-9e8a-44d9-8de6-6a9e22f811d0" contextRef="C_9444a584-901b-44fb-95ce-d2000dc58dd6" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92038386-1f6f-40e9-b16f-44a7abd71bed" contextRef="C_e00b2f45-4b2c-4c07-b7e3-9f43f7606c50" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">165,751</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3c62f48-f248-4210-aa60-70d0e0efad5f" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">165,752</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:8pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">Issuance of common stock in IPO, net of underwriters' fees and issuance costs of $</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7d5549a-e2d2-4baa-b0f5-d414eaf6df92" contextRef="C_9444a584-901b-44fb-95ce-d2000dc58dd6" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,684</ix:nonFraction></span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9bcda1fc-ff86-40e0-8c1b-106ea0179f39" contextRef="C_9444a584-901b-44fb-95ce-d2000dc58dd6" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,238,951</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e97ecda5-e4a5-4fae-b5fb-2740277f8210" contextRef="C_9444a584-901b-44fb-95ce-d2000dc58dd6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09835c4a-9b21-4216-ab43-df66f69d3960" contextRef="C_e00b2f45-4b2c-4c07-b7e3-9f43f7606c50" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">110,182</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf640e31-50b0-4808-8bd9-626efd8f28b3" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">110,183</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:8pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Release of common stock from vesting restrictions</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbcc7517-ddc3-40bd-b8ac-248ec440b2ba" contextRef="C_9444a584-901b-44fb-95ce-d2000dc58dd6" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">69,529</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:8pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2df2dc92-9df3-4a27-b4eb-82c41630a99c" contextRef="C_9444a584-901b-44fb-95ce-d2000dc58dd6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">81,272</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d6fe948-2c19-440e-b15e-163e856c6cb4" contextRef="C_e00b2f45-4b2c-4c07-b7e3-9f43f7606c50" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">217</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86e6dc59-f8d7-4232-9fac-49fbcbd0505c" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">217</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:8pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation<br/>&#160;&#160;&#160;expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40ab7d3a-b8bc-4f6d-83e4-c7cc13d93003" contextRef="C_e00b2f45-4b2c-4c07-b7e3-9f43f7606c50" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,763</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4d61872-87bb-4248-978b-8ab429a8a399" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,763</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:8pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cumulative translation adjustment arising during the period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b92a337-b60e-409e-a87a-f44fae31ad5f" contextRef="C_ba1eafbf-79c8-4ea9-b601-011eeea8dba7" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">98</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_455696d5-7963-42e4-8cc8-55639fb04a6e" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">98</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:8pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_171cc944-dd22-4ee2-804f-6397b7af564d" contextRef="C_cc8621bc-02a4-40ab-b23b-4c8af4926152" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">69,104</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_218f7b9a-f1b0-4d46-abb2-4154444ce315" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">69,104</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ffc733e-f74d-4f26-9c58-c7a25c73b9d4" contextRef="C_3a41894a-8ad8-4c44-9399-b1722da555e7" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">23,713,196</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_154f369e-203d-4970-a9f4-8d069612b281" contextRef="C_3a41894a-8ad8-4c44-9399-b1722da555e7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1395f24-c710-4667-90af-898699b0cea5" contextRef="C_c59812be-057a-482f-bae8-fa2c033d1afd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">282,566</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64b9822f-da52-46b2-ae6e-1cf1dfb352df" contextRef="C_a065b967-ade2-4903-9ca0-ebd7ce31343d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">81</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2012fd46-6130-43d1-8dc2-c5f39e7deb3d" contextRef="C_15495aa7-f537-415e-97da-a0992d3b9cb6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">102,856</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_84a6ca9e-19a2-4686-8293-c201af4d21e4" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">179,631</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:8pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of stock under the employee stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2af936c4-9607-4bb9-a588-5d66c0c6fde6" contextRef="C_ace6a7aa-5e97-4501-8932-98392f77ce72" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,694</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7dcf88e5-1361-4ab0-b7a0-9f6cfcdd17fb" contextRef="C_a035c4f4-0bbe-47a2-a989-557b4c88dd4e" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f269a52c-d03c-4e65-af2b-11cfacb5f8e9" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:8pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82f5fec3-8a3b-4b40-8735-fcccf5c53ee0" contextRef="C_ace6a7aa-5e97-4501-8932-98392f77ce72" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">100,351</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c5495b8-6e06-4796-9aa2-0fb96928b207" contextRef="C_a035c4f4-0bbe-47a2-a989-557b4c88dd4e" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3790b9d-f266-4219-95fb-a04fbbb55fae" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">213</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:8pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7ca102a-a2dd-41ee-a2f4-0c3fd5996824" contextRef="C_a035c4f4-0bbe-47a2-a989-557b4c88dd4e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,048</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96dfb0d6-2709-454f-9c1f-0e2159dbcfc9" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,048</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:8pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain on marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78de7753-7714-4eaf-b900-dd39299fe3bc" contextRef="C_ed06b17b-3586-4df6-a87e-12566f6bab76" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52cb2f60-cb5c-4ca7-9e26-739bc36633f7" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:8pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cumulative translation adjustment arising during the period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1eac2848-b226-4ac3-9673-32b7ba0b2985" contextRef="C_ed06b17b-3586-4df6-a87e-12566f6bab76" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7006f713-35b7-4524-9b2c-ada5d042d60b" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:8pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e5dea5c-8bf9-47ee-9603-36a485af7832" contextRef="C_cce7a15c-5959-4b95-821c-ff224707de79" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">78,626</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39daaa92-8761-4f2f-8072-6393a8166729" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">78,626</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_761b82d1-0115-4770-81b4-025cb20fa7eb" contextRef="C_37a6b7a6-092b-457c-bee8-fde979f4e845" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">23,823,241</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b212a709-35bd-4a1f-ac7b-1ff21624c8f6" contextRef="C_37a6b7a6-092b-457c-bee8-fde979f4e845" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7de8b86-da29-463b-bb76-f5795f245e4d" contextRef="C_c24a5f2f-a1e3-4f88-98c5-79645a25bbbf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">289,867</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4d79735-0b40-4fb0-8a5b-242761fb3be3" contextRef="C_a65d95cd-5bc9-4e3d-baa3-39ba00afc7f4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc74b73b-4dc2-4602-92c1-b71c7b11c073" contextRef="C_240e4da2-412b-4131-b975-ff30d06f0d88" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">181,482</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e304adbc-3266-46ca-a1da-dc126d529540" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,421</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PEPGEN INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_of_cashflows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONSOLIDATED STATEMEN</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TS OF CASH FLOWS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(IN THOUSANDS)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9222a781-9076-49ac-b4c4-d1e1bf5b5fdf" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">78,626</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be411d1f-8f09-43ab-bcb6-0ff849fbe526" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">69,104</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net loss to cash used in operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41a85b79-9fa7-4ef3-bd56-8832526c4e07" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,184</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88be1916-cc2a-4803-ba63-788895ac1c3e" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">493</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3734a177-34af-49f5-a555-949b3a6a0f28" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,048</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a526cc7-4911-4881-9c66-59b86188c700" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,763</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization and interest accretion related to operating lease</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2de0257b-4be5-41ec-94d5-27cde1775c66" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="pepg:AmortizationAndInterestAccretionRelatedToOperatingLeases" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">334</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of premium and discounts on marketable securities, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30496c3e-b806-4764-9d08-6cd406433e17" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="pepg:AmortizationOfPremiumAndDiscountsOnMarketableSecuritiesNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">220</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of preferred stock warrant liability</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0dce626a-7477-4f0f-84c0-9f79421f29bb" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">58</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss on disposal of fixed assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43edbcec-8da1-4308-93cb-07e48f66fa45" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">134</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other receivables</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee293b76-97c0-4f88-a60b-0f2e11027753" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:IncreaseDecreaseInOtherReceivables" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4dbc2696-5ead-4293-ad21-f23eb84fa89f" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:IncreaseDecreaseInOtherReceivables" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,183</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaids and other current and non-current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edc0b29e-6c7b-422f-8846-5495b172249b" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,038</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bafa77ce-f41a-41b7-9116-dca860668cfa" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,784</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_408133b7-39f2-4183-a31c-236d6b489ff8" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">369</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3bd95018-f5a0-46ae-bb6d-e4823954c453" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,407</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other non-current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aae62784-e255-4c1d-9ea5-7913f83cd86f" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,422</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0aedf8ab-9e3e-45f0-83e6-013d4ba42690" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,531</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities, current and non-current</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e049c95f-2a9c-43ed-9da2-dbd206b35ed6" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,166</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3945967-ed3d-4d6b-a3fb-3a0f95b10706" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,016</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f55fab2a-227d-4e8f-8ff2-0182f6014a2d" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">68,997</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6aa4b57f-08df-4911-9080-5d01eca2f160" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59,265</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6987c41a-b05d-4d64-97ca-22f8bcdf3ae1" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,599</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c22debf6-2e37-4dac-8bd7-5cd31448cfcc" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,755</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_305edf21-2e80-477f-b9c5-815fa034f67c" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,404</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ce8a8dd-eb64-4d6f-8739-e31f2a7ce5d4" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">32,003</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6168a072-86ba-4c08-987b-c51c19e53c4b" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,755</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock upon initial public offering, net of underwriters&#8217; fees</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ae44f3f-e5e0-4938-8b13-59f637a01f7d" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,267</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payment of offering costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1a337e5-cc3c-45e5-bea8-934d429b1216" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="pepg:PaymentOfOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">442</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f0b1cf5-0e95-476e-8a42-aed041efcd5f" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="pepg:PaymentOfOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,697</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of common stock upon exercise of Series A-2 warrants</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28221503-7dd6-4731-ab6b-1fa24cad66fa" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">406</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from employee equity plans</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c4bcd11-3b42-4153-a2b9-d6eb5ea9b255" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">253</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b59e62f-6e13-436d-952c-8ab6fd7b2a0c" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">217</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6c192c7-7c71-4555-ac73-b42facbc6968" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">189</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa6d4571-4aec-4910-a0e5-bc2f7c9eac79" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112,193</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effect of exchange rate changes on cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5f08ecf-9952-4036-96b2-644678c69554" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">286</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8f88b28-fdf0-45cf-9852-f4bdd11dc076" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">316</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net (decrease) increase in cash, cash equivalents and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97464cab-4a71-4b5f-aaef-e24fc35893d5" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">100,903</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0dd526cd-1c58-4b69-a540-97941a4adeae" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">48,857</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash at beginning of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1db823b-2b89-47cf-9f71-c07cc62dddbe" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">183,225</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed10ac15-d9dd-4434-8367-5e82641f5d64" contextRef="C_1b696bc0-9c03-4cef-975e-0195f8d44c1a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">134,368</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash at end of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3b145bc-27a4-4a79-b614-de4366052e54" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,322</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63a61b4a-de44-40f1-baa1-9130f77dce13" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">183,225</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Components of cash, cash equivalents and restricted cash</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_973e1de5-93d5-4c15-9785-bae668a8333f" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,774</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6c4d886-1465-4855-906c-70b727c6d8f6" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">181,752</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7633b09d-4953-4434-9f35-65a962d0c788" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,548</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1509dc39-6498-463e-8ef3-3f1742c24fc5" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,473</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash, cash equivalents and restricted cash at end of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e6ba3f1-046c-41cd-bb27-d48447952018" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">82,322</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69081f88-f212-46d4-931c-03c5f44aa51b" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">183,225</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental noncash investing and financing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment included in accounts payable and accrued expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81e86b6c-26dc-4df0-a7cc-9038e75ac62d" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="pepg:PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7cb52d9-a6e8-4694-88e8-31335c523601" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="pepg:PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">363</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8da6c8e-7963-425d-ba5c-e40ee0fddcbb" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,702</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease assets obtained in exchange for new operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7807cb92-c5bc-4233-a2b2-4cdb041e9a12" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,549</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PEPGEN INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notestoconsolidatedfinancialstatements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES T</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">O CONSOLIDATED FINANCIAL STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b550aaa6-b3b0-43be-80d9-e2a4c707431c" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of Business and Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PepGen Inc. (PepGen or the Company), is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The Company's principal offices are located in Boston, Massachusetts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company was initially formed as PepGen Limited on January 25, 2018, in the United Kingdom, or the U.K. On November 9, 2020, PepGen Limited completed a corporate reorganization, or the Reorganization. As part of the Reorganization, PepGen Limited formed PepGen Inc., a Delaware corporation with nominal assets and liabilities, for the purpose of consummating the Reorganization. In connection with the Reorganization, the existing stockholders of PepGen Limited exchanged each of its classes of shares of PepGen Limited for the same number and class of common stock of PepGen Inc. on a one-to-one basis. The newly issued stock of PepGen Inc. had substantially identical rights to the exchanged shares of PepGen Limited. As a result of the exchange, PepGen Inc. became the sole stockholder of PepGen Limited. Upon the completion of the Reorganization on November 23, 2020, the historical financial statements of PepGen Limited became the historical financial statements of PepGen Inc. as the Reorganization was deemed to be between entities under common control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Initial Public Offering and Follow-On Offerings</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 10, 2022, the Company closed its initial public offering, or IPO, in which the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ff5b85a-3010-4f82-aa3b-07d206633d93" contextRef="C_d1b4f98a-2717-48fb-ae1c-8c5f9097d55f" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_390343bc-dca4-441b-af85-50e90e3231ca" contextRef="C_620ef023-203d-4a5a-845f-4edc70fd7788" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">12.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97344f0d-4628-4bc7-960e-bd7abf0d098e" contextRef="C_d1b4f98a-2717-48fb-ae1c-8c5f9097d55f" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">108.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. In connection with the IPO, the Company granted the underwriters a 30-day option to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5620c06-9173-44d6-9c50-e337c6e6adba" contextRef="C_ff132215-5434-4c88-b5f1-c47dfe048266" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,350,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional shares of common stock. On May 16, 2022, the underwriters exercised the option in part and the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f88acaf3-3c0f-4588-b59a-51369d7295fd" contextRef="C_5bca00da-1c31-464f-a7f2-5cd7315f851e" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,238,951</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock for gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1046314d-d96c-4b3a-b503-a77e1eb30f8e" contextRef="C_5bca00da-1c31-464f-a7f2-5cd7315f851e" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. From the IPO and option exercise by the underwriters, the Company received approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d470d703-3826-4873-ad5b-a5f643dc933e" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="pepg:ProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">122.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in gross proceeds and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7214dcf2-f24e-42fb-9836-301a0a96950f" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="pepg:NetProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">110.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in net proceeds, after deducting underwriting discounts and offering expenses payable by the Company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Immediately prior to consummation of the IPO, all </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_440b8b98-eff6-4dc5-9f56-da118eedb851" contextRef="C_2fed675d-4772-487a-92d4-4d992856e675" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,546,805</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> outstanding shares of the Company&#8217;s redeemable convertible preferred stock, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3cb6ebf2-4910-4c87-a6a0-f6b6d911d9ab" contextRef="C_740f6998-3da5-4c11-9020-117389e3b4ab" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">35,529</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> preferred stock warrants that were exercised on May 4, 2022 (see Note 3), converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da1a3f56-0298-45a7-801c-70f1db1fe990" contextRef="C_740f6998-3da5-4c11-9020-117389e3b4ab" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,359,856</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 5, 2024, the Company sold shares under its At-the-Market Equity Offering Sales Agreement, or Sales Agreement, with Stifel, Nicolaus &amp; Company, Incorporated dated as of August 8, 2023, resulting in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06a4d228-e85d-445b-93f3-4409ca002157" contextRef="C_a903df65-a661-4f64-9e9c-45d340ce2506" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. On February 9, 2024, the Company sold shares in a follow-on offering, referred to as the Follow-on Offering, pursuant to an underwriting agreement with Leerink Partners LLC dated as of February 6, 2024, resulting in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f883901b-17ac-422d-a451-825fd34de35a" contextRef="C_e7e9bfb4-48e5-4056-bafa-50d040cb558e" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">76.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting underwriting fees of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77631167-315d-43ac-b748-5d014723420d" contextRef="C_e7e9bfb4-48e5-4056-bafa-50d040cb558e" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Net proceeds from sales under the Sales Agreement and Follow-on Offering, after deducting underwriters' fees and before deducting costs of the offerings, were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7272b92f-2540-4a1f-a87a-62a96395d4e2" contextRef="C_f91c8a3a-fd8f-4f54-b410-a52327d04868" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">86.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity and Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since inception, the Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations. The Company&#8217;s primary uses of cash and cash equivalents to date have been to fund research and development activities, business planning, establishing and maintaining the Company&#8217;s intellectual property portfolio, hiring personnel, leasing premises and associated capital expenditures, raising capital, and providing general and administrative support for these operations. As of December 31, 2023, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1fdb468a-7de5-4545-9747-6bb2cfdf60df" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">181.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. To date, the Company has funded operations primarily through private placements of convertible preferred stock and its IPO. As of December 31, 2023, the Company had cash, cash equivalents, and marketable securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4dcdd752-721c-47fa-894b-f36da2222c6e" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">110.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, excluding net proceeds from the Sales Agreement and Follow-On Offering. Based on its current operating plans, the Company believes that its cash, cash equivalents, and marketable securities as of December 31, 2023, as well as proceeds from the Sales Agreement and Follow-On Offering (see Note 12) will be sufficient to fund its currently planned operations for at least the next 12 months from the filing of these consolidated financial statements.</span></p><p style="text-indent:5.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As the Company continues to pursue its business plan to successfully develop and obtain regulatory approval for the Company&#8217;s product candidates, it expects to finance its operations through the sale of equity, debt financings or other capital resources, which could include income from collaborations, strategic partnerships or marketing, distribution, licensing or other strategic arrangements with third parties, or from grants. However, there can be no assurance that any additional financing or strategic transactions will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that the Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">does not obtain additional funding, it may need to delay, reduce or eliminate its product development or future commercialization efforts, which could have a material adverse effect on the Company&#8217;s business, results of operations or financial condition.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation and Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. The consolidated financial statements include the accounts of PepGen Inc. (a U.S. corporation) and its wholly owned subsidiaries PepGen Limited (a U.K. corporation) and PepGen Securities Corp. (a U.S. corporation). All intercompany accounts and transactions have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reclassifications</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain amounts disclosed in the prior period financial statements have been reclassified from their original presentation to conform to the current period presentation. The reclassification had no effect on net income, earnings per share, retained earnings, cash flows or total assets.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_93b2f0e1-af8d-410f-a03d-7d6c68c5a43c" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a768a06b-78b2-4a7f-9985-3a5531bb2cb3" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management bases its estimates and judgments on historical experience, knowledge of current conditions, and beliefs of what could occur in the future, given the available information. On an ongoing basis, management evaluates such estimates and assumptions for continued reasonableness. In particular, management makes estimates with respect to accruals for research and development activities, for the valuation of intellectual property, for the fair value of common stock and convertible preferred stock warrants and stock-based compensation expense. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation. Actual results could differ materially from those estimates and assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8a4ea5ff-daed-4eef-b21a-2e8146995529" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, or the CODM. The Company&#8217;s CODM is its chief executive officer who reviews financial information together with certain operating metrics principally to make decisions about how to allocate resources and to measure the Company&#8217;s performance. The Company has determined that it operates as a single reportable segment. The Company&#8217;s CODM evaluates financial information on a consolidated basis. As the Company operates as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cdb6cdfb-fe20-449a-b96b-cf8efe7b6192" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment, all required segment financial information is presented in the consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a6741793-e7ce-433d-85b7-bd25d38775da" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Currency Remeasurement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s reporting currency is the U.S. Dollar. The functional currency of PepGen Limited is the British Pound. The assets and liabilities of PepGen Limited are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the cumulative translation adjustment, a component of accumulated other comprehensive loss in stockholders&#8217; equity (deficit).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_80907b71-1f9c-47b3-aedb-91d39480cd4b" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ConcentrationRiskCreditRisk" escape="true" continuedAt="F_80907b71-1f9c-47b3-aedb-91d39480cd4b_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_80907b71-1f9c-47b3-aedb-91d39480cd4b_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and money market accounts. As of December 31, 2023, the Company&#8217;s cash, cash equivalents, and marketable securities were held by four financial institutions in the U.S. and one financial institution in the U.K. At times, the Company&#8217;s deposits held in the U.S. and U.K. may exceed the respective insured limits of the Federal Depository Insurance Corporation and Financial Services Compensation Scheme.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9f2bed1d-6da0-47c0-b3cc-c6bcf37a93db" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates fair value. As of December 31, 2023 and 2022, cash and cash equivalents consisted primarily of checking and money market funds composed of U.S. government obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_abf7a75b-9af0-4d87-92ab-eab4430e32e9" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies all cash whose use is limited by contractual provisions as restricted cash. Restricted cash arises from the requirement for the Company to maintain cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61b28f6c-dc6a-43a9-b6e2-e279eb576302" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:RestrictedCashAndCashEquivalents" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as collateral under a lease agreement. As of December 31, 2023 and 2022, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_abcafa4d-c0ad-4a4b-b6ce-c96ddd780b03" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d06d491b-759e-4909-b394-ee97cd840c95" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of restricted cash was recorded in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0e60f457-09a0-4d36-973d-dc52a1d8e6c2;"><span style="-sec-ix-hidden:F_82e8c746-990f-4d25-9100-51e93f9ca429;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">other assets</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on the consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_197fcdd4-38ba-494e-a165-f6915cfb4526" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s marketable securities consist of U.S. treasury notes which are classified as available-for-sale and are reported at fair value. Unrealized gains and losses on available-for-sale debt securities are reported as a component of accumulated other comprehensive loss in stockholders&#8217; equity (deficit). Realized gains and losses are based on the specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluates its marketable securities with unrealized losses for other-than-temporary impairment. When assessing marketable securities for other-than-temporary declines in value, the Company considers such factors as, among other things, how significant the decline in value is as a percentage of the original cost, how long the market value of the investment has been less than its original cost, the Company&#8217;s ability and intent to retain the investment for a period of time sufficient to allow for any anticipated recovery in fair value, and market conditions in general. If any adjustment to fair value reflects a decline in the value of the investment that the Company considers to be &#8220;other than temporary,&#8221; the Company reduces the investment to fair value through a charge to the statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_00555125-44db-4539-be2d-da37bea2eaa6" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1: Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access. </span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2: Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3: Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For certain financial instruments, including cash and cash equivalents, prepaid expenses, accounts payable, as well as certain accrued liabilities, the recorded amount approximates estimated fair value due to their relatively short maturity period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5c996abe-5506-4c78-9c3e-71f761cfa0df" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful lives of the respective assets. Maintenance and repairs that do not improve or extend the life of the assets are expensed when incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7be8d0c9-2340-4254-bde1-65e0015519db" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="pepg:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated useful lives of the Company&#8217;s property and equipment are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:80.236%;"/>
          <td style="width:1.94%;"/>
          <td style="width:17.824%;"/>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory and computer equipment</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_f0864a44-4b82-44bc-a5a9-15acd947f88f" contextRef="C_220d4a87-56e9-4b2f-88b9-0f2f98c86ac0" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_7c8acd75-4f4b-4720-899d-998dbc7329d1" contextRef="C_2d325b41-5448-4a9d-a322-34100e9ca687" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 years</span></ix:nonNumeric></span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_227f086b-8491-47c8-898f-46568f5d3006" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:DeferredChargesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Deferred Offering Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company capitalizes within other long-term assets certain legal, accounting, and other third-party fees that are directly related to the Company&#8217;s in-process equity financings, until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds received as a result of the offering. Should a planned equity financing be abandoned, terminated, or significantly delayed, the deferred offering costs are immediately written off to operating</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expenses. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, deferred offering costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_796ff137-04ff-47f9-bcde-b86b49b6df26" contextRef="C_8dfabb69-ba07-4d32-a14c-6d3c76995bf3" name="us-gaap:DeferredOfferingCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million were recorded within other assets on the consolidated balance sheets. Subsequent to the completion of the IPO in May 2022, deferred offering costs totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f82386dc-9e6b-46cd-b603-d340683cf56a" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:DeferredOfferingCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million were recorded within stockholders&#8217; equity (deficit) as a reduction of additional paid-in-capital generated from the IPO.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6b417dba-c43b-433d-9e71-fbb70590aa47" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ffab2137-f2e6-4bde-aa5c-8d9fda57d076" contextRef="C_4d0b0ba5-3b8a-4068-b299-799ed4f36e53" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_22564d2e-9950-4f90-9c71-7b1c975f76e5" contextRef="C_4d0b0ba5-3b8a-4068-b299-799ed4f36e53" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ASU 2016-02, Leases (Topic 842), or ASC 842. Under ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances presented in the arrangement, including whether the Company controls the use of identified assets. The Company classifies leases with a term greater than one year as either operating or finance leases at the lease commencement date and records a right-of-use assets and current and non-current lease liabilities, as applicable on the balance sheet. The Company has elected not to recognize on the balance sheet leases with terms of one year or less, but payments are recognized as expense on a straight-line basis over the lease term. If a lease includes options to extend the lease term, the Company does not assume the option will be exercised in its initial lease term assessment unless there is reasonable certainty that the Company will renew based on an assessment of economic factors present as of the lease commencement date. The Company monitors its plans to renew its material lease each reporting period. If a lease includes provisions for leasehold improvements for which the Company has an obligation to pay, the Company determines if the improvements should be considered lessor or lessee assets. If the improvements are considered lessor assets, the Company records the payments in the calculation of the lease liability and corresponding right-of-use asset.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lease liabilities and the corresponding right-of-use assets are recorded based on the present value of lease payments over the remaining lease term. The present value of future lease payments are discounted using the interest rate implicit in lease contracts if that rate is readily determinable; otherwise the Company utilizes information available at the commencement of the lease to calculate the incremental borrowing rate, or IBR, which reflects the fixed rate at which the Company could borrow on a collateralized basis over a similar term, the amount of the lease payments in a similar economic environment. In order to determine the appropriate incremental borrowing rate, the Company used available third-party information, including comparable company collateralized borrowing information. After lease commencement and the establishment of a right-to-use asset and operating lease liability, lease expense is recorded on a straight-line basis over the lease term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company enters into contracts that contain both lease and non-lease components. Non-lease components include costs that do not provide a right-to-use a leased asset but instead provide a service, such as maintenance costs. The Company has elected to account for the lease and non-lease components together as a single component for all classes of underlying assets. Variable costs associated with the lease, such as maintenance and utilities, are not included in the measurement of right-to-use assets and lease liabilities but rather are expensed when the events determining the amount of variable consideration to be paid have occurred.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee4bea4a-313b-40e8-8b8e-fc3e46bf9e13" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. The recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset or asset group to the estimated undiscounted future cash flows expected to be generated by the asset or asset group.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the carrying amount of an asset or asset group exceeds its estimated undiscounted future cash flows, an impairment charge is recognized as the amount by which the carrying amount of the asset or asset group exceeds the estimated discounted future cash flows of the asset or asset group. There have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15e1c58c-f1b0-4e50-8440-f484d25cf729" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2e910111-7b16-4169-8de6-b3acd514662f" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> such impairments of long-lived assets for the years ended December 31, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_39ae7e18-8fd9-42b4-8209-e193e94ef1da" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" escape="true" continuedAt="F_39ae7e18-8fd9-42b4-8209-e193e94ef1da_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Commitment and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_39ae7e18-8fd9-42b4-8209-e193e94ef1da_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes a liability with regard to loss contingencies when it believes it is probable a liability has been incurred, and the amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount the Company accrues the minimum amount in the range. The Company has not recorded any such liabilities as of December 31, 2023 and 2022 that were material to the consolidated financial statements</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae531f62-118c-4d8a-9e8e-7886b25ebfc7" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:PreferredStockTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Convertible Preferred Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company recorded convertible preferred stock at fair value on the dates of issuance, net of issuance costs. Upon the occurrence of certain events that are outside the Company&#8217;s control, including a deemed liquidation event, holders of the convertible preferred stock could cause redemption for cash. Therefore, convertible preferred stock was classified outside of stockholders&#8217; deficit on the consolidated balance sheets as events triggering the liquidation preferences are not solely within the Company&#8217;s control. No accretion was recognized as the contingent events that could give rise to redemption were not deemed probable. Upon completion of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IPO, all preferred stock was converted to common stock and as such </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d3f0c5b-81b5-40e1-92ed-a9e296f15127" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d322073d-bea7-46b1-9b5f-1040d7be8a09" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d4894129-c795-4de1-aa17-54b4332c4c59" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4199d7d1-d428-4c9e-9df7-49741ee52ebc" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> amounts were issued or outstanding as of December 31, 2023 and 2022.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3affdff0-c2ba-4e5b-ac95-293b2794f98b" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="pepg:PreferredStockWarrantsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preferred Stock Warrants</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classified warrants to purchase its Series A-2 convertible preferred stock as a liability on the consolidated balance sheets as these warrants were freestanding financial instruments that could have required the Company to transfer assets upon exercise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_909b2c2c-f2fc-42ca-b053-1d1eb121516a" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true" continuedAt="F_909b2c2c-f2fc-42ca-b053-1d1eb121516a_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development costs consist of salaries, benefits, and other personnel-related costs, including stock-based compensation, laboratory supplies, process development costs, fees paid to other entities to conduct certain research and development activities on the Company&#8217;s behalf, including contract manufacturing organizations and contract research organizations, and allocated facility and other related costs. Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized as prepaid expenses until the related goods are delivered or services are performed. During the year-ended December 31, 2022, the Company received &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29f15c09-b0fc-484b-ac08-2c5fd64edd37" contextRef="C_4284776a-c9e1-4a96-bba1-46cb3d689de2" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_GBP" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2440153c-e6ad-4b6d-a1e1-264a4b8ac775" contextRef="C_f4a43b6a-4e2b-469c-a21b-5b9a3de9dfc0" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million) relating to its 2021 U.K. research and development tax credit for research and development activities undertaken by its U.K. subsidiary. As of December 31, 2023 and 2022, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ac48ddd-b0db-479f-a921-26c1a6dde75f" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_80e0cda1-ecd1-48e3-9206-d7becc49d019" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> research and development tax credits were recorded in other receivables on the consolidated balance sheets, respectively.</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_909b2c2c-f2fc-42ca-b053-1d1eb121516a_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers under the service agreements. The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The historical accrual estimates made by the Company have not been materially different from the actual costs.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c0253ae8-e895-4a8f-81be-aed276c65830" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation-Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or ASC 718. ASC 718 requires all stock-based payments to employees, non-employees and directors, to be recognized as expense in the consolidated statements of operations based on their grant date fair values. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model, or Black-Scholes, for stock option grants to employees, non-employees and directors. The fair value of the Company&#8217;s common stock is used to determine the fair value of restricted stock awards.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s stock-based compensation awards are generally subject to service-based vesting conditions. Compensation expense related to awards to employees, non-employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Black-Scholes requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends.  The Company determines the expected volatility using the historical volatility of a peer group of comparable publicly traded companies with product candidates in similar stages of development to the Company&#8217;s product candidates. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term for stock options granted to employees, non-employees and directors whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the Company&#8217;s IPO, there was no public market for its common stock, and consequently, the estimated fair value of its common stock was determined by the board of directors as of the date of each stock option grant, with input from management, considering third-party valuations of its common stock as well as its board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent third-party valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or Practice Aid. The Practice Aid identifies various available methods for allocating the enterprise value across classes of series of capital stock in determining the fair value of the Company&#8217;s common stock at each valuation date.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subsequent to the Company&#8217;s IPO, the fair value of the common stock underlying the stock-based awards is the closing price of the Company&#8217;s common stock on the date of grant.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5c5a8c6d-956b-4f68-8a83-7ef57128bd89" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts or existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company records a valuation allowance to reduce deferred tax assets to an amount for which realization is more likely than not.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained upon examination by the tax authorities, based on the merits of the position. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12625635-baf8-44a8-8a53-6ae91d2b48c8" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_65319430-b597-437b-a5ad-2feea0aa0e0e" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> interest or penalties charged in relation to the unrecognized tax benefits.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bb931870-610e-4b4b-80c3-3d2ef4bb19f4" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="pepg:ComprehensiveLossPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss is composed of two components &#8212; net loss and other comprehensive loss. Other comprehensive loss refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders&#8217; equity but are excluded from net loss. The Company&#8217;s other comprehensive loss consists of foreign currency translation adjustments and unrealized gains and losses on available-for-sale marketable debt securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_011ed5fa-324c-42c2-85f8-8723355592b7" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="pepg:NetLossPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is anti-dilutive. The Company&#8217;s potentially dilutive securities include unvested common stock under the Company&#8217;s equity incentive plan which have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_601cf422-f937-4294-a969-6d0340114949" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.967%;"/>
          <td style="width:1.16%;"/>
          <td style="width:1%;"/>
          <td style="width:13.357%;"/>
          <td style="width:1%;"/>
          <td style="width:1.16%;"/>
          <td style="width:1%;"/>
          <td style="width:13.357%;"/>
          <td style="width:1%;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1552c5a4-e8b7-4188-912d-30792e35ef19" contextRef="C_2f09d803-162d-4289-ba95-128a23f2de31" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,233,203</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33bd0337-412c-4834-b046-7c6a9b775c05" contextRef="C_9cb04199-144a-4871-b5ab-87a87eb6a48d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,341,834</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f43b30b0-6ac0-46fb-b592-e2ba4b939a96" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,233,203</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80bf527a-faac-4e63-bb11-2d0dff23c2c3" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,341,834</ix:nonFraction></span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7fb3f7bb-426f-43f9-856b-55b59bcd7fd0" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="pepg:EmergingGrowthCompanyStatusPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Emerging Growth Company Status</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company is an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act, or JOBS Act, and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company may take advantage of these exemptions until the Company is no longer an &#8220;emerging growth company.&#8221; Section 107 of the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards and as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of the IPO or such earlier time that it is no longer an &#8220;emerging growth company.&#8221; As a result of the Company having elected the extended</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">transition </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act, 2016-13 and ASU 2019-11 are effective for the Company for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_766d6532-1806-4ada-b7ce-d611d032fcbb" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB or other standard-setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the JOBS Act of 2012 and has elected not to &#8220;opt out&#8221; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and non-public companies, the Company can adopt the new or revised standard at the time non-public companies adopt the new or revised standard and can do so until such time that the Company either (i) irrevocably elects to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for non-public companies. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial statements and disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective January 1, 2022, the Company adopted ASC 842. Upon commencement of the Company's lease in December 2022, the Company recognized lease liabilities totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a70d7749-86da-453a-a732-0eec38c5e62c" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">24.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and right-of-use assets totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8fb1620-2a29-4627-8db5-11d31a8ab86a" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">26.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, or ASU 2016-13. The standard changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today&#8217;s &#8220;incurred loss&#8221; approach with an &#8220;expected loss&#8221; model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard&#8217;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The effective date of this update is for fiscal years beginning after December 15, 2022, and interim periods therein. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2adc4213-7d03-4b40-affc-324ffbe311e7" contextRef="C_23a4b3c2-3578-4710-8ebf-43d479465cfb" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ASU 2016-13 effective </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d278a7b5-872d-4a7c-a801-4cc0abb4c602" contextRef="C_23a4b3c2-3578-4710-8ebf-43d479465cfb" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, with </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_647543fc-1d1f-4a4d-ba04-609ea6db298f" contextRef="C_23a4b3c2-3578-4710-8ebf-43d479465cfb" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> material impact on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740), or ASU 2019-12. The standard simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and also improves consistent application by clarifying and amending existing guidance. The standard is effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_13962768-5bf3-4eec-a396-cc8be46a2839" contextRef="C_fa6a276c-2e4d-4050-a264-a051017ad010" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ASU 2019-12 effective </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_08690fb9-366e-4046-a575-14efa8ec0d8b" contextRef="C_fa6a276c-2e4d-4050-a264-a051017ad010" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, with </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_164618f5-53f9-419d-b8fe-fae852a33871" contextRef="C_fa6a276c-2e4d-4050-a264-a051017ad010" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> material impact on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures, or ASU 2023-07, to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 on a prospective basis. Early adoption and retrospective application is permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, or ASU 2023-07, which requires public entities to disclose information about their reportable segments&#8217; significant expenses on an interim and annual basis. ASU 2023-07 is effective for the Company beginning the year ended May 31, 2025. The Company is currently evaluating the impact of this ASU 2023-07 on its consolidated financial statements and related disclosures.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e64ddd38-c491-413b-a5f8-d5bc3600821b" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14aa4fda-6e23-4d89-9852-c1c7a420bc5c" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:MarketableSecuritiesTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth marketable securities for the year ended December 31, 2023 (in thousands). The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_874bbcb9-d95c-400d-a3c9-2b9623e59e96" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t hold any marketable securities during the year ended December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.16%;"/>
        <td style="width:2%;"/>
        <td style="width:1%;"/>
        <td style="width:11.700000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:2.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.38%;"/>
        <td style="width:1%;"/>
        <td style="width:2.3%;"/>
        <td style="width:1%;"/>
        <td style="width:13.84%;"/>
        <td style="width:1%;"/>
        <td style="width:2.62%;"/>
        <td style="width:1%;"/>
        <td style="width:7.84%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury-backed money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9851112-cfef-405f-84e2-262b425144e1" contextRef="C_111dcd21-eeba-473b-9067-9dc4b9836ccf" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,622</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd4890b7-6aa2-43a5-84de-171e11135932" contextRef="C_111dcd21-eeba-473b-9067-9dc4b9836ccf" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d3f304c-bd30-4b4c-8ec6-aaa80d59f970" contextRef="C_111dcd21-eeba-473b-9067-9dc4b9836ccf" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,633</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_371be5d6-590c-4e20-b482-541e33e8a6fb" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,622</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_760d8176-91c9-44b9-a4da-f7e1a70ef617" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11a53c69-e4dc-45a1-8a80-33677d9e60bf" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,633</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6e6fac3-5e93-4fd5-b060-dfa46f86415f" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table set forth the fair value of the Company&#8217;s financial assets measured at fair value on a recurring basis and indicates the level within the fair value hierarchy utilized to determine such values (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash Equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury-backed money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a87d0b2-376f-4c19-89b9-072843fbf5f2" contextRef="C_4665c752-93dc-481c-88bb-900dcc8ff971" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,397</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_759f6ab8-f85e-4cb5-9c92-da357cdc140e" contextRef="C_d8e10c34-dfed-494a-8b1a-5d7203d659eb" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,397</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ccd320ba-a545-42bb-a010-30d19895acbc" contextRef="C_ddcf7e0e-5706-4523-945c-daec00947c1e" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,980</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2357866b-e28a-46e3-92e3-c66948a61f70" contextRef="C_887c0bf2-95aa-4fe1-afb6-f5b7822e931f" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,980</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable Securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_526555e5-c052-407e-984d-4d2d51f0f1c8" contextRef="C_ddcf7e0e-5706-4523-945c-daec00947c1e" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,633</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07707d48-3c03-49cc-b68d-267b7abbef39" contextRef="C_887c0bf2-95aa-4fe1-afb6-f5b7822e931f" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,633</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20145002-5d23-47cf-bed5-d643a0a97caa" contextRef="C_fe73f47a-1a8a-4c3f-bc3a-56c5282d62d9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">106,010</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0df2f15c-882a-44ab-88ed-51bbdae853ba" contextRef="C_eb8cf3d7-367c-4f24-aa0c-6cc587368dd2" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">106,010</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.184000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury-backed money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6c5b069-4ff0-482f-8919-ab07a14254d5" contextRef="C_a76bcc79-0abb-40aa-b47b-a2d80c882380" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,645</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a23c7ad8-5ded-4867-95dc-b274b2414837" contextRef="C_f589bb63-125f-4e69-a1dc-e5029e610005" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,645</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e97e16b9-b2fb-4f1d-ba28-f1a1abace658" contextRef="C_30fabfc5-c97f-4da0-9e33-dae485ef6dee" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,645</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ee755c7-5235-43db-9a80-1d4854a6a2de" contextRef="C_bd645434-03f7-4e7a-9254-fc4113a4fc17" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,645</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds are highly liquid investments that are valued based on quoted market prices in active markets, which represent a Level 1 measurement within the fair value hierarchy. These money market funds are classified on the balance sheet under cash and cash equivalents.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preferred Stock Warrant Liability</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the November 24, 2020 Stock Purchase Agreement (see Note 9), the Company granted warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc0a5200-901f-484d-8c4d-28454ccc6cee" contextRef="C_79b1260c-c408-4a48-8c54-3595577f6b00" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">35,529</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series A-2 convertible preferred stock at a price per share equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba3d8857-0e76-46ca-888a-292c17f03139" contextRef="C_79b1260c-c408-4a48-8c54-3595577f6b00" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.42</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and with a term ending upon the earlier of an underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, the consummation of a Deemed Liquidation Event, as such term is defined in the Company&#8217;s Restated Certificate of Incorporation, or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14a18fdb-4b7c-4c17-8c90-474d0361aaaa" contextRef="C_ae4f1a1a-7f76-43a6-b05d-f7cb7ac0bb50" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As the warrants were for preferred stock, which did not qualify for equity classification, the warrants were recorded as a liability and were required to be remeasured to fair value at each reporting date. The warrants were exercised on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c0a19928-745a-4714-91d3-865c92c17c50" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">May 4, 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, just prior to the completion of the IPO, for proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c126462-81e5-46c8-b44b-1852a118025a" contextRef="C_479f1274-d273-4c6d-b379-65dc65120fec" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Immediately prior to the consummation of the IPO, the warrants were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a926ccb-fd56-4930-9a3c-ff8bfd52ec62" contextRef="C_479f1274-d273-4c6d-b379-65dc65120fec" name="pepg:ClassOfWarrantsOrRightsNumberOfSharesConvertedToCommonStock" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">34,901</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock.</span></p><p style="text-indent:5.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As there are several inputs that are not observable in the market, the warrant valuation represented a Level 3 measurement within the fair value hierarchy. The Company&#8217;s valuation of the preferred stock warrants utilized the Black-Scholes option-pricing model, which incorporates assumptions and estimates to value the preferred stock warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The quantitative elements associated with the Company&#8217;s Level 3 inputs impacting the fair value measurement of the preferred stock warrant liability included the fair value per share of the underlying Series A-2 convertible preferred stock, the remaining contractual term of the warrants, risk-free interest rate, expected dividend yield and expected volatility of the price of the underlying preferred stock. The most significant assumption in the Black-Scholes option-pricing model impacting the fair value of the preferred stock warrants was the fair value of the Company&#8217;s Series A-2 convertible preferred stock as of each remeasurement date. The Company determined the fair value per share of the underlying preferred stock by taking into consideration its most recent sales of its convertible preferred stock. The Company historically had been a private company and lacked company-specific historical and implied volatility information of its stock. Therefore, it estimated its expected stock volatility based on the historical volatility of publicly traded peer companies for a term equal to the remaining contractual term of the warrants. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining contractual term of the warrants. The Company had estimated a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d8c45c8-0d25-47fb-a500-468bff2ef5d0" contextRef="C_298b30ab-8f35-409c-81dc-e0ab49287a93" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="U_pure" scale="-1" decimals="1" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% dividend yield based on the expected dividend yield and the fact that the Company has never paid or declared dividends.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized changes in the fair value of the warrant liability as a component of other income (expense) in its consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_daf7da48-07f1-4345-93f2-57d81d941cad" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the Level 3 warrant liability through exercise in the second quarter of 2022 was as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.58%;"/>
        <td style="width:1.88%;"/>
        <td style="width:1%;"/>
        <td style="width:18.54%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Series A-2 Preferred<br/>Stock Warrant Liability</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de54adcb-9b1d-4b7e-9a95-2155263d9b51" contextRef="C_09aa4d44-be62-4c19-89e9-09be49174654" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">226</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4775cc6c-5e56-4e36-b8bc-a2368e72b7db" contextRef="C_084747ab-da2f-409a-8832-1a799b9b3b81" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">58</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of preferred stock warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c9a0905-bb38-448b-ac03-7429f0c5e784" contextRef="C_084747ab-da2f-409a-8832-1a799b9b3b81" name="pepg:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExerciseOfPreferredStockWarrants" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">168</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_47624e70-d227-4ad8-884c-4512974f2cd1" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. Property and Equipment, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14b700df-1cff-4024-ae67-2c2d6eb2192e" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The cost and accumulated depreciation of property and equipment were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30e8e947-96fd-4f3b-9f35-daf2ade0b8cc" contextRef="C_6b88145a-4875-4cd0-a443-e63d1611c62d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,821</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbd03486-965e-49a3-ae64-6b06a276acbd" contextRef="C_d4800734-4394-4f05-a937-22e162de9696" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,424</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer and office equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30c03ffb-145c-4cf2-ae00-4a831459d9f5" contextRef="C_83c51675-48f0-45b3-8010-597a2244a8c3" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,446</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa011324-d676-4cc3-91d1-3d0da4865d0d" contextRef="C_2a6bbe33-4c45-482c-ac03-94f727c30255" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">171</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in process</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63d70448-0dd2-46fb-8610-b9a81682ec30" contextRef="C_d198184c-cc7e-4c68-a75d-06a166129ca1" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43b57935-678e-411b-86d5-ae7691c391c3" contextRef="C_0eec95c7-6d1e-4442-a8e7-29920d1d09af" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,129</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6aeb554f-2b05-40c7-972e-527222668d95" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,336</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c98ea80-c6c6-408b-8354-723c0dd82f2e" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,724</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97ed0f69-a8a7-4ef9-a4a6-287a30d6da62" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,572</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d126f790-4e69-42d6-8138-5afbba60488f" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">389</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b90a0d4-fc1d-4e29-90a9-00470001a10a" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,764</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9844159a-8a7e-4438-9c55-f333e155acfb" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,335</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25d2e069-28fb-4d17-be4d-6cb2f5fab8b5" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68f26589-364b-4c96-9793-648e8eada024" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_55eafd63-2159-4506-b6a6-cd4beabbd58f" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="pepg:AccruedLiabilitiesCurrentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Accrued Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d1fc47d-2181-4d5e-9729-51ad2f9f7f0a" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="pepg:ScheduleOfAccruedLiabilitiesCurrentTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_029f0c59-80dc-4172-9a97-d70514266aa1" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="pepg:AccruedResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,521</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3ae8672-2426-4e9c-b615-1d82f65feeb9" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="pepg:AccruedResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,840</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee-related expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d51d6fd2-55f5-41d8-815b-8589dcac1454" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,368</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c4424f5-6ee7-4829-aace-7e13d35e234d" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,440</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Taxes payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53bc5d23-7408-4f00-a86c-b210365ec7d6" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:TaxesPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,574</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08002aff-6f5b-4a44-b86f-9e2cb49d30a5" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="pepg:AccruedProfessionalServicesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">715</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ccf1829-9944-4399-8cb9-8a5f062221c6" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="pepg:AccruedProfessionalServicesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">932</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99527efe-17f3-4960-8e33-89dac3625c90" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">918</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9187588f-7d59-498e-b3b8-0794faf7af35" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,127</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_772d0dc7-53ae-4e02-8cc9-358c564a10d7" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,522</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0a8e66d-677f-4461-9644-2616418bdd0b" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,913</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3686a7d1-7a9d-49f1-ad25-f8076ab27209" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="pepg:LeasesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2021, the Company entered into a non-cancellable operating lease agreement, or the Harrison Lease, pursuant to which the Company leases </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c564f2dd-18e6-4fb6-b428-977f47424083" contextRef="C_18a316cc-fb97-4041-99e0-a3525fa31567" name="pepg:LeasedSpace" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">31,668</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office and laboratory space located in Boston, Massachusetts, or the Premises. The Harrison Lease commenced for accounting purposes when the Company gained access to the Premises on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d154ae7a-2203-4465-a00e-e981d8aeb613" contextRef="C_580f0221-c422-43d6-9cb9-c47b83af1d6b" name="pepg:OperatingLeaseCommencementDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 29, 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or the Lease Commencement Date. The Harrison Lease has a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3709f856-b689-41de-918d-afdb97d52a3b" contextRef="C_18a316cc-fb97-4041-99e0-a3525fa31567" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nine years and two months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the Lease Commencement Date. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_829b0913-5657-4d43-8f2e-d6a056fa4691" contextRef="C_d913f63c-8af0-45d4-9fb8-34b4620d0aa9" name="us-gaap:LesseeOperatingLeaseDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s obligation for the payment of base rent for the Premises began in May 2023, and is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb1e8615-2282-4dd1-a9fd-752cc43b0229" contextRef="C_580f0221-c422-43d6-9cb9-c47b83af1d6b" name="pepg:OperatingLeaseMonthlyRentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million per month, increasing up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d7cd6a7-7a15-4a72-a0a9-435931e6052c" contextRef="C_580f0221-c422-43d6-9cb9-c47b83af1d6b" name="pepg:OperatingLeaseIncreaseInMonthlyRentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million per month during the term of the Lease.  </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_13ecc270-525d-4ac0-9a90-4269613b3329" contextRef="C_d913f63c-8af0-45d4-9fb8-34b4620d0aa9" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has one </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0120af5a-6df8-4600-8eb4-b1ad31f105d7" contextRef="C_d913f63c-8af0-45d4-9fb8-34b4620d0aa9" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">option to extend</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> the term of the Harrison Lease, for a period of an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c6ba1324-b926-4c36-9e76-064ac46ce8bd" contextRef="C_580f0221-c422-43d6-9cb9-c47b83af1d6b" name="pepg:OperatingLeasePeriodOfExtension" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></span></ix:nonNumeric></span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Due to the timing of the Lease Commencement Date at the end of 2022, there was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fa9440a-3f3e-496f-8520-2fdb4c4cd5c8" contextRef="C_d913f63c-8af0-45d4-9fb8-34b4620d0aa9" name="pepg:FixedLeaseRentExpense" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> fixed lease rent expense associated with the Harrison Lease in 2022. At December 31, 2023, the Harrison Lease was the only lease for which the Company recorded a lease liability and corresponding right-of-use asset.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The landlord completed significant leasehold improvements to the Premises, a portion of which the Company was obligated to pay per the terms of the Harrison Lease. The Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f770acb4-1671-453f-92c6-981783e38291" contextRef="C_941e7577-cf0a-4629-9509-58cf297868bf" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the improvements prior to lease commencement in 2022, and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5428dfd4-1138-4f3c-82d7-658903dc1ab6" contextRef="C_7ff7e6d1-9dc6-4e1d-af82-7945a62662d8" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the improvements in 2023, for total payments to the landlord for improvements of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_307a4ce0-97c4-42a8-94e8-e5a36919c03d" contextRef="C_7ff7e6d1-9dc6-4e1d-af82-7945a62662d8" name="pepg:AggregateOperatingLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company determined that the landlord is the accounting owner of the improvements, and payments by the Company for the improvements are included in the calculation of the right-of-use asset and lease liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During 2022 and the first quarter of 2023, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_12dd1eba-fd6e-4960-a7de-a275db7f8648" contextRef="C_472ca393-199b-4e03-9b1a-59688620fedb" name="us-gaap:LesseeOperatingLeaseDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company leased office space in Cambridge, Massachusetts, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9415d8cd-dfe7-4123-ab9b-b9784b14423f" contextRef="C_472ca393-199b-4e03-9b1a-59688620fedb" name="us-gaap:LesseeOperatingLeaseOptionToTerminate"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the terms of which were month-to-month, with a 30-day written </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1d26b7f6-a074-45be-9b07-9931003fd7ee" contextRef="C_472ca393-199b-4e03-9b1a-59688620fedb" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">notice of cancellation</span></ix:nonNumeric></span></ix:nonNumeric></span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a739867e-2708-4f44-be71-72b03d29b339" contextRef="C_6eb59534-d6e4-4470-9e92-dc335995eadd" name="us-gaap:LesseeOperatingLeaseDescription" continuedAt="F_a739867e-2708-4f44-be71-72b03d29b339_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company terminated this lease in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d54e3924-9222-41b4-b021-39379285e1c9" contextRef="C_472ca393-199b-4e03-9b1a-59688620fedb" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also leased laboratory space at the University of Massachusetts, Mount Ida Campus in Newton, Massachusetts, with an </span></ix:nonNumeric></span><span style=""></span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a739867e-2708-4f44-be71-72b03d29b339_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">initial </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">lease term from February 1, 2022 to January 31, 2023, which the Company extended until March 2023</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company also leased space at Innovation Building, University of Oxford in Oxford, U.K. The Company terminated its lease in Oxford in July 2022. All of these leases had initial terms of under </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b3cc2d1f-5c13-496d-9d30-4dc929bda7a6" contextRef="C_3ed7174f-94bd-4691-abc3-6e866114de8b" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months and are considered short-term lease costs and are not recognized on the consolidated balance sheets.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary of Lease Costs</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8e0783a8-6bef-41f2-ae8d-dad17e9b195b" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of lease cost under ASC 842 for the leases were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82c7a957-2174-458f-bb11-c55581cb9862" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,799</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_840d416e-7c89-4b8b-b08a-48cbec82b37b" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">993</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1748466e-2c91-4484-902e-6505f7fea8a7" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9887893-d115-4460-9ccd-4be0e9697f75" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,294</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0aaed132-f336-4ffd-8e2f-73554b72a79a" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,980</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_575c7083-553e-47f3-8d24-5ae29ba0e278" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,294</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a4530757-f6d0-4087-8a19-a24c81c97d2c" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="pepg:SupplementalDisclosureOfCashFlowInformationRelatedToLeasesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supplemental disclosure of cash flow information under ASC 842 for the leases was as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"/>
        <td style="width:1.94%;"/>
        <td style="width:1%;"/>
        <td style="width:15.823%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,  2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating cash payments for operating leases</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aee636a0-32ca-48e2-b789-6d2bed8ac368" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,299</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash payments for operating leases during 2023 related to tenant improvements of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b56cfb0-215d-4d5e-8550-535d89c2404c" contextRef="C_098c1eb1-fac5-4644-b049-d1ecd9083a38" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_135a7b7e-403d-4e1a-bf63-a10f8723ef50" contextRef="C_d913f63c-8af0-45d4-9fb8-34b4620d0aa9" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in rent payments in line with the Harrison Lease. Additionally, the Company made payments on variable lease costs throughout the year of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d901221f-576f-4007-8550-569b7fa723bb" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. These payments related to parking, management fees, and other costs associated with maintaining our office and lab space.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The remaining lease term for the Harrison Lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e287c816-9028-46b7-95d9-ab42ca28c3a4" contextRef="C_48600fa6-eba6-438a-9b5f-dff15a734745" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8.4</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years, and the discount rate is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94744cf2-a39e-408b-9c85-6f11bd986d3f" contextRef="C_48600fa6-eba6-438a-9b5f-dff15a734745" name="us-gaap:LesseeOperatingLeaseDiscountRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">8.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a0b84ae-ef90-4834-9877-123ae194a53f" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease payments under the non-cancelable operating lease consisted of the following as of December 31, 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"/>
        <td style="width:1.94%;"/>
        <td style="width:1%;"/>
        <td style="width:15.823%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53703d61-e48a-41b6-9581-926bab766b07" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,004</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa8d323a-5ba6-4cb9-9cd3-8dfdc0edee07" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,094</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5a9d3b2-506b-4c53-a533-e2d2af52e990" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,187</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8361e51-d53c-4898-9bd6-ec767a8ed5a6" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,282</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11117963-db4b-43fd-960d-2c33532a848b" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,381</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ccbceaf-1f7a-47f1-a1d5-673efa7ab3e5" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,079</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total future minimum lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7aa2e2ba-2844-4221-b4ce-639c482c026c" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,027</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7342d9e9-e745-4e5e-8b60-b435a47d541f" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,923</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Present value of lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12d18867-4a18-4f50-9287-182ca3aaac89" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,104</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Included in the consolidated balance sheet (in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa1485df-2ac0-45ff-b8c4-64d52aaab26d" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,004</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability, net of current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_524c42b4-f1db-44cb-b3c9-ac48a5437ad4" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,100</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9cb42b6c-29a6-46c6-9131-56d3ea1394c6" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,104</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_972ad9fe-9bad-430a-8fea-4c9a051e4ed2" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Related Party Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Technology License Agreement with Oxford University Innovation Limited</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2018, the Company, Oxford University Innovation Limited, or OUI, and the Medical Research Council of United Kingdom Research and Innovation, or MRC (or collectively the Licensors), entered into a license of technology agreement, or the License Agreement, which was subsequently amended in December 2018 and further amended and restated in November 2020. The Licensors and affiliates held shares of Series A-1 and Series A-2 preferred stock, Series B preferred stock and Class A common stock. The License Agreement provides the Company with an exclusive world-wide license to licensed data and technology owned by OUI and MRC in respect of CPP for treatment of Duchenne muscular dystrophy, spinal muscular atrophy, and other conditions. The License Agreement provides the Company with the rights to grant and authorize sublicenses to make, use, sell, and import products and otherwise exploit the patent rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As consideration for the license, the Company made an initial upfront payment in 2018, as well as a Restatement Completion Fee and a License Data Fee in 2020 totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a536bd46-6791-4d59-9204-944ff412e9d6" contextRef="C_9b497aad-3cba-4deb-9dd2-e0a9d56f3614" name="pepg:AdditionalPaymentsOfRestatementCompletionFeeAndLicenseDataFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company could be required to make milestone payments to the Licensors upon achievement of certain patent and commercial milestones related to the patents and commercialization of certain of the Company&#8217;s product candidates. The aggregate potential milestone payments are $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27b985f3-3951-487f-93ef-e8c67a541333" contextRef="C_9b497aad-3cba-4deb-9dd2-e0a9d56f3614" name="pepg:AggregatePotentialMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company also agreed to pay the Licensors low single digit royalties on net sales of any licensed products that are commercialized by the Company in excess of a threshold amount between &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_094c276b-63df-4069-be54-508d51ad0222" contextRef="C_30c84240-eef7-4c05-8cf3-d66492402ca5" name="pepg:SublicenseesThresholdAmount" unitRef="U_GBP" scale="6" decimals="-6" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27302211-c2b1-40fd-8c90-e9a2b2ef349a" contextRef="C_85e7bad8-943c-4a0e-ad95-12e210a9becd" name="pepg:SublicenseesThresholdAmount" unitRef="U_GBP" scale="6" decimals="-6" format="ixt:num-dot-decimal">30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7969a41-4624-4ad1-9d62-5cdd4ad8f704" contextRef="C_85e7bad8-943c-4a0e-ad95-12e210a9becd" name="pepg:SublicenseesThresholdAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_403c455b-0415-4ba1-9008-7e3d331f357f" contextRef="C_30c84240-eef7-4c05-8cf3-d66492402ca5" name="pepg:SublicenseesThresholdAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">38.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023), subject to certain adjustments. The term of the License Agreement continues until the later of (i) the date on which all the patents and patent applications covered thereunder have been abandoned or allowed to lapse or expired or been rejected or revoked or (ii) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6fa1998-d2d1-4bb3-9eb5-b5c01f6efaae" contextRef="C_9b497aad-3cba-4deb-9dd2-e0a9d56f3614" name="pepg:TermOfLicenseAgreement" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years from the date of the original agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon completion of the IPO, the Company became obligated to pay OUI an exit fee between </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8fee6fad-7b1e-474b-8217-ea0b5e81c83b" contextRef="C_59392f99-502b-454a-8db2-aeb447f458ec" name="pepg:PercentageOfExitFee" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aca340ce-9ff3-4b6a-8b06-c23796946b2a" contextRef="C_e714e23e-c60b-4649-bcf1-f9525f905459" name="pepg:PercentageOfExitFee" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the value determined in an acquisition or initial public offering, not to exceed &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8fa495d0-91af-4e81-b72d-6ff14bb2209e" contextRef="C_e714e23e-c60b-4649-bcf1-f9525f905459" name="pepg:RequiredToPayExitFeeAmount" unitRef="U_EUR" scale="6" decimals="-6" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00c51419-7b70-437f-8e22-d3bd76499c19" contextRef="C_e714e23e-c60b-4649-bcf1-f9525f905459" name="pepg:RequiredToPayExitFeeAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of the IPO date). The exit fee due to OUI, based on the proceeds of the IPO, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e83dca53-9782-4e9d-95b1-ebb448688c0b" contextRef="C_c3ab2e29-df24-48f1-bf82-ebac3d3a83b1" name="pepg:RequiredToPayExitFeeAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which was paid during the second quarter of 2022 and included in research and development expense on the consolidated statement of operations. One member of the Company&#8217;s board of directors is also employed by Oxford Science Enterprises, which is an affiliate by OUI.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the Company paid office space rent to OUI. For the years ended December 31, 2023 and 2022, total rent payments were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a8db0b3-0fe6-47a2-96fa-5f486482ebc7" contextRef="C_76920238-6f16-4c2c-b840-91aee4e50447" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">nil</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7d82dbb-399f-4257-b4b8-e39d80fead1a" contextRef="C_1b8a0d2c-51ea-4fba-866a-5ab866ff3776" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eee0870e-c368-4a0c-b949-06f5c6970095" contextRef="C_dc45efd8-3a91-4f49-a118-89ede6cb57a1" name="pepg:RelatedPartyTransactionsOtherCostsPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_41350681-4ab7-4877-ae94-63cf513a8361" contextRef="C_ad331ffb-3ca8-41af-9e8c-a5d2e3f07401" name="pepg:RelatedPartyTransactionsOtherCostsPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the years ended December 31, 2023 and 2022 to Oxford Science Enterprises as compensation for their board seat. As of December 31, 2023 and 2022, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5afbbd4e-5ec4-49bc-b3c8-b00d1350de8c" contextRef="C_b4470897-58c2-4502-9300-1a8a6d7d7faf" name="pepg:RentPayableToRelatedParties" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_bc168918-e03f-448e-a123-f816dd89ec2c" contextRef="C_030a5a87-1169-4748-9cd4-a4a73f0d0618" name="pepg:RentPayableToRelatedParties" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">nil</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was due to OUI by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Services Agreement with RA Capital Management, L.P.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2020, the Company entered into an agreement, or the Services Agreement, with Carnot Pharma, LLC, or Carnot, under which Carnot provided research and other services to the Company. Carnot is an entity controlled by RA Capital Management, L.P. Entities affiliated with RA Capital Management, L.P. purchased shares of Series A-2 convertible preferred stock in the Company&#8217;s preferred stock financing in November 2020 and May and July 2021. In addition, entities affiliated with RA Capital Management, L.P. purchased shares of the Company&#8217;s Series B convertible preferred stock in the Company&#8217;s preferred stock financing in July 2021. Two members of the Company&#8217;s board of directors are also affiliated with RA Capital Management, L.P.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Services Agreement, the Company compensated Carnot on a fully burdened cost basis for personal time devoted to Company projects. In addition, the Company reimbursed Carnot on a costs basis for any subcontractor costs incurred. The Company paid Carnot on a quarterly basis, in arrears, for services performed and costs incurred. The Services Agreement was terminated in April 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expenses incurred by the Company under the Services Agreement with Carnot for the year ended December 31, 2023 and 2022, totaled </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9963e971-11fc-4b05-aaf0-aeb6c0a71fe1" contextRef="C_f814e08d-65a5-4cb9-880c-4b1766772c26" name="us-gaap:OperatingCostsAndExpenses" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">nil</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_883f8948-5810-4419-88a3-529402b77b6e" contextRef="C_7fb2ae36-5ee1-44d5-910b-7802e0cbbbc7" name="us-gaap:OperatingCostsAndExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. Additionally, the Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cbe2ef1-751b-4854-baee-aaa10deae51a" contextRef="C_24eafb5a-baba-449c-8e96-c46f37a25e6c" name="pepg:RelatedPartyTransactionsOtherCostsPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ded85f89-696c-46d9-bcb3-c467e7996151" contextRef="C_c12cd4a1-d2bb-4e7d-be33-635f490062b1" name="pepg:RelatedPartyTransactionsOtherCostsPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the years ended December 31, 2023 and 2022 to RA Capital Management, L.P. as compensation for their board seat. As of December 31, 2023 and 2022, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_282d75a2-6bae-437b-bed1-80efeebd3a48" contextRef="C_de36be0e-422a-44fa-b610-cce5387a9700" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b3a9dbf3-dd6a-4d39-a628-c5bc370f8efb" contextRef="C_e0c2b471-faa6-4641-8385-0e58de723dee" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">nil</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was due to Carnot by the Company for services rendered under the Services Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_737c87b2-a109-41fc-b0eb-2356f926c5cc" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legal proceedings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is not party to any litigation and does not have contingency reserves established for any litigation liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to the agreements, the Company agrees to indemnify, hold harmless, and to reimburse the indemnified party for losses suffered or incurred by the indemnified party, including in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third-party with respect to the Company&#8217;s products. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company&#8217;s request in such capacities. The Company&#8217;s maximum exposure under these arrangements is unknown as of December 31, 2023. The Company does not anticipate recognizing any significant losses relating to these arrangements. The term of these indemnification agreements is generally perpetual any time after execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements may be unlimited. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_95526d9d-595a-453d-97e2-93c1ed4c0ea0" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. Convertible Preferred Stock and Stockholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse Stock Split</span></p><p style="text-indent:5.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 29, 2022, the Company filed a charter amendment to affect a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e453c843-0440-43f2-8bdc-8cb11918a963" contextRef="C_5ce499b8-803d-4c0a-b7dc-bd9d43f1ccdf" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_11100503-2fd3-4c49-87ab-244664e4d838;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.018</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for 1 reverse stock split</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of its issued and outstanding shares of common stock, which resulted in a proportional adjustment to the existing conversion ratios for each series of the Company&#8217;s preferred stock. Accordingly, all share and per share amounts for all periods presented in the accompanying consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse stock split and adjustment of the preferred stock conversion ratios.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Series A-1 Convertible Preferred Stock and Series A-2 Convertible Preferred Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the November 24, 2020 Stock Purchase Agreement, the Company agreed to issue an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3dd6e79-74fa-4c48-9f02-6dc16996e9ec" contextRef="C_6be9b902-7f6b-479b-bfa6-7743f9105ed0" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,939,069</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series A-2 convertible preferred stock to new and existing investors at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3d9ddd1-46e3-4d3a-9a8b-1c5a9d622b59" contextRef="C_6be9b902-7f6b-479b-bfa6-7743f9105ed0" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">11.42</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, in three closings, and elected to convert </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1363b465-b0a2-4619-9f91-f43844f168c6" contextRef="C_e9bca87a-c16a-42e1-91d3-d72a8f122225" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,348,693</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of outstanding Class A and Class B common stock into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51260d16-3b85-48d8-bf22-895e6f4b8938" contextRef="C_9262d127-7f2e-41a9-86ad-3e2211e86b50" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,372,970</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series A-1 convertible preferred stock. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de4780a8-c918-4a31-8474-1d12272ea5a9" contextRef="C_e8c98aaa-dcdb-45ee-9cad-d9b7440c3550" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,033,117</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock held by certain founding investors and employees were not modified and continued to exist as Class A common stock. The Series A-1 and Series A-2 convertible preferred stock was converted to common stock immediately prior to the consummation of the IPO in May 2022 (see Note 1).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Series B Convertible Preferred Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2021 the Company entered into the Series B Stock Purchase Agreement, whereby the Company agreed to issue and sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44c7f1fa-e79e-4b60-95df-896ac29e565c" contextRef="C_ce675452-0281-4938-89df-5ecb187847bf" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,234,766</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series B convertible stock to new and existing investors at a per share price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a28197d-0260-4b7d-8e83-b8391ef988d0" contextRef="C_ce675452-0281-4938-89df-5ecb187847bf" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">15.55</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for aggregate gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_388a0d95-4c14-4233-af14-efd53f1f8950" contextRef="C_c4ecf543-b902-40c7-b9ae-990d6d5dc573" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">112.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Series B convertible preferred stock was converted to common stock immediately prior to the consummation of the Company's IPO in May 2022 (see Note 1).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Third Amended and Restated Certificate of Incorporation, dated May 10, 2022, the Company has the authority to issue a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44681358-9113-4eac-95df-af83a3adc61d" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock (par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5584d775-9dde-4c94-b243-d94e5ac7cd5c" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share) and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d901513-a384-49c0-b566-9c467f091e26" contextRef="C_9e4cd814-3cb3-4300-b818-efc911437b4a" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of undesignated preferred stock (par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8dc87438-897b-4d9a-9b01-3a8524a8e3f7" contextRef="C_9e4cd814-3cb3-4300-b818-efc911437b4a" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share). In connection with the IPO, the Company re-designated all shares of Class A common stock as shares of common stock. Each share of common stock has the right to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30279cd5-24db-4ac5-9ce6-e4aceb8397bb" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="pepg:NumberOfCommonStockVote" unitRef="U_Vote" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1150500-b7db-47a9-bba5-728318447128" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:DividendsCommonStockCash" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_29239234-1005-4362-b9e2-5d20cb51ad99" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:DividendsCommonStockCash" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cash dividends have been declared by the board of directors during the year ended December 31, 2023 and December 31, 2022.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_27ba53a3-13ac-447a-ba02-10bd80cc6bc4" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="pepg:ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has reserved the following shares of common stock for issuance, as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options issued and outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42f42e76-7fe4-446d-98ef-83d8e671b562" contextRef="C_cab43832-788b-441d-b9a4-b33219debd4f" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,233,203</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21800f5f-128d-4227-b12e-859020e94eb3" contextRef="C_585c525a-f403-4998-a8ec-14fc01861152" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,341,834</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Authorized for future stock awards or option grants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f167bf53-c5fa-4f53-80c4-203abea0fc9d" contextRef="C_99f0f78d-bedd-484e-bfa2-ac51788e3369" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,091,187</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa2615d0-f471-4356-a3bf-1f19b382de9a" contextRef="C_d7f2ab9a-431e-4fa5-8e9c-4fbda0da11cc" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">901,462</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Authorized for future issuance under employee stock purchase plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_437d042f-4109-4635-ab30-df684c0f1808" contextRef="C_79566393-e152-4220-b13f-d5411f25b12a" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">216,306</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_659fd800-ee9d-4f0c-909f-7122946c09d6" contextRef="C_d2b7323c-10fa-445b-aaed-2945a4bc04a2" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">226,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63b96317-5865-425a-aeb3-5cf38f943151" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,540,696</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f77e2128-0ee1-4298-997a-b6ead5cf170b" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,469,296</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Shares of Common Stock Subject to Repurchase</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2020, in connection with the Series A-2 convertible preferred stock financing, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4b2920f-fac4-4545-86b7-de774425d511" contextRef="C_c0719f76-c7a1-4758-8910-36fbdccb7a19" name="pepg:NumberOfFoundingStockholdersEntered" unitRef="U_Stockholder" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> founding stockholders entered into Stock Restriction Agreements, or Restriction Agreements, whereby </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77c426c5-0c46-4729-89b1-64fbc493b944" contextRef="C_896cd8db-b4db-45ff-915a-26b26be0959d" name="pepg:NumberOfSharesRestrictedAndSubjectToRepurchase" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">139,057</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares that were previously vested and not subject to repurchase became restricted and subject to repurchase. The repurchase rights lapsed as to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d36d18f-92bb-4074-81ed-ac5627ebe7c7" contextRef="C_c0719f76-c7a1-4758-8910-36fbdccb7a19" name="pepg:PercentageOfRepurchaseRightsLapseOnOneYearAnniversary" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on the one-year anniversary of the Restriction Agreements and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a209067-8bc4-4d5c-a7aa-ff7ad4648bbf" contextRef="C_c0719f76-c7a1-4758-8910-36fbdccb7a19" name="pepg:PercentageOfRepurchaseRightsLapseOnSecondAnniversary" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on the second anniversary of the Restriction Agreements. Shares subject to repurchase by the Company are not deemed, for accounting purposes, to be outstanding until those shares vest and therefore are not included in the shares outstanding on the consolidated balance sheet.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the vesting restrictions placed on these previously vested shares, the Company was required to determine the measurement date fair value of the shares, which was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a32e90f-6ee1-498c-8175-03c8273b1a7c" contextRef="C_896cd8db-b4db-45ff-915a-26b26be0959d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.37</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a9c0080-c8f0-464b-9c32-0c98ba30418d" contextRef="C_896cd8db-b4db-45ff-915a-26b26be0959d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in aggregate. The measurement date fair value of the restricted stock was recognized as stock-based compensation expense over the vesting period. As of December 31, 2023 and 2022, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb3e69a3-9e32-41e9-9f79-712f375f8e60" contextRef="C_16414ef5-2d6c-482f-bb76-768259311b2c" name="pepg:SharesOfRestrictedStockSubjectToRepurchase" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_40f358df-8b4f-464f-943f-ac770a758b4b" contextRef="C_8f9f5a3b-bb7f-443b-98eb-04f3e2b9c50d" name="pepg:SharesOfRestrictedStockSubjectToRepurchase" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">zero</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were subject to repurchase by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_afd69b93-74aa-451a-8e6d-0b275d938e9c" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company maintains three equity compensation plans; the 2020 Stock Plan, or the 2020 Plan, the 2022 Stock Option Incentive Plan, or the 2022 Plan, and the 2022 Employee Stock Purchase Plan, or the ESPP. As of the Company's IPO in May 2022, the Company's board of directors determined that no further awards would be made from the 2020 plan. The number of shares of common stock that may be issued under the 2022 Plan is subject to increase by the number of shares under any outstanding stock options forfeited and not exercised under the 2020 Plan. Additionally, the number of shares reserved for issuance under the 2022 Plan automatically increases on the first day of each fiscal year in an amount equal to the lower of (1) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12619112-7348-45a0-9346-2062571e9152" contextRef="C_b1cd4d63-b40b-4d86-834f-9218d8c92734" name="pepg:CommonStockOutstandingPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the shares of common stock outstanding on such date and (2) an amount determined by the Company&#8217;s board of directors. The 2022 Plan allows the board of directors to grant incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock units, unrestricted stock awards, cash-based awards, and dividend equivalent rights to the Company&#8217;s officers, employees, directors and other key persons. As of December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ae649ab-583e-4a58-b157-b366bff5c62e" contextRef="C_0686ad9d-2e32-4f08-a030-a696dc15aec5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,091,187</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares remained available for grant under the 2022 Plan and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1afdee70-a8ad-4400-96ed-2836b0a50b6a" contextRef="C_452249ff-841b-462f-a646-241176965c50" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">216,306</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares remained available for grant under the ESPP.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Option Valuation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In determining the fair value of the stock options granted, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;The Company&#8217;s expected term represents the period that the Company&#8217;s stock-based awards are expected to be outstanding. For stock options with service-based vesting periods, the expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;The Company has historically been a private company and lacks significant company-specific historical and implied volatility information. The expected volatility is estimated based the average historical volatilities for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, stage in the life cycle and area of specialty. The Company will continue to apply this process until enough historical information regarding the volatility of its own stock price becomes available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk-Free Interest Rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Dividend Yield</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_442ca51e-742c-4bfd-be39-a0ea9d0a9245" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8fb7a5ef-d7fd-4900-9975-9dbedf859b1f" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of stock options was estimated using the following weighted average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.343%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.343%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate %</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06de1448-aa73-41b1-b967-ca50fe442b72" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.19</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9261349f-4cb0-4a55-9705-6d53ec8d568c" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.95</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility %</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34e2b803-4528-44c0-ac08-f977c1b68c65" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">65.13</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9471a86-548d-4155-9b43-c4dd4140075e" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">71.68</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_8b4afdb2-e98e-47c1-88db-9fbd2b915d53" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.05</span></ix:nonNumeric></span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_cc9bdc07-4e79-4c32-83b9-e03047829428" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.08</span></ix:nonNumeric></span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Option Activity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9dfc082d-eac7-4104-a019-d404065cb2fa" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock option activity under the 2020 Plan and 2022 Plan, are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.662%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:8.942%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.662%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stock<br/>Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Remaining<br/>Contractual<br/>Term<br/>(In Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(In Thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46fbc827-0f81-45da-8a1d-b2a80d28bdbc" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,341,834</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1af84df-8e40-4cba-a6bd-f698d98bd6a2" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.52</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_163aee20-e2ff-4d59-8340-bc28c90641e6" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.7</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_927d0617-71dc-4264-9e1c-4f1769ca2928" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,877</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3902ed29-0570-42d2-afa3-f5825823567a" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,421,936</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ad39aed-2813-4ed1-918d-15e7417819be" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.70</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_868ab850-deb5-45f8-b717-a37397e8676f" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">100,351</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5157fdcb-a557-4a61-9699-e81ce1804855" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.12</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Canceled/Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_37038635-2928-47a1-bd37-293f72931ae5" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">430,216</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dabfd917-6d7e-4107-8b7e-e75008d047c8" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.13</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d3515b7-6a6f-4ca7-9546-decf4678a274" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,233,203</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f5b57bc-2e57-4c36-878c-7c96a59126ed" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.83</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_43deff4a-40ed-43d6-af7b-f68c47dc094b" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_246ee5ca-5b91-4c1d-80c6-4e8e7fe0a48a" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,147</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and exercisable as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96f7f044-b40e-477a-9184-cd7469dd9ac7" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,477,013</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c36b763b-f22c-411d-9db6-08520265e50b" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.87</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_28e5f65f-2614-4bc7-8905-0a4bed293b46" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.9</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d040ae9b-2807-4821-8a6d-c36fdd47eae0" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,427</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf426203-7d15-4c0d-bd1d-cf41a33cd510" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,233,203</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ec0d763-99d8-4ab6-9cfa-64bb4aa63419" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.83</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_80df22da-5885-4e95-a6c2-a0f2588eab42" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c56ffd8-0a49-4515-911f-41db5ab32d95" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,147</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise prices of the stock options and the fair value of the Company's common stock for those stock options that had exercises prices lower than the fair value of the Company's common stock. The total intrinsic value of the stock options exercised during the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d10e18e-87f4-405e-8599-ed8700a8e354" contextRef="C_74f25be0-4a88-4a9d-915a-d6fbbd72d532" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6cfceb3b-6d07-44f3-a96e-3d177e6decac" contextRef="C_b89ce0c5-83ee-4433-97d2-dc32416736cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The intrinsic value is the difference between the estimated fair value of the Company&#8217;s common stock at the time of exercise and the exercise price of the stock option. During the years ended December 31, 2023 and 2022, the total proceeds to the Company from stock option exercises was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1635e8ff-222c-43ef-91a9-5fea276895a2" contextRef="C_74f25be0-4a88-4a9d-915a-d6fbbd72d532" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_138c8633-13a2-4aea-bd2b-5bd6f05af41a" contextRef="C_b89ce0c5-83ee-4433-97d2-dc32416736cf" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average grant date fair value of stock options granted during the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c6e604e-35cc-4e47-aa98-ed19c5faac56" contextRef="C_74f25be0-4a88-4a9d-915a-d6fbbd72d532" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.56</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba458dd5-0203-4454-8434-409ffd496a45" contextRef="C_b89ce0c5-83ee-4433-97d2-dc32416736cf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.66</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e204b202-7e90-43b3-87c4-bbb7b07c245a" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense recognized for stock option grants included in the accompanying consolidated statements of operations and comprehensive loss is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e084d7ed-5c40-46bb-98e0-e0fd25f21415" contextRef="C_0917bb69-33a3-4140-b895-0b204ca96986" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,966</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83de3c80-d765-4766-be9f-449e13c45011" contextRef="C_abeb202e-1d0f-4fd4-950d-779ee59e02dd" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,695</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_168d1745-7add-4078-a243-8cca4f9387af" contextRef="C_d3eca86e-4d27-4894-81cf-8b20a08cff1a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,082</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a585af6a-0774-45e5-a8e8-7bbf5c6bd3f7" contextRef="C_f5fe547c-69eb-4ca8-ab02-fd92fb002da6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,068</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f73aedc-6fc3-47be-bf23-80581b44f24d" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,048</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_485c15c0-0455-4a1b-a8a6-82094aa65c03" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,763</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d207a04-0107-49f7-a585-b4535c479442" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,233,203</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> vested and unvested stock options outstanding as of December 31, 2023. As of December 31, 2023, total unrecognized compensation expense related to stock options was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80b7066d-df88-4460-8ad3-9b53586a55ee" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. This amount is expected to be recognized over a weighted average period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eb1230c9-ef75-47c2-9abc-a5ce7a182db2" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.49 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6b115b5a-ee3c-4499-84fa-1b61168fae68" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_58145a35-4038-4670-9aa2-3158aee4ab6b" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s loss before income taxes for the years ended December 31, 2023 and 2022 were generated in the following jurisdictions (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.92%;"/>
        <td style="width:1.72%;"/>
        <td style="width:1%;"/>
        <td style="width:13.76%;"/>
        <td style="width:1%;"/>
        <td style="width:1.72%;"/>
        <td style="width:1%;"/>
        <td style="width:7.880000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Domestic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae6e914c-334b-42ce-a0d5-59810a2921de" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">78,195</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f080439-d05a-4e44-b672-64e6b87fb443" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">96,781</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e073fbeb-6b24-43ed-89f3-a3608061da90" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">358</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b9f08f7-f153-46fa-b2c8-07a81d99c7d3" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,383</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Worldwide</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_abe75cd3-1b8b-4a30-8956-ad7dc3243a75" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">78,553</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbe5e30c-a753-4972-8d21-029a00995d42" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">65,398</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The foreign income for the year-ended December 31, 2022 was due to the transfer of intellectual property, or IP, from PepGen Limited to the parent company, PepGen Inc., in an arm&#8217;s length transaction at fair value pursuant to an asset transfer agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dee150b0-b3f6-445d-a507-4d0bb9910963" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of net deferred income taxes consisted of the following as of December 31, 2023 and 2022 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.92%;"/>
        <td style="width:1.72%;"/>
        <td style="width:1%;"/>
        <td style="width:13.76%;"/>
        <td style="width:1%;"/>
        <td style="width:1.72%;"/>
        <td style="width:1%;"/>
        <td style="width:7.880000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_abaeccce-49a0-4a7b-a5eb-f76e8178a21c" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,038</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3e62500-18fd-45a6-95eb-313f08a2c772" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">474</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e1dbdd7-c503-41ec-bb72-27b9ee448ad3" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,547</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c245fcf0-3a7d-41fd-9949-98e8d5398be9" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,287</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_afd29507-c210-4d75-90c5-14fbac4eb2e7" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">577</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2cc3a092-b750-4a29-9cae-bf8dc2ab520f" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">523</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized Section 174 R&amp;D Costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_434ca816-6701-4be0-8aaa-ef60655be084" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="pepg:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,470</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3811c280-c5e9-4ca0-bef4-d5ce95f3b28b" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="pepg:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,818</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c60d87c-0f23-489d-82ed-d10bd9a7f36f" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,510</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b318fd7-b85f-4897-9e55-b45c53953bc4" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,081</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a082464-4afe-43f3-8843-92359d122d86" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="pepg:DeferredTaxAssetsRightOfUseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,485</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6e4e470-6adf-4126-980e-472053a68775" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="pepg:DeferredTaxAssetsRightOfUseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,760</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible asset amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8559ed18-d763-441e-87a4-aa8a1781f652" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="pepg:DeferredTaxAssetsIntangibleAssetAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,425</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_37804b13-417a-4dcf-bd13-a5db5e807e7a" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="pepg:DeferredTaxAssetsIntangibleAssetAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,879</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d6e1f8ff-4b1d-48c7-a7f1-2fc0ab896329" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8fde5448-ecd8-4349-bb00-61c0075c743c" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,073</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8bdcfa55-1b8b-4277-bbb6-b8e3216818b3" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,822</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use-Asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6155311c-df2f-426e-9916-d35135f01228" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="pepg:DeferredTaxLiabilitiesRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,444</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f4289dc-e6f8-4d5c-92ce-ef6cb106c86c" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="pepg:DeferredTaxLiabilitiesRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,233</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed Assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a68bf275-9272-4986-ba00-69da4bb855ec" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,474</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0e5470d-4369-4671-83f6-75cdd618b993" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a24e9bff-543d-49fb-b3e2-ee0c26497a14" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1feba35-b123-448c-ae16-8025f5b087bb" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,918</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20130f32-ad37-4232-aa7a-c9306ccd9eb9" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,280</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a88fc20b-dfd2-46c8-82da-f73285f13247" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,155</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_903078de-9b07-49a3-bdf2-acd10d8eaf79" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,542</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_276c93fe-f0fa-4df7-b0e6-06af0c061c87" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,155</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_207ad11c-d309-48bb-b59b-31354845cc00" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,542</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3146437b-859d-45ce-bdb6-40f612836651" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of income tax expense were as follows for the years ended December 31, 2023 and 2022 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.748%;"/>
        <td style="width:3.759%;"/>
        <td style="width:1%;"/>
        <td style="width:17.057%;"/>
        <td style="width:1%;"/>
        <td style="width:3.759%;"/>
        <td style="width:1%;"/>
        <td style="width:12.677000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current expense:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;U.S. Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39eacbb8-1549-49ce-8b70-8e2a2e5cbdf8" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a3b749c8-e064-46a9-94ab-350370b7a73f" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e71c26c1-3aa3-4db6-8adb-95e82a933ac1" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,683</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0fb94be-3055-4acc-a0e2-c3590beaaf07" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9159a38a-c773-4c8f-a404-750826df21bf" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,706</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred expense:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;U.S. Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f59b544-81ec-45d7-9c2c-ce3f6a80e7e4" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43b18d9f-ddb6-495d-8a8f-6c614c0c6e54" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,706</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8dc8f141-488c-496c-9ca4-03200b51063a" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations is summarized for the years ended December 31, 2023 and 2022, as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.892%;"/>
        <td style="width:1.259%;"/>
        <td style="width:1%;"/>
        <td style="width:14.234000000000002%;"/>
        <td style="width:1%;"/>
        <td style="width:1.259%;"/>
        <td style="width:1%;"/>
        <td style="width:8.356%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax at statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_13b7c1bf-0b5b-40f4-8de8-a67470829cc9" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0527d328-6e5b-4904-b2b8-38983ffe6f11" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State tax (net of federal benefit)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e67eaef6-63c5-4d81-898b-61e918e5f9bb" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8e2ed1b-66bf-4db5-b119-c7b1fd139a1c" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_339bf87a-c7bc-4e2f-86f5-b9343cecab38" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="pepg:EffectiveIncomeTaxRateReconciliationPermanentDifferences" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63b0fb03-7235-4371-8f58-8e6a763d04c9" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="pepg:EffectiveIncomeTaxRateReconciliationPermanentDifferences" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e245922a-1a2e-42ae-a48a-0f59d85d4af4" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06e288f6-921d-4166-9d8d-809d0685c03c" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">GILTI Inclusion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52be8d6b-238b-4022-ad22-26be75740133" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_913d3970-e879-4731-b5ff-09009dfb9133" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">8.9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.K. R&amp;D credit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65c8c430-6c08-4cec-904d-d334fdd1e8ed" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="pepg:EffectiveIncomeTaxRateReconciliationUkRDCredit" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad91b5f1-2f9f-462a-847a-6fab265b1bf0" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="pepg:EffectiveIncomeTaxRateReconciliationUkRDCredit" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign rate differential</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_986caebd-8eca-4714-a71c-7bf6b4b95eb4" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ea7421f-3671-4b88-9106-956c8e7ea8de" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ec1a847-9f4f-4cbf-8972-374a152a4c3b" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">23.9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42af1697-cbc2-4834-8ded-d3facafd9008" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">23.4</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25fbbc6a-5935-4f4a-878c-ef74dc7b334c" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65f6270e-9b70-4b0e-96fa-4770fe9d235b" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax expense (benefit)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75a44165-3805-4ac8-92ad-7a2337a86fbf" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8bd0880a-1fca-4cc3-9e8b-5b0c22280749" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">5.8</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s income tax expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d950eb6-9a33-42d2-a07f-304120e54721" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2023 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f97ef4c4-9dea-4315-98dc-99211f6c271b" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2022. The income tax expense for the year ended December 31, 2023 was state taxes on interest income generated from the Company's cash equivalents and marketable securities. The income tax expense for the year ended December 31, 2022 was due to the IP transfer noted in the paragraph below.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 1, 2022, or the Transfer Date, the Company&#8217;s wholly owned subsidiary, PepGen Limited, transferred all IP assets to the parent company, PepGen Inc., in an arm&#8217;s length transaction at fair value pursuant to an asset transfer agreement. The fair value of the IP assets was a non-recurring fair value measurement. The Company engaged valuation specialists to calculate the IP value, and the IP value was measured using the historical cost method. The historical cost method estimated the fair value of the IP assets using the historical cost base of the IP assets and the expected market return as of the Transfer Date. The significant assumption inherent in estimating the fair value using the historical cost method was the expected market return. The Company utilized a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19fffd9d-610f-4d78-b09e-40538920c2fd" contextRef="C_369017c2-22f5-42b3-85de-349e0de7ffa4" name="pepg:ExpectedMarketReturn" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% expected market return, which a third-party investor may expect as a return on their investment, and which is based on studies of venture capital investment returns. The Company calculated the fair value of the IP assets by computing the present value of the historical cost base using the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3007e2e2-7638-474d-98f5-d472a4b2187f" contextRef="C_369017c2-22f5-42b3-85de-349e0de7ffa4" name="pepg:ExpectedMarketReturn" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% expected market return. The expected market return assumption used in the estimation of the IP assets represents a Level 3 input of the fair value hierarchy (see Note 3).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has federal net operating losses, or NOLs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_417f3ad5-9eb6-44e5-bba7-170895cb38f0" contextRef="C_36f077db-3490-4321-ac37-fd742c52e7c4" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">23.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and federal research and development, or R&amp;D, credits of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c885e2e-f7b7-4430-89f8-3dc47b6947be" contextRef="C_36f077db-3490-4321-ac37-fd742c52e7c4" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023, before consideration of limitations under Section 382 of the Internal Revenue Code, or Section 382, as further described below. The R&amp;D credits will expire beginning in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d725b462-192e-45d2-8845-5af173f1e3f7" contextRef="C_56d10337-c99d-4729-a0be-2f97270f71c5" name="pepg:ResearchAndDevelopmentCreditsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2041</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The Company has state NOLs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7cc2173-fada-4b49-8894-fb259d2461d0" contextRef="C_6da82c22-e37a-42bc-980f-059274a23288" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">36.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and state R&amp;D credits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de25bc81-8ecd-4485-8c15-6384fb192f3e" contextRef="C_6da82c22-e37a-42bc-980f-059274a23288" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million which begin expiring in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6edc8c75-8729-46a0-aeb9-71b73f6ad90f" contextRef="C_efb79f6f-7f45-4f73-8424-9da26d4e839d" name="pepg:OperatingLossCarryForwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2042</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The future utilization of the Company&#8217;s state NOLs and federal and state R&amp;D credits to offset future taxable income may be subject to a substantial annual limitation as a result of changes in ownership by stockholders that hold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8a5ed95-1dcd-4ea9-b639-a4262fee5560" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="pepg:ChangesInOwnershipByStockholdersHoldingPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% or more of the Company&#8217;s common stock. An assessment of such ownership changes under Section 382 was not completed through December 31, 2023. To the extent that an assessment is completed in the future, the Company&#8217;s ability to utilize tax attributes could be restricted on a year-by-year basis and certain attributes could expire before they are utilized. The Company will examine the impact of any potential ownership changes in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to taxation in the U.S. and the U.K. The Company&#8217;s federal and state returns since inception are subject to examination due to the carryover of NOLs. The Company has not been, nor is it currently, under examination by any tax authorities. The U.K. tax returns from </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3062ccf9-2ebd-48c3-88e3-8f9f10106df3" contextRef="C_0cb40be6-2cf0-473a-a7d2-976e96f36428" name="us-gaap:OpenTaxYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2018</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and forward are subject to examination by the U.K. tax authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_06551429-2517-4a14-83c5-276f8c6a9fa2" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the reconciliation of the beginning and ending amount of total unrecognized tax benefits for each of the periods indicated:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.44%;"/>
        <td style="width:3.6%;"/>
        <td style="width:1%;"/>
        <td style="width:15.34%;"/>
        <td style="width:1%;"/>
        <td style="width:3.8%;"/>
        <td style="width:1%;"/>
        <td style="width:16.82%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at beginning of the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50100a32-7b46-4bb6-9376-17db92214cb5" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">673</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0d9c7df-b85e-4ae8-97ec-12771cd9c94f" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">751</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to prior year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Decrease related to prior year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Currency translation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2a2fc2d-b9a4-4a8c-975a-975bea2a556e" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0eb08e66-5b50-44b9-9a96-a0d8cccc2d26" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at the end of the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fce87866-ba3e-4321-894c-3a4299a21570" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">713</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f47a796b-7a58-4df0-a43c-b4e38f227908" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">673</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company does not expect the amount of unrecognized tax benefits to change significantly in the next twelve months. The Company&#8217;s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. It had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a30b25a8-eb0f-4619-b36f-da8a8e2e95be" contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_cad40be5-2a65-463e-b7f2-5aa2a9897dbf" contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> accrual for interest or penalties on its consolidated balance sheets at December 31, 2023 or 2022. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2bb95f0-9249-4ac0-a90d-3cd37254b47d" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4942e0c9-d04e-44cd-89ec-5b44242d7aa8" contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> interest and/or penalties were recognized in 2023 or 2022.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6607fe81-fce3-4d27-bca1-04d49df407ee" contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. Subsequent Events</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 5, 2024, the Company sold shares under the Sales Agreement, resulting in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba507625-9db1-4931-b774-5f16bfec2e8f" contextRef="C_e1609515-c590-4eef-875c-348138380b4c" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. On February 9, 2024, the Company sold shares in the Follow-on Offering, resulting in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d914a0e-b1d8-4c06-af38-32e7204b70cb" contextRef="C_e7e9bfb4-48e5-4056-bafa-50d040cb558e" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">76.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting underwriters' fees of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bb9b6da-4eea-41e1-adc9-3dcd07263c59" contextRef="C_e7e9bfb4-48e5-4056-bafa-50d040cb558e" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Net proceeds from sales under the Sales Agreement and Follow-on Offering, after deducting underwriters' fees and before deducting costs of the offerings, were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ee47895-fdde-413d-95b4-3ba63a9dc2e4" contextRef="C_f91c8a3a-fd8f-4f54-b410-a52327d04868" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">86.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>2
<FILENAME>pepg-ex10_19.htm
<DESCRIPTION>EX-10.19
<TEXT>
<html>
 <head>
  <title>EX-10.19</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:0.93in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 10.19</font></p>
  <p style="margin-left:0.053%;font-size:10pt;margin-top:4.15pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.565%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;">EMPLOYMENT AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:1.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.857%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.056%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Employment Agreement (&#x201c;Agreement&#x201d;) is made between PepGen Inc. (the &#x201c;Company&#x201d;), and Mary Beth DeLena and is effective as January 15</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, 2024 (the &#x201c;Effective Date&#x201d;).</font></p>
  <p style="margin-left:0.92%;text-indent:6.848%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.926%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS, the Company desires to employ you and you desire to be employed by the Company on the new terms and conditions contained herein.</font></p>
  <p style="margin-left:0.92%;text-indent:6.857%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.056%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:</font></p>
  <div style="margin-left:7.602%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;" id="x__employment_"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:0.935%;text-indent:13.755%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.13%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__term____the_company_shall_employ_you"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Company shall employ you and you shall be employed by the Company pursuant to this Agreement commencing as of the Effective Date and continuing until such employment is terminated in accordance with the provisions hereof (the &#x201c;Term&#x201d;). Your employment with the Company will be &#x201c;at will,&#x201d; meaning that your employment may be terminated by the Company or you at any time and for any reason subject to the terms of this Agreement.</font></div></div>
  <div style="margin-left:0.935%;text-indent:13.699%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.731%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__position_and_duties___you_shall_serv"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Position and Duties</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. You shall serve as the General Counsel and Secretary of the Company and shall have such powers and duties as may from time to time be prescribed by the Chief Executive Officer (the &#x201c;CEO&#x201d;). You shall devote your full working time and efforts to the business and affairs of the Company and will not engage in any other business activities during your employment by the Company, except as expressly authorized in writing and in advance by a duly authorized representative of the Company.</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;" id="x__compensation_and_related_matters_"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Compensation and Related Matters</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:0.935%;text-indent:13.775%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__base_salary___your_initial_base_sala"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Base Salary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Your initial base salary shall be paid at the rate of $425,000 per year. Your base salary shall be subject to periodic review by the Board or the Compensation Committee of the Board (the &#x201c;Compensation Committee&#x201d;). The base salary in effect at any given time is referred to herein as &#x201c;Base Salary.&#x201d; The Base Salary shall be payable in a manner that is consistent with the Company&#x2019;s usual payroll practices.</font></div></div>
  <div style="margin-left:0.935%;text-indent:13.68%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__annual_discretionary_incentive_compe"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Annual Discretionary Incentive Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. You shall be eligible to receive annual cash incentive compensation as determined by the Board or the Compensation Committee. Your initial target annual incentive compensation shall be 40% percent of your Base Salary. The target annual incentive compensation in effect at any given time is referred to herein as &#x201c;Target Bonus.&#x201d; The actual amount of your annual incentive compensation, if any, shall be determined in the sole discretion of the Board or the Compensation Committee. Except as otherwise provided in the severance section herein, to earn incentive compensation, you must be employed by the Company on the day such incentive compensation is paid.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.55in;min-height:0.68in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:0.935%;text-indent:13.85%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:2.796%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__expenses___you_shall_be_eligible_for"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. You shall be eligible for reimbursement for all reasonable and documented expenses incurred by you during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its executive officers.</font></div></div>
  <div style="margin-left:0.935%;text-indent:13.87%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.935%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;" id="xd__other_benefits___you_shall_be_eligib"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Other Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. You shall be eligible to participate in or receive benefits under the Company&#x2019;s employee benefit plans in effect from time to time, subject to the terms of such plans, which terms are subject to change by the Company.</font></div></div>
  <div style="margin-left:0.935%;text-indent:13.736%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;" id="xe__paid_time_off___you_shall_be_eligibl"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Paid Time Off</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. You shall be eligible to take paid time off in accordance with the Company&#x2019;s applicable paid time off policy for executives, as may be in effect from time to time.</font></div></div>
  <div style="margin-left:0.935%;text-indent:13.755%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:2.13%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;" id="xf__stock_option__subject_to_the_approva"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Stock Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Subject to the approval of the Board (or a duly authorized committee thereof), and subject to your continued employment with the Company through the date the Option (as defined below) is granted by the Board, the Company intends to grant you an option to purchase up to 125,000 shares of its common stock (the &#x201c;Option&#x201d;), at an exercise price that is no less than the fair market value per share of such Common Stock as of the date of grant of the Option. The Option will be an incentive stock option under Section 422 of the Internal Revenue Code to the extent permitted by applicable law, and otherwise will be a non-qualified stock option. The Option will be subject to standard vesting terms (25% cliff at first anniversary of the Effective Date, and the balance vesting monthly over the following thirty-six (36) months), subject to your continued employment with the Company as of each such vesting date.</font></div></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.926%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Option will be subject to the terms of the Company&#x2019;s equity incentive plan then in effect (&#x201c;Plan&#x201d;), and the Company&#x2019;s standard form of stock option agreement and grant notice, which</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.019%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">you will be required to sign (together, with the Plan, the &#x201c;Equity Documents&#x201d;). Beginning in the calendar year 2025, and subject to the approval and discretion of the Board (or a duly authorized committee thereof), and subject to your continued employment with the Company on the date of grant, you will be eligible to receive additional equity awards on an annual basis.</font></p>
  <div style="margin-left:0.935%;text-indent:6.859%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;" id="x__termination___your_employment_hereund"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Your employment hereunder may be terminated without any breach of this Agreement under the following circumstances:</font></div></div>
  <div style="margin-left:14.269%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.776650219873791%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__death___your_employment_hereunder_sh"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Death</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Your employment hereunder shall terminate upon death.</font></div></div>
  <div style="margin-left:0.935%;text-indent:13.718%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__disability___the_company_may_termina"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Disability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Company may terminate your employment if you are disabled and unable to perform or expected to be unable to perform the essential functions of your then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period. If any question shall arise as to whether during any period you are disabled so as to be unable to perform the essential functions of your then existing position or positions with or without reasonable accommodation, you may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom you or your guardian has no reasonable objection as to whether you are disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue. You shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and you shall fail to</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.73in;min-height:0.86in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.583%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">submit such certification, the Company&#x2019;s determination of such issue shall be binding on you. Nothing in this Section 3(b) shall be construed to waive your rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. &#167;2601 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">et seq</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. and the Americans with Disabilities Act, 42 U.S.C. &#167;12101 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">et seq.</font></p>
  <div style="margin-left:0.935%;text-indent:13.68%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__termination_by_company_for_cause___t"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination by Company for Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Company may terminate the your employment hereunder for Cause. For purposes of this Agreement, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean any of the following:</font></div></div>
  <div style="margin-left:0.935%;text-indent:20.662%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:20%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.747337606621915%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;" id="xi__conduct_by_you_constituting_a_materi"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">conduct by you constituting a material act of misconduct in connection with the performance of your duties, including, without limitation, (A) willful failure or refusal to perform material responsibilities that have been requested by the CEO; (B) dishonesty to the CEO with respect to any material matter; or (C) misappropriation of funds or property of the Company or any of its subsidiaries or affiliates other than the occasional, customary and </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">de minimis </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">use of Company property for personal purposes;</font></div></div>
  <div style="margin-left:0.935%;text-indent:20.951%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.602%;min-width:20%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.747337606621915%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;" id="xii__the_commission_by_you_of_acts_satis"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the commission by you of acts satisfying the elements of (A) any felony or (B) a misdemeanor involving moral turpitude, deceit, dishonesty or fraud;</font></div></div>
  <div style="margin-left:0.935%;text-indent:20.775%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.796%;min-width:20%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.747337606621915%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;" id="xiii__any_misconduct_by_you__regardless_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">any misconduct by you, regardless of whether or not in the course of your employment, that would reasonably be expected to result in material injury or reputational harm to the Company or any of its subsidiaries or affiliates if you were to continue to be employed in the same position;</font></div></div>
  <div style="margin-left:0.935%;text-indent:20.605%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2%;min-width:20%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.747337606621915%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;" id="xiv__continued_non_performance_by_you_of"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">continued non-performance by you of your duties hereunder (other than by reason of your physical or mental illness, incapacity or disability) which has continued for more than 30 days following written notice of such non-performance from the CEO;</font></div></div>
  <div style="margin-left:0.935%;text-indent:20.805%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.935%;min-width:20%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.747337606621915%;text-indent:0;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;" id="xv__a_breach_by_you_of_any_of_the_provis"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">a breach by you of any of the provisions contained in Section 8 of this Agreement or the Restrictive Covenants Agreement (as defined below);</font></div></div>
  <div style="margin-left:0.935%;text-indent:21.962%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:8%;min-width:20%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.747337606621915%;text-indent:0;display:inline-flex;justify-content:flex-start;">(vi)</font><div style="width:100%;display:inline;" id="xvi__a_material_violation_by_you_of_any_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">a material violation by you of any of the Company&#x2019;s written employment policies; or</font></div></div>
  <div style="margin-left:0.935%;text-indent:20.775%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:2.796%;min-width:20%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.747337606621915%;text-indent:0;display:inline-flex;justify-content:flex-start;">(vii)</font><div style="width:100%;display:inline;" id="xvii__your_failure_to_cooperate_with_a_b"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">your failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation.</font></div></div>
  <div style="margin-left:0.935%;text-indent:14.245%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:5.463%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;" id="xd__termination_by_the_company_without_c"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination by the Company without Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Company may terminate your employment hereunder at any time without Cause. A termination due to your death or disability under Section 3(a) or (b) shall not constitute a termination without Cause.</font></div></div>
  <div style="margin-left:0.935%;text-indent:13.736%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;" id="xe__termination_by_you___you_may_termina"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination by You</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. You may terminate employment hereunder at any time for any reason, including but not limited to, Good Reason. For purposes of this Agreement, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; shall mean that you have completed all steps of the Good Reason Process</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.73in;min-height:0.86in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.056%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(hereinafter defined) following the occurrence of any of the following events without your consent (each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Good Reason Condition</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;):</font></p>
  <div style="margin-left:7.602%;text-indent:14.662%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.463%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.873417173531895%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;" id="xi__a_material_diminution_in_your_respon"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">a material diminution in your responsibilities and duties that occurs within the 12 months following a Sale Event;</font></div></div>
  <div style="margin-left:7.602%;text-indent:15.175%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:4.537%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.873417173531895%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;" id="xii__a_material_diminution_in_your_base_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">a material diminution in your Base Salary except for across-the- board salary reductions based on the Company&#x2019;s financial performance similarly affecting all or substantially all senior management employees of the Company;</font></div></div>
  <div style="margin-left:7.602%;text-indent:14.662%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.463%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.873417173531895%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;" id="xiii__a_material_change_in_the_physical_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">a material change in the physical Company office location at which the Company requires you to provide services to the Company, such that there is an increase of at least forty (40) miles of driving distance between the Company&#x2019;s prior office location and its new location (and to avoid doubt, a home or remote office does not constitute a Company office location for these purposes);</font></div></div>
  <div style="margin-left:7.602%;text-indent:14.838%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:2.537%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.873417173531895%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;" id="xiv__a_material_breach_by_the_company_of"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">a material breach by the Company of the compensation provisions of this Agreement.</font></div></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Good Reason Process</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; consists of the following steps:</font></p>
  <div style="margin-left:7.602%;text-indent:15.899%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:8.537%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.873417173531895%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;" id="xi__you_reasonably_determine_in_good_fai"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">you reasonably determine in good faith that a Good Reason Condition has occurred;</font></div></div>
  <div style="margin-left:7.602%;text-indent:15.22%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:4.796%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.873417173531895%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;" id="xii__you_notify_the_company_in_writing_o"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">you notify the Company in writing of the first occurrence of the Good Reason Condition within 60 days of the first occurrence of such condition;</font></div></div>
  <div style="margin-left:7.602%;text-indent:14.949%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.204%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.873417173531895%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;" id="xiii__you_cooperate_in_good_faith_with_t"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">you cooperate in good faith with the Company&#x2019;s efforts, for a period of not less than 30 days following such notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cure Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), to remedy the Good Reason Condition;</font></div></div>
  <div style="margin-left:7.602%;text-indent:16.235%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:10.269%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.873417173531895%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iv)</font><div style="width:100%;display:inline;" id="xiv__notwithstanding_such_efforts__the_g"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">notwithstanding such efforts, the Good Reason Condition continues to exist; and</font></div></div>
  <div style="margin-left:20.935%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:8.432302535888194%;display:inline-flex;justify-content:flex-start;">(v)</font><div style="width:100%;display:inline;" id="xv__you_terminate_employment_within_60_d"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">you terminate employment within 60 days after the end of the Cure</font></div></div>
  <p style="margin-left:7.587%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Period.</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.926%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If the Company cures the Good Reason Condition during the Cure Period, Good Reason shall be deemed not to have occurred.</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.056%;text-align:left;" id="if_your_employment_with_the_company_is_t"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If your employment with the Company is terminated for any reason, the Company shall pay or provide to you (or your authorized representative or estate) (i) any Base Salary earned through the Date of Termination; and (ii) any unpaid expense reimbursements (subject to, and in accordance with this Agreement) (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Accrued Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <div style="margin-left:7.602%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;" id="x__notice_and_date_of_termination__resig"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notice and Date of Termination; Resignations Upon Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:0.935%;text-indent:13.813%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:2.537%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__notice_of_termination___except_for_t"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notice of Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Except for termination as specified in Section 3(a), any termination of your employment by the Company or any such termination by you shall be </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.73in;min-height:0.86in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:0.935%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:2.537%;min-width:13.333%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">communicated by written Notice of Termination to the other party hereto. For purposes of</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.73in;min-height:0.86in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">5</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.056%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">this Agreement, a &#x201c;Notice of Termination&#x201d; shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon.</font></p>
  <div style="margin-left:0.935%;text-indent:13.793%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.398%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__date_of_termination____date_of_termi"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Date of Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. &#x201c;Date of Termination&#x201d; shall mean: (i) if your employment is terminated by death, the date of death; (ii) if your employment is terminated on account of disability under Section 3(b) or by the Company for Cause under Section 3(c), the date on which Notice of Termination is given; (iii) if your employment is terminated by the Company without Cause under Section 3(d), the date on which a Notice of Termination is given or the date otherwise specified by the Company in the Notice of Termination; (iv) if your employment is terminated by you under Section 3(e) other than for Good Reason, 14 days after the date on which a Notice of Termination is given, and (v) if your employment is terminated by you under Section 3(e) for Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, in the event that you give a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement.</font></div></div>
  <div style="margin-left:0.935%;text-indent:13.68%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__resignations_from_other_positions_up"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Resignations From Other Positions Upon Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. In connection with your termination of employment for any reason, you shall be deemed to have resigned from all officer and board member positions that you hold with the Company or any of its subsidiaries and affiliates. You shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.868%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;" id="x__severance_pay_and_benefits_upon_ter_1"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Severance Pay and Benefits Upon Termination by the Company without Cause or</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">by You for Good Reason Outside the Sale Event Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. If your employment is terminated by the Company without Cause as provided in Section 3(d), or you terminate employment for Good Reason as provided in Section 3(e), in either case outside of the Sale Event Period (as defined below), then, in addition to the Accrued Obligations, and subject to (i) you signing a separation agreement and release in a form and manner provided by the Company, which shall include, without limitation, a general release of claims against the Company and all related persons and entities, a reaffirmation of all of your Continuing Obligations (as defined below</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">), </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">and, in the Company&#x2019;s sole discretion, a one-year post-employment noncompetition agreement, and shall provide that if you breach any of the Continuing Obligations, all payments of the Severance</font></div></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.463%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amount shall immediately cease (the &#x201c;Separation Agreement and Release&#x201d;), and (ii) the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven (7) business day revocation period:</font></p>
  <div style="margin-left:0.935%;text-indent:14.266%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:5.602%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__the_company_shall_pay_you_an_amount_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the Company shall pay you an amount equal to 9 months of your Base Salary (the &#x201c;Severance Amount&#x201d;); provided in the event you are entitled to any payments pursuant to the Restrictive Covenants Agreement, the Severance Amount received in any calendar year will be reduced by the amount you are paid in the same such calendar year</font></div></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.056%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">pursuant to the Restrictive Covenants Agreement (the &#x201c;Restrictive Covenants Agreement Setoff&#x201d;); and</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.73in;min-height:0.86in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">6</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:0.935%;text-indent:13.661%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:1.463%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__subject_to_your_copayment_of_premium"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">subject to your copayment of premium amounts at the applicable active employees&#x2019; rate and your proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#x201c;COBRA&#x201d;), the Company shall pay to the group health plan provider, the COBRA provider or you a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to you if you had remained employed by the Company until the earliest of (A) the 9 month anniversary of the Date of Termination; (B) your eligibility for group medical plan benefits under any other</font></div></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.056%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">employer&#x2019;s group medical plan; or (C) the cessation of your continuation rights under COBRA; provided, however, if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to you for the time period specified above. Such payments shall be subject to tax-related deductions and withholdings and paid on the Company&#x2019;s regular payroll dates.</font></p>
  <div style="margin-left:0.935%;text-indent:13.699%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.731%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__the_company_shall_pay_you_a_prorated"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the Company shall pay you a prorated portion of your Target Bonus for the year in which the Date of Termination occurs (the &#x201c;Termination Year&#x201d;) (which portion shall be prorated by multiplying the Target Bonus amount by x/12, with x representing the number of completed full calendar months in the Termination Year prior to the Date of Termination), which portion the Company shall pay during the year following the Termination Year, on or around the same time the Company pays bonuses to other employees with respect to the Termination Year.</font></div></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.056%;text-align:left;" id="the_amounts_payable_under_section_5__a__"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The amounts payable under Section 5 (a) and (b), to the extent taxable, shall be paid out in substantially equal installments in accordance with the Company&#x2019;s payroll practice over 9</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.852%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">months commencing within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the Severance Amount, to the extent it qualifies as &#x201c;non-qualified deferred compensation&#x201d; within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;), shall begin to be paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A- 2(b)(2).</font></p>
  <div style="margin-left:0.935%;text-indent:6.849%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.731%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;" id="x__severance_pay_and_benefits_upon_termi"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Severance Pay and Benefits Upon Termination by the Company without Cause or</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">by the You for Good Reason within the Sale Event Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The provisions of this Section 6 shall apply in lieu of, and expressly supersede, the provisions of Section 5 if (i) your employment is terminated either (a) by the Company without Cause as provided in Section 3(d), or (b) by you for Good Reason as provided in Section 3(e), and (ii) the Date of Termination is within 12 months after the occurrence of the first event constituting a Sale Event (such period, the &#x201c;Sale Event Period&#x201d;). These provisions shall terminate and be of no further force or effect after a Sale Event Period.</font></div></div>
  <div style="margin-left:0.935%;text-indent:13.813%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.537%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__if_your_employment_is_terminated_by_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If your employment is terminated by the Company without Cause as provided in Section 3(d) or you terminate employment for Good Reason as provided in Section 3(e) and in either case the Date of Termination occurs during the Sale Event Period, then, in </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.73in;min-height:0.86in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">7</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:0.935%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.537%;min-width:13.333%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">addition to the Accrued Obligations, and subject to the signing of the Separation Agreement and</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.73in;min-height:0.86in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">8</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.824%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Release by you and the Separation Agreement and Release becoming fully effective, all within the time frame set forth in the Separation Agreement and Release but in no event more than 60 days after the Date of Termination:</font></p>
  <div style="margin-left:7.602%;text-indent:14.728%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.873417173531895%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;" id="xi__the_company_shall_pay_you_a_lump_sum"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the Company shall pay you a lump sum in cash in an amount equal to (A) 1.0 times your then current Base Salary (or your Base Salary in effect immediately prior to the Sale Event, if higher) plus (B) your Target Bonus for the Termination Year ((A) and (B), the &#x201c;Sale Event Payment&#x201d;); provided the Sale Event Payment shall be reduced by the amount of the Restrictive Covenants Agreement Setoff, if applicable; and</font></div></div>
  <div style="margin-left:7.602%;text-indent:14.838%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.537%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.873417173531895%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;" id="xii__notwithstanding_anything_to_the_con"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">notwithstanding anything to the contrary in any applicable option agreement or other stock-based award agreement, all time-based stock options and other stock-based awards subject to time-based vesting held by you (the &#x201c;Time-Based Equity Awards&#x201d;) shall immediately accelerate and become fully exercisable or nonforfeitable as of the later of (i) the Date of Termination or (ii) the effective date of the Separation Agreement and Release (the &#x201c;Accelerated Vesting Date&#x201d;); </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">that any termination or forfeiture of the unvested portion of such Time-Based Equity Awards that would otherwise occur on the Date of Termination in the absence of this Agreement will be delayed until the effective date of the Separation Agreement and Release and will only occur if the vesting pursuant to this subsection does not occur due to the absence of the Separation Agreement and Release becoming fully effective within the time period set forth therein. Notwithstanding the foregoing, no additional vesting of the Time-Based Equity Awards shall occur during the period between your Date of Termination and the Accelerated Vesting Date; and</font></div></div>
  <div style="margin-left:7.602%;text-indent:15.038%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.731%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.873417173531895%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;" id="xiii__subject_to_your_copayment_of_premi"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">subject to your copayment of premium amounts at the applicable active employees&#x2019; rate and your proper election to receive benefits under COBRA, the Company shall pay to the group health plan provider, the COBRA provider or you a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to you if you had remained employed by the Company until the earliest of (A) the 18 month anniversary of the Date of Termination;</font></div></div>
  <p style="margin-left:7.587%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.056%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(B) your eligibility for group medical plan benefits under any other employer&#x2019;s group medical plan; or (C) the cessation of your continuation rights under COBRA; provided, however, if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to you for the time period specified above. Such payments shall be subject to tax-related deductions and withholdings and paid on the Company&#x2019;s regular payroll dates.</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.056%;text-align:left;" id="the_amounts_payable_under_this_section_6"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The amounts payable under this Section 6(a), to the extent taxable, shall be paid or commence to be paid within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payments to the</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.056%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">extent they qualify as &#x201c;non-qualified deferred compensation&#x201d; within the meaning of Section 409A of the Code, shall be paid or commence to be paid in the second calendar year by the last day of such 60-day period.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.73in;min-height:0.86in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">9</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:14.269%;display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.776650219873791%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__additional_limitation_"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Additional Limitation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:7.602%;text-indent:14.728%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.873417173531895%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;" id="xi__anything_in_this_agreement_to_the_co"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution by the Company to or for the benefit of you, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Code, and the applicable regulations thereunder (the &#x201c;Aggregate Payments&#x201d;), would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which you became the subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only occur if it would result in you receiving a higher After Tax Amount (as defined below) than you would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code: (1) cash payments not subject to Section 409A of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity- based payments and acceleration; and (4) non-cash forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. &#167;1.280G-1, Q&amp;A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treas. Reg. &#167;1.280G-1, Q&amp;A- 24(b) or (c).</font></div></div>
  <div style="margin-left:7.602%;text-indent:14.685%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.873417173531895%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;" id="xii__for_purposes_of_this_section_6_b___"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For purposes of this Section 6(b), the &#x201c;After Tax Amount&#x201d; means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on you as a result of your receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, you shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes.</font></div></div>
  <div style="margin-left:7.602%;text-indent:15.576%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:6.796%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.873417173531895%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;" id="xiii__the_determination_as_to_whether_a_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to Section 6(b)(i) shall be made by a nationally</font></div></div>
  <p style="margin-left:7.587%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.926%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">recognized accounting firm selected by the Company (the &#x201c;Accounting Firm&#x201d;), which shall provide detailed supporting calculations both to the Company and you within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or you. Any determination by the Accounting Firm shall be binding upon the Company and you.</font></p>
  <div style="margin-left:0.935%;text-indent:13.813%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.537%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__sale_event____sale_event__is_defined"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Sale Event</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Sale Event</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; is defined in the Equity Documents, which definition is reproduced here for reference: the occurrence of any of the following events: (i) the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (ii) a merger, reorganization or consolidation pursuant to which the holders of the Company&#x2019;s outstanding voting power and outstanding stock immediately prior to</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.73in;min-height:0.86in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">10</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.056%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction, (iii) the sale of all of the Stock (as defined in the Equity Documents) of the Company to an unrelated person, entity or group thereof acting in concert, or (iv) any other transaction in which the owners of the Company&#x2019;s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result of the acquisition of securities directly from the Company.</font></p>
  <div style="margin-left:7.602%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;" id="x__section_409a_"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:0.935%;text-indent:13.813%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.537%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__anything_in_this_agreement_to_the_co"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section 409A of the Code, the Company determines that you are a &#x201c;specified employee&#x201d; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement or otherwise on account of your separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after your separation from service, or (B) your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.</font></div></div>
  <div style="margin-left:0.935%;text-indent:13.68%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__all_in_kind_benefits_provided_and_ex"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></div></div>
  <div style="margin-left:0.935%;text-indent:13.928%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__to_the_extent_that_any_payment_or_be"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To the extent that any payment or benefit described in this Agreement constitutes &#x201c;non-qualified deferred compensation&#x201d; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon your termination of employment, then such payments or benefits shall be payable only upon your &#x201c;separation from service.&#x201d; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h).</font></div></div>
  <div style="margin-left:0.935%;text-indent:13.68%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;" id="xd__the_parties_intend_that_this_agreeme"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement or the Restrictive Covenants Agreement is intended to constitute a separate</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.73in;min-height:0.86in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">11</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.</font></p>
  <div style="margin-left:0.935%;text-indent:14.388%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:6.398%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;" id="xe__the_company_makes_no_representation_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;" id="x__continuing_obligations_"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Continuing Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:0.935%;text-indent:13.718%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa__restrictive_covenants_agreement___as"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restrictive Covenants Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. As a condition of your employment, including your opportunity to receive the compensation and benefits provided in this Agreement, you are required to enter into the Employee Confidentiality, Assignment, Nonsolicitation and Noncompetition Agreement , attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> (the &#x201c;Restrictive Covenants</font></div></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.056%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Agreement&#x201d;). For purposes of this Agreement, the obligations in this Section 8, those that arise in the Restrictive Covenants Agreement and any other agreement between you and the Company relating to confidentiality, assignment of inventions, or other restrictive covenants shall</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">collectively be referred to as the &#x201c;Continuing Obligations.&#x201d;</font></p>
  <div style="margin-left:0.935%;text-indent:13.736%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__third_party_agreements_and_rights___"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Third-Party Agreements and Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. You hereby confirm that you are not bound by the terms of any agreement with any previous employer or other party which restricts in any way your use or disclosure of information, other than confidentiality restrictions (if any), or your engagement in any business, except as previously disclosed in writing to the Company. You represent to the Company that your execution of this Agreement, your employment with the Company and the performance of your proposed duties for the Company will not violate any obligations you may have to any such previous employer or other party. In your work for the Company, you will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and you will not bring to the premises of the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment or other party.</font></div></div>
  <div style="margin-left:0.935%;text-indent:13.718%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__litigation_and_regulatory_cooperatio"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Litigation and Regulatory Cooperation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. During and after your employment, you shall cooperate fully with the Company in (i) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while you were employed by the Company, and (ii) the investigation, whether internal or external, of any matters about which the Company believes you may have knowledge or information. Your full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after your employment, you also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while you were employed by the Company. The Company shall reimburse you for any reasonable out-of-pocket expenses incurred in connection with your </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.73in;min-height:0.86in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">12</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:0.935%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.87%;min-width:13.333%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">performance of obligations pursuant to this Section 8(c).</font></div></div>
  <div style="margin-left:0.935%;text-indent:13.87%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:2.935%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;" id="xd__relief___you_agree_that_it_would_be_"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Relief</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. You agree that it would be difficult to measure any damages caused to the Company which might result from any breach by you of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">you agree that if you breach, or propose to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company.</font></div></div>
  <div style="margin-left:0.935%;text-indent:13.68%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.9014788270327565%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;" id="xe__protected_disclosures_and_other_prot"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Protected Disclosures and Other Protected Action</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Nothing contained in this Agreement, any other agreement with the Company, or any Company policy limits your ability, with or without notice to the Company, to: (i) file a charge or complaint with any federal, state or local governmental agency or commission (a &#x201c;Government Agency&#x201d;), including without limitation, the Equal Employment Opportunity Commission, the National Labor Relations Board or the Securities and Exchange Commission; (ii) communicate with any Government Agency or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including by providing non-privileged documents or information; (iii) exercise any rights under Section 7 of the National Labor Relations Act, which are available to non-supervisory employees, including assisting co-workers with or discussing any employment issue as part of engaging in concerted activities for the purpose of mutual aid or protection; (iv) share compensation information concerning yourself or others (provided that this does not permit you to disclose compensation information concerning others that you obtain because your job responsibilities require or allow access to such information); (v) discuss or disclose information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that you have reason to believe is unlawful; or (vi) testify truthfully in a legal proceeding. Any such communications and disclosures must not violate applicable law and the information disclosed must not have been obtained through a communication that was subject to the attorney- client privilege (unless disclosure of that information would otherwise be permitted consistent with such privilege or applicable law).. In addition, for the avoidance of doubt, pursuant to the federal Defend Trade Secrets Act of 2016, you shall not be held criminally or civilly liable under any federal or state trade secret law or under this Agreement or the Restrictive Covenants Agreement for the disclosure of a trade secret that (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.73in;min-height:0.86in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">13</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:0.935%;text-indent:6.84%;font-size:0;margin-top:12.1pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;" id="x__consent_to_jurisdiction___the_parties"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Consent to Jurisdiction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The parties hereby consent to the jurisdiction of the state and federal courts of Massachusetts. Accordingly, with respect to any such court action, you (a) submit to the exclusive personal jurisdiction of such courts; (b) consent to service of process; and</font></div></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:4.491%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c) waive any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process.</font></p>
  <div style="margin-left:0.935%;text-indent:6.984%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.602%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;" id="x0__waiver_of_jury_trial___you_and_the_c"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Waiver of Jury Trial</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. You and the Company irrevocably and unconditionally WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY PROCEEDING (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR YOUR EMPLOYMENT BY THE COMPANY OR ANY AFFILIATE OF THE COMPANY, INCLUDING WITHOUT LIMITATION YOURS OR THE COMPANY&#x2019;S PERFORMANCE UNDER, OR THE ENFORCEMENT OF, THIS AGREEMENT.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.887%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;" id="x1__integration___this_agreement__the_eq"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Integration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement, the Equity Documents and the Continuing Obligations constitute the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter. In signing this Agreement, you agree that you are not relying on any prior or contemporaneous promise, representation, communication or agreement by or with the Company or any Company agent, director or representative, in each case except as is expressly set forth herein.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.849%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.731%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;" id="x2__withholding__tax_effect___all_paymen"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Withholding; Tax Effect</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. All payments made by the Company to you under this Agreement shall be subject to, and net of any tax or other amounts required or permitted to be withheld by the Company under applicable law. Nothing in this Agreement shall be construed to require the Company to make any payments to compensate you for any adverse tax effect associated with any payments or benefits or for any deduction or withholding from any payment or benefit.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.849%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.731%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;" id="x3__assignment___the_company_may_assign_"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Assignment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The Company may assign its rights and obligations under this Agreement (including the Continuing Obligations) without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets or to any other person or entity. This Agreement shall inure to the benefit of and be binding upon you and the Company, and each of yours and the Company&#x2019;s respective successors, executors, administrators, heirs and permitted assigns.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.877%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.13%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;" id="x4__enforceability___if_any_portion_or_p"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Enforceability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.984%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;" id="x5__survival___the_provisions_of_this_ag"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Survival</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of your employment to the extent necessary to effectuate the terms contained herein.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.73in;min-height:0.86in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">14</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:0.935%;text-indent:6.964%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:3.333%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.</font><div style="width:100%;display:inline;" id="x6__waiver___no_waiver_of_any_provision_"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.906%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.537%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">17.</font><div style="width:100%;display:inline;" id="x7__notices___any_notices__requests__dem"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to you at the last address you has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.73in;min-height:0.86in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:3pt;font-size:10pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">15</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:0.935%;text-indent:7.122%;font-size:0;margin-top:4pt;justify-content:flex-start;margin-bottom:0;margin-right:5.463%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.</font><div style="width:100%;display:inline;" id="x8__amendment___this_agreement_may_be_am"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement may be amended or modified only by a written instrument signed by you and by a duly authorized representative of the Company.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.887%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:2.269%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">19.</font><div style="width:100%;display:inline;" id="x9__no_other_severance_rights___section_"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Other Severance Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Section 5 and Section 6 of this Agreement are mutually exclusive and in no event shall you be entitled to payments or benefits pursuant to both Section 5 and Section 6 of this Agreement. You are not entitled to or eligible for severance or change in control benefits under any other agreement with, or policy or practice of, the Company.</font></div></div>
  <div style="margin-left:0.935%;text-indent:7.053%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:4.537%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">20.</font><div style="width:100%;display:inline;" id="x0__governing_law___this_is_a_massachuse"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This is a Massachusetts contract and shall be construed under and be governed in all respects by the laws of the Commonwealth of Massachusetts, without giving effect to the conflict of laws principles thereof.</font></div></div>
  <div style="margin-left:0.935%;text-indent:7.003%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:3.87%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">21.</font><div style="width:100%;display:inline;" id="x1__counterparts___this_agreement_may_be"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Counterparts</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document.</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.857%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.056%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">IN WITNESS WHEREOF, the parties have executed this Agreement effective on the Effective Date.</font></p>
  <p style="margin-left:44.267%;font-size:10pt;margin-top:12.25pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">PEPGEN INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.296%;"></td>
    <td style="width:3.28%;"></td>
    <td style="width:47.425%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: December 6, 2023</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ James McArthur</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">James McArthur</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:2.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:44.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXECUTIVE</font></p>
  <p style="font-size:10pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:4.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.296%;"></td>
    <td style="width:3.28%;"></td>
    <td style="width:47.425%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: December 6, 2023</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Mary Beth DeLena</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Mary Beth DeLena</font></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:7.7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.49in;min-height:0.68in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.08%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.565%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font></p>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.565%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restrictive Covenants Agreement</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.49in;min-height:0.68in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>pepg-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 23.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We consent to the incorporation by reference in the registration statements (Nos. 333-264822 and 333-270790) on Form S-8 and No. 333-272378 on Form S-3 of our report dated March 6, 2024, with respect to the consolidated financial statements of PepGen Inc. and subsidiaries.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">/s/ KPMG LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Phoenix, Arizona<br>March 6, 2024</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>pepg-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 31.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, James McArthur, certify that:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of PepGen Inc.;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.296%;"></td>
    <td style="width:3.28%;"></td>
    <td style="width:47.425%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 6, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ James McArthur</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">James McArthur</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>pepg-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 31.2</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Noel Donnelly, certify that:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of PepGen Inc.;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.296%;"></td>
    <td style="width:3.28%;"></td>
    <td style="width:47.425%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 6, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Noel Donnelly</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Noel Donnelly</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>pepg-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 32.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report on Form 10-K of PepGen Inc. (the &#x201c;Company&#x201d;) for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), the undersigned officer of the Company hereby certifies, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, to his knowledge, that:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.296%;"></td>
    <td style="width:3.28%;"></td>
    <td style="width:47.425%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 6, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ James McArthur</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">James McArthur</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>pepg-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 32.2</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report on Form 10-K of PepGen Inc. (the &#x201c;Company&#x201d;) for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), the undersigned officer of the Company hereby certifies, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, to his knowledge, that:</font></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.296%;"></td>
    <td style="width:3.28%;"></td>
    <td style="width:47.425%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 6, 2024</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Noel Donnelly</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Noel Donnelly</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial Officer and Principal Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>8
<FILENAME>pepg-ex97.htm
<DESCRIPTION>EX-97
<TEXT>
<html>
 <head>
  <title>EX-97</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.12in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 97</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:34.187%;text-indent:30.19%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:21.648%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">PEPGEN INC. COMPENSATION RECOVERY POLICY</font></p>
  <p style="margin-left:38.08%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adopted as of November 10, 2023</font></p>
  <p style="margin-left:11.293%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">PepGen Inc., a Delaware corporation (the &#x201c;Company&#x201d;), has adopted a Compensation Recovery Policy (this &#x201c;Policy&#x201d;) as described below.</font></p>
  <div style="margin-left:11.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.51914466486968%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Overview</font></div></div>
  <p style="margin-left:11.293%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.787%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defined below) in accordance with rules issued by the United States Securities and Exchange Commission (the &#x201c;SEC&#x201d;) under the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), and the Nasdaq Stock Market. Capitalized terms used and not otherwise defined herein shall have the meanings given in Section 3 below.</font></p>
  <div style="margin-left:11.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.51914466486968%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Compensation Recovery Requirement</font></div></div>
  <p style="margin-left:11.293%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event the Company is required to prepare a Financial Restatement, the Company shall recover reasonably promptly all Erroneously Awarded Compensation with respect to such Financial Restatement.</font></p>
  <div style="margin-left:11.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.51914466486968%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Definitions</font></div></div>
  <div style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.8457544394060026%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Applicable Recovery Period&#x201d; means the three completed fiscal years immediately preceding the Restatement Date for a Financial Restatement. In addition, in the event the Company has changed its fiscal year: (i) any transition period of less than nine months occurring within or immediately following such three completed fiscal years shall also be part of such Applicable Recovery Period and (ii) any transition period of nine to 12 months will be deemed to be a completed fiscal year.</font></div></div>
  <div style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.8457544394060026%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Applicable Rules&#x201d; means any rules or regulations adopted by the Exchange pursuant to Rule 10D-1 under the Exchange Act and any applicable rules or regulations adopted by the SEC pursuant to Section 10D of the Exchange Act.</font></div></div>
  <div style="margin-left:18%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.064634146341463%;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Board&#x201d; means the Board of Directors of the Company.</font></div></div>
  <div style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.398%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.8457544394060026%;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Committee&#x201d; means the Compensation Committee of the Board or, in the absence of such committee, a majority of independent directors serving on the Board.</font></div></div>
  <div style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.602%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.8457544394060026%;display:inline-flex;justify-content:flex-start;">e.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Covered Person&#x201d; means any Executive Officer. A person&#x2019;s status as a Covered Person with respect to Erroneously Awarded Compensation shall be determined as of the time of receipt of such Erroneously Awarded Compensation regardless of the person&#x2019;s current role or status with the Company (e.g., if a person began service as an Executive Officer after the beginning of an Applicable Recovery Period, that person would not be considered a Covered Person with respect to Erroneously Awarded</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.69in;min-height:0.82in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.12in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:21.293%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Compensation received before the person began service as an Executive Officer, but would be considered a Covered Person with respect to Erroneously Awarded Compensation received after the person began service as an Executive Officer where such person served as an Executive Officer at any time during the performance period for such Erroneously Awarded Compensation).</font></p>
  <div style="margin-left:18%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.064634146341463%;display:inline-flex;justify-content:flex-start;">f.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Effective Date&#x201d; means October 2, 2023.</font></div></div>
  <div style="margin-left:18%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.204%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.064634146341463%;display:inline-flex;justify-content:flex-start;">g.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Erroneously Awarded Compensation&#x201d; means the amount of any Incentive-Based Compensation received by a Covered Person on or after the Effective Date and during the Applicable Recovery Period that exceeds the amount that otherwise would have been received by the Covered Person had such compensation been determined based on the restated amounts in a Financial Restatement, computed without regard to any taxes paid. Calculation of Erroneously Awarded Compensation with respect to Incentive-Based Compensation based on stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in a Financial Restatement, shall be based on a reasonable estimate of the effect of the Financial Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was received, and the Company shall maintain documentation of the determination of such reasonable estimate and provide such documentation to the Exchange in accordance with the Applicable Rules. Incentive-Based Compensation is deemed received, earned or vested when the Financial Reporting Measure is attained, not when the actual payment, grant or vesting occurs.</font></div></div>
  <div style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.8457544394060026%;display:inline-flex;justify-content:flex-start;">h.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Exchange&#x201d; means the Nasdaq Stock Market LLC.</font></div></div>
  <div style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.731%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.8457544394060026%;display:inline-flex;justify-content:flex-start;">i.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">An &#x201c;Executive Officer&#x201d; means any person who served the Company in any of the following roles at any time during the performance period applicable to Incentive- Based Compensation and received Incentive-Based Compensation after beginning service in any such role (regardless of whether such Incentive-Based Compensation was received during or after such person&#x2019;s service in such role): the president, principal financial officer, principal accounting officer (or if there is no such accounting officer the controller), any vice president in charge of a principal business unit, division or function (such as sales, administration or finance), any other officer who performs a policy making function or any other person who performs similar policy making functions for the Company. Executive officers of parents or subsidiaries of the Company may be deemed executive officers of the Company if they perform such policy making functions for the Company.</font></div></div>
  <div style="margin-left:18%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.064634146341463%;display:inline-flex;justify-content:flex-start;">j.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Financial Reporting Measures&#x201d; mean measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#x2019;s financial statements, any measures that are derived wholly or in part from such measures (including, for example, a non-GAAP financial measure), and stock price and total shareholder return.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.93in;min-height:1.06in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.12in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:18%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.269%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.064634146341463%;display:inline-flex;justify-content:flex-start;">k.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Incentive-Based Compensation&#x201d; means any compensation provided, directly or indirectly, by the Company or any of its subsidiaries that is granted, earned or vested based, in whole or in part, upon the attainment of a Financial Reporting Measure and any other equity-based compensation provided by the Company or any of its subsidiaries, including, without limitation, stock options, restricted stock awards, restricted stock units and stock appreciation rights.</font></div></div>
  <div style="margin-left:18%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.537%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.064634146341463%;display:inline-flex;justify-content:flex-start;">l.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">A &#x201c;Financial Restatement&#x201d; means a restatement of previously issued financial statements of the Company due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required restatement to correct an error in previously-issued financial statements that is material to the previously-issued financial statements or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.</font></div></div>
  <div style="margin-left:13.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.269%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.8457544394060026%;display:inline-flex;justify-content:flex-start;">m.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;Restatement Date&#x201d; means, with respect to a Financial Restatement, the earlier to occur of: (i) the date the Board concludes, or reasonably should have concluded, that the Company is required to prepare the Financial Restatement or (ii) the date a court, regulator or other legally authorized body directs the Company to prepare the Financial Restatement.</font></div></div>
  <div style="margin-left:11.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.51914466486968%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exception to Compensation Recovery Requirement</font></div></div>
  <p style="margin-left:11.293%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.25%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company may elect not to recover Erroneously Awarded Compensation pursuant to this Policy if the Committee determines that recovery would be impracticable, and one or more of the following conditions, together with any further requirements set forth in the Applicable Rules, are met: (i) the direct expense paid to a third party, including outside legal counsel, to assist in enforcing this Policy would exceed the amount to be recovered, and the Company has made a reasonable attempt to recover such Erroneously Awarded Compensation; or (ii) recovery would likely cause an otherwise tax-qualified retirement plan to fail to be so qualified under applicable regulations.</font></p>
  <div style="margin-left:11.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.51914466486968%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Recovery from Participating Employees.</font></div></div>
  <p style="margin-left:11.293%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In addition to (and without limiting) the provisions of paragraph 2 above, in the event the Company is required to prepare a Financial Restatement after the Effective Date, the Company may recover from any current or former employee of the Company who is not a Covered Person (each a &#x201c;Participating Employee&#x201d;) and who received Incentive-Based Compensation from the Company during the three completed fiscal years immediately preceding the date on which the Board or the Audit Committee determines that the Company is required to prepare a Financial Restatement, the amount that exceeds what would have been paid to the Participating Employee under the Financial Restatement; provided that, this paragraph 5 will apply only to the extent the Board (or a duly established committee thereof), in its sole discretion, determines that the Participating Employee committed any act or omission that materially contributed to the circumstances requiring the Financial Restatement and such act or omission involved any of the following: (i) misconduct, wrongdoing or a violation of any of the Company&#x2019;s rules or of any</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.93in;min-height:1.06in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.12in;min-height:0.25in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:11.293%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">applicable legal or regulatory requirements in the course of the Participating Employee&#x2019;s employment by the Company; or (ii) a breach of a fiduciary duty to the Company or its stockholders by the Participating Employee.</font></p>
  <div style="margin-left:11.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.51914466486968%;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Recovery Where Intentional Misconduct.</font></div></div>
  <p style="margin-left:11.293%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.398%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In addition to (and without limiting) the provisions of paragraphs 2 and 5 above, in the event the Company is required to prepare a Financial Restatement after the Effective Date and the Board (or a duly established committee thereof), in its sole discretion, determines that a Covered Person&#x2019;s or a Participating Employee&#x2019;s act or omission contributed to the circumstances requiring the Financial Restatement and such act or omission involved any of the following: (i) willful, knowing or intentional misconduct or a willful, knowing or intentional violation of any of the Company&#x2019;s rules or any applicable legal or regulatory requirements in the course of the Covered Person&#x2019;s or the Participating Employee&#x2019;s employment by the Company or (ii) fraud in the course of the Covered Person&#x2019;s or the Participating Employee&#x2019;s employment by the Company, the Company may recover from such Covered Person or Participating Employee up to 100% (as determined by the Board or a duly established committee thereof in its sole discretion) of the Incentive-Based Compensation received by such Covered Person or Participating Employee from the Company during the three fiscal years preceding the date on which the Company determined that it is required to prepare a Financial Restatement.</font></p>
  <div style="margin-left:11.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.51914466486968%;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tax Considerations</font></div></div>
  <p style="margin-left:11.293%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.38%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To the extent that, pursuant to this Policy, the Company is entitled to recover any Erroneously Awarded Compensation that is received by a Covered Person, the gross amount received (i.e., the amount the Covered Person received, or was entitled to receive, before any deductions for tax withholding or other payments) shall be returned by the Covered Person.</font></p>
  <div style="margin-left:11.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.51914466486968%;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Method of Compensation Recovery</font></div></div>
  <p style="margin-left:11.293%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.787%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Committee shall determine, in its sole discretion, the method for recovering Erroneously Awarded Compensation hereunder, which may include, without limitation, any one or more of the following:</font></p>
  <div style="margin-left:21.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.236846454040449%;display:inline-flex;justify-content:flex-start;">a.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">requiring reimbursement of cash Incentive-Based Compensation previously paid;</font></div></div>
  <div style="margin-left:21.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:4.398%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.236846454040449%;display:inline-flex;justify-content:flex-start;">b.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer or other disposition of any equity-based awards;</font></div></div>
  <div style="margin-left:21.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:2.667%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.236846454040449%;display:inline-flex;justify-content:flex-start;">c.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">cancelling or rescinding some or all outstanding vested or unvested equity-based awards;</font></div></div>
  <div style="margin-left:21.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.236846454040449%;display:inline-flex;justify-content:flex-start;">d.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">adjusting or withholding from unpaid compensation or other set-off;</font></div></div>
  <div style="margin-left:21.333%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:5.731%;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.236846454040449%;display:inline-flex;justify-content:flex-start;">e.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">cancelling or offsetting against planned future grants of equity-based awards; and/or</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.93in;min-height:1.06in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="min-height:1in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:14.667%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.905874632322783%;display:inline-flex;justify-content:flex-start;">f.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">any other method permitted by applicable law or contract.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.787%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, a Covered Person will be deemed to have satisfied such person&#x2019;s obligation to return Erroneously Awarded Compensation to the Company if such Erroneously Awarded Compensation is returned in the exact same form in which it was received; provided that equity withheld to satisfy tax obligations will be deemed to have been received in cash in an amount equal to the tax withholding payment made.</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Policy Interpretation</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.324%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall be interpreted in a manner that is consistent with the Applicable Rules and any other applicable law. The Committee shall take into consideration any applicable interpretations and guidance of the SEC in interpreting this Policy, including, for example, in determining whether a financial restatement qualifies as a Financial Restatement hereunder. To the extent the Applicable Rules require recovery of Incentive-Based Compensation in additional circumstances besides those specified above, nothing in this Policy shall be deemed to limit or restrict the right or obligation of the Company to recover Incentive-Based Compensation to the fullest extent required by the Applicable Rules.</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Policy Administration</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.787%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall be administered by the Committee; provided, however, that the Board shall have exclusive authority to authorize the Company to prepare a Financial Restatement. In doing so, the Board may rely on a recommendation of the Audit Committee of the Board. The Committee shall have such powers and authorities related to the administration of this Policy as are consistent with the governing documents of the Company and applicable law. The Committee shall have full power and authority to take, or direct the taking of, all actions and to make all determinations required or provided for under this Policy and shall have full power and authority to take, or direct the taking of, all such other actions and make all such other determinations not inconsistent with the specific terms and provisions of this Policy that the Committee deems to be necessary or appropriate to the administration of this Policy. The interpretation and construction by the Committee of any provision of this Policy and all determinations made by the Committee under this Policy shall be final, binding and conclusive.</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Compensation Recovery Repayments not Subject to Indemnification</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.787%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything to the contrary set forth in any agreement with, or the organizational documents of, the Company or any of its subsidiaries, Covered Persons are not entitled to indemnification for Erroneously Awarded Compensation or for any losses arising out of or in any way related to Erroneously Awarded Compensation recovered under this Policy.</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img224999359_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )D!8(# 2(  A$! Q$!_\0
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MTR+_ %*?[HI]>JSX\****0!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !6=\0O^1@MO^P?;?\ HL5HUG?$+_D8+;_L'VW_ *+%:T/XB]#H
MI?!+Y?J<G1117< 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?17
MPJ.?A[8<@X>7@#I^\;K7SK7T5\*CGX>Z?SG#R]NG[QJX<P_A+U._+_XK]/\
M([.BBBO&/9"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H
M5/\ ID@R?]6G&/=JFJ)<_:I.>-B\?BU,1+1112&%%%% !1110 4444 %%%%
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M1I""Q ..< <UFUN^-?\ D=M:_P"OR3_T(UA5Z$'>*;//J*TFD%%%%40%%%%
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MNBOY4DFN^NOW.Y*K/^9MM/M9:?>K'3ZGX[U2#1?#RZ=I\%SK6L1+(D9RL2<
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M8YMZGS?[2ED^4$$C!&.1D9[9KH[5_!T_A2_UU_!HC2WGC@CB_M68F5FY//;
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M#&8HY-QX4]1C./TJY16$YQ;O!6^9O"$DK3=_D%%%%9&H4444 %%%% 'GT/\
MJ(_]T?RHHA_U$?\ NC^5%=QPGGL7^I3_ '13Z[&V\ B2TA?^UE&Y%./LYXX^
MM2_\*^7_ *"Z_P#@.?\ XJK=6%]SQ_J=;M^*_P SB:*[;_A7R_\ 077_ ,!S
M_P#%4?\ "OE_Z"Z_^ Y_^*I>UAW#ZG7[?BO\SB:*[;_A7R_]!=?_  '/_P 5
M1_PKY?\ H+K_ . Y_P#BJ/:P[A]3K]OQ7^9Q-%=M_P *^7_H+K_X#G_XJC_A
M7R_]!=?_  '/_P 51[6'</J=?M^*_P SB:*[;_A7R_\ 077_ ,!S_P#%4?\
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M8-EM%#M-L6SM4#.=W>M*5>$9W;-J>$K*+37;JCQ:BO4/^%/I_P!#"G_@&?\
MXJC_ (4^G_0PI_X!G_XJNOZU1[_@P^J5NWXH\OHKU#_A3Z?]#"G_ (!G_P"*
MH_X4^G_0PI_X!G_XJCZU1[_@P^J5NWXH\OHKU#_A3Z?]#"G_ (!G_P"*H_X4
M^G_0PI_X!G_XJCZU1[_@P^J5NWXH\OHKU#_A3Z?]#"G_ (!G_P"*H_X4^G_0
MPI_X!G_XJCZU1[_@P^J5NWXH\OHKU#_A3Z?]#"G_ (!G_P"*H_X4^G_0PI_X
M!G_XJCZU1[_@P^J5NWXH\OHKU#_A3Z?]#"G_ (!G_P"*H_X4^G_0PI_X!G_X
MJCZU1[_@P^J5NWXH\OHKU#_A3Z?]#"G_ (!G_P"*H_X4^G_0PI_X!G_XJCZU
M1[_@P^J5NWXH\OHKU#_A3Z?]#"G_ (!G_P"*H_X4^G_0PI_X!G_XJCZU1[_@
MP^J5NWXH\OHKU#_A3Z?]#"G_ (!G_P"*H_X4^G_0PI_X!G_XJCZU1[_@P^J5
MNWXH\OHKU#_A3Z?]#"G_ (!G_P"*H_X4^G_0PI_X!G_XJCZU1[_@P^J5NWXH
M\OHKU#_A3Z?]#"G_ (!G_P"*H_X4^G_0PI_X!G_XJCZU1[_@P^J5NWXH\OHK
MU#_A3Z?]#"G_ (!G_P"*H_X4^G_0PI_X!G_XJCZU1[_@P^J5NWXH\OHKU#_A
M3Z?]#"G_ (!G_P"*H_X4^G_0PI_X!G_XJCZU1[_@P^J5NWXH\OHKU#_A3Z?]
M#"G_ (!G_P"*H_X4^G_0PI_X!G_XJCZU1[_@P^J5NWXH\OHKU#_A3Z?]#"G_
M (!G_P"*H_X4^G_0PI_X!G_XJCZU1[_@P^J5NWXH\OHKU#_A3Z?]#"G_ (!G
M_P"*H_X4^G_0PI_X!G_XJCZU1[_@P^J5NWXH\OHKU#_A3Z?]#"G_ (!G_P"*
MH_X4^G_0PI_X!G_XJCZU1[_@P^J5NWXH\OHKU#_A3Z?]#"G_ (!G_P"*H_X4
M^G_0PI_X!G_XJCZU1[_@P^J5NWXH\OHKU#_A3Z?]#"G_ (!G_P"*H_X4^G_0
MPI_X!G_XJCZU1[_@P^J5NWXH\OHKU#_A3Z?]#"G_ (!G_P"*H_X4^G_0PI_X
M!G_XJCZU1[_@P^J5NWXH\OKZ)^%7_)/;#A?OR]/^NC=:X;_A3Z?]#"G_ (!G
M_P"*KLO#L6M>&-(31['35U."W9L70E$6XL=Q&TY(QNQ^%<N+JPJT^6#ZG3A:
M<Z,^::T^_P#([NBN9_MKQ-_T+(_\"EH_MKQ-_P!"R/\ P*6O-]F_Z:/0^L0[
M/[G_ )'345S/]M>)O^A9'_@4M']M>)O^A9'_ (%+1[-_TT'UB'9_<_\ (Z:B
MN9_MKQ-_T+(_\"EH_MKQ-_T+(_\  I:/9O\ IH/K$.S^Y_Y'345S/]M>)O\
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M9'_@4M1S:SXD,$@;PWM!4Y/VI3CBA0?]-">(AV?W/_(ZJBN9_MKQ-_T+(_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K8TLYM3R#ASVZ<"L>MC2S_HK<]'/\A43V
M+AN7:**KW5_9V(!N[N"W!Z&60)G\S625S5NVY8HK)_X2GP]_T'M+_P# R/\
MQH_X2GP]_P!![2__  ,C_P :KDEV(]I#N:U%9/\ PE'A[_H.Z9_X%Q_XTO\
MPE'A_P#Z#NF?^!<?^-')+L'M(=S5HK*_X2?P_P#]!S3/_ N/_&C_ (2;0/\
MH.:;_P"!<?\ C1R2[![2'<U:*R_^$FT#_H-Z;_X%Q_XT?\)+H/\ T&]-_P#
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MF0&Q@]#^5-J,6]-+/KOL).4DM=;KIMN26WC>SD\,S:Q/;R0M#*8'M\[F\SL
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M$[EMI0H<'LP(((K5HIIM.Z$TI*S(;6UALK6*UMHQ'#$H1$'8"IJ**0PHHHH
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M;YH.Q\IBGBOIO_A%O#W_ $ =+_\  ./_  H_X1;P]_T =+_\ X_\*U_M"/\
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MX4OKD>P?V9/^9'S\*<*]_P#^$=T/_H#:?_X"I_A2_P#".Z)_T!]/_P# 5/\
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M%3^P-+^8$Y^R1]OPKHAC*<(\L8E5,#4G+F<D?-(IU?2__"+>'O\ H!:9_P"
MD?\ A1_PB_A__H!:9_X"1_X57U^/8S_LV?\ ,?-0IPKZ4_X1CP__ - +3/\
MP$C_ ,*/^$8T#_H!Z9_X"1_X4OK\>P?V9/\ F/FX4X5]'_\ ",Z!_P! /3?_
M  $C_P *7_A&= _Z >F_^ D?^%+Z]'L']F3_ )CYR%.%?1?_  C6@_\ 0$TW
M_P !$_PH_P"$:T'_ * FF_\ @*G^%+Z['L+^S)_S'SN*<*^AO^$;T+_H"Z=_
MX"I_A2_\(WH7_0%T[_P%3_"E]=CV#^S)_P R/GH4\5]!?\(YH?\ T!M._P#
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M% !1110!Y]#_ *B/_='\J*(?]1'_ +H_E17<<)T5E_QX6W_7)?Y"IZJ62/\
MV?;_ +UO]4O8>@]JL;'S_K6Z^@_PKG>X)Z;#Z*C\M\?ZY^GH/\*78^?]:W7T
M'^% [^0^BH_+?'^N;\A_A2['_P">K=^P_P * OY#Z*C\M_\ GLWY#_"C8_\
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MOL:5%0^5)_S\2=^R_P"%+Y4G_/P_;^%?\.]9&UWV):*A\J3_ )^)._\ "O\
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M?PK_ (4!=]B:BH?*D_Y^)._9?\*7RI/^?A^W\*_X=Z N^Q+14/E2?\_$G?\
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MDKA5'XFI%97171@RL,A@<@B@!:*** "BFJZ.SJK*Q0[6 .=IP#@^G!!_&G4
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M/HQL;J]%Z#;6LGE32>6V V<8''/4=,U5M_'/ANZN([>+4U,DC!5#1.H)/N5
M%<BHD'A71X+.T\Z34-2-PEL'";HT)PN3TX5>36_?Q>(?$L*:;=Z+%IMHSJ\T
M[W2S-M5@<(%Z-[TW2@M_S7],E59O;\G_ $CIUU"U?4GT]9<W21B5DVGA2< Y
MQC\,YJ.#5[&ZU">Q@F,MQ!Q*$C8JA]"V-H/MG-<!J%YK,FJ^)KW3(66"-DAF
MND/SJD?#K'_M<EB>P'J17>:)9Z?9:3!'I:K]E90Z,O._(^\3W)J)TU!7-(5'
M-V1H4445B;!1110 56;3[)[Q;QK.W:Z486<Q*7'T;&:LT47L%KA1110 4444
M %006=K;2S2P6T,4DS;I6C0*7/JQ'4\GKZU/10 4444 5[73[*QW_9+2"W\P
MY?R8PFX^^!S5BBBAN^X)6V(YX(;J%H;B*.6)QADD4,I^H-%O;P6D"P6T,<,*
M_=CC4*H[\ 5)11?H%NI!!9VMM+-+!;0Q23-NE:- I<^K$=3R>OK4]%% !111
M0 4444 %%%% !1110 4444 %%%% !7#_ !DA9]'T&X&=B-)&?3)"X_\ 037<
M5!XAT ^)_!MSIZX$ZMYEN2?XQR,^F<D?C5TIJ%2,F15@YTY11\Y"G"G302VL
M\D$\;1RQL4=&&"I'4&FBO;/"8\4\4P4\5+$.%/%,%/%)B'BGBF"GBI8APIXI
M@IXJ1#Q3Q3!3Q4L!XIPIHIPI,0\4\4P4\5+$/%/%,%/%2P'"GBF"GBI$/%;'
MQ4/E6GAJT;_60V9W9Z\A!_[*:D\*:*VL:NF]<6D!$D[GH .@_'_&N7\<Z\GB
M+Q7<W<)S;1XA@/JBYY_$DG\:*2YJJMT.NFN6C*3^U9+Y'.BG#I313ATKM,1X
MIPIHIPJ1#Q3A313A28#A3Q3!3Q4L0\4X4T4X4@'"GBF"GBI$.%/%,%/%)@.%
M.%-%.%2(>*<*:*<*0AXIPIHK?\*:*^L:NF]<6D!$D[GH .@_'_&HDTE=E0@Y
MR48[L?\ $O\ =6?ART;_ %D-H=V>O1!_[*:X$?>%;OC77%U_Q/<741S;QXAA
M/JJ]_P 22?QK"'45M1BXTTF=&(DI56UM_D2K4JU$M2K5,YR5:E6HEJ5:AB)5
MK;\*P-<>)].1025F5S]%^;^E8BUZ7\/?#[V\3:O<IAI5VP*>H7NWX]O_ *]8
M59*,6;X6DZE5)'>4445YI].%%%% !1110 4444 %%%% !1110 4444 %1S#,
M8^4GYUX!Q_$*DJ.<9C'&?G7O_M"A R2BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ J*YYM91P?D/7ITJ6HKG'V6;/38?Y4T#):***
M0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y]#_J
M(_\ ='\J*(?]1'_NC^5%=QPG167_ !X6W_7)?Y"IZ@LO^/"V_P"N2_R%3USO
M<:V"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CO
M?]<O^XO\JDJ.]_UR_P"XO\J:W*B8NNZ8^LZ+<:>EQ]G,X"F39NP,@GC(ZXQ6
M0OAK69H?LM_XGFFL678\,%I'"S+Z;QD@>OJ,BNHHK6-2459"E3C)W9DR:%"U
M_I4T3+%;Z<KB.W"9!++M!SGC'/;O5.#PL+>/4]EV/-NUECA?RO\ CW21BQ &
M>3DCGC[HKHJ*/:2[A[./8Q+?PZMO?:3.+@&/3;8P1Q>7C<Q !;.>.!T_6MNB
MBI<G+<J,5'8S-$T==(TY[5YOM#R2R2RR,F-Y8YZ9/; HT326T6UDM%N3-;>8
MS0(R8,2DYVYSR!]!6G13<V[WZB4$K6Z!1114E!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6Q
MI8_T4\#[YZ'KP.M8]:^E_P#'JW"_?/3Z#K43V+AN<QXR^'-AXH)O+=UL]2[R
MA<K+[./Z]?K7D]_\.O%.G2%6TN2X7L]L?,!_ <_F*^C:*UI8NI35MT8UL'3J
M.^S/F(>%?$0_Y@.J?^ <G^%.'A;Q#_T =4_\ Y/\*^FZ*V_M"78P_LV'\Q\S
M#POXA_Z 6I_^ DG^%/'A?Q!_T M3_P# 23_"OI:BE]?EV#^S8?S'S6/#'B#_
M * >I_\ @))_A3QX9U__ * >I?\ @))_A7TC12^O2["_LR'\Q\X#PSK_ /T!
M-2_\!)/\*</#6O?] 34O_ 1_\*^C:*/KTNP?V9#^8^=1X:UW_H":E_X"O_A3
MAX;UW_H"ZC_X"O\ X5]$44OKLNP?V9#^8^>AX<US_H"ZC_X"O_A3AX<US_H#
M:C_X"O\ X5]!T4OKDNPO[+A_,SY_'AW6_P#H#:A_X"O_ (4X>'M;_P"@/J'_
M (#/_A7OU%+ZW+L']EP_F9X&/#VM?] ?4/\ P&?_  IX\/ZU_P! B_\ _ 9_
M\*]YHH^M/L']EP_F9X5'X=UIVP-)OA]8&'\Q6]I7P^U2[=7OMMG#U.2&<_0#
M^M>KT5$L3)[%0RRDG>3;/)?%5YJ<&EOX>\+^'M52S;BXN_L<@:;U ^7.#W/?
MH.*\]'A;Q#_T =4_\ Y/\*^G*C#,;AUR-H12![DG_ 5K3Q;@K*)=3 J;NY'S
M2/"WB'_H ZI_X!R?X4X>%_$'_0"U/_P$D_PKZ8HJOK\NQ']FP_F/FD>%_$'_
M $ M3_\  23_  IW_",:_P#] /4__ 23_"OI2BCZ_+L+^S(?S'S</#.O_P#0
M#U+_ ,!)/\*4>&=?_P"@'J7_ ("2?X5](44OKTNP?V9#^8^<AX:U[_H":E_X
M"/\ X4X>&M>_Z FI?^ K_P"%?1=%+Z[+L']F0_F/G8>&]=_Z NH_^ K_ .%.
M'AO7?^@+J/\ X"O_ (5]#T4?79=@_LR'\S/GH>'-<_Z VH_^ K_X4X>'-<_Z
M VH_^ K_ .%?0=%+ZY+L+^RX?S,^?QX=UO\ Z VH?^ K_P"%.'A[6_\ H#ZA
M_P" S_X5[]12^MR[!_9</YF>!CP]K?\ T!]0_P# 9_\ "G#P_K7_ $"-0_\
M 9_\*]ZHH^MOL']EP_F9X./#^M?] B__ / 9_P#"I$\.ZT[8&DWH^L##^8KW
M2BE]:?8/[+A_,SRG2OA]JEVZM>[;.'J<D,Y^@'3\:U?$FE:[#I3:%X8T9DLW
M'[^Z,\8:7U RV>>Y/TQBO0:*CV\N:[.B&!IPBU&^O7J>"#X<^*Q_S"O_ "8B
M_P#BJ=_PKSQ2'4'2^3G'^D1?_%5[S43_ /'Q'SSAN/RK7Z[4[(R>6TN[_#_(
M\07X>^*1_P PO_R8B_\ BJD7X?\ B@?\PS_R8B_^*KW"BI^N3[(/[,H]W^'^
M1XD/ /B8?\PS_P CQ_\ Q568/A]XBD8![2.(>KS*?Y$U[)12>*GY!_9E'N_Z
M^1Q.A?#RVL95N-2E6ZE4Y$2C]V/KGEOTKM@   !@#M116$IRD[L[*5&%)6@K
M!1114FH4444 %%%% !1110 4444 %%%% !1110 5',,QC@'YUZG_ &A4E1S_
M .K'"GYU^]_O"A R2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ J*YXM9N<?(W/X5+4=Q_P >TN/[A_E30,DHHHI %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'GT/^HC_P!T?RHHA_U$
M?^Z/Y45W'"=%9?\ 'A;?]<E_D*GJI900G3[?]TG^J4?='H#4_D19SY2=<_=%
M<[W!7L245'Y$.,>5'C&/NBE\F+.?*3.2?NB@>H^BH_(A_P">4?I]T4>1%_SR
M3N?NCOUH#4DHJ/R(?^>2?]\BCR(O^>2=_P"$=^M :DE%1^1#_P \D_[Y%'D0
M_P#/)._\(H#4DHJ/R(O^>2=OX1VZ4>1#_P \H_\ OD4!J245'Y$7_/).W\([
M=*/(AQCRH_3[HH#4DHIGDQ Y\I.H/W12>1#C'E1XQC[HH#4DHJ/R(LY\I,YS
M]T4>1#C'E1XQC[HZ4!J245'Y$6<^4F<Y^Z*/(AQCRH\8Q]T=* U)**C\B+.?
M*3KG[HH\B'&/*CQC'W10&I)4=[_KE_W%_E2^3%G/E)G)/W145Y!$)E B0#8O
M\(]*%N5&Y%13/*C_ .>:_E1Y4?\ SS3_ +Y%45J/HIGE1_\ /-?RH\J/_GFG
MY4!J/HIGE1_\\T_*CRH_^>:_E0&H^BF>3'_SS3_OD4>5'_SS7\J U'T4SR8_
M^>:?]\BCRH_^>:^O2@-1]%,\F+_GFGI]T4>5'G/EKGKTH#4?13/)BQCRT]/N
MBCRH\Y\M?7I0&H^BF>5'C'EIC&/NBCRH_P#GFOKTH#4?13/)BQCRT]/NBCRH
M\Y\M?RH#4?13/)B_YYI_WR*/*C_YYK^5 :CZ*9Y4?_/-/^^11Y4?_/-?RH#4
M?13/*C_YYI^5'E1_\\T_*@-1]%,\J/\ YYK^5'DQ_P#/-/\ OD4!J/HIGE1_
M\\U_*CR8_P#GFG_?(H#4?13/*C_YYKZ]*/)B_P">:>GW10&H^BF>5'G/EKGK
MTH\F+&/+3T^Z* U'T4SRH\Y\M?7I1Y4>,>6F,8^Z* U'T4SRH_\ GFOKTH\F
M+&/+3T^Z* U'T4SRH\Y\M?RH\F+_ )YI_P!\B@-1]%,\J/\ YYK^5'E1_P#/
M-/\ OD4!J/K7TL_Z*W(/SGIVX%8OE1_\\U_*M;3+>![9MT438?\ N#C &*F>
MQ4+W-*BH?LEM_P ^\7?^ =^M+]EM\_ZB+M_ .W3\JRT-M26BH?LEM_S[Q=_X
M!WI?LMO_ ,\(NH/W!VZ?E1H&I+14/V2VQC[/%C&/N#I2BUMP<B"('(/W!U'2
MC0-26BH?LEMC'V>+&,8V#I2_9;?.?(BSG.=@ZT:!J2T5#]DML8^SQ8QC&P=,
MYQ^=+]EM\Y\B+.<YV#KZT:!J2T5#]DML8^SQ8QC&P=,YQ^=+]EM\Y\B+.<_<
M'6C0-26BH?LEMC'V>+&,8V#IUI?LMOG/D19R3G8.IZT:!J2T5#]DML8^SQ=,
M?<'2E^RVY.3!%U)^X.IZT:!J2T5#]DMC_P N\78?<';I2_9;?_GA%W_@'?K^
M=&@:DM%0_9;?_GWB[?P#MTH^R6W_ #[Q=_X!WZT:!J35$O\ Q^2#/_+-./Q:
MC[+;Y_U$7;^ =NGY5"MK;?:Y!Y,?$:\;!@9+9_.C06I;HJ+[+;_\\(NH/W!V
MZ?E2?9+;&/L\6,8^X.E&@]2:BHA:VX.1!$#D'[@ZCI2?9+;&/L\6,8QL'2C0
M-2:BHOLMOG/D19SG.P=:3[);8Q]GBQC&-@Z9SC\Z- U)J*B^RV^<^1%G.<[!
MU]:3[);8Q]GBQC&-@Z9SC\Z- U)J*B^RV^<^1%G.?N#K2?9+;&/L\6,8QL'3
MK1H&I-147V6WSGR(LY)SL'4]:3[);8Q]GBZ8^X.E&@:DU%1?9;<G)@BZD_<'
M4]:3[);'_EWB[#[@[=*- U)J*B^RV_\ SPB[_P  []?SI/LMO_S[Q=OX!VZ4
M:!J345#]DMO^?>+O_ ._6E^RV^?]1%V_@';I^5&@:DM%0_9+;_GWB[_P#O2_
M9;?_ )X1=0?N#MT_*C0-26HWSY\?3&#_ $IOV2VQC[/%C&/N#I3&MH!<1$01
MCJ<A!U&,4*PM2S14/V2VQC[/%C&,;!TI?LMOG/D19SG.P=:-!ZDM%0_9+;&/
ML\6,8QL'3.<?G2_9;?.?(BSG.=@Z^M&@:DM%0_9+;&/L\6,8QL'3.<?G2_9;
M?.?(BSG/W!UHT#4EHJ'[);8Q]GBQC&-@Z=:7[+;YSY$6<DYV#J>M&@:DM%0_
M9+;&/L\73'W!TI?LMN3DP1=2?N#J>M&@:DM%0_9+8_\ +O%V'W!VZ4OV6W_Y
MX1=_X!WZ_G1H&I+14/V6W_Y]XNW\ [=*/LEM_P ^\7?^ =^M&@:DU%1?9;?/
M^HB[?P#MT_*D^R6W_/O%W_@'>C0-2:BHOLMO_P \(NH/W!VZ?E2?9+;&/L\6
M,8^X.E&@:DU%1"UMP<B"('(/W!U'2D^R6V,?9XL8QC8.E&@:DU1SG$8Y ^=>
MO^\*3[+;YSY$6<YSL'6HIK6W6,8AA4;E7_5@\;AQ0K"=RU147V6WSGR(LYSG
M8.OK2?9+;&/L\6,8QL'3.<?G1H/4FHJ+[+;YSY$6<Y^X.M)]DML8^SQ8QC&P
M=.M&@:DU%1?9;?.?(BSDG.P=3UI/LEMC'V>+IC[@Z4:!J345%]EMR<F"+J3]
MP=3UI/LEL?\ EWB[#[@[=*- U)J*B^RV_P#SPB[_ , []?SI/LMO_P ^\7;^
M =NE&@:DU%0_9+;_ )]XN_\  ._6E^RV^?\ 41=OX!VZ?E1H&I+14/V2V_Y]
MXN_\ [TOV6W_ .>$74'[@[=/RHT#4EHJ'[);8Q]GBQC'W!TI1:VX.1!$#D'[
M@ZCI1H&I+14/V2VQC[/%C&,;!TI?LMOG/D19SG.P=:- U):*A^R6V,?9XL8Q
MC8.F<X_.E^RV^<^1%G.<[!U]:- U):BN?^/6;_</\J3[);8Q]GBQC&-@Z9SC
M\ZCN+:W^SRGR8P=K'(09SCK]:%83N6J*A^R6V,?9XL8QC8.G6E^RV^<^1%G)
M.=@ZGK1H/4EHJ'[);8Q]GBZ8^X.E+]EMR<F"+J3]P=3UHT#4EHJ'[);'_EWB
M[#[@[=*7[+;_ //"+O\ P#OU_.C0-26BH?LMO_S[Q=OX!VZ4?9+;_GWB[_P#
MOUHT#4FHJ+[+;Y_U$7;^ =NGY4GV2V_Y]XN_\ [T:!J345%]EM_^>$74'[@[
M=/RI/LEMC'V>+&,?<'2C0-2:BHA:VX.1!$#D'[@ZCI2?9+;&/L\6,8QL'2C0
M-2:BHOLMOG/D19SG.P=:3[);8Q]GBQC&-@Z9SC\Z- U)J*B^RV^<^1%G.<[!
MU]:3[);8Q]GBQC&-@Z9SC\Z- U)J*B^RV^<^1%G.?N#K2?9+;&/L\6,8QL'3
MK1H&I-147V6WSGR(LY)SL'4]:3[);8Q]GBZ8^X.E&@:G"0_ZB/\ W1_*BFPH
MODQ_*/NCM[45VG$=)9?\>%M_UR7^0J>H++_CPMO^N2_R%3USO<:V"BBBD,**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CO?\ 7+_N+_*I
M*CO?]<O^XO\ *FMRHE:BJ>JZE#I&F3W]PLC10KN81@%CSCC)'K7*Q?%'09)4
M1H;Z)6."[Q+A?<X8G\@:UC3G)7BA2JP@[29VU%,BE2>))8G#QNH964Y!!Y!%
M/J"PHHK,AURVG\0W&BK',+F"(2LQ V$''0YSGYAVII-[";2W-.BBBD,****
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M[Y[2Q(]%5Q_[-6]I7Q&LKIUBOX&M'/'F [TS[]Q4NA-="X8^A)VO8[6HE/\
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MUVZTV4Y\IOD;^\AY4_EBMA&9&#*2&!R".QK8^*D:S3Z)J@4![NS^8COC!_\
M9Z*3Y:EELSKC+VE%I[Q_)GGXJ05&*D%=3,"1:D6HUJ1:EB'BI!48J05+$2"I
M!48J05#$2+3UIBT]:EB.V\">)'LKU-+N7)M9VQ&6/^K?MCV/3Z_C7J-?/L;,
MCAE)# Y!'8U[U8SFZT^VN#C,L2OQ[@&N'$02=T>WEE9RBX/H6****YCU HHH
MH **** "BBB@ J-_]?'QV;G\JDJ-_P#CXC^C?TH0F24444#"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "HYO]6.OWUZ?[PJ2HYAF,<$_.
MO3_>%"!DE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !45Q_QZR_[A_E4M17/_ !ZS=/N-U^E"!DM%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!Y]#_J(_]T?RHHA_U$?^Z/Y45W'"
M=%9?\>%M_P!<E_D*YGQUHE[K<&EQV=L+A8;M9)E+* $QS]XC/TKIK+_CPMO^
MN2_R%3UC&;A+F0I14HV92M-'TS3Y3+9:=:6TA7:7A@5"1UQD#IP/RKC=3\/^
M(]&UJ_O_  XEO>6NI$FXLYF"X8YR>J\<GD$'GIQFN_HIPJ2B[[BE34E;8\[\
M&^"[^PUQ=8OK2UTX1QLBVD#M(23D;B2S8_ GZ"G:-X*NI_!.IZ1JD M[B6\>
M>W)<-M.U0K?*3W!![XS7H5%6\1-N_I^!*H02L<%X0\'2CPW>:=XEL21+=^<$
M,^2WRCG*-ZY[TWQ)X3NK)=%_X173$<65R]P8WFX#?*1G>P)!V]C7?T4>WGS<
MWX= ]C'EY?\ ASC--U+Q]+J5NFH:)80V;.!-(C@LJ]R/WA_D:Q;&S\<:!J6J
MMIFC6LT%W=/*&GE0DC)QC$@QP>]>FT4*M:_NK^OF#I7ZLX72O!-W=:3K#Z],
MO]H:N!O,?S"''*^Q(..!QP.:HP1?$?3;$:1;VUG-%&!%'>[UW*O8C+#I[KGZ
MUZ111[>75)A[%=&T<5;^&=;\/>#X[70[U#J8F^T3[E4I,2,%!N''10#QG';/
M!9Z3KNL>*!KFIVR:4UM:M!;1K*LS;V!^?CC W'@^@^M=K12]M+7N^H_9+3L>
M=W^D^,/$&G0Z#JMM;B-;C?+J@E3#H"<8C&#GGC@=!G')KT)%"(J#HH &:=14
MSJ.2M:Q48*.H4445F6%%%% !1110 5'>_P"N7_<7^525'>_ZY?\ <7^5-;E1
M*U<G:>*-<U&V6ZL/"YGM7+>7*;]$W $C.",CI6SXBNQ8^'-1N<D%+=]O^\1@
M?J16!I/AWQ%:Z1:0P>)_L\0B4B'^SXVV9&2,DY/)ZUT4U'EO*WSO^AG4<N:T
M;_*WZG4:=/=W-DDM]9BSG8G=!YHDV\\?,..>M6JXSQ?<MI TR]@G$NLP(RY\
MO_6Q;#O9U7HH(#>W.*BO-.CMH=(TF.]8#5YF>^OE;:]QA=V-W8,3@#TX[G)[
M.]GW#VMKJVQW%%<(L5CX8\47$6CYCMH=.DGO8/-+HK#E"<DD,?3T/O6<?#=O
M:^%-*NY#-)K%S/#]GE,S#R6=P^%7.!@;B>.I)IJDN^XG6?;;S/3*YC_A)-8N
M;BY&F>'/MEM#,\(G^VI'O*G!P"/6NAN[B.TLY[F:3RXHD9W?:6V@#).!UK@=
M6T'1=*T.SO\ 2IYWU)Y(_L,_GLSS%GS@+TQACT _7E4HQ>Z_K\!U926S_K\3
MI]2UZ\M[]+#3M'DO[L1":5?.$21J3C[[#!.>U7=%U9-9TU;I8GA<,T<L3]8W
M4X8>_P!?Y=*J:E-9ZUIU[##J\]D;.0K/- YC:)E'\6?X?IUQUIG@O!\(Z>PA
M2/*'.T$;OF(W<]SC/XTFER7MJ--\]KZ&]11161J%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5QOQ?L
MWN/#.D7ZC*V\K1,?3</\4_E7958N-(M]>\-W>F70'E3Y4,.2IXPWU!Y_"JA/
MV<U/L34A[2#AW/F,4X5?US0[WP]JLVGWT962,_*V/ED7LRGN#5 5[:::NCP9
M)IV8\4\4P4\4F(<*>*8*>*3$/%/%,%/%2Q#A3Q3!3Q4B'BGBF"GBI8#Q3A31
M3A28AXIXI@IXJ6(>*>*8*>*E@.%/%,%/%2(D16=@J@EB< #N:V/BI(L,^B:6
M&!>TL_F [9P/_9*T?">DQ1!_$&J$0Z=9#S SC[[#ICUP?S.!7GWB#69?$&NW
M6I2C'FM\B_W4'"C\L44ES5+K9'7&/LZ+;WE^2,\5(*C%2"NIF!(M2+4:U(M2
MQ#Q4@J,5(*EB)!4@J,5(*AB)%IZTQ:>M2Q$L:L[A5!+$X '<U[U8P&UT^VMS
MC,42IQ[ "O-O GAM[V]35+E"+6!LQAA_K'[?@.OU_&O4:X<1--V1[>647&+F
M^H4445S'J!1110 4444 %%%% !4;_P#'Q']&_I4E1O\ \?$?&>&Y].E"$R2B
MBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'.,QC@G
MYU[X_B%25'.,QC@'YUZ_[PH0,DHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *BN/^/67C/R'@_2I:BN?^/6;_ '#_ "IH&2T444@"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SZ'_41_
M[H_E11#_ *B/_='\J*[CA.BLO^/"V_ZY+_(5/4%E_P >%M_UR7^0J>N=[C6P
M4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4=[_KE
M_P!Q?Y5)4=[_ *Y?]Q?Y4UN5$S-0T^UU6RDL[V,R6\F-R!BN<'(Y!!ZBL/\
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M_OX__P 17LE%'UNJ+^SZ)XX/A/KH_P"7O3?^_C__ !%.'PHUW_G[T[_OX_\
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M V)GW[G]*[:BIE7F^I4,!0B[VN-1%C1410J*,!5& !3J**Q.P**** "BBB@
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MYPQG;)TS]PTOFC/W7_[Y-/HH'J1^</[LG_?!I?-']U^_\)I]% :D?G#^Z_\
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M\P9^ZW_?)H\P8^Z_K]TT^B@-1GF#^ZW_ 'R:/,&/NO\ ]\FGT4!J,\P>C?\
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M:_\ ]!S4O_ N3_&E]1EW%_:</Y3Z1HKYP'B;7_\ H-ZE_P"!<G^-.'B77O\
MH-ZE_P"!;_XT?49=P_M.'\I]&T5\ZCQ+KO\ T&]2_P# I_\ &G#Q)KO_ $&M
M1_\  I_\:7U*7</[3A_*?1%%?/0\1ZY_T&M1_P# I_\ &G#Q'KG_ $&=1_\
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M_C6QIOCK7K)QON_M,>>4G&[/X]?UJ7A9+9CCF=-O5,]GHK"\.^*;+Q##B/\
M<W2C+P,<D>X/<5NUS2BXNS.^$XSCS1=T%%%%(L**** "BBB@ HHHH **** "
MBBB@ HHHH *C;_7Q\]F_I4E1O_Q\1_1OZ4(3)****!A1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !4<_\ JQR?OKT&?XA4E1S?ZL<L/G7[
MO^\*$#)**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"HKCFUE[_(>GTJ6HKG!M9LC(V-Q^%-;@R6BBBD 4444 %%%% !1110 4444
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M,;.&J_KR*ISE*ZEN/HHHK$V"BBB@ HHHH *CO?\ 7+_N+_*I*CO?]<O^XO\
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M'5QZ?O<X_(BO7:**SJ5.?IW_ !-*=/DZ]OP/.;#4H?#.L^(K+4XYO/O)3-;
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MW?U%1ZS\OPJT,KQ_I"']'KU*BI]OJM-O\A_5]'KO_G<\[\>/<:'K,>KVB_\
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MC_\ B*7_ (5+H/\ S]ZE_P!_$_\ B*[RBCZQ5_F#ZI1_E.$'PGT(?\O>I?\
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MO](QUB_(T?O\]8^H['\:EHHN%B'_ $C'6+./0]:8WG_:(\^7CGL?;-6:B?\
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M3447"Q%^_P ]8\9]#TJ.8W C&6B!RHS@]=PJS4<YQ&.<?.O_ *$*$Q-"?O\
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M\8/##^\OM[=JW5'^ER'G[B_S:N9Q<6TSU(5(U(J47H2T445)H%%%% !1110
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M);,Y5=0,X"B,G<?D^]G.?\\U%J=M=:3XYT"VTN-;B:VTX(L<C;/-"A\C/8D
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MTJ2HW_X^(_HW]*$)DE%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ J.89C'!/SKT_WA4E1SC,8X)^=>^/XA0@9)1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI4E1/_Q\1?1OZ4(3):***!A1110 4444 %%%% !1110 4444 %%%% !1110
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MY_\ 5CI]]>O^\*DJ.<XC'('SKR1G^(4(&24444 %%%% !1110 4444 %%%%
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M"98@=!\_>N<L+7[;J-M:;]GGRI'NQG;N(&<=^M4N1ZI&<U7@TI/?S_X)H?\
M"4:S_P _S=OX5_PI/^$HUG_G^?\ [Y7_  K?;P%9_:3:+XBMC==! 8P&SC.,
M;\_I63'X5E_L_5;B>X$<NGN4:,)N#X]#D8'X5*E39I*EB8[W^_M\RM_PE&L@
MY^W-_P!\K_A1_P )1K./^/Y_^^5_PK8A\%V9TZSN[O7X+3[3$LBI+&!U . 2
MXSC-1'P3,GB&+3'O%\J:(RQ7"QYW =MN>OXT<U,/8XG3?7S[_,S/^$HUG/\
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M-+$./,F[6OOT*?\ PDFK8_X_&_[Y7_"C_A)-6_Y_&_[Y7_"KP\*Y?1%^V_\
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MU[&/[1DZ8^ZO^%+_ ,)AK_\ T$7[G[J]_P *PZ*.2/8/;U?YG]YN?\)?K_\
MT$9/^^5_PH_X3#7_ /H(R=_X5[_A6'11R1[![>K_ #/[S<_X3#7_ /H(R=OX
M5_PH_P"$PU__ *",G?\ A7_"L.BCDCV#V]7^9_>;G_"8:_\ ]!&3M_"O;\*3
M_A+M>SG^T9,XQ]U?\*Q**.2/8/;U?YG]YN#QAKX_YB,G4'[J]OPI/^$OU_\
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MG[J_X5AT4<D>P>WJ_P S^\V_^$OU[&/[1DZ8^ZOU]*&\7Z\P(.HR8.<_*O\
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M\W?(SXQ_>X'/]W\*X&TNY[&ZCN;9]DT9RC8!P?H>*+JZFO;J2YN'WS2-N=L
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M #[4G_"M+G_H)1=_^69_QKT:BCV\^X?V=A^WXGG7_"M+C_H)Q=1_RR/X]_\
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MV[_Y]Z3_ (5I<_\ 02B[?\LC^/>O1J*/;S[A_9V'[?B>=?\ "M+C_H)1=_\
MED?P[_Y]Z3_A6EQ_T$HNW_+(_CWKT:BCV\^X?V=A^WXGG/\ PK2Y_P"@E%W_
M .61_#O2_P#"M+C/_(2B[?\ +(_CW_S[5Z+11[>?</[.P_;\3SG_ (5I<_\
M02B[_P#+,_XTO_"M+C_H)Q=1_P LC^/?_/M7HM%'MY]P_L[#]OQ/.?\ A6ES
MC_D)19Q_SS/7\Z4?#2XSSJ<6,C_ED>G?O7HM%'MY]P_L[#]OQ/.?^%:7./\
MD)19Q_SS/7\Z7_A6EQG_ )"46,_\\CT_.O1:*/;S[A_9V'[?B><_\*TN<?\
M(2BSC_GF>N?KZ4O_  K2XS_R$XL9_P">1Z?G7HM%'MY]P_L[#]OQ/.?^%:7.
M/^0E%G'_ #S/7/U]*7_A6EQG_D)Q8S_SR/3\Z]%HH]O/N']G8?M^)YS_ ,*T
MN<?\A*+./^>9Z_G2_P#"M+C/_(3BQD_\LCT[=Z]%HH]O/N']G8?M^)YS_P *
MTN<?\A*+I_SS/7\Z7_A6EQGC4XNI_P"61Z=N_P#GWKT6BCV\^X?V=A^WXGG/
M_"M+G_H)1=O^61_'O2_\*TN/^@E%W_Y9'\._^?>O1:*/;S[A_9V'[?B><_\
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M_P"0E%G'_/,]<_7TKT:BCV\^X?V=A^WXGG7_  K2XS_R$XL9_P">1Z?G2?\
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M>W::3_K6QZ;1117,=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX4445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDSPZK8R+"GF2E+A"(TQG<V#P,=S0_:+N"]F^Q'_8&G?\\I?_  (D_P#BJ/[
MT[_GE+_X$2?_ !5!\0Z0=-NK^'4K2XMK9=TKPSHX7T&0< GMFH-)\10:O:Z5
M<0266+V$R/']K!D1@JDHJ@?.5W8;ICCCFC]Y:^H7IWMH3_V!IW_/*7_P(D_^
M*H_L#3O^>4O_ ($2?_%5/'J^F37[6,6HVCWB9#6ZSJ9!CKE<YXJ.?7M'M9O*
MN-6L8I=YCV27"*=PQE<$]>1Q[BE>?F.T/(9_8&G?\\I?_ B3_P"*H_L#3O\
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MC/[S(&P^V3QWHM];TF[5VMM4LIEC0R.8[A&"H.K'!X'O1>?F*T/(C_L#3O\
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MJC)8G  JG8ZQIFILZV&HVEVR %Q;SK(5'O@\4N:>]Q\L-K$/]@:=_P \I?\
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M_P"!$G_Q5/77M'>YCMEU:Q:>0X2(7"%G.2, 9R>01]0:T*'*:WN"4'M8S/[
MT[_GE+_X$2?_ !5']@:=_P \I?\ P(D_^*JS?:G8:8B/?WUM:(YPK3RK&&/H
M,FE74+)A;%;RW(NO^/<B5?WW&?DY^;CGBB\]]0M#;0J_V!IW_/*7_P ")/\
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M @'KZ4U=1L7BMY5O+=H[D[8&$JD2GKA3GYNAZ>E+FF/EAY%7^P-._P">4O\
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M[&\T_P ?3V!1K:5K,[XQA9#D;F'J"<\CKUYSFO3-0T]K[R6CO[RSEB8E7MG
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
' **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img224999359_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (I!4 # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#U^**_U+5M
M7 UJ]M8K:Z6&**". J%\B)SR\;$G+MWJQ_8U_P#]#+JO_?NU_P#C-&C?\A3Q
M#_V$$_\ 26"MBM)2:=EY=#.,4U=^?5]S'_L:_P#^AEU7_OW:_P#QFC^QK_\
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M<[_I(.1?TV8_]C7_ /T,NJ_]^[7_ .,T?V-?_P#0RZK_ -^[7_XS6Q11SO\
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MK_\ &:/[&O\ _H9=5_[]VO\ \9K8HK/G?])%\B_ILQ_[&O\ _H9=5_[]VO\
M\9H_L:__ .AEU7_OW:__ !FMBN<N?&>G6OBZ'PT\-T;V7&UU1?+&03R=V>WI
M51<I;+\$*2C'=_BRW_8U_P#]#+JO_?NU_P#C-']C7_\ T,NJ_P#?NU_^,U67
MQEIS>,G\+B&Z^W*,F3:OE_<#]=V>A].M=#1)RC:Z_!!%1E>SV\V8_P#8U_\
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MT&K[_OB#_P"-UH44<S#V:\_O9G_V==?]!J^_[X@_^-T?V==?]!J^_P"^(/\
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MB#_XW6A5'4]8L-'B22_G\E';:IV,V3^ -)-O1%2C&*O)V7JQO]G77_0:OO\
MOB#_ .-T?V==?]!J^_[X@_\ C=78I$FB26,Y1U#*<=0>E/I78^1?TV9_]G77
M_0:OO^^(/_C=']G77_0:OO\ OB#_ .-UH44<S#V:\_O9G_V==?\ 0:OO^^(/
M_C=']G77_0:OO^^(/_C=:%%',P]FO/[V9_\ 9UU_T&K[_OB#_P"-T?V==?\
M0:OO^^(/_C=:%%',P]FO/[V9_P#9UU_T&K[_ +X@_P#C=']G77_0:OO^^(/_
M (W6A11S,/9KS^]F?_9UU_T&K[_OB#_XW1_9UU_T&K[_ +X@_P#C=&H:YIVE
M3Q0WMQY4DWW!L9L\X[ UH4[LE*#;2>WF_P#,S_[.NO\ H-7W_?$'_P ;H_LZ
MZ_Z#5]_WQ!_\;J'4/$ND:5=?9KV[\J;:&V^6[<'W -0P>,- N)5BCU%-S' W
MHR#\R *=I;V_ ASHI\KEKZ_\$N?V==?]!J^_[X@_^-T?V==?]!J^_P"^(/\
MXW6@#D9'2BINS7D7G][,_P#LZZ_Z#5]_WQ!_\;H_LZZ_Z#5]_P!\0?\ QNI=
M1U.STFV%Q?3>5$6"!MI;D_0'TJ"[U[3+&RM[RYN=EO< &)_+8[@1D< 9''K3
M7,]D0_9J]Y;>?_!'?V==?]!J^_[X@_\ C=']G77_ $&K[_OB#_XW5V*1)HDE
MC.4=0RG'4'I3Z5V7R+^FS/\ [.NO^@U??]\0?_&Z/[.NO^@U??\ ?$'_ ,;K
M0HHYF'LUY_>S/_LZZ_Z#5]_WQ!_\;H_LZZ_Z#5]_WQ!_\;K0HHYF'LUY_>S/
M_LZZ_P"@U??]\0?_ !NC^SKK_H-7W_?$'_QNM"BCF8>S7G][,_\ LZZ_Z#5]
M_P!\0?\ QNC^SKK_ *#5]_WQ!_\ &ZT**.9A[->?WLS_ .SKK_H-7W_?$'_Q
MNC^SKK_H-7W_ 'Q!_P#&ZT**.9A[->?WLS_[.NO^@U??]\0?_&Z/[.NO^@U?
M?]\0?_&ZT**.9A[->?WLS_[.NO\ H-7W_?$'_P ;H_LZZ_Z#5]_WQ!_\;K0H
MHYF'LUY_>S/_ +.NO^@U??\ ?$'_ ,;H_LZZ_P"@U??]\0?_ !NM"BCF8>S7
MG][,_P#LZZ_Z#5]_WQ!_\;H_LZZ_Z#5]_P!\0?\ QNM"BCF8>S7G][,_^SKK
M_H-7W_?$'_QNC^SKK_H-7W_?$'_QNM"BCF8>S7G][,_^SKK_ *#5]_WQ!_\
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M-YBH%(*L%8';P1DC!_G6='XK\8>,?$=[;^%IK:SL;,X+S("&&2 6)5CEL'
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M/^P?=_\ HRWK8K'N?^1QTS_L'W?_ *,MZV*J6R_KJR([O^NB"BBBI+"BBB@
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MU9TZNK]V_1K[FMSU.O,=?_L[_A8K_P!K?\>.U?,^]_SRX^[SUQTKTZO,=?\
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M $<]:%9^C?\ 'C)_U]W/_HYZ?0A_&O1_H5]&_P"0IXA_[""?^DL%;%8^C?\
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M+8=2--_&E\Q+[2+#4;)+.ZME:W0@K&I* $# QM(]:BN]!TR^LK>SN;;?;VX
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MZ#HTVHSO,)H;J#SDBP1MV?.<97!/)KH/'7CE_"\EI86%HMWJ=URD;9VJ,X'
MY))X 'H:Y/XR7EM?Z7H=S9W$=Q \DX66)@RMC:#@CKR#3O'SC1OBIH>L7@/V
M+;&2^,A=K'=^60?QJ(4XR4&U_-I^A<ZDHN:3_EU_4Q/B%K?B.^TJRL_$>BI8
MS"7SHI(CE'&T@CJ<$9'?\*[_ %[QHOA3PYH\-O;?:]1NX(Q!#SC[H&3CD\D
M#O7*?%WQ'I&K:?IMIIU[!=R+(96:%@P1=N "1W.>GMS53XBV\L=]X4O6GEM;
M<V<,?VJ,$F%E()88QR 01R.E7&"G&"DK;Z&<IRIRFXN^VITUM\0/$&D:O9VG
MB_18;*"\.V*>#.%Z<GYFSC(R.",U=\4^.=3L?$\7ASP_IL-WJ#*&8SMA<D9P
M!D=N<YKB]0\/:7J$EM;ZA\4!>%_FB65&F52??S"%/UP:Z+QKHWA#5-8ACO\
MQ"NGZVB)&\O4' R"XZ*>G.X5')2YD[='T=O4T4ZO*U?JNJOZ&SX<\1>,+C6_
M[/U_PV((R.;FW^XAZC)+$'\#FNVKQ'0M7U?P_P".=-T:S\1KKEC<2*CB.0R(
MJL><9)P0/FX->W5SXF'+)-6U[?\ !.C#3YHM.^G?_@!1117,=(4444 %%%%
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MK.YCN)9F7>8CN55!!ZCC.0*[&YJHDMCQ8QHO#NI)^_KZW(O$^HMJOP_L+U@
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MZX*CCW&:R_B+J$\CVUHL,BVP^<3ACLE)'3I@X^O>M+XB7%HVAP1ET:=Y5>(
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M>7D]2O5?\/PIO@"UDM?#.^4;1/,TJY_NX S_ ..UF?#4?+JC#[A:/;_X]_\
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M (JC_A9&L?\ /M8_]^W_ /BJX^BMO90['#]<K_S,[#_A9&L?\^UC_P!^W_\
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MM_\ XJC_ (61K'_/M8_]^W_^*KCZ*/90[!]<K_S,[#_A9&L?\^UC_P!^W_\
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M#V!SBDL8X9?AUX1CN I@?7E60-T*EFSG\*GVLKW>UU^5R_91M9;V?YV.:L?
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M^1PUSX7UJTLVNY[%UA098AE)4>X!R/RJOIVBZCJQ?[#:M*$^\V0JC\20*W?
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MRRL4$:)9S>=%(H._=DGGG'4^E9E%'*A.M-N[9T4GC&^>4SK9Z?%=D8-TEO\
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M+4K6MPELERT$JP.<+*4(5CZ ]#2<8CC5J+9[%G5-6N]8NA/=N"5&U$485!Z
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M+/2F(N)U RPR=N.PR%)YZ5H:AX"\/:AX?OM2\)ZS/>R6(+313 '( ).,*I'
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MYXUY)1<WNG]]SHE0BW)06S7W6.'UGX<QIX^M/#FD7$WE2VPGDFN2&,8RP)X
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M+G=M-]1JA#F;DK1]W]+G/C3/"\]S)8PZE=Q3J"%N9]@@9A^H'^?2I[JWDN/
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M]F?\*\L-XN_]8WEX*_Z[!SG_ &,Y]\4[1-,N?"KW>J:L$MU6!HXHS(I:5ST
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M]A_VT_\ 1C5AB?@/2RO^,_3]4>(_%'_DHVJ_]L?_ $2E<A77_%'_ )*-JO\
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MR$=HH%/1%4X)'N2"<^F*.1WL-UUR<QJQ^(-,D=%\]TW\*987C4_BP I^C?\
M'C)_U]W/_HYZRYXD(*, R,,%3R#5_P .HL>CA$&%6XG 'H/.>G*'*B*59U)Z
MKH_T&:-_R%/$/_803_TE@K8K'T;_ )"GB'_L()_Z2P5L5,]_N_(Z(;??^844
M45)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !115:_O8=.L9KN<XCB4L?4^PH
M+Z_M=-MFN+N98HQW/4^P'>LO2O$J:O>^3#8W$<>"?,EPIX[X].GYU@6]K+K]
MR-9UBWBD@C8;($D),:]CC\:Z"V+">V1?G-O(4R/XHF'RM^@H W**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***1F5%+,0%'))/2@!:*J?
MVE:_\]&Q_>V-M_/&*EEN4CM6N 0ZA<C:?O>E $U%9XLA<0^;=-YLAYP?NK[
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M/R% %FH9KJ&W($L@!/11R3^ YI#=Q&UDG1PZ(I)Q["J]C&H5GEP9GY=CW_\
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MD'SD]S3DM(I8)HV0-D!AN&<8J4%VA*@953DGTI(@6D"AMN[C- #+&&."4 8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1CDJ>F.M/N7C288.U9%#KZ8-+:V":C#'=WJDLR +'G  [$^I--N=*B:/%O\
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M 4444 %%%% !1110 4444 %%%1SSQVT#S2MM1!DF@"2J.L726FEW#L?F*%5
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M4X.!]*FBMX8!B*-5'H!BI* *T>GPHX=B\C#D%V)Q]*L_2BB@ S1110 4444
M%%%% !1110 4444 %%%% &5/_P CAIG_ &#[O_T9;UL5CS_\CAIG_8/N_P#T
M9;UL54ME_75D1W?]=$%%%%26%%%% !1110 4444 9^L_\>,?_7W;?^CDK0K/
MUG_CQC_Z^[;_ -')6A3Z$+XWZ+]0HHHI%A1110 4444 %%%% !1110 4444
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M+;K'#;[.IY+$]6;N3[FJTTL]M9SA&>:%HR'A=BW&.JD\@U5L]4AEB59Y%CE
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M]9U?A.C"_'\B#1O^0IXA_P"P@G_I+!6Q6/HW_(4\0_\ 803_ -)8*V*RGO\
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M?K<KG+)<CUXZCISD?A6MI^AQ64#;G,ES*099CU8@Y_*M!+6-23C.<]?0G.*
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MF#4D-I(THFN64LOW%7HO^)]Z9"T#^S;8_P !4'^$,P7\@<59CCCA0)&H51P
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MQ6//_P CAIG_ &#[O_T9;UL54ME_75D1W?\ 71!1114EA1110 4444 %%%%
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M%:7$YDG\VXD/4R/6MI47E6(XQO=I,'J,G.*NT 0VMI!90+#;QB.->@%3444
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M,'/KD56?2BTFXW+D8QEAEL>A/<?6M&B@!L:+'&J*,*HP*=110 4444 %%%%
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M;O\ =B-XXC]YG&"1Z =?Q- $T%E;7$$<SPH&=0Q '<C-33V[-"(82B)W^GH
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ML**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ[+2O&.EZDJJ\GV:4J21+PF0<$*YX;_ UYG>Z9>V+2">$Q*VZ(2/\T$<;<@
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M &$$_P#26"MBLI[_ '?D=T-OO_,****DH**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBHKJ;R+664#)520/>@!)KN"!@LDF&/10"3^0YK-NKJ 3&>)]VX /&05;V(!Z
MU;M[-5@W%B9&Y9O4^]5IX$N(S&X^A[@^HH A_M"UQQ)D_P!T*<_E31'<&\$\
MBF, ?NP#GCZ^M0VB[T_>+\WZ>G]*OI*40I@%3V/:@!S/YQ4%0'SRW3--D81
MQSJ"GH?Z4DD;BW,D?SXZ@=15> 7-];D%OW.?E;;EOJ/04 ->$;?,A;?'W]5^
MHJ&I6M)[9Q-;S,S)G*N!\P[CC%3_ &4W$0FB15)&=JMD-]/\#0 RVO'MSM/S
M1_W3_2M&2_A6$.A!+' '<?6L8@@D$$$=C24 =&>M%-B;?"C>J@TZ@ HHHH *
M*** "H;FZ@LH#-<RK%&.K,:FKS_7=:?4;Q!$\\=LA5X"$7:>2&<]^_'\N: (
M=7UNZU?>5WI (U8)#+D+\V<N.YP!QVQ6>66.9Y0P>02JWVE!D -QA@/QZ4X+
MY31QB.3<K>6\L&"7# D8!ZDUTFA^&T1([J]53*JJ<!=HC('H.I]Z ,JPT.XO
M/WK'[/$P?+XR9 Q[(?N\?TKHK32[.Q'[B$!NNYOF/3'4U>=@3A1A1T%.CCSA
MV_U>[!H CHJS-Y"2?(H8%>QX!JM0 4444 %%%% !1110 A (((R#U!K)O?#]
MM<,'@Q"X8,$"YC)'JOTXK7HH X*[L)].4QW"[(V!WL3E9=IR N/N\5&=XDVH
MK>;EUBMR2#$#A@P]_P#/:O0'C2:-HW 96&"#T(KFM1\.&)M]F)#&6&^-<>8!
M@@X8GI[4 7M$\5EV,5_)YD995%UM"!21T8>F>_\ ^NNM1UD171@R,,AE.017
MDRL&,1;RS.JH(E7D#G'S^_\ C6WHVOW&DNUM*'G@B5FE7*@)\W5/7KT/Z4 >
M@44R&:*XB$L$J2QGHZ,&!_$4^@ HHHH RI_^1PTS_L'W?_HRWK8K'G_Y'#3/
M^P?=_P#HRWK8JI;+^NK(CN_ZZ(****DL**** "BBB@ HHHH S]9_X\8_^ONV
M_P#1R5H5GZS_ ,>,?_7W;?\ HY*T*?0A?&_1?J%%%%(L**** "BBB@ HHHH
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M>[4U7XGMM%8F@^*+#78PL3>5<@9:!SS]1ZBMNN1IIV9[4)QG'FB[H0D*I9B
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M[8KTN2011M(PRJC)'M6<J'4HDE#02P,<JPYX]1]16D//8F7EN:,;B2-7 (#
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M!L$\_>% &SX8T422)>2I'P-L9"8R 3\YSW-=1<R#B).$7]33HU6SLE51AB
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MRKKR"/8UYA6WH_B6ZTM#;29N+%N&A8\K[J?X34RI]8FU+%]*GW_YG4V-V_\
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M "#G_P"OJY_]'/45'>)IAU:JUY$&C?\ (4\0_P#803_TE@K8K'T;_D*>(?\
ML()_Z2P5L5G/?[OR.R&WW_F%%%%24%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9]SE-25L_>
MBPOU!Y_F/RJW<7"6T89\DDX55&2Q]!6?<23W*8:&)0#E?G.Y3ZYQ0!.\SR
MXQ[51O)%22W!0.=Y.T]Q@@_S%5A=WBL8G6(2#U!_/C@U:MX8S\]R"9C_ ,M
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M_P#7W;?^CDK0I]"%\;]%^H4444BPHHHH **** "BBB@ HHHH **** "BBB@
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M+4-1L5N+FTEFGA  %Q#(8&PJ]E]NGOBO2_&(SX4O1M)^X<C^'YU^8\'@=3[
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M>4 94_\ R.&F?]@^[_\ 1EO6Q6//_P CAIG_ &#[O_T9;UL54ME_75D1W?\
M71!1114EA1110 4444 %%%% &?K/_'C'_P!?=M_Z.2M"L_6?^/&/_K[MO_1R
M5H4^A"^-^B_4****184444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5SD3[;J\,G$AN'S],_+_X[
MMKH9)$BC,DCJB+R68X _&N8U:]L59[VUN%,G D0JP63L"&Q@'WJZ;LS#$1YH
M6)&(+$CI69(D#:NX:0QN8T.0,@GYNOX8IAUAF7$5J^X]W88_3)-2PV*L[3K.
M9)7Y82#:<UON<*5MQ\D31L 2#GD%3FHVDDB1FC<JP'44Y7,;!U.".]0-<?VA
M+]G%N#,1D2*<!1ZD=Z!EG2+K>DX;!D\TLP''7D'_ #Z5?=M[9K)_L>6)Q)%>
MR).!UV#:?8CT_&K%NES=;HYKC8R'#K&FT_GD\'U&*$2TMT5]>CN9M*EMX[*2
M]DN"! @B+>2!]Y\]L]!]*YB#P7K<N#)!';CUFE4?H,G]*]%#N$";V( P!G@"
MFU46XK0RJTX5)7=S \/>%Y-%U#[7/?Q.?+9&CB0D'(]3COCM6_156XU*SM7"
M33JK'MU-)OJRHPLN6")Y9!%&SMT49K,NM5DBMY)%A&T*?O''TYJ*ZU>WNP(;
M;S)AG+>7&3G':BVT^:^:.:]3RX%(9+<CDG@Y;\1G%2W?8VC!1UF3:/9LNFV[
M3##LN\K[G)Y_ C\JU0,  =!115)6,Y2<G=A1113)"BBB@#&\60/<>%[Z..&2
M5]JE4C7<20P(R.XXY]LUYJW@W6[E9W.@_.7)^T-+Y*9//RA\#';^M=[XUU#4
M+); VMY-!%*C*PC<KDJ?;V(KAI9Y9VW32O(WJ[$G]:%3<M298J-%\MK_ ('6
M>&$7P[!=?;]1TZWDD+D):2[PF4 & H..1FI=.U^TU7$5Z4M+T\"4#$4A]_[I
M]^GTKBJFM+2:^NXK6W3?+*P515JDDMSF>+G*2LOD=Q>V4F\12EXB.H7^(?7T
MI(HDAC"1J%459<+;6=MI\4AECMEV^83G<W<CT'H*@8[4+>@J%W.N3>PM5Y;V
M"&38[_,.2 "<5%->O#$6**3_  C."3Z4MO:LJ[W_ -8_S.<]Z3?1%**2O(>U
M["4S%(KD],&JC7,F=L4ADE/15YQ]?05>-I ZX>%&SURHYJ1(TC&$15'H!BBS
M8*4%LBM;6ACC!D;,C<N1W-6@ HP.E+15)6(<FW=A115>6\BBD\O#NXY(1<XH
M;L"BY;$Y(4$DX JK=7BQV[LFXMC P.YZ5'+=F5,)!.1W^0@FECM9)9%DN,*B
MG*Q YY]2>]2W?1%QBHZR)+>U,4:J>,=>>]6J**I*Q#;;NPHHHH)*MYJMMI3V
M[7!7]])Y:J>^>^/:I)K:&Y:-Y[>%GC.5<KDC\^GX5S_BP,RV%U;V[W$EI=+(
MXB&6"@'.*Z#2[J/5;6WN(/N3 $>WJ/PJKZ: UW-2;]WIL2]V.?ZUY-=3&36)
M+P2QPF:64Q3SG.]00NPK_#CUKTKQ1?BQTV>4;OW49QMZACP/Z5YE;HT:W$D;
M6)\M0D\;MO$F!DOGWS6<][&U!:-FQX4@>[\46Y,:DI*TKJAQ 55<;U]6#$>M
M>S:'_P @Y_\ KZN?_1SUY?\ #RQ9KJ:[:&3RX8_+7S1M\J5CN=57TQMZ_P!:
M]0T/_D'/_P!?5S_Z.>LI_"=5%_O?D0:-_P A3Q#_ -A!/_26"MBL?1O^0IXA
M_P"P@G_I+!6Q6<]_N_(ZH;??^84445)04444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5:Y)DECM0[)O!
M9F4X.T8X'US5FJ-^ICDBN1G:@*N1V!QS^8H 26WB@PL:@*>V*S9[01S1O  H
M=MK+T&3T/]/QJ_NW_-G.>^:J7>^?$,2E]K!I"!]W'3\<T 3LC)PRE:5)"K$D
M!L]=U()'$?EEB5]Z'EME0"1C$V/O'D?4T 5I#;&^@=0RMYARK<C.#C%:LTR2
M1@+US^58;6UQ<;B H0GAG)!/N .E686N]XAD:+>1PS9^;Z8ZG\J )I.;FVQ]
M[S"?PP<UJFJEM9F-S+*^^0C&<8 'H!VJU0 4444 %%%% !1110 4444 %%%%
M !7,^,K0R6<%R"ORDQ'S%RBA_P"(^A&!S[UTU175NMW:36SDA)49"5Z@$8XH
M \K#@0QO$T,6#A%0;V?L2?PR:ZOP]>+<:>(0P)M_D& 1N3^%L'IFN;N4>RO9
MH9I%BD8L)3Y!!51PN.WS#FIM/NIM.NUD*W)0+EE8J?W*CCWR": .UHI%8.@9
M3E2,@TM !1110 4444 %%%% !1110 4444 %%%% !1110 59M(LN9&^ZO\ZB
MBB:9]J].Y]*=J-Y%8V<F3B.)2SD=?I0!@>*]10QBT\Q%,YY+9.U1R.!ZD8_.
MN7(:2WPB0S><V=B+AXV/) 'IP:LWDTUW<S23"Y1-VV4 +A%!RG3DXSDT_3+*
M;5=3B!C4[^5G5MGR*V') YY!Q^- '6^$['[-IGV@@DSX,99MS"(?=![#J>!Z
MUOTV-$BC6.-0J* JJ!@ #H*=0!E3_P#(X:9_V#[O_P!&6];%8\__ ".&F?\
M8/N__1EO6Q52V7]=61'=_P!=$%%%%26%%%% !1110 4444 9^L_\>,?_ %]V
MW_HY*T*S]9_X\8_^ONV_]')6A3Z$+XWZ+]0HHHI%A1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M""?^DL%;%8^C?\A3Q#_V$$_])8*V*RGO]WY';#;[_P PHHHJ2@HHHH ****
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MBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*BNKZXU:0W$T@F>.*.5=A:,Q#=EMHZ,>V?I2(S7&RWMP]Q&MRFR:-OWN7YP
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M!6Q64]_N_([H;??^84445)04444 %%%% !1110 4444 %%%% !1110 4444
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M7<_RA!W)S4MO8K%&D$48VIE .WR\$'ZCG/K5TZ59RJ1<6T,Q/>2,$@>F<<T
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MO^NB"BBBI+"BBB@ HHHH **** ,_6?\ CQC_ .ONV_\ 1R5H5GZS_P >,?\
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M]M.TR2:,9E)"1CU8]* -"J.IWGV6# 8*S@X;/3%<U%H]RR^;-J5VLS89RLF
M"?Z=1^%6_P#A'=1FF23^V)U5,J%FB#D#H><_K0 7+QVD)DN9W4#(*ASDG/('
MOW'UQ4OA^PDEN9=3NK8PLWR01MP0O]X\]3Q^56K+PW:6TRW%P\E[<KTEGP2/
MH!Q6S0   9P.M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &5/_P CAIG_ &#[O_T9;UL5CS_\CAIG_8/N_P#T
M9;UL54ME_75D1W?]=$%%%%26%%%% !1110 4444 9^L_\>,?_7W;?^CDK0K/
MUG_CQC_Z^[;_ -')6A3Z$+XWZ+]0HHHI%A1110 4444 %%%% !1110 4444
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M\*N6S"*%4,,9('7')^IIEY91W&>BRK]V0#D'^H]J;81SS6JN8\=NO<<$?F*
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MR>_TJ'KH:PM%<Q>A@$?)Z^@Z"IJ**HS;N%%%%,04444 %%%% !1110 4444
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M6R?_ !^C['XC_P"@OIG_ (+9/_C];5%'._Z2#D7]-F+]C\1_]!?3/_!;)_\
M'Z/L?B/_ *"^F?\ @MD_^/UM44<[_I(.1?TV8OV/Q'_T%],_\%LG_P ?H^Q^
M(_\ H+Z9_P""V3_X_6U11SO^D@Y%_39B_8_$?_07TS_P6R?_ !^C['XC_P"@
MOIG_ (+9/_C];5%'._Z2#D7]-F+]C\1_]!?3/_!;)_\ 'Z/L?B/_ *"^F?\
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M ,_]I_X"O_\ ':/[(U'_ )_[3_P%?_X[6W11[20?5Z?;\S$_LC4?^?\ M/\
MP%?_ ..T?V1J/_/_ &G_ ("O_P#':VZ*/:2#ZO3[?F8G]D:C_P _]I_X"O\
M_':/[(U'_G_M/_ 5_P#X[6W11[20?5Z?;\S$_LC4?^?^T_\  5__ ([1_9&H
M_P#/_:?^ K__ !VMNBCVD@^KT^WYF)_9&H_\_P#:?^ K_P#QVC^R-1_Y_P"T
M_P# 5_\ X[6W11[20?5Z?;\S$_LC4?\ G_M/_ 5__CM']D:C_P _]I_X"O\
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J7_\ CM:&G6CV-F(9)5E<R22,ZIM!+N6.!DX^]ZU;HI.3>Y<*4(.\4?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img224999359_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %0 G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBO$H+30[CQ-XE.K>&-8U>0:E*$DL(G94&X
M\':Z\UM2I<]]=OZ[HQJU?9VTW_KLSVVBO*]>TC2KW4/ FF#3+BVTV4W(^QW!
M9)$!"'#?-N!S[U:-K%X&\<0VFC!TT^]L)II+1Y&=%DC4L&&3D9V@?B?PKV":
MT>NKV[?,CV[3U6FBW[_(]*HKS'PUX,T_Q=X:77=9FN+C5K]GD%T)F!@(8A0@
M!Q@8Z$<=.E=)\/-6N]8\(6\U](99XG> RGK(%. 3ZG&.>]3.DHIV=[:,NG5<
MFKJUU='545YC-XZ\5&RUO4+:RTDV6DWCPR&3S \BA@ % .,CJ23W&!QSTFE^
M*;G4?&2Z6(85LWTI+]3@F0,S*,$YQC#>E$J$XJX1Q$).R.JHKSBV^(.JW/AR
MUFCL[1]5OM1:RME^98EQCYFY)[]B/TJMXYN-?E^'VIQ:_8VL$T5S$(YK23,<
MRENH!)88]\9S5+#RYE%Z:V)>)CRN4==+GJ%%>:^*_B5<Z1XAN]-LCIT:6: R
M&\65FF<C.U-@P#V^;C-6=:\?WD6DZ;J&G#2[6&YMOM$C:C,20<XV)&AWL<Y^
M8#'TI+#5-';<;Q-/57V/0:*\W_X3_6;S1O#4^G65E]LU:66"19MVQ74A0PP<
MA<G)')QQ[UV5Q>:EIWA2YO;T6C:C;VLDSB$-Y1=5) &3G' J9491M<J-:,KV
M-:BN%?QGJ*Z3X2NQ#:^9K%U'#<#8V%5B =GS<'ZYJE-XQ\62OXAFT^QTEK/1
M;B19#,7#R1KG[H#8W *22<9R,"J6'F_Z^1+Q$%_7E<]'HKRR;5]9UCXB^';J
MP:U6"XL!<0PSLY5$8'S-P'\?# $<<#-23_$C5+7Q';6LZ:.UK/=B$VT$K2W$
M:%MNYG4F,'OMSGV'6G]6GT[$_68=>]CT^BO(K7Q--HWC;Q#IMA'"^IZEJ444
M!N,B)!R"S8()ZX '/\CJ>+/B+>:'KLFE6TFF)):PJT\EW',1*Y4-M0)G;P?X
MCWZ\<OZK/F2774/K4.5M]-#TFBLG1M7;7_#-OJEG&L,ES"61)?F5'Y&#C&0&
M'MD>E<M8^.]0U&VT&VAM[9=5O;R2"\B*L5A6/[Y W9!P5(R3WK)4I._D:.K%
M6\_Z_4[^BO-)/B'JW_"676G+!I44%M=^2;:YE,5P\8(!=78B,YSD#K@\ CFO
M2Z*E*4+<W4=.K&I?EZ!17':]XBUZW\96OA_1;?3W:XLS/YEWO 0AFY)4\C"X
MP!G)ZU1M?'&J77@Z2_,&F0ZC%?FQE>XG$5NA')<[FR0 ?N@DGJ/2J5"32?<E
MUX)M=COZ*\?U/QA<^*OAMXG2[6T:2SDMPLUH'6.16E7& _S#[IZXZ]*Z/0?&
MTM[I6J:L([<:+I<&Q%Y\^:15!SUPJGH,CO[&JEAII7?>WY?YDQQ,&[+M?\_\
MCO:*\Q\-?$^XU+7+.RO_ .SGBO VT6BS![=@,@2;QAL]/ESTK$\6^(=>\2^!
M9]3DL["+1);D)"$9O/7:V S9^4C@CC!R1VJEA9\W++0EXN'+S1U/::*YKX@?
M\B%K'_7#^HKSC3=(CN)?#\GAKPWK.G:FDD4D^H3JZ0,FWYSDL00>>!C(.,'.
M*FG14X\S=OZ]2JE=PERI7_KT/;**\5L[X:'\5=1U:5REHU]-:7![892R_JOZ
M51\,ZC>Z9JGB#7 1]LGTF6]7<,[6>52#[]C6GU1VNGT7XF?UM7LUU?X'O%%>
M7Q>!=.E\#KKK7%W_ &Z]F+[^T?M#[Q)LW^N,=L]<=Z[?PGJ<^L^%--U"ZQY\
MT(,A QD@X)Q[XS6$Z:BKQ=];&T*CD[25M+FS17DNB^*KW2?"6B_V/I=BKWVI
MO;?9]TFWD]F9R02>YR/:NM\,>(=7O/$&JZ'KD%DEW9+'()+,ML96&?XCGN*J
M>'E&[[?\,*&(C*R[_P##G6T5Q&O>)O$$'C$Z#HUOISYLOM.^[WC:03G[IYX&
M ,=3UK(L?B)KL]OHVIW.GZ>FEWMTME($9S*7Z%UYP%ST!R>.O.:%AYM70/$0
M3LSTZBN!N?'5]I^F>(4O(+;^U=.NE@MXE5@LPDQY9QG/(R>M6+OQ'XEN=:_L
M/1K336O[2T2:^ENBXBWL =B!3GOU)/Z9*]A/^OZ\Q^WA_7]>1VU%>0>)/$^J
M^(=(\.W-HD-JS:D()X'=B#<(P*@XZIT/J/UKK;#Q3JDFH^);*[BL_,TBUCD0
MQ*V&<QEFSD\KD<=#BJEAY*-_ZWL3'$1<K?UM<[*BO(I=:UC6]=\%:K:P69U2
MXM[K:CEEA!PRY/). !G&<G%;$GQ$OM-T36CJEG:_VMIURML! 6\EV?.UN?FP
M I)'4X[9X'AIZ6W_ .#82Q,'>^B_X%ST6BO-M"^)-W?Q:O%)#9WUU9VC7<3:
M>LJI(!@%2)!NR"0<^GTJ[X(\:ZEXBO\ R;TZ3+$\'F*UE(4DB<8RCQR'<>#]
MY05]SV4L/4BFWT*CB:<FDNIWE%%%8&X4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !14<\7GV\L/F21^8A7?&<,N1C(/8UA_\(J?^@_KG_@7_P#6
MII+JR)RDOA5SH**Y_P#X19O^@_K?_@5_]:C_ (1>3_H8-9_\"?\ ZU5:/<CG
MJ?R?BCH**Y__ (1B7_H8-8_\"!_A1_PC,_\ T,&K_P#?\?X46CW#GJ?R?BCH
M**Y__A&;C_H8=6_[^C_"C_A&KG_H8=5_[^#_  HY8]P]I4_D_%'045S_ /PC
M=W_T,6J?]]C_  H_X1R\_P"ABU+_ +Z'^%'+'N'M*G\GXHZ"BN?_ .$=OO\
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M>2+]W&%.0$B#87/<@UK?V+KG_0S2_P#@*E']BZ[_ -#/)_X!I1[:=[\WX?\
M %R*UO9O[U_F4-4\%W=QK5YJ6CZ_/I+7Z*EXD<(?S-HP"IR"AQGD<\TS4? D
MESK%IJ-EKES:RQ6@LYGDC$\DL>>3N<_*Q!/.#_/.E_8VO?\ 0SO_ . 4?^-'
M]C^(/^AG;_P!C_QH522^TON_X W%/_EV_O7^9DZ?\/OL$&@1?VIO72+F6=3]
MGP90YS@_-QCUY^E=?>VD=_87-G-N\JXB:)]IP=K @X_.L;^R/$/_ $-!_P#
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MJNN-J5U;PF&(_95A.,8R[ DOP>_/O6C]I\5_\^&F_P#?YJ/M7BK_ *!VG?\
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M\*.1_P!-![>/9_<_\CH**Y_^V/$/_0KG_P #X_\ "C^V-?\ ^A8;_P #8_\
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M'XPU"ZTKPCJ5]92^5<PQ;HWVAL'([$$4XQYFDNHI2Y4V^AN45Y?X5\6:I?\
MB33;6'Q!_;T-Q$YO(O[.^S_9, $-N &>>/3\2*S]#\?:]/X7U#[9>"359C"-
M.?RD&0\AC)P%P<%3U%=#PL_R_$YUBX?G^![!17F6E^*O$&L:%X:L+:]CCU75
M3.\U_)"I\J.-V^Z@ 4D@8Z?SR-C3]4U_2/$<N@:G=1:O)+9M=VDZPK S,./+
M8 [0,C@^_7TF5"2NFU?_ "*CB(RLTG;_ #.UHKS[1-2\7)XE73M0O;:\FELG
MN)[;RE5;&3^!2Z9R#QUR<<^]6_#=[XCA\63:7K>IV]XAM/.($ A\N3=C;%D
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MF\1_]!72O_!;)_\ 'ZB7O.[E^?\ D7'W591_+_,UZ*R/LWB/_H*Z5_X+9/\
MX_1]F\1_]!72O_!;)_\ 'ZGE7?\ /_(?,^WY?YFO161]F\1_]!72O_!;)_\
M'Z/LWB/_ *"NE?\ @MD_^/T<J[_G_D',^WY?YFO161]F\1_]!72O_!;)_P#'
MZ/LWB/\ Z"NE?^"V3_X_1RKO^?\ D',^WY?YFO161]F\1_\ 05TK_P %LG_Q
M^C[-XC_Z"NE?^"V3_P"/T<J[_G_D',^WY?YFO161]F\1_P#05TK_ ,%LG_Q^
MK5C%JD;L;^\LYT(^406C1$'W)D;/Z4.*[C4GV+M%%9+V_B$NQ35-+"YX!TZ0
MD#Z^?S22OU&W;H:U%9'V;Q'_ -!72O\ P6R?_'Z/LWB/_H*Z5_X+9/\ X_3Y
M5W_/_(GF?;\O\S7HK(^S>(_^@KI7_@MD_P#C]'V;Q'_T%=*_\%LG_P ?HY5W
M_/\ R#F?;\O\S7HK(^S>(_\ H*Z5_P""V3_X_1]F\1_]!72O_!;)_P#'Z.5=
M_P _\@YGV_+_ #->BLC[-XC_ .@KI7_@MD_^/T?9O$?_ $%=*_\ !;)_\?HY
M5W_/_(.9]OR_S->LWQ!I/]NZ#>:7Y_D?:4V>9LW;>0>F1GIZU%]F\1_]!72O
M_!;)_P#'Z/LWB/\ Z"NE?^"V3_X_32L[I_G_ ) W=6:_+_,T+.W^R6-O;;M_
MDQK'NQC.!C.*XO3?AK!8W/A^:34/..D!\CR-OG9=G3^([=I?WS[5TGV;Q'_T
M%=*_\%LG_P ?H^S>(_\ H*Z5_P""V3_X_5QDXWM+?^NWF1*"E:\=OZ[^1@Q?
M#[[/X>TFRMM6E@U+2GD>VU".$#&]RS!D).5(.,9_3(-W2_"=W9WMWJM]K<E_
MK,L!MX;J2W5$@7MMC!QUY/(S[9).C]F\1_\ 05TK_P %LG_Q^C[-XC_Z"NE?
M^"V3_P"/TW4D[WDON_X E3BMHO[_ /@F#H7@?4-*^U07?B'[;8W@D^U0FR5'
MF9P06,F2V>:F\/>!Y-&U.WO+O6);\6<!M[*-H5C$*$\@D$[CCC/'\L;'V;Q'
M_P!!72O_  6R?_'Z/LWB/_H*Z5_X+9/_ (_3=63O>2U\O^ )4HJUHO3S_P""
M:]%9'V;Q'_T%=*_\%LG_ ,?H^S>(_P#H*Z5_X+9/_C]8\J[_ )_Y&O,^WY?Y
MFO161]F\1_\ 05TK_P %LG_Q^C[-XC_Z"NE?^"V3_P"/T<J[_G_D',^WY?YF
MO161]F\1_P#05TK_ ,%LG_Q^C[-XC_Z"NE?^"V3_ ./T<J[_ )_Y!S/M^7^9
MKT5D?9O$?_05TK_P6R?_ !^C[-XC_P"@KI7_ (+9/_C]'*N_Y_Y!S/M^7^9K
MT5D?9O$?_05TK_P6R?\ Q^C[-XC_ .@KI7_@MD_^/T<J[_G_ )!S/M^7^9KT
M55L8]0C1Q?W-M.Q/RF"W:( >X+MG]*M4F4@HHHI#"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** / ?$/QP\3:1XFU738+#27@M+R:"-GBD+
M%4<J"<2 9P/2J*?'WQ3(P5;'1A]89?\ XY7">-U=?'GB!L<'4KG_ -&M6*LJ
M8Y'-9<S3.-U)7T/6W^.GBZ-<_P!GZ*1CJ(9?_CE0#X_^*2<?V?H^?^N,O_QR
MO,4E8*5R<'UII1"X.<'U%7&O;XD:>U3:/5X/CMXJGE$8L=&#>AAE'_M2G-\=
MO%"L1_9^D''7$4O_ ,<KR28,T@9#AO4&D22:,$8))[U4:RWLC=QBU:,CUA_C
MUXH'W;#1\^AAE_\ CE.C^//B=E);3M)^HAE_^.5Y7&LTAR8R?>KZQ%8=N<9]
M:SJXE6LDD9PW?-<](3XZ^*&;!T[2?PBD_P#CE6K;XV>))+I8Y[+240]Q%)_\
M<KRH28)3OCC%".\A!?("]ZY93F^MCKI5Z4+.<;GKU_\ &3Q#;']S;:4ZXZF&
M0_\ M2L*Z^/'C2VRW]F:*4[-Y$O_ ,<KC$8&(?/D$\"M,6A6R#RQ!X90<#TK
M&.*G2LI.YR8VJW4=3#KW=VNQLP_M#^*"<2Z=HX^D,O\ \<J['\?/$LAR+#2
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M9?\ VK7NM>%?LY8QXEP,'_1<_P#D6O=:I'53^%!11106%%%% !1110 4444
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M++.[$ !C[55DW1N<@BIK:4KEQ]!7K9;AJ57$14]GN=DG)TU%/1%A=1DMFVE
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MJ,>74#NDG/2O/Q%!MN74(REU1"'P>1Q3AM)RI_"D90W0BFB%NHKSM"]"T@&
M5/([4XL<9%5E8J>>#4P?O4M&;B>Y_LZG/_"2<8_X]?\ VK7N5>(?L\%&'B,K
M_P!.V?\ R+7M]5'8ZZ/P(****9J%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 ?%GCD'_A/_$9_ZBES_P"C6K#C?8X;&<5T'C?GQ]XC_P"P
MI<_^C6KGV7%);V.=2:E<T(KP".2/RTP_7(Y%3VMZL!<&,-D8!;M67&:LH,GF
MOH,"J+@J=EJ;/%UG)2;V-%R;J/=G##H:W[& ZEHXT"9%-RQ:XTYL]9?XHO\
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MOHIA*N<L!VK+N+JX\]9)!G: N0,<"M"TN!Y;1^<R*R_='0FHR\<P\N9< _Q
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M,<4Q[=9!D_>]:WI8APT94:UM&1(^<9Z^M:"23&U:7*["VT@5DS(81T_&B*7
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M#BX>SK2C:QWT7>""BBBN<U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** ,B;PKX=N)Y9YM TN2:5BTDCV<99R3DDDCDDU&/!OA93D>&]'!]
M18Q?_$UMT4K(KGEW,0^#O"Y.3X;T<GWL8O\ XFE'@_PP.GAS2/\ P!C_ /B:
MVJ*N,Y1^%V)>NYB_\(=X8_Z%O2/_  !B_P#B:;_PA?A4G/\ PC.C9_Z\(O\
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M   B_P#B:U/ML7]R?_OP_P#A1]MB_N3_ /?A_P#"@#*_X0GPH?\ F6-%_P#
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MG&0/RJ?[;%_<G_[\/_A1]MB_N3_]^'_PHY5V"R+%8O\ PB'AD_\ ,NZ1_P"
M4?\ \36E]MB_N3_]^'_PH^VQ?W)_^_#_ .%.P-)[F</"/AH=/#VDC'_3E'_\
M33O^$5\._P#0 TO_ , X_P#"K_VV+^Y/_P!^'_PH^VQ?W)_^_#_X4N5=B?9P
M[&>?"7AL]?#^E?\ @%'_ (4J>%/#D9RF@:4O^[9QC^E7_ML7]R?_ +\/_A1]
MMB_N3_\ ?A_\*.5=@]G#L4#X4\.L<G0-*/ULX_\ "F_\(CX:_P"A>TG_ , H
M_P#XFM'[;%_<G_[\/_A1]MB_N3_]^'_PHY5V#DCV,[_A$?#6,?\ "/:3_P"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
0@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img224999359_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $8 Z@# 2(  A$! Q$!_\0
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MGS1NWY)Y..G-4L3#F;:ZW_,3PTN5*_2WY&%=>'?%WBO6M+EU^'3;&SL)A/\
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MGMTQTH=:E:7G<:HU;Q\K'FVHVE[J'PEN/$EYKM]/=73;I8'ES"5\S:%"=!C
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^TO%_P#T ;/_ ,"Q1_:7B_\ Z -G_P"!8KIZ*.==D'L9?SO\/\CF/[2\7_\
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M7_\ 0!L__ L4?VEXO_Z -G_X%BNGHHYUV0>QE_._P_R.8_M+Q?\ ] &S_P#
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M/\CF/[2\7_\ 0!L__ L4?VEXO_Z -G_X%BNGHHYUV0>QE_._P_R.8_M+Q?\
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MO%__ $ ;/_P+%']I>+_^@#9_^!8KIZ*.==D'L9?SO\/\CF/[2\7_ /0!L_\
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M Q'3G@US.J^ Y[C7+S4M-O[2 WNTSI=6*7&U@,;D+=,^E=?96HL[&&VRI\M
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MSJP<VU+OW_R/.A2FH)./;M_F<^FN:IX+?Q5I!OI=033[5+FSEN3N9"Y P3W
MW _A[T^X\*ZG9^$#XF3Q1JAU9+87A)FS$?EW%=OICC^E=-I'@."VM-5_MB]D
MU2\U1-EU.XV?*!P%';']!Z5D_P#"N=8>R&CR^+KE]#''V?R0'*?W=^>GZ>U2
MJL+Z.VU]-]"W2G;57WMKL==H6J7&K^$[+4UC3[5<6HD"$X4OC]!FO/=!\8Z[
MI7@G5=:OHHKP1WQ1"\S%BQ<*R].% QBO4K.T@L+*"TMD"00((XU'8 8%<(_P
MYO3X>U30UUB(V=U<BY@W6_S1-OW-D[OFR !VK&E*G=J6UU]QK5C4LG'>S^\L
M:GXVU/2+>P@OK'3X-2U!V:))+O;#%$ #ND<CKSC I]GX\GO_  W>WMK86\M_
M9W MYHQ=KY(S_P M!(>"F/QJ_P")O"']NMIUU!<Q07UB"$:: 31NI !#(>O2
ML^[\!7-YX?BLY-2MEO8KQ;M98K!(XB5Z*T:XW#GO5)T7%7W^9+592=MOD9LO
MCK5-3\->)([>&TBO]-B#?:+6X+QE&!RR-CJ,<>M)9^-M0TCPWH%K<Q63:C?0
M[XY;F[*1"(*/GD=A]X^GK6K:>!+I6UXWVK+<MK%LL4KK $,; $9 !QM /3VZ
MU6?X>WLNFZ6LFJVLFH:8&BADDL@\30D !'0GDC&<^]7S4-NGS[?YD<M??K\N
M_P#D*OQ)$GAX7,-C'+J9OAIZV\<X:-I3R&#CJN.<U!H=_J]Q\5KB'58OLTBZ
M8,P13F2(G</F7I_+-:,_@26Z\/1V<VHPIJ$-T+N&ZMK-(51QT&Q>H^O-3:+X
M3U*R\62^(-2U=+V>6U\AE6W\L#D$8Y/''ZU/-249<OGW*Y:K<>;R['74445Q
MG8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!Q/Q5GFMO!,DD,TL+?:(ANB<JV-W/(KD_#$DS>---'AR?Q%+9?-]O_M3/EA,
M<8SW_P#K5Z)XO\//XGT(Z='<K;L9DDWLFX?*<XQD5NJ,* 3G ZUTQK*%+EM=
MZG-*BY5>:]EH>)>#O$EWH;ZM>7MY-+!<0730"60L!+"1A1GU#T[PWK.K>'/#
MWBZYFNIKB]M4MPGG.7".^><$]MWZ5TLWPM-QH=II\NHH6@U"2Z+B$_,CXW)C
M/L.:W(/!,#7GB1KV99K36BF8D7:8PH(ZYY/?\*Z)UJ+OY_HU^ASQHU5;R_5?
MYG*WWA;4]*\)MXFA\4:HVK10"Z<O+F)^ 2NWT_SBO0M&U)M5\-6>HNFU[BV6
M5E'&"5R<5QW_  KG6)K--(N_%MS+H:D#[,(0'9!T4OGI_G%=[#:16UBEG;H(
MX8XQ&BCHH P*YZTXR25[N_X'11A).]K*WXGG&D>,KC3_  CX?DL-+\Y]1O9+
M989;MG8'<<?.V3U]>E=1X8\2WNK:IJNE:I8Q6M]I[)N$,N]'5AD$$@'_ /76
M58_#Z:TTOP[9G48V.D7QNV;RB/-!8G:.>.O7FMO3/#CZ?XMUG6FN5=-06,+$
M$P4VC'7/.:JHZ34K;Z]^_P#D*FJJ<;^7;M_F8'B'4]>B^)VB6-EY1M7A=UA>
M9E63@[F8 =0.E8>F^*=:T.'Q1?Q6(OK"TU:4S23W)#(A8 *@P>G7TYKMM=\,
MW6H^(]+UNPU!+6YLE:,B2'S Z-U[C!QG\ZSV\"2GP]XDTL7Z9U>[>Y63RCB(
M,0<$9YZ>U.-2ERI/R_,F5.IS-KS_ "(M;^(#6FJ)8:=#8F06JW4LE_=B!,,,
MJBD]6(KI?#FNP>)-!M=5MT,:S Y0G)1@<$9[\BN;U'P!-->V]]87UK'<BTCM
M9A=6:SH^P8#*&^Z:ZO2+ Z9I<%H\D<CH/F>.%8@Q[G:O K.I[+D7)N:4_:\[
MYMCA9OB)K4=AJ>I1Z';R6&F7K6\\GVDAF 8 ;5QUY&?K71Q^*))?&T&AI;I]
MGFL/M@FW'=DG&,=*S6\!3'PMKVC_ -H)NU2\>Y67RCB,,RG!&>?NU/?^#KY]
M8L-5TO5UL[J"S%G*6MQ('0=P">#5OV+VTW[^5OU(7MEOY=O,H6_Q$N;C0;>X
M338Y-2O-0>QM;=9<(2I^\S$<"H_%>J:])X UW^T]/_LVYM_+$<UM<;EE!9>5
M(PP_&I;;X<26WAZWLDU8K?V=\U[:W@B^ZQ[,I//3FKEYX1UG5?#NJZ?J?B#[
M3/?;-A%N%B@"D'Y5!SSCUIWHJ2<>_GW_ ,A6K.+4NWEV,^_\>3:;/!I5G#9/
M/;V,<]Q)?W@@#94$*F?O,1S5Z#QX+ZY\+_9+1?L^M>9O+M\T13J!C@\Y%1ZG
MX!FGU)-1L+^UBN&MH[><75DMPC;!@.H;[IXJQJ7@NZN(=$ELM3BMM1TIF*3?
M9%$;[OO?NUP!^%+]PTO^#V_S'^_3?_ [_P"16N?'\]I:^)IWTY9!I%TMO&$<
M_/N.-S'' '>M+PGXDO=>>?[1'IAB10R36-X)@2>Q4@$?C5/2O!NIZ7;:WY>N
MAKS4IEF^TM:JV#@Y!4G!!S^%/\-^"I=(U^?6KR[MI;J2'R EI:BWCQD$D@$Y
M;CK2E['E=M_GY#C[;F5_T\SL****Y3J"BBB@ HHHH **** "BBB@"*;H**)N
M@HH EHHHH *CGN(;6%IKB:.&)>KR,%4?B:DJ"\LK74+9K:\MXKB!\;HY4#*<
M<\@TU:^HG>VA6_M[1_\ H+6'_@2G^-']O:/_ -!:P_\  E/\:J?\(=X9_P"A
M?TS_ ,!4_P */^$.\,_]"_IG_@*G^%7^[\S/]YY%O^WM'_Z"UA_X$I_C1_;V
MC_\ 06L/_ E/\:J?\(=X9_Z%_3/_  %3_"C_ (0[PS_T+^F?^ J?X4?N_,/W
MGD6_[>T?_H+6'_@2G^-']O:/_P!!:P_\"4_QJI_PAWAG_H7],_\  5/\*/\
MA#O#/_0OZ9_X"I_A1^[\P_>>1;_M[1_^@M8?^!*?XT?V]H__ $%K#_P)3_&J
MG_"'>&?^A?TS_P !4_PH_P"$.\,_]"_IG_@*G^%'[OS#]YY%O^WM'_Z"UA_X
M$I_C1_;VC_\ 06L/_ E/\:J?\(=X9_Z%_3/_  %3_"C_ (0[PS_T+^F?^ J?
MX4?N_,/WGD6_[>T?_H+6'_@2G^-']O:/_P!!:P_\"4_QJI_PAWAG_H7],_\
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M-_T%K#_P)3_&K[*&4JP!4C!![UB_\(=X9_Z%_3/_  %3_"JCR_:)ES?9+?\
M;VC_ /06L/\ P)3_ !H_M[1_^@M8?^!*?XU4_P"$.\,_]"_IG_@*G^%'_"'>
M&?\ H7],_P# 5/\ "J_=^9'[SR+?]O:/_P!!:P_\"4_QH_M[1_\ H+6'_@2G
M^-5/^$.\,_\ 0OZ9_P" J?X4?\(=X9_Z%_3/_ 5/\*/W?F'[SR+?]O:/_P!!
M:P_\"4_QH_M[1_\ H+6'_@2G^-5/^$.\,_\ 0OZ9_P" J?X4?\(=X9_Z%_3/
M_ 5/\*/W?F'[SR+?]O:/_P!!:P_\"4_QH_M[1_\ H+6'_@2G^-5/^$.\,_\
M0OZ9_P" J?X4?\(=X9_Z%_3/_ 5/\*/W?F'[SR+?]O:/_P!!:P_\"4_QH_M[
M1_\ H+6'_@2G^-5/^$.\,_\ 0OZ9_P" J?X4?\(=X9_Z%_3/_ 5/\*/W?F'[
MSR+?]O:/_P!!:P_\"4_QH_M[1_\ H+6'_@2G^-5/^$.\,_\ 0OZ9_P" J?X4
M?\(=X9_Z%_3/_ 5/\*/W?F'[SR+?]O:/_P!!:P_\"4_QH_M[1_\ H+6'_@2G
M^-5/^$.\,_\ 0OZ9_P" J?X4?\(=X9_Z%_3/_ 5/\*/W?F'[SR+?]O:/_P!!
M:P_\"4_QH_M[1_\ H+6'_@2G^-5/^$.\,_\ 0OZ9_P" J?X4?\(=X9_Z%_3/
M_ 5/\*/W?F'[SR+?]O:/_P!!:P_\"4_QH_M[1_\ H+6'_@2G^-5/^$.\,_\
M0OZ9_P" J?X4?\(=X9_Z%_3/_ 5/\*/W?F'[SR+?]O:/_P!!:P_\"4_QH_M[
M1_\ H+6'_@2G^-5/^$.\,_\ 0OZ9_P" J?X4?\(=X9_Z%_3/_ 5/\*/W?F'[
MSR+?]O:/_P!!:P_\"4_QH_M[1_\ H+6'_@2G^-5/^$.\,_\ 0OZ9_P" J?X4
M?\(=X9_Z%_3/_ 5/\*/W?F'[SR+?]O:/_P!!:P_\"4_QH_M[1_\ H+6'_@2G
M^-5/^$.\,_\ 0OZ9_P" J?X4?\(=X9_Z%_3/_ 5/\*/W?F'[SR+?]O:/_P!!
M:P_\"4_QH_M[1_\ H+6'_@2G^-5/^$.\,_\ 0OZ9_P" J?X4?\(=X9_Z%_3/
M_ 5/\*/W?F'[SR+?]O:/_P!!:P_\"4_QH_M[1_\ H+6'_@2G^-5/^$.\,_\
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M]N6F_P#" ZKY03[;9AACYMTN31S!8]%_X2*P]+O_ ,!)?_B:/^$BL/2[_P#
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M*QT]%%%4(**** "BBB@ HHHH ***S=5U9M+$6W3-0O?,S_QYQ!]F/[V2,=:
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M Q0RIN/0,5!<*TD9B7^/Y6(., ]33V;YMN#TZT#@T$&6='%H;*/3F2W@A?\
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M%'X&H/LR+.UP=_F,H7[QV@#VZ?C2$39Y_P#KTX]*:JL%&6R<<DT?,. O/O0
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M=Z $J(1F.3*-\AR64]R>]2FDZT '04 #=N[XQ4<4COD-$R8]>]2T (RAE*L
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M*.HH^J4NP?VIB>Z^X^CO#VK'7?#UAJAA\DW4*R&/=NVY[9P,UIUS?P__ .1
MT/\ Z]$KI*\M[GTT7=)A1112&%%%% !1110 4444 13=!11-T%% $M%%% !1
M110!RVF,$TP.P.%DE/'/_+1NU:'!^E4M)_Y!R_\ 727_ -&-5P#J#ZUFRD)M
M!'(S]:6@Y['%+QVI#(Y8DFC,<BAE/4&G*,* .@&*=TJ++K-M/S(V3GCY?;WH
M DIU-YSD'CTI<T !SVIGW%CW,23E3QU(YJ3-)D$%.^=P_D:8#0BJS,!@MU]Z
M"P! ) )Z>]./*X-,DB63;N!)4[@?0T@'"FL$;Y6 .><'VH8M&A;:7(' '4T8
M) ) !H 7:-V<#/3-.I,]C0#^5  ^ N['2CCTJ"Y:0>5L4$%P'SV%3@;1CM3L
M F2#@C(]:=D$<44U55"Q50"QR<=S2 7<,D9&?2BDVKOW8&[&,^U*#0 8H  [
M8I:* %S1FDZ4AZ4 .Q\V3C/TZ4N>*CCE$B!ESCW&*?F@ )IF2Z<J5)[&GTW.
M: %'3THHQ4>S ;RVV,3DG&>: )M!_P"8E_U^M_Z"M:]8^@<C4<]?MK?^@K6Q
M6BV("L?7OO:9_P!?@_\ 0'K8K'U[[VF?]?@_] >FP*LMN)KB*1Y9@(B2(U?:
MI/\ M =:L]0#32/2G*1C'YU!H)T[_C28&3ZTX_>I,XPQS2$+@CI3221[4,Q'
MU//--)9HR$(#$<-C(% RG";Z2Y8W"P"V"#;L)+,W?(Z 5>HQM3H20.U'3OQ3
M; -K2,%7J>_I5A(XK=690!GECW)I88]BY(Y/Z5',VZ7'9?YT;(G<C,YFD9?+
M940@@G^(TK. I8J3@= ,TF.XZT[-%QC%?<FX*W(SR,56LKQ+Z!Y426-HW*/'
M*FUE(_SG-6C@MC-*(U>3<Q(V]"#0 S=QUIW?T]JK"T8W+3/=3.O\,1P%3\AD
M_C5K:,<\_6@"J+>-KQ;K<3)&K1@AN,'!((_"K()/>J<-E'97$LT4GEP..8NB
M*W=AZ9JP)H_*\T.ICQG<#Q^=##<D(SQ63>6+1S&6QA7[3/*IEE:0C"COZGC@
M 5>ANXKF'SH2SIV(4C/TS4.G7YODE=[6>V*.5VSK@GWIJZU L2P/*Z-Y\B;3
MG"$#=]:D(P"?ZTX'-'%(!@(/?-+NR<$?A0>F>II(X;EB-\:)GJ0V<46&/)R.
M3BJ]W//';-]CMFN90<A <9]>3Q5Y+=5!+G><\9]*E "C  %-(FY4M8Y9X4DN
M(VMW/)BW D?4BK7EJH&T8QUIW;O0&##C/XT[(5S*O[F:.Y6"WL;BX=USN4;5
M4>['BK!!4;3D$5)=S/$(6#HD>\>8S?W:DE@67GI0UH5<H+=1R7SVR!B\:!V;
M'RC)( SZ\=*CU0_Z /\ KO#_ .C%J^+=E'&/PJAJJD6(R"/W\/;_ *:+4V!V
MZ'344459 4444 %%%% !1110 5@>+-4UK2M.BDT32Q?S/+MD+. (4P3O()&[
MG QD=:WZY?QEIEUJ8TM8]+75;.&X:2YLVF6,2#8P4G=PP#$'% &'X9TV5O%<
M>K:EI.M?VDZ,INY(X8+=1@\%(W);T!;<>>U>B5Q_@Y=<TR+^S+O0&M;$3RM!
M)]L200Q$ED3 .>,X]JZF]O;;3K.6\O)T@MXANDED.%4>I- 'GWBO0X]3O]2M
MH_#ND_:YDWK?SZB$=1@#S60#. ?SQCO7HL*&."-&(9E4 D# /'I7C^L7VF3:
MYJ$]CK_AQX-0CFCDN;BZ(EC65$4C 4[@NPE1D=><=:]>MD6.UA1'+JJ* Q[C
M'6@"6O&]'O)K?Q&MTYT6[U2ZUFXMI;=X";Z'!<*^\L2 JA>,!=I]:]DJ!;*T
M6[:[6UA%RPVM,(QO(]"W6@#RCPJ-(,W@F733;?V\[3'5#$?WQ'EMYWF]_P#6
M;?O=\8K6\1GQ0=7\-_VNFD"R_MJ'8;1I#)G#[<[N.G6O08K*T@N);B&UACGE
M_P!9(D8#/]2.37,^./\ 7^&/^PW!_)Z .MHHHH **** "BBB@ HHHH ****
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MH!48R3]:7-&1NQD9]*10^]M^W;GY0.OXT $;"1 PS@]B,5)@ 4A&12CI0 :
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MWE[5?:<8!(SBGC@4 +36(12S$ #DGTIU1M(OFB(YW%=WX4 .# @$'@T45&I
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MZ39VUR^MPAI8H@K$$/GD>M 'H-%%% !1110 4444 %%%% !1110 5Y'\8O\
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M".M4]5_X\Q_UVA_]&+0@.GHHHJR HHHH **** "BBB@ HHHH **** "BBB@
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M $#;;_OV*/\ A'=&_P"@;;?]^Q6G10!F?\([HW_0-MO^_8H_X1W1O^@;;?\
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ME=V6?=MV97(!&[/'2O5*** "BBB@ HHHH **** "BBB@""Z(" DX Y)-%)>
MF' 4,<'@]#QTHH L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
E110 4444 %%%% !1110 4444 5KS_4GYBO!^8=1QUHHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img224999359_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %M PL# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%,ED$43R$,P12Q"C)./2@!]%<W_ ,)G:_\
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M3.U_Z!FK_P#@&?\ &C_A,[7_ *!FK_\ @&?\:/9R[!]9I?S'245S?_"9VO\
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M17-_\)G:_P#0,U?_ , S_C1_PF=K_P! S5__  #/^-'LY=@^LTOYCI**YO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVXQQ45(14+V_,NG.3G:_Y$.HW/\ :OB?^RVD*:=IT*W=Z<X#L<^6A]A@L?7
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MX"#:/H*N480:OI_EW(C*<T[:_P"?;\C/\*:ZT.D6=I J3Q6L'GZK>R2_+"S
MN4'7<_)R.@]:FG\9ZO%80ZFOAX?V?=2)':LUSB4EV 1G3;PISV)/2C4O#=MI
M":O-%LMM"N=-\FYAA0ET=00'50.?E)SWXK'T^[O]9U3P[I/]HZ9?6EFPN)&T
M\LV5C7"-(3PASCY?6GRPDW-+07-.*4&]3T#5]2BT?2+O49^8[:)I"!WP.!^)
MXKFH-0O-%L[)&MC?^(M98S/$9-BI@9.3SM1 0O Y_&K_ (\B>;P3J80$E$61
M@/[JNK-^@--U32]0N=5TW7=$EM#-% T+1W);8\;[3D%<D$$#ZUC34>77K?\
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M6B@!L<:1($C140=%48 IU%% !1110 4U(TB7;&BHO7"C IU% !1110 4444
M%%%% !1110 4444 %%%% !1110 445SWC'Q'<>&M"GO;33)K^X6-W55XC0*,
MEI&[#]3T% '0T5S-_K^I2:AINE:1#:F^NK0WDLER6\N*,8'1>22S8'I@UGVO
MC'4]9&G66EV=I%JDR3O="Y=FB@\E_+8#;@L2Y&.G'- ';45D>&M:.O:+'>20
MB"X622">(-N"2(Q1@#W&1Q[5KT %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 45C^(V9+*(JS*?,Z@X[&N:\Z;_ )ZR?]]F
MMZ=#GC>YSU,1R2Y;'>T5Y]'?":66**Z+R1$"15D)*$]CZ5$=7MQ:&[.HI]F4
MX,OG?*#G&,Y]:T^JON9_7%V/1J*\^@OA=0+-;W9EB;[KI(2#^-2>=-_SUD_[
M[-+ZJ^X?6UV.]HKG_#;N[W.YV; 7J<^M=!6$X<DN4Z:<^>/,%%%%06%%%% !
M1110 4444 %%%% $;_ZV/ANIZ=.G>I*C<9EC.&.">0>!QWJ2@ HHI#R" <>]
M #1-$TS0B1#*@#,@89 /0D?@?RJ&#4+*ZN)8+>[@EFA.)(XY S)]0#D5Y_9Z
M>VAZ_P"-Q93W,]T=+AF\^>0O(\FV;!SVZ# & ,53DM[?3=(\$W>BQQI>RV<H
M\R(#?*IM6=BV/O?.%//>@#TR'4+*YN9;:"[@EGA_UD22!F3Z@'(JS7F.GVEC
M96GPZNM-CC6YG8+)+&!OE1[=FEW'JWS $Y[UHZUXZ\1:#:7-]>^"I%L+=L-.
M-1B/RE@H;:!GN.* .]HJ!9IF /V8X/\ MCW_ /K?G1YT^/\ CU/_ 'V/;_Z_
MY4 3T5!YLV?^/8_]]CW_ ,!^='G3X_X]C_WV/;_$_E0!/14'G3_\^Q_[['O_
M (#\Z/.G_P"?8_\ ?8]O\3^5 $]%0>=/_P ^Q_[['O\ X#\Z/-G_ .?8_P#?
M8]O\3^5 $]%0>=/C_CV/_?8]#_@/SH$LV?\ CV./7>/;_$_E0!/14'G3X_X]
M6Z?WQZ'_ .M^=+YLV?\ CW/7^^/4?_7_ "H FHJ#SI\9^RMG'3>/0_\ UOSI
M1+-NQ]G(&>N\>O\ AS^% $U%5_.GQG[*V<9QO'7'3\^*=YLV<?9SC/7>/7_)
MH FHJ#SI]N?LK9QTWCT_QXI?-FSC[.<9Z[QZ_P"'- $U%5_.GQG[*V<=-X]/
M\>*=YLV['V<XSUWCU_PYH FHJOYT^W/V5LXSC>/3_'BAI9MK#[.0/7>..O/]
M: +%%<%YTN/];)_WV:/.F_YZR?\ ?9KJ^JON<?UM=CO:*\Z@U6"ZGD@M]066
M6+[Z)-DK]1FI([X2RRQ1W1>2(@2(LA)0GIGTI_57W#ZXNQZ#17!>=-_SUD_[
M[-'G2_\ /63_ +[-+ZJ^X?6UV.]HKG?#\T_^D81Y?N]7Z=?7_/%;?FS_ //L
M?^^Q[_X#\ZPG'EE8Z:<^>/,3T5!YL_\ S['_ +['M_B?RH\Z?_GV/_?8]_\
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M[L2F46&)"-I<!<D>F?2G_P!DZA_SZO\ F/\ &IE4BW>Y4:<TK6-/PS_R\_\
M ?ZUT%8N@6EQ:_://B:/=MQGOUK:KSZS3F['I4$U3284445D;!1110 4444
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MC!KUVYMXKNUEMIT#PS(8W4_Q*1@C\JYS3_!4-I<6376IWE_;:>C)96UQMVQ
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M_ GBN/QIX2M-:2'R7DRDL6<A'4X(!].X^M=)0 4444 %%%% $;G$L8W,,D\
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M/^_?U]_I^5+LN,_Z]<9_YY^X]_3/YU-10!!Y=SC_ (^$SC_GG[?7UI=D^?\
M7KC/_//W^OIQ4U% $'EW./\ CX3./^>?L/?Z_G2^7<9_UZ_]^_K[_3\O>IJ*
M (!'<=YU_P"_?T]_K^?M1Y=SC_CX3_OW]??Z?E4]% $.RXS_ *]<9_YY^_U]
M,TGEW./^/A,XZ^7[?7UJ>B@"'9<9_P!>N,]/+[9^OI2>7<X_X^$SCKY?L/?U
MS^=3T4 0^7<?\]U_[]_7W^GY4GEW'_/=/^_?T]_K^?M4]% '"?%9)A\/+[?,
MK#?%D!,9^<>_T_+WKI]%2<Z'IQ$RA?LT7&SMM7W],USOQ9_Y)W?_ ._%_P"A
MK73Z)_R -._Z]8O_ $$5N_X*]7^2,%_&?HOU+'EW./\ CX3..OE^WU]>:79<
M9_UZXST\OW^OI4U%8&Y!Y=SC_CX3..OE^P]_7/YTICN.TZ_]^_K[_3\O>IJ*
M (/+N/\ GNO_ '[^GO\ 7\_:@QW..+A/^_?U]_I^53T4 0[)\_Z]<9_YY^X]
M_3/YTGEW./\ CX3./^>7M]?6IZ* (=D^?]>N,_\ //W^OI@4GEW./^/A,_\
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MM\2;3:VR"XN'"QVP(QG/\(QQQ7N6C:8-'TBWT\75S=B!=OGW+[Y'Y)RQ[]:
M)-3L(M5TJ[T^<D174+PN1U 8$'^=<A:^$M7NSH]GK+V'V#2(GCC>UW>9<9B,
M0)!&$&TDD G)QVKN:* .*TOPQK8N-"M]4N+-K#0\F!X=WF7+!#&A8$87"DYP
M3D^U9OQ-\,:!:> =8OK;1-.ANU".)X[9%<,9%R=P&<\UZ/7&_%;_ ))GK/\
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M%O79UQGAW_DIWC/_ *YV/_HMZ .SHHHH **** "BBB@ HHHH **** "BBB@
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MKM[+^OF?2OA[5O[>\.Z?JWD^3]LMTF\O=G;N&<9[UI5S7P\_Y)UX>_Z\(O\
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M]<=*NQR)+&LD;!T895E.017E^I6]S;ZA,ETI\TN23V;/<>U=SX7@N+?1(UN
M5+,613U"FHHUY3FXM&V*P5.C1C4C*[?]:&TOWA]:]D^#7_),=-_ZZ3_^C7KQ
MM?O#ZU[)\&O^28Z;_P!=)_\ T:]98W:)T9-O/Y?J=[1117 >Z%%%% !7,^)_
M!OA_Q'=V>H:RK;M/.\,)MBLN0VU_5<J#SZ5TU>06/P[.M>)M6EU]K@7*ZDTL
MJFX+1ZC:'F--@8;0I"]NV* /2M T;3-&L9$TI1Y5S,]R\F_>9'<Y+;N_I] *
MU:X?X7Z;=:9HFHQS6IL+:34)9+33VE$C6D1QA#R<<Y..V:[B@".>:*V@DGGD
M6.*-2[NQP%4#))-9]WXCT>QTZWU"YU&".UN0#!(6XD!&1M[GCFN:\?RWEQ&V
MG/I=[<:1]EDFN7MT#"5P#MC;)&%'WCZX ]:R/"EW'_:'@RYOE:VA/AYXK<W.
M%_> Q[B.<<H,CVS0!Z7;7,%Y;1W-M,DT$JADDC8,K ]"".M<CX=_Y*=XS_ZY
MV/\ Z+>J'AAO$"^#8W\-Q::Z/J%VT0O6=4\@S.4*;.WIVQ3?!;:T?'?B\ZK%
M8B_V6>];9V\O'EOMP6&?K0!Z)14.ZYS]R+&?[QZ9^GI2;KO'^KASC^^?0>WK
MF@">BH=US_SSB_[Z/O[?3]:3==?\\XO^^S[>WU_2@">BH-UUC_5Q9_WS[^WT
M_6EW7.?N18S_ 'CZCV],T 345!NN\?ZN'./[YZX^GK2[KG/W(L9_O'IGZ>E
M$U%0;KK',<6<?WSZ#V^M!:YSQ'%C_?/O[?3]: )Z*@#7/>.+_OL^WM]?R%&Z
MZQ_JXLX_OGW]OI^M $]%0[KG/^KBQG^\?7Z>F:3==8_U<6<?WSUQ]/6@">BH
M=USN^Y%C/]X],_3TI-UUC_5Q9Q_?/7 ]O7- $]%0;KG_ )YQ?]]GW]OI^M&Z
MZ_YYQ?\ ?9]O;Z_I0!R'Q9_Y)W?_ ._%_P"AK73Z)_R -._Z]8O_ $$5R?Q6
M,Y^'E]O2,#?%G#'^^/;Z?K73Z*;C^P].PD97[-%R6.<;5]O3-;O^ O5_DC!?
MQGZ+]34HJ#==X_U<.<?WSUQ]/6EW7.?N18S_ 'CTS]/2L#<FHJ#==X_U<.<?
MWSZ#V]<T%KGM'%_WV??V^GZT 3T5!NNL_P"KB_[[/M[?7]*"UUCB.+/^^??V
M^E $]%0[KG/W(L9_O'ID>WIFDW7>/]7#G']\]<?3UH BU?\ Y M__P!>\G_H
M)KY<T;_D"6/_ %P7^5?3NK&?^Q[[*1[?(DY#'.,'V],5\Q:-_P @2Q_ZX+_*
MNW!?$SR,X_AQ]2[1117H'SYG2?\ (QV__7K)_P"A"M&LJ6YMU\2VZF>,,+=U
M(+#@EA@?6M6H@]7ZFM5-*-^WZL*BN?\ CTG_ .N3?R-2U%<_\>D__7)OY&K>
MQG'='T%\//\ DG7A[_KPB_\ 0172URO@ SCX>>']B1D?8(L98C^$>WUKH]UU
M_P \XO\ OL^_M]/UKPC[8GHJ#==?\\XO^^S[>WU_2E4W&Y=Z1A>^&/O[?3]:
M '.,RQ' .">2>1QVK&\3^+](\(VT$^J22C[0Y2*.&(R.Y R2%'8#DFME_P#6
MQ<+U/7KT[5POQ'N=.TO4/#FKSWEW%?VMTXMX+2V\][E&7]ZFWTV]^U %G2?B
M9H&K:Y!IEK%>+#<LT=I?/;E;>Y<#)5&[GKV[5VM>6^=X8O[WP5?:;?2)H<=X
MT-EIUO!@+=D,<R9.5V@MQZGTKU*@ KG(_&-G-XLO-#2-MEG:-<379/R JP#(
M/4C/)[=*V[^&XN-/N(;2X^S7$D;+'-MW>6Q'#8[XKSVR\(:Y:^)(K.2XMFT[
M^Q)K1IXK5E!+N."2Y^<D[B>_/K0!O:5XSFOKS3?M>D26=CJP8Z?<-,&,F%+
M.F/D+*"1R>G.#4/Q6_Y)GK/^Y'_Z,6L[3+;5M1D\*:9<Z1=69T-@]Y/* (F*
M1-&HC;/S[BV?8#GFLOXC^$I[+P9J^H-XHUZY12K_ &6>=&A.9%^4@*#@9]>U
M 'JL?^K7Z"G562V^13YTW0?Q_P"?7]*=]EX_U\W_ 'W]/\/U- $]%0?9N?\
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M_P"29ZS_ +D?_HQ: .PC_P!6OT%.IL?^K7Z"G4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!#=?\><_P#US;^5<-\'?^1#7_KZE_I7<W7_ !YS
M_P#7-OY5PWP=_P"1#7_KZE_I6\?X,O5?J82_C1]'^AW]%%%8&X4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110!Q/Q9_Y)W?_ ._%_P"AK73Z)_R
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MB@ K$\8_\B1KW_8.N/\ T6U;=8GC'_D2->_[!UQ_Z+:@#YOT[_D%VG_7!/\
MT$59JMIW_(+M/^N"?^@BK->Y'9'Q=3XV%%%%,@**** %7[P^M>R?!K_DF.F_
M]=)__1KUXVOWA]:]D^#7_),=-_ZZ3_\ HUZX<;M$]K)MY_+]3O:***X#W0HH
MHH *\M\21^%_B!>:<VK7]\NG+J$FF16*Q[!+=KG+%AD@  XZ5ZE7B+^$/']G
M>1)9Z1IDUM::[-JT#R7FUI-Q;"D=A@T =U\.8X["QU30[?49[VVTB]:TA\^$
M(T2A0=F1]\#/WO>NTKC/A[H^MZ9'KEUKUM;VUWJ6HM=B*"7S%4%5'7ZBNSH
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M+OW+:JH\D#^[MQR/UH ^G/\ A%M0_P"ANUO_ ,@?_&Z/^$6U#_H;M;_\@?\
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M:9+)$S X)5E!!!QGVZ5D]23TJBN,_P"%EZ3_ - OQ#_X)Y__ (FC_A9>D_\
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M]$^O/_!C!_C1_P );XM_Z)]>?^#&#_&@#M:Q/&/_ ")&O?\ 8.N/_1;5B_\
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M!),,22LQ=V'IN/;VKC-3U.^D^'[>'_M<XU&#SH9YQ(1(888_-W[NN64QC/\
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M?*C*.">"Y49 )/'%7O */9/KVF7$<45W;WYDEBMO^/=!(BLHB'4#')![D^M
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M5F8E2.N016]10!GZ1H>GZ'!)%80E/-??+([L[R-C&69B23@=S6A110 4444
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MLX#%H^DDW)9FR7E *H/4G+,Y/KCUKJ:* "BBB@ HHHH **** "BBB@ HHHH
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)** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img224999359_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &! @$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2BBB@!:*** "BBB@
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M1%E6)K/5!*PRJ&VY(]AFNJT?58=:TV.^@BFCC<D!9DV,,''2N2UC_DKV@_\
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MQ=*\,V>CZQJ&HVDDRF^;=+"2/+#>H&..]/T_P]:Z=KFHZM%)*T]_M\U6(VC
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M^\<^]:-%2FUL4TGN9[Z)I\D-C"UN#'8,KVRY/R%1@?7BN+URQN-0UBXDO?!
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MW5M.O]86Z@:/87OY&',B@\9]": /9J*AM,_8X,DD^6O)^E34 %%%% !1110
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M7_\ R/.C?]>MS_[)705\H2P7W]J6H.NZN6,;X<W;;EZ< U;^SW__ $,.M?\
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M9MM0M9;:<WMP_ERKAMI<X./>NXHHH **** "BBB@ HHHH \2^,/_ "/V@?\
M7C-_Z$*Y.NL^,/\ R/V@?]>,W_H0KDZ[\-\!\IG/^\_)?J%%%%;GDA1110 4
M444 :/@G_DK>@?\ 7"X_]!KZ(KYW\$_\E;T#_KA<?^@U]$5YU?\ B,^RRO\
MW2'S_-A11161WA63XG?38_"^IOK"%].6V<W"KG)3'(&.]:U<Q\1O^2<^(/\
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MKFO"OCK1?%S7$.GO-%=VW^NM;F,QRI[E3VKI: "BBB@ HHHH **** "BBB@
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $HHHH 6BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2BBB@!:*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
BBBB@ HHHH **** "BBB@ HHHH **** "BBB@!**** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img224999359_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_6.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" IF"F8# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BF4Y: %HHHH **** "BFMUH6@!6IM/I-HH %I:**
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M1110 4444 %%%)D4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGH=G\6;Q6'[YOSKJ])^+]T-N9C^=>))8E:NV^Z''-9RH4WT-8UZD>I]+Z/\
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M4K4V@!]%%% !1110 4444 %%%% !5>:K%024 :>A#]\M>L>'?]6OTKRC0?\
M7)]:]7\/?ZM?I05T'>*/^/-_I7R-\;/NS_C7USXH_P"/-_I7R-\;/NS_ (U]
M!EOQ(^:S+X6?''C'_C]?ZUDV7W:UO&'_ !^O]:R;+[M?H5/X$? /XB[12;J
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFM&>A4M8>G>)H+[&&'-;2L'4$<BN9IQW.A23V!J-M.HI%"9%+36%.H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ^O]:R+.M?QA_P ?K_6LBSK]#A\)\#/XB]1112 **** "BBB@ HHHH ****
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M>J*Q-+\36E_&")5!K76XC;HZG\:\QQ:W/44D]B2BD#!NG-+4E!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(W2EI&Z4 )NIU,I
MR]* %HHHH **** "BBB@ HHJM=72P+UH LTR258UR37/WGB-(<_-7.ZAXR4!
MOG_6@#J=0UA(5/S5R^H^+A#GYZY'5O%WF X?]:XS5->>0G#58KG<:EXUSGY_
MUKEM2\3-/G#5QUQJ4CD\U"MPS=3027[Z_>5CS68SNS=:FSNI=HH B3=4H&:5
M5%/X]J &8]J6ANM% !12[:2@ INZG4R@!P.:6FK3J "BBB@ I",TM% #=M.H
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"H)*GJ"2@#4T'_6+7J_AW_5K]*\HT'_6+7J_AW_5K]*.I70?XH_X\W^E?(GQ
MKZ35]=^*/^/-_I7R)\:^DU?09;\2/F\R^$^.?&'_ !^O]:R+.M?QA_Q^O]:R
M+.OT.'PGP,_B+U%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(
M3BEH ***:S!5R: '4UG51DD5CZAK"P9^:N6U+Q@L61O_ %H ZW4M6CA4X:N+
MUCQ4(=V'KE]6\9;\C?\ K7&:KKSSDX:K)N=1JGC,MD!ZY6_\1-<9^:N=N+IY
M">:KJS$\T"+MU<--WJDR,QJ9>U.VB@"*-2M2K2T4 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU_K619U^AP^$^!G\1>HHHI %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,/\ C]?ZUD6=?H</A/@9_$7J***0!1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *@DJ>H)* -30?]8M>K^'?]6OTKRC0?]8M>K^'?]6OTHZE
M=!_BC_CS?Z5\B?&OI-7UWXH_X\W^E?(GQKZ35]!EOQ(^;S+X3XY\8?\ 'Z_U
MK(LZU_&'_'Z_UK(LZ_0X?"? S^(O4444@"BBB@ HHHH **** "BBB@ HHHH
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M=*,5R^C>-8-45<,IS731R"1 PZ&O%E%QW/:C)2U0NVE7I2T5)84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %)G'6D9U7J<5F:EJT<,9PU %V:\CB!R:P-8\1)&C
M,!7,:YXI$>[#5P&L>+&DW#?^M.P'0>(/%1&[#5P>H>(GD8_-6??:HURQYK+D
MRQS5$%FXO&F)R:J^7NYI50U(O% #%CVU)3J1J $HHHH ***90 ^BD6EH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "H)*GJ"2@#4T'_ %BUZOX=_P!6OTKRC0?]8M>K^'?]6OTH
MZE=!_BC_ (\W^E?(GQKZ35]=^*/^/-_I7R)\:^DU?09;\2/F\R^$^.?&'_'Z
M_P!:R+.M?QA_Q^O]:R+.OT.'PGP,_B+U%%%( HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***5: $HI6ZU'0 ^F4^DVT
M (M.I-M+0 4444 %,9-U/IRT 4I+,-34A^SMD5>:H)EW55Q6-;1_%,NGL,.1
MBO4?!GQ:GM9HP9B,>]>&M;MVJU8R/:N&S6%2C"HM3>G6G3>A^@_PO^,PD\K?
M/^M?4/@_XEVM];HK2*>/6OR0\-^/I=)D3]X1CWKWKX?_ !RDC:-6G/YU\MC,
MLYM8GU&#S/ETD?IA:ZQ;WF-C?K5^OE_X=?%R.^\O=-GIWKW_ $#Q3;:E @\P
M;OK7R5;#RI.S/JZ.(C55T=#13%D5_NL#3ZY3J"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;12T %%%% "[J2BB@ HHHH *;MIU% " 8I:** "BBB@ HHHH **** "BBB@
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M% !1110 4444 %%%+MH 2BBB@!"W-&ZD:DH ?11106%*M)2K00*!BFT[=3:
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MHHJ2@HHHH **3=1D4 +1110 444FZ@!:*3(I: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH :U)3Z* "BBB@ HHHH ****
M"BBB@ HHHH **0D#K5>:^CA4DF@"2:X6$9-8FJ>($A4@,*RM>\2+&K8:O-=>
M\5%F8!_UH Z#Q%XI^]AZ\XUGQ$\K-AJHZAK33L?FK(D8S,3UJR!TEZTS<FF;
M=U(L.*D Q0 FP4ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 -YI5I-M*!B@!:*** "BBB@ HHHH **** "BBB
M@ I&8+U.*;+((UR:YS5M=6W!^:@#1U/5$@C.&K@]>\5^5O :LGQ!XMX8!Z\[
MU;7&N&;#58&MK'BAIF8;OUKE+R]:9B<U3EF>1NM(N3UH(&$%FJ6-:513UH &
MI*4FDH **** "FM3J:U !S3J93Z "BBB@ HHHH **** "BBB@ HHHH ****
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MY&*RU?FM_P 3865L5S<;?,>:]B.J/)EHRU12+2TR0I-M+10 WH:%ZTI&:-M
M"T44W)H =13<FE!S0 M%%% !3<FG4R@=QRFEIE+DT"'44@:EH *5:2E!Q0 N
MT5'(VRI-U5;IMJT 3V_[QL5TVCZ"]YC"YKF-#_?72K[U]&_#/P<-0CC.S-<V
M(J*DKG30I^U=CB;+P.[*"8_TK03P7M_@_2OH*7P+':6NXH.GI7*7]G#;RE3@
M5Y*Q3EL>M]54-SRB3P:/[GZ5FWWA7RE)VUZ\T,#>E8NL01>6V,5I&M*YG*C&
MQX9K&F?9\\5S,S!6(KT+Q:BJ7Q7F=_(5F_&O7I/F1Y-7W62R98<4MKITUQ(
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.OT.'PGP,_B+U%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=1114%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !115:ZO%@4\T 23S"&,DFN7UOQ MNK?-5?7/$BQQM\U>8>)/$Q
MDW -^M585RUXC\5%MP#UY[JFJ/<,>:AU#4GFD/-4U^?K3)$#LS<U*HXHVBG4
M %%%% #LBFM110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ J"2IZ@DH U-!_P!8M>K^'?\ 5K]*\HT'_6+7J_AW_5K]*.I7
M0?XH_P"/-_I7R)\:^DU?7?BC_CS?Z5\B?&OI-7T&6_$CYO,OA/CGQA_Q^O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/+%/I=M $>S%%2%::U ",-RTWR@>U+3EZ4 -6,+3MM+10 QHPU1M;*>U3T4
M5_LJ^E/6 "I:*+@-"XI=M+10 W8*3RQ4U-:@!H7%+110 A7-,\L&I** &JFV
MG44C4 +13*?0 4QHPU/HH A:W4TW[*OI5BB@"%;<+VJ18PM.HH **** "@\T
M44 )Y(I/+Q4BT-0 T<4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX_7^M9%G6OXP_P"/U_K619U^AP^$^!G\1>HHHI %%%% !1110 4444 %%%%
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MD,**1:6F2%%%% !1110 4444 %%%% !1110 C=*;3Z* "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !4$E3U!)0!J:#_K%KU?P[_JU^E>4:#_K%KU?
MP[_JU^E'4KH/\4?\>;_2OD3XU])J^N_%'_'F_P!*^1/C7TFKZ#+?B1\WF7PG
MQSXP_P"/U_K619UK^,/^/U_K619U^AP^$^!G\1>HHHI %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444F10 M%%% "$XHW
M4C4 9H =116??:DMO&W- $>I:DMLIYKS?Q1XDX8!JF\4>(MH8!J\MUS6FFD/
MS58$.M:NTTC?-6&TADI))3(Q-"4$"+3\BANE(M #J*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHH **** "BBB@ HHHH#J07'2K6A_\?2_6J=Q]TU;T'_CY7ZT/X1QW/H'X?\
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M=11161J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 -:DI]% #*?12$X&30 %L#-8>M:PMO&WS8JUJFI);P
MMSVKRSQ9XD^^ U %/Q9XDW;P&KS#5-0::0\U9U;5&N)&YK*9=YS5D OS<FI
MH%(J[13J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\HGVN5YAM&3/H/[PHZUEZ1JT=Y OS9.*U*^1E%Q=F?9QDI*Z%HHHI%A1110
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M30,4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD;YLUSGS-)DU]CA<+&C$^"QF,E7D.D4R-FI47BG+TI:] \Q+J%%%%!04444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *@DJ>H)* -30?]8M>K^'?]6OTKRC0?]8M>K^'?]6OTHZE=!_B
MC_CS?Z5\B?&OI-7UWXH_X\W^E?(GQKZ35]!EOQ(^;S+X3XY\8?\ 'Z_UK(LZ
MU_&'_'Z_UK(LZ_0X?"? S^(O4444@"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLT*L#GBO@<11=*5F?I&&K*M"Z)Z***Y3L"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHIK,%&: &7$PAC)-<?XBUX1QL-U:GB#4Q#"><<5X
M_P"*M>)9QNJ@,SQ-K1F9L-7$S3-)(<FK-Y>F=CS5/;ELTR!RC(I](O2EH **
M7::3&* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ J"2IZ@DH U-!_UBUZOX=_U:_2O*
M-!_UBUZOX=_U:_2CJ5T'^*/^/-_I7R)\:^DU?7?BC_CS?Z5\B?&OI-7T&6_$
MCYO,OA/CGQA_Q^O]:R+.M?QA_P ?K_6LBSK]#A\)\#/XB]1112 **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"6YJRHR*3;SFEKI.5*P4444#"G+3:5: '4FT4M%.X#****0!1110 44NTTE
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M10 4444 %%%% !1110 4444 %%%% !1110 44UJ%H =1110 4444 %%(U-H
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MW+3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BE6G4
M,HHHH **** "BBB@ HHHI7 ****8!1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %HHHH **** "E!I** %W4E%% !3*?M-+M/I0 U>E.W4E% !12[:2@ HHHH
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M$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:M44 5OL,/\ =I?L47]T58HH A^R1?W:/LL?]VIJ* (OL\?]VE\A/2GY%+0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0^L3NKCJ***0PHHINZ@!U%(#FEH **** "BBB@ HHHH **** "BBB@ HHHH
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M2 DI&I:* &4^BB@ HHHH*N%%%%!(4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M->FZTW[EJ\WU7_6'ZT 4(4Q5BHHJEH **1J3F@!U%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 444F10 M-W4,>*C\MFZ4 /
M\P4JJ6Z4D=K(S=*V=-TAY&'% &3]@>3H*MVFBR.P^4UW>E>%3,!E/TKKM-\%
M#@[/TH \_P!(\-NQ&5KN-)\)A@,I^E=99^%5AQ\E;]GIJP@<4#L8%CX115!V
M5KP>'XX<<"MA0 ,#I2U!15ALEA[5:HHH **** "BBB@ HHHH **** "BBB@
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M.Y:^(E%Q=F??PDI*Z&TY:0C%*M26+1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% #=M*O2EHH ***3(H 6BBB@ HHHH *K7TPA@)SBII'V+FN?\ $6I".!AG
MM0!R'BK7?+W#=7D^N:H;B1N:V_%VJ%I'PU<'+<&20U9 R3+-FI$6DV[J>O:@
M!=M(>*=2-0 E%%% !3)/NT^FM0!';_ZP5Z)X7N BKS7GL:[7!KI-)U#R5'.*
M .]U6Z#6YY[5Y9XC.Z1L>M=1=ZQYD9&>U<IJ3><QH H:8QCF!Z5Z7X=U81H
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MW:UK35X]HR:F?5(CGD4 9VFZ*MO(#BNTLKI+:#&>U<G)JT:]#52X\0;5(#4
M7?%FH+(K<UYW)>>7<9![UJ:IJAGSS7,73%FS0!V^D:T=H&ZMQ6^U+US7FVG7
M31L.:['2=4  R: +UQH?F\XJ*/P^5YQ6O%JL149-2-JD6T\B@##N+'[.IK!U
M"?9D9KH-4U)&4X-<=J5QYC'% "P3[I178:/<!5'-<#;R;7S706.H>6O6@#H]
M7N T35P&I?-*?K6_>:EYBD9KG;IM[&@"",5+MIBKBI* &LM-VT]J2@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJCMWK/$=.\N@"PUT7[TW<:C5:?0 X3%:7[0?6HMM)M]J )&E+4@F*TW;05H
MF^U'IFF-(7J/RZ<!B@ VT]9C'3::RYH G^V$]ZB9O,ZU'MIZ]* &^74T=R8>
MAIE,9: +ZZRZ]&IW]N2?WJRS'2>70!IMK#M_%43:DS=ZI>6:7RZ )VG+U&R[
MJ15I] #5&SFK,=\T/0U7(S3&3- &BNM2+_%3CKDG]ZLKR:3RZ -"35&DZFJ[
M2>94(CJ0#% #?NU*ER5[U$W>D"\T 3M<EN],)W4Q5I] !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$&KF21ANKF9)/,.:H@@A6K'I3%%/:@!**** "BBDW4 .!HW4S=2[J %HHHH
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M.9!N[U])?#_6!<1IELU\3F.%Y6Y'W^5XOVB46>G44Q6W*"*?7S)]6%%)D4M
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% "-3:?10 4444 %%%% !2%L#-+4-U)Y<)- &=JVH"
M&%N<<5Y)XQUC=O :NH\6:SY08;J\CU[5/M$C#-6!S^I7!DF-0PY-+*-[$TZ,
M;:"!:*&ZT4 %%%% !36IU% #*5:=10 4444 %%%*M ";313J;0 4444 %%%%
M !13J:W6@ HHHH **** "BBB@ HHHH ***:6Q0 ZBF>92[J '4RCS*-_O0 J
MTZD!S2T %%-+4GF4 /HINZDW;: 'T4SS*=D4 +129%)NH =13=U&Z@!U%-W4
MZ@ HI-U .: %HHV^U% !1110 4444 .I&I** "BBB@ HHHH **** "BBB@ I
M,BEIK4 +NI:93Z "BBB@!",TFVGK2[10 VBG4V@ HHHH **** "BBB@ HHHH
M **0G%-\R@!6:F>92J-]6[?37F88% $$,!F; %;6F^'GF8'::UM#\-/(RY7]
M*]+\/^%1A<K^E '+:'X3(924KT71?#JQJN5K:L]#C@5> *TXH5B7 J;E6(H+
M&.%0 *L!0O04M%(84444 %)D4-3: 'T444 %%%% !1110 444UJ %R*6F4^@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "FM3J* &4^BB@ HHHH *CEMTF^^N:>W2C(H Q
M-6\+VFI0LOEC.*\,^)'PEBN5DVPYZ]J^CZS[[28;Y2' YKJHXB5)W3.6M0C5
M5FC\U_B%\%) TK+ ?RKP'Q3\.)M-D<^41CVK]</$OPRM[Z%R(U;CTKYL^*7P
M85EE*0_I7UF#S2]HL^4QF5V]Y'YU7ENUFQ!&,56CNN:]O\??"N>SFD(B(&?2
MO)]1\-2V+'<A&*^KIU8U%='R]2C.F[,H))NJ2JK-Y+8-2+<!N*T,2:BD5MU+
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !113'E$= !(^T53D
MNMW I\TWF<"K>CZ%)J%P %)R:>B5V%G)V0W2M+?4)P I.37N/PV^%DFH2Q,8
MB?PJW\,?A3+>31,T1.?:OLSX5?"=+.&)GB X':O QV.5-6BSW\#@'4=Y(S/A
M3\(TLXXF>+'X5]!Z=IMOHMJ. I HM;.WT6UX &!7!^-/' MU=5?]:^3_ 'F*
MF?3RE3P<"[XT\8K;QNJ/BO!?%7C&2XD<;R>?6F>)O&#WC,-^?QKA;JX-Q(23
M7U6#P:IJ[1\9CL?*L[)C;J\:YD))S21J#2+'4BKMKV?)'A:MW8;=M/6FT4BA
MS4VBD9L4#L+2\U%YPIWFT$W'4JTQI13?.% 7)Z93/.!I0U.PQU%%%( HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBFL^V
M@!U%1><*7SA0*Y)13/,%*'H"XZBBB@844SS!1YF:& ^BF4;OK33 ?13?,IU(
M HHHH **** "BBBE8 JO<?**L5%,NZJ0F7/#]X8;A3G'-?0?PY\0^6(P6KYS
MM!Y,@->@>$=?-O*@W5Y>,H^VB>ME]?V,S[%T75%N;=><UKYW5Y-X$\0?:(XQ
MNKU2W;?"K=>*^ Q%+V4K'Z7AJRJPN2-3J**Y#K"BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH 3=2TRG+0 M%%% !1110 4444 %%%% !1110 4444 %%%% !2K244
M*W2FM2T4 (M+110 4444 %,9J&:FKF1@* $WG-6[2S:X8<5/9Z6UPPXKN/#O
MA9F925H SM#\+M,RG;^E>D^'_"XC"DK6OH'AM8U7*UUEO9I H %065]/TU((
MQ\M: 4+T% &*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI&INXT
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MD?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7 S6OILAN& KFX86D<<5U6A6QC9210!T%GIYVAL5;93#Q5ZQ*>4!4=Y&#R*
M*#1";K4;6JI2R7 @'-9-]K07C- &BUNLG K/OM#W*3MJ72M0%Q(*ZG[.LEOG
MVH \IU&R^SL>*RF;YC77^)X1&S8KC6/[PT 3 9IU(M+0 4444 %%%% !1110
M 4444 %%%% !1110 44NVDH **** $)Q1NH:FT /HHI&.!0 M0LQS0TE2V]N
MTS#B@!+>%I6%=3H>@M,R_+4FA>'VF93MKT_P[X:"*I*T 5?#OA?;M)6O0M+T
MM;=1Q4VGZ>EO&.*OJ .E06+1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% "-TI-M.HH ;NI5Z4VG+0 M%%% !1110 4A.*6D:@!-U.IE/H 8
MZ+(I5AD&O/O''@>'5(WQ&#FO0_O4UXU<889K2$W!W1$X*:LSX2^*GP=^:5EA
M_2OD_P ?> 9=.DDQ&1SZ5^M?C+P?!J5NY" Y'I7RS\5O@^)EE98?7M7UF S'
MI)GRN/R^^L4?G+>6LEG(0013+>4L>:]G^('PUET^20B(C!]*\AO[!]/E8%2,
M&OLJ=6-171\;4I2IO4DHJE'=;CBKJ?,M:;&>X44-\M0RR;5-(![MQ5!O,:0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM+110 4444 %-*BG44 -\L4>6*=13N SRQ3U7BBBD [^&FT44 -V"CRQ3J*
M&^6*/+%.HH ;L%.HHH **** "BBB@ HHHH **** "BBB@ HHHH *;)]TTZD;
MI0!#&NV4&NW\*:G]EF3G%<9C%6K&]-O(O-9U(^TC8THS]G*Y]2^!?$/F+&NZ
MO8M,F\VW#5\K_#W6B9(QNKZ4\*W@N+-><\5\#F%'V<C]&RNO[2&IT-%%%>(?
M0A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% $4TGEJ37#^+M2'E,,UTVL7?DQMSBO*_%>J;MPS0)GGWB:X,DS\US4;$
MM6KJ\WFNQK+C7YJLDL444C=* %HINZG4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% "K0U -(30 A:EII&*5>E "T444 %%%% !1110 4QFI
M6:F["U "QQF1L5T.BZ.TTB\=ZJZ1IK32+Q7J/A?P[G:2M %SPMX?V[<K7H]C
MIZVZ+Q4&EZ:MNJ\5KU!84444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% $4\?F+BN>UKP^+J%AMS734U\,N#T-:0FX.Z,JE
M-5%9GSKXV\&G]X0E>)Z_X?:UD;Y<5]H:[H*WD;_+GBO#_'?A'R_,(3]*^LP&
M.O:+9\;F67VO)(^>)4,;8-+&:V->TE[>9N,<UBA2G!KZV,E)7/C)1<79DM+N
MIBM3J!",:3)I2,T;: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@3"BDW4M PIE/IE #EI:1:"
M<4K@+12;J6F 444A.* %HI <TM2 44450!1110 4444 %(WWJ6DVU(#:?2;:
M6J **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $:JK
M,5F%6ZJR)\X--$R._P# >H&&:/G'-?3O@76 UNB[NU?(OANY^SS+SBO=_ >O
M8\L;J^:S*AS*Y]5E-?DLCZ'@E$D8-2UBZ#>?:(5YS6U7Q$X\KL?H$)<RN-_B
MIU)CG-+4EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 445#-,(U/TH Y/Q9>>2C\UXMXDU,M,PSWKTKQM??*XS7B>N7):X;GO31+
M*LTGF$U&JTR)MU350@I&I:* &4^BB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "DR*6H3)SB@ ;.:T]+LS<.!
MC-06=J;AA@=Z[_PKX=+LA*T :/A?PV6*$K7JFAZ2MNHR*A\/Z*MO&I*UT2H%
MZ"H+%QCI2T44 %%%% ";J-U(U"T .HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH :RAA@C-<=XK\.K>1OA<UV=1S0K,I##-:TZ
MCIRNC&I35169\J>./!QA9R$_2O']8L6M9",8K[/\:^&%NH7(3-?.WC;PBT,D
MA"=_2OM<OQJDK,^"S/ NFW**/)HV-3U)>6IM7((Q519@QQ7TF^J/EMM&3T44
M4AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 444UFQ0 ,:ADD(Z5:MXS,V.M;%GX<>ZP0N:ES4=QQIRGL<UY
MK9Z4]9#79?\ "$R;<[*HW?AM[?)VU*K0EHC1T:D=T8"L:*GFMS$V"*@)K3T,
MMAW\-12,:DC^; K2L](:ZQ@9J6U'5C47+1&)YC>E/60FNNC\&R2+G95>Z\+O
M;@DK4^V@]"_836K,!:&6K-U:FW)R*J>9N;%:;[&>VC#GVHY]*M0VYD[5973&
M;G%+F2'RM[&8":<M77L#'VJM)&4IIIARM;C*5:2E6@0;:2GTR@ HHHH **7;
M24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !497
MFI** 8^VN/)8<UZ/X'UPK-&-U>63,5KH_!]X8[E.>]88BDITV=.%K.%1(^Q_
M =]]IA3FNY7TKQ[X:ZJ/*C!:O6X)Q,H(K\WQ<'&HS]2P513I(GHHHKA/0"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&^Z:P-:O_
M "8VYK=E;;&QKS[Q;J'EJPS0!Q?BS4O,+C->8:E\\I-=+KVH>9(PSFN8F;>Q
MJR"*$8J:F(,4^@!5I:0&C=0 E%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 444R0\4 #-20VQED  IL*F1L5UF@Z
M*;B13MS0!>\+Z"9F7*U[%X;T%88T.VLCPOX?$2J2M>@V<(AB  J"R2&(1+@5
M)110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% %6\M5NHB",UYCXX\(K-&Y"5ZO69K%BMU;GBNJ
MA6=*2:.3$48UH-,^,?&OAMK69R$Q7G[6YAD.:^IO'?A'SO,8)7@_B;P\UG(Q
MVXK[[!XI5(I,_-L=@W2G=(Y99*=5>13')@U,GW:]4\=#J***!A1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\J1<78_3*<N:*8ZBBBH-0HHHH **** "BBB@ HHHH 93EI:* "BBB@ HHHH
M**** "H+QMD)-3U0U>3R[4T <-XHU+:K#->2>(+SSI&YKLO&.H;6<9KS*^NO
M,D/-604)EW/3T&!2=:D6@!**** %6EIM&30 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4RGT4 -6F,^#4A.*@*EGH L00F9@
M!78^&]#:213MK*\/:6;B1>,UZ_X5\/A50E: -GPMHHA1"5KL8XECZ5#96HMH
MP *LU!84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *1J6FM]WB@!F[<<5HZ?8&XD7C-9T
M$;/(!7>>%=*,SIE: -[PGH9#(2M>N:'9+#"..U8OA_11'$IVUUD$?EIBI99+
M1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH 9(V!38SO;%+(,U8TVV,DHXH U-&TLW$BG%>M>$=#V["5K
M \(Z+YFPE:]:T72Q;QKQCBI8&E9VXAA48JS2=!2TBPHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"F,V*?5>7.: +,,7FMBNI\/Z.9)%..]8.C6YFD7CO7K?A'1=P4E: .C\)Z7Y
M*+\M=W&H10!6?IMB+=%XQ6G4%A1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%(3B@!:*;NIU !1110 4444 (>E5KR$30L".U6J1J:T=Q-75CQ3XA>'_.6
M0A:^>O$V@FWF<[<<U]F>(=&%U"YVYKP7X@>&_)\PA/TKZS+<5]EGQN:8.]Y(
M\!F'DL135;=5K7;9H9F&,50M\]Z^Q6JN?#R]UV+"TM%%( HHHI7 ****8!11
M10 4444 %%%% !1110 RE6EVT 8H 6BBB@ HHHH *CD3-244 11YC8&M>SU0
MVZCFLLC%,Y]Z32EN.,G'8ZC_ (21MN-U4+O5FGS\U8OS4Y<U"I16I;K2EN.F
M8R-G-"K2K2UH9@ORU:ANO+[U5IO-#5P5XF@^H%AUJK),7J"E7K244AN38K?-
M46PALU-2$9IB+5G=FW;K6K'X@95QNKG2#2?-4.FI;EQJ2CL;MSK33 C=63<2
M&9LU N:D6G&*CL3*;EN,5*DHHJKB"BBB@!=QHYI**=@"BBBD 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110)!2-2T4K
MC*CR%9!7>^ [PK<1\UP4R_O!74>$93#<)]:RQ$>:F;8>7+51]=_#^_#6R#/:
MO05PRUXCX!U;;'&-U>P:;<^=&O/:OSG&4^6;/U/!55.FD:%%%%><>D%%%% !
M1110 4444 %%%% !1110 44F12T %<UX@N?+1N:Z1ONFN&\77/EH_-- >=>*
M+[<SC->=Z@WF,:Z+Q!?;I6&:YB5O,)K0@AC6IJ8HP:?4@%%%% !1110 4444
M %)NI:90 ^BD6EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI&H :6Y
MI\5N9F%5RWS5T.@V?VB1>*H#8\+Z.6D0[>]>U^%M-$4:Y%<MX5T'Y4.VO1M-
MM_)0<8J&4B\!MX%&12TW^*I&.HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ***3(H 6BBB@ HI,BC(H 6BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHI,B@!:*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BDW4M !1110 4444 %%%% !1110 44FZEH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ***:1B@!U-:G4UJ $I],I] !1110 F12;J&I* 'T4BTM $<B"12I'6O
M,_B!H8FCDPM>G^]86O:<+J-AC.:ZL/4=.=SDQ-/VE-H^.O&7AYHYG(7O7#R0
M&%L&OI'QYX7VB0[*\&\1V?V69AC%?H&#Q'M8I'YICL.Z,VS%5J?MJM#)EL59
M/:O49Y*$HHHI#"BBB@ HHHH **** "BBB@ HHHH ***1J #=2TBTM T%%%%
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M1110 4444 %%%% !1110 4444 %-:G4A&: &T^DVTM !1110 4444 %%%,H
M?12+2T %%%% !1110 4444 %%%% #6I*?2;: %HHHH *1J1J2@ I],I] !11
M10 4444 %%%% !36IU)M% #:5:-M*!B@!:*** "BBB@ HHHH *1J6B@!E*M&
MVEVB@!:**1NE "T4WFG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4FVEHH *
M*** "F21B1<&GT4 <%XZT426[D+VKYB\>Z.8YGP*^Q-?MOM%N1C/%>#>/?#/
MF&1@GZ5])EF(Y'9GRN;8;G5T?-S0&*0\4_=6]K^E&UD;C%<X6VO7W$9<ZN?
M2BX.S)Z*1:6F2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS)&Y[U9!RU]\TAIL*\4Z;YF-)'0 ^BBB@ HHHH **** "BBB@ HHHH ****
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M6YH \K\:7>TOS7DNI76^5N:]"\=7'[QZ\KNI"TQ^M60/ZFA:(_NBG4 %%%%
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 JTZF4;C0
M4444 %%%% !1110 44FZDW+0 ZBF^8*;YPH%<DINZF^8#3@N[I0,3=3#-BK"
MV;2=!3_['E?HM&@K2Z%+[4*59PU7U\-SOT4U;MO"-P[#Y#2<X+J4J=1]#,CC
M,G2KD>EM-_#74Z;X'G9AF,UU^F^ Y.,Q_I7%4Q4(=3OI82<]T>8Q>&9)NBG\
MJO6_@>:3^ _E7M6F^!0N,I^E=3I_@V%<905YU3,E'8]2GE;EN> V?PYF=A^[
M/Y5TVE_#27C,9_*O>;3PU:0@95:TH[.RM^RBO-J9I-['K4LIA'5GD6F_#HQ@
M93]*Z.Q\'I#C* 5VMUJ-E;J<%17-:IXLMK?.' KB>(JU3L^KT:)H6>C6T"C(
M K5C>SM\9VBO+-4^(T4(;$E<5K'Q:,>[$OZU4<+5JDRQE&BCZ&D\165OGYE%
M8^I>.K2%3AU_.OE;6OC)*N[$Q_.N.U#XPSR$_O3^==]+*9RU9YU3.J<=$?4N
MN?$B&,-B0?G7)K\3E>XVB7OZU\QZE\39IE/[T_G69I?CJ6:^7,A//K7J0RGE
MCJ>/4SKFE9'WWX%\5#4&3Y\Y]Z]?M3N@0^U?(?P7\1&X,.6STKZQT2X$UA&<
M]J^1S"C[&=C[;+<1[:G<T:***\D]H**** "BBB@ HINZG4 %%%% ",<"L'7K
MO;;L,UM7#;8S7%>)+O:C#- 'E_C.;S'?FO-YA^^KN/$\WF2-S7%2C][5D$D?
MW:?38_NBG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 +Q0U&ZAC@4 1,U3V\7FL!5.5OFK7T*$S2 4 =/X:T@M(AQ7LGA:Q\
ME%R*Y3PGH^Y4.*])T^S\A1Q28T:-%%%24)MI:** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D;I2TC=* $YHYHV
MT;: %6EI%Z4M !1110!',VV-C7G?C#Q-_9ZN=V*]!O#BUD/M7SW\6M0:&.7!
MQ79AH*<K,Y,1/DC<Y+Q5\7FLI' FQ^->?7WQXE5B!/\ K7D_Q"UR?[5( QZU
MYY"]U>38!8\U]C1P-/ENSY"MC9\UD?2"_'*X;I,?SIZ_&ZY_Y['\Z\=T7PO>
M72 [6-;#^";Q>=K4/#T4["5>LU<]1A^-L^X?OC^=;^E_&B1F7=-^M>%-X3O(
MN=K51NH;S3^?F&*7U6E+8I8FK'<^SO"?Q82X9-TP_.O9?#_BZUOH5!D!S[U^
M9EC\0KK1Y!N=ACWKU7P#\>'6:-&FQ^->;B<M;5XGI8?,DG:1^@L<R3*"C!A4
ME>+?#WXFQZM'&#+G/O7K]C>)=PJRG-?-U*4J;LSZ&G5C45T6JK7TGEPDU9K-
MUIMMHQ]JR6YJ]CSWQAXL.G1N=^,5X9XF^-!L9F'G8Q[UU7Q:OWBAFP>U?%/Q
M-\13PW4I#'KZU]3@<+&JM3YC'8J5)Z'T[HOQV$UPJF?OZU[5X)^(2ZH$_>9S
M[U^5VE^/[BUU!09#U]:^K/@?\0&NI(%:3/XUV8S+5"/,CDP>8N<K-GZ!Z7=?
M:X V<U=KE? -\+W3%;.3BNKKXR<>631]?3ES13"BBBH- JGJ=P+6S=R<5;/'
M-<=X\UQ+/3I1NQP:NG'FDD9SERQ;/+_B-\2QH_F?O=N/>O"=2_:$,5X4%QW]
M:Y'X^>-I(Y+@(Y[]Z^/M5\<7,FI-^\;[WK7W&"RV-2%VCXO&9A*,[(_23P1\
M9SJDT8\[.3ZU](^"=;_M2%#G.17YA?!'Q)/<7$&7)Y%?HA\&;HS6L.3V%>1F
M6%C1V/6RW$RK6N>N.=B$UQ'BK7_L,;G=C%=K<'$+?2O%/B?>M#;RX.*\3#Q4
MI:GLXB;A&YPOB[XL'3V<>;C'O7F.H_'F19"!/^M>=_%'7)EN)0&->0+<75[=
M8!8Y-?98?!4W&[/D*^-GS61],)\<KB3D3'\Z?_PNVY_Y['\Z\;T'PO>7<:G:
MQK:D\$WJC[C?E6CP]%.PHUZS5STZ'XW7!89F/YUN:9\:969=TWZUX>?"-[&,
M[6JE<V=Y8<X88J'AJ,M$3]8JQ>I]C^$_BREPR;IA^=>R>&_&MM?1J#(IS[U^
M:-KX]NM'<9=ABO3/ _QV>.:)&FQ^->=B,L;5XGI4,R4=)'Z'PW,=PH*.#4M>
M#_#OXJ1ZK'$#+G/O7M.FZBEY"I#9KYNK1E2=F?0TJT:JNB_1116!T!1110 4
M444 ,D;RU)KD_$VL&QA9MV,5U=Q_JS7E7Q'NFALY2#VK>C'FE8PK2Y8W/,_'
M'Q6.F-(/-QCWKR;4/CY)YQ43]_6N ^,WB26*XF <]Z\0L;ZZU"^P&8Y-?:8;
M P<.9GQF(QTU/E1]5)\<;B1<B8_G3O\ A=MS_P ]C^=>1:#X5O+JW5MK'(K2
ME\%WB_PM5.A13L"KUFKGI9^-UQ_SV/YU'_PO"YW?ZX_G7F;>#;S;]UJ@_P"$
M-O=WW6_*E[&B'MZQ[)I_QIN)' \X_G7K'@'XB2ZE)&#)G-?+6D^$;Q9%RK5[
MG\,=#N+>6+<#VKBQ-&E&.AVX>M5<M3ZHTF^,UF&SGBN)\=^()-/C<JV,5U_A
MFW;[  ?2N0^(GAV2\L9BH[5\[3Y?::GT%3F]GH>$:U\8);&\*F;'/K76>!OB
M^M].BM-GGUKYJ^+NFW>EWDK ,,&N-\#^.I].U)%=R,'UKZKZC"I2YHGS/UV=
M.I:1^J7AG6H]4LE8,"<9K:W5\V_!SXD)=6<2M+R0.]?0.D:@M] &!SQ7R6(H
MNE)H^HH5E5BFC2HI!5'4M02SC))QQ7,E?0ZF[&;XLUI-+M3E@#C-?/7C3XO"
MQD=5F[^M:?QJ^(2VMO*%DQQZU\3^,/'-QJ&I.J.3EO6OI,#@?:*\CYS'8WV;
MM$^G='^+TMY= "8GGUKV_P !>)9-0V%FSFOC#X3:3=:I<1,0Q!-?9_PY\.R6
M<$3,N.E+'4Z=/1#P52I4=V>M0-NA1O:I#TID*^7$H]J;=7"V\99CBOFSZ+H/
MDD6-<L<"N6\3>++?3X6'F 8]ZY[QMX\CTNWD_> 8]Z^6?B5\;"LDB)-Z]Z]/
M"X.59GFXG&1HH]3\;_%Q;3>$F_6O#_$OQVN(Y&V3'\Z\GU7QU=:[<%5=FR?6
MH[?P?>ZU\V&.:^HI8.G27OGS-7&5*K]PZ>\^/5]DXF;\Z@A^/5_G_7-^=4K?
MX+7UT,^4Q_"IW^!E]&N?*;\JZ;89:&%\3N='I/QZO&D :9OSKU+P?\;'G9 \
M_P"M?/5U\+;[3\MY;#'M64T]YH$@SN&*SGAJ-56B:0Q-:D_>/T7\$_$>&^6/
M=*#^->J66H0WT89'!X]:_-'P3\7YM/FC5Y2.?6OJ+X:_%Y-0C13+DX]:^<Q>
M7RIZH^@PN/C4T9]+T&L3P[K::I""&R2/6MLUX;7*[,]J,N970+TKF/&FJ?V9
M9LV<<9KJ*\S^,-P8=-D(./E_I6M%<TTC.M+E@V>&>/?C(=)FD'G;<'UKB]'_
M &@O/O OVCOZUX/\=O$L]O>3A7(Y->%Z'XVNH]2&7;&[UK[JAEL)TN8^'K9C
M.%6Q^M/PY^)B:MY>90<^]>VV=TMU;HZG.17YK?!?XE/') 'E].]?;GP^\=1W
M]G$OF9/UKYG'8-TI:'TN!Q:JQU/5J*BMYQ<0JX[U+7BGLA4%U)Y<1/M4]4]2
M_P"/9S[4UN)['E'Q#\9G1XW._&/>O&%^-1_M#R_.[XZUH_'[4GMH9L-CK7QT
MOB:?^WL;SC=Z^]?5X/"1J4[L^5QF,E3J<J/TD^&OC ZU'&=^[->L+RHKY7_9
MTU)[B"#<<]*^IU^X/I7@8RFJ=1I'O82HZE--CZ***XCM"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "D:EI&Z4 )S3J;MI0<T )(NZ,CVKRSX@Z3]H23"YKU1JYW7],%S&Y(S7
M5AJGLYIG'BJ?M(6/D'Q=H)AF<[>]<-<1^2Q%?0?C_0?+\P[:\'U^$PS,/>OT
M/!U?:Q1^9XZC[&3*"-FGU6MVS5FO1>AY:"BBBD,**** "BBB@ HHHH ****
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MK.;[U,D<OW:=2+2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?$R2'_A(O^!U]L_M%+F&?Z&OBA$_XJ+_ ('7WN7?P3X/,?XI]S?LSM_H]O\
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MJ]2G1A%;'DSK5)ZW++>)+F3JYI/[7F?J34 M!4BVXK2T>QSWGW%:[=^II/\
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MN:\=7BVNAS G!Q5T]9(SG\+/A#]H';]KG^IKQ+PA_P A9<?WJ]+^/NM!]0G
M;O7F_P .HS>:LG&?FK]"PZY</=GP-=\U>Q]J?!3?Y,/T%?1'/V#GTKQCX+Z*
M5LXFQV%>VW4?E6/X5\?BY*50^PPL7&FKGSY\8O\ 4S?2OC[Q(W_$T;_>KZ]^
M,+?NYOI7R!XC.=5/^]7OY?\ "?/YA\1[I\#;59GBR*]I\?>'A<:"^%S\M>-?
M =_WD0^E?4NHZ/\ VAH9&,Y6N#%3Y*R9W82'/1L?FW\1-#>RUIV"X :O3_@;
MXD.GW$*,V,$5L?&GP3]GNIG\OOGI7D/AO6CHNJ*N[;AJ]N+6(HV/'_W>M<_3
M'P/KR7VEQ?,#Q7*_%;7!96<K!L<5YK\(_B LUC&ID[>M4_C5XL#:;)A^U?-1
MPS5>Q]'+$IT.8^=/B9XK:^OI(]V<G'6H/AQX;.I:A&Y3.6]*X'4M0?4M>*YR
M-]?4GP%\'_:O)<IGOTKZ6JUAZ)\Y13Q%8]A\$^&Q8:*ORX^6OG_]HK$:RBOL
M?^QQ9Z*RA<86OB[]I"3$DX]S7A8&?M*]SV,='V="Q\]^!OF\0)_O_P!:_1;X
M!_\ 'C!]!7YT> ^=>3_?_K7Z*_ /_CR@^@KT,X^$X\I^(]NO/^/=_I7@WQ2_
MU$U>\WG_ ![O]*\'^*7^IF_&OFL)\9]'BO@/C?X@?\?S_6MGX4_\A"+ZBL?X
M@?\ (0?ZUL_"G_D(0_45]G+^"?(Q_C'WC\+?^02O^[7=UPGPK_Y!*_[@KNZ^
M$K?&S[6C\"$R*0FAJ ,UB;#JR/%&/[)ESZ5KUS_C:<0:'*2<<5=/XD1/X6?%
M7QP*?:)\^IKY^TUO^)H,?WJ]9^.FN!;V=0W<UY#X18WVJ+WYK] PL>6C=GP>
M)?-6LCZD^#N[]S^%?7GA;/\ 9JY]*^9O@]HI$<)V^E?4&@P^38J*^4S"2<M#
MZG 1:@:E%%(W2O'/6%HI%Z4M $5Q_JS7DGQ._P"/.;Z&O6[C_5&O(OB@?] F
M^AKKP_QHY,1\#/@OXW2#[5,/<UX7INERWFH#8">:]I^,\A;4)1[G^=8/PM\/
MKJ6J1@KG)K]#HR]G0N?GE:'M*UC1\.>![ZXMU(5L8K5F\ WR_P #5];_  _^
M%D,VFQN8AT]*Z6X^$\!/^I'Y5XD\R2DT>]#+WRIGPW)X%O\ GY6JFO@._P#.
M^XW7TK[G;X2P'_EBOY5%_P *A@W?ZD?E4_VDAO+6?,G@7P=>6\T>Y6ZU]2_#
MG2Y;>./<#TK1TGX:PVK*1$!^%=]HOA]+-1A<5Y>*QBJ'IX;"NF=#HZE85SZ5
MHU!:Q^6F*FKPWJSVH["U%<7"6\99CBI%Z5P/Q$\3KI%K(=^,#UJH1<Y61,YJ
M"NSF/C!XBMQI\J[AG;ZU^<7QZO!=7%QLYY-?0?Q2^*1NII8A+GJ.M?/^L:3+
MXHF8A2^ZON,MH_5US2/B\RK?6'RQ/FRWAD^V@[3G=7U#\"]1%G-!OXZ=:Y^W
M^#,JMYOD^_2M6QT^3PO*IP5VU[6(J0KQY8GC4*<Z,N:1^B7PG\36\EG"NX9P
M*]EMYEGC#*<BOSX^$_Q0:"XBB,O?'6OM+X=^)DU2Q0E\Y%? X[#2I2N?=8+$
MJI&QW=%%%>0>N>'?&O/V>;\:^'?'N?M[Y_O5]X_%^R,UO-@>M?#WQ,L3;W4C
M8[U]=E<E:Q\IF47>X[X;[?M4>?6OM;X1X\F+'H*^"_ >K"#4(USCFON+X(WP
MNHH>?2GF<6HW)RV:O8]\I:2EKY ^M"DW4M,H ?12+2T <YXLQ]G;/I7R7\:E
M7RIOQKZJ\<S"WLF;./EKXS^,^NJ6F7=ZU[N71<I(\3,))1/FK4L_VTV/[U?5
M?[..[S[?/M7RU#']LU;(&?FKZY_9YT\Q2VYQZ5]#F#M1L?.X#6M<^R+;_CUB
M_P!P?RKRSX]_\@5O]RO5+;B"(?[(_E7E?Q[_ .0*W^Y7Q>&_BH^SQ'\)GYM_
M$;_D-R?[U>J? 9C]JA^HKRSXD?\ (:?_ 'J]1^!/_'Q#]:^YJ_[N?#4?]X/O
MWP&J2:8@//%8OQ)\'1ZM9RX3.1Z5=^'\Q6SB'M7:W%LEU&4<9R*^'E-TZET?
M<1@JE.S/S=^,'PZ?3;J618\8)[5YAX7\23:!J2H6*X:OO;XV> 4NK.9UC!X/
M:O@[Q[X9ETG5794( :OL,#B%B*?+(^1QE!X>IS1/LCX'^/A>QP!I,_C7TU'?
M)<Z>6#=5K\U?@_XW;2;J)'<C!]:^T?!?CQ-2TU1YF<KZUXN/PKC/F1[> Q2G
M"S/)_P!H]=T4^/>OB7;CQ%_P.OMSX\ 75G,PYX-?%5Q'Y?B'_@?]:]W+OX5C
MP\R_BW/MW]FC_CWM_P *^M8_N+]*^2OV:/\ 46_X5]:Q_<7Z5\IF'\9GU& _
M@H?1117F'I!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6%XJM_.LCQVK<
MJCJL/G6Y&,\5I3?+),SJ+FBT?+GQ%T@F60[:\<O;,PS-D5]0^/-#\SS#MKP3
MQ1IWV>1^,5]]E]?FBD?F^98?EFV<ANVFGU7D;$F*G7[HKW6?/]1:***D8444
MC4 &ZEIE/H ****L HHHJ $VT;:6B@=A ,4M%% @HI"<4TO0%R1:5NE5VFQ3
M&N:=A<R+--:JXN,U-'F2C8$[B9-,9VK2M]/:;M6C;^&WFQ\M9NI&.Y?LY2V.
M7:5_2E61V[5W$/@>2;'R&M:S^&LLF/W?Z5G+$TX[LUCA:LMD>?6]N\A'%;-G
MHKS8^6O2]-^%\F1F.NLTWX:F/&8_TKSZN/IQV9Z5'+:DMT>2V?A%IL?)6[9_
M#TS8^3]*]AM?!*6^,I6O::/!;]0*\JIF3Z'L4LK7VCR>Q^%N_'[O]*Z/3_A6
MJXS'^E>DPW%I:J,E:;-XHLK?^):X)XZM/8].GE]"GJSF['X=Q0*"4'Y5J1^'
M(+4<@"H;[XA6<*G$BUR>K?$ZW"MB4?G6:]O4>IJWAZ2T.V6:VL^XIDGBZUM/
MXE%>):U\3E^;;+^M<#K7Q.D.[$OZUUT\OG4W.*IF5.EL?2M]\3;6WSB11^-<
MQJGQB@C! E'YU\J:Q\1[AMV)3^=<=J'CRZD8_O&_.O4I9.MV>-6SUK8^J]6^
M,229 E_6N,U?XI&;=B7]:^;Y/%US(>7;\Z/[?FDZL:]6GED8'CU,XG4/6-8^
M($LN[$A_.N*U3Q9<2Y_>'\ZYAM1>3^(TPOYG6N^&&C#H>94Q4Y]1]YKES(Q^
M<_G5(ZE<,>6-6/)#4"W7TKK2BNAR.4I=2%;R4]2:E$SMUIXA4=J=L%&A%F-4
MGO2[0U.V^U+3*0WRQZ4NT>E+12N4)M%+112 **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ ILGW33J;)]TT"9FX_T@?6O9/A3=>3<1<]Z\@V_OQ]
M:],^'L_DW$?/>N?%+FIV.G!OEJIGW1\,]4W6L0SVKU6WE\Q<U\\_#'5#Y,0W
M5[QHLWG0@^U?EV,I\LV?K^ J<U-&I29%+3?XJ\T]8=1110 4444 %8^M2;8V
MK8KG_$4FV-J /,_%-URW->9ZL^YS7;^*+KYFK@+V3<QJR"@OWJF7I4:_>-2T
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4C=*6D:@!C-3HEW\5%)P:LZ>N^0"@#H-"L-\B\
M=Z]A\'V7EJG%<%X7L=S+Q7K7A^S\N->*!HZ6,811[4^D7[HI:@H**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\O\ Q<5O+FQZ&OD3Q,LG]J'C^*OMOXF:*UU'* N:^9M>\$R2:@3Y?\7I7V.
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MWS%59=IK]5?&G@Z'4K5\(#D>E?*GQ2^"[7#2M'#Z]J^NP&/37+,^6QV :?-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO8Y7P/X>&FQH-N,5Z$O2JUO9K;\ 5:K@G+G=SOA'E5@HHHK,T"BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 44G-'- "T444 %%%% !1110 4444 %%%% !1110 4444 %)MI:* "BBB@
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M6MHI:.8.4A52M/5:?12N6%%%%( HHHH **** "DVTM% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !112-0 U6J_8P[W%9R_>%;F
MD1[V6@#NO"=K\R<5[%H:[8!]*\S\*VN"E>I:6NV$?2DRD7Z***D84444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG-!(_*,RI\LVSF=WS5-53=^\JTO2O;9\^A:;M-.HJ2A%I:** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM6Q3JQLR*.%5)W1?4;5 IU%%>:>@%%%% !36IU% #*?2;12T %%%% !1110
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MH **** "BBB@ HHI-P% "T4SS!2A@U #J*** "BFE@*3S5]: 'T4SS!1Y@H
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MZ5R6O>$?L&[Y<5<,7";LB*F#G35V<$O2EJ6ZC\F0BH-U=9Q>0ZBBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,D^[3FIM #+
M=/WPKU+P+%\R5YO91[IA7JO@>'#)Q0![%I*[;1:NU5TW_CU6K506%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9GUL9*2NA]%%%06<[XF_X]Y/I7QQ^T!_JY_QK['\3?\ 'O)]*^.OV@/]7/\
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MA$&*Z[3='BT]0% XKR<3F#J['K8; *EJQFD:+#I]LBA<&KE[\EN<59JIJ/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD^1J[.X_U+5POB9_E:J0F>5^)GRS5P]US(:['Q$WSM7'7'^LS3)".GTR.GT
M%%+MHVT )1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDP?XJW_A&Q-W']:^[DK4#X:,KUS[;^&_^HBKV&'_ %*_2O'/AKG[/%7L</\
MJ5^E?$XGXS[?#_"24RGTW;7$=0JTM(!BEH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZNDXQU%%% !1110)!3J;2[J!@W2FM3MU-;I0!6N>E6-%_P"/H?6H+A:L:/\
M+<#ZT2^$F/Q(]\^&<FV2+\*^KO 4F88Z^2?AM)B2+ZBOJWX>O^[C^E?"YHM3
M]%R=Z(]<@_U:_2BDM_\ 4K]**^./N4%U_J6KS_Q0WRO7H%U_J6KSSQ1]UZ:&
M>4^(#^\:N2N/O5U>O?ZQZY2X^]5$!'3Z9'3Z %7I0W2DHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ)H\>IV+J5YQZ5M8IK@.,'I7D1DXNZ/6:YE9GQE\9OA.;QIG6'/7M7R5XF\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@!DE+;_ 'Q224MK_K!]: .Q\.QY=?K7K?AF/"K7E?AM?F7Z
MUZWX;7Y5XH [*W_U8J6HX?\ 5BI*@L1:6D Q03B@!&I*4FC;0 ZBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA'E88S O$2YHGS;8^$YY,#8:[WP;X5EMIT9D(KUK3_ ,$;#Y!6Z/#4&GP[@
M,55;'\ZY48T,MY'S,;HMX-.L I..*\[^(>N)<,5#9K3\5ZZ-/C=5;'XUXUKG
MB-KRZ(+9YJ<+AW*7.:XO$*$?9G=>!T,UZI]Z]FG@(TL_[M>-_#613*C,:]KO
M+N+^R\9'2L,7?VB1T8&WLVSYN^*2[9I*\RT7_D(CZUZ?\4V$DTA%>7Z.-NH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 R3[M+:_-(*;)TIUG]\4 =YX97YEKUOPZOR+7E'A=
M?F6O7/#Z_*M '5P_ZL4^F1?<%/J"PIK"G44 -YIU%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4FZAJ;0
M ^BBDR* %HHHH **** "BBB@ HHHH **** "BDR*6@ HHHH **** "DW4M,H
M ?12+2T %%%% !1110 444F10 M%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !112-0 9%+3*<M "T444 %%%%
M !1110 4444 %%%% !112-0 FZG4RG+0 M%%% !1110 4444 (U S2T4 %)N
MI::W6@!0<TM-6G4 %-W4ZF4 .!S2TU:=0 444W=0 ZBBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;01FEHI#(6@#4T6X6K%%!-B#RZ3[.#4^VEI[!9$2PA:EHHI#L%%%% PHHHH
M**** "BBF4 /HIJTZ@"*;I3[3_6"F2]Z=:_>%-[ MSTKP1)BXC_"OJ_X62;E
MBKY+\%M_I$?UKZM^%3<1?A7R6:+W3[3)_B1]$6?_ !ZQ?2BBP_X]8_I17P,M
MS](6PZ]_X]VKRSQ=_'7J=Y_Q[M7EOBY?OT(9Y/K'^L:L1_O5N:PO[PUAM]ZJ
M(')TIU-3I3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH CEIUC_K*;)3K'_64 >C>$S\R5ZYH/^K6O(O"O5:]<T%OW:T =/']T4ZFQ
M_=%.J"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M**=P"EW4E%(!=U)110*P44450PI"<4M-:I 56IVZHZ?0 NVDIV136H ****
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M5TMPLY;%!9-]2U--ICV_457W;3BB]]AV:W'4444[@%-:G44@&4^BB@ HHHH
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MEKUSPZW[M:\>\-M\RUZUX;;Y5H [:+[@I]16YS&*EJ"PHHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?'G[LWXU\Q:3_P AU?\ ?KZ=^/'W)OQKYBTO_D.+_O5]Y@_X)\+C?XR/N_\
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M8Y@PKZ'EY5H?,N?-JR5>E+0.:*07"BBB@84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 48S12K0!!<+4NE_P"M%1W'2GZ7_KA5/X25\1[+
M\/?]9%7U=\-U_=Q?2OE3X<I^^C_"OJ_X<KMCCKXC-.I^@9.MCV6T_P"/=:*+
M3_CW6BOB3[Y;"W'^I:N!\3+\K5W\_P#JVKA_$J?*U- SQ_Q$N':N0N/O5VOB
M1?G:N*N/]815$A'3Z9'3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6PKH[GJ4<4JVQZ-13(6W1@T^O/.\**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK4ZDVB@!%IU)M%+0
M!E>(&VV+_2OF3XJW6WS>:^F/$S;=/?Z5\G_%RZVM-S7O96KS/G,VE:!\[>*Y
M]]P_-<7-R]=)XBGW7#\]ZYMN6K](HJT3\KK.\B6/[M%(C<4M:F(4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%1N^* $D)7I6EX
M?DD^U+UZU6M;?[2P&,UVWA?PRSR(VVLJLU&.IM1IRG)-'KWPV4R1Q[J]6?3;
M>6W^8#.*\S\+QC2H5)XQ5W6?'RV<9'F8Q7R%:G*I4]P^THU(T:=IG:6F@V33
M<A>M:&H:3;0VI*!>E>(+\7%AN,>;W]:Z73_B4FJ($\S.1ZU,L+6CJRH8NA)-
M(Y3XC,T/F;*\.U"\F^U')/6OH_7M)_MN)G SD5X_XL\)&RD9MN*]S!U(I<KW
M/ QU&;?,MC-\.ZT89%RV*];\.:\EQ&JLPKY\:<V<V <8-=-H_BHV>WYL5U5\
M/SJZ.3#8KV;LSZ#>&VFCW?+FLFYO$MI,(:\_L_B!O4+YE7[?5'U!P0<YKS/8
M2C\1ZWUB,_A/1])N%NP-W-.UJS"6[,H[5A:'.UOMS74><M]'L-<<ERRN=D7S
MQL>+>*FN6D95S7"W6BW%XQ)4FOHN\\%QWC%BM55\"P1G!45Z,,9&"T/-J8*=
M1W9\X-X5G0D[#43:4]OU!KZ8G\ PM&2$'2O/O%WA,6:L0F*ZZ6.51V."M@'3
M5SR;=MI-PI^J1F&8CIS4$+9KT^ESR]G8EHHHH&%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% %>XZ58TD?OA]:KW'2K&D?Z]?K3?PD
MQ^(]N^&\?[R/\*^KOAY'B*/Z5\M?#5/WD5?5OP_3]U']*^&S1ZL_0\G6QZM;
M?ZE?I13K?_4K]**^,/NUL+-_JS7&^(DRC5V4GW#7*>((\QM30SQWQ,N&>N$N
MN)#7H/BI,,]>>WW^L-40+']VGU''TJ2@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** $:FTYNE-H O:;)MF'UKU?P5+G97CMG)MF%>K>
M!ILLE 'M.G_\>ZU9JIIAS:K5NH+"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ INZE:FT /HI%I: "BBB@ JK
MJ7_(/G_W35E:JZG_ ,@^?_=--;B>Q\)_M,?\?$WU-?-O@U0VN+G^]7T?^TTV
M)Y_J:^:/!\A_MY?]ZOT+!?[N? 8S_>#[_P#@9;0M9P94=!7T5;PQI"H51C'I
M7S5\#IF^QP_05](Z;(7MQFOC,9?VC/KL&_W:+>T>E&T>E+17GGI!1110 E(S
M!5)/0"E8[5)KG?$6O+8V<OS8XJHQ<G9$RDHJ[/$OCMXE%G#. ^.#WKX,^(7B
M9]0U"1-V>:^B?VA?&7F&=0_KWKY/MH9-9UC&"V6K[S+:*A3YF?"YE6YZG*B]
MX?\ #\M_('V$Y]J]1T#P_<6BKA2*[OX5_"]KZUC8Q9XSTKUNW^%?EJ/W7Z48
MC&14N4,/@I<O,>'"WNMF/FI%M[I?[U>\?\*S.W_5_I1_PK$_\\_TKA^M0.SZ
MK,^=M4TNYNHR"":\U\5>$YHPSE#^5?:)^%^[_EE^E<GXV^$Q73Y'$7;TKIHX
MV,78YZF"E)7/B33KN32=14?=P:^N_P!G_P 7&22!6?T[U\S_ ! \,OH^I.0I
M&#Z5V?P7\3-I]]$I;'([UZ6*@J]&Z.#"R="K9GZE>&;Y;S2XB#DXK7KR#X6>
M,%NK&(%\\"O6;:X$\085^=UJ;A)IGZ!1J*<4T3T445@;GG?CW_4R?2OCOXQ?
M>DK[$\?-^YDKXX^,+?--]37T.7;H^?S#9GDGAG_D+)_O5]P? +_50_05\->&
M9/\ B;I_O5]R?  YAA^@KT,R_AGG99\9]#T445\<?8C1VK/US_D'/6@.U9^N
M?\@YZJ.Z)ELSY:^+W_+;\:^6-<_Y"1_WJ^I?C W^N_&OE76Y/^)D?]ZOM<O^
M ^,QOQGL7P?_ ./J+ZU]N>!?^0.GT%?#_P 'V_TF+ZU]P> _^0,GT%>/F?Q'
MLY;\)N:C_P ><GTKYD^+W_+?\:^F]1_X\Y?I7S'\83@3?C7%@?C.K'?PSY/\
M28;46SZUZ?\ !^&)KJ+=CJ*\F\5W'EZ@WUKM_A;K@M[J/+8Y%?7UHMTM#Y"C
M)*J?H'X'BBCT6,QCG S725Y3\._&2+IJJ7!&!78MXPB7NM?#U*<N=GW%.I'D
M1T=%<S_PFL/JM)_PF\/JM9>SEV-/:1.JHKEU\91/T9:NVWB!+@C#"ER2'SQ-
MNN4\7'_19/I72PSB5<BN:\6K_H<A]JNE\1-3X3XG_:"^]-^-?.'A7_D/+_OU
M]%_M"-AIOQKYN\*R?\3Y?]^OT#!_P#X+%?QS]%?V<^+.#Z5]!+TKY[_9O/\
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M*LD?EDG=BK3J1:6J8!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\@&!Z5W-O;B%< 5\?BL0ZTF?5X7#^QBB:BFK]XTZO//1"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#F/'$PCTIA[&OASXV77[^;GN:^SOB+>>78R
M#/8U\._&.?S+B;ZFOK,EA[USXO/I^[8\-FDW71^M78_NUG-_Q\&M*/[HK]!>
MQ^91U'4445)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>$G=G'^'?#(TZ-0%QBNM@C\M<4_:*7I7-*3D[LZ(Q459"T44F14E"T4W=3J
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M&F>,^'_A6EFRYB_2O2]#\.0V*CY,5NA%7HH'X4^N2=:53<Z:=&-/8:JA1@#
MIU%%8'0)M%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 @XJ*XD\M"
M:E:L_5I/+A/TJHJ[)D[*YYC\2]0_T>09[&OB_P"*=QYEQ+SW-?57Q-U#]U*,
M^M?(GQ$F\R>3ZU]QD]/EL?GN>5.:Z/+67_2#]:T$^[5+;^^/UJZOW:^TD?!1
M'4445!H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M"K2[12+2Y% #&J-@>U2T4 )#,\; YK=TW6GAQEJP6IOF%>E3*"EN.,W'8[@^
M)SLQNK'U#6FFS\U<[Y[^M*)"W6LU1C'4UE7E+06XF>1CS42*:DZFG 5L8[@J
MU<L[CR6!'%50,4,2.E+?0%IJ=%'K3+'C=6;?7YN.^:S-[>M/4ENM1[-1U1;J
M.2L0M'ELU(I*]#4FVF[16AG8O6-^\+#YJZ"#Q$5CQNKCF8K1YSUG*DI&L:LH
M;'0ZEK+7&<-6#+(\C9)IJL6ZT[:*J,5%$2FYN[!:6BBJ$%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!3OC\IJ]X5^:^3ZU0
MOS\IJ]X0.Z^C^M.7P,5+^(CZ_P#@O;[EAX]*^K-#A\NS7Z5\R? ^WWQP_A7U
M-81^7:H/:OR[,Y?O6C]?RB-J*99HHHKQ#WPJ"\7=;N*GJ.;F%OI0!X[X\3'F
M5XUJ?^N;ZU[=X\CX?BO%-4C_ '[?6J0$,/W:FJ*'I4M,@***5: $HIU-H **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:WW:=2-0!&G^LKIM!FVNO
MUKF/XA6UI,VV1: /9/"]QD)S7HNGMNB'TKR;PG<\IS7JFDMNA'TJ"S0HHHH
M**** $R*6F4Y: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "FM3J* &4^BB@ HHHH *3(I&I* '9%&13:* 'TUJ5:6@!E.
M6C:*6@ HHHH **** $R*6F4Y: %HHHH *93Z* $7I2T44 %)D4-3: 'TUJ5:
M6@!JFG444 %%%,H ?135IU !1110 444UJ '44RGT %%-:DH ?13** 'T444
M %%%% !1110 4C=*6B@!-U+110 444UJ '44U:=0 4444 %%%% !1110 4RG
MT4 ,IRT 8I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I,BEIE #Z*:M.H *3(I:*
M"BBB@ I,BAJ;0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *P_$DWEV[?2MRN4\;3>7:O]*UI*\TC"L[0;/ /B=J'$@S7RUXVF\R:3ZU[W
M\4=4^:49]:^<O$EQYTS<]Z_1LMI\L4S\OS6IS2:.3Q^^S5M?NU7_ .6E6/X:
M^B9\LA<BEIE/J;%A1136H =135IU !13*<M "T444%!11102%%%% !1110 4
M444 %%%% !1110 4444 %%%% !3=M.HH ;L%-VBI** &*M.7I2T4%!11102-
MVBGJM)10 ZFT44#N(5W4FP4ZBG<0NVCBDHI %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 444UJ *E\NY:TO!D).H1_6J%P
MNZNC\$6NZ^CX[U-1VIL=)7J(^R?@3#^ZAX]*^FH5VQH/:OG3X(0[8H?PKZ-C
M_P!6OTK\KS%WK,_8\K5J"'4445Y1[(4R3_5M]*?37^ZWTH \O\<0[E>O%]8A
MQ.U>Z>,H]RO7C6NP[9FJQ,YY1MIX.:'&TTBT$CJ***  M3>:5J;0 Y>E+2+2
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 *M+3:-
MWO0 444NV@!**5EQ24 %%%% !2K24HXZT +12;J-U "4JTE*#0 -TI*7=24
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MHW4 YH -HI:** &4]13=M.H 5NE)2[J2@ HHHH **** "BBB@ HHHH ****
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M5DZU9)+D4M-6G4 (W2DVFG44 (O2EHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;@*=YPI"%IE.R*3B@:'44F12TT4%%%%# ****0!1110 4444 %%%% !1110
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M9!9I5I*5: %IM.IM !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM[:DI,GI&Z4M(U8'H";J7=3:5: '4444 %%%% !1110 4444 %%%% !1110
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M10 4444 %%,IRT +1110 4444 %%%% !1110 444W=0%QU%,IZ]: "BG4C4
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M_B_K7WU!^TH:GPE9>SKZ'Z=_ G4OMFEH"<Y7^E>M3?ZF3_=/\J\%_9QN"]C
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M:N[C;=&#7@GPWU[SEC&[TKW/3Y/,M5:OE:T>5G[!@:WM::+=%%%<YZ04444
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M[*?0U\5S<L[GV=N:%C\XOV@/#+6]U,P3N>U>&^#]6;1]83)VX:ONGXZ> 3J
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M9($SZ5U-<YX7MC;Q(,=JZ.O@:GQ'W=/X0HHHJ#0**** "BBB@ HHHH ****
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M#Y=NOTKQ?X8Z3^YB.*]VTB#R;<#':OS/,*G--GZOEM/E@F:5%%%>,>\%%%%
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MQE;&+/I7I<?^K7Z5Q/@VQ-O:QC':NWC^[7Q-9WFS[.BK1'4445B;A2-2TC4
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MKJ0;R^_I7T9\,_#36<<65QQ7N8ZO&4+(\3!47&>I[EX5^6U ]JWJR=!A\FW
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MHUT+FU!SVK2;I7(^!;[[3:ISGBNNKYJ2L['ZO1ES03%HHHJ3<**** "BBB@
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M/\-XX;@-Y7?TKV4Z?">JTY+&).BU/UF5K!]6C>YE^']%CT^W7"XQ6W_%35
M I]<DGS.YU1BHJR"BBBD4%%%% #67<I'K7$^)O"L>H;LIG-=Q3&B5NHS6D)N
M#NB)14E9GAEQ\-8UF+"+OZ5T&@^$_L3+A,5Z:VGPMU6A;&)>@KHEB)25F<\<
M/&+NBMH]N8(P,=JT3TIH0)TIR]*Y'J=459"UBZYIXO%8$9K:IK(&ZBA.SN#5
MU8\HU+P.EQ(3Y>:?I?@E+=P=F/PKT]K.-NJTJVL:]%KI]O*UCG]A&]S&T?3!
M;*O&*WEZ4BQJO04ZN>3YC=*P4445)1%(N48>HK@?%'A8:@S93.:]#J)[=).H
MK2$W!W1$XJ:LSQ:W^':)-N\O]*[?0?#HLU4!<5U_V&+^[4BP(O05K.O*>YC&
MC&.Q':Q>6@%6*0#%+7,=(4C*&ZC-+10!0OM'MKZ,J\8Y]J\X\6?#FWN@VV('
M\*]5%1S0),,,,UK3JRINZ,9TXSW/E37_ (1AF;;#^E<==?!V4N<0G\J^T)-#
MM9OO)5=O"UBW6/\ 2O2CF$HGGRP$9,^-K?X.R[AF$_E78>'OA&(W7=#^E?3*
M^%K%>B?I5B'0K6'[J42S"4D$<!&+/.?"OPWM[?86B'Y5Z-8Z':V* +&,BKL<
M*0C"C%/X->;.K*;U9Z,*<8;"*H7H,4ZBBLC4*:XW*13J* .,\1: M]NRN:XM
M_A^AFSY??TKV)HD?J*9]CB_NBNF-9Q5D<\J*D[LX+1?":VF/DQ7:Z=;BW4"K
M:VZ+T%.V;>E9RJ.6YK&*CL.R*6FK3JR+"F2QB5"II]% '*ZYX4AOE;* YKSG
M5OA;!-*6$(_*O;V4-UJ&2SBDZK73"O*&QSSHQGN>,:-\.DM)01'C\*])T/21
M9QJ ,5NK8Q+T6I5B5>@I3K.>XX4E#851\N*;)"DBD,H(I_04M<YN<KK_ (1M
MKZ-CY8.:\C\4?"J*=G*P_I7T*RAA@U6FTV";[RUTTJ\J?4YJE"-3<^.-8^#K
M,QVP_I65!\'9=W^I/Y5]H2>&[.;JGZ5%_P (K8C_ )9C\J]!9C)*QPO+XMGR
MYH/PAVR*6A_2O9/!_P .8+783$!^%>C0Z#:0_=3]*OPVZ0KA1BN6KC)U#HI8
M2-,K6.DP6,85$&:N]!2T5P7N=X4444 %%%% !129%+0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%(U !NI:93Z "BBB@#F_%NHBSMG.<<5\F?&;Q
ME\LR[_7O7T%\7=7^QVLV&QQ7P/\ &+QENN)EW]SWKVL#1YG<\',*W(K'C_Q%
MU/[9<RG.>37F\4?[XFM_6-2^V3,<YYK*2/#$U]9!<JL?%R]Z5R=?NBANE"]*
M6J$,IR]*6B@ HHHH **** "BBB@ HHHH *7^&DHH 7^&DHHH **** "BBB@
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MW-2*S5-Y:^E+M% )-#%SWIX%+104%%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH/05FZ7:HJ@@5KKTKRZU1U)79[%"DJ4;(6BFM3JYSI"BBB@ HHHH *;MIU%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** *FH7 MX2QXKQOXG^-$M[&5/,QP>
M]>D^-M16QT]CNP=M?%/QJ\?&&2=!)Z]Z]#"T?:,\W&5O9Q/&/C7XE-]/-A\\
MGO7S?>2-)=,<]Z[KQAXB.H7$GS9R:XAH]TF:^RHQ]G&Q\+6G[25RS"/D%24V
M/Y5%.K8P"BDW4 YI,!:***$ NVF2':*?NJ.8_*:8$"3;I@OO7I'@CPY_:DB#
M;G->76__ !]CZU]'?!.Q6XEB)'I6->7+&YT8>//*QW?AOX1)<6ZLT7;TK=;X
M26T/6(?E7KNCQP:?IJL0!@5P/C'XA6NFS,N]1@^M>$JM2;T/H'2ITXZG/+\+
M;3_GFM2_\*IM-N?+'Y5FP_%ZU9L>8OYU?_X6U:^7_K%_.K:JF5Z)SWB#X;6U
MO&Q" 5Y%XJ\.QV;/@8KUOQ!\2K>ZC8"0'\:\B\5^(X[QGVG.:[*//U.*M[/[
M)YSJ40A8BLU9/FJ[JDQE8XK,0'=TKU(['E/<N;N*2FK0S<4"'45"6-*I-.P$
MM%(M(U(!V12\569V[5&TC^E.P%QF%%4E=R>E3QL>]38":BE7WIK4P%HJ%F-)
MEJ+ 3;A1N'K59F:H]S^E.P%S=[TZJJ%JL)TI /W4;J2B@ HHHH =_#4;2=LT
MZ0X6L\S-YP ]: -FSM3<. !FO1?!O@M]0=,QD_A7/>!])-]-'E<\U]7_  I\
M"QLL3,@_*N'$5O9H]##4/:,X>/X3 6>\P]O2O*_'WA4:5OPN,5]WZMX>@L],
M;Y0.*^2OC;$D<DP4>M<>'K.I([<1AXTXW/FR>3;,5]ZGC;<M4+QO].;ZU:C?
M"5[1X87#$+3M)B:XN0.O-.6(W' KL/!GAMIKQ"5[U,I**'&+DSMO!/@4ZA&A
M,><^U=GJ'PO$-J6\O''I7HOPQ\-QPV\>Y>PKOM?TF!;$X Z5XD\0^<]ZGAER
M79\6>)O#7V%V&W%<#?P^2Q%?07Q'L$C>3 KP;7EV2-7J49<R/(K0Y692ODU)
M5:%N:LUU,Y@HHHI ,HI=M+MI, !S2TBTM,+A1110 UA4;*:FI&H J/&WK5>2
M&0]ZTN*7:/2G<5C'\B5>YJU;/-"P^8U>VCTII4#I3N%C6TW7)K9A\YKJ;'XA
M2V>,RXQ[UYZS%>E9.J7$J+\I-9NFI;FGM'#8^F?!?Q==KB-?.[^M?5OPI\=-
MJ*Q?/G.*_-'P'<7$FH1C)ZBOOC]GW39KA8"V>U>1C*,(*Y[F7UIS=C[,\-WI
MN+=2:Z*N;\-V+6]N@/H*Z2OE*F^A]C&]M0(S2T45F6%%%% !1112U ****8!
M112-0 9%+3*?0!#<1K)"X([5\\_&+1UDCFPM?13]*\A^)^G_ &B.7C-=6'E:
M1Y&94_:46CX6\7:3Y=X_R]ZP881'[5ZOXZT7R[B0[:\TO(O)8BOJJ<N:)^-X
MFC[.HR)0*=44;9-2UH<R"BBB@8^FM244 -:BBE6@:%HH7I10(**** "BBB@!
M](U-HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *,BBFU+ =12+2T@"BBBK *C9=N:DIK]Z ([>\:&<8..:]
MJ^%WB!HYH@6[UX:R_O :[;P?JOV*9/FQ6-:'-$[,%6=*HF??/@/7EFLT!;M7
M<Q2B1<BOF7X<>,@RQ)O_ %KZ!\.ZA]LA4YSQ7RU:FX,_7\!BE6@D;M%%%<Q[
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %5KJ\6U4DFK-<)X^UT:;;R'=C%7&/,[$2ERJYQ7QB\8+#93*'[>M?GM\9O
M%3W%U-A^YKWCXR?$?S!,GF_K7R#XVU;^T+ASG.37U.!H<JNSX_,<1SNR.0>\
M:XF.3GFK"H.M4[>/$F:O+7NM'SR%HHHI#&[32KWI:* "BBB@ J.;[E25#-]V
M@=RE;_\ 'XGUKZ<^!8_>1'Z5\QVO_'V/K7TW\"S\\0^E<N+^ ZL'\9]#ZY?O
M;:*Q4]%KXS^,WC.ZM[R4*[#D]Z^UM4TA[[12 ,Y6OD?XO?#>XO+N4B,GFO.P
M;CS>\>GC(S<?=/ K?QY?"3F1NOK6FOQ O,?ZQOSK0M_A+=>8?W3=:TQ\);G;
MGRC^5>W*5(\'DJG/+XUN9N"[?G5NVU*6^QDDYJS=?#V>SY,9%/T_2C:2 ,,4
MKQMH-*2^(F326F7.,U6NM+:'G%=UHEFEP N,FMRX\$O=0EE3/'I6'M+/4W5-
MR6AXRV5.*<BF2NL\0>$Y-/8DIBLW2=,:XF";>:UYDU<RY6G9F?%I[2=JG_LP
MJN2M>EZ9X'>2W#^7Q6;KFB_85(*XK+VJO9&_L6E=GG-Q'Y1J*)3(V*U+JW\Z
M0J!6OH'A:2ZD4[,UJY)*[,.5MZ%'3?#[WF/ES716_P .Y)ESY?Z5Z3X7\$^4
MJETKOK+1[:W0!@M<4\19Z'?3PZ>Y\Z7GP]DMU)\O]*Y;5-):Q8\8Q7U;J^BV
M]Q"0JJ:\K\6^"VEWE$JJ=>^Y-3#\NQX6UUM?%7+9?.Z5=USPS-9S$E"*?H-B
M9)E4CG-=C:M='#RN]F)'I+2<@5(FBNS8VUZGX?\ !;7D*D)FM23P"T# F.N?
MVRV.I4':YY?8>#GN\?)^E7IOAY)''N\O]*]AT'0(K<@.HKJ_^$?M[J#"J":Y
MY8AIG3'#)H^4]0\//9L<KBL>1#'Q7T3XL\!G:[+'^E>,^)=#:Q=P5QBNNG54
MSBJ4G YD-3J@SB0BIEK<YQ:1FVTM13<*: %#>9Q6CIF@O=S A<UF::OG7"CW
MKVOP!X86Z16*?I652?(C2E#VCL6? .A"QDC+KBOJ#X<ZE#;I&N1FO%KS3QI%
MON QBI_"?C1H;Y8]_>O)JQ=57/<HR5%I'T]XBO!-IS;3_#7QY\;<^9-]37TO
M:ZL;_222<_+7S;\;EV^:?K6.%7+.QMC'S0N?,5Y_Q]M]:5I-JU%?3#[<P]ZO
M6=BUYC S7T>R/E]V:?AFW^V7*C'>OHKX=^$0ZQN4KR?P/X9=)HV9>,^E?2/@
M^2+3[5-V <5YF(GT1ZF&I]6=SI,:Z3;J.F!4>L:\)867=6!K/B1?+PK5R\FL
M/-GFO+5-O5GK2J6T1RWC_P#?>8?:O O$R[9GKW?Q8_F0N3Z5X7XH_P!>U>QA
MSQL1O<YJ'[U6ZK0]35FNYG %%%%( I?X:2B@!VVDVTE% K!1111:PPI&I:*
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M HHHH **** "BBD)Q0 M%-W4Z@ HHHH **** "BBFL=JDGTH CN)EMXV=C@
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ML"#?GBOF,33<97/UG*L9&K346SM**:IW*"*=7 ?1A1110 44F11D4 +1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 44F12T %-:G4UJ $I],I] ";J,BFTJT .HHHH 2J&L7RVMG(2<'%
M6YY!#"SGL*\B^)GCE-/MI5\S'!K2G!S=D95)J$;L\A^.7C?[*LP63U[U\/\
MQ \9O>7D@+YY]:]7^-/CS[=+,!)GKWKY=UJ^>ZO&.<\U]A@Z"C&[/A\=7<Y:
M$EQ)]H;=UHBCVTRV&5%3UZAY(4444 %-VFG44 -VFE^[2TUJ %W4M-6G;30
M5'-]VI*CF^[0!0M_^/M?K7TS\#C\T7X5\RV[?Z6OUKZ?^ \?F/#^%<N*^ Z\
M'\9[_P"(+J2/16VG^&OBSXT:Y=1WTV&;J>]?=^H>'S=:*>,_+7R9\7OAZ]Q>
M2GR\\GM7FX.<8RU/5QD)..A\OVOB"\\X_.U:J^(KW'WF_.NP@^&,BR9\O]*U
M%^&<FW_5_I7N2J0/!5*H<%'K5S+]XM^=)-=.RY-=Q-X!>W_Y9UG7/A-^0%I*
M<>@>SDMSG--F>250.N:]N^&>FS37$1YQD5PWAOP7(UTN4[U]&?#GPREC#&S+
MC%<F(J)+0[,-2;>I[U\+84M+6/S/3O75^,;JWET]U0C.*\IF\61Z';[5?;BL
MR/XA?VG(8_,R#QUKY]TI2ES'T:JQC'D/%OC7I<TDLS(#BO M,M98=6&_/WJ^
MSO%7AM-:M'?;N)%> ^(O!9T_4BX3&#7M8>HN7E/#Q-%\W,CVKX*QQM:QYQTK
MK/B=^YTJ39Z5YE\,]8&FA$+8KT3Q!<#7+%E!W9%<,TU5N=U-ITK(^*OB'?7'
M]H2#)QFN,^U2&,YKZ$\;?#.2YN'D\O.?:O.;[P#) 2OE_I7MTZD;(\*I2GS-
MG$Z#>2"_3'K7U[\%II)((LYZ5\_>'/A_*]XA\OO7U-\*_#9TVW0E<8%<^*J1
M<=#KP5.2E=F_X\C_ .)<Q/I7A=EA=:'^]7M?Q(O5AL'7/:O"--N/.UH8/\5<
M=%7@SLQ#]]'T=X5F*Z4,'^&O&/C=?2+'+@FO9_",.[25_P!VO&?C=;[8Y?QK
M.C_%-*]_9'RCJ5V\FI')[UZA\.9"KQUY=J2@:DWUKU/X:Q[I(Z]FM\)X-'XS
MZ$T*Z?[&O/:N;\9-O5\UU.AVW^ACZ5S/C.+:KUY$/B/9E\)XCXB0>8]<C+_K
M!78>(O\ 6/7(2_?->Q#8\:6Y5N*Z/P2P6^CSZU@RQ[JT]!D^S7"GIBJEK$F.
MDKGV)\,YH&M(P<=*ZOQ-8)=6K;/2O O _C3['&@+XKTZ#QU#<0@-(.GK7AU*
M<E*Y]!3J1E"S.(UWP6UU=$E>]=7\/? 0AN(R4[^E.F\2VC/DLM=GX&UVVFN$
M"L*<Y2Y0ITX<YZSHOAX1Z:%Q_#7D/Q6\*B99#MKZ!TF:)M/!![5Y-\5M0AAB
MER1WKSJ,GSGIUH1]F?(NJ^&4M;XG;WKNO @2WD0=*Y?Q5KD7VQ]K#K46@>)E
MMYE.['->W*+E'4^?BXPF?2,$2W5CC.>*X3Q!X-6\G)V]Z31?'D2P@-)6M%XM
MM;B0?,#7$HR@]#T)2A46I7\,>!1%(OR?I7J.G^$P+8?+VK&\.ZQ;2;<$5Z'8
MZE#Y'4=*Y:DY=3JI4XI'D?CCPN%AD^7M7S/X\T40S/QWKZ^\>:A#Y,G(Z5\K
M?$:\C::3![UWX63/-Q<8GCMQ!Y<AJN&YJY?2!I&Q5+;7M1/#>Y)12+2;30RR
M3(I&I**" HHHH **** "BBB@ HHHH *:S<&E:H@W.* *<T!DF7CO7M/P7T<R
M7\.5[UYII>FFZG7C/-?2OP2\,E;F [.]<V(J*,#LPM-RJ'VG\$]%$=A"2O:O
M;54*N!7 _"NQ^RZ:G&/EKT"OB*\N:;/OZ$>6""BBBN<Z HHHH **** "BBB@
M HIE.7I0 C4E.(S1MH 6BBB@ HHHH Y_Q1:_:8&&,\5\X_$CP[_K#MKZENK<
M31D8KR3XC:&&@D.VNW#SY6>#F6']I!L^*/%5E]FF<8Q7)J_[PBO2OB18^1<2
M\8YKR[<1,?K7U-+WHGY#BH^SJ6-!?NTVE7I1MJC&XM%%% @HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&I*=1M% $<B;J;&OE
M,#4U,F^[03;J=5X7\1-9W"#=CFOIGX6^,C)Y2EZ^.+65HYP<U[#\.?$AM)(\
MOBN#$TE)'T&5XQTII-GWEH^H)=VB'/-:&>M>1^!?%RW%O&N_]:]4L;@7$ (K
MYN<'%GZSAZ\:T4T6J:U.I",UD=@VBG;:-M "T444 -:DIW44;: %HHHH **:
MW6A>M #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&I:*
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M_K7BQP\HO0]V6)A.-F;$/AJV5ONK5_\ X1ZVV?=%<6OCI?[]2?\ "?+M^_\
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MCO71Z!?_ &-EYQ7I5%S1L>73]V5SZ;T76(ULP-PZ5S/C#5$D5L&N#M/&1CA
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $;I2;:=10
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN?:@!**** "BBB@ HHHH *1NE+2-0 VGTRG+0 M%/I&H ;5>Z;:N:L55OO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK&IS[5%'$RI.S/?J4(8B-X'Y/>*O"%Q8S/\ NR.?2N->WEADPP(K] ?B/\#
M1*ZP^O:OF#QU\,Y=+D<B(C!]*^EHXJ-1'S>(P<J3N>40MM7DU+N'K4.IV<UE
M(5*D5#;R,W6NWS/.\B]NHZFHU-/I#"BBB@ HHHH *7=244 .W4VBBDP"E S2
M4JTP#C\:2G<4V@2%W4;J2BAC"BBBDBD%%%%,D**** "BBB@ HHHH ***1J '
M;J-V:@8FE4FG8"6BBBD 4;_>FM4#LW:D@+&X>M+5/<_K4R$]ZJP)DU%"]J5J
M18E%1-FD4F@@FHI%I: "BBB@!?6DHHH+$:EI&%+00%%%*M "\4C4O%(U D)1
M110,**** "BBB@ HHHH **** "BBB@!-M+110 Y>E#4@:@MQ0!&S4R2/SEQ3
M9VVU<TF'[5*J]:/,-]#:\#Z&TU_&<9^:OO#]GOP[Y:P$KZ5\S?"WPF;BXA;9
MGFONCX,^'OL<,.5QP*\''5=+'T.6T?>N>\:7;BWLHU Q\HJ]4<*[8U'M4E?*
MGV*"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 UOF
M4BN0\3:.+J%_E[5V-07%NLT; ^E5&7*S&K352-F?'_Q1T#[/YIVU\V^(E\FY
M8>]?:?Q>T?\ =S87M7R!XRT]H[M^.]?382?-$_)L[H>SGH<[:MNQ5FJUNA3B
MK->@?,K8*1J6B@H;3J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ H/-%% $;H ,TRVO'MY@0:G;D&H##\V:"7=.Z/
M7/AWXQ:SDC#/WKZI^'_CA;B&-3)^M?!.G:DUE(I!Q@U[-\.?'3PS1@O^M>7B
M</S*Z/K\IS)T9*+9]SVEVMS&&4YJ?[M><> O&"7=N@+YR/6O0X9UN%RIKYZ<
M7%V9^G4:L:L5)#Z*?2;14'3<%I:**!!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&?#[:E,F%SDUR-K"9+I1CO7T-\'O#(O)(25STK*M/DC<Z*%/VDK'?_"GX?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4U>M.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M&[J/O4E.6@ 7I2T44 9NO0B:P<$9KY?^*WATS-*0M?5=XGF0LM>4^/?#8N(9
M&VYKKP]3ED>)F>']M3/AK7M'-K</E<<US\C;#BO8OB+H7V620[<5XS?L8[@B
MOJ*4N97/R+%TO8S:)D;=3JBMVW+4M:G)T"BBB@ HHHH **** "BBB@ HHHH
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M\P?6K86D(S2T4AC0,TZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@!",UC>(--6ZM'X[5M5%<+YD+K[4T[,B45)
M69\D_%S0=OFD+7S%KU@8;IN.]?<OQ.\/FZCE.W-?*_C7PR;>9SM[U])A*JM8
M_+,ZPC4W)(\VA&T5-1>)Y#$5%$^ZO3/D-G8EHHHH*"BANE-H =1110&X4444
M!L%%%-H =12+2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***9)*L8RQQ0
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M6 HJ&.';4VZNDXQU,I>:2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***90F ^D+4VHII=II[@,NE,BX%;O@?1VN-0C^7O6?I\/VR15 SFO:/A;X+-
MS=0MY>>?2L*D^2)M3@YR5CZ7_9_\*AT@)3T[5]EZ#I:6=C&,8.*\.^"OAG[#
M;PDICI7T+&NQ%%?%XJIS3/O,%3Y*8^BBBN$]$**** "BD:FT /HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=D58XV[U.M.XHVTA#J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(W-2_P"LY-2+"!VKT$E%6/EY2=1W81J-HXJ3@4VB@!6ZTE%% !1110 4444
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M1J+0^8JT)TWJ<Y"VX5)5.:0V[$&GPW&^MS LT4BMFEH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@!:*** "D6AJ;0 ^BBB@ HHHH *93Z3^*@!:7^&DI=U ;@.])2\TE !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M53@A:***XCT HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MFM0M &-XAT\7D##&>*\!^(_@O<DC[*^EI(PZ8-<;XVT%;BS8A<\5U4:G(SR,
M=A56@V? 7C/2#8S.-N*X8,1(17T#\4O"S)-*0GZ5X=?:<UO,V1CFOIZ,^:)^
M18[#NE49"O:GU%N XJ13D5N>?<6BBB@84444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )M% &*6B@!&Z
M55U*W%Q:LI&:MTU@",&@35U8\#^)'@\7"R,$_2OF#QQX;-E*_P N.?2OOCQ)
MHJW5K(=N>*^7OBMX9VM*0GK7M8.MK9GPN<X%6<TCY<N<QS$=*GA;Y:O:UI;P
M739&.:SU^08KW]&C\WE%QE9DU%(K9I:0!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%RIR*?6)VA1110 4444 %%%% !1110 FT4M%% !1110 4444 %%%% !1110
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MU<"OC:U1U)7/NZ%-4XV0ZBBBN<Z HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** (9HQ)"RGTKR'XB>$Q=12$)FO8UZ5EZ
MQI:7MNPQDXK6G/D=SCQ-%5H-,^#/'WA4V<LAV8KR74 ;>4CWK[&^*GA$;92$
M]>U?+/BS0GM[I_E[U]/AZO.C\ES3".C-V1SMN^ZIJKQJ8NM3*^ZNP\!#J***
M"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C:*** "BBB@
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M #4BR!J2^TF>VE.5(JM'N5L&NXX"Y12*XQ2T""BG<>AI&H 2BBB@ HHI"<4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^M+M6@'%.H!C**5NM)0 4444 %%%% !1110 4444 %%%%!84FVEHH("BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH 3H*Q=>TL7T3<9S6W374,N#33L1**DK,^;?B1X(5HY&"?I7S%XST(V<[
MX7'-?H#XRT%;JU;"YXKY=^)7@E@TC!./I7MX2MT9^?YSE^\HH^:E4QN0:L;A
M6IK6CFQF;*XK#\S#8KW4[GP$E[-V99HI%Z4M(04444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 074(N(]I&:\U\=^#5NK=VV9X]*]/_BJM?VPNK=E89K2G-P=SEK48UHM
M,^$/B1X/:UFD(3'6O%[VQ>WG;(QS7W3\1_ XNED8)G\*^7_''A!K&60A,?A7
MTF'KJ2L?E6:Y?*E-R2/-D;:N*>K;JKWB-#*5([TZW?*UZ!\SUL3T444%!111
M0 VG+THV^U% !1113L 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***=MH ;12D8I* "BBB@:"BBB@04444 %
M%%% !11104Q]-:C)I*2)"BBBF 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% T%%%%*X@HHHI@%%%%!84444$#Z:W6EW4C=: $HHHH 3;2T45 !11
M15( HHHI@%%%% !1110 4444 %%%% !3:=2;: !:6BB@!<FDHHH *1OO4M(1
M0 B]:=0JT[;0%QM%%% !1110 4444"84444#"EW4E% !1110 4444 %+NI**
M "BBB@!<FDHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "ER:2B@!=
MU&ZDHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%.6@!M%.:FT %/IE%
M#FIM%% !1110 4H&:2E6@ VFDI],H ****$ 4444#N%%%%!-@HHHH&%%%% !
M1110 4444 %%%% !1110 44NTTE!84444$!1110 4444K %%%%, HHHH+"BB
MB@@**** "BBB@ HHHH+"BBB@@**** "BBB@ HHHH **** "BBB@ HHHH *7:
M:530U!8VBBBFR&@HHHI .6EIE% !113N*+V&AM%#TU>M AU%%% !1110 444
M4 %%/IK4 )1110 4444 %%%% 6"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN33EH ****5P"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 #4VG4FV@!:**3)]* %HI-U&X>M "T4W=]*7</6@;!J%I&
M844"'44 T4V 4Y:;2@XI .IE+NI* 04;OK13-K4[#8^BFJIIU(04444 %%%%
M !1110 4444 %%%% #Z*3=1NH &IM*3FDH **** "BBB@ HHHW#UH **3</6
MC</6@!:*3</6C</6@!:*,BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@!&^]29-+MHVT "_>I:0"EJ "BBBK ***3</6@!:*3</6C</6
M@+BT4;AZT4 %)NI6Z5'M/I0!)12+GO2T %%%%-@%%-R:7=2 6BBBD@"BBBF
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M[RR-KD8Q5J2EL92HRI_$4Z*9YGS8I]49A1110)A1110,**** "BBB@ HHHH
M**** "BBB@ HHHH *4#-)3EH -M-I],H **1C@4Q9-S8H ;(3VJ'YZZ'3=':
M](P,UTUGX DG4'R_TJ'.,=S:&'G4^$\Y^?T-)^\]*]6C^&TC?\LZ>_PSD _U
M?Z5/MH&WU&KV/*%W^E2*QKT&\\!O;@G9TKE]1TEK-B,52FI;&$\/.G\11AA,
MG:KG]FL5SBK6B6?G2A<=Z[VV\+F2WW;>U1*IRG11H.HM#R^>V,7:JV[YL5UO
MB72_L9;C%<8S_O,5<9<VIS58^SE8GHI%/ I:LS&-FH6+"M&VMS,V*W;7PNUP
MF0M2Y);EQIRGL<G&6[U/6_?>'6M5)*XK!F_<MBFFGL*4'#<2G;:8K;JDIDC2
M,4E.:FT %%)NI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *5>M)10 [(I&ZTF110
M 4444 %13-QQ232;:2!3<,%'-!+?06T1II0 .]>F>"?![7TR$IG\*R_!_A-[
MRX0[,\^E?3?PU\!"%8BT?IVKBQ%=06A]#EF7RK23:-7X=> 1;1QL8_3M7MVF
MV2V=LJJ,'%0:1I4>GVZ@+SBM1>E?-5*CF[GZKA,+'#P20M)NI::U8G>*#FAN
ME(M.H ;MI5Z4M% !129%&10 M%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 444UJ '44RGT -*Y!%<MXF\.I?P/\N<UU=,D02*01Q33<
M7=&=2FJBLSY)^)G@$+YA6/\ 2OG'Q-X?DL[AOE(P:_0CQEX76^CD^3-?-GQ$
M\ F-I&$?Z5[N%Q'1GYUG&6:N44?-:_N>#Q4RR[JT_$.BO9S,-N*Q(<JW->TO
M>5SX647!V9:HI%8-2T %%%%) %%/I",TP&T444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4C-MI:@G- F2*OG<"MC2?#LEU(I"DU5\/V
M9NKA01WKWCP3X026%&*=JPJU%31Z.#PKQ#,;PGX4\G873]*]-T_3[:&,;@HJ
M'4+./2+<D # KS_6O'GV-V4/C\:\Q\U5Z'TR5/!JTCTV1;-?[M1J;/=_#7A]
MU\2WW'Y_UJO_ ,+*?_GI^M:K#R,GF5&Y] [;.2/'RU@:YH,-Y&VQ0:\FL_B<
M[2A3)^M>E>%?$RZHJ[FSFIE3E3U-Z>*HXGW3SOQ/X1:,LP3CZ5YQJEBUJQ!&
M*^J-9T>*\M20 >*\0\;>'3'(^U:Z*-6^C/'Q^#Y/>B>:QON;%78]/:;H*2#2
MI/M.,=Z]'\,>%C=(N4_2NR4U'4\>A1E5=CSJ32WAY(-9EU)Y7%>TZ[X+:&W)
M"=O2O(_$>CRV\S#:>M*%13'B</*BMBWX3837:_6OHSP=I:26:G':OG/P;;M'
M>+D=Z^F_!4FVQ4>U<F*\CU\I5]SE/B%IZ0P.0,<5\^ZU,([IQ[U](?$<&2W?
M'I7SGK6FR37CX!ZUIAGIJ<^:1]_W2M;W&5JPLH:FV^CS*OW34AL7CZBNQV/%
M2D*#12!=M+D4B@IK.%IU)Y#2=* (S,*07 J8:3+)T4T[^Q9U_A/Y4:"M+L1+
M*&I](;-XNHHSMX- :]1:1F"TOWJ0PENU QOFBD\X4[[(Q[4X:;(W0&@6I&)@
M:>K9IW]F2KU!H\HQ]: UZC6^Z:K%SOJRWW353_EL*:).U\(V(NI4!%>Y>%_#
M,;0H2E>1?#V(-,E>_:5(+6R4^U>7B).^A];EE.+CS,L_V5:VZ\A14#QV:_W:
MXWQ;XT^PLP#8KSZY^)[!R/,_6LHT9R5SLK8RC1ERL]PVV?\ LU7NEL]I^[7A
M_P#PM!O^>GZT/\3"_'F?K5_5YF#S*C8[SQ*MOL;;BO(/$FU9&VUI7WC,W8/S
MY_&N;OKAKQB:ZZ5-QW/$Q5>-7X3&W_O*LJWRBF_8VW9Q2^44KK9Y*3'Y%)NI
M*-A:D4&\4X&D6U8]J7RRG6@6H4UI M*U'V=I.E :D9F%(+@&IQI$S]%-+_8D
MZ_PFC0+2[$2RAJ>#2&Q>/J*3[O!H#7J.I"P%+]ZD,#-VH&)YE)YHI?LS^E.^
MP22=!0+4B\\4JS U+_8\QYVFD_LV2/J#1H%I=A%;-+3?+,?6EW"G88M%%,D;
M;2 5OF'%3V%@TTPXJ*T'F-BNW\-Z2)G4XJ)RY4:T:?M)'2^"?#X;866O7]+T
M:WAA7<HKE_#NF_9HE(':KNL:\;&$\XQ7D3DYO0^RP\(4*=Y(Z-H[2-L';4C_
M &-EXVUX=K7Q*:WF8>9CGUJA;_%1GX\S]:M8>;5S)YC1B['KFOPVK1MC'2O&
M?&$:+(VVM&;QZ;J/[^?QKC]<UC[5(>:ZJ5.47J>9C,3"JO=-7PC )+I?K7NF
MEZ.C::#CM7B'@5MUTGUKZ!TQPNFC_=K+$73.S+8IP;9XS\2+,0[\#%>/R-B<
MCWKVGXH.#YE>*2<W!^M==#X3PLPTJZ%I7XH\RB.%G7@5)]C=>U=&AP*YK:'M
M:9<UZOH,,)MQG%>/:?(;>0'I79Z;X@,48&ZN6I%O8]3"U%#<WO%4,2PMMQTK
MR35.+@X]:[76-:-Q&1FN*O5,LA-7232U,<7-3>A7BDJ3S134M6I_V5SQBMC@
MU&F84SSQ4XTN63HII?[#FZ[33T':78KK+NJ9:/[-DAZ@TF/+ZT,->HZ@FD#
MT%=U(8UI0M-\\5(+)Y.@IW]BS-SM-&@K2Z$0F%/5MU+_ &5+'U!H\EH^M 6?
M4****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4-THHH ;3J-HHH *C:3%/9A5213(P H!LD:,SM@#-=7X3\-O
M>7"?)GFJ_AG0'OID&W/-?0?PY^'^?*8Q_I7-7K*"/4P6!EB)IV-GX:^ 1B)F
MC_2OH7P_H":?;K\N*S_"?AU+&)/EQBNO5=O0\5\S6J.;/UC X..'@M!PI:**
MYCUPHHHH **** "BBB@!K4+2[11M% "T444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,&VV+?2OFCQK*/M3\]ZK"Q1CFU1I;FGX1OFFO$R>]?3O@%A]E0^U?*/@A_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWKU^^\%JBGY:RK?PNL5P/E[T_;)F/U&461^$?#+3LC%:]L\+Q#1HU)XQ7/\
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M PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKE1/JE\9I&.<UCR#=3FD,C')HKM2L>%)\SN(J[:6BBF(**** "BBB@ HHHH
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M+\O.*V >/2@* N!VH(Q7D-W/MHQ459"Y%+35IU(L**** $R*6F4JT .HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP-%(M+28!1110@$W4;J2BF NZEIJ]:=0%@HHHH ***5: $V^U%/IE !1110
M444J]: #;01BE6AJ &T444 %%%% !1110 4444 %%%% "$4E/VTE  !BBBB@
M HHHIL HHI=II )1110 4444 %%%% !111D4 .W4C=:2B@!5ZTNZFT4 %%%%
M !1110 4444"04444#"BBB@ I&Z4M% $'E_/TKJ_#6J?874YQ7-T>>T70U+7
M,K%4Y>S=T>O?\)L/L^W?V]:X;Q-JGVYF.<US/]I2^IQ2^<TO4U$::B[G54Q4
MJRY60>7\^<5..***U.)(,XHW>](U)0,=12+2T %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %!-%(U "@T[;3%J2@!E%*U)0 4444%A11100%%%% !2,V*&;%122&@
M5P9CS3[>W>:0 "G65NUQ)@#->@^%/!KWTB'83^%1*:BM3:C1E6E:)%X1\)O?
MR)E,U]#_  ]^' 3RV,?Z5-\/_AV(A&S1_I7O7A_0HM/MU^49Q7AXC$WT1^B9
M5E2BE*:(O#F@QZ? OR\@5O\ 6@  8 P*=7CN5]3[:$%35D%%%%(T"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%.6@!M%/IE
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M13:<M PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A-+2$4  -+2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@5PHHHH&%%-H!H =4,DVVG-,!3/)-PP H)?D-5C,0!70Z#X;>^D
M7Y2<U-X<\)RWDJ?(3S7O7P_^');RRT?Z5S5JR@CUL'@9XB2NC&\"_#MG:,M'
M^E?0O@SP/';*F4_2M3PIX)CM8T)C KN[6S2U0!17SU;$.;/TK 9;&BDVAMGI
M\5K&%"C(J[2?=HS7"?2)*.B%HIE*M QU%%% "9%+3*<M "T444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHJ!21UJ96S5F"8[)I***3&%%%%" ****8!1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 44[;2$8H 2BBFL: %XJ-FR*8VYNE36-G)-(!C-
M M7H0K:O,X"BNS\)^$I;V9,H3^%:_A'P3)?2(3'G\*^@_ ?PS$8C8Q_I7%6Q
M"@K'N8'+9UY)M&3X!^&PVQEHOTKWCPUX02QB3Y,5?\.^&X[")04P![5TJJ$&
M!Q7S]6LYL_3L%@84(K0;#$(4"@5+12-TKD/:%HINZG4 )M%&T4M% !1110 F
MT4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNU9?BMC)"Q2O//#7BHQJJEZ[>"^34H\$YS7F.')*Y];#$*M3Y3RW5([C[0V
M>M:.BI,K#=FO0?\ A%H;CYL"J]UHL5BI( %:^T3T./ZK*+YFS-:0+!R:X3Q)
M,C2'!KH=>U,6RL :\WU+4FN+C&<\UO3CU.#%54ERFYX>L_M%P,#/->JZ7I)A
MMP<=JXCX?V)FE0D5[,UBL.GYQVKGK2UL=^ HWAS'G7B"^^SJPSBO,==OO.9N
M<UUWCR^\F1P#7F4UV99#S731CI<\S&U?>Y2)OOU(O2DI5KJ/)2%HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTM% !1110 UHPU,\@5+10*Q$(13_ "Q3J?0%B+RQ2JN*>U-H&!&:;Y8IU%
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M-IR]* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 444A.* %I-M&ZEH **3=0O2@!:*1NE)NH %ZU#>6JW495AFI^
M:*!-7//?$7@>._5SY>?PKQSQ?\+0N]A%^E?4A 9>:Q]8T2*^A;Y!DUU4ZTH'
MD8K+Z=9/0^!O%G@=[-GPGZ5YKJ&FRV\AX-?<_B_X<K=;R(_TKQ'Q=\,&A+D1
M?I7MT<4GHS\]Q^4R@VXH^>XE93S5I6Q70ZYX9DL';Y,8KE;A9(VQBO2C)2U1
M\O*G*F[,M%MU-VU621N]65.5IDW%HHHH&%%%% !1110 4444 %%%% !1110
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M11128!2KUI*<M" -M-I],9N:8#MU(3FDHH!A1110-!1111804444 %%)NI:
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MHA113=U2;CJ*1>E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<=QNJ96S3Y=,>U)W#%5VDV<5MZ'EV<=R:BHUF!J0&@JX4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "D:EI",T )NIU-VTZ@!N.*KW=HMU'@C)JR#2T":NK,XC
M6/ L=ZK'RP?PKROQA\+4VN1%^E?17UJAJ6FQWL)!4$UTTZTHL\S$8&G6CL?"
M'C#P"]LS[8R/PKR_4_#LT,A^4U]Z>)OAXEZ'(CS^%>1>*/A5Y8=A%^E>U1Q2
M>Y\'CLFDFW%'RBUH\+<BI%8*.:]'\4>"9+-FPE>=ZAI\MO(1M(YKTX34CY*K
M0E1=F() :<#5-5=>M6(VK1F%R2BC(HJ1A13MM-H ;2K1MI0,4 #=*;3J3;0
MM%%% D%%%% PIM.I-M  M+0!BB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX#5ZTZDVTM, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UJ=10 U:=110
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MI7JN@?#&)54F(?E7GU<8EHCZG"Y+*I9M'B7A+X:MN3=%^E>T^%?AW$JIF/\
M2NXT_P &168'R**Z&TLTMEPM>/4Q#EL?9X3+(45JC)L?"=M:J,J,_2M6"PBM
M_NBK=)D5R79[<:<8[(6BBBD:!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %(U+10 RGT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !4<T*S*589I_-+0!R>M>%8[
MS=\F<UY_KOPO2XW'ROTKVO(ICQ))]X _A6\:TH['#5P=.KNCY1\0?"<)N(B_
M2O,_$/P_>UW8C_2ON+5-!AND.%'Y5Y[XB\ )=;L1_I7H4L6^I\UC,GBU[J/A
M?6O#TT#MA#7.2V,\;=#7V!KWPC,NXB+]*\^UKX3O!N/E?I7J0Q46?&XC**L7
MHCP)(77J#4J@KUKOM9\%R6>[Y/TKC=0T^2WS\IKKC-2V/&J4)4MRMN'K2Y%4
M6,BMT-.5VJ['/S%RBHU8XYIX-(L6BBB@!=II2M)DTI:@!M%%% !1110 4444
M %%%% !1112L 4444P"BBB@ HHHH **** &MFH'5JLT4":*3(WK3?+D]:O[1
M2;1Z4[D\I35&J9%-3[112'RA1110402*:A,;>M7:-HH)Y2CY;^M"QOZU=VCT
MI=H]*=Q<I7C5JGVTM%(I*P4C9QQ2T4#(VW9I5SD4_(HH)Y0I'I:*"BJRM3-K
M5=HVBG<GE*:JU2QJ:GVBBD'*%%%%!04444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYRI%5)K,P=16ETSDY)1W&@T5"TP2D^U#UH%<GHJ-9@U/# T#N+1110,****
M"BBB@ HHHH **** "BBD:@!:*;3J "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** &TJTM% !1110 49%%-H =12+2T %%%% !1110 4444
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M@HHHH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "9%&ZD:DH ?29%+3*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ***90 ^BFK3J "BBB@!K(&ZU"UC$W458II% K)E)])MY.JU"
M_A^TDZK^E:F11D4[LGV<>QBR>%;*3/R_I69>> [693M1376\&CBJ522ZF4L/
M3ENCRK4OA[$<XC%<CJGPZ5LXC_2O?IK=9>HJC-HT<G85M&M)'!4R^G+9'S%J
M7PWSG$?Z5S&H?#5^<1?I7UM-X6AD_A%4Y/ \,G\"UU1Q31YE3)XRZ'QE??#&
M7G$1_*L&\^&,_:(_E7W#)\.H)/X%JI-\+[=Q_JUK>.-L>;4X?YMCX4F^&LZY
M_=-^557^'\\>?W9_*ON&\^%,//[H?E7/W_PKC7.(OTKH6.3/.J</N)\:2>"Y
M8_X#^50-X7DC_@-?6%]\,57.(OTKG;[X:[<XC_2M5BDS@GD\H]#YK?0WC_A-
M0-IK+_#7O=]\.V7.(_TK"NOA_(,_N_TK58A,X99;./0\<:T*]JC92O:O4;KP
M#*.D9_*L>Z\"SKG$9_*M55BSDE@ZD>AY^TVVF?;,5U=UX)N.?W;?E6;-X-N0
M?N'\JU4XG-*C570Q1>CUI?M@]:TCX1N5_@/Y4G_"*W ZH?RJN:)CR5.QG_:A
MZTOVGWJ]_P (U.O\)H_X1Z;^X?RHNA\D^Q1^T4X7%7/[ F'\/Z4W^PYO[IHN
MA<L^Q5^T4OVBK']BR^E']DS>AHN@Y9%?SZ7SJF_LN3TI/[-<=0:- M(B\ZE\
MZI/L+?W32?8V]*!68SS:/,J1;-O2E^QMZ4#LR+SJ/.I_V-O2C[&WI0.S&>;1
MYE.^RMZ4?96]*!68WS*/.IWV5O2E^QMZ4!J,\ZFM-4OV%O[M']GN>U 69#YM
M+YU3?V9)Z4G]F/Z4M M(B^T4?:*G_LN3TI?[)D]*>@<LBM]HI/M566T>7^[^
ME']B3'^&BZ#EEV*WVJD^T^]7?[ F;^$TO_"-S-_":+H.6?8H?:QZTGVP5H_\
M(O.?X#1_PB=PW\!_*B\0Y*G8S?MPI1>;JT_^$0N3_ ?RJ:'P;<G^!ORI<T1J
MG5?0RDFW5.L9?M716?@FX./W;?E6W9^!9CC,9_*H=2*.F&&J2Z'$)8,_:IUT
M=V_AKTZQ\ 2''[L_E6[9_#QSC]W^E9.M$[89?.70\:7P[(W13^531^$Y7_@-
M>]6?PX)Q^[_2MVS^&@.,Q?I6+Q*1W0RB4NA\WIX)F?\ @;\JF7X?3OC]V?RK
MZHL_A>A _=?I6]8_"N)L9B'Y5B\8D=D,BE+H?(EO\-9V/^J/Y5N6'PQFX_='
M\J^O+/X4P@?ZH?E6K;_#&WC_ (%K"6..^GP];H?*6G_#.08S$?RKJ=-^&IXS
M%^E?2,/@&"/^!:NP^#H8\?*M82QESU*62J&Z/"].^' &,Q_I73Z?\.X^,Q_I
M7K47AZ&/L*N1:;''V%<TL0V>I3RV$=T<#IWP]AXS&/RKHK7P-:1J-RJ/PKI4
M18^E/R*P=23/0AA:<>AC)X7LDQA!^53)H-K'T7]*T]HHR*CF9NJ4%LBI'I\$
M?05.ENB=!3]M.J3112V"BD)Q2?Q4#'4FZEIE #LBEIE*M #J*** &4JTZB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\&47/[K]*R[CX0A<_NOTKZC:SBDZH*J3:+!)T45HL5(YI911>R/E:;X3A?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img224999359_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )R!98# 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **#10 444'I0 44=J* "BBB@
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M[BCJ2N/<XX_&B6'J17,T$<13D^5,[&BN'F^)5E:^,W\/W5JT2K*(OM)<;<D
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M/] D\/\ A:&&YCV7DS&:<'KN/8_08J95(^RY[^\U;_@_<5&G+VO);W4[_P#
M^\Y3PK_R4?Q?_N-_.KGP=_Y NI_]?9_E4GAW0M3M/'/B:]GLY$MKE&$,AQA^
M>U<YX:/CGPK;W5K9^&_.2:4R;I.H[=C5RM.,HIK[/4B-X2C)I_:Z&G\7;2"P
M.E:U:A8M02?:&48+@<C/K@_SI0[2?&^UD<89K)"?J4J73_"?B+Q1KUOJ_BUD
MAM[8AH;-#U.<\CL/U-7?&WAO5DUZS\4>'D$M[;@++ ?XU'3'KP<8I1E%)4V]
M;-7Z:CE&3;J):73MUTZEWXJ?\B'=_P#71/YU!/KJ^'OA+9WF[$S6:1PCN7*X
M'Y=?PKGM6?QEX]C@TF?1/[,L_,#3RN3V^O\ *KWBCPOJ.M:_HFAQVDHT*Q11
M)/T4\<_H,?C2C"*C&$WLVV.4Y.4IP71)'&3Z7:Z3X/TG7[2^MSK,4XGE02 L
M58Y (]L<_6O0?&NJ1:U\*7U&'[LZ1MCT.1D?G5J3X4^%6B=4M)$8J0&\TG!]
M:Y*UT#Q)!X&UKPW-IL[A)5>T<8PXW<@?EG\:OVD*C4KZI]>S_P B/9SIIQMH
MUT[K_,]%\%?\B7I'_7LM;U>4:3K7C_2-*M=/B\*H\=O&(U9LY('K\U>E:1/=
MW6D6L]_ +>[DC#2Q#^!NXKDK4W%N5UJ^YUT*BE%1L]%V+M%%%8&X4444 %%%
M% !1110 54T\@VS8@\C]XWR^O/7\:MU5L-WV=MTXG.]OF';GI^%/H+J6J***
M0PHHHH **** "BBB@ HHHH **** "BBB@ KS3QS_ ,E+\)_7_P!FKTNO-_B'
MIFN2^*-%U31]->\-FI8@=,[L@'FNC#6]IKV?Y'/B;^ST[K\SO-4L+74M-N+6
M\B22%T(8,,XXZUXOH<K_ /"L?%=IO+P6\P$1^IY_D*Z*[O/B1XBA:P&EPZ9%
M*-LDN<?*>O))/Y5J7G@LZ/\ #6^T;34:ZNY5#.0,&1\CI[5M3M27+)K5KY&-
M2]5\T4[)/YG$^#)'\)>(M%NI&*V.LVP5F)X#9QS]#C\Z;XP=_%NN:]?[B;'1
MX/+BP>-V<?SS74ZIX0OM1^%.G6?V5UU2R4.D7\6<\C\J6S\'WFG?"B^L4M6?
M5+Q?,EC'WBV1@?@*V]K#F]I?6]OQW^XQ]E/E]G;2U_PV^\Y[Q'_R3;P;_P!=
M1_6O9A#%/9K%-&LD;( RL,@C%>5^(?#FMS_#_P ,V=MITLEY:-NEB&,IP>M6
MWUOXDWT(M+?08;)F&WSC_#[\FLJD/:17*UHWU\S6G/V<G=/5+IY$7@)!I7Q(
M\0:39D_8!DA ?E4@C'\R*[/QW_R(NL_]>S55\#^#AX7M)IKJ87&IW1W7$O4>
MN >_UK1\86EQ?^$-4M+6)I9Y8"J(O5CZ5E4G&5=-/MJ:TX2C0:?GH>9^&_%'
MB.W\'P:;I_AB6ZB,;(EQR5;.><?C2R17G@/X:7-O>$1:GJTI5(5;)C4CGIWQ
M_.O0_ EA=:;X.L+2\A:&>-2&1NHY-<MKOAK4/%WQ$C&HV4R:':(55R<"3C)Q
MSW/\JW56#J2322O=^=C!TIJG%W;=K+RN<G>VEGX-3PYK>FW=O-<Q "]CCD!+
M$\G@>Q(KU'QA<Q7OP[U.ZA(:*6S+J?8XK)U#X3^')-.N$L[:2*Y,9\I_,)PV
M..*H:18>('^%^J:'?Z=,EW%&T=N#C]XIY 'TI2G"IRS3U3Z]KCC"=/F@UHUT
M[V.B^'/_ "(6E_[A_P#0C6!X/_Y*IXK^G_LPKI_ UC<Z;X.T^TO(6AGC0AT;
MJ.36-X8T;4+/XB>([^XM7CM;G_4RGH_(Z5ES*]77?_,TY7:EIM_D<1X2U_7=
M'NM:32-";44DNR789^0Y.!Q7H&CZ[K>LZ7JHU?16TX1P-Y9.?G^4YZUQNACQ
MMX6NM36Q\.&XCNK@R;I/J<8P?>NLT?5_%NK_ &VUUC0DLX3;/L=<Y9\8 ZFM
ML0DVY)+UOJ98=M)1;?72VAYIH?A^Z;PB/$VDEEU'3KHLP7^-!@_I_*NA\:>(
M;?Q-X9\.:A!@,;W;+'GE' &175_#'1K[2/#,UKJ=HT$C3L=CXY! KB_$_P /
M-4LO$T;:+:RS:7+,L_EH>(FSR,5HJL)UGS/;9_H9NE.%%<JWW7ZGK'B/_D6]
M2_Z]G_D:Y?X1?\B)'_U\2?S%=9KD,ESH5_!"A>62!U51W)'2N?\ AII=[H_@
M^.TU"W>"<3R,4?K@GBN*+7L&O-';)/VZ?DSKZ***YSH"BBB@ HHHH **** "
MBBB@ HHHH **** "JFID#39R;?[0-O\ JO[WM5NJNI;O[.FV7 MVV\2GHOO3
MCN*6Q:HHHI#"BBB@ HHHH *S?$/_ "+FI?\ 7L__ *":TJHZU#)<Z'?0PH7D
MD@=54=R151^)$R^%GCW@CQ1K^E^%_L>F>');^,RN1.,[<G'&,=JK:GHVK>'?
MA[?SWZ>1/JMZADA7^!!N.#CU)Z5Z/\,]*OM'\(+:ZA;O;S^>[;'ZX.,5M^)-
M!@\2:'<:;.VP2#*.!DHPZ&NZ6(C&JTEI?5G#'#RE23;UMH4=+CCT#P'#)IEH
M)FBLQ*L2=97VY[=R:P-!\>W>H>+8-)O= %A<7"$L['Y]H!([<CBLO3=0\=^#
M;<:7+HO]J6L/RPRQDGY>W([?45-H=CXFUWXA6OB/5-)%A!#$8]I;MAL<=2<M
M4^SBE)RL][.Y7M)-Q4;K:ZL8USX:C\4?$/Q99'Y;A(O,MW_NN"F/SZ?C5J/Q
M--J'PXUO0]4W1ZMI\)C99/O.H.,^Y'^%=)X>T;4;7XH>(-2GM72SN(L13'HY
MRG3\C6;\2_ UUJ<JZOHD3-=L/*N(4X,B^M:*I&4XPD]-+>3,_9RC"4XK76_F
MC5\%ZWIFC> =&.I7T-J)(VV>:V-V&/2L_P")FK6&K^ )9].NXKF);F-2T;9
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MP=;6E] T$ZNY*-U&3Q755S5VG4DUW.F@FJ44^P4445D:A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  :*#10 4'I13
M9'6.-G=@J*"68G  ]: '=J*SQKNDX_Y"5I_W^7_&C^W=)_Z"5I_W^7_&GROL
M1[2'=&A16?\ V[I/_02M/^_R_P"-']NZ3_T$K3_O\O\ C1ROL'M(=T:%%9_]
MNZ3_ -!*T_[_ "_XT?V[I/\ T$K3_O\ +_C1ROL'M(=T:%%9_P#;ND_]!*T_
M[_+_ (T?V[I/_02M/^_R_P"-'*^P>TAW1H45G_V[I/\ T$K3_O\ +_C1_;ND
M_P#02M/^_P O^-'*^P>TAW1H45G_ -NZ3_T$K3_O\O\ C1_;ND_]!*T_[_+_
M (T<K[![2'=&A16?_;ND_P#02M/^_P O^-']NZ3_ -!*T_[_ "_XT<K[![2'
M=&A16?\ V[I/_02M/^_R_P"-']NZ3_T$K3_O\O\ C1ROL'M(=T:%%9_]NZ3_
M -!*T_[_ "_XT?V[I/\ T$K3_O\ +_C1ROL'M(=T:%%9_P#;ND_]!*T_[_+_
M (T?V[I/_02M/^_R_P"-'*^P>TAW1H45G_V[I/\ T$K3_O\ +_C1_;ND_P#0
M2M/^_P O^-'*^P>TAW1H45G_ -NZ3_T$K3_O\O\ C1_;ND_]!*T_[_+_ (T<
MK[![2'=&A16?_;ND_P#02M/^_P O^-']NZ3_ -!*T_[_ "_XT<K[![2'=&A1
M6?\ V[I/_02M/^_R_P"-']NZ3_T$K3_O\O\ C1ROL'M(=T:%%9_]NZ3_ -!*
MT_[_ "_XT?V[I/\ T$K3_O\ +_C1ROL'M(=T:%%9_P#;ND_]!*T_[_+_ (T?
MV[I/_02M/^_R_P"-'*^P>TAW1H45G_V[I/\ T$K3_O\ +_C1_;ND_P#02M/^
M_P O^-'*^P>TAW1H45G_ -NZ3_T$K3_O\O\ C1_;ND_]!*T_[_+_ (T<K[![
M2'=&A16?_;ND_P#02M/^_P O^-']NZ3_ -!*T_[_ "_XT<K[![2'=&A16?\
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MX6A7S&^5O7/6K=5K$2B ^;,LK;V^9?3/ HZ%=2S145Q=06D7FW,T<,><;G8
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M4<O_ ,(!HG]R?_OZ:/\ A -$_N3_ /?TUU%%'M)]P^JT/Y4<O_P@&B?W)_\
MOZ:/^$ T3^Y/_P!_37444>TGW#ZK0_E1R_\ P@&B?W)_^_IH_P"$ T3^Y/\
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M?RHY?_A -$_N3_\ ?TT?\(!HG]R?_OZ:ZBBCVD^X?5:'\J.7_P"$ T3^Y/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 !HH-% !0>E%!Z4 ':BCM10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 52
MTSR?LK>0[LGF-R_7.>:NU6LO.\@^=&L;;VP%Z8SP:?074LT444AA1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M5+5O)_LJX^T.Z0[?F9.H&>U7:K7_ )WV&;R(UDEV_*C]":<=Q2V+-%%%(844
M44 %%%% !1110 4444 %%%% !1110 44A( R2 />H#>P9(5]Y&<A!NZ?3ZT
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M1UB((T5!G"C R<FG5#:7=O?VL=U:S)-!(NY'0Y!%35!84444 %%%% !1110
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MZH)4+,NX ,,D>OTH DHJ+[5;[-_GQ;-VW=O&,^GUIPEC,IB#KY@&2N>0/7%
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MG5Z?LY>3(2*:14A%-(K<Q(R*:14A%--,9],>"O\ D2M&_P"O5/Y5O5A>"_\
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MK%\/>*M)\417$FES-(L#['W(5_$>U16GC/0[[Q&^A6MX);U 2=BY3CJ-W3-
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M8ML7+#!..HIU%04,\J,!1L7"_=XZ?2N6\:IID5I:37VJ7&E@7*L);=6)D8=
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M_A&['[%<S7-MY?[N:?[[C)Y.:;NXW8EI*R-:N0N[JTUWQM!IJRZC!<:2PN&
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MU--=AR#3333C333&@21XI5DC8JZ$,K X((Z&MY_B?XP1BJZH^!P,QK_A6O\
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MZ5N_\+1\8_\ 04;_ +]+_A7T?_9>G_\ /C;?]^E_PH_LO3_^?&V_[]+_ (4
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M>#7F%[\&+>:[DDM-7:"!CE8V@WE?;.X9K?#58P34CGQ-*4VG$\>)II->M_\
M"D_^H]_Y*_\ V=)_PI/_ *CW_DK_ /9UU?6:7<YOJU3L>1DU=TC2KC6]5M]/
MM5)EF<*#C(4=R?85Z=_PI+_J/?\ DK_]G77^#? =EX16643&ZO)>#.R;<+Z
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MK>QM@1#!&(TW')P*LUYDG>39Z459)'@7Q3/_ !75S_USC_\ 017%$U]!>,/
M%GXKFCN1<&TNT&TRA-P=?0C(_.N5_P"%*?\ 4>_\E?\ [.N^EB*:@DV>?4P\
MW-M(\E)II->M_P#"D_\ J/?^2O\ ]G1_PI+_ *CW_DK_ /9UI]9I=R/J]3L>
M1&O9_A1X/%K:C7[Z+]_,,6RL/N)_>^I_E1IOP8M+:_BGO=4:Z@0Y,*P;-WL3
MN/%>GHBQHJ(H5%& !T KGQ&(4H\L#HH4'%\TAU%%%<1V!1110 4444 %%%%
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M\C_IW?\ PI#X=UO_ *!%_P#^ [_X5ZG,NYY7*^QF$TTFM/\ X1S7/^@/?_\
M@,_^%(?#FN?] >__ / =_P#"GS+N/E?8RZ^DOA__ ,B'I'_7'_V8UX5IW@W7
M]2OH[6/2[J,N>7FB9%4>I)%?1>B:6FBZ)9Z;&Y=;>,)N/\1[G\ZY,7).*2.S
M"Q:;;+]<EX7&E#Q#K9L-+O;2X,O^D33YV3')Y7)Z5UM<I>7]]X6N+_5-6O)K
MW3I942UMX(07BSZGCCZUQPU32.J6C39U=%8<WBFRAU.]L&AN/-M+/[8[!1M*
M>@YZU7A\::?/8Z1=K;W8CU2X%O""@RK>K<\#\Z7)+L/GCW.DHKG#XST\2:TG
MD76=(0O/\@^88S\O//Z4]/%UB]_I%FL%SYFJ0^="=@PJXS\W/!H]G+L'/'N7
M]=>9-%N6@OX["4+\MS(H*Q^Y!XIVBM,^CVS3WT=]*4^:YC4*LASU '%<U?\
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M> #Z^E>0_P#"!^*/^@-<_I_C77A5!+F;U./%<\GRI:'/$TTFNC_X0/Q1_P!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** &NZQHSL<*HR3[5D6GBK1KZ[CM;>Z+S2'"KY3#/?J16G=_\ 'G/_ -<V
M_E7DGA,_\558?]=#_P"@F@#V&BBB@ HHHH ****  T4&B@ H/2B@]* #M11V
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#=_P#'
MG/\ ]<V_E7D?A(_\578?]=#_ .@FO7IT,EO*B]60@9]Q7!:#X+U33==M;R=K
M<Q1,2VUR3T(]* /0:*** "BBB@ HHHH #124M !0>E%!Z4 ':BCM10 4444
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MJHGF_P!G Y.WKC?G[V*2HM]1NLET/0**X;5O&&HR?\(V-"@BDEU52YBG!X7
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MA60J.Q-9?B'Q#=VNJ6NB:/;QS:I=*7W2D^7"@ZLV.3]*A0;EREN:4>8U]9U
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MIMAJ]Q9WEMJ)95,,6PQ,!GCU%)496O\ UH-UHWM_6IVU%%%8FP4444 %%%%
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MGM;R#4$=HY(8]AC91G'N*/8RM</;1O8[6BBBLC4**** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *0@$8(R*6B@ HHHH 1F"J68X &2:S[?7])N[A8+?4())F.%17R3
M5N[_ ./*?_KFW\J\9\%_\CE9?[[?R- 'ME%%% !1110 4444 (:6@T4 %!Z4
M4'I0 =J*.U% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !533R#;-B#R/WC?+Z\]?QJW56PW?9VWSB<[V^8=N
M>GX4^@NI:HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "JFID#39R;?[0-O^J_O>U6ZJZCN_L^;9<"W;;Q
M*>B^]..XGL6J***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH AN_P#CRG_ZYM_*O%_!1_XK.R_WV_D:]HN_^/*?_KFW\J\6\$G_ (K2R_WV
M_P#030![?1110 4444 %%%%  :*#10 4'I10>E !VHH[44 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5--,
M9MF\N%HE\QOE;USUJW5:R$H@/FS+*V]OF7TSP*?074LT444AA1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5/5
M#&-,N#+"TT>WF->K<U<JMJ E-A,(9EADV_+(QX6G'<4MBS1112&%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% &9KL.I3:9*-+F2.XVGY74$.,
M=/:O'_#>G:R?$Z)91&.[@<[VD7B/L2:]SJ-+>&.625(D623&]PH!;'3)H ($
MDC@C263S9 H#/C&X^N*DHHH **** "BBB@ -%!HH *#THH/2@ [44=J* "BB
MB@ HHHH **** "BBJMV+XE?LC0 ?Q>:"?Y4 6J*S=NL_\]++_OAO\:-NL_\
M/2R_[X;_ !H TJ*S=NL_\]++_OAO\:-NL_\ /2R_[X;_ !H TJ*S=NL_\]++
M_OAO\:-NL_\ /2R_[X;_ !H TJ*S=NL_\]++_OAO\:-NL_\ /2R_[X;_ !H
MTJ*S=NL_\]++_OAO\:-NL_\ /2R_[X;_ !H TJ*S=NL_\]++_OAO\:-NL_\
M/2R_[X;_ !H TJ*S=NL_\]++_OAO\:-NL_\ /2R_[X;_ !H TJ*S=NL_\]++
M_OAO\:-NL_\ /2R_[X;_ !H TJ*S=NL_\]++_OAO\:-NL_\ /2R_[X;_ !H
MTJ*S=NL_\]++_OAO\:-NL_\ /2R_[X;_ !H TJ*S=NL_\]++_OAO\:-NL_\
M/2R_[X;_ !H TJ*S=NL_\]++_OAO\:-NL_\ /2R_[X;_ !H TJ*S=NL_\]++
M_OAO\:N6PN1%_I31&3/_ "S! Q^- $U%%% !1110 4444 %%%% !1110 444
M4 %%%% !5+3#$;5O)C=%\Q^&ZYSR:NU7LO.\@^>R,^]L%>F,\4^@NI8HHHI#
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK/N[O4(9REMIHGCP/G\X+
MS]#4/V_5_P#H##_P)7_"@#6HK)^WZO\ ] 8?^!*_X4?;]7_Z P_\"5_PH UJ
M,C.,UD_;]7_Z P_\"5_PKD/%%Q=0ZE!=M UG=%?X9P^<=#QTI7 ]%R/6BN3\
M$16[VLUUYQENW;$@8_='_P!?UKK*8!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 52U;RAI5QY\;R1;?F5.IY
M[5=JM?\ GBQF^S,BS;?E+] ?>G'<4MF6:***0PHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HJ.=I5A9H8Q)(!\JLVT'\:SOM6L_\ 0,M_
M_ G_ .QH U:*R_M6L_\ 0,M__ G_ .QH^U:S_P! RW_\"?\ [&@#4HK+^U:S
M_P! RW_\"?\ [&C[5K/_ $#+?_P)_P#L: -2BLO[5K/_ $#+?_P)_P#L:/M6
ML_\ 0,M__ G_ .QH U**R_M6L_\ 0,M__ G_ .QH^U:S_P! RW_\"?\ [&@#
M4HJM9RWDBN;NVCA(/RA)-^?T%6: "BBB@ HHHH **** "BBB@ HHHH ****
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M2U#6-2>X1FO[C)B3I(?2AX=]Q_VA&U^4]UHKY_\ [5U'_G_N?^_AI#JVI?\
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MIQW%+8L4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ]FHKQG_ (7T/^A=_P#)O_["C_A?0_Z%W_R;_P#L* /9J*\9_P"%]#_H7?\
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M9_X7T/\ H7?_ ";_ /L*/^%]#_H7?_)O_P"PH ]FHKQG_A?0_P"A=_\ )O\
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MM>9 %.,9QD'N,UXM#XI\:_$<C08&C2)SF>2%-@"?[1]/;O5S5?$.F?#W39=
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M^%S>+/6S_P"_'_UZ /HFBOG;_A<WBSUL_P#OQ_\ 7H_X7-XL];/_ +\?_7H
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MX/(P=,/_ '];_&NUHH \,\2P1VGB*]MX5VQ1/L1?0 #%9!K:\7'_ (JS4O\
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M2B@#B_\ A5/@_P#Z!A_[^M_C1_PJGP?_ - P_P#?UO\ &NTHH XO_A5/@_\
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M $%(_P#OT?\ &O3**?MI]Q?4Z/8\S_X57/\ ]!2/_OT?\:3_ (55/_T%8_\
MOT?\:]-HH]M/N'U.CV. N?AJ)=/LH(]0Q+ K*S,G# L6X'U-4_\ A5D__04C
M_P"_1_QKTNBE[6?<;PE%]#S/_A5<_P#T%(_^_1_QI/\ A54__05C_P"_1_QK
MTVBG[:?<7U.CV/-[7X6;+J)[G45DA5@718\%AZ9S5K5OAO\ ;M3GNK:^$,<K
M;O+9,[3_ (5WU%+VL[WN/ZI1M:QYI_PJR?\ Z"D?_?H_XTG_  JR?_H*1_\
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MCN"T<D9RDJ=1[?2N:_X5=9_]!&;_ +X%=]15J<DK)F,\/3F[R6IP'_"K;/\
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MXT^@NI;HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "JFI9_LZ?%P+<[?]:?X?>K=5-4*+IDYD@,Z[>8AU
M;FG'="ELRW1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-$B%R@=2X&2N>15&?7=*MKCR)K^!)<X*E^A]ZQ-+D6;7O$%Z9PD2A8EESPH
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M-=S.LH ;"Q,W!]P*ICQSH##*W4A'J(7_ ,* .CHID4JS0I*ARCJ&4D8X-/H
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MRL8FIV5G;>(]"CM+:.&3S&),:A<H!WQ6;_IFI^*M1F.GPWXM6$444TNT1CU
MP<YKKIM,AGU6WU!V?S8$9$4$;>>M4K_PU;7E\;V&XN+.Y88=[=\;Q[BE&:ZA
M4H2;;7>]OE8H:/I][%XDEO#96]E"T.R6*&4-ENQ( XK0\4WDUCX>N98&*R$!
M P_AR<9JSI6C6NDI)Y!D>24YDEE;<SGW-6KJUAO+:2WN$#Q2##*>XJ7)<R9K
M&E)4G%:-W,BRT#2+?1426V@D1H@TDKJ"6R,DYKF+)8K/P'JLD7W;B=HH_<9"
MBNA7P=;;! ]_?R6@Z6[2_+].G2K7_"-68T:+2Q),((Y!(#N&XD'//%6II=;F
M#HSEM%*R:^\S=:T:\N;;26LT@G-FH+6TQ^5^!5,7EH-+UR1=,73]1BAV3(I!
M!STQCBM_4O#T&H7<=VES<VMPB[!) ^,CT(IB^%[)=+N+$R3M]I8--,SY=R/4
MXH4U;4<J$^9N*_JUEYHRX=*M-'\%27<=O']K-J7,I7YLL/7MUK0@D33/!".S
M ".TX]R1_B:UYK*">P:RD7= R>61GMC%8/\ PA=H]L;:>_OIH ,1QM(,)[CB
MES)_$^I3I3A_#72QCW\(3PAH.G2,$6YD3S#GL<G^M;NK:+HMGX=N4:TACBCB
M)#A1NSC@YZYS5'6].@OM>T;2'W&W2%V(S@X P/Y5>C\(VVY!=WM[>0QG*0S2
M93VR.]4Y*R=_,SC3E>244]E^!AWMO]J\*Z%'<1*US-+'&KNN6VYSC/TJUXGM
MPE[INE65I"L,[F22%2(EE*]B170ZMHT.K6\,3220-"X>)XC@J1Z5%=>'K6]T
MZ&TN)KAWA.4N"_[P'US251:,J6'E9I=EKZ?YF!>Z7?7#V:QZ-96,L4JM')'.
M V!U&,#/%6]-M(-9\1ZG=7Z"8VL@AAB?E4&.N/>M"R\-6UK>)>3W-S>7$?\
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M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*>H(ZTM% %:+3K*"7S8K2!)/[RQ@&K-%%%Q));!1110,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ,9ZT8HHH " 1@C(IJQH@PJ*H] ,4ZB@ QS1@9SWHHH :8HR^\HN_^]CF
MG8YS37=8T9V.%49)]JQK+Q=H>H7J6EK>^9.YPJ>6PS^)% &R8T9@Q12PZ$CF
MG8HHH :L:)G:BKGK@8S3J** &I&D>=B*N>N!C-.QSGO110 8YS1110 4'I10
M>E !VHH[44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %5[+SO(/GHB/O; 7IC/%6*IZ9Y7V5O)D:1?,;ENN<
M\BGT%U+E%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 56O_.^PR_9T1YL?*K]"?>K-4M6\K^RKCSY'CBV_
M,Z=1SVIQW%+8NT444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!#=_\>4__ %S;^5>,>"S_ ,5E9?[[?R->SW?_ !Y3_P#7-OY5XOX*/_%9
MV7^^W_H)H ]NHHHH **** "BBB@ -%!HH *#THH/2@ [44=J* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#O\ X4?\)!8_]/'_ (#O_A0!J45E_P#"06/_ $\?^ [_ .%'_"06/_3Q_P"
M[_X4 :E%9?\ PD%C_P!/'_@._P#A1_PD%C_T\?\ @._^% &I167_ ,)!8_\
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M3-+9HH<W<XXVQG"@^YKF9/B;J&\E+&W5>P))K2.&J25TC*>)I1=FST^BO/\
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M8S;-Y<+1+YC?*WKGK5RJUD)1 ?.E65M[?,OIG@4^@NI9HHHI#"BBB@ HHHH
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MK1K"U,6UEK]A?&RN9[F7, DB)*QJ>["MVJDNJZDP?1] HHHJ2PHHHH ****
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MM--=;_,7U5*2<7I:WR/*Q9?8Q+!>Z;<O<9PA4D#^7-:]_ISP^$H!'9S1R27
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MVF9]5D(DE,@V(0..#5Q5TT1-V:9T5% ((R.114%A1139)4AB:25U1%&69C@
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M0XK9O]>_[R4_[1[?A7+BYI4^7N=>#@Y5.;L;=%%%>4>N%%%% !1110 4444
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MQHKM]Y@,$_6GT<R6R#E;W9%;6\-I;1V]O&L<4:[55>@%2T45!84444 %%%%
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MN:%%0+>6SS"%;B)I2,A X)Q]*0W]F)?*-U")/[GF#/Y4N5]A\R[EBBF22QQ
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M>*6(YCEC.&4UG7'A<7JC[;J-U.5(VY( 'X5=.I%<NMK&=6G)\WNWOL5+V/\
MLQ]!O,8$>(7^A'_ZZFM%.MZQ<ZAG$%L##;$]-W=J/$TT%Y9Q:7;LLUU)*H55
M.=F.I/I6M'I4$>CC31E8MFPE3@^YIN=H)O=_D)0;J-+96?SL<I';1Z=$MKK6
MD[D>7_C]1LDDG@D]:U=2L[2X\3Z=";>)LQM)(2N=PQ@9]:LQ^',M"MSJ%S<0
M0L&2)R,9'3/K5C4-'^V7T5Y%=RVTT:&/<@!ROXTW5BY7OW[V%&C)1M;MVOH9
M=YIMK?>)[:R,8%M;6Y<QKP,D]/I2BPMKWQ%+8M$J6=G&KK HPKLW.2.];-OI
MB0:E+?>:[R21K&=WH*AO]%2[O%O(;B6UNE7:9(_XAZ$=ZA55M?I^);HNU[=?
MP,W4K2WL->TIK&-89I'*ND? 9/<5'9:=;:IXDU.XN0LBPN$6,]#QU([UK6.B
MQ6=TUY-/+<W1&/-E/W1[#M6+HVDM?Q2ZG#>3VUQ+,^63D,N>X-6IKE>NRM?Y
MD2IOF7N[N]O16+4]K;V'BFP%B@B:56\Z.,8!4#@D5#H&F6U_-?:A=0K*9+AU
M0.,@#/7%:]AHL-E)+.TLL]S*,--*<G'H/2K&FV":;9BVC=G 8MN;J23FHE62
MC9/71%QHMR3DM-7;[CF[-DM-"UXP\0++(L2YZ#&*6]M#)HFAZ:25,SKNQUP!
MDUKKH$"Z1-IXFDV2N79^,Y)S5J738YKNSG+L/LH.Q>QR,53K1O==_P!-"50E
MRV:Z6_'4PM<TVTLCI8M(%BF^TJJLHP2.^3WKJJIW>GQWEU:SN[ V[EU4="<=
MZMLP1&8] ,FL9SYHQ74Z(0Y92?0Y?3].M=4U_4[NY42B*;RTC/3@=2.]226T
M%CXNLTL4$9EC;SXTX&!T.*J:#H[W=H=1AO9[:>61]Q0Y##/H:WM/T:&QDEF,
MDD]S*,--*<MCV]*WJ349-7Z6L<U*#E%/EMK>_P")C:-IMK=MJ&IW,"S$S/Y:
MN,@ =\>M2^']/M]2M7U*]1;B:9V $@R$4'  ':MO3K"/3K(6R,SJ"22W4Y.:
MSO\ A'##)+]BU"YM8I3EHT((_#/2I=52YE>W;T*5%Q47RW[^IF)-_9,VNBP.
M((4#*O54<^E:6E:'8-I<<ES#'<33IODED^8DGW[5>M='L[33Y+-$+1R9\PL<
MER>Y-4$\-,D/V9-4NUM/^>((Z>F>N*'5C*]G;]05*46FU??3MJ8EFD=IH6O2
MP,2F\Q(QYR.G]:Z"[9;#PFP! V6P4?4C%20:!:P:1+IH9VBD)))ZCT_+%4Y/
M"_VBV%O=:E=31)Q&I( 7_&G*I"<KM]11I5(1LET^[<I/"\HT719&*0/#YDP!
MQO\ :MM]'TZW*745HB26ZED\OY<X'?'6EU'1H=02#,DD,T'^KEC.&6FV>CF"
MZ-S<7L]U+MV#><*!]!4RJ)JZ=O(N-)Q=G&^VO8YS2TN;J)[Z;1?M[W#$^:\J
MX ] #TJ5/M^EZ!>*8S;":<+ #(&\M6Z\BM7_ (1PQ-(MKJ-U;P2'+1(1@?3T
MJX-%LQI)TTJQ@(YRV3GUSZUI*M"_E==S*-"=O.S[?Y7*W_"/Z5#IC1RPH0$R
M\S?>S_>S4?A&(1Z&&&?GD8Y/4C.,T-X:>6#[-/JEW+; 8$9('TR>]:NGV2:?
M8Q6L;%EC&,GJ:RG-<C7->[-H4WSJ7+9)%FBBBN<Z0JIIP46S;9S,/,;YCVYZ
M?A5NJNG_ /'NW^C^1^\;Y?7GK^-/H+J6J***0PHHHH **** "BBB@#/UR4PZ
M)>..HB('X\5EW6D-+X8M##Q=VL:R1L.N>I%;.I6":E8O:R.R(^,E>O!JRB".
M-4'10 *VC4Y(JV]S&=+GD[[6L<G;:DNM:YI+C[T43/(O]UNAJSI]M%K.KW]U
M>CS5@D\J*)^54#OBM"TT"ULM6EOXBP:0'Y,# SUIEQH(:]DN[.\FM))?]8(\
M$-[X-:NI"]HNVGZF$:52UYJ^OZ6*D-O!9>+TALE$:20%IHTZ#T..U:^JW3V6
ME7-S&,O'&2OUJ/3=(@TTR.K/+/*<R32'+-5V6))X7BD4,C@JP/<5E.:<D][?
MB;PA)0:V;_ P]'T6RDTN.>ZA2YGN%WR22#<3GT]*S-)TV":VUR* DQEO+C/7
MIDC^E:B>&FBB-O'JEVEH3_J@1T],]<58M;>P\-V#QM<!8RQ?,C#)]AZUK[3?
ME=VS!4OAYHV2W,-;^34M%T[2K=CYT_R3'NJ*>:L:EID]KJ4-Q#IZ7UG%"(U@
MR/D]\5-X5TT1+/J+Q[&N7)C4]53.?UJY/H3O>37%MJ-S;^=_K%4Y!^F>E5*I
M&,W%;?Y^A,:<I4U)J[T^Y>IEN--?PA>36UKY:_,WERC.Q^G%+>VEOIW@\&*"
M-9IHDC9@N"V2.IK8_L.V&C/IJLXC<<OG+$^M1?V"9+%;6XOIIE617!('&WH*
ME58WWZW*=&=MM;6^9F:A8P:-H]NEI&J7$[+$UQCY@&Z\U>O="TJVT696MXUV
M1EO-(^;..N?K6I?V$&HVC6TX.P\@C@@^HK,_X1PRA([O4;JXMT/$3$ 'ZXZU
M,:MTKRL[_>5*C9M*-U;3R,><27^B:':3RD&>3YF)YVCH:T]8T;2K70IV%ND9
MB3<D@X;=VYZDU#J]E%J7B&ST\EDCBMV?]V<;3GC^57!X=\YX_MU_<7<<9RL;
MD!?QQUK1S2Y7>W6WS,XTV^9<M^E_D94]N^K7.A6MUGF RR\\G JU>V5M:^)]
M)6TA2%B&W[!C*@=ZVO[.B_M5;_<V]8O*5.P%$FG1R:K#?L[;XD**O;GO6?ME
M\K/[W<T]@_G=?<K&39M_Q.=<O">(E$8_ 9J'0]&LFT(W5S DLDZ,Y+C.!ST]
M*UET:);:^A$K_P"F,6=NXSZ58BLDATT62,P01^6&[XQBB556M%]OP0XT7>\E
MW^]LS_"JN/#\&XD@EBF?[N>*K>)XTO+O2[!W*"68DD'L!6W8VB6-E#:QDLL2
M[03U-8&K6::MXI@M79T6*W+[D."ISP:*<DZSGZL52+5%0ZZ(DUS2-,M-!F>.
MWCA>)<QN.&W=N>IJK<V[:M=:):76>8#++ZG '\ZTU\/>;)&U]?W%VD9RL;D!
M?QQUJ]_9T?\ :HO][;UB\H)V S35516]WKJ)T7)WM9::>C,.>PMKCQ!%I2Q+
M#9Q1><\2?*)6Z<^M+KEC:6,^GSV42P71G5%$8QN7OD5JZEHT=_/%<)-+;W,7
M"RQGG'H:9::''#>"\N;B6[N5&%>4\+]!0JJT=]N@W1>JMN]RC!;)K'B"^>]Q
M+%:,(XH6^Z/<BJ^H:99Q>)],6UC6-V;?(B<# Y!Q6I=:$LM^U[:W<UI.XPYC
MP0WU!I++P]#::BM\;F>:X"D,TASNSW]J:JQ6J?2UOD)T9/1QZWO\R+0R)M6U
MBX]9P@_ 55CNO+O=?U*,AC"HC0]1P/\ &KK^'R+R>:VO[BV2<YEC3&"?;TJQ
MIVB6VG6L]NK-)',26#\]L8I.<-7?>WZ#5.II&UK7U^__ #*&BZ-97&E)<W<2
M7,]RN^223YCSZ>E4=5@*ZC9Z1:VLD]K#'YI@$NW?SW)ZCVK17PT8XC;QZG=I
M:$Y\D$?EGKBK5[HD-T+=HYI8)[<;8Y4;YL>ASUIJK%3NY7_0ETI.'*HV>G;7
MO_3,86=XVJV4\&C"Q,3?O&25?F3T('6K&CVD.L3W6HWR+,_FM'&C\A%'M6C9
M:*MM>?;)[J>ZN NU6D/"@^@%0R>']EU+-97T]IYQRZ1X*D^N#TH=6+TO;SU_
MX<:HR5G:_EI_PQG6]A:V_C<+:J%1("[(O16/''I75UDZ9H$&F7DMTDTLLDB[
M6,AR2?7-:U8UIJ35G>R-J$'!.ZM=A11161L%%%% !1110 54U0*=-G#SFW7;
MS*/X?>K=5-3S_9L^+?[1\O\ JO[WM3CNA2V9;HHHI#"BBB@ KG[@^?XUM8^T
M%NS_ (FN@K&O- ^TZD]]'?7%O*R!#Y1 XK6DTF[OH95HR:5E?5&A?WT&GVCW
M%Q(%51WZD^@KDQILK>$;FY==DKS&Z0$<@9_PS6U#X9M5G6>[FGO77E?/?<!^
M%6=8U"TLK"99Y$W%"%BS\S9X  K2$E%J,-7<RJ0<TY5-%9F1/.?$%Y86,9W6
MR1K/<D'CV7\ZAU"UELM3O+NYTI;^TD PX()B4#H!VK4\,Z3_ &9I0\Q<3S?.
M_MZ#\J8WAHXEBCU*Z2VE8EXL@]>HS5^TA&3BGHOZZ&;I3E!2:U?]+<S=4MM/
MGT/2ULX!LFF1(RXRP!/(S4_B#3K8OING6\*0I/<9<1C' '6M2\T.&XLK:VAD
M>W^S,&B9.2"*D720;FSN)KB262V# %L?,3W-)5DK.^U_^ 4Z#=TUO;_@F/J-
ME;IJ=AH]O&MO;3Y>;9P9 O0$TOB33K&QTI9[:%(+B-U\IHQ@DYZ>];&IZ1#J
M8B9G>*:(YCEC.&6J\&@C[7'<WMY->21<QB3 53ZX%*-5>ZV]NG<)47[T5'?9
M]C-O;5-6\3VMM=GY(;8.Z XW$]1]*=XAL;.PCLY[.)(+H3JL?E#!8=Q4::=_
M:WB34IA<2P26[(D<D9Y!QS6M:Z$D=XEY=W,UY.GW#+T3Z"K<U!QUV6Q*@YJ5
MEN]S/%A#JGBV[DN%#QVL:+L/0L1GFG:?!%:^+;];=!'"MNI95&!NSZ5LVE@E
MI=75PKLSW+AFSVP,8%,BTR.*ZO;@2/ON@ ?]G QQ63JK57TLE^1HJ+T=M;M_
MF<T)#'X)O)AUNIV(_P"!-BK6I:+86/A:4^0IF6,'S3][?QWK3?08'TF#3O-<
M10L&SQEL'/-6]1L$U*S-M([(A922OL<U7MES*STO<GV#Y7=:VM\R6S#"RMPY
MRPC7)]\5SU]9Q:KXPC@G&^&"WWLOJ2>A_2NF VJ .W%5(=.CAU2>_#L9)D"$
M'H /2LJ<^5M]3:I3YDH]+G,74;3>()+2#3!<6MFHVVR.$7<>=Q'>K=A:7B^(
M(;E-,%C#Y;+,JR*0W!P<#WK3OM$2ZO1>P7,MK<A=I>/^(>XIUGHL5J9WDN)Y
MYIUV/)(W./0>E;.M'E^5NO\ G8P5"7/KWOT^72YS<UJVG-=_VKI?VNWFD+&[
M1LL 3Q[BKVH6=A/J&B116\;1R?/DKDL@7@'/;FK2^&/W0MGU&Z>S!SY!(P?;
M/I5S4-&6[EM98;B2VDM@50Q@'@]N:;K1NM>_?L)496>G;M??74S+JTAN_$$&
MD[%BL88O.,*?*')/?':F:_96MA-I\UE$L%T;A441#&Y>^16I>:(EV;>47,T5
MU NU9T/S$>_K26FAQPWBWES<2W=PHPC2GA/H*E54K.^W3N4Z4G=6WZ]C/?3X
M=5\77!N%WPVT*#8>A8^M43')<:]=+'I8N[:T(CC@#JB)WS@]:ZFVL$MKR[N5
M=F>Y92P/; P,53NM"66_:]M;N:TG<8<QXPWU!HC65[-Z6L$J#M=+6]WM^IF6
M,%W::I=7JZ=]BMQ;DO$LBL"XY!P.E3Z#I=K>:<M_>QI<W%SEV:0;L<]!Z5IZ
M?I$-@)CYDL\LW^LDE;):J2>&S 'BM-2NH+9SDPJ1@?0]J'54KJ]M@C2E&S:O
MOII_PQ5\/V5O;^(=5-L?W,86-1G(&>2!^(J]XJD,?AZY"G&_"'Z$\U8TG1H-
M'298'=A*VX[SDBC7K-[_ $6Y@C&9"NY!ZD<U+FI5E*^FA2IN-!QMKJ97B6U@
M70+:+RD9]T<4;8Y'(SC\J9X@L+>*TL;"VB2'[3<JK^6N,@ \U?:P.M:%:+<&
M2WF4*^<<JPJ8:/ODLY;B[EFDM7+AFQ\Q/K51J*-DWLV3*DYW:6Z1FZQIUG96
MUC:VT"1^==1HQ Y8#GD]^E6/%;;]/@M0</<7"(!Z\U?U72X]5MTC>1XGC<.D
MB=5(JFOAT/=V]W=7UQ<30.&4OC'';%*%2.DI/5#G3E[T8K1V*M]90ZGXL@MI
MANAM[;>5]23T-+]EAM/&$(M(EB46K-*J# /8<5L0Z='#JEQ?AV,DRA"IZ*!Z
M4JZ?&NJR:AN8R/$(MIZ 9S2]KI:^EK%>QUO;6]S$T"R@U:.;5+Y%N)I9&55?
MD1J.P%2:E!IFF6:6*63SFYEW);HQ^8_T%3'P[Y<LILK^XM8IB6>.,C&?;TI\
M_AZ)X;18;F>&6USY<H;+<]<YJG4BYWYM.Q"IS4+<NO?37O\ TS&\J5/$6E*=
M-AL7+,?W3@EE Y!Q5U=-LKCQ=<*UK"T<=N"RE!@NQZGWQ5ZUT%(-2CU"6[GG
MN%4@M(1@Y&.G:G3:,S:JU]#>2P-(%$B*!A@*;JQ;T?3S[BC1DEJNOEM8P3Y]
M[KEVW]F?;8+5A#%%YBJL>/8]:GLXKRPO[Z_73_LEL+8LT(D5@7 ST'2M6ZT(
M27SWEK>36DT@Q)Y>,/\ 45/I^D06$<PWR3O/_K7E;):B5:/+I^O_  P1H2YM
M>][Z?Y7,[0](M+G3DO;R-+JXN1O=Y!NQGL/2H?#=K!!K>K?9CNA1EC3G..Y'
MYU:3PVT"M#;:G=0VS$GR5(X]@>U7-)T>#1XYD@=V$C[CN[>U*=16E[U[E0I.
M\;QM;J:-%%%<IUA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 !HH-% !0>E%!Z4 ':BCM10 4444 %%%% !1110 4444 %%%
M% !5!M%TQI?--C 7SG.P5?HIJ36S$XJ6Z   8 P!1112&%%%% !1110!6ATZ
MSM[A[B&WC29_O.!R:LT44VV]Q));!1112&%%%% ".H=&0]&&#BH+*SAL+5+:
M $1KTR<FK%%.[M85E>X4444AA1110 4V1!)&T;=&!!Q[TZB@"O96<-A:);0
MB-!QDYJQ113;;=V)))604444AA1110 4444 %%%% !1110 4444 %%%% !57
M3\_9VS<"<[V^8=N>GX5:JIIQ0VS;(#"/,;Y3]>OXT^@NI;HHHI#"BBB@ HHH
MH **** "BBB@ HHHH **** "JUUI]I>LC7-NDI3[N\9Q5FBFFUJA-)JS$ "@
M   #H!2T44AA1110 4444 5180#4FO\ !\]D$><\8JU113;;W$DEL%%%%(84
M444 %5DL84U"2^ /G.@C)SQ@59HIIM;":3W"BBBD,**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *JZEG^SI]MP+<[?]:?X?>K55-4*#3)S
M) 9TV\Q#JU..Z%+9ENBBBD,**** "BBB@ JM+IUG/=+<RVT;S*,*[#)%6:*:
M;6PFD]PHHHI#"BBB@ HHHH K6MA!9R3R1 [IWWN2<Y-6:**;;>K$DDK(**BN
M+B&TA::>0)&O5CT%#W,,=L;AY%$(7=O)XQZT6871+15634K.*T6ZDN$6%AE7
M)QGZ4VSU6QOU=K:X238,L!P1^!I\DK7L+GC>URY16 GBBS;6)+8SQ"V$8*R<
MY+YZ5NRR)#$TDC!4498GL*<J<HVNA0J1G=Q>Q'<7=O:J&N)XX@> 78#/YU*"
M&4$$$'D$5R5K=Z;JOB:[DN9(YD55CME<9![DBNHMKB"XMUEMW5XCP&7IQ55*
M?)8BE5Y[VV)J*J?VG9?9?M/VE/(W;-^>,YQBHH]=TR6[%JEY&TI. !T)] >E
M1R2[%^T@NIH45#<W4%G$9;B5(D'=CBJD.NZ9/'))'>1E8QE\Y! ]<&A0DU=(
M;G%.S9HT5AZ3XCM]0N)X7DC5A*5A49RZCO5S3!$D5Q.EZUQ')*S;G/">P]A5
M2IRC?F)C5C.SB:%%9JZ_I3W'D+>Q%R<#G@GZ]*MW-[;6FS[1.D8D.%+'&34N
M$D[-%*<6KID]%4+76]-O+@P6]VCR]EY&?IGK4EYJEEI^!=7*1D]%)R3^ YHY
M)7M;47M(VO?0MTQ)HI-VR1&VG:<'.#Z5#;7]M>VQGMIEDC'4CM]?2N22W>3P
MC<7J,5E6Z:Y4@]<'_P#75PI<V^FR(J5N7X==&_N.VHJ*WE\^UBF'21 WYC-2
MUD]#9.X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%%  :*#10 4'I10>E !VHH[44
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M^AC$0S[8YJ6YL8;N6WDEW9MY/,3![T.NN9/U8EAWRM>B,61([_QB8;H!H[:
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MD49%+10 F11D4M% "9%&12T4 )D49%+10 F11D4M% "9%&12T4 (2*,BEHH
M3(H)&*6B@!,BC(I:* $R*,BEHH 3(HR*6B@!,BC(I:* $R*,BEHH 3(HR*6B
M@!,BC(I:* $R*,BEHH 3(HR*6B@!,BC(I:* $R*,BEHH 3(HR*6B@!,BC(I:
M* $R*,BEHH 3(HR*6B@!,BC(I:* $R*,BEHH 3(HR*6B@!,BC(I:* $R*,BE
MHH 3(HR*6B@!,BC(I:* $R*,BEHH 3(HR*6B@!,BER*** "D48&,D_6EHH *
M3(I:* $R*,BEHH 3(HR*6B@!,BC(I:* $R*,BEHH 3(HR*6B@!,BC(I:* $R
M*,BEHH 3(HR*6B@!,BC(I:* $R*,BEHH 3(HR*6B@!,BC(I:* $R*,BEHH 3
M(HR*6B@!,BC(I:* $R*,BEHH 3(HR*6B@!,BC(I:* $R*,BEHH 3(HR*6B@!
M,BC(I:* $R*,BEHH 3(HR*6B@!,BC(I:* #.:1AN4C)&>XI:* "C-%% "9%&
M12T4 )D49%+10 F11D4M% "9%&12T4 )D49%+10 F11D4M% "9%&12T4 1O%
M#(ZL\:,R_=++DBGY%+10%A,BC(I:* $R*,BEHH 3(HR*6B@!,BC(I:* $R*,
MBEHH 3(HR*6B@!,BC(I:* $R*,BEHH 3(HR*6B@!,BC(I:* $R*,BEHH 3(H
MR*6B@!,BC(I:* $R*,BEHH 3(HR*6B@!,BC(I:* $R*4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img224999359_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_8.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %, Z@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"HYYDM[>2>3.R-2[8] ,U)5/5_\ D#7W_7!__0332NQ-V1R/_"V_"V>)+L_]
MNYKH(?%.F3:O%IF^2.XF@$\?F)M5TQG@UYAX4LO$4OA^TDL]>T>VM23MAN$4
MN!GG.16Q\4C%<PZ5962--K9!:)K<\B/'S=.QKME0I\_(O/\ K8XHUZGL^=^7
M];G;V'BK2M1MKZZAF9;6R<I+/(NU,CK@]ZRK'XF^&+^_6SCO)$=SM5Y8RJ$_
M6N.U*>RF^#UD-.1DM8IXUO4'W@0WS[OQK:\9S>&&^'KBW-DQ:)?L8BQNW\8Q
MCFI5&%[-/5V]!NO.UTUHK^IUMQXHTNU\10:%-,RWLZ!XP5^4@YQSZ\5/;:Y9
M76N7>D1,YN[5%>4%<  ],&O)M8T>]UGQ/IT,<C1ZE!HD<\9[^8N2!6U\.]8;
M7?&^L7\D9BF:TB65#V=2 ?U%$L/%0YD]D..(DY\K6[.X\0>*=*\,01RZE.4,
MIPB(NYF]<"J]CXUT34M$NM5MKAFM[4$S*4PZ#_=K \<0V]QXIT<V^HP6>L1*
MS0+=QYAD3N">@/%<ZM]&8/%UG=6%I#JC61DEGLI-T4B\8XZ TH4(R@GU_P""
M$Z\XS:Z?\ ]#O/&6CV.B6FK3S.(+O'D(J9D?/3"U*?%.G)J9TY_.2Y%G]M9&
MCQB/W]^.E>3:"+O1[WPUKOB*-)M+FC^SVQ)R+7^ZQ'3GDUU.K$-\4;\@@@^'
MW(([_>JI8>"=O44<1-J_H:47Q8\*RRHGVBY0,P&]X"%'N35_6OB#H.@:A]BO
M99S,8UD'E1%@5;H<BO.M#TGQ7KO@:UTRUT_35TNX!5;I\>:%WDD^O7-:.H6V
ML6/Q&^R:':VM[<0:5#$PNL8VCC//?BK="ES-=K]?ZL0J];E3[VZ?U<[:/Q]H
M$N@2:S'<2-:QR"*0",[U8] 15Q?%>E-XB30C*ZWSQB159<*P(SC/KBO--=\/
M:EI'@;6;_5EACN]1O8I&@@^Y& ?RINOZ5=:EX\NY;!V2_L=/ANH,?Q,H&1^(
MJ5AZ3V>FOZ?YE/$55NM=/U_R/5+;Q!I]UJ>H6"2,LVG@&X+C"J",]:P&^*7A
M5;W[-]LD/S[?-$1\OZY]*X&'4YM>T[QOJ-JCQR30PLZ#J,8#C]#6YJ6L:+9^
M"-/BL-$M=4L9(/WX60(8R ,Y[YSFCZM%.S3?_#7#ZS)JZ:7_  ]CU..1)HED
MC8.C@,K Y!%.K)\,7L>H>&M/NHK86T<D(*P@Y"#L*UJXI*S:.V+NDPHHHI#"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KC]1^)GAW2]1N+&YDN?
M/@<HX6$D CWKL*\\\*OIZ^*O%XOFMAF]&/.*],'.,UM2C%IN2O8QJRDFE%VN
M=#-XVT2'2;35//=[*ZD$2RHF0C>C?W:N7WB+3]/U*QT^5W>YO?\ 4I&N[(]3
MZ#WKB/!^E6.NV'BNP10=)GO6%N5'RK[K].*7X8Z>]R][K6H3M<W-LQL8"W)1
M$]/<UK*C3BF^WZ[?\$RC6J2<5W_3?_@&_??$GPUI^J/837<AD1]CND9**?<U
M:UWQQHGAYK<7LLI%PGF1M%&7!7US7G0B6#3-8ETBZTO4-)DF9IK6]'ESJ<_,
M 3S]*[-9K'4OA:UU;6@BA%BPC23YB@ Q@$TY4:<;:/L3"M4E?57W"+XJ>&9H
MI9%ENML2[F)@/2I+#XG^&=0O8K2.XGCDE;:IEA*KGZURE_#&OP.M9%B02%4^
M8*,GYO6JEU_;>JZII.AZ_;Z=ID,CQS131IS+C^$,.,U:H4G?Y]>WR(=>JK>B
MZ=_F>C^(/&FB>&I(XM0N6\Y^1%$N]@/4CTI^G^+]&U31Y]3M+GS(+=2TJ[<.
M@'JM<EH1TZ'XE:^NK&(7>%%L;@C_ %>.V:S;Y[*3Q;XE;1]GV0:6PN3#]PR?
MAQ4*A#;6]D[]#1UYKWM+7:MU.GM?BKX6NKF*%;BX0R,%#R0D*,^IKH[77;&[
MUJZTF%G-U;1K)("OR[3TP>]>4:7H?BOQ'X3T_318:;#I<@0BZX\P*#G/KFM!
M]/U^3XC:M;^']0AM9(K6%9'G7=N4 #TJIT*=VD]O,F%>K9-K?R.XG\:Z/;+J
M;2/-C36"W&(^A/3'K4A\7Z0NL66EM,ZW-Y$LL(9, @].?6O)I([V'1O&T>HS
M)->+)$)9$& QSU%7M;T>;6O%&F06LACNX=%2>!A_?7D"G]6I]7_5D+ZS4Z+^
MKL]6M]<LKK7+K1XV?[7;1K)("O&#TP:TJ\M^'FL/KOCC5KZ:,QSFRC29#V=2
M ?Y5ZE7+6I^SERG51J>TCS!11161J%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%(S*BEG8*HZDG J+[7;?\ /Q%_
MWV*+!<FHJ'[7;?\ /Q%_WV*/M=M_S\1?]]BG9BNB:BH?M=M_S\1?]]BC[7;?
M\_$7_?8HLPNB:BH?M=M_S\1?]]BC[7;?\_$7_?8HLPNB:BH?M=M_S\1?]]BC
M[7;?\_$7_?8HLPNB:BH?M=M_S\1?]]BC[7;?\_$7_?8HLPNB:BH?M=M_S\1?
M]]BC[7;?\_$7_?8HLPNB:BH?M=M_S\1?]]BC[7;?\_$7_?8HLPNB:HYH4N()
M(9!E)%*L/8\4W[7;?\_$7_?8H^UVW_/Q%_WV*+,+HX\_"?PD3G[#+_W_ &_Q
MK<L/"NE:;J?]HP0N;D1"%7D<MM0=AGI6I]KMO^?B+_OL4?:[;_GXB_[[%:2J
MU):-LSC2IQU21F6?A;2+%K_R;7]W?G=<1,Q*,?\ =/ K-LOAOX6L-06]ATX&
M56W*'<LH/T/%=+]KMO\ GXB_[[%'VNV_Y^(O^^Q252HNK&Z=-]$5#H=@=>76
MO+;[<L/DA]QQL],=*BT_PWI>E:M>:G9VYCN;S_7$,<'G/3M6A]KMO^?B+_OL
M4?:[;_GXB_[[%+FEL/EAN9VO>&=)\2VZ0ZI:B81G*,"59?H152P\$:!IFEW>
MGVMELANU*S'>2[#TW=<5N?:[;_GXB_[[%'VNV_Y^(O\ OL4U.:7*F["<(-\S
M2N9MQX8TJZ\.IH4UOOL$0(J%CE0.F#US4<7A/28;M;H1RM,MG]B#-*3^Z]/U
MZUK?:[;_ )^(O^^Q1]KMO^?B+_OL4N>?<?)#L0:3I=IHNF0:=8H4MH00BEB2
M,DGJ?<FHUT2Q37I-:$;?;GA$+/N.-H[8JW]KMO\ GXB_[[%'VNV_Y^(O^^Q2
MO*[?<=HV2[%76=&LM>T]K'4(VDMV8,55BO(Z<BF0:!I]OK3ZO'$PO'A$);><
M;1T&*N_:[;_GXB_[[%'VNV_Y^(O^^Q0I22L)QBW<S=,\,:3I%W>W-G;;'O3F
M<$DJWX'@=:RF^&GA1K_[8=,&_=NV;SLS_N]*Z?[7;?\ /Q%_WV*/M=M_S\1?
M]]BJ52HG=-B=.FU9I#XHHX8EBB14C4855& !3ZA^UVW_ #\1?]]BC[7;?\_$
M7_?8J+,NZ)J*A^UVW_/Q%_WV*/M=M_S\1?\ ?8HLPNB:BH?M=M_S\1?]]BC[
M7;?\_$7_ 'V*+,+HFHJ'[7;?\_$7_?8H^UVW_/Q%_P!]BBS"Z)J*A^UVW_/Q
M%_WV*/M=M_S\1?\ ?8HLPNB:BH?M=M_S\1?]]BC[7;?\_$7_ 'V*+,+HFHJ'
M[7;?\_$7_?8H^UVW_/Q%_P!]BBS"Z)J*A^UVW_/Q%_WV*E!# $$$'H12'<6B
MBB@ HHHH **** "BHC=6X.#/$"/]L4GVNV_Y^(O^^Q3LQ71-14/VNV_Y^(O^
M^Q1]KMO^?B+_ +[%%F%T345#]KMO^?B+_OL4?:[;_GXB_P"^Q19A=$U%0_:[
M;_GXB_[[%'VNV_Y^(O\ OL46871-14/VNV_Y^(O^^Q1]KMO^?B+_ +[%%F%T
M345#]KMO^?B+_OL4?:[;_GXB_P"^Q19A=$U%0_:[;_GXB_[[%'VNV_Y^(O\
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M +XH_P"$,\-_] :T_P"^*W:*/:3[L/9P[(PO^$,\-_\ 0&M/^^*/^$,\-_\
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M_P! :T_[XH_X0SPW_P! :T_[XK=HH]I/NP]G#LC"_P"$,\-_] :T_P"^*/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@"CJ6EPZHMJLQ8"VN8[E-IZLAR,^U9;^#=.EFNC+)-)!.)=
ML#-\D1E(+E?<D?A7144 8]GX;L8+2Y@NE^W_ &IUDG:Z ?S"H"KD=. H_*N<
MATK3].^+%O'96-O;(^CN76*,*&/FCKBN[KD)_P#DKEI_V!I/_1HH ZSR8SU1
M>?;\:/)C/\"_E3Z* &>3&?X%_*CRH_[B_E3Z* ,35/$>@Z-<>1J-W#!*5W[6
M4]/7@4:9XDT#6KG[/I]Y#/+M+;54\CUY%6=?BC;0-29HT8_99>2H/\!J/PU%
M&OAS3&6- WV6/D*!_"* *7C3Q):>#?#%SK-Q;><(\*L:C[S,>!^=<;X)^,6E
M^)K&[DU+3WLYK;YG\J-I4V'OD#C\:U/C3?&P^&=_((89M[QQ[9DW+@MU^M?/
MW@_QCJ&CZ!J.F:='%']I4B5DMM[.",8+9XII7(G-05V?2-]\1_".FI$]_>-;
M+,-T9FMW7>#W&1SVKIK*XLM2LHKRS>*>WF7<DB<A@:^3_$ESJGC<6 N[DB2R
M@$2*T!C4+_4U[Q\$05^%VGJQR5EF7\G--Q:W)IUH5+J+V/0##&<Y1>?:@PQG
M.47GVI]%2:C##&<Y1><YXH,,9SE%YSV_&GT4 ,,,9SE%YSV]\T&&,YRB\Y[>
M^?YU2U76]-T2*.34;I+=)&VH6!Y/X5GVGC?PY?7,=M;:K#)+(^Q% /+>G2@#
M=,,9SE%Y]O?/\Z/)C/\  OY>^?YT^N<\;>*!X3\-7>I+;R7$\<9,4:H2"?\
M:(Z"@#H/)C_YYKS[>^?YT>3&?X%_+WS7CGPH^+FI^+-4NM.UNV4M@-#-;0G"
MY.-K8SCZU[-0 SR8_P"XOY>^:/)C_N+^7XT^B@!GE1_W%_*CRH_[B_E3Z* &
M>3'_ '%_*CR8S_ OY4^B@!GE1G^!?RH,,9ZHOY4^B@!GDQG/R+S[4&*,YRB\
M^WXT^B@!ABC.<HO.>WOF@PQG.47GV]\T^B@!AAC/5%_+WS_.@PQGK&OY>^?Y
MT^B@!AAC/6-?R]\_SH\F,]47\O?/\Z?10 SR8S_ OY>^?YT>5'_<7\O?/\Z?
M10 SRH_[B_E[YH\J/^XOY>^:?10 SR8_[B_E^-/HHH **** "BBB@ HHHH *
M*** "N./A"ZBMM.>&6UENK&ZNIE6X0F-UF9B0>^0&'Y&NQHH X&+X?W5M;FR
MAOXC:W4=JMX60[\PMN^3L >G/3%;.K^!](UB_EOKIKT3.!GRKET7@8Z UTM(
MWW3]* .-^& -Q\/-*DGDDEDQ("[N23B5L9-=<+>,8X/'^T:Y/X5_\DXTK_MK
M_P"C7KL: (OL\8['_OHT?9XQV/\ WT:EHH B^SQCL?\ OHT?9XQV/_?1J6B@
M"+[/&.Q_[Z-'V>/T/_?1J6B@"+[/'Z'_ +Z-'V>/T/\ WT:<\L<>-[JN>FXX
MIHN(&( FC)/0!A0 ?9X_0_\ ?1H^SQ^A_P"^C4M% $7V>,=C_P!]&C[/&.Q_
M[Z-2T4 1"WC'8_\ ?1H%O&,<'C'\1J6B@"(6\8QP>,?Q'M0+:(   \?[1]<U
M+10!%]GC'8_]]'US0+>,=C_WT?7-2T4 1"WC&.#Q_M'US1]GC&.#Q_M'US4M
M% $0MXQV/_?1H^SQCL?^^C4M% $7V>/T/_?1H^SQ^A_[Z-2T4 1?9X_0_P#?
M1H^SQ^A_[Z-2T4 1?9X_0_\ ?1H^SQ^A_P"^C]:EHH B^SQ^A_[Z/KFC[/'Z
M'_OH^N:EHH B^SQ^A_[Z/KFC[/'Z'_OH^N:EHH B^SQCL?\ OH^N:!;QC'!X
MQ_$?7-2T4 1"WC&.#QC^(^N:!;QC'!XQ_$?7-2T4 1"WC&.#QC^(_6@6\8QP
M>,?Q&I:* (A;QC'!X_VC0+>,8X/'^T:EHH B%O&,<'C_ &C0+>,=C_WT:EHH
M 8D21G*@],=:?110 4444 %%%% !1110 4444 %%%% !1110!A:YXMTK0)5@
MNFGEN67<(+>%I'QZX'2HM&\:Z1K5RMK%]IM[EONPW4#1,WTSUJ36O$MGH4TG
MVNUG7]UNCG$?[MVP?EW#H?KQS3/"^O3^(K=[B?3U@1 ICD#A@Q(Y ]Q_6@#H
M:**\GN-<U6WN-5NXKF<B5+T0.7R'"2*%PG\&Q=W)ZT >L5R$_P#R5RT_[ TG
M_HT4W2=6_LI-<7-YJ%G97$2P>4#-(0\2,V/7YF)]JS-/UR/5_BI%,EE?6PBT
MAP5NH#&S9E7H.] 'HE%1&=1GY7XS_#[XH,ZC/R/QG^'WQ0!+141G49^1^_\
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M9-RD?,6S[54(\SL88BM[*'-=+U/0]+^*D?A#PU>KI'A(6MQ/<RL+AG78,N2
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M 2T5%YZ_W7_[Y]\4>>O]U_\ OGWQ0!+141G4?P/_ -\^^*EH **** "BBB@
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MXB_Y%C5O^O.;_P! -?,>B?\ (#LO^N*_RKZ<\1?\BQJW_7G-_P"@&OF/1/\
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M MT&.6_[Z/KF@"6BHA;H.[?]]&@6Z#'+\?[1H EHJ(6Z#NW_ 'T:/LZ>K?\
M?1H EHJ+[.@[M_WT:/LZ>K_]]&@"6BHOLZ>K?]]&C[.GJW_?1H EHJ+[.GJW
M_?1H^SIZM_WT: ):*B^SIZM_WT:/LZ>K?]]&@"6BHOLZ#NW_ 'T:/LZ#NW_?
M1]<T 2T5$+=!CEN/]H^N:!;H,<MQC^(^N: ):*B%N@QRW&/XCVH%NB@ %^,?
MQ'US0!+140MT&.6X_P!H^N:!;H,<MQ_M'US0!+140MT&.6X_VCZYH%N@[O\
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M(;E/0\^U4="^(VLVEK=K%X)O9@]]<R$B\B&UFE8E?PSC\*=F1[2/<].\1?\
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M$OY#_&@"6BHO.;_GA+^0_P :/.;_ )X2_D/\: ):*B\YO^>$OY#_ !H\YO\
MGA+^0_QH EHJ+SF_YX2_D/\ &CSF_P">$OY#_&@#E/B9XKO/!O@NXU6PMQ-<
MAUC0L,JA;^(CT%<O\&?B-K/C8:C:ZQ%&TEJ%=;B)-H()QM(]:[CQ!X?TK7[>
M0:I87$Z>608S.ZH1[JK@'UY%<S\-/"VBV'AG3M0M=.FBN9,N[Q3N%=@[ $KO
MP<#U% 'HU%1><W_/"7\AZ_6CSF_YX2_D/7ZT 2T5$)F_YX2_D/7'K0)F./W$
MO;L/7'K^- $M%1"9CC]Q*,X[#UQZT"9CC]Q*.G8>OUH EHJ(3,<?N)1G'8>O
MUH$S''[B49QV'^- $M%1"9CC]Q+V[#_&@3,<?N)>W8?XT 2T5$)FX_<2_D/\
M:!,Q_P"6$OY#_&@"6BF)(7.#&Z\9RV*?0 4444 %%%% !1110 4444 %%%%
M!1110!P'Q0MG-KI.H&/198;*Y+R1:Q-LA?*%0,8.X\Y%9OPZCUZ._N;RTL?#
M0T6_N/,F.EW;,L)5 N%0+@'@9Z=:N?$F\M!>Z3LU31K>]L)S.8M34NC*RE1P
M._7![8JI\/%U>35[^]M;_P /75A=7 >\%@CJ4(3"A1TSQR>] 'J%%%% !7(3
M_P#)7+3_ + TG_HT5U]<A/\ \E<M/^P-)_Z-% '7T444 %9'B7Q'9>%M';4[
M])G@$B1[84#,68X'!([UKUP'QC_Y$(_]?UM_Z,% ,?J_CZUFT2_C&BZPI>WD
M7+11X&5/7YZCT/Q[:P:!81'1=8;9;H-RQ1X. .GSUB:I_P @F\_ZX/\ ^@FF
M:1_R!++_ *X+_*M>1'#]:G:]B3XD^(K+Q3\'9-4L%F6![R) LR;6!63!R,GN
M*\YK>NO^3=/^XF?_ $>:P:TH=3BS;>'S ]*]>^"O_),[+_KO/_Z,->0GI7KW
MP5_Y)G9?]=Y__1AHQ'0>4[S^1Z%1117,>T%9VO\ _(MZI_UZ2_\ H!K1K.U_
M_D6]4_Z])?\ T T >2^#_P#D3-%_Z\X_Y5/H7_'I=_\ 7_<_^C6J#P?_ ,B9
MHO\ UYQ_RJ?0O^/2[_Z_[G_T:U;H\F6[]1_A;_D(?$O_ *]8/_2=Z\QT3_D!
MV7_7%?Y5Z=X6_P"0A\2_^O6#_P!)WKS'1/\ D!V7_7%?Y4Z/Q,C,?X$/ZZ%^
MN]^"/_(8\5_]=+?_ - -<%7>_!'_ )#'BO\ ZZ6__H!JZ_PF.5?QGZ?JCV.B
MBBN0]\**** &3,$@D<J7"J25'?CI7RSX UNP;XW>>N@PHEU<O'#$N3]F;)^<
M>_K]:^J:XW1]&TRW^)&N7<-A;QW'D0'S%C (+;MQ_''- '95\PW_ /R-WB;_
M +"DO]*^GJ^8;_\ Y&[Q-_V%)?Z5K1^,X,R_W=^J&UM?#[_DK6C?]>MS_P"@
MUBUM?#[_ )*UHW_7K<_^@UO6^!GDY?\ [Q'Y_D?0U%%%<9]*%%%% !1110 5
M\[?&+3+;4_BBL=RK%4TR-AM..=[5]$UX%\4O^2K'_L%1_P#H;5=-7DKG-C).
M-"3B[,X@:#:*4VRW0V#"8F/RCVKH_"%NEOXPT!5+,1>K\SG+?=;O5"M3PO\
M\CIH/_7ZO_H+5U3BE%V/!P]2<JT%)]4?1E%%%<1].%%%% !1110 4444 -=$
MD0HZJRGJ&&0:9!:V]L"+>"*('J(T"Y_*N<^(.LW.A>$+F^M+M;20.B&=H_,\
MM68 L%[D"LOP-JL5_J=PD?CA]?VPY\AK41;.?O9 'TH [RJDVEZ?<6AM)K&V
MDMBQ<PO$I0MG.=I&,Y).:MUE:SKD>CM:1?9Y;BXNW9(HH\#.U2Q))( P!0!;
M?3;"6X@N)+*V>:W&(9&B4M&/13C(_"K+?=/TKEV\=Z;L@FB@NI;=H(;B:54
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MIZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?,-__P C=XF_["DO]*]FT+XC:1X@UV'1X(-8MKJ='>/[7;>6I"\GG->,W_\
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MI>&E+>,M! 8K_IJ\CZ-77/X6?/X7^/#U1]'45$86.?WK_G[YJ6N$^J"BBB@
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M4 1>0H_B?_OJN9\>^'=,UOP?J$>HP>>(('EB+'E'"D@@UU=9/BC_ )%35O\
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MV2.0JR_..A%=5I.KV&N:;#J&FW*7%K*,I(G^>M<G\8O^25ZW_P!<U_\ 0UH
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MFB*S1J&,;[QM8@\$ XS4/A70YH=;N-:U'7+;4[^2V%N@MD5$2/.<X'4DXYH
M[&N0\:R7<E[H^GPRQQP73S>:996C0E4RH9EP>O8'G%=?5>\L;74(#!>6\4\1
M.=DBAAG\: /+)-9N+JS>\-Y=6TEI864E@K3$EV>0JY/_ #TS@+SV-=KJ_BV7
M2[^2T'A_5KL(H/G6\0*'(SP<UMR:982RV\LEG SVXQ"QC&8_IZ5:;[I^E '%
M?"J8GX;Z0?*DY$AZ=,RO78^<?^>,GY#UKD_A7_R3C2O^VO\ Z->NQH B\X_\
M\9/R%'G'_GC)^0J6B@#@_BGK.IZ5X3@ETJYFL;F6^AA\Y5!(5B0>M>=ZM-XL
M_LB]\WQ?J,L?DON0PQ@,,'(Z5WGQE_Y$^R_["MM_Z$:Y+6?^0-?_ /7!_P"5
M;T8*2=S&I)IJQ0TJ;Q9_95F(O&&HQQ^2FU!#&0HQP.E=1X7UK5-6^%?B5]5N
MIKZ>![J 3.H!*JN!TK&T;_D$6/\ UQ3^5:/@?_DE7B[_ *^KW^5.K",4K!3D
MVW<\4C_U:?[H_E4-G_J6_P!]OYTX[A"C"41J%&21GM4%HRR B&[#@-DC97L.
M5I)'EJ/NL]6^!+;?&.MD*6_T*/@?[]>]^<?^>,GY"O!O@/\ \CGK?_7C'_Z'
M7OU>+B?XLO4]6A_#B1><?^>,GY#UH\X_\\9/R'K4M%8FI%YQ_P">,GY#UH\X
M_P#/&3\AZU+10!$)C_SQD_(>N*!,?^>,GY#UQ7 ?$/X@ZGX#7[3)96,MI*VR
MW!F;S9#C)^7L!5[P!XQU+QI9+J9M;*/3V#*3%*3(L@_A*GI0!#\7I"WPIUX&
M-U_<Q\G_ *ZK7SB.@^E?27QA_P"23Z__ -<D_P#1B5\VCH/I7IY=]KY?J<&.
M^S\Q:]G^!#E;+7@$9O\ 2(N1_N5XQ7M7P%_X\=>_Z^(O_0*VQ_\ "^9E@_XG
MR/6A,>/W,GY"@3'C]S)^0J6BO&/4(O./_/&3\A1YQ_YXR?D*EHH B\X_\\9/
MR%>-_&?X?/K=@VOP7MT)K;[T,[;D"D@80=J]IKF/B%_R(^I?[J_^A"@#+^&O
M@H^"=!B@>[N[F:5=\B;OW2D_W5[?6HOC'^^^%FL921=JHWI_&*[NV_X]8O\
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MQO+?57_M)KV19+AY$VARJA5X'3 45SMCX?TK1?BK##IUE%;QRZ0[.J=&(E%
M'H&Y?4?G1N7U'YTPP1'.8UYSV]\T&"(YS&O/M[YH ?N7^\/SK@/C&0? 1P1_
MQ_6W_HP5WA@B/6->?;\:X'XPQHO@,E5 /VZW_P#1@H$]C%U0C^R;SD?ZA_\
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M7!W_ /R-WB;_ +"DO]*=/^(3B_\ <_G^HVMGX?''Q9T8G_GUN?\ T&L:MCP
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M0^)?_7K!_P"D[UYCHG_(#LO^N*_RIT?B9.8_P(?UT+]=[\$?^0QXK_ZZ6_\
MZ :X*N]^"/\ R&/%?_72W_\ 0#5U_A,<J_C/T_5'L=%%<?KGQ(T#1]2DTE;I
M+G5QA5M$;!9CT7<> :Y#WSL**^:/#WQ5\;/\1)(KM9+F#S'$UAA5$:#/0GIC
MUS7N?AOQYX>\53R6VEW\<MS$NZ2'N/IZ_A0!YOH7_(8\4_\ 88F_I3[+_D:=
M5_ZXP_UJKILLT&H>*Y(+<W$@UB7$88*3T[FH8+C6H=8N[TZ!*4N$1 OGKD;<
M_P"-;1V1YM1>_(V=-_Y*WX<_Z]+K_P!!%<#?_P#(W>)O^PI+_2N]TLD_%CPT
M67:QL[HD9Z?**X*__P"1N\3?]A27^E.G_$(Q?^Y_/]1M;7P^_P"2M:-_UZW/
M_H-8M;7P^_Y*UHW_ %ZW/_H-:UO@9Y^7_P"\1^?Y'T-1117&?2A1110!XOXY
MTFRUKXNR6]_&TL,>BQ.J"1E ;S7&>#Z5SM]X,\/IXETF!;#]W*DQ<&1B3M (
MYS77^)?^2RW'_8"B_P#1SUG:A_R-NB?]<[C_ -!%:Q2L<-:4E4:3_JP:;X8T
MC2?$NA75C;-%-_:$:[O-8\%6R,$UG?%+_DJQ_P"P5'_Z&U=0/^0SH?\ V$HO
M_07KE_BE_P E6/\ V"H__0VIQ_B(SJMO"3O_ %L<Y6IX7_Y'30?^OU?_ $%J
MRZU/"_\ R.F@_P#7ZO\ Z"U=$_A9X^%_CP]4?1E%%%<)]4%%%% !1110 444
M4 <E\1+_ $^U\+RPWRV<IF8".&ZG,2L<]<CGCKQ7*>#M)UR6$W^B^-(+F)9%
MSIZYEB1<\J6;Y@<9Q6GXEBO;3XB1:LWAFZUJT33_ "H?*56$4A?).&[XIWA:
M.]NOB!=ZK_PC5UHMI)IXBD$JJHED#Y!PO?&>: /0Z**P/%,EK%9Q-<W5S&Q8
MK#;VS[7GD(X [\=?3UH WZ1ONGZ5Y?>7VM6L=PNH:G)'?:786+Q^6PVS2NY$
MA(_BS@+^-=5JWB]]+OY+/^P-7NMB@^;;P;D.1G@T 5?A7_R3C2O^VO\ Z->N
MQKB?A5-GX;Z0?+DY$AZ=,RO78B8G'[J3\J ):*B$V?\ EE)^5 F/_/*3\J .
M ^,O_(GV7_85MO\ T(UR6L_\@:__ .N#_P JZKXQ2;_"%E\CK_Q-+8\C_:-<
MEK#_ /$FO_E;_4/V]C730^%F%;=#]&_Y!%C_ -<4_E6CX'_Y)5XN_P"OJ]_E
M69H[_P#$HL?E;_4IV]JT/!$F/A7XN&QS_I5YT'M3K[(5+=GB\?\ JD_W1_*G
M4V/_ %2?[H_E3J]M;'DL]+^ _P#R.>M_]>,?_H=>_5\__ EMOC+6S@G_ $*/
MI_OU[WYQ_P">4GY5X&(_BR]3V:'\.)+147G?],I/RH\X_P#/*3\JQ-26O,?B
MT VJ^#P0"/M\O!&?^61KTD3$_P#+*3\J\S^*\F[5O!WR./\ 3I>H_P"F9JH?
M$B9?"SF=<BC&@:B1'&#]ED_A']TU>BBBV1_NH^@_@'I6=X@NH8O#^H^8X3-N
MZ_,0.2IP*O6MU%/#"\3!U9005(.:[^IQ]#.B '[/OC( 8']J3_\ HZ.O,AT'
MTKTR-O\ BP'C)=I_Y"<YSCC_ %T=>9CH/I5X#>?R_4G&[1_KL+7M7P%_X\=>
M_P"OB+_T"O%:]G^!$FVRUX;&/^D0\@?[%:X_^%\S/!_Q/D>Q45%YQ_YY2?E[
MT><?^>4GY5XQZA+147G'_GE)^5'G'_GE)^5 'GWQ3U?6=/N/#UII&IR:>;VY
MDCEDC16) 3(X->/?$73?%&HZ=!/=ZW<:K! ?FCD54V9[X'6O4_BQ+NUOP?\
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M>U<A=O-+XBUVZ2POS#=7\DT3?97^9#C!Z5]144U-J7,14PT:E/V;V/EO=/\
M] ^__P# 5_\ "M3P=>G2_B'IFJ7EG?QV<,$Z22&U<X++@=J^D**J55R5F8T<
M!3HS4XMW1RG_  L7P_\ WKW_ , I/\*X?QQ\=;?P]>6UKH^G-=LZ^9*URK1
M#/0 C)/%>QUSWB3P1X>\6R02:SIR7$D'W'R5./0D=161W'E&I?M&1PZE9K9Z
M*7LVC1K@RN5<$C)"CH<>O>IT_:&@?Q@MC_9+#2&E$0FR?.YXW;/KVZUZ-?\
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M4C&[1_KL+7M7P%_X\=>_Z^(O_0*\5KVKX"_\>.O?]?$7_H%:X_\ A?,SP?\
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MMT_@7H%%<]K_ (Y\-^&+N&UUC58;6>8;E1LDX]3CH*K:I\1_">C:G;Z=>ZQ
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MJ+Y$,T1"(N&3/RI]X_[W %>IQVMO$&$<$2!A@[4 S226EO(K!H4R5VY"C(%
M'D%]X@U'5/!LL;ZLE])<VCO<(L0_T8B0!3QT],'K6^=7UF'68=#74Y"OVR&,
MSF)=VQH]Q'IU'6NVTK1K/2-,BL+>,-%&NW+@$MSGD]ZN^3'NW>6F[.<[1F@#
MS0>,]5_X2*2&UD-S!MNE$;[-V^)25^0?,O([]>U0'Q-J\FH65I::^MPES]EW
MR+"I,32,0X]/PZBO3Y+6%UDP@1G!!=!AN1C.?6LS2?#=KI5Q+<^=/=7$BJIE
MN"I(5>@& !WZ]: .:\/:QK,NKV$=WJ!N(9KN[M71H@ORQ E6R._'-=]3!%&I
M!"*""2,#N>M/H **** "L7Q?_P B9KG_ %X3_P#H!K:I&4,I5@"",$'O0!YI
M=-K&G-X9O'N(KMX=.NI((4@*G>+<$ \G/I3+;Q?JBZ9/+/>K)%(+<1RQR1%D
MDDSN4D?*B\<%NGO7INQ,J=JY7[O'3Z4P6T 1D$$>QCEEV#!/O0!YGIGB#7-;
M^QVDM^T(>TOC*855FD,<FQ/FQCIW'6NO\!L6\":*6F:9OLJ;G8Y.<<@_3I6^
ML,2$%8T4C."% I41(UVHJJH[*,"@!U%%% !1110 4444 %%%% !1110 4444
M %%%% '&Z]X9U*\U74)+%K?[/JD-O%.TI(:'RG)R!_%E21[&KFK>$9=3U"2Z
M3Q%K%FK@#R+:951<#' (KIJ* .#T_P"&2Z78QV=GXIUZ&"/.U$G4 9.3_#ZF
MN-^(OP8UG7OLESI>MW&H3P@HT>I3=%/.5(''TKVZB@#Q;2/V=]&&DVZZSJ%Y
M)?!<R^0X" ^BY&<58N/V=?#,KHT>HZB@!^8%E;</3IQ7L-8GBG77\/Z5'=I'
M"S27$< ,TFQ%W'&2?04 <M-\([&XTR#3)O$&MO96Y5HH#.NU"OW2/E[5B>+_
M (1:4OAC4+J?5]5N&M8'FC6:52-P&?[M=K:>+C(]S'.+-O(EBC,]K-YL3%^W
MJ"/>K;^)M%NX+A)UD:S"/NEEMV,,H'# '&#Z8[]LT[L+'!^&/@_I*^'K*>WU
M?5K?[1"DSK%*H&X@$_PUL6OPEL[*PN+&V\0ZY%:W+,TT2SKARWWB?E[UT \7
M:+9V7*3VZQ-'$MN;<A@&^YA1V/M3SXRTO"JJW3W!=D:V6 F5"O+;E[8%%V%C
MBA\!?#@&!J6K8'_39?\ XFE_X4-X<_Z"6K?]_E_^)KU&*59H4E3.UP&&00<?
M0T^J]I/NR>2/8\WTOX.:9HEQ+<:9KNM6LTJA'>.=064'.#\M:W_"!3_]#?XA
M_P# A?\ XFNRHJ6V]64E;8\UUGX+Z1XAFCEU?6M8O)(E*HTLRDJ/3[M7;3X7
MP6%I':VGB36X;>(;4C29 %'_ 'S7>,P52QZ 9-<O_P )1?-ICZW'IB-HZ@ON
M\W]\T8ZR!<8Q@9QG.*0&!J/P;TG5W#ZCJ^J73A2H>5HV8#TSMJ2;X16%Q!8P
M3>(-;>*PXM5,ZXBXV\?+Z<5UP\2::8I9!*Q2*X2V8A?XW"E?PPPJ,>*-.^WB
MTE%Q!O\ ,\N6:%DCDV?>P3Z8/]* /.?&7P\A\/>#]4U:UU_6&GM83(@DF4KG
M(Z_+6O:?"FSGLX)F\0:WN>-7.)UZD9_NUK7GC;1[F6>UOK&5],^Q+<R-<6Y(
MD5I5C7"$?,"6!_I6B/%EC;RS02QRQM$T,45LL)\UF=20NWIG"D^P%5S2[BY5
MV.:'P=TT:3<:4-=UK[!<N9)K?SUVNQ())^7U JC_ ,*%\.?]!+5O^_R__$UV
MTOC#2X45F%T3Y9EE46[;H$!(+.,<<@_ED<4-XQTA;Z2U\R8B*1(Y9A$?*C9P
M"F6Z<Y'YT*4ELP<4]T<5_P *&\.?]!+5O^_R_P#Q-:.E?"6ST195TSQ#KEJL
MQ#2".=1N(&!GY:Z[3/$-EJT[1VJW!7YBDK0D)(%."5;ZUJT.<GHV)1BMD<;_
M ,(%/_T-_B'_ ,"%_P#B:Y_6O@;H^OWHO-0UK5KBYP%:6616)4=!TKU*BI*/
M+9?@1X<F^S^9?ZDWV<!8LLGR@=!]VFWGP&\.7]X;NZU#5)+@XRYD4$XZ=%KI
M8O%.K2VE]J*:;;/8V=Q)$ZK,?-*H<%@",>^,UI+XHM3YI6*><K($1+>%G8Y7
M=SV'!H YN]^%%IJ36K7GB+7)C:G,!:=?W9QCCY?2N!^)WP?M;#PY)K-KK5]-
M-;,H9+Q]X*LP'RX'')KUP^.-&*VYB-S,9X6G58X&)5%;:Q8=L'K527Q;HNH7
M-UI]];">R#Q*)3#YD+;^5+<8'.,47"QR7A[X'V.G:1#'+K^J"9US*+:4)&2?
M12#6L?A#IYT/^Q#K^MG3,8^S>>NS&<]-OK74IXIL'6;R8+R589?(_=V[$,X.
M"J_3UZ>]1?\ "9Z2;=)5^TNYW[H5@8R1[/O%E[ ?_JHN%CB_^%"^'/\ H):M
M_P!_E_\ B:7_ (4-X<_Z"6K?]_E_^)KKI/'FB1Q+*7N3$8$N6=8&(CC<X#-Z
M5JZ7K5IJ[7"6_FK);L!)'+&48 C*G![$=*OVD^[)Y(]CC=)^$EEH23)I?B'7
M+19F#R"*=1N(& 3\M:/_  @4_P#T-_B'_P "%_\ B:[*BHW*/!_'/P*U?6]<
MAOM.UMKL2*$G?47S(F.X('(]JHZM^SI?R:G;&QUM)+5D19WN03(I P<>H]!V
MKZ&HH ^>+_\ 9VU)_$\9M-81M*8JSSS$F= .HQT)XX-;?Q'^#VM:U863:3K=
MYJ4MN2#!J,XP >ZG'7CO7M,S^5#))C.U2V/7 KD[;Q[977AS2M2C>U:ZOI((
MS:+<*60R.%/'7C.>G:@#R6\^%-QX7^'UO+J6K7:WLEY"DEO;S?N4#2 <<<D=
M<^M=A?\ P#\/ZE*L]QJVK22\ O+*K$@=NE=Q-X@T'49/LES'YT'F,(Y)8-T4
MDD>20AQRPP?R.*#XSTJ..X:=;NW,$23%)K=E9D9MJLH[C/'K3NPL<Y_PJ*P_
ML1=&_P"$@UO^S5  MO/78 #D<;?6L_\ X4-X=_Z"6K?]_E_^)KM-$\3-K.NZ
MII_V"XMTLA&5>9-I;<N>1VKH*:E*.S$XI[H\K_X4-X<_Z"6K?]_E_P#B:T=)
M^$EEH4<R:7XAURT69M\@BG4;FQC)^6O0Z*'.4MV)12V1RMAX,FL;Z&Y;Q/KE
MP(VW&*:=2C^Q&WI75445)04444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<YKWCSPQX8OD
MLM:U:*TN7C$JQNCDE22 > >X/Y5T=>8^(-2_X1_XNOJ=WH^J7UE-H:6RM9V3
M3C?YS-@XX''\Z /1K*^M-1LHKVSN(Y[:90T<L;95@?0U.2!U(%>%RZ!>V>C:
M&VO:'J4WAU[B\GN-*L06>%I&S#N5""0!G@'@FJNL:%J0\)>'YM6L=7N[FW$W
MV>PDMY+A-I?,8D9'#(X7 SSC\* /?\@'KUJM?ZC::7:-=7LZPP*0I=O4G 'X
MDBO#/&.D^)]0\6:?</:W=H'M+<6316\MS]DE'W@&5@%.>I;.17HOCH3"V\,"
M=@T(U6W^TL1@$X.,_P# L4 =L&4XP1S1D8SD8KPV?P?+=:I?ZE)9:DMW)XGD
MB\R-I$S:M]X@#C:?[WZU7NK$:58Z?IVK6FH2:#'K5S&MC&["60?\LRH)#,H/
MH?>@#V_4-5L=*A2:]N%AC=]BD@G+8)QQ]#3[#4+35+&&]LIUFMYEWQN,C</7
MFO(/"%I)J'AO3[:&WN6M;8W]Q\^7.[E44MW;FLO1M-U[1?!^K_VA',E[/I8>
MSO6!C$$0.&@)/"-W]\T >Y7^I6>F6;W=[.L-NF-TAR0,G SCWJR"&4$$$'D$
M5X+H::.%\2?V?97=I8/X?5C%>N22^3\P!)P"?SZU[+X7\_\ X172OM7^O^R1
M[_KM% &M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !6'XJT>YUO2X8+0VXEBN8Y\7 .Q@IS@XK
M<HH XR3PC>WMQ<75Q]@MI9FA'EVJMM*(<DL2!EN<4K^%=6G\/R^'IKFQ&FJA
M6&01L9&PVY-X/&!CG'6NRHH \^U'0-1L;""2WL=)AO3>0!?LL+E2 3DN>N/Y
M59O/"&I7B33SKIDUY<3&1B3(GD' "F-U^;/KTS7<44 5=-MIK/3+:VN+EKF:
M*,*\S=7('6K5%% !1110 C*'0J>A&#7#:AX:\4IH?]A:5?Z:NG!6BW31MYK0
MMGY.. 0#@-^E=U10!Q4WA/5?/DBM9[..QFO(+MQ(&,J;%4%!V/W!S]:HS?#_
M %&_OX'U"\MWC1[CS)@\CRRK(K*/O':F PX7CBO0Z* .#N?"&NZC)NO;O3U\
MNSAM8_)5^=DZ2%FSTR$Q@=#6A>^&-0;Q#<ZU97%L)S-#)#'*&VD+&R.K8Z9W
M9!'I7644 <1>>$-1N]5DU2>+1[NXNH%BN([B)RD94G:4[D8;!!QG%00Z'JUY
M?ZWIT1M;?2Y+N$LS1,),(J$A!]W!V@>W-=]10!RFC>&KW3_$#7Y:TM;<JXDA
MLRX6X8GAF0G:I'JO4DUU=%% !1110!QD'AS7H++4-,2?3UM+VYED:;YS(J.>
M0!TW8_"FW7@_41<,UG=0M;&;>;:621%<; HW%""2,9QT-=K10!YGIGAO7M$U
M2VTZT>RD;^SY5EFD1Q&-\I(VX[C/0ULP^"9K;1KK3H;J,B62W9&8'I&03GZX
MKLZ* .2NO#&I-I(M;>\C#?;7N7C\QXUE0DG863YA^%<RFB7W@QY9_M%NUW=B
M<;4M9GB"O@@*5!.X$=^M>IT4 <+I?A._;PTT,SQPS7.G00%'!RC+R<_G70Z;
MH\UEK^J:@\J-'>)"J* <KL4@Y_.MFB@ HHHH **** (YT,L$D8."RE0?J*Y2
MW\&F'PAH^D9M?M5E);/),(\!O+=6;'?D UU]% '"6?@:[LHWMH/[+C"&9K>_
M$)-RA?=M/H&&[J.PJO'X!U)KI[B:XM$9K:.#"/+(6*R!RS,Y))//TKT.B@#&
ML=)N+/Q+JFH%XFM[U(OEYWJR+M^F#6S110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !115;4;HV.EW=VJAC!"\H4]]JDX
M_2@"S17$Z#K_ (IU[0+'5HH-'BCNX1*L;M(2H/8FK%_K'B?3+)[R>'2'BC*[
MUC,@8@L!QGZT"NCKJ*!R*YRYU358/&-O:.D":8]O(X .9'91G)]![4#.CHKC
M=(US4Y)M&N[NX22WU9I%$"Q@>20"5P>IX'.:M:WXKN=*U&[MH--^TI:6JW,K
M^:%X+$;0,=>* .HHKD1XRG^WG3&TT#4G>,11>=\I5U+9)QQ@ Y%*GB>\O[!/
M*MOLEY]MDMW0G> (P2QS[@4 =;17#:/X\-]H7VR.W^TE&CMBV[9YMRQQM [
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MA+::C>:CIDVFRW5Z\JV\SJS!<* 25X[4Q&UJNI1:3I\MY-'+(J#B.%"[,?0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]W:?94Q_",A@P_V@17/OX8U)]7@MXQ<1V45^MV[M,IC? Y;;C.2>WKS7?44
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)
MFC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +1
M29HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "
MT4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0
M M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,
MT +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)F
MC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +12
B9HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4E% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img224999359_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_9.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )& S<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !3)E9X)%0X<J0I]#BGT4 >=GPOXN)/_ !-3_P"!3T?\(OXN_P"@J?\
MP*>O1**U]M(XOJ-/N_O/._\ A%_%W_05/_@4]'_"+^+O^@J?_ IZ]$HH]M(/
MJ-/N_O/._P#A%_%W_05/_@4]'_"+^+O^@J?_  *>O1**/;2#ZC3[O[SSO_A%
M_%W_ $%3_P"!3T?\(OXN_P"@J?\ P*>O1**/;2#ZC3[O[SSO_A%_%W_05/\
MX%/1_P (OXN_Z"I_\"GKT2BCVT@^HT^[^\\[_P"$7\7?]!4_^!3T?\(OXN_Z
M"I_\"GKT2BCVT@^HT^[^\\[_ .$7\7?]!4_^!3T?\(OXN_Z"I_\  IZ]$HH]
MM(/J-/N_O/._^$7\7?\ 05/_ (%/1_PB_B[_ *"I_P# IZ]$HH]M(/J-/N_O
M/._^$7\7?]!4_P#@4]'_  B_B[_H*G_P*>O1**/;2#ZC3[O[SSO_ (1?Q=_T
M%3_X%/1_PB_B[_H*G_P*>O1**/;2#ZC3[O[SSO\ X1?Q=_T%3_X%/1_PB_B[
M_H*G_P "GKT2BCVT@^HT^[^\\[_X1?Q=_P!!4_\ @4]'_"+^+O\ H*G_ ,"G
MKT2BCVT@^HT^[^\\[_X1?Q=_T%3_ .!3T?\ "+^+O^@J?_ IZ]$HH]M(/J-/
MN_O/._\ A%_%W_05/_@4]'_"+^+O^@J?_ IZ]$HH]M(/J-/N_O/._P#A%_%W
M_05/_@4]'_"+^+O^@J?_  *>O1**/;2#ZC3[O[SSO_A%_%W_ $%3_P"!3T?\
M(OXN_P"@J?\ P*>O1**/;2#ZC3[O[SSO_A%_%W_05/\ X%/1_P (OXN_Z"I_
M\"GKT2BCVT@^HT^[^\\[_P"$7\7?]!4_^!3T?\(OXN_Z"I_\"GKT2BCVT@^H
MT^[^\\[_ .$7\7?]!4_^!3T?\(OXN_Z"I_\  IZ]$HH]M(/J-/N_O/._^$7\
M7?\ 05/_ (%/1_PB_B[_ *"I_P# IZ]$HH]M(/J-/N_O/._^$7\7?]!4_P#@
M4]'_  B_B[_H*G_P*>O1**/;2#ZC3[O[SSO_ (1?Q=_T%3_X%/1_PB_B[_H*
MG_P*>O1**/;2#ZC3[O[SSO\ X1?Q=_T%3_X%/1_PB_B[_H*G_P "GKT2BCVT
M@^HT^[^\\[_X1?Q=_P!!4_\ @4]'_"+^+O\ H*G_ ,"GKT2BCVT@^HT^[^\\
M[_X1?Q=_T%3_ .!3T?\ "+^+O^@J?_ IZ]$HH]M(/J-/N_O/._\ A%_%W_05
M/_@4]'_"+^+O^@J?_ IZ]$HH]M(/J-/N_O/._P#A%_%W_05/_@4]'_"+^+O^
M@J?_  *>O1**/;2#ZC3[O[SSO_A%_%W_ $%3_P"!3T?\(OXN_P"@J?\ P*>O
M1**/;2#ZC3[O[SSO_A%_%W_05/\ X%/1_P (OXN_Z"I_\"GKT2BCVT@^HT^[
M^\\[_P"$7\7?]!4_^!3T?\(OXN_Z"I_\"GKT2BCVT@^HT^[^\\[_ .$7\7?]
M!4_^!3T?\(OXN_Z"I_\  IZ]$HH]M(/J-/N_O/._^$7\7?\ 05/_ (%/1_PB
M_B[_ *"I_P# IZ]$HH]M(/J-/N_O/._^$7\7?]!4_P#@4]'_  B_B[_H*G_P
M*>O1**/;2#ZC3[O[SSO_ (1?Q=_T%3_X%/1_PB_B[_H*G_P*>O1**/;2#ZC3
M[O[SSO\ X1?Q=_T%3_X%/1_PB_B[_H*G_P "GKT2BCVT@^HT^[^\\[_X1?Q=
M_P!!4_\ @4]'_"+^+O\ H*G_ ,"GKT2BCVT@^HT^[^\\[_X1?Q=_T%3_ .!3
MT?\ "+^+O^@J?_ IZ]$HH]M(/J-/N_O/._\ A%_%W_05/_@4]'_"+^+O^@J?
M_ IZ]$HH]M(/J-/N_O/._P#A%_%W_05/_@4]'_"+^+O^@J?_  *>O1**/;2#
MZC3[O[SSO_A%_%W_ $%3_P"!3T?\(OXN_P"@J?\ P*>O1**/;2#ZC3[O[SSO
M_A%_%W_05/\ X%/1_P (OXN_Z"I_\"GKT2BCVT@^HT^[^\\[_P"$7\7?]!4_
M^!3T?\(OXN_Z"I_\"GKT2BCVT@^HT^[^\\[_ .$7\7?]!4_^!3T?\(OXN_Z"
MI_\  IZ]$HH]M(/J-/N_O/._^$7\7?\ 05/_ (%/1_PB_B[_ *"I_P# IZ]$
MHH]M(/J-/N_O/._^$7\7?]!4_P#@4]'_  B_B[_H*G_P*>O1**/;2#ZC3[O[
MS*\/65_8:4L&HSF:X#DEMY;CMR:U:**S;N[G7"*A%170****104444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?#O7O^$R3PZR6RZK)$;@1;AM'&[;Z9]NE?9U9YT/2FU<:L=.MCJ(&T77ECS
M.F-W6@#G?AC_ &TOA"*+7-*M].N(G,:Q0)LW*.-Q'0$UV5%% !1110 4444
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MHP<^W&.];_\ PL'PM_8TNKC6(#813_9VF&2 ^>G_ ->@#DO^$9^+O_0]:?\
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M_L(0_P#LU>E6'_(/MO\ KDO\A0!8HHHH **** "BBB@ HHHH **** "BBB@
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M4K@0JX<L<=\88U[%7E?Q0_Y'KP%_V$#_ $KU2@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'GUS\(M)FUJ_U:#6M=L[F^E,LWV2\$8))SCA>E;?AWP5;^'GN3
M_:^KZDEPGEM'J-UYR@>PQ7344 ><M\&M##RPP:GK-OI<K[Y--AO"L#<\C'I7
M877AG2+OPVWA^6RC_LPQ>4( ,!5'3'H1USUS6M10!P>E_"K2K#4[2\N]3U;5
M%LFW6MO?W)DBA/8A?:MCQ3X*TWQ6UM//+<V=]:DFWO;.3RY8\]1N]/:NDHH
MYGPMX'TWPM-=7<4]W?:C=8$U[>R^9*P'09["LO5_A;I>HZK=:A::GJNE->'-
MW%I]R8XYCZE?4UW5% &=H>B:?X=TB#2],@$-K",*O4D]R3W)]:T:** /*_"W
M_)>/%O\ U[1?TKU2O*_"W_)>/%O_ %[1?TKU2@ HHHH **** "BBB@ HHHH
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M% !1110 4444 >5_%#_D>O 7_80/]*]4KROXH?\ (]> O^P@?Z5ZI0 4444
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M^YFC"L;HAHX44?P@CCI7!>&M0AM)/'_BC0H1%HB0LUJ -J2RQH2SJ/3(H ]
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M4K+5/C;XJNK&ZBN()+:,I)&V0V,9Q7KU !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MROPM_P EX\6_]>T7]*]4H **** "BBB@ HHHH **** "BBB@#EG_ .2I0_\
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M'^E>J5Y7\4/^1Z\!?]A _P!*]4H **** "BBB@ HHHH **** "BBB@ HHHH
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M10 4444 %%%% 'E?Q0_Y'KP%_P!A _TKU2O*_BA_R/7@+_L('^E>J4 %%%%
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M_1-]0_[_ /\ ]A1_PM;Q9_T3?4/^_P#_ /85ZU10!Y+_ ,+6\6?]$WU#_O\
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MXK\:Q>&-"U%].LH+1;R^O(@#(0WW$7/3J#6G\6+B*'X::NKD;IXUAC']YV8
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M[YKXB&X";K"6,GY4XX&1ZU[*#D @YKB+KX=M>M]FNO$.I3Z49Q.;*0JPR#N
MW8SC-=LH"J%'0# H 6BBB@ HHHH **** .1^*'_)-==_Z]C3_AG_ ,DT\/?]
M>4?\J9\4/^2:Z[_U[&G_  S_ .2:>'O^O*/^5 '5T444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% '.>(/ GAKQ1()=6TJ&>8#
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M=\"_]##;_DW^%:/_  KWPA_T+FG?]^11_P *]\(?]"YIW_?D4 9W_"W? O\
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M&W_)O\*/^%N^!?\ H8;?\F_PK1_X5[X0_P"A<T[_ +\BC_A7OA#_ *%S3O\
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MVCVO$X8'IT(KUJ@ HHHH **** /)/B9_R4OP;_VU_E6]6#\3/^2E^#?^VO\
M*MZFA,****8@HHHH **** "BBB@ HHHH YSP+_R6_P 2?]@Y/_0EKV"O'_ O
M_);_ !)_V#D_]"6O8*DH**** "BBB@ HHHH **** "BBB@#/U#0],U2\LKN]
MM(YKBQD\VW=LYC;U%:%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 >6?'W_DGT'_ &$(?_9J]*T__D&VO_7)?Y"O-?C[_P D^@_["$/_ +-7
MI6G_ /(-M?\ KDO\A0!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* .+^+/_ "3'6_\ KC_458^&/_),O#W_ %Y)_*J_Q9_Y)CK?_7'^HJQ\,?\
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MMNLBX8PJ-JMCW_I4]Q\'?!%U<RW$ND;I)7+N?-;DDY/>NY1%C1410J*,!0,
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M5_BS_P DQUO_ *X_U%6/AC_R3+P]_P!>2?RH ZRBBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'O6/^^S_ (T?\(QXC_Z'O6/^^S_C7645K[./8X_K-7N<G_PC'B/_ *'O6/\
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MHZC!I5DUW<^9Y2D ^7&7/Y#F@"W17,_\)[HG_3]_X!2__$T?\)[HG_3]_P"
M4O\ \30!TU%<K+\0_#]N@>:2[C4L%!>SD )/0?=ZU)_PGFB>E]_X!2__ !-
M'345S/\ PGNB?]/W_@%+_P#$U);^-='NKF."/[;OD8*NZSD S]2O% '14444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG#2XS^=?8&!Z48'I33L1*/-UL?('V_Q7_P _OB__ +ZE_P :1[[Q:5^6^\7
M^YE_QK[ P/2C ]*?-Y$^R_O,^.OMOC+_ )__ !7_ .1?\:/MOC+_ )__ !7_
M .1?\:^Q<#THP/2E?R'[-_S,^+]1U#Q&D"?VAJ'B(1&12OV@R ;QTQD]:M_;
M?&1Y^W^*SG_KK_C7N/QUP/#.D_\ 84B_K7I]N!]FBX_@'\J+^0<C[L^/_MOC
M+_G_ /%?_D7_ !I1>^,<C-_XKQ[>;_C7V)@>E&!Z47\@]F_YF?('V_Q7_P _
MOB__ +ZE_P :/M_BO_G]\7_]]2_XU]?X'I1@>E/F\B?9?WF?(UAK7BVQUBPN
MS-XJG@AG1YHI#*0Z Y(Q7LO_  NR#_H4]>_\!S_A7JF!Z48'I2;N:1CRJUSR
MO_A=D'_0I:]_X#G_  H_X79!_P!"EKW_ (#G_"O5,#THP/2D4>5_\+L@_P"A
M2U[_ ,!S_A1_PNR#_H4M>_\  <_X5ZI@>E&!Z4 >5'XVP@''A+7B>P^SG_"J
MW_"\I?\ H2-<_P"_?_UJ]>P/2C ]* /(?^%Y2_\ 0D:Y_P!^_P#ZU,E^.5SY
M+^3X(UKS<'9OC.,]L\=*]AP/2C ]* /!_P#A>7BS_H1IORE_^)H_X7EXL_Z$
M6;\I?_B:]XP/2C ]* / YOCSXGMH6FG\%/%$O+.YD 'U)6EC^._BF:-9(O!,
MCQL,JR^801[';7H_Q8P/ACKG'_+#^HK3\"@?\()HG'_+G'_*@#RC_A>7BS_H
M19ORE_\ B:/^%Y>+/^A&F_*7_P")KWC ]*,#TH \@7XY3[!O\$:WNQSB,XS^
M5+_PO*7_ *$C7/\ OW_]:O7L#THP/2@#R'_A>4O_ $)&N?\ ?O\ ^M5D?&R'
M'/A+7L_]>Y_PKU7 ]*,#TH \K_X79!_T*6O?^ Y_PH_X79!_T*6O?^ Y_P *
M]4P/2C ]* /*_P#A=D'_ $*6O?\ @.?\*/\ A=D'_0I:]_X#G_"O5,#THP/2
M@#RO_A=D'_0I:]_X#G_"O3+"Z%]I]O=B-XA-&LFQQAER,X/O5C ]** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** *@TRP&I'4A9P"]*;#<;!O*^F>N*MT
M5S&M>(+O3_&>@:3$L9M[_P WS2PY&T9&* .GHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ***X'4/'/B*76;ZQ\.^#[F_AL7V37%Q,(%=L9P@;K]: .TN
M--L;J[@N[BTAEN+<YAE= 6C^A[5:KEM#\=Z9J_A*X\03*]E%:;UNXIOO0NGW
ME/K7,?\ "T->BTY?$%QX-GC\-,0WVK[0IE6(G D,?7'>@#U"BH;2[@O[.&[M
M9!)!,@>-UZ,I&0:FH **** "BBB@ HHHH **** "BBB@ HHHH ***R_$6O6?
MAG0;O5[Y]L%NA;'=SV4>Y/% %J^TVQU.)(K^TAN8T8.JRH& 8=",]ZM    #
M %9/A[5+K5O#]KJ5_8_8)9X_,,#/N**>1DX':N,?XCZ]J#WEYX<\)OJ6C6CL
MC737"QM+M^]L4\G% 'I-%97AW7[/Q-H=OJMB3Y,PY5N&1AU4^X-:M !1110
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M8K"^X:>BGY-I'4YY-=CX-;Q"N@QV_B:%%U"W)B,T;AA.HZ/QT)'K0!T%%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI'_@''_A0!YM_P -'>'?^@7??FM'_#1WAW_H%WWYK7I/_"$^%?\ H6](_P#
M./\ PH_X0GPK_P!"WI'_ (!Q_P"% 'FW_#1WAW_H%WWYK1_PT=X=_P"@7??F
MM>D_\(3X5_Z%O2/_  #C_P */^$)\*_]"WI'_@''_A0!YM_PT=X=_P"@7??F
MM'_#1WAW_H%WWYK7I/\ PA/A7_H6](_\ X_\*/\ A"?"O_0MZ1_X!Q_X4 >;
M?\-'>'?^@7??FM'_  T=X=_Z!=]^:UZ3_P (3X5_Z%O2/_ ./_"C_A"?"O\
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M_0+OOS6C_AH[P[_T"[[\UKTG_A"?"O\ T+>D?^ <?^%'_"$^%?\ H6](_P#
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MQZE<1*S]0BM@#\*PM3B;X9>-AK-N"/#6LRA+Z(?=MISTD'H#WJK\/=6U/3O
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MB\\"Z[XEAMI/[/E\117Z*%^_ APS8].]>_Z=?6VI:=;WEI*LD$T8=&4Y!!%
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MI=*2 PY0!3CF@#WBBH[>47%M%, 0)$#8/;(J2@ HHHH **** "BBB@ HHHH
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MBB@ HHHH **** "O-M8^&#ZI\3[3Q$+B(:6&6:YM23F29!\AQC'H>O:O2:*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)-N.2??FNUJ*YMH+RVDMKF))H)5*O&XRK ]B* /-$\/^([/PRUM!XWMCX=6
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
? "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img224999359_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_10.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &C X0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:YIVKW#3"YT\DPA' 4Y]1CFMBHEB'R)+>VK]2XX=<[;VNK+T1X1!Q\+O%O\
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M1_PC_BC_ *&;_P A5UU%'M'_ $@^JP[O[W_F<C_PC_BC_H9O_(5'_"/^*/\
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M*/\ H9O_ "%7744>T?\ 2#ZK#N_O?^9R/_"/^*/^AF_\A4?\(_XH_P"AF_\
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M;=;/\#2AS/?I=?B+1117,=(4444 %%%% !1110 4444 %%%% !1110 4444
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M5\9W ,5G;)#<22K<Q3MY<#, @)SR!C/M73?:(?\ GM'_ -]"C[1#_P ]H_\
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MXOJ*-%1DI+H%%%%8FP4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC_GKJ7_@PF_^*KI:*/:S[A[*GV.:_P"$&TC_ )ZZE_X,)O\ XJC_ (0;2/\
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MDCL*[BN;\5C_ $OP[_V%8_\ T!ZNG4FY6;(J4X*-TCI****P-PHHHH ****
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MUKFTZ=/V3DHI:>1M4445F=04444 %%%% !1110 4444 %%%% !1110 4444
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MX]T+Q9X-\'7FN1?$'5[E[=HP(G15#;G5>N?>O7H[:X=$D_M"X 8E]H6/ !7
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MUE<%&4:G<J2K@,$CR"6R#]SJHX';'7)YHELKF3?LU.YBW,S#:D9V@K@ 90\
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M1E#!(L@ELAON=0/E';'4$\T2V5S)OV:I=1[F9AM2([01@ 90\ \C/.3SD<4
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M 0.E06'BFXA6X;4I()P+:*XC^SK@EGZ1XR<G-'++R)]I2TU>OF_\S6^PZ_\
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M==W(QGOB@#MJ\Y\?_P#)1?AW_P!?MQ_Z M>C5YSX_P#^2B_#O_K]N/\ T!:
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MQ<_Y)5X@_P"N"_\ H:UX=:?\>5O_ -<D_D*UP^[.#-MH?,FHHHKI/$*.L_\
M(#OO^N#?RKZ#\"6,;> O#LOFW.38028$[A<^2%QC.,8YQTSSUKY\UG_D!WW_
M %P;^5?1O@+_ ))[X<_[!MO_ .BUKEK[H]W*?X<O4U%TR)0H$]V=HC S<N<[
M#QGGG/?^]WS5BW@6VA\M7D<9)S)(7/)SU//?\*EHK ]4**** "BBB@ HHHH
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MM#@<KM(QGICD#H#SUJ%;.T4KB]N#M\O&;QSG9TS\W.>_][OFEU[_ )%W4_\
MKTE_] -?%]CIMK-91221DNPY.X^M;4:,JSY8F56K&DKR/LW[#9[-GVVYQLV9
M^VOG&[=G.[KGC/7''2L?PG:6K^%-/+7<ZEHGR%NW&-_!Q@\8[?W>V*^4AI%E
MG_5'_OLU'!I=F\",T9)(Y^<UO]0JWM=&'UVG:]F?9BVMHL@<7DY(=7P;MB,J
MNT#&>F.2.A/)YI8].MS&%2YNV551,_:W)^5MPR<]3W/4C@\5\;#2++/^J/\
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M54LSN>N !T'))%=+7.>*_#]QK(L+NQ%BU_I\K20)?Q%X7W*58-CD<'((Z$4
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M<_Y)5X@_ZX+_ .AK7AUI_P >5O\ ]<D_D*]Q^+G_ "2KQ!_UP7_T-:\.M/\
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MO^[W[]O6IH9HKB/S(94D3)&Y&!&0<$9'N,5@>J/HHHH **** "BBB@ HHHH
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MW/ ]37G9C\,3OP'Q2/7J\(_:#_Y#7A3_ ';K_P!IU[<=1LE#%KRW 4,23*O
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MH XDD/&X#G!'YUV=%/GBD[+\?^ +DDVKO\/^"?.7QP1(_B3IJ1JJJ-)&%48
M_>R5P->@?'/_ )*9I_\ V"1_Z->O/Z]7 ?POF>=C?XOR"BBBNPY#6\&HLGQ)
M\,(ZJRF\Y##(/%?5_P!DMAN_T>+YLY^0<YZ_G7REX*_Y*9X7_P"OS^E?6=>'
MC?XS^7Y'L83^$C+UV&(:!J;B) WV:9L[1G.PC/UQQ7Q[IG_(-@_W3_,U]C:]
M_P B[J?_ %Z2_P#H!KXYTS_D&P?[I_F:UR_^(_0SQWP+U+=%%%>N>6 ZU[A^
MS_#$_@;42\2,3JLN25!)PL9'ZUX>.M>Y_L^_\B+J'_85F_\ 0(Z\[,?AB=^
M^*1ZF;: @@PQD'(/RCG/7\Z\+_:!1$UOPJ515+"Y)P,9.(^M>\UX1^T'_P A
MKPI_NW7_ +3KSJ/\2/JCNJ_PY>C/*Z***^B/""G6P#:WHP(!!U& $$<'YQ3:
M=:_\AS1?^PE!_P"ABL,3_!EZ&V'_ (L3[$%M ""(8\@@CY1VZ?E2?9;?;CR(
ML8QC8.F<X_/FIJ*\ ]L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /.OB;'/876F:_#XKLO#WV59(?-GM_-:;
M?@E .X^7.,'IFK/PYU+4]96ZOKCQA8Z_9X"*MM:>2T3]?F'7D>M'CK3=377M
M(\0:?H\&N"PCECDTZ1PKX<K^\CSQN&W'T-,\$6.I3^*-4\0:AHL&@B[MHX8]
M/216D<(S$RR;>,\X''2@#OZ*** "BBB@#SOXY?\ ))=6_P!^#_T<E>@6_P#Q
M[1?[@_E7G_QR_P"22ZM_OP?^CDKT"W_X]HO]P?RH DKY,T3_ (]KK_K\F_\
M0J^LZ^3-$_X]KK_K\F_]"K:A\1YV:?P/F:=%%%=9\\%=Y\"O^0AXP_Z^8/\
MT%ZX.N\^!7_(0\8?]?,'_H+UA7^%'J95_%?I^I[)7D?Q[_Y OAS_ +"Z?^@M
M7KE>1_'O_D"^'/\ L+I_Z"U<T=SVZGP/T/.^]%'>BO0/D K'\4_\B[=?5/\
MT(5L5C^*?^1=NOJG_H0J9_"S;#?QH>J_,^L;/_CQM_\ KFO\JGJ"S_X\;?\
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M]&KSGQ__ ,E%^'?_ %^W'_H"T >C4444 %4=:_Y .H_]>LG_ *":O51UK_D
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M=>[UX1^T'_R&O"G^[=?^TZ\ZC_$CZH[JO\.7HSRNBBBOHCP@IUK_ ,AS1?\
ML)0?^ABFTZU_Y#FB_P#82@_]#%88G^#+T-L/_%B?9-%%%> >V%%%% !1110
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MHEW).UK>3-+N@>/ 9!C[P&>AKVED5OO*#]17G/CU%7XB_#S:H'^FW'0?["T
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MV@^6S'HHQPN/K]:ZY=7L7=469BS,BC]VW5UW+V[C\N]<5\#_ /DDFD?[T_\
MZ.>O0Z\0]<^;_C5<Q7GQ#TNX@8M$^D J2I&?WLG8\UPE>@?'/_DIFG_]@D?^
MC7KS^O:P'\+YGDXW^+\@HHHKL.0T_"=Q%:?$/PU/.VV)+O+':3CCT'-?5$VM
M:?;[_,F8;'9&_=,<%5#'H/0U\N>"O^2F>%_^OS^E?6=>'C?XS^7Y'L83^$C'
MUF^MY_#FH&-R=]K(%^4C.8BPZCTKY!TS_D&P?[I_F:^QM>_Y%W4_^O27_P!
M-?'.F?\ (-@_W3_,UKE_\1^AGCO@7J6Z***]<\L!UKVGX":C:VW@G4XY9"KK
MJCD@(QP&$:KT'K7BPZU[G^S[_P B)J'_ &%9O_0(Z\[,?AB=^ ^*1Z4VL6**
MS-,P"B1C^[;HAPW;L?S[9KQ'X^W,-QKGAE8F+&(W*/\ *1@[8SWZ\$5[Y7A'
M[0?_ "&O"G^[=?\ M.O.H_Q(^J.ZK_#EZ,\KHHHKZ(\(*(9%BUC1Y'.$34(&
M8XS@!A13K7_D.Z+_ -A*#_T,5AB?X,O0VP_\6)]=KK%BSJHF;+-&H_=MU<97
MMW'Y=Z8-<TXQ^9Y[;=@DSY3_ '2VP'I_>X_^M6C17@'MA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S\W@7P
MG<3R3S>'-,DED8L[M;*2Q/)).*N:5X;T30Y))-*TFSLGD&UVMX50L/0XK4HH
M **** "BBB@#SOXY?\DEU;_?@_\ 1R5Z!;_\>T7^X/Y5Y_\ '+_DDNK?[\'_
M *.2O0+?_CVB_P!P?RH DKY,T3_CVNO^OR;_ -"KZSKY,T3_ (]KK_K\F_\
M0JVH?$>=FG\#YFG11176?/!7>? K_D(>,/\ KY@_]!>N#KO/@5_R$/&'_7S!
M_P"@O6%?X4>IE7\5^GZGLE>1_'O_ ) OAS_L+I_Z"U>N5Y'\>_\ D"^'/^PN
MG_H+5S1W/;J? _0\[[T4=Z*] ^0"L?Q3_P B[=?5/_0A6Q6/XI_Y%VZ^J?\
MH0J9_"S;#?QH>J_,^L;/_CQM_P#KFO\ *IZ@L_\ CQM_^N:_RJ>N ^L/FKQ=
M_P E>\5_6V_]%+52K?B[_DKWBOZVW_HI:J5VT?@1\UF'^\R^7Y(****T.(ZK
MX-_\E)UW_L'1_P#H0KW:O"?@W_R4G7?^P='_ .A"O=JX9_$SZK"?P(>B.*^+
MG_)*O$'_ %P7_P!#6O#K3_CRM_\ KDG\A7N/Q<_Y)5X@_P"N"_\ H:UX=:?\
M>5O_ -<D_D*UP^[.#-MH?,FHHHKI/$*.L_\ (#OO^N#?RKZ-\!?\D]\.?]@V
MW_\ 1:U\Y:S_ ,@.^_ZX-_*OHWP%_P D]\.?]@VW_P#1:URU]T>[E/\ #EZG
M0T445@>J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5YSX__P"2B_#O_K]N/_0%KT:O.?'_ /R47X=_]?MQ_P"@+0!Z-7*?
M$W_DF7B+_KQD_E75URGQ-_Y)EXB_Z\9/Y4 ?+-KQ9PG_ *9K_*DDN83$X$BD
ME3_*G6O_ !YP?]<U_E4N3ZU]&DW%6/!;2D[D$=S"(D!D7(4?RJ;(9,@Y!'!I
M<GUI#]T_0U236Y+:>Q]$_ [_ ))+I'^_/_Z.>O0Z\\^!W_))=(_WY_\ T<]>
MAU\T?0'SI\<_^2F:?_V"1_Z->O/Z] ^.?_)3-/\ ^P2/_1KUY_7M8#^%\SR<
M;_%^04445V'(;'@K_DIGA?\ Z_/Z5]9U\F>"O^2F>%_^OS^E?6=>'C?XS^7Y
M'L83^$C/U[_D7=3_ .O27_T U\<Z9_R#8/\ =/\ ,U]C:]_R+NI_]>DO_H!K
MXYTS_D&P?[I_F:UR_P#B/T,\=\"]2W1117KGE@.M>Y_L^_\ (BZA_P!A6;_T
M".O#!UKW/]GW_D1=0_["LW_H$=>=F/PQ._ ?%(]8KPC]H/\ Y#7A3_=NO_:=
M>[UX1^T'_P AKPI_NW7_ +3KSJ/\2/JCNJ_PY>C/*Z***^B/""G6O_(<T7_L
M)0?^ABFTZU_Y#FB_]A*#_P!#%88G^#+T-L/_ !8GV31117@'MA1110 4444
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M9([1F,;>C =#]:G\S6/^A3\0_P#@ ]:>TAW.7ZEB/Y6=I\&_^2DZ[_V#H_\
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M[*RGH00,$4\Z7KY!'_"+Z[T_Y\)/\*KZU1_F%]7J_P I]!? [_DDND?[\_\
MZ.>O0Z\ \!^,-3\*>#K+1KGPGXJ>:!I"S06#;#N<L,9P>]='_P +2O?^A0\8
M_P#@ ?\ &O /:.0^.?\ R4S3_P#L$C_T:]>?UT_CR\UKQ9XJMM5M_"OB-8HK
M,6Y6>Q?=G<S<8SQS7/\ ]EZ__P!"OKO_ ( 2?X5ZN#KTX4[2=CS<51G.I>*(
M**1H=42]2R;0=66[D0ND!M&#LHZD+C)'O5C^R]?_ .A7UW_P D_PKJ^M4?YC
MF^KU?Y31\%?\E,\+_P#7Y_2OK.OD?0[?7=+\5:1JLGA;7S%93^:ZI8/N(QVX
MKUS_ (6E>_\ 0H>,?_  _P"->1BIQG5<HO0]3#1<::4CTS7O^1=U/_KTE_\
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M]!6?X9U^]U:74;'4[&*TU#3Y5CF%O-YL3!EW*5; /3J",B@#H:*** "BBB@
MKAO&6DZA?^._ ]Y:6DDMM97-P]S*O2(,B@$_7FNYKFO%_BZ/PO#9JEN;J[NI
MXXUB!QL0NJM(Q[*-P^I(% '2T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% "$!E*L 0>"#WKE_",<D>K>*B\;H'U4E"RD!AY4?(]174T4 %%%
M% !1110 5Y[XZ\7);:HGAQI[NPMIH=]Y?PV<LS!#QY<6Q3AR.K'[HZ9/3T*B
M@#/T,V!T*Q_LN,QV A46ZF-D(0#CY6 (_'FM"BB@ HHHH *BN9)(;666*$S2
M(A98E(!<@< $\#/2I:* /--%OX-8^(=IJFD6NKQRR02)JZ7\+K';C:-J+O&
MV\=(^",DUZ7110 4444 %%%% '$^-[+Q'<WEO/IMA8WMA:P22&*>Y:(^<00'
MP%;=M4G XY/L*T?A]]M'@+15U"V2WG6U11&K%OE &TG(!!(ZCL:Z6B@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
ABB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img224999359_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_11.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &? X0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"6D+(Q7\O_ *W:O7ETG346V5-/M5%J28 (5'E$]2O'R_A4CV%G+>1WDEK
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MK,>W;\"?JTEK?O\ B>1:H]SX9\(W&ASEY-/U>W@O;)_[DFY"Z?Y]O6O<X?\
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MPSX=U/3?AK=:/=0*E](EP%C$@();.WD<=ZCA\(W=Q\)4\.W<2)?I =J[P0)
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M4?\ ";Z#_P _4G_?A_\ "NAP/2C ]*+P[?C_ , .6M_,ON_X)SW_  F^@_\
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M'_PKH<#THP/2B\.WX_\  #EK?S+[O^"<]_PF^@_\_4G_ 'X?_"C_ (3?0?\
MGZD_[\/_ (5T.!Z48'I1>';\?^ '+6_F7W?\$Y[_ (3?0?\ GZD_[\/_ (4?
M\)OH/_/U)_WX?_"NAP/2C ]*+P[?C_P Y:W\R^[_ ()SW_";Z#_S]2?]^'_P
MH_X3?0?^?J3_ +\/_A70X'I1@>E%X=OQ_P" '+6_F7W?\$Y[_A-]!_Y^I/\
MOP_^%'_";Z#_ ,_4G_?A_P#"NAP/2C ]*+P[?C_P Y:W\R^[_@G/?\)OH/\
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M;\?^ '+6_F7W?\$Y[_A-]!_Y^I/^_#_X4?\ ";Z#_P _4G_?A_\ "NAP/2C
M]*+P[?C_ , .6M_,ON_X)SW_  F^@_\ /U)_WX?_  H_X3?0?^?J3_OP_P#A
M70X'I1@>E%X=OQ_X <M;^9?=_P $Y[_A-]!_Y^I/^_#_ .%'_";Z#_S]2?\
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MH>AW>I/&9/(3*QCJ[$X5?Q) K%C\/Z_=6GVNZ\27<&INN\10*@MXF_N[""6
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M1;N8Y;J5KB65I'9BSLQ))SU)/<U3G.9%1?NXXJ.-G#C;D\]!5[RHX]LK9P@
M(/8]A[THQ=R[JM%N*MW%4+'&L0^7=W'7ZU&T=K;M^\<R'K@4X2HRO(OS.H[B
ML\DDDGJ:N\;M177?^NX5JBBHZ)_D?6'P$=)/AL&C4JOVV7 )Z?=KT^O+/V??
M^29#_K]E_P#9:]3H.&4G)W84444""BBB@ HHHH **** "BBB@ HHHH ****
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M5 A5B0I5NN>#7IVI"^.FW TTPB]*$0F;.P-V)Q14C*#2=@@XS3:N8_D^,O\
MG^T/_P !)?\ XY1Y/C+_ )_M#_\  27_ ..5S?AS6=>B\:2:+/JZ:TD=JTEX
M5A""UF'\ (QGG _&J?AKQM?"YDNM3U+[3;C3I;N[AV*/LDBR;5C&!D9'8\FJ
M=*>MK?<2JL-+W^\[#R?&7_/]H?\ X"2__'*@-_XCT_6M*MM1FTN:WO9VA/V>
M"1'7$;/G)<C^&M'PQ_:3:%!<:O*7O+G,[(0 (@W(08]!@?G57Q#_ ,A_PQ_U
M_2?^B)*S3]YQ=NIHU[JDF^AT5%%%8&X4444 %%%% !1110 4444 %%%% !4-
MQ=V]H%,\JQANF>]35@^)O]7;?[S?TJZ<5*23,ZLW"#DC1_M?3_\ GZ2C^U]/
M_P"?I*XRN>B\2W!U2W@N=)EM[6ZF:&"9V^9F'<KU KK6%3V9QO&270]4_M?3
M_P#GZ2C^U]/_ .?I*X#4I]0MX4.GV*7<A;#(\HCVCUR:QK;Q%J=SI-]?+I,1
M^ROM"+/N$F/OX..WZ\TUA$U>X/&270]8_M?3_P#GZ2C^U]/_ .?I*\NL/$J:
MMJ<-MIT EA\D2W$S-CRL]%QW-;U)X5+<%C)/9'>0SQ7$0DA<.AZ$5)69H/\
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M]S2,OW=S,20/;FL*W)*/,GK_ ,/_ %\S>ESQERM:?\-_7R-VBBBN8Z HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *Y#Q%_R47P7];W_T2*Z^N0\1?\E%\%_6]_\ 1(H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-HYVK.P4444A!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 V22.*)Y)75(U!9F8X  ZDGTKS+7?%^HWOBV72]!\1^&=/LX+5)
MA/>.LIG9BP(4@X&W XZ\UZ7<6\-U;2V]Q&LD,J%)$89#*1@@^V*\DU[P_IO_
M  E4GA_POX \/W,]M;)<W,]\HC0!R0JJ ,D_*>: /0_"<M_-H@?4=4T[4I_,
M8?:-/&(L=AU/(K<KD_AU=6=UX5_T318=',-S+!<6D./+69&VN5(Z@D=:ZR@
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M2+_P@MAI3W]M%]J=A#>1^4<1K&'*RYYSO+1ANO"-QS7#$Y(S2[22!2C&4G:
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M@YXQ0JDN"[8..PIR@D<=!0,;CQFK55J*5O\ (?LTW<^G_@, /AN,# ^VS?\
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M-4\D3/&55(BVW>S, !GGUH<&I*/+J_,%*\7+FT7D5_\ A*+G_H5]=_[]1?\
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M4/\ DF7B#_KU/\Q76UR7Q0_Y)EX@_P"O4_S% '6#H*6D'04M !1110 4444
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MU9QV9+I0EN@HHHK,T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@"KJ5C%JFEW=A,6$5S"\+E3R P(./?FN&M_
MA1':6\5O;^,/%,,$2A(XTO@%10,  ;> *]#HH P_"OA>U\):0VG6EQ<W"O.\
M[RW+AG9V.220!6Y110 4444 %<AXB_Y*+X+^M[_Z)%=?7(>(O^2B^"_K>_\
MHD4 =?1110!R'_-8_P#N7_\ VXKKZY#_ )K'_P!R_P#^W%=?0 4444 %<E\4
M/^29>(/^O4_S%=;7)?%#_DF7B#_KU/\ ,4 =8.@I:0=!5?49WM=,N[B, O%"
M[KGID*2*$KZ W;4LT5R>F#Q;J.E6=\-8TM/M,"3;/[/8[=R@XSYOO5K[%XM_
MZ#>E_P#@N?\ ^.UHZ:3MS+\?\C-5&]5%_A_F=%17._8O%O\ T&]+_P#!<_\
M\=H^Q>+?^@WI?_@N?_X[2Y%_,OQ_R'SO^5_A_F=%17._8O%O_0;TO_P7/_\
M':/L7BW_ *#>E_\ @N?_ ..T<B_F7X_Y!SO^5_A_F=%17._8O%O_ $&]+_\
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M84444B HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *Y#Q%_R47P7];W_T2*Z^N0\1?\E%\%_6]_\ 1(H
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MGL:/QKT-?@[K?4ZEI9/O*W_Q-+_PI[6R?^0EI?\ W];_ .)H<;["4T>>C,;
MD<CUH W=_FKNQ\*M68[?M]B.<<^9S_X[4_\ PI[6P?\ D):7_P!_6_\ B:=U
M>S7NCYUW//U7!/=NGTH>/?$<,"?2O0/^%/:X3_R$M+_[^M_\30/@[K9./[2T
MOG_IJW_Q-6JD4M8_C_7S!SC:USSA%.[!'(I^T;LL.GI2R(8IW1L?*2I(]0:4
M.0NWUK.+C>['%*UAI([4Y,;N>E&U2H)/.?TI"<# Z4VK-292'%@6R0/H.* #
MU(^6FX.W/:C)*]>G:AW;]_?<=^Q]1_ 3'_"MQCI]MF_]EKT^O+_@%_R34?\
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M_CE,F?Q//!)"VJZ"%=2I(M9>_'_/3WJ'_A6FF_\ 0:\2?^#>7_&C_A6FF_\
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MV)?['&O(?'"N=*.A6HTCS0_E;_+'F;,<>;GI_%Z4 >WJL-M"J(J11* JJ %
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 @4 8 &/2E  & ,"BB@!  .
M@ I:** "BBB@ HHHH **** "BBB@ HHHH ***CGGBMH'GGD6.)!EG<X 'N:
M;L/P"02!D=*6LO\ X231/^@K9_\ ?Y:/^$DT3_H*V?\ W^6JY9=C/VM/^9?>
M:851C  QTXHP 2<#)[UF?\))HG_05L_^_P M'_"2:)_T%;/_ +_+1RR[![6G
M_,OO-/ SG SZT8&<X&?6LS_A)-$_Z"MG_P!_EH_X231/^@K9_P#?Y:.678/:
MT_YE]YJ45E_\))HG_05L_P#O\M'_  DFB?\ 05L_^_RT<LNP>UI_S+[S4I
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M86#R&#S,%(.0O4U$K=0H.2=TM.O8D^SB%BTQ P?NBD:X@; :)I.<Y9L'/?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG_D)_P#"CDEV#VU/^9?>;%%8_P#PE.B_\_G_ )"?_"C_ (2G1?\ G\_\A/\
MX4<DNP>VI_S+[S8HK'_X2K1?^?W_ ,A/_A1_PE6B_P#/[_Y"?_"CDEV#VU/^
M9?>;%%8__"5:+_S^_P#D)_\ "C_A*M%_Y_?_ "$_^%')+L'MJ?\ ,OO-BBL;
M_A*M%_Y_?_(3_P"%'_"5:+_S^_\ D)_\*.278/;4_P"9?>;-%8W_  E6B_\
M/[_Y"?\ PH_X2K1?^?W_ ,A/_A1R2[![:G_,OO-FBL;_ (2K1?\ G]_\A/\
MX4?\)5HO_/[_ .0G_P *.278/;4_YE]YLT5C?\)5HO\ S^_^0G_PH_X2O1?^
M?W_R$_\ A1R2[![:G_,OO-FBL;_A*]%_Y_?_ "$_^%'_  E>B_\ /[_Y"?\
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M7_A+=#_Y_O\ R$_^%'_"6Z'_ ,_W_D)_\*.278/;4_YE]YM45B_\);H?_/\
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M_P#_ ,@R?_$T>SGV8>VI_P R^\WJ*P?^$S\/_P#/_P#^09/_ (FC_A,_#_\
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MCV4^S%[6G_,OO-RVMH;2 0V\:QQ@DA5Z9))/ZDU+7/?\)SX<_P"@C_Y D_\
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6_P#($G_Q-%'LJG\K^X/:T_YE]Y__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img224999359_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_12.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (* YP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^\IQOXX&/U[U9HH J_81Q_I$_P!UE^_ZGK]:468#[O/G^\K8W\<#&/H:LT4
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MBQ?^$BT7_H+67_?]?\:/^$BT7_H+67_?]?\ &N(\?^$_#]GH]B]MH]G$S:A
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M.^-M%F+VD.Z/9O#^I:UJ,<S:QH)TED($:_:DFWCU^7I6U7B'_#0S?]"?>_\
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M[@_E4E>:?:!1110 4444 %%%% !1110 4444 %%%% !1110 57DL;.9]\MK
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MEI,GA2Q^TWB.\6-2XPHR<G96B-8\=EAGPIIX&>3_ &G_ /84<[#V,/Z;-?\
ML.[_ .@]?_\ CG^%']AW?_0>O_\ QS_"MB,N8T,BA7(&Y0<X/I3J.=A[&']-
MF!/X;FNH'@N-:OI(G&&0[<$?E5U=%MEF,OFW.XO')CSFQE!@<>GJ.]:5%)R;
MW*C3C%W1\P^!ACQ#XH'_ $^O_P"AM7<5Q'@?_D8O%'_7Z_\ Z&U=O6T-CSL1
M_$844451@'>L3X3VJ77Q8\2%VD'E$2+L<KDAN^.H]JV^]9?P>_Y*OXJ_W/\
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MP+39M\Z[QY)A_P"/AONEMV>O7/>K=I8Q6<D[QO*QG<.V^0L 0 .,]!Q5JB@
MHHHH **** "BBB@ HHHH **** $(W*1ZC%?/-A=^+?@YK>JV,>@3:II%Y,9H
M)8U8CVY .#C@@U]#,=JD^@S7SUINK?$_XE:KJ=UH&K1:;I]M.8E1WV!?0<*2
M3B@#5\"Z1XMU;Q7K'Q!U72VM[E[9H[*SD^0R-C &#R  .IZYK<^!WAW5-'T3
M5KW5[62UN;^\+>5*,, N03CZD_E5GP/X:^(VE^(5N?$_B*WO].\ME,*2LQW=
MC@H*],H **** "BBB@ HHHH *BNO^/.;_KFW\JEJ*Z_X\YO^N;?RH \A_9X_
MY%?5_P#K^/\ *O8Z\<_9X_Y%?5_^OX_RKV.@#F;"PL[WQ-KINK6&<H\.WS8P
MV/D[9K6_L+2/^@79_P#?A?\ "J.C_P#(S>(/]^'_ - JMXYO[G3]#26UF:*0
MS ;EZXP:UU<DD^QQIPA2<Y*]F_S9K_V%I'_0+L_^_"_X4?V%I'_0+L_^_"_X
M5P-A!XMU*U2XMM2!5QD S '\JZ'5;#Q+)I6G1V5P1=(I%PPD W'^M-Q:=N8F
M%:,HN2IO[MS=_L+2/^@79_\ ?A?\*/["TC_H%V?_ 'X7_"O.M5?Q7HT"2WM\
MZ*[;5Q*"37:>#+B\NM 2>]D>1W<E6?J11*$HQYKA2K4ZE3V?)9^:-'^PM(_Z
M!=G_ -^%_P */["TC_H%V?\ WX7_  JY/-';P/-*P6-%+,Q["O.K/5]6\3^*
M#':7<MM9ALD*?NH/ZFIBI2N[FE:=.DU'ENV=S_86D?\ 0+L_^_"_X4?V%I'_
M $"[/_OPO^%8GC+5[S3X[.QL7\N:Z;;YI[ 8']:S(+C6?#?B*QL[Z^%Y!><8
MST/2FHR:O<B=:E&?+R[6N^USKO["TC_H%V?_ 'X7_"C^PM(_Z!=G_P!^%_PK
MFVOKK7?&R065P\=E8?ZUT/#GN/Z5VE3+FCU-:;IU+VCHG8YR_P!/LK+6]&:U
MM((&:=@QCC"DC8?2NCK%UC_D,Z+_ -=V_P#0#6U1+9%4DE*27?\ 1'%>*?\
MDH/@W_KK<?\ HNNUKBO%/_)0?!O_ %UN/_1==K4&P4444 %%%% 'R/KNDVNK
M?$_Q-'=!BJ7#,-IQSD4?\(=I/]R7_ONKUW_R53Q5_P!=C_Z$*T:[J$(N";1\
MOF>*K4\2XPDTM/R,#_A#M)_N2_\ ?='_  AVD_W)?^^ZWZ*U]E#L<'UW$_SO
M[S _X0[2?[DO_?==-\%[*'3_ (L7EO "(ULVQDY]*@J_\)/^2Q7W_7DW]*PQ
M$(QC=(]3*,15J5FIR;5CZ*HHHKC/HPHHHH **** "BBF331V\+S3.L<:#<S,
M< #U- #Z*P_^$R\-?]!VP_[_ *T?\)EX:_Z#EA_W_6@#)UK_ )*CX9_Z]KG_
M -!%=E7F^K^)]"D^)'AVY35[-H8[>X#R"884D#&376?\)EX:_P"@Y8?]_P!:
M -RBL/\ X3+PU_T'+#_O^M:-AJ=CJD)FL+N&YC4[2T3A@#Z<4 6Z*** /F+P
M/_R,7BC_ *_7_P#0VKMZXCP/_P C%XH_Z_7_ /0VKMZWAL>7B/XC"BBBJ, [
MUE_![_DJ_BK_ '/_ &:M3O67\'O^2K^*O]S_ -FK.IL=>$^)GO5%%%9'H'S;
M\4/^2X_]N4?\C4%3_%#_ )+C_P!N4?\ (U!7=AO@/E<Z_P!X7I_F%%%%=!Y
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M&'_:FO\ _0O+_P"!J_X4?VIK_P#T+R_^!J_X5N9'J*J:I>&PTF[O$57:"%I
MI/!(&<4<R[![.7\[_#_(R,:QJ.K:?)<Z4MK%;R,[/]H5\Y4CH/K71UX%8_'/
MQ;J5O]HL_"<$T.XKO61L9%6?^%Q^-_\ H3(O^_C4.[Z#@HPO>5V_0[_Q3_R4
M'P;_ -=;C_T77:U\Z:E\1?&6I:YI.J/X25'TYG9$#G#[EV\UK_\ "X_&_P#T
M)D7_ '\:E9E\\>Y[I17A1^,GC< D^#8L#_IHU=W\,?'5UX[TB]O+RRBM)+>?
MR=D;$YXSWI6&I)[,[JBDR/449'J*!GRM=_\ )5/%7_78_P#H0K1K.N_^2J>*
MO^NQ_P#0A6C7H8?^&CY#-O\ >I?+\@HHHK8\T*O_  D_Y+%??]>3?TJA5_X2
M?\EBOO\ KS;^E<^)^ ]C)/\ >'Z?Y'T5129'J*,CUKA/J1:*3(]11D>HH 6B
MDR/449'K0 M8/C;_ )$?6_\ KSD_]!-;N1ZBL'QL1_P@^M\C_CSD_P#030!Y
ME\(_^2>VG_763^==S7#?"/\ Y)[:?]=9/YUW-:+8Y)_$PHHHH)(+W_D'7?\
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M>(_B,****HP#O6)\)[."[^+'B,SH6,)$L?S$88-P>*V^]9?P>_Y*OXJ_W/\
MV:LZFQUX3XF>R+X:TI(3$+8["CQX\UONN<L.O<U)_8&FYSY!SYD<O^L;[R#"
MGKV%:5%9'H'S-\1+."P^-*V]LA2);-" 6)Z@D]:*G^*'_)<?^W*/^1J"N[#?
M ?*YU_O"]/\ ,****Z#R JAI2*_Q<\,JPR/,!_G5^J6D?\E>\,_]=!_6L<1\
M!Z>4?[TO1GT@?#6E-!Y)MCY?EO%CS6^ZQRPZ^M2-H.FO,)3 =XD24'S&^\B[
M5/7L*TJ*\\^N,K_A&]*VA?LQP(GA'[UON,<L.OK3QH6G+<>>(#YGF)+GS&^\
MB[5/7L*TJ* ,I?#>E+$8Q;'88WBQYK?=8Y8=?6GC0=.#%A <F5)O]8WWU7:I
MZ^E:5% &2?#.DFV^SFV/E>4\./-;[K'+#KZU(V@::\HE: EQ*DP/F-]Y%VJ>
MO85I44 9)\-Z45"_9C@1-#_K6^XQR1U]:E&A:<+@7 @/FB1)<^8WWE7:IZ^E
M:-% &4OAO2EB,8MSM,3PX\UONL=S#KZT\:%IRN7$!W&99\^8WWU7:#U].U:5
M% &0?#.DFV^SFV;RO*:''FO]QCDCKZU*V@Z:THD,!W"5)@?,;[ZKM4]?2M*B
M@#)/AO2C&$-L=HB:''FM]QCN(Z^O>I?[#T_[2+CR#YHD67/F-]Y5V@]?2M&B
M@#*'AO2EC,8MCM,30X\QON,=Q'7UIZZ#IRR&00'<9EGSYC??5=H/7T[5I44
M9'_",:3]F^S_ &9O*\IH=OFO]QCDCKZU*V@Z<T@D,!W"99\^8WWU7:#U]*TJ
M* ,D^&]*,0C-L=@A:''FM]QCN(Z^O>I?[#T_[3]H\@^;YJRY\QOO*NT'&?2M
M&B@#*'AO2A'Y8MCM\EH<>:WW&;<1U]>]/70=.28RK =YF6?/F-]]5V@]?3M6
ME10!X#\=M+L]-D\*Q6D11$F95!<M@%@>Y]:Q*Z;]H7_CY\,?]?!_F*YFNS"[
M,^<SWXX?,****ZCP0KG/&/\ QXVG_7PM='7.>,?^/&T_Z^%K.K\#.W+_ />H
M>I]0VWAC21IL5L+9O*^S>1M\U_N'DC.?7O5HZ%IQ??Y!W><+C_6-]\+M!Z^G
M;I5VW_X]HO\ <'\JDKS3[0R6\-:4T A-L?+$)@QYK?<)W$=?6I6T/3VN?M!@
M/F^:)MWF-]\+M!QGTXK1HH R?^$:TK9L^S';Y)@QYK?<+;B.OKWJY::=:V,E
MQ);QE&N'#R'<3D@!1UZ< 5:HH **** "BBB@ HHHH **** "BBB@#E9_ .D3
M>.X_&+-<?VA'%L"!_P!V>,9QC.<&O+_#7PY^'7CE[^XM[G4H[V*=_M-NUPH*
M'<>1\OW?>NEU;X\^'=(UB]TV?3=3>6TF>%V1$VDJ<$CYNG%>*>-/$OA^_P!;
M;5_"*:II-Q<[DO(\!%96^\1M;OW% 'J7@;3/ VA?%5=,\,RWMW>1V\HFN))@
MT28'*C Y->W5X;\%-8\&0Z@-(T;3KXZM+"7FOKJ-1N Z@8)P/:O<J "BBB@
MHHHH **** "HKK_CSF_ZYM_*I:BNO^/.;_KFW\J /(?V>/\ D5]7_P"OX_RK
MV.O'/V>/^17U?_K^/\J]CH **** "O,/CW_R3&X_Z^8OYUZ?7F'Q[_Y)C<?]
M?,7\Z +F@?\ (MZ5_P!></\ Z *T*S] _P"1;TK_ *\X?_0!6A6AQ/<****
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M7Y!1116QYH5?^$G_ "6*^_Z\F_I5"K_PD_Y+%??]>3?TKGQ/P'L9)_O#]/\
M(^BJ***X3ZD**** "BBB@ K!\;?\B/K?_7G)_P"@FMZL'QM_R(^M_P#7G)_Z
M": /,?A'_P D]M/^NLG\Z[FN&^$?_)/;3_KK)_.NYK1;')/XF%%%%!)!>_\
M(.N_^N$G_H)KF?V=_P#D2[__ *_6_D*Z:]_Y!UW_ -<)/_037,_L[_\ (EW_
M /U^M_(5,C>CU/8****DV/F+P/\ \C%XH_Z_7_\ 0VKMZXCP/_R,7BC_ *_7
M_P#0VKMZWAL>7B/XC"BBBJ, [UE_![_DJ_BK_<_]FK4[UE_![_DJ_BK_ '/_
M &:LZFQUX3XF>]4445D>@?-OQ0_Y+C_VY1_R-05/\4/^2X_]N4?\C4%=V&^
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M]EU]3%^Q>(/^@O;?^ O_ ->C[%X@_P"@O;?^ O\ ]>KNJ:O9:/;>?>3!%/
MY+?04FDZQ::U;-<6;,45MIW+CFB\K7M^ N6GS<G,[^K*?V+Q!_T%[;_P%_\
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M^@FN1_9^L+2Y\'WDD]M%(Z:AO5F7)# <'\*ZZ]_Y!UW_ -<)/_037,_L[_\
M(EW_ /U^M_(5,C>CU/4/[#TK ']GVW".@_=C[KG+#Z$]:<NBZ8LAD6QMPY='
MW!!G<@PI^H'2KU%2;'S#X'&/$/B@#_G]?_T-J[BN(\#_ /(Q>*/^OU__ $-J
M[>MX;'EXC^(PHHHJC .]8WPEM8+GXK^)3/"DABQ)'N&=K!N"/>MGO67\'O\
MDJ_BK_<_]FK.IL=>$^)GM*Z#I*Q^6-.M@A1TV^6,;6.6'XGK3_[&TW)/V&WR
M723[@^\HPI^H'2KU%9'H'S1\1[:"S^-:PVT*11"SC(1!@<@YIM3_ !0_Y+C_
M -N4?\C4%=V&^ ^5SK_>%Z?YA11170>0%4-*57^+GAD,H(\P<'\:OU2TC_DK
MWAG_ *Z#^M8XCX#T\H_WI>C/I8Z#I+1>4=.MC'L:/;Y8QM8Y8?0FG-HVFM()
M&L8"X=9 Q09W*,*?J!Q5ZBO//KCF_$&E:?:Z1YT%G#')&RHCJ@!56D!('L3S
M71I]Q?I61XH_Y 4G_72/_P!#%:Z?<7Z53^%&2_BOT7ZGG?B'PSJ5S=:CJ5_=
M[[>%"T.._H,=JT_AQ_R 9O\ KN?Y"MWQ+_R+>H?]<36%\./^0#-_UV/\A6KD
MY4G<XE2C3Q:Y>J9REY#!I/C"X.M0&X@9V?"M]X'H:N>#;7[7XNDN[%##9Q%C
MM+9(4]%JC;7-MI_BNZDUVV>8;VR&&<'/!P>M6O#D@NO'23Z7"\-H68LGHF._
MXXK>5^5^GR."G;VD7_>VZGJM>5>.-=.IZF;&!B;>V../XG[FNNMO&,5SXD;2
M!:NHW%!+N[CVKC--O(_#/BNY?4[9VPS $#)&3P1FL:4'%MM:G;C*T:D5&,M&
M[-G2>$/$.F-:QZ/#$]O/M(4O_P M&[_C7/V=[:Z%'JMAJFFF6[E9MKLN<@].
MO;O2)./$'CF"XTZW:./S%<\8.!U8^E>E:I/:V-E+>W,<;"%2P+ $Y[ 4Y-1>
MVY-*,JT+W7N72=M+'FD!O5T.WT! 8YKV7S65N/+C]_0<9KN]&U+0[2&'2K._
M@9XQM #?>/?GN:XPV-[=^'=3\02AC<W1^3U6+/./:J%[_87_  CMC_9^[^UM
MR[L9SGOG\<8JY14]#*G5E1]ZW32_;R\^IZ_7+>$=,L9-'6X>TA:;[7)+YA09
MWABH.?4#BNAL?-^P6_G?ZWRUW9]<5D>#O^1?7_KO+_Z&:YOLL]1N]6+\G^AX
MIKEK;V7QWNH+6%(8A9Y"(, $@$\5TE8'B;_DO]W_ ->8_D*WZN&QR8K^(%%%
M%6<P5S=BBO\ 'CPV&4$")CS_ +KUTE<YI_\ R7CPY_UQ;_T%ZB>QTX7^(>\C
M0M*";!IUL%\LQ8\L?<)R5^A/-/&CZ:LGF"Q@#^8)=P09W@;0WUQQ5VBL3TCP
M/X]:?9V$OA:.TMHH$6=E41J  -P./SK"KIOVA?\ CY\,?]?!_F*YFNS"[,^<
MSWXX?,****ZCP0KG/&/_ !XVG_7PM='7.>,?^/&T_P"OA:SJ_ SMR_\ WJ'J
M?4]MH&D#3XH!IML(O(\K9Y8QL/)7Z9YJP='TXMN-C!GS1-G8/O@;0WUQQ5FW
M_P"/:+_<'\JDKS3[0SCH.DM$(CIUL8Q&8MIC&-A.2OTSS4ATC3FG\\V4!E\P
M2[R@SO"[0WUQQ5VB@#._L'2=NW^SK;'E&''EC[A.2OTSS5FWL;6T>9[>WCB:
M9@TA1<;R  "?P %6** "BBB@ HHHH **** "BBB@ HHHH Q-3\'^'-9O&N]2
MT6SNKA@ 9)8@S$#IS4FD>%M"T"6672=*M;-Y5VR&% NX>AK7KR+7/C_H>EZO
M<6%GIMW?^0Y1I8V"J2#@X]10!W^@>#=#\,W5Y=:99+%<7CEYI2<LV3G'L,]J
MWJ\U\$?&"U\:^(!I,6C75HQC:3S)'!'';I7I5 !1110 4444 %%%% !45U_Q
MYS?]<V_E4M177_'G-_US;^5 'D/[/'_(KZO_ -?Q_E7L=>.?L\?\BOJ__7\?
MY5['0 4444 %>8?'O_DF-Q_U\Q?SKT^O,/CW_P DQN/^OF+^= %S0/\ D6]*
M_P"O.'_T 5H5GZ!_R+>E?]></_H K0K0XGN%%%% '*?$K_DGNK_]<OZUV7PR
M_P"2:Z!_UZ+_ #-<;\2O^2>ZO_UR_K79?#+_ ))KH'_7HO\ ,U,CHH['65E^
M)/\ D6-4_P"O63_T$UJ5E^)/^18U3_KUD_\ 034FI\^?#+_D3Q_U\R?TKL:X
M[X9?\B>/^OF3^E=C71'8\FM_$84444S(;+_JG_W3_*I_V>_^1>UO_L('^502
M_P"J?_=/\JG_ &>_^1>UO_L('^59U.AVX/J>PT445D=Q\JW?_)5/%7_78_\
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MNK_]<OZUV7PR_P"2:Z!_UZ+_ #-<;\2O^2>ZO_UR_K79?#+_ ))KH'_7HO\
M,U,CHH['65E^)/\ D6-4_P"O63_T$UJ5E^)/^18U3_KUD_\ 034FI\^?#+_D
M3Q_U\R?TKL:X[X9?\B>/^OF3^E=C71'8\FM_$84444S(;+_JG_W3_*I_V>_^
M1>UO_L('^502_P"J?_=/\JG_ &>_^1>UO_L('^59U.AVX/J>PT445D=Q\JW?
M_)5/%7_78_\ H0K1K.N_^2J>*O\ KL?_ $(5HUZ&'_AH^0S;_>I?+\@HHHK8
M\T*O_"3_ )+%??\ 7DW]*H5?^$G_ "6*^_Z\F_I7/B?@/8R3_>'Z?Y'T5111
M7"?4A1110 4444 %8/C;_D1];_Z\Y/\ T$UO5@^-O^1'UO\ Z\Y/_030!YC\
M(_\ DGMI_P!=9/YUW-<-\(_^2>VG_763^==S6BV.2?Q,****"2"]_P"0==_]
M<)/_ $$US/[._P#R)=__ -?K?R%=->_\@Z[_ .N$G_H)KF?V=_\ D2[_ /Z_
M6_D*F1O1ZGL%%%%2;'S%X'_Y&+Q1_P!?K_\ H;5V]<1X'_Y&+Q1_U^O_ .AM
M7;UO#8\O$?Q&%%%%48!WK+^#W_)5_%7^Y_[-6IWK+^#W_)5_%7^Y_P"S5G4V
M.O"?$SWJBBBLCT#YM^*'_)<?^W*/^1J"I_BA_P EQ_[<H_Y&H*[L-\!\KG7^
M\+T_S"BBBN@\@*I:1_R5[PS_ -=!_6KM4M(_Y*]X9_ZZ#^M8XCX#T\H_WI>C
M/J:BBBO//K@HHHH **** "BBB@ KF];\3W^DZA]FM_#&J:C'M#>?;!-F?3E@
M:Z2B@#S^_P#B;<Z6D#7O@W7(5GF6"(L(_FD;HOWN^*M_\)SJW_0BZ]^4?_Q5
M,^)O_'EX<_[#]I_[-7<4 5=-NY+[3H+J6TFM))%W-!-C>GL<$BK5%% !1110
M!\]>)O\ DO\ =_\ 7F/Y"M^L#Q-_R7^[_P"O,?R%;];0V/-Q7\0****LY@KG
M-/\ ^2\>'/\ KBW_ *"]='7.:?\ \EX\.?\ 7%O_ $%ZB>QTX7^(?1-%%%8G
MI'AG[0O_ !\^&/\ KX/\Q7,UTW[0O_'SX8_Z^#_,5S-=F%V9\YGOQP^84445
MU'@A7.>,?^/&T_Z^%KHZYSQC_P >-I_U\+6=7X&=N7_[U#U/KBW_ ./:+_<'
M\JDJ.W_X]HO]P?RJ2O-/M HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1
MAN4CU&*^=M \477P8U[6M%UC2+B>SN;@SV]Q$/OCL<GJ,?D:^B3G!QUKP^/X
MJ7OA74[W1/B%I#RB-G>TN%C5_,7)V@YX/U'XT 'PY34_&WQ3O?'D^GR66G)"
M88-XQYAV[0!ZX')->XUY%\.]<\7^-?%8UZZM?L'AF*)TMK<':KD]"!_$??I7
MKM !1110!D^(?$VD>%M.-]K%XMO#G:N02SGT4#DFLCPY\2?#'BB_^P6%ZZWA
M&Y8+B(QLX_V<]:TM6\*:5K>LZ=J>H0M--IY)@1F^0$]RO0FN"\;26NO_ !.\
M+:1H\:R:GIUT+J\N(Q_J(1_"Q]_3_&@#M_$_C;0O""P_VM=E)9\^5#&A>1\=
M2%';WI_ACQCHGB^VEFTB[\TPG;+$Z%'0^ZFN/\&6T>M_%+QAK=XHEEL9H[&U
MW<^4H!W8],X'YFI-:MX]%^-7AZ]M$6+^UH)K>Z"\"0J-RDCUXH ]*J*Z_P"/
M.;_KFW\JS-=\5:'X9$']LZC#9^?GR_-.-V,9Q^8K"N/BEX(>VE5?$5D24( W
M>U '(_L\?\BOJ_\ U_'^5>QUXK^SW>VL?AK5EDGC1C=E\,P'R[>OTKV'^T;+
M&?M4./EYWC^+[OY]J +-%5O[1L@,_:H<?-_&/X?O?EWH.H60('VJ'G;CYQ_%
M]W\^U %FO,/CW_R3&X_Z^8OYUZ-_:-ED#[7#D[L?./X?O?EWKS3X[75O/\,[
ME(9XY&6>%B%8$@$\'\: -'0/^1;TK_KSA_\ 0!6A6?H'_(MZ5_UYP_\ H K0
MK0XGN%%%% '*?$K_ ))[J_\ UR_K79?#+_DFN@?]>B_S-<;\2O\ DGNK_P#7
M+^M=7\-;VU3X=:%$]Q$LBVR*5+#(+$X'XU,CHH['9UE^)/\ D6-4_P"O63_T
M$U;&HV1SB[AXW?QC^'[WY=ZR_$>H69\+ZJ?M4.!:L#\X_B4[?S[5)J>"_#+_
M )$\?]?,G]*[&N.^&7_(GC_KYD_I78UT1V/)K?Q&%%%%,R&R_P"J?_=/\JG_
M &>_^1>UO_L('^502_ZI_P#=/\J=\ +F"'P]K?FS(G_$QV_,V.2.!^-9U.AV
MX/J>S455_M*RV[OM<.W#'.\=%^]^7>E_M&R&/]*AY*@?..K?=_/M61W'R]=_
M\E4\5?\ 78_^A"M&LRY97^*7BEE((,S<C_>%:=>AA_X:/D,V_P!ZE\OR"BBB
MMCS0J_\ "3_DL5]_UY-_2J%6_A3-%!\8;QI9$C#6A4%CC).,#ZUSXGX#V,D_
MWA^G^1]'455_M&R !^UP\AF'SCHOWC^'>E_M"SWA?M4.XE0!O'5ON_GVKA/J
M2S158:C9'I=P]&/WQT7[WY=Z!J%F20+J'(*J?G'5ONC\>U %FBJO]I6.S?\
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MPE>3>0SP,8T4C&>1]">:!\<=($GF#P;J._<'W>4N=P& ?J!Q6?\ "4 MXFR
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M&/\ KX/\Q7,UV879GSF>_'#YA11174>"%<YXQ_X\;3_KX6NCKG/&/_'C:?\
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M?_K^/\J]CH **** "O,/CW_R3&X_Z^8OYUZ?7F'Q[_Y)C<?]?,7\Z +F@?\
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MEJ*Z_P"/.;_KFW\J /(?V>/^17U?_K^/\J]CKQS]GC_D5]7_ .OX_P J]CH
M**** "O,/CW_ ,DQN/\ KYB_G7I]>8?'O_DF-Q_U\Q?SH N:!_R+>E?]></_
M * *T*S] _Y%O2O^O.'_ - %:%:'$]PHHHH Y3XE?\D]U?\ ZY?UKLOAE_R3
M70/^O1?YFN-^)7_)/=7_ .N7]:[+X9?\DUT#_KT7^9J9'11V.LK+\2?\BQJG
M_7K)_P"@FM2LOQ)_R+&J?]>LG_H)J34^?/AE_P B>/\ KYD_I78UQWPR_P"1
M/'_7S)_2NQKHCL>36_B,****9D-E_P!4_P#NG^53_L]_\B]K?_80/\J@E_U3
M_P"Z?Y5/^SW_ ,B]K?\ V$#_ "K.IT.W!]3V&BBBLCN/E6[_ .2J>*O^NQ_]
M"%:-9UW_ ,E4\5?]=C_Z$*T:]##_ ,-'R&;?[U+Y?D%%%%;'FA5_X2?\EBOO
M^O)OZ50J_P#"3_DL5]_UY-_2N?$_ >QDG^\/T_R/HJBBBN$^I"BBB@ HHHH
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M*** "BBB@ HHHH **** "BBB@ HHHH P?$OC/0O"4<+:Q>B%YL^5&JEG?'7
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M?_$UPOQ<^)?A+Q1X$FTW2-4-Q=M-&XC\B1> >>64"@#N- _Y%O2O^O.'_P!
M%:%>?Z1\4/!]KHFGV\VJE98K:.-U^SR'#!0"/N^M7/\ A:_@O_H+G_P&D_\
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MXQR!72?\+!\,?]!$_P#?A_\ "MXM6/+JTYN;:1T]%<Q_PL+PQG_D(G_OR_\
MA1_PL'PQ_P!!$_\ ?A_\*=T1[*?9G2R_ZI_]T_RJ?]GO_D7M;_["!_E7)/\
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MY]_PNWX?_P#0</\ X"S?_$T?\+M^'_\ T'#_ . LW_Q- 'H-%>??\+M^'_\
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M;_XFC_A=OP__ .@X?_ 6;_XF@#T&BO/O^%V_#_\ Z#A_\!9O_B:/^%V_#_\
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M(#./#UASU_="NEHH YG_ (5YX0V;/^$=L-OIY0I3\/?"!QGP]8<=/W0KI:*
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M3]T*/^%>^$"V[_A'K#(X_P!4*Z6B@#FA\/?" )(\/6&3U_="D_X5YX0";/\
MA';#;Z>4*Z:B@#FC\/?"! SX>L..G[H4?\*]\(;MW_"/6&>G^J%=+10!S0^'
MOA $D>'K#)Z_NA2?\*\\(;-O_".V&W_KD*Z:B@#FC\/?"!QGP]8<=/W0H_X5
M[X1W;O\ A'K#.,?ZH5TM% '-#X>^$!G'AZPYZ_NA2?\ "O/"&S9_PCMAM]/*
M%=-10!X'\8_#.B:3JOA./3]+MK9)[W9*(TQO7*\&O5A\/O".0W_"/6&<8SY0
MK$^)/@C4?%VH>'Y["6%%T^Z\Z7S#C(R#Q^5>@ 8 % '-CX>^$!G'AZPYZ_NA
M2?\ "O/"&S9_PCMAM]/*%=-10!S1^'OA XSX>L..G[H4?\*]\(;MW_"/6&<8
M_P!4*Z6B@#FA\/?" SCP]8<]?W0I/^%>>$-FW_A';#'_ %R%=-10!Y+\6?!O
MAO3?AQJEY9:-9P7,039)'& RY8"M'P!X(\,7W@31;NZT.REN);52\CQ@ECZF
MNB^(/AZZ\4^"K_1[)XTN+@*%,APO# _TJ[X1TF?0?"6F:7<LC3VL"QN4Z$CT
MH J#X>^$ "!X>L.>O[H4G_"O/"!39_PCMAM';RA7344 <T?A[X0)!/AZPR.G
M[H4?\*]\(;BW_"/6&3_TR%=+10!S0^'OA  @>'K#GK^Z%)_PKSPAM"_\([88
M'_3(5TU% '*W?P_\)"UE<>'[ ,L;$'RAQQ7F7P-\+:%K/A[4Y]2TJUNI4O"B
MM*F2%QTKW.=#+;RQCJR%1^(KAOA7X+U#P5HU]::C)"\D]R95,1R,8H UQ\/?
M" ! \/6&#U_="C_A7GA J%_X1ZPP/^F0KIJ* .:/P]\(E@W_  CUAD=/W0H'
MP]\(!BW_  CUAD]?W0KI:* .9'P\\(!2H\/6&#U_="@_#SP@5"GP]88'3]T*
MZ:B@#FC\/?"!8-_PCUAD=/W0K0TGPUHNA2RR:7IEM:/* ':),%@*U:* "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKF:.#:%$$9^ZO'MZUS5WJGB;QQXOU/2?#NK#1M*TAA#/>"(2O--UP!G@#ZT
M>GT5P'@[7=<L_%%[X/\ $UREY>0Q"YM+U$">?$>#D>HKOZ "BBB@ HHHH **
M** "BBB@ HHKS'[-\0O%VKZC,FJ-X8TVVE,5K%]F$DDP'\;9(X- 'IU%>?\
M@SQ;J?V7Q#8>)GAEO= <B6YA&U9DV[@V.QP*Q=+B^(/C32W\26GB--(AG+/8
M:>+8."@^[O8GO^- 'K5%<G\/O%<WBOP^\E]"(-3LYFM;V->@D7J1['K764 %
M%%% !1165XDUZU\-:#=:I=<I"ORH.LCG[JCW)H U:*\S^%GB+Q)K.J>(+7Q)
M*IGM9(RD*J (@P)V\>G%,GU#Q1XZ\5:I8Z!K T72-*?R)+E81*\\W<#)& *
M/3Z*\_\ !7B+6H/$NH>#O$TJ7.H6L8N+:]1=HN(3W(]17H% !1110 445#=W
M<%A9S7=S((X(4+NYZ  9- $U%<)\/M7U[Q/-J/B&^E,6C7$A33+0H ?+!QYA
M/7G_ !J/QGKVN77B:P\(>&9TM+ZXC-Q=7KH'^SPCC@=R30!W]%>7P:IXH\"^
M+=,TWQ#JPUK2-6;R8KMH1&\$W8'!.0:]0H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!"0JEF(  R2>U>3:UJ5[\5=7D\.Z&QB\,VTH&I:@.DY!SY:'N/6NJ^)
M&@>(/$WA@Z7X?OH+2260"=IG90\>.5RH)YXKG]&T/XE:!I4&FZ;'X4@MH5PJ
MJTWYGY.30!+XFMX;'XI> X$4);1Q7$48[ A5P/R%:?Q?>)/A;K?FXP8E5<_W
MBPQ^M3>*?"6H^)_#VG,]W#:>(;!UN(;B+)C68#D=,[36#=>%/&WC*>SL_%T^
MF6VCVTJRS16#,6NF7D Y' S0!WOAT.OAG2@_WQ9Q _78*TZ15"J%4  #  [4
MM !1110!F^(-9A\/>'[[5IU9H[6%I"J]6QT%>')XF\/R_#GQ1?ZAKEI+XEUV
MVD:2%6),8(PD2_05[_/!#<PO#/$DL3C#(ZAE(]P:Y;Q1X&TS5O"^IZ?IVE:9
M!>W%NT<,I@50C$<'(&1^% ' >(=:TW6/@7:+I]Y'<"SDLTN@G_+/#KD&O8E9
M/[+5LCR_(S[8VUSUKX'L#X"/ANYM[>+SK58;A[9 NYP/O9P,G/<URO\ PCOQ
M._L7_A&1J6D_8-GD?VEE_/\ *Z?=Q]['']: +_P3P? #.O\ JGO[AHO]W=QB
MO1JR_#NA6GAK0+/1[+/D6L80,W5CW)]R:U* "BBB@ KPZRT?6_B3\0=7U^WU
MM]*M=*F:PM&CC#N,?>(!X&3U->XUYJ_A'Q7X7U_4K_P=<Z?-9:E+Y\UC?%E\
MN0]65@.AH CT?6?$%EJFO>#O$%XE_<1:<]U9WJH$:1"",,!W%:WP@9#\+]%"
M8XC8-_O;CFE\)>$-4M-<O_$?B:\M[K5[R(0!+<'RH8@<[5SR:R(/"WC?PA=7
MUMX2GTRYTBZE::*&^9E:V9NN,#D9H E\*E7^-/C-HON+!;J^/[^/\*])KE/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"O._BC\3)?A]'8+!IGVN6[W'<[%40+CCCJ>:]$JM>:?9ZA&([VUAN$!R%E0,
M ?QH ^?/^&D]4_Z %K_W]:C_ (:3U3_H 6O_ ']:O=O^$7T'_H#6/_?A?\*/
M^$7T'_H#6/\ WX7_  H \)_X:3U3_H 6O_?UJ/\ AI/5/^@!:_\ ?UJ]V_X1
M?0?^@-8_]^%_PH_X1?0?^@-8_P#?A?\ "@#PG_AI/5/^@!:_]_6H_P"&D]4_
MZ %K_P!_6KW;_A%]!_Z UC_WX7_"C_A%]!_Z UC_ -^%_P * /"?^&D]4_Z
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MO_?UJ/\ AI/5/^@!:_\ ?UJ]V_X1?0?^@-8_]^%_PH_X1?0?^@-8_P#?A?\
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M_P * /"?^&D]4_Z %K_W]:KNC_M$WU]K-G:7&@1>5/*L;&*1BPR<9'K7M/\
MPB^@_P#0&L?^_"_X5)!X>T:VF6:#2K..13E76%01^E &E1110 4444 %%%%
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M?] "U_[^M7NW_"+Z#_T!K'_OPO\ A1_PB^@_] :Q_P"_"_X4 >$_\-)ZI_T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSJQ.1Z<FNAH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M144= HP* ,7QGSX*UK'_ #YR_P#H)KBO@$"/AI&""/\ 29.OUKU'K2 !1@
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M<'L3D]J]1CC2*)(XU"H@"JHZ #H* /FG4_!2^./BWXQT[>T5S&C36S_P[QC
M/L<UU/P]\53ZMH.H?#K74-GK$$$EM;LR[1(,$8^H_45[=M .0!GUJ.=',$AM
MQ&)]I\LN.-V.,^U 'SOX%\?3?"NSO/#'B'0KSS8YV>%HDY?/UZCT(JW\*M5N
M-6^,GB'5;ZT-D\ML\KPN,&,9&,^^*U5O_C3I$LUK+HUIJH:1C#<%HR%STQR#
MCZBM#P9\,M:33O$5_P"(K\V^M:[&8W>!@S0J3D\CC)Z<=J (?@_OUCQMXS\2
MJ/\ 1;BX$$3>N"2?TQ7L=8'@WPK:^#?#5MH]JV\1Y:24C!D<]2:WZ "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
<* "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img224999359_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_13.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,"!#@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGC,8."^\8_.GI(DB!T=60]&!R*X7X@Z=:Z3\,[FRLH5A@B,855_WA^9J_P"
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MV(8AG:H_O8/0_3BHG"DHWC+7T*A.JY)3CIZG84445@= 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!7O\ _D'7/_7)_P"1KP3P-X+N/%4%]+!J[V/D2*I54+;L
M@\\,/2O?KJ-IK2:)<;GC91GU(KQ[2_ /C[1%E33-2M;996#.$F/)'_ :[<+/
MEA)*23TW.+%0YIQ;BVM=CJO"OP]N_#FMIJ$VNR7B*C+Y31E0<CK]XUK^./$=
MKX<\.3RSJDLTZF*&!^1(2.X]!WKF]'T+XBP:Q9RZCK44MFDRM,@ER63/(^[Z
M4NI^!]:\3^-8]0UR2W72(6_=V\<A8E!T'0=>]#2E4YJDTTNWY FXT^6E!IOO
M^9YOI-MJ'@Z]T;Q+?:>KV<[%D##H.F?8XY%>^W$T>L^&YI;&421W5LQB=>^5
M.*;KV@VFOZ'-I=P@6-UQ&0/]6P^Z1]*YOX?>'_$?AB.;3]2>UET\DO$8Y"6C
M;N,$=#_/ZT5:L:T>=Z27XH*5*5&7(M8O\&8'P6O(8H-4TR0[+L2B38W!(Q@_
MD?YUZP3@9-><>*/AO<SZN=<\-7@LK\MO>/)52W<@CIGN.E94V@_$[5H?L-WJ
M$4-NPVNXE W#O]T9-%2,*TO:*25][BISG1C[-Q;MM8@T>9-9^.-Q>6/S6\)<
MM(O0@)LS^)_G5CQ[_P E5\.?[\/_ *,KM?!O@RS\(6#I&_GW<V/.G(QNQV [
M"LGQ1X/U/6/'&D:Q;-;BUM&C,@=R&^5\G QZ52K0=71Z)6)=&:I:K5NY@^/=
M&NO"GB*#QCHR[4,G^E1KTW'J3[-T/O6=;:Q:Z]\8]-U*T;,4T<9QW4^7RI]P
M:]DO+.#4+*:TN8Q)!,A1U/<&O+?#WPQU70?&L&H+-;R:?!*Q4ESYA7!QQCK^
M-%*M!P?/NDUZA6HSC47(M&T_1GK-5=1L+74]/GL[V-9+>52KJ?3^E6JPO%NB
M77B#0)K"SOWLY7YW#HX_NMWP:XH?$M;'=/X7I<\\U/X6:KHAEO\ PUK$@V N
M(F8QO@=@PX/XXKIOACXKO?$FD7$>H$27-HP7S<8WJ1QGWXKF1X<^)HL/[(^W
MQ_92NSS//'W<8QNQNQ7=^"?"47A'1VMO-\ZYF;?-(!@$]@/85VUIITVIR4GT
ML<-"#51.$7%=;GB[^&;SQ)XF\2I8D-<6LTTRQ?\ /0>800/?FO2?AKXSM=0L
MH]!NHH[/4+5=B1JNQ9 /0=F]1^-6?"'A#4]#\7ZSJEVT!M[PR&,1N2W,FX9&
M/2H/&WP[DU>_CUC0I4M-35P9,L55R.C9'1OYU=2K3J/V<GII9]F32HU*2]I%
M:]5W1H?%+_D0;[_>3_T(5+\/_P#DFVF_]<9/_0VJOJ^B^(]>\!2Z5?BS&IDH
M/,20[' (.X\<'VK7\*Z/<Z-X/L]+NC&;B&-U8H<KDL2.?QKF;2H\E];_ *'1
M%-U^>VEOU/'/!/A:_P#$EQJILM8DT_R)%W[ ?GR6QT(Z8_6O1/#'PQMM$U9=
M5O[^34+R,YC++M53Z\DDFI/AWX1U+PO)JK:@T!%TZ-'Y3ENF[.<@>HKN:TQ.
M)DYN,'H1AL-%04IK4\<^+D#7/B[0X$D,;RJ$5Q_"2X&:T&^$=[>2*-2\3W$\
M .2FPDGZ98@?E6MXT\':GK_B?2-1LVMQ!:%3)YCD'AP>!CT%=[0\1*%."@PC
MAXSJ3<T<OKNEVNC?#K4-/LDV00V;JH)R3QU)]:R/@]_R)!_Z^Y/Y+76>(K";
M5/#M_8V^SSIX61-YP,D=S63X \/7OAGPV;"_,1F\]I,Q,6&"![#TK-33HR3>
MK9HX-5XM+1(XGP-;Q7?Q)\46T\:R0RQ3(Z,."#(N14%A-/\ "_QO)I]R['0[
MXY5R>%'9OJ.A]JZKPIX0U/1?&VKZO=-;FVNU<1A');EPPR,>@K;\9>%X?%6A
M26;;5N4^>WD/\+^_L>AK:5:/M.5ZQ:5S"-"?L^9:23=CA?@T0;[7"#D%EP?Q
M-5M GCT;XU:E%?D1FYDE2-WXY8AE_,<?C72_#?P;JGA1[\ZBUN1.%V>4Y;IG
M.<@5=\;^ ;;Q6$NH)1:ZE$,+-C(<=@W]#3E5A[:2;T:M<4*53V,6EK%WL7?&
M/AW4/$5E;0Z?J;6#Q2%F92?F&,8X-<%\/FU&T^(U]I5YJ,]T+:.1"7<E201S
M@U8BTKXIV<0M([Z*2,#:LIE5B!]2,UK^"/ NK:-KT^N:S?1374RL&1,L2202
M2W'I25J=*47)/M8;O4JQDHM=[GH=%%%<!Z 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,.7&=X_B4?\ A86B_P!VZ_[X'^-'_"PM%_NW7_? _P :O?\ "&Z!_P! ]?\
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M.\?Q*/\ PL+1?[MU_P!\#_&C_A86B_W;K_O@?XU>_P"$-T#_ *!Z_P#?Q_\
M&C_A#= _Z!Z_]_'_ ,:+TNS#EQG>/XE'_A86B_W;K_O@?XT?\+"T7^[=?]\#
M_&KW_"&Z!_T#U_[^/_C1_P (;H'_ $#U_P"_C_XT7I=F'+C.\?Q*/_"PM%_N
MW7_? _QH_P"%A:+_ ';K_O@?XU>_X0W0/^@>O_?Q_P#&C_A#= _Z!Z_]_'_Q
MHO2[,.7&=X_B4?\ A86B_P!VZ_[X'^-'_"PM%_NW7_? _P :O?\ "&Z!_P!
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M\:+TNS#EQG>/XE'_ (6%HO\ =NO^^!_C1_PL+1?[MU_WP/\ &KW_  AN@?\
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M79ARXSO'\2C_ ,+"T7^[=?\ ? _QH_X6%HO]VZ_[X'^-7O\ A#= _P"@>O\
MW\?_ !H_X0W0/^@>O_?Q_P#&B]+LPY<9WC^)1_X6%HO]VZ_[X'^-'_"PM%_N
MW7_? _QJ]_PAN@?] ]?^_C_XT?\ "&Z!_P! ]?\ OX_^-%Z79ARXSO'\2C_P
ML+1?[MU_WP/\:/\ A86B_P!VZ_[X'^-7O^$-T#_H'K_W\?\ QH_X0W0/^@>O
M_?Q_\:+TNS#EQG>/XE'_ (6%HO\ =NO^^!_C1_PL+1?[MU_WP/\ &KW_  AN
M@?\ 0/7_ +^/_C1_PAN@?] ]?^_C_P"-%Z79ARXSO'\231O$]AKEQ)#:"8.B
M;SO4 8SCL36S6=I^A:;I4K2V5J(G==K$.QR/Q-:-9RY;^Z=5)5%']Y:_D%%%
M%2:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(2%4LQ  Y)/:@!:*X2Y
M^)*SW\MKH&BWFK"$X>:($(#['!_I6OX6\96OB9[FV^S365];'][;3?> ]16L
MJ%2*YFC*->G*7*F=)17.^)O&%EX;\F%HI;N_G.(;2#EV]_85C6OQ':+5+>RU
MS0[K2A<G$4TIRN>V>!1&C4DN9()5Z<7RMG=T445D:A1110 4444 %%%% !16
M1XEUZ#PWHDVHS+O*X6.,'F1ST K%'BC4IO%^B:6+:.!+JT-S=1-\SQG!P,_E
M6D:4I*ZV_P C.56,79[_ .9V-%%%9F@4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **:[K&C.[!4499F. !ZFL_1M?TKQ
M#;2W.D7T5Y#%(8G>(Y < $C]10!I45A^(O&.@>%%B.M:E#:M+DQHV2S#U '.
M*M:'X@TGQ)8?;='OHKNWW;2T9^Z?0CJ#0!I45R^M?$7PGX?U$Z?J>M00W2XW
MQX+%,_WL#BNAL[RVU"SBN[.>.>WF4/'+&V58'N#0!/1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ_<%'V2V_P"?>+M_ .W2@!_G1_\ /1/^^A1YL?\ ST3\Z9]DMO\ GWB[_P
M[T?9;?.?L\6<Y^X/I0 _S8_^>B?]]4>=%_ST3_OH4S[);#_EWB[?P#MTH^R6
MV,?9XNF/N#US0 _S8_\ GHG_ 'T*/-C_ .>B_G3/LEL>MO%W_@'?K1]EM\Y^
MSQ9SG[@],4 /\V/_ )Z)_P!]"CSHO^>B?]]"F?9+88Q;Q<8_@';I1]DML8^S
MQ8QC[@H ?YL?_/1?SH\V/_GHOYTS[+;YS]GB[_P#OUH^RVX.?L\78_<';I0
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MYL?_ #T7\Z/-C_YZ)_WT*9]EM\Y^SQ9SG[@^E'V2V'_+O%V_@';I0 _SHO\
MGHG_ 'T*/-C_ .>B?G3/LEMC'V>+'3[@^M'V2V/_ "[Q=_X!WZT /\V/_GHG
MYT>='_ST3_OH4S[);_\ /O%Z_<%'V2VQC[/%_P!\"@!_G1_\]$_[Z%'FQ_\
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M =^M #_-C_YZ+^='FQ_\]$_[Z%,^RV^<_9XLYS]P?2C[);#_ )=XNW\ [=*
M'^=%_P ]$_[Z%'FQ_P#/1/\ OH4S[);8Q]GBQT^X/7-'V2V/_+O%W_@'?K0
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M_P#V!F_FU 'JM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7E5Y_R<MI__8&;^;5ZK7E5Y_R<MI__ &!F_FU 'JM%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E5Y_P G+:?_
M -@9OYM7JM>57G_)RVG_ /8&;^;4 >JT444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %>57G_)RVG_]@9OYM7JM>57G_)RVG_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXI3?6P)S*.,]CVZT 6**K_;K;./-&<@=#WYI!?VQ (E'(!Z'OTH LT56-_;
M$F48 )Z'MUI?MUMG'FC.2.A[<T 6**KB^MB0/-'..Q[]*3[?;8SYHQC/0^N*
M +-%49M9TVW;;/?6\38)VR2!3@=>#3/[>T?./[4L\YQ_KU],^M.S%=&C16=_
M;^CG'_$TL^<?\MU[].]'_"0:/C/]J6?3/^N7UQZT<K[!=&C16<=?T<?\Q2S[
M_P#+=>WXT?V_HY./[4L^H'^O7OSZT<K[!=&C16=_PD&CXS_:EGV/^N7O^-']
MOZ./^8I9]_\ ELO;KWHY7V"Z-&N7\0_#_0/$UX+R^MY%N<8:2%]I8>_K6O\
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M,=\<UT7PQTZ_=-:\3:I:M:7&N7?VB.!_OQP@80,.QQS7>LBL064$@Y&1TIU
M%"30](ED:232[)W8EF9K=223U).*\R>SM;/]I'3X[6VA@3^QV;;$@49^;G K
MURO*KS_DY;3_ /L#-_-J /5:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH X;XN?\D_N?^NT7_H0KJ]%_P"0#IW_ %ZQ_P#H(KE/BY_R3^Y_
MZ[1?^A"NKT7_ ) .G?\ 7K'_ .@BNB7\"/J_T,E_%?HB]1117.:A1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7F?BG_DLGA?_ '#_ .S5
MZ97F?BG_ )+)X7_W#_[-71AOB?H_R,JWPKU1Z91117.:A1110 4444 %%%%
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M4 >JT444 %%%% !1110 4444 <?X<\/:3J&C)<W=C%+,TD@+MG)PY [UK?\
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M10 4444 %%%% !1110 4444 %%%% !1110!PWQ<_Y)_<_P#7:+_T(5U>B_\
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M1110!!??\>%S_P!<F_D:X7X-_P#(CO\ ]?DG\EKNK[_CPN?^N3?R-<+\&_\
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.=I%MY&A4-*%)12<
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MO]NAQG]YTS_JF]<>E!O81G_6<9_Y9MV_"K%% %?[9#G'[SKC_5MZ9]*/ML)
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M5F^\.Z5J5T;F[LTEF("ECGH.E8/AWQ)I&G:.EK=WR13+)(60JQQER1T%:O\
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M?^N3?R-<+\&_^1'?_K\D_DM=$/X$O5?J92_B+T?Z'H-%%%<YJ%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY4K_ +/J:]0-Q*,_Z',>O=.WX]Z\D_0"Q15?[1+G'V27KC.5]/K^% N)>/\
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MNGK]:/M$N?\ CTEZGNO^- %BBJXN)21_HDPZ=U[_ (]J/M$N,_8YNF<;D_\
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M6;-)G-HW"C )X(]>:]3HH \GT23QA\.[6Y\.P>&)]=L(Y7?3KNWF5,(Q)V2
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M_LU>F5YGXI_Y+)X7_P!P_P#LU=&&^)^C_(RK?"O5'IE%%%<YJ%%%% !1110
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M^_X\+G_KDW\C7"_!O_D1W_Z_)/Y+71#^!+U7ZF4OXB]'^AZ#1117.:A1110
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MO/D@HHHH **** "BBB@ HHHH **** "LKQ+_ ,B[>_[@_F*U:RO$O_(NWO\
MN#^8J9_"S?#?QX>J_,^CO O_ "(/A[_L'0?^BQ705S_@7_D0?#W_ &#H/_18
MKH*\L^Z"BBB@ HHHH **** "BBB@ HHHH **** (+[_CPN?^N3?R-<+\&_\
MD1W_ .OR3^2UW5]_QX7/_7)OY&N%^#?_ "([_P#7Y)_):Z(?P)>J_4RE_$7H
M_P!#T&BBBN<U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KYJ\7?\EH\2_\ 7*+_ - 2OI6OFKQ=_P EH\2_
M]<HO_0$K6C_$1PYE_NL_ZZD=%%%>B?&!1110 4444 %%%% !1110 4444 %(
M_P!QOH:6D?[C?0T#1Z1^S_\ \DS'_7]-_P"RUZE7EO[/_P#R3,?]?TW_ ++7
MJ5>2?H 4444 %%%% !1110 4444 %%%% !1110 5YGXI_P"2R>%_]P_^S5Z9
M7F?BG_DLGA?_ '#_ .S5T8;XGZ/\C*M\*]4>F4445SFH4444 %%%% !1110
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M'_OZK_U_R_SK?#_&>7G'^ZOU1LT445WGR04444 %%%% !1110 4444 %%%%
M!65XE_Y%V]_W!_,5JUE>)?\ D7;W_<'\Q4S^%F^&_CP]5^9]$>!Y+@> _#X$
M (_L^#!WCIY8K>$MSQFV';^,?C6/X%_Y$'P]_P!@Z#_T6*Z"O+/NBOYMSC_C
MV&<?\]!ZT&6YYQ;#O_&/PJQ10!7\VYS_ ,>XQG^^*!+<\9MAV_Y:#\:L44 5
MO-NL?\>PS@_\M!2^;<Y/^C#J?XQ^%6** ,V36((93'++:QNI 96N5!'KQ3!K
MMKC_ (^++.!_R])Z_6N/T'PWHNN>)_%DNJ:9;7<D>HA4:9 Q4>6IP/QKHO\
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MUI]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5Y5>?\G+:?\ ]@9OYM7JM>57G_)RVG_]@9OYM0!ZK1110 4444 %%%% "'[I
M^E?)WA_[^J_]?\O\Z^L3]T_2OD[P_P#?U7_K_E_G6^'^,\O./]U?JC9HHHKO
M/D@HHHH **** "BBB@ HHHH **** "LKQ+_R+M[_ +@_F*U:RO$O_(NWO^X/
MYBIG\+-\-_'AZK\SZ.\"_P#(@^'O^P=!_P"BQ705S_@7_D0?#W_8.@_]%BN@
MKRS[H**** "BBB@ HHHH X[P;_R,7C#_ +"8_P#1:UV-<=X-_P"1B\8?]A,?
M^BUKL:J6Y=3XON_(RO$NH3:5X8U/4+8J)[>V>6,L,C<!D9%>,:;\2/B-K$<C
MZ;:0W2QD*YBL\A3Z'FO8O%]I<7_@[5[2TB,MQ-:R1QH.K,1@"O$;7PS\2/!V
MF3W=BDEM;_ZV9()4<\#J5]A6E-*VNYO047%WM?S/4OA[J_BO54OSXGL_LYC9
M/(_<>7N!!SW.>U=M7GOPN\=77BRRN;74@AO[3!,B# D0]R.QS7H59S5I&-5-
M3::L>':O\2?&8\8ZAH^D);S^5.\<,0MMSE1^/-;7A;Q+\1;WQ+96VLZ9Y6GN
MQ$S_ &0I@8/?/'-<W?>!O'(\8:EK6CVQ@8W$C12^>JL5/H#ZBM+P/\0O$-OX
MMC\.>)BTK2R>3F5 LD4F. 2.H/\ 6MFE;W4CJE&+C[B3T^9=NO&_C+Q-KVH6
MO@VUMQ96#;6EE4$R$$]SZX.!71>!/'C:_I.H'6(TM+[3"1=8X7:,_-CMT.1[
M5S$GACQMX+U[4IO"<<%WI^H/OVR8)C))QD$CD9//2N9O=(U31H#X::=)/$'B
M&82WVQLB&($D GW.6/L*7+%JR)Y(25E;]?.YZ+\//$>N>*]6UC4YG"Z'YFRT
MB9/F!'H?IU]S7H5>.V/Q1T7PO9Q:/HVCW=[I]B/+DNT&T,>[?B<]<5ZAH6N6
M/B+2(=3T^0O!*.XP5(Z@CL16<XM.]M#&K!IWM9&E7'^,O^1A\'_]A,_^BVKL
M*X_QE_R,/@__ +"9_P#1;4H[D4_B^_\ (["BBBI("BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KYJ\7?\EH\2_\ 7*+_ - 2OI6O
MFKQ=_P EH\2_]<HO_0$K6C_$1PYE_NL_ZZD=%%%>B?&!1110 4444 %%%% !
M1110 4444 %(_P!QOH:6D?[C?0T#1Z1^S_\ \DS'_7]-_P"RUZE7EO[/_P#R
M3,?]?TW_ ++7J5>2?H 4444 %%%% !1110!QW@W_ )&+QA_V$Q_Z+6NQKCO!
MO_(Q>,/^PF/_ $6M=C52W+J?%]WY!6;K.OZ5X>M%NM6O8[6%WV*SY.3Z #FM
M"21(HVDD8*B@LS$X  [U\V^.=>O/'.L7][:*QTG2H\IZ!2P7=]6)X]A3A#F9
M5&ESO78^A-'UO3=?L?MNE7:7-MO*>8H(&X=1R/>M"O./@E_R(;_]?LO\EKT>
ME)6=B:D>632.8O/B)X3T^]FL[O6H8KB%BDB%'RI';@4_3O'WA;5K^*QL-8AG
MNI3A(U5@6/7N*\$U232/^%F:H^N).^G_ &J7S%@/SD]L?C7I/@+2_A[?ZS'>
MZ!+=#4;7+K#<.0V,8)P>HY[5I*G%*^IO.C",;ZG:ZWXX\.>'KH6NIZI%#<$
MF, LP'J<#BM?3M3LM7L8[W3[F.XMI/NR1G(_^L:\*\-OX9B\4^)!XZ"?;O.;
M8;D$KC)SC_:^[C]*;X0\3'PKX9\47]H7%G+<"'34D[R'//X+M)H=/30'05M-
M]#VC3_%6D:IKM]HUI<E[VR_UJ;3CWP>AP>/K6S7!?#'PVOAW01=7[*-5U,^=
M+YA^8 \A>>>^3[FN]K.22=D8324K1"N/\9?\C#X/_P"PF?\ T6U=A7'^,O\
MD8?!_P#V$S_Z+:B.X4_B^_\ (["BBBI("BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\JO/^3EM/_[
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M'\/:IX6U+P]-)>R.X5MO#[A@;N.1Z8KT?X3:%?:%X,"7\;137,S3B)N"BD
M$=NF?QKN"B,P8JI9>A(Y%.JI3NMBYU>962W"N/\ &7_(P^#_ /L)G_T6U=A7
M'>,O^1A\'_\ 83/_ *+:ICN13^+[_P CL:***D@**** "BBB@ HHHH ****
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M!7EGW04444 %%%% !1110!S%_P##[PQJ=_/?7>G,]S.VZ1UN)5W'UP& JO\
M\*P\(_\ 0,D_\"YO_BZZ^BJYI=R_:3[G(?\ "L/"/_0,D_\  N;_ .+H_P"%
M8>$?^@9)_P"!<W_Q==?6!J_A_4=2OC<6WB;4M/CVA?(MUB*@CO\ ,I/ZT<TN
MX>TGW9G_ /"L/"/_ $#)/_ N;_XNC_A6'A'_ *!DG_@7-_\ %T[_ (1#6/\
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M!*^E:^:O%W_):/$O_7*+_P! 2M:/\1'#F7^ZS_KJ1T445Z)\8%%%% !1110
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M#_H8K#_O[1_PL3P>20/$>GDCJ/-'%','/Y(J^3\1/^?OPW_WZF_QH\GXB?\
M/WX;_P"_4W^-6O\ A8?A#_H8K#_O[1_PL/PA_P!#%8?]_:.8.?R15\GXB?\
M/WX;_P"_4W^-'D_$3_G[\-_]^IO\:M?\+#\(?]#%8?\ ?VM^SO+?4+.*[M)D
MFMY5W1R(<AAZBCF#G\D<MY/Q$_Y^_#?_ 'ZF_P :KMH'BW4];TB[UF[T<V^G
MW/GA;5)%9CM*X^;([UW%%','M'V"BBBI("BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\JO/^3EM/\
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M"228, %&>F!7J%?,'PB_Y+#8_P#7G-_Z":^GZPDK.QQU(\LG$****D@****
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M_P "6_QI^QF'U:IV/L3[);?\^\7_ 'P*E50JA5  '0#M7QM]JUK_ *&'5?\
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M_P 31_PK'XF_WM$_[^'_ .)H^LP#^QL3Y??_ , S:*TO^%8_$W^]HG_?P_\
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M_OX?_B:/^%8_$W^]HG_?P_\ Q-'UF ?V-B?+[_\ @&;16E_PK'XF_P![1/\
MOX?_ (FC_A6/Q-_O:)_W\/\ \31]9@']C8GR^_\ X!FT5I?\*Q^)O][1/^_A
M_P#B:/\ A6/Q-_O:)_W\/_Q-'UF ?V-B?+[_ /@&;16E_P *Q^)O][1/^_A_
M^)H_X5C\3?[VB?\ ?P__ !-'UF ?V-B?+[_^ 9M%:7_"L?B;_>T3_OX?_B:/
M^%8_$W^]HG_?P_\ Q-'UF ?V-B?+[_\ @&;2/]QOH:T_^%8_$W^]HG_?P_\
MQ-(?AA\3""-VB<_]-#_\31]9@']C8GR^_P#X!VW[/_\ R3,?]?TW_LM>I5X=
MX5\)_%OP=HW]E:4V@"V\QI?WKEFW-C/./:MO;\;?[_AK_P >K@/JSU:BO*=O
MQM_O^&O_ !ZJVH7?QHTW3KF^G?PYY-O$TK[02=JC)Q^5 'K]%>*^'M;^,/B7
M0K75[!_#_P!EN5+)YBE6P"1R/PK4V_&W^_X:_P#'J /5JY+XG_\ ),?$7_7D
M]<MM^-O]_P -?^/50UK1_C)KVC7>E7K^'?LUU&8I-A(;!]#B@#Q*P_X\(/\
M<%6*Z^+X)_$"&)8U;2=JC S.?_B:?_PI?XA?WM(_[_'_ .)KJ5:*1Z$<3!)(
MXVHY8?-Q^\D3']QL9KMO^%+_ !"_O:1_W^/_ ,31_P *7^(7][2/^_Q_^)H]
MM$;Q--G"?8S_ ,_-Q_WW1]C/_/S<?]]UW?\ PI?XA?WM(_[_ !_^)H_X4O\
M$+^]I'_?X_\ Q-+VD"?;TCA/L9_Y^;C_ +[I!8A69A<3@MU._K7>?\*7^(7]
M[2/^_P ?_B:/^%+_ !"_O:1_W^/_ ,31[2 >WI'"?8S_ ,_-Q_WW1]C/_/S<
M?]]UW?\ PI?XA?WM(_[_ !_^)H_X4O\ $+^]I'_?X_\ Q-'M(![>D<)]C/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C^+(WF\(:S'
M$C/(]E*JJHR2=AX K8HH XKX2VT]I\,M&@N89(95C;='(I5A\YZ@UVM%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5XM<?%OQA<^+=6T/0?"MMJ+6$K*2KMNV@X!/(KVFOF;1KOQ?:?%OQ:W@^RM+
MJZ:5Q,MST";^"/F'.: /2/!/Q8N];\5/X8\1:&VDZI@F,9.&P,X(/(XY!Y%;
MMGXJ\13_ !+NO#\WAR2/1HXRR:C\V#\N0<]#D\8'(KRSPI<WL7QMBN?B#!/;
MZY<1A+ (BB <$#H?J![]:ZJP\1ZK_P -!ZMI4VHW+:7!:&1;4N?+4B-3D#\3
M0!Z[17@&DW7CGXO:IJE]IGB.30]'M)3% D#,I8]1G;@GC!))[\5K>*_$_BWX
M:?#>TMM2U6*_UZ\G:*.Z*Y\F,#.<G[Q]R._?% 'M-%?,&H>+[[PU;VFM:3\2
MY];O]ZFYT^97\L@]< DC Z=JZGXF^,O$1UKP9)X9OYK9M4MU=(%?Y'=V4*&'
M0XSB@#W:BOG[Q3IOQ'^'-E#XG?Q?+J<:R*+JWD9C&"3T"G@KVXP:O?%3Q]K'
M]A>%;C2[RXTK3=7B$US=P*2Z9V_*".1@$G Y- 'N=%>6_"B2XEO+]D\?#Q'I
M^Q?*@E!\^,GJS;CE?3 )'TKU*@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *R?$GB/3O"FAW&KZI*4MX1T'+.QZ*H[DUK5X
M9^T>\GV;PU"Y863W$IEQTR N/T+4 26_Q3^(7B-6OO#7@L/IBN=KRY)=?J2
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %>!1>&_B7X9^(&OZWX?
MT&VN(K^5@K3SQX*;L@@;P17OM% 'BVB> _&WB3Q]8^*?&[VMLEA@PVT+!B<<
M@87( R<DYS6O8^#M:C^.VI^(I[(#1KBU,2S^:OS$HHQMSNZ@]J]2HH \*MO"
MGQ#^&FLZD/"%G;:KHU[(9%BD89C/;()!R.G&0<"MC7/!'BWQ]\.K>'Q%]CMO
M$=I.9[?81L=3_"^,@'Z9' ]Z]=HH \%CT'XAW\MG8#P/X;T[RG3S[UXHV60#
MKD9/![X&?I5?XV6-U_PFG@NQTMHK:\VB.W9!L2.3S%"D=< '%?05<5XL^'R>
M*?%F@ZZVH-;G29%<1",-YF'#=>W3% 'G.O:-\6O'\-OX?UG3[+3]/213<7*.
MNV3'\1PQ)]< "NT\6Z9XJT?1]%TSPKH^G:MI-G$(KFUNPI>0 8'WL #'.0<Y
M]J]'HH \8^&?@/7;'Q]>^*=2TBVT&UDA:./3[>0,"6QV!.!QGZ]J]GHHH **
M** "BBB@ HHHH **** "BBB@ HHJO>WMMIUG+>7<HBMXAN=R#@#\*$KZ(&[:
MLL45R_\ PL7PE_T&8O\ OV__ ,31_P +%\)?]!F+_OV__P 36GL:G\K^XR]M
M3_F7WG445R__  L7PE_T&8O^_;__ !-'_"Q?"7_09B_[]O\ _$T>QJ?RO[@]
MM3_F7WG445R__"Q?"7_09B_[]O\ _$T?\+%\)?\ 09B_[]O_ /$T>QJ?RO[@
M]M3_ )E]YU%%<O\ \+%\)?\ 09B_[]O_ /$T?\+%\)?]!F+_ +]O_P#$T>QJ
M?RO[@]M3_F7WG445R_\ PL7PE_T&8O\ OV__ ,31_P +%\)?]!F+_OV__P 3
M1[&I_*_N#VU/^9?>=117+_\ "Q?"7_09B_[]O_\ $T?\+%\)?]!F+_OV_P#\
M31[&I_*_N#VU/^9?>=117+_\+%\)?]!F+_OV_P#\31_PL7PE_P!!F+_OV_\
M\31[&I_*_N#VU/\ F7WG445R_P#PL7PE_P!!F+_OV_\ \31_PL7PE_T&8O\
MOV__ ,31[&I_*_N#VU/^9?>=117+_P#"Q?"7_09B_P"_;_\ Q-'_  L7PE_T
M&8O^_;__ !-'L:G\K^X/;4_YE]YU%%<O_P +%\)?]!F+_OV__P 31_PL7PE_
MT&8O^_;_ /Q-'L:G\K^X/;4_YE]YU%%<O_PL7PE_T&8O^_;_ /Q-'_"Q?"7_
M $&8O^_;_P#Q-'L:G\K^X/;4_P"9?>=117+_ /"Q?"7_ $&8O^_;_P#Q-'_"
MQ?"7_09B_P"_;_\ Q-'L:G\K^X/;4_YE]YU%%5--U.SU>Q2]L)UGMW)"R*"
M<'!Z^XJW4--.S-$TU=!1112&%%%% !1110 5SOC7P?8>-O#DVDWQ*$G?#,HR
MT3CHP_D1W!KHJ* /"K/0OC/X.LO[)T>>RU.PBRL#LR%D7MC>00/;G%8.D^$?
MBII_BY_$]YX<M]4U0_<DO+J,B,],J!(,8' ]*^DZ* /$?%OA3QU#XVTCQSH5
MA!/J7V6-+NU\Q<1R;=K#DC*D'&0<TW0/"'CVY^+^G^+?$=C;K&8V\TP2IM@&
MQE5,9R<9'3/7K7N%% 'S_IO@OQKX1\7:Q+:>%=-UX7\S/#?74BXC!8G)R<CK
MR,=N*V/A]\-=;M=/\::9XEMTMX]854CFA=65C^\RR@'@ L" 0*]HHH \&T#2
M_B_X,LI/#6F:?8W=GO86]Z[J1$">6&6!QWP0:U?AAX$\3>&H?%D>LVP\V^0K
M#*)E;SVP_P W!R,Y!YQUKV2B@#S?X+>%M9\)>$KNQUNT^S7$EZTJIYBOE2B#
M.5)'4&JWA+P=K.G_ !9\5:S?V032]0#+!+YBMY@+#^$'(X]17J-% 'A%EX6^
M(_PRU+4+?PG9VVKZ-=R%XUE89C/;(+ @@<'&0<5L^(/ OBSQ[\/;)=?^QV_B
M:QG:6':P*2*?X7QP"?;(X'J:]>HH \'BT+XA:E=6=H? _AO3!%(IN+MX8V64
M#KD G@^BC\JK_&BRO6\?>#;/1VBM[U8=EJ1\J(P<;<>@XKZ KB_$_@!/$GC'
M0_$#7[0'2SD0B//F?-GKVH \YUW1/BO\0EMM"UO3[/3=-CE#7%Q&ZXD(_BX8
MD^P  S76>,-.\7:8FEZ?X?\ #VF:WH%K;"&2UN=ID8@8R=V,=/X??->G44 >
M0_"3P)K>@^(]7U_5;"#28KU-D.G02;@@+9[$X QQSWKUZBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "N<\>_P#(BZO_ -</ZBNCKG/'O_(BZO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV>?>;J-?GDR,9KK*Q?$G^HL?^OR/^=%2G%0;2)P6+KSQ$(RFVFSZPA_U,?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.^%M(\+6TL.EV[(9GWS2R.9))6]69N36S10!FW.A6%WKMEK,T;&]LD>.%PY
M ?[V1T/2M*BB@#D_AQ_R)D'_ %WG_P#1K5UE<G\./^1,@_Z[S_\ HUJZRM:_
M\27JS*A_"CZ(****R-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7.>/?\ D1=7_P"N']17
M1USGCW_D1=7_ .N']16E'^)'U1G6_AR]&;EC_P >%M_UR7^0J9_N-]*AL?\
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M7K>KZM \QN-5:-YP[ J"B[1M&../K0!4\"ZA9:GX'T>XL"OD"U2/:O\  R@
MJ?0@@BN;^(<B7GBWP5I5J=VHC4Q=X7DQPH/G)] >E7[KX:V*ZA<7NAZMJNA2
M7+;YXM/G"PR-W8H00#[C%:7ASP3I7ANYGOHGNKW4K@8FO[Z7S9F']W=V'L!0
M!B7GPUT_4=3U75K'Q#JUI?7<QD9[.[VQQR  #*#@XQWK2^&VN7VO^"[>ZU)U
MENXI9;:291@3>6Y7?^./SJI>_"_39[Z\GLM6UG2X;YR]W:V-ULBE8]3C!P3W
MQ75Z3I5EH>EV^FZ= L%I;ILCC7L/KW/O0!R/@'_D9_'7_88'_HI:[NLK2?#]
MIHU]JMW;/,TFIW/VF<2," VT+\O' P/>M6@#D_AQ_P B9!_UWG_]&M765R?P
MX_Y$R#_KO/\ ^C6KK*UK_P 27JS*A_"CZ(****R-0HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "N<\>_P#(BZO_ -</ZBNCKG/'O_(BZO\ ]<?Z
MBM*/\2/JC.M_#EZ,W+'_ (\+;_KDO\A4]8UGX@T5;&W5M8T\$1J"#<IZ?6I_
M^$BT3_H,Z?\ ^!2?XTG"5]AJ<;;FE16;_P )%HG_ $&=/_\  I/\:/\ A(M$
M_P"@SI__ (%)_C2Y)=A\\>YI45F_\)%HG_09T_\ \"D_QH_X2+1/^@SI_P#X
M%)_C1R2[!SQ[FE16;_PD6B?]!G3_ /P*3_&C_A(M$_Z#.G_^!2?XT<DNP<\>
MYI5PWBC2M<L?&=AXMT*P34VBM&L;JQ,HC=HRVX,C'C(/7/:NG_X2+1/^@SI_
M_@4G^-'_  D6B?\ 09T__P "D_QHY)=@YX]SE-#T[7]<\=IXIUK2UTBWM+-K
M2TM&F$LK[F!9W*\ <<"N]K-_X2+1/^@SI_\ X%)_C1_PD6B?]!G3_P#P*3_&
MCDEV#GCW-*BLW_A(M$_Z#.G_ /@4G^-'_"1:)_T&=/\ _ I/\:.278.>/<TJ
M*S?^$BT3_H,Z?_X%)_C1_P )%HG_ $&=/_\  I/\:.278.>/<TJ*S?\ A(M$
M_P"@SI__ (%)_C1_PD6B?]!G3_\ P*3_ !HY)=@YX]S2HK-_X2+1/^@SI_\
MX%)_C1_PD6B?]!G3_P#P*3_&CDEV#GCW-*BLW_A(M$_Z#.G_ /@4G^-'_"1:
M)_T&=/\ _ I/\:.278.>/<TJ*S?^$BT3_H,Z?_X%)_C1_P )%HG_ $&=/_\
M I/\:.278.>/<Q?AQ_R)D'_7>?\ ]&M765R?PW(;P7;E2"#/.01W_>M765=?
M^)+U9%#^%'T04445D:A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %07D$-U9RP7$4<L3C#1R*&5A[@]:**J'Q(F?PLP?^$8\/\ _0"TS_P$C_PH
M_P"$8\/_ /0"TS_P$C_PHHKU#R@_X1CP_P#] +3/_ 2/_"C_ (1CP_\ ] +3
M/_ 2/_"BB@ _X1CP_P#] +3/_ 2/_"C_ (1CP_\ ] +3/_ 2/_"BB@ _X1CP
M_P#] +3/_ 2/_"C_ (1CP_\ ] +3/_ 2/_"BB@ _X1CP_P#] +3/_ 2/_"C_
M (1CP_\ ] +3/_ 2/_"BB@ _X1CP_P#] +3/_ 2/_"C_ (1CP_\ ] +3/_ 2
M/_"BB@ _X1CP_P#] +3/_ 2/_"C_ (1CP_\ ] +3/_ 2/_"BB@ _X1CP_P#]
M +3/_ 2/_"C_ (1CP_\ ] +3/_ 2/_"BB@ _X1CP_P#] +3/_ 2/_"C_ (1C
MP_\ ] +3/_ 2/_"BB@ _X1CP_P#] +3/_ 2/_"C_ (1CP_\ ] +3/_ 2/_"B
MB@ _X1CP_P#] +3/_ 2/_"C_ (1CP_\ ] +3/_ 2/_"BB@ _X1CP_P#] +3/
M_ 2/_"C_ (1CP_\ ] +3/_ 2/_"BB@#;TZTMK*R2"TMXK>%2=L<2!%&3D\#B
MK5%%>94^-GJ4_@04445!84444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
<4 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img224999359_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_14.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *T!#@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP_T_Q6PNA(;34$&!.@R& Z!AW^O6B,J492A?W9?@$HU91C.WO1_$ZXD*"20
M.237C5Y<IXJ^--HVGGS(+,JKRKT(3)8_3)Q5UOAIXLGC^QS^*";/IC<YR/IG
M^M=MX3\&Z=X2M62UW2W$G^MN)/O-[#T'M1%TZ*;4KMZ#DJE9I.-DG<XCXQ_\
MA3P]_O2?S2M;XG>%)+VV3Q#I8*:C8X9S']YT'.1[KU^E:GC7P5+XLN]-FCO4
MMA9EB0T9;=DJ?4>E=@0",$9%+V_)&'+NKW'[#GE4YMG:Q\_WOB9?%/BKPS=L
M-MS&8XKA<<;P_4>QZU] 5YI-\)HT\5IJUC?I!;+<+.+8Q$[<') .>GIZ5Z71
MBITY**I[(,+"I%R=3=C9/+\I_-V^7M.[=TQWS[5YKJOPGT75D-_H5\;0R#?'
ML.^$_3N!]#QZ5W>N:/#KVC7&FSR2QQS+@O$V&'^?3O7FJ_"WQ):1O967B798
MN>5RZ\?0&EAVHZJ?*QXB+E9.',B?X2:WJ4UWJ.B7L[7$-JNZ-V;=MPVT@'T/
M45S>I^'AXG^*NM:;YWDNP=XWQD!@JXS[5ZGX.\&VGA"PDBBD,]S,09IV&-V.
M@ [#DU3L?!,MG\0+KQ,;Y&2<-^X\L@C( ZY]JU5>"J3G'333U,7AYNG"$M==
M?0Y7P/XPN?#E_P#\(GXE7[/Y3;()FX">BD]U/8UWGC?GP/K/_7J_\JJ^,_!%
MEXNM%W,+>^B_U5P%SQ_=([BHK/PMJR>#KSP_?ZM'="2$Q03F(AD4]CSR!VK.
M4J<FJBT=]5^II&-2"=-ZJVC_ $*?PC_Y$6+_ *^)/Z5P&@>%+;Q9XY\06UU<
MSP+#-+(##C)/F8[_ %KUKP=X<?PMH"Z;)<K<,LC/O5=HY]JS?#'@J7P_XEU3
M5GO4F6^+D1B,J4W/NZYYJU7495)1>^WWDNA*4:<9+;?[B/0?AAH.A7Z7P,]W
M<1G=&9V!"'U  '/UKG?C:,VNC#_II+_):]7KD/'7@R7QA%9)%>I;?9F=B6C+
M;LX]QZ5G1KOVRG49I6H+V+A31B0_!K16$;RZA?NN 2NY1G]*[1-+LM%\-S6%
MA L-O% ^U1]#DD]S6HB[(U7.< "F74)N+2:$':9$9,^F1BLIUISMS,TA1A"_
M*K'FGP4_Y FJ?]?*_P#H-5=+_P"2]ZA_NM_Z*%=?X&\(2>$+&[MY+Q+DSRB0
M%4*XP,>M16G@J6V^(5QXG-ZC1R@CR/+.1E0O7/M73*M!U*COHUH<T:,U3IQM
MJGJ<=XGT^X^'GC&#Q)ID9_LVZ?;/$O0$\LOT/4>XIOPXNX;_ .)>LW=N289H
MY)$)&#@N#7JVKZ5:ZUI5QIUXFZ&9=I]0>Q'N#S7'>"?AU+X2UF:^;44N4>(Q
MA!$5(Y!SG/M1&O"5)J7Q6MZA+#SC6BX_#>_H<OK\X\,?&>+5;T;;2YVOYA'
M4J$/Y$5Z5XCT*V\6Z$+(W;1PR,LBRPX.<=,>U+XF\+:=XJT_[+?(0R\Q3)]^
M,^W^%<#'\,_%.FY@TSQ.4MCT7<ZX'TY%)3A447S<LD4X3IN2Y>:,C(T+14\.
M_&.TTR*XDFCCR0S]3F,FO<*\^\+?#1]%UR/6=1U:2\O(\E< X.01R223UKT&
ML\544Y*SO9%X6FX1=U:["BBBN8Z@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'_"'Z!_T#U_[^/\ XT?\(?H'_0/7_OX_^-%Z79ARXSO'\3/_ .%AZ+_<NO\
MOA?_ (JC_A8>B_W+K_OA?_BJT/\ A#] _P"@>O\ W\?_ !H_X0_0/^@>O_?Q
M_P#&B]+LPY<9WC^)G_\ "P]%_N77_?"__%4?\+#T7^Y=?]\+_P#%5H?\(?H'
M_0/7_OX_^-'_  A^@?\ 0/7_ +^/_C1>EV8<N,[Q_$S_ /A8>B_W+K_OA?\
MXJC_ (6'HO\ <NO^^%_^*K0_X0_0/^@>O_?Q_P#&C_A#] _Z!Z_]_'_QHO2[
M,.7&=X_B9_\ PL/1?[EU_P!\+_\ %4?\+#T7^Y=?]\+_ /%5H?\ "'Z!_P!
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M/^$/T#_H'K_W\?\ QH_X0_0/^@>O_?Q_\:+TNS#EQG>/XF?_ ,+#T7^Y=?\
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M,_\ X6'HO]RZ_P"^%_\ BJ/^%AZ+_<NO^^%_^*K0_P"$/T#_ *!Z_P#?Q_\
M&C_A#] _Z!Z_]_'_ ,:+TNS#EQG>/XF?_P +#T7^Y=?]\+_\51_PL/1?[EU_
MWPO_ ,56A_PA^@?] ]?^_C_XT?\ "'Z!_P! ]?\ OX_^-%Z79ARXSO'\3/\
M^%AZ+_<NO^^%_P#BJ/\ A8>B_P!RZ_[X7_XJM#_A#] _Z!Z_]_'_ ,:/^$/T
M#_H'K_W\?_&B]+LPY<9WC^)G_P#"P]%_N77_ 'PO_P 51_PL/1?[EU_WPO\
M\56A_P (?H'_ $#U_P"_C_XT?\(?H'_0/7_OX_\ C1>EV8<N,[Q_$S_^%AZ+
M_<NO^^%_^*H_X6'HO]RZ_P"^%_\ BJT/^$/T#_H'K_W\?_&C_A#] _Z!Z_\
M?Q_\:+TNS#EQG>/XF?\ \+#T7^Y=?]\+_P#%4?\ "P]%_N77_?"__%5H?\(?
MH'_0/7_OX_\ C1_PA^@?] ]?^_C_ .-%Z79ARXSO'\3/_P"%AZ+_ '+K_OA?
M_BJ/^%AZ+_<NO^^%_P#BJT/^$/T#_H'K_P!_'_QH_P"$/T#_ *!Z_P#?Q_\
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M-'_"'Z!_T#U_[^/_ (T7I=F'+C.\?Q,__A8>B_W+K_OA?_BJ/^%AZ+_<NO\
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M9WC^)G_\+#T7^Y=?]\+_ /%4?\+#T7^Y=?\ ?"__ !5:'_"'Z!_T#U_[^/\
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M\?Q,_P#X6'HO]RZ_[X7_ .*H_P"%AZ+_ '+K_OA?_BJT/^$/T#_H'K_W\?\
MQH_X0_0/^@>O_?Q_\:+TNS#EQG>/XF?_ ,+#T7^Y=?\ ?"__ !56=/\ &NEZ
ME?16<"7 EE.%W(,=,^M3_P#"'Z!_T#U_[^/_ (U-:^&='LKE+BWLE2:,Y5M[
M'!_$TFZ5M$QQCB[KF<;?,UJ***R.T**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ***XC6/&>JMKTVB>&]&:]NH/]?+-E8T_E^>?IFKA3E-V1$ZD8*[
M.WHKAM(\9ZM%XD@T'Q+I<=G<7*YMYH6RCGTZGTK:\5>*K7PO8I)(C3W<S;+>
MV3[TC?X53HS4E'N2JT'%R[&_17F]YXP\:Z-:KJ>J>';9=/R/,6.3+Q@^O)_E
M7?:;J$&JZ;;W]LQ:&>,.A/7!I3I2@KO8(58S=EN6J***S-0HHHH **** "BB
MLCQ-KL7AW0;G49,,R#;$G]]ST%.,7)V0I245=FO17GWB'7M>@T3PVI=+34]1
MNT698AT0]N<\\KFO0:J=-Q2;ZD0J*3:70****@T"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q?$/B
M;3/"UM%<ZB9%69]B^6FXD@9K0U#4+72K&6]O91%;Q#+N1TYQ3;.[L=:TZ&\M
MREQ;3+N1BO4?0U<5;WI+0B3O[L7J>?Z/</\ $#QK:Z[&@@TO201$K./,D<]R
M!T'^%6;5!K_Q?O)9OG@T> )$I'"N>_ZFJNC06L'QFO8]%54M%M#]K6+[@?C^
MN/QS5GP?,D'Q+\5VLS 3RNLB ]64$YQ_WT*[):7<?Y=/*[.*.ME+^;7SLCL/
M$JQ/X8U03 &/[+)D'_=-8WPS+GP#IOF')^?'TWG%0?$O6%LO#+Z;"0]]J)$$
M,0^\03R?Z?C71>'M-_L?P]8:>2"T$*HQ'=L<G\ZY]J&O5_D=&]?3HOS&>)-6
M;0O#M]J:(LC6\>Y48X!.0 /UKC['Q=XP\0:4E]HV@VRPJOS//)_K6'4(..*O
M_%:X:'P--$GWKB>.(#UYW?\ LM=1901:3HD$"J%CM;<+@>BK_P#6IQY84U)J
M[;%+FG4<4[)(X;3?B)JWB&!+31M$#ZJF?M7FOB&'!P#GOGTK2\/>+-7D\32>
M'?$&GQ6]YY7FQ20ME7'^?Y57^$]LH\.7=_@;[R\D<MZ@<#]<_G2)F\^-4AZI
M9Z?C([$X_P :UFJ?-."CHD90E4Y83<M6S0\1^-&T[58]%T>Q;4M7<9,2G"QC
M_:/TYK,N_%WBKPXGVOQ#HMN;!C@RVCY,1/3//K4'P\DB;Q=XJ^UD?VF;HXW<
M-Y88]/;I^E;'Q)U>ST[P=>V\[H9KM/*BB)Y)/?'MUH48QFJ7+?8?-*5-U>:V
M_P"!J>$M:N?$'ARWU.Z@2%YBV$0DC .!UKFIO^*U\?K /GT?0VW2?W99_3\/
MZ'UHGU:3PK\,=*M[8%M2NH$AM4'4NXSG\,_GBNE\)>'T\-^'H++(:<_O+B3^
M_(>I_I^%0[4^::ZW2+5ZG+!]+-_Y'.^*LWOQ,\*60/$/F7+#Z<C_ - JU?>-
MI[O75T;PQ9QZC.A_TBX=B(8A]1U_SUKE/&.G:IXB^(6I6^DW!CN+'31PIP9
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !114<-Q#<Q^9!-'*F<;HV#
M#/U% $E%5;W4[#345[Z]M[96Z&:0)GZ9J:&>*XB66"5)8V&5=&# _0B@"2BJ
M5SK&F6=RMO<ZC:0SMTCDF56/X$U=!! (.0: "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M L457^Q09SA\YS_K&^GK0+& 8P'XQ_RT;MT[T 6**K_88,8VOTQ_K&_QH-E
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MI2I=F^9CDG))-:5% ',>)/A_X<\5W<=YJ=FYNXUV">"5HG*^A*D9'UK2\/\
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M6_\ X"#_ !H^P>(_^@U;_P#@(/\ &CE7</:R_D?X?YF[16%]@\1_]!JW_P#
M0?XT?8/$?_0:M_\ P$'^-'*NX>UE_(_P_P S=HK"^P>(_P#H-6__ ("#_&C[
M!XC_ .@U;_\ @(/\:.5=P]K+^1_A_F;M%87V#Q'_ -!JW_\  0?XT?8/$?\
MT&K?_P !!_C1RKN'M9?R/\/\S=HK"^P>(_\ H-6__@(/\:9)9^(XXG?^VK<[
M5)Q]D'^-/E7</:R_D?X?YG045G:#>2ZAH=I=SD&65-S$#'<UHU+5G8TC)2BI
M+J%%%%(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2$9"$\X^E6[6[M[ZW6>UF2:)NC(<BB^E^4:BF^55'?Y?Y&/]K\3?] NQ_P#
MD_X4?:_$W_0+L?\ P)/^%7X=9L)]4FTV.<&ZB&63'\JOTF[;H:AS;3?X?Y&%
M:ZMJ8UB"PU"R@A\Y'=6BE+?=_#WK=K"O?^1STK_KWF_I6[1*VC'1;]Y-WL_T
M04445!L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %>4C_ ).7/_8%_K7JU>4C_DY<_P#8
M%_K0!ZM1110 4444 %%%% &'XP_Y%6]_X!_Z&M;:_='TK$\8?\BK>_\  /\
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MMC7/^A9E_P# N.C^V-<_Z%F7_P "XZ)<TM[?@.E[*E?E3U\G_D)X-_Y%R/\
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M_"BSM:XW*+DIN+NO(R+SX>(]U(]EJ,EM!*<O%MSCVZC(KIM&T>VT33UM+;)
M.6=NK'U-4/-\6?\ /MI'_?V3_"CS?%G_ #[:1_W]D_PIR<I*S9%.-*G+FC!W
M]&.O?^1STK_KWF_I6[7/6MCK4^NVU_J264:01N@%N[$G=]1[5T-3/HC:C?WF
MU:[_ $04445!L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% '.^(O'7AOPI+'%K.J16\T@W+%@LY'K@ X'
MUK2T;7-,\0Z<M_I-[%=VK$@21GH1V(Z@^QKRN?6=(\#_ !=UZ[\4J&&IPQR6
M%R(S,411AH]HR5Y]N:9X/U%(=)^('C#1XQ:Z1<EI+&$84[T0AGVC[N6YQ0!W
M.J_$[P=HNJOIM]K4,=U&VV155F$9]&(&!74VUS!>6T5S;2I+!*H=)$.0P/0@
MUQ/PT\-Z=!\-M.6:TBFDU*W%S>/*H9I7D&3N)Z]<55^$PDL(/$7A\N6@TG5)
M(;?))VQM\P7GTH ]%KRD?\G+G_L"_P!:["?XB>#K:>2";Q)IL<L3%'1IP"K
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MSG.S(Y0>W0X]Z]IK,T?3='\/Z;'I^E0V]I:1Y(CC(_$D]S[FK_GP_P#/6/\
M[Z% $E%1^?#_ ,]8_P#OH4?:(?\ GM'_ -]"@"2BH_M$/_/:/_OH4>?#_P ]
M8_\ OH4 245']HA_YZQ_]]"C[1!_SVC]?O"@"2BH_M$(_P"6T??^(4>?#G_6
MQ_\ ?0H DHJ/[1#_ ,]H^W\0H^T0?\]H_P#OH4 245']HA_YZQ_]]"CSX?\
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M:WQCR(_^^!1]F@_YXQ_]\BI:* (OLT'_ #QC_P"^11]FM_\ GA'_ -\"I:*
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M6K6QB3[,TV8 <Y&,<YKV&I::T9T1DI)2B[HB^S09SY,>>OW11]F@_P">$?\
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MT4 1?9K?&/(BQT^X*/LT!_Y8Q]_X!WZU+10!%]F@SGR8\]?NBC[- .D$?;^
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MO[UU9HD;<(E4< GH3R3Q7I=>/?\ #0.F_P#0M:O_ -\K1_PT#IO_ $+6K_\
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M_9:XT]:[+]H'_5^%/^P@?_9:XT]:[,+LSYO//XD/1A11174>$%%%% !1110
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M%V\_W1_,5](>"?\ D1M"_P"O&'_T$5Q8GXD?3Y)_ EZ_HC>HHHKF/:"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S;XZ36L7
MPPNQ=1-(7FC2(*V,/DX)]A@UP-Q\"-+B^'!UA=4G_M-;+[86)'DGY-VW&,XQ
MQG->U^+O#%GXP\-76BWK,B3 %)%ZQN.0P_&O%G^&WC=K'_A&I_'5B-!7Y2AG
MYV@_=V]<>V<4 <E9:7)X7\":'\0O#^I75O<?:O(N[9VRC$$CC'53MY!SU]J^
MJ[*Y%Y86]T!@31+)CTR ?ZUYCK?PE@U?PKX=T+2=8$>E:;/OG7 ;[1D_,^1_
M%RV!T^8UZE%$D,*11C"(H51Z <4 /HHHH **** "BBB@ KRD?\G+G_L"_P!:
M]6KRD?\ )RY_[ O]: /5J*** "BBB@ HHHH \8_:!_U?A3_L('_V6N-/6NR_
M:!_U?A3_ +"!_P#9:XT]:[,+LSYO//XD/1A11174>$%%%% !1110 4444 %%
M%% !1110!H_#'_DM'_<.?^E?1%?._P ,?^2T?]PY_P"E?1%>;5^-GVV _P!V
MAZ!11169UA1110 4444 %%%% !1110 4444 <1\7O^25Z[_UQ7_T-:\2TO\
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M\FEO)&^]%G>,X81$_-@_EGVS7"^'_@EX4U70+&_F\3W4TMQ"LC-#,BJ"1D@
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MH **** "BBB@ HHHH **** -'X8_\EH_[AS_ -*^B*^=_AC_ ,EH_P"X<_\
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MO^O&'_T$5Q8GXD?3Y)_ EZ_HC>HHHKF/:"BBB@ HHHH **** "BBB@ HHHH
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MF%%%% &;=''BOPH?^HK#_P"AK7U']NM\9WGIG[A]<>E?+MU_R-?A3_L+0_\
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M1_W#G_I7T17SO\,?^2T?]PY_Z5]$5YM7XV?;8#_=H>@4445F=84444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5)L%%%% !1110 4444 %%%% !1110 4444 %%%% !113)I5@@DF?.V-2QQZ
M9H >0",'D5'';PPH4BAC1#U55 !KRO\ X:%\&?\ /+4__ =?_BJ/^&A?!G_/
M/4__  '7_P"*H ]6CC2&-8XD5$4855& !["G5C>%O$]AXOT*+6--$PMI695$
MR[6RIP>,GTK9H **** "BBB@ HHHH *\I'_)RY_[ O\ 6O5J\I'_ "<N?^P+
M_6@#U:BBB@ HHHH **** /&/V@?]7X4_["!_]EKC3UKLOV@?]7X4_P"P@?\
MV6N-/6NS"[,^;SS^)#T84445U'A!1110 4444 %%%% !1110 4444 :/PQ_Y
M+1_W#G_I7T17SO\ #'_DM'_<.?\ I7T17FU?C9]M@/\ =H>@4445F=84444
M%%%% !1110 4444 %%%% '$?%[_DE>N_]<5_]#6O$M+_ .039_\ 7%?Y5[;\
M7O\ DE>N_P#7%?\ T-:\2TO_ )!-G_UQ7^5=6%W9X6>_!#U+=%%%=A\V%%%%
M !1110 4444 %%%% !1110!FW7_(U^%/^PM#_P"AK7U77RI=?\C7X4_["T/_
M *&M?5=>?B/XC/K\I_W2/S_,****Q/2"BBB@ HHHH **** "BBB@ HHHH AN
MO^/.?_KFW\J^4/"O_(,F_P"OF3^=?5]U_P ><_\ US;^5?*'A7_D&3?]?,G\
MZZ,-\9Y.<_[M\T;E%%%=Q\H%%%% !1110 4444 %%%% !1110!E>)?\ D7;S
M_='\Q7TAX)_Y$;0O^O&'_P!!%?-_B7_D7;S_ '1_,5](>"?^1&T+_KQA_P#0
M17%B?B1]/DG\"7K^B-ZBBBN8]H**** "BBB@ HHHH **** "BBB@!&^Z?I6'
MX-_Y%.P_W6_]#-;C?=/TK#\&_P#(IV'^ZW_H9JE\+_KN8O\ C1]'^:,OQ?X:
MU77KZ!K>6$6T28".Y!W$\G&/2N2\6:)I^A2VT%I<O)<%<RJQ!V^A]L^E=EXN
M\6C1@;*T&Z]9<EB.(P>_N:YGPWH$.I7']IZU>Q>6S;Q')*-TI]6YX%=--R4;
MRV/,Q4*<ZCA35Y/=]CI+S0;KQ/X<TL27K0,L*NRLNX.V!@GG_.:X_6]&T;2]
M-"1:E]HU)7VR1IROO],5Z/J?B/2]%BB-Q-Q(N8UB7=N ],<5PGB+2]%DTR36
MK&_+33R!_)9@22QY&.HQ2I2E?78K%TZ=FXV<K:ZG7^!C<'PK;_: W#,(]W]S
M/%:VJZ9#J^GR64[.L<F,E#@\5A>$=:9_"GVK4I@L=NQ3S7X^4=/\*W]/U.RU
M6W,]E<+-&#M)7L:QFFI-G=0<)48P;O='&:MX)T32=+GO9;BZQ&N0-P^8]AT]
M:Y[POI]W+#J6H6^X&WMG52O4L1T'X9K6^(.KM=W\.D6YW"(AI /XG/0?A_6N
MT\.Z2NC:)!:8'F8W2GU8]?\ "MG.487ENSA5"G5Q#C35E'\SSFPC\.'PC</=
M/_Q,^=O)W9[8]O6K(U:[3P78Z/%N:ZO7*H.XBW8'YGCZ5V&H>&?#L/G:E<V2
M*L8,CX)"G\*XH2W+V6H>*=@C;<(+, <1@\9'T' ]ZI24]3.I2G1T=MK:=NK9
MZ)H.EPZ-I4-DA4NHS(1U9CU-:=>57.B76F^'H/$,6K2&Y8JY ;U]#W->CZ/>
M/?Z-:7<HQ)+$&8>]85(V]Z]ST,-6YOW;C:RT]#/TS_D;M=_W+?\ ]!-;U8.F
M?\C=KO\ N6__ *":WJB>_P!WY&M#X7ZO\V%%%%2;!1110 4444 %%%% !111
M0 4444 %%%% !1110 4C*&4JP!!&"#WI:@OI&BT^YD0X=(F93Z$ T >6V7PJ
MGT'XF_VGH\5B_AV\4F\M;I _EG^Z@/OR/3D5Z-_PCFB?] >P_P# 9/\ "O+O
M"'Q%U:+X,:KXIU6;[;>VLSI%O 4$DJ%!QV!;-<U:Q?%Z_P##+>-8_$.R+8;I
M+(MC=&.<A,;<8&<'M0!]"6UK;V<(AM8(X(ADA(U"J/P%2URWP\\5MXS\%V6L
M2QK'</NCG5>@=3@D>QZ_C74T %%%% &?K>LV?A_1;O5;^3R[:UC,CGN?0#W)
MX'UK,\%^,+7QKX?.KVUM-:Q"9XBDY&X%<9/'UKF]1/\ PG_CU-)0;_#V@R":
M]/\ #<W7\$?N%ZGWK#\&W4ME\&/%5Q%D2)=7Y7'8]* -ZX^*WFSWDFB>&-5U
MC3;-V2:^M@HC)7[VS/WL5V>@:]8>)=%M]6TR;S;6=<J>A4]U([$5C_#6TAL_
MAMX?BA10K64<C8'5F&XG\236)\+8Q9ZCXRTV(G[-:ZR_E+V4, 2!^- 'HM>4
MC_DY<_\ 8%_K5B^^,T%EJ%S:'PIK\I@E:,NEN"K;3C(YZ<5RWAGQ7'XD^/@U
M)=,OK-6TIHO)N(\2?+SG'H: /=Z*@^U+G'E3=<?ZL^F:07:G_EE/V_Y9GO0!
M8HJO]K7&?)GZ9_U9]<4?:U!_U4W?_EF>U %BBH/M2G_EE-V_Y9FD^UKC/DS]
MO^69H \@_:!_U?A3_L('_P!EKC3UKKOCY*)8_"F$=<:@WWE(_NUR)ZUV879G
MS>>?Q(>C"BBBNH\(**** "BBB@ HHHH **** "BBB@#1^&/_ "6C_N'/_2OH
MBOG7X;2"/XR[BK-_Q+GX49/:OH(W:C/[J?O_ ,LSVKS:OQL^VP'^[0]"Q14'
MVI<X\J;KC_5GTS2?:U./W,_;_EF>]9G66**K_:UQ_J9^A_Y9GUI?M2YQY4W4
M_P#+,T 3T57%VI(_=3\X_P"69[T?:UQGR9^F?]6: +%%5S=J,_N9^,_\LSVI
M?M2YQY4W7'^K- $]%5Q=J<?NI^<?\LSWH^UKC/DS],_ZLT 6**KF[49_=3\9
M_P"69[4OVI<X\J;KC_5F@#C_ (O?\DKUW_KBO_H:UXEI?_()L_\ KBO\J]G^
M+=R)/A;KH$<HS"OWD(_C%>,:7_R";/\ ZXK_ "KJPN[/"SWX(>I;HHHKL/FP
MHHHH **** "BBB@ HHHH **** ,VZ_Y&OPI_V%H?_0UKZKKY4NN/%7A0_P#4
M5A_]#6OJ/[6N/]3/TS_JSZXKS\1_$9]?E/\ ND?G^98HJN;M1G]S/QG_ )9G
MM2_:ESCRINN/]6?3-8GI$]%5_M:G'[J?M_RS/>C[6N,^3/TS_JSZXH L457^
MUJ/^64W?_EF>U+]J7./*FZ@?ZL^E $]%5_M:XSY,_;_EF:/M:\_N9^__ "S/
M:@"Q14'VI<X\J;KC_5FD%VIQ^ZGYQ_RS/>@"Q15?[6N,^3/TS_JS0;M1G]U/
MQG_EF>U #KK_ (\Y_P#KFW\J^4/"O_(,F_Z^9/YU]4W-RIM9AY4P^1ADQGTK
MY6\*\Z7-_P!?,G\ZZ,-\9Y.<_P"[?-&Y1117<?*!1110 4444 %%%% !1110
M 4444 97B7_D7;S_ '1_,5](>"?^1&T+_KQA_P#017S?XE_Y%V\_W1_,5]%>
M"[D+X)T-?+E/^A0C(0X^X*XL3\2/I\D_@2]?T1TE%5_M:XSY,_0'_5F@W:C/
M[F?C/_+,]JYCVBQ14'VI<X\J;KC_ %9I!=J<?NI^<?\ +,]Z +%%5_M:XSY,
M_3/^K/K0;M1G]U/QG_EF>U %BBH/M2YQY4W7'^K/I2?:U_YXS]O^69[T 6**
MK_:UQGR9^_\ RS-+]J7/^JF[_P#+,T 3T5 +M3_RRF[?\LSWI/M:XSY,_3/^
MK/KB@"=ONGZ5A^#?^13L/]UO_0S6JUTNT_NI^A_Y9GM7+Z9%XFTK3X;&&WT]
MXXLA6?S,G.3S@>]7'6+1A4;C44K7T?Z$NO>"4US5&O6OWA+*%V"(-T]\UF?\
M*QC_ .@M)_WX'^-;(O/%9Q_HFF]O^>O?\*/MOBO&?LFF],_\M?7Z5HIS2LF<
MTJ%"<G*4'=^I+/X2L[O0+;2[B1F-L,1SJ,,#]/Z5@1_#)!+^\U-C'GHL0!/Z
MUM&\\5C/^B:9QG_GKV_"C[9XKSC[)IG7'_+7_"DI36S'.C0FTY0>GJ7+CPW9
M2^'3HT.Z&# PPY.<YR?6F^'?#L?AZSFACN&EDE;<SLN.W'%51>^*R!_HFF\X
M_P">O?\ "@WOBL G[)IO0G_EK_A4^]:US7]VI*:@[K38KV'@:.UUM=3N;][J
M0.9-K1@98]\Y[5UM<U]L\5Y(^R:9U(_Y:_X4"\\5D_\ 'IIG;_GKW_"B5Y;L
M*?)25H1:^1<\2Z//KFF"S@NA "X9\KD,!VJPVBV3Z(-):/\ T41A,#KQW^N>
M:R_MOBO&?LFF],_\M?7'I0;SQ6,_Z)IO?_GKV_"C6UKA>#DY.+N]-C+C^'$8
MF59M3FDM%;(BVX/TZ\?6NVABC@A2&)0L:*%51V KG?MGBO./LFF=<?\ +7TS
MZ4?;/%9Q_HFF]O\ GKW_  IR<I;L5)4Z5^2#7R)],_Y&[7?]RW_]!-;U<[HT
M6H0:CJ%_J4*"2Z6/"VZL0-F1W'N*VC=J,_NI^_\ RS/:HGN;44^77N_S98HJ
M#[4N<>5-U _U9],TGVM<?ZF?M_RS-2:EBBJ_VM?^>,_?_EF>U+]J7./*FZD?
MZLT 3T57%VIQ^ZGYQ_RS/>C[6N,^3/TS_JS0!8HID<@E!(5UP<?,N*?0 444
M4 %%%% !1110 4444 %0W4)N+.:$$ R1L@)[9&*FHH ^?4^!/C"#1I=(A\5V
MPTZ5MSVP5PC'(.2/P%=YKOA?Q0OP?MO#>EW,)U6.*.UD>,[5>(':1D]/EQG\
M:]$=UC1G=@J*,EF. !6*_C/PRCE6U_3@PX(^TK_C0!3^'WA/_A"_!MGH[RK+
M.FZ29UZ%V.3CV'3\*ZBJUC?V>IVJW5C<Q7,#$@21,&4D<'D59H **** /.A\
M']*BFN)+77-?M1/*TSQV]\8UW,<DX%8/PN\ LOAS5VOYM5ADN9;JT^S7+L(R
MC<"38>K'KNKV.B@#R+P]XTO_  -X?7PSKGA[5[C4=-4P6KV=JTD5T@^X0PZ<
M8%=1\,] U#1]"NKW6$$>J:M=/>W$8.?++=%_ 5VM% !7E(_Y.6/_ &!?ZUZM
M7E(_Y.7/_8%_K0!ZM1110 4444 %%%% 'C'[0/\ J_"G_80/_LM<:>M=E^T#
M_J_"G_80/_LM<:>M=F%V9\WGG\2'HPHHHKJ/""BBB@ HHHH **** "BBB@ H
MHHH T?AC_P EH_[AS_TKZ(KYW^&/_):/^X<_]*^B*\VK\;/ML!_NT/0****S
M.L**** "BBB@ HHHH **** "BBB@#B/B]_R2O7?^N*_^AK7B6E_\@FS_ .N*
M_P J]M^+W_)*]=_ZXK_Z&M>):7_R";/_ *XK_*NK"[L\+/?@AZENBBBNP^;"
MBBB@ HHHH **** "BBB@ HHHH S;K_D:_"G_ &%H?_0UKZKKY4NO^1K\*?\
M86A_]#6OJNO/Q'\1GU^4_P"Z1^?YA1116)Z04444 %%%% !1110 4444 %%%
M% $-U_QYS_\ 7-OY5\H>%?\ D&3?]?,G\Z^K[K_CSG_ZYM_*OE#PK_R#)O\
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M$FGDA5I6>_$9#D<@KQC!XQ7K?C+0='\1>&[BRUV5XM.0B:619-FW;SDGTKP
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ME8ZG:2VETDLQ:*5=K %R1Q7>T44 %%%% !17GFI>,O$VI^*K_0?"&D6LO]G
M"ZO-0=DCWG^%<#FK_A+QK=:I>ZMI'B"PCT[5]* >X6-]T3QD9#J?2@#M**\O
MMO&OCCQ+#<:OX6T'3WT2.1U@-Y*RS707JR@<#)Z5V7@_Q1;^+O#T.J01/ Y8
MQSP/]Z*1>&4_C0!O5Y2/^3ES_P!@7^M>K5Y2/^3ES_V!?ZT >K4444 %%%%
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MK_OTG_Q5'_#0F@?] /6O^_2?_%5PF31DUT_55W/%_MV7\GX_\ [O_AH30/\
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MOH(SW'/^AMW_ .6B_A^=> ?#'_DM'_<.?^E?1%>;5^-GVV _W:'H5_/N,_\
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MT7UH,]QG_CT;J?XU]*LT4 5A/<9_X\V[?QK^-'GW./\ CS;..GF+Z_Y-6:*
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M\(**** "BBB@ HHHH **** "BBB@#1^&/_):/^X<_P#2OHBOG?X8_P#):/\
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M?J>IT445R'T(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %>4C_DY<_\ 8%_K7JU>4C_DY<_]@7^M 'JU%%%
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M_7V?_016C6=I?^OU+_K[/_H(K1J8[&U?X_N_(****HQ"BBB@!K_ZM_\ =/\
M*O2/@#_R3I_^OZ;^E>;O_JW_ -T_RKTCX _\DZ?_ *_IOZ5R8KH?09%]OY?J
M>IT445R'T(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %>4C_ ).7/_8%_K7JU>4C_DY<_P#8%_K0!ZM1110
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M"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M- 'JM%>5;_C7_P \O#O_ 'T:-_QK_P">7AW_ +Z- 'JM%>5;_C7_ ,\O#O\
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MGBCP[X[\):=#>ZFNF+#-.L"^4VX[FSCC'3BCZQ /[&Q/E]Y;HK0_X5I\3/\
MGGHW_?[_ .M1_P *T^)G_//1O^_W_P!:CZQ /[&Q/E]YGT5H?\*T^)G_ #ST
M;_O]_P#6H_X5I\3/^>>C?]_O_K4?6(!_8V)\OO,^BM#_ (5I\3/^>>C?]_O_
M *U'_"M/B9_SST;_ +_?_6H^L0#^QL3Y?><[=?\ (U^%/^PM#_Z&M?5=?.#_
M  K^),E_87ACTCS;&X6XB_?<;E((SQR.*[K?\:_^>7AW_OHUR59*4KH^@P%"
M="@J<]]?S/5:*\JW_&O_ )Y>'?\ OHT;_C7_ ,\O#O\ WT:S.P]5HKRK?\:_
M^>7AW_OHT;_C7_SR\._]]&@#U6BO*M_QK_YY>'?^^C1O^-?_ #R\._\ ?1H
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M !'?ZY-'H_VN]V^:%F^7Y0 ,#'L*NG)1DFSEQM*5:A*G'=F?16A_PK3XF?\
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M_P"^C7.>L>JT5Y5O^-?_ #R\._\ ?1HW_&O_ )Y>'?\ OHT >JT5Y5O^-?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=\$&GZE?>-=>^-&M^&=$\03V5N1EBSDK!& I)4=CD@<>M 'T#17@8O\ Q?\
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MC&&PW([C\*\\\+Z-XXGT-?&.L>*9VC_LV62*Q5V  \H[6/.-W1L\_6HO!OQ
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M&.N20V>Y[9Z5[!10!P'PC\%ZCX)\)/9ZI*INKB<S-$C;EBX QGN>.<5W]%%
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M\5)?R2R:DK*T!0 )EE;KW^[0!P^B>"O&OBWQ_8^)_&\4%G;Z<0UO:Q,#D@Y
M !.!GDDG-2>,=-^(>IZAJEG<>$]$UK3[DE;*<[0UNN, Y)#9'7GOTXKV>B@#
MB/A5X0OO!?@M--U*57NI)FG=$;<L><?*#WZ?F:[>BB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY:0VZJWY@<4 :<2E(D1F+,J@%CW]Z?110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
)44 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img224999359_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_15.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )8 D(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNG&*6O<YZ4U9J4F].QPMMXJ\5ZY!8>$8)KJ#4TN&2>[$K"0J/[Q'/R_-GGG
MKLO'?B"]\(Z'IFC:7<S2ZA=9C^U3OODP, G+?Q$M^'/M7'?\(1XDT72M/\4V
MBW,NL_:#+-;*A:10W0E<9)Z[A_M>QKK/&FAZCXR\/Z5K6GV<UOJ=H"S6DZ&-
M^<9 #8Y!7(]0:TG[/VD=N77[_P#(SA[7V<KWYK*WI_F96M:9XU\%Z9'KQ\3S
MWPC9?M-O*S,BY..C$@C) Z \U:^(7B:\N/ ^A:MIMW<V37<@9_(E9#]PY4D'
MD BJNM:GXU\::;'H)\,36 D9?M-Q*K*C8.>K  #(!ZD\5:^(7AF\M_ ^A:3I
MMI<WK6D@5_(B9S]PY8@#@$FE&W-#VEKW\MARORS]G?EMY[F5XE7QEHFC67BB
M;Q-,SW,BEK6(E8XMP+* ,[6'&#Q^=>O:1>-J&C6-ZP :XMXY3MZ990>/SKAO
MB#IM_>_#C3;6ULKF>X1X"T443,ZXC(.0!GBNP\,Q26_A31X9HWCECL84='4A
ME8( 00>AKGK24J2?6[.BC%QJM:VLCA/B9KNJ6GB'3-*AU232=.N(M\EY&#G=
MN(/*\\ #@?WJL^$-/UA-:6>U\=0:SIH&98GD,DA'^Z2=G..<_A6EXXOM;MWA
MBM?"]MK6FL,RAE,CYYR-N...AP:X?2O#^K:MXUT[4--\,3>'+:VD5YC(7 (!
MR?O 9R., 8]:UA9T;:+3R_X>YC.ZK7U>OG_PU@\4:U'X=^,\FJRQM*MO$"$4
MX+$VY4#\R*ZCX<IJ^O--XGU75[B1)I&6"RCG81)C@Y3./H/Q/6LW5/#4VJ_&
MF.6\TJXGTEE4O*T+>22L/&6QC[P QGVJWX0T[5/!OC:^T7['=S:)=GS(+E(6
M:.-L9&Y@,#CY3[@'I55'%TDH_%RK[NPJ:DJK<OAYG]_<;X0U74;GXM>(;*>_
MNI;6))S'!),S(F)4 PI.!@$C\:Y_PPOBOQ7JNKV%OXDO+2U@E+23-([LIRP5
M5Y! X/0CIWKH/"&E:C;?%KQ#>SV%U%:RI.(YY(65'S*A&&(P<@$_A7(^#=7U
MK1=>URZTK2GU.+?BXMXR=_WFVL, DXY['K5)?%R6O9$-VY>>]KL[#P!KVLV_
MBK4?"FMW37DEN&:.=V+-\I'&3R00<\\USOAA?%?BO5=7L+?Q)>6EK!*6DF:1
MW93E@JKR"!P>A'3O71^ ="UFX\5:EXKUJT:S>Y#+% X*M\Q'.#R   .:X[P;
MJ^M:+KVN76E:4^IQ;\7%O&3O^\VUA@$G'/8]:+)N?):]EZ7"[2ASWM=^MCL/
M &O:S;^*M1\*:W=->26X9HYW8LWRD<9/)!!SSS5/X>:OJ=[J?B=+O4;NX6&,
MF(2SLXCY;[N3QT[5=\ Z%K-QXJU+Q7K5HUF]R&6*!P5;YB.<'D   <U2^'FD
M:G9:GXG>[TZ[MUFC(B,L#().6^[D<]>U1/D]^UKV7W]2X<]X7O:[^[H9'@R'
MQ=XPTN\BB\475K#;/N$C2.\DCL!A=V<A1M]>YX-;WP^\8Z@WA;7IM6N'NGTI
M?,5I#ER"&^4GORO7WJQ\'],U#3-,U-+^QN;1GF0J)XFC+#!Z9'-9OP\\-7TF
MG^++#4K*ZLTOD2.-IX63.?-Y&0,XR#^555E!\Z=K*W_!%2C-<C5[N]_T(?#-
MKXU\6VD_B&+Q/):NLK""VY,;D8."N=H7G'(-:7PBU?4]5N->.HWMS<%&A*I-
M*SB/)DR%R3CH/R%9OABZ\:^$[6?P[#X:DN':5C!=$$1(3@9+ ;2O&>H-3_!-
M767Q"7Y.^ %NQ(\S-%9?NYO2VEK6VN%%_O(+6^M[WWL>A^*_^1.US_L'S_\
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MGS?$/P-')I-KI3WMJK-Y3+;M.BY[J4.1ZX/KTKH/ 7A_Q)-XCN?$OB*2>!Y
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MH^.O^@+8_P#?8_\ CE']H^.O^@+8_P#?8_\ CE'LWW7WA]97\LON9V%%<?\
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M+8_]]C_XY1_:/CK_ * MC_WV/_CE'LWW7WA]97\LON9V%%<?_:/CK_H"V/\
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M4=Q!'=6TMO,NZ*5"CC.,@C!KD_[1\=?] 6Q_[['_ ,<H_M'QU_T!;'_OL?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHK#\1^*;/PTMI]IMKNYDNY/*ABM(P[LWT)'J.
MGK3C%R=D*4E%79N45QK_ !'L;8HVHZ)KVG0,P4W%W8[(USZG)/Y"NBU/55TV
MP6[2SN[Y7955+*+S6(/\6,CCWJG3FK76Y*JP=[/8T****@L**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+J;4(A&6<#"HHR<\]Z]+NK.UOHA%=V\4\8.X)*@89]<&DMM>_P#E_P $'O\
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M#Z9JS10!7-[ "06;@X^Z?I0;Z !CN;Y>ORG_ #WJQ10!7-[ "1N;CC[I]_\
M T?;H!GYFX('W3[?XU8HH KF^@&[+-\O7Y3]:#>P#.6;@X^Z?7%6** *YOH!
MN^9OEZ_*:#>P D;FX./NG_/:K%% %8WT !.YN.OR'V_QI3>P#.6;CK\I_P ]
MJL44 5S>P#.6;@X/RGU _K0;Z ;OF;Y>ORFK%% $*744C[%)W9Q]T_Y[5-11
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5XQX'_ .3@?&7^Y_5:]GKQ
MCP/_ ,G ^,O]S^JT >ST444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW1RH>"*MU6T_3K/2K)+.PMX[>V3.R*,85<G)P/J:LT, HHHH **** "BBB@
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MCP/_ ,G ^,O]S^JU[/7C'@?_ ).!\9?[G]5H ]GHHHH **** "BBB@ HHHH
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M^E8VFW4][817%Q:FV>0;O*+;B!VS5Q?O#ZU#I16EBE5D^ITM%%%>>=X4444
M%%%% !1110 4444 8NI_\?A_W15,C(((R#4$_C"0ZK?65IX>OKXV<@CDDBV8
MR1GN:/\ A*-1_P"A-U3\D_QKMC*2BE;\4<<HQ;;O^ D%A9VTC206L,;MU9$
M)J6.*.($1QJ@)R=HQD^M1_\ "4:C_P!";JGY)_C1_P )1J/_ $)NJ?DG^-5[
M27;\43[./?\ !BM:6S!PUO$1(<N"@^8^_K3C;0%T<PQ[XQA&VC*CV]*9_P )
M1J/_ $)NJ?DG^-'_  E&H_\ 0FZI^2?XT>TEV_%![./?\&3UN:?_ ,>2?C_.
MN<_X2C4?^A-U3\D_QK4\.Z\NNP73"RFLY+6<P212XR& !/3ZUE5<I1V_$UI*
M,9;FS1117*=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2.XXZ>WM^M9&A9HJL;5CN_TJ<9]"../I2FV8D_Z3,,G/4<<].E %BN6\'_\
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M3T445)J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6QTC3=,+FPT^UM2^ Q@A5-WUP.:^<?#OA3Q;\7DO/$=SXD:T59C'#'EB >N
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M_P#035?PG_R*.D?]>D?_ *"*L:[_ ,B_J7_7K)_Z":K^$_\ D4=(_P"O2/\
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MSY2XS]*]E_:%_P"2:Q_]A"+_ -!>O&[/_CR@_P"N:_RKT<OWD<.-VB5LZO\
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M3KS:W\7O$NK&QG@-U!O\@\LG*C!Z4 ?0%%5S=,"1]FFX/H/?W]OUI#=L ?\
M1I^"/X1ST]_?]* +-%5C=L-W^C3G'HHY_6E-TPS_ *-,<''W1SS]: *^N_\
M(OZE_P!>LG_H)JOX3_Y%'2/^O2/_ -!%&N73'0-2'V:;BVD_A']TU7\*W++X
M3TD?9YCBUC&0!@\=?T_6M/\ EW\S/_EY\CH**K&[8!C]EGX_V1SP/?W_ $I3
M=,-W^C3''HHY_6LS0L5\I>-?^2S>(O\ >7_T!:^I3=,,_P"C3G!Q]T<\CW]_
MTKY9\9-N^,GB(E2N67@]?N+6^%_C1,<1_"9!1117O'CA1110!M?"3_DLZ?\
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MU]-U\_7_ (LO4]JC_#CZ!11161H%%%<'\5?'%_X$T"TU#3[:WN)9[D0E9\X
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M!7-6^(]G+OX/S//?VA?^2:Q_]A"+_P!!>O&[/_CR@_ZYK_*O9/VA?^2:Q_\
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MKJ/^%T^ _P#H-C_OR_\ A7F7A7Q]X;T[XP^)M<NM0V:=>+B"7RV.[D=L9[4
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MG'A[_KQC_E745Y%X)^+'@S2?!.C:?>ZL([FWM4CE3RG.U@.1P*WO^%T^ _\
MH-C_ +\O_A7A'KG?T5Q.G_%KP7JFHV]A::N)+FXD6*)/*<;F)P!TKMJ "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#W[KJZ* .4_P"%:>"O^A:T_P#[]T?\*T\%?]"UI_\ W[KJZ* /G[X=^$M
MU+XH^-+"]TFVGM+24BWA=<K&/,(X_"O5O^%:>"O^A:T__OW6%X'\&ZOH/Q$\
M5ZS?1Q+9ZE(6MRL@8D;R>1VX->D4 <I_PK3P5_T+6G_]^Z/^%:>"O^A:T_\
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M=IXKWVO.OC!X/U?QEH&GVFCQQ/-!=B5Q)($&W:1W^M &G8_#?P9)I]L[^'+
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M+"\@T;1HI&%Q=0M$9IG& %5N>!7IE%"T!A1110 4444 %%%% !1110 4444
M%%%% !1110!Q?B/Q/K/ACQ3;S75A)<^&)H"KRVD!DE@FSU8#DKCT%<_IME<>
M-_'FH>((["YL-(.F/IZ27,9C>Y9OXMIYP/>O5**5N_\ 5QW['CNE^*M0\->"
M)/"-QH6IR:]:Q/9VJQ6[-'.#D(X<< 8()S7H/@;0I?#7@K2M)G(\^"$>;@Y
M<G)'YFNAHIW$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!ROQ+_ .2;>(/^O-_Y5R'[/BJWPY<,H/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"RA6&V@0)'&O10*?03W/*?#/AG2/%7@?5M>UJ!9M6NIKEI+IV.^W*,P55/\
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A%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img224999359_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_16.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (R Y # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\A\#?\
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MKUZBM'B*<DE.%[*VYFL/4BVX3M=WV/)OB)K']O\ PMTO5?(\C[1=JWE;]VW
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MQC<HR:V_$S6#2C**>_X'D"_'#:@7_A'>@Q_Q^_\ VNNS\$>-?^$R@O)?[/\
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MQU_T&K'_ +X'_P ;H_L[QU_T&K'_ +X'_P ;H]FNZ#ZP_P"27X?YG845Q_\
M9WCK_H-6/_? _P#C=']G>.O^@U8_]\#_ .-T>S7=!]8?\DOP_P SL**X_P#L
M[QU_T&K'_O@?_&Z/[.\=?]!JQ_[X'_QNCV:[H/K#_DE^'^9V%%<?_9WCK_H-
M6/\ WP/_ (W1_9WCK_H-6/\ WP/_ (W1[-=T'UA_R2_#_,["BN/_ +.\=?\
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MT&K'_O@?_&Z/[.\=?]!JQ_[X'_QNCV:[H/K#_DE^'^9V%%<?_9WCK_H-6/\
MWP/_ (W1_9WCK_H-6/\ WP/_ (W1[-=T'UA_R2_#_,["BN/_ +.\=?\ 0:L?
M^^!_\;H_L[QU_P!!JQ_[X'_QNCV:[H/K#_DE^'^9V%%<?_9WCK_H-6/_ 'P/
M_C=']G>.O^@U8_\ ? _^-T>S7=!]8?\ )+\/\SL**X_^SO'7_0:L?^^!_P#&
MZ/[.\=?]!JQ_[X'_ ,;H]FNZ#ZP_Y)?A_F=A17'_ -G>.O\ H-6/_? _^-UU
ML(D6",2L&D"C>1T)[U,HVZFE.HY[Q:]1]%%%2:A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXO\ A1_;FH_\_'_CB_X5GTG:GRQ[!S2[F@=<U'_GX_\ '%_PI/[<U+_GY_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCBCAB6**-4C4855& !["H[>UM[.+RK6"*"/.=D2!1GUP*Q_[9US_ *%#4_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5EUJ5EU429"&DI3251 AK#\$?\ASQ5_U_+_Z!6X:P_!'
M_(<\5?\ 7\O_ *!6B^"7]=2'\<?ZZ'9UC^)?$MCX5TL7]^LSQM((PL(!8DY/
M0D>AK8KSCXE(-5UWPWH6-RS3-/(/55'^&ZHHP4YI2V+K3<(-QW.MTOQ1I^J^
M&CKR"6"R579O/ #*$)!R 2.WK5'PMX[TSQ==7$&GVU[&8$#NTZ*!R< ##'FO
M+K+4IKSP#H_A*R8_:M1NW$IZ[(@^<_3//_ 36YX+U&U\->%O$?B18=\/VD0V
MR$X+A>$&?^!#/TKJEAHQC+O?3[SEAB92E'M;7[KGKM%>92ZAXYC\)GQ5)K%I
M$H07']FFT788R>/G^]G!SC]:L>*/'%\O@/2=4TEOL]_J4BJJ[ Y7KN # @\@
M#IWK#ZO)M)-/6QO]9BDVTUI<]%JM?:A9Z9;&XO;F."('&Z1L9/H/4^PKSO7=
M8\8^';O0Y[K5;29[Z98GTY+90HZ _/\ >/7DC'/;%4O'-EJ6K_$O1])CU7"L
M!<0*+=6%KCJ3S\^2F>?I3AA[M7>FK^X4\19.RUT7WGH&O^)[+PZUBEU#<2O>
MS"&%(%4G=QUR1QR*VJ\E\41:MJ'Q#\/:1;3Q7=]80":2XGBVIOSDN57I]U2!
MZX%;6B:QXAMOB-/X=U#5(M4MUMO.:06ZQ&(X! POU Y)ZBB5#W$T];7%&N^=
MIK2]CT"BL..V\0_\);+<27UL-"\K$=LH!D+X').SUS_%Z5N5SM6ZG2G?H%-=
MUC1G=@J*"69C@ >IIU<G\0997T&WTN!BLFJ7<=GN4\A6.6_08_&G"/-)(4Y<
ML7($^(>C27**(-0%D\GE)J)MB+9FSC ?Z\9QBNLKD/'T=O8?#NZLH8E"%(K:
M"(#/.Y0H ]L?I756T;16D,;'+(BJ3ZD"KFH\JE$B#ES.,B6BBBLC4*S;'7;'
M4M4OM/M)#+)9;1.ZX*!FS\N>Y&.?2FZ[I4VLV2VD>I7%C$S9F:VP'=,'Y0Q^
M[VY]JYSX9:=;6>CZA<6B;;:XOY?(&2?W:G:O)Z]#6L81Y')O4RE.7M%%+0[>
MBBBLC4*Q]>\36'AY8%N1/-<7!*P6UM'YDLI'7:M;%9=]:Z397Q\0WQ2*:" Q
M>?)(0J(3G@9QG/MGM50M?4F=[:$.A>*+#7WN(88[FVN[?'G6MW%Y<J ]"1Z5
MM5QWAY;C7/%=SXI^SR6M@UJ+2T608>==VXR$=AZ9[5V-55BHRLB:4G*-V%%%
M%9F@4444 %%%% !7+ZAX[TZROY[."QU/47MCMN'L;4RI">X8Y'Z9KI998X(7
MEE<)&BEF8] !U->7:+KNN:1HNI7&C>'9+_26N);BWO97$3%6.23'RS@>HQD#
MM6]&FI7;_.QA6J.-DORN>DZ;J5IJ^GPW]C,)K:891QQ['CL<U;KG_!5C!8>%
M+);>Y^TI,IN#,%VABYW' [#GI705E-)2:1K!MQ384A(4$D@ <DGM2UC^+$N)
M/"6K):;C.;63:%ZGY3G'X4HJ[2')V39D_P#"QM$-S@0WYL?,\HZE]G/V4-G&
M-^?7OBNN!!&1TKS'5_%?AR+X6_8[.Y@DDFLU@2UC(+HQ !++U7!YR?ZUZ#H\
M<D.B6$4N1(EO&KY]0HS6U6FHJZ5M;&-*HY.S=]+EVBBBL#<\F@_Y&?Q)_P!?
MY_D*OU0@_P"1G\2?]?Y_D*OUZ,O\OR/-CM]_YEC3O^0G:?\ 79/YBO0J\]T[
M_D)VG_79/YBO0JY:^Z.NALPHHHK W"BBB@ HHHH *Q-?\*Z9XFDL_P"U4>>W
MM7\P6Q8B-V[%Q_%CT/%;=9>M>)-&\.I$^L:E;V2RDB,S/MW$>E &C##%;Q+%
M#&D<:#"H@P /0"B5_+B=\9VJ3BN6_P"%G>"/^AGT[_O\*CG^)G@EK>55\3:<
M24( \X>E %#0+C1_B]X+2_U;1HT5I'1!NR\94_>5P 0?I7<65J+*QAM1+)*(
MD"!Y#EF ]3ZUYO\  /\ Y)A!_P!?,O\ Z%7I] !1110 4444 %%%% !1110!
MA>-?^1$\0?\ 8.N/_1;5R?P)_P"24:?_ -=I_P#T8U=9XU_Y$3Q!_P!@ZX_]
M%M7)_ G_ ))1I_\ UVG_ /1C4 >DT444 %%%% !1110 4444 %%%% !1110
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M54D[^:?W&,,+3BK>37WGF=UIWC?6_#MOX:FTNVT^!52*XOOM2N)(U_NH.1G
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MO+D.#T(]O6NNH **** "BJ=]JVGZ;);1WU[!;O<R>5 LKA3(_HOJ:L3W$-K
M\]Q*D42#+.[8 'N: )**RM)\3:'KLDD>E:M9WKQ_?6"8.5_*K6HZG8:1:-=Z
MC>06ENO629PJC\30!;HJCI6M:7KEL;G2K^VO80<%X) X!_"KU &%XU_Y$3Q!
M_P!@ZX_]%M7)_ G_ ))1I_\ UVG_ /1C5UGC7_D1/$'_ &#KC_T6U<G\"?\
MDE&G_P#7:?\ ]&-0!Z31110 4444 %%%% !1110 4444 %%%<]+XTT:&9XGD
MN-R,5.+=R,C\* .AHKF5\?: TKQ+<3&1,%E%N^5STSQ5RP\5:7J5XEK;R3&5
M\X#PLHX]R* -JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K+K4K+JHDR$-)2FDJB!#6'X(_Y#GBK_K^7_P!
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M_HQJQ?$GP0\%Z7X7U;4+:WO!/;6<TT9:Y)&Y4)&1]16U\"?^24:?_P!=I_\
MT8U 'I-%%% !1110 4444 %%%% !1110 4444 <WI7_(]>(/^N5M_P"@FNDK
MF]*_Y'KQ!_URMO\ T$UTE !1110 4444 %%%% !1110 4444 %%%% !1110
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M^@1H_P#W^;_&CV$NZ^\/;Q[/[COJ*X'^W?'W_0(T?_O\W^-)_;WC[_H$:/\
M]_F_QH]A+NOO#V\>S^X[^BN _M[Q[_T"-'_[_-_C1_;_ (]_Z!&C_P#?YO\
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MD?\ ?UO\:GZO+NOO']8CV?W'H]%><?\ "5^./^@3I'_?UO\ &D_X2SQO_P!
MG2/^_C?XT?5Y=U]X?68]G]QVU\N=7TMO+1MKR?,7P5^0]!GG]:TJ\OG\0^,Y
M[NVN'TC2B]N6*$2M@97!S\WH:L?\);XW_P"@3I'_ '\;_&J>'DTM5]XEB(W>
MC^X](HKS;_A+O&W_ $"=(_[^/_C1_P )=XV_Z!.D?]_'_P :7U:?=?>/ZS#L
M_N/2:S47_BI9G\M/^/.,>9O^8_._&,]/?'>N(_X2_P ;?] G2?\ OX_^-5AX
MD\8KJ+WHTC2O-:)8B?-;&T$D?Q?[1IK#R5]5]XGB(NVC^X]2HKS7_A,/&O\
MT"=)_P"_C_XT?\)AXU_Z!.D_]_&_QI?5I]U]X_K,.S^X]*HKS3_A,?&O_0)T
MG_OXW^-'_"9>-?\ H$Z3_P!_'_QH^K3[K[P^LP[/[BC!_P C/XD_Z_S_ "%7
MZRM(CU$WNIWFI0Q12W=QYNV)LCISBM6NF6YRQV+&G?\ (3M/^NR?S%>A5Y[I
MW_(3M/\ KLG\Q7H5<M?='70V84445@;A1110 4444 %%%% 'D'BYO#VD?&6Q
MU7Q))9RV,]AY"+/A_(E#9!9#V(S@XZUU_P#;7P\//VSP[S[Q5Q_Q)NOAA%XJ
MV^+8+E]3\A#F)'(V<XZ<>M<?]N^!/_/I??\ ?N3_ !H ^@=(N-*N; 2:,]H]
MIN(!M=NS/?[O%7ZY+X<2^&I?"<;>$TD32_-?:) 0=V>>O-=;0 4444 %%%%
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M<<\=^]5"HFG?R7RU)G3::MKN_GH0^)R=2N]:?.8-+TYT'IYL@R3^"@#\:9>
M3_\ "$6LO-NX$C*1P66-2O\ .K]OHNHCP3J4%Q$&U:_6625 P^^W &<XZ8'6
MK=SX??4/#&GVCR&UOK2.)XI1AC%*JC\QVI\\597V_P M_O)<).[MOK^.WW'0
M&N4M@+?XEWD<'RI<6"RS*!P7#8!/OBI!J/BZ%1;OH%K/*!C[4EX%C)]=I&ZK
M>@Z)/82W5_J-PMQJ5V097081%'1%SV%0ER)W>YJWSM66Q/XAU,Z/H%Y?JH9X
MD^0'IN)P,^V2*YJXT+5D\.SZB^O7LE\ULTDL3L# P*Y*A,<<<9%=5K.FQZQH
M]SI\C;5F3:&QG:>H/X$"N:D7Q;-H\FCOIULK"$Q&_%P"'&,<)P0Q'<X%.D]-
M+;_@156NM[6_$JQ:A>0^%_#6F:?,(+G4%">>5SY: 98@>O-3:K;:AX3MX]5@
MUB^O(4D474%X_F!E)P2O'RG_ #]96\.Z@WAW1#!Y<.JZ8%94E.5;C#(2,]?7
M_P#727MKX@\3+#8ZAIT.FV*R*]PWV@2M* <X4#IGW_\ K5I>-^EM;F=I6ZWT
ML5?%&HO%K\4&HZA?Z;I#0!HYK,$%Y,\@L 3T[5J:-=0VFEWUU%KC:M:0H94#
MD-+& "2&;J<X[@5+JO\ ;UKJ!ELK:'4M/>,*;-W6-D;U#$<CZU1T;P_.]_J%
M[>V%OIT5W!]G%G;L#P>K,1QGZ4KQ<-?Z_4JTE/3]?^&.=AUZPU&'[7J7BR_M
M+QR6$%HKK'%Z*0%^;\ZZ[PCK,FM:,TLTBRRPRM"TJKM$F.0V.V015"P7Q/H-
MFNF1:9!J,,65@N5N!%A>VY3R<>W_ ->M_28M0AL0-4N4GNF)9C&H54ST4<<@
M>IYHJN-M/S_X'YBI*5]?GI_P?R+II.]*:3O7.=(AIIIQIIIB$-)2FDH 0TVG
M&FT" TVG&FTP TVG&FT"$I#2TAI@-I.U+2=J!"&CM0:.U,!II*4TE A#3:<:
M;3 2DI:2@18T[_D)VG_79/YBO0J\]T[_ )"=I_UV3^8KT*N>ONCIH;,****P
M-PHHHH **** "J>J:58ZUITMAJ5K'<VLHP\<@R#_ ('WJY10!Y-=?#3Q9X>D
M9_ WBR6"U)R+"_.]$'HK$'CVP/K5<Z;\;+T>0^JZ19KWF0#/X?*?Y5[#10!Y
MYX>^%=M::C'K'B74KC7]70[DDN3^ZB/^RG3_ #TKT.BB@ K$\4^&+3Q;I2Z;
M?33):^:DKK$0/,VG.T^U;=<WXV\17WA;1%U6TTTW\,4J_:D4G<D7=@!UQ0!Y
MW\3]7T^^>R\)P:1+IP2]B5-7N+;RK6W"\_(^.3VXP*V/'<:ZIX[\#Z#<L);!
MY'N95/*S% , CH14/C_Q]X5UWP)=Z;IMW#JU]J*+%;6< WR%R1@D=L=?PJKX
MEM+KPFG@/Q#J*R31Z2HMM0=06,:LH!8_0T :GQALK>RT'3-?MHDBOM,U"!X9
M8UVMM+8*9'8^E,@1-?\ CK.+Y5EBTK2XY+:)QE5>3!+8/?GK5+Q_XFTKQQ!I
M7A;PW=QZE<WM[%).;?YEAA4[F9CV[58U6]M_ WQ?&L:HQATG5M/2V^UL#LBD
MCZ!CVR!0!-XNMHM&^+?@W5;)%AFOFFM+K8,><FT$9^AY_*N^U#7M(TF5(]2U
M6RLY'&Y5N+A8RP]0"17G%]JMKX\^*GAM-"F%YI^B^;<WMU'S&&8 (H;N<CI[
MUUGBKX=>&_&=Y!=ZU:RS301^6A29DPN<]CZF@"IXO\6^&[CP5KL,/B#2I)9-
M/G5$2\C+,3&P  !Y-9GP)_Y)1I__ %VG_P#1C5E>)O@KX)TSPKJ]_;6%PMQ;
M6<TT9-TY 94)!QGGD5J_ G_DE&G_ /7:?_T8U 'I-%%% !1110 4444 %%%%
M !7,?$+_ )$NZ_Z[VW_I1'73US'Q"_Y$NZ_Z[VW_ *41T S1?_6-]33:<_\
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M6_6!IW_([:[_ -<;;_T$UOT RMJ7_()OO^O:7_T U8\(_P#(E:#_ -@ZW_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH \Y\3_&7P-J7A35[&UU65[BYLIHHE^RRC+,A &2O')K1^!/_)*-/_Z[3_\
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M\OE< !9PF%]QM H U**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ JEK'_($O_P#KVD_]!-7:I:Q_R!+_
M /Z]I/\ T$T 4_"/_(EZ%_V#X/\ T6M;-8WA'_D2]"_[!\'_ *+6MF@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q?%5MK=UH,
MR>';R.UU,$-$\JY4\\@_45M44 ?/]OI/Q:_X3R\*7UJ+_P"QIOG8?N2F> .,
M;JWY-(^-,D;(=8TL!AC( !'Z59\=3^)O$_Q!M_!V@ZP^CV\5E]KN;F/(8G.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBJ-UK6E64YAN]3LX)0 2DLZJPS[$T 7JI:Q_R!+_ /Z]I/\
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M4X@HHHH K:E_R";[_KVE_P#0#5CPC_R)6@_]@ZW_ /1:U7U+_D$WW_7M+_Z
M:L>$?^1*T'_L'6__ *+6ID;T>ILT445!L%%%% !1110 4444 %%%% !1110
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M0C_74****Q.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P!&-76>-?\ D1/$'_8.N/\ T6U<G\"?^24:?_UVG_\ 1C4 >DT444 %%%%
M!1110 4444 %<Q\0O^1+NO\ KO;?^E$==/7,?$+_ )$NZ_Z[VW_I1'0#-%_]
M8WU--IS_ .L;ZFFUJ<04444 5M2_Y!-]_P!>TO\ Z :L>$?^1*T'_L'6_P#Z
M+6J^I?\ ()OO^O:7_P! -6/"/_(E:#_V#K?_ -%K4R-Z/4V:***@V"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X#XN?\
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M\:_\B)X@_P"P=<?^BVKD_@3_ ,DHT_\ Z[3_ /HQJ /2:*** "BBB@ HHHH
M**** "N8^(7_ ")=U_UWMO\ THCKIZYCXA?\B7=?]=[;_P!*(Z 9HO\ ZQOJ
M:;3G_P!8WU--K4X@HHHH K:E_P @F^_Z]I?_ $ U8\(_\B5H/_8.M_\ T6M5
M]2_Y!-]_U[2_^@&K'A'_ )$K0?\ L'6__HM:F1O1ZFS1114&P44A.%)P3@=!
MWKGF\1:H&8#PKJ1 . ?,BY_\>H Z*BN2M_&=Y=7EW:Q>%]2::T94F7?%\I90
MP_BYX(K5TW6+Z]N_)N-"O;)-I/FRO&5SZ<,30!L4444 %%%% !1110 4444
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MO5>;B/XC/?P/\"/]=0HHHK$ZPHJ.:>*WC\R:5(T_O.P _,U7_M73O^@A:_\
M?Y?\: +E%4_[5T[_ *"%K_W^7_&K$,\5Q'YD,J2)_>1@1^8H DHHHH ****
M"BBB@ HHHH **** "BBB@ KFO'7A&'QIX8FTMY?(G!$MO/CF.0=#].QKI:*
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ML32O^@;:?]^5I\.EZ?;RK+#8V\<B]'2, C\:MT4!<CN/^/6?_KDW\C3/ _\
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M:U>ZUX5\9O\ D>;'_L&#_P!&M10_B(>-_@2_KJ<!1117IGSH4444 =]\&O\
MD>[S_L&'_P!&K7NU>$_!K_D>[S_L&'_T:M>[5YE?^(SZ+!?P(_UU"BBBL3J"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN)\7>+M5M-
M>LO#/ABSM[K6KJ-IG>Y8B*WC'\38Y.?2@#MJ*X+P_P"+M>M?%47A?QC9V<-_
M<Q--9W=DQ\F<+]Y0&Y! KO: ,+QK_P B)X@_[!UQ_P"BVKD_@3_R2C3_ /KM
M/_Z,:NL\:_\ (B>(/^P=<?\ HMJY/X$_\DHT_P#Z[3_^C&H ])KE_B+_ ,B'
MJ?TC_P#1B5U%<O\ $7_D0]3^D?\ Z,2@#2D_UC?4TVG2?ZQOJ:;6IQ!1110!
M'<?\>L__ %R;^1IG@?\ Y$+P_P#]@^#_ - %/N/^/6?_ *Y-_(TSP/\ \B%X
M?_[!\'_H J9&U'J;]<Q\0O\ D2[K_KO;?^E$==/7,?$+_D2[K_KO;?\ I1'4
M&[-%_P#6-]33:<_^L;ZFFUJ<04444 5M2_Y!-]_U[2_^@&K'A'_D2M!_[!UO
M_P"BUJOJ7_()OO\ KVE_] -6/"/_ ")6@_\ 8.M__1:U,C>CU-FN8\??\BN/
M^OZS_P#2B.NGKF/'W_(KC_K^L_\ THCJ#5[&@_WV^M)2O]]OK25J<84444 <
M_P"./^1-O_K#_P"CDKN*X?QQ_P B;?\ UA_]')7<5$MSHH[!1114FH4444 %
M%%% !1110 5PGQ;_ .1/@_["-M_Z'7=UPGQ;_P"1/@_["-M_Z'50^->IE7_A
M2]'^1Y=1117O'PH4444 (G_(1TO_ +"5K_Z.6OHVOG)/^0CI?_82M?\ T<M?
M1M>7C?XB]#Z?)?\ =WZ_H@K@/BY_R*^G_P#84@_]FKOZX#XN?\BOI_\ V%(/
M_9JYJ?QKU/2Q'\&?H_R/,J***]T^&"BBB@"2R_Y#VA_]A6U_]&"OHBOG>R_Y
M#VA_]A6U_P#1@KZ(KR\;_$7H?49+_N[]7^2"BBBN,]<**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP[XT?\CCI?_8/?_T8
M*]QKP[XT?\CCI?\ V#W_ /1@K6A_$1S8S^!(\\HHHKU#YP**** .Z^#_ /R4
M*7_L&2?^C(Z]ZKP7X/\ _)0I?^P9)_Z,CKWJO,Q'\1GT.!_@1_KJ%>%?&;_D
M>;'_ +!@_P#1K5[K7A7QF_Y'FQ_[!@_]&M10_B(>-_@2_KJ<!1117IGSH444
M4 =]\&O^1[O/^P8?_1JU[M7A/P:_Y'N\_P"P8?\ T:M>[5YE?^(SZ+!?P(_U
MU"BBBL3J"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O-M
M(&[X_P#B$L,E=+@VY[=.E>DUP'BWP]K]IXMM/%_A:&"ZNT@-M>6,TGE_:(\Y
M&&Z CWH J_$$!?B)X D7B47DRAAUP5&1]*O>.O$WC+0]1M8?#7A@:M;R0[I9
M3N^1LD;>".V#531M!\2>(_&EEXI\564&F)IL3I8Z?%,)65WX9V8<=*]&H \.
MU;QC\4M7T:^TV7X?[([N!X&90^5#*5)'/7FLSP;K'Q-\&>&H-$M? CW$4+.P
MDE5@QW,6['WKZ$HH \:_X6%\5O\ HGB_D_\ C6=KOBOXHZ]HUQILW@ QQS;<
MN@?(PP;U]J]VHH \2/C?XI$D_P#"O%Y]G_\ BJ/^$V^*7_1/%_)__BJ]MHIW
M9'LX]CP"U^*WCR]UBZTBV\%V\NH6HW3VZ^9NC''4;O<?G6E_PFWQ2_Z)XOY/
M_P#%58\#?\G"^-O^N'_LT=>RT78>SCV/$)/&GQ2DC=#\/  RE<X?N,?WJ9I'
MC#XI:/HUEID7P_WQVD"0*[!\L% &3S[5[E11>Y2BEL>-?\+"^*W_ $3Q?R?_
M !K.UOQ7\4=<TJ33YO !C1WC<L@?/R.KCOZK7NU%(9XD?&_Q2))_X5XO/L__
M ,51_P )M\4O^B>+^3__ !5>VT4[LCV<>QX!9_%;QYJ&JW>F6G@NWFOK/_CX
M@3S-T?..?FK2_P"$V^*7_1/%_)__ (JK'PZ_Y+GX]^I_]#%>RT78>SCV/#;C
MQA\4;BUF@/P]"B6-D) ?(!&/[WO3M+\9_%/2])L]/C^'^]+6!(%9@^2%4*">
M?:O<**5[E**6QXU_PL+XK?\ 1/%_)_\ &L_6O%GQ1UK3_L<W@#8GG13;E#YS
M'(K@=>Y7'XU[K10,\2/C?XI$D_\ "O%_)_\ XJC_ (3;XI?]$\7\G_\ BJ]M
MHIW9'LX]CP"Q^*WCS4]1O-/LO!5O/=V3;;F%/,+1')&#\WJ#6E_PFWQ2_P"B
M>+^3_P#Q56/A?_R6'XA_]?)_]&O7LM%V'LX]CP36/$?Q.UG2IM/E\ &-)2A+
M('R-K!N[?[-:W_"POBM_T3Q?R?\ QKV6BE<I)+8\:_X6%\5O^B>+^3_XT?\
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M0_E/FCPJOQ(\*:S+J5MX)FFDDM_LY216P!N#9X/7BNR_X6%\5O\ HGB_D_\
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M_P !4_\ BZZ:B@#F?^$PE_Z%7Q%_X"I_\71_PF$O_0J^(O\ P%3_ .+KIJ*
M.9_X3"7_ *%7Q%_X"I_\71_PF$O_ $*OB+_P%3_XNNFHH YG_A,)?^A5\1?^
M J?_ !='_"82_P#0J^(O_ 5/_BZZ:B@#F?\ A,)?^A5\1?\ @*G_ ,71_P )
MA+_T*OB+_P !4_\ BZZ:B@#F?^$PE_Z%7Q%_X"I_\737\7RLC+_PBOB+D8_X
M]4_^.5U%% &'X-M+BP\%Z-:7<+0W$-I&DD;=48*,@XK<HHH **** "BBB@ H
MHHH **** "BBB@#BK34KS0=;U])?#^L7275_Y\4UK"CHR>3&O4L#G*GM5_\
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MKIJ* .9_X3"7_H5?$7_@*G_Q='_"82_]"KXB_P# 5/\ XNNFHH YG_A,)?\
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M;7O"FO:HMU8H9FL[JX,L-PJ\LI![X!Q79Z9XNTV\\&6GB:[GCL[.:!99&E;
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M2M8MUV)>6;X9E_NL.C"NMHH XWPY\/+31M=?7K_4;S5]89/+6ZNV!\M?1%'
M_P#KFJ5S\,6AU2\O-!\2ZIHT=ZYDGMK=@8]QZLH(^4FN_HH Y.P^'>@V7A*Y
M\.R1275M=L9+F6=\R32'G>6]<@5@_P#"I9);1=+N_%^N7&BJ1FR>0#<H_A9L
M9*^U>E44 06=G;Z?90V=K$L5O"@2-%Z*HZ"IZ** .>\)>%(?"EOJ$,-R\XO+
MR2[8N -I<]!5_P 0:0FO^'[[29)6B2[A,1=1DJ#WK2HH H:)I::+HEEIB2-(
MEK$L0=A@L ,9J_110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img224999359_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_17.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %. 90# 2(  A$! Q$!_\0
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M<_\ \5A_U O_ "-1_P 5A_U O_(U')YA[;^Z_N.@HKG_ /BL/^H%_P"1J/\
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MR2#\QQW(SD ]JO\ _%8?]0+_ ,C4?\5A_P!0+_R-2=2;OJM?^&&E!6]UZ?\
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M5+4&JU"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$VJ&N;,D@%2B@[&8?+DC%>Q4 %8?C.22+P5K1BN(K:0V4J+-,VU(RRD!B<'
M&<UN4R:&*X@DAGC26*12KHZAE8'@@@]10!X[\+8!X?\ $]SHB6FB7EQ_8L=X
ME]I.1GY@OE2.2023A@>/7OQT&K_$#Q5H6E7&IZE\/IX+.W7=+)_:UNVT9QT7
M)/7L*[#1O#6B>'5F&CZ5:6/G$&0P1!2^,XR>^,G'IDU@?%K_ ))7X@_Z]Q_Z
M&M '9(V^-7QC< <4ZHX/^/>+_<'\JDH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,VZU"[347M+6T@EV1)*
MS2SF/[Q8  !&_N?K3/MNK?\ /A9?^!C_ /QJD/\ R,5W_P!>D'_H<M6JO3L<
M]Y.^OY?Y%;[;JW_/A9?^!C__ !JC[;JW_/A9?^!C_P#QJJUMK^EW=^;&"\1[
M@9&P \XZX.,'\#4VH:I9:5"LM[.(D8[5R"23]!S3Y=;6)]IIS<^GR'_;=6_Y
M\++_ ,#'_P#C5'VW5O\ GPLO_ Q__C55Y==TR&W@G>Z7RIU+1LJLV0.I.!P!
MWSTJVEW!)=/;))NE1 [  D 'ID].<=.M%O(%.^BG^7^0S[;JW_/A9?\ @8__
M ,:I]KJ%V^HI:75I!%OB>56BG,GW2H((*+_?_2IJJC_D8K3_ *])_P#T.*EI
MV*O)6U_+_(UJ***@Z HHHH **** "BBB@ K)U[PQHGB>VCM]:TZ&]CB;=&)
M<H>^".16M7)>,O$.MZ=J.C:+X<MK&75=4:8I)?LPAC2)0S%MOS$G< ,4 ;^_
M2_#^G00M)::?91@0PJ[K&@XX49P.@/'M5U65U#*05(R"#P17DMCXMU?XBWVE
M6%GX9M#%IM]')JUY>C?%;R1N0R09'+E<X/. XSCK7J]O;PVMO';V\210QJ%2
M-% 50.@ '2@"2BBB@ KB_BU_R2OQ!_U[C_T-:[2N+^+7_)*_$'_7N/\ T-:
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M_BU_R2OQ!_U[C_T-: .P@_X]XO\ <'\JDJ.#_CWB_P!P?RJ2@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K/N=4^SWK6L=E<W#K&LC&(
MQ@ ,6 ^\P_NFM"LD_P#(Q7?_ %Z0?^ARU449U&U:P_\ M:?_ * ]]_WU#_\
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M^2>^)?\ L%77_HIJZ"N?\=_\D]\2_P#8*NO_ $4U=!0 4444 %%%% !1110
M4444 %%%% !1110 52UB".ZT/4+>:X%M%+;2(\YQB)2I!;YN..O/'%7:P?%E
MWIXT.^TN\OK&VFU"QN4A6\DVJX6(ER<$$JH.6QT% 'D>D6_AW6[[2]&LOB?K
M4KVS_P#$O2:WVQET&T;&=-K$9P.I]*]KT:PN-,TF"SNM1GU&:/=NNIP \F6)
M&<<< @?A7BD4VK:E!X?T=/'/@>Z_LVX@:RA4MNDE0;8LX/)!(X&,GUZ5[7HJ
M:JFDP+K<MI+J(W><]HK+$?F.W:&Y^[C/OF@"_5'6=4@T31;W5+D.T-I"TSJ@
MRS!1G 'J>E7JI:O<7UKI%W/IEG]MODB)@MRX02/V!8D #/O0!S7A'QQ=^(=6
MGTO4_#\^CW8M4OH4>X682P.<*V0!M.?X33?BU_R2OQ!_U[C_ -#6LKX>V7B=
M+[46\4>&I+2\OHB]SJ[:E%*TC @+$D:<QH%9B.>,=R:R/B-\/M.TGX?:S?0Z
MIKDLD,(94N-2DD0_,!RI.#0!ZY!_Q[Q?[@_E4E1P?\>\7^X/Y5)0 4444 %%
M%% !1110 4444 %%%% !1110 45S=CI>GW,<\L]A:RR-=W&7>%6)_?..I%6?
M[$TG_H%V7_@.G^%7RKN8*K)J]OQ_X!MT5B?V)I/_ $"[+_P'3_"C^Q-)_P"@
M79?^ Z?X4N5#]I/M^/\ P#;HK$_L32?^@79?^ Z?X4?V)I/_ $"[+_P'3_"C
ME0>TGV_'_@&W16)_8FD_] NR_P# =/\ "K&@(D6E&.-51%N;A551@ "9\ "A
MI6N.-1N5FC3HHHJ34Y_PS_Q_>(_^PJW_ *)AKH*Y_P ,_P#']XC_ .PJW_HF
M&N@H **** "BN,^*<DT'@*YN;:ZN[6>&XMBDMK</"PW3(C E""05=A@\=#U
M(\9_M/5_^@_KG_@UN/\ XNMJ5"5171QXG&T\.TIIZ]CWGQW_ ,D]\2_]@JZ_
M]%-705\LZOJ.J/HM^DFMZS(C6\@9)-3G96&TY!!?!'L>*N_VGJ__ $']<_\
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MAI4445!N<_X9_P"/[Q'_ -A5O_1,-=!7/^&?^/[Q'_V%6_\ 1,-=!0 4444
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MO2PXP:E=L\0ABN&GOU;6-<(BU"[A3_B<77")/(BC_6=E4#\*E^SS?]!?7/\
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M@O G_)//#7_8*M?_ $4M<>-^S\SV,F^W\OU.@HHHK@/<"BBB@ HHHH ****
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M-_\ ]?%I_P"E,5>(U[=\5_\ DG-__P!?%I_Z4Q5XC7;@OA9XV<?''T*>J_\
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M$T8 ^A9OYUZCX#T<VTWBLWFFF(2Z_<20>=!MWQ%(\,N1RO!P1QP:Z_[!9_\
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M((ZBGUY+\.+^[TKQ3+H%K%,-#NUFN;6PN'S<Z6JLH E4DE%<L=JDY&/K7K5
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M6H0VQ=K:0]\1MP,X'8&NJM;2WL;6*UM((X+>)0L<42A50#L . *FHH ****
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MJJ!T  Z"GT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?&^NO#=^+B]T6>1M0T[6Q-B\TZX&.&8G+=L'KQS_ +/J-O +>)5W&1\ /*P
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=110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img224999359_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_18.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $S 9X# 2(  A$! Q$!_\0
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M_P#RH1_X4_:U'O;\";4ELG]TO\CG]<\#:I<:PFJV4NE7]S):K;W(U:V#*7
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M3^Z_\CH**Y_^U_$7_0K_ /E0C_PH_M?Q%_T*_P#Y4(_\*GD?]-%>WCV?W/\
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MBB@ HHHH **** "BBB@ KD_&OC>/PC';(+:WGN;D,8Q<7T-K& N,DLYR>O\
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M -/90ZE6 *D8((X(JUL83^)^G^9YYI4,FD2Q22V]JUS<6L\D-Q!,SL"%)^8
ME3Z<"K?A^*.TU?1WMW8M>VCO<Y<G>W)R<^_%=/9:!I>G3O/:V:1R.""<EN#Z
M9/'X4MCH6F:;<//9VBQ2N,%@2>/09/'X5LZB=SAAAI1:VT_X'EU,_5[G4F\0
MV6G6-Z+5)XG9F,2O@C/.#]/6N9U6YN=:T32'G?-SYDZEE &YEZ<#Z"NROK2Z
M?5(KJWMK9Y8T(CGE=QL'=2HZY['MR<' !H1:1=1BW$6FV40B=IH-T\C>23U#
M<_,3QR.!D\''S9JK&/3\#IG@:E1-\ZL^[].GR?\ 31S\5Z^K^*=-U([O+,D<
M*9' (0%Q_P!]-7:ZW_R -1_Z]9?_ $$UDPZ-<0B 0:990B*0S0[IY&\D]PW/
MS$X'(X'H<?-H:B]S)X;U%[J)(G-M*1&C;MHV'@GN?I_]<CJ*4E9 L+.C3DYR
M3;[._3^OZL=#11161V!1110 4444 %%%% !1110 4444 %%%% !7"_%+2-,N
MO#3:G=Z':ZI>6A6.V%U(Z1Q^9(JEG*D849!/L.HZUW5<IX\L+K5-%-B/#D6O
M:?+S<VOVXVLN5(*E#C!Y'(++T'6@#EO _P /M8\/^)X-2N]&\(6T"(X,NF/=
M&894@8\PE<>OM7JE>.>&_#\.BZU'?>'?A5>6-^@9!<7VKE(T!&#G+/GCT4U[
M!%YGDIYP42[1O"'C/?&>U #Z*** "N+\3?\ )2O W^_??^B*[2N+\3?\E*\#
M?[]]_P"B* .THHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH **** "BBB@ HHHH **** "L/Q=KL_ASPW<:E:V)OKA7CBB@WA SNZH,L>
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M2E'9MP$!Q]XGU- 'J-%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA_U\7?\ Z4RUVE<7\)_^2<V'_7Q=_P#I3+7:5XTOB9]C2^"/H%%%%26%%%%
M!1110 4444 %%%% !1110 4444 %<_XWN]9L?"-]<:#'+)J"!-ODQ"614W@.
MR(>'8+N(4]2/PKH*Y[QN^FQ^%;EM6O-0L[,,F^;3RXF4[AC&P$]<9XZ4 <5X
M U_Q%J?B&"U>;6+JPA%T+N?4;'R0PW PL&P/GZC:!T)/:O5J\;\&2:9-\0].
M/AW5_%&I6BVTYO%U&24PQ'"[&^<#).6&.>QXQS[)0!#=S/;6<T\5O)<21H66
M&(C=(0.%&2!D].2!7)/\0$M8]3AO],>'4K"2UC-I'.LF]KDXB&[C!SG.1P!G
MD$5T^JF_&DW?]E"$ZAY3?9O/)$?F8^4MCG&>M><Z;\/M7B\)W%M<QVQUV2]@
MU*:^ENVD%W/'('VM\@*)@;1C.,YQZ@'=^']=77+:[+6S6US973VES"S;MLBX
M/#=P592#@<'I6%XF_P"2E>!O]^^_]$5/I?A)YM%UJVUL[7UB_>\FCM+AAY0^
M0*JR *>D:Y.!R3VKFY?"&E>&/B=X-?3C=YG:]#_:+J2;I <8WDXZ]J /4:**
M* "BBB@ HHHH **** "JE_?BQ6']Q+.\TGEHD6W).UF_B('13WJW69JW_'UI
M7_7V?_1,M..Y%1M1T#^UI_\ H#WW_?4/_P <H_M:?_H#WW_?4/\ \<K-UG6[
MC2W/DZ9+<QI&999=VQ$&<8!(Y/M5][^*/2SJ#*_E"'SBN/FVXST]:OEZV,%4
MU:YMOZ[#_P"UI_\ H#WW_?4/_P <H_M:?_H#WW_?4/\ \<K+TC7I=1NQ;7-@
M;61[=;F+]Z) \9.,\ 8[<5:U#7=-TN817MR(G*;P-C'(SCL*?+K:PE63CS<V
MGR7Z%K^UI_\ H#WW_?4/_P <H_M:?_H#WW_?4/\ \<K%U3Q7!IYL'BA%S;W8
MW"57V[5R.<8]^G'2IO\ A(E/B@:,MON'.9_,Z$+N(QCZ=Z.1[V)]O&]N;LOO
MVZ&O;:I]HO5M9+*YMW:-I%,IC((4J#]UC_>%:%9(_P"1BM/^O2?_ -#BK6J)
M'33;=[A11534;[^S[;S_ ++=7/S!?+MH][?7'I4FA;HKF9?&D$-Q!!)HNMK+
M.2(D-GRY R<<^G-:6FZW_:-PT/\ 9FI6N%+;[JWV*>G&<]>: -2BBB@#R/XS
M?\ACPY_U[WG_ *%;UYS7HWQF_P"0QX<_Z][S_P!"MZ\YKU,)_#/F<T_WA^B*
M=O\ \A&]_P" ?RJY5.W_ .0C>_\  /Y5<K>.QPU-_DOR/;OA/_R3FP_Z^+O_
M -*9:[2N+^$__).;#_KXN_\ TIEKM*\:7Q,^QI?!'T"BBBI+"BBB@ HHHH *
M*** "BBB@ HHHH **** "N;\>7FJ6'@Z]N-',RW0,8,D$/FR1QEU$CJG\1"%
MB![5TE<UX_;5E\&7QT7[9]KS'N^P@&X\K>OF>4#_ ![-V._ISB@#D?!6L^+]
M5\70WM\;]=+U%;F8V<]GY<=K K!8#N/(D8ACCN#GWKU.O*_!*^,[CQ='JVIM
MJ\5GJ*W$]Q9WAQ#:Q;@MO&J'E9>"6QV(SSU]4H **** "N+\3?\ )2O W^_?
M?^B*[2N+\3?\E*\#?[]]_P"B* .THHHH **** "BBB@ HHHH *S-6_X^M*_Z
M^S_Z)EK3K/U2VN9S:26JQ,\$_F%97* C8Z]0#_>':G'<BHKQ,+7[;5YIF2VM
MHKVTEA*B-BJF"7M(">>_8_E5AX-5.FC3,!G-GM:^:08\W&,%<9/^]_6K^-8_
MY\['_P #'_\ C5&-8_Y\['_P,?\ ^-5KS:6T.7V:NWKK_78YWPSHU[8:B9WL
M180BW$<B><)3,^?O?[/TJ[?6,LOB>*\V(;=;5H"[.O$C$X7!.<G(_.M7&L?\
M^=C_ .!C_P#QJJ=QI-W=3F:?2]/=V7:<WCX/OCR^H&0#U&:4IR;NK#I4:27)
M*]M]%_PQS:Z!=RV.EV\\2#R(;B&7,J_)(^=@Z]<E:ET71KVTU'3;NZ";UDF^
MTL94.QV4*J]>2>.!ZUM?V#-QG2=//RE3F]D.?]H_N^6Y/S=>3S1_8,W&=)T\
M_*5.;V0Y_P!H_N^6Y/S=>3S0ZE1Z:?>4L)A$T[RTMT[6_P OQ-!2#XBM<$'%
MK.#@]/GAK7K%TW3;JWOH))(+:&&&"2,"*=I&9G9#DY0?W3D\DDUM5F^AO!*[
MMM<**Y#XFQ1S>!+F*5%DC>[LE=&&0P-U%D$=Q7G'_"-Z%_T!=._\!4_PJX0Y
MC*MB%2:31ZMK/_(U>&O^NMQ_Z):N@KYWOO#^C)J^EHND6"H[R!E%L@#80D9X
MYK2_X1O0O^@+IW_@*G^%5[%]S%XZ*Z'NU%>2> ]-L-/^(</V*RMK;?I5UO\
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M-Q>6UW-XR\6R7%KN\B5KZ,M'N&&VGR^,CB@#T"BN'_X5Q+_T/7C+_P &"?\
MQNC_ (5Q+_T/7C+_ ,&"?_&Z .XHKA_^%<2_]#UXR_\ !@G_ ,;KG[7PK?S^
M/M1T%O&WBP6MM80W*.+]=Y9W<$$[,8^4=J /6**X?_A7$O\ T/7C+_P8)_\
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MV/PJATVT6UL?&7BVWMU+,L<=]&J@L2Q./+[DD_C5C_A7$O\ T/7C+_P8)_\
M&Z\]N[N>]!<L4CN**SM#TEM%TT6;:EJ&HD,6\^_E$DISVR .!]*T:104444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img224999359_19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_19.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '+!#@# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPXZ5Z+16OMY7;6[,E0C91>R.'\+:7J'A?Q3?:4YN;O3[U/M4=VT?"R_Q!B.
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M^_/_ ->N"HH^KTOY4'UBK_,SO?\ A;_BGULO^_/_ ->C_A;_ (I];+_OS_\
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M_P 4^ME_WY_^O1_PM_Q3ZV7_ 'Y_^O7!44?5Z7\J#ZQ5_F9WO_"W_%/K9?\
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M5?YF=[_PM_Q3ZV7_ 'Y_^O1_PM_Q3ZV7_?G_ .O7!44?5Z7\J#ZQ5_F9WO\
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M29M!G1/"PABX611 L>!Y@E'][KG-8^IZ]-I'@R5_#MX]K;S:S.(VA.&\O (
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M.Z6?B3::4+0&R>S65XMQZ^5N)S]:(H?#VFZ9X9%QH4=Y<:F")Y'E9<+YFW(
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M^N<]ZL3>*]8GUFXU:6X5KRX@-O(YC&-A7:0!T'%3[*K_ #?UT_X)?MJ7\O\
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M(P?,I/L.51<LHKN4Z***U,2>R_X_[;_KLG_H0J_XI_Y&S5O^OI_YU0LO^/\
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M[5;'0M4EU%]1G$9EN("HBB9\$* 1D]>M)I]C%X8O_$>KKN,>F.]G8E^2TSY
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MG;-9I3YES+;U?Y&CY.5\KW]%^9R==18^!-1O;"QO/MNG0)?KFV6>?:TC9QM
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M5/X@UF  =!2]C&=I+;^F"K2A>,M_Z0O:BBBN@YPHHHH W?$?_'MH7_8,C_\
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M)M*LX7M&DLK7RYOL8_<HQ.=B>H QS7'445M""A'E1E.;G+F844451!N>#O\
MD;+#ZO\ ^@&L0_>/U-;?@[_D;+#ZO_Z :Q#]X_4U"^-^B_4M_ O5_H)1115D
M%O3+]]+U6UOXD5WMI5E56Z$@]#6A8>)[JPUR]U)8(94O=XN;60$QR*QR5/\
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M*** "BBB@ HHHH **** "BBB@ HHHH GLO\ C_MO^NR?^A"K_BG_ )&S5O\
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M;B*Z\6ZO/ 08I+N0J1W&:R***Z(JR2.>3YFV%%%%,04444 ;OC/_ )''4_\
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M1T)'T-*68]68_4T_8Z[Z J^FVIZ5KEWHFI_#^^NH[S49I)]3,BF5%#&8IP"
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M%/7/K%_W^/\ A1_PIZY]8O\ O\?\*/KE'N'U>M_(SR>BO6/^%/7/K%_W^/\
MA1_PIZY]8O\ O\?\*/KE'N'U>M_(SR>BO6/^%/7/K%_W^/\ A1_PIZY]8O\
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MO6_D9Y/17K'_  IZY]8O^_Q_PH_X4]<^L7_?X_X4?7*/</J];^1GD]%>L?\
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M6VFM[BZU2[U); %K.WE"J V, D@?,<< FMK^U;+_ )[C\C]?2C^U;+_GN/\
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MYO[0L;^3S+JQN3&9,8WH?F1L?[I_2E*DTKW'&JF[6-NBBBLS0**** "BBB@
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M+NW-X;,3)]H">88L_-MSC./3-4^9:,E<KU1#]ADQ_P ?US^8_P */L,G_/\
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MT[2XK5'$=O9L7,CL,%F; X Z"FJD'%_UT)=.:DD_ZU.YHHHKC.T*!THH'2@
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MNNP6?<I_;I/^?&Y_(?XTGV^3'_'C<_D/3ZU=HHNNP6?<I_;I,_\ 'C<_D/\
M&C[=)_SXW/Y#_&KE%%UV"S[E+[?)C_CQN?R'IGUI?MTG_/C<_D/\:N4C,JXW
M,!DX&3WHNNP6?<J?;I,_\>-S^0_QI/M\F,_8;GIZ#T^M7:*+KL%GW*?VZ3_G
MQN?R'^-'VZ3/_'C<_D/7ZU<HHNNP6?<I?;Y,?\>-S^0_QH^W2?\ /C<_D/\
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M9H_LJR_Y]U_,_P">U&@:EO(]11D>HJI_9=EG/D+^9]<T?V59?\^Z_F?\]Z-
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MI^M TJR'_+N/S/\ GO1H&I;R/449'J*J?V58_P#/NOYGTQ1_9=D?^7=?S/\
MGM1H&I;R/449'J*J?V799SY"_F:/[*L<8^SKC&.I],4:!J6\CU% (]153^R[
M+_G@OYG_ #VH&EV7'[A?S/KFC0-2WD>HHR/454_LJQQC[.N.G4^F*/[+LO\
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MKVWUCQ;:3:?*L]O9VTGFS)RNYR,+GUXS6T8IQO;N9N3YK7.CHHHK$T"BBB@
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MBLR_=)&2/I1Y,0E\WRT\S^_M&?SKS?\ X77H?_0.U#_OE/\ XJC_ (77H?\
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MT@P&5$8C\":K?\+8\/\ _/EJ7_?*?XU<<-52MRF,Z])RNI'<T5PW_"V/#_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML_\ OEJ/^%*:Q_T%+/\ [Y:CZU1_F#ZI6_E/,J*]-_X4IK'_ $%+/_OEJ/\
MA2FL?]!2S_[Y:CZU1_F#ZI6_E/,J*]-_X4IK'_04L_\ OEJ/^%*:Q_T%+/\
M[Y:CZU1_F#ZI6_E/,J*]-_X4IK'_ $%+/_OEJ/\ A2FL?]!2S_[Y:CZU1_F#
MZI6_E/,J*]-_X4IK'_04L_\ OEJ/^%*:Q_T%+/\ [Y:CZU1_F#ZI6_E/,J*]
M-_X4IK'_ $%+/_OEJ/\ A2FL?]!2S_[Y:CZU1_F#ZI6_E/,J*]-_X4IK'_04
ML_\ OEJ/^%*:Q_T%+/\ [Y:CZU1_F#ZI6_E/,J*]-_X4IK'_ $%+/_OEJ/\
MA2FL?]!2R_[Y:CZU1_F#ZI6_E/,J*]-_X4IK'_04L_\ OEJ/^%*:Q_T%+/\
M[Y:CZU1_F#ZI6_E/,J*]-_X4IK'_ $%+/_OEJ/\ A2FL?]!2S_[Y:CZU1_F#
MZI6_E/,J*]-_X4IK'_04L_\ OEJ/^%*:Q_T%+/\ [Y:CZU1_F#ZI6_E/,J*]
M-_X4IK'_ $%+/_OEJ/\ A2FL?]!2S_[Y:CZU1_F#ZI6_E/,J*]-_X4IK'_04
ML_\ OEJ/^%*:Q_T%+/\ [Y:CZU1_F#ZI6_E/,J*]-_X4IK'_ $%+/_OEJ/\
MA2FL?]!2S_[Y:CZU1_F#ZI6_E/,J*]-_X4IK'_04L_\ OEJ/^%*:Q_T%+/\
M[Y:CZU1_F#ZI6_E/,J*]-_X4IK'_ $%+/_OEJ/\ A2FL?]!2S_[Y:CZU1_F#
MZI6_E/,J*]-_X4IK'_04LO\ OEJ/^%*:Q_T%+/\ [Y:CZU1_F#ZI6_E/,J*]
M-_X4IK'_ $%+/_OEJ/\ A2FL?]!2S_[Y:CZU1_F#ZI6_E/,J*]-_X4IK'_04
ML_\ OEJ/^%*:Q_T%+/\ [Y:CZU1_F#ZI6_E/,J*]-_X4IK'_ $%+/_OEJ/\
MA2FL?]!2S_[Y:CZU1_F#ZI6_E/,J*]-_X4IK'_04L_\ OEJ/^%*:Q_T%+/\
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M:C_A2FL?]!2S_P"^6H^M4?Y@^J5OY3S*BO3?^%*:Q_T%+/\ [Y:C_A2FL?\
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MMG&?I6G1D>HHR/44VVU85E>X449'J*3(]12&+129'J*7(]10 449'J*,CU%
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M/^7=*MT4<S#E14_LNRQC[,F/_K8H_LRR/_+LG^?_ -56Z*.9]PY45/[,LO\
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M_P#UU;HHYF'*NQ4_LNRQC[,F*/[,LLY^SIZ_KFK=%',^X<J*@TRR_P"?9/\
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M7(VKGUXSBNB(!&",@]C3(X8H5VQ1)&N<X10H_2M%-)6(<;NX^BBBLRPHHHH
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M8 R.3MZ]\?A7I--**6#%06'0XY%.K2I4Y[.QG3I\EU<****S- HHHH ****
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MHO-9\.:7+S;SWAEE4]'\M=P!_''Y5/IGA 6FIP7]]JU[J4MJI6V%P1B+/!.
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MK8GRKB( D ]5(/!!XX]JNFTGJ143:T,_PU&EIKWB*RMP$M8[B.1(UX5&=,L
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M#^,M%C=D:X?*D@XB;_"D_P"$UT/_ )^)/^_3?X5L&PLR23:P$GOY8H^P6?\
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M9C_\)KH?_/Q)_P!^F_PH_P"$UT/_ )^)/^_3?X5L?8+/_GT@_P"_8H^P6?\
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M?_/I!_W[%%X=F'+B/YE]S_S,?_A-=#_Y^)/^_3?X4?\ ":Z'_P _$G_?IO\
M"MC[!9_\^D'_ '[%'V"S_P"?2#_OV*+P[,.7$?S+[G_F8_\ PFNA_P#/Q)_W
MZ;_"C_A-=#_Y^)/^_3?X5L?8+/\ Y](/^_8H^P6?_/I!_P!^Q1>'9ARXC^9?
M<_\ ,Q_^$UT/_GXD_P"_3?X4?\)KH?\ S\2?]^F_PK8^P6?_ #Z0?]^Q1]@L
M_P#GT@_[]BB\.S#EQ'\R^Y_YF/\ \)KH?_/Q)_WZ;_"D_P"$UT/_ )^9/^_3
M?X5L_8+/_GT@_P"_8H^P6?\ SZ0?]^Q1>'9ARXC^9?<_\S'_ .$UT/\ Y^)/
M^_3?X4?\)KH?_/Q)_P!^F_PK8^P6?_/I!_W[%'V"S_Y](/\ OV*+P[,.7$?S
M+[G_ )F/_P )KH?_ #\2?]^F_P */^$UT/\ Y^)/^_3?X5L?8+/_ )](/^_8
MH^P6?_/I!_W[%%X=F'+B/YE]S_S,?_A-=#_Y^)/^_3?X4?\ ":Z'_P _$G_?
MIO\ "MC[!9_\^D'_ '[%'V"S_P"?2#_OV*+P[,.7$?S+[G_F8_\ PFNA_P#/
MQ)_WZ;_"C_A-=#_Y^)/^_3?X5L?8+/\ Y](/^_8H^P6?_/I!_P!^Q1>'9ARX
MC^9?<_\ ,Q_^$UT/_GXD_P"_3?X4?\)KH?\ S\2?]^F_PK8^P6?_ #Z0?]^Q
M1]@L_P#GT@_[]BB\.S#EQ'\R^Y_YF/\ \)KH?_/Q)_WZ;_"C_A-=#_Y^)/\
MOTW^%;'V"S_Y](/^_8H^P6?_ #Z0?]^Q1>'9ARXC^9?<_P#,Q_\ A-=#_P"?
MB3_OTW^%'_":Z'_S\2?]^F_PK8^P6?\ SZ0?]^Q1]@L_^?2#_OV*+P[,.7$?
MS+[G_F8__":Z'_S\2?\ ?IO\*/\ A-=#_P"?B3_OTW^%;'V"S_Y](/\ OV*/
ML%G_ ,^D'_?L47AV8<N(_F7W/_,QO^$UT/\ Y^7_ ._3?X4O_":Z'_S\2?\
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MC_A-=#_Y^)/^_3?X5L?8+/\ Y](/^_8H^P6?_/I!_P!^Q1>'9ARXC^9?<_\
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M #,?_A-=#_Y^)/\ OTW^%'_":Z'_ ,_$G_?IO\*V/L%G_P ^D'_?L4?8+/\
MY](/^_8HO#LPY<1_,ON?^9FVGBO2;V[BMH)W:60X4&,C)HK32SM8W#I;0JPZ
1%4 (HJ)6Z&U-32]]I^A__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img224999359_20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_20.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ( !#@# 2(  A$! Q$!_\0
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M?!-'*O\ >1@P_2DFN[:W=$FN(HWD.$5W +?3/6G9BNB:BFNZQHSNP55&2Q.
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MX)7ZCM2FX@6X6W,T8F8;A&6&XCUQ19A=$M%%%(84444 %%%% !1110 4444
M%%%% !1110 4444 %>>_$:T@OM;\+6MS&)(9;LHZ$XR#MXKT*N/\;:%K&JW>
MCW>CK;M-8S&4B=L ],?RK;#M*HFW;?\ (QQ";IM)7V_,P_&'A&P\,Z4?$'A_
M?I]Y9NK820[9%)P00?K3OB5(VK>"='DP$:[GB//\)93_ (U:N/#7BKQ3+%!X
MEN[2VTR-P[V]GDF7'8DUK>,_#MUK6E:?::<L2_9KJ.0AFV@(OI71&HE*'-*[
M3W_X)SRIMQGRQLFMO^ <SIOBZ;2OAQ?6MR2-6TUS8*IZECPA_+/_ 'S2_":Q
MFTR]UZSN3F>)X@_UP2:TM3\ -??$&VUH%!8?++<19^]*O3COGC]:UO#NA7FF
M>(_$%]<>7Y-].KP[6R<#/7TZT3J4_9R4>NOXK3\Q0IU/:1<OLZ?*SU_(Y'Q=
MHEQ9^,]$U.[U&6Z:YU%5BC(PL,8((4#UR>M>JUR_BS0;W6=1T*>T\O997?G2
M[VP=O'3UZ5U%859\T(^1T4H<LY>9Q?Q5_P"1!O/^ND?_ *$*X?[/8:C?:(OA
M/0[^SU"*5'FN6C9$"@?-DDUZ3XYT2[\0^%;C3K'R_/=T(\QL#A@3S6[:1-#9
M01/C<D:J<>H%:4ZRITU;>[_0SJ474JMO:R.'^(,[:M>Z;X2MYQ$UZ_FW,F?N
M1+S^I'Z4[P%.FI>'K_PQJ8$LE@[6TBD_?B.<'CMU%,A\ _VWK^J:KXHB60S.
M%M8HICA(QTR1CV_6I;#P3+X<\96VH:"B)ILL)BNXGE.1Z$9Z]OUJG*G[/V:>
MJU^?K^!*C4]I[1K1Z?+T_$PKSP?H,7Q/T_2TT]!92V32/%N;!8;N>OM6Q\0]
M-L]'^&5S96, AMXY8RJ DXS(">M:]WH-[-\1+'6T$?V.&T:%\M\VXY[?B*E\
M<Z+=^(/"MQIUCY?GR.C+YC8'# GG\*7MKSIWEHK7^\?L;0J6CJ[V^XXW7/'<
M-YX,N]/&BZM&7M/+$LEOA!P!DGTK1N]8N-#^#-C=VA*SM:0Q(XZIN &:ZG6]
M+N;_ ,&W6EP;/M,MIY*[FP-V,=:K6_AE;KP';>'M2P&6U2)V0YVL!U'T(I*I
M3LM.H.G4N]>AFZ/\.?#PT2%;VT%Y=31AY;F1CO+$9)!SQ5?P#-<:=K>N>&'G
M>>VT^0-;NYR55OX?Y?K3;6W^(6C68TNV33KV*,;(+N5R&5>V1WQ6WX0\,/X?
M@NKB]N?M6IWLGF7,V."?0>W)ISD^67-*]]OZZ!"*YH\L;6W_ *ZF-\-O^/OQ
M1_V$W_K5GXD7]W#INGZ99S&!M3NEMWE4X*J>N/SK+T[0_&V@7^JMID.F/!>7
M33@S2'/)..GM70ZQX<NO%'A6&UU1XK;5(R)5EAY6.0="/;%$G%55-M6_X HJ
M3HNFD[_\$KM\,_#)TO[&MCMDVX%R&/F;O[V:S?!_B&]A\#:NURYN)](:6))&
MYWA1E<_YZ4]A\2'M/[/*:8K$;#?A^<=,X]<>U=#X>\+6NA>'#I)/GB4-]H=O
M^6K,,-_A2E*T&JDN;7U]2HQO-.G'ET]/0XW0/#^CR>$7\5>(K>35;JY4S2%@
M7(&[ "KFMOP%/X<GM]1L]#MKN*,2;IXKH'C<,8 )Z<51L=%\8^$?,L=%%GJ6
MEEBT*7#[7BSVK4\&Z#J^FWVK:EK!MEN-0D#F. DA<9[_ (U562<9/FOVU_0B
ME%J44HV[Z?J<GJ$VJ_#S4KS2=+@>:SU;G3AG_4RD@$?AG^7O7>>$/#<?AK14
MMR1)=RGS+F;N[GKSZ#I5;Q3H-[J^L:!=6OE^78W7FS;VP=O'3UZ5U%9U:O-!
M=WN:TJ7+-]EL%%%%<QTA1110 4444 %%%% !1110!3U/_CQ/_72/_P!#6KE5
M-2_X\C_UTC_]#6K=/H+J%%%%(84444 %%%% !7!?$N-;YO#^DMRMW?KO7U4=
M?YUWM<3XQT+7]0\1:/J6CI:N-/#,!<.0"Y]OH*VP[2J)MF.(3=-I*YD^-?!F
MCZ%H$FLZ.CZ?>VC*\;Q2'GD#')JSX[O)K[X<:>LGR7&H/;JP/J>34Q\+>(_$
MMU"?%=[;)80N'%C: XD(Z;B:U/%GA^[UNZT-+98A:V=VL\VYL8"] !W[UNJB
M3BI2NUK?]#G=-N,G&-DU:WZG*^&?$[>&O .H6MS\]_IMR]K%'U+NQ^48],Y_
M 5'\+-.NH/$^O37S%[J,*DKGGYV.YA^8_2MK_A 3+\1Y==F9#I^5G6+=RTP&
M.1[')K4\'Z#?:/)K-Q?^69[Z\:9=C9^7MG\S53J0Y)<N\K?\,*G2GSQYMHW_
M .'//6O-!G\8^);C6=(N]1S<>7 ((BX7;P>01C.!71^&+6^\/_#C6KB\BEMX
MW6:6VMY3\T2%< 'TKH/!&@7F@Z?>K?B/[3=7;SGRVW#!QCG\ZN>,--O-8\+7
MNG6 0W$ZA1O;:,;@3S]!4SK)R5-;:?@.%%J+J/?7\3R_P:;KQ5IUMX72Y&GZ
M=:IYMTJG$UUN8G ]%Y%>PZ=IMGI-C'9V,"0P1C 51^I]3[UQVL^"+O[+I.H:
M')';:WI\4<6XG"2J  0?U_"NULWN9+.%KN)(K@J/,1&W -WP?2HQ%13UB].W
MF:8>FX:26O?R.!^*EW]@D\.WGE-+Y%Z9/+7JV #BE\'Z<OBZZ'BS6;B*[E#%
M;:T4Y2U /0C^]_\ KK<\6Z#>ZS?Z%-:"/997@FFWMCY>.GKTK/N/"NIZ'XF&
MK^%S"+>Y/^F6,K[$;_:7T-7&<?9**=GK^>WE<B4)>U<FKK3\M_.QB?$+2KG6
M/'ND6ME,8;L6;R0N./G0LP'YBH/$?B/_ (2+X?VS3KY6H6VH10W<)X*N,\X]
M#797VA7MUX^TC6T$8M;:V>.4%OF#$-T'?J*P?&OP]NM6UB+4M&:.-I64W<3M
MM5RIX;ZU5.I#W(R>W^;T(J4Y^_**W_R6I<^(=Y=FVT;1+6=K<:I<"*653@A!
MC(_'/Z59N/AGX:?2C:0V7DS*GR7*L?,#=B3WYK0\5^&%\2:1% LYM[RW<2VT
MX_@<?TK!E3XC7=H=->/38=PV/?*_.WH2!Z_A6<)/D2A*UMS6<5SMSC>^W]="
M/PSXFOD^&NHWMPYFNM,$L2R-SOVCY2?7K^E'A#P5I.I^'H-6UF'^T+[4%\Z2
M69B<9Z <\5TVB^%K+2/#']AG,T+HPG9NLA;[QKFK+2O&OA:)M-TD66I:<I/V
M=KA]KQ GH?6GSJ7,J;M=^FA/(X\KJ*Z2]=3?70;/P[X0U&QL?-\GR97 D<L1
ME3P/:O,?"ES<^++/3O"370L-.MXVDG ;$EW\Y.U?;FO3M.TW7CX8O;;6;V*Z
MO[A)-NQ=JQ[APN>XS7/I\/9Y?!FFVS2):Z[IX9H+F)NAW%@I/<<_A3IU(Q4E
M)ZWW^_452G*3BXK2VWW:%GXAV%KIGPUN+.SA2&"(QA44=/F%0WOPZT&7PZ+F
MR@:RO4MQ+'/%(P(8+GGFKFLZ1XA\0> I=-O8K9-4)0%DE^1\$'=TX^E49=)\
M>ZM9+I=W<Z=863((Y9+?+.5QC ^H^E$)-124[6;OKZ?>$XIR;<+W2MIZ_<,M
M?%U^WPADUDL3?QH8/-(ZMNVA_K@Y^M6_#WP^T*30;>;4K47UY=1"6:XE8EBS
M#/!SQUK?C\+Z='X4/AT(WV,Q&,G^(GKN^N>:YFRLO'WA^T&EV2:?J%K&-EO<
M2N59%[9'?'XTE-235-\NOIH4X.+BZBYM/74/!B2:3XGUOPH9GGT^!1+;B0Y*
M*V,K].?TK @U1_#7A'Q5H0;$]M<F*V4==LIP/TR:[GPCX7GT5KS4-2N1=:M?
M-NGD7[JCLH]JQ]?\"3ZKX_L=8C,8L04>Z4M@EDSCCOVJE4@ZC4GII\VO\]2'
M3J*FG%:Z_)/_ "T.=T:^N/!?A[Q1HMU)BXMHEE@)XR9%"\?0D5J:MI0T?X)&
MU*A9#$DDG^\S G^=7O&7@2X\0^*--U"W:-;<;4O S8+*K9&!WXS70>,M'N=;
M\*W>FV03SI0H0.=HX8'^E-U8N47?=IOY?TP5*24U;9-+Y_TD<AX.O[GPY(OA
MC4Y2\%U;?:-.G;HP9<E/Y_Y(K7^%/_(EK_U\R_SJ[K_A+^W/"=K8EA%J-I$A
MMYE/W)%4#KZ'%/\  6A7OAWPREAJ'E_:!*[G8VX8)]:BI.$J;:W;7ZZETZ<X
MU$GLD_TT.GHHHKC.P**** "BBB@ HHHH I7W_'Q8_P#7;V_NM5VJ=[_Q\677
M_7?^RM5RF]D);L****0PHHHH **** "O-IM(L/%'Q7U.'4(%GM[*RC7820-Q
MP>WU->DUYRNA^,]-\3ZUJ6EPZ:RW\@(:>0DJHSCI710=N:SL['/B%?ENKJY7
MN-)@\&_$30X]$:2*WU(M'<6N\LI [\_YXK+^*:W%_P"*X8[0XDTVP-V3[;__
M *P-=IH'A.\AUAM>\07JWNJ%-D:H,1P+Z**$\,75SXTUG4[Q8OL=W9"UBPV6
MP0 <CMWK>-:,9J3=VEOW,)492@XI63>W8Y_QGXFDUCPY8Z7ID@$U_:?:KIP?
M]5"%R<_4C'X59\+_ /$H^#,MR<AGMIY?Q.0/Z57T;X>:AI7A/682T4FK7L?D
M1$O\J19Z9]^?TK?U+PY?O\-D\/V7EFZ%O'"=SX7C&[G\#1*5-)4XO2X1C4;=
M22UL>86MKI%]X0MK"P\.W\^OR@;;I8F502V<[LX(Q77?$:2;3O!V@6%WNN)O
M.B\X*<F0HOS?6O1-+M/L&DV=G@#R(4CXZ< "L'Q!H-[JWBK0+Q!&;&Q=I)@S
M<Y[8'?I26(4JB;V5V-X=QIM+=V6QA>'--/CN6/Q%K<\<UK&Y%KIT;9CBQ_?]
M37HJJ%4*H  & !VKB;;POJ?AWQ<]]H/E-I-X<W=H[[=C>J?S_2NWK"O)-KE>
MG3R-Z$6D^9:]?,\V33X_&GQ"U6+5BTFGZ3MCAM=Q"LQZL1^!_2NIT[P7HFD:
MS_:FGVS6TOEF/RXW(C/OM]:R]9\-:Q9>(G\0^&98!<SJ$NK6?A)<=\^M6-%C
M\976M+>:Q):6=BB%?L<'SESZD]OSK2<FXWC*RMM_P#.$5&5I1N[[_P#!,&WT
M^+QMX_U<:N6EL=)98H+3<0I)S\Q'X'\Z9XPT*T\&FR\1: GV*6*X2*:%&.R5
M#VQ6OJ_AK6;#Q'+X@\,2P>=<*%NK2?A)<=P?6JS>'?$GBK4K27Q-]EM=.M9!
M*MG;MN,C#^\?2M(S5U+F]VVW_ ,Y0=G'E]Z^_P#P2C\6+6358?#]M!\LMQ.R
MIGU*C%,E\7SW/PSB@0G^V)Y/[,*9^82="?\ OG^==1XKT&]U?4M!GM!'LL;O
MSI=S8^7CI^594'@%HOB0^N%D_L[)N$BW<B8C!X_7-*%2G[.*ETU_';YCG3J>
MTDX]=/PW^16^$ELUEH^L6KD%X;YHV(]0H%<1I;>'WT?58+W0[V]U)[B40RV\
M3$#^Z,@\8/M7JG@W0+W0DU<7GEYN[UYX]C9^4],^].\#:%>^'])N[:^\OS);
MN29?+;<-IQC^5-UTI3E?>W42H.481MM?H<SJ=KJ%E\$F@U3=]J6-<J_WE7>-
MH/N!BLS0F\'S/IL1\*:D+EO+'GF)MF_CYL[NF>:]"\9:3=:YX6O-.L]GGRA=
MN]L#A@>OX5@V:_$2TMH+9;;1S'$BQ@F1LX Q2A4YH/6S;?6P5*?+-:722Z7+
MWC7PQH]_I.I:I<V2R7L5H^R4L01M4D=ZI?#SPQH\7A_2=92R47YB),VXY))(
MZ9QTKJ];LYM0\/WUG%M\^>W>-<G W%2*K^%=-N-'\+Z?I]UM\^"/:^PY&<D]
M:Q]J_8\M^OX6-W27MN:W3\;G,^%5#?$GQ@"."8@?RK&\7^#]!T[7?#<%KIZ1
MQ75V8YE#-\Z\<=?>NNT+0+W3O&7B#5)_+^S7Q0P[6RW YR.U+XHT&]U?6= N
MK7R_+L;GS9M[8.WCIZ]*TC5M5NGI;]#*5*]*S6M_U&:QH6FZ#X%UV#3+5;>.
M2UE=E4DY.PCO61#JT^B?!:VOK4XG6T54;^Z6;&?PS78>(+*;4O#NHV-OM\ZX
MMWC3<<#)4@9K-TWPT&\!V_A[5 I/V;RI?+.<'U!]N#41J+E7/KJ:2IOF?)IH
M96@?#W07T&"74;47UY=1"6:XE8EBS#/!SQUJ'P.9M&\4:UX7$[S65J%FMMYR
M8U./ES^(_*FV5GX^T"T&EV::?J%M&-EO<ROM9%[9'?'XUM>$?"\VB&[O]1N1
M=:M?-ON)0/E'HH]JN<O=ES2O?;^NAG"/O1Y8VMO_ %U/.HSJ.D>*]?\ $]@6
MDCL;\QW=N/XX6)R?PQ74"^M]2^*^B7UJX>"?3&=&'I\U;?AOP]<Z=J7B&6^2
M)H-0N2\:@[LH<]1^-8>@^ ;[0?'HU"&5'TB-)!"K/\T88?=Q]36DJD)7N]4O
MOT(C2G&UEHWKY:GHM%%%>>>@%%%% !1110 4444 %%0W-W;V4!FN9DBB!P7<
MX%4?^$DT3_H*6O\ W\%-)O8F4XQ=FS4HK+_X231/^@I:_P#?P4?\))HG_04M
M?^_@I\LNQ/M:?\R^\U**R_\ A)-$_P"@I:_]_!1_PDFB?]!2U_[^"CEEV#VM
M/^9?>:E%9?\ PDFB_P#04M/^_HH_X231?^@I:?\ ?T4<LNP>UI_S+[S4HK+_
M .$DT7_H*6G_ ']%'_"2:+_T%+3_ +^BCEEV#VM/^9?>:E%9?_"2:+_T%+3_
M +^BC_A)-%_Z"EI_W]%'++L'M:?\R^\U**R_^$DT7_H*6G_?T4?\))HO_04M
M/^_HHY9=@]K3_F7WFI167_PDFB_]!2T_[^BC_A)-%_Z"EI_W]%'++L'M:?\
M,OO-2BLO_A)-%_Z"EI_W]%'_  DFB_\ 04M/^_HHY9=@]K3_ )E]YJ45E_\
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M[^BC_A)-%_Z"EI_W]%'++L'M:?\ ,OO-2BLO_A)-%_Z"EI_W]%'_  DFB_\
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M;F[M[* S7,R11 X+N<"J/_"2:+_T%+3_ +^BA)O84IQB[-FI167_ ,))HO\
MT%+3_OZ*/^$DT7_H*6G_ ']%/EEV)]K3_F7WFI167_PDFB_]!2T_[^BC_A)-
M%_Z"EI_W]%'++L'M:?\ ,OO-2BLO_A)-%_Z"EI_W]%'_  DFB_\ 04M/^_HH
MY9=@]K3_ )E]YJ45E_\ "2:+_P!!2T_[^BC_ (231?\ H*6G_?T4<LNP>UI_
MS+[S4HK+_P"$DT7_ *"EI_W]%'_"2:+_ -!2T_[^BCEEV#VM/^9?>:E%9?\
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M4IQCHW8U**R_^$DT7_H*6G_?T4?\))HO_04M/^_HI\LNQ/M:?\R^\U**R_\
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M:/\ A$]$_P"?!/\ OH_XUM44<\NX?5Z7\J^XQ?\ A$]$_P"?!/\ OH_XT?\
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MHG_/@G_?1_QK:HHYY=P^KTOY5]QB_P#")Z)_SX)_WT?\:/\ A$]$_P"?!/\
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MN1]15JBI<Y-W;&H12LD<M;?#KPQ;2I(-/:79]U9IGD4?@3BMJ_T:PU(6BW,
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M2^*!>7UT%BU!MMM!.8P"?XSCKZ?A7H>FZ99Z/8165A L-O']U!^I)[FL2[\
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MG6C&/*U_6EBZE&4I.2?]:W/-;>P@TJQ\?V%NN(;>T2-1ZXA//XU!JVE:G;>
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M(C.>?2M'5](C\.^$X?$NGZU>OJ:B.3S9+@NET6(RI7I@Y[5W\&C6%O/J$R0
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MCD]/:IE6@W=_UI8<:-2*LK?T[G-:!I$?BO2[G7-4U>]BOC<2*&BN#&MH%;
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MKEU&.2XM%AXPJYQZUHHIHS<G<[V)]Z@T^JED<Q"K=9F@4444 %%%% !1110
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M=1112&%%%% !1110 4444 %%%% %.]S]HLO^NWO_ '6JY5*]_P"/BQ_Z[?\
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M79M=M%4[KB$?\#%><?$"\MM0L8WM[A'E@DW;5YR#UK/70M>D.&EM8L^LI/\
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MH)KL8/AS2I=/M0LS[Y6.6(Z?05TJ\"FK&%Z"GUFW<U2L%%%% !1110 4444
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MT/\ ",T 9V:,U>:W0^HJ,VH[$4 5<T9J<VK?YYJ,PN.U #,T9H*L#C'Y4W-
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M=(__ $-:N54U+/V(X_YZ1^O]]?2K=/H+J%%%%(84444 %%%% !1110 4444
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M*@[);R[>2\_R.R-*-*'M*V[V7ZOR.A@8LH)]*GID:;%Q3Z]$XPHHHH ****
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MFI-2QP+&.!6\L3-QY3&.&BI<S""/RT J:BBN<Z HHHH **** "BBB@ HHHH
M**** *5[_P ?%C_UV_\ 96J[5*]_X^+'_KM_[*U7:;V0ENPHHHI#"BBB@ HH
MHH **** &2#*&O-_%\;6FO:?>D?NV#0D_P"T#N'Z9KTL\BN?\1:+'JVGRVTF
M5W<JXZHPZ,/I6E*?)-2,JU/VD'$X^&<:;K:RR'_1[E5"OV##I^8KL5O4^SX#
M C%>?B[DT[.E:[!@=$D_A<>JGO\ 3J*F;48K*T:.UN>&'WW/*CVS64<!6C7E
M*E9PEKZ,/KU+V*C6NIQT]403J]]KNHB.0JKS!5(YZ "NBT[P39-A[D273?\
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M5C)5U);W_ ^E8'WQ@^U$ENK]:2V7;$,^E,N;I8E/->:>D1_98H^3BG?:8H^
M17!Z[X^@MG>&RVSNO#2$_(O^-<D?%&NZDQ^S"ZF!_P">*87\_P#Z]=,,--KF
MEHO,Y)XR$9<L4Y/R/:A?1D]:F2='Z$5XK%J_B6R_>2V%]L[G!;^1-=#HGCB&
MY<13/Y<@."'XP??T_$4WA6U>#3]"5C8IVJ1<?4]-SD<5@^)(=2GL3'IFWS6;
M#DG!"^U6;74E=1DU+-J$*C+, /4FN.I3YHN#TN=U.:34UJ9>B:"MA$-^'G(^
M=_Z#VKHHXPBX%4+?489?N,K#V-:".'&14TJ4*45""LD5.I*I)RD[L=1116A
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 444UV"KF@!V:,UAZAKEO9$"1\%ONJ.IJ:RU-;@ C/T-.SM<5UL:U-*(W
M50?J*53D9I:0R(VT1_AQ]#4?V-,]3CZ"K-% $0MHA_#GZFGA$7[J@?04ZF22
M!!DF@!]%4_MR;L9&:LI('&10 ^BBB@ I-PJK=W*P1EB0 !DD]JY^V\30W<S+
M"&9%_C]?PII-[";2W.KHJI:7(F4$'-6Z0PHHHH **** "BBB@ HHHH ****
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M&-Z]11N8QKU*TFL/3<K=3V7^U8MF%93]#FO.O&OBF2:9],M)"JJ/](=3R?\
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M110!3U/_ (\C_P!=(_\ T-:N54U+_CR.,_ZR/IG^^OI5NGT%U"BBBD,****
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M2[M[L6BBBLC<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$)QG\JH6^OQ6H86GF_,,$J":VA0J1U<U]YS3Q-*6D8-_(])TW63;-Y3NIDC
MWX/7WJ[J'BN".V)>0>P!R37F4<NH3LLT6GSEF'#GCC\34HM=;E.%LD3_ 'W
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !65J]R+:UEE/2-"Q_ 9K5K#\0P-<:;<Q+]YXF4?4@T S@]#LSJ+1RW
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MS8Z9]GAN;!"1]HB"EB./3.<=Z?LZ<I-+]?EOU_ 7M*L8IO\ 3Y[=/Q.ZTCQ
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MXO!=BWCA20+"R29+*1_%Z'/:K$5S!.[I%/'(R<,J."5^OI7FNN()M.\6Q,Q
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MVJJC  ]!3Z@%[:EW07,)=/OJ)!E?KZ5/0[]05N@4444AA1110 4444 %%%%
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M*FI248W7_#E4ZKE*S_X8Z:BBBL#<**** "BBB@ HHHH **** "BBB@ HHHH
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M;2&X83QJ]T+21'CVM!*>@<'IVY]ZNW.MV=KJJ:=*S"8V[7+MCY8XUZECV_\
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MZ"FNR*A+E0O<L>*P+WQA96FJ2:9%:7UW?(BOY-O#NRK#.<]!^-9?B36[36O
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M\4"#X?V^JS RW2QB 1_Q23@[ OU+"K5*<-5O>Q#JPGH]K7.L(!&",CTH  &
M.*\ML;C4M/\  ?BNZO;Z62\^TO")-YPC< [?0 L>GI4B-81ZEHZ>&-6OKO43
M/']I03O+%Y7_ "T+YX'M3^K[ZB^L;:'IQ /4 _6EKSG3/$5_=:WKFF:2?/U&
M6^?#SL?*M85PN['?G.%'XUV>C:0-'M'5[JXN[B0[YIYG)+M[#HH]A6<Z?)NS
M2%7GV1I$ ]0#]:H:O97=]:*ECJ$EC.CAUD50P./X6!Z@U@:1XQFO-8U:VN=.
MO8X+9_D8P8\M0FX[SG@GM5NS\:65_92WMO8ZD]HB!EE%L2)"3C:HZDY_"CV<
MXO8/:PDMQ;/0-2FU:VU'6]1BNFM-WV>*WA\M%9A@L<DDG''XUT=8=CXHMKR:
MYMY;2\L[F"'SS#<Q[6:/^\O/-4K;Q[IER+69;6_6RN76-+QX,1;SP 3GUXST
MIRA4ENMA1G3BM'N=0%"] !GTH"@= !]*Y^]\7V=GJ$]HMI?7(MF5;F6WAWI"
M6Z ]_P JFU+Q-:Z?>K8Q6UW>WA3S6@M8MS(G8MT J/9S[%^TAW-ND*@XR <=
M*YRZ\:Z=;0V3&WOGEO5<P0);GS&*G!7;V/Z4U-;L+.?6-1G>_5H((9;BWEY$
M((. J^OK3]E+L+VL>Y=72YQXPFU1MAMGL5MP,\[@Y;IZ8-;(  P!Q7,Q^.-/
M8Q2R6FH06,S!([V6W*Q,3TYZ@'U(J$>++@>-)=(.FWC6RPJ0RP9.XMC?G/W,
M=ZITYO=;$JI36SW.LI-HW9P,^M4M8U>UT/3)=0O"XMXL;BBY(R<=/QK*_P"$
MQM!:QRM8:@LD\A2VMS!^]G &=RKG[ON<5"A)JZ1;G%.S9T>**Y>\\81+H>HW
M-M9W@OK1?GM9(?WD9()5F&?N\=13[#Q7YOA^VO[C3=1,TH1!$EL29&*YRHS]
MWW-/V4[7L+VL+VN-FT7Q(&GAMO$2?99F8[IK8-+$#V5@0..V16WI>G0:1I=O
MI]MN\J! BECDGU)]R>:QY?$-CJ>A:MYPOK%K2,BYC*[)X@1D%?J.AI]UXHLM
M*DLK 0WUU<SVPE@2*/>\B].3Z]SFJ:G)6L2G3B^:YT-%8=MXKTR?1[G4I&EM
MH[5S'<1S)M>-Q_"5]>1C'7-)I_BFVO;Z*SFL[ZQFG4M +N'8)0.3@^N.<'FH
M]G+70OVD=-3=I%=77<C!AZ@YKG+CQG8I-.L%G?W5O;L4GNK> M'&1UY[X[XJ
MCX0U6&R\'Z6[1SRK=7+QH8HRV-SL06]![U7LI<MV3[6/-9,[*BH;NYCLK.:Z
MESY<*%VVC)P!DUS\'CC39["2_-O>QV0"^5-)"0)V8X"QCJQJ(PE)72+E.,79
MLZ:D5U<$JP8 XX.>:Q-.\46M]J"V$UK>6-W(I>*.[BV>8HZ[3R#CTK(\.ZM:
MZ-X9NKJ[9]IU*X1$12SR,93A5 ZDU7LI6)]K&_D=G16/I?B*WU*\:R>VN[*\
M">8(+J/8SIG&Y>Q%+XAFMH;6T:ZN+J%6NXE0VS8+,6X!_P!D]ZGD?-RL?.N7
MF1KT5S5UXULH+Z\LX;+4+J:R;%P+>#<$&,YSG_Z];MA?6^IV$%[:OO@G0.C8
MQD&APE%7:'&<9.R98HHHJ2@HHHH **** "BBB@ KS"":TTOQ)XA.J>&;Z^\^
M]+PRQV/FKMQV)KT^BM*=3DOIN9U*?/;78\[U>7_A*-*M- TG0KFRCGEW22W-
MH8EM44YW#MN/:L35EN])\#7'A^[TT^;97D1BE6,^7=J7R#G^\>XKU^L;Q/HL
MFO:2MG%,L3">.7<PR,*V<5M3KI-1:TO<QJ4&TY)ZVL<GKFHS^+[*TT6RT34+
M:X%Q&\TEQ!Y:6P4Y)#=SV&*R-?.K7EQK=IJ":\]SN9+*WLDQ;O'CAF(Z^^:]
M<HI1Q"CLARP[EO(X#1+"Y7Q)X:FEM)52'1/+9VC("/Z'T-4-4T#4K^;Q:+>S
M=B;ZVN8HW7:MP$7+*#T->G44EB&G=+^KW&\.FK-_U:QYEXJUV7Q'I-K8V/A[
M5!*ES$\K2VI408/;U]..U+K^FWTL?CH16=PYN%MO)VQD^9@+G;ZX]J],HH5?
MELHK^KI_H#P_-=R?]6:_4X[Q!8S._A(06TC"WO(R^Q#^[79CGT%9VDW5[X/D
MU/3KG0KZ]-Q=23P7%I%O68-T#G^$CWKT*N4N?!MR;JYDL/$>I64-RY>6%6#C
M)Z[2W*T0J)KEEL*=)I\T=RM\+RS>%)6>(1,;V8F,=%.>GX4S49I=*^(_VR6R
MO);:[L5MXY+>(N ^_OZ>M=3I&DVNB:9#86:E88AU8Y+$\DD^I-7JF55>TE*V
MC*C2?LXQ;U1YOHVI7'A+2;O0K[1-0N;KS93$\$&]+D,3@ENWOFJ7_".ZG>>'
MM)\(M:F.4$W5S>-&2EJ"Q(1&[MSC@UZK15?6'>Z6N_S)^KIJS>FWR/+9(=0'
MA.UT&729H[K3=0@!,,)\N9 W^L4]_>M6*\F\(^)];EO=*O;F#495G@N;2'S,
M\8V-CICM7>T4.O?1K1C5"UFGJBGI5R]YID%Q)9263.N?L\@ 9/KBN ET#4M1
MT7QA:Q6[K+-JIGA20%1,H*G SU!QBO2Z*B%5P;:1<Z2FDFSSG6=2G\6Z;9Z)
M8Z)J%M<^=$TLEQ!Y:6P0@DAN_3 Q4UI>S>#]<UM;[2KZZCOKC[1!<VL/F;QC
M&QL="/ZUZ!15>V5N6VA/L7?FOJ<58I=W?C^RU%]-GM(7TG:5=>(VWD[21QG'
M:KOQ M;BZ\*O]F@DG>*>*4I&,L55P3@=ZZBBI]K[RE;8KV7NN-]SB(9GUGQU
MHNJQ6-W':K93+NN("A5L\9],]JQ/$4NJ7&M:Q;7Z:[@C;I\.G)B*52O5F'7G
MKFO4J*J->SO8B5"ZM?K<\ABDN-&?P/)-IEQ<2V]K-YENL?[Q1W(4]QUKI+>6
M?Q1XWTW5;73[NTLM/BD$DUS%Y;3%A@( >2!UKH+[1);OQ3I>K+,BQV<<J-&1
MRVX=C6U5SK)I-+6S_%LF%!IM-Z77X)')^-K.:\N/#PBMWF6/4XWDVH6"J,\G
MT%"V4W_"TWO#;/Y/]F;!-L^7=O'&?7%=9162JM1MZ_B:NDG*_I^!Y6^B:D^F
M7\\6GRRFT\0&]^RLN//C']T'KUS6K>7LWC'7=#%AI=_;16%T+FXN;J'RMH ^
MX,]2:[^BK=>^MM2%A[:7T//+#0;V]\$>)+!(&M[JZO+AH_,7;O&[(_ XQFL.
MVL9-1CT_2YH?%$D\<D8EMYMJ0P;>K!L8P.U>OT4UB6KZ">&3MJ & !1117,=
M(4444 %%%% %/4_^/(_]=(__ $-:N54U+_CR/7_61],_WU]*MT^@NH4444AA
M1110 5Y]>^&M3/BK4_$%E#FZMIXWMH9N8[A/+ 8#T;T:O0:*TIU'"]NIG4IJ
M=K]#F;*.ZO?%]OJTEA-;Q-I9C(F !CD\P':??%95[X=U"]M?$D<4 62748[J
MV63A9M@0X^A*D5W=%-56G="=)-69Q>I3:CXJ%A8+HMY8K'<QW%S/=!0L80YP
MF"=Q)XS3K6;4/#%_J\+:-=WT5Y=O=V\UH VXOCY'R1MP1U]*[*BCVNG+;07L
MM>:^IY]JWAK4]9\2R:LD'V>Y@M8);=)B'A:4%BT;>O7KVJY/)JLFI:5XE.C7
M!>&&2VNK(8,B;B#O3G##(_$5VM%/VST30>Q6K3W.%,6I>(/%JW3Z5<V%B=.G
MMEFG #EFQR0#Q[4V*?6+?PG_ ,(W_P (]</?+ ;191M^S,N-N\MGTYQC-=TS
MJ@!=@H)QR<<TZCVVRMH'L=W?4\^USPOJ<0TB#3MTHDM%TR^E':(%3O\ T8?C
M4\'AR]B\<I$MOMT."4W\3#H)B@3;^!RU=U13]O*UA>PC>YR6EZ7=P^%-=M9+
M9EGN+B[:-".7#D[3^/%;F@P2VWA[3H)D*2QVT:.IZ@A0"*OLZH,NP49QDG'-
M.K.4W+<TC!1V/*=5TS6M0T_4;>\T[6+O5GE;8XEVVJQALKM .#QVQG-=EI5A
M<Q>+[^\EMV6&2QMXTD/0L,Y'X<5TE%7*NY*UOZT_R,XT%%WO_6O^9P4FA:F-
M-DGAM"]Q::V]_';,0OGIGL>F<'(^E2ZG=ZEK^J:)Y&@WMO;VMZDT\URJJ5P"
M,*,G(YY-=Q11[9[M#]BK63,CQ5;3WOA74[:VC:6:6W=41>K$CI7+:IH=U;ZS
M:ZF]MJ<]M)8QV\JZ?,4EB=?49&Y3G\#7H%%*%5P5D.=)3=V<58>&DO\ PUJ\
M#V-W92W[94W=QYLI91\CG^Z<CI[5%IF@ZIK.B:S<ZO']EU/48!:HIY\M$7 _
M!FR3]:[JBG[>6HO81T_K^NIYG:Z-+<16>G76BZ\\J.BS^;>D6R;2/F5LG<.,
M@8KKM#LKFVUWQ!/-$R17%Q&T3'^,", D?C6Z2 "2< =2:%974,I!4\@@\&B=
M9R5@A147<YG7+:]LO$UAKUM9R7T,4#VTT,6/,4,00Z@]>F"*AL8+[5O$MSK<
MMA-8VZ61M8(YP!+*2=Q8@'@#H*ZVBI]H[6MY%.GK>_F8GA"TN+'PGIUK=1-%
M/''AT;J#DUS/B6SNO[8O;C3=)U:WU1@HM[NRE!AG../-!.!CIR.E>@T4XU6I
M.5MQ2I)P4;[' 6NHW^E^-]6EETR>^W6MJMRUHH9T?8>BDC*DYIM]I.JZIIOB
M/4CI\D$NHB&."T)'F;8R/F;' )YX]JZZTTG[+KVHZGYV[[8L2^7C[NP$=??-
M:=6ZUG>*[?A8A4;IJ3[_ (W.2U+1+O4=?OU"-'!<:*;43=A(7/%/T35]3@M[
M#29_#MY'<1!89I05$"JHQO#9YZ=,9KJJ*CVEU9HOV=G=,X./1=0_L:.!K-]X
MUXW!4C_EEYA.[Z8K8U?3+B\\66$J1N+<65Q#),/X"V,5TE(RAE*GH1@T.JV[
M^OX@J*2MZ?@< MQK6C^#YM"?07DDM[9XENE=?L[1@'YR<Y'';'6NG\)#'A#2
M!_TZ1_\ H(K/;P/;-$;7^U-4_LYB2UD;C*$9SMSC=CVS73QQI#$D4:A40!54
M#@ =JJK.+5EWN32A).[[6'4445@;A1110!3O?^/BQ_Z[?^RM5RJ=[_Q\677_
M %WO_=:KE-[(2W85D3>%]'GUZ/6I+)&OTQB3)ZCH<=,UKT4*36S!Q4MT%%%%
M(9SGCFWN[OPO+;V=M+<2/+%NCB&6*!P6_056N-8\0:G"UGI6A3V+.-OVN^95
M6(=,A022?2NLHK2-2RM8SE3O*]SCF\-M877A?3[2*26SLII)YYS_ ']IP6]R
MS&J^E>&+V/Q=>/=+_P 2>TN6N[*/L\L@&3_P'G\37<U1?6-.CCN)'NXPEO((
MIB3]QSC"GWY'YU2JS>G];DNC!.[_ *T.,30]2D\&6EE):2"XNM5$]RA_@3S2
MQ)]L 5WJQQP(WE1*O?"*!FI*@N;RWLUC-Q,L8ED$2;OXF/05,IN94(*!PUIX
M4U ^&+.^@'V3Q%;2RW"%N-VYR3&_J",5V>DWD]_IL-Q=6<EG.P_>02=5;O\
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M!!VCBL9?PDGNF;1_BMK9HOT445@;A1110 4444 %%%% !1110 4444 %%%%
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M5HQD.H6N^"%9MJQ *#@DCH >M1:9X:U&+4]3O'L;"QBNM/-M%;VS9V-DXW'
MSUZU=T_P]>VUWX;ED,6W3K)X)\-_$54#'J.#0_9K^O+_ #!>T:_KO_D7]"UN
MXU*XO;*^LA:7UFRB1%DWJP895E/I6U6/9:9/;^)M4U!RGD74<*QX/.5!SG\Z
MV*PG:^AO"]O>"BBBH+"BBB@ HHHH **** "BBB@ HHHH **** *5[_Q\6/\
MUV_]E:KM4[W_ (^+'_KM_P"RM5RF]D);L****0PHHHH R]=UI-$LXY/(>XN)
MY5AM[>,X,CGH,GH/>J'_  D-_I]I>7.O:4+2&WB\T2PS"57YQL['=^E6/$FD
M7.IV]I-8R1QWUC<+<0>:#L8@$%6QV()YJC>:=K7B72[_ $_5K>TL;>6(+%Y<
MAE;S <ACP!MXZ=:V@H<JO\^YA-SYG;Y=AMOXLNX[NS75-,CM;:\D$44D=TLC
M(Q^Z' Z9]1G%8&H?\@CQ5_V&8O\ T*.M+3/#5XE_9F?P_H=JD#!I;B/+M)CI
ML&!MY]:GN_#%_-8:Y"IAWWNH)<Q9;^ %"<\=?E-;)PC+3R_,R:J2CKY_D;UM
MJXN/$%]I7DE?LL4<GF;OO;\\8]L5S>LZK_:]A8R>3Y7D:^EOC=G.QB,_C6A>
MV&M6/B>XU72K>VNX[NW2*2.:4QF-E)PV<'(P>E4+3POJR:-;6]T]N]TNL?;I
M61B%*[LG''7GI414%:5^W_!+FYN\;=_^ :6N>(=3TN><Q:5 ]K"N\R37BQM*
M,9(1?;WJ*\\7R^9I,6EZ8][)JENTT(,@0)@ _-GMS67J/A;5)M6U>46&GWWV
M[_47=W(2;92N-H3!Z=1C%:6E>';ZSN_#LLIBVZ?8R6\V&SEB%QCCIP:=J:2?
M];?YBO4;:_K?T[&^]U-;Z0]W<PJLT<!DDC1L@,%R0#_6N9M_%^L7&DIK2^'&
M_LSR_,;_ $@>=M[LJXY ^N372:S_ ,@/4,_\^TG_ *":X[1X_%=QX-L]-AAL
M#%/:(B7S2D%(V7NF.6 ..N.*BG&+C=I;EU)24K)O8UKSQ9</J=I8:-IOVY[N
MT%U'(TH1%0GJW%-3Q1JM\)Y]*T,7=I;L8Y)&N AE=?O",$<@'(R<9J?3?#DF
MF:[:31,K6=OIBV8)/S%@V<XJI::=XCT"*YT_2X+*ZM))7DMYII2C0[R20RX.
MX GC%5:GLK?,F]3=W^19E\8136&FR:7:27EWJ6[R+<L$V[?OER>@7O3IO$MY
MINF33ZMI1@N%E2&".*976X=N@5N,>^>E44\)W^DVNCW&ES0SW^GB02K-\J7
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M#F$3!1J$H)+(#U,>/O8]\5N-INLZ+K-[=Z1;VUW:WVUW@EE,312 ;<@X(*D
M<4Y1I7]W^OQ)C*K;WOZ_ @\%W4E[J_B2>:UDM93=H'AD()0A #R.H]Z["N<\
M+:3JNGW6K76K/;M/?3K*/()VJ N,<^G2NCK&JTYZ?UH;T4U#7S_,****S- H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M *FI?\>1Q_STC]?[Z^E6Z;)&DJ;)%#+D'!]0<C]:=3OH*VH4444AA1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %.]S]HLO^NWO_=:K
ME,>))&1G4$H=RD]CTI]-L204444AA1110 4444 %%%% !1110 4444 17,"7
M5K-;R9V2HR-CK@C!IEC9QZ?86]G#N\J"-8TW')P!@9JQ13N[6%97N%%%%(84
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5+5-+M]7M5M[DN$65)
M1L.#N5@P_45=HIIM.Z$TFK,****0PHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **0L!WH!!Z4 +1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444F1ZT +1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#'--U/Q*H"1V4=QDW<=N;@19CW;P&7/YC/3-/V4A>UB=+16(_BJP0LS1W/D
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M>*9'X56.RF@^V$M(%7<;>/&T=B,<Y[TL&MWFIR2?8K2+[-&B&5I9,/EU#?*
M.P(Z]:J:7KK6F@L&CWFTT]+C<S\N3GC]*K]X3^[OL:;^'H6\/1:0MS.B1[2L
MRD;P5;<#Z=14+>&O,D:ZFU"=]0W*T=UM4&,+G "XQCYCGUS6;K&L7U[IUP]O
M;Q+9QW4<#2&4B3(=<D#&,9.,9R:F37KT8AL;-96V3S,UQ.> C[<#COV]*:C4
MMN)RIWM8N?\ "-;=DT>H7"WHE:5[G:I+EEVD8Q@# &/3%.M_#%M;V$EH+B9E
M>U6V+L1NP"QS]?F-4I_%5VUI=7EE8Q/;VD"2S"6;:Q+*&PO'8'J>M:FH:I-
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M=VPD?;L)W%=R_P!TX/(]C5^BES-.]QN*:M8S7T#2Y'A8VB@Q*J*%8@;5^Z"
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944 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>img224999359_21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_21.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +;!98# 2(  A$! Q$!_\0
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MGUHY]:**  44@Z4M !1110 4444 (.II:0=32T %%%% !1110 4444 %%%%
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M%_"6G^%89X["25UF8,WF-GI7GMC\'I+O3[:Y&O.GG1+)M\D\9 ./O5Z#X/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC2OR]0HHHK(U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M (.II:0=32T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 @I:0=*6@
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M[R@"&"[@N7F2&57:%]D@'\+>AJ5F"*68X4#)-<]X:_Y".O\ _7^W\A6Y=_\
M'E/_ -<V_E0)Z(H?\)-HO_01A_6D_P"$FT7_ *",/ZUY-N]Z-WO77]7B>1_:
M53LCUG_A)M%_Z",/ZT?\)-HO_01A_6O)MWO1N]Z/J\0_M&IV1ZS_ ,)-HO\
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M_#7_ $&+?]?\*^?]_O1O]Z/J4.[#ZU+R/H#_ (3?PU_T&+?]?\*/^$W\-?\
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MVEZ4?LUM!\A:/@L>_-9NF^*=2T^X#/<//">'CE.X$4)S:ND-JA&7(V[]^AE
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MV"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!!TI:0=*6@ HHHH
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M36-3O8=-TYX[AU:2/+D'K7+[LG-="9M+U+2K..YO3;RVZ[67;G-<X3R<=.U
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MC<X\2R_[B_RJG?W6AI=VDNDPW2+&^Z7SN<CVYK:U#6_".J7AN[NTOWE( ..
M<?0T]FFD2O>A*$IJ]T[G/:+9S:AK%M;P*2V\,3Z ')-=K)J,'_"R57>,"+R=
MV?XL5B2>+[/3[5[?0--6U+\--)RU<IYTGF^;O;S-V[=GG/K0XN;N] 5:-!*,
M'S.Z;[:=#3UZUELM;NX95(/F%AGN#WK.&6(4#)/ %=6GB72=9M8X?$-HQFC&
M%N(>I'O2P:GX4T5C<6-O<7ET/]7YWW5--3:5FM29482ES1FN5_?]Q/XE'V'P
M[HFGRG_2%PS+GD"JGCHXU>V_Z]EK U'5;C5=1-[=-ER1P.B@=A747^N^%-5D
MBFO;6_:5(PGR\#C\:E1<;.U]S252-932:6UK]D<M86TU]?P6T"EI)'  '\ZZ
MKQ;/&?%&FVR,&:W5$<CUR*@_X2W3=+@=- TL0RN,&:8Y('^?>N8CNV.HI=SL
MSMY@=SW/-59R=VK&;E"E#DB[MM7[:'>W.HK8_$%XI3^XN8UB<'IR.*98:9_P
MB[ZSJDZX6',=MG^+/3'Z"N4\1ZM#JNM/>VH=$(7;O&""*O>(?%?]M:596B*Z
MF,;IR>C,!@8]N]1[-V2[[G1]9A>;>Z;<?G_5RXLC2_#NYD<Y=KO<Q]237) _
M,/J*UX]:MU\(R:25D^T--Y@;'RX^M8@;!!]ZU@K7]3CKS4N6SZ(Z[QP?](TW
M_KT6N5S6OXDUFWUB6S:W611# (VWC&2/2L3-%-6BDQ8F:E5;B]"3-&:CS1FK
M,+GJ_P /_P#D6C_UW?\ D*G\6_ZG3/\ K_B_G5?X??\ (L_]MW_I5CQ;_J=,
M_P"O^+^=>;5^-GU>$_@0]#HJ\P^-9QH6F'_IY/\ Z":]/KR_XV_\@#3?^OH_
M^@FM<)_'B&+_ (,CQ7?1OJ.BOH;'S]V2;Z-]1T46"[)-]&^HZ*+!=DF^C?4=
M%%@NR3?1OJ.BBP79)OKTSX>:C)I?@CQ-?1(DCP[&"R#*G@]17E]=5H'B6STO
MPAKNDSI,;B_"B)D4%1@'KS[UCB(<\+)=5^9OAY\L[M]'^1H3_%/7I+=HK9+6
MTWC!:&( _G5SX63//KVJR2,7=K*0LQ/)-><UU/@?Q)9^&M1O+B]29TFMFA7R
ME!(8_4]*BK1BJ4E!:LJE6DZD7-Z(Z7PPW_"5^ M5\.-\UY9,;BT'<C/0?CD?
M\"I?$;?\(MX%TKP^OR7EZPN+H=P/0_I7'>$O$)\->)K?4L.T()65%ZLAZTOB
MSQ$?$?B:;4P'$.0(D;JJ"H]C+VMOL[_/^M2_;1]E?[6WR_K0[3QM=QV7CGPW
M<RD"..*!F)[#(R:R_BQ936_C!KX@FWO8D>)^QPH!'Z?K61XW\1VGB2_LY[-)
M42&V6)O- !)'IS6KHGCNQFT5-!\5V!OK",8AF3_6Q^G_ .L4H4YPC&:6RLT.
M=2,W*#>[NF<-OKTR&-M(^"US]K^1]0F!A0]2,@Y_2JL5S\,M-G%Y%%J-ZZ_,
MEO(/ES[_ /UZYKQ9XNO/%5Y&\L:P6L(VP6Z=$'^-7+FK-))I)WU(C:BFV[MZ
M:&%OHWU'1758Y;LDWT;ZCHHL%V2;Z-]1T46"[)-]&^HZ*+!=DF^C?4=%%@NR
M3?7=?"5L^.HO^N$G]*X&N[^$?_(]1?\ 7"3^E8XG^#+T-L,W[6/J?0=%%%?-
MGT85D^)IEM_#MY*UU!:A5&9KB+S$7YAU7O6M65XDN#:^'KN87J66Q0?M#P^:
M$^8?P=_3\:J'Q(F?PLTHCF%#D'*CD# -/ID1S"AW;LJ.<8S3ZDH**** "BBB
M@ HHHH **** "BBB@ HHHH ***:[!$9B<  DT >*OK6J6_Q0UC4-+TIM1DB)
MA*C/R@8&>/I76:9XR\5WFJ6UM<^%FMX9'"O*<X0>M4_A2KW5]K^IMSYUSM!_
M$FO3*[<14C&7(XWLDOP.+#TY2CSJ5KMLY3QQXN;PS90Q6D0GU*[;9;QGL?4U
MSK^'/B#)9G4'\2B.ZV[_ +(JG:.^W/3]*9\2A-IGBK0/$,ENTUC;'9)@9VG.
M?Y']*U]5^*/AZ'2W>PN6N[IUQ% B'=N/KQQ1",HPBZ<;WWTO\@G*,IR525K;
M:V^9;\ >*;CQ+I,POD"WUI)Y4V!@'WK%U;Q)KOB7Q//X>\+RI;16O_'S>GG!
M]O\ /-:/PTT&[TK19[R_4QW5_)YS(>JCMFN5\(:W:>"O%&N:=KV;5IYC(D[*
M2&&2?R(.<TU"//-P5[;(3G+D@INU]V=#INC^.=&URV#ZO'JEA(?WYFXV#V[Y
MJ7Q[K6I66LZ#IVFW+P/=3CS"O\2Y'%:FC^.M*U[7'TW3A/.JIN^T!#Y>?3-<
MYKV=0^,6BVN<K:Q>;C\S4QYG4O45K)O8J7*J=J;O=I;GI5!( R>@HJ.=#);R
M(IP64@'\*XSL/.+OQ#X@\8:_<Z5X9G6RL;4[9KPC))]JR/$S^./!.GF9]<-]
M:S_NS+MPT3=L9Z5)X%\0V'@^ZU31]>)LY_/+K(ZG#?C53XB>-K/Q+'::+I)>
M6V>=3+.5(5CT 7/UKTXP:JJ"C[OI^-SS)33I.;E[WK^%CT6VOKNU^'R7UU,S
MW:V7F-(>I;&<U7^'5]?ZEX3AO=1N7GFE=B&;TS3O&5O/%\/+VWMU9I$ME3"]
M<#&:YGPM\0/#VB^"+6![@_:X(R/LRH2S-7,H.=-N*NVSI<U"HE)V21J>&=:U
M#5/B+K]L]W(]A:*%BB_A!R!_C6AXQ7Q'(UO'I%_:Z?9L#]HNIF 9#VQFN>^$
M#&]37-4D7#W%R#],Y)'ZUA:[=Z?JGQ'OK3Q;>SV^FVWRV\0+*C#\/7UK7V?[
MYI?97:_X&7M/W*;^T^]OQ+46LZWX:\3:9 _B>#7+:[DV2)&P;;SCL3@UWGCS
M59M&\'7UY;2M%. %C=>H8D"O++2+P]>?$G2+?PY;M'9Q.&:1BQ\PCG(W=J[7
MXP7!7PM;6:_>NKI$'X<U52"=6FK;[Z6)IS:I5'?;;6YD:78>/?$/AZ'4G\0&
MR41EHH]OS2@=V(Z9KIOAOK^H:[H,_P#:+"2YMIC$9/[WUK;N#_9?@]^B_9[+
M'XA,5S?PEMS'X/-PWWKF=W/\JRG-3IR=EOH:P@X5(J[VU.+\4:3X@NO'^FZ9
M/K FGD<RV[;3BW!.>GX5ZAHMKJVBZ%=-K.I?;KA-T@DQC"@=*X?5M7LM-^-"
MWFJRBWMH+3:KL"03M..GU-=GXAUJ";P#?:K:N6AEMF,;8QD'BJK.4HPC;1VZ
M$T5&,IROJK]3-^&^J:EK6@WEY?73S,]PPA+_ ,*UPNJZ/XDO/B-9:9-K8EOH
MT,\$^TXA')QC\*]#^&=J;7P+8AAS)ND_,UA:(!J'QHU>XSN%I!L4^G0?U-.,
M^6I4<>E_\A2AS4Z:EUM_F;6NW6I^&OAQ/)<:@TVI1Q[?M(X)8G@C\*TO#=_*
MO@NSU#4YV>3[/YLTC]?6N>^+MQM\*P6@^]<W2*H]<<UOZEILLW@273[93YIL
MPBJ.YV]*Q:3IIOJS9-JHTNB..M-0\6^/[B>XTJ_&D:3&Y2-PN6D(_G70^%+/
MQ=IVJ7-IK5W'>Z>J@Q7#'YV/L/\ &N=\ ^-]$T7PTFEZK/\ 8KJU=@R.A^;G
M.>!79^'/%EKXGM;N>QM[A4@<JK2)@2<<$&M*W/&\5'W?3]3.CR2M)R][U_0Q
M?%47BBXU8QV^MV>CZ4%!6=W 9F[CFL;PKKNL6'CE- N]:BUFUGC++/&P;:0"
M>H^G2N;TZX\/ZSK>J77C>_G\^.4K%;LS*H4'MC^57_A]%IEY\3;JXTFV:"RM
MX&,*,23CA<\^N:V=-1IR4ELNWZF*J.52+B]WW_0Z7XJPZNNB27EMJ8M]/6/R
MYK<#F4L:9\//#_B"QM+"ZGU<'36BW+9A>F>E3_%^5T\&K& =DEP@<@= .:WO
M"GB#2=6L(K33+D3-:P()-JD '&.]8<TEAU9=>QORQ>(=WT74Q)=;U"?XMPZ3
M!<R+8PVY::(="<$C/YBK_CCQ=)X<M[:UL81/JEZVR",C('N?SK!\)DZA\5?$
M5]C*PKY(/OD#^E0?$,2Z/XWT+Q%-$\NGP$+(5&=A!S^N?TJE3BZL8M;+[W:Y
M+J25*4D]W]RO8EE\.?$$6;:@?$H%T%W_ &15^7UVYZ5T7@+Q1-XFT1Y+M%2\
MMY#%-MZ$^M9^L?%#0(M+<Z;<F\O)%VQ0QH<[CZY%3?#?0KG0_#LL]\FRYNY#
M.Z'^$=A4U+NDW45GTTL53LJJ5-W776YS,^L>+-:^(>K:/HFH>5;1G:6<96%0
M "1[YS4T%[XF\)>-=-TS4M7.IVU]_>&,=N/2K7PK N]3\2ZF1GSKO"-Z@EB?
MZ4:UG4/C-I-OU6TA\P_CFM6USNG962_0R2;@JEW=O]3TNBBBO./1"BBB@ HH
MHH **** "BBB@ HHHH 0=*6D'2EH **** "BBB@#%\5?\B_<_5?YUYQFO1O%
M?_(O7/\ P'^=>;YH =FC--S1F@!V:,TW-&: '9HS3<T9H =FC--S1F@!V:,T
MW-&: '9HS3<T9H =FC--S1F@!V:,TW-&: '9HS3<T9H =FC--S1F@!V:,TW-
M&: +MUJ5Q>6MO;S,"D PIQS53--S1F@!V:,TW-&: '9J:UNI+.ZCN(]N]#D9
M&15?-&: )[FYEN[EYYFS(YR346:;FC- &_X1_P"0\G^XU>B5YUX0_P"0^G^X
MU>BT <]X:_Y".O\ _7^W\A6W=_\ 'E/_ -<V_E6)X:_Y".O_ /7^W\A6W=_\
M>4__ %S;^5"%+8\#<_.WUIN:20_O&^M,S7K'QI)FC-1YHS0(DS1FH\T9H DS
M1FH\T9H DS1FH\T9H DS1FH\T9H DS1FH\T9H DS1FH\T9H DS1FH\T9H DS
M1FH\T9H DS1FH\T9H DS1FH\T9H DS1FH\T9H DS1FH\T9H DS1FH\T9H DS
M1FH\T9H ]=^'O_(L#_KN_P#2K/BW_4Z9_P!?\7\ZJ_#O_D5A_P!=W_I5KQ;_
M *G3/^O^+^=>95^-GUF$_@0]#HJ\O^-W_(OZ;_U]'_T$UZA7EWQO_P"1?TW_
M *^C_P"@FML)_'B&+_@R/$,T9I,T9KZ$^?L+FC-)FC- 6%S1FDS1F@+"YHS2
M9HS0%A<T9I,T9H"PN:,TF:,T!87-&:3-&: L+FC-)FC- 6%S1FDS1F@+"YHS
M29HS0%A<T9I,T9H"PN:,TF:,T!87-&:3-&: L+FC-)FC- 6%S1FDS1F@+"YK
MO/A%_P CW%_UPD_I7!9KO/A!_P CW'_U[R?TK#$_P9>AMAU^]CZGT+1117SA
M]$%97B28V_A^[E6ZDM2JC]]'%YK+\PZ+WK5K*\1R&+P_=NLUW"0H_>6<>^4?
M,/NKWJH?$B9_"S2B.8D.2<J.2,9I],B.8D.2?E'+#G\:?4E!1110 4444 %%
M%% !1110 4444 %%%% !2,H92K $$8(/>EHH KV=A::?&T=G;10(QW,L:!03
MZ\58HHH;ON"5MB.:"*YA:&>-)(V&&1QD'\*SK7PUHEE.)[;2[6.4'(98QD?2
MM6BFI-:)B<4]6@JCJ&C:;JNW[=8P7!7H9$!(_&KU%";6J!I/1E6QTVRTV+RK
M*UAMT/41H!FE_L^S^W?;?LL/VK&WSM@WX],U9HHN]PL@HHHI#*%_HFEZHP:^
ML+>X8=&D0$C\:\Z\::?:#QMX5T:SMXH(#+YK)&H SN'^%>J50FT33KC58=3F
MM(WO81B.4CE?I6U*KR.[\S&K2YU9>1>(#*58 @\$'O67%X9T2&Y-Q'I5HLO]
MX1"M6BLE)K8U<4]RO9V%II\;1V=M% C'<5B0*"?7BJ]_H6E:I(LE]I]O<2*,
M!I$!./K6A11S.][ARIJUBC#HVF6\L4L.GVT<D0VQNL0!4>QJ6[T^SOQ&+NUA
MG$;;D\Q VT^HS5FBCF>]PY5M89-#'/$T4R+)&XPRL,@BF6UK;V4"P6L,<,2]
M$C4 #\*FHI7Z#MU,^_T/2]4D62^L(+AT&%:1 2!5A["TDLOL;VT36NW;Y)0;
M<>F*L44^9]Q<J[$<,,5M"D,,:QQ(,*BC  ]A44&GV=M<RW$%K#'-+_K)$0!G
M^I[U9HHNPLBO=V%G?B,7=M%.(VW)YB!MI]1FK &!@444KCL9=WX<T6_N//NM
M,M993U=HQD_7UK0@@AMH5A@B2*-1A41< ?A4E%-R;5FQ**3ND9=SX<T6\NOM
M-QIEK+,3DNT8)/UJU;Z98VMPUQ;V<$4S+M9TC )'IFK5%/FEM<7+'>Q#=6EO
M?6[6]U"DT+?>1UR#4.GZ3I^E(RV%G#;AOO>6N,_6KE%*[M8=E>Y6M]/L[266
M6VM8HI)CF1D0 N??UJ6>WANH6AN(DEB;AD=<@_A4E%%WN%EL9=IX;T6QG\^V
MTRUBE'1UC&1]*U" 001D&BBAMO<$DMBO9V%GI\;1V=M%;HQW%8D"@GUXI!I]
MF+XWHM8?M17;YVP;\>F:LT478604444AA1110 4444 %%%% !1110 4444 (
M.E+2#I2T %%%% !1110!G:W8RZEI<UK"5#OC!;IUKD?^$(U'_GM;_F?\*[X=
M32T <!_PA&H_\]K?\S_A1_PA&H_\]K?\S_A7?T4 <!_PA&H_\]K?\S_A1_PA
M&H_\]K?\S_A7?T4 <!_PA&H_\]K?\S_A1_PA&H_\]K?\S_A7?T4 <!_PA&H_
M\]K?\S_A1_PA&H_\]K?\S_A7?T4 <!_PA&H_\]K?\S_A1_PA&H_\]K?\S_A7
M?T4 <!_PA&H_\]K?\S_A1_PA&H_\]K?\S_A7?T4 <!_PA&H_\]K?\S_A1_PA
M&H_\]K?\S_A7?T4 <!_PA&H_\]K?\S_A1_PA&H_\]K?\S_A7?T4 <!_PA&H_
M\]K?\S_A1_PA&H_\]K?\S_A7?T4 <!_PA&H_\]K?\S_A1_PA&H_\]K?\S_A7
M?T4 <!_PA&H_\]K?\S_A1_PA&H_\]K?\S_A7?T4 <!_PA&H_\]K?\S_A1_PA
M&H_\]K?\S_A7?T4 <!_PA&H_\]K?\S_A1_PA&H_\]K?\S_A7?T4 <!_PA&H_
M\]K?\S_A1_PA&H_\]K?\S_A7?T4 <!_PA&H_\]K?\S_A1_PA&H_\]K?\S_A7
M?T4 <GH/AB\TO5%N9I(60*00I.?Y5UE%% '/>&O^0CK_ /U_M_(5O31^;!)'
MG&]2N?3(K!\-?\A'7_\ K_;^0KH: /.6^%[LQ/\ :J\G_GC_ /7I/^%6O_T%
M5_[\_P#UZ]'HK;V]3N<7]G8?^7\6><?\*M?_ *"J_P#?G_Z]'_"K7_Z"J_\
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M/&,=175T4X3<)*4=PG!3CRRV/&O^%%S?]!]/_ 8__%4?\*+F_P"@^G_@,?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M $+UW_W_ %_PH_X:3TS_ *%Z[_[_ *_X5C89[E17AG_#2>F?]"]=_P#?]?\
M"C_AI/3/^A>N_P#O^O\ A2 ]SHKPS_AI/3/^A>N_^_Z_X4?\-)Z9_P!"]=_]
M_P!?\* /<Z*\,_X:3TS_ *%Z[_[_ *_X4?\ #2>F?]"]=_\ ?]?\* /<Z*\,
M_P"&D],_Z%Z[_P"_Z_X4?\-)Z9_T+UW_ -_U_P * /<Z*\,_X:3TS_H7KO\
M[_K_ (4O_#2>F?\ 0O7?_?\ 7_"@#W*BO#?^&D],_P"A>N_^_P"O^%)_PTGI
MG_0O7?\ W_7_  H ]SHKPS_AI/3/^A>N_P#O^O\ A2_\-)Z9_P!"]=_]_P!?
M\* /<J*\,_X:3TS_ *%Z[_[_ *_X4?\ #2>F?]"]=_\ ?]?\* /<Z*\,_P"&
MD],_Z%Z[_P"_Z_X5U7@+XNV?CS79-+M]*GM62$S%Y)0P(! QP/>@#TFN=\6_
MZG3/^O\ B_G715SOBW_4Z9_U_P 7\Z .BHHJIJ=P]KI5W<18\R*%W7([@$T
M6Z*^5&^/WC4,1YEEP?\ GW%)_P +_P#&O_/2R_\  <46 ^K**^4_^%_^-?\
MGI9?^ XI?^%_>-?^>EE_X#BG8#ZKHKY5'Q\\;'_EI9?^ XI?^%]^-O\ GI9?
M^ XJU2FU>P7/JFBOE3_A?WC7_GI9?^ XH_X7]XU_YZ67_@.*AQ: ^JZ*^4_^
M%_\ C7_GI9?^ XH_X7_XU_YZ67_@.*+ ?5E%?*J_'WQJW22RS_U[BD/Q^\;
MXWV7_@.*0[.USZKHKY3_ .%_^-?^>EE_X#BC_A?_ (U_YZ67_@.*=A'U917R
MG_PO_P :_P#/2R_\!Q1_PO\ \:_\]++_ ,!Q18#ZLHKY3_X7_P"-?^>EE_X#
MBE_X7_XU_P">EE_X#BBP'U717RI_PO[QK_STLO\ P'%'_"_O&O\ STLO_ <4
M6 ^JZ*^4_P#A?_C7_GI9?^ XH_X7_P"-?^>EE_X#BBP'U917RI_PO[QK_P ]
M++_P'%'_  O[QK_STLO_  '%%F!]5T5\J?\ "_O&O_/2R_\  <4?\+^\:_\
M/2R_\!Q19A8^JZ*^5/\ A?WC7_GI9?\ @.*4?'WQJ?\ EI9?^ XIJ+;L@/JJ
MBOEE?CWXS[O9_P#?@4K?'GQF,8ELC_V[BNA82HQ7TN?4M%?+7_"^O&?_ #TL
M_P#P'%>T?"?Q9J?C#PS-?ZJT1G6<QCRTVC%*KA:E*/-($TSO:***YAA63XE@
M%QX=O(C:K=!E'[EIO*#?,/XNU:U9/B6,3>';R-H+:<%1^[NI/+C;YA]YNU5#
MXD3/X6:<0Q"@QC"CC.<4^F1#$*# 'RC@'(%/J2@HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (.E+2#I2T
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M;_J=,_Z_XOYUT5<[XM_U.F?]?\7\ZD#HJH:Y_P @#4/^O:3_ -!-7ZH:Y_R
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MNG]*]9KR;XV_ZSP?_P!A=/Z5ZS0 4444 %%%% !1110 4444 %%%% !1110
M5FZ.H5+W"!<W<AX0KGIS[_6M*L[2!A;SC&;N0_=(]/7K]>E &C1110 4444
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MBBD 444M #EY-2XJ)>HJ<5ZF!BG%D2$Z4?2@T"NY[V)' TWDFEZT@JI7=DP
M<=:#1FF.U8U*BA$$AKMDTRBBO&J3<Y79H@I*6DK(84444 %>N_L[?\C]=?\
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MX6@4M=E.G&*(;$*TQEQ4M-(S3JTHR6@)D5)3B.:::\V2L[%A1114@%+BDI:
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M )^KO_OH4<N%_F?W!S5NR.G_ .$Z\,?]!FU_[ZJCI?C7PY$MWOU6!-UR[#<
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MCEPO\S^X.:MV1T__  G7AC_H,VW_ 'U1_P )UX8_Z#-M_P!]5S'_  I;0/\
MGZN_^^A45S\&M!AM9I5N;O*(S#YAV%')A?YG]P<U;LCO-+U_2]9:0:=>Q7!C
MY8(<XK2KQ?X&_P#'YJO_ %S3^=>T5EB*2I5'!&E*;G!284445@:!1110 444
M4 %%%% "#I2T@Z4M !1110 4444 -/1OI7POXE_Y&G5O^OR7_P!#-?=!Z-]*
M^%_$O_(TZM_U^2_^AFF@,NBBBJ **** "BBB@ HHHH 6EI!2TD4.0$L !DGI
M711^#O$A4$:%J&/^O=O\*YZ)S'*KCJIR*^F?"6K_ !2\0:#:ZO;3:*]K<*=B
MS*5; )'./I7=0KNGV^9+1X-)HNH:=*!J%G/:GJHFC*;OIGK5W3[G2=-UZTO=
M0L3?6D3AI+8/MWXZ<_6O2_BGH?CW4=-CU/6VTX6-F.8K1R I/\1W<DUX\1&5
M<,"6V@KM/>O;HPC7@IM^MCIA5O1=.WS9['<?%_P)/_KO!6[C'^KCKR?QMJ^C
M:YX@:\T/2_[-LS&J^1@?>'4\5E[%;()Q44MLZ#)7 KDQ67QI:P.6*D]2IBFU
M/]GF9=ZQ2%>S!3BHF5E.&4@^XQ7C2C9E#:**7&:BUP$HQ3MAI""*MTI)7:%<
M;12T5%@$HI:2D N:*2EI#"DQ2T'&*8'V7\*O^2::)_UP_K795QOPJ_Y)IHG_
M %P_K795 CGO#7_(1U__ *_V_D*Z&N>\-?\ (1U__K_;^0KH: /F7]H+_D=[
M;_KT7^9KQYNM>P?M"''C>V_Z]%_F:\>->C5G^YA'R)6[$HI*6N)E!2T4E PH
MHHH$%)112 **** "E#%0<'&>*2B@:=@HHHH$+1FBB@ HS115)L S1111=@%%
M%)4@%%%% !1110 4444AA7KO[.W_ "/UU_UXO_Z$M>15Z[^SM_R/UU_UXO\
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M!^-O^L\'_P#873^E>LU\[_$#XC:/XROO#-OIT-Y&]OJ:2.9X2@(R!Q7T.#D
M^M "T444 %%%% !7 ?&"-W\$.54L%F0L0.@KOZ:\:2H4D174]589!K2E/DFI
M=B9QYHN)RWPV5D\ Z6&4J=A.",=S75TBJJ*%50JCH , 4M3.7-)R[A%<L4@H
MHHJ2@HHHH *S='4*M[A0N;N0\1E,]/7K]>]:59NCXVWN,?\ 'W)TW>WK_3B@
M#2HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY"NAH ^7_P!H?_D>[7_KS7^9KR&O7OVA_P#D>[7_ *\U_F:\AJUL "ES24M
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M;>V$W[AB3R>.IKTFO+='_P"3@M;_ .P<G\Q0!ZE1110 5G:025O,L3BZD'+
MXZ>E:-9VD?=O,G_EZD[J?3T_KS0!HT444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %5[[_D'W/_ %R;^1JQ5>^_
MY!]S_P!<F_D::W$]CQ_X&_\ 'YJO_7-/YU[17B_P-_X_-5_ZYI_.O:*ZL=_'
M9CAOX:"BBBN0W"BBB@ HHHH **** $'2EI!TI: "BBB@ HHHH :>C?2OACQ)
M_P C3JW_ %^2_P#H9K[G/1OI7POXD_Y&G5O^OR7_ -#--#1F&E'6DHJXNS F
MHI%.12UZT6G&Z,Q1C//2AL;CC..V:**?*%]+!11Q15I=!!UH*X."*?D;0 .?
M6I;>UN;^Z2WMH9)[B0X6-!EF^@INGI=CT15*BFE#70?\(;XE_P"@#J'_ 'X:
MLR6PNK>:2*X@DAD0X9'4@C\*Y94J<BXIR=D4",4E6-F:B9,5A4PTX*_05QE+
MFD(HKFV&/#XJ0.*@HKHIXJ<-!-7/?_A%):^(OAIK_AN6&)YX@[H&7).Y>#^8
MKPZVO[[1M1\ZRNI;:YA8@21,5((-;W@'QS<>!-8GU""W%SYL)C\IFVJ3V)KF
M[^Z^W:A<7?E)%YTC2;$Z+DYP*B=9R;[,+%W7_$>J>)]2^WZO=-<7&P(&(Q@#
MVK-#4RBHA-Q>@[$P-.S4(-2 UZ5&LY+0AHZWX;W-A;^/M*.IPI+:R2^6RR#(
M!88!(K8^,WARU\.^.F2PMH[:TN8%F2./H#T;]17G]O.]K=17$1Q)$X=3[@Y%
M>@?$_P >Z;XX_LE[2TFCN+6'9-+(1AB<< ?7/YU3O[5-;=0Z'!PW<ENOR8SD
M'GVKT>W^//C"VMHX%6P(C4*#Y&.!]#7F)IM*I2@]T4ZDI))O8ZOQI\1];\<V
MUK;ZLML$M79T\F/:<D8.?RKCCTJ1Q4=>95I\CL-'V7\*O^2::)_UP_K795QO
MPJ_Y)IHG_7#^M=E6 '/>&O\ D(Z__P!?[?R%=#7/>&O^0CK_ /U_M_(5T- '
MR_\ M#_\CW:_]>:_S->0UZ]^T/\ \CW:_P#7FO\ ,UY#5+8 I:2EI@%%)10,
M****!!1110 4444 %%%% "TE%% PHHHH 6DHHH$%%%% !112@$TTK@ &31CF
MI%C)ZTIBKICA*K5TA<R(J*<5(IM82BXNS&)12TE0 5Z[^SM_R/UU_P!>+_\
MH2UY%7KO[.W_ "/UU_UXO_Z$M)@?4-<[XM_U.F?]?\7\ZZ*N=\6_ZG3/^O\
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M-*QG7[:05?//'UH^!BZ9;^(/%=IH^^XT^.5/L]XV?WB<X!H ]LHHHH ****
M"BBB@#R;XV_ZSP?_ -A=/Z5ZS7DWQM_UG@__ +"Z?TKUF@ HHHH \MD_Y.(C
M_P"P77J5>6R?\G$1_P#8+KU*@ HHHH **** "O+='_Y."UO_ +!R?S%>I5Y;
MH_\ R<%K?_8.3^8H ]2HHHH *SM(&%O/E(S=R'E"N>GKU^M:-9FC;=E[M*'_
M $N3.S?UXZ[N_P!./2@#3HHHH **** "BBN1\8>*M;\/W-O%I7A:\UA)$+/+
M P 0YZ'WH ZZBO'U^,7B!M8?25\"7QU!(Q(UOYGSA3WQCI7<>#_$NL>(%N3J
MOAJZT?RL;#.P(DSZ?2@#J**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *KWW_(/N?\ KDW\C5BJ]]_R#[G_ *Y-_(TUN)['C_P-_P"/S5?^
MN:?SKVBO%_@;_P ?FJ_]<T_G7M%=6._CLQPW\-!1117(;A1110 4444 %%%%
M "#I2T@Z4M !1110 4444 -/1OI7POXE_P"1IU;_ *_)?_0S7W0>C?2OA?Q+
M_P C3JW_ %^2_P#H9IH#+HHHJ@"BBB@8M%)10 M+NI**I2:V$.WTN^F45HJT
MUU"QVFE_%/Q?I%I;VEIK$BVUO&(XHF4%54# %,\0_$GQ-XIM(K35+_?!&V[9
M&@0,??'6N.HIJJKW:!::HN7-TUU('D.3C%5RPJ/-%5[>RLD5.4IR<I.[8I.:
M*3-&:P<KO40&BBDJ0"BBB@ HHHH$%%%% "YI0:;133L!(&I=U1YHK:-=H+#B
M<TVBBLIR<G<9]E_"K_DFFB?]</ZUV5<;\*O^2::)_P!</ZUV59".>\-?\A'7
M_P#K_;^0KH:Y[PU_R$=?_P"O]OY"NAH ^7_VA_\ D>[7_KS7^9KR&O7OVA_^
M1[M?^O-?YFO(:I %*<9XI!0:!A1113$%%%% !1110 4444 %%%% !1110 44
M44 %%%% !3E&325/$E=6%H.K-(4G9#T %/SFFD<4H'%?1P3C[BT,@/2F8IYI
MI%345]00AYJ!NM3-TJ UY.-ELBXB4E+2&O+985Z[^SM_R/UU_P!>+_\ H2UY
M%7KO[.W_ "/UU_UXO_Z$M2P/J&N=\6_ZG3/^O^+^==%7.^+?]3IG_7_%_.I
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M'_7M)_Z":OU0US_D :A_U[2?^@F@#X1?[[?4TE*_WV^II*H!:0TM)0,****
M%-)110 4444 %%%% !1113$%%%% "T4E+0ADJ5=@5&0C!+'I5%*NV\FP@U[F
M71;V!25]2::UEBC#,C 'H<=:AN-/O8!F:SN(Q_MQ,/YBM_2/$K:9J]G>7=I'
MJ$%L^\6\O"D]ORKUB;]H?2IE G\,2R^S2H1^HKHQ\ZL8I<M_F.LJ7/\ NF[>
M9\\MUIM=/X\\2V?BSQ/)JECIPL(7C5?)&.H')XXYKF*^?F[DB4445F 4444
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M*BBB@ K.T@DK>;BQ_P!*DQF17]/[O3Z'D5HUG:0"%O,@C_2I.J*OIZ=?J>:
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M^=>T5U8[^.S'#?PT%%%%<AN%%%% !1110 4444 (.E+2#I2T %%%% !1110
MT]&^E?"_B7_D:=6_Z_)?_0S7W0>C?2OA?Q+_ ,C3JW_7Y+_Z&:: RZ***H H
MHH% #A3MO%""IUC+5V8?#2JNR&VDB +2XJU]F;'2H7C*FNVOEE6E'FDB(S1
MPYI*<1337E2C9V+"DI:2LQ!1110 4444#"BBB@ HHHH$%%%% !1110 4444
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MA#2445X[=S0*2BBI *]=_9V_Y'ZZ_P"O%_\ T):\BKUW]G?_ )'^Z_Z\7_\
M0EI,#ZAKG?%O^ITS_K_B_G715SOBW_4Z9_U_Q?SJ0.BJAKG_ " -0_Z]I/\
MT$U?JAKG_( U#_KVD_\ 030!\(O]]OJ:2E?[[?4TE4 M)2TE PHHHH$%%%%
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M7&_"K_DFFB?]</ZUV50!SWAK_D(Z_P#]?[?R%=#7/>&O^0CK_P#U_M_(5T-
M'R_^T/\ \CW:_P#7FO\ ,UY#7KW[0_\ R/=K_P!>:_S->0U2 7M24II*8,**
M** "BBB@ HHHH **** "BBB@ HHHH **** %J6,]JBI0=IXK:A4]G-2!JZ+@
M4XY'%(W'2FK<97!I&D4CBOI'B*$H>Y(QLQ1S36.*89*86)KSZN+@E9;E*(K-
MFF445Y52HYN[+2"BBDK(84444 %>N_L[?\C_ '7_ %XO_P"A+7D5>N_L[?\
M(_77_7B__H2TF!]0USOBW_4Z9_U_Q?SKHJYWQ;_J=,_Z_P"+^=2!T54-<_Y
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M <W\0/\ DGVO?]>4G\JXCX>_\D^T3_KV'\S7;_$#_DGVO?\ 7E)_*N(^'O\
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M3_GCJ'_?@T!='J-%>7?\+Y\)[E!BOQN( )@QUKT^-Q+$DB]& 8?C0,=1110
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M/_@2G^-'_"C?'G_0,A_\"4_QKZXHHN!\D?\ "CO'F/\ D%P_^!*?XT?\*/\
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M "BBB@ HHHH *\MT?_DX+6_^P<G\Q7J5>6Z/_P G!:W_ -@Y/YB@#U*BBB@
MK-T=@RWN'5L7<@.V0OCIQST^E:59VDLS+>;F9L74@&YPV.G''3Z'F@#1HHHH
M YOX@?\ )/M>_P"O*3^5<1\/?^2?:)_U[#^9KM_B!_R3[7O^O*3^5<1\/?\
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M-2BBBD,**** "BBB@ HHHH 0=*6D'2EH **** "BBB@!!U-+2#J:6@ HHHH
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M+HEHJ+[5;_\ />+_ +[%'VJW_P">\7_?8HL%T2T5%]JM_P#GO%_WV*/M5O\
M\]XO^^Q18+HEHJ+[5;_\]XO^^Q1]JM_^>\7_ 'V*+!=$M%1?:K?_ )[Q?]]B
MC[5;_P#/>+_OL46"Z):*B^U6_P#SWB_[[%'VJW_Y[Q?]]BBP71+147VJW_Y[
MQ?\ ?8H^U6__ #WB_P"^Q18+HEHJ+[5;_P#/>+_OL4?:K?\ Y[Q?]]BBP71+
M147VJW_Y[Q?]]BC[5;_\]XO^^Q18+HEHJ+[5;_\ />+_ +[%'VJW_P">\7_?
M8HL%T2T5%]JM_P#GO%_WV*/M5O\ \]XO^^Q18+HEHJ+[5;_\]XO^^Q0+F G
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MP^\/\\XJH?$B9_"S3B_U*?=^Z/N]/PI],BYA3E3\H^[T_"GU)04444 %%%%
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M1FF9HS0%Q^:,TS-&: N/S1FF9HS0%Q^:,TS-&: N/S1FF9HS0%Q^:,TS-&:
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MYFNW^('_ "3[7O\ KRD_E7$?#W_DGVB?]>P_F:NGN<V)^%'2T445J<84444
M%<S\1/\ DG^L_P#7 _SKIJYGXB?\D_UG_K@?YTGL5#XD=UX"_P"1"T/_ *]$
M_E715SO@+_D0M#_Z]$_E715@>F%>??&K_DF&H_[T?_H5>@UY]\:O^28:C_O1
M_P#H5 'GFG?\@RU_ZY+_ "JU573O^09:_P#7)?Y5:KTUL?)2^)A1113$%%%%
M '->./\ D Q_]?$?\Z^F;/\ X\;?_KFO\J^9O''_ " 8_P#KXC_G7TS9_P#'
MC;_]<U_E7%B/C/>RW^#\R:BBBL#T#R/]H+_D4-+_ .PBG_H)K@CUKO?V@O\
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MZ_TK.M_#9W9;_O4/ZZ'U51117FGV84444 %%%% "#I2T@Z4M !1110 4444
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MLOJ%R^GI8M)FW1MRICH:JU458RJU%-IKLD+12451G<6BDHH"YZAX!_Y%P_\
M7=_Y"IO%O^ITS_K_ (OYU!X!_P"1</\ UW?^0J?Q;_J=,_Z_XOYUYU7XV?38
M7^!'T.BKGO'7_(D:O_U[FNAKGO'?_(CZO_U[FG2^./JC2K\$O0^=,T9IN:3-
M?0GA7'YHS3,T9H"X_-&:9FC- 7'YHS3,T9H"X_-;W@H_\5GI?_785SV:L6-]
M<:=>Q7EJ_ESQ-N1L9P:F<>:+0X2M),Z?XA2/%X\O)(V*NC*RL.H( KO_  Q?
M6?C>VT^]G*IK&ER N1U=?7Z'^=>.:EJ5UJU])>WLGF7$GWFP!G\J?I6L7^B7
M@N]/G,,V"N0,Y'N*YYX=RIJ*W1O"NHU&^C/2K6^M[+XT7OVA@@ES&K'L2HQ7
M(>)?#&LVWB&Z0V5Q-YDI9)$0L&!/K6#?ZE=ZEJ$E]=2E[F0@LX&.1]*WK3XB
M>);.V6!+_>JC"F10Q'XT*E.#3C;:P.K"::EWN=-XCC.A?"K3M'OB!?2R;Q'G
ME!N+?UQ^->9YJSJ.J7NK7;75]<//,?XF/3Z>E4\UK2IN$==WJ9U:BF]-D>BW
MW_)%K+_K\_\ BJNWUM+XD^%&F+I2>;)8N!-"GWN 0>/QS^->?2:[J,NBIH[S
MYL4?>L6T<'Z]>]+I&O:EH4YFTZZ>%F^\!R&^HK)T)6NM[W-/;QO9[6L=5\/O
M#^J#Q/!>RVTMM;6V7DDD7:,>E=/H6H6VM:CXNL;.15GN]QA;.-PQC^=<!J?C
MOQ#JMLUM<7Q6%N&6,!<_7%85K>7%C<I<6LSQ3(<JZ'!%*5"=2\I:,<:\864=
M4:L/A/79]1^PKILXFW8)9<*/?/I77^$K6:Q\(>+;6X0I-$H5U/8X-<_)\1_$
M\ML83?XR,%P@#8^M9%KXAU2SM;RVANF$5Y_KPP!+_B:J4*LXVE;H3&=.#O&_
M4S<TN:9FC-=)A<?FC-,S1F@+C\T9IF:,T!<?FC-,S1F@+C\U:TO_ )#%C_U\
M1_\ H0JEFKFE'_B<6/\ U\1_^A"D]@3U/J,=**!THKYL^A"LOQ&[)X?NV22[
MC8*,/9KNE'S#[H_SQ6I67XC#'P_=A4OG.T86P.)C\P^[_GIFJA\2)G\+-*+_
M %2<D_*/O=?QIU,B_P!4GWONC[W7\:?4E!1110 4444 %%%% !1110 4444
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M<#_.NFKF?B)_R3_6?^N!_G2>Q4/B1W7@+_D0M#_Z]$_E715SO@+_ )$+0_\
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M6[?,.C=JJ'Q(F?PLTHAB%!AA\HX;K^-/ID0Q$@P1A1P3G%/J2@HHHH ****
M"BBB@ KSC4I-9\:>.-1T/3]9N-)TK2(T$\MJ!YD\SC.W)Z "O1Z\\\)S1Z9\
M3O&.F7+JDUU)%>P[CC>A7!QZX- %CP;J.K:?XEU+PEK5^VH26T:W%K=R* \D
M1XPV.X/>N[KSW2Y4U3XT:I=VK"2"RTY+61U.1YA;=C-.\3_#K4=?UR74+?Q7
MJ-A&X $$)^5<4 8WQM_UG@__ +"Z?TKUFO'+[X'7>HB+[5XQU&<POOC\T9V-
MZCWJW_PJ#5_^A[U?_OJ@#UBBO)_^%0:O_P!#WJ__ 'U1_P *@U?_ *'O5_\
MOJ@":3_DX>/_ +!=>I9'K7CW_"D+O^T!?GQCJ1NPNSSOXMOIFK7_  J'5_\
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MW';QD^M 'K5%>3_\*@U?_H>]7_[ZH_X5!J__ $/>K_\ ?5 ':?$#_DGVO?\
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M/@G>ZA;-;7GC/4YX&^]')R#^% '-:=_R#+7_ *Y+_*K5::_ 9T4*OBN^"@8
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ME8/?TK1L[&ZLKI9(=71K$<[7;)QZ5!!K5FFNW:;]EO.-OF+QAO6@"RD^K27
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MGITZ5W&J?\BC>_\ 7@__ *+-8_PM_P"28>'?^O-?ZT ==1110 4444 %%%%
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MAS3_ /KYC_\ 0A5#-7M&_P"0YI__ %\Q_P#H0J9?"RH_$CZO'2B@=**^6/J
MK*\2N(_#UXYDL8P%'S7Z;H1\P^\/\\XK5K)\32B'P[>2&>W@"J/WEQ%YD:_,
M.J]ZJ'Q(F?PLTXN84Y4_*/N]/PI],B.84.0?E'(& :?4E!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 4+;1=.L]6O-4M[94O;P*+B4,27"\+QG'
M'M4.N>&]'\2VT5OK%C'=QQ.)$#$@JP[@@@UJT4 12VT,UH]K(@:%T,;)GJI&
M"/RJ'3--L]'TVWTZPA$%I;ILBC!)"KZ9/-6Z* "BBB@ HHHH **** "BBB@
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M[#IG\OUH ]2M)_M5G#<>6\?FHK['&&7(S@^]1ZE?)IFEW5_*K-';Q-*RKU(
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M>C>*O^1?N?JO\Z\XH 6BDHI"%HI** %HI** %HI** %HI** %HI** %HI**
M%HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** /2_#7_( M?\
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MH&-9U=:=U<Y6K.PN:,TE%,0N:,TE% "YHS244 +FC-)10 N:O:+_ ,AW3_\
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M;YE[K5K>73[BV=%U,3B V%P)"<;=AKK(X1X-\,W)N67^T[X;%C!R4&.]8?\
MPFVO^7L^VG_>VC-8ES=3WD[37$KRR-U9CDT.,I:2V%&I2I7=.[?GT.NTFWFN
MOAU?Q01-+(;@85!DGI6/:>$];O)51;"6-2<%Y!M454L-=U/2X6ALKQX8V.XJ
MH')J:?Q-K5RFR74IRI[ X_E1RS3=@=2C*,>>]TK=#H-?GM-!\.IX>M95FN)#
MON)%/ -5Y/\ DET7_7Y_6N2))))))/4FK!U"[.GBP,S?90^\1=MWK3]G9+UN
M#Q*;DVM+67D>A^&WL]<T2SN+UOWVDL22>X XS61X;U!M4^(+7;'/F!]OL,<5
MR5O?75I%-%!.T:3+MD4?Q"DL[VXT^X6XM)6BE4$!E[9J?9;^9?UOX+K;?SM_
MP!^H?\A*Z_Z[/_,UTFB_\B#KG^^M<F[M([.YRS')/J:GBU"Z@LIK.*9EMYCF
M2,=&JY1NK&%.HH3<GU3_ !*]%)15F M%)10 M%)10 M%)10!ZW\//^17'_7=
M_P"E6?%O^ITS_K_B_G5;X>?\BN/^N[_TJSXM_P!3IG_7_%_.O,J_&SZO"?P(
M>AT5<[X\_P"1%UC_ *]FKHJYWQY_R(NL?]>S4Z7\2/JC6K_#EZ'S%1117TI\
MV%%%% !1110 4444 %%%% !7<_"3_D?+?_KE)_*N&JWINJ7NCWBW>GW#07"@
M@.N,X/7K458N<'%=2Z4E":D^A:\2$_\ "3:F,G_CYD[_ .T:C\/_ /(R:9_U
M]1_^A"J4\\EU<23S.7ED8L['N3U-)#-);SQS1.4DC8,C#L1T-/E]WE%S>]S'
MJ7C_ %B30?BQ8ZC&3^Y@CW#U4D@C\JZ/QE=Z=X;\,ZAJ>FX%SK>W:P[Y'4?A
M7B>J:O?ZU=_:M1N7N)]H3>V,X'0<47>K7]_:VUK=74DL%LNV%&Z(*Y?JND+O
M;?S.KZUK.RWV\CT6Q_Y(1>?]=_\ V<5+X8FM/&_P_;PK/.D.IVAWVQ<_> Y!
M_4@UYRFN:E'H[:2MVXL'.YH,#!/6J4,\MO,LT,CQR(<JZ'!!^M5]7;3UUO=$
M_6$FM-+69NW7@?Q-:71MWT>Z=@<!HT+*WT(KO?"6B#X>Z7=^(]?*Q7;1%+>V
MS\W/;ZGBN.@^)7BJ" 1#4V8 8#.H)K!U/6=1UFX\_4;R6X?MO/ ^@[42A6J+
MEG9+R",Z5-\T+M^9!>74E]>SW<IS)-(9&/N3FH***ZEH<KU"BBB@ HHHH **
M** "BBB@ J]HO_(=T_\ Z^8__0A5&KVB_P#(=T__ *^8_P#T(4I;,<=T?6(Z
M44#I17RY].%97B12_A^[4+?L2HXT]MLY^8?</K_3-:M97B2,S>'[N-8;F8E1
MB.UDV2-\P^ZW:JA\2)G\+-*+_5)][[H^]U_'WI],B&(D&"/E'!/-/J2@HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $'2EI!TI: "BBB
M@ HHHH Q/%7_ "+US]5_G7G&:]'\5_\ (O7/U7^8KS>@!<T9I** %S1FDHH
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MZJ_#O_D5A_UW?^E6O%O^ITS_ *_XOYUYE7XV?683^!#T.BKG?'G_ "(NL?\
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M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:** #-&:** #-&:** #-&:** #-&:** #-&:** #-&:** #-&:** #-&:**
M#-&:** #-&:** #-&:** #-7]$_Y#VG?]?,?_H0JA5_1/^0]IW_7S'_Z$*F6
MS''='UF.E% Z45\P?2A63XE(7P[>$G3Q\H_Y"(S!]X??]OZXK6K)\3.L?AV\
M=I;2(!1E[M-\0^8?>'>JA\2)G\+-.+_4I]W[H^[T_#VI],BYA0Y!^4<KT_"G
MU)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% %34;"/4K)[65F5'QDKUK"_X0:P_Y[S_ )BNHHH Y?\ X0:P_P">
M\_YBC_A!K#_GO/\ F*ZBB@#E_P#A!K#_ )[S_F*/^$&L/^>\_P"8KJ** .7_
M .$&L/\ GO/^8H_X0:P_Y[S_ )BNHHH Y?\ X0:P_P">\_YBC_A!K#_GO/\
MF*ZBB@#E_P#A!K#_ )[S_F*/^$&L/^>\_P"8KJ** .7_ .$&L/\ GO/^8H_X
M0:P_Y[S_ )BNHHH Y?\ X0:P_P">\_YBC_A!K#_GO/\ F*ZBB@#E_P#A!K#_
M )[S_F*/^$&L/^>\_P"8KJ** .7_ .$&L/\ GO/^8H_X0:P_Y[S_ )BNHHH
MY?\ X0:P_P">\_YBC_A!K#_GO/\ F*ZBB@#E_P#A!K#_ )[S_F*/^$&L/^>\
M_P"8KJ** .7_ .$&L/\ GO/^8H_X0:P_Y[S_ )BNHHH Y?\ X0:P_P">\_YB
MC_A!K#_GO/\ F*ZBB@#E_P#A!K#_ )[S_F*/^$&L/^>\_P"8KJ** .7_ .$&
ML/\ GO/^8H_X0:P_Y[S_ )BNHHH K6%DFGV4=K&S,B# +=:LT44 5[:QM[.2
MXDA3:UQ)YDASU;UJQ110!QES\.-.NKJ6=[NX#2,6(&.YSZ5%_P *PTS_ )_+
MG_QW_"NXHK3VT^YRO!8=Z\IP_P#PK#3/^?RY_P#'?\*/^%8:9_S^7/\ X[_A
M7<44_;3[A]1P_P#*</\ \*PTS_G\N?\ QW_"C_A6&F?\_ES_ .._X5W%%'MI
M]P^HX?\ E.'_ .%8:9_S^7/_ ([_ (4?\*PTS_G\N?\ QW_"NXHH]M/N'U'#
M_P IP_\ PK#3/^?RY_\ '?\ "C_A6&F?\_ES_P"._P"%=Q11[:?</J.'_E.'
M_P"%8:9_S^7/_CO^%'_"L-,_Y_+G_P =_P *[BBCVT^X?4</_*</_P *PTS_
M )_+G_QW_"C_ (5AIG_/Y<_^._X5W%%'MI]P^HX?^4X?_A6&F?\ /Y<_^._X
M4?\ "L-,_P"?RY_\=_PKN**/;3[A]1P_\IP__"L-,_Y_+G_QW_"C_A6&F?\
M/Y<_^._X5W%%'MI]P^HX?^4X?_A6&F?\_ES_ .._X4?\*PTS_G\N?_'?\*[B
MBCVT^X?4</\ RG#_ /"L-,_Y_+G_ ,=_PH_X5AIG_/Y<_P#CO^%=Q11[:?</
MJ.'_ )3A_P#A6&F?\_ES_P"._P"%'_"L-,_Y_+G_ ,=_PKN**/;3[A]1P_\
M*</_ ,*PTS_G\N?_ !W_  H_X5AIG_/Y<_\ CO\ A7<44>VGW#ZCA_Y3A_\
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MU2C_ "GF'_"D=&_Z"5[^2_X4?\*1T;_H)7OY+_A7I]%'UNM_,'U2C_*>8?\
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M!]5H_P H4445SG0%-DBCFC,<J*Z-U5AD'\*=10  8&!THHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>img224999359_22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_22.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )=!#@# 2(  A$! Q$!_\0
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M\OO/0,48J&ZNH+*TENKF58H(E+N['A0*\YD^*&H:E=2)X:\/3WT,9P97!Y_
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M3<7.VB*=6"DH7U9U6*,5RWB7Q@?#VMZ5IPL_.^W-MW[\;/F Z=^M/\9^+?\
MA$[6SF^R?:/M$WE8W[<<9S0J4W:RWV!U8*]WMN=-BC%,B?S84DQC<H;'UJCK
M>NZ?X?T][W4)Q'&O1>K.?11W-0DV[(MR25V:.*,5R'@OQPOC">]5+(VR6^TJ
M2^XL#GK^5=?3G"4)<LMR83C./-'8,48HHJ2PQ1BBB@ Q1BBB@ Q1BBB@ Q1B
MBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@
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M!;WY^\<=.PK2-.4:OM7+2][W,Y58RH^R2UM:UA/&6JWDWPCT,NS%KK8)F]0
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M'YT +12;E_O#\Z-R_P!X?G0 M%)N7^\/SHW+_>'YT +12;E_O#\Z-R_WA^=
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M?W'_ $&I/^^#_C7<T4>VGW#ZC0[?BSAO^%?W'_0:D_[X/^-'_"O[C_H-2?\
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MY:X)<MO88Z]NM%:O>BLVVW=G3""A%1CL@HHHI%!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !WHH[T4 %%%% !1110 4444 %%%% !
M1110 4444 4KN\GBN8X+>!9792WS/MP!^%1_:=5_Z!\/_?\ _P#K4Z3_ )#D
M'_7%OYU?H SOM.J_] ^'_O\ _P#UJ/M.J_\ 0/A_[_\ _P!:M&B@#.^TZK_T
M#X?^_P#_ /6H^TZK_P! ^'_O_P#_ %JT:* ,[[3JO_0/A_[_ /\ ]:C[3JO_
M $#X?^__ /\ 6K1HH SOM.J_] ^'_O\ _P#UJ/M.J_\ 0/A_[_\ _P!:M&L^
M?7=)M;AH+C4K6*93AD>4 CZTFTMRX4YS=HJXGVG5?^@?#_W_ /\ ZU'VG5?^
M@?#_ -__ /ZU7H9HKB)989$DC;HZ,"#^(J.UO;6]1GM;B.958JQC8, 1VHNA
M<LM=-BK]IU7_ *!\/_?_ /\ K4?:=5_Z!\/_ '__ /K5:EO;6&YBMI;B))Y<
M^7&S ,V/0=ZK3Z[I-K<-;W&I6L4RG!1Y0"*')+=E1I5)?#%OY"?:=5_Z!\/_
M '__ /K4?:=5_P"@?#_W_P#_ *U6FO+91"3<1 3G;$=P^<]<#UHN+VUM7B2X
MN(HFE;;&KL 7/H!WHNB>23=K%7[3JO\ T#X?^_\ _P#6H^TZK_T#X?\ O_\
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M=_\ ?0_PK0HH&9_]FR_]!&[_ .^A_A1_9LO_ $$;O_OH?X5H44 9_P#9LO\
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M1N_^^A_A6A10!G_V;+_T$;O_ +Z'^%']FR_]!&[_ .^A_A6A10!G_P!FR_\
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M_P"?Z/\ [\__ %Z/L^I?\_T?_?G_ .O0!?HJA]GU+_G^C_[\_P#UZ/L^I?\
M/]'_ -^?_KT 7Z*H?9]2_P"?Z/\ [\__ %Z/L^I?\_T?_?G_ .O0!?HJA]GU
M+_G^C_[\_P#UZ/L^I?\ /]'_ -^?_KT 7Z*H?9]2_P"?Z/\ [\__ %Z/L^I?
M\_T?_?G_ .O0!?HJA]GU+_G^C_[\_P#UZ/L^I?\ /]'_ -^?_KT 7Z*H?9]2
M_P"?Z/\ [\__ %Z/L^I?\_T?_?G_ .O0!?HJA]GU+_G^C_[\_P#UZ/L^I?\
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MI]0:^2U\;^*SC_BHM3_\"&I-V$W8^UZ*^+!XV\5'_F8M3_\  AJ#XW\4@?\
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M)UXK_P"ABU/_ ,"6_P :3_A.O%?_ $,6I_\ @2W^-2XV&?;U%?$7_"=>*_\
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M4 %)2TY$+=*<*<IRY8@W8;0*G\E?4YICQE/I75/!U::YI+0E23&444E<S&%
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M8-<_Z]H__0C7C;&O9/V=/^1@US_KVC_]"-:1W-(;GT-1116AL%%%% !1110
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M^O:/_P!"->,FO9OV=/\ D/ZY_P!>T?\ Z$:N.YK#<^AJ***T-0HHHH ****
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M,?\ (V:/_P!?D7_H0K[<KXC\,?\ (V:/_P!?D7_H0K[<K6&QM3V"OBKXE?\
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M_(?US_KVC_\ 0C7BYKV?]G/_ )#^N?\ 7M'_ .A&JCN7'<^AZ***T-0HHHH
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MP]_U^I7VI4L85X3^T/"99] QV$W_ ++7NU>)_'T@3:'GTE_]EK.;M$B;M$\
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MI562;)-,8@ <XJ)F&>O%=48)';"FD(S4PFAC3:V2-TA:2DHJBA<4F*":,YH
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M<57=ASS4SG*;U.BG2C%60LLQ;BJY;FE+5&3S22.A("<TAHIM44+129Q1NYH
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MQ24'BDS04V+2T@I10"'9XII-&:3-*PW(,TF:,TE,AL****8@I*6DH$%%+24
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M_P!"->+9KVC]G/\ Y&#7?^O:/_T*B.XX[GT/1116AJ%%%% !1110 5YC<_\
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MO ?W+[_>3^M=C0!\X?M)_P#(Q:)_UZ/_ .AUXGGBO;/VD_\ D8]#_P"O1_\
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M:X[P']R^_P!Y/ZUV- 'SA^TG_P C%HG_ %Z/_P"AUXC7MW[2?_(Q:)_UZ/\
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MLNATNRZ%(G--SCBEQQ3&-)$HU?#1_P"*LT?_ *_(O_0A7VW7Q%X8/_%6:/\
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MJ^)7_)2?$'_7X]6MRSEJ***JX@HHHH ****$ 4444-C"BBDI %%%% !1110
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M8X)J5SM'%5R<T(:#.:]I_9R_Y#^N_P#7M'_Z$:\5S7M/[./_ "']=_Z]H_\
MT(U:W+CN?1-%%%6:!1110 4444 %>8W/_'U-_P!=&_F:].KS&Y_X^IO^NC?S
M- %=J8:>U,- ##3#3S3#0 TTPT\TPT =GX#^Y??[R?UKL:X[P']R^_WD_K78
MT ?.'[27_(QZ)_UZ/_Z'7B->W?M)?\C'HG_7H_\ Z'7B-(I;!112T#0E+24M
M PI*7--H$PHHHH)"BBBF 4444 %%%%( IPI!2B@I#A0:!TI*1H%!HI*!,***
M*"0I*4TVF)A112T"/>_V:?\ 7^(?]V'_ -FKZ"KY]_9J_P!?XA_W8?\ V:OH
M*F2SF?B)_P D\U[_ *\WKXXX*C-?8_Q#_P"2>:]_UYO7QJ3QBLI[F-3<1CGB
ME44@%2*,=:AF;8IX%".!UIKMFD44K:"MH29.<TUS2YP*B=B:$M02U&$Y-!/&
M*;FDK2QK8****8PHHHH *<HIHIXXI"89JW9+^^!ZU47DU:MW\N57%1/:QG4^
M%I'01$A,+ZU;5U1"6[U6BE64B0G)(ZBE>3L!P:\J2NSQ9*[LQX9N-IRM4M0F
M^39Z>E2RSK"A&>>U9$\ID8GUK:E3N[F]&E>5R(DDTT]:":.M=AWH08.:8Q.,
M4\D5"35(M(:33:4FE4<59IL:WA9?^*KTC_K\B_\ 0A7V[7Q+X7'_ !56D?\
M7Y%_Z$*^VJN!=-A7Q5\2O^2D^(/^OQZ^U:^*OB5_R4GQ!_U^/6B-#EJ***H
MHHHH$%%%%, HI**D84444@"BBB@ H%%+3 ****: L+TIP]Z8C94>U/S7T5&2
MY4T8L-W/%([$+S1TY-0NV34XC$.G!W>K!*XTTE%%>$W<U"BBBI ****D9U7P
MT_Y*5X>_Z_4K[4KXK^&G_)2O#W_7ZE?:E)@%>#_M%'%QH'TF_P#9:]XKP?\
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M*/\ A%/#W_0#T_\ \!D_PIA<^&:*^YO^$4\/?] /3_\ P&3_  H_X13P]_T
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M 33_ /P'7_"BP<Q\-9%+D>M?<G_"*>'O^@)I_P#X#)_A1_PBGA[_ * FG_\
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M3P]_T ]/_P# 9/\ "C_A%/#W_0#T_P#\!D_PH ^&*6ON;_A%/#W_ $ ]/_\
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M^%'_  BGA[_H":?_ . R?X4[!RGP_N7UHW+ZU]P?\(IX>_Z FG_^ R?X4?\
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M?^ Z_P"%)_PBWA__ * NG_\ @.O^%+D*]F?%GF+MP2*A=U_O"OMG_A%M _Z
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M<K/K&BOD[_A?'CS_ )_;3_P$2C_A?'CS_G]M/_ 1*=PY6?6-%?)W_"^/'?\
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M'X\^._\ G]M/_ 1*;@TKA<^LJ*^3?^%\^//^?VT_\!$H_P"%]>//^?VT_P#
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M]9_^ BT?\+U\=_\ /]9_^ BT7071]6T5\I?\+U\=_P#/]9_^ BTG_"]?'?\
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M_D8M$_Z]'_\ 0Z\1->W?M)?\C%HG_7H__H=>(FN8]5;"4444 %%%% !1110
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M+$!%0,N#5E3ZBHY,=:M&J(*2G&DJRQ*2EHH 2BBB@ KVO]F__D/Z[_U[1_\
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M'VJKE7&=#2@T$4E,8]3A@<UH(0P4Y%98.*N6KY.,_2LZD=+F56.ES0'L*>H
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M&&KQFE*GU,VNXV1<J35$U>D;:#CI5(]:\#.^3GC;<UIC:***\ U"OL[X4_\
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MT =1\//^1JC_ .N;_P C7K]>0?#P_P#%5QC_ *9O_*O7ZX<3\9]%E7\!^O\
MD?./[2''B/1/^O1__0Z\5->U?M)?\C'H?_7H_P#Z'7B@Z5RL]BGM80]:,T&D
MH#J+BCM1VI:10F:*2G#F@0E!HQ2T ,---.-(:HS8E+244"%HHHH&.III0:#0
M-ZH;11102%+24M #J0T"@TBMT-I:0THID@:2EI* /=OV:_\ D*:]_P!<8OYF
MOHBOG?\ 9J_Y"FO?]<8O_0C7T13)9RWQ(X^'&O?]>C5\CJ^Z,#VKZW^)7_)-
M]?\ ^O1J^0[8[L+7/774Y<0NH\CY?:FAL'%/E4J^*C[UBMC!:HD4!ACH:%!)
MI@/.<<T]6]:&)DD<QB;@\>E75D$B@K68<\D4^.5HSD'CN*B4+ZF<Z=]4:3C:
M 2:9O.*K&XRN,4PSDC':H4&9JF^I%<R;G/H.E47JU,.?:JS]*ZJ:LCMII)$1
MI5.#2&DK4W+ .5J,\'-$;8XIS#(J=F1LR6-LBDE&0?:H4;:U6>&6I:LR6K.Y
M2-)3W7!-,K0U0HJ1:BIRFA@RQ&WK4KXQ585."&3D5DUU,9*SN57&&I$.#4LH
M[U".M:+5&JU1*1D5%T-3*>*8Z]Z$Q)]#7\+'=XLT?_K\B_\ 0A7VY7Q!X5_Y
M&W1Q_P!/L7_H0K[?K2)K *^,?BG_ ,E/\0?]?1_D*^SJ^,/BG_R5#Q!_U]'^
M0JXNS+.0HI>U)6C$%+244 *#@YJ9'#=>M04H.*Z:&(E2EIL)JY;5<J33,XZ5
M&)2*3S/2O3ECJ+BN7<CE8Z1LC%0TI.>:2O(Q%5U9\S+2L)1117,4 I:2EI@%
M%)2T(!**#12 **** "EI*6F@$-%+24F 4444 %?9WPI_Y)=X?_Z]1_,U\8U]
MG?"G_DEWA_\ Z]1_,T =C7AW[03;;CP^<X_UO_LM>XUX1^T4<2:!_P!M?_9:
MB?PDSV/'G;?@U#)U!J6W421$^@J%AP3V]*YD<PH;(%/*C&]3GUJ%3@$"G@X'
M H D ^7-7+6]VX20Y'8GM5,L"O-1'.>V*NG-P=T1*"DK,Z)/WCC:<#UJ.7]V
MY!/-9D%VZ#:3D=J?)>9;)'->DL73<+=3F]A)/R+<\Y2(D]<<?6L&=RQ)]:O2
M3&7AOP%9TH(8UQUJWM&=%&GRE5^M-IS]:94(ZD21MS4C?,*KCUJ=&W+28F-1
MMC>U6@0R>]59!CFGPR=J30FKH;.O.:@J[,NY,BJ9&#3BQQ>@E7(M,U"1 Z6%
MTR,,AEA8@C\JI'FN_P!-^,OC/2=-MM/M+NT6WMHQ'&&ME)"CIS5EG)KI>I#!
M_LZ\_P"_#?X59CTS42.=/N_^_+?X5UZ_'3QT?^7VS_\  1:>OQQ\=9YO;/\
M\!5J&D2TCBIM)U$C']GW?_?EO\*J'2-3S_R#KS_OPW^%>C-\;?' '%Y9_P#@
M*M5G^.7CM6Q]ML__  $6G&P1L<*FE:EC_D'7G_?AO\*)=)U$*6.GW0 &23"W
M'Z5W*_'3QV3_ ,?MG_X"+1<?&KQM=6TMO+>6ACE0HV+51P1@T:#=CSA&P:]L
M_9S_ .0_KG_7M'_Z%7B97;P*]J_9Q.=>US_KVC_]"JH[C6Y]$T445984444
M%%%% !7F'B]&;Q#<8'I_Z"*]/IC11L<M&A/J15TY\CN<^)H>VBHWL>)-&_\
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M/^%)_P * \$?\\[_ /\  D_X46)<KGRG17U9_P * \$?\\[_ /\  D_X4?\
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M_P"!1_PI#\"?!I_AU#_P*/\ A1[)A["1\RL>*:"1UKZ</P)\&D?=U#_P*/\
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M:C_X%'_"E;X#>"VZKJ/_ (%'_"A0:$H-,^6**^I/^%!>"O[NH?\ @4?\*/\
MA07@K^YJ'_@4?\*KE*Y3Y<'6I5-?3W_"@O!7]W4/_ H_X4H^ ?@L?PZC_P"!
M1_PI.(G$^:/O**AF7C-?3X^ _@T# &H_^!1_PH/P&\&,,%=1_P# H_X5*@T+
MD=SY9'!J8'(S7T[_ ,*"\%?W=0_\"C_A2_\ "A/!8_AU'_P*/^%4XC<3Y>D]
M:]G_ &</^0_KO_7M'_Z%7='X!^"C_#J/_@4?\*Z/PA\.=!\$75S<:0MR)+E
8DGG2[Q@'(Q32L-*QUM%%%44%%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>img224999359_23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_23.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *: Q4# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W\T4'I10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<_%X
MUT&;63I*WH^VB0Q>65(^8=LU2C*6R)<HQW9T%%%<_<^-=!M-8.E37H%X'"%
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%%  >E%!Z44 %%%% !1110
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M'U!]:V:*IUIN7,WJ2J,(QY4M"O86<>G:?;6418QV\:Q*6/) &!FIG4.C(>C
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M1W_"::%_S^C_ +Y-'_"::%_S^C_ODTW_ (0G0/\ GR/_ '];_&C_ (0G0/\
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MX0G0/^?(_P#?UO\ &C_A"= _Y\C_ -_6_P :/W7F'^U_W?Q'?\)IH7_/Z/\
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M_P :/W7F'^U_W?Q'?\)IH7_/Z/\ ODT?\)IH7_/Z/^^33?\ A"= _P"?(_\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 'I10>E% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !Z44'I1
M0 4444 %<7K/_)6/#7_7E=_^RUVE0265K+>Q7DEO&US"K+'*5&Y >H![9Q0!
MPVC:A::%\2?%=KJ=S#:&]\B[MGG<()4";6P3P<$5R7VB,ZFWC#/_ !*#XEW>
M=CY?*$?E^;_N[N]>MZMX?TC74C75=-MKP1G*>?&&V_3-6/[.LO[._L_[)!]B
MV>7Y&P;-OICIB@#B]:U*SUSXA^%K+3+F&[>T::\N'@<.(DV;5R1P,DUG:W\.
M_%^HZW>7EGXZO;2VFE+QVZ%L1@]AS7>Z3X?T?0ED72M-M;,2'+^1&%W?7%:5
M 'B/@9_$>D?&>Z\-ZIXBN]3@@L6D/FN2I)VD<'N,U[=7CVF?\G.:I_V#!_)*
M]AH **** &2L4B=AU5217F'A?5OB+XJT"#5[:^T2&*8MMCDMV)&#CL:].G_X
M]Y?]P_RKB/@[_P DTTWZR?\ H1H 7[)\3/\ H*Z#_P" S_XT?9/B9_T%=!_\
M!G_QKNJ* .%^R?$S_H*Z#_X#/_C1]D^)G_05T'_P&?\ QKNJ* .%^R?$S_H*
MZ#_X#/\ XT?9/B9_T%=!_P# 9_\ &NZHH X7[)\3/^@KH/\ X#/_ (UE^(M0
M^(_ASP_>:O/J&ARQ6L>]D2V<%A[<UZ=7'_%+_DF>N_\ 7L?YB@#IM-N'N]+M
M;B3&^6)7;'3)&:M50T/_ ) .G_\ 7O'_ .@BK] !1110 4444 5K^22.V#1E
M@WF(/E&>"P![>E6:IZF-UF 5S^]CXP3_ !BKE !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 !Z44'I10 4444 %%%% !1110 4444 >/:9_R<YJ
MG_8,'\DKV&O'M,_Y.<U3_L&#^25[#0 4444 1S_\>\O^X?Y5Q'P=_P"2::;]
M9/\ T(UV\_\ Q[R_[A_E7$?!W_DFFF_63_T(T =W1110 4444 %%%% !7'_%
M+_DF>N_]>Q_F*["N/^*7_),]=_Z]C_,4 =#H?_(!T_\ Z]X__015^J&A_P#(
M!T__ *]X_P#T$5?H **** "BBB@"GJ?_ !YCC/[V/_T,5<JGJ?\ QYCC/[V/
M_P!#%7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/_D Z?\ ]>\?_H(J_5#0_P#D Z?_ ->\?_H(J_0 4444 %%%% %/4^+0<?\
M+6/U_OBKE4]3R+08Q_K8_7^^/2KE !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/_D Z?\ ]>\?_H(J_5#0_P#D Z?_ ->\?_H(J_0 4444 %%%% %/4QFS'/\
MRUC_ /0Q5RJ>IC-F/^NL?_H8JY0 4444 %%%% !1110 4444 %%%% !1110
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M%%+LB&4&-ISS[^];OPU&FVS:WIMAK.H:I+9W7E3R7ASM8 _=/<<4 =[1110
M4444 %%%% 'CVF?\G.:I_P!@P?R2O8:\>TS_ ).<U3_L&#^25[#0 4444 1S
M_P#'O+_N'^5<1\'?^2::;]9/_0C7;S_\>\O^X?Y5Q'P=_P"2::;]9/\ T(T
M=W1110 4444 %%%% !7'_%+_ ))GKO\ U['^8KL*X_XI?\DSUW_KV/\ ,4 =
M#H?_ " =/_Z]X_\ T$5?JAH?_(!T_P#Z]X__ $$5?H **** "BBB@"GJ8S9C
M_KK'_P"ABKE4]4YLQG_GK'Z_WQ5R@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#015^@ HHHH **** *>J8^QC/_ #UC]?[X]*N53U/'V,9_YZQ^O]\>E7*
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M /!/ _AFR\+?M WFE6+RM!!IY=3*V6R0N<G\:][KQ[3/^3G-4_[!@_DE>PT
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MO>/_ -!%7Z "BBB@ HHHH IZGQ:#_KK'Z_WQZ5<JGJ?_ !YC_KK'Z_WQ5R@
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MS?\ WI^B"BBBMCS HHHH **** "O1O@;_P @#6?^PE)7G->C? W_ ) &L_\
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M]3_X]!_UUC_]#%7*IZF<6@_ZZQ_^ABKE !1110 4444 %%%% !1110 4444
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MR?\ H1KMY_\ CWE_W#_*N(^#O_)---^LG_H1H [NBBB@ HHHH **** "N/\
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M %%%% !1110 4444 %%%% !1110 4444 %<_XC_Y".@_]?P_]!-=!7/^(_\
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M !7'_%+_ ))GKO\ U['^8KL*X_XI?\DSUW_KV/\ ,4 =#H?_ " =/_Z]X_\
MT$5?JAH?_(!T_P#Z]X__ $$5?H **** "BBB@"GJ?_'F.<?O8_\ T,5<JGJ?
M_'F.<?O8_P#T,5<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *\=?4?%VM>+?$5M9>)38VMA="*.(6ZOP5!ZU[%7D7A__D<_&?\ V$%_
M] %5%79E6DXPNB3[#XX_Z'9O_ -:/L/CC_H=F_\  -:Z.BM.5')[>?<YS[#X
MX_Z'9O\ P#6LK5[/QBMWI@E\7M(QN0(S]E4;&P>?>NXK&US_ (_='_Z^Q_Z"
M:.5#5:=]RK]A\<?]#LW_ (!K1]A\<?\ 0[-_X!K71]Z*.5"]O/N<Y]A\<?\
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M ';4444 %%%% !1110!X]IG_ "<YJG_8,'\DKV&O'M,_Y.<U3_L&#^25[#0
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MZ?\ T UE5^!G5@OX\3Z#HHHK@/I HHHH ^??B+_R5V[_ .P?%_.LBM?XB_\
M)7;O_L'Q?SK(KT,/_#/D<W_WI^B"BBBMCS HHHH **** "O1O@;_ ,@#6?\
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M^@ HHHH **** *>IMMLP2<?O8^<X_C%7*IZFVVT!W8_>QC.<?QBKE !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7D7A__D<_&?\ V$%_
M] %>NUY%X?\ ^1S\9_\ 807_ - %5#<QK_ SIZ***V. **** "BBB@ JO?\
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MZ?\ T UE5^!G5@OX\3Z#HHHK@/I HHHH ^??B+_R5V[_ .P?%_.LBM?XB_\
M)7;O_L'Q?SK(KT,/_#/D<W_WI^B"BBBMCS HHHH **** "O1O@;_ ,@#6?\
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MXS_[""_^@"O7:\B\/_\ (Y^,_P#L(+_Z *J&YC7^!G3T445L< 4444 %%%%
M!5>__P"0==?]<F_E5BJ]_P#\@ZZ_ZY-_*@$6/A)_R372OH__ *&U=M7$_"3_
M ))KI7T?_P!#:NVKG/5"BBB@#A?C%_R2S6/^V/\ Z-2O.[?_ (]HO]P?RKT3
MXQ?\DLUC_MC_ .C4KSNW_P"/:+_<'\JZL-U/(S7[/S)****ZCR HHHH ****
M "JUK_R4'PG_ -?I_P#0#5FJUK_R4'PG_P!?I_\ 0#657X&=6"_CQ/H.BBBN
M ^D"BBB@#Y]^(O\ R5V[_P"P?%_.LBM?XB_\E=N_^P?%_.LBO0P_\,^1S?\
MWI^B"BBBMCS HHHH **** "O1O@;_P @#6?^PE)7G->C? W_ ) &L_\ 82DK
MFQ7PH]S(_P")/T/4Z***XCZ4**** "BBB@ HHHH **** "BBB@ /2B@]** "
MBBB@ HHHH **** "BBB@#Q[3/^3G-4_[!@_DE>PUX]IG_)SFJ?\ 8,'\DKV&
M@ HHHH CG_X]Y?\ </\ *N(^#O\ R333?K)_Z$:[>?\ X]Y?]P_RKB/@[_R3
M33?K)_Z$: .[HHHH **** "BBB@ KC_BE_R3/7?^O8_S%=A7'_%+_DF>N_\
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M_P" S_X4?\+T\"?]!&X_\!G_ ,* /2**\W_X7IX$_P"@C<?^ S_X4?\ "]/
MG_01N/\ P&?_  H [S4_^/08_P">L??'\8]C5RO+[WXW>!I[<(FH3D^8C<V[
MC@,"?X3Z?_JJQ_PO3P)_T$;C_P !G_PH ](HKS?_ (7IX$_Z"-Q_X#/_ (4?
M\+T\"?\ 01N/_ 9_\* /2**\W_X7IX$_Z"-Q_P" S_X4?\+T\"?]!&X_\!G_
M ,* /2**\W_X7IX$_P"@C<?^ S_X4?\ "]/ G_01N/\ P&?_  H ](HKS?\
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M8_\ HU*\[M_^/:+_ '!_*KOQ&^+/A'Q%X#U+2].O9I+N?R]BM R@XD5CR1Z
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M $?_  BGA_\ Z MC_P!^%_PH_P"$4\/_ /0%L?\ OPO^%;%% &/_ ,(IX?\
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M_A1_PBGA_P#Z MC_ -^%_P *V** ,?\ X13P_P#] 6Q_[\+_ (4?\(IX?_Z
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ME^&=,;4=7NEMK56"ER">3T  Y- &G17G_P#PNOP#_P!!S_R7D_\ B:/^%U^
M?^@Y_P"2\G_Q- 'H%%>?_P#"Z_ /_0<_\EY/_B:/^%U^ ?\ H.?^2\G_ ,30
M!Z!17G__  NOP#_T'/\ R7D_^)H_X77X!_Z#G_DO)_\ $T >@45Y_P#\+K\
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M !-'_"Z_ /\ T'/_ "7D_P#B: /0**\__P"%U^ ?^@Y_Y+R?_$T?\+K\ _\
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M (T?\*N\$?\ 0MV7Y'_&NNHH Y'_ (5=X(_Z%NR_(_XT?\*N\$?]"W9?D?\
M&NNHH Y'_A5W@C_H6[+\C_C1_P *N\$?]"W9?D?\:ZZB@#D?^%7>"/\ H6[+
M\C_C1_PJ[P1_T+=E^1_QKKJ* .1_X5=X(_Z%NR_(_P"-'_"KO!'_ $+=E^1_
MQKKJ* .1_P"%7>"/^A;LOR/^-'_"KO!'_0MV7Y'_ !JG>^.=9_X2G5M%T;PL
M^I?V9Y7G2B\2+[Z!A@-]?TJUH?C^WU#61HFJZ;=Z-JS+NC@NA\LP_P!AQP:
M'?\ "KO!'_0MV7Y'_&C_ (5=X(_Z%NR_(_XU _Q%M(OB8?!DUHR.8U9+HO\
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M\W?B+^PFTP6O]K39^U;MV[/MVKUZN?\ "WAR3P\NIA[A9OMM[)=#"XVACTH
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M&@NK;1;*&^N&N+M(5$TK=7?')X]ZO444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <%X4_Y*
MIX\_WK+_ -$BJ_Q?6%=$TF=<#48]3@^QD?>W%OF _#K5BZ\(>)[;Q=K6M:%K
MEC:QZIY1>*XMC(5V(%&#D>]6-*\"3G7(=;\2ZO)J]];_ /'LA0)#![JOK[T
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M128%&!0 M%)@48% "T4F!1@4 +128%&!0 M%)@48% "T4F!1@4 +37)",1U
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9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>img224999359_24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_24.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &D M # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'\4:]'X:\/W.I
MR)O:, 1QYQO<G '^>U;%<M\0]$N->\'W-M:*7N(V6:-!U<KU'UP3CWK2DHN:
M4MC.JY*#<=S L/#OC'7[!-5OO%,^GSSJ)(;:W4A$!Y&X CVXYK;;5M5\)^")
M[[Q'-!=WL&0GE#&\DX4$XZYZD#I570_B/X?DT2'[?>+97<$82:"52&#*,'''
M-5]=N1\1/A[>OI%O<*\<NZ-)4VF4H<_+ZY'Z\5TM3<DJD;1OV_4YDX*+=.5Y
M6[W_  *VG^'_ !AXAL4U6_\ %%QITDZB2&VME(5 >1N (]N.:T/"7B#5HO$%
MWX6\1,DM] GF07*# F3W]\'/Y^E'A_XCZ!+HL"ZC>+8WD$8CGAE4@AE&#CCG
M^=9WAF63Q9\1;GQ/;PO'I=M!]F@D=<&4_P"2Q]N*<E)J2J1LEMI]PHN*<73E
M=O?7[[E6V/B#7_%/B.WA\4S:=#8W&V-"H88);CJ.!MK0\*>)-6OM"\26U[=)
M<W&EJZQ7L0 $GRM@^AP5S^-<T/",/BK7O&P!87UO< VQ#8&27R".^=N/:NA\
M':AI]Q\.-3L[>UCM+RTMY4NX0,$OL(WG//./S!':KJ*/)HNW3;_AS.DY<^K[
M]=_^&,73I/$]UX,;Q&/&+1.B22?9YE4@[">,GN<>G>M76_%>JW'PFM-<AE:T
MOI)%5WB&,X8@D>QQFN,C\)0GX?6'B>V@,\MO,SWD#N=LD8<CMTQCG'8D]J[+
MQY?6&H_">WN=,5$LVDB$<:#'EXR-N.Q'2KE&+G&RO[W;;R(A*2A*[M[O=Z^9
M8MM \1N87/C_ ';MI*!%Y]OO5?\ &/B+5(]7L?#.@%%U.\7>\[#(A3GG]"?P
M]ZYFSM_A7;26]PMZRSQ%7'S3'##!]/6M7Q8\GASQUIGBUH9)M,>'[/<-&N3'
MG.#^H_(BLW&\U==[75M?U-5*T'9]5>SOI^A/_P (GXRT^2"YL?%TEU-O'G17
M:DQD=\#)_+CZT[QCI?B2VAU+6K/Q/+;V\,7FK:)%P-JC(!SW()_&K]]\2_#-
MI;QR07AO9)&55AMT)?D^AQCZ=:O^,7$G@35I & :S<X88(R.X[5DI5%*+FM_
M)&KC3<9*#V\V<[X*T[Q)?V^F:W>>)YIK:53(]HT?4<C&<_TJWX.UF\N]=\5)
M?7;R6]G=%8@YXC0%NGX ?E6GX _Y$32/^N/_ +,:YSP3 +O7/&]L6P);ID)'
M;)<4Y/F]I?I_F3%<OL[=?\B'3Y_$OQ"N+F]M-6DT;18I3' (!^\DQW)R#Z=\
M=JECU+Q!X'\0V-CK.H'5-(OW\J.YD7$D3]!G\QU)X^E5O _B2T\(P7'ACQ"W
MV&YMIF:.213LD4G.0?S.?0TWQ'JL'C[Q'I.C:'NN+>UG%Q=704A$ ]"?;/U.
M*U<7SN+C[GI^-S-27(I*7O\ KU[6)/B'X@U_2?%]A%H\\IC6U^T26R\K(%9B
MV1W^4?I6SK_BC[=\-)]=TBX>&1D0AE/S1MN 93[]1576L?\ "Y=!![V+C_T9
M7)^.-/NO!JZE9VD>[0]9PR)V@E!!P/R_+Z4H0A+DC;71^NNH3G.'M)7TU7II
MH>N:#/+<^'=,GF<O++:Q.[GJS%02:P?''B:[T6*RT[28UDU;49/+@#<A!P"V
M/J1^OI6UX:_Y%;2/^O*'_P! %<E\1;6ZL=4T7Q3;P/<1:;)_I$:CD(2#G^8_
M$5STHQ=:S\_^ =-64E1NO+_@C7\'^,H;;[9#XQN)-1 W>2X/DL?[O)Q^E7]
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MWRW_ ,51_;GB[_H!Q?\ ?+?_ !5=E15\Z_E1S_5Y_P#/Q_A_D<;_ &YXN_Z
M<7_?+?\ Q5']N>+O^@'%_P!\M_\ %5V5%'.OY4'U>?\ S\?X?Y'&_P!N>+O^
M@'%_WRW_ ,51_;GB[_H!Q?\ ?+?_ !5=E11SK^5!]7G_ ,_'^'^1QO\ ;GB[
M_H!Q?]\M_P#%4?VYXN_Z <7_ 'RW_P 57944<Z_E0?5Y_P#/Q_A_D<;_ &YX
MN_Z <7_?+?\ Q5']N>+O^@'%_P!\M_\ %5V5%'.OY4'U>?\ S\?X?Y'&_P!N
M>+O^@'%_WRW_ ,51_;GB[_H!Q?\ ?+?_ !5=E11SK^5!]7G_ ,_'^'^1QO\
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MQ_A_D<;_ &YXN_Z <7_?+?\ Q5']N>+O^@'%_P!\M_\ %5V5%'.OY4'U>?\
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M7944<Z_E0?5Y_P#/Q_A_D<;_ &YXN_Z <7_?+?\ Q5']N>+O^@'%_P!\M_\
M%5V5%'.OY4'U>?\ S\?X?Y'&_P!N>+O^@'%_WRW_ ,51_;GB[_H!Q?\ ?+?_
M !5=E11SK^5!]7G_ ,_'^'^1QO\ ;GB[_H!Q?]\M_P#%4?VYXN_Z <7_ 'RW
M_P 57944<Z_E0?5Y_P#/Q_A_D<;_ &YXN_Z <7_?+?\ Q5']N>+O^@'%_P!\
MM_\ %5V5%'.OY4'U>?\ S\?X?Y'&_P!N>+O^@'%_WRW_ ,51_;GB[_H!Q?\
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MJ=NUTJ(^ XVG<Q4 -T+;@1@<UM4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 445Y/H6J_$#Q9>ZZ^G:[I=G;6&IS6:1S66]B%(P<@^A'Y4 >L5Y%X
MT^#<WBGQM%K2:C%'%*Y,P^SI^Z"H-GRX_>DMG.XCCBM[^Q_B?_T->B_^"X_X
MT?V/\3_^AKT7_P %Q_QH YG5?@E/J'C>+61JD B.9'(LXU577;L'E8VN" V2
M3Z4]?@K,/B(/$']IP>2'^U?\>D>/-\S[GE8VXV?Q9SNYQ71_V/\ $_\ Z&O1
M?_!<?\:/['^)_P#T->B_^"X_XT <[IOP6FL?B'_PD!U.%H4D6Y7_ $6/#2%R
M67R\84;<88'(.37L-<!_8_Q/_P"AKT7_ ,%Q_P :/['^)_\ T->B_P#@N/\
MC0!W]%>4>);WXC>$],CU.[\0Z3<P?:886BCL-K$.X7J3[UZO0 4444 %%%%
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MI'9>H4*A.[IR/6@#KKOX@VEK>7)_LN_DTJTN/LMUJB*ODQ29 /&=Q520"P&
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MO\(_^9Q_[&&Y_DM>D5YO\(_^9Q_[&&Y_DM 'I%%%% !1110 4444 <#\8?\
MD1D_["%K_P"C5KOJIZEI5CK%H+74;:.Y@#K)L<<;E.0?P(JY0 4444 %%%%
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M %%%% '!6'_)=-8_[ D'_HPUWM<%8?\ )=-8_P"P)!_Z,-=[0 4444 %%%%
M!1110 4444 %%%% !1110 5P'PW_ .0WXY_[#TO_ *"M=_7 ?#?_ )#?CG_L
M/2_^@K0!W]%%% !1110 4444 ><_$W_D9/ 7_8:7^5>C5YS\3?\ D9/ 7_8:
M7^5>C4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YQXH\4:[H
M5WJ6G7HM[BRO(I/LMQIS9N[,,I 9X"=SA3SN7TZ5Z/7@.NVMD/BIJ$5]J6G:
M8&U*"^&H:E$\-RJQ@9C@D/R%#C&<CZ&@#=^#NASQWQUFV^P0:=]@6UE%E>F?
M[;.&R9W!^XV,C!YYKV&O.H==^'UKXUANM%9+O6[[]Q(-(!E4J2/GE"?)Q_>/
M(YKT6@ HHKS?3_&^M7&I:?/*^FM;7VIO8'2HU;[7;*"P\QCGDC;N8;0 #P?4
M ](HKSNZ\6>)&T_4?$]G'8'0;"XDC^R-&QGGBB<I)('SA3D,0,'@<]:[B;5=
M.MDB:XOK: 2KN3S953</49- '':?_P ERUK_ + MO_Z,:N]KSS1KNVO/C=K,
MMK<13Q_V+ -\3AAGS#W%>AT 9/BC_D4=:_Z\9_\ T6U?"U?=/BC_ )%'6O\
MKQG_ /1;5\+4 %%%% !73?#K_DI'AO\ [",/_H8KF:Z;X=?\E(\-_P#81A_]
M#% 'VS1110!##_K9_P#?_H*FJ&'_ %L_^_\ T%34 %%%% !7F_PC_P"9Q_[&
M&Y_DM>D5YO\ "/\ YG'_ +&&Y_DM 'I%%%% !1110!\TZI_R//BS_L*/_(4R
MGZI_R//BS_L*/_(4RO2H_ CXO,?]ZGZA1116AQ%/5?\ D#WO_7!_Y5]#^"?^
M1%T'_L'P?^@"OGC5?^0/>_\ 7!_Y5]#^"?\ D1=!_P"P?!_Z *X\5NCZ3(_X
M<_4WJ***Y3W0HHHH **** "BBB@ HHHH \+\5WEJ_C"_ET2PGTL?;DTR_P!2
MBF1H[B:0?=EM3_K$^;!88/UKJ?AWH/\ PC6M7%C>^&IK34#!M74HIVGM9(E(
M^1"QS%R<[#^=0ZUX=U:P\<2^(QX-TOQ #('MYK>;[/<0D# W*QV.1V;K^E;5
MGJOCW6M2ML:!::#IR2!KA[V<3S2J#RJ*G"Y]2: .WHHHH **** ."L/^2Z:Q
M_P!@2#_T8:[VN"L/^2Z:Q_V!(/\ T8:[V@ HHHH **** "BBB@ HHHH ****
M "BFNZ1H7=E51U9C@"H#?61!!N[<@_\ 30?XT 6<CUK.TS1=/TB>_FLH?+DO
M[@W-P=Q.^0@ GGIT[5DGPQX,))-AIN3[C_&L3P[X>\*SMK'VBSL'$>I2I'O8
M':@"X YZ=: /0J*QM,L?#VC-(VG)96QD #F-P-V.G>M-+RVE<)'<0NQZ*K@D
MT 34444 %%%% 'G/Q-_Y&3P%_P!AI?Y5Z-7G/Q-_Y&3P%_V&E_E7HU !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %9>O/HD.F/<>(/L(L8_O->
MJI0$_P"]QFM2N)^*&@:AX@\-VD6F6=O>7-M?Q77DW,@2)E3.0^>"#G&/>@"_
MX8USP9>W$EEX9NM+:4)YCQ62JIVY R0 .Y%=/7">!_[8DU"66\\*Z#I=J8BJ
MW.FS([,V1\IVCIU/X"N[H 0@E2 <'L:\DTSPQJD4FE6O_"-/;Z]:Z@L]YXA,
MD9$T8<EVW@[WWJ=NPC S[5ZY10!YC<:;XBMM U7P7;:++)'>7$XMM3$B>1'!
M-(78N"=VY0S# !S@<UV6I^#_  _K26JZKI-M>FUC\N)ITW%5XX'Y5N44 >9^
M&=%TS0OC-K-II5C#9VXT>%O+A7:,F0Y/Z"O3*X+3_P#DN6M?]@6W_P#1C5WM
M &3XH_Y%'6O^O&?_ -%M7PM7W3XH_P"11UK_ *\9_P#T6U?"U !1110 5TWP
MZ_Y*1X;_ .PC#_Z&*YFNF^'7_)2/#?\ V$8?_0Q0!]LT444 0P_ZV?\ W_Z"
MIJAA_P!;/_O_ -!4U !1110 5YO\(_\ F<?^QAN?Y+7I%>;_  C_ .9Q_P"Q
MAN?Y+0!Z11110 4444 ?-.J?\CSXL_["C_R%,I^J?\CSXL_["C_R%,KTJ/P(
M^+S'_>I^H4445H<13U7_ ) ][_UP?^5?0_@G_D1=!_[!\'_H KYXU7_D#WO_
M %P?^5?0_@G_ )$70?\ L'P?^@"N/%;H^DR/^'/U-ZBBBN4]T**** "BBB@
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MQCU>]M(+N&/^QXDVW4!B?(D/8]N:]2K@K#_DNFK_ /8$@_\ 1AKO: "BBB@
MHHHH **** "BBB@ HHHH XWXL?\ )+?$'_7M_P"S+52R^%/@633;:63P[;%F
MA5F.]^3@9_BJW\6/^26>(/\ KV_]F6NHTS_D%6?_ %P3_P!!% 'FA\-_"0$C
M^R(^/^G>Y_PK+T;PY\,]VH_;]'&/MLGV?=;W'^JP-N,#IUKVFB@#SG2_ 7PR
MUEI%L="AD,8!;<DZ8S_O8S6=J'A#0/"_Q,\%MHNF16;3RW0E*,QW 1<=2?4U
MZO7">+_^2D^!/^NMW_Z*% '=T444 %%%% 'G/Q-_Y&3P%_V&E_E7HU><_$W_
M )&3P%_V&E_E7HU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M<'\6[6\NO!T:0075Q9+>PMJ,-IGS9+4'YP,<^E=Y7GWC'1='T]))+[4-=!US
M5+>-5L[LJ8Y,%1M_NIC)(]AZ4 8GPW@T]O'NH7?A&PO;+PNU@J3"='2.2Z#<
M% _/"Y!KURO(_AA>:))XINHK"3Q&=]O(UI+J=YYL-U$D@1G0=B& 'XFO7* "
MBBB@ HH[T4 <%I__ "7+6O\ L"V__HQJ[VN"T_\ Y+EK7_8%M_\ T8U=[0!D
M^*/^11UK_KQG_P#1;5\+5]T^*/\ D4=:_P"O&?\ ]%M7PM0 4444 %=-\.O^
M2D>&_P#L(P_^ABN9KIOAU_R4CPW_ -A&'_T,4 ?;-%%% $,/^MG_ -_^@J:H
M8?\ 6S_[_P#05-0 4444 %>;_"/_ )G'_L8;G^2UZ17F_P (_P#F<?\ L8;G
M^2T >D4444 %%%% 'S3JG_(\^+/^PH_\A3*?JG_(\^+/^PH_\A3*]*C\"/B\
MQ_WJ?J%%%%:'$4]5_P"0/>_]<'_E7T/X)_Y$70?^P?!_Z *^>-5_Y ][_P!<
M'_E7T/X)_P"1%T'_ +!\'_H KCQ6Z/I,C_AS]3>HHHKE/="BBB@ HHHH ***
M* "BBB@#S;XAZUX9U71[J"?7WTR]T7482EVML\GV>YP63( ^8$!LXXJC\-=0
MT_7?%][J]SXJBUS7/L8@58+)X(H+<,"<;@,DL0:Z7XASZMIVD6=[HMG<7'EZ
MA%+?16<(>:6$9R I'.3M!]JYWX=0>++;Q.TFMF^,-]IQO+A+B,".VF:4[(HS
MVPG5>U 'JE%%% !1110!P5A_R736/^P)!_Z,-=[7!6'_ "736/\ L"0?^C#7
M>T %%%% !1110 4444 %%%% !1110!QOQ8_Y)9X@_P"O;_V9:ZC3/^059_\
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MAKO:X*P_Y+IK'_8$@_\ 1AKO: "BBB@ HHHH **** "BBB@ HHHH XWXL?\
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M8]7NKK2+S2Y/['B7R+O&_ D//!/!S^E>I5P5A_R735_^P)!_Z,-=[0 4444
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M\$_\B+H/_8/@_P#0!7'BMT?29'_#GZF]1117*>Z%%%% !1110 4444 %%%%
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MW%:'Q6T:[U?PS:-9VMI<O97\5V\=Y,L<)1-V=^[@J<XQ[U!\.[^ZU.[GN/\
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MBV^Y>8BN03NQD_\ UZ /5*X.QT>TTKXQ/+;B0S7FD33SR2R%V9O/CP,GH .
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M?^S+74:9_P @JS_ZX)_Z"*Y?XL?\DL\0?]>W_LRUU&F?\@JS_P"N"?\ H(H
MM4444 %<)XO_ .2D^!/^NMW_ .BA7=UPGB__ )*3X$_ZZW?_ **% '=T444
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MG-]9?%2_T^YLY9?"HCN(FB8J)\@,"#C\Z\I_X9Q\4?\ 03TK_OM__B:^G**
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MG_T&=%_[Y3_XW0![%17CO]F_'/\ Z#.B_P#?*?\ QN@:;\<PP)UG13SW5?\
MXW0![%145L)Q:PBY9&N @\PH,*6QSCVS4M #719$9'4,C#!5AD$>E9&G>$O#
MND7S7VG:)86MTV<RPP*K<]<$#C\*V:* "F2Q1S1/%*BR1N"K(XR&'H13Z* ,
M?2_"GA_1+M[K2]%L;.X<8:6&!5;'ID#I6Q110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !4+VEM*Y>2WB=CU9D!-35E>)=:_X1WP]=ZNUL]S'
M:J'DC1L'9D!C^ )/X4 7?L%G_P ^D'_?L4?8+/\ Y](/^_8K!U_QI9:#J^AV
M$D33?VK+M$J-\L*Y50[>Q9U'XTFI>*+^+Q)+HFCZ)_:4UO;)<7#FZ6%8][,%
M7D').TGZ4 ;_ -@L_P#GT@_[]BI8XHX4V1(J+Z*,"N9\)^*-4\36\%[)H LM
M/F5BDYO5D;*L5QM '<&NIH **** "BBB@ QFDP/04M% "8'H*,#T%+10 F!Z
M"C ]!67J&M+8:YH^F&!G;4GE59 V!'L0OR.^<8JIK/BRUT/4WM;J"3R8],GU
M&293G"1%05V]R=WZ4 ;^!Z"C ]!7.:%KNNZE<0&^\.?8[*YA\Z*=+Q)2G0A7
M7 P2#VR*;'XTLY/'+^&1;R;EC.+O/[MI@H<PC_:"$-^= '2X'H*,#T%<C%<L
M!XU#7!#)*WE@ORO^BQGCTYYK$^'T4Z:VJ-"-/$>EPN]L+IYOMF\*1.-W QAE
M..<L<]L@'I.!Z"C ]!2T4 )@>@HP/04M% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !116'XP_M%?"&J2Z3.\-_# 9H67J63YMOXXQ^-
M &Y17F/BCQK??:-"O](G*:?!:QZKJ2@ [[>1T0+^ +M_P&MB9;_Q+XVU6R@U
MB^L-.TRW@C/V-U4R3OESDE3T0IQ[T =M17"_#ZSO[NP35K[Q!JMVZSW$)@FD
M3RF"R,@) 4'. #UZUW5 !1110 4444 %%%% !1110 45R'C#Q$/#VN^&I+F]
M:UT^:>=+G"E@X$1*@@ G[V.E9I\:KK/C!+;PY??:T31[J8VYC95:<-'Y>=P'
MJ1QZT >@T5YQX#O8]4N+6:3Q;J<NL)$3J6DWNU,.1R!$5!0*W0KQCN:6Z\5:
MHGC)M42?_BE[6]71YX]O!E8<S9]%D*1_G0!WD6HVLUW>6R2$RV>WSAM/R[EW
M#Z\5FZ1XMTG6KB*"U>X22>(S0">V>(3(,99"P 8<CIZUFB:[TWQ3KF[2+^>&
M^,/DSP(K)Q&%.26!&#[5F^$/#FH:-J.DR7\=Y=1_V8L<9GFW_P!GR@#S$ Z8
M<8P>2-F,X- 'H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 57OK.'4=/N;*X7=#<1-%(/56!!_G5BB@
M#QO0="U3Q-X=U]-0@EAO=/L$T6S9U*[I+<E_-'LS^7S_ +-=?\-VN=4T_4/$
MU]:R6UUK%SO\J1<,D<:B-1CMRK'_ (%7:T4 <I\-HY(OA_I:2QO&X$N5=2I'
M[U^QKJZ** "BBB@ HHHH **** "BBB@#BO&>E_VOXI\)VSM>1P^=<EY;25XG
M3]R<?.O*Y/'7FLR;0;70_'0=DU74K)]"NO/2XFDNRX\R+Y%#$\D9^4=:](HH
M \BTS7+'0-2BE\*WNJWV@PV<\U[I\\<CK:;5S&L9<;E8M\NS)]<#%,;PQXUM
M?"$5X8M)>_M[HZVQ4R?:'G)+LG3;DJ3'CIC%>P44 8=IIF@:]#;ZX='M7FNX
MDF\R:V7S>5& V1G(''/I6JME:)+#*EM"LD,9BB<( 40XRH/8<#CV%3T4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4$ @
M@C(/:BB@#@_#'P]?2=+U^PU*YCN8M0#6MOLS^ZM &$:'(ZC>U:O@3PW>^&?#
MQMM4NH[O4IIFFN9X\[7/"KC(!X15'X5T]% &)X3T:XT'0_L-S)'))]HGEW1Y
MQAY&<=>^&%;=%% !1110 4444 %%%% !1110!B:MHUQ?^(M U&*2-8M.EF>5
M6)W,'B*#;^)[U%J&B7MQXMM=8MIX8U@TZXM5#@L1([(5;'<#8<\BN@HH X"Y
MT#Q;J^HZ??W\>B6U[I2RO;W%N[L;B5HV10<KE(\MN(^8G I(?A+HI\,?V9=3
M7LES)"1-,+R4*TQY:39NV_?^;&*] HH H:)#J%OH=E#JTL4M_'"J3R0DE78#
M!89 //6K]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
H0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>img224999359_25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_25.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'B E4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\.I:;XLN]3:VNS*UW%.V)(VPNTX=MP# =^[>];'C3Q:R?#JVO].F>.YU,1I
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M/>)<6A98FB PX))&<D<<]1GC%7/#EOJ>L:AXE\87]HUG#=V,D%O$_4KM'/T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_H:/_*?'_C1_9'B+_H:/_*?'_C7044<[_I(/81[O[W_F<_\ V1XB_P"AH_\
M*?'_ (T?V1XB_P"AH_\ *?'_ (UT%%'._P"D@]A'N_O?^9S_ /9'B+_H:/\
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M]_YG/_V1XB_Z&C_RGQ_XT?V1XB_Z&C_RGQ_XUT%%'._Z2#V$>[^]_P"9S_\
M9'B+_H:/_*?'_C1_9'B+_H:/_*?'_C7044<[_I(/81[O[W_F<_\ V1XB_P"A
MH_\ *?'_ (T?V1XB_P"AH_\ *?'_ (UT%%'._P"D@]A'N_O?^9S_ /9'B+_H
M:/\ RGQ_XT?V1XB_Z&C_ ,I\?^-=!11SO^D@]A'N_O?^9S_]D>(O^AH_\I\?
M^-']D>(O^AH_\I\?^-=!11SO^D@]A'N_O?\ F<__ &1XB_Z&C_RGQ_XT?V1X
MB_Z&C_RGQ_XUT%%'._Z2#V$>[^]_YG/_ -D>(O\ H:/_ "GQ_P"-']D>(O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJEJ<VI06ZMI=E;7<Q<!DN+DP*%]=P1\GIQC\:NT4 -B,AB0RJJR$#<JMN /<
M X&1^ IU%% !1110 4444 %%%% !1110 4444 %%%% !1110 453N-5L+2ZA
MMI[J..:9F6-">I"ES]/E!/-)/JVGVUU#;37<233;O+4MUVKN;GMA3GF@"[15
M.XU6PM+F"WGNHTEG8I&I/4A2Y^GR@GGTJV"& (((/((H 6BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKS;6/BM=6'B7
M4]&L/!VK:JVGNJ2S6@+J"RAAD!3C_P"M57_A;6N?]$T\2?\ ?IO_ (B@#U.B
MO+/^%M:Y_P!$T\2?]^F_^(H_X6UKG_1-/$G_ 'Z;_P"(H M^,?A;_P )3XMM
M-8^WK$BG$B"%, *AV[@0?-^;&0Q'RY%1^)OA2?$'BVSUC[?'&J#$B"W0*-J
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M#/\ D1?#_P#V#;?_ -%K0!N4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117/\
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !5>^G2SLI[QX]_P!GB>3
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M\CU\1_\ L+#_ -"DKU*O+?A;_P CU\1_^PL/_0I*]2H **** "BBB@ HHHH
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MI_Z,6MKP9_R(OA__ +!MO_Z+6@#<HHHH **** "BBB@ HHHH **** "BBB@
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M/_1BUM>#/^1%\/\ _8-M_P#T6M &Y1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M<%\4;CP]INF66JZ_8W=R;9Y!:- &*I*R'A]I'!Q7>U6U&6&#3+N:XB$L,<+N
M\9&=R@$D8^E 'S%IEU\(9=$AFU#0M3343&3)% \S1A^> 2_3I7O7PT5%^'6C
M>7IS:<C1,RVK.S% 78]6YYSGGUKR[2?%_P 1[V.PAT32O#MI:WEG+>6%JL1
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M\UV_F7$D5VJM*W/+$+R>3U]:N?\ "K[K_HH'C#_P/'_Q->@T4 >??\*ONO\
MHH'C#_P/'_Q-8.MZ#J?@_P 1>$Y(/&'B*^CO=7BMIH;R\W(R')(P ,].]>OU
MY]\2_P#D->!?^P_#_(T >A4444 %%%% !1110!Q/Q>_Y)3K_ /UQ3_T8M;7@
MS_D1?#__ &#;?_T6M8OQ>_Y)3K__ %Q3_P!&+6UX,_Y$7P__ -@VW_\ 1:T
M;E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK9W&CWT(\*^+$,EO(@9]+(494C).[@5M?"?_ ))9X?\ ^O;_ -F:@#LZ***
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MO_H!KG/A/_R2SP__ ->W_LS5T>N_\B]J7_7K+_Z :YSX3_\ )+/#_P#U[?\
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MKG/A/_R2SP__ ->W_LS5T>N_\B]J7_7K+_Z :YSX3_\ )+/#_P#U[?\ LS4
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M?^ ,7_Q-)XGN/%4"6W_",6.FW3$MY_VV5DVCC;MQU[_I7.?VC\6/^@%X:_\
M J2@#F_AMX:T*]\9^/X+O1=.GBMM3"0)+:HRQ+F3A01P.!P/2O2/^$(\*?\
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MJGEZ_H&GV-EY9/G6]WYC;N,#'YUUE?'_ -GT#_H(_P#DZ?\ &C[/H'_01_\
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M1[Z$>&O%*&2WD0,^F$*,J1DG=P*VOA/_ ,DL\/\ _7M_[,U='KO_ "+VI?\
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M!HU@EWCY P/TZBO2ZY9:MV/<I)QIQ4M[(****1H%%%% !1110 4444 %%%%
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M_KV_]F:@#LZ*** "BBB@"E>:QIFGRB*]U&TMI&&X)-.J$CUP3TJL?$^@8/\
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M;R^4TN^[MPB8&.,ACSS7;T %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCZWLH=2N;J 6CLZ&W9026 !SD'TKK:* /-K7X/PV42Q6OC'Q3!&O18[X*!^
M6NZT;33H^D6]@U[=7IA!'VB[??*^23\Q[]<?05?HH **** *FHZKI^CVOVK4
MKZWLX,[?,N)0BY],GO4MI>6U_:QW5G<17%O(,I+$X96'L1P:XK4;:#5OC)8V
M=_%'<6UEHKW4,4JAE$K3!"V#QG:,5%X3EAT'Q!X]L[>!QIUA<17<=M F=I>
M.ZHH]2. .YH [#7?^1>U+_KUE_\ 0#7.?"?_ ))9X?\ ^O;_ -F:L;4_BKI]
MWI5Y;1^'/%'F30/&N=,;&2I [UD>!?B';>'/!.E:1?>'?$IN;6'9(8M-8KG)
M/!R/6@#V.BO/?^%O:9_T+GBG_P %9_QH_P"%O:9_T+GBG_P5G_&@#T*BO/?^
M%O:9_P!"YXI_\%9_QH_X6]IG_0N>*?\ P5G_ !H ]"HKSW_A;VF?]"YXI_\
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MVVS:DV=IW.JG."#T-<._Q-\9VFJ:+;7?AG3C_;T&[3HHKIMZM@$&1CP!\P)
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M5V]9>OZ!8>)--^Q:@LFQ9%ECDB<I)%(OW71AR"/6@#G6X^-R>5C)\/GSL?\
M7?Y<_P#CU=M6%X>\)V'AV6YN(9[R\O;K:)[R^G,LKA?NKGL!D\ "MV@ HHHH
M **** "BBB@ HHHH **** "N)^+'_)/[K=_J3<VHF]-GGIG/M7;55U'3[35M
M-N-/OH5FM;B,QRQMT93UH Y+QI@>+O QBQY_]I2!<=?+\A]_X=/TKMZYC1/
MNF:)J<>H_:]2O[J&,PVSZA=&;[.AZK&#TS@#/)QWKIZ "BBB@ HHHH ****
M"J>J+IKV135A:FU9T!%UMV%MPV_>XSNQCWQ5RJ.L:18Z]I4^F:E )[2<8="2
M.AR"".000""/2@#A[_\ M2R^*VB7NO"UGLIFN+32C:95H&9=Q,H;[Q*+C(.
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M,.H>%_%-[HT'A*XOH[?9BX69E#[D#= AZ9QU[5A_\- ZM_T(=U_X$/\ _&J
M/=**\+_X:!U;_H0[K_P(?_XU1_PT#JW_ $(=U_X$/_\ &J /=**\+_X:!U;_
M *$.Z_\  A__ (U1_P - ZM_T(=U_P"!#_\ QJ@#W2BO"_\ AH'5O^A#NO\
MP(?_ .-5W'PZ^(5WXZDU%;K0)=*^R",J9)"WF;MWJJ]-OZT =Y1110 4444
M%%%% !1535;QM.TB]ODA,S6T#S"('!<JI.W\<8KQ;_AH'5O^A#NO_ A__C5
M'NE%>%_\- ZM_P!"'=?^!#__ !JC_AH'5O\ H0[K_P "'_\ C5 'NE%>%_\
M#0.K?]"'=?\ @0__ ,:H_P"&@=6_Z$.Z_P# A_\ XU0![I17A?\ PT#JW_0A
MW7_@0_\ \:H_X:!U;_H0[K_P(?\ ^-4 >Z45X7_PT#JW_0AW7_@0_P#\:H_X
M:!U;_H0[K_P(?_XU0![I17A?_#0.K?\ 0AW7_@0__P :H_X:!U;_ *$.Z_\
M A__ (U0![I17A?_  T#JW_0AW7_ ($/_P#&J/\ AH'5O^A#NO\ P(?_ .-4
M >Z45X7_ ,- ZM_T(=U_X$/_ /&J/^&@=6_Z$.Z_\"'_ /C5 'NE%>%_\- Z
MM_T(=U_X$/\ _&J/^&@=6_Z$.Z_\"'_^-4 >Z45X7_PT#JW_ $(=U_X$/_\
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-** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>img224999359_26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_26.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (V!98# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^@G9_P#?]?\ &C^VM*_Z"=G_ -_U_P :.5B]I#N7J*H_VUI7_03L_P#O^O\
MC1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_
M ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]
MI#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7
M_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\
MC1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_
M ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]
MI#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7
M_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\
MC1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_
M ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]
MI#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7
M_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\
MC1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_
M ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]
MI#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7
M_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\
MC1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_
M ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]
MI#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7
M_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\
MC1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_
M ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]
MI#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7
M_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\
MC1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_
M ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]
MI#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7
M_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\
MC1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_
M ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]
MI#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7
M_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\
MC1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_
M ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]
MI#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7
M_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\
MC1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_
M ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]
MI#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7
M_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\
MC1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_
M ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]
MI#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7
M_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\
MC1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_
M ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]
MI#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7
M_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\
MC1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_
M ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]
MI#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7
M_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\
MC1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_
M ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]
MI#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7
M_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\
MC1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_
M ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]
MI#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7
M_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\
MC1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_
M ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]
MI#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7
M_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\
MC1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_
M ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]
MI#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7
M_03L_P#O^O\ C1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\
MC1_;6E?]!.S_ ._Z_P"-'*P]I#N7J*H_VUI7_03L_P#O^O\ C1_;6E?]!.S_
M ._Z_P"-'*P]I#N7J*B@N(+J/S+>:.5,XW1L&'YBBD6G?8YJ_P# >G:A?37<
MMS=*\K%B%*X!/X57_P"%;Z7_ ,_=Y_WTO^%=E16GM9]SF>#H-W<3C?\ A6^E
M_P#/W>?]]+_A1_PK?2_^?N\_[Z7_  KLJ*/:S[B^I4/Y3C?^%;Z7_P _=Y_W
MTO\ A1_PK?2_^?N\_P"^E_PKLJ*/:S[A]2H?RG&_\*WTO_G[O/\ OI?\*/\
MA6^E_P#/W>?]]+_A7944>UGW#ZE0_E.-_P"%;Z7_ ,_=Y_WTO^%'_"M]+_Y^
M[S_OI?\ "NRHH]K/N'U*A_*<;_PK?2_^?N\_[Z7_  H_X5OI?_/W>?\ ?2_X
M5V5%'M9]P^I4/Y3C?^%;Z7_S]WG_ 'TO^%'_  K?2_\ G[O/^^E_PKLJ*/:S
M[A]2H?RG&_\ "M]+_P"?N\_[Z7_"C_A6^E_\_=Y_WTO^%=E11[6?</J5#^4X
MW_A6^E_\_=Y_WTO^%'_"M]+_ .?N\_[Z7_"NRHH]K/N'U*A_*<;_ ,*WTO\
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M\_[Z7_"C_A6^E_\ /W>?]]+_ (5V5%'M9]P^I4/Y3C?^%;Z7_P _=Y_WTO\
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M\*WTO_G[O/\ OI?\*[*BCVL^X?4J'\IQO_"M]+_Y^[S_ +Z7_"C_ (5OI?\
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MW>?]]+_A7944>UGW#ZE0_E.-_P"%;Z7_ ,_=Y_WTO^%'_"M]+_Y^[S_OI?\
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M/Y3C?^%;Z7_S]WG_ 'TO^%'_  K?2_\ G[O/^^E_PKLJ*/:S[A]2H?RG&_\
M"M]+_P"?N\_[Z7_"C_A6^E_\_=Y_WTO^%=E11[6?</J5#^4XW_A6^E_\_=Y_
MWTO^%'_"M]+_ .?N\_[Z7_"NRHH]K/N'U*A_*<;_ ,*WTO\ Y^[S_OI?\*/^
M%;Z7_P _=Y_WTO\ A7944>UGW#ZE0_E.-_X5OI?_ #]WG_?2_P"%'_"M]+_Y
M^[S_ +Z7_"NRHH]K/N'U*A_*<;_PK?2_^?N\_P"^E_PH_P"%;Z7_ ,_=Y_WT
MO^%=E11[6?</J5#^4XW_ (5OI?\ S]WG_?2_X4?\*WTO_G[O/^^E_P *[*BC
MVL^X?4J'\IQO_"M]+_Y^[S_OI?\ "C_A6^E_\_=Y_P!]+_A7944>UGW#ZE0_
ME.-_X5OI?_/W>?\ ?2_X4?\ "M]+_P"?N\_[Z7_"NRHH]K/N'U*A_*<;_P *
MWTO_ )^[S_OI?\*/^%;Z7_S]WG_?2_X5V5%'M9]P^I4/Y3C?^%;Z7_S]WG_?
M2_X4?\*WTO\ Y^[S_OI?\*[*BCVL^X?4J'\IG:+H\&B6'V2WDD=-Q;,F,\_2
MBM&BH;;=V=$8J*Y5L%%%%(H**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFN+??FZN;E3&B)['U_SBNNM3J2FYK;H^ECDHU*<8*#WZKK<A^*C;](TK3(U
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@!LD4<J;)$5U]&&10B)&H5%55'0*, 4ZB@ HHH
MH :J*@(10N>3@8IU%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !14<\\5M \\\J10QJ6=W8!5 [DGI4.G:E
M9:O81WVGW,5S:RYV2Q-E6P<'!^HH M45S\'CCPO=:S_9$&NV4E_O,8A649+#
MJH/0GVJSKGBC0_#:1-K.IV]EYN?+$KX+8ZX'4T :]%5=.U*RU:QCO=/NHKJU
ME&4EB8,I_&K5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4453L-5T_51,=/O8+H0R&*4PR!MCCJ#CO0!<HK%A\
M7^'+G5O[*AURPDO]Q3[.LZE]P[8SU]JVJ "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* ,;Q)X;L/$UC%:ZEYSVT4HF:%)"JRD X5P/O+WQ[5Y_H%[-I?[.MQ=6I*2Q
M6ER(RO&W,CC(^F:]8891@.XKD?#/A&6S^&X\,:N8V:2*:*8PMN&'9CD$@<X8
M=NM &'XB\-:;9_!)[>V@CB:RT]+F&95PRRJ ^\'KDG//O3O!BIK_ (\U[5]0
MB26X@M+*"$.N?*5XA(^T'IEC^E0R^&?&^I>'8O!VH/IJZ0H6";5(Y6\Z6W4\
M 1XP&( !.?6M;4/#^O:'XHGUWPM#974=[;QP7=C=2F(9C&$=& /8D$8H /!D
M,>F>-/&.DVJ".S6XANHXU&%1I8_G ';)7/XU;\7^.CX3O+:W&@:IJ7G1E]]G
M%N"8.,'WJ?P=H%_I*ZEJ.L30RZMJEQ]HN/(!\N(!0J1J3R0 .O>NGH \MC^-
M5J+^SM;OPQK5E]KG6!)+B(*NXG'XUZE7EWQC_P"/KP9_V&HZ]1H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y3QIJ]U%
M';>']'?&LZL3'$XY^SQ#_63'_='3U)%<3HD:^%/!WQ&CTL&(6$\RP'J01",'
MZYYKT'7O!/A_Q->Q7FK6)GN(H_*219Y(R%SG'RL.]<SX;^%FG:5/XD$]NJQ:
MDTL%N4N)'*VSJ 0P8XW9'7D^] $'B+PKI.G_  :D%K:Q13Z?9+>07"J!(LR
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 45R'BKXD:'X5O%TZ07-_JSXV6%E&9)3GID=JQ7^*&L6T9N
M+OX>^(8K0<F14#,H]2O44 >DT5@>%O&6B>,K)[G1[KS#$0)H77;)$3T#+^!]
MJWZ "BBB@ HHHH IWTFHH4^P6]O+G._SI2F/3& <UYUX%CU2U\1^+I+6"UEE
MGOA),LDI4(W(PI"G(X//%=!\0/$UQH&GP0V1V7-R6 DQG8HZX]^17E^C>)]3
MT74GO()RYF??.CG(E^OOR>:Z*=%RC<\C%YA"C6]FV_.UCWZ(R&)#*JK(0-P4
MY /?!I]065TE[8P748(2:-9%!Z@$9J>N<]9.ZN@HHHH&%%%% !1110 4444
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M!%'L!@5+45LV^UA;S?-R@/F8 W<=>*EKF9[*M;0****!A1110 4444 %%%%
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MGBS6CR);W[-&?]E,_P"*UWU;U])*/9(SI:IONPHHHK T"BBB@ HHHH ****
M"FNB2(4=593P589!IU% '-:G\/\ POJI+3Z1 DA_C@S&?_'<"L<_#_4],RWA
MWQ5?V@'2"Y_?1_3GI^1KO:*UC7J)6OIYZD.G!ZV. &H?$;1CB[TNPUJ$'[]M
M)Y;G\#C^531?%'2X)!#K5AJ.D2YQBX@)4GV(Z_E7<U'-!#<1F.>))8SU5U#
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MH:UJ2D[)OH1"*5[(****R+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/_=N3_44<M'^9_=_P0O4[+[_ /@'=T5P7_"I]'7_ %.IZQ'_ +MU_P#6I?\
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M+X0216=Y#->:A9+9PVB.#*9G 39L'.02<\=J]"TJU>ST6RM)#\\-ND3$'N%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,?RK>AI)R[)_Y&=75)=V=[1116!H%%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI7AB&&;5)FB29BJ%4+9(^E>9>#_'F@:1KOB6YO+F1(KZ\$L!$3'<O/Y=:O\
MQR_Y!&E?]=W_ )"O$1U%>KA<)"I2YG?4XJU>4)V1]A0RI/#'-&<HZAE/L:P_
M&>GG4/"UXJ9\V%?.C(Z@KSQ^&:U-*_Y!%E_UP3_T$5:95="C %6&"#W%>8GR
MRNCIJ052FX/JC/T'4!JNA6=Z.LL0+>S=#^H-:-<AX()L)-6T)S\UE<EHP?\
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M!]*N4F7%MK5!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB?\ D=5_[!Y_]&5LUI4J2E9-G)A,+2HN3@K.X4445D=H4444 %%%% !1110
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M2TJ@,N<@@YY'6NQF:-()&FV^4%)?=TQCG->':EXBM5\43:AIMA!]F\Q6$4J
MJQ4%<X'0'.<44H<Z<3AQ^(6'G"IZKY?\ ]MM[VUNRPMKF&;;][RY V/RJ>N;
M\'ZYI^NZ>\UI9Q6DZ$+/&B@<]CD=1UKI*RDN5V.ZC452"FG>X4445)J%%%%
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M":W9EF1P4*]<YKZ0A9V@C:08<J"P]#7#>$O!.E03-J$GFSRP7$B1B0C:-K$
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M681[HMC@C!P=W3T%9<WPO\*>+-$TIM%UR[2WM+<VJ7%I<!S+"224<_4GC]*
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M/\FIP3QY-]Z71X![!B1^AKK:*CG\D='U9]9R^_\ R1R1T;QA-_K/$D$/M%;
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M]CX1TBTN8S%/#9Q)(C=58* 16Q4%E>V^HV,%[:2>9;SQB2)\$;E(R#@\U/0
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MBBB@ HHHH *3:O\ ='Y4M%   !T&**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH R?%$(N?">L0D2D/93+B$9<_(>%'<^U>%>$==TK1/#-II^J?"W4+N
M\A!$EP-.#^:<GYB6&<XKWS7-2_L?0=0U/R_,^R6\DVS^]M4G'Z5XBI^($_@9
MOB(/&;*^TW0TT)^X\L-C;UQGVQ^.: /;M$GBN=#L)X;-[**2!&2V=-IA! PI
M Z8Z8J_67X<U8Z[X:TW53'Y;7=LDQ3^Z64$BM2@#%\3WVLV6F#^P=.6]OYG$
M:&1PL<.0?WC]RHQT')XK&\+>*KF7X6Q^)=:D66>*WFFG:- H;8S#@#V6NQD_
MU3_[IKS'PSITVL? &33[8;I[BSNHXQZL7DP/SH ;/J?CW2/#L?C&^U2TGM0%
MN+G1EM541P,1D++]XLH.>>.#7IUO/'<VT4\1S'*@=3Z@C(KR[7?&^C:O\*6L
M+&[BFU;4+5;"/3U8&<3, A4IU&.2?I7I.F6C66CV=F[9:&!(B1ZA0* +E>:_
M#/CQ;X]_["H_D:=+\'-/EF>0^*?%2EF+874!@9]/EJA\'=,32-<\:V4=Q<3K
M#J"1"2X?<[ !N2>YYH ]7HHHH IZK_R![[_KWD_]!-?(YZFOKR_57TZY1A(5
M:)@1&,L00>@[FO#+GX>Z<)+?[/;^)75I<3%[ #:F#R/4YQ^9KTLOJQ@I<QQX
MJ#DU8/A?XNM/#-KJ*W=G?3),Z'S+>+>%P#UYXZUZ-;_%7PG,<27LUL?2:W<?
MR!IOP[T*RT&*_ALTU0"5D9C?V_E=,_=]:ZZ?3[*Z_P"/BSMYO^ND2M_,5EB*
ME*55MI_?_P  NE"<8))F3;>-_"]WCRM=L<GL\H0_DV*UH-0LKE=T%W!*/5)
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M'/\ .G[."WG]UPYY/:)U5[K^CZ<";S5+.#':2=0?RS7/W?Q1\)VIVI?O=/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH I:Q/;6NB7]Q>Q>;:Q6TCS1@9WH%)
M88[Y&:\$N?#7@>#PS_:J^/-2/A223<NCH_S,^<^6!G.<^J^^>]>[:IJ2PVE]
M!9-!<:I%;/+%9%QN<A3M!7.<$X'XUX%+\,-<TNT/CMY]$?5()S<SZ6T:"V0?
MW<YV[AZ=/0YH ]\\.W%O=^&M,N+2U-K;26L;16Y&#$A487\!Q6G6=H&I-K'A
M[3M2>(0M=VT<QC5MP0LH. >_6M&@ ZU%;VT%I L%M#'#$N=L<:A5'?@"I:*
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MW;W::7"(T=U P[=<8&/45T1E+=RO]YYV(DIKV2C9MI=/5_A<[:.-8HDC081
M%4>@%.HHKG/1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDH **** "BBB@ KS7X9_\C;X]_["H_D:]*KS7X9_\C;X]_["H_D: /2J***
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHZ#)H **Y2V^)/A*\UE=*@U=&N7D,2'RG$;N/X5D(VD
M_0UU= !7FOPS_P"1M\>_]A4?R->E5YK\,_\ D;?'O_85'\C0!Z51110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*O>+_ \GBN\MKA/$.J:6(8RFRSDVA\G.3[T ><^*?!]SX>OX$$BRP7<OEV[
MX))Z CMUKTCP1X3?PU:S27,BO=W&-P3H@';/>O)_'O@.X\.2Z"@\4:O>_P!H
M7RVA-S)N\H-CYD]&KL_^%.3_ /0]>(_^_P#6TZTI1Y6>=0RVC1JNI%>GD>HT
M5Y=_PIR?_H>O$?\ W_H_X4Y/_P!#UXC_ ._]8GHGJ-%>7?\ "G)_^AZ\1_\
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M+OQ)X-TW5Y?&>OP27,98QQS_ "KR1QGZ4 >Y45Y=_P *<G_Z'KQ'_P!_Z/\
MA3D__0]>(_\ O_0!ZC17EW_"G)_^AZ\1_P#?^N1O? 6H6_Q0TWPXOB[7VM[F
MQ>X:Y,QW*1N^4=L<4 >_T5Y=_P *<G_Z'KQ'_P!_Z/\ A3D__0]>(_\ O_0!
MZC17EW_"G)_^AZ\1_P#?^LWQ#\*[O2O#6JZC%XU\0RR6MI+,L;3<.50D X]<
M4 >QT5XIX1^&5YKGA+2]4F\9^(+>6ZMUD:))^$)[#-;7_"G)_P#H>O$?_?\
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M "5Z^U>M5S_B[PI#XNT^ULY[F2W6WNX[H,B@DE.W/UH Y#_A;&L?]$X\2?\
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M"R@+;BD*;03ZGU-:%%% '(>.?"%SXKFT)[>ZB@&FWZ7;^8"=ZCL,=ZZ^BB@
MHHHH *0*%Z #Z4M% !1110 4A4$@D XZ9[4M% !1110 4A&5(]:6B@#E/A_X
M4N/!WA^;3KFYBN'>[EG#Q@@ ,<@<UU=%% !1110 A4$@D D=*6BB@ HHHH *
M0*%&%  ]!2T4 %%%% !7(:_X/N=7\>^'?$,=U%'#I0D\R)@=S[@1P>E=?10
M4444 %%%% " !1@  >@I:** "BBB@!-H+!L#(Z&EHHH **** *>K6;:CHU]8
MHX1[FWDA5FZ LI&3^=9G@K0)O"_A#3M&N)HYI;6,HTD8(5N2>,_6M^B@ HHH
MH *3:-V[ SZTM% !1110 4$ C!Y%%% "  # &!Z"EHHH **** .2?PC<M\4H
M_%GVF+[.FG&S\C!W[MV<YZ8KK:** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 4444 %%%% !114-W=V]C:2W5W-'!;Q*7DDD;"J!W)H E(# @@$'J#0 %
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M4()9+6ZV# ,D;%21]< _C7)>'O%>D?#\:UH/B.Y-E-!?37-KOC8BY@D;<I3
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M SWQ5'4[^XU3QKK]EJGBVX\.VVFQ1M90PR)%YJE23*2P.\9XP.E;.B?\E?\
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M3][.<YXZ4 >IT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M44>VJ?S/[P]C3_E7W'+_ /"N_"O_ $##_P"!,O\ \51_PKOPK_T##_X$R_\
MQ5=111[:I_,_O#V-/^5?<<O_ ,*[\*_] P_^!,O_ ,51_P *[\*_] P_^!,O
M_P 57444>VJ?S/[P]C3_ )5]QR__  KOPK_T##_X$R__ !5'_"N_"O\ T##_
M .!,O_Q5=111[:I_,_O#V-/^5?<<+?>%]'T'7?#T^F6A@DDOO+<^<[97RW.,
M,Q'4"NZKG/$W_(6\-_\ 81_]I/71TZDG)1;?]7%3BHRDDOZL%%%%9&H4444
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ME#X<A30O*-FEOBT\D[DVX^7![BOG?PS;^ ;GP1K=QXNG4>)O-F,OGR,)U?\
MA\L=^?KSG-?2MI:6]A:16EI!'!;PJ$CBC7"HHZ "LRX\)>';K4_[3N-#T^6^
MSGSWMU+D^N<=: /GM6_XLOX-CO'F309-6D&I-%G(3S6QG';&ZN@DB\*V7Q2\
M,#X>SQ!G5QJ/V.4O$(,=6.3@XS^0KVV'0M)M]*.E0Z99IIYR#:K"HB.3D_+C
M')-1:5X9T+0C(VE:19632C#F"!4+#T) Z4 ?.NDIIWA'7M+E>/P]XGM9]4Q#
M>6\S?;$<M@%ESSCK@@C/>JTT=Q?:UXN&MCPV+XW$BN^MS2)/&G\)A '0#&,<
M].U?1MMX-\-6>I_VE;:#IT5[N+"=+=0P)ZD''!]Z?J?A3P_K5TMUJ>BV%Y.H
MP))[=7;'IDB@#R#6(I[;X!:)8W5];WMU/>P1V4T#LX<>82N"P!X7CI7ND((A
MC#=0HS7+ZSX(@UGQ1H>J37)6RT@,T5@L8"&3LV?; XQV%=70 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 5=2TVSU?3I]/OX%GM+A-DL3]&%
M2VUM#9VL5M;1+%!$@2.-1@*H& !4M% !1110 4444 %%%% !7-:-X.M]&\7Z
MWXACNI9)=6V;XF4!8]OH:Z6B@ HHHH **** "BBB@ HHHH **** *%WHNFW^
MI66HW5G%+>6)8VTS#YH]PP<?6K]%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!SGC;_D Q?]?UK_Z.6NCKG/&W_(!B_P"OZU_]
M'+71UH_X:]7^AG'^(_1?J%%%8^M6VO3R1'1[ZVMD /F":/<2>V.#4)78YRY8
MW2OZ$FM^(-.\/VRS7\Q7?PB*,L_T%4]#\9Z/K]P;>UDD2?&1',NTL/;D@UYE
MX]M-;M]3MWUBX2X+18CDB7:O!.1C Y_Q%8OA^WOKG7K*/3CMNO-!1\9"X[GV
M'>NJ.'BX7N>'5S6M'$<BCI?;J?0]%<YIUEXKBOXGO]5LIK4']XB0X)&.QP*Z
M.N5JW4]NG-S5W%KU,GQ%XBL?#.E&_OO,8%UBBAA7=)-(QPJ(O<FN>_X2[Q7!
M''=77@2Z%FQ&Y8+R.6= >YC Y^@.:C\=.EGXN\&:E>$+IL%Y-'*[?=CE>/$;
M$]N<C/O5_P =G7+70;K5M&UT:>ME:R3-%]D283$#(Y;[O3M2-#JU.Y0<$9&<
M'J*6O+]9N4\176EV1AUW4K\Z9%<3VVGWBVL$>_I([97YB0<#G@=*R+%O$^O^
M!-+5'N[^*SU&X@OK:*]$5S=0H2% ER,E>_(SB@#UV_U&TTR%)KV=88WD6)6;
MN['"C\35JO$=7M=,UGP79B*\UT26.M16LEO?W!66W+2KE#@_-@?=8Y/O70W'
MAO[=\0#H3:MJJ:1:Z1'*UNEVX:9S*^-SYW?KSQZ4 >FT5Y9X9T0^,?#4OB+4
MM=U.&_>280FVNVC2Q",550H."0%!.[.:@T[6-2\9CPGI.HW\]K;WEE/<W4MJ
M_E->-&P0 ,.0I!W$#VH ]:HKS'Q'X>N-)E\/:/IGB#5H;>]U?:VZZ+O#'Y+E
MD5C\V#CN3@G--EDN? WB/7;/2[B[N;-= ;4HK>ZF:;RYD<KD%B3@]2,]J /4
M**\4L8?$;:-I^NZ;9:_+K$OE3O>W.IPFVN Q!93'YFT(02   1Q6TNA3^)?$
M/C0WFKZE'#:7"+:0P73QK#)Y"-O^4\\D<'CKQS0!ZC5&VOYY]5O;.33YX8;?
M9Y=R^-D^X9.WOQT.:\GM[?48_A]H_C6;6]1FULSVQD=K@B)HVF6,Q^6/EQM/
MIG/.:M^+M5O[>7QOY5[/&MO+I?E;9"/+#.N['ID9S0!ZW17'>)[Z:#QUX+M(
MKET6XGNO,C5L"0+ Q&X=P#BN1T5+W0O$FGR^*&UR&_N;YHDU*&\$UE>%R?+C
M9,_(,8 ^4'(ZT >OT444 <YXF_Y"WAO_ +"/_M)ZZ.N<\3?\A;PW_P!A'_VD
M]='6D_AC_74SA\4OZZ!11169H%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 <YXV_Y ,7_7]:_^CEKHZYSQM_R 8O\ K^M?_1RUT=:/^&O5_H9Q_B/T
M7ZA11169H5K[3K/4K?R+VVCGCZ[9%S@^H]*KZ;H.EZ06:PLHH788+J/F(],G
MFM&BG=VL0Z<'+F:U[A1112+*VH:=9ZK8RV5_;17-K*,/%*NY6'TKEA\,/#I
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M^NIG#XI?UT"BBBLS0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 8GBO3[K4]#,%D81<+/%*GGDA#L<-@D GM6;]N\:?\^V@?\ ?Z;_
M .)HHKMH0C*&J.*O.49^ZQ?MWC3_ )]M _[_ $W_ ,31]N\:?\^V@?\ ?Z;_
M .)HHK;V,.QC[:?</MWC3_GVT#_O]-_\31]N\:?\^V@?]_IO_B:**/8P[![:
M?</MWC3_ )]M _[_ $W_ ,31]N\:?\^V@?\ ?Z;_ .)HHH]C#L'MI]P^W>-/
M^?;0/^_TW_Q-'V[QI_S[:!_W^F_^)HHH]C#L'MI]P^W>-/\ GVT#_O\ 3?\
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A%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>img224999359_27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_27.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'M T,# 2(  A$! Q$!_\0
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M4@=Z]!HIRKJ4.5QZ6W9,:#C/F4NM]D>4^"_!<&HVOB"'7M'>-I;D^1+/ 4D
M.>48C/H>.*N>#XO$FC'4_"EQ%<HJ(_\ 9VI"W)B5L9&6*D8Z'!Z8(]*]*HHE
MB)2O=:/\ CAHQM9ZK\3QV[U+Q++:2:?X@\!C6+X95;[[/P>>#E%Q_P!\E>*)
M-&\1:+\*%T5;&ZGO=1NB6BAC,A@B."0Q&0,E?_'C[U[%15?6MK16]Q?5=[R>
MUCR2]^%&L)X?DMQXIN;F*&,O'8>4WEE@"0H&_ Y[X[]*I:Y#KVK?#G0(I-&U
M)[ZRNO+DB-L^\JJ_*V,9QC SZYKVBBA8N>CEK9W!X2&JCI=6//(/B%XAEN(X
MW\ ZI&KN%+DR84$]?]57::WI::UH=[ILC;!<Q-'N_ND]#^!Q5^BL93C=."L;
M1A*S4W>YY-I&M>-/!VGC0YO"T^HK!E;>> ,5QG(R54@CGV-7= \.:T;'Q-X@
MUF$IJ6IVDL<=J@RR@J>,#//"@#KQ7IE%:O$7O:*3>YE'#VM>3:6QY]\//"EC
M_P (A!_;/A^V^V^9)N^V6:^9C=QG<,]*[]$2.-410J* %51@ #L*=16-2HYR
M<F:TZ:IQ44>4/X;OK_QQXR:6RN5M[K3Y(X)6A8)(Y\LKM;H>5Z"L"U\+ZR_P
MYU>:YTV^;4)[J!(X6@;S2D8P#MQG&&(_"O=J*Z%BY+2W;\#!X2+UOW_$Y\VT
MQ^'?V4P2>?\ V3Y?D[#NW>5C;CKG/&*SOAC976G^";>"\M9K:<2R$QS1E&Y;
MC@\UV-%8>T?*X]W<W5-<REV5CR^]LO$?@GQAJ.KZ/I;:KINIOYLT,0)=6R3V
MR0<EL'!&#3(K3Q)X]\3Z;>:KI+Z3I.G2><(ILAW;(..0"<[0,X  S7J=%:_6
M'O97VN9?5EM=VWL<M\1K2YOO 6IVUI;RW$[^5MBB0NS8E0G ')X!-5;WPU-K
MWPML='8&"\6QMRBR@KLD5%^5AU'<'TS79T5G&JXQ271W-)4E*3;ZJQY59>+/
M'&E:9'I,OA"XN+N!!%'=*CE" , G (/U#"DC\(:MIOPTU\W44EQJ^INLTD$*
M[V'S@XP.IY8G']*]6HK3ZQ;X8I:W9G]6O\4F]+(\FUWP=>7_ ,.M%O;6VGCU
MG3[54:$(1(Z'[R;>N1G./KZU3ET35C\%H; :9>F\%[N-O]G?S -QYVXSBO9:
M*:Q4K)6V=Q/"1;;ONK'DFM:!K7BOQ-H^FHE[IUGIUBA^VM ^U9=H)VG@;L[1
MP<C:?2H-:\&^(O#6J:7X@AU._P#$-Q!.JLODN\BIR<?>8[3\P[=?>O8J*%BI
M*R2T[ \)%W;>O<;&XDC5P& 8 @,,$?4'I3J**Y3J"BBB@ HHHH **** "BBB
M@ HHHH ***H:QI%OK=@;.Y>1(RP;,9 .1]0::WU%)M*Z5V7Z*X__ (5OH_\
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M/_S\WW_?Q/\ XFC_ (5OH_\ S\WW_?Q/_B:.6'?\ ]I7_D7W_P# .PHKC_\
MA6^C_P#/S??]_$_^)H_X5OH__/S??]_$_P#B:.6'?\ ]I7_D7W_\ ["BN/\
M^%;Z/_S\WW_?Q/\ XFC_ (5OH_\ S\WW_?Q/_B:.6'?\ ]I7_D7W_P# .PHK
MC_\ A6^C_P#/S??]_$_^)H_X5OH__/S??]_$_P#B:.6'?\ ]I7_D7W_\ ["B
MN/\ ^%;Z/_S\WW_?Q/\ XFC_ (5OH_\ S\WW_?Q/_B:.6'?\ ]I7_D7W_P#
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M?]_$_P#B:.6'?\ ]I7_D7W_\ ["BN/\ ^%;Z/_S\WW_?Q/\ XFC_ (5OH_\
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MTA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 53OM6TW2_+_M#4+2T\S.S[1,L>[&,XR1G&1^=7*\?^(EYI-U\
M2=)LM:DV:7;0;K@X<\MN./D^;G"#CUK:A3]I*S,:]7V<;GJ-GKFD:C-Y-CJM
MC=2XSL@N$=L?0&IH]0LI;Z2QCO+=[N)=TD"RJ9$'')7.0.1^8KQ:&+PW>?$#
MP_'X)M[A?)N!)=2;I-I0$$_?Y'RA@>@Y KI+#Q@_V#Q=XBCTS3(FLI1#;SI
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ML=TJ178F,Q] %X /3MQFO4Z*GZQ)7LEKZ_YE?5HNUV]/3_(****YSH"BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M (BC^SZO=?U\@_M&EV?]?,^C:*^<O^%H>,O^@Q_Y+0__ !%'_"T/&7_08_\
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M^0%><UTTIN2?-NFT<M:"@UR[-)GU+X4_Y$[0_P#L'P?^BUK7K(\*?\B=H?\
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MV,Q8G+9._)X?[P& "  * /M.BOC0_%KQX;BXG_X26[WSO$[C:FT&,@KM7;A
M<?,% #?Q9S4<7Q4\<PWBW2^)KXR++), [!DW. &!0C:5&.%QM7JH!- 'V?17
M)^#=-CO/!6B7ES=:E-<7>CQ+-(^HSDMYBAV;[_#[F.'&& P 0 !70'3(#<7$
M_F7>^=XG<?:Y=H,9!7:N[" X^8* &_BSF@"Y16?%HUK#>+=++?&199)@'OYV
M3<X 8%"^TJ,<+C:O50":CAT"S@0HDVI$&W:V^?4KASL9BQ.6<G?D\/\ > P
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M;BPQPV=R]%(!HY)=@>(HK[:^]'O%%>+^&/B!_;_B>T\-7GAS4M/354V?:/\
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MC3LQ7+U%4?[;TG_H)V7_ ($)_C5U65U#*P92,@@Y!%(8M%%% !1110 4444
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M,_X]7_Z^)_\ T:U7*4=BZGQOU-#P9_R5[PG_ -OG_HAJ^D*^;_!G_)7O"?\
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M R,8P<J>#T85Z5XF)_X3_P #CMM']*BAN8[WXA^+?"MRX6#5(?W9)^[*(EY
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M7M=_[=__ $GCH \_HHHH **** /M_P "?\D\\-?]@JU_]%+705Q_A+1K74/
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MA5__ $BNJZ"@ HHHH *\_P#C;_R2'7?^W?\ ]'QUZ!7G_P ;?^20Z[_V[_\
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MK6:<>Q^5!^CFJ^&DS)+GQ4;^7?HO,]GHHHK@/>"BBB@ HHHH **** "BBB@
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M338D-NUJ52U10868LT? ^X6))7H22:^5/C;_ ,E>UW_MW_\ 2>.@#S^BBB@
MHHHH ^W_  )_R3SPU_V"K7_T4M=!7'^!="T=O /A^4Z58F2;1(()7-NF9(W0
M.Z,<<JS,S$'@DDGDUT$&@Z/;;_L^E6,6_P G?Y=NB[O*QY6<#G9@;?[N!C%
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M9HW]H1^%);*Y@G:"YM9;V<M#*AY7._GMSBO7@ JA1T P* %HHHH *Y_QE_R
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M 4444 %<_P",O^0';?\ 85TW_P!+8:Z"N?\ &7_(#MO^PKIO_I;#0!T%%%%
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M,O/7@GKZ\58_X1JP_P">^J_^#:Z_^.46CW_#_@A>7;\?^ :]9%S_ ,CCIO\
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MO:HP$*L&6/D?<# $+T! - &I15.;2=-N7#SZ?:2N+A;H,\*L1,JA5DY'WPH
M#=0 !4<^A:/<[/M&E6,NSSMGF6Z-M\W/FXR.-^3N_O9.<T :%%9<WAK0;E D
M^B:;*@MUM0KVJ,!"K!ECY'W P!"] 0#4DN@Z//>->2Z58R732QSM,]NA<R1@
MB-RV,[E!(!ZC/% &A15,:3IHN+>X&GVGGV[RO!)Y*[HFD),A4XR"Q)+$=<\U
M7F\-:#<H$GT3394%NMJ%>U1@(58,L?(^X& (7H" : / _&G_ "5[Q9_VY_\
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M7A))XHY4#W+A74, RPEE//<, 0>Q -?0D6A:/!>+>1:58QW2RR3K,EN@<22
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MO0*\_P#C;_R2'7?^W?\ ]'QUSGLGC]%%%>B?&A1110!H>#/^2O>$_P#M\_\
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M.&QG<P !/4XYJO\ \(GX;\CR/^$?TKR?*\CR_L4>WR]_F;,8^[O^;'3=SUH
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M )#GA/\ ["LG_I%=5T%<_P"(?^0YX3_["LG_ *175=!0 5\@?&W_ )*]KO\
MV[_^D\=?7]?('QM_Y*]KO_;O_P"D\= 'G]%%% !1110!]O\ @3_DGGAK_L%6
MO_HI:Z"N?\"?\D\\-?\ 8*M?_12UT% !1110 4444 %%%% !1110!\W^-/\
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M/#4^M+J)\8VWAJ1W :W\.V5XJN,]"S$ 'Z+CVKZH3'EK@DC Y/>G44 %%%%
M!7/^,O\ D!VW_85TW_TMAKH*Y_QE_P @.V_["NF_^EL- '04444 >?\ _-PO
M_<J?^W=>@5Y__P W"_\ <J?^W=>@4 %%%% !7G__ #<+_P!RI_[=UZ!7G_\
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MODG90!)(HR.O3\<=J]#T/6[/Q#I4>H6)?RG)4K(NUD8'!!'8US6H^"+B'2M
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M_P#1\=<Y[)X_1117HGQH4444 :'@S_DKWA/_ +?/_1#5](5\W^#/^2O>$_\
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M $4 <'X+\:>%;7P+X>M[CQ+HT,\6F6R21R7\2LC")0006R"#QBMS_A._!_\
MT->A_P#@QA_^*KH** .?_P"$[\'_ /0UZ'_X,8?_ (JC_A._!_\ T->A_P#@
MQA_^*KH** .?_P"$[\'_ /0UZ'_X,8?_ (JC_A._!_\ T->A_P#@QA_^*KH*
MY_P;_P @2Y_["NI?^ELU !_PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8
MP_\ Q5=!10!S_P#PG?@__H:]#_\ !C#_ /%4?\)WX/\ ^AKT/_P8P_\ Q5=!
M10!\P^+=:TJY^*7B:\@U.SEM9OLOE31SJR/B!0=K X.#P<51_M;3?^@A:?\
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MK&V&P,:$W).YS_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\
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M"2)0>D$X+3$#_ME+_P!]4W4XC;W^I^!4+"/4]7@GB53TMI09)0/8&*0?\"H
M[7_A8&@?:8K;_B;?:)D,D47]BWFYT&,L!Y62!D<CU%=%;7"7=M'<1K*J2*&4
M2Q-&P'NK ,I]B :Y'40!\7M  X TF[_]#BKLZ "BBLSQ%=SV'AG5+RV?9/!:
M2R1O@':P4D'!X/- &G17F6J_$>R3X;PW5CXGTQM?:WMR4CN(7D,C%-X\OGGE
MN,<5L>*?$$UAXBT[3[O63H&E7%N\AU+9'^\F!XBWRJT:?+EN1DXP#UH [6HX
M8(;9"D$4<2%V<JBA069BS'CN6))/<DFL71)[ZUTZ[N=2U6UU'3E_?6E^A4/)
M!MW$R;%"9'."O!&.!7-^#/%&LWNM0KK4H-KK=J]]I<9C53"JN<QD@<GRVC;D
MD]: .XM-1M+ZT>ZMI=\*.Z,VTC#(Q5A@C/!!K)LO&FB7[VRPR7J)=$+!-/IU
MQ#%(3]T"1XPG/;GGM63X=U2.STVYTBXLM5CO'N[O;G2[GRSNE=E/F>7LP00<
M[L<UDZ?HFL:?I'A66_N]5U#2XU@^U:8UO&'MI  8WQ'&)&5&'*DD]"2<$$ ]
M,HHHH ***Y3X@7ESI/A]-8LKF5+RQG1X;96;;>$G;Y)5?O;@>.#@X- '3RP0
M2O%)-%&[0,9(V=03&VTJ6![':S#/H2.]5],U2QUFQ6]TZX2XMF9E65,[6*L5
M./49!YZ&L/0M-M->\#6L6HW<NJPW\8GGD>5P)2QW%<9!" \;.F!@CK4'PRC2
M'P1!%$BI&EU=*JJ,!0)WP .PH Z^BBB@ HHHH ***\XTB^N9/B5<>'9-9N9+
M"Q>2[@)EDW32,%S SG[PBW%MN>CID?+0!VMWJ.DZ +6&>2&T%[=>5 BICS9I
M"6. HZDEB3ZDDFM*O'/%.J17WB#3M5U&RU6*6TUF""SA?2[G"0ACO<-Y>UG<
M@$!23M"@=Z]B!W*",X(SR,4 +1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !117.>.]6NM#\'7NHV=P+>:$QXE(4A09
M%!^\".A- '1T5Q&N^.]+>71K?0?$>F7%S<:G!#+%;7,4SM$Q.X8!) Z<CI2:
MSKS1^*[G3=3\2-X;LXX8WLY-L"?;"?OGS)D=3M.!M7#<Y.01@ [BH8HK>QLT
MBABC@MH(PJ1QJ%5$48  '0 #H*Q&U*_\.^$;R_UZXM[F:S1V6:!2OGJ/N$KC
M =N 0.,GCT&5X3U36YH]4T7Q'*)M6A@CN498PNZ*5.@"@ [7#K^ H Z=M:T]
M-!_MLW'_ !+O(^T^<$8_N\9SMQNZ=L9JK8^*=+U"]CLXS>PSR@F);O3Y[828
MY(4RHH8XYP,G'-<BE_\ :_A:V@Q6&L+J2Z1Y)BDTJYC&\1X*AFC"DYZ<\]LU
MHQ:7J>G^+=*EU*^U+6-/*,+9WAC'V.XVD%G$4:Y5E) 8\*>O4$ ';4444 %%
M%4]5MUN])NX'NI;17B8&XBD,;1<?># C&.M %B>"&ZMY;>XBCF@E0I)'(H97
M4C!!!X((XQ5<ZK8KK"Z2;E/M[0FX$ Y;RP0NX^@R<<]><=#7+?#[5+S7HKS4
MM1NG-TGEVPME9A&J!0RRA#CF3=OSC@$+G@TV#1=/TGXJ6\ME;".6[TVYEN)6
M9G>5O-B^\S$D@= ,X X&!0!V]%%% !1110 445B>+=R>&;VXCOWL9;9?M$<Z
MLP 9#N 8#[RDC!7N#0!KS00W*!)XHY4#JX5U# ,K!E//<, 0>Q -51K&GMK;
M:,+E3J*P?:6@ )(CSMW$]!SVZUS?AS6;H^$-0\1745Y=7\CRR2Z=%OD:W=/E
M%NB8ZC R0.22>A%<SX4N+>+XGI--'?MJ6H:6SW<LNFW$(,IE!P-Z#$:J H)X
MX'.30!ZQ1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 9LV@:7<:_;:Y+:*VIVT30P
MS[CE4;J,9P?J1GDTLNA:9-KT&N26BMJ5O"T$4^3E48Y(QG'XXSR?6M&B@"E+
MI-E-K%OJTD&;ZWB>&*7>WRHY!88S@Y*CJ.U7:** "LSQ%:3W_AG5+.V3?//:
M2QQID#<Q4@#)X'-:=% '$:WH&IWGPFAT2"VWZBMK;1F'S%'S(4W#<3CC![UJ
MZE-X@T_6H[FULVU7298!%+9PO%'-#(,GS%+E0ZD8!!88P" >:Z*B@#RZX\(:
MM<6FK6^FZ0NC:=K=Q;PRV,<L:_9X%SYTK*A*!W&%PA;L3SG&KKW@?[%;V&I^
M'%OYM4TNX26WAN-3FE5X\A9(P)9"JY0GGCH*[RB@! <J"002.A[4M%% !111
M0 54NM-M+VZL[FXB,DMFYD@)<@*Q4KG&<$X) R#C)Q5NB@"II^FVFEPR0V<1
MBCDE>9DWD@.QRQ )X!))P,#DT:;IEGI%D+.QA\J .[A-Q;YF8LQR23R235NB
M@ HHHH **** "LJ+PWI,$5JD=J5^RW+74+>:^X2MNW,6SEL[FR"2#FM6B@"I
M?Z99ZFMN+R'S1;SI<1?,5VR+]T\$9QGH>*MT44 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 >)^)/C_ #>'/$NI:-/X1D+V=P\0=[XQF10?E?:8N RX8<G@CDUE
M_P##37_4H_\ E2_^U5] 44 ?/_\ PTU_U*/_ )4O_M5'_#37_4H_^5+_ .U5
M] 44 ?/_ /PTU_U*/_E2_P#M5'_#37_4H_\ E2_^U5] 44 ?/_\ PTU_U*/_
M )4O_M5'_#37_4H_^5+_ .U5] 44 ?/_ /PTU_U*/_E2_P#M5'_#37_4H_\
ME2_^U5] 44 ?/_\ PTU_U*/_ )4O_M5'_#37_4H_^5+_ .U5] 44 >9_#;XL
MS?$+6;NR7P[)8P6UOYKW(N3*H;< J'Y% )!8CG^ \>GIE%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!P?Q,\5^*O#-OIR^%O#LFK3W+R&9Q;2SK"JA< K'@Y8MP2?
MX3P<\>=_\+3^+_\ T(7_ )1[O_XNOH"B@#Y__P"%I_%__H0O_*/=_P#Q='_"
MT_B__P!"%_Y1[O\ ^+KZ HH ^?\ _A:?Q?\ ^A"_\H]W_P#%T?\ "T_B_P#]
M"%_Y1[O_ .+KZ HH ^?_ /A:?Q?_ .A"_P#*/=__ !='_"T_B_\ ]"%_Y1[O
M_P"+KZ HH ^?_P#A:?Q?_P"A"_\ */=__%T?\+3^+_\ T(7_ )1[O_XNOH"B
M@#Y__P"%I_%__H0O_*/=_P#Q='_"T_B__P!"%_Y1[O\ ^+KZ HH \3\-_$KX
MFWOB73;35_ TD6GW%PD4\J:;<Q&)6.W?N8L %SN.1T!&1U'ME%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %!X'3
M/M12-D*2H!.. 3C- 'G=[XJ\;Z-=VVH:OHVCP:+<7B6HM4N6:]3>^U6R,QL>
M^U>WYTW4_&/B^6[U>^\/Z5I4^A:/*\-Q]IE=;BX:,9D\O'RKCI\WI7->(_$6
MC>(KJ)H],U*Q^(]JXAM+2(2EH2'ZEL"-HB"22?X35M?%MIX-T_Q%X8U2"[&M
M7-U<R6$$=NSB\$V2A0@8ZG!R1T_"@#U:QU&WU#2;?4H6/V>>%9U)'\)&?Y5S
MUM\3/!EW=+;1:_;>:T!N0'5D C R22P !P,X/..U7]!TV71_ ]AIT_\ KK:P
M2)_]X)@_K7F=CIUDWP]^&T;6D)1]6A=E*#YF(D))^IH ])TGQQX:UO1[K5M/
MUBWDL;3/VB5LQ^5C^\& (]N.>U5M"^(_A+Q+?QV.D:PES=2;ML0BD5CM&2?F
M48&._>N(\6Z?)/J7C4VUD]U''/IEU=6L2Y:>-.77'<X'3OBA?&_AC7OB1H.H
MZ.CO#96-V9[LV[1* (P?+^8#)7KZ#/O0!U&H^,M1M_$$=K;6]L;%M9@TOS)%
M8LQ:,O(1@@<$J!QV:NC'B71\:DQOXQ'IAQ>3,"(XCC)!<C:2.X!)'&<5YOKN
ME7,_@_P=#]HEL;[4M:CN9IXL%XGF$CDC/<;L#TP*K744\/P_U#PC)8FXO/#]
MY!+<VT* -?V@E#^8%'4LN=W^T#GK0!WNA?$?PEXEOX['2-82YNI-VV(12*QV
MC)/S*,#'?O74UY-9>+?#OBSXJ^&IM!C>006MTDET;=HA]P8C^8#)7KZ#/O7K
M- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %!SCCK12,"5(!()'!':@#R#73>>
M&/%.EI_PG6JW?B.]NXS]AF(CL7A9\,-A&U/E! ^8L2.!DU9GLM=\4)XA\2VW
MBC5=.?3KF>'3K.VD"VY$/&9$(^?<P/6IM3L?B#K>ES>$M3TJPGMY9-K^(&N4
M \L/N#"!0") , 8P,BBZTKQOH:ZSH&AZ/:7VFZI-)+!J4EVL1M/-^^'0_,^"
M205_^M0!WFB:N=5\*V&L% #<6B7!0=B5R17#VGQ:NIK73+^;PA?QZ=J/[FWN
M(YU<R7.#B)4P#@D8#G S[<UW>GZ4NE>&[;28#O6VM5@0]-VU<9KBK/POK,7A
M'P+8O9XN=+OX9KQ/-3]TBA\G.<'J.F: +=M\2C#I&M7&NZ#<Z9J&DR1QR6*3
M+.96E_U81EP"6R/I[TNC>/=8NO%-AH.M^$9]'N+V.2:.1[Q)D*(N>"HZ]B.,
M<5G^+/#M[+<>)M0-Q:6 >6PN-/N;N95B>6'^%N> 3A>?7BL\:QXNU+XC:(=5
MT"WTZ:WL+R2"SCO8YY)&V ;R1@*I. ,GUS0 ^?Q+-:_$F+5;W5YH-"W7L/E&
M9A#L@C0%BO0L9"_8G@ 5TU]XYN=/\.V^I3:!<_;+^Y$&FZ:)!YT^1E2^1B/(
M!)'S;1UYX&-=?#PZG-X0M-6L$O;&SM+D:@SNO$TBJ=V,Y)+[CD9P>:K7VF^)
M-/T71UF>T?5]"U(IIIN[F.-=5A*%0@.>)"AQSCE<T =%X8\:ZCK7B2ZT'5O#
M<VC7MM:BY=9+E9E(+;1M*C##W]<BNRKS/PEJ&NZK\5-3GUS38--EBTF-%M(K
ME9VA!E)&]EXW'!/TQ7IE !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &=KFER:QH\]C#J%
MUI\L@&RZM7VR1L#D$>HXY'<9%8/A_P 'ZG9:VNL>(?$T^N7L,+06Q-JEM'"K
M$%CL3.6.!SZ5U]% !6=KFER:QH\]C#J%UI\L@&RZM7VR1L#D$>HXY'<9%:-%
M '(>'_!^IV6MKK'B'Q-/KE[#"T%L3:I;1PJQ!8[$SEC@<^E=?110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% %74=.L]6T^:PU"VCN;2==
MLD4@R&%9'AOP-X:\(O,^A:5':23##R;WD<CTW.20/:NAHH *S=<T#2O$NF/I
MVL64=W:.02CY&".A!&"#[@@UI44 8WAWPGH7A.TDM=#TZ.SBD;<^TLS.>V68
JDG\36S110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>img224999359_28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_28.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'V UL# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTJX4Y3NUTU(G4C!I/KH>@4445!845R_C;QI;^#K")W@>>ZN=P@C'"Y7&2Q[
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M UKXPLI;F#Q#/%=67)@G,P=R<]01U4CGGD<5PLVK?#SQ+)<OJVGSZ'=ACAX
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M_P""-?U[3_B#+X7U749+Z,M)'NE8N0RJ6# GGD#H?6K_ ,$_^1?U+_KZ'_H
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M6[G3AK^RC?L%%%%8FX4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW9:22L@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *X>_^'?V[4;F[_M79Y\KR[?L^=NXDXSNYZUW%%5&<H[&56A3J
MJTU<\_\ ^%8_]1?_ ,EO_LZ/^%8_]1?_ ,EO_LZ] HJ_;U.YA]0P_P#+^+_S
M//\ _A6/_47_ /);_P"SH_X5C_U%_P#R6_\ LZ] HH]O4[A]0P_\OXO_ #//
M_P#A6/\ U%__ "6_^SH_X5C_ -1?_P EO_LZ] HH]O4[A]0P_P#+^+_S//\
M_A6/_47_ /);_P"SH_X5C_U%_P#R6_\ LZ] HH]O4[A]0P_\OXO_ #//_P#A
M6/\ U%__ "6_^SH_X5C_ -1?_P EO_LZ] HH]O4[A]0P_P#+^+_S//\ _A6/
M_47_ /);_P"SH_X5C_U%_P#R6_\ LZ] HH]O4[A]0P_\OXO_ #//_P#A6/\
MU%__ "6_^SH_X5C_ -1?_P EO_LZ] HH]O4[A]0P_P#+^+_S//\ _A6/_47_
M /);_P"SH_X5C_U%_P#R6_\ LZ] HH]O4[A]0P_\OXO_ #//_P#A6/\ U%__
M "6_^SH_X5C_ -1?_P EO_LZ] HH]O4[A]0P_P#+^+_S//\ _A6/_47_ /);
M_P"SH_X5C_U%_P#R6_\ LZ] HH]O4[A]0P_\OXO_ #//_P#A6/\ U%__ "6_
M^SH_X5C_ -1?_P EO_LZ] HH]O4[A]0P_P#+^+_S//\ _A6/_47_ /);_P"S
MH_X5C_U%_P#R6_\ LZ] HH]O4[A]0P_\OXO_ #//_P#A6/\ U%__ "6_^SH_
MX5C_ -1?_P EO_LZ] HH]O4[A]0P_P#+^+_S//\ _A6/_47_ /);_P"SH_X5
MC_U%_P#R6_\ LZ] HH]O4[A]0P_\OXO_ #//_P#A6/\ U%__ "6_^SH_X5C_
M -1?_P EO_LZ] HH]O4[A]0P_P#+^+_S//\ _A6/_47_ /);_P"SH_X5C_U%
M_P#R6_\ LZ] HH]O4[A]0P_\OXO_ #//_P#A6/\ U%__ "6_^SH_X5C_ -1?
M_P EO_LZ] HH]O4[A]0P_P#+^+_S//\ _A6/_47_ /);_P"SH_X5C_U%_P#R
M6_\ LZ] HH]O4[A]0P_\OXO_ #//_P#A6/\ U%__ "6_^SH_X5C_ -1?_P E
MO_LZ] HH]O4[A]0P_P#+^+_S//\ _A6/_47_ /);_P"SH_X5C_U%_P#R6_\
MLZ] HH]O4[A]0P_\OXO_ #//_P#A6/\ U%__ "6_^SH_X5C_ -1?_P EO_LZ
M] HH]O4[A]0P_P#+^+_S//\ _A6/_47_ /);_P"SH_X5C_U%_P#R6_\ LZ]
MHH]O4[A]0P_\OXO_ #//_P#A6/\ U%__ "6_^SH_X5C_ -1?_P EO_LZ] HH
M]O4[A]0P_P#+^+_S//\ _A6/_47_ /);_P"SH_X5C_U%_P#R6_\ LZ] HH]O
M4[A]0P_\OXO_ #//_P#A6/\ U%__ "6_^SH_X5C_ -1?_P EO_LZ] HH]O4[
MA]0P_P#+^+_S//\ _A6/_47_ /);_P"SH_X5C_U%_P#R6_\ LZ] HH]O4[A]
M0P_\OXO_ #//_P#A6/\ U%__ "6_^SH_X5C_ -1?_P EO_LZ] HH]O4[A]0P
M_P#+^+_S//\ _A6/_47_ /);_P"SH_X5C_U%_P#R6_\ LZ] HH]O4[A]0P_\
MOXO_ #//_P#A6/\ U%__ "6_^SH_X5C_ -1?_P EO_LZ] HH]O4[A]0P_P#+
M^+_S//\ _A6/_47_ /);_P"SH_X5C_U%_P#R6_\ LZ] HH]O4[A]0P_\OXO_
M #//_P#A6/\ U%__ "6_^SH_X5C_ -1?_P EO_LZ] HH]O4[A]0P_P#+^+_S
M//\ _A6/_47_ /);_P"SH_X5C_U%_P#R6_\ LZ] HH]O4[A]0P_\OXO_ #//
M_P#A6/\ U%__ "6_^SH_X5C_ -1?_P EO_LZ] HH]O4[A]0P_P#+^+_S//\
M_A6/_47_ /);_P"SH_X5C_U%_P#R6_\ LZ] HH]O4[A]0P_\OXO_ #//_P#A
M6/\ U%__ "6_^SH_X5C_ -1?_P EO_LZ] HH]O4[A]0P_P#+^+_S//\ _A6/
M_47_ /);_P"SH_X5C_U%_P#R6_\ LZ] HH]O4[A]0P_\OXO_ #//_P#A6/\
MU%__ "6_^SH_X5C_ -1?_P EO_LZ] HH]O4[A]0P_P#+^+_S//\ _A6/_47_
M /);_P"SH_X5C_U%_P#R6_\ LZ] HH]O4[A]0P_\OXO_ #//_P#A6/\ U%__
M "6_^SH_X5C_ -1?_P EO_LZ] HH]O4[A]0P_P#+^+_S//\ _A6/_47_ /);
M_P"SH_X5C_U%_P#R6_\ LZ] HH]O4[A]0P_\OXO_ #//_P#A6/\ U%__ "6_
M^SH_X5C_ -1?_P EO_LZ] HH]O4[A]0P_P#+^+_S//\ _A6/_47_ /);_P"S
MH_X5C_U%_P#R6_\ LZ] HH]O4[A]0P_\OXO_ #//_P#A6/\ U%__ "6_^SH_
MX5C_ -1?_P EO_LZ] HH]O4[A]0P_P#+^+_S//\ _A6/_47_ /);_P"SH_X5
MC_U%_P#R6_\ LZ] HH]O4[A]0P_\OXO_ #//_P#A6/\ U%__ "6_^SH_X5C_
M -1?_P EO_LZ] HH]O4[A]0P_P#+^+_S//\ _A6/_47_ /);_P"SH_X5C_U%
M_P#R6_\ LZ] HH]O4[A]0P_\OXO_ #//_P#A6/\ U%__ "6_^SH_X5C_ -1?
M_P EO_LZ] HH]O4[A]0P_P#+^+_S//\ _A6/_47_ /);_P"SKI/#7A[_ (1V
MUGA^U?:/-</GR]F.,>IK<HI2JSDK-ET\)1IRYH*S^84445F=(4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
MV1Q%$\A#$*I8A02>/0#K0 ZBO*O^%KZS9BPU36/"<FG^'[^]-E%+)/\ Z0C9
M(#/&0, [3Q['D\9W/$OCC4[3Q9#X6\-:/'J>J_9C=SF:X$4<,><#)QR2<?F/
M7@ [FBN;\#^+X/&GAX:E';/:SQRM;W-L[;C#*O5<X&>"#T[UTE !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !4<\\5K;RW$\BQPQ(7=V. J@9)/MBI*1E5U*L
M 5(P01P10!XQ\6+FVN-+TCQY8ZK#JNF6%VBQZ:YW6L[AF!;((RX/U&!Z9S:T
M#S!^TIKD\VY%N]$CD@1SR%Q ",>N5;]:Z>U^$G@VTU-+V+3&PDWVA+9IW,"R
M?WA&3M_#IP*T_$W@30/%MQ!<ZI:R?:[=2D=S!,T4BJ<Y7*GD<G@^I]30!Q'P
M6%T=&\6W5IY<@EUB8VWF,1&[ #G(!X.1R :[OSO&'_/CH?\ X&3?_&JT=%T7
M3O#VDP:7I5JMM9P A(U)/4Y))/))/<U?H R?#6IW6KZ*MW>Q0Q7 GGA=(22@
M,<SQ\$\G[OM]!6M7/^#/^1??_L(7W_I5+704 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!S_@S_D7W_P"PA??^E4M=!7/^#/\ D7W_ .PA??\
MI5+704 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M= '==J*!T%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2_&&D64@;+L;F)MP].O%-T/7[*SBE75?&.D7K,08RMQ$NT=^_-:W_"*>'/\
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MKH*YSP+$(/"XA#.PCOKU0TC%F.+J49)/)/O71T %%%% !1110 4444 %%%%
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M;:V[?AY'=HZR(KHP96&0P.01ZUPMGXC\6:K8:A>V5KI*0V4\T>)A(6FV$_=
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PW
MXK_$+QEX5\8BTTJ9+;2WAC*S36@9-YSD;]I]N*I:/XJ^)^N[!I_BSPK*S?P>
M=%O7ZKMS^E=)\2_B_)X0U\^'[?2;::1X5D:XNY&,0#9X**I)Z>M>3W,'A?Q9
M?)=:UXQT'2'8Y,&DZ',JY/7+%%Y]R3_B ?4>A)JD>AV::W)#)J8C N7A'R,_
M?' X_"K[*&4JP!4\$$=:Q/!MM86?@[2;?2[QKRPCMU6"X88,BCH<5N4 0_8[
M7_GVA_[X%2-&CIL9%9?[I&13J* "BBB@#G_!G_(OO_V$+[_TJEKH*Y_P9_R+
M[_\ 80OO_2J6N@H **** "BBB@ HHHH **** "BBB@ HHHH **** "N$D3Q+
MHOC37]0T_P .?VE:ZA]GV2?;HX<>7'M/!R>I/ITKNZ*N$^6^E[D3AS6UM8Y#
M_A(?&7_0B_\ E7A_PH_X2'QE_P!"+_Y5X?\ "NOHJO:1_D7X_P"9/LY?SO\
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MV[=:[6BBE.?,[VL*$.56O<****@L**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /+_ (EZSX1TG5[6WO/"47B+Q%>1_N+5
M+=7D*#.,G!('!Q@'H>*XQM>TC2'6?Q/\%X]-TTL%>[2V#B/)QR"@'?U'MFM7
MQ3XGA\&_'6YUF]TR^O8#I"6\?V6/<5<L#GD@= P_&F^)OC3I>N>%M6TJ/PWK
MBRWEG+!&TD"[59D(4GYN@)!H ]CT<:<-&LSI"PKIS0JUL(  GED9&T#M@U=K
ME/AFKI\-/#R2*RNMF@(88(KJZ "BBB@ HHHH Y_P9_R+[_\ 80OO_2J6N@KG
M_!G_ "+[_P#80OO_ $JEKH* "BBB@ HHHH **** "BN6\4ZUK5CK6B:5HB:>
M9]1\_+7H?:OEJK=5.1P3V/:H?^+C?]2K_P"3%:JD[)MK4R=57:2>AU]%<A_Q
M<;_J5?\ R8H_XN-_U*O_ ),4>R_O(/:_W7]QU]%<A_Q<;_J5?_)BC_BXW_4J
M_P#DQ1[+^\@]K_=?W'7T5R'_ !<;_J5?_)BC_BXW_4J_^3%'LO[R#VO]U_<=
M?17(?\7&_P"I5_\ )BC_ (N-_P!2K_Y,4>R_O(/:_P!U_<=?17(?\7&_ZE7_
M ,F*S=>UKQ[X=T6XU6[3PT\$&W<L0G+'<P48!('4CO35%MV30G625VF>@T44
M5B;!7/Z-_P C7XE_ZZV__HE:Z"N?T;_D:_$O_76W_P#1*T =!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 <5XZ^(MOX/N+33;73KC5M<O1NM["W^\5SC<Q ) X., YP?3-<
MLWQ<\2Z%)%/XM\"W>GZ9(P5KN%R_E9Z9&,?AD'ZTSQ7J=OX+^.5CXCUM)%TB
M]TPVD=V$++#(&)(.,GIZ=G^M3?$?XG^$;SP3J.E:?J$>IWVH0&""WMT+G<W
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M+X8$GX8^'223_H2#FNMH **** "BBB@#G_!G_(OO_P!A"^_]*I:Z"N?\&?\
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M00?-%-A1112*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_7Q=_P#I3+7:5Q?PG_Y)S8?]?%W_ .E,M=I7B3^)GV=+X(^B"BBBI- HHHH
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M&^,W_(8\.?\ 7O>?^A6]><UZF$_AGS.:?[P_1!5.V_X_[W_>3_T$5<JG;?\
M'_>_[R?^@BNA[HX8;2]/U1<HHHID'MWPG_Y)S8?]?%W_ .E,M=I7%_"?_DG-
MA_U\7?\ Z4RUVE>)/XF?9TO@CZ(****DT"BBB@ HHHH **** "BBB@ HHHH
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MNF2VE\TJZE>*7CB#)S=2GUSW]*[+6-7@T6Q^UW$4\J;@NV%-S9/Y<5G>#/\
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M7L\EY>%#D>:YR5![A1M4'T45NT4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445R?BCQ]8>&M
M3M]*33]1U75)HC.+/3H?,D6,9^=AD8'!% '645D>&?$NF^+="@U?2I&>VER,
M.NUT8<%6'8BM>@#C/AU_Q[^(O^P[<_R2NSKR_P *>,M \.R>(+35;_[/.^LW
M$JIY,CY4[1G*J1U!KH?^%H>#?^@Q_P"2TW_Q%=-6C4<VU%_<<U*M34$G)?>=
M?7":==WW@^?5M/DT34KZ*6[DNK*6TA,BN'YV,1]T@]S5S_A:'@W_ *#'_DM-
M_P#$4?\ "T/!O_08_P#):;_XBE"G4C=.#:?DQSJ4I--32:\T:'@S1[C1/#-O
M;7@ NW9YIPN,!W8G''ID#\*K:=:W"?$36[I[>5;>2TMU24H0C$9R >A(J#_A
M:'@W_H,?^2TW_P 169-XW\&RS/*OB>]C;<6BVQ2XB)^]@%,'/HV<=L4.-:[?
M(]?(JF\.TDZB5O\ AOZ_I%#7-*U&;PSXXBCT^Z>2YU&-X$6%B95#1Y*C'S#@
M\CTJ_P"+-'U*3Q,T%A;S-9:]#%;WLL:DB'RW&68CIF,E>>M,_P"$R\%+_JO$
M]_'L_P!3A)F\HG[V-R'=G_:SCMBC_A,O!2_ZKQ/?Q[?]3A)F\HG[V-R'=G_:
MSCMBJ4L0O^7;_JW^0.GA'_R^_K7S\_S\KZ^F6$\'Q*U6X%K+'9FPACCE\LA"
M1CY0>G'I775YU_PF7@I?]5XGOX]O^IPDS>43][&Y#NS_ +6<=L5IP_$OP7!"
MD2:PVU%"C=;S,>/4E<FLY4ZTWK!E\^'@O<J)Z^GZ_P!?GV5>.>-O^:A?]?&C
M?^C(Z[3_ (6AX-_Z#'_DM-_\17G_ (BU2SUK3?'NH:?-YUK+<:1LDVE<XE13
MP0#U!K2G3G%2<DUM^:.>M4A))1:>_P"3.,HHHKTSY,IW?_'Y8?\ 79O_ $6]
M7*IW?_'Y8?\ 79O_ $6]7*E;LN?PQ]/U85V/PI_Y*'_W"KC_ -&V]<=78_"G
M_DH?_<*N/_1MO66)_A/^NIUY;_O4?G^3/<:***\D^I/(_C-_R&/#G_7O>?\
MH5O7G->C?&;_ )#'AS_KWO/_ $*WKSFO4PG\,^9S3_>'Z(****Z3S@HHHH ]
MN^$__).;#_KXN_\ TIEKM*XOX3_\DYL/^OB[_P#2F6NTKQ)_$S[.E\$?1!11
M14F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %>3:*9F_:;\1></D71D\G/]W]Q_[,6KUFN.\2^
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MT[7-,AN(OM+7\ES' O!\G"+N ],D"O:: "BBB@ HHHH **** "BBB@ HHHH
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MH **** "BBB@ HHHH **** "J.IZM;:3&DES'>.'. +6RFN2/J(E8CZFKU%
M'/\ _"9:7_SZZY_X(KW_ .,T?\)EI?\ SZZY_P""*]_^,UT%% '/_P#"9:7_
M ,^NN?\ @BO?_C-'_"9:7_SZZY_X(KW_ .,UT%% '/\ _"9:7_SZZY_X(KW_
M .,T?\)EI?\ SZZY_P""*]_^,UT%% '/_P#"9:7_ ,^NN?\ @BO?_C-'_"9:
M7_SZZY_X(KW_ .,UT%% '/\ _"9:7_SZZY_X(KW_ .,T?\)EI?\ SZZY_P""
M*]_^,UT%% '/_P#"9:7_ ,^NN?\ @BO?_C-'_"9:7_SZZY_X(KW_ .,UT%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
1HHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>img224999359_29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_29.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '^ Z@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"%>:1_SWO?^_B__$UK:GW.3GQ/\B^\Z+^U-/\ ^?\ M?\ O\O^-']J:?\
M\_\ :_\ ?Y?\:YW_ (5YI'_/>]_[^+_\31_PKS2/^>][_P!_%_\ B:+4^X<^
M)_D7WG1?VII__/\ VO\ W^7_ !H_M33_ /G_ +7_ +_+_C7._P#"O-(_Y[WO
M_?Q?_B:/^%>:1_SWO?\ OXO_ ,31:GW#GQ/\B^\Z+^U-/_Y_[7_O\O\ C1_:
MFG_\_P#:_P#?Y?\ &N=_X5YI'_/>]_[^+_\ $T?\*\TC_GO>_P#?Q?\ XFBU
M/N'/B?Y%]YT7]J:?_P _]K_W^7_&C^U-/_Y_[7_O\O\ C7._\*\TC_GO>_\
M?Q?_ (FC_A7FD?\ />]_[^+_ /$T6I]PY\3_ "+[SHO[4T__ )_[7_O\O^-'
M]J:?_P _]K_W^7_&N=_X5YI'_/>]_P"_B_\ Q-'_  KS2/\ GO>_]_%_^)HM
M3[ASXG^1?>=%_:FG_P#/_:_]_E_QH_M33_\ G_M?^_R_XUSO_"O-(_Y[WO\
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M +_+_C1_:FG_ //_ &O_ '^7_&N=_P"%>:1_SWO?^_B__$T?\*\TC_GO>_\
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M[_PKS2/^>][_ -_%_P#B:/\ A7FD?\][W_OXO_Q-%J?<.?$_R+[SHO[4T_\
MY_[7_O\ +_C1_:FG_P#/_:_]_E_QKG?^%>:1_P ][W_OXO\ \31_PKS2/^>]
M[_W\7_XFBU/N'/B?Y%]YT7]J:?\ \_\ :_\ ?Y?\:/[4T_\ Y_[7_O\ +_C7
M._\ "O-(_P">][_W\7_XFC_A7FD?\][W_OXO_P 31:GW#GQ/\B^\Z+^U-/\
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M'_"O-(_Y[WO_ '\7_P")HM3[ASXG^1?>=%_:FG_\_P#:_P#?Y?\ &C^U-/\
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MI'_/>]_[^+_\31_PKS2/^>][_P!_%_\ B:+4^X<^)_D7WG1?VII__/\ VO\
MW^7_ !H_M33_ /G_ +7_ +_+_C7._P#"O-(_Y[WO_?Q?_B:/^%>:1_SWO?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS^GO7):KK=OJ'A62ZNO$^K7>KS)B2QB)C@BR<$,,8P![\DBO>E544*JA5'0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=;EU*'.WTTL5+72--LF#VNGVL+@?>CA53^8%7:**Q;;W-DDM@HHHI#"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *"0!DG %%,FACN()()D62*12CHPR&!&"#0 X$$ @@@]Q2U%
M;6T-G;16UM$D4$2A(XT& JCH /2I: "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKS[Q7X^USPY=:A<1>%GET3
M3?+^TWLUP(C+NQ_JE(^;&: /0:*\\UWXC:E:ZI?V^A>'FU*WTJVCNM2E><1&
M-77>%08.6V\TNI_$:^GN;:W\*:'_ &M(VG)J<YDG$0CA;[JC@Y<^E 'H5%9/
MA[Q!9^(O#ECK=N?+@NXPZK(0"IZ%3[@@C\*U$=)!E&5AZ@YH =1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!PWQ'_P"/CPA_V,-K_P"S5W-<-\1_^/CPA_V,-K_[-7<T %%%% !1110
M4444 %5[_P#Y!US_ -<F_D:L57OO^0?<_P#7)OY&@"2W_P"/:+_<'\JDJ.W_
M ./>+_<'\JDH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N*^'G^O\ %O\ V'[G^2UVM<5\//\ 7^+?^P_<_P EH [6BBB@
M HHHH **** *FF_\>AZ_ZV3K_OM5NJFF_P#'F<?\]9?3^^WI5N@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM%%% !1110 4444 5-._X]#DY_>R?^AM5NJFF_\ 'H>G^MEZ?[[5;H ****
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MCUR=6FFQO<@)R< #)H [ZBBB@ HHHH **** *FF_\>AZ?ZV7I_OM5NJFG?\
M'H<C'[V3_P!#:K= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 445F>(DO9?#U]%IT#3W;Q%(XUN/())XXD_A(&2#[4 6)M5
MTZVG$$]_:Q3'I&\RJWY$U:!#*&4@@\@CO7A,^C_V)%';:C\.O#"23G"R:AK:
M--*W<[W&2?<5ZIX+T"/0-#6-+>6T:<B5[)KMKB.V)'*1L?X>_P"- &7\0O'M
MQX,MHS::-/?RL!))*05@A3<%RS_WB2 %%+X[\:WGA:ZT2ULK>P>34WD4R7US
MY,4>Q0>6QQG.*L_$O1=0\0>!+[3=,@$]W*T12,N%SB12>20.@-5_&]KJ<LFG
MM;>$--\1VB*ZS0W#(LL9(&"A?Y<''/?B@"#4O&FN6&EZ);)I=A<^(-8F=+>"
M"Z+6X11DN9,<C;CIZUK>#O%4OB*QOEU"S6PU+3;EK6\A#[D5QSE6[J0:X2S\
M$^)_#NA^&-2LK*&[U+2+JYE?3%N  L,__+-';C*\?F:Z;PAX5NYM+U^;Q391
M)+K]VT\]BLFX11X"JA9>IP.<4 )\1)HI+CP@$D1C_P )!:\!@?[U=Y7DOBKP
M+X9\-:IX3O-'TF*TN&UZVC,BNY)7)..2?05ZU0 4444 %%%% !1110 57OO^
M0?<\X_=-_(U8JO??\@^Y_P"N3?R- $D'_'O%_N#^525'!_Q[Q?[@_E4E !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!G:QH&D^(+>.WU?3[>]AC?
M>B3H&"MC&1^!KP^Z@LH(+_Q/;>$_"R^'].U(V;6CP'[4X60(7#9P&R<A<=*^
M@:\'M)M#C\3:AJ?B#P5K%Y>1:I(8[VUML6T@#X1W3>$W#UP<]>M 'NZD%01T
MQQ2T Y -% !1110 5Q7P\_U_BW_L/W/\EKM:XKX>?Z_Q;_V'[G^2T =K1110
M 4444 %%%% %33>+0\?\M9?_ $-JMU4TW_CT/_763_T-JMT %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XSXML?.\>
M^(2_AA?%1N;*&"%8G5FT]MK<.#]P,?FW#T^M>E^#],O=&\':3INHR^;>6ULD
M<K;MW('3/?'3/M7B^L^*] U'Q]KFI6WB77](D6"&%396S$3[0<@KLR,'H3UR
M<5[)X)N;N\\%Z1<7PNOM,ENK2?:O]:3ZMP.3]* -^BBB@ HHHH X;XC_ /'Q
MX0_[&&U_]FKN:X;XC_\ 'QX0_P"QAM?_ &:NYH **** "BBB@ HHHH *KW__
M "#KGI_JGZ_0U8JO??\ (/N?^N3?R- $EO\ \>T73[@Z?2I*C@_X]XO]P?RJ
M2@ HHK,U$:X9E_LMM.$6WYOM2N6S[;3TH TZ*Y.:_P#%D.K6FGG^Q"US')('
MVR_+LV\8SWW?I6I9CQ)]JC^VOI)ML_/Y*R!_PR<4 ;%%%% !1110 4444 %%
M%% !1110 445DWEIKLET[V>JVD$!QMCDLC(P]?F\P9_*@#6HKDXG\42:[<Z;
M_;&G@0V\4X?^SVR=[.,8\WML_6MG3[;68;@M?ZE:W,.W 2*T,1SZYWG^5 &G
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $,]W;6H4W%Q%#
MN.%\QPN?IFI5974,C!E/0@Y!KR/QQHUO;_$%M9\0>'9_$.D7-HD,$=NWF26C
MJ3NQ%D%@>N1TJS\-8WB\6ZF-"TS5]/\ "AM5*P:BC(!<[N?*#$D+MZ^_X4 >
ME:C:R7VFW-K#=RVDDT91;B'&^,D?>&>XKY]M;/3D%]H5]XH\4ZE:#4)!<Q:=
M9,]O(?,W$,VW[Q/+8XSG%?1E>%+J1T+Q/?Z?IWCN_M+&34W\YH]%22TAG=\F
M(RG.#DX..,T >Z* % '0#BEH'0<YHH **** "N*^'G^O\6_]A^Y_DM=K7%?#
MS_7^+?\ L/W/\EH [6BBB@ HHHH **** *FF_P#'H>O^MDZ_[[5;JIIN/L9Q
M_P ]9?3^^WI5N@ HHHH **** "BBB@ HHHH **** "BH+R"2YM7ABN9;9V'$
ML04LOTW C]*P_":7\MM-=WNKW5X?/G@$<J1JH"2LH/RJ#G"CO0!T=%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %<IXN\87.@7VF:5I>D/JNK:D7,$ E$2A4 +,S'ZUU=>;?%AH
M9FT2PM=+OKW7999)+"2PN1!-!L4%V#D$=".#UH U=(\=7;ZW;:+XD\/7.B7M
MWN%J[2K-#.5&2H=>C8[&NTKS#P5X<_X25=%\67_B;5M4BMBSVMI=HB>3*,HV
M_;]X@@BO3Z /&/%6O+9?$S6+2?QA#X7C%M;LKPV2RO=':?OL0>5[#T->I^')
MUN?#EA,FIG5%>$$7I0(9_P#:P.E>:^,=5N;KQIK5E)XDL_#T6EV,=Q;B6WB=
MKQF!))+CE01MP/6O0?!FI7&L>#-(U&ZMUMY[BU21XT7:H)'4#L#U_&@#=HHH
MH **** .&^(__'QX0_[&&U_]FKN:X;XC_P#'QX0_[&&U_P#9J[F@ HHHH **
M** "BBB@ JO??\@^Y[_NF_D:L57O_P#D'7/_ %R;^1H DM_^/>+_ '!_*I*C
MM_\ CWB_W!_*I* "BBB@#"O_ /D<]&_Z]KG_ -IUNUA7_P#R.>C?]>US_P"T
MZW: "BBB@ HHHH **** "BBB@ HHHH **** ,.V_Y'C4?^P?;?\ H<U;E8=M
M_P CQJ/_ &#[;_T.:MR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#PSXH:5<3>*]9O;GP]K5^?[.B32;RQ1F2UG&YBQVGCYMOZUZ+X+\
M<:?XFBCL46]34H+97N$N;9XN> QR1@\FF>(_%?B#0];2UM/#":E9R*#')'J$
M44K-W C;DX]JRO#&K:UKGQ-NKZ[T35])L5TD0B&]7"-*)0<KC@\'Z\&@#T:O
M"+^SG/AO73%K*#P/_;#FZ4V;&Z#>>N]4/0IO_B/(%>[UPES\*])N=5FG.HZF
MFFSW7VR?24GQ;22YSN*XS@GDC- '=+C8NW[N.*6CI10 4444 %<5\//]?XM_
M[#]S_):[6N*^'G^O\6_]A^Y_DM ':TC,J*68@*!DDG@"EIKHDL;1R*KHP*LK
M#((/8T 0Q7UI,X2*Z@D<]%60$FK%<OX=TG3;;7]?D@T^UBDBO$6-DA52@-O%
MD @<=3^==10 4444 5-.S]D.3G][)_Z&U6ZJ:;_QYG_KK+_Z&U6Z "L?Q/:"
MYT*[E%Q=026\$DJ-;7#Q'<%.,[2,_0UL5GZ]_P B[J?_ %Z2_P#H!H A\.V@
MM=%MG^T74[S1)([7-P\IR5&<%B<#V%:U4M&_Y >G_P#7M'_Z"*NT %%%% '/
M7OB+4+368].3P_<S-,':&1;B(*ZIMR>6R/O#@UT(Z#(Q6%?_ /(Z:+_UZW7\
MXJW: "BBB@ K#\)_\@>;_K_N_P#THDK<K#\)_P#('F_Z_P"[_P#2B2@#<HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KE_%?@R/Q/>:?>QZM?Z9?6'F"">S<*P#@!@<CD<"NHK
MS/XKQV]W=Z%I\6CWFJ:M<-,;6.VOS:%%507)8<'MC- %?2M#U;X>Z[H.E+XL
MGN]+U"[E1;.6Q3)8AI&)D!R,G)KU2O*O!7@ZPUJ/0O%5MKWB"2&VD>2.PU"Y
M$RQ2#=&Z\C(P<C/M7JM 'D_B[Q!HUIXQUBU\7V]@(+>RCFT5KJP$Q=\-OVMC
MD[MHVUWO@^[U&^\'Z3=:M$(K^6V1YD";,$C^[VXQQVK'\4>/-$T/5?[/N=-O
MM2N;:,7$XM+3SA:QGH[G^&NJT_4+75=.M[^RE$UK<1B2*0=&4C(H LT444 %
M%%% '#?$?_CX\(?]C#:_^S5W-<-\1_\ CX\(?]C#:_\ LU=S0 4444 %%%%
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M])?_ $ UH5GZ]_R+NI_]>DO_ * : 'Z-_P @/3_^O:/_ -!%7:I:-_R ]/\
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M/AN=<_XGOGKI_G?\)#<?;=A?:!L7/E^^['7M7HL44<$211(L<:*%5%& H'0
M5QOP\_U_BW_L/W/\EH G\0Z[X@\-^%[C6+JVTV8VMH[RQQ.XS+O CVY_AP><
M\YZ5F_\ "0?$EHV*>"K')6/9G4DQG^///0]O3OFM'XI_\DRUW_K@/_0UKK(?
M]1'_ +H_E0!YEIFN>/$UC6&@\'6KEK]6G0ZD@*+Y$8"@]VQM.>G)&*FN_&?C
MO2_L']J>$["V2ZG6T\T7X=1-(V(S@9.T=_TQ77:'_P AOQ'_ -?L?_I/%63\
M1O\ CPT#_L/67_HR@#:D/B/RI?*72_,\F'R]QDQYF?WN?]G'W>_K4N=<\\X7
M3_)^UC'+[OL^WG_MIN_#%:=% '/Z:=?^Q1_)IH/^E>8-S_ZSS#Y>,?P]=W>K
M#GQ)Y#[%TKS?L\6S+2;?.S^\S_L8^[W]:NZ;_P >A_ZZR_\ H;5;H \K\8:=
M-K/Q+TC3]7(^P-:W4D"6L\D98#R\%\$<Y)Z<8IFJ?#_P]#H]]*D5[O2WD9<W
M\Q&0I[;JU_$O_)5_#G_8-O/YQUH:S_R M1_Z]9?_ $$U2V,:C:D<W8?#[P[)
MIEI(T-[N>"-CB_F')4'^]1X6TV71/B5JFGZ(<6HL[226.[GDDPK.^\KDGYN!
MCM73Z9_R"+'_ *]H_P#T 5F^'_\ DKFN?]@BU_\ 0WH8J;;D=3&?$&8O,73<
M9F\S:7Z?\L<?^S?I4;'Q-]F.U=)\_P"R+C+2;?M.?F]_+QT[YK:KQ?P_:ZKK
MNG37]QXKU^*1KNXC"0W85%59"  ,'L*25S6<U!79W&I'7/\ A.](V+I_DXFV
M;B^[R<1>9G_;ST[8ZUMQG7_,B\Q=-V>9-YFTOG9SY6/?IN_2O+KG0;T>(]-C
M/BOQ"Q:"X(D-V-RXV< [>A[_ $%6[W1-1M]/N9T\7^)-\4+NN;P8R%)'\-/D
M9G[>!Z"3XF^S<+I7VC[(.K2;?M.>??R\?CFN-^*T-W<Z%:P:C%:/92:Q:+$J
M;B64@[P^>/O9QCM76>!KNXOO NAW=W,\]Q-91O)*YRSL5&236#\6?^0!I'_8
M9M?YFDMS2?PLX[_A#O#6[_D!V77_ )YUG:-X4\/36+O+HUF["YG4$IV$C #\
M *ZS^+\:R]!_Y!TG_7U<?^C6KKLKGBJ<N5ZE&PT6VTGXC>%&T+3[*VGDFG$A
M(*AD\L[NG?&<>^*]B0Z[]HC\Q=.\G[1+OVE]WDX/EX_V\XW=O2O,[3_DI/A+
M_?NO_1)KV"N:I\1ZF%;=)-G@FI?;#X\\0?VB+<7G^B^<+?)CW>4/NYYQ]:S=
M9GACBMU>6-6^TQ'#, <;NM;7B'_DI?B?_>MO_1(JI);P2MNE@B=L8RZ G]:Z
MZ6M-'BXMI8F3?]:#T9) &1E93T*\@UU/PK.KCPYJWV!;(Q?;KS9YY;/GY79G
M'\'KWKED18U"HJJHZ!1@"NY^#O\ R*VI?]A>Y_FM1B/A1T97\<O0ZB[N-;M8
M+F>1])BAC6%EDF=U51_RV+'L /N_K68OC&T^T+N\0^&?)^U-NQ?#=]GV_+CG
M[^[KVQ4_Q$_Y)OXC_P"P=-_Z :^?K:PLC:0$V=N28UR?*'I]*QI4O:7U.S&X
MY851;5[GKFE>*RFOZQ++KGA=7DMH\M]M^1IPIV;3GE,?>[YZ5N?\):LI>.#7
MO"[RLL(A7[;G+D_O0<'I_=Q^->!06-F=0O%-I 0/+P/+''%/NK.UB>R>.VA1
MA>V^&6, _P"L6K>':3=SEAF\9U(T^7>W7N?2P.N?:!E=/\G[6<X+[OL^WC_M
MIN_#%6=/^W&R3^TA;BZRV\6Y;9C)QC//3&??-6J*YSV HKSG1?#6E>(=+U/7
M-0DN(I[B_NI(KR*Z>-X8UD95((.  %^E<T^N:O=/X2UNYNIBVEV27=T1\HN(
MI9Q#O8#CE!O_ #H ]KHKS.6^NO$7Q1T.ZAN)%TFUENHK>-'(6X,<>))3CJ [
M*H_W2>]:_@^SFM_%WBII;^ZOMLMO%YL[Y^;R][!5'"@;P, =J .TWKO";AN(
MSMSSBEK@/$'B"#0?&-]JDT?F_9-.M[6&,-C=+/*QP3V&$!)[ 4ZU^(4[)/Y]
ME;2BVN+599[25VB\J9RFX%E!W*<9'H0: .]I&=5QN8#<<#)ZFN$U+XC+;7\E
MI;6T'SSO!;7%S*5B81 >:YVJ3M#$(,#D@] *IS>)VUV3P_=M9/YEI<7MQ)!
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MQR<G[=%S_P!LEKV>O&8O^1Z\8_\ 7_%_Z*6KI?$98O\ A,T:***Z3R K*O\
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M:V?AY_R3KP]_UX1?^@BL;XL_\@#2/^PS:_S-8+<]&?PLR?XOQK+T'_D'2?\
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M*4)=']__  #3\&_\E2\-_P#;Q_Z*:OH:OGGP;_R5+PW_ -O'_HIJ^AJX*_\
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M]GNSY2.LX,190?EB,61[$&OH&OG_ $S3;34M9U>ZN?!FL>(G&K3JNJ)=M&I
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M445YA]P%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!Y?XCU;Q'X9\=7MS##I=UINH10K;PZCJB0%9%!#% W0'/(QV!S7HFE2
MW<^E6TM_:QVMTR RP12;U0^@;O7E?C?1Y[;QAK%]>>%4\16^J64<%D[2H/LC
M*"&!#'Y020VX>E>A^"]/NM*\%Z/87MPL]S!:HDDBMN!('0'N!TS[4 ;M%%%
M!1110!PWQ'_X^/"'_8PVO_LU=S7#?$?_ (^/"'_8PVO_ +-7<T %<1\)O^1
MMO\ KYN?_1SUV]<1\)O^1 MO^OFY_P#1ST =O1110 5Q%U_R6O3_ /L!R_\
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M!/\ D6W_ .O^Z_\ 1K4X;AB?@.EJIJO_ "!K_P#Z]I/_ $$U;JIJO_(&O_\
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MPF_Y$"V_Z^;G_P!'/7;UQ'PF_P"1 MO^OFY_]'/0!V]%%% !7$77_):]/_[
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M $!JF?PLVP_\6)[51117(>T?--__ ,C;XF_["T_\Z93[_P#Y&WQ-_P!A:?\
MG3*]*E\"/BL?_O,_4****T.,T_!O_)4O#?\ V\?^BFKZ&KYY\&_\E2\-_P#;
MQ_Z*:OH:O/K_ ,1GV&4_[I'Y_F%%%%8GHA1110 4444 %%%% !1110 4444
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M<C'[V3_T-JMU4TW'V,X_YZR_^AM5N@#S_P 2_P#)5_#G_8-O/YQUNUA>)?\
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M13(.5\=_\>NA?]ANT_\ 0C7IM>9>._\ CUT+_L-VG_H1KTVH9T4OA"O&8O\
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M0 4444 %<5\//]?XM_[#]S_):[6N*^'G^O\ %O\ V'[G^2T 3?%/_DF6N_\
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M_P!@BU_]#>MRL/P__P E<US_ +!%K_Z&]#V"G\1W]>2>!/\ D6W_ .O^Z_\
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MS/J.BBBO,/N HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[#=I_P"A&O3:\R\=_P#'KH7_ &&[3_T(UZ;4,Z*7PA7C,7_(]>,?^O\ B_\
M12U[-7C,7_(]>,?^O^+_ -%+5TOB,L7_  F:-%%%=)Y 5E7W_(V>$/\ L*C_
M - :M6LJ^_Y&SPA_V%1_Z U3/X6;8?\ BQ/:J***Y#VCYIO_ /D;?$W_ &%I
M_P"=,I]__P C;XF_["T_\Z97I4O@1\5C_P#>9^H4445H<9I^#?\ DJ7AO_MX
M_P#135]#5\\^#?\ DJ7AO_MX_P#135]#5Y]?^(S[#*?]TC\_S"BBBL3T0HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N*^'
MG^O\6_\ 8?N?Y+7:UQ7P\_U_BW_L/W/\EH F^*?_ "3+7?\ K@/_ $-:ZR'_
M %$?^Z/Y5R?Q3_Y)EKO_ %P'_H:UUD/^HC_W1_*@!]<;\1O^/#0/^P]9?^C*
M[*N-^(W_ !X:!_V'K+_T90!V5%%% %33?^/,]/\ 6R]/]]JMU4TW_CT/_763
M_P!#:K= 'G_B7_DJ_AS_ +!MY_..MVL+Q+_R5?PY_P!@V\_G'6[5+8YZOQ!6
M'X?_ .2N:Y_V"+7_ -#>MRL/P_\ \E<US_L$6O\ Z&]#V"G\1W]>2>!/^1;?
M_K_NO_1K5ZW7DG@3_D6W_P"O^Z_]&M3AN&)^ Z6JFJ_\@:__ .O:3_T$U;JI
MJO\ R!K_ /Z]I/\ T$UJ<2W-SX>?\DZ\/?\ 7A%_Z"*QOBS_ ,@#2/\ L,VO
M\S6S\//^2=>'O^O"+_T$5C?%G_D :1_V&;7^9K!;GIS^%F2>II*4]325V'@E
M2T_Y*3X2_P!^Z_\ 1)KV"O'[3_DI/A+_ '[K_P!$FO8*YJOQ'KX3^$CPSQ#_
M ,E+\3_[UM_Z)%05/XA_Y*7XG_WK;_T2*@KKH_ CQ,=_O$OZZ!WKN/@[_P B
MMJ7_ &%[G^:UP_>NX^#O_(K:E_V%[G^:UGB=D=65_'+T-SXB?\DW\1_]@Z;_
M - ->#VO_'G!_P!<U_E7O'Q$_P"2;^(_^P=-_P"@&O![7_CS@_ZYK_*C"[LR
MSWX8?/\ 0EJK??\ +G_U_6__ *-6K55;[_ES_P"OZW_]&K714^!GC8/_ 'B'
MJOS/J.BBBO,/N HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** .&^(_P#Q\>$/^QAM?_9J[FN&^(__ !\>
M$/\ L8;7_P!FKN: "N(^$W_(@6W_ %\W/_HYZ[>N(^$W_(@6W_7S<_\ HYZ
M.WHHHH *XBZ_Y+7I_P#V Y?_ $:*[>N(NO\ DM>G_P#8#E_]&B@#MZKWW_(/
MN?\ KDW\C5BJ]_\ \@ZYS_SR?^1H D@_X]XO]P?RJ2H[?_CVB_W!_*I* /.+
M/_DJWBW_ *][/_T UTE<W9_\E6\6_P#7O9_^@&NDJUL<U3XF%%%%,@Y7QW_Q
MZZ%_V&[3_P!"->FUYEX[_P"/70O^PW:?^A&O3:AG12^$*\9B_P"1Z\8_]?\
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MFB"QQ)G+'<#QQ72Q_$_P2L2 ^([/(4#JW^%=3]BM?^?:'_OV*/L=K_S[0_\
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M,>?E)Y YJ]]BM?\ GVA_[]BI(X8H01%&B ]=J@9KG/7'T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <-X\U#5
M9=<\.>&=*U"336U665I[N( R)'&H8A<]"<]?:H?!WB.ZL-.\26OB+4&NAH%X
MT)O3&2\D6T,I95'+ 'M6SXO\)R>)/[.NK+4GTW5=-F,MI=K&) NX8964]01C
M\JD\(>%1X7T^Y26]DO[^]N&NKR[D4*99&]%'0 #I0!Y_XU^(OAC5I?#C65]-
M*+/68+F?_0YALC7.6Y7GKT'-=7_PMWP5_P!!2;_P!G_^(KMMJG^$?E1M'H*
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M)IV^RR_(FTC/W>>3VKZ$VCT%&T>@I.JVK%0PD(24DV<3_P +=\%?]!2;_P
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTC,@!!VYW <"O8*0 *,  #VH AL[*UT^TBM+*WBM[:)=L<42A54>@ J>BB@
JHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>img224999359_30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_30.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %) H0# 2(  A$! Q$!_\0
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MR*+%YY87"$"/.-_7[N>,]*F_M"RS;#[7;YNAFW'F#]\,9^3GYN.>*\X\8_\
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M]#LC>VH4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB'V7&!U-26.E:=I8D&GV%K:"3&_[/"L>['3. ,]3^=-_MC3/^@C9_P#?]?\
M&D_MK2O^@G9_]_U_QH]ZU@YJ=[Z"W6CZ7?7*7-WIMG<7$8 26:!790#D8)&1
MR2:9=Z#H^H7!N+W2;"YF( ,DULCL0.G)&:=_;6E?]!.S_P"_Z_XTG]MZ2/\
MF*67_@0G^--.:!RIO>Q)!I>GVSPO!86L30H8XFCA53&I.2JX' SV%)_96G>7
M<Q_V?:[+IBUPODKB8^KC'S'ZTS^W-)_Z"EE_X$)_C2'7=('75;$?]O"?XTO>
M#FI]T.AT;2K>SELX=-LXK6;F2%(%5'^J@8/04LFCZ7*LJR:;9NLR*D@:!2'5
M?N@\<@8&!VIG]O:/_P!!:Q_\"$_QH_M[1_\ H*V1^EPO^-/WPYJ?=%YT22-D
M=0R,"&5AD$'L:IVFBZ58+*MGIEG;+,NV40P*@<>AP.1R>OK3?[=TC_H*6?\
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M#\JOUG_VYIG_ #^1GZ9H_MS3/^?Q/UI-2>X*=-;-&A16?_;FF_\ /VA^@/\
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M2&T_YYS_ /?(_P :0^([,?\ +.?_ +Y'^-<V:8:/91#VLCIO^$DL_P#GE/\
M]\C_ !I/^$FLO^>5Q_WR/\:Y<TPT>RB+VLCJCXGLA_RRN/\ OE?\:;_PE-C_
M ,\KC_OE?\:Y4TP]*?L8B]M(]"L[J.]M4N(PP1\X##G@X_I4]9GA_P#Y =O_
M ,"_]"-:=<TE9M'5%W284444AA1110 4444 %9GB.!+KPSJEM(URL<UI+&[6
ML9>4*RD$HHY+8/ '.:TZ* /,+M[VXT[4TMY=0U'0[&[TRXC::W/F,(YP]PJ
M*I=514;&#R6 Z8$D#-#K:>()H;@Z4VOSS))Y#G:C6:PB0KC(4NKC./X@>AS7
MI=% '$:7;^*X/!6EIH0TV"Y9I))$U:*7Y8V=F0!5(*M@C(/3I5_P/KNK:W8:
MHNM)9+>Z?J4MBYLE<1ML"G(#$G^(UU%<7\//O^+?^QCNO_08Z .THHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H+O\
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MI'LC+;6#E>V>%SCVS725GZ[?2:7X?U&_B7=);6TDJ C()521GVH=64UR]_\
M@?Y#5*,'S=O^#_F:%%8'AV[O6O-0L+V[-X;80NLSHJL=Z9((4 <$'''0]ZW9
M"XC8QJK. =H9L GMDX./R-92CRNQK&7,KCJ*P_#%[?WMI?'498Y)X;Z:',2;
M5 4X  ZX^O-:]RDTEK*EO*L,S*0DC)O"-V.W(S],T2C9V81ES*Z):*PO#T]Y
M/<ZAOOI+_3T=%M;F5$5G.#Y@!15#*#C!QUR,G%;-PLKVTJV[K',4(C=EW!6Q
MP2.XSVHE&SL$975R2BN?\.WEZ]]JEA?7$TLEJ\9C^T)&LNQE^\?+ 3:65L=Q
M@Y[5T%$H\KL$9<RN%%%%24%>3Z+_ ,@#3O\ KUB_]!%>L5Y/HO\ R -._P"O
M6+_T$5TT-G\OU.;$;KY_H>B^'_\ D!V__ O_ $(UIUF>'_\ D!V__ O_ $(U
MIUA/XF;P^%!1114E!1110 5FZU9ZG?6:P:7JBZ;(6^>?[.)FVX/"@G .<<D'
MZ5I5RGCS7=5T#2;:XTJXTFWD>?9)+JL<S0JFTGDQ [>0.6P/QQ0!BWOAR\T*
M>REG^(VOQ7-[<K:P>=''-&\S D+LV8 (4]<#CK7>V4=U%91)>SQSW*C#RQQ>
M6KGUVY./SKS2WL_&_C&]T*[OM0\&W&E:?J,=\9-)FG=V*AA@$Y7HYXX[<UZ1
MJMI-?Z5=6EO=M:331-&MPBY:,D8R!D<T 8J^-],DL]7N88[B5--NTLB$49GE
M?9M6/) .6D503@=^G-!\8PFWC5--O'U%[UK'^SPT?F"54\PY;?L"^7\^=W0C
MN<5S\7@W6K:VUM%>TD_XF-C>V$4<?DI(+=8/E^\VP'RM@],9Z'%6H]"UBWOU
MU]+%7N7U:6\DL/.4,(GMU@P'^[O&Q6QG&"1GH: .OTK4H-7TRWO[8.(IER%<
M893G!4CU!!!]Q7+_  \^_P"+?^QCNO\ T&.K%GX3O'\+:?I\VLZAIES"7EE;
M3)D&6=BQ7+H<@%L X'2J'POMFL[7Q/;-<SW+1>(+E#-.09),+'RQ  S] * .
M[HHHH **** "BBB@ HHHH **** "BBB@#G[;_DH>I_\ 8*M/_1MS705S]M_R
M4/4_^P5:?^C;FN@H *Y^;_DH=G_V"I__ $;#705S\W_)0[/_ +!4_P#Z-AH
MZ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.!CC/OG]*UG2ESI-[G)1QT'1E.UN4Z'2[5+:&X*V_D-+<RRNNXG<2Y^;D]P
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M-N:Z"@ KGYO^2AV?_8*G_P#1L-=!7/S?\E#L_P#L%3_^C8: .@HHHH ****
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M9QWQ7LE9SIRINTD;T,13KQYJ;N@HHHJ#8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .?U_\ Y&#PK_V$)?\
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M>-^'O%^G7/B721/H/ADWOVB.QM6TZ9)9;>!H=R%#C)5<[6P !FO9* "BBB@
MKB_AY]_Q;_V,=U_Z#'7:5Q?P\^_XM_[&.Z_]!CH [2BBB@ HHHH **** "BB
MB@ HHHH *\A\*?\ (GZ)_P!>$'_HM:]>KR'PI_R)^B?]>$'_ *+6N[ _$SDQ
M?PHUZHZITT[_ +"NG_\ I7%5ZJ.J=-._["NG_P#I7%7?6_AR]&<E/XUZG%W7
M_(8UG_L*WO\ Z4R4RGW7_(8UG_L*WO\ Z4R4RE1_AQ]$?/8O_>)^K_,?:_\
M(8T;_L*V7_I3'7T37SM:_P#(8T;_ +"ME_Z4QU]$UY^-_B+T/?R7_=WZ_H@H
MHHKC/8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG>))]G,:A"SVY&6D95YVG SDX.!P<=Q150DXR4D*45)69YGY/B'_ *%'5/\
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M3IIW_85T_P#]*XJO51U3IIW_ &%=/_\ 2N*N^M_#EZ,Y*?QKU.+NO^0QK/\
MV%;W_P!*9*93[K_D,:S_ -A6]_\ 2F2F4J/\./HCY[%_[Q/U?YC[7_D,:-_V
M%;+_ -*8Z^B:^=K7_D,:-_V%;+_TICKZ)KS\;_$7H>_DO^[OU_1!1117&>P%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YG
M-_R-WBC_ *_XO_22WJ6HIO\ D;O%'_7_ !?^DEO4M>WA_P"%$\NM_$9D>*O^
M1/UO_KPG_P#1;5C>+?\ DH'B/_KYA_\ 26"MGQ5_R)^M_P#7A/\ ^BVK&\6_
M\E \1_\ 7S#_ .DL%1/^/'T9R8S_ '27JC*HHHKH/GSVSP)_R3SPU_V"K7_T
M4M=!7/\ @3_DGGAK_L%6O_HI:Z"OGS[\*\Q^*L^IKJ^@V^GRZR%>"[>2/2VG
MW,5:  L(>2!N/)X&[WKTZBG%\KN14ASQ<;M7[;GSS_Q47_4\_P#E2KVKP9#<
MP>"M$2^-V;PV43W/VN1WE\UE#/N+DMG<3P>G3@#%;E%74J<_1+T,J&']C?WG
M*_=W/.VLM5B\8W:)%<.UQJ7G@&P4V[0_9PHE,Y&5D4C8 &!P/N$'=4_@&SN(
M[F%SIMS81VNBV>GS)/$R;IXS)N"E@-X7=]\9!W\$X-=[169T'E$FF>(9H2[7
M/B)7F@UAY EQ.N'CN/\ 10 #\ORDE0,;@,<J,4MSJ.K6.K6,]Z^NG4'OT;R%
M\P036RVS/L51\C-N5B5 +Y'(QBO5JHIHNE1:H^J1Z99IJ#C:UVL"B5AZ%\9/
MYT >=V&D:YI'BE)6BNC:M:6(O6MHF7S;EGN&+9'5%E?+J.S@L=H(:YX(GOCX
MDAM[JXUDS+I ?4(=0D?:+HR ,R*YZ<, 4&S ^7O7HQ (P1D&J6G:-I>D"4:9
MIMG9"5MT@MH%CWGU.T#)H Y?PQHVK6T.J70U+4(2VI:A)#I\L4*PMNFDV-DQ
M^9@Y# [\'CMQ7+Z7;^*7TI4FO==>66ZL!= VMQ T;&X7SMKO*Y(";MQC BQR
M.XKUVB@#RV.'Q%I2R74<>NWVTZI"+:2XF(:))/\ 1^3DY*\J_+L#U/%9R6_B
MQH9S9P:B]Q!/=OILMPDY*A[(;,-.2V/,) WG[W! ^Z/8Z* .0\!QZC';7OVR
M[O[B NGE?;+.> JVWY\>?+)(1G'7"Y^[D5U]%% !1110 4444 %%%% !1110
M 5'<6\%W;R6]S#'-!(I5XY%#*P]"#P14E% &5I7AG0M#EDETK1K"QDD&'>WM
MU1B/3('3VK5HHH 9Y,6UU\M-LA)<;1AL]<^M,-I;-;?9C;Q&#&/**#;^72IJ
M*    8 P!7%_#S[_ (M_[&.Z_P#08Z[2N+^'GW_%O_8QW7_H,= ':45C^(O$
M4/AVWM))+*[O'N[C[/%%:[-Q;8[Y.]E &V-N_I7(:AKNG:I=?:+KPIXF,FT+
M^[OXHQ@>R70'Z5<:<Y*\5<ESBMV>CT5Y%X0UNSMM#T6^?P[XEN;X6<3O<?VA
M&R2N8QN?:]R."23@J.O05V%O\0M+-OJ,^HV>H:7'IZ0/+]IC20L)G:--HA:0
MG+*1CW%#IS2NT"G%Z7.MHKSO4OB+HMU,C6/B6]LD"X9/["N)-Q]<F/BLK1/B
M/!/;P7.H>*[G=YC>9 F@3$,H<@#<J'J /IFER2[$^UI_S+[SUFBL'0O&>A^)
M;R:TTJXN)IH8Q)()+*>(*I.!EG0#)(.!G)P<=#C>J6K%IIJZ"BBB@85Y#X4_
MY$_1/^O"#_T6M>O5Y#X4_P"1/T3_ *\(/_1:UW8'XF<F+^%&O5'5.FG?]A73
M_P#TKBJ]5'5.FG?]A73_ /TKBKOK?PY>C.2G\:]3B[K_ )#&L_\ 85O?_2F2
MF4^Z_P"0QK/_ &%;W_TIDIE*C_#CZ(^>Q?\ O$_5_F/M?^0QHW_85LO_ $IC
MKZ)KYVM?^0QHW_85LO\ TICKZ)KS\;_$7H>_DO\ N[]?T04445QGL!117G_C
MB%Y/%FCQK?:E!'-8W32):W\\"L4>#:2$<#(\Q^>^1G.!BH0<Y**)E)15V;.K
M>)-7TE'FD\.,]N)TA207J L7D$:'&.,EA]*U=,O=3NI)!?Z3]A50"K?:5EW'
MTXZ5XWK-OJ%S;M;P6/BF4K<1,'DUMF1E256) :YZX4XR 0<'@\C4LH9[MW$P
M\46849#3ZY,0WL-EPWZXKH6#FW;_ #_R,?K,+7_R_P SV*BO/O#WC'2_#WA2
MQ37-1O&FFNK](&>.>[D=(KITY8!F^4%!ECZ5B^)_&WAY]+U2]T[Q+XABOO(=
MX(UMKE(E?;\H^:+ &?4XKGY'V-?:06[/6Z*\YT[QOX1T^Y,W_"0Z_<_*5\NY
MLKIU^N/*ZUVFAZ]IWB/3S?Z7+++;>8T8>2WDARRG#8#J"0#D9'&01U!I.+6X
MXSC+X7<TJ***10445E^)-5FT/PUJ6K06T=T]E;O<&%Y3$'5!N8;@K8.T''')
MP..H -2BO*/$/B[5I&MS=Z)+$0&V_P!FZO>X/3[WDVQ_#/O7/:5XHU5?^/G3
M=;DE^TR%/-U34D&S>=@.+8C 7 R2,CD@'(&KHS3LT1[2#ZGO%%<%_P + U&V
M^W_VAH=K']FTJZU)/L^H-)YGD;,H<PKMSY@YYZ=*Y36_B7]O@B35?!5E>1JV
M47[;++M..N%MSBE[*=VK;$3Q%*%N9[['M%%?.%CXOTN"XU!YOA_:RI-<>9"K
MM/B)/+1=J_Z,>,JQ[<L>.Y]0\*?$&_\ $/B*'2'T&UM(S;27#2I?M(51"BX"
MF%<G,B]QQD]L%.G)*[0HXFE*2@GJSOZ***@W"BBB@#S.;_D;O%'_ %_Q?^DE
MO4M13?\ (W>*/^O^+_TDMZEKV\/_  HGEUOXC,CQ5_R)^M_]>$__ *+:L;Q;
M_P E \1_]?,/_I+!6SXJ_P"1/UO_ *\)_P#T6U8WBW_DH'B/_KYA_P#26"HG
M_'CZ,Y,9_NDO5&511170?/GMG@3_ ))YX:_[!5K_ .BEKH*Y_P "?\D\\-?]
M@JU_]%+705\^??A1110 45DZWXDTSP[]E_M)[E/M3E(?)M)I]S ;B/W:M@X!
M.#U ..AQF?\ "PO#W][5/_!->?\ QJFHM[(3:6YU-%<M_P +"\/?WM4_\$UY
M_P#&JMV_C3P[/I\M^^JQ6EM%<?97>_5K3$NP/LQ*%.=I!^E#BUN@33V-ZBN?
M_P"$[\'_ /0UZ'_X,8?_ (JC_A._!_\ T->A_P#@QA_^*I#.@HK/TS7M'UOS
M?[)U6QO_ "<>9]EN$EV9SC.TG&<'\C6A0 4444 %%%% !1110 4444 %%%%
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M2F4J/\./HCY[%_[Q/U?YC[7_ )#&C?\ 85LO_2F.OHFOG:U_Y#&C?]A6R_\
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M*]6X^^WYUK_\([XR_P"A[_\ *1#_ (ULZ1XET[6Y3%:&=6,*W$?G0M'YL3'
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MMA>^4Y*J&"%9%R!Q^]C)!Z?-R<<]-6;;;NS>,8Q7+%604444B@HHHH ****
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M_")?$/\ Z*?_ .4"W_QH T9_#.LR0ZW80W]G#8ZM<2222^4S31HZJK!>0N[
M.">A.<'&*GFT#4SXA@O%>QFL;142RMY@_P#H^%PS@#@N<D!CT' QELX__")?
M$/\ Z*?_ .4"W_QH_P"$2^(?_13_ /R@6_\ C0!Z!17G_P#PB7Q#_P"BG_\
ME M_\:/^$2^(?_13_P#R@6_^- 'H%%>>2>&/'T6/,^*B)GINT*W&?_'J?_PB
M7Q#_ .BG_P#E M__ (J@#T"BO/\ _A$OB'_T4_\ \H%O_C1_PB7Q#_Z*?_Y0
M+?\ QH T+'P2--L=&DLY+>+5M.?#7*Q8$\3']Y&W<@CD>C!33;#P/]B\0F]+
MV<ML+^:_1GB8S!Y"S%<[MHPSMA@,XP/4FC_PB7Q#_P"BG_\ E M_\:1?"GQ"
M==R_%$,/4:#;G_V:@#HO#6BZCH5I;:;)>V\FFV4'D6Z)"1(P!&TNQ)&0HQP.
M22>.E4-4\.WM['K5C!(B"[O;748)9%R@:-HBT9QSU@SG_II[5F_\(E\0_P#H
MI_\ Y0+?_&C_ (1+XA_]%/\ _*!;_P"- &ZFB:M-J4^K75]:1Z@+-K2S\F!F
MCA#,&9F#-ER65./EX7WS6=)X+O;I-5N);NSM[Z[EM)H!;6Y$,4EN_F(S*3EB
MS<,>/E ';-4_^$2^(?\ T4__ ,H%O_C1_P (E\0_^BG_ /E M_\ &@#3?P_?
M1Z7=V[O'-=ZOJ27%W)$I6.)!L!P"2?\ 5Q!0>['. .G6UY__ ,(E\0_^BG_^
M4"W_ ,:ZGPYI^L:;ISP:WKO]LW1E++<_9$M\)@87:IQP03GW]J ->BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH \-\,VMA;?#OP#>:=#;1ZZ^I0HLD*@2R(TK>:K
M$<E?+#$YXXSV%=%8>*=8EU*PNI-4+SW>OS:9+HYC3;#"N_D87>&4('+$X(8\
M8Q7H5GHNE:?*9;+3+.VD(P7A@5#CZ@5.MC:+>->+:P"Z9=K3",;R/0MUQ0!Y
M9I/C#Q!;^)K^#4+F2\\R*^DL%MS#+;3^2<J!L DB9?ND-G<2>^*U?AWK^N:M
M>Q"_O1=6UQI4-XWFR0&2.9CSM6+D1L"<!N04//-=Y%I]E!=RW<-I;QW,O^LF
M2,!W^I R:=;6-I9F0VMK! 96WR>5&%WMZG'4T <%XBTYH?C!X-U![RYE\^2[
M1(&?]U"JVK?=7U)))/T':O1*BDMH)9HII(8WEA),3LH+)D8.T]LCCBI: "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#F?B+_ ,DW\2?]@Z;_ - -<DRV
M^C^(O"\WARTMA=OI-S)?06JA?.C2%3'O"]_-*@$_WCBO4)H8KB%X9XTEB<%7
M1U#*P]"#UJ"RTS3]-#BQL;:U#_>\B)4W?7 H \YT#Q1J\XTAQKD5\VJ:'-J%
MSYR(([&90I4_( 0F792&)/[OUSG%L?'/B6T\(:\UW=SR:O;VEK/'*WV>:%4E
MD\LSQ/& I4C+[7&%V]2,U[%!8VEK)+);VL$+S'=*T<84N?5B.I^M-M]-L+2.
M6.VLK:%)B3*L<2J')ZY '/XT <[X)U#4[QM7M[^X^T16MR$MY))H9)E!0%DD
M\KY<@GCO@C-<SX>%AJWQ3EN/#UE!:Z;I!N8+R]#?/?7,FTLG/S,JD9R>,].,
M5Z9:VEM90""TMXK>%>D<2!%'X"JUOH6D6ET+JVTJQAN%)(ECMT5QG@\@9[F@
M"_1110 4444 %%%% !1110 4444 <%XGM;&\^*7AF+48+:>#[!>G9<(K+G,7
M9N*Y[1M6O;-+/2+&^-CH=[XCO+6VO8MI$=NB%DBC+@J TBNH.#P,"O4[W2M.
MU(H;ZPM;HIG89X5?;GKC(XI\MC:36?V26U@DML >2\8*8'0;>E 'D^H>*_%$
MOA_39K+4%E"W=]#*\+P17%Y#$2L<T8D78P &Y@H&>,8!-+JWCC6[@P3:=?M;
M0KH5OJ,,DXMX$FD=B"TWF'[G 4JAXWGG[M>JSZ;875LEM<65M-!'C9%)$K*N
M.F 1@4Z:PL[EH6GM()6@.8B\88QGU7(X_"@#$\67^J6_A@#3K:X^W7;) 9+>
M(RFU##YY<+DG: <>K;>U8?P8D0_#'3X46<"&:Y3=,A4M^_D.<D<]><=\CM7?
MU%;VT%I"(;:&.&)22$C4*HR<G@>Y)H EHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIDSF."1QC*J2,_2N4M/',2Z
M;8RWME<-++907=Q);(OE1+(Q0'YGW?>'0 G'KS5QA*6Q$IQB]3KJ*Y_Q)KMU
MHMUI@@@2:*>23[0"#N$:(78KSU !..<XQ6>_C":.Z3,<<EL=6>SW00O*QB$'
MF!E"Y).>X!&.W>FJ4FKH3JQ3LSL**XFY\9W.RY>)[6TA35([)9KVWD0)&T0<
MLZLR$'/KCC\ZD@\<QVUM*U[Y=Z/M9MK>XL J1W&$#DKYCXX.5P&.3TS3]A,G
MV\#LJ*C@E$]O',%=!(H8+(I5AD9P0>0?:N+3Q?>'4VA%YI<CC539#3DC/VDQ
M^9MWY\P]!\Q^7& >14QIN5[%RJ*-KG<45R+^)K[[+'JAN=)M[.:X,<%I<OY<
MLJ*^TD2,X4-P6V[3V&>]07WC*]LU\1AH+<&Q+BR8@XD*(C,K\]?G!&,9&?0U
M2HR>Q+K16K.UHK%\4ZK<:-HIN[41F4SQ1#S(FD #N%)VJ06.#T!YK-FUS58[
M"%X[BW>:>^AM5:;2I[8('."=DC@MVZ$"E&FVKCE4478ZRBN5F\1:C92WVGSQ
MVL^H12VT=O+&K1Q/YY(4LI+$;2K9P3D 8QGAFJ>(M5T2WU6&Z%G<7=O8F]MY
MHXF1& .TJR%B00>X;D'MCEJE)Z"=6*U.MHKC];\0ZQX=BN4NC8W4C64MS;2Q
M0/&H:,KN5U+L2,.I!!'<8H;Q;=FXT"WC@A\V[<I?!E/[I@VPA>>#O#XSGA3F
MCV,FKK8'6BG9[G845BZ9JUY>^(-5L+BU2WBM$A:+YMSL',@);' SL! '8\G/
M 9)XLT^&Z>WE2='2::%BR@ &-%<G.>A#+CW(J?9RO8KVD;7-VBN?G\6VEM+I
M:3VEU&-2\M86<QKAGQA2I?<2-RY*A@,]>M3:)XFM->N+B*U@N56$D&5PI5B&
M((^5B5/?:P4X.<4.G)*]@52+=KFU16'>>*;*PUN'2[J*:)YB0DK-'M.%+9V[
MM^WY2-VW&>]9B^.4^TR3RV-S#IRV"W:%XQYL@:0(K* Q&T@]#AO;D9:I3>R$
MZL%NSKZ*YI/&=L]T;5]/O[:7S7MRTJ1E4E6,R;3M<Y.T9XXY'(J.V\;6CQVH
MDM;MQ)':F6X2)%C0S@;,J7+#)/0;L>O<GLI]@]K#N=317*VOC:TDFM+5X;F>
MXN-Q'DQ*N%$KQYV%RS8V$G;NP!N( X$ \>P6EM-)JEJ\,GVV>WAB$D2%DB/+
M$O(%R,@$9R2> 1S3]C/L+VT.YV-%<X_C73%2>98KE[6"VCNI+E541A9!E!RP
M.6Z=.#UQUIEOXWTZ\B3[)!<7-R\Y@%M T4C9";R=RN4(V]PWMUXI>RGV'[6'
M<Z:BN4;Q1>+\/E\0"U22Z,>[RU&%'S[<D%@<?CFKZ>*+5M16T-K=JIN!:FX*
MKY:S%=WEG#9SCC(&W/&:'3D"JQ_KS-RBN>U#Q#-I_BRVT^2*,V$EN'DFY#1N
MS[%)YQMS@=,Y8'IFL_3?&4TT^GB]@/EW-G+,WV2UEE8.LH0<)N(7&>HZ]^U"
MI2:N@=6*=F=C17"1^,[N==*,E[I>F)>1W3M->1-M!CEV*H!D3!(.3D]NE:Q\
M1W2^!!KTD$:SB,.5VL48;]NY1UPP^8#/0CDTW1DOR$JT7^9TM%<_'XNLC,8;
MBUO+25&=94G5?W96/S>2&(Y0,1@G[ISC%2ZIK<MMH-GJ5M"%-S-;+Y<XY597
M4'(!^\ WJ1GUJ?9RND5[2-F^QMT5S*^(;UH!:&. :K_:7V(IM8IM^_YFW.<>
M3\W7K5G6?$<.B7Q2X61XEM&N&2*(,QQ(B<,6']_ICGU&,%^SE>PO:1M<W:*Y
M.]\674GV.+3K"6*>74OL%P+I$;R2$WGA9 "2,$$$C /? ,[>-],73DO3#=")
M[);T JH.QG" 'YL Y([X [T>RGV#VL.YTM%<S+XQM(8[2ZE2>"VE@GF*/"&9
MA&4P597*D'>,%=P;(Y&.97\701A8WTW4!>&Y2U^R%8_,#M&9%.=^W!53SNX/
M7%'LI]@]K#N=#16?9:O#J&B)JEM#.T;QEUBVCS"1D%<9QG(QUQ[XK"7QNEY/
M8QZ?9R/YNHK97!9XG$>8R^0R2%3^!.-K C. 4J<G?R&ZD5;S.MHKE_$?B6?2
M]36S@DMH0EM]HDDN()9%(W;0"8_]6O!RYR!QQ0/$=ZVN;42V;3?[0&G8VGS=
M_E;]^[.-N>,8]\]J:I2:N)U8IV.HHK#UKQ3::)</#/:W<QCM_M,K0JI6.+=M
M+'+#H<<#)YX!YQ"GB^VD/DIIVH&]^TFV%GMC$A8()"<E]H&T@Y+4E3DU>PW4
MBG:YT5%<=JWC21-)AO\ 2XDV-:R74@ND(**'5!D C&23_P!\FM&3Q;:K%;O%
M8WTXN5DEA$:IEX4 )E +#Y/F&,_,>PI^RG;87M87M<Z"BLN77K6'0+?5S',T
M5PD30Q*H,CF3 1 ,XW$L!UQ[XJF/&%@JR&>"ZMVBCG:1957*M#@NG#$%L,&&
M"01WI*G)[(;J16[.@HKG$\;:4VLQZ6XDCN'D6(AWC!21E#!"N_?W R%*YXS5
MJT\117OA^XUF.SN8[:*-Y$$VT&0*"21M8XY!'./RH=.2W0*I%[,V:*XJV\6W
M\UC@36$EY-+;11+]GFC$1E)R65SEU '#J0&YZ5MZ=K;OH%W?7T8\VQ>>.<0#
MAC$S E03W"YP3QG&>].5*4=Q1JQEL;5%<S%XVLY;F*$Z=J,?F20IO=$VJ)CB
M)CA\X;Z9&.0*@_X3FUM[4R36MW/L26:62&%$6.-)FB)(,A/!7MDGK@= >RGV
M#VT.YUM%9^JWTMFMI%;JIN+NX6"/>"57@LQ(!&<*C'K6?9>+K.\N1%]COHE9
M9S%*T082^2VV0*$+,2#TXY[9/%)0DU=#<XIV9T%%<YJOBJ&VTF6XM8KA9@\<
M:&[L9XU!=@N<,H+8R3M7DXQWHL]?N'M["::2UGCENWLYFABDB96YV$H_*'(P
M5.?O @XX+]G*U["]K&]KG1T5S&L>)I]*\0BVD@VZ=#9M=3R^6'9_F"A4PX(Y
M('W3R1VY$S>+K=)$MVTW4!>M<BU-KMCWARAD!)W[<%1U#&CV4K7#VL;V9T-%
M8VM>)+?1)TADM+NYD:WEN<6ZJ<)'C<3N8?WO\G ,4'BJVN+6]F2RO ;0(S(X
MC4LCKN5P2^T+MY^8KC'.#Q25.35[#=2*=KF]17'KX]LW>.[QLTPV4\[EL&3S
M$F2(*"&*8)8\YQT.0*E/Q T@V*7,:32,UP;;R4DA)#A=WWO,V'(QC#$DG &0
M0*]C/L3[:'<ZNBLZ^UF"PTR&]DAN&\YHTB@6/$K.^ J[6Q@\\Y(QSFJ4/BJV
MN+NSM([*]-Q<R31M&50& Q,H?>=V,#<#\I;(Z9XS"A)J]BG.*=KF]1114EA1
M110 4444 %%%% !1110 4444 -=!)&R'.&!!Q7/CP9IPLOLOG76S[%#99W+G
M9$Y=3]WKD\]O85ORB0Q.(F5)"IV,Z[@#V)&1D>V1]:\TT3Q/K=II5DB(+S;:
M17EU-=2@%Q([# >68;  N,@,,G[J]]J49--Q9C5E%-*2/0KK38;N_L;R1I!)
M9.[QA2,$LI4YX]#[5F6/@_3=/:$V[W"K#>O>QH7!"LT?E[>GW0O0=?>L>;Q-
MKK7[10?V<D;7=U:Q^9"[%?)4ON.'&<@$8X]<]J9?^-+Z'3]-N[=;9FEM+6YN
M8#"3L$K ??+J%[@ !SQR .:I4ZFR9+J4]VCHF\-V;7CW)EGWO?)?$;ACS%0(
M!T^[@?7/>I]8TA-9M/L\EU<0(<AO*VD.I&"K*ZLI'U&1CC%<8OBC6+6ZOK.S
MC%PZ7%[.7N&4A8XY=H7+RH%4 \G)P,?+6O%XEU)O$-O;S16D6GW$BQ1LO[W+
M&(.5\Q&(5\GA64 J"0U#IU$[WV!5*;5K;F]IUC)IX%M'*38PP10V\;'++M!!
M).,G(V]2>AZ4_3M-ATQ+A(6D83W$EPV\@X9VR0,#I7*>)-3O]+\3RW:7 >"U
MTWS8[8LZIO:01[GPV& W9Y'0<8/-3+XBUEM:CT8/IQN/MK6\ER(7*%1")>$W
MY#?PD;CZ^U+V<FKWW'[2*=K;&G-X4M98Y;87M['ITTGFR6",GE$EMQ )4NH)
MYPK <G&,TFH>$=.U/3]1LKA[C9?7/VEW5P&C?:J?*<<#"XYSU-9OQ!U>]L-'
MD@LOM<!:)I7NX(9&" $80.H(4DGJ2. >Y%;&MZK<6MMIWV$1I+?W4<"27,3;
M8PRLV63*G.%QC(Y(H7M+*2>X/V=W%K874?#.F:A'+MA6TN)9$E>ZMHT65F1@
MP))4YY Z@TRY\//>6JPW.LZC*T<Z3Q2E8 T;)DC&(P".>X/2N8T_Q+JT.CI&
MD]JT\<%]>RS71:02"*=U"*0PP,?Q<X&.#5__ (2W44U1#-;VZZ?+D1!079V$
M(DV>8K';)DGY'1<@$ACTJO9U%I?8GVE-ZVW-G_A&;22VNX[FXNKF>Z='>ZD9
M5E5DQY978 %VD9&!USG.34<WA6VNK6_BO;R\NIKV'R)+F1D#K'V50JA0,Y/W
M<DGG/&,.S\5Z_=:<TOV*R$\T$$UJ&DB3(D<+@+YY+\'@DQY(Q@&ND\.:I+J^
MD+<SF/SED>.0)&\>TJQ&&1N58=QD@'."1S4R52"O<J+IS=K%:X\*07T-VE_J
M%]=R7-L;7S9#&K1QDY8*$0+R0,D@G@4]?"FGIJ,UZKW EENH[HC<-H9-V !C
MA278D>K'FLF]B^U:SXE>?4+V!+*UBDA:*\DC2$E');:&"GH#\P(XJ$>+-62U
M29TM%^RVEE+=1RJ?,F>8@-M(("8^C9/'%5RS:T?].Q+E!/5?TKG60Z;#!JMW
MJ*M(9KJ..-U)&T!-V,<?[9S^%9>H^#]-U.YU">=[@-?1HD@1@ NW'*\<$A0#
MZ@5S^I^*]4B@U2.YCM400326OEF0>8J2;<K+&Y#<?>'[ME)'!%6I/%VIVU],
M\T-K+9I<7D"Q1HRRGR(V<'<6(YVXQM]_:DJ=1:I_T@=2F]&OZ9KWOA*RO=5;
M4#<W4+L\$ACB*!2T+90\J3^&<<],\U/8>';>PU>;4_M-S/<21F$&=E.Q-V[;
MD*&;' !8L<#KUJGX>UG4;[49+2_DL9<6-O=*]HC+@R%\J<LW3:,>N<]\#+N/
M&&IV,^HFZ@M/+CBN)+555B)!&^T$2*S*V/XP0C+QP:.6H_=N/FIKWK&Q+X/L
M)M5>^:XNOGN1=- "GEF39L)/R[B"N>">,G&,U"O@BR$#PR7^H2QFW6UC5W3]
MU$KAU5<+V( R<G'?I5&]OM<;6-)M$U'33=_:948P;_+*^07'F1[LY[@;O[IX
MZ543QQJ]S%:36VGP;!8P7=SYC(BGS&((5GE3:/E.#A^3@CUI1JV5G_70ERI7
M=U_74Z.7PM8RW#SM+<;FO'O" RXWM%Y1'3IMY^O?M447@W3HK46ZS710"T&2
MRY_T?&S^'OCG],5C3Z]J=QK]G()H8[2._O+=;=-P=O*ADYD^;# D!@,#'R]<
MU!?>*KZ]L]-1)(X3-;:==R-;LRL'EG"NN<_=QQCZY)H4*FBN#G2U=C>?P98R
M6T%JUW>FUBD\TP,R%7;S&D!Y7*G+D90J2, DX%/?PE;>8TT&H7]O.;B:=9HF
M3<GF_P"L090C:2 >02"!@BJ7AWQ-J>KZA$+FSABL[E)7A^9%==C[<8\UF?OD
M[$P<>M1:CXPNM+U2]MIX8#%:2,\K*#D0%$\L]>I=\'M\IJ;5>;EOJ.]+EYK:
M&Q)X7L9H;Z.62Y<7D$,$C/+EAY6=K!CSNR<Y).2*:_AE9!%(^JZDUY%,9H[M
MI$+H2NTJ%V; I';;[]>:Q[KQ3JEI>Z9;NMLTKR6L%]$MNP$3RD='9QCJ<*%<
M_+DD9XN:!X@U'4-<GLK^.VC4QO- L2D[D$FT%9 S(XP1G[A!_A]!QJ)7N-2I
MMVL:'_"-V?\ PC']@>=<?9=FSS"P,G7.<D8SGVIB>&+5-1%V;J[=?/%T8"RB
M-IPNWS#A0<XYP#MSSBL]_$E\-;>,+:"R34DTXPLK><2T>[S-V< <]-O(!.:R
M[;QIJ_\ 9PN+F.P9KBQ6YAV1N@B9IA%\^6.Y1N#'&. 1[T*%1]=_U!SI=5M^
MAUUUHEG>7\MU<*TGFVAM'B)^0QDY/OG\:K:3X9L]&>T>":YD:VMGME,K [E9
MPY)P!DY%8VI^)-;LGM["W73[N^8W#230 &,+'M."KRIL;#C(WM@#.#GC3U?7
M[FS\-V6H6]LC7-XT"*F]9%0R8[[E5L9P/F /'(I<L[)7W'S4[MVV)[#PW9Z=
M<VD\,L[-:I.B!V!!$L@=LX'J./;UJYJVF0ZQI<^GW#2+#.NUFC.&'.>#^%<O
M+XNU2QL4N+VTMPS&XM@J%23<K@QJ=DCA=PW KDD$=:E@\2ZP^OFT>TMC:PW:
M6<SY1,N4#%E+2[NIX38<@?>ST'3J7YK@JE.W+8GO_"(N+.2U69[EKNYCEO+J
MZD_>;% 4A0JA>4RF.!AB3FMS4],AU6U2WG:142:.8&,@'<C!AU!XR!7*1>*]
M:31[34+B&SD%_$Z6R10NNVXW!8T8ESD-\QXP>,>]=%K:P"QB:\N;M%5P!%92
M-&]PY!P@VG=[X!'3DX!HDIIJ["+@T[(<-!LQXB;7,R_:3#Y6S=\G^_C'WL8&
M<]!TJ/5O#EGK,YFN))U8VYM\1L -I='SR#SF,?AFN/U:35K*R@M[G4KQ;FPT
MPW4Y2X*F,>9PV0P$[@+MVM@'DYR>>NUG5;J"72K:P:!)-0F*":Y1F1 $9_N@
MJ23C &10XR333_I"4H---?TQW_".6?VK[1YD^_\ M#^T,;ACS/*\O'3[N.W7
M/?M5.R\&VNGKB#4M24K;BVA;S$!AC#AP%PHS@C^+.0<'(KFQXNU'3/!UG<Q2
MQW-VEO)<3)*C3%D$C+N,A= H!P!]YCD87 K?F\1:E%J5Y8B&U\VU%Q,Q<E%\
ME45HB6+8&6< GI\C<"J<*JTO_2$ITGK;^F/7P+I/V58':X=0MPK'*IN,Q4LV
M%4 $;%QM  QT-6HO"]JD\5Q-=W=Q<I=+=&:5EW.RQF-00J@8"L>@!SSFF>&-
M8O=3CNXM26*.[MW4/&D31E 1QD%F4]"0RNP((Z'BH?$<%Y<ZC;I:SF81P2.^
MGPZ@UI,_*@2*R\MCD88A<L,FIO/FY6RK0Y>9(O#P[9?\(U)H)>8VCQO&6+#>
M Q)SG&,@GT^N:JP^$+2&9)OMMZ\RW<=YO8Q\NB&,# 0 *5., #'&,5S4WB._
MMBNH:;=2S6L&D).T>H#<TF)BIR$(4/\ [7/3H<YK7N/$NJ?VC,ENMEY*ZA_9
MR0R*WF%S$6#EMV,9Q\N.F3FJY*BZD\]-]#7U?P[;:Q(SR7%S 9(#;3>0RCSH
MB<E&R#QUY&#R>:;_ ,(S9#6!J EN JRB<6H91")0FP/C&<[>.N.^,UAZ;XSO
M=2GL8DMX ;R2!$.QL9"![D=>J]![]<U9\,^(M3U2]MH[Y;3R[JR>Z3R(V4H5
MD"8)+'=G.>@Q[]:3A4BMQJ=.3V-75?#EGK$ET]Q).IN+,V;^6P&$+;LC(/.?
M_P!54-4\,RFY:^TMG%\]W]I\UKD1>6?+$9"_NI 00!D$>^:BO_$]W;>*;>P@
M\B6T:[CM9OW)!C9DW8WEQENAP$( ZD$XJ7PQK^HZG=S6VIQVT4ODI/&D*'E&
MZ,KAF21#QA@0<@Y44)5(QOT!NG*5NHFG^#((= ;3[RYEEEFMHX)9$(^4*Q;"
M9!/WF/7.:AU?PI<^6O\ 8LA24-.5:2Z$8B67&Z-0(GRA(SC@CL1VJ3>*-=-W
M)'#_ &<D;7-Y;Q[X78KY&6#'#C.0,8XP><G[M!\9:K-+ UO8P>2MK:W%QO9%
M!\[KAWE7:!T'ROD\<5256][_ -;$-TK6M_6YT9T""3PY:Z/--)BVCA5)X\*Z
MO'MVNO7!RH/?\:K2>$=.GLX[>XDN)F6[^V/,[ /*YZAL #:1P0 !@"LJY\6W
MT.NR6T0MYK3_ $I%;R"NV2%"Q7<7R^#C.$ YP&.*O^&M<U'4KM[?4!:DFRM[
MQ&MT9-HEW94Y8YQMZ\9]*AQJ17-?S+4J<GRV\B\OA^*/59+Z&]O8DEF$\MK'
M(%BDD"[=QXW= ,C=@D#(-3V6C6MEHBZ0N^6U$;1D2'EE;.02,>IJE8W6OOXD
MNX;NRMTTY8XRCK.QP3YF2O[H;B<+D9^7C&<UE^(UNO[0O+I;J>>UMK=&D@L=
M1-O/:?>)DV?=DR " Y ^4X!I6DWRME-Q2YDC07P?:>5()+V^EF(A6*X=D\R
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MYTENC/QT^8C/%7%AB29YEC199  [A0&8#.,GOC)_.GT4KMCLD%%%%(84444
C%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>img224999359_31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img224999359_31.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +J TD# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[LO_ 'ZB_P */M/Q!_NR_P#?J+_"O1J*/:_W4'U-_P#/R7WGG/VGX@_W9?\
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M=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU_Y^8?\ OL4 344 Y&1THH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \S^-?_(!\/_\ 8=MOY/6S
M\6+.6^^%VNQ0J6=85FP.XCD5S^BFM;Q3X4LO%MG9VU[-/$EI=QW:&$@$LF<
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MN]IMC;9^TOG:6W9SG[V>_6I#HEJ7+^9<Y,Z3_P"O;&Y!@#KT]1T-:5% &4-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7D
M?[0__)/X/^OQ/Y&O7*\C_:'_ .2?P?\ 7XG\C0!ZAI/_ "!K'_KWC_\ 015R
MJ>D_\@:Q_P"O>/\ ]!%7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O(_VA
M_P#DG\'_ %^)_(UZY7D?[0__ "3^#_K\3^1H ]0TG_D#6/\ U[Q_^@BKE4])
M_P"0-8_]>\?_ *"*N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^O>/_P!!%7*IZ3_R!K'_ *]X_P#T$5<H **** "BBB@ HHHH **** "BBB@
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M*LR^JX4$\$=#WH ^E:*X?X8^/SX\T2>6YMEM=1M)/+N8ESMSV(SR._':NXH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\L&:T?;&O3"@8QP,4 ?4%%</\.O$'BW78;X^*=$.F/$RB$&%DW@YS]X\UW%
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M_P"0-8_]>\?_ *"*N53TG_D#6/\ U[Q_^@BKE !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/^$_]1JG_82G_F*I?"S"?\6'S.@HHHJ3<**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ&]^$?CRXOK
MB:'QY/'')(S*GVB8;03P.M>W5%<+(]M*L1VR%"$/H<<4 ?.-[\+]8U+3[J\O
MOB+:W5KILK":2:>618)%Z]>AKHOA'87<WB9KQ/'W]M6]O$RR69FF)YX#;7XQ
M7E<5_/!X>O\ P1%ITZ:[?ZL!.YSEE'"ICK][)_&O3/#.A:=X>^/5II'A^":*
M*TTW;?%BV)'VY+<^N5]O2@#WFBBB@ HHHH **** "BBB@ KR/]H?_DG\'_7X
MG\C7KE>1_M#_ /)/X/\ K\3^1H ]0TG_ ) UC_U[Q_\ H(JY5/2?^0-8_P#7
MO'_Z"*N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <]X
M<_Y"GB#_ *_O_9%KH:Y[PY_R%/$'_7]_[(M=#53W,,-_#^;_ #84445)N%%%
M% !1110 4444 %%%% !1110 445#=7=M90F:ZGCAC'\4C!1^M FTE=DU%<9J
M/Q)TJWD\G3XY;^<G"B-<*3_6J!E\=>(QA%32+5N_W7Q]>O\ *M%2EN]#DECJ
M=^6G>3\O\]CM-0UC3M*CWWUY%#QG#-R?H.M<'XF\?6>I:5>Z?IMI/.LD95YB
M,*@]:T]/^&NG1R>?JEQ/?SDY;<Q"D^_<_G74-HNG'3)-.6TBCM9%VM'$-F1^
M%4G3B^YG..+KQ:T@G\W_ )'SK70>#M$MM?UY;*[>58O+9CY9 )Q]0:[G7?!&
M@V7V#R+1E\ZZ2-_WK'*G.1UKI-*\(Z-HMX+NQMFCFVE=QD9N#[$UO/$1Y=#R
M,/E-15ESV:5K_P!6*UIX \-VF"-/$S#O,[-^F<?I6U;:7868Q;65M"/^F<2K
M_(5;HKD<I/=GT4*%*G\$4OD   P!BBBBI-0HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *Y_PG_J-4_["4_\ ,5T%<_X3_P!1JG_82G_F*I?"S"?\6'S.
M@HHHJ3<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!K'_ *]X_P#T$5<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH Y[PY_R%/$'_ %_?^R+70USWAS_D*>(/^O[_ -D6NAJI[F&&_A_-_FPH
MHHJ3<**** "BBB@ HHHH **P]6\7Z)HVY;F]1I1_RRB^=OQ Z?C7,MXWUS7'
M,7AW1G*]//E&0/QZ#\ZM4Y/4Y:F,HTWRWN^RU9Z"[K&A=V"J!DDG %<OJOQ
MT'3=RI<_:Y1_#;_,/^^NE8Z^"-:UIA)XBUEV7KY$)R!_3]*Z72O".B:/M:VL
MD:4?\M9?G;\ST_"JM".[N9^TQ57X(\J[O5_<CF1X@\8>(N-(TT6-LW2>8<X]
M03_0&I;?X=/>S"Y\0:K<7DO=58X'MD_TKO:*/:M?"K#6!C+6M)S?GM]QGZ9H
M6F:.FVPLHH3C!<+EC]6/-:%%%9MM[G7&,8JT59!1112*,#Q1_P PK_K^C_K6
M_6!XH_YA7_7]'_6M^J?PHQA_$G\@HHHJ38**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KG_  G_ *C5/^PE/_,5T%<_X3_U&J?]A*?^8JE\+,)_
MQ8?,Z"BBBI-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=M J,["=4QNSC[WT-)_:NN?]"W)_X&1?XU!H=Y#J'B/5+JW+&&2" J71D/\
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MH.^* -*BLZUURPO988X'F+3&0)NMY%'[MMK9)48YZ9Z]LUHT %%%% !1110
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M5J22M8YYTZCFI*2T\O\ @C()TN;>.>(DQR*&4D8X-2445!T+S"BBB@ HHHH
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MZ&D9/E9TMI%+!:0Q37#7$J(%>9E"ER!R2!P,^U3445!F%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
MUP6C8 X)! -.JN;RW::2UCN83=*N?*#C>..XZT >%V_Q0\3?#>[FT/QM82WP
M56:SN@P+2+V^;^(>_4=ZV?AU-XS\:>+(O&.M?Z+HJ1.EG:@D*0W&Y1WZ?>/7
MM570_@K<Z_/=:SX^O[BYO[D$)"DN3$.V6Z<=@.!3_ 6E:QX"^([>$UUVWOM&
MFB>5;?SE,D)P",QYRF0>O0T >U4444 %%%% !1110 4444 %>1_M#_\ )/X/
M^OQ/Y&O7*\C_ &A_^2?P?]?B?R- 'J&D_P#(&L?^O>/_ -!%7*IZ3_R!K'_K
MWC_]!%7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .>\
M.?\ (4\0?]?W_LBUT-<]X<_Y"GB#_K^_]D6NAJI[F&&_A_-_FPHHHJ3<****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#EO&G_ #!/^PG%_6NIKEO&
MG_,$_P"PG%_6NIJGLBG\*"BBBI)"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *Y3P+_ ,>NM_\ 88N?YBNKKE/ O_'KK?\ V&+G^8JELRU\+.KH
MHHJ2 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "O#_#W_)SWB#_ *XG_P!%)7N%>*^*?A#XGU3QYJ7B
M/1O$$.GF[*[=K.K@!%4@D?2@!GAEC_PTQXD&3CR>G_ $I;;_ ).GO/\ KR'_
M **2L>+X'>.(=3DU*+Q;"E]*,27"R2!V'3ENIZ"NE\"_"KQ#X>\<KXCUK6X=
M0?R6C8Y=I&R !RWIB@#U^BBB@ HHJMJ,EU#IEU+8P"XNTB8PPE@N]\<#)X&3
M0!9HKRJS\ ^+=2TMM4UOQ=J=EK4@,@@MY5\F ]EP.&%/TGXB7\'P?N_$&H!)
M]2LY'M P&%FD#[%/XDB@#U*BO)T\">+)?#XUIO&.IC7VB^T"$/\ Z.&QG9M]
M.U=GX"\2MXL\'V6J2HJ7)W17"+_#(A*M^>,_C0!TM>1_M#_\D_@_Z_$_D:]<
MKR/]H?\ Y)_!_P!?B?R- 'J&D_\ (&L?^O>/_P!!%7*IZ3_R!K'_ *]X_P#T
M$5<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y[PY_R%
M/$'_ %_?^R+70USWAS_D*>(/^O[_ -D6NAJI[F&&_A_-_FPHHHJ3<**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#EO&G_,$_["<7]:ZFN6\:?\P3
M_L)Q?UKJ:I[(I_"@HHHJ20HHHH **** "BBB@ HHHH **** "BBB@ HII=!U
M8#ZFF-<0*,M-&![L* ):*HR:UI</^MU*S3_>G4?UJG)XO\-0_P"LU_3%/I]J
M3/\ .G9CY7V-&34;&&0QRWENCCJK2J"/PS7*>"-1L8K;61)>6Z;M6N&&Z51D
M9'/6O"_'=Y;7_C75+JTF2:"2;*2(<AA@=#7.UNJ.FYVQPUX[[GV/%-%/&)(9
M$D0]&1@0?Q%/KBOA-_R3?3/]Z;_T:]=K6$E9V..4>6304444B0HHHH ****
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MZT:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *\C_:'_ .2?P?\ 7XG\C7KE>1_M#_\ )/X/^OQ/
MY&@#U#2?^0-8_P#7O'_Z"*N53TG_ ) UC_U[Q_\ H(JY0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!SWAS_D*>(/^O[_ -D6NAKGO#G_
M "%/$'_7]_[(M=#53W,,-_#^;_-A1114FX4444 %%%% !1110 444R66.&,R
M2R+&@ZLQP!^- #Z*X[6?B?X7T;<AO?M<P_Y9VPWG/UZ?K7,/XY\;>)V,?AGP
M^;2 \"YN!N/UR<*/UJU!LT5*3UV/5)IXK>,R32I&@ZL[  5Q^L_%/POI&Y%N
MVO9QQY=JN_GZ\#]:YV#X6ZUKDHN/%OB.>8'DV]NV?PR>!^ KM-&\"^&]""FS
MTR+S!_RUE&]_S-%H+?4JU..[N<0WC/QYXI)3P[H/V"V;@7$_)^NYL#]#4MM\
M*=3UB07'BSQ%<73'DP0,<?\ ?1_H/QKU,  8 P!V%+1SV^'0/:M?"K'/Z/X)
M\.Z$!]ATR$2#_EI(-[G\36KJ6EV6KV+65_;I/;.06C;H<'(JW14W>YDY-N[9
MYMXJ\#^&[+^R?LVDP1^=?QQR8!^93G(KJK#P3X<TN]CO++2H(;B,Y210<BJO
MC3_F"?\ 83B_K74U3D[+4TE.7*M0HHHJ#(**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KE/ O\ QZZW_P!ABY_F*ZNN4\"_\>NM_P#88N?YBJ6S
M+7PLZNBBBI("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\
MC_:'_P"2?P?]?B?R->N5Y'^T/_R3^#_K\3^1H ]0TG_D#6/_ %[Q_P#H(JY5
M/2?^0-8_]>\?_H(JY0 4444 -D=8HVD;[J@L?H*Y*+XD:'/$LL,&J21L,JZ:
M?*01[$"NHO?^/"X_ZY-_(U@_#[_D0-$_Z]E_K5*UKLN*7+=D'_"P](_Y]-7_
M /!=+_A1_P +#TC_ )]-7_\ !=+_ (5UE&:+KL%X]CD_^%AZ1_SZ:O\ ^"Z7
M_"C_ (6'I'_/IJ__ (+I?\*ZS(]:*+KL%X]CD_\ A8>D?\^FK_\ @NE_PH_X
M6'I'_/IJ_P#X+I?\*ZRC-%UV"\>QR?\ PL/2/^?35_\ P72_X4?\+#TC_GTU
M?_P72_X5UA( R3@"FHZ2*&1E93W4Y%%UV"\>QRO_  L/2/\ GTU?_P %TO\
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M_6NIJGLBG\*"BBBI)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI"))4#,0HQR37&>.OAH?%=Y9S65S;6*P(RLOD_>R0<\8K6^T>/O^@?X?_P#
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M.[J&%RCWD\-KN!Z*[@'],UWM<1\6=+N-4^'UZ+2-I+BU>.[1%&2WEL&(_+-
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M_$T?\+T\ ?\ 06F_\ Y?_B:Z/_A ?"7_ $+VG_\ ?D4?\(#X2_Z%[3_^_(H
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M /?D5)!SG_"]/ '_ $%IO_ .7_XFC_A>G@#_ *"TW_@'+_\ $UT?_" ^$O\
MH7M/_P"_(H_X0'PE_P!"]I__ 'Y% '.?\+T\ ?\ 06F_\ Y?_B:/^%Z> /\
MH+3?^ <O_P 371_\(#X2_P"A>T__ +\BC_A ?"7_ $+VG_\ ?D4 <Y_PO3P!
M_P!!:;_P#E_^)H_X7IX _P"@M-_X!R__ !-='_P@/A+_ *%[3_\ OR*/^$!\
M)?\ 0O:?_P!^10!SG_"]/ '_ $%IO_ .7_XFC_A>G@#_ *"TW_@'+_\ $UT?
M_" ^$O\ H7M/_P"_(H_X0'PE_P!"]I__ 'Y% '.?\+T\ ?\ 06F_\ Y?_B:/
M^%Z> /\ H+3?^ <O_P 371_\(#X2_P"A>T__ +\BC_A ?"7_ $+VG_\ ?D4
M<Y_PO3P!_P!!:;_P#E_^)H_X7IX _P"@M-_X!R__ !-='_P@/A+_ *%[3_\
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ME_\ B:/^%Z> /^@M-_X!R_\ Q-='_P (#X2_Z%[3_P#OR*/^$!\)?]"]I_\
MWY% '.?\+T\ ?]!:;_P#E_\ B:/^%Z> /^@M-_X!R_\ Q-='_P (#X2_Z%[3
M_P#OR*/^$!\)?]"]I_\ WY% '.?\+T\ ?]!:;_P#E_\ B:/^%Z> /^@M-_X!
MR_\ Q-='_P (#X2_Z%[3_P#OR*/^$!\)?]"]I_\ WY% '.?\+T\ ?]!:;_P#
ME_\ B:/^%Z> /^@M-_X!R_\ Q-='_P (#X2_Z%[3_P#OR*/^$!\)?]"]I_\
MWY% '.?\+T\ ?]!:;_P#E_\ B:/^%Z> /^@M-_X!R_\ Q-='_P (#X2_Z%[3
M_P#OR*/^$!\)?]"]I_\ WY% '.?\+T\ ?]!:;_P#E_\ B:/^%Z> /^@M-_X!
MR_\ Q-='_P (#X2_Z%[3_P#OR*/^$!\)?]"]I_\ WY% '.?\+T\ ?]!:;_P#
ME_\ B:/^%Z> /^@M-_X!R_\ Q-='_P (#X2_Z%[3_P#OR*/^$!\)?]"]I_\
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M'2DA865X)IO,DVX7CIZ]*]$0810>H%+10 4444 %%%% !1110 4444 %%%%
M!1110 5SG@:^NM1\+0W-Y*TLS229=NI <XK?N)X[6VEN)3MCB0NY] !DUR?P
MUN=_A.&U>*2*XMR?,5Q_?.\$?4,*TBOW;?FOU,I/]XEY/]#L****S-0HHHH
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MCSZK4JSC)_UY:[G9>&=5?6_#5AJ,BA9)X@S@=,]#_*M:N7^'7_(A:5_US/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M= T^]FB\F2>VCD:,?PDJ"10!C>*?^0_X5_["#?\ HIJZFN6\4_\ (?\ "O\
MV$&_]%-74UI/X8_UU,X?%+^NB"BBBLS0**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*Y;6/^2A>&/^N-Y_Z"E=37+:Q_R4+PQ_UQO/_04K2E\3]'^3,ZOP_-?FCJ:\
M+/P*UZ*[NI;3Q5;PQSS-+L^RDXR<^M>Z45";6Q4X1FK25T>&_P#"D?%/_0XV
M_P#X!_\ UZ/^%(^*?^AQM_\ P#_^O7N5%5[27<Q^JT/Y%]R/(?"?P?U?0O&N
MF^(-0\0P7JV7F#REMRA(9&7KG_:S7KU%%2VWJS:,8Q7+%613U/2K'6+06NH6
MZSP"19 C$CYE.5/'H15RBBD48VO>$]#\3+'_ &OIT5P\7^KD.5=/HPP1531_
M 7AK0KW[=9:9']L P+B9FED'T+$X_"NDHH I6FDV-A>WMY:VZQW%\ZR7+@DF
M1@, G/MZ5#>^'M)U'5K+5+NRCEOK$DV\YR&CSUZ'G\:TZ* "N/G^%O@JYN9K
MB70HVEF=I)&\Z0;F)R3PWK7844 <O-\.O"=QIEOILNCQM:6SM)#&99/D9NIS
MNSSBI]%\#>&/#US]ITK1;:WN.TN"SCZ,Q)%=#10!6U#3K/5;&6RO[:*YMI1A
MXI5W*:YFU^&'@^TNH[A-&1VB;=$DLCR)&?96)%=?10!G:QH6E^(-/-AJME%=
M6N0PC<=".A!'(/TJMH/A/0O#23+I.G16YF_UK\L[^Q8DG'M6U10!R1^&7@XZ
MBU\=#@\UG\PKEO++>NS.W]*ZP *    . !2T4 <MXI_Y#_A7_L(-_P"BFKJ:
MY;Q3_P A_P *_P#80;_T4U=36D_AC_74SA\4OZZ(****S- HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KEM8_Y*%X8_ZXWG_H*5U-<MK'_)0O#'_7&\_]!2M*7Q/T
M?Y,SJ_#\U^:.IKD)?BGX'@F>&7Q':+(C%64[N".".E=?7Q68(I=3U0O&K'[9
M+R1_M&IA'F=CHIT^>7*?47_"V/ G_0RV?_CW^%'_  MCP)_T,MG_ ./?X5\P
M_9+?_GBG_?-'V2W_ .>*?]\UK[!]SH^J/N?56E?$+PEK>I0Z=INN6US>39\N
M)-V6P"QZCT!-=-7RG\,(HXOC'X=$:*H(GS@?],9*^K*RE'E=CFG'DDXA17&?
M%&]N['P:9+.\EM)7O+>(S1-M95:0 X/T-<YKKWG@R]TBYTOQ=>ZE)<WT=N^F
MW<J3><C=2N ""/6I(/5J**Y?QSXAO-#TNU@TN-'U74KE;.T#C*J[9)8^P )H
M ZBBN"D\"3QV@GOO&NL)J)'_ !]?:%1 WLG3'M^M=?HZ3QZ1;1W-^E_.B!9+
MI%"B5AU. 2!0!>HK@O'LES+XB\-:;'JUUIUO=RRB:2WD"$@)D<GWJGI%Y>Z'
M\1[30(/$5QK=C=VLDLJ7#+(]LRXP=R@<'T- 'I-%>1_!WQ3J][)<:=KMY)<R
M72-=V4LAR2@<HR_@0#^--^(?BG5U\<Z1I^D7DEO965[:QWYC./,::0 (?^ @
M_G0!Z]17 ZE>:QXL\8W7A[2]1ETO3--1&OKJ #SI9&Y$:$_=&.I_QJ#6O#NM
M^$M-EUKP_KVH736BF6:POY/-CN$'+ 'JK8R0?PH ]%HKR?Q9XEAU/6_!SMK]
MQHND:E:7%Q-+'.(N0J%02>.N178:#I8CT6\?2/$USJ)NEQ#=7,BW"Q, >0!C
MUY&>PH ZBBO*M3M[[PGJ.CR6GBR_U/5;B\C@N+*:166=2?G.P<I@<UZK0!RW
MBG_D/^%?^P@W_HIJZFN6\4_\A_PK_P!A!O\ T4U=36D_AC_74SA\4OZZ(***
M*S- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KEM8_P"2A>&/^N-Y_P"@I74URVL?
M\E"\,?\ 7&\_]!2M*7Q/T?Y,SJ_#\U^:.IKXO0_\3+5/^OR7_P!"K[0KRVX^
M 7A"YNIKA[C5@\KM(P6Y4#).3_!2A+E=SHI5.27,>#9'K1D>M>Z_\,^>#O\
MGYUC_P "5_\ B*/^&?/!W_/SK'_@2O\ \16OM_(Z?KGD>5_#/_DL?ASZ3_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5RVL?\E"\,?\ 7&\_]!2NIKR'XWNR2Z$R
M,5.)^0<?\\ZWP\>>IR][_D88B7)3YNUOS1Z]17R1]IG_ .>\G_?9H^TS_P#/
M>3_OLUU_V?\ WOP_X)R?VA_=_'_@'UO17R1]IG_Y[R?]]FC[3/\ \]Y/^^S1
M_9_][\/^"']H?W?Q_P" ?6]%?)'VF?\ Y[R?]]FC[3/_ ,]Y/^^S1_9_][\/
M^"']H?W?Q_X!];T5\D?:9_\ GO)_WV:/M,__ #WD_P"^S1_9_P#>_#_@A_:'
M]W\?^ ?0^I_#VTO-5N=1T_6=7T>6\.;M-/N B3GIN(*G#8[C%;VA:%8>'-)B
MTW3HREO'DY9MS,Q.2S$]23WKY:^TS_\ />3_ +[-'VF?_GO)_P!]FC^S_P"]
M^'_!#^T/[OX_\ ^MZ*^2/M,__/>3_OLT?:9_^>\G_?9H_L_^]^'_  0_M#^[
M^/\ P#ZWHKY(^TS_ //>3_OLT?:9_P#GO)_WV:/[/_O?A_P0_M#^[^/_  #Z
MWHKY(^TS_P#/>3_OLT?:9_\ GO)_WV:/[/\ [WX?\$/[0_N_C_P#ZWHKY(^T
MS_\ />3_ +[-'VF?_GO)_P!]FC^S_P"]^'_!#^T/[OX_\ ^MZ*^2/M,__/>3
M_OLT?:9_^>\G_?9H_L_^]^'_  0_M#^[^/\ P#ZWHKY(^TS_ //>3_OLT?:9
M_P#GO)_WV:/[/_O?A_P0_M#^[^/_  #Z.\4_\A_PK_V$&_\ 135U-?-GP_ED
MD\>Z.'D=@)C]XY_A-?2=<V)I>R<8WOI^IT8:K[52E:VOZ!1117,=04444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
,4 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>41
<FILENAME>pepg-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-06T13:38:02.7902+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://pepgen.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:pepg="http://pepgen.com/20231231" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" namespace="http://xbrl.sec.gov/country/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" namespace="http://xbrl.sec.gov/ecd/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" id="StatementConsolidatedBalanceSheets1">
        <link:definition>100010 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails2" id="DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails2">
        <link:definition>100020 - Disclosure - Leases - Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2" id="StatementConsolidatedStatementsOfCashFlows2">
        <link:definition>100040 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>100050 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" id="StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>100060 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1">
        <link:definition>100070 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100080 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (PARENTHETICAL)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3" id="StatementConsolidatedStatementsOfCashFlows3">
        <link:definition>100090 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation1" id="DisclosureNatureOfBusinessAndBasisOfPresentation1">
        <link:definition>995455 - Disclosure - Nature of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995465 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurements1" id="DisclosureFairValueMeasurements1">
        <link:definition>995475 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet1" id="DisclosurePropertyAndEquipmentNet1">
        <link:definition>995485 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>995495 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>995505 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>995515 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies1" id="DisclosureCommitmentsAndContingencies1">
        <link:definition>995525 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquity1" id="DisclosureConvertiblePreferredStockAndStockholdersEquity1">
        <link:definition>995535 - Disclosure - Convertible Preferred Stock and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensation1" id="DisclosureStockbasedCompensation1">
        <link:definition>995545 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>995555 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995565 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995575 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995585 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>995595 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>995605 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>995615 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>995625 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityTables" id="DisclosureConvertiblePreferredStockAndStockholdersEquityTables">
        <link:definition>995635 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables" id="DisclosureStockbasedCompensationTables">
        <link:definition>995645 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>995655 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" id="DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>995665 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995675 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails">
        <link:definition>995685 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerS" id="DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerS">
        <link:definition>995695 - Disclosure - Summary of Significant Accounting Policies - Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>995705 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfMarketableSecuritiesDetails" id="DisclosureFairValueMeasurementsSummaryOfMarketableSecuritiesDetails">
        <link:definition>995715 - Disclosure - Fair Value Measurements - Summary of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>995725 - Disclosure - Fair Value Measurements - Summary of Fair Value of Financial Assets Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfWarrantLiabilitiesDetails" id="DisclosureFairValueMeasurementsSummaryOfReconciliationOfWarrantLiabilitiesDetails">
        <link:definition>995735 - Disclosure - Fair Value Measurements - Summary of Reconciliation of Warrant Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfCostAndAccumulatedDepreciationOfPropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentNetSummaryOfCostAndAccumulatedDepreciationOfPropertyAndEquipmentDetails">
        <link:definition>995745 - Disclosure - Property and Equipment, Net - Summary of Cost and Accumulated Depreciation of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>995755 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" id="DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
        <link:definition>995765 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>995775 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails" id="DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails">
        <link:definition>995785 - Disclosure - Leases - Summary of Components of Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalDisclosureOfCashFlowInformationRelatedToLeasesDetails" id="DisclosureLeasesSummaryOfSupplementalDisclosureOfCashFlowInformationRelatedToLeasesDetails">
        <link:definition>995795 - Disclosure - Leases - Summary of Supplemental Disclosure of Cash Flow Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails" id="DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails">
        <link:definition>995805 - Disclosure - Leases - Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>995815 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" id="DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails">
        <link:definition>995825 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceOnAnAsconvertedBasisDetails" id="DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceOnAnAsconvertedBasisDetails">
        <link:definition>995835 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Issuance, on an As-Converted Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" id="DisclosureStockbasedCompensationAdditionalInformationDetails">
        <link:definition>995845 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfWeightedAverageAssumptionsUsedToComputeEstimatedFairValueOfStockOptionsDetails" id="DisclosureStockbasedCompensationScheduleOfWeightedAverageAssumptionsUsedToComputeEstimatedFairValueOfStockOptionsDetails">
        <link:definition>995855 - Disclosure - Stock-Based Compensation - Schedule of Weighted Average Assumptions Used to Compute Estimated Fair Value of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails" id="DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails">
        <link:definition>995865 - Disclosure - Stock-Based Compensation - Summary of Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" id="DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails">
        <link:definition>995875 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeForIncomeTaxesDetails" id="DisclosureIncomeTaxesScheduleOfLossBeforeForIncomeTaxesDetails">
        <link:definition>995885 - Disclosure - Income Taxes - Schedule of Loss Before for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails" id="DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails">
        <link:definition>995895 - Disclosure - Income Taxes - Components of Net Deferred Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails" id="DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails">
        <link:definition>995905 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails" id="DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails">
        <link:definition>995915 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense to Statutory Federal Income Tax Rate to Loss from Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>995925 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails">
        <link:definition>995935 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>995945 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" xlink:href="pepg-20231231.xsd#StatementConsolidatedBalanceSheets1" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="pepg-20231231.xsd#StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" xlink:href="pepg-20231231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="pepg-20231231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3" xlink:href="pepg-20231231.xsd#StatementConsolidatedStatementsOfCashFlows3" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="pepg-20231231.xsd#DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="pepg-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="pepg-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerS" xlink:href="pepg-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerS" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="pepg-20231231.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfMarketableSecuritiesDetails" xlink:href="pepg-20231231.xsd#DisclosureFairValueMeasurementsSummaryOfMarketableSecuritiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="pepg-20231231.xsd#DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfWarrantLiabilitiesDetails" xlink:href="pepg-20231231.xsd#DisclosureFairValueMeasurementsSummaryOfReconciliationOfWarrantLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfCostAndAccumulatedDepreciationOfPropertyAndEquipmentDetails" xlink:href="pepg-20231231.xsd#DisclosurePropertyAndEquipmentNetSummaryOfCostAndAccumulatedDepreciationOfPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="pepg-20231231.xsd#DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="pepg-20231231.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" xlink:href="pepg-20231231.xsd#DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceOnAnAsconvertedBasisDetails" xlink:href="pepg-20231231.xsd#DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceOnAnAsconvertedBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:href="pepg-20231231.xsd#DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails" xlink:href="pepg-20231231.xsd#DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" xlink:href="pepg-20231231.xsd#DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="pepg-20231231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="pepg-20231231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails2" xlink:href="pepg-20231231.xsd#DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2" xlink:href="pepg-20231231.xsd#StatementConsolidatedStatementsOfCashFlows2" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="pepg-20231231.xsd#StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="pepg-20231231.xsd#StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="pepg-20231231.xsd#DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails" xlink:href="pepg-20231231.xsd#DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails" xlink:href="pepg-20231231.xsd#DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeForIncomeTaxesDetails" xlink:href="pepg-20231231.xsd#DisclosureIncomeTaxesScheduleOfLossBeforeForIncomeTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails" xlink:href="pepg-20231231.xsd#DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails" xlink:href="pepg-20231231.xsd#DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails" xlink:href="pepg-20231231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="pepg-20231231.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation1" xlink:href="pepg-20231231.xsd#DisclosureNatureOfBusinessAndBasisOfPresentation1" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="pepg-20231231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurements1" xlink:href="pepg-20231231.xsd#DisclosureFairValueMeasurements1" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet1" xlink:href="pepg-20231231.xsd#DisclosurePropertyAndEquipmentNet1" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpenses" xlink:href="pepg-20231231.xsd#DisclosureAccruedExpenses" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureLeases" xlink:href="pepg-20231231.xsd#DisclosureLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:href="pepg-20231231.xsd#DisclosureRelatedPartyTransactions" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies1" xlink:href="pepg-20231231.xsd#DisclosureCommitmentsAndContingencies1" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquity1" xlink:href="pepg-20231231.xsd#DisclosureConvertiblePreferredStockAndStockholdersEquity1" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensation1" xlink:href="pepg-20231231.xsd#DisclosureStockbasedCompensation1" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="pepg-20231231.xsd#DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="pepg-20231231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="pepg-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="pepg-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="pepg-20231231.xsd#DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:href="pepg-20231231.xsd#DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpensesTables" xlink:href="pepg-20231231.xsd#DisclosureAccruedExpensesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesTables" xlink:href="pepg-20231231.xsd#DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityTables" xlink:href="pepg-20231231.xsd#DisclosureConvertiblePreferredStockAndStockholdersEquityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:href="pepg-20231231.xsd#DisclosureStockbasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="pepg-20231231.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="pepg-20231231.xsd#DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalDisclosureOfCashFlowInformationRelatedToLeasesDetails" xlink:href="pepg-20231231.xsd#DisclosureLeasesSummaryOfSupplementalDisclosureOfCashFlowInformationRelatedToLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfWeightedAverageAssumptionsUsedToComputeEstimatedFairValueOfStockOptionsDetails" xlink:href="pepg-20231231.xsd#DisclosureStockbasedCompensationScheduleOfWeightedAverageAssumptionsUsedToComputeEstimatedFairValueOfStockOptionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:href="pepg-20231231.xsd#DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering" xlink:label="pepg_TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA2PreferredStockWarrantLiabilityMember" xlink:label="pepg_SeriesA2PreferredStockWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_HarrisonLeaseMember" xlink:label="pepg_HarrisonLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_RelatedPartyTransactionsOtherCostsPaid" xlink:label="pepg_RelatedPartyTransactionsOtherCostsPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ComputerAndOfficeEquipmentMember" xlink:label="pepg_ComputerAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_RequiredToPayExitFeeAmount" xlink:label="pepg_RequiredToPayExitFeeAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_CarnotPharmaLlcMember" xlink:label="pepg_CarnotPharmaLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ResearchAndDevelopmentExpenses" xlink:label="pepg_ResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_PercentageOfExitFee" xlink:label="pepg_PercentageOfExitFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TenantImprovementMember" xlink:label="pepg_TenantImprovementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryNotesSecuritiesMember" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_UndesignatedPreferredStockMember" xlink:label="pepg_UndesignatedPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_LeasedSpace" xlink:label="pepg_LeasedSpace"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AggregateOperatingLeaseCost" xlink:label="pepg_AggregateOperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:label="pepg_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering" xlink:label="pepg_TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_OperatingLeasePeriodOfExtension" xlink:label="pepg_OperatingLeasePeriodOfExtension"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ClassAAndClassBCommonStockMember" xlink:label="pepg_ClassAAndClassBCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ChangesInOwnershipByStockholdersHoldingPercentage" xlink:label="pepg_ChangesInOwnershipByStockholdersHoldingPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TermOfLicenseAgreement" xlink:label="pepg_TermOfLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_LeasesDisclosureTextBlock" xlink:label="pepg_LeasesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_NetLossPerSharePolicyTextBlock" xlink:label="pepg_NetLossPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AtTheMarketEquityOfferingSalesAgreementMember" xlink:label="pepg_AtTheMarketEquityOfferingSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AdditionalPaymentsOfRestatementCompletionFeeAndLicenseDataFee" xlink:label="pepg_AdditionalPaymentsOfRestatementCompletionFeeAndLicenseDataFee"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_OperatingLeaseMonthlyRentExpense" xlink:label="pepg_OperatingLeaseMonthlyRentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AccruedLiabilitiesCurrentDisclosureTextBlock" xlink:label="pepg_AccruedLiabilitiesCurrentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_OperatingLossCarryForwardsExpirationYear" xlink:label="pepg_OperatingLossCarryForwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_StockRestrictionAgreementsMember" xlink:label="pepg_StockRestrictionAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_UkTaxAuthoritiesMember" xlink:label="pepg_UkTaxAuthoritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_StockPurchaseAgreementMember" xlink:label="pepg_StockPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TechnologyLicenseAgreementMember" xlink:label="pepg_TechnologyLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_PaymentOfOfferingCosts" xlink:label="pepg_PaymentOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AmortizationOfPremiumAndDiscountsOnMarketableSecuritiesNet" xlink:label="pepg_AmortizationOfPremiumAndDiscountsOnMarketableSecuritiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_NumberOfFoundingStockholdersEntered" xlink:label="pepg_NumberOfFoundingStockholdersEntered"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_PercentageOfRepurchaseRightsLapseOnSecondAnniversary" xlink:label="pepg_PercentageOfRepurchaseRightsLapseOnSecondAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA2ConvertiblePreferredStockMember" xlink:label="pepg_SeriesA2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="pepg_EmergingGrowthCompanyStatusPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_FollowOnOfferingMember" xlink:label="pepg_FollowOnOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_PercentageOfRepurchaseRightsLapseOnOneYearAnniversary" xlink:label="pepg_PercentageOfRepurchaseRightsLapseOnOneYearAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SharesSalesAgreementAndFollowOnOfferingMember" xlink:label="pepg_SharesSalesAgreementAndFollowOnOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ClassOfWarrantsOrRightsNumberOfSharesConvertedToCommonStock" xlink:label="pepg_ClassOfWarrantsOrRightsNumberOfSharesConvertedToCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA1ConvertiblePreferredStockMember" xlink:label="pepg_SeriesA1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_DeferredTaxAssetsRightOfUseLiability" xlink:label="pepg_DeferredTaxAssetsRightOfUseLiability"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ServicesAgreementMember" xlink:label="pepg_ServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TemporaryEquityStockIssuedDuringPeriodSharesStockUponExerciseOfWarrants" xlink:label="pepg_TemporaryEquityStockIssuedDuringPeriodSharesStockUponExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="pepg_DeferredTaxLiabilitiesRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AccruedProfessionalServicesCurrent" xlink:label="pepg_AccruedProfessionalServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_NumberOfSharesRestrictedAndSubjectToRepurchase" xlink:label="pepg_NumberOfSharesRestrictedAndSubjectToRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExerciseOfPreferredStockWarrants" xlink:label="pepg_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExerciseOfPreferredStockWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_FixedLeaseRentExpense" xlink:label="pepg_FixedLeaseRentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_CommonStockOutstandingPercentage" xlink:label="pepg_CommonStockOutstandingPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_DeferredTaxAssetsIntangibleAssetAmortization" xlink:label="pepg_DeferredTaxAssetsIntangibleAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesBStockPurchaseAgreementMember" xlink:label="pepg_SeriesBStockPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="pepg_AccruedResearchAndDevelopmentExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB" xlink:label="country_GB"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_NumberOfCommonStockVote" xlink:label="pepg_NumberOfCommonStockVote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_StockOptionsIssuedAndOutstandingMember" xlink:label="pepg_StockOptionsIssuedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SublicenseesThresholdAmount" xlink:label="pepg_SublicenseesThresholdAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AtTheMarketIssuanceSalesAgreementAndFollowOnOfferingMember" xlink:label="pepg_AtTheMarketIssuanceSalesAgreementAndFollowOnOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_OperatingLeaseIncreaseInMonthlyRentExpense" xlink:label="pepg_OperatingLeaseIncreaseInMonthlyRentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ScheduleOfAccruedLiabilitiesCurrentTableTextBlock" xlink:label="pepg_ScheduleOfAccruedLiabilitiesCurrentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AmortizationAndInterestAccretionRelatedToOperatingLeases" xlink:label="pepg_AmortizationAndInterestAccretionRelatedToOperatingLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_OxfordScienceEnterprisesMember" xlink:label="pepg_OxfordScienceEnterprisesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_EffectiveIncomeTaxRateReconciliationUkRDCredit" xlink:label="pepg_EffectiveIncomeTaxRateReconciliationUkRDCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised" xlink:label="pepg_ProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_UsTreasuryBackedMoneyMarketFundsMember" xlink:label="pepg_UsTreasuryBackedMoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_OxfordUniversityInnovationLimitedMember" xlink:label="pepg_OxfordUniversityInnovationLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ExpectedMarketReturn" xlink:label="pepg_ExpectedMarketReturn"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_PreferredStockWarrantsPolicyTextBlock" xlink:label="pepg_PreferredStockWarrantsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AtTheMarketIssuanceSalesAgreementAndSecondaryOfferingMember" xlink:label="pepg_AtTheMarketIssuanceSalesAgreementAndSecondaryOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SharesSalesAgreementMember" xlink:label="pepg_SharesSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SharesOfRestrictedStockSubjectToRepurchase" xlink:label="pepg_SharesOfRestrictedStockSubjectToRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SupplementalDisclosureOfCashFlowInformationRelatedToLeasesTableTextBlock" xlink:label="pepg_SupplementalDisclosureOfCashFlowInformationRelatedToLeasesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_LaboratoryAndComputerEquipmentMember" xlink:label="pepg_LaboratoryAndComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AuthorizedForFutureStockAwardsOrOptionGrantsMember" xlink:label="pepg_AuthorizedForFutureStockAwardsOrOptionGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock" xlink:label="pepg_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ComprehensiveLossPolicyTextBlock" xlink:label="pepg_ComprehensiveLossPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="pepg_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_OperatingLeaseCommencementDate" xlink:label="pepg_OperatingLeaseCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="pepg_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TemporaryEquityStockIssuedDuringPeriodValueStockUponExerciseOfWarrants" xlink:label="pepg_TemporaryEquityStockIssuedDuringPeriodValueStockUponExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ResearchAndDevelopmentCreditsExpirationYear" xlink:label="pepg_ResearchAndDevelopmentCreditsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_RaCapitalManagementLPMember" xlink:label="pepg_RaCapitalManagementLPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TwoThousandTwentyTwoEquityIncentiveAwardPlanMember" xlink:label="pepg_TwoThousandTwentyTwoEquityIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_RentPayableToRelatedParties" xlink:label="pepg_RentPayableToRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_NewtonMassachusettsMember" xlink:label="pepg_NewtonMassachusettsMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" xlink:label="pepg_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_NetProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised" xlink:label="pepg_NetProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_CambridgeMassachusettsMember" xlink:label="pepg_CambridgeMassachusettsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AggregatePotentialMilestonePayments" xlink:label="pepg_AggregatePotentialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" xlink:label="pepg_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SecondaryOfferingMember" xlink:label="pepg_SecondaryOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="pepg_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesBConvertiblePreferredStockMember" xlink:label="pepg_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlanMember" xlink:label="pepg_AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility %</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding, Weighted Average Remaining Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Underwriter's fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Issuance costs of Series B convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reconciliation of Warrant Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, Issuance of convertible preferred stock, net of issuance cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Conversion of Convertible Preferred Stock Upon Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity conversion of convertible preferred stock upon initial public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, Conversion of convertible preferred stock upon IPO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment estimated useful lives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense related to unvested stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SeriesA2PreferredStockWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-2 Preferred Stock Warrant Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SeriesA2PreferredStockWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A-2 Preferred Stock Warrant Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SeriesA2PreferredStockWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-2 Preferred Stock Warrant Liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_HarrisonLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Harrison lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_HarrisonLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Harrison Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_HarrisonLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Harrison Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares agreed to issue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible preferred stock shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liability, net of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Release of common stock from vesting restrictions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_RelatedPartyTransactionsOtherCostsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_RelatedPartyTransactionsOtherCostsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions, Other Costs Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_RelatedPartyTransactionsOtherCostsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party transactions, other costs paid.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, convertible preferred stock, and stockholders' equity (deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total liabilities, convertible preferred stock, and stockholders' deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ComputerAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer and Office Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ComputerAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer And Office Equipment Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ComputerAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer and office equipment member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Common Stock in IPO, net of underwriters' fees and issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split, conversion ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding vested and unvested stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stock Options, Outstanding as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stock Options Outstanding as of December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value of stock options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares, issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Allowance for Credit Loss [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement date aggregate fair value of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable, Trade</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Reserved shares of common stock for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initially common stock reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive (Loss) Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_RequiredToPayExitFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Required to pay exit fee amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_RequiredToPayExitFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Required to Pay Exit Fee Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_RequiredToPayExitFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Required to pay exit fee amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative translation adjustment arising during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Remeasurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Fixed Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_CarnotPharmaLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carnot Pharma, LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_CarnotPharmaLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Carnot Pharma, LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_CarnotPharmaLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carnot Pharma, LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Cost and Accumulated Depreciation of Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options, Vested and expected to vest as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reductions in research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend Yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Expected Dividend Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase related to prior year tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Income Tax Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_PercentageOfExitFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of exit fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_PercentageOfExitFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Exit Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_PercentageOfExitFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of exit fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TenantImprovementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant Improvement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TenantImprovementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TenantImprovementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant improvement member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Vested and expected to vest as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Notes Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_UndesignatedPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Undesignated Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_UndesignatedPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Undesignated Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_UndesignatedPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Undesignated referred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_LeasedSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leased space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_LeasedSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leased Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_LeasedSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Leased space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax at statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Comprehensive Income [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaids and other current and non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expenses, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CIK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants purchase granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AggregateOperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total payments to the landlord for improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AggregateOperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Operating Lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AggregateOperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate operating lease cost.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair value of financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to extend lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Foreign Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss before income tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss before income tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Process</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of stock under the employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Penalties and Interest Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrual for interest or penalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrual for interest or penalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits, interest on income taxes expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Interest on Income Taxes Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Class A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds issuance or sale of equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to extend lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of estimated useful lives of property and equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Estimated Useful Lives of Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from employee equity plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on disposal of fixed assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of stock under the employee stock purchase plan, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from underwriters exercised option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Present value of lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Conversion of Convertible Preferred Stock Upon Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity shares conversion of convertible preferred stock upon initial public offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, Conversion of convertible preferred stock upon IPO, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_OperatingLeasePeriodOfExtension_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease period of extension.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_OperatingLeasePeriodOfExtension_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Period Of Extension</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_OperatingLeasePeriodOfExtension_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional period of lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development (including related party amounts of $29 and $475,respectively)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, by Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ClassAAndClassBCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A and Class B Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ClassAAndClassBCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class A and Class B Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ClassAAndClassBCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class A and Class B common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross proceeds from issuance of convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible preferred stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ChangesInOwnershipByStockholdersHoldingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Changes in ownership by stockholders holding percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ChangesInOwnershipByStockholdersHoldingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Changes In Ownership By Stockholders Holding Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ChangesInOwnershipByStockholdersHoldingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in ownership by stockholders holding percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon initial public offering, net of underwriters' fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares remaining available for grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary, Sale of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; 500,000,000 shares authorized as of December 31, 2023 and 2022, respectively; 23,823,241 and 23,713,196 shares issued and outstanding as of December 31, 2023 and 2022, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and exercisable , Weighted Average Remaining Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TermOfLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of license agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TermOfLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term of License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TermOfLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term of license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2019-12</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2019-12 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_LeasesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Leases disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_LeasesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_LeasesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease related to prior year tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_NetLossPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net loss per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_NetLossPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Loss Per Share [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_NetLossPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current and non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Taxes Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Taxes payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Taxes Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-02 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-02</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase related to current year tax positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AtTheMarketEquityOfferingSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-Market Equity Offering Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AtTheMarketEquityOfferingSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At the Market Equity Offering Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AtTheMarketEquityOfferingSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market equity offering sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AdditionalPaymentsOfRestatementCompletionFeeAndLicenseDataFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional payments of restatement completion fee and license data fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AdditionalPaymentsOfRestatementCompletionFeeAndLicenseDataFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Payments of Restatement Completion Fee and License Data Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AdditionalPaymentsOfRestatementCompletionFeeAndLicenseDataFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional payments of restatement completion fee and license data fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_OperatingLeaseMonthlyRentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease monthly rent expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_OperatingLeaseMonthlyRentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Monthly Rent Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_OperatingLeaseMonthlyRentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Monthly rent expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Option to purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock and Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AccruedLiabilitiesCurrentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AccruedLiabilitiesCurrentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued liabilities Current Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AccruedLiabilitiesCurrentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued liabilities current disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_OperatingLossCarryForwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carry forwards, expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_OperatingLossCarryForwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carry forwards Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_OperatingLossCarryForwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carry forwards expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Vested and exercisable as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_StockRestrictionAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Restriction Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_StockRestrictionAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Restriction Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_StockRestrictionAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Restriction Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_UkTaxAuthoritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">UK tax authorities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_UkTaxAuthoritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UK Tax Authorities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_UkTaxAuthoritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UK tax authorities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_StockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_StockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_StockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Lease Payments Under Non-cancelable Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TechnologyLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Technology License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TechnologyLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Technology License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TechnologyLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Technology license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_PaymentOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_PaymentOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_PaymentOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AmortizationOfPremiumAndDiscountsOnMarketableSecuritiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of premium and discounts on marketable securities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AmortizationOfPremiumAndDiscountsOnMarketableSecuritiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Premium And Discounts On Marketable Securities Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AmortizationOfPremiumAndDiscountsOnMarketableSecuritiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of premium and discounts on marketable securities, net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_NumberOfFoundingStockholdersEntered_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of founding stockholders entered</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_NumberOfFoundingStockholdersEntered_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Founding Stockholders Entered</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_NumberOfFoundingStockholdersEntered_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of founding stockholders entered.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_PercentageOfRepurchaseRightsLapseOnSecondAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of repurchase rights lapse on second anniversary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_PercentageOfRepurchaseRightsLapseOnSecondAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Repurchase Rights Lapse on Second Anniversary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_PercentageOfRepurchaseRightsLapseOnSecondAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of repurchase rights lapse on second anniversary.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SeriesA2ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-2 Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SeriesA2ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A-2 Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SeriesA2ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-2 convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging growth company status.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Status [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fixed lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Amounts of Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash payments for operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_FollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow-on Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_FollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Follow-on Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_FollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow-on offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at beginning of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Internal Revenue Service (IRS) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Internal Revenue Service (IRS)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Open tax year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options, Vested and exercisable as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currency translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Currency translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_PercentageOfRepurchaseRightsLapseOnOneYearAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of repurchase rights lapse on one-year anniversary.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_PercentageOfRepurchaseRightsLapseOnOneYearAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Repurchase Rights Lapse on One-Year Anniversary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_PercentageOfRepurchaseRightsLapseOnOneYearAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of repurchase rights lapse on one-year anniversary.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock issued in connection with exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock Options, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, convertible preferred stock, and stockholders' equity (deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SharesSalesAgreementAndFollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Sales agreement and Follow-on Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SharesSalesAgreementAndFollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Sales Agreement and Follow-on Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SharesSalesAgreementAndFollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares sales agreement and follow-on offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ClassOfWarrantsOrRightsNumberOfSharesConvertedToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of warrants or rights number of shares converted into common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ClassOfWarrantsOrRightsNumberOfSharesConvertedToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrants or Rights Number of Shares Converted to Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ClassOfWarrantsOrRightsNumberOfSharesConvertedToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrants or rights number of shares converted to common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ClassOfWarrantsOrRightsNumberOfSharesConvertedToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series A-2 convertible preferred stock warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SeriesA1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-1 Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SeriesA1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A-1 Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SeriesA1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-1 convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_DeferredTaxAssetsRightOfUseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets right of use liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_DeferredTaxAssetsRightOfUseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Right Of Use Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_DeferredTaxAssetsRightOfUseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Services Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ServicesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Services agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise price, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TemporaryEquityStockIssuedDuringPeriodSharesStockUponExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, Issuance of Series A-2 stock upon exercise of warrants, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TemporaryEquityStockIssuedDuringPeriodSharesStockUponExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares Stock Upon Exercise Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TemporaryEquityStockIssuedDuringPeriodSharesStockUponExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary Equity Stock Issued During Period Shares Stock Upon Exercise Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement date fair value of shares vested per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax liabilities right of use asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right Of Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use-Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use-Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AccruedProfessionalServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AccruedProfessionalServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Services Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AccruedProfessionalServicesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued professional services current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated other comprehensive (loss) income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Charges, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate changes on cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected recognition period of unrecognized compensation cost related to unvested share options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest, Weighted Average Remaining Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares authorized and reserved for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_NumberOfSharesRestrictedAndSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares became restricted and subject to repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_NumberOfSharesRestrictedAndSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares Restricted And Subject To Repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_NumberOfSharesRestrictedAndSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares restricted and subject to repurchase.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Penalties and Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest or penalties were recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest or penalties were recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary Equity Beginning Balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary Equity Ending Balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible preferred stock shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business and Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant liability activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of preferred stock warrant liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExerciseOfPreferredStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of preferred stock warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExerciseOfPreferredStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Exercise of Preferred Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExerciseOfPreferredStockWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement with unobservable inputs reconciliations recurring basis liability exercise of preferred stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock Options, Canceled/Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_FixedLeaseRentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fixed lease rent expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_FixedLeaseRentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fixed Lease Rent Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_FixedLeaseRentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed lease rent expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_CommonStockOutstandingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock outstanding percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_CommonStockOutstandingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Outstanding Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_CommonStockOutstandingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock outstanding percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_DeferredTaxAssetsIntangibleAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Intangible Asset Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_DeferredTaxAssetsIntangibleAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible asset amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_DeferredTaxAssetsIntangibleAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets intangible asset amortization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Options Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SeriesBStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Stock Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SeriesBStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Stock Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SeriesBStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B Stock Purchase Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Weighted Average Assumptions Used to Compute Estimated Fair Value of Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future minimum lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_GB_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED KINGDOM</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_GB_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United Kingdom</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_GB_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Oxford, United Kingdom</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_NumberOfCommonStockVote_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock vote</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_NumberOfCommonStockVote_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Common Stock Vote</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_NumberOfCommonStockVote_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common stock vote.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Net Deferred Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-13</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-13 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock upon IPO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current expense:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_StockOptionsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options Issued and Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_StockOptionsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock options issued and outstanding [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_StockOptionsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options issued and outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_StockOptionsIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options to purchase common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currency translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SublicenseesThresholdAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublicensees threshold amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SublicenseesThresholdAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublicensees Threshold Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SublicenseesThresholdAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublicensees threshold amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Taxes Paid, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AtTheMarketIssuanceSalesAgreementAndFollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-Market Equity Offering Sales Agreement and Follow-on Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AtTheMarketIssuanceSalesAgreementAndFollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Issuance Sales Agreement And Follow on Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AtTheMarketIssuanceSalesAgreementAndFollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market isssuance sales agreement and follow on offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction , Expenses from Transactions with Related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Costs and Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Costs and Expenses, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_OperatingLeaseIncreaseInMonthlyRentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease increase in monthly rent expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_OperatingLeaseIncreaseInMonthlyRentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Increase In Monthly Rent Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_OperatingLeaseIncreaseInMonthlyRentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in monthly rent expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease assets obtained in exchange for new operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise price, Canceled/Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued upon conversion of redeemable convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Option, Quantitative Disclosures [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ScheduleOfAccruedLiabilitiesCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ScheduleOfAccruedLiabilitiesCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities Current [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ScheduleOfAccruedLiabilitiesCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of accrued liabilities current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercised, date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and exercisable, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AmortizationAndInterestAccretionRelatedToOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization and interest accretion related to operating lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AmortizationAndInterestAccretionRelatedToOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization and Interest Accretion Related to Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AmortizationAndInterestAccretionRelatedToOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization and interest accretion related to operating leases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_OxfordScienceEnterprisesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Oxford Science Enterprises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_OxfordScienceEnterprisesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Oxford Science Enterprises [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_OxfordScienceEnterprisesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Oxford Science Enterprises.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStockCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash dividend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStockCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends, Common Stock, Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Due to related party for service rendered</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_EffectiveIncomeTaxRateReconciliationUkRDCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.K. R&amp;D credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_EffectiveIncomeTaxRateReconciliationUkRDCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation, UK R&amp;D credit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_EffectiveIncomeTaxRateReconciliationUkRDCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, UK R&amp;D credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2023 and 2022, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Received from IPO and option exercise by underwriters</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering and Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance initial public offering and stock options exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_UsTreasuryBackedMoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury-Backed Money Market Funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_UsTreasuryBackedMoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury-Backed Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_UsTreasuryBackedMoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">US Treasury-backed money market funds.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_OxfordUniversityInnovationLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Oxford University Innovation Limited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_OxfordUniversityInnovationLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Oxford University Innovation Limited [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_OxfordUniversityInnovationLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Oxford University Innovation Limited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ExpectedMarketReturn_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected market return</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ExpectedMarketReturn_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expected Market Return</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ExpectedMarketReturn_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected market return.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_PreferredStockWarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_PreferredStockWarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Warrants [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_PreferredStockWarrantsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AtTheMarketIssuanceSalesAgreementAndSecondaryOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-Market Equity Offering Sales Agreement and Secondary Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AtTheMarketIssuanceSalesAgreementAndSecondaryOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Issuance Sales Agreement And Secondary Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AtTheMarketIssuanceSalesAgreementAndSecondaryOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market issuance sales agreement and secondary offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SharesSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SharesSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Sales Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SharesSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary Equity Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary Equity Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SharesOfRestrictedStockSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares subject to repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SharesOfRestrictedStockSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Of Restricted Stock Subject To Repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SharesOfRestrictedStockSubjectToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares Of restricted stock subject to repurchase.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SupplementalDisclosureOfCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Supplemental disclosure of cash flow information related to leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SupplementalDisclosureOfCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Disclosure Of Cash Flow Information Related To Leases [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SupplementalDisclosureOfCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Disclosure of Cash Flow Information Related to Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value of Financial Assets Measured at Fair Value on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leaseholds and Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leaseholds and Leasehold Improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_LaboratoryAndComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory and computer equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_LaboratoryAndComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory And Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_LaboratoryAndComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory and Computer Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AuthorizedForFutureStockAwardsOrOptionGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Authorized for Future Stock Awards or Option Grants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AuthorizedForFutureStockAwardsOrOptionGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Authorized for future stock awards or option grants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AuthorizedForFutureStockAwardsOrOptionGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Authorized for future stock awards or option grants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reserved Shares of Common Stock for Issuance, on an As-Converted Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Shares Reserved For Issuance [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of common stock shares reserved for issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ComprehensiveLossPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Comprehensive loss.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ComprehensiveLossPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Loss [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ComprehensiveLossPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary Equity Stock Issued During Period Shares New Issues.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, Issuance of convertible preferred stock, net of issuance cost, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_OperatingLeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease commencement date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_OperatingLeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Commencement Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_OperatingLeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Existence of Option to Terminate [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation, permanent differences.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Permanent Differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TemporaryEquityStockIssuedDuringPeriodValueStockUponExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, Issuance of Series A-2 stock upon exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TemporaryEquityStockIssuedDuringPeriodValueStockUponExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value Stock Upon Exercise Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TemporaryEquityStockIssuedDuringPeriodValueStockUponExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary Equity Stock Issued During Period Value Stock Upon Exercise Of Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate %</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from warrant exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Warrant Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock upon exercise of Series A-2 warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Discount Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ResearchAndDevelopmentCreditsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development credits expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ResearchAndDevelopmentCreditsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Credits Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_ResearchAndDevelopmentCreditsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock upon IPO, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits, income tax penalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_RaCapitalManagementLPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RA Capital Management, L.P.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_RaCapitalManagementLPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">RA Capital Management, L.P. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_RaCapitalManagementLPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">RA Capital Management, L.P.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, GILTI, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">GILTI Inclusion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GILTI Inclusion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Terminate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease termination term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TwoThousandTwentyTwoEquityIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TwoThousandTwentyTwoEquityIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Two Equity Incentive Award Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TwoThousandTwentyTwoEquityIncentiveAwardPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty two equity incentive award plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental noncash investing and financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_RentPayableToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rent payable to related parties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_RentPayableToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rent Payable To Related Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_RentPayableToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent payable to related parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash and Cash Equivalents, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Foreign currency translation adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative translation adjustment arising during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Loss Before for Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign rate differential</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_NewtonMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Newton Massachusetts.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_NewtonMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Newton Massachusetts [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_NewtonMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Newton, Massachusetts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property and equipment included in accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Property and equipment included in accounts payable and accrued expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment included in accounts payable and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity (deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stockholders' deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_NetProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Net Received from IPO and option exercise by underwriters</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_NetProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds From Issuance Initial Public Offering And Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_NetProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds from issuance initial public offering and stock options exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross proceeds in underwritten public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from sale of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_CambridgeMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cambridge Massachusetts.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_CambridgeMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cambridge Massachusetts [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_CambridgeMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cambridge, Massachusetts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State tax (net of federal benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Income Tax Expense to Statutory Federal Income Tax Rate to Loss From Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Long-Lived Assets to be Disposed of</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairments of long-lived assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income tax expense (benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AggregatePotentialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate potential milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AggregatePotentialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Potential Milestone Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AggregatePotentialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate potential milestone payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Two Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty two employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Outstanding as of December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Outstanding as of December31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SecondaryOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Secondary Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SecondaryOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Secondary Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SecondaryOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Secondary Offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets capitalized research and development costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capitalized Research And Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized Section 174 R&amp;D Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of Common Stock in IPO, net of underwriters' fees and issuance costs, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee-related expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Authorized for Future Issuance under Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Authorized for Future Issuance under Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pepg_AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Authorized for future issuance under employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMember" xlink:to="us-gaap_OtherAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering" xlink:to="pepg_TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_SeriesA2PreferredStockWarrantLiabilityMember" xlink:to="pepg_SeriesA2PreferredStockWarrantLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_HarrisonLeaseMember" xlink:to="pepg_HarrisonLeaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_RelatedPartyTransactionsOtherCostsPaid" xlink:to="pepg_RelatedPartyTransactionsOtherCostsPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_ComputerAndOfficeEquipmentMember" xlink:to="pepg_ComputerAndOfficeEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_RequiredToPayExitFeeAmount" xlink:to="pepg_RequiredToPayExitFeeAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_CarnotPharmaLlcMember" xlink:to="pepg_CarnotPharmaLlcMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_ResearchAndDevelopmentExpenses" xlink:to="pepg_ResearchAndDevelopmentExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_PercentageOfExitFee" xlink:to="pepg_PercentageOfExitFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_TenantImprovementMember" xlink:to="pepg_TenantImprovementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryNotesSecuritiesMember" xlink:to="us-gaap_USTreasuryNotesSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_UndesignatedPreferredStockMember" xlink:to="pepg_UndesignatedPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_LeasedSpace" xlink:to="pepg_LeasedSpace_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_AggregateOperatingLeaseCost" xlink:to="pepg_AggregateOperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:to="pepg_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering" xlink:to="pepg_TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_OperatingLeasePeriodOfExtension" xlink:to="pepg_OperatingLeasePeriodOfExtension_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_ClassAAndClassBCommonStockMember" xlink:to="pepg_ClassAAndClassBCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_ChangesInOwnershipByStockholdersHoldingPercentage" xlink:to="pepg_ChangesInOwnershipByStockholdersHoldingPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_TermOfLicenseAgreement" xlink:to="pepg_TermOfLicenseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201912Member" xlink:to="us-gaap_AccountingStandardsUpdate201912Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_LeasesDisclosureTextBlock" xlink:to="pepg_LeasesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_NetLossPerSharePolicyTextBlock" xlink:to="pepg_NetLossPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_AtTheMarketEquityOfferingSalesAgreementMember" xlink:to="pepg_AtTheMarketEquityOfferingSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_AdditionalPaymentsOfRestatementCompletionFeeAndLicenseDataFee" xlink:to="pepg_AdditionalPaymentsOfRestatementCompletionFeeAndLicenseDataFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_OperatingLeaseMonthlyRentExpense" xlink:to="pepg_OperatingLeaseMonthlyRentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_AccruedLiabilitiesCurrentDisclosureTextBlock" xlink:to="pepg_AccruedLiabilitiesCurrentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_OperatingLossCarryForwardsExpirationYear" xlink:to="pepg_OperatingLossCarryForwardsExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_StockRestrictionAgreementsMember" xlink:to="pepg_StockRestrictionAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_UkTaxAuthoritiesMember" xlink:to="pepg_UkTaxAuthoritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_StockPurchaseAgreementMember" xlink:to="pepg_StockPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_TechnologyLicenseAgreementMember" xlink:to="pepg_TechnologyLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_PaymentOfOfferingCosts" xlink:to="pepg_PaymentOfOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_AmortizationOfPremiumAndDiscountsOnMarketableSecuritiesNet" xlink:to="pepg_AmortizationOfPremiumAndDiscountsOnMarketableSecuritiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_NumberOfFoundingStockholdersEntered" xlink:to="pepg_NumberOfFoundingStockholdersEntered_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_PercentageOfRepurchaseRightsLapseOnSecondAnniversary" xlink:to="pepg_PercentageOfRepurchaseRightsLapseOnSecondAnniversary_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_SeriesA2ConvertiblePreferredStockMember" xlink:to="pepg_SeriesA2ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="pepg_EmergingGrowthCompanyStatusPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_FollowOnOfferingMember" xlink:to="pepg_FollowOnOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_PercentageOfRepurchaseRightsLapseOnOneYearAnniversary" xlink:to="pepg_PercentageOfRepurchaseRightsLapseOnOneYearAnniversary_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_SharesSalesAgreementAndFollowOnOfferingMember" xlink:to="pepg_SharesSalesAgreementAndFollowOnOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_ClassOfWarrantsOrRightsNumberOfSharesConvertedToCommonStock" xlink:to="pepg_ClassOfWarrantsOrRightsNumberOfSharesConvertedToCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_SeriesA1ConvertiblePreferredStockMember" xlink:to="pepg_SeriesA1ConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_DeferredTaxAssetsRightOfUseLiability" xlink:to="pepg_DeferredTaxAssetsRightOfUseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_ServicesAgreementMember" xlink:to="pepg_ServicesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_TemporaryEquityStockIssuedDuringPeriodSharesStockUponExerciseOfWarrants" xlink:to="pepg_TemporaryEquityStockIssuedDuringPeriodSharesStockUponExerciseOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="pepg_DeferredTaxLiabilitiesRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_AccruedProfessionalServicesCurrent" xlink:to="pepg_AccruedProfessionalServicesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_NumberOfSharesRestrictedAndSubjectToRepurchase" xlink:to="pepg_NumberOfSharesRestrictedAndSubjectToRepurchase_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExerciseOfPreferredStockWarrants" xlink:to="pepg_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExerciseOfPreferredStockWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_FixedLeaseRentExpense" xlink:to="pepg_FixedLeaseRentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_CommonStockOutstandingPercentage" xlink:to="pepg_CommonStockOutstandingPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_DeferredTaxAssetsIntangibleAssetAmortization" xlink:to="pepg_DeferredTaxAssetsIntangibleAssetAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_SeriesBStockPurchaseAgreementMember" xlink:to="pepg_SeriesBStockPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="pepg_AccruedResearchAndDevelopmentExpensesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_GB" xlink:to="country_GB_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_NumberOfCommonStockVote" xlink:to="pepg_NumberOfCommonStockVote_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201613Member" xlink:to="us-gaap_AccountingStandardsUpdate201613Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_StockOptionsIssuedAndOutstandingMember" xlink:to="pepg_StockOptionsIssuedAndOutstandingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_SublicenseesThresholdAmount" xlink:to="pepg_SublicenseesThresholdAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_AtTheMarketIssuanceSalesAgreementAndFollowOnOfferingMember" xlink:to="pepg_AtTheMarketIssuanceSalesAgreementAndFollowOnOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_OperatingLeaseIncreaseInMonthlyRentExpense" xlink:to="pepg_OperatingLeaseIncreaseInMonthlyRentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_ScheduleOfAccruedLiabilitiesCurrentTableTextBlock" xlink:to="pepg_ScheduleOfAccruedLiabilitiesCurrentTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_AmortizationAndInterestAccretionRelatedToOperatingLeases" xlink:to="pepg_AmortizationAndInterestAccretionRelatedToOperatingLeases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_OxfordScienceEnterprisesMember" xlink:to="pepg_OxfordScienceEnterprisesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStockCash" xlink:to="us-gaap_DividendsCommonStockCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_EffectiveIncomeTaxRateReconciliationUkRDCredit" xlink:to="pepg_EffectiveIncomeTaxRateReconciliationUkRDCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_ProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised" xlink:to="pepg_ProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_UsTreasuryBackedMoneyMarketFundsMember" xlink:to="pepg_UsTreasuryBackedMoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_OxfordUniversityInnovationLimitedMember" xlink:to="pepg_OxfordUniversityInnovationLimitedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_ExpectedMarketReturn" xlink:to="pepg_ExpectedMarketReturn_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_PreferredStockWarrantsPolicyTextBlock" xlink:to="pepg_PreferredStockWarrantsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_AtTheMarketIssuanceSalesAgreementAndSecondaryOfferingMember" xlink:to="pepg_AtTheMarketIssuanceSalesAgreementAndSecondaryOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_SharesSalesAgreementMember" xlink:to="pepg_SharesSalesAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_SharesOfRestrictedStockSubjectToRepurchase" xlink:to="pepg_SharesOfRestrictedStockSubjectToRepurchase_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_SupplementalDisclosureOfCashFlowInformationRelatedToLeasesTableTextBlock" xlink:to="pepg_SupplementalDisclosureOfCashFlowInformationRelatedToLeasesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_LaboratoryAndComputerEquipmentMember" xlink:to="pepg_LaboratoryAndComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_AuthorizedForFutureStockAwardsOrOptionGrantsMember" xlink:to="pepg_AuthorizedForFutureStockAwardsOrOptionGrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock" xlink:to="pepg_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_ComprehensiveLossPolicyTextBlock" xlink:to="pepg_ComprehensiveLossPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="pepg_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_OperatingLeaseCommencementDate" xlink:to="pepg_OperatingLeaseCommencementDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="pepg_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_TemporaryEquityStockIssuedDuringPeriodValueStockUponExerciseOfWarrants" xlink:to="pepg_TemporaryEquityStockIssuedDuringPeriodValueStockUponExerciseOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_ResearchAndDevelopmentCreditsExpirationYear" xlink:to="pepg_ResearchAndDevelopmentCreditsExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_RaCapitalManagementLPMember" xlink:to="pepg_RaCapitalManagementLPMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_TwoThousandTwentyTwoEquityIncentiveAwardPlanMember" xlink:to="pepg_TwoThousandTwentyTwoEquityIncentiveAwardPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_RentPayableToRelatedParties" xlink:to="pepg_RentPayableToRelatedParties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_NewtonMassachusettsMember" xlink:to="pepg_NewtonMassachusettsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" xlink:to="pepg_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_NetProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised" xlink:to="pepg_NetProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_CambridgeMassachusettsMember" xlink:to="pepg_CambridgeMassachusettsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_AggregatePotentialMilestonePayments" xlink:to="pepg_AggregatePotentialMilestonePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" xlink:to="pepg_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_SecondaryOfferingMember" xlink:to="pepg_SecondaryOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:to="pepg_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_SeriesBConvertiblePreferredStockMember" xlink:to="pepg_SeriesBConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pepg_AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlanMember" xlink:to="pepg_AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA1ConvertiblePreferredStockMember" xlink:label="pepg_SeriesA1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA2ConvertiblePreferredStockMember" xlink:label="pepg_SeriesA2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesBConvertiblePreferredStockMember" xlink:label="pepg_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesA1ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesA2ConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesBConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA1ConvertiblePreferredStockMember" xlink:label="pepg_SeriesA1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA2ConvertiblePreferredStockMember" xlink:label="pepg_SeriesA2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesBConvertiblePreferredStockMember" xlink:label="pepg_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesA1ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesA2ConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesBConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA1ConvertiblePreferredStockMember" xlink:label="pepg_SeriesA1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA2ConvertiblePreferredStockMember" xlink:label="pepg_SeriesA2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesBConvertiblePreferredStockMember" xlink:label="pepg_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TemporaryEquityStockIssuedDuringPeriodSharesStockUponExerciseOfWarrants" xlink:label="pepg_TemporaryEquityStockIssuedDuringPeriodSharesStockUponExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TemporaryEquityStockIssuedDuringPeriodValueStockUponExerciseOfWarrants" xlink:label="pepg_TemporaryEquityStockIssuedDuringPeriodValueStockUponExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering" xlink:label="pepg_TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering" xlink:label="pepg_TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="pepg_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_22"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_23"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_25"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_26"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesA1ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesA2ConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesBConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pepg_TemporaryEquityStockIssuedDuringPeriodSharesStockUponExerciseOfWarrants" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pepg_TemporaryEquityStockIssuedDuringPeriodValueStockUponExerciseOfWarrants" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pepg_TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pepg_TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pepg_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_22" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_23" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_25" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_26" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA2ConvertiblePreferredStockMember" xlink:label="pepg_SeriesA2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesBConvertiblePreferredStockMember" xlink:label="pepg_SeriesBConvertiblePreferredStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesA2ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA2ConvertiblePreferredStockMember" xlink:label="pepg_SeriesA2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" xlink:label="pepg_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesBConvertiblePreferredStockMember" xlink:label="pepg_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_PaymentOfOfferingCosts" xlink:label="pepg_PaymentOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AmortizationAndInterestAccretionRelatedToOperatingLeases" xlink:label="pepg_AmortizationAndInterestAccretionRelatedToOperatingLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AmortizationOfPremiumAndDiscountsOnMarketableSecuritiesNet" xlink:label="pepg_AmortizationOfPremiumAndDiscountsOnMarketableSecuritiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesA2ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pepg_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="pepg_PaymentOfOfferingCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pepg_AmortizationAndInterestAccretionRelatedToOperatingLeases" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pepg_AmortizationOfPremiumAndDiscountsOnMarketableSecuritiesNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurements1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpenses" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AccruedLiabilitiesCurrentDisclosureTextBlock" xlink:label="pepg_AccruedLiabilitiesCurrentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="pepg_AccruedLiabilitiesCurrentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_LeasesDisclosureTextBlock" xlink:label="pepg_LeasesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="pepg_LeasesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquity1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensation1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_PreferredStockWarrantsPolicyTextBlock" xlink:label="pepg_PreferredStockWarrantsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ComprehensiveLossPolicyTextBlock" xlink:label="pepg_ComprehensiveLossPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_NetLossPerSharePolicyTextBlock" xlink:label="pepg_NetLossPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="pepg_EmergingGrowthCompanyStatusPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pepg_PreferredStockWarrantsPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pepg_ComprehensiveLossPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pepg_NetLossPerSharePolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pepg_EmergingGrowthCompanyStatusPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:label="pepg_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pepg_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ScheduleOfAccruedLiabilitiesCurrentTableTextBlock" xlink:label="pepg_ScheduleOfAccruedLiabilitiesCurrentTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="pepg_ScheduleOfAccruedLiabilitiesCurrentTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SupplementalDisclosureOfCashFlowInformationRelatedToLeasesTableTextBlock" xlink:label="pepg_SupplementalDisclosureOfCashFlowInformationRelatedToLeasesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="pepg_SupplementalDisclosureOfCashFlowInformationRelatedToLeasesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock" xlink:label="pepg_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="pepg_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AtTheMarketEquityOfferingSalesAgreementMember" xlink:label="pepg_AtTheMarketEquityOfferingSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SecondaryOfferingMember" xlink:label="pepg_SecondaryOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_FollowOnOfferingMember" xlink:label="pepg_FollowOnOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised" xlink:label="pepg_ProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AtTheMarketIssuanceSalesAgreementAndFollowOnOfferingMember" xlink:label="pepg_AtTheMarketIssuanceSalesAgreementAndFollowOnOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_NetProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised" xlink:label="pepg_NetProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AtTheMarketIssuanceSalesAgreementAndSecondaryOfferingMember" xlink:label="pepg_AtTheMarketIssuanceSalesAgreementAndSecondaryOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SharesSalesAgreementAndFollowOnOfferingMember" xlink:label="pepg_SharesSalesAgreementAndFollowOnOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pepg_AtTheMarketEquityOfferingSalesAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pepg_SecondaryOfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pepg_FollowOnOfferingMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="pepg_ProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pepg_AtTheMarketIssuanceSalesAgreementAndFollowOnOfferingMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="pepg_NetProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pepg_AtTheMarketIssuanceSalesAgreementAndSecondaryOfferingMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pepg_SharesSalesAgreementAndFollowOnOfferingMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB" xlink:label="country_GB"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ResearchAndDevelopmentExpenses" xlink:label="pepg_ResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="pepg_ResearchAndDevelopmentExpenses" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_LaboratoryAndComputerEquipmentMember" xlink:label="pepg_LaboratoryAndComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pepg_LaboratoryAndComputerEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerS" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_StockOptionsIssuedAndOutstandingMember" xlink:label="pepg_StockOptionsIssuedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pepg_StockOptionsIssuedAndOutstandingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA2ConvertiblePreferredStockMember" xlink:label="pepg_SeriesA2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ClassOfWarrantsOrRightsNumberOfSharesConvertedToCommonStock" xlink:label="pepg_ClassOfWarrantsOrRightsNumberOfSharesConvertedToCommonStock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesA2ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="pepg_ClassOfWarrantsOrRightsNumberOfSharesConvertedToCommonStock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfMarketableSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_UsTreasuryBackedMoneyMarketFundsMember" xlink:label="pepg_UsTreasuryBackedMoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="pepg_UsTreasuryBackedMoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossTable" xlink:to="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_UsTreasuryBackedMoneyMarketFundsMember" xlink:label="pepg_UsTreasuryBackedMoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryNotesSecuritiesMember" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="pepg_UsTreasuryBackedMoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryNotesSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfWarrantLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA2PreferredStockWarrantLiabilityMember" xlink:label="pepg_SeriesA2PreferredStockWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExerciseOfPreferredStockWarrants" xlink:label="pepg_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExerciseOfPreferredStockWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="pepg_SeriesA2PreferredStockWarrantLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="pepg_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExerciseOfPreferredStockWarrants" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfCostAndAccumulatedDepreciationOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ComputerAndOfficeEquipmentMember" xlink:label="pepg_ComputerAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pepg_ComputerAndOfficeEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="pepg_AccruedResearchAndDevelopmentExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AccruedProfessionalServicesCurrent" xlink:label="pepg_AccruedProfessionalServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="pepg_AccruedResearchAndDevelopmentExpensesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="pepg_AccruedProfessionalServicesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_CambridgeMassachusettsMember" xlink:label="pepg_CambridgeMassachusettsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_HarrisonLeaseMember" xlink:label="pepg_HarrisonLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_NewtonMassachusettsMember" xlink:label="pepg_NewtonMassachusettsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TenantImprovementMember" xlink:label="pepg_TenantImprovementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB" xlink:label="country_GB"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_LeasedSpace" xlink:label="pepg_LeasedSpace"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_OperatingLeaseCommencementDate" xlink:label="pepg_OperatingLeaseCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_FixedLeaseRentExpense" xlink:label="pepg_FixedLeaseRentExpense"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_OperatingLeaseMonthlyRentExpense" xlink:label="pepg_OperatingLeaseMonthlyRentExpense"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_OperatingLeaseIncreaseInMonthlyRentExpense" xlink:label="pepg_OperatingLeaseIncreaseInMonthlyRentExpense"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_OperatingLeasePeriodOfExtension" xlink:label="pepg_OperatingLeasePeriodOfExtension"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AggregateOperatingLeaseCost" xlink:label="pepg_AggregateOperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="pepg_CambridgeMassachusettsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="pepg_HarrisonLeaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="pepg_NewtonMassachusettsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pepg_TenantImprovementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pepg_LeasedSpace" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pepg_OperatingLeaseCommencementDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pepg_FixedLeaseRentExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pepg_OperatingLeaseMonthlyRentExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pepg_OperatingLeaseIncreaseInMonthlyRentExpense" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pepg_OperatingLeasePeriodOfExtension" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pepg_AggregateOperatingLeaseCost" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_VariableLeaseCost" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalDisclosureOfCashFlowInformationRelatedToLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AdditionalPaymentsOfRestatementCompletionFeeAndLicenseDataFee" xlink:label="pepg_AdditionalPaymentsOfRestatementCompletionFeeAndLicenseDataFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_OxfordUniversityInnovationLimitedMember" xlink:label="pepg_OxfordUniversityInnovationLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TechnologyLicenseAgreementMember" xlink:label="pepg_TechnologyLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AggregatePotentialMilestonePayments" xlink:label="pepg_AggregatePotentialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_OxfordScienceEnterprisesMember" xlink:label="pepg_OxfordScienceEnterprisesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ServicesAgreementMember" xlink:label="pepg_ServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SublicenseesThresholdAmount" xlink:label="pepg_SublicenseesThresholdAmount"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_CarnotPharmaLlcMember" xlink:label="pepg_CarnotPharmaLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TermOfLicenseAgreement" xlink:label="pepg_TermOfLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_RaCapitalManagementLPMember" xlink:label="pepg_RaCapitalManagementLPMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_PercentageOfExitFee" xlink:label="pepg_PercentageOfExitFee"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_RequiredToPayExitFeeAmount" xlink:label="pepg_RequiredToPayExitFeeAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_RentPayableToRelatedParties" xlink:label="pepg_RentPayableToRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_RelatedPartyTransactionsOtherCostsPaid" xlink:label="pepg_RelatedPartyTransactionsOtherCostsPaid"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pepg_AdditionalPaymentsOfRestatementCompletionFeeAndLicenseDataFee" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pepg_OxfordUniversityInnovationLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pepg_TechnologyLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pepg_AggregatePotentialMilestonePayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pepg_OxfordScienceEnterprisesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pepg_ServicesAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pepg_SublicenseesThresholdAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pepg_CarnotPharmaLlcMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pepg_TermOfLicenseAgreement" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pepg_RaCapitalManagementLPMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pepg_PercentageOfExitFee" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pepg_RequiredToPayExitFeeAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pepg_RentPayableToRelatedParties" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pepg_RelatedPartyTransactionsOtherCostsPaid" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_StockPurchaseAgreementMember" xlink:label="pepg_StockPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA2ConvertiblePreferredStockMember" xlink:label="pepg_SeriesA2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesBStockPurchaseAgreementMember" xlink:label="pepg_SeriesBStockPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ClassAAndClassBCommonStockMember" xlink:label="pepg_ClassAAndClassBCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_StockRestrictionAgreementsMember" xlink:label="pepg_StockRestrictionAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA1ConvertiblePreferredStockMember" xlink:label="pepg_SeriesA1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesBConvertiblePreferredStockMember" xlink:label="pepg_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_UndesignatedPreferredStockMember" xlink:label="pepg_UndesignatedPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_NumberOfSharesRestrictedAndSubjectToRepurchase" xlink:label="pepg_NumberOfSharesRestrictedAndSubjectToRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_NumberOfFoundingStockholdersEntered" xlink:label="pepg_NumberOfFoundingStockholdersEntered"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_PercentageOfRepurchaseRightsLapseOnOneYearAnniversary" xlink:label="pepg_PercentageOfRepurchaseRightsLapseOnOneYearAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_PercentageOfRepurchaseRightsLapseOnSecondAnniversary" xlink:label="pepg_PercentageOfRepurchaseRightsLapseOnSecondAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_NumberOfCommonStockVote" xlink:label="pepg_NumberOfCommonStockVote"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SharesOfRestrictedStockSubjectToRepurchase" xlink:label="pepg_SharesOfRestrictedStockSubjectToRepurchase"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pepg_StockPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesA2ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pepg_SeriesBStockPurchaseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_ClassAAndClassBCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pepg_StockRestrictionAgreementsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesA1ConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesBConvertiblePreferredStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_UndesignatedPreferredStockMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStockCash" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pepg_NumberOfSharesRestrictedAndSubjectToRepurchase" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pepg_NumberOfFoundingStockholdersEntered" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pepg_PercentageOfRepurchaseRightsLapseOnOneYearAnniversary" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pepg_PercentageOfRepurchaseRightsLapseOnSecondAnniversary" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pepg_NumberOfCommonStockVote" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pepg_SharesOfRestrictedStockSubjectToRepurchase" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceOnAnAsconvertedBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_StockOptionsIssuedAndOutstandingMember" xlink:label="pepg_StockOptionsIssuedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AuthorizedForFutureStockAwardsOrOptionGrantsMember" xlink:label="pepg_AuthorizedForFutureStockAwardsOrOptionGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlanMember" xlink:label="pepg_AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlanMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pepg_StockOptionsIssuedAndOutstandingMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pepg_AuthorizedForFutureStockAwardsOrOptionGrantsMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pepg_AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlanMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TwoThousandTwentyTwoEquityIncentiveAwardPlanMember" xlink:label="pepg_TwoThousandTwentyTwoEquityIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" xlink:label="pepg_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_CommonStockOutstandingPercentage" xlink:label="pepg_CommonStockOutstandingPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pepg_TwoThousandTwentyTwoEquityIncentiveAwardPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pepg_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pepg_CommonStockOutstandingPercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfWeightedAverageAssumptionsUsedToComputeEstimatedFairValueOfStockOptionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeForIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="pepg_DeferredTaxLiabilitiesRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="pepg_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_DeferredTaxAssetsRightOfUseLiability" xlink:label="pepg_DeferredTaxAssetsRightOfUseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_DeferredTaxAssetsIntangibleAssetAmortization" xlink:label="pepg_DeferredTaxAssetsIntangibleAssetAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="pepg_DeferredTaxLiabilitiesRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="pepg_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="pepg_DeferredTaxAssetsRightOfUseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="pepg_DeferredTaxAssetsIntangibleAssetAmortization" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="pepg_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_EffectiveIncomeTaxRateReconciliationUkRDCredit" xlink:label="pepg_EffectiveIncomeTaxRateReconciliationUkRDCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="pepg_EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="pepg_EffectiveIncomeTaxRateReconciliationUkRDCredit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ExpectedMarketReturn" xlink:label="pepg_ExpectedMarketReturn"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_UkTaxAuthoritiesMember" xlink:label="pepg_UkTaxAuthoritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ResearchAndDevelopmentCreditsExpirationYear" xlink:label="pepg_ResearchAndDevelopmentCreditsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_OperatingLossCarryForwardsExpirationYear" xlink:label="pepg_OperatingLossCarryForwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ChangesInOwnershipByStockholdersHoldingPercentage" xlink:label="pepg_ChangesInOwnershipByStockholdersHoldingPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="pepg_ExpectedMarketReturn" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="pepg_UkTaxAuthoritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="pepg_ResearchAndDevelopmentCreditsExpirationYear" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="pepg_OperatingLossCarryForwardsExpirationYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="pepg_ChangesInOwnershipByStockholdersHoldingPercentage" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OpenTaxYear" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_6"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SharesSalesAgreementMember" xlink:label="pepg_SharesSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_FollowOnOfferingMember" xlink:label="pepg_FollowOnOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SharesSalesAgreementAndFollowOnOfferingMember" xlink:label="pepg_SharesSalesAgreementAndFollowOnOfferingMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pepg_SharesSalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pepg_FollowOnOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pepg_SharesSalesAgreementAndFollowOnOfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA1ConvertiblePreferredStockMember" xlink:label="pepg_SeriesA1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA2ConvertiblePreferredStockMember" xlink:label="pepg_SeriesA2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesBConvertiblePreferredStockMember" xlink:label="pepg_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesA1ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesA2ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA1ConvertiblePreferredStockMember" xlink:label="pepg_SeriesA1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA2ConvertiblePreferredStockMember" xlink:label="pepg_SeriesA2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesBConvertiblePreferredStockMember" xlink:label="pepg_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesA1ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesA2ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA1ConvertiblePreferredStockMember" xlink:label="pepg_SeriesA1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA2ConvertiblePreferredStockMember" xlink:label="pepg_SeriesA2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesBConvertiblePreferredStockMember" xlink:label="pepg_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TemporaryEquityStockIssuedDuringPeriodSharesStockUponExerciseOfWarrants" xlink:label="pepg_TemporaryEquityStockIssuedDuringPeriodSharesStockUponExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TemporaryEquityStockIssuedDuringPeriodValueStockUponExerciseOfWarrants" xlink:label="pepg_TemporaryEquityStockIssuedDuringPeriodValueStockUponExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering" xlink:label="pepg_TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering" xlink:label="pepg_TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="pepg_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesA1ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesA2ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pepg_TemporaryEquityStockIssuedDuringPeriodSharesStockUponExerciseOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pepg_TemporaryEquityStockIssuedDuringPeriodValueStockUponExerciseOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pepg_TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pepg_TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pepg_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA2ConvertiblePreferredStockMember" xlink:label="pepg_SeriesA2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesBConvertiblePreferredStockMember" xlink:label="pepg_SeriesBConvertiblePreferredStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesA2ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA2ConvertiblePreferredStockMember" xlink:label="pepg_SeriesA2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" xlink:label="pepg_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesBConvertiblePreferredStockMember" xlink:label="pepg_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_PaymentOfOfferingCosts" xlink:label="pepg_PaymentOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AmortizationAndInterestAccretionRelatedToOperatingLeases" xlink:label="pepg_AmortizationAndInterestAccretionRelatedToOperatingLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AmortizationOfPremiumAndDiscountsOnMarketableSecuritiesNet" xlink:label="pepg_AmortizationOfPremiumAndDiscountsOnMarketableSecuritiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesA2ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pepg_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="pepg_PaymentOfOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pepg_AmortizationAndInterestAccretionRelatedToOperatingLeases" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pepg_AmortizationOfPremiumAndDiscountsOnMarketableSecuritiesNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AtTheMarketEquityOfferingSalesAgreementMember" xlink:label="pepg_AtTheMarketEquityOfferingSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SecondaryOfferingMember" xlink:label="pepg_SecondaryOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_FollowOnOfferingMember" xlink:label="pepg_FollowOnOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised" xlink:label="pepg_ProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AtTheMarketIssuanceSalesAgreementAndFollowOnOfferingMember" xlink:label="pepg_AtTheMarketIssuanceSalesAgreementAndFollowOnOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_NetProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised" xlink:label="pepg_NetProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AtTheMarketIssuanceSalesAgreementAndSecondaryOfferingMember" xlink:label="pepg_AtTheMarketIssuanceSalesAgreementAndSecondaryOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SharesSalesAgreementAndFollowOnOfferingMember" xlink:label="pepg_SharesSalesAgreementAndFollowOnOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pepg_AtTheMarketEquityOfferingSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pepg_SecondaryOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pepg_FollowOnOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="pepg_ProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pepg_AtTheMarketIssuanceSalesAgreementAndFollowOnOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="pepg_NetProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pepg_AtTheMarketIssuanceSalesAgreementAndSecondaryOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pepg_SharesSalesAgreementAndFollowOnOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB" xlink:label="country_GB"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ResearchAndDevelopmentExpenses" xlink:label="pepg_ResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DeferredOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="pepg_ResearchAndDevelopmentExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_LaboratoryAndComputerEquipmentMember" xlink:label="pepg_LaboratoryAndComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pepg_LaboratoryAndComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerS">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_StockOptionsIssuedAndOutstandingMember" xlink:label="pepg_StockOptionsIssuedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pepg_StockOptionsIssuedAndOutstandingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA2ConvertiblePreferredStockMember" xlink:label="pepg_SeriesA2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ClassOfWarrantsOrRightsNumberOfSharesConvertedToCommonStock" xlink:label="pepg_ClassOfWarrantsOrRightsNumberOfSharesConvertedToCommonStock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesA2ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_MarketableSecuritiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="pepg_ClassOfWarrantsOrRightsNumberOfSharesConvertedToCommonStock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfMarketableSecuritiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:label="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_UsTreasuryBackedMoneyMarketFundsMember" xlink:label="pepg_UsTreasuryBackedMoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="pepg_UsTreasuryBackedMoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_UsTreasuryBackedMoneyMarketFundsMember" xlink:label="pepg_UsTreasuryBackedMoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryNotesSecuritiesMember" xlink:label="us-gaap_USTreasuryNotesSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="pepg_UsTreasuryBackedMoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryNotesSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfWarrantLiabilitiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA2PreferredStockWarrantLiabilityMember" xlink:label="pepg_SeriesA2PreferredStockWarrantLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExerciseOfPreferredStockWarrants" xlink:label="pepg_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExerciseOfPreferredStockWarrants"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="pepg_SeriesA2PreferredStockWarrantLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="pepg_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExerciseOfPreferredStockWarrants" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfCostAndAccumulatedDepreciationOfPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ComputerAndOfficeEquipmentMember" xlink:label="pepg_ComputerAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pepg_ComputerAndOfficeEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_CambridgeMassachusettsMember" xlink:label="pepg_CambridgeMassachusettsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_HarrisonLeaseMember" xlink:label="pepg_HarrisonLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_NewtonMassachusettsMember" xlink:label="pepg_NewtonMassachusettsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TenantImprovementMember" xlink:label="pepg_TenantImprovementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_GB" xlink:label="country_GB"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_LeasedSpace" xlink:label="pepg_LeasedSpace"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_OperatingLeaseCommencementDate" xlink:label="pepg_OperatingLeaseCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_FixedLeaseRentExpense" xlink:label="pepg_FixedLeaseRentExpense"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_OperatingLeaseMonthlyRentExpense" xlink:label="pepg_OperatingLeaseMonthlyRentExpense"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_OperatingLeaseIncreaseInMonthlyRentExpense" xlink:label="pepg_OperatingLeaseIncreaseInMonthlyRentExpense"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_OperatingLeasePeriodOfExtension" xlink:label="pepg_OperatingLeasePeriodOfExtension"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AggregateOperatingLeaseCost" xlink:label="pepg_AggregateOperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="pepg_CambridgeMassachusettsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="pepg_HarrisonLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="pepg_NewtonMassachusettsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pepg_TenantImprovementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pepg_LeasedSpace" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pepg_OperatingLeaseCommencementDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pepg_FixedLeaseRentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pepg_OperatingLeaseMonthlyRentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pepg_OperatingLeaseIncreaseInMonthlyRentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pepg_OperatingLeasePeriodOfExtension" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pepg_AggregateOperatingLeaseCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_VariableLeaseCost" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AdditionalPaymentsOfRestatementCompletionFeeAndLicenseDataFee" xlink:label="pepg_AdditionalPaymentsOfRestatementCompletionFeeAndLicenseDataFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_OxfordUniversityInnovationLimitedMember" xlink:label="pepg_OxfordUniversityInnovationLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TechnologyLicenseAgreementMember" xlink:label="pepg_TechnologyLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AggregatePotentialMilestonePayments" xlink:label="pepg_AggregatePotentialMilestonePayments"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_OxfordScienceEnterprisesMember" xlink:label="pepg_OxfordScienceEnterprisesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ServicesAgreementMember" xlink:label="pepg_ServicesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SublicenseesThresholdAmount" xlink:label="pepg_SublicenseesThresholdAmount"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_CarnotPharmaLlcMember" xlink:label="pepg_CarnotPharmaLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TermOfLicenseAgreement" xlink:label="pepg_TermOfLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_RaCapitalManagementLPMember" xlink:label="pepg_RaCapitalManagementLPMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_PercentageOfExitFee" xlink:label="pepg_PercentageOfExitFee"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_RequiredToPayExitFeeAmount" xlink:label="pepg_RequiredToPayExitFeeAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_RentPayableToRelatedParties" xlink:label="pepg_RentPayableToRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_RelatedPartyTransactionsOtherCostsPaid" xlink:label="pepg_RelatedPartyTransactionsOtherCostsPaid"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pepg_AdditionalPaymentsOfRestatementCompletionFeeAndLicenseDataFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pepg_OxfordUniversityInnovationLimitedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pepg_TechnologyLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pepg_AggregatePotentialMilestonePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pepg_OxfordScienceEnterprisesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pepg_ServicesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pepg_SublicenseesThresholdAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pepg_CarnotPharmaLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pepg_TermOfLicenseAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pepg_RaCapitalManagementLPMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pepg_PercentageOfExitFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pepg_RequiredToPayExitFeeAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pepg_RentPayableToRelatedParties" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pepg_RelatedPartyTransactionsOtherCostsPaid" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_StockPurchaseAgreementMember" xlink:label="pepg_StockPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA2ConvertiblePreferredStockMember" xlink:label="pepg_SeriesA2ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesBStockPurchaseAgreementMember" xlink:label="pepg_SeriesBStockPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ClassAAndClassBCommonStockMember" xlink:label="pepg_ClassAAndClassBCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_StockRestrictionAgreementsMember" xlink:label="pepg_StockRestrictionAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesA1ConvertiblePreferredStockMember" xlink:label="pepg_SeriesA1ConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SeriesBConvertiblePreferredStockMember" xlink:label="pepg_SeriesBConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_UndesignatedPreferredStockMember" xlink:label="pepg_UndesignatedPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash" xlink:label="us-gaap_DividendsCommonStockCash"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_NumberOfSharesRestrictedAndSubjectToRepurchase" xlink:label="pepg_NumberOfSharesRestrictedAndSubjectToRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_NumberOfFoundingStockholdersEntered" xlink:label="pepg_NumberOfFoundingStockholdersEntered"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_PercentageOfRepurchaseRightsLapseOnOneYearAnniversary" xlink:label="pepg_PercentageOfRepurchaseRightsLapseOnOneYearAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_PercentageOfRepurchaseRightsLapseOnSecondAnniversary" xlink:label="pepg_PercentageOfRepurchaseRightsLapseOnSecondAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_NumberOfCommonStockVote" xlink:label="pepg_NumberOfCommonStockVote"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SharesOfRestrictedStockSubjectToRepurchase" xlink:label="pepg_SharesOfRestrictedStockSubjectToRepurchase"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pepg_StockPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesA2ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pepg_SeriesBStockPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_ClassAAndClassBCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pepg_StockRestrictionAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesA1ConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pepg_UndesignatedPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStockCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pepg_NumberOfSharesRestrictedAndSubjectToRepurchase" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pepg_NumberOfFoundingStockholdersEntered" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pepg_PercentageOfRepurchaseRightsLapseOnOneYearAnniversary" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pepg_PercentageOfRepurchaseRightsLapseOnSecondAnniversary" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pepg_NumberOfCommonStockVote" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pepg_SharesOfRestrictedStockSubjectToRepurchase" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceOnAnAsconvertedBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_StockOptionsIssuedAndOutstandingMember" xlink:label="pepg_StockOptionsIssuedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AuthorizedForFutureStockAwardsOrOptionGrantsMember" xlink:label="pepg_AuthorizedForFutureStockAwardsOrOptionGrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlanMember" xlink:label="pepg_AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlanMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pepg_StockOptionsIssuedAndOutstandingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pepg_AuthorizedForFutureStockAwardsOrOptionGrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pepg_AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TwoThousandTwentyTwoEquityIncentiveAwardPlanMember" xlink:label="pepg_TwoThousandTwentyTwoEquityIncentiveAwardPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" xlink:label="pepg_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_CommonStockOutstandingPercentage" xlink:label="pepg_CommonStockOutstandingPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pepg_TwoThousandTwentyTwoEquityIncentiveAwardPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pepg_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pepg_CommonStockOutstandingPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ExpectedMarketReturn" xlink:label="pepg_ExpectedMarketReturn"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_UkTaxAuthoritiesMember" xlink:label="pepg_UkTaxAuthoritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ResearchAndDevelopmentCreditsExpirationYear" xlink:label="pepg_ResearchAndDevelopmentCreditsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_OperatingLossCarryForwardsExpirationYear" xlink:label="pepg_OperatingLossCarryForwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_ChangesInOwnershipByStockholdersHoldingPercentage" xlink:label="pepg_ChangesInOwnershipByStockholdersHoldingPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="pepg_ExpectedMarketReturn" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="pepg_UkTaxAuthoritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="pepg_ResearchAndDevelopmentCreditsExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="pepg_OperatingLossCarryForwardsExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="pepg_ChangesInOwnershipByStockholdersHoldingPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OpenTaxYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SharesSalesAgreementMember" xlink:label="pepg_SharesSalesAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_FollowOnOfferingMember" xlink:label="pepg_FollowOnOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_SharesSalesAgreementAndFollowOnOfferingMember" xlink:label="pepg_SharesSalesAgreementAndFollowOnOfferingMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pepg_SharesSalesAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pepg_FollowOnOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pepg_SharesSalesAgreementAndFollowOnOfferingMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_RestrictedCash" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="pepg_PaymentOfOfferingCosts" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pepg_AmortizationAndInterestAccretionRelatedToOperatingLeases" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pepg_AmortizationOfPremiumAndDiscountsOnMarketableSecuritiesNet" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="12" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_PaymentOfOfferingCosts" xlink:label="pepg_PaymentOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AmortizationAndInterestAccretionRelatedToOperatingLeases" xlink:label="pepg_AmortizationAndInterestAccretionRelatedToOperatingLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AmortizationOfPremiumAndDiscountsOnMarketableSecuritiesNet" xlink:label="pepg_AmortizationOfPremiumAndDiscountsOnMarketableSecuritiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfMarketableSecuritiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfCostAndAccumulatedDepreciationOfPropertyAndEquipmentDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pepg_AccruedResearchAndDevelopmentExpensesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_TaxesPayableCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pepg_AccruedProfessionalServicesCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="pepg_AccruedResearchAndDevelopmentExpensesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_AccruedProfessionalServicesCurrent" xlink:label="pepg_AccruedProfessionalServicesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeForIncomeTaxesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="pepg_DeferredTaxLiabilitiesRightOfUseAsset" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="pepg_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="pepg_DeferredTaxAssetsRightOfUseLiability" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="pepg_DeferredTaxAssetsIntangibleAssetAmortization" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="pepg_DeferredTaxLiabilitiesRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="pepg_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_DeferredTaxAssetsRightOfUseLiability" xlink:label="pepg_DeferredTaxAssetsRightOfUseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_DeferredTaxAssetsIntangibleAssetAmortization" xlink:label="pepg_DeferredTaxAssetsIntangibleAssetAmortization"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="pepg_EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="pepg_EffectiveIncomeTaxRateReconciliationUkRDCredit" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="8" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="pepg_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent"/>
          <link:loc xlink:type="locator" xlink:href="pepg-20231231.xsd#pepg_EffectiveIncomeTaxRateReconciliationUkRDCredit" xlink:label="pepg_EffectiveIncomeTaxRateReconciliationUkRDCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="pepg_AmortizationAndInterestAccretionRelatedToOperatingLeases" name="AmortizationAndInterestAccretionRelatedToOperatingLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pepg_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" name="ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pepg_OperatingLeaseIncreaseInMonthlyRentExpense" name="OperatingLeaseIncreaseInMonthlyRentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pepg_NumberOfSharesRestrictedAndSubjectToRepurchase" name="NumberOfSharesRestrictedAndSubjectToRepurchase" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pepg_OperatingLossCarryForwardsExpirationYear" name="OperatingLossCarryForwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pepg_PercentageOfExitFee" name="PercentageOfExitFee" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pepg_ResearchAndDevelopmentCreditsExpirationYear" name="ResearchAndDevelopmentCreditsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pepg_TemporaryEquityStockIssuedDuringPeriodSharesStockUponExerciseOfWarrants" name="TemporaryEquityStockIssuedDuringPeriodSharesStockUponExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pepg_TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering" name="TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pepg_OxfordScienceEnterprisesMember" name="OxfordScienceEnterprisesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_NewtonMassachusettsMember" name="NewtonMassachusettsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_AmortizationOfPremiumAndDiscountsOnMarketableSecuritiesNet" name="AmortizationOfPremiumAndDiscountsOnMarketableSecuritiesNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pepg_AdditionalPaymentsOfRestatementCompletionFeeAndLicenseDataFee" name="AdditionalPaymentsOfRestatementCompletionFeeAndLicenseDataFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pepg_ComprehensiveLossPolicyTextBlock" name="ComprehensiveLossPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pepg_UkTaxAuthoritiesMember" name="UkTaxAuthoritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_SeriesA2PreferredStockWarrantLiabilityMember" name="SeriesA2PreferredStockWarrantLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_ComputerAndOfficeEquipmentMember" name="ComputerAndOfficeEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_RelatedPartyTransactionsOtherCostsPaid" name="RelatedPartyTransactionsOtherCostsPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pepg_LeasedSpace" name="LeasedSpace" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pepg_SharesSalesAgreementAndFollowOnOfferingMember" name="SharesSalesAgreementAndFollowOnOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_UndesignatedPreferredStockMember" name="UndesignatedPreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_ClassOfWarrantsOrRightsNumberOfSharesConvertedToCommonStock" name="ClassOfWarrantsOrRightsNumberOfSharesConvertedToCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pepg_SharesSalesAgreementMember" name="SharesSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_NetLossPerSharePolicyTextBlock" name="NetLossPerSharePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pepg_LeasesDisclosureTextBlock" name="LeasesDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pepg_StockPurchaseAgreementMember" name="StockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_AggregatePotentialMilestonePayments" name="AggregatePotentialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pepg_CommonStockOutstandingPercentage" name="CommonStockOutstandingPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pepg_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pepg_AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlanMember" name="AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_StockRestrictionAgreementsMember" name="StockRestrictionAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering" name="TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pepg_UsTreasuryBackedMoneyMarketFundsMember" name="UsTreasuryBackedMoneyMarketFundsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_AtTheMarketIssuanceSalesAgreementAndSecondaryOfferingMember" name="AtTheMarketIssuanceSalesAgreementAndSecondaryOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_RequiredToPayExitFeeAmount" name="RequiredToPayExitFeeAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pepg_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pepg_ResearchAndDevelopmentExpenses" name="ResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pepg_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" name="PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pepg_AccruedProfessionalServicesCurrent" name="AccruedProfessionalServicesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pepg_AuthorizedForFutureStockAwardsOrOptionGrantsMember" name="AuthorizedForFutureStockAwardsOrOptionGrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_CambridgeMassachusettsMember" name="CambridgeMassachusettsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_DeferredTaxAssetsRightOfUseLiability" name="DeferredTaxAssetsRightOfUseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pepg_AggregateOperatingLeaseCost" name="AggregateOperatingLeaseCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pepg_TenantImprovementMember" name="TenantImprovementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_NetProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised" name="NetProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pepg_RentPayableToRelatedParties" name="RentPayableToRelatedParties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pepg_TwoThousandTwentyTwoEquityIncentiveAwardPlanMember" name="TwoThousandTwentyTwoEquityIncentiveAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pepg_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" name="TwoThousandTwentyTwoEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_PercentageOfRepurchaseRightsLapseOnOneYearAnniversary" name="PercentageOfRepurchaseRightsLapseOnOneYearAnniversary" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pepg_OperatingLeaseMonthlyRentExpense" name="OperatingLeaseMonthlyRentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pepg_OperatingLeasePeriodOfExtension" name="OperatingLeasePeriodOfExtension" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pepg_AtTheMarketEquityOfferingSalesAgreementMember" name="AtTheMarketEquityOfferingSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_SeriesA2ConvertiblePreferredStockMember" name="SeriesA2ConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_EffectiveIncomeTaxRateReconciliationUkRDCredit" name="EffectiveIncomeTaxRateReconciliationUkRDCredit" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pepg_FollowOnOfferingMember" name="FollowOnOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_ScheduleOfAccruedLiabilitiesCurrentTableTextBlock" name="ScheduleOfAccruedLiabilitiesCurrentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pepg_DeferredTaxAssetsIntangibleAssetAmortization" name="DeferredTaxAssetsIntangibleAssetAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pepg_SublicenseesThresholdAmount" name="SublicenseesThresholdAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pepg_LaboratoryAndComputerEquipmentMember" name="LaboratoryAndComputerEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_SeriesA1ConvertiblePreferredStockMember" name="SeriesA1ConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_SeriesBStockPurchaseAgreementMember" name="SeriesBStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_HarrisonLeaseMember" name="HarrisonLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_StockOptionsIssuedAndOutstandingMember" name="StockOptionsIssuedAndOutstandingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_ExpectedMarketReturn" name="ExpectedMarketReturn" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pepg_ProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised" name="ProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pepg_ServicesAgreementMember" name="ServicesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExerciseOfPreferredStockWarrants" name="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExerciseOfPreferredStockWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pepg_TemporaryEquityStockIssuedDuringPeriodValueStockUponExerciseOfWarrants" name="TemporaryEquityStockIssuedDuringPeriodValueStockUponExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pepg_RaCapitalManagementLPMember" name="RaCapitalManagementLPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_OxfordUniversityInnovationLimitedMember" name="OxfordUniversityInnovationLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_NumberOfFoundingStockholdersEntered" name="NumberOfFoundingStockholdersEntered" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pepg_SharesOfRestrictedStockSubjectToRepurchase" name="SharesOfRestrictedStockSubjectToRepurchase" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pepg_AccruedLiabilitiesCurrentDisclosureTextBlock" name="AccruedLiabilitiesCurrentDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pepg_AccruedResearchAndDevelopmentExpensesCurrent" name="AccruedResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pepg_SupplementalDisclosureOfCashFlowInformationRelatedToLeasesTableTextBlock" name="SupplementalDisclosureOfCashFlowInformationRelatedToLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pepg_ChangesInOwnershipByStockholdersHoldingPercentage" name="ChangesInOwnershipByStockholdersHoldingPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pepg_PercentageOfRepurchaseRightsLapseOnSecondAnniversary" name="PercentageOfRepurchaseRightsLapseOnSecondAnniversary" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pepg_PaymentOfOfferingCosts" name="PaymentOfOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pepg_EffectiveIncomeTaxRateReconciliationPermanentDifferences" name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pepg_EmergingGrowthCompanyStatusPolicyTextBlock" name="EmergingGrowthCompanyStatusPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pepg_NumberOfCommonStockVote" name="NumberOfCommonStockVote" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pepg_ClassAAndClassBCommonStockMember" name="ClassAAndClassBCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_AtTheMarketIssuanceSalesAgreementAndFollowOnOfferingMember" name="AtTheMarketIssuanceSalesAgreementAndFollowOnOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_SecondaryOfferingMember" name="SecondaryOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_TechnologyLicenseAgreementMember" name="TechnologyLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pepg_PreferredStockWarrantsPolicyTextBlock" name="PreferredStockWarrantsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pepg_FixedLeaseRentExpense" name="FixedLeaseRentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pepg_OperatingLeaseCommencementDate" name="OperatingLeaseCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pepg_TermOfLicenseAgreement" name="TermOfLicenseAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pepg_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock" name="ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pepg_CarnotPharmaLlcMember" name="CarnotPharmaLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413952173616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 01, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PEPGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001835597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,354,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">Portions of the registrant&#8217;s Definitive Proxy Statement relating to its 2024 Annual Meeting of Stockholders to be filed hereafter are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PEPG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-3819886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">321 Harrison Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">797-0979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Phoenix, AZ, USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413951937584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 80,774,000<span></span>
</td>
<td class="nump">$ 181,752,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable Securities</a></td>
<td class="nump">29,633,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,271,000<span></span>
</td>
<td class="nump">4,331,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">112,678,000<span></span>
</td>
<td class="nump">186,083,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,764,000<span></span>
</td>
<td class="nump">3,335,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">23,620,000<span></span>
</td>
<td class="nump">26,549,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,990,000<span></span>
</td>
<td class="nump">1,473,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">143,052,000<span></span>
</td>
<td class="nump">217,440,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,005,000<span></span>
</td>
<td class="nump">1,362,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">13,522,000<span></span>
</td>
<td class="nump">11,913,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">3,004,000<span></span>
</td>
<td class="nump">5,553,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">17,531,000<span></span>
</td>
<td class="nump">18,828,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">17,100,000<span></span>
</td>
<td class="nump">18,981,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">34,631,000<span></span>
</td>
<td class="nump">37,809,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2023 and 2022, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 500,000,000 shares authorized as of December 31, 2023 and 2022, respectively; 23,823,241 and 23,713,196 shares issued and outstanding as of December 31, 2023 and 2022, respectively</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">289,867,000<span></span>
</td>
<td class="nump">282,566,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">34,000<span></span>
</td>
<td class="num">(81,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(181,482,000)<span></span>
</td>
<td class="num">(102,856,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">108,421,000<span></span>
</td>
<td class="nump">179,631,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock, and stockholders' equity (deficit)</a></td>
<td class="nump">$ 143,052,000<span></span>
</td>
<td class="nump">$ 217,440,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413952055872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">23,823,241<span></span>
</td>
<td class="nump">23,713,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">23,823,241<span></span>
</td>
<td class="nump">23,713,196<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413952019024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 68,126<span></span>
</td>
<td class="nump">$ 54,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">16,640<span></span>
</td>
<td class="nump">14,224<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">84,766<span></span>
</td>
<td class="nump">68,301<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(84,766)<span></span>
</td>
<td class="num">(68,301)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">6,400<span></span>
</td>
<td class="nump">2,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(187)<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">6,213<span></span>
</td>
<td class="nump">2,903<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income tax</a></td>
<td class="num">(78,553)<span></span>
</td>
<td class="num">(65,398)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(73)<span></span>
</td>
<td class="num">(3,706)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (78,626)<span></span>
</td>
<td class="num">$ (69,104)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (3.3)<span></span>
</td>
<td class="num">$ (4.42)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (3.3)<span></span>
</td>
<td class="num">$ (4.42)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic</a></td>
<td class="nump">23,796,000<span></span>
</td>
<td class="nump">15,639,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted</a></td>
<td class="nump">23,796,000<span></span>
</td>
<td class="nump">15,639,728<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413952154704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (78,626)<span></span>
</td>
<td class="num">$ (69,104)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Cumulative translation adjustment arising during the period</a></td>
<td class="nump">104<span></span>
</td>
<td class="num">(98)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (78,511)<span></span>
</td>
<td class="num">$ (69,202)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413951593296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series A-1 Convertible Preferred Stock</div></th>
<th class="th"><div>Series A-2 Convertible Preferred Stock</div></th>
<th class="th"><div>Series B Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary Equity Beginning Balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,454<span></span>
</td>
<td class="nump">$ 44,639<span></span>
</td>
<td class="nump">$ 112,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity Beginning Balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,372,970<span></span>
</td>
<td class="nump">3,939,069<span></span>
</td>
<td class="nump">7,234,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2021</a></td>
<td class="num">$ (32,082)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,653<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="num">$ (33,752)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">963,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_TemporaryEquityStockIssuedDuringPeriodSharesStockUponExerciseOfWarrants', window );">Temporary equity, Issuance of Series A-2 stock upon exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_TemporaryEquityStockIssuedDuringPeriodValueStockUponExerciseOfWarrants', window );">Temporary equity, Issuance of Series A-2 stock upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering', window );">Temporary equity, Conversion of convertible preferred stock upon IPO, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,372,970)<span></span>
</td>
<td class="num">(3,974,598)<span></span>
</td>
<td class="num">(7,234,766)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering', window );">Temporary equity, Conversion of convertible preferred stock upon IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,454)<span></span>
</td>
<td class="num">$ (45,213)<span></span>
</td>
<td class="num">$ (112,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock upon IPO, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,359,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock upon IPO</a></td>
<td class="nump">165,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">165,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock in IPO, net of underwriters' fees and issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,238,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Common Stock in IPO, net of underwriters' fees and issuance costs</a></td>
<td class="nump">110,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">110,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Release of common stock from vesting restrictions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">4,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Cumulative translation adjustment arising during the period</a></td>
<td class="num">$ (98)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity Ending Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (69,104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,104)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="nump">179,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">282,566<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="num">(102,856)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,713,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock under the employee stock purchase plan</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock under the employee stock purchase plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="nump">100,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">7,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Cumulative translation adjustment arising during the period</a></td>
<td class="nump">$ 104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity Ending Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (78,626)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78,626)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 108,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 289,867<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="num">$ (181,482)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,823,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity conversion of convertible preferred stock upon initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity shares conversion of convertible preferred stock upon initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_TemporaryEquityStockIssuedDuringPeriodSharesStockUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Stock Issued During Period Shares Stock Upon Exercise Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_TemporaryEquityStockIssuedDuringPeriodSharesStockUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_TemporaryEquityStockIssuedDuringPeriodValueStockUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Stock Issued During Period Value Stock Upon Exercise Of Warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_TemporaryEquityStockIssuedDuringPeriodValueStockUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413957652240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (PARENTHETICAL)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="nump">$ 12,684<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413951995184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (78,626)<span></span>
</td>
<td class="num">$ (69,104)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,184<span></span>
</td>
<td class="nump">493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">7,048<span></span>
</td>
<td class="nump">4,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_AmortizationAndInterestAccretionRelatedToOperatingLeases', window );">Amortization and interest accretion related to operating lease</a></td>
<td class="num">(334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_AmortizationOfPremiumAndDiscountsOnMarketableSecuritiesNet', window );">Amortization of premium and discounts on marketable securities, net</a></td>
<td class="num">(220)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of preferred stock warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">4,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaids and other current and non-current assets</a></td>
<td class="nump">2,038<span></span>
</td>
<td class="num">(1,784)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="num">(369)<span></span>
</td>
<td class="num">(1,407)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other non-current liabilities</a></td>
<td class="nump">1,422<span></span>
</td>
<td class="nump">5,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities, current and non-current</a></td>
<td class="num">(1,166)<span></span>
</td>
<td class="num">(2,016)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(68,997)<span></span>
</td>
<td class="num">(59,265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,599)<span></span>
</td>
<td class="num">(3,755)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(29,404)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(32,003)<span></span>
</td>
<td class="num">(3,755)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock upon initial public offering, net of underwriters' fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_PaymentOfOfferingCosts', window );">Payment of offering costs</a></td>
<td class="num">(442)<span></span>
</td>
<td class="num">(2,697)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from issuance of common stock upon exercise of Series A-2 warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee equity plans</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="num">(189)<span></span>
</td>
<td class="nump">112,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash</a></td>
<td class="nump">286<span></span>
</td>
<td class="num">(316)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(100,903)<span></span>
</td>
<td class="nump">48,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">183,225<span></span>
</td>
<td class="nump">134,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">82,322<span></span>
</td>
<td class="nump">183,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Components of cash, cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">80,774<span></span>
</td>
<td class="nump">181,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">1,548<span></span>
</td>
<td class="nump">1,473<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Total cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">82,322<span></span>
</td>
<td class="nump">183,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental noncash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses', window );">Property and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="nump">$ 2,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Lease assets obtained in exchange for new operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,549<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_AmortizationAndInterestAccretionRelatedToOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization and interest accretion related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_AmortizationAndInterestAccretionRelatedToOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_AmortizationOfPremiumAndDiscountsOnMarketableSecuritiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of premium and discounts on marketable securities, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_AmortizationOfPremiumAndDiscountsOnMarketableSecuritiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_PaymentOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_PaymentOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property and equipment included in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413952057632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (78,626)<span></span>
</td>
<td class="num">$ (69,104)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413955241328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140414046826096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Business and Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of Business and Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PepGen Inc. (PepGen or the Company), is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The Company's principal offices are located in Boston, Massachusetts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company was initially formed as PepGen Limited on January 25, 2018, in the United Kingdom, or the U.K. On November 9, 2020, PepGen Limited completed a corporate reorganization, or the Reorganization. As part of the Reorganization, PepGen Limited formed PepGen Inc., a Delaware corporation with nominal assets and liabilities, for the purpose of consummating the Reorganization. In connection with the Reorganization, the existing stockholders of PepGen Limited exchanged each of its classes of shares of PepGen Limited for the same number and class of common stock of PepGen Inc. on a one-to-one basis. The newly issued stock of PepGen Inc. had substantially identical rights to the exchanged shares of PepGen Limited. As a result of the exchange, PepGen Inc. became the sole stockholder of PepGen Limited. Upon the completion of the Reorganization on November 23, 2020, the historical financial statements of PepGen Limited became the historical financial statements of PepGen Inc. as the Reorganization was deemed to be between entities under common control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Initial Public Offering and Follow-On Offerings</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 10, 2022, the Company closed its initial public offering, or IPO, in which the Company sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">108.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. In connection with the IPO, the Company granted the underwriters a 30-day option to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,350,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional shares of common stock. On May 16, 2022, the underwriters exercised the option in part and the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,238,951</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock for gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. From the IPO and option exercise by the underwriters, the Company received approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">122.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in gross proceeds and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">110.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in net proceeds, after deducting underwriting discounts and offering expenses payable by the Company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Immediately prior to consummation of the IPO, all </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,546,805</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> outstanding shares of the Company&#8217;s redeemable convertible preferred stock, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35,529</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> preferred stock warrants that were exercised on May 4, 2022 (see Note 3), converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,359,856</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 5, 2024, the Company sold shares under its At-the-Market Equity Offering Sales Agreement, or Sales Agreement, with Stifel, Nicolaus &amp; Company, Incorporated dated as of August 8, 2023, resulting in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. On February 9, 2024, the Company sold shares in a follow-on offering, referred to as the Follow-on Offering, pursuant to an underwriting agreement with Leerink Partners LLC dated as of February 6, 2024, resulting in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">76.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting underwriting fees of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Net proceeds from sales under the Sales Agreement and Follow-on Offering, after deducting underwriters' fees and before deducting costs of the offerings, were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">86.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity and Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since inception, the Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations. The Company&#8217;s primary uses of cash and cash equivalents to date have been to fund research and development activities, business planning, establishing and maintaining the Company&#8217;s intellectual property portfolio, hiring personnel, leasing premises and associated capital expenditures, raising capital, and providing general and administrative support for these operations. As of December 31, 2023, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">181.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. To date, the Company has funded operations primarily through private placements of convertible preferred stock and its IPO. As of December 31, 2023, the Company had cash, cash equivalents, and marketable securities of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">110.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, excluding net proceeds from the Sales Agreement and Follow-On Offering. Based on its current operating plans, the Company believes that its cash, cash equivalents, and marketable securities as of December 31, 2023, as well as proceeds from the Sales Agreement and Follow-On Offering (see Note 12) will be sufficient to fund its currently planned operations for at least the next 12 months from the filing of these consolidated financial statements.</span></p><p style="text-indent:5.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As the Company continues to pursue its business plan to successfully develop and obtain regulatory approval for the Company&#8217;s product candidates, it expects to finance its operations through the sale of equity, debt financings or other capital resources, which could include income from collaborations, strategic partnerships or marketing, distribution, licensing or other strategic arrangements with third parties, or from grants. However, there can be no assurance that any additional financing or strategic transactions will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that the Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">does not obtain additional funding, it may need to delay, reduce or eliminate its product development or future commercialization efforts, which could have a material adverse effect on the Company&#8217;s business, results of operations or financial condition.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation and Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. The consolidated financial statements include the accounts of PepGen Inc. (a U.S. corporation) and its wholly owned subsidiaries PepGen Limited (a U.K. corporation) and PepGen Securities Corp. (a U.S. corporation). All intercompany accounts and transactions have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reclassifications</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain amounts disclosed in the prior period financial statements have been reclassified from their original presentation to conform to the current period presentation. The reclassification had no effect on net income, earnings per share, retained earnings, cash flows or total assets.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413957577904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management bases its estimates and judgments on historical experience, knowledge of current conditions, and beliefs of what could occur in the future, given the available information. On an ongoing basis, management evaluates such estimates and assumptions for continued reasonableness. In particular, management makes estimates with respect to accruals for research and development activities, for the valuation of intellectual property, for the fair value of common stock and convertible preferred stock warrants and stock-based compensation expense. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation. Actual results could differ materially from those estimates and assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, or the CODM. The Company&#8217;s CODM is its chief executive officer who reviews financial information together with certain operating metrics principally to make decisions about how to allocate resources and to measure the Company&#8217;s performance. The Company has determined that it operates as a single reportable segment. The Company&#8217;s CODM evaluates financial information on a consolidated basis. As the Company operates as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment, all required segment financial information is presented in the consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Currency Remeasurement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s reporting currency is the U.S. Dollar. The functional currency of PepGen Limited is the British Pound. The assets and liabilities of PepGen Limited are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the cumulative translation adjustment, a component of accumulated other comprehensive loss in stockholders&#8217; equity (deficit).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and money market accounts. As of December 31, 2023, the Company&#8217;s cash, cash equivalents, and marketable securities were held by four financial institutions in the U.S. and one financial institution in the U.K. At times, the Company&#8217;s deposits held in the U.S. and U.K. may exceed the respective insured limits of the Federal Depository Insurance Corporation and Financial Services Compensation Scheme.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates fair value. As of December 31, 2023 and 2022, cash and cash equivalents consisted primarily of checking and money market funds composed of U.S. government obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies all cash whose use is limited by contractual provisions as restricted cash. Restricted cash arises from the requirement for the Company to maintain cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as collateral under a lease agreement. As of December 31, 2023 and 2022, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of restricted cash was recorded in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0e60f457-09a0-4d36-973d-dc52a1d8e6c2;"><span style="-sec-ix-hidden:F_82e8c746-990f-4d25-9100-51e93f9ca429;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">other assets</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on the consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s marketable securities consist of U.S. treasury notes which are classified as available-for-sale and are reported at fair value. Unrealized gains and losses on available-for-sale debt securities are reported as a component of accumulated other comprehensive loss in stockholders&#8217; equity (deficit). Realized gains and losses are based on the specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluates its marketable securities with unrealized losses for other-than-temporary impairment. When assessing marketable securities for other-than-temporary declines in value, the Company considers such factors as, among other things, how significant the decline in value is as a percentage of the original cost, how long the market value of the investment has been less than its original cost, the Company&#8217;s ability and intent to retain the investment for a period of time sufficient to allow for any anticipated recovery in fair value, and market conditions in general. If any adjustment to fair value reflects a decline in the value of the investment that the Company considers to be &#8220;other than temporary,&#8221; the Company reduces the investment to fair value through a charge to the statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1: Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access. </span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2: Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3: Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For certain financial instruments, including cash and cash equivalents, prepaid expenses, accounts payable, as well as certain accrued liabilities, the recorded amount approximates estimated fair value due to their relatively short maturity period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful lives of the respective assets. Maintenance and repairs that do not improve or extend the life of the assets are expensed when incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated useful lives of the Company&#8217;s property and equipment are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:80.236%;"></td>
          <td style="width:1.94%;"></td>
          <td style="width:17.824%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory and computer equipment</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 years</span></span></p></td>
         </tr>
        </table></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Deferred Offering Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company capitalizes within other long-term assets certain legal, accounting, and other third-party fees that are directly related to the Company&#8217;s in-process equity financings, until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds received as a result of the offering. Should a planned equity financing be abandoned, terminated, or significantly delayed, the deferred offering costs are immediately written off to operating</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expenses. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, deferred offering costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million were recorded within other assets on the consolidated balance sheets. Subsequent to the completion of the IPO in May 2022, deferred offering costs totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million were recorded within stockholders&#8217; equity (deficit) as a reduction of additional paid-in-capital generated from the IPO.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ASU 2016-02, Leases (Topic 842), or ASC 842. Under ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances presented in the arrangement, including whether the Company controls the use of identified assets. The Company classifies leases with a term greater than one year as either operating or finance leases at the lease commencement date and records a right-of-use assets and current and non-current lease liabilities, as applicable on the balance sheet. The Company has elected not to recognize on the balance sheet leases with terms of one year or less, but payments are recognized as expense on a straight-line basis over the lease term. If a lease includes options to extend the lease term, the Company does not assume the option will be exercised in its initial lease term assessment unless there is reasonable certainty that the Company will renew based on an assessment of economic factors present as of the lease commencement date. The Company monitors its plans to renew its material lease each reporting period. If a lease includes provisions for leasehold improvements for which the Company has an obligation to pay, the Company determines if the improvements should be considered lessor or lessee assets. If the improvements are considered lessor assets, the Company records the payments in the calculation of the lease liability and corresponding right-of-use asset.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lease liabilities and the corresponding right-of-use assets are recorded based on the present value of lease payments over the remaining lease term. The present value of future lease payments are discounted using the interest rate implicit in lease contracts if that rate is readily determinable; otherwise the Company utilizes information available at the commencement of the lease to calculate the incremental borrowing rate, or IBR, which reflects the fixed rate at which the Company could borrow on a collateralized basis over a similar term, the amount of the lease payments in a similar economic environment. In order to determine the appropriate incremental borrowing rate, the Company used available third-party information, including comparable company collateralized borrowing information. After lease commencement and the establishment of a right-to-use asset and operating lease liability, lease expense is recorded on a straight-line basis over the lease term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company enters into contracts that contain both lease and non-lease components. Non-lease components include costs that do not provide a right-to-use a leased asset but instead provide a service, such as maintenance costs. The Company has elected to account for the lease and non-lease components together as a single component for all classes of underlying assets. Variable costs associated with the lease, such as maintenance and utilities, are not included in the measurement of right-to-use assets and lease liabilities but rather are expensed when the events determining the amount of variable consideration to be paid have occurred.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. The recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset or asset group to the estimated undiscounted future cash flows expected to be generated by the asset or asset group.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the carrying amount of an asset or asset group exceeds its estimated undiscounted future cash flows, an impairment charge is recognized as the amount by which the carrying amount of the asset or asset group exceeds the estimated discounted future cash flows of the asset or asset group. There have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> such impairments of long-lived assets for the years ended December 31, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Commitment and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes a liability with regard to loss contingencies when it believes it is probable a liability has been incurred, and the amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount the Company accrues the minimum amount in the range. The Company has not recorded any such liabilities as of December 31, 2023 and 2022 that were material to the consolidated financial statements</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Convertible Preferred Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company recorded convertible preferred stock at fair value on the dates of issuance, net of issuance costs. Upon the occurrence of certain events that are outside the Company&#8217;s control, including a deemed liquidation event, holders of the convertible preferred stock could cause redemption for cash. Therefore, convertible preferred stock was classified outside of stockholders&#8217; deficit on the consolidated balance sheets as events triggering the liquidation preferences are not solely within the Company&#8217;s control. No accretion was recognized as the contingent events that could give rise to redemption were not deemed probable. Upon completion of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IPO, all preferred stock was converted to common stock and as such </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> amounts were issued or outstanding as of December 31, 2023 and 2022.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preferred Stock Warrants</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classified warrants to purchase its Series A-2 convertible preferred stock as a liability on the consolidated balance sheets as these warrants were freestanding financial instruments that could have required the Company to transfer assets upon exercise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development costs consist of salaries, benefits, and other personnel-related costs, including stock-based compensation, laboratory supplies, process development costs, fees paid to other entities to conduct certain research and development activities on the Company&#8217;s behalf, including contract manufacturing organizations and contract research organizations, and allocated facility and other related costs. Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized as prepaid expenses until the related goods are delivered or services are performed. During the year-ended December 31, 2022, the Company received &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million) relating to its 2021 U.K. research and development tax credit for research and development activities undertaken by its U.K. subsidiary. As of December 31, 2023 and 2022, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> research and development tax credits were recorded in other receivables on the consolidated balance sheets, respectively.</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers under the service agreements. The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The historical accrual estimates made by the Company have not been materially different from the actual costs.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation-Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or ASC 718. ASC 718 requires all stock-based payments to employees, non-employees and directors, to be recognized as expense in the consolidated statements of operations based on their grant date fair values. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model, or Black-Scholes, for stock option grants to employees, non-employees and directors. The fair value of the Company&#8217;s common stock is used to determine the fair value of restricted stock awards.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s stock-based compensation awards are generally subject to service-based vesting conditions. Compensation expense related to awards to employees, non-employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Black-Scholes requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends.  The Company determines the expected volatility using the historical volatility of a peer group of comparable publicly traded companies with product candidates in similar stages of development to the Company&#8217;s product candidates. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term for stock options granted to employees, non-employees and directors whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the Company&#8217;s IPO, there was no public market for its common stock, and consequently, the estimated fair value of its common stock was determined by the board of directors as of the date of each stock option grant, with input from management, considering third-party valuations of its common stock as well as its board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent third-party valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or Practice Aid. The Practice Aid identifies various available methods for allocating the enterprise value across classes of series of capital stock in determining the fair value of the Company&#8217;s common stock at each valuation date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subsequent to the Company&#8217;s IPO, the fair value of the common stock underlying the stock-based awards is the closing price of the Company&#8217;s common stock on the date of grant.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts or existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company records a valuation allowance to reduce deferred tax assets to an amount for which realization is more likely than not.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained upon examination by the tax authorities, based on the merits of the position. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> interest or penalties charged in relation to the unrecognized tax benefits.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss is composed of two components &#8212; net loss and other comprehensive loss. Other comprehensive loss refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders&#8217; equity but are excluded from net loss. The Company&#8217;s other comprehensive loss consists of foreign currency translation adjustments and unrealized gains and losses on available-for-sale marketable debt securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is anti-dilutive. The Company&#8217;s potentially dilutive securities include unvested common stock under the Company&#8217;s equity incentive plan which have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.967%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:1%;"></td>
          <td style="width:13.357%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:1%;"></td>
          <td style="width:13.357%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,233,203</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,341,834</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,233,203</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,341,834</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Emerging Growth Company Status</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company is an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act, or JOBS Act, and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company may take advantage of these exemptions until the Company is no longer an &#8220;emerging growth company.&#8221; Section 107 of the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards and as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of the IPO or such earlier time that it is no longer an &#8220;emerging growth company.&#8221; As a result of the Company having elected the extended</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">transition </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act, 2016-13 and ASU 2019-11 are effective for the Company for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB or other standard-setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the JOBS Act of 2012 and has elected not to &#8220;opt out&#8221; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and non-public companies, the Company can adopt the new or revised standard at the time non-public companies adopt the new or revised standard and can do so until such time that the Company either (i) irrevocably elects to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for non-public companies. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial statements and disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective January 1, 2022, the Company adopted ASC 842. Upon commencement of the Company's lease in December 2022, the Company recognized lease liabilities totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">24.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and right-of-use assets totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">26.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, or ASU 2016-13. The standard changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today&#8217;s &#8220;incurred loss&#8221; approach with an &#8220;expected loss&#8221; model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard&#8217;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The effective date of this update is for fiscal years beginning after December 15, 2022, and interim periods therein. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ASU 2016-13 effective </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, with </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> material impact on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740), or ASU 2019-12. The standard simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and also improves consistent application by clarifying and amending existing guidance. The standard is effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ASU 2019-12 effective </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, with </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> material impact on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures, or ASU 2023-07, to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 on a prospective basis. Early adoption and retrospective application is permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, or ASU 2023-07, which requires public entities to disclose information about their reportable segments&#8217; significant expenses on an interim and annual basis. ASU 2023-07 is effective for the Company beginning the year ended May 31, 2025. The Company is currently evaluating the impact of this ASU 2023-07 on its consolidated financial statements and related disclosures.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413957666192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth marketable securities for the year ended December 31, 2023 (in thousands). The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t hold any marketable securities during the year ended December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.16%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.700000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.84%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury-backed money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,622</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,633</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,622</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,633</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table set forth the fair value of the Company&#8217;s financial assets measured at fair value on a recurring basis and indicates the level within the fair value hierarchy utilized to determine such values (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash Equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury-backed money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64,397</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64,397</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,980</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,980</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable Securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,633</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,633</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106,010</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106,010</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury-backed money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,645</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,645</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,645</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,645</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds are highly liquid investments that are valued based on quoted market prices in active markets, which represent a Level 1 measurement within the fair value hierarchy. These money market funds are classified on the balance sheet under cash and cash equivalents.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preferred Stock Warrant Liability</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the November 24, 2020 Stock Purchase Agreement (see Note 9), the Company granted warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35,529</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series A-2 convertible preferred stock at a price per share equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.42</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and with a term ending upon the earlier of an underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, the consummation of a Deemed Liquidation Event, as such term is defined in the Company&#8217;s Restated Certificate of Incorporation, or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As the warrants were for preferred stock, which did not qualify for equity classification, the warrants were recorded as a liability and were required to be remeasured to fair value at each reporting date. The warrants were exercised on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">May 4, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, just prior to the completion of the IPO, for proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Immediately prior to the consummation of the IPO, the warrants were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">34,901</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock.</span></p><p style="text-indent:5.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As there are several inputs that are not observable in the market, the warrant valuation represented a Level 3 measurement within the fair value hierarchy. The Company&#8217;s valuation of the preferred stock warrants utilized the Black-Scholes option-pricing model, which incorporates assumptions and estimates to value the preferred stock warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The quantitative elements associated with the Company&#8217;s Level 3 inputs impacting the fair value measurement of the preferred stock warrant liability included the fair value per share of the underlying Series A-2 convertible preferred stock, the remaining contractual term of the warrants, risk-free interest rate, expected dividend yield and expected volatility of the price of the underlying preferred stock. The most significant assumption in the Black-Scholes option-pricing model impacting the fair value of the preferred stock warrants was the fair value of the Company&#8217;s Series A-2 convertible preferred stock as of each remeasurement date. The Company determined the fair value per share of the underlying preferred stock by taking into consideration its most recent sales of its convertible preferred stock. The Company historically had been a private company and lacked company-specific historical and implied volatility information of its stock. Therefore, it estimated its expected stock volatility based on the historical volatility of publicly traded peer companies for a term equal to the remaining contractual term of the warrants. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining contractual term of the warrants. The Company had estimated a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% dividend yield based on the expected dividend yield and the fact that the Company has never paid or declared dividends.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized changes in the fair value of the warrant liability as a component of other income (expense) in its consolidated statements of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the Level 3 warrant liability through exercise in the second quarter of 2022 was as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.58%;"></td>
        <td style="width:1.88%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.54%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Series A-2 Preferred<br/>Stock Warrant Liability</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">226</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of preferred stock warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">168</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413957592992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. Property and Equipment, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The cost and accumulated depreciation of property and equipment were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,821</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,424</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer and office equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,446</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">171</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in process</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,129</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,336</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,724</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,572</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">389</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,764</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,335</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the years ended December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413957666192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_AccruedLiabilitiesCurrentDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Accrued Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,521</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,840</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee-related expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,368</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,440</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Taxes payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,574</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">715</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">932</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">918</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,127</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,522</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,913</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_AccruedLiabilitiesCurrentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities current disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_AccruedLiabilitiesCurrentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413952636688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_LeasesDisclosureTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2021, the Company entered into a non-cancellable operating lease agreement, or the Harrison Lease, pursuant to which the Company leases </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">31,668</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office and laboratory space located in Boston, Massachusetts, or the Premises. The Harrison Lease commenced for accounting purposes when the Company gained access to the Premises on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 29, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or the Lease Commencement Date. The Harrison Lease has a term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nine years and two months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> from the Lease Commencement Date. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s obligation for the payment of base rent for the Premises began in May 2023, and is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million per month, increasing up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million per month during the term of the Lease.  </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has one </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">option to extend</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> the term of the Harrison Lease, for a period of an additional </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Due to the timing of the Lease Commencement Date at the end of 2022, there was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> fixed lease rent expense associated with the Harrison Lease in 2022. At December 31, 2023, the Harrison Lease was the only lease for which the Company recorded a lease liability and corresponding right-of-use asset.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The landlord completed significant leasehold improvements to the Premises, a portion of which the Company was obligated to pay per the terms of the Harrison Lease. The Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the improvements prior to lease commencement in 2022, and paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the improvements in 2023, for total payments to the landlord for improvements of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company determined that the landlord is the accounting owner of the improvements, and payments by the Company for the improvements are included in the calculation of the right-of-use asset and lease liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During 2022 and the first quarter of 2023, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company leased office space in Cambridge, Massachusetts, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the terms of which were month-to-month, with a 30-day written </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">notice of cancellation</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company terminated this lease in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also leased laboratory space at the University of Massachusetts, Mount Ida Campus in Newton, Massachusetts, with an </span></span><span style=""></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">initial </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">lease term from February 1, 2022 to January 31, 2023, which the Company extended until March 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Company also leased space at Innovation Building, University of Oxford in Oxford, U.K. The Company terminated its lease in Oxford in July 2022. All of these leases had initial terms of under </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months and are considered short-term lease costs and are not recognized on the consolidated balance sheets.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Summary of Lease Costs</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of lease cost under ASC 842 for the leases were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,799</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">993</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">188</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,294</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,980</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,294</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supplemental disclosure of cash flow information under ASC 842 for the leases was as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,  2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating cash payments for operating leases</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,299</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash payments for operating leases during 2023 related to tenant improvements of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in rent payments in line with the Harrison Lease. Additionally, the Company made payments on variable lease costs throughout the year of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. These payments related to parking, management fees, and other costs associated with maintaining our office and lab space.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The remaining lease term for the Harrison Lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8.4</span></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years, and the discount rate is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease payments under the non-cancelable operating lease consisted of the following as of December 31, 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,004</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,094</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,187</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,282</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,381</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,079</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total future minimum lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,027</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,923</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Present value of lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,104</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Included in the consolidated balance sheet (in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,004</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability, net of current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,104</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_LeasesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leases disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_LeasesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413957752256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Related Party Transactions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Technology License Agreement with Oxford University Innovation Limited</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2018, the Company, Oxford University Innovation Limited, or OUI, and the Medical Research Council of United Kingdom Research and Innovation, or MRC (or collectively the Licensors), entered into a license of technology agreement, or the License Agreement, which was subsequently amended in December 2018 and further amended and restated in November 2020. The Licensors and affiliates held shares of Series A-1 and Series A-2 preferred stock, Series B preferred stock and Class A common stock. The License Agreement provides the Company with an exclusive world-wide license to licensed data and technology owned by OUI and MRC in respect of CPP for treatment of Duchenne muscular dystrophy, spinal muscular atrophy, and other conditions. The License Agreement provides the Company with the rights to grant and authorize sublicenses to make, use, sell, and import products and otherwise exploit the patent rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As consideration for the license, the Company made an initial upfront payment in 2018, as well as a Restatement Completion Fee and a License Data Fee in 2020 totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company could be required to make milestone payments to the Licensors upon achievement of certain patent and commercial milestones related to the patents and commercialization of certain of the Company&#8217;s product candidates. The aggregate potential milestone payments are $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company also agreed to pay the Licensors low single digit royalties on net sales of any licensed products that are commercialized by the Company in excess of a threshold amount between &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.5</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">38.2</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023), subject to certain adjustments. The term of the License Agreement continues until the later of (i) the date on which all the patents and patent applications covered thereunder have been abandoned or allowed to lapse or expired or been rejected or revoked or (ii) </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years from the date of the original agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon completion of the IPO, the Company became obligated to pay OUI an exit fee between </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the value determined in an acquisition or initial public offering, not to exceed &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of the IPO date). The exit fee due to OUI, based on the proceeds of the IPO, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which was paid during the second quarter of 2022 and included in research and development expense on the consolidated statement of operations. One member of the Company&#8217;s board of directors is also employed by Oxford Science Enterprises, which is an affiliate by OUI.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the Company paid office space rent to OUI. For the years ended December 31, 2023 and 2022, total rent payments were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">nil</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the years ended December 31, 2023 and 2022 to Oxford Science Enterprises as compensation for their board seat. As of December 31, 2023 and 2022, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">nil</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was due to OUI by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Services Agreement with RA Capital Management, L.P.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2020, the Company entered into an agreement, or the Services Agreement, with Carnot Pharma, LLC, or Carnot, under which Carnot provided research and other services to the Company. Carnot is an entity controlled by RA Capital Management, L.P. Entities affiliated with RA Capital Management, L.P. purchased shares of Series A-2 convertible preferred stock in the Company&#8217;s preferred stock financing in November 2020 and May and July 2021. In addition, entities affiliated with RA Capital Management, L.P. purchased shares of the Company&#8217;s Series B convertible preferred stock in the Company&#8217;s preferred stock financing in July 2021. Two members of the Company&#8217;s board of directors are also affiliated with RA Capital Management, L.P.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Services Agreement, the Company compensated Carnot on a fully burdened cost basis for personal time devoted to Company projects. In addition, the Company reimbursed Carnot on a costs basis for any subcontractor costs incurred. The Company paid Carnot on a quarterly basis, in arrears, for services performed and costs incurred. The Services Agreement was terminated in April 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expenses incurred by the Company under the Services Agreement with Carnot for the year ended December 31, 2023 and 2022, totaled </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">nil</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. Additionally, the Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million during the years ended December 31, 2023 and 2022 to RA Capital Management, L.P. as compensation for their board seat. As of December 31, 2023 and 2022, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">nil</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was due to Carnot by the Company for services rendered under the Services Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413957577904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Commitments and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legal proceedings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is not party to any litigation and does not have contingency reserves established for any litigation liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to the agreements, the Company agrees to indemnify, hold harmless, and to reimburse the indemnified party for losses suffered or incurred by the indemnified party, including in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third-party with respect to the Company&#8217;s products. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company&#8217;s request in such capacities. The Company&#8217;s maximum exposure under these arrangements is unknown as of December 31, 2023. The Company does not anticipate recognizing any significant losses relating to these arrangements. The term of these indemnification agreements is generally perpetual any time after execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements may be unlimited. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413952636688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Convertible Preferred Stock and Stockholders' Equity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. Convertible Preferred Stock and Stockholders&#8217; Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse Stock Split</span></p><p style="text-indent:5.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 29, 2022, the Company filed a charter amendment to affect a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_11100503-2fd3-4c49-87ab-244664e4d838;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.018</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for 1 reverse stock split</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of its issued and outstanding shares of common stock, which resulted in a proportional adjustment to the existing conversion ratios for each series of the Company&#8217;s preferred stock. Accordingly, all share and per share amounts for all periods presented in the accompanying consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse stock split and adjustment of the preferred stock conversion ratios.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Series A-1 Convertible Preferred Stock and Series A-2 Convertible Preferred Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the November 24, 2020 Stock Purchase Agreement, the Company agreed to issue an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,939,069</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series A-2 convertible preferred stock to new and existing investors at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.42</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, in three closings, and elected to convert </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,348,693</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of outstanding Class A and Class B common stock into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,372,970</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series A-1 convertible preferred stock. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,033,117</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock held by certain founding investors and employees were not modified and continued to exist as Class A common stock. The Series A-1 and Series A-2 convertible preferred stock was converted to common stock immediately prior to the consummation of the IPO in May 2022 (see Note 1).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Series B Convertible Preferred Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2021 the Company entered into the Series B Stock Purchase Agreement, whereby the Company agreed to issue and sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,234,766</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Series B convertible stock to new and existing investors at a per share price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.55</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for aggregate gross proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">112.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Series B convertible preferred stock was converted to common stock immediately prior to the consummation of the Company's IPO in May 2022 (see Note 1).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Third Amended and Restated Certificate of Incorporation, dated May 10, 2022, the Company has the authority to issue a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">500,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock (par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share) and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of undesignated preferred stock (par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share). In connection with the IPO, the Company re-designated all shares of Class A common stock as shares of common stock. Each share of common stock has the right to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cash dividends have been declared by the board of directors during the year ended December 31, 2023 and December 31, 2022.</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has reserved the following shares of common stock for issuance, as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options issued and outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,233,203</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,341,834</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Authorized for future stock awards or option grants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,091,187</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">901,462</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Authorized for future issuance under employee stock purchase plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">216,306</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">226,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,540,696</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,469,296</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Shares of Common Stock Subject to Repurchase</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2020, in connection with the Series A-2 convertible preferred stock financing, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> founding stockholders entered into Stock Restriction Agreements, or Restriction Agreements, whereby </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">139,057</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares that were previously vested and not subject to repurchase became restricted and subject to repurchase. The repurchase rights lapsed as to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on the one-year anniversary of the Restriction Agreements and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% on the second anniversary of the Restriction Agreements. Shares subject to repurchase by the Company are not deemed, for accounting purposes, to be outstanding until those shares vest and therefore are not included in the shares outstanding on the consolidated balance sheet.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the vesting restrictions placed on these previously vested shares, the Company was required to determine the measurement date fair value of the shares, which was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.37</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in aggregate. The measurement date fair value of the restricted stock was recognized as stock-based compensation expense over the vesting period. As of December 31, 2023 and 2022, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were subject to repurchase by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413957644416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company maintains three equity compensation plans; the 2020 Stock Plan, or the 2020 Plan, the 2022 Stock Option Incentive Plan, or the 2022 Plan, and the 2022 Employee Stock Purchase Plan, or the ESPP. As of the Company's IPO in May 2022, the Company's board of directors determined that no further awards would be made from the 2020 plan. The number of shares of common stock that may be issued under the 2022 Plan is subject to increase by the number of shares under any outstanding stock options forfeited and not exercised under the 2020 Plan. Additionally, the number of shares reserved for issuance under the 2022 Plan automatically increases on the first day of each fiscal year in an amount equal to the lower of (1) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the shares of common stock outstanding on such date and (2) an amount determined by the Company&#8217;s board of directors. The 2022 Plan allows the board of directors to grant incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock units, unrestricted stock awards, cash-based awards, and dividend equivalent rights to the Company&#8217;s officers, employees, directors and other key persons. As of December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,091,187</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares remained available for grant under the 2022 Plan and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">216,306</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares remained available for grant under the ESPP.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Option Valuation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In determining the fair value of the stock options granted, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Term</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;The Company&#8217;s expected term represents the period that the Company&#8217;s stock-based awards are expected to be outstanding. For stock options with service-based vesting periods, the expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options.</span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Volatility</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;The Company has historically been a private company and lacks significant company-specific historical and implied volatility information. The expected volatility is estimated based the average historical volatilities for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, stage in the life cycle and area of specialty. The Company will continue to apply this process until enough historical information regarding the volatility of its own stock price becomes available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk-Free Interest Rate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expected Dividend Yield</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">zero</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of stock options was estimated using the following weighted average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.343%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.343%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate %</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.19</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.95</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility %</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65.13</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71.68</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.05</span></span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.08</span></span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Option Activity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock option activity under the 2020 Plan and 2022 Plan, are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.942%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stock<br/>Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Remaining<br/>Contractual<br/>Term<br/>(In Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(In Thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,341,834</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.52</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.7</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,877</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,421,936</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.70</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100,351</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Canceled/Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">430,216</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.13</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,233,203</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.83</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,147</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and exercisable as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,477,013</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.87</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.9</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,427</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,233,203</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.83</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,147</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value of stock options is calculated as the difference between the exercise prices of the stock options and the fair value of the Company's common stock for those stock options that had exercises prices lower than the fair value of the Company's common stock. The total intrinsic value of the stock options exercised during the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. The intrinsic value is the difference between the estimated fair value of the Company&#8217;s common stock at the time of exercise and the exercise price of the stock option. During the years ended December 31, 2023 and 2022, the total proceeds to the Company from stock option exercises was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average grant date fair value of stock options granted during the years ended December 31, 2023 and 2022 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.56</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.66</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense recognized for stock option grants included in the accompanying consolidated statements of operations and comprehensive loss is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,966</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,695</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,082</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,068</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,048</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,763</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,233,203</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> vested and unvested stock options outstanding as of December 31, 2023. As of December 31, 2023, total unrecognized compensation expense related to stock options was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. This amount is expected to be recognized over a weighted average period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.49 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413957663760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s loss before income taxes for the years ended December 31, 2023 and 2022 were generated in the following jurisdictions (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.92%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.76%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.880000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Domestic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78,195</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,781</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">358</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,383</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Worldwide</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78,553</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,398</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The foreign income for the year-ended December 31, 2022 was due to the transfer of intellectual property, or IP, from PepGen Limited to the parent company, PepGen Inc., in an arm&#8217;s length transaction at fair value pursuant to an asset transfer agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of net deferred income taxes consisted of the following as of December 31, 2023 and 2022 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.92%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.76%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.880000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,038</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">474</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,547</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,287</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">577</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">523</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized Section 174 R&amp;D Costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,470</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,818</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,510</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,081</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,485</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,760</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible asset amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,425</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,879</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,073</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,822</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use-Asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,444</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,233</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed Assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,474</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,918</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,280</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,155</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,542</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,155</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,542</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of income tax expense were as follows for the years ended December 31, 2023 and 2022 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.748%;"></td>
        <td style="width:3.759%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.057%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.759%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.677000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current expense:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;U.S. Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,683</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,706</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred expense:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;U.S. Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,706</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations is summarized for the years ended December 31, 2023 and 2022, as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.892%;"></td>
        <td style="width:1.259%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.234000000000002%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.259%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.356%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax at statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State tax (net of federal benefit)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">GILTI Inclusion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.K. R&amp;D credit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign rate differential</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax expense (benefit)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s income tax expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2023 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2022. The income tax expense for the year ended December 31, 2023 was state taxes on interest income generated from the Company's cash equivalents and marketable securities. The income tax expense for the year ended December 31, 2022 was due to the IP transfer noted in the paragraph below.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 1, 2022, or the Transfer Date, the Company&#8217;s wholly owned subsidiary, PepGen Limited, transferred all IP assets to the parent company, PepGen Inc., in an arm&#8217;s length transaction at fair value pursuant to an asset transfer agreement. The fair value of the IP assets was a non-recurring fair value measurement. The Company engaged valuation specialists to calculate the IP value, and the IP value was measured using the historical cost method. The historical cost method estimated the fair value of the IP assets using the historical cost base of the IP assets and the expected market return as of the Transfer Date. The significant assumption inherent in estimating the fair value using the historical cost method was the expected market return. The Company utilized a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% expected market return, which a third-party investor may expect as a return on their investment, and which is based on studies of venture capital investment returns. The Company calculated the fair value of the IP assets by computing the present value of the historical cost base using the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% expected market return. The expected market return assumption used in the estimation of the IP assets represents a Level 3 input of the fair value hierarchy (see Note 3).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has federal net operating losses, or NOLs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">23.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and federal research and development, or R&amp;D, credits of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023, before consideration of limitations under Section 382 of the Internal Revenue Code, or Section 382, as further described below. The R&amp;D credits will expire beginning in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2041</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The Company has state NOLs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">36.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and state R&amp;D credits of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million which begin expiring in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2042</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The future utilization of the Company&#8217;s state NOLs and federal and state R&amp;D credits to offset future taxable income may be subject to a substantial annual limitation as a result of changes in ownership by stockholders that hold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% or more of the Company&#8217;s common stock. An assessment of such ownership changes under Section 382 was not completed through December 31, 2023. To the extent that an assessment is completed in the future, the Company&#8217;s ability to utilize tax attributes could be restricted on a year-by-year basis and certain attributes could expire before they are utilized. The Company will examine the impact of any potential ownership changes in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to taxation in the U.S. and the U.K. The Company&#8217;s federal and state returns since inception are subject to examination due to the carryover of NOLs. The Company has not been, nor is it currently, under examination by any tax authorities. The U.K. tax returns from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2018</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and forward are subject to examination by the U.K. tax authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the reconciliation of the beginning and ending amount of total unrecognized tax benefits for each of the periods indicated:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.44%;"></td>
        <td style="width:3.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.34%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.82%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at beginning of the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">673</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">751</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to prior year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Decrease related to prior year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Currency translation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at the end of the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">713</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">673</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company does not expect the amount of unrecognized tax benefits to change significantly in the next twelve months. The Company&#8217;s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. It had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> accrual for interest or penalties on its consolidated balance sheets at December 31, 2023 or 2022. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> interest and/or penalties were recognized in 2023 or 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413957565808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. Subsequent Events</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 5, 2024, the Company sold shares under the Sales Agreement, resulting in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. On February 9, 2024, the Company sold shares in the Follow-on Offering, resulting in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">76.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting underwriters' fees of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Net proceeds from sales under the Sales Agreement and Follow-on Offering, after deducting underwriters' fees and before deducting costs of the offerings, were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">86.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413948252688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management bases its estimates and judgments on historical experience, knowledge of current conditions, and beliefs of what could occur in the future, given the available information. On an ongoing basis, management evaluates such estimates and assumptions for continued reasonableness. In particular, management makes estimates with respect to accruals for research and development activities, for the valuation of intellectual property, for the fair value of common stock and convertible preferred stock warrants and stock-based compensation expense. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation. Actual results could differ materially from those estimates and assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, or the CODM. The Company&#8217;s CODM is its chief executive officer who reviews financial information together with certain operating metrics principally to make decisions about how to allocate resources and to measure the Company&#8217;s performance. The Company has determined that it operates as a single reportable segment. The Company&#8217;s CODM evaluates financial information on a consolidated basis. As the Company operates as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> operating segment, all required segment financial information is presented in the consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Remeasurement</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Currency Remeasurement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s reporting currency is the U.S. Dollar. The functional currency of PepGen Limited is the British Pound. The assets and liabilities of PepGen Limited are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the cumulative translation adjustment, a component of accumulated other comprehensive loss in stockholders&#8217; equity (deficit).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and money market accounts. As of December 31, 2023, the Company&#8217;s cash, cash equivalents, and marketable securities were held by four financial institutions in the U.S. and one financial institution in the U.K. At times, the Company&#8217;s deposits held in the U.S. and U.K. may exceed the respective insured limits of the Federal Depository Insurance Corporation and Financial Services Compensation Scheme.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates fair value. As of December 31, 2023 and 2022, cash and cash equivalents consisted primarily of checking and money market funds composed of U.S. government obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies all cash whose use is limited by contractual provisions as restricted cash. Restricted cash arises from the requirement for the Company to maintain cash of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as collateral under a lease agreement. As of December 31, 2023 and 2022, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of restricted cash was recorded in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0e60f457-09a0-4d36-973d-dc52a1d8e6c2;"><span style="-sec-ix-hidden:F_82e8c746-990f-4d25-9100-51e93f9ca429;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">other assets</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on the consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s marketable securities consist of U.S. treasury notes which are classified as available-for-sale and are reported at fair value. Unrealized gains and losses on available-for-sale debt securities are reported as a component of accumulated other comprehensive loss in stockholders&#8217; equity (deficit). Realized gains and losses are based on the specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluates its marketable securities with unrealized losses for other-than-temporary impairment. When assessing marketable securities for other-than-temporary declines in value, the Company considers such factors as, among other things, how significant the decline in value is as a percentage of the original cost, how long the market value of the investment has been less than its original cost, the Company&#8217;s ability and intent to retain the investment for a period of time sufficient to allow for any anticipated recovery in fair value, and market conditions in general. If any adjustment to fair value reflects a decline in the value of the investment that the Company considers to be &#8220;other than temporary,&#8221; the Company reduces the investment to fair value through a charge to the statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1: Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access. </span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2: Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3: Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For certain financial instruments, including cash and cash equivalents, prepaid expenses, accounts payable, as well as certain accrued liabilities, the recorded amount approximates estimated fair value due to their relatively short maturity period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful lives of the respective assets. Maintenance and repairs that do not improve or extend the life of the assets are expensed when incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated useful lives of the Company&#8217;s property and equipment are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:80.236%;"></td>
          <td style="width:1.94%;"></td>
          <td style="width:17.824%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory and computer equipment</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 years</span></span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Deferred Offering Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company capitalizes within other long-term assets certain legal, accounting, and other third-party fees that are directly related to the Company&#8217;s in-process equity financings, until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds received as a result of the offering. Should a planned equity financing be abandoned, terminated, or significantly delayed, the deferred offering costs are immediately written off to operating</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expenses. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, deferred offering costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million were recorded within other assets on the consolidated balance sheets. Subsequent to the completion of the IPO in May 2022, deferred offering costs totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million were recorded within stockholders&#8217; equity (deficit) as a reduction of additional paid-in-capital generated from the IPO.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ASU 2016-02, Leases (Topic 842), or ASC 842. Under ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances presented in the arrangement, including whether the Company controls the use of identified assets. The Company classifies leases with a term greater than one year as either operating or finance leases at the lease commencement date and records a right-of-use assets and current and non-current lease liabilities, as applicable on the balance sheet. The Company has elected not to recognize on the balance sheet leases with terms of one year or less, but payments are recognized as expense on a straight-line basis over the lease term. If a lease includes options to extend the lease term, the Company does not assume the option will be exercised in its initial lease term assessment unless there is reasonable certainty that the Company will renew based on an assessment of economic factors present as of the lease commencement date. The Company monitors its plans to renew its material lease each reporting period. If a lease includes provisions for leasehold improvements for which the Company has an obligation to pay, the Company determines if the improvements should be considered lessor or lessee assets. If the improvements are considered lessor assets, the Company records the payments in the calculation of the lease liability and corresponding right-of-use asset.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lease liabilities and the corresponding right-of-use assets are recorded based on the present value of lease payments over the remaining lease term. The present value of future lease payments are discounted using the interest rate implicit in lease contracts if that rate is readily determinable; otherwise the Company utilizes information available at the commencement of the lease to calculate the incremental borrowing rate, or IBR, which reflects the fixed rate at which the Company could borrow on a collateralized basis over a similar term, the amount of the lease payments in a similar economic environment. In order to determine the appropriate incremental borrowing rate, the Company used available third-party information, including comparable company collateralized borrowing information. After lease commencement and the establishment of a right-to-use asset and operating lease liability, lease expense is recorded on a straight-line basis over the lease term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company enters into contracts that contain both lease and non-lease components. Non-lease components include costs that do not provide a right-to-use a leased asset but instead provide a service, such as maintenance costs. The Company has elected to account for the lease and non-lease components together as a single component for all classes of underlying assets. Variable costs associated with the lease, such as maintenance and utilities, are not included in the measurement of right-to-use assets and lease liabilities but rather are expensed when the events determining the amount of variable consideration to be paid have occurred.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. The recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset or asset group to the estimated undiscounted future cash flows expected to be generated by the asset or asset group.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the carrying amount of an asset or asset group exceeds its estimated undiscounted future cash flows, an impairment charge is recognized as the amount by which the carrying amount of the asset or asset group exceeds the estimated discounted future cash flows of the asset or asset group. There have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> such impairments of long-lived assets for the years ended December 31, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitment and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Commitment and Contingencies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes a liability with regard to loss contingencies when it believes it is probable a liability has been incurred, and the amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount the Company accrues the minimum amount in the range. The Company has not recorded any such liabilities as of December 31, 2023 and 2022 that were material to the consolidated financial statements</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Convertible Preferred Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company recorded convertible preferred stock at fair value on the dates of issuance, net of issuance costs. Upon the occurrence of certain events that are outside the Company&#8217;s control, including a deemed liquidation event, holders of the convertible preferred stock could cause redemption for cash. Therefore, convertible preferred stock was classified outside of stockholders&#8217; deficit on the consolidated balance sheets as events triggering the liquidation preferences are not solely within the Company&#8217;s control. No accretion was recognized as the contingent events that could give rise to redemption were not deemed probable. Upon completion of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IPO, all preferred stock was converted to common stock and as such </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> amounts were issued or outstanding as of December 31, 2023 and 2022.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_PreferredStockWarrantsPolicyTextBlock', window );">Preferred Stock Warrants</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preferred Stock Warrants</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classified warrants to purchase its Series A-2 convertible preferred stock as a liability on the consolidated balance sheets as these warrants were freestanding financial instruments that could have required the Company to transfer assets upon exercise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development costs consist of salaries, benefits, and other personnel-related costs, including stock-based compensation, laboratory supplies, process development costs, fees paid to other entities to conduct certain research and development activities on the Company&#8217;s behalf, including contract manufacturing organizations and contract research organizations, and allocated facility and other related costs. Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized as prepaid expenses until the related goods are delivered or services are performed. During the year-ended December 31, 2022, the Company received &#163;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million) relating to its 2021 U.K. research and development tax credit for research and development activities undertaken by its U.K. subsidiary. As of December 31, 2023 and 2022, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> research and development tax credits were recorded in other receivables on the consolidated balance sheets, respectively.</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers under the service agreements. The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The historical accrual estimates made by the Company have not been materially different from the actual costs.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation-Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or ASC 718. ASC 718 requires all stock-based payments to employees, non-employees and directors, to be recognized as expense in the consolidated statements of operations based on their grant date fair values. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model, or Black-Scholes, for stock option grants to employees, non-employees and directors. The fair value of the Company&#8217;s common stock is used to determine the fair value of restricted stock awards.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s stock-based compensation awards are generally subject to service-based vesting conditions. Compensation expense related to awards to employees, non-employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Black-Scholes requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends.  The Company determines the expected volatility using the historical volatility of a peer group of comparable publicly traded companies with product candidates in similar stages of development to the Company&#8217;s product candidates. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term for stock options granted to employees, non-employees and directors whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to the Company&#8217;s IPO, there was no public market for its common stock, and consequently, the estimated fair value of its common stock was determined by the board of directors as of the date of each stock option grant, with input from management, considering third-party valuations of its common stock as well as its board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent third-party valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, or Practice Aid. The Practice Aid identifies various available methods for allocating the enterprise value across classes of series of capital stock in determining the fair value of the Company&#8217;s common stock at each valuation date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subsequent to the Company&#8217;s IPO, the fair value of the common stock underlying the stock-based awards is the closing price of the Company&#8217;s common stock on the date of grant.</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:5.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts or existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company records a valuation allowance to reduce deferred tax assets to an amount for which realization is more likely than not.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained upon examination by the tax authorities, based on the merits of the position. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> interest or penalties charged in relation to the unrecognized tax benefits.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_ComprehensiveLossPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss is composed of two components &#8212; net loss and other comprehensive loss. Other comprehensive loss refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders&#8217; equity but are excluded from net loss. The Company&#8217;s other comprehensive loss consists of foreign currency translation adjustments and unrealized gains and losses on available-for-sale marketable debt securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_NetLossPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Net Loss Per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is anti-dilutive. The Company&#8217;s potentially dilutive securities include unvested common stock under the Company&#8217;s equity incentive plan which have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.967%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:1%;"></td>
          <td style="width:13.357%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:1%;"></td>
          <td style="width:13.357%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,233,203</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,341,834</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,233,203</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,341,834</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_EmergingGrowthCompanyStatusPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Emerging Growth Company Status</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company is an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act, or JOBS Act, and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company may take advantage of these exemptions until the Company is no longer an &#8220;emerging growth company.&#8221; Section 107 of the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards and as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of the IPO or such earlier time that it is no longer an &#8220;emerging growth company.&#8221; As a result of the Company having elected the extended</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">transition </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act, 2016-13 and ASU 2019-11 are effective for the Company for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB or other standard-setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the JOBS Act of 2012 and has elected not to &#8220;opt out&#8221; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and non-public companies, the Company can adopt the new or revised standard at the time non-public companies adopt the new or revised standard and can do so until such time that the Company either (i) irrevocably elects to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for non-public companies. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial statements and disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective January 1, 2022, the Company adopted ASC 842. Upon commencement of the Company's lease in December 2022, the Company recognized lease liabilities totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">24.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and right-of-use assets totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">26.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, or ASU 2016-13. The standard changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today&#8217;s &#8220;incurred loss&#8221; approach with an &#8220;expected loss&#8221; model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard&#8217;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The effective date of this update is for fiscal years beginning after December 15, 2022, and interim periods therein. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ASU 2016-13 effective </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, with </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> material impact on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740), or ASU 2019-12. The standard simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and also improves consistent application by clarifying and amending existing guidance. The standard is effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ASU 2019-12 effective </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, with </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> material impact on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures, or ASU 2023-07, to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 on a prospective basis. Early adoption and retrospective application is permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, or ASU 2023-07, which requires public entities to disclose information about their reportable segments&#8217; significant expenses on an interim and annual basis. ASU 2023-07 is effective for the Company beginning the year ended May 31, 2025. The Company is currently evaluating the impact of this ASU 2023-07 on its consolidated financial statements and related disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_ComprehensiveLossPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Comprehensive loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_ComprehensiveLossPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_EmergingGrowthCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Emerging growth company status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_EmergingGrowthCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_NetLossPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net loss per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_NetLossPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_PreferredStockWarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_PreferredStockWarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480598/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413957654896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock', window );">Summary of Estimated Useful Lives of Property and Equipment</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated useful lives of the Company&#8217;s property and equipment are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:80.236%;"></td>
          <td style="width:1.94%;"></td>
          <td style="width:17.824%;"></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory and computer equipment</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and fixtures</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3 years</span></span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.967%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:1%;"></td>
          <td style="width:13.357%;"></td>
          <td style="width:1%;"></td>
          <td style="width:1.16%;"></td>
          <td style="width:1%;"></td>
          <td style="width:13.357%;"></td>
          <td style="width:1%;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31,</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
          <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
          <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,233,203</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,341,834</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,233,203</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
          <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,341,834</span></p></td>
          <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of estimated useful lives of property and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413952195888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Summary of Marketable Securities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table sets forth marketable securities for the year ended December 31, 2023 (in thousands). The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t hold any marketable securities during the year ended December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:36.16%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.700000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.84%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.84%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury-backed money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,622</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,633</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,622</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,633</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Fair Value of Financial Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table set forth the fair value of the Company&#8217;s financial assets measured at fair value on a recurring basis and indicates the level within the fair value hierarchy utilized to determine such values (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash Equivalents:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury-backed money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64,397</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64,397</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,980</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,980</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable Securities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,633</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,633</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106,010</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">106,010</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.184000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Treasury-backed money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,645</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,645</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,645</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,645</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Reconciliation of Warrant Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the Level 3 warrant liability through exercise in the second quarter of 2022 was as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.58%;"></td>
        <td style="width:1.88%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.54%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Series A-2 Preferred<br/>Stock Warrant Liability</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2021</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">226</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of preferred stock warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">168</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413957717792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Cost and Accumulated Depreciation of Property and Equipment</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The cost and accumulated depreciation of property and equipment were as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,821</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,424</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer and office equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,446</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">171</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Construction in process</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">69</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,129</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,336</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,724</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,572</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">389</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,764</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,335</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413957713072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_ScheduleOfAccruedLiabilitiesCurrentTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses consisted of the following (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,521</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,840</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee-related expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,368</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,440</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Taxes payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,574</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">715</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">932</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">918</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,127</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,522</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,913</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_ScheduleOfAccruedLiabilitiesCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of accrued liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_ScheduleOfAccruedLiabilitiesCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413955175248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Cost</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of lease cost under ASC 842 for the leases were as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,799</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">993</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">188</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,294</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,980</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,294</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_SupplementalDisclosureOfCashFlowInformationRelatedToLeasesTableTextBlock', window );">Supplemental Disclosure of Cash Flow Information Related to Leases</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Supplemental disclosure of cash flow information under ASC 842 for the leases was as follows (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,  2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating cash payments for operating leases</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,299</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments Under Non-cancelable Operating Leases</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future minimum lease payments under the non-cancelable operating lease consisted of the following as of December 31, 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,004</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,094</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,187</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,282</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,381</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Thereafter</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,079</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total future minimum lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,027</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,923</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Present value of lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,104</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Included in the consolidated balance sheet (in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,004</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability, net of current portion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,104</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_SupplementalDisclosureOfCashFlowInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental disclosure of cash flow information related to leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_SupplementalDisclosureOfCashFlowInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413957607440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock', window );">Schedule of Reserved Shares of Common Stock for Issuance, on an As-Converted Basis</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has reserved the following shares of common stock for issuance, as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock options issued and outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,233,203</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,341,834</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Authorized for future stock awards or option grants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,091,187</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">901,462</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Authorized for future issuance under employee stock purchase plan</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">216,306</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">226,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,540,696</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,469,296</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of common stock shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413952035712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted Average Assumptions Used to Compute Estimated Fair Value of Stock Options</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of stock options was estimated using the following weighted average assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.343%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.343%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate %</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.19</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.95</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility %</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65.13</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71.68</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.05</span></span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.08</span></span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Options Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock option activity under the 2020 Plan and 2022 Plan, are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.942%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Stock<br/>Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-Average<br/>Remaining<br/>Contractual<br/>Term<br/>(In Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(In Thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,341,834</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.52</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.7</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,877</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,421,936</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.70</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100,351</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.12</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Canceled/Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">430,216</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12.13</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,233,203</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.83</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,147</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and exercisable as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,477,013</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.87</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.9</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,427</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,233,203</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.83</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.4</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,147</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-based Compensation Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense recognized for stock option grants included in the accompanying consolidated statements of operations and comprehensive loss is as follows (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,966</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,695</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,082</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,068</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,048</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,763</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413953188864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Loss Before for Income Taxes</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s loss before income taxes for the years ended December 31, 2023 and 2022 were generated in the following jurisdictions (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.92%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.76%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.880000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Domestic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78,195</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,781</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">358</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,383</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Worldwide</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78,553</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">65,398</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Net Deferred Income Taxes</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of net deferred income taxes consisted of the following as of December 31, 2023 and 2022 (in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.92%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.76%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:7.880000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,038</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">474</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,547</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,287</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">577</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">523</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized Section 174 R&amp;D Costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,470</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,818</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,510</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,081</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,485</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,760</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible asset amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,425</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,879</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,073</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,822</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use-Asset</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,444</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,233</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed Assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,474</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,918</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,280</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,155</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,542</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,155</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,542</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The components of income tax expense were as follows for the years ended December 31, 2023 and 2022 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.748%;"></td>
        <td style="width:3.759%;"></td>
        <td style="width:1%;"></td>
        <td style="width:17.057%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.759%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.677000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current expense:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;U.S. Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,683</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,706</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred expense:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;U.S. Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">73</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,706</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Income Tax Expense to Statutory Federal Income Tax Rate to Loss From Operations</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations is summarized for the years ended December 31, 2023 and 2022, as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.892%;"></td>
        <td style="width:1.259%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.234000000000002%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.259%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.356%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax at statutory rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State tax (net of federal benefit)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Permanent differences</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development credit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">GILTI Inclusion</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.K. R&amp;D credit</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign rate differential</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.4</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax expense (benefit)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.8</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of Unrecognized Tax Benefits</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the reconciliation of the beginning and ending amount of total unrecognized tax benefits for each of the periods indicated:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.44%;"></td>
        <td style="width:3.6%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.34%;"></td>
        <td style="width:1%;"></td>
        <td style="width:3.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.82%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at beginning of the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">673</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to current year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">751</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase related to prior year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Decrease related to prior year tax positions</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Currency translation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at the end of the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">713</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">673</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413951197296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 09, 2024</div></th>
<th class="th"><div>Feb. 05, 2024</div></th>
<th class="th"><div>May 16, 2022</div></th>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 04, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,421,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued in connection with exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_ProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised', window );">Received from IPO and option exercise by underwriters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_NetProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised', window );">Net Received from IPO and option exercise by underwriters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181,482<span></span>
</td>
<td class="nump">$ 102,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,238,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued in connection with exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,238,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,351<span></span>
</td>
<td class="nump">81,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Gross proceeds from underwriters exercised option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriter's fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion of redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,359,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Preferred stock warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,529<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,546,805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pepg_AtTheMarketEquityOfferingSalesAgreementMember', window );">At-the-Market Equity Offering Sales Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds issuance or sale of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pepg_FollowOnOfferingMember', window );">Follow-on Offering | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds issuance or sale of equity</a></td>
<td class="nump">$ 76,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriter's fees</a></td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pepg_SharesSalesAgreementAndFollowOnOfferingMember', window );">Shares Sales agreement and Follow-on Offering | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds issuance or sale of equity</a></td>
<td class="nump">$ 86,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_NetProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance initial public offering and stock options exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_NetProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_ProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance initial public offering and stock options exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_ProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pepg_AtTheMarketEquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pepg_AtTheMarketEquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pepg_FollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pepg_FollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pepg_SharesSalesAgreementAndFollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pepg_SharesSalesAgreementAndFollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413952671696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Cash</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList', window );">Restricted Cash, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Assets, Noncurrent<span></span>
</td>
<td class="text">Other Assets, Noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairments of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense', window );">Unrecognized tax benefits, interest on income taxes expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense', window );">Unrecognized tax benefits, income tax penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock shares Issued | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock shares outstanding | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development tax credits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">20,104,000<span></span>
</td>
<td class="nump">24,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 23,620,000<span></span>
</td>
<td class="nump">$ 26,549,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in Accounting Principle, Accounting Standards Update, Adoption Date</a></td>
<td class="text">Jan.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member', window );">ASU 2016-13</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in Accounting Principle, Accounting Standards Update, Adoption Date</a></td>
<td class="text">Jan.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member', window );">ASU 2019-12</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in Accounting Principle, Accounting Standards Update, Adoption Date</a></td>
<td class="text">Jan.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 3.4<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-5<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-5<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-5<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-5<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-4<br><br>Reference 42: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -SubTopic 20<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-6<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 91: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 92: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes cash restricted to withdrawal or usage, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413955122016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pepg_LaboratoryAndComputerEquipmentMember', window );">Laboratory and Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pepg_LaboratoryAndComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pepg_LaboratoryAndComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413951571920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">4,233,203<span></span>
</td>
<td class="nump">3,341,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pepg_StockOptionsIssuedAndOutstandingMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">4,233,203<span></span>
</td>
<td class="nump">3,341,834<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pepg_StockOptionsIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pepg_StockOptionsIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413951153472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 04, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 24, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable Securities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,633,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrants exercised, date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  04,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 406,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pepg_SeriesA2ConvertiblePreferredStockMember', window );">Series A-2 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants purchase granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants purchase granted | shares</a></td>
<td class="nump">35,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises | $</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_ClassOfWarrantsOrRightsNumberOfSharesConvertedToCommonStock', window );">Class of warrants or rights number of shares converted into common stock | shares</a></td>
<td class="nump">34,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_ClassOfWarrantsOrRightsNumberOfSharesConvertedToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights number of shares converted to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_ClassOfWarrantsOrRightsNumberOfSharesConvertedToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pepg_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pepg_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413951850112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Marketable Securities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 29,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">29,633<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=pepg_UsTreasuryBackedMoneyMarketFundsMember', window );">U.S. Treasury-Backed Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">29,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 29,633<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-30<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-31<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionQuantitativeDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pepg_UsTreasuryBackedMoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pepg_UsTreasuryBackedMoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413952532352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Fair Value of Financial Assets Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of financial assets</a></td>
<td class="nump">$ 106,010<span></span>
</td>
<td class="nump">$ 18,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of financial assets</a></td>
<td class="nump">106,010<span></span>
</td>
<td class="nump">18,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Treasury-Backed Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash Equivalents</a></td>
<td class="nump">64,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Treasury-Backed Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash Equivalents</a></td>
<td class="nump">64,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash Equivalents</a></td>
<td class="nump">11,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable Securities</a></td>
<td class="nump">29,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Treasury notes | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash Equivalents</a></td>
<td class="nump">11,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable Securities</a></td>
<td class="nump">$ 29,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pepg_UsTreasuryBackedMoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pepg_UsTreasuryBackedMoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413952623872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Reconciliation of Warrant Liabilities (Details) - Series A-2 Preferred Stock Warrant Liability<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExerciseOfPreferredStockWarrants', window );">Exercise of preferred stock warrants</a></td>
<td class="num">$ (168)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExerciseOfPreferredStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliations recurring basis liability exercise of preferred stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExerciseOfPreferredStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=pepg_SeriesA2PreferredStockWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=pepg_SeriesA2PreferredStockWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413948330192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Summary of Cost and Accumulated Depreciation of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 6,336<span></span>
</td>
<td class="nump">$ 3,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(1,572)<span></span>
</td>
<td class="num">(389)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">4,764<span></span>
</td>
<td class="nump">3,335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">4,821<span></span>
</td>
<td class="nump">2,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pepg_ComputerAndOfficeEquipmentMember', window );">Computer and Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,446<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 1,129<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pepg_ComputerAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pepg_ComputerAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413952072592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expenses</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413952632816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_AccruedResearchAndDevelopmentExpensesCurrent', window );">Research and development expenses</a></td>
<td class="nump">$ 9,521<span></span>
</td>
<td class="nump">$ 4,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee-related expenses</a></td>
<td class="nump">2,368<span></span>
</td>
<td class="nump">2,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_AccruedProfessionalServicesCurrent', window );">Professional services</a></td>
<td class="nump">715<span></span>
</td>
<td class="nump">932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">918<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 13,522<span></span>
</td>
<td class="nump">$ 11,913<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_AccruedProfessionalServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued professional services current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_AccruedProfessionalServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413953158896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,799,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">993,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pepg_TenantImprovementMember', window );">Tenant Improvement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=pepg_HarrisonLeaseMember', window );">Harrison Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company&#8217;s obligation for the payment of base rent for the Premises began in May 2023, and is $0.2 million per month, increasing up to $0.3 million per month during the term of the Lease.  The Company has one option to extend the term of the Harrison Lease, for a period of an additional five years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Option to extend lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company has one option to extend the term of the Harrison Lease, for a period of an additional five years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Option to extend lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_LeasedSpace', window );">Leased space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_OperatingLeaseCommencementDate', window );">Lease commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 29,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_FixedLeaseRentExpense', window );">Fixed lease rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_OperatingLeaseMonthlyRentExpense', window );">Monthly rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_OperatingLeaseIncreaseInMonthlyRentExpense', window );">Increase in monthly rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_OperatingLeasePeriodOfExtension', window );">Additional period of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lease discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=pepg_HarrisonLeaseMember', window );">Harrison Lease | Leaseholds and Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost improvements</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_AggregateOperatingLeaseCost', window );">Total payments to the landlord for improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pepg_CambridgeMassachusettsMember', window );">Cambridge, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company leased office space in Cambridge, Massachusetts, the terms of which were month-to-month, with a 30-day written notice of cancellation<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate', window );">Lease, Existence of Option to Terminate [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToTerminate', window );">Lease termination term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the terms of which were month-to-month, with a 30-day written notice of cancellation<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pepg_NewtonMassachusettsMember', window );">Newton, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company terminated this lease in January 2023. The Company also leased laboratory space at the University of Massachusetts, Mount Ida Campus in Newton, Massachusetts, with an initial lease term from February 1, 2022 to January 31, 2023, which the Company extended until March 2023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_AggregateOperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate operating lease cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_AggregateOperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_FixedLeaseRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed lease rent expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_FixedLeaseRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_LeasedSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leased space</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_LeasedSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_OperatingLeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease commencement date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_OperatingLeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_OperatingLeaseIncreaseInMonthlyRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease increase in monthly rent expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_OperatingLeaseIncreaseInMonthlyRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_OperatingLeaseMonthlyRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease monthly rent expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_OperatingLeaseMonthlyRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_OperatingLeasePeriodOfExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease period of extension.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_OperatingLeasePeriodOfExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to terminate operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pepg_TenantImprovementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pepg_TenantImprovementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=pepg_HarrisonLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=pepg_HarrisonLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pepg_CambridgeMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pepg_CambridgeMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pepg_NewtonMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pepg_NewtonMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140414048684544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Components of Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Fixed lease cost</a></td>
<td class="nump">$ 3,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">$ 1,294<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 4,980<span></span>
</td>
<td class="nump">$ 1,294<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413955031008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Supplemental Disclosure of Cash Flow Information Related to Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash payments for operating leases</a></td>
<td class="nump">$ 5,299<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413954118592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 3,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">3,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">3,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">3,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">3,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">12,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">28,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(7,923)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liability</a></td>
<td class="nump">20,104<span></span>
</td>
<td class="nump">$ 24,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability</a></td>
<td class="nump">3,004<span></span>
</td>
<td class="nump">5,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="nump">$ 17,100<span></span>
</td>
<td class="nump">$ 18,981<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413950962880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details)<br> &#8364; in Millions, &#163; in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Due to related party for service rendered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,005,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,362,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=pepg_TechnologyLicenseAgreementMember', window );">Technology License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_AdditionalPaymentsOfRestatementCompletionFeeAndLicenseDataFee', window );">Additional payments of restatement completion fee and license data fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_TermOfLicenseAgreement', window );">Term of license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=pepg_TechnologyLicenseAgreementMember', window );">Technology License Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_SublicenseesThresholdAmount', window );">Sublicensees threshold amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,200,000<span></span>
</td>
<td class="nump">&#163; 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=pepg_TechnologyLicenseAgreementMember', window );">Technology License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_SublicenseesThresholdAmount', window );">Sublicensees threshold amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,500,000<span></span>
</td>
<td class="nump">&#163; 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=pepg_TechnologyLicenseAgreementMember', window );">Technology License Agreement | Oxford University Innovation Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_RentPayableToRelatedParties', window );">Rent payable to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=pepg_TechnologyLicenseAgreementMember', window );">Technology License Agreement | Oxford University Innovation Limited | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_RequiredToPayExitFeeAmount', window );">Required to pay exit fee amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=pepg_TechnologyLicenseAgreementMember', window );">Technology License Agreement | Oxford University Innovation Limited | IPO | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_PercentageOfExitFee', window );">Percentage of exit fee</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=pepg_TechnologyLicenseAgreementMember', window );">Technology License Agreement | Oxford University Innovation Limited | IPO | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_PercentageOfExitFee', window );">Percentage of exit fee</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_RequiredToPayExitFeeAmount', window );">Required to pay exit fee amount</a></td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="nump">&#8364; 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=pepg_TechnologyLicenseAgreementMember', window );">Technology License Agreement | Oxford Science Enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_RelatedPartyTransactionsOtherCostsPaid', window );">Compensation paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=pepg_ServicesAgreementMember', window );">Services Agreement [Member] | Carnot Pharma, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Related Party Transaction , Expenses from Transactions with Related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Due to related party for service rendered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=pepg_ServicesAgreementMember', window );">Services Agreement [Member] | RA Capital Management, L.P.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_RelatedPartyTransactionsOtherCostsPaid', window );">Compensation paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_AdditionalPaymentsOfRestatementCompletionFeeAndLicenseDataFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional payments of restatement completion fee and license data fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_AdditionalPaymentsOfRestatementCompletionFeeAndLicenseDataFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_AggregatePotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_AggregatePotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_PercentageOfExitFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of exit fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_PercentageOfExitFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_RelatedPartyTransactionsOtherCostsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party transactions, other costs paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_RelatedPartyTransactionsOtherCostsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_RentPayableToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rent payable to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_RentPayableToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_RequiredToPayExitFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Required to pay exit fee amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_RequiredToPayExitFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_SublicenseesThresholdAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublicensees threshold amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_SublicenseesThresholdAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_TermOfLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_TermOfLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=pepg_TechnologyLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=pepg_TechnologyLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pepg_OxfordUniversityInnovationLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pepg_OxfordUniversityInnovationLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pepg_OxfordScienceEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pepg_OxfordScienceEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=pepg_ServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=pepg_ServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pepg_CarnotPharmaLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pepg_CarnotPharmaLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pepg_RaCapitalManagementLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pepg_RaCapitalManagementLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413951285408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 29, 2022</div></th>
<th class="th">
<div>Nov. 24, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($) </div>
<div>Stockholder </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split, description</a></td>
<td class="text">1.018 for 1 reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Number of shares agreed to issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,823,241<span></span>
</td>
<td class="nump">23,713,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td>
<td class="nump">0.982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividend | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_NumberOfCommonStockVote', window );">Number of common stock vote | Vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pepg_SeriesA2ConvertiblePreferredStockMember', window );">Series A-2 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pepg_UndesignatedPreferredStockMember', window );">Undesignated Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pepg_StockPurchaseAgreementMember', window );">Stock Purchase Agreement | Series A-2 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Number of shares agreed to issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,939,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pepg_StockPurchaseAgreementMember', window );">Stock Purchase Agreement | Class A and Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,348,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pepg_StockPurchaseAgreementMember', window );">Stock Purchase Agreement | Series A-1 Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,372,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pepg_StockPurchaseAgreementMember', window );">Stock Purchase Agreement | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,033,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pepg_SeriesBStockPurchaseAgreementMember', window );">Series B Stock Purchase Agreement | Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Number of shares agreed to issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,234,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds from issuance of convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pepg_StockRestrictionAgreementsMember', window );">Stock Restriction Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_NumberOfSharesRestrictedAndSubjectToRepurchase', window );">Number of shares became restricted and subject to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_NumberOfFoundingStockholdersEntered', window );">Number of founding stockholders entered | Stockholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_PercentageOfRepurchaseRightsLapseOnOneYearAnniversary', window );">Percentage of repurchase rights lapse on one-year anniversary.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_PercentageOfRepurchaseRightsLapseOnSecondAnniversary', window );">Percentage of repurchase rights lapse on second anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Measurement date fair value of shares vested per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Measurement date aggregate fair value of shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_SharesOfRestrictedStockSubjectToRepurchase', window );">Shares subject to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_NumberOfCommonStockVote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock vote.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_NumberOfCommonStockVote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_NumberOfFoundingStockholdersEntered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of founding stockholders entered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_NumberOfFoundingStockholdersEntered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_NumberOfSharesRestrictedAndSubjectToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares restricted and subject to repurchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_NumberOfSharesRestrictedAndSubjectToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_PercentageOfRepurchaseRightsLapseOnOneYearAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of repurchase rights lapse on one-year anniversary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_PercentageOfRepurchaseRightsLapseOnOneYearAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_PercentageOfRepurchaseRightsLapseOnSecondAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of repurchase rights lapse on second anniversary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_PercentageOfRepurchaseRightsLapseOnSecondAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_SharesOfRestrictedStockSubjectToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Of restricted stock subject to repurchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_SharesOfRestrictedStockSubjectToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pepg_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pepg_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pepg_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pepg_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pepg_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pepg_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pepg_ClassAAndClassBCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pepg_ClassAAndClassBCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pepg_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pepg_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pepg_SeriesBStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pepg_SeriesBStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pepg_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pepg_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pepg_StockRestrictionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pepg_StockRestrictionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413951806768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Issuance, on an As-Converted Basis (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="nump">5,540,696<span></span>
</td>
<td class="nump">4,469,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pepg_StockOptionsIssuedAndOutstandingMember', window );">Stock Options Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="nump">4,233,203<span></span>
</td>
<td class="nump">3,341,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pepg_AuthorizedForFutureStockAwardsOrOptionGrantsMember', window );">Authorized for Future Stock Awards or Option Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="nump">1,091,187<span></span>
</td>
<td class="nump">901,462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pepg_AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlanMember', window );">Authorized for Future Issuance under Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="nump">216,306<span></span>
</td>
<td class="nump">226,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pepg_StockOptionsIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pepg_StockOptionsIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pepg_AuthorizedForFutureStockAwardsOrOptionGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pepg_AuthorizedForFutureStockAwardsOrOptionGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pepg_AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pepg_AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413952639776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding vested and unvested stock options</a></td>
<td class="nump">4,233,203<span></span>
</td>
<td class="nump">3,341,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense related to unvested stock options</a></td>
<td class="nump">$ 20.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected recognition period of unrecognized compensation cost related to unvested share options</a></td>
<td class="text">2 years 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option Activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of stock options exercised</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of stock options granted</a></td>
<td class="nump">$ 8.56<span></span>
</td>
<td class="nump">$ 7.66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pepg_TwoThousandTwentyTwoEquityIncentiveAwardPlanMember', window );">2022 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares remaining available for grant</a></td>
<td class="nump">1,091,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_CommonStockOutstandingPercentage', window );">Common stock outstanding percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pepg_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember', window );">2022 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized and reserved for issuance</a></td>
<td class="nump">216,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_CommonStockOutstandingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock outstanding percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_CommonStockOutstandingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pepg_TwoThousandTwentyTwoEquityIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pepg_TwoThousandTwentyTwoEquityIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pepg_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pepg_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413948227888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Weighted Average Assumptions Used to Compute Estimated Fair Value of Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate %</a></td>
<td class="nump">4.19%<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility %</a></td>
<td class="nump">65.13%<span></span>
</td>
<td class="nump">71.68%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 18 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413952639296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Options Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options Outstanding as of December 31, 2022</a></td>
<td class="nump">3,341,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock Options, Granted</a></td>
<td class="nump">1,421,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock Options, Exercised</a></td>
<td class="num">(100,351)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock Options, Canceled/Forfeited</a></td>
<td class="num">(430,216)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Outstanding as of December 31, 2023</a></td>
<td class="nump">4,233,203<span></span>
</td>
<td class="nump">3,341,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock Options, Vested and exercisable as of December 31, 2023</a></td>
<td class="nump">1,477,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Stock Options, Vested and expected to vest as of December 31, 2023</a></td>
<td class="nump">4,233,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding as of December 31, 2022</a></td>
<td class="nump">$ 9.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">13.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise price, Exercised</a></td>
<td class="nump">2.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise price, Canceled/Forfeited</a></td>
<td class="nump">12.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding as of December31, 2023</a></td>
<td class="nump">10.83<span></span>
</td>
<td class="nump">$ 9.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and exercisable as of December 31, 2023</a></td>
<td class="nump">8.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and expected to vest as of December 31, 2023</a></td>
<td class="nump">$ 10.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted Average Remaining Life</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable , Weighted Average Remaining Life</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, Weighted Average Remaining Life</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 2,147<span></span>
</td>
<td class="nump">$ 12,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested and exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">1,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 2,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413951902080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 7,048<span></span>
</td>
<td class="nump">$ 4,763<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">2,966<span></span>
</td>
<td class="nump">1,695<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,082<span></span>
</td>
<td class="nump">$ 3,068<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413951594736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Loss Before for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (78,195)<span></span>
</td>
<td class="num">$ (96,781)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(358)<span></span>
</td>
<td class="nump">31,383<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income tax</a></td>
<td class="num">$ (78,553)<span></span>
</td>
<td class="num">$ (65,398)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413951183472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Net Deferred Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 8,038<span></span>
</td>
<td class="nump">$ 474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">4,547<span></span>
</td>
<td class="nump">1,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">577<span></span>
</td>
<td class="nump">523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts', window );">Capitalized Section 174 R&amp;D Costs</a></td>
<td class="nump">29,470<span></span>
</td>
<td class="nump">11,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">2,510<span></span>
</td>
<td class="nump">1,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_DeferredTaxAssetsRightOfUseLiability', window );">Right-of-use liability</a></td>
<td class="nump">5,485<span></span>
</td>
<td class="nump">5,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_DeferredTaxAssetsIntangibleAssetAmortization', window );">Intangible asset amortization</a></td>
<td class="nump">7,425<span></span>
</td>
<td class="nump">6,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other, net</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets</a></td>
<td class="nump">58,073<span></span>
</td>
<td class="nump">27,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right-of-use-Asset</a></td>
<td class="num">(6,444)<span></span>
</td>
<td class="num">(6,233)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed Assets</a></td>
<td class="num">(1,474)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(7,918)<span></span>
</td>
<td class="num">(6,280)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">50,155<span></span>
</td>
<td class="nump">21,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (50,155)<span></span>
</td>
<td class="num">$ (21,542)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_DeferredTaxAssetsIntangibleAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets intangible asset amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_DeferredTaxAssetsIntangibleAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_DeferredTaxAssetsRightOfUseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets right of use liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_DeferredTaxAssetsRightOfUseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax liabilities right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413952075024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Income Tax Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,683<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current expense</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">3,706<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 3,706<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413951615552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Income Tax Expense to Statutory Federal Income Tax Rate to Loss from Operations (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax (net of federal benefit)</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credit</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent', window );">GILTI Inclusion</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(8.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_EffectiveIncomeTaxRateReconciliationUkRDCredit', window );">U.K. R&amp;D credit</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(23.90%)<span></span>
</td>
<td class="num">(23.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax expense (benefit)</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(5.80%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation, permanent differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_EffectiveIncomeTaxRateReconciliationUkRDCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation, UK R&amp;D credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_EffectiveIncomeTaxRateReconciliationUkRDCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413948357088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,000<span></span>
</td>
<td class="nump">$ 3,706,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_ExpectedMarketReturn', window );">Expected market return</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,547,000<span></span>
</td>
<td class="nump">1,287,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_ChangesInOwnershipByStockholdersHoldingPercentage', window );">Changes in ownership by stockholders holding percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Accrual for interest or penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Interest or penalties were recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_ResearchAndDevelopmentCreditsExpirationYear', window );">Research and development credits expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS) | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pepg_OperatingLossCarryForwardsExpirationYear', window );">Operating loss carry forwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS) | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=pepg_UkTaxAuthoritiesMember', window );">UK tax authorities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_ChangesInOwnershipByStockholdersHoldingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in ownership by stockholders holding percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_ChangesInOwnershipByStockholdersHoldingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_ExpectedMarketReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected market return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_ExpectedMarketReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_OperatingLossCarryForwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carry forwards, expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_OperatingLossCarryForwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pepg_ResearchAndDevelopmentCreditsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development credits expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pepg_ResearchAndDevelopmentCreditsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pepg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=pepg_UkTaxAuthoritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=pepg_UkTaxAuthoritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140413948327120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of the period</a></td>
<td class="nump">$ 673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase related to current year tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation', window );">Currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation', window );">Currency translation</a></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at the end of the period</a></td>
<td class="nump">$ 713<span></span>
</td>
<td class="nump">$ 673<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140414048688432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - Subsequent Event - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Feb. 09, 2024</div></th>
<th class="th"><div>Feb. 05, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pepg_SharesSalesAgreementMember', window );">Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds issuance or sale of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pepg_FollowOnOfferingMember', window );">Follow-on Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds issuance or sale of equity</a></td>
<td class="nump">$ 76.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriter's fees</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pepg_SharesSalesAgreementAndFollowOnOfferingMember', window );">Shares Sales agreement and Follow-on Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds issuance or sale of equity</a></td>
<td class="nump">$ 86.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pepg_SharesSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pepg_SharesSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pepg_FollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pepg_FollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pepg_SharesSalesAgreementAndFollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pepg_SharesSalesAgreementAndFollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>103
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M+_5\%B797[3+M^U?M9"?)H+%^V(X@CBD^7_\M@=Q5##L5A2X^P+W/P5.KZ+
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M@L79RPW! >%R _A^Q9@XO)$[*)Z;NOT_4$L#!!0    ( .R"9EC^IFQ9<04
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MG/?U<PY@!P?*'G@.(-!C651\;N1"U!>FR=,<2LPGM(9*SFPI*[&07;8S><T
M9UI4%J9C63.SQ*0RPD"/K5D8T$84I((U0[PI2\S^7D)!#W/#-IX&[L@N%VK
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M,)?& /Y_$4+O'LP'FJ9Z\A-02P,$%     @ [()F6!:31AP" P  _@<  !@
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6RM56UOVC 0_BNGK)HV:6T@0&@[
MB-0"52NU!36T^S#M@TD.XC6QF>U MU^_<T(SV@8T3?L2O^3NN><YVW>]M52/
M.D$T\)2E0O>=Q)CEJ>OJ*,&,Z2.Y1$%_YE)ES-!2+5R]5,CBPBE+7:_1\-V,
M<>$$O6)OHH*>S$W*!4X4Z#S+F/IYCJE<]YVF\[QQQQ>)L1MNT%NR!89H[I<3
M12NW0HEYAD)S*4#AO.^<-4\'76M?&#QP7.NM.5@E,RD?[>(J[CL-2PA3C(Q%
M8#2L<(!I:H&(QH\-IE.%M([;\V?TBT([:9DQC0.9?N&Q2?K.L0,QSEF>FCNY
MOL2-GH[%BV2JBR^L2]LN18QR;62V<:9UQD4YLJ=-'K8<FOX.!V_CX+UV:.]P
M:&T<6H70DEDA:\@,"WI*KD%9:T*SDR(WA3>IX<*>8F@4_>7D9X+!^#8<7U\-
MSZ:C(813&FY&M],0QA<P&-],[D:7H]OPZF$$U^,PA$.X#X?PX> C'  7,$UD
MKIF(=<\UQ,4BNM$F[GD9U]L1M^G!C10FT3 2,<8O 5P242GQGI6<>WL1AQ@=
M0:OY";R&UZHA-/A[=V\/G5:5V%:!U]J!%QIFD*Z[ 3F'@<SHC27V\J\0KD0D
M,X2O9S-M%-WC;W7I*]';]>CV;9_J)8NP[Q"P1K5")WC_KNDW/M=)_T]@+Q+1
MKA+1WH<>W%(I2J6NO2.E9[?PM/5F%1QVCWW/[[FK;?HU9OY)L]&NS%X0ZU3$
M.GN)#?(L3YFM(D#'(+2=V\(2?Z=G5YP<4UQSL8 X5W8P"<(2%9=QG98R6&>+
MY#;#4LA;F\.3XWH5?J7"WZOB7E#Q3ODOC&%!11M( 97C1S1LEB)HC(B[X5B;
M?O\MY>8KQGN#_^/-Z5;2NOL/Z,6KV76'NG5WJ/-&2(V9?T)O_57VW:U2FJ%:
M%!U&0R1S8<I:5.U63>RLJ-VO]L^IN96]Z ],V1EOF%IPH2'%.4$VCKIT *KL
M-N7"R&51L&?24/DOI@DU:%36@/[/I33/"QN@:OG!;U!+ P04    " #L@F98
M8R-)6I,)  #;6   &    'AL+W=O<FMS:&5E=',O<VAE970V+GAM;+V<;7/;
MN!6%_PI&W>DF,W$D@A1?4MLSML2W:39V;6<[_<A(L,6&(K4D92?]]24I6A1
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MN^PE8.T%36O>(DN*YE_RTI:=C,AB6Y39N@VN:K".T]UK]*UMB(, 33\20-L
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M]X]95KY^J)_<NG^>\>5_ 5!+ P04    " #L@F98@(YN2&,"  #D!   &
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M%+@.4/<;QN3>T GZQ9S^!E!+ P04    " #L@F989#JB:T,"  "*!@  &0
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M.RSUSP*$"=#/<\[5<6(V&'X_R1M02P,$%     @ [()F6+#44Z24"P  IQT
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M'&$\XBMPCDY?6WHITB6N4K:G6<>X0J0+56./*"+3#J+VB]WP/99D!-^C(";
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M$&PE']>D,?'P KQ?6I3]](4/Z'^;/?\O4$L#!!0    ( .R"9E@S6"VHBR,
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MEH!HDA]3=U4NYR>NB:"A)<1$ND_+35Z3(1+,$YZ<V$_ZWN4DJ8N\ BME$B0
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M=2<2\$=_34/O5D-M<W[\^HQCMV?8S1C:PGXP&JQO_&?GQ]^#@I[L#K44U>$
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M970Q,RYX;6RE6%USV[@5??>OP&C=K3,CZX.2'=NQ/2,[V=8S2>N)-[L/G3Y
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M5.,]4?U+^[<,]?G):?@V<EXX^J'>W&2]AOKK\-F?G-=PNN3FC;/T6YN=*_I
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M(-&3*5TPBZI>^Z;4P-(ZJ1 ^#8)+OV!<>K-);5OJV4155G )2TU,511,/R]
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M$A+J"\$>3%EQO6%">V%%QJ3VAG&FC3Y+N4ZA*OA2"0;%;KF7>L44:F-\986
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M\[DV2=E?4'>\^U!^WOHTX4TC:2;G9MNUI>,&>N5]""O@^.KU ,,N$DY8^V3
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M.5W[RZ7@J$^T ._G&M-"O"$%NZ^]U_\!4$L#!!0    ( .R"9EA<R.@KV D
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MUX7SNB[XXNN&YZ<J3AAM_K7MI]'%.$@XB<9CJO1^6-L7\N1U%U6+TH2KI#
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MX*U,/<F_90^VWOV2[?JL<=K/LU),J @>QHD0]IIJ/>AJDQ\C=#&DZNI&D0"
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M@(^<_G)&> \1:0OX$W05XM71/=45,R;>009_F@:N"!"1K\ 4 2ZS@%O'<LP
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MS $#E3[/'9M;8!&9(\C^YI-IR03N2/9<TMO@3IG]"JY 7:K9J)Q'8#,&B3<
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M#X#2.-!^(H0^&"9!^T\)_P!02P,$%     @ [()F6.5Z!@_! @  U04  !D
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M>LL,:2,:"=Y5OQO)"45)>70&5P7N<_-;0)<L^_3$EQ+LZ31T"$I+85H#7%8
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M'P TWH'.UUJ[_<(G&#\I\S]02P,$%     @ [()F6)T<+#:<!   ^ H  !D
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MA]34=#-G-1NKEFZVF2I+DY);+F@T1<T"]'^FE-UNV,!NV!W_ U!+ P04
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M767<B?[2,EY7;L-MVTVIJLOVEYOQB]KK>05!AEJK=1[U[@8W _*!95"^^:Z
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M0;=+&^A/TP8YZ/[L.VQZR-FB@H8/4)H#I;E0F@>E^2B:*KPN?*"7"A\H-'R
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MUEMUZ.XT3?O!31X@:A+G; .MU#]^=A(20H/;;)[Z"\3&S\?V]_';$S/>$OK
M5@ </29QRB;&BO/LPC19L(($LQ[)(!6_+ A-,!=)NC191@&'N5$2FXYE#<T$
M1ZDQ'>=Y=W0Z)FL>1RG<4<3628+ITQ7$9#LQ;&.7\25:KKC,,*?C#"]A#OQK
M=D=%RJPH891 RB*2(@J+B7%I7_B.)0WR$M\BV+*]9R2[<D_(@TS<A!/#DBV"
M& (N$5A\;6 &<2Q)HAT_2JA1U2D-]Y]W].N\\Z(S]YC!C,3?HY"O)L;(0"$L
M\#KF7\CV-R@[-)"\@,0L_T3;LJQEH&#-.$E*8]&")$J+;_Q8"K%GX(R.&#BE
M@7-@X+I'#-S2P'VK0;\TZ!\:.$<,!J5!WG6SZ'LNG(<YGHXIV2(J2PN:?,C5
MSZV%7E$J!\J<4_%K).SX]!I'%'W#\1K0+6"VIB!& 6?H$[H,PTCZ$L?H)BU&
MI/3L!P\XCF+V<6QR4;^DF$%9UZRHRSE2E^V@6Y+R%4-^&D+8!)BBX57KG5WK
MKQPE\18_(:M_BAS+<=#7N8<^G'Q$;(4IL+;FJ6$>!#WDVCG-K6@GR#Q.]-Y.
M=-Y&]-7$SV330T[18VN/U IL2.I6 \+-:W!?'1"GZ K'. T S?,EZU=*UEF4
M+D_1=92*_$B,C#G'/!\Q:(8S.3X8^NMW040W(IO]W=+!JZ+Z?GOU<EV\8!D.
M8&*(A8\!W8 Q_?DG>VC]TN91G3!/)\S7!&OXL%_YL*^BBVE!'\0LO8^%ZR!8
M4S&/Q1!Y1B=M_E"BNOJC@)WE,+E';:;.^=!U+<L:FYM]K5\6/"CA:VI70\!!
M)>! *>"=V*V 4@B16("#!Y1ABC;Y(OFLGKY72FY7-0O8:%^DGI#2/M#R;<5\
M34UK"#JL!!TJ!?V.*<5R7^% DS;=E.9===,)\W3"?+5*MH6> %/5,GY6"7[V
M-L'A$6@0,0A/42C6ZC;ME:2NVJN;)3?L?,?.M\0VN74VQM<$:WA@5'E@],H:
M0@* D*$%)0G:%OZHW'%T.59"NSI#)\P;O5BR^];PQ<KN:ZJSH?EYI?FY4G,O
MVD0AI"'Z,X(X;)-7:=]57ITP3R?,UP1K.,&VZIC">M\S9%F_)C=JI7E::;XN
M6M.3>]&AK9Q0_F,F(GIQ#@IW,^OIV,Q2DSK[1"?-TTKS2]J@]?#:%-JIA7:4
M0L^!RC/ZY2<'S4BZ <HC>7RO#Z)S>1!MU5T)[JR[3IJGE>;KHC5=5 ?&]CM'
MQK;6T%@KS=-*\W71FIZLPV-;'1]_7B?W0!%9[(YE#&5K&JPP [24:3'?GA5!
MGAK?V5$Z:9Y6FE_2]I<Z=S!PSH\L=W5\;?]? ;8:W%E[G31/*\TO:>=[VMMV
MK^\<T;X.Q6UUE'ES]T>KL%I#<*TT3RO-UT5KZE]'YO;9.^\C6@-ZK31/*\W7
M16MZLH[P;76(_Y_WD=$KJVOI :UAO%::KXO6]$ =[]OJ@/]?OF0IJ<UW&=:+
M=QDS=>V=E=<:XNNB-2_>ZAC?44:>TUF,&6L,?4(1E=>R#*75O"AOIX(BI!'3
M(4HY$<DD(6FY]:LF2-F&Q@3IGQ^^V9ZIF]K535IIOBY:X29S[Z8W ;K,K]BE
MONN4%]>F56YUC7^97UX?Y,_L"Z^XC*\QQ7\#;C%=1F*7B6$AD%;O3*A/B^OV
M(L%)EM\GWQ/.29(_K@"'0&4!\?N"$+Y+R JJ/SU,_P%02P,$%     @ [()F
M6'9QF].U @  &P@  !D   !X;"]W;W)K<VAE971S+W-H965T,S<N>&ULO59=
M3]LP%/TK5QF:0(+FJY^LC42IV)"&QBBPAVD/;GK;6'7BS'9:V*^?[82LT](R
M@;:7QG9\[CDG/K8[W'"QD@FB@H>497+D)$KEIZXKXP13(EL\QTR_67"1$J6[
M8NG*7""96U#*W,#SNFY*:.9$0SMV+:(A+Q2C&5X+D$6:$O$X1L8W(\=WG@9N
MZ#)19L"-ACE9XA3577XM=,^MJ\QIBIFD/ .!BY%SYI^.?<\ [(Q[BANYU09C
M9<;YRG0NYR/',XJ08:Q,":(?:SQ'QDPEK>-[5=2I.0UPN_U4_<*:UV9F1.(Y
M9U_H7"4CI^_ '!>D8.J&;SY@9:ACZL6<2?L+FVJNYT!<2,73"JP5I#0KG^2A
M^A!;@"#8 0@J0&!UET16Y80H$@T%WX PLW4UT[!6+5J+HYE9E:D2^BW5.!5=
M$"K@GK "X0J)+ 3J3ZXDG,"T7"?@"[@B8H6*S!C"%.-"4$51PN%$CU$FC^
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MF:#?+SA73QUSH=3_!Z*?4$L#!!0    ( .R"9EA%KC'4"P0    8   9
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M?IC9QH_*;;#K*RG-=N((VK^2^ ]02P,$%     @ [()F6,K6 PE= P  N X
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M;O^!^!R"4^+0$V);MM.2/OOW=+N9;J*$E8YVI:.=XSE_T?&$+"*6J#T!?G[
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M"!.@QU><J^>.N73:?XSH#U!+ P04    " #L@F985X+=/)P'  !E,0  &0
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M>>\FE,6Z1-+*B5/1[Q0MA$]%_\A*G)'^T"[]+U&Z8"1>R1OR!G&.HO668]'
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MD4N=Y7OZ\Q-!-WJ7^X(*05-]N,8HQDPUD+\O*16'$W6!XW]6S/\%4$L#!!0
M   ( .R"9EAO;3<$L0(  -D'   9    >&PO=V]R:W-H965T<R]S:&5E=#0T
M+GAM;*V576^;,!2&_XK%JJF3UO*50-(1I"99M4FK5#5M=S'MPH&38-78S':2
M[M_/-H2E24JG:C=@FW->O\\!?)(-%X^R %#HJ:1,CIQ"J>K"=6560(GE.:^
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MNC$_/?N. /9%R/V57H>L0R4B<B<2L2P;Z,7(R?2D-?=0/Q1*8U :A])\*"U
MT4Q%-7ZH=W:LU0CT858HC4%I'$KSH;0 13/ET[BMGMUM/>R:%_H\+)3&H#3N
M[3O)[=>\4"/V\UZK[/9WMH",9;8L=_?,R:SPQ:L-\K9'MSN(7I7[9KX[?NV>
M3]R6X]P]#ZK]01M\M5WIG<B6H5Z&1G*ANW).3G59S*H=0*LW*EV7&U ^IDJE
M<?ER)85>MQ0-].>+-%5O;XH.MONPCO\/4$L#!!0    ( .R"9EC7OHZLU@D
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MS/$"!M($X/.U$'H_,2U^=Z5+_@502P,$%     @ [()F6 "?ME;)!   =!0
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M%/AE*61.-4[ERE6E!)I:4,[=P/,B-Z>L<.*A79O)>"@JS5D!,TE4E>=4[B;
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M8?P3E6N&LU<!&4)BO\'&(IOYMEEH4=4CXDIH'#CKRQR_"4 : [R?":'W"W-
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M:%,>73,S/S H[03S?2&$WG;L O4O4?P/4$L#!!0    ( .R"9EBQJ)1\"P,
M ,\,   9    >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;+67;6_:,!#'OXJ5
M5=LJK>0!"-!!I):N6J5UJXJZO9CVPB07L.K8J6V@_?:SDY"%+HV@2GD1[,3W
M]_TN9_LRWG!Q+Y< "CTFE,F)M50J/;5M&2XAP;+#4V#Z2<Q%@I7NBH4M4P$X
MRHP2:GN.X]L))LP*QMF]&Q&,^4I1PN!&(+E*$BR>SH'RS<1RK>V-6[)8*G/#
M#L8I7L ,U%UZ(W3/+E4BD@"3A#,D()Y89^[IU,T,LA$_"6QDI8T,RISS>].Y
MBB:68SP""J$R$EC_K6$*E!HE[<=#(6J5<QK#:GNK?IG!:Y@YEC#E]!>)U')B
M#2T408Q75-WRS5<H@/I&+^149E>T*<8Z%@I74O&D,-8>)(3E__BQ"$3%P.V]
M8. 5!MZ^!MW"H)N!YIYE6!=8X6 L^ 8),UJKF486F\Q:TQ!F7N-,"?V4:#L5
MS%9S"0\K8 I]6>NK1"?H+(J(B3&FZ(KEF6(B_O$"%"94'NLAS\WTK;O9!?IX
M=(R.$&'HFE"J;>385MI),Y4=%@Z=YPYY+SAT"?,.<D:?D.=XO1KSZ3[F_3IS
M6X>FC(]7QL?+]'HOQ0=3D.AL(0!T\JHZGD8!LPQ/98I#F%AZG4D0:[""]^]<
MW_E<1]>2V YKMV3M9NK=/7,!_?ZF1Z K!8G\4T?>;9.\);$=\EY)WFM\R]_U
M?ID*'@)$$A$I5YB%@+C>[O3K1SQ&.BQ$/=7%H%'XT!CD8GXF9C;@=3#JC,;V
MN@:M7Z+U&]$N.=5;]8E>OS_B& 1ABSJ*1HU#*5H2V\'U2UR_W1SVVR1O26R'
M?%"2#]XJAP?_I=W [XR<RL\MDS ';73EE:##$G38"'K'(A ;012(#Q+% +6G
M3*[A5J&Z'>\91N-$K\08E1BCYI-EB;4HR@\8O#U@$&81VF_--LH?FKDMB>U$
MPG7^%2%.NZNVT&L)OBVU7?I*">:^U<HME*M9/O0[PV=IWCS_H7QVI=HTI?XU
M%@O")*(0:WFG,]#[O\BKY[RC>)H5H'.N=#F;-9?ZBP.$&:"?QYRK;<?4M.4W
M3/ 74$L#!!0    ( .R"9EC+XRYMA@,  *D8   -    >&PO<W1Y;&5S+GAM
M;-U9T4[;,!3]E2B,":2)- VDS6@K;960)FT3$CSL#;F-TUIRG,QU6<OC?F6O
M^XI]RKYDOG&:A.+;%1X&62H:^Q[?<X^OKY-:#!9JS>G5G%+EK%(N%D-WKE3^
MUO,6TSE-R>(DRZG02)+)E"C=E3-OD4M*X@4XI=SK=CJAEQ(FW-% +-.+5"V<
M:;84:NCZ?F5SS.U#K*WAJ>L8OG$6TZ%[<_3ZZS)3YZ\<<S]X<W#0.>G<')]O
M(T<E=.QZ5N*S/8A16HPTW$NMOG8(UA=&W]N/?A<Y1MVW4__Z@2:Z@OZ6Z>@^
M=3'Z4!,9OT/$K=?91Q&N!Z/U+6IT7FI!T,&<NW9-O[__1$35R&Y5@5U5IZD*
M=3ZU.C=<"T>OW'&C09*)>N,%KC%H9I)2YY;PH3LFG$TD Z^$I(ROC;D+AFG&
M,^DHO>-U*!\LBSL#^Z8'#X.2)V4BDT5L$\%\3\KA6\"F!P(9YY7 KFL,HT%.
ME*)27.A.,;@P/H"<LGV]SK7"F21KOWOFU@[%30>99#*FLGX N1O3:,!I G(D
MF\WAKK+< U"I+-6-F)%9)DBA8>-1-C3ME')^!4_*+\D][E726+.BMD75U(+*
MIJ$Q'>!OLAGN)FW_2;Q.SFXS]7ZIIR.*/M0GO90T8:NBOTHJ 1B[C[.3/.?K
M=YS-1$K-Y/<..!J0C9\SSR2[T]&@5*;:0*7KW%*IV+1I^29)?DU7:E-.JP37
MW&VAYG^;YQD55!+>%*UK_R5G^<F*@]YS22Z>*MN"K1K+7S\O7>19&T2&;1#9
MBIKLMT%DU *1O6=[:CY&I-\&D=TVB S:(+(%;YS@96YNK_QUWC@"W#L 5%8'
M#EI#]S,<V7@=U)DL&5=,E+TYBV,J'IP#-+TB$T[O\^OQ,4W(DJOK"ARZ=?L3
MC=DRC:I1EY"(<E3=_@C3\\/JE*=C,1'3%8W'95?.)D73T0T=M;S 81NY*"X[
M@OD8S(X AL7!%& ^Q@N+\S_-IX_.QV"8MKX5Z:,^?=3'>-F0<?'!XMA](GW9
M9QI%01"&6$;'8ZN",9:W,(0_.QNF#3RP.!#I<;G&5QNOD-UU@*WIK@K!9HI7
M(C93/-> V/,&'E%D7VTL#GA@JX#5#L2WQX&:LOL$ :PJI@W;P3@211@"M6BO
MT3!$LA/"Q[X^V"X)@BBR(X#9%00!AL!NQ!%, 6C D" HWH-;[R-O\Y[RZG].
MC/X 4$L#!!0    ( .R"9EB7BKL<P    !,"   +    7W)E;',O+G)E;'.=
MDKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<
M'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X9
M9K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.5
M6QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,
M<6*T_C6"R0_L?@!02P,$%     @ [()F6 7E6:39!   '2@   \   !X;"]W
M;W)K8F]O:RYX;6S%FEMOXC@4@/^*Q=.LM+- +LQ,-8Q$6[I%:@$5U->5FYC6
M:F(S=M++_/HY#F7WA+9'^W*:)XB3.%^.'7_'3KX_6G=_8^V]>"H+X\>]NZK:
M'O7[/KM3I?1_V:TRL&=C72DKV'2W?;]U2N;^3JFJ+/K18##JEU*;WH_O^[J6
MKH\W;*6R2EL#A:'@6JM'_]_^L"D>M-<WNM#5\[C7_"]43Y3:Z%+_4OFX-^@)
M?V<?SZW3OZRI9+'*G"V*<6^XVW&M7*6S5\6K +F6-[XIJ>3-E020<6\T@ HW
MVOFJ.:*I7P+C@X*#=UMU9<]T42EW*BOUM[/U5IO;4 W<11_=1A.'_>\NB$?N
M_X31;C8Z4Z<VJTMEJET<G2H"H/%W>NM[PLA2C7O[0X0TN9B:"H(D9F97%1P;
M[A0N/<MW=UT!+HJA.]*PP\WR!IP/\F0Q7RTN9J>3]?14'$\N)O.3J5B=3Z?K
M%0*,","H,T#Q:3E!D#$!&7\@Y&H-/Y?3.0 NSL1B.;U"D D!F70&>;*X7"+(
ME(!,.X2<7R/($0$YZA#RGPA!?B$@OW0'.5F=(\BO!.177LBE?!8/7BR5:TXW
MF1*GVF>%];53"/$;@?B-%W%FO,Z5$VLG<U")F#@GS:T*9WD\A@^H07S RSB7
M%<1+V(TXKKTVROM&.L?2:P^E&)-T#;-L5G592O<<.%?ZUF@X38(?)UEF:_ C
MQJ2,,V16SIG43ES+HE;B4LG0$U\U-N6:(;-L(#';0MKTO,LK?M9Z&T[X4\Q5
MA1$ITPR950,MZFH%=$]0B5>MT%%R&3+;Y0*:LTU#663(K)&K4 A16LK0FC"^
M&"^;A+M%2"EDR.T06Y:Z:GI_T]M.((>',5"93+?#2"EDR.P0@'H(TPBXJE@Z
MM5'.05!7E<WN S3&I#0R9/9( _09AF05XEB&!^-P'A!1#HF8'3(SF2V56,NG
M5M-&E# B=F'<>/6S#I.HZ</!&!R1DQ)F19 F:V6 $:6*B%D5-&:,,2E=1,RZ
M>$>XXA/,ZHMV;Z3L$3';@Q!O0,68E%8B9JT<RG<?QC\P(&65B-DJ.PN_B45Y
M).K2(^UGFO)(U)%'7N*)%T0HG<0?J).WFCJFO!(S>X6<+[6:.J8L$W=JF01C
MDHM?G5HFQ9B496)FR]"8(XQ)629FMLQ[,OPL)GFN\10OIBP3,UOF?<PFSAB3
M<DW,[!H2L_VD4^Z)F=U#8^)$+:;<$S.[A\J  !6O<U/N29C=0V/B=P8)9:&$
MV4*O$C4((52;UT6C)HQ)62AAMM!+NO8R_L!>6;SS'BNA+)0P6^A?3#3.A_S(
MFN9)PICD2QAF"[V%N:JWVZ)YXO&XF5 62CYDI>R@1Y[53=ITJ5N-3EDHZ6P)
MK>FO&).R4,*^CD9-+?#PGE 62CJ= >%\,Z$LE'0U ]H-4?A%)F6AE-E"!&9X
MJ# F9:&4>XV-P(0A"F-2%DJYYT(49BN12RD+I<P6:DU[VZ/GA?5X*2NE+)0R
M6^@ $WD20.>MODE^#,!L(2*: 1EC4A9*F2UT@'FE,FLR7>A=![48D[)0RFRA
M \S#= YC4A9*F2U$1K/]I%,62KDM=/ANHAU2_*4*9:%18Z'^_G.T7&VT4?D<
M+N&A/)-%MG0B_.Q>BR=I>(FUJ8OB!,H6YL+*?/]UV_[+O!^_ 5!+ P04
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M+\NOG7B_:"\X)_AWY_$O4$L#!!0    ( .R"9EATTL9BW@$  %HC   3
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M[ U02P$"% ,4    " #L@F98!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .R"9E@9Z QV[@   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( .R"9EB97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ [()F6)ILX -;"   0S4  !@
M         ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( .R"9EC^IFQ9<04  "\6   8              " @9X0  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #L@F984K5V&H0"  "*!P
M&               @(%%%@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ [()F6"^R@_0W!   8 \  !@              ("!_Q@  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( .R"9E@6DT8< @,
M /X'   8              " @6P=  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    " #L@F988R-)6I,)  #;6   &               @(&D
M(   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ [()F6(".
M;DAC @  Y 0  !@              ("!;2H  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( .R"9EA!0RJOW@<  ,@C   8
M  " @08M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #L
M@F98](9.!4P"  "D!0  &               @($:-0  >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ [()F6&0ZHFM# @  B@8  !D
M         ("!G#<  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    " #L@F98L-13I)0+  "G'0  &0              @($6.@  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( .R"9E@S6"VHBR,  #1T
M   9              " @>%%  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ [()F6"$?6SB0"   1A<  !D              ("!HVD
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #L@F98XJ^]
M_?4"  #!!@  &0              @(%J<@  >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( .R"9EBR CNTL@(  -0%   9
M  " @99U  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
M[()F6/W$@@;&!P  Z!,  !D              ("!?W@  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    " #L@F98V )71Y,(  !/%P  &0
M            @(%\@   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( .R"9EA,L,W.MP0  # +   9              " @4:)  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ [()F6! 'Y4,E"
M^14  !D              ("!-(X  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    " #L@F987,CH*]@)  !>&@  &0              @(&0
ME@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( .R"9EA#
M+$@V @L   <>   9              " @9^@  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ [()F6+V'#,6Q @  A 8  !D
M     ("!V*L  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .R"9ECE>@8/P0(  -4%   9              "
M@4_?  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ [()F
M6+CU\:GZ P  ]0D  !D              ("!1^(  'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    " #L@F9812Y=/?\"  !>!@  &0
M        @(%XY@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( .R"9EB='"PVG 0  /@*   9              " @:[I  !X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ [()F6#[V8A^1!@  YQ$
M !D              ("!@>X  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    " #L@F98?#.XV D)  !-7@  &0              @(%)]0
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( .R"9EC>,RYU
M50<  -<Y   9              " @8G^  !X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ [()F6,UE[BES @  3 <  !D
M ("!%08! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #L
M@F98G:H0K?@"  "A"0  &0              @(&_" $ >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( .R"9EA(JIF$)04    A   9
M          " @>X+ 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#
M%     @ [()F6'9QF].U @  &P@  !D              ("!2A$! 'AL+W=O
M<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " #L@F981:XQU L$
M&   &0              @($V% $ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM
M;%!+ 0(4 Q0    ( .R"9E@G94_=P0(  %8&   9              " @7@8
M 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ [()F6,K6
M PE= P  N X  !D              ("!<!L! 'AL+W=O<FMS:&5E=',O<VAE
M970T,"YX;6Q02P$"% ,4    " #L@F984E[]^FP"  #-!0  &0
M    @($$'P$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (
M .R"9EA<>(#?WP(  &\(   9              " @:<A 0!X;"]W;W)K<VAE
M971S+W-H965T-#(N>&UL4$L! A0#%     @ [()F6%>"W3R<!P  93$  !D
M             ("!O20! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"
M% ,4    " #L@F98;VTW!+$"  #9!P  &0              @(&0+ $ >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( .R"9E@\(*1B5P(
M /8$   9              " @7@O 0!X;"]W;W)K<VAE971S+W-H965T-#4N
M>&UL4$L! A0#%     @ [()F6#\KN,5R P  J@P  !D              ("!
M!C(! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " #L@F98
MTVBQMUP(  "350  &0              @(&O-0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0W+GAM;%!+ 0(4 Q0    ( .R"9EC7OHZLU@D  &9F   9
M      " @4(^ 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%
M  @ [()F6-5^QS]N P  W@T  !D              ("!3T@! 'AL+W=O<FMS
M:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " #L@F98 )^V5LD$  !T%
M&0              @('T2P$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+
M 0(4 Q0    ( .R"9EBI2' N_@(  %<(   9              " @?10 0!X
M;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ [()F6+3NP;7=
M!   _A<  !D              ("!*50! 'AL+W=O<FMS:&5E=',O<VAE970U
M,BYX;6Q02P$"% ,4    " #L@F98W]\.URL#  #&"P  &0
M@($]60$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( .R"
M9EB+?9FSK@(   ('   9              " @9]< 0!X;"]W;W)K<VAE971S
M+W-H965T-30N>&UL4$L! A0#%     @ [()F6"^#U9(8!   ; \  !D
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M=#4Y+GAM;%!+ 0(4 Q0    ( .R"9EBQJ)1\"P,  ,\,   9
M  " @2MS 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @
M[()F6,OC+FV& P  J1@   T              ( !;78! 'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    " #L@F98EXJ[',     3 @  "P              @ $>
M>@$ 7W)E;',O+G)E;'-02P$"% ,4    " #L@F98!>59I-D$   =*   #P
M            @ $'>P$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ [()F
M6)@;6I[[ 0  RR,  !H              ( !#8 ! 'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ [()F6'32QF+> 0  6B,  !,
M         ( !0((! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $0 1 "3
)$@  3X0!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>138</ContextCount>
  <ElementCount>358</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100050 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100060 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100080 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (PARENTHETICAL)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (PARENTHETICAL)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100090 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Nature of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation1</Role>
      <ShortName>Nature of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurements1</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet1</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies1</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Convertible Preferred Stock and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquity1</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensation1</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurements1</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet1</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpenses</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pepgen.com/20231231/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityTables</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquity1</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensation1</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Nature of Business and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Summary of Significant Accounting Policies - Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerS</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Fair Value Measurements - Summary of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfMarketableSecuritiesDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Fair Value Measurements - Summary of Fair Value of Financial Assets Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Fair Value of Financial Assets Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Fair Value Measurements - Summary of Reconciliation of Warrant Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfWarrantLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Reconciliation of Warrant Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Property and Equipment, Net - Summary of Cost and Accumulated Depreciation of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfCostAndAccumulatedDepreciationOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment, Net - Summary of Cost and Accumulated Depreciation of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Leases - Summary of Components of Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails</Role>
      <ShortName>Leases - Summary of Components of Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Leases - Summary of Supplemental Disclosure of Cash Flow Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalDisclosureOfCashFlowInformationRelatedToLeasesDetails</Role>
      <ShortName>Leases - Summary of Supplemental Disclosure of Cash Flow Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Leases - Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails</Role>
      <ShortName>Leases - Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Issuance, on an As-Converted Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceOnAnAsconvertedBasisDetails</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Issuance, on an As-Converted Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Stock-Based Compensation - Schedule of Weighted Average Assumptions Used to Compute Estimated Fair Value of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfWeightedAverageAssumptionsUsedToComputeEstimatedFairValueOfStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Weighted Average Assumptions Used to Compute Estimated Fair Value of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Stock-Based Compensation - Summary of Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Income Taxes - Schedule of Loss Before for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Loss Before for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Income Taxes - Components of Net Deferred Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Components of Net Deferred Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense to Statutory Federal Income Tax Rate to Loss from Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Income Tax Expense to Statutory Federal Income Tax Rate to Loss from Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="pepg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pepgen.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="pepg-20231231.htm">pepg-20231231.htm</File>
    <File>pepg-20231231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img224999359_0.jpg</File>
    <File>img224999359_1.jpg</File>
    <File>img224999359_10.jpg</File>
    <File>img224999359_11.jpg</File>
    <File>img224999359_12.jpg</File>
    <File>img224999359_13.jpg</File>
    <File>img224999359_14.jpg</File>
    <File>img224999359_15.jpg</File>
    <File>img224999359_16.jpg</File>
    <File>img224999359_17.jpg</File>
    <File>img224999359_18.jpg</File>
    <File>img224999359_19.jpg</File>
    <File>img224999359_2.jpg</File>
    <File>img224999359_20.jpg</File>
    <File>img224999359_21.jpg</File>
    <File>img224999359_22.jpg</File>
    <File>img224999359_23.jpg</File>
    <File>img224999359_24.jpg</File>
    <File>img224999359_25.jpg</File>
    <File>img224999359_26.jpg</File>
    <File>img224999359_27.jpg</File>
    <File>img224999359_28.jpg</File>
    <File>img224999359_29.jpg</File>
    <File>img224999359_3.jpg</File>
    <File>img224999359_30.jpg</File>
    <File>img224999359_31.jpg</File>
    <File>img224999359_4.jpg</File>
    <File>img224999359_5.jpg</File>
    <File>img224999359_6.jpg</File>
    <File>img224999359_7.jpg</File>
    <File>img224999359_8.jpg</File>
    <File>img224999359_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="517">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>110
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "pepg-20231231.htm": {
   "nsprefix": "pepg",
   "nsuri": "http://pepgen.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "pepg-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "pepg-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"
     ]
    }
   },
   "keyStandard": 302,
   "keyCustom": 56,
   "axisStandard": 23,
   "axisCustom": 0,
   "memberStandard": 29,
   "memberCustom": 32,
   "hidden": {
    "total": 8,
    "http://fasb.org/us-gaap/2023": 5,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 138,
   "entityCount": 1,
   "segmentCount": 62,
   "elementCount": 631,
   "unitCount": 10,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 517,
    "http://xbrl.sec.gov/dei/2023": 39,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1",
     "longName": "100010 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_032b677e-9240-4c97-8fd4-3e95b8fe0a15",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_032b677e-9240-4c97-8fd4-3e95b8fe0a15",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100030 - Statement - CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_032b677e-9240-4c97-8fd4-3e95b8fe0a15",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_032b677e-9240-4c97-8fd4-3e95b8fe0a15",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
     "longName": "100050 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss",
     "longName": "100060 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1",
     "longName": "100070 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
     "shortName": "CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_f58e97f2-94c9-4dc7-ac7d-e3f44208d56a",
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f58e97f2-94c9-4dc7-ac7d-e3f44208d56a",
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "longName": "100080 - Statement - CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (PARENTHETICAL)",
     "shortName": "CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (PARENTHETICAL)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_9444a584-901b-44fb-95ce-d2000dc58dd6",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3",
     "longName": "100090 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_6aa00088-cf17-4c43-988e-abab7676b8a0",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6aa00088-cf17-4c43-988e-abab7676b8a0",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation1",
     "longName": "995455 - Disclosure - Nature of Business and Basis of Presentation",
     "shortName": "Nature of Business and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995465 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurements1",
     "longName": "995475 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet1",
     "longName": "995485 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpenses",
     "longName": "995495 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "pepg:AccruedLiabilitiesCurrentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "pepg:AccruedLiabilitiesCurrentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureLeases",
     "longName": "995505 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "pepg:LeasesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "pepg:LeasesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions",
     "longName": "995515 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies1",
     "longName": "995525 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquity1",
     "longName": "995535 - Disclosure - Convertible Preferred Stock and Stockholders' Equity",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensation1",
     "longName": "995545 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxes",
     "longName": "995555 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureSubsequentEvents",
     "longName": "995565 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995575 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "995585 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "pepg:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "pepg:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "longName": "995595 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables",
     "longName": "995605 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpensesTables",
     "longName": "995615 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "pepg:ScheduleOfAccruedLiabilitiesCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "pepg:AccruedLiabilitiesCurrentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "pepg:ScheduleOfAccruedLiabilitiesCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "pepg:AccruedLiabilitiesCurrentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesTables",
     "longName": "995625 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "pepg:LeasesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "pepg:LeasesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityTables",
     "longName": "995635 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Tables)",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "pepg:ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "pepg:ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables",
     "longName": "995645 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables",
     "longName": "995655 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
     "longName": "995665 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Details)",
     "shortName": "Nature of Business and Basis of Presentation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "pepg:ProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995675 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
     "longName": "995685 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_220d4a87-56e9-4b2f-88b9-0f2f98c86ac0",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pepg:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_220d4a87-56e9-4b2f-88b9-0f2f98c86ac0",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pepg:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerS",
     "longName": "995695 - Disclosure - Summary of Significant Accounting Policies - Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss per Share (Details)",
     "shortName": "Summary of Significant Accounting Policies - Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "pepg:NetLossPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "pepg:NetLossPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "longName": "995705 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_032b677e-9240-4c97-8fd4-3e95b8fe0a15",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ae4f1a1a-7f76-43a6-b05d-f7cb7ac0bb50",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfMarketableSecuritiesDetails",
     "longName": "995715 - Disclosure - Fair Value Measurements - Summary of Marketable Securities (Details)",
     "shortName": "Fair Value Measurements - Summary of Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_032b677e-9240-4c97-8fd4-3e95b8fe0a15",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_032b677e-9240-4c97-8fd4-3e95b8fe0a15",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "995725 - Disclosure - Fair Value Measurements - Summary of Fair Value of Financial Assets Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Summary of Fair Value of Financial Assets Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_fe73f47a-1a8a-4c3f-bc3a-56c5282d62d9",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fe73f47a-1a8a-4c3f-bc3a-56c5282d62d9",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfWarrantLiabilitiesDetails",
     "longName": "995735 - Disclosure - Fair Value Measurements - Summary of Reconciliation of Warrant Liabilities (Details)",
     "shortName": "Fair Value Measurements - Summary of Reconciliation of Warrant Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_09aa4d44-be62-4c19-89e9-09be49174654",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_09aa4d44-be62-4c19-89e9-09be49174654",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfCostAndAccumulatedDepreciationOfPropertyAndEquipmentDetails",
     "longName": "995745 - Disclosure - Property and Equipment, Net - Summary of Cost and Accumulated Depreciation of Property and Equipment (Details)",
     "shortName": "Property and Equipment, Net - Summary of Cost and Accumulated Depreciation of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_032b677e-9240-4c97-8fd4-3e95b8fe0a15",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_032b677e-9240-4c97-8fd4-3e95b8fe0a15",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "longName": "995755 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails",
     "longName": "995765 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_032b677e-9240-4c97-8fd4-3e95b8fe0a15",
      "name": "pepg:AccruedResearchAndDevelopmentExpensesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pepg:ScheduleOfAccruedLiabilitiesCurrentTableTextBlock",
       "div",
       "pepg:AccruedLiabilitiesCurrentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_032b677e-9240-4c97-8fd4-3e95b8fe0a15",
      "name": "pepg:AccruedResearchAndDevelopmentExpensesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pepg:ScheduleOfAccruedLiabilitiesCurrentTableTextBlock",
       "div",
       "pepg:AccruedLiabilitiesCurrentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
     "longName": "995775 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "pepg:LeasesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_098c1eb1-fac5-4644-b049-d1ecd9083a38",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "pepg:LeasesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails",
     "longName": "995785 - Disclosure - Leases - Summary of Components of Lease Cost (Details)",
     "shortName": "Leases - Summary of Components of Lease Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "pepg:LeasesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:ShortTermLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "pepg:LeasesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalDisclosureOfCashFlowInformationRelatedToLeasesDetails",
     "longName": "995795 - Disclosure - Leases - Summary of Supplemental Disclosure of Cash Flow Information Related to Leases (Details)",
     "shortName": "Leases - Summary of Supplemental Disclosure of Cash Flow Information Related to Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pepg:SupplementalDisclosureOfCashFlowInformationRelatedToLeasesTableTextBlock",
       "div",
       "pepg:LeasesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pepg:SupplementalDisclosureOfCashFlowInformationRelatedToLeasesTableTextBlock",
       "div",
       "pepg:LeasesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails",
     "longName": "995805 - Disclosure - Leases - Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases (Details)",
     "shortName": "Leases - Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_032b677e-9240-4c97-8fd4-3e95b8fe0a15",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "pepg:LeasesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_032b677e-9240-4c97-8fd4-3e95b8fe0a15",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "pepg:LeasesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "longName": "995815 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_032b677e-9240-4c97-8fd4-3e95b8fe0a15",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9b497aad-3cba-4deb-9dd2-e0a9d56f3614",
      "name": "pepg:AdditionalPaymentsOfRestatementCompletionFeeAndLicenseDataFee",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
     "longName": "995825 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Additional Information (Details)",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_5ce499b8-803d-4c0a-b7dc-bd9d43f1ccdf",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5ce499b8-803d-4c0a-b7dc-bd9d43f1ccdf",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceOnAnAsconvertedBasisDetails",
     "longName": "995835 - Disclosure - Convertible Preferred Stock and Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Issuance, on an As-Converted Basis (Details)",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity - Schedule of Reserved Shares of Common Stock for Issuance, on an As-Converted Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_032b677e-9240-4c97-8fd4-3e95b8fe0a15",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pepg:ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_032b677e-9240-4c97-8fd4-3e95b8fe0a15",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pepg:ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
     "longName": "995845 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_032b677e-9240-4c97-8fd4-3e95b8fe0a15",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_032b677e-9240-4c97-8fd4-3e95b8fe0a15",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfWeightedAverageAssumptionsUsedToComputeEstimatedFairValueOfStockOptionsDetails",
     "longName": "995855 - Disclosure - Stock-Based Compensation - Schedule of Weighted Average Assumptions Used to Compute Estimated Fair Value of Stock Options (Details)",
     "shortName": "Stock-Based Compensation - Schedule of Weighted Average Assumptions Used to Compute Estimated Fair Value of Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails",
     "longName": "995865 - Disclosure - Stock-Based Compensation - Summary of Stock Options Activity (Details)",
     "shortName": "Stock-Based Compensation - Summary of Stock Options Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_77094e71-f93f-47be-9749-eda2c5ae4461",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails",
     "longName": "995875 - Disclosure - Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation - Summary of Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeForIncomeTaxesDetails",
     "longName": "995885 - Disclosure - Income Taxes - Schedule of Loss Before for Income Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Loss Before for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails",
     "longName": "995895 - Disclosure - Income Taxes - Components of Net Deferred Income Taxes (Details)",
     "shortName": "Income Taxes - Components of Net Deferred Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_032b677e-9240-4c97-8fd4-3e95b8fe0a15",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_032b677e-9240-4c97-8fd4-3e95b8fe0a15",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails",
     "longName": "995905 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Details)",
     "shortName": "Income Taxes - Schedule of Components of Income Tax Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails",
     "longName": "995915 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense to Statutory Federal Income Tax Rate to Loss from Operations (Details)",
     "shortName": "Income Taxes - Reconciliation of Income Tax Expense to Statutory Federal Income Tax Rate to Loss from Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "995925 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_369017c2-22f5-42b3-85de-349e0de7ffa4",
      "name": "pepg:ExpectedMarketReturn",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails",
     "longName": "995935 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_77094e71-f93f-47be-9749-eda2c5ae4461",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6c95e5db-bd37-4cf6-b968-bd6049101b26",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://pepgen.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "longName": "995945 - Disclosure - Subsequent Events - Additional Information (Details)",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_e1609515-c590-4eef-875c-348138380b4c",
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e1609515-c590-4eef-875c-348138380b4c",
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pepg-20231231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate201602Member",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASU 2016-02",
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842)."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_AccountingStandardsUpdate201613Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate201613Member",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASU 2016-13",
        "label": "Accounting Standards Update 2016-13 [Member]",
        "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_AccountingStandardsUpdate201912Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingStandardsUpdate201912Member",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASU 2019-12",
        "label": "Accounting Standards Update 2019-12 [Member]",
        "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r404",
      "r405"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Due to related party for service rendered",
        "totalLabel": "Accounts Payable, Current, Total",
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r734"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accrued expenses",
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pepg_AccruedLiabilitiesCurrentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "AccruedLiabilitiesCurrentDisclosureTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses",
        "label": "Accrued liabilities Current Disclosure [Text Block]",
        "documentation": "Accrued liabilities current disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_AccruedProfessionalServicesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "AccruedProfessionalServicesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional services",
        "label": "Accrued Professional Services Current",
        "documentation": "Accrued professional services current."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_AccruedResearchAndDevelopmentExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Accrued Research And Development Expenses Current",
        "documentation": "Accrued research and development expenses current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfCostAndAccumulatedDepreciationOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfCostAndAccumulatedDepreciationOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r150",
      "r574"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated other comprehensive (loss) income",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r85",
      "r156",
      "r570",
      "r590",
      "r594"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13",
      "r32",
      "r429",
      "r432",
      "r502",
      "r585",
      "r586",
      "r845",
      "r846",
      "r847",
      "r855",
      "r856",
      "r857"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r372",
      "r373",
      "r609",
      "r855",
      "r856",
      "r857",
      "r908",
      "r932"
     ]
    },
    "pepg_AdditionalPaymentsOfRestatementCompletionFeeAndLicenseDataFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "AdditionalPaymentsOfRestatementCompletionFeeAndLicenseDataFee",
     "crdr": "credit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional payments of restatement completion fee and license data fee",
        "label": "Additional Payments of Restatement Completion Fee and License Data Fee",
        "documentation": "Additional payments of restatement completion fee and license data fee."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r183",
      "r184",
      "r185",
      "r186",
      "r196",
      "r227",
      "r228",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r284",
      "r371",
      "r372",
      "r373",
      "r402",
      "r403",
      "r404",
      "r405",
      "r415",
      "r416",
      "r417",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r458",
      "r459",
      "r465",
      "r466",
      "r467",
      "r468",
      "r477",
      "r478",
      "r480",
      "r481",
      "r482",
      "r483",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r544",
      "r545",
      "r546",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r334"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pepg_AggregateOperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "AggregateOperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total payments to the landlord for improvements",
        "label": "Aggregate Operating Lease cost",
        "documentation": "Aggregate operating lease cost."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_AggregatePotentialMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "AggregatePotentialMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate potential milestone payments",
        "label": "Aggregate Potential Milestone Payments",
        "documentation": "Aggregate potential milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r757",
      "r769",
      "r779",
      "r805"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r760",
      "r772",
      "r782",
      "r808"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r773",
      "r783",
      "r800",
      "r809",
      "r813",
      "r821"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r379"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_AmortizationAndInterestAccretionRelatedToOperatingLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "AmortizationAndInterestAccretionRelatedToOperatingLeases",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization and interest accretion related to operating lease",
        "label": "Amortization and Interest Accretion Related to Operating Leases",
        "documentation": "Amortization and interest accretion related to operating leases."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_AmortizationOfPremiumAndDiscountsOnMarketableSecuritiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "AmortizationOfPremiumAndDiscountsOnMarketableSecuritiesNet",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of premium and discounts on marketable securities, net",
        "label": "Amortization Of Premium And Discounts On Marketable Securities Net",
        "documentation": "Amortization of premium and discounts on marketable securities, net."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "terseLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r152",
      "r175",
      "r210",
      "r221",
      "r223",
      "r260",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r419",
      "r421",
      "r460",
      "r565",
      "r645",
      "r734",
      "r746",
      "r870",
      "r871",
      "r918"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "terseLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r157",
      "r175",
      "r260",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r419",
      "r421",
      "r460",
      "r734",
      "r870",
      "r871",
      "r918"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Fair value of financial assets",
        "terseLabel": "Fair value of financial assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "pepg_AtTheMarketEquityOfferingSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "AtTheMarketEquityOfferingSalesAgreementMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-the-Market Equity Offering Sales Agreement",
        "label": "At the Market Equity Offering Sales Agreement [Member]",
        "documentation": "At the market equity offering sales agreement."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_AtTheMarketIssuanceSalesAgreementAndFollowOnOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "AtTheMarketIssuanceSalesAgreementAndFollowOnOfferingMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-the-Market Equity Offering Sales Agreement and Follow-on Offering",
        "label": "At The Market Issuance Sales Agreement And Follow on Offering [Member]",
        "documentation": "At the market isssuance sales agreement and follow on offering."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_AtTheMarketIssuanceSalesAgreementAndSecondaryOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "AtTheMarketIssuanceSalesAgreementAndSecondaryOfferingMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-the-Market Equity Offering Sales Agreement and Secondary Offering",
        "label": "At The Market Issuance Sales Agreement And Secondary Offering [Member]",
        "documentation": "At the market issuance sales agreement and secondary offering."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r752",
      "r765"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r752",
      "r765"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r752",
      "r765"
     ]
    },
    "pepg_AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceOnAnAsconvertedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Authorized for Future Issuance under Employee Stock Purchase Plan",
        "label": "Authorized for Future Issuance under Employee Stock Purchase Plan [Member]",
        "documentation": "Authorized for future issuance under employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_AuthorizedForFutureStockAwardsOrOptionGrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "AuthorizedForFutureStockAwardsOrOptionGrantsMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceOnAnAsconvertedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Authorized for Future Stock Awards or Option Grants",
        "label": "Authorized for future stock awards or option grants [Member]",
        "documentation": "Authorized for future stock awards or option grants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r279",
      "r564"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Total",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r279",
      "r559",
      "r860"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceOnAnAsconvertedBasisDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63"
     ]
    },
    "pepg_CambridgeMassachusettsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "CambridgeMassachusettsMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cambridge Massachusetts.",
        "label": "Cambridge Massachusetts [Member]",
        "terseLabel": "Cambridge, Massachusetts"
       }
      }
     },
     "auth_ref": []
    },
    "pepg_CarnotPharmaLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "CarnotPharmaLlcMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carnot Pharma, LLC",
        "label": "Carnot Pharma, LLC [Member]",
        "documentation": "Carnot Pharma, LLC."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "terseLabel": "Cash and cash equivalents",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r148",
      "r714"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r118"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and marketable securities",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedPeriodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r94",
      "r172"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r94"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental noncash investing and financing activities",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r140",
      "r141",
      "r182",
      "r227",
      "r228",
      "r262",
      "r263",
      "r264",
      "r270",
      "r271",
      "r284",
      "r402",
      "r415",
      "r416",
      "r423",
      "r424",
      "r425",
      "r437",
      "r438",
      "r448",
      "r458",
      "r459",
      "r464",
      "r465",
      "r466",
      "r477",
      "r480",
      "r481",
      "r482",
      "r498",
      "r544",
      "r545",
      "r583",
      "r584"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r140",
      "r141",
      "r227",
      "r228",
      "r262",
      "r263",
      "r264",
      "r270",
      "r271",
      "r272",
      "r284",
      "r402",
      "r415",
      "r416",
      "r417",
      "r423",
      "r424",
      "r425",
      "r426",
      "r437",
      "r438",
      "r439",
      "r442",
      "r448",
      "r458",
      "r459",
      "r464",
      "r465",
      "r466",
      "r477",
      "r480",
      "r481",
      "r482",
      "r498",
      "r544",
      "r545",
      "r583",
      "r584",
      "r830"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r183",
      "r195",
      "r267",
      "r406"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "pepg_ChangesInOwnershipByStockholdersHoldingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "ChangesInOwnershipByStockholdersHoldingPercentage",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in ownership by stockholders holding percentage.",
        "label": "Changes In Ownership By Stockholders Holding Percentage",
        "terseLabel": "Changes in ownership by stockholders holding percentage"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "pepg_ClassAAndClassBCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "ClassAAndClassBCommonStockMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class A and Class B Common Stock",
        "label": "Class A and Class B Common Stock [Member]",
        "documentation": "Class A and Class B common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r153",
      "r154",
      "r155",
      "r175",
      "r199",
      "r200",
      "r202",
      "r204",
      "r208",
      "r209",
      "r260",
      "r292",
      "r294",
      "r295",
      "r296",
      "r299",
      "r300",
      "r305",
      "r306",
      "r309",
      "r312",
      "r320",
      "r460",
      "r600",
      "r601",
      "r602",
      "r603",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r633",
      "r654",
      "r676",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r829",
      "r852",
      "r858"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceOnAnAsconvertedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r208",
      "r305",
      "r306",
      "r307",
      "r309",
      "r312",
      "r318",
      "r320",
      "r600",
      "r601",
      "r602",
      "r603",
      "r723",
      "r829",
      "r852"
     ]
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercised, date",
        "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable",
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock warrants exercised",
        "terseLabel": "Number of warrants purchase granted",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "pepg_ClassOfWarrantsOrRightsNumberOfSharesConvertedToCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "ClassOfWarrantsOrRightsNumberOfSharesConvertedToCommonStock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrants or rights number of shares converted into common stock",
        "label": "Class of Warrants or Rights Number of Shares Converted to Common Stock",
        "documentation": "Class of warrants or rights number of shares converted to common stock.",
        "verboseLabel": "Series A-2 convertible preferred stock warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r286",
      "r287",
      "r700",
      "r869"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Commitment and Contingencies",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r701"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class A Common Stock",
        "label": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceOnAnAsconvertedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reserved shares of common stock for issuance",
        "terseLabel": "Initially common stock reserved for future issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common Stock",
        "terseLabel": "Common stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r736",
      "r737",
      "r738",
      "r740",
      "r741",
      "r742",
      "r743",
      "r855",
      "r856",
      "r908",
      "r931",
      "r932"
     ]
    },
    "pepg_CommonStockOutstandingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "CommonStockOutstandingPercentage",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock outstanding percentage",
        "label": "Common Stock Outstanding Percentage",
        "terseLabel": "Common stock outstanding percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r633"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r79",
      "r633",
      "r651",
      "r932",
      "r933"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.0001 par value; 500,000,000 shares authorized as of December 31, 2023 and 2022, respectively; 23,823,241 and 23,713,196 shares issued and outstanding as of December 31, 2023 and 2022, respectively",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r568",
      "r734"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r162",
      "r164",
      "r169",
      "r560",
      "r579"
     ]
    },
    "pepg_ComprehensiveLossPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "ComprehensiveLossPolicyTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Comprehensive loss.",
        "label": "Comprehensive Loss [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "auth_ref": []
    },
    "pepg_ComputerAndOfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "ComputerAndOfficeEquipmentMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfCostAndAccumulatedDepreciationOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer and Office Equipment",
        "label": "Computer And Office Equipment Member",
        "documentation": "Computer and office equipment member."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r128"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfCostAndAccumulatedDepreciationOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in Process",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued upon conversion of redeemable convertible preferred stock",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r50",
      "r78",
      "r105",
      "r315"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r833",
      "r854"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current expense",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r401",
      "r409",
      "r854"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current expense:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r833",
      "r854",
      "r906"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossTable",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss [Table]",
        "documentation": "Disclosure of information about allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Offering Costs",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Deferred tax liabilities",
        "negatedTotalLabel": "Deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r120",
      "r395"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred offering costs",
        "label": "Deferred Offering Costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "pepg_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets capitalized research and development costs.",
        "label": "Deferred Tax Assets Capitalized Research And Development Costs",
        "terseLabel": "Capitalized Section 174 R&amp;D Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Research and development tax credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r905"
     ]
    },
    "pepg_DeferredTaxAssetsIntangibleAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "DeferredTaxAssetsIntangibleAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Intangible Asset Amortization",
        "terseLabel": "Intangible asset amortization",
        "documentation": "Deferred tax assets intangible asset amortization."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Net deferred tax assets",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r905"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, net",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r905"
     ]
    },
    "pepg_DeferredTaxAssetsRightOfUseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "DeferredTaxAssetsRightOfUseLiability",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets right of use liability.",
        "label": "Deferred Tax Assets Right Of Use Liability",
        "terseLabel": "Right-of-use liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r905"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r905"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r905"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Other",
        "terseLabel": "Other, net",
        "negatedLabel": "Other, net",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r905"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "terseLabel": "Fixed Assets",
        "negatedLabel": "Fixed Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r905"
     ]
    },
    "pepg_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax liabilities right of use asset.",
        "label": "Deferred Tax Liabilities Right Of Use Asset",
        "terseLabel": "Right-of-use-Asset",
        "negatedLabel": "Right-of-use-Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Total",
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r43"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "terseLabel": "Depreciation expenses",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r212"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensation1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r336",
      "r367",
      "r368",
      "r370",
      "r729"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCommonStockCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsCommonStockCash",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash dividend",
        "label": "Dividends, Common Stock, Cash",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r751",
      "r752",
      "r765"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r751",
      "r752",
      "r765",
      "r801"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "terseLabel": "Net loss per share, basic",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r197",
      "r199",
      "r202",
      "r203",
      "r204",
      "r206",
      "r446",
      "r447",
      "r561",
      "r580",
      "r715"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "terseLabel": "Net loss per share, diluted",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r199",
      "r202",
      "r203",
      "r204",
      "r206",
      "r446",
      "r447",
      "r561",
      "r580",
      "r715"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "terseLabel": "Effect of exchange rate changes on cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Income tax expense (benefit)",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Tax at statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r387",
      "r411"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r900",
      "r907"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign rate differential",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r900",
      "r907"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationGiltiPercent",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, GILTI, Percent",
        "negatedLabel": "GILTI Inclusion",
        "terseLabel": "GILTI Inclusion",
        "documentation": "Percentage of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI)."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "terseLabel": "Other",
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_EffectiveIncomeTaxRateReconciliationPermanentDifferences": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferences",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation, permanent differences.",
        "label": "Effective Income Tax Rate Reconciliation, Permanent Differences",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State tax (net of federal benefit)",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r900",
      "r907"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research and development credit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r900",
      "r907"
     ]
    },
    "pepg_EffectiveIncomeTaxRateReconciliationUkRDCredit": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationUkRDCredit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseToStatutoryFederalIncomeTaxRateToLossFromOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.K. R&amp;D credit",
        "documentation": "Effective income tax rate reconciliation, UK R&amp;D credit.",
        "label": "Effective Income Tax Rate Reconciliation, UK R&amp;D credit"
       }
      }
     },
     "auth_ref": []
    },
    "pepg_EmergingGrowthCompanyStatusPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "EmergingGrowthCompanyStatusPolicyTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging growth company status.",
        "label": "Emerging Growth Company Status [Policy Text Block]",
        "terseLabel": "Emerging Growth Company Status"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "terseLabel": "Employee-related expenses",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense related to unvested stock options",
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected recognition period of unrecognized compensation cost related to unvested share options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Stock Option Activity",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CIK",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfCostAndAccumulatedDepreciationOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab Equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r142",
      "r166",
      "r167",
      "r168",
      "r178",
      "r179",
      "r180",
      "r184",
      "r192",
      "r194",
      "r207",
      "r266",
      "r273",
      "r322",
      "r371",
      "r372",
      "r373",
      "r404",
      "r405",
      "r427",
      "r429",
      "r430",
      "r431",
      "r432",
      "r434",
      "r445",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r502",
      "r585",
      "r586",
      "r587",
      "r609",
      "r676"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r757",
      "r769",
      "r779",
      "r805"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r766",
      "r776",
      "r802"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "pepg_ExpectedMarketReturn": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "ExpectedMarketReturn",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected market return",
        "label": "Expected Market Return",
        "documentation": "Expected market return."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant liability activity",
        "terseLabel": "Change in fair value of preferred stock warrant liability",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r451",
      "r456"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r451",
      "r456"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Fair Value of Financial Assets Measured at Fair Value on Recurring Basis",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r117"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r67",
      "r68"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r451",
      "r515",
      "r516",
      "r517",
      "r721",
      "r722",
      "r725",
      "r726",
      "r727"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r451",
      "r453",
      "r454",
      "r457"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurements1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r324",
      "r329",
      "r451",
      "r515",
      "r725",
      "r726",
      "r727"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r324",
      "r329",
      "r451",
      "r516",
      "r721",
      "r722",
      "r725",
      "r726",
      "r727"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r451",
      "r517",
      "r721",
      "r722",
      "r725",
      "r726",
      "r727"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r66"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Reconciliation of Warrant Liabilities",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r66"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "pepg_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExerciseOfPreferredStockWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExerciseOfPreferredStockWarrants",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of preferred stock warrants",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Exercise of Preferred Stock Warrants",
        "documentation": "Fair value measurement with unobservable inputs reconciliations recurring basis liability exercise of preferred stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r515",
      "r516",
      "r517",
      "r721",
      "r722",
      "r725",
      "r726",
      "r727"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r457"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r19"
     ]
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOptionQuantitativeDisclosuresLineItems",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Option, Quantitative Disclosures [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r462",
      "r463"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfMarketableSecuritiesDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r281",
      "r282",
      "r303",
      "r318",
      "r435",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r578",
      "r720",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r862",
      "r863",
      "r864",
      "r865"
     ]
    },
    "pepg_FixedLeaseRentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "FixedLeaseRentExpense",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed lease rent expense.",
        "label": "Fixed Lease Rent Expense",
        "terseLabel": "Fixed lease rent expense"
       }
      }
     },
     "auth_ref": []
    },
    "pepg_FollowOnOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "FollowOnOfferingMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Follow-on Offering",
        "label": "Follow-on Offering [Member]",
        "documentation": "Follow-on offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Remeasurement",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r773",
      "r783",
      "r809"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r773",
      "r783",
      "r809"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r773",
      "r783",
      "r809"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r773",
      "r783",
      "r809"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r773",
      "r783",
      "r809"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "GB",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "United Kingdom",
        "verboseLabel": "Oxford, United Kingdom"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal of fixed assets",
        "label": "Gain (Loss) on Disposition of Assets",
        "totalLabel": "Gain (Loss) on Disposition of Assets, Total",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "General and Administrative Expense, Total",
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r656"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "pepg_HarrisonLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "HarrisonLeaseMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Harrison lease.",
        "label": "Harrison Lease [Member]",
        "terseLabel": "Harrison Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r752",
      "r765"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Impairments of long-lived assets",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r100"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r410"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeForIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeForIncomeTaxesDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss before income tax",
        "terseLabel": "Net loss before income tax",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r86",
      "r122",
      "r210",
      "r220",
      "r222",
      "r224",
      "r562",
      "r576",
      "r717"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfLossBeforeForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r410"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r285",
      "r661"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r661"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r382",
      "r388",
      "r393",
      "r399",
      "r407",
      "r412",
      "r413",
      "r414",
      "r605"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "totalLabel": "Accrual for interest or penalties",
        "terseLabel": "Accrual for interest or penalties",
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "totalLabel": "Interest or penalties were recognized",
        "terseLabel": "Interest or penalties were recognized",
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      },
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax expense",
        "terseLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Provision for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r138",
      "r193",
      "r194",
      "r213",
      "r386",
      "r408",
      "r581"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r384",
      "r385",
      "r393",
      "r394",
      "r398",
      "r400",
      "r599"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "terseLabel": "Research and development tax credits",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for taxes",
        "label": "Income Taxes Paid, Net",
        "totalLabel": "Income Taxes Paid, Net, Total",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other non-current liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities, current and non-current",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r849"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other receivables",
        "label": "Increase (Decrease) in Other Receivables",
        "documentation": "Amount of increase (decrease) in receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaids and other current and non-current assets",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r764",
      "r773",
      "r783",
      "r800",
      "r809",
      "r813",
      "r821"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r825"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r825"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r825"
     ]
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InternalRevenueServiceIRSMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Internal Revenue Service (IRS)",
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r211"
     ]
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Investments, Fair Value Disclosure",
        "totalLabel": "Investments, Fair Value Disclosure, Total",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "pepg_LaboratoryAndComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "LaboratoryAndComputerEquipmentMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory and computer equipment.",
        "label": "Laboratory And Computer Equipment [Member]",
        "terseLabel": "Laboratory and Computer Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r733"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of Lease Cost",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "pepg_LeasedSpace": {
     "xbrltype": "areaItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "LeasedSpace",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leased space",
        "label": "Leased Space",
        "documentation": "Leased space"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leaseholds and Leasehold Improvements [Member]",
        "terseLabel": "Leaseholds and Leasehold Improvements",
        "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pepg_LeasesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "LeasesDisclosureTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases disclosure.",
        "label": "Leases Disclosure [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description",
        "terseLabel": "Lease, description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Lease discount rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option to extend lease term",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToTerminate",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Existence of Option to Terminate [true false]",
        "documentation": "Indicates (true false) whether lessee has option to terminate operating lease."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments Under Non-cancelable Operating Leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Option to extend lease",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToTerminate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseOptionToTerminate",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Terminate",
        "terseLabel": "Lease termination term",
        "documentation": "Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "terseLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r175",
      "r260",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r420",
      "r421",
      "r422",
      "r460",
      "r632",
      "r716",
      "r746",
      "r870",
      "r918",
      "r919"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities, convertible preferred stock, and stockholders' equity (deficit)",
        "terseLabel": "Total liabilities, convertible preferred stock, and stockholders' deficit",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r121",
      "r572",
      "r734",
      "r853",
      "r866",
      "r911"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities, convertible preferred stock, and stockholders' equity (deficit)",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "terseLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r147",
      "r175",
      "r260",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r420",
      "r421",
      "r422",
      "r460",
      "r734",
      "r870",
      "r918",
      "r919"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Marketable Securities",
        "label": "Marketable Securities [Table Text Block]",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r331",
      "r542",
      "r582",
      "r624",
      "r625",
      "r684",
      "r686",
      "r688",
      "r689",
      "r691",
      "r711",
      "r712",
      "r719",
      "r723",
      "r728",
      "r735",
      "r872",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend Yield",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r331",
      "r542",
      "r582",
      "r624",
      "r625",
      "r684",
      "r686",
      "r688",
      "r689",
      "r691",
      "r711",
      "r712",
      "r719",
      "r723",
      "r728",
      "r735",
      "r872",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      },
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "verboseLabel": "Net loss",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r96",
      "r123",
      "r145",
      "r161",
      "r163",
      "r168",
      "r175",
      "r183",
      "r187",
      "r188",
      "r189",
      "r190",
      "r193",
      "r194",
      "r201",
      "r210",
      "r220",
      "r222",
      "r224",
      "r260",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r447",
      "r460",
      "r577",
      "r653",
      "r674",
      "r675",
      "r717",
      "r744",
      "r870"
     ]
    },
    "pepg_NetLossPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "NetLossPerSharePolicyTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net loss per share.",
        "label": "Net Loss Per Share [Policy Text Block]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "pepg_NetProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "NetProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net Received from IPO and option exercise by underwriters",
        "label": "Net Proceeds From Issuance Initial Public Offering And Stock Options Exercised",
        "documentation": "Net proceeds from issuance initial public offering and stock options exercised."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies [Line Items]",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r189",
      "r196",
      "r206",
      "r227",
      "r228",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r284",
      "r371",
      "r372",
      "r373",
      "r402",
      "r403",
      "r404",
      "r405",
      "r415",
      "r416",
      "r417",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r458",
      "r459",
      "r465",
      "r466",
      "r467",
      "r468",
      "r477",
      "r478",
      "r480",
      "r481",
      "r482",
      "r483",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r544",
      "r545",
      "r546",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r597"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r189",
      "r196",
      "r206",
      "r227",
      "r228",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r284",
      "r371",
      "r372",
      "r373",
      "r402",
      "r403",
      "r404",
      "r405",
      "r415",
      "r416",
      "r417",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r458",
      "r459",
      "r465",
      "r466",
      "r467",
      "r468",
      "r477",
      "r478",
      "r480",
      "r481",
      "r482",
      "r483",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r544",
      "r545",
      "r546",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r597"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_NewtonMassachusettsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "NewtonMassachusettsMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Newton Massachusetts.",
        "label": "Newton Massachusetts [Member]",
        "terseLabel": "Newton, Massachusetts"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r761",
      "r773",
      "r783",
      "r800",
      "r809"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense)",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pepg_NumberOfCommonStockVote": {
     "xbrltype": "integerItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "NumberOfCommonStockVote",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common stock vote",
        "label": "Number of Common Stock Vote",
        "documentation": "Number of common stock vote."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_NumberOfFoundingStockholdersEntered": {
     "xbrltype": "integerItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "NumberOfFoundingStockholdersEntered",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of founding stockholders entered",
        "label": "Number of Founding Stockholders Entered",
        "documentation": "Number of founding stockholders entered."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "pepg_NumberOfSharesRestrictedAndSubjectToRepurchase": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "NumberOfSharesRestrictedAndSubjectToRepurchase",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares became restricted and subject to repurchase",
        "label": "Number Of Shares Restricted And Subject To Repurchase",
        "documentation": "Number of shares restricted and subject to repurchase."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OpenTaxYear": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OpenTaxYear",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Open Tax Year",
        "terseLabel": "Open tax year",
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction , Expenses from Transactions with Related party",
        "label": "Operating Costs and Expenses",
        "totalLabel": "Operating Costs and Expenses, Total",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r220",
      "r222",
      "r224",
      "r717"
     ]
    },
    "pepg_OperatingLeaseCommencementDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "OperatingLeaseCommencementDate",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease commencement date.",
        "label": "Operating Lease Commencement Date",
        "terseLabel": "Lease commencement date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fixed lease cost",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost improvements",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r733"
     ]
    },
    "pepg_OperatingLeaseIncreaseInMonthlyRentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "OperatingLeaseIncreaseInMonthlyRentExpense",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease increase in monthly rent expense.",
        "label": "Operating Lease Increase In Monthly Rent Expense",
        "terseLabel": "Increase in monthly rent expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease liabilities",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liability",
        "totalLabel": "Present value of lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 0.0
      },
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liability",
        "verboseLabel": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails2": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, net of current portion",
        "verboseLabel": "Lease liability, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "pepg_OperatingLeaseMonthlyRentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "OperatingLeaseMonthlyRentExpense",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease monthly rent expense.",
        "label": "Operating Lease Monthly Rent Expense",
        "terseLabel": "Monthly rent expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalDisclosureOfCashFlowInformationRelatedToLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash payments for operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r495"
     ]
    },
    "pepg_OperatingLeasePeriodOfExtension": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "OperatingLeasePeriodOfExtension",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease period of extension.",
        "label": "Operating Lease Period Of Extension",
        "terseLabel": "Additional period of lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "pepg_OperatingLossCarryForwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "OperatingLossCarryForwardsExpirationYear",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carry forwards, expiration year.",
        "label": "Operating Loss Carry forwards Expiration Year",
        "terseLabel": "Operating loss carry forwards expiration year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating losses",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Business and Basis of Presentation",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r115",
      "r595",
      "r596"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_OtherAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Assets",
        "label": "Other Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other assets."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r64"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Assets, Noncurrent, Total",
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent, Total",
        "terseLabel": "Cumulative translation adjustment arising during the period",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r12",
      "r116"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain on marketable securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r160"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign currency translation adjustment",
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total",
        "terseLabel": "Cumulative translation adjustment arising during the period",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain on marketable securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r160",
      "r259"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "terseLabel": "Other income (expense), net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r759",
      "r771",
      "r781",
      "r807"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r762",
      "r774",
      "r784",
      "r810"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r762",
      "r774",
      "r784",
      "r810"
     ]
    },
    "pepg_OxfordScienceEnterprisesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "OxfordScienceEnterprisesMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oxford Science Enterprises",
        "label": "Oxford Science Enterprises [Member]",
        "documentation": "Oxford Science Enterprises."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_OxfordUniversityInnovationLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "OxfordUniversityInnovationLimitedMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oxford University Innovation Limited",
        "label": "Oxford University Innovation Limited [Member]",
        "documentation": "Oxford University Innovation Limited"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "pepg_PaymentOfOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "PaymentOfOfferingCosts",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of offering costs",
        "label": "Payment of Offering Costs",
        "documentation": "Payment of offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Underwriter's fees",
        "negatedLabel": "Issuance costs of Series B convertible preferred stock",
        "terseLabel": "Net of issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "pepg_PercentageOfExitFee": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "PercentageOfExitFee",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of exit fee",
        "label": "Percentage Of Exit Fee",
        "documentation": "Percentage of exit fee."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_PercentageOfRepurchaseRightsLapseOnOneYearAnniversary": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "PercentageOfRepurchaseRightsLapseOnOneYearAnniversary",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of repurchase rights lapse on one-year anniversary.",
        "label": "Percentage of Repurchase Rights Lapse on One-Year Anniversary",
        "documentation": "Percentage of repurchase rights lapse on one-year anniversary."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_PercentageOfRepurchaseRightsLapseOnSecondAnniversary": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "PercentageOfRepurchaseRightsLapseOnSecondAnniversary",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of repurchase rights lapse on second anniversary",
        "label": "Percentage of Repurchase Rights Lapse on Second Anniversary",
        "documentation": "Percentage of repurchase rights lapse on second anniversary."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r305"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r633"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding shares",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r633",
      "r651",
      "r932",
      "r933"
     ]
    },
    "us-gaap_PreferredStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Text Block]",
        "terseLabel": "Convertible Preferred Stock",
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized at December 31, 2023 and 2022, respectively",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r567",
      "r734"
     ]
    },
    "pepg_PreferredStockWarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "PreferredStockWarrantsPolicyTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock warrants.",
        "label": "Preferred Stock Warrants [Policy Text Block]",
        "terseLabel": "Preferred Stock Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses and other current assets",
        "terseLabel": "Prepaid expenses and other assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gross proceeds in underwritten public offering",
        "terseLabel": "Gross proceeds from sale of shares",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "pepg_ProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "ProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Received from IPO and option exercise by underwriters",
        "label": "Proceeds from Issuance Initial Public Offering and Stock Options Exercised",
        "documentation": "Proceeds from issuance initial public offering and stock options exercised."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net proceeds from issuance",
        "terseLabel": "Issuance of common stock upon initial public offering, net of underwriters' fees",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gross proceeds from issuance of convertible preferred stock",
        "terseLabel": "Proceeds from issuance of convertible preferred stock, net of issuance costs",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds issuance or sale of equity",
        "label": "Proceeds from Issuance or Sale of Equity",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r600"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds from underwriters exercised option",
        "label": "Proceeds from Stock Options Exercised",
        "verboseLabel": "Proceeds from exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r18"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from employee equity plans",
        "label": "Proceeds from Stock Plans",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from warrant exercises",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from issuance of common stock upon exercise of Series A-2 warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "pepg_PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment included in accounts payable and accrued expenses",
        "documentation": "Property and equipment included in accounts payable and accrued expenses.",
        "terseLabel": "Property and equipment included in accounts payable and accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfCostAndAccumulatedDepreciationOfPropertyAndEquipmentDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNet1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r129",
      "r132",
      "r133"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfCostAndAccumulatedDepreciationOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfCostAndAccumulatedDepreciationOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "terseLabel": "Total property and equipment",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r149",
      "r575"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfCostAndAccumulatedDepreciationOfPropertyAndEquipmentDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfCostAndAccumulatedDepreciationOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfCostAndAccumulatedDepreciationOfPropertyAndEquipmentDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total property and equipment, net",
        "totalLabel": "Total property and equipment, net",
        "terseLabel": "Property and equipment, net",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r563",
      "r575",
      "r734"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r129",
      "r132",
      "r573"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Cost and Accumulated Depreciation of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfCostAndAccumulatedDepreciationOfPropertyAndEquipmentDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment estimated useful lives",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "pepg_RaCapitalManagementLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "RaCapitalManagementLPMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RA Capital Management, L.P.",
        "label": "RA Capital Management, L.P. [Member]",
        "documentation": "RA Capital Management, L.P."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r323",
      "r331",
      "r362",
      "r363",
      "r364",
      "r518",
      "r542",
      "r582",
      "r624",
      "r625",
      "r684",
      "r686",
      "r688",
      "r689",
      "r691",
      "r711",
      "r712",
      "r719",
      "r723",
      "r728",
      "r735",
      "r738",
      "r868",
      "r872",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r323",
      "r331",
      "r362",
      "r363",
      "r364",
      "r518",
      "r542",
      "r582",
      "r624",
      "r625",
      "r684",
      "r686",
      "r688",
      "r689",
      "r691",
      "r711",
      "r712",
      "r719",
      "r723",
      "r728",
      "r735",
      "r738",
      "r868",
      "r872",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r766",
      "r776",
      "r802"
     ]
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable Convertible Preferred Stock",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r506",
      "r507",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r650",
      "r652",
      "r683"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent expense",
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r506"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r507",
      "r917"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r658",
      "r661"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r506",
      "r507",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r650",
      "r652",
      "r683",
      "r917"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r504",
      "r505",
      "r507",
      "r508",
      "r606",
      "r607",
      "r608",
      "r659",
      "r660",
      "r661",
      "r680",
      "r682"
     ]
    },
    "pepg_RelatedPartyTransactionsOtherCostsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "RelatedPartyTransactionsOtherCostsPaid",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation paid",
        "label": "Related Party Transactions, Other Costs Paid",
        "documentation": "Related party transactions, other costs paid."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_RentPayableToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "RentPayableToRelatedParties",
     "crdr": "credit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rent payable to related parties.",
        "label": "Rent Payable To Related Parties",
        "terseLabel": "Rent payable to related parties"
       }
      }
     },
     "auth_ref": []
    },
    "pepg_RequiredToPayExitFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "RequiredToPayExitFeeAmount",
     "crdr": "credit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Required to pay exit fee amount",
        "label": "Required to Pay Exit Fee Amount",
        "documentation": "Required to pay exit fee amount."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_ResearchAndDevelopmentCreditsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "ResearchAndDevelopmentCreditsExpirationYear",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development credits expiration year.",
        "label": "Research And Development Credits Expiration Year",
        "terseLabel": "Research and development credits expiration year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "terseLabel": "Research and development (including related party amounts of $29 and $475,respectively)",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r381",
      "r926"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "pepg_ResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "ResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expenses.",
        "label": "Research And Development Expenses",
        "terseLabel": "Reductions in research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r755",
      "r767",
      "r777",
      "r803"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r756",
      "r768",
      "r778",
      "r804"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r763",
      "r775",
      "r785",
      "r811"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Restricted Cash, Total",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r851",
      "r927",
      "r929"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Restricted Cash and Cash Equivalents, Total",
        "terseLabel": "Cash",
        "label": "Restricted Cash and Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r118",
      "r148",
      "r172",
      "r566"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r842",
      "r851"
     ]
    },
    "us-gaap_RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes cash restricted to withdrawal or usage, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "terseLabel": "Accumulated deficit",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r107",
      "r571",
      "r589",
      "r594",
      "r604",
      "r634",
      "r734"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r178",
      "r179",
      "r180",
      "r184",
      "r192",
      "r194",
      "r266",
      "r273",
      "r371",
      "r372",
      "r373",
      "r404",
      "r405",
      "r427",
      "r430",
      "r431",
      "r434",
      "r445",
      "r585",
      "r587",
      "r609",
      "r932"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Lease assets obtained in exchange for new operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r733"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_ScheduleOfAccruedLiabilitiesCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "ScheduleOfAccruedLiabilitiesCurrentTableTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities Current [Table Text Block]",
        "documentation": "Schedule of accrued liabilities current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "pepg_ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reserved Shares of Common Stock for Issuance, on an As-Converted Basis",
        "label": "Schedule Of Common Stock Shares Reserved For Issuance [Table Text Block]",
        "documentation": "Schedule of common stock shares reserved for issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of Net Deferred Income Taxes",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Income Tax Expense to Statutory Federal Income Tax Rate to Loss From Operations",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "pepg_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of estimated useful lives of property and equipment.",
        "label": "Summary of Estimated Useful Lives of Property and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Loss Before for Income Taxes",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosurePropertyAndEquipmentNetSummaryOfCostAndAccumulatedDepreciationOfPropertyAndEquipmentDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70",
      "r657",
      "r658",
      "r661"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r335",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Options Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r55"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Weighted Average Assumptions Used to Compute Estimated Fair Value of Stock Options",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceOnAnAsconvertedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r53",
      "r104",
      "r106",
      "r107",
      "r153",
      "r154",
      "r155",
      "r208",
      "r305",
      "r306",
      "r307",
      "r309",
      "r312",
      "r318",
      "r320",
      "r600",
      "r601",
      "r602",
      "r603",
      "r723",
      "r829",
      "r852"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r731",
      "r902"
     ]
    },
    "pepg_SecondaryOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "SecondaryOfferingMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secondary Offering",
        "label": "Secondary Offering [Member]",
        "documentation": "Secondary Offering."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226",
      "r621",
      "r622",
      "r623",
      "r685",
      "r687",
      "r690",
      "r692",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r713",
      "r724",
      "r738",
      "r873",
      "r930"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r225",
      "r718"
     ]
    },
    "pepg_SeriesA1ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "SeriesA1ConvertiblePreferredStockMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A-1 Convertible Preferred Stock",
        "label": "Series A-1 Convertible Preferred Stock [Member]",
        "documentation": "Series A-1 convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_SeriesA2ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "SeriesA2ConvertiblePreferredStockMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A-2 Convertible Preferred Stock",
        "label": "Series A-2 Convertible Preferred Stock [Member]",
        "documentation": "Series A-2 convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_SeriesA2PreferredStockWarrantLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "SeriesA2PreferredStockWarrantLiabilityMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A-2 Preferred Stock Warrant Liability",
        "label": "Series A-2 Preferred Stock Warrant Liability [Member]",
        "documentation": "Series A-2 Preferred Stock Warrant Liability."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Convertible Preferred Stock",
        "label": "Series B Convertible Preferred Stock [Member]",
        "documentation": "Series B convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_SeriesBStockPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "SeriesBStockPurchaseAgreementMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Stock Purchase Agreement",
        "label": "Series B Stock Purchase Agreement [Member]",
        "documentation": "Series B Stock Purchase Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_ServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "ServicesAgreementMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Services Agreement [Member]",
        "documentation": "Services agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement date aggregate fair value of shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement date fair value of shares vested per share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfWeightedAverageAssumptionsUsedToComputeEstimatedFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfWeightedAverageAssumptionsUsedToComputeEstimatedFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility %",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfWeightedAverageAssumptionsUsedToComputeEstimatedFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate %",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r335",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized and reserved for issuance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares remaining available for grant",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options, Vested and exercisable as of December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value of stock options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Stock Options, Canceled/Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Option to purchase",
        "terseLabel": "Stock Options, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value of stock options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding vested and unvested stock options",
        "periodEndLabel": "Stock Options, Outstanding as of December 31, 2023",
        "periodStartLabel": "Stock Options Outstanding as of December 31, 2022",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r342"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding as of December 31, 2022",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding as of December31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r342"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Vested and exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options, Vested and expected to vest as of December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Vested and exercisable as of December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Vested and expected to vest as of December 31, 2023",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceOnAnAsconvertedBasisDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise price, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise price, Canceled/Forfeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r340",
      "r359",
      "r360",
      "r361",
      "r362",
      "r365",
      "r374",
      "r375",
      "r376",
      "r377"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfWeightedAverageAssumptionsUsedToComputeEstimatedFairValueOfStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, Weighted Average Remaining Life",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and exercisable , Weighted Average Remaining Life",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest, Weighted Average Remaining Life",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offering price per share",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_SharesOfRestrictedStockSubjectToRepurchase": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "SharesOfRestrictedStockSubjectToRepurchase",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares subject to repurchase",
        "label": "Shares Of Restricted Stock Subject To Repurchase",
        "documentation": "Shares Of restricted stock subject to repurchase."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance, shares",
        "periodEndLabel": "Ending Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_SharesSalesAgreementAndFollowOnOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "SharesSalesAgreementAndFollowOnOfferingMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Sales agreement and Follow-on Offering",
        "label": "Shares Sales Agreement and Follow-on Offering [Member]",
        "documentation": "Shares sales agreement and follow-on offering."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_SharesSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "SharesSalesAgreementMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Agreement",
        "label": "Shares Sales Agreement [Member]",
        "documentation": "Shares sales agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r733"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r173"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r153",
      "r154",
      "r155",
      "r175",
      "r199",
      "r200",
      "r202",
      "r204",
      "r208",
      "r209",
      "r260",
      "r292",
      "r294",
      "r295",
      "r296",
      "r299",
      "r300",
      "r305",
      "r306",
      "r309",
      "r312",
      "r320",
      "r460",
      "r600",
      "r601",
      "r602",
      "r603",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r633",
      "r654",
      "r676",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r829",
      "r852",
      "r858"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r30",
      "r142",
      "r166",
      "r167",
      "r168",
      "r178",
      "r179",
      "r180",
      "r184",
      "r192",
      "r194",
      "r207",
      "r266",
      "r273",
      "r322",
      "r371",
      "r372",
      "r373",
      "r404",
      "r405",
      "r427",
      "r429",
      "r430",
      "r431",
      "r432",
      "r434",
      "r445",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r502",
      "r585",
      "r586",
      "r587",
      "r609",
      "r676"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r225",
      "r226",
      "r621",
      "r622",
      "r623",
      "r685",
      "r687",
      "r690",
      "r692",
      "r699",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r713",
      "r724",
      "r738",
      "r873",
      "r930"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r207",
      "r543",
      "r598",
      "r620",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r633",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r652",
      "r655",
      "r656",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r676",
      "r739"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r207",
      "r543",
      "r598",
      "r620",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r633",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r652",
      "r655",
      "r656",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r676",
      "r739"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r758",
      "r770",
      "r780",
      "r806"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares converted",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock upon IPO, shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r29",
      "r50",
      "r107",
      "r302"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of stock under the employee stock purchase plan, shares",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r78",
      "r79",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of Common Stock in IPO, net of underwriters' fees and issuance costs, shares",
        "terseLabel": "Number of shares sold",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r78",
      "r79",
      "r107",
      "r600",
      "r676",
      "r694"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionsActivityDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options, shares",
        "verboseLabel": "Common stock issued in connection with exercise of stock options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Stock Options, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r78",
      "r79",
      "r107",
      "r346"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock upon IPO",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r30",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of stock under the employee stock purchase plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r78",
      "r79",
      "r107"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Common Stock in IPO, net of underwriters' fees and issuance costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r78",
      "r79",
      "r107",
      "r609",
      "r676",
      "r694",
      "r745"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r30",
      "r107"
     ]
    },
    "pepg_StockOptionsIssuedAndOutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "StockOptionsIssuedAndOutstandingMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityScheduleOfReservedSharesOfCommonStockForIssuanceOnAnAsconvertedBasisDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOutstandingPotentiallyDilutiveSecuritiesExcludedInCalculationOfDilutedNetLossPerS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options Issued and Outstanding",
        "label": "Stock options issued and outstanding [Member]",
        "documentation": "Stock options issued and outstanding.",
        "verboseLabel": "Options to purchase common stock"
       }
      }
     },
     "auth_ref": []
    },
    "pepg_StockPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "StockPurchaseAgreementMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Purchase Agreement",
        "label": "Stock Purchase Agreement [Member]",
        "documentation": "Stock purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchased During Period, Shares",
        "terseLabel": "Release of common stock from vesting restrictions",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r78",
      "r79",
      "r107",
      "r603",
      "r676",
      "r696"
     ]
    },
    "pepg_StockRestrictionAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "StockRestrictionAgreementsMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Restriction Agreements",
        "label": "Stock Restriction Agreements [Member]",
        "documentation": "Stock Restriction Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity (deficit)",
        "terseLabel": "Total stockholders' deficit",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r82",
      "r83",
      "r98",
      "r635",
      "r651",
      "r677",
      "r678",
      "r734",
      "r746",
      "r853",
      "r866",
      "r911",
      "r932"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock and Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r174",
      "r304",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r319",
      "r322",
      "r436",
      "r679",
      "r681",
      "r698"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split, conversion ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split, description",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "pepg_SublicenseesThresholdAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "SublicenseesThresholdAmount",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublicensees threshold amount",
        "label": "Sublicensees Threshold Amount",
        "documentation": "Sublicensees threshold amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r510"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r510"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r510"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r510"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r510"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r511"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "documentation": "Different names of stock transactions and the different attributes of each transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_SupplementalDisclosureOfCashFlowInformationRelatedToLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "SupplementalDisclosureOfCashFlowInformationRelatedToLeasesTableTextBlock",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental disclosure of cash flow information related to leases",
        "label": "Supplemental Disclosure Of Cash Flow Information Related To Leases [Table Text Block]",
        "terseLabel": "Supplemental Disclosure of Cash Flow Information Related to Leases"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Taxes Payable, Current, Total",
        "terseLabel": "Taxes payable",
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "pepg_TechnologyLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "TechnologyLicenseAgreementMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Technology License Agreement",
        "label": "Technology License Agreement [Member]",
        "documentation": "Technology license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityAbstract",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Abstract]",
        "terseLabel": "Convertible preferred stock:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock",
        "periodStartLabel": "Temporary Equity Beginning Balance",
        "periodEndLabel": "Temporary Equity Ending Balance",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r294",
      "r295",
      "r296",
      "r299",
      "r300",
      "r378",
      "r569"
     ]
    },
    "pepg_TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Conversion of Convertible Preferred Stock Upon Initial Public Offering",
        "documentation": "Temporary equity conversion of convertible preferred stock upon initial public offering.",
        "terseLabel": "Temporary equity, Conversion of convertible preferred stock upon IPO"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Temporary equity, par value",
        "verboseLabel": "Price per share",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r46"
     ]
    },
    "pepg_TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Shares Conversion of Convertible Preferred Stock Upon Initial Public Offering",
        "documentation": "Temporary equity shares conversion of convertible preferred stock upon initial public offering.",
        "terseLabel": "Temporary equity, Conversion of convertible preferred stock upon IPO, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Number of shares agreed to issue",
        "verboseLabel": "Convertible preferred stock shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Temporary Equity Beginning Balance, shares",
        "periodEndLabel": "Temporary Equity Ending Balance, shares",
        "label": "Temporary Equity, Shares Outstanding",
        "terseLabel": "Temporary equity, shares outstanding",
        "verboseLabel": "Convertible preferred stock shares outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "pepg_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "documentation": "Temporary Equity Stock Issued During Period Shares New Issues.",
        "terseLabel": "Temporary equity, Issuance of convertible preferred stock, net of issuance cost, shares"
       }
      }
     },
     "auth_ref": []
    },
    "pepg_TemporaryEquityStockIssuedDuringPeriodSharesStockUponExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesStockUponExerciseOfWarrants",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity, Issuance of Series A-2 stock upon exercise of warrants, shares",
        "label": "Temporary Equity Stock Issued During Period Shares Stock Upon Exercise Of Warrants",
        "documentation": "Temporary Equity Stock Issued During Period Shares Stock Upon Exercise Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Temporary equity, Issuance of convertible preferred stock, net of issuance cost",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_TemporaryEquityStockIssuedDuringPeriodValueStockUponExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueStockUponExerciseOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity, Issuance of Series A-2 stock upon exercise of warrants",
        "label": "Temporary Equity Stock Issued During Period Value Stock Upon Exercise Of Warrants",
        "documentation": "Temporary Equity Stock Issued During Period Value Stock Upon Exercise Of Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_TenantImprovementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "TenantImprovementMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tenant Improvement",
        "label": "Tenant Improvement [Member]",
        "documentation": "Tenant improvement member."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_TermOfLicenseAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "TermOfLicenseAgreement",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of license agreement",
        "label": "Term of License Agreement",
        "documentation": "Term of license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfMarketableSecuritiesDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfReconciliationOfWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r303",
      "r318",
      "r435",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r578",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r862",
      "r863",
      "r864",
      "r865"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "pepg_TwoThousandTwentyTwoEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "TwoThousandTwentyTwoEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Employee Stock Purchase Plan",
        "label": "Two Thousand Twenty Two Employee Stock Purchase Plan [Member]",
        "documentation": "Two thousand twenty two employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "pepg_TwoThousandTwentyTwoEquityIncentiveAwardPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "TwoThousandTwentyTwoEquityIncentiveAwardPlanMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Plan",
        "label": "Two Thousand Twenty Two Equity Incentive Award Plan [Member]",
        "documentation": "Two thousand twenty two equity incentive award plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r183",
      "r184",
      "r185",
      "r186",
      "r196",
      "r227",
      "r228",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r284",
      "r371",
      "r372",
      "r373",
      "r402",
      "r403",
      "r404",
      "r405",
      "r415",
      "r416",
      "r417",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r458",
      "r459",
      "r465",
      "r466",
      "r467",
      "r468",
      "r477",
      "r478",
      "r480",
      "r481",
      "r482",
      "r483",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r544",
      "r545",
      "r546",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_USTreasuryNotesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasuryNotesSecuritiesMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasury notes",
        "label": "US Treasury Notes Securities [Member]",
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "pepg_UkTaxAuthoritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "UkTaxAuthoritiesMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UK tax authorities.",
        "label": "UK Tax Authorities [Member]",
        "terseLabel": "UK tax authorities"
       }
      }
     },
     "auth_ref": []
    },
    "pepg_UndesignatedPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "UndesignatedPreferredStockMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Undesignated Preferred Stock",
        "label": "Undesignated Preferred Stock [Member]",
        "documentation": "Undesignated referred stock."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uncertain tax position",
        "label": "Unrecognized Tax Benefits",
        "periodStartLabel": "Balance at beginning of the period",
        "periodEndLabel": "Balance at the end of the period",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r390"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Foreign Currency Translation",
        "terseLabel": "Currency translation",
        "negatedLabel": "Currency translation",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from foreign currency translation."
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "terseLabel": "Decrease related to prior year tax positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits, income tax penalties",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties Expense",
        "documentation": "Amount of expense for penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increase related to current year tax positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation",
     "crdr": "credit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation",
        "terseLabel": "Currency translation",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from foreign currency translation."
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increase related to prior year tax positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense",
     "crdr": "debit",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits, interest on income taxes expense",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Expense",
        "documentation": "Amount of interest expense for an underpayment of income taxes."
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "pepg_UsTreasuryBackedMoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pepgen.com/20231231",
     "localname": "UsTreasuryBackedMoneyMarketFundsMember",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasury-Backed Money Market Funds",
        "label": "US Treasury-Backed Money Market Funds [Member]",
        "documentation": "US Treasury-backed money market funds."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42",
      "r126",
      "r127",
      "r130",
      "r131"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://pepgen.com/20231231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r733"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants term",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "terseLabel": "Weighted-average common shares outstanding, diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r204"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://pepgen.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "terseLabel": "Weighted-average common shares outstanding, basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r204"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(27)",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-15"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "SubTopic": "20",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-3"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-4"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-3"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-5"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-30"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-31"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-32"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-5"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>111
<FILENAME>0000950170-24-027178-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-027178-xbrl.zip
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MPG"YE,R9[2LJ%9+8.(@*E^+Q@RW^^>$MMOBNPH(MT.N)H.\+/4[?.SCDOKY
MI:6ND1WYSCHVKJ[ZPU"-,].^JU+?<O ->@G<+^ELL/#[1P0"^Z7S^U1L\OSU
M15B!A#F7RX7,\BO&_K#E5^3[54O1 Y3]T3U/V%<,RF]2XNV8OW?5VA[.E2@
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MR(;PJ );8Z3W0\BB[5=!H=[0W5^.#6U>O@J8L.#(E[!B3/^:SM=+\X%CCY8
M'E5<-*.RXDC4>9;HXC6:FZCQY>+D>0_%9AS_TQW;S8^^I$7@CT:=4@\G-#LT
M$F14XZ+G?_!%G$@%!A!*P&0M\JVLQ!L=9S=LE]W=<3GW%]?,YZPG6[ NHK\B
M :\$8PUW@C/3(0-<CQ^CK6U2O#F>HYW3]J<;CV]M& ZO"OU6 V,T@S+2DIL'
MT^8$!"+N@/#!A!>LNK0,:O<]\W549!#W=1=$0@Y&S*D:T-+5T.0EUI*MHGW1
M7%>:-?N.^E;N/<F/=]T@QF79BWA!'3ML9NL_1F <[Z$[<7.(! !,AVPE8)%I
M)Z8J1@CLKD4;>TN8]>+PX&2N=RT_WXXTJ^/V\ U.1N[T]M'BC!PJG3ME"^P+
M<Z#<V;2UB$Z]J6O=-8U<5<,=+K]0$?3C*UWB:[+$*)$I*N@6P9C$\^;M8KH'
MAL79&#U$IS4\00+ 0AHEN0]+TQ9UP8^8I;OME(MY0A%60BN[Y82&-YKCBYV)
MP@\3/T#Y*)]VWK_6POI@RI=^NW,8<&+';=[U<,I0-][+9MDGY0%NZ:2SP(/
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MMLB?^\L"/PKU:!ARO%5\NU=BL3-?N]A8A]H7%\;\G8NT_ZNB-PK$";DQFB4
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M2LG=C7TO$XCXG/[H-V9V_D-F,F__CR+P_W%_T_[U.T9@'2CA+P9SM9-B>JQ
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M$=/,KERE]\L5:1"=C@(G$TV;,R6U1?0/G>[WP1YP?NJ%3FB;V/QPUWMSNW!
M?2]Q-'3/'<<,; L+B&RL'6="?DWIO7I=-9R8VQ9IK9,=E6'XY%LD&9F"X8*$
M^(3-'JM<X-RO>62*@NBC;4UHV,2<\;NN7 /5?28M5(W;G*5>%E?X;?5PO7<A
M/QM4KN]"*>C66V.K\[J4SC@D@KGU#2/BA<(:Y&6A7*%0NN@U\[D;FY'6UL .
M5OORO_S,X/ZG_3ZADMZN2OUC!RM 2(A-_W=?ZR1)DL&E0K85UE+?''[D3\_A
MAY.N&6K,%@\RCMXA'9?B.&V(4-"GN5ZW<=R\34@$DN"\]:?81ZL]3_ E".[3
M>O[.-=C,HX$:^/''G[,$3Z_S6U"S&]![,EY 267EZB/'31X,C/>TJHDROWQJ
M\)*>_BH*80HU[E8CMW9.!*/8 KEYIP-_88S\HJC+F*CD=@)?U8X^)PG_5<7Z
MJ01Z;A:#DLG11XAGD>YP?G.LF[HR$8Y0*C'<UAJL]U<:0$!OPE;A0<]5%'XN
M//*P2.=2.6W%]NFJ/)/TP)G<CPM]F-U>WC3]H?Y93=<LU>/#<P/!K[075Y?N
M^BSR0T^RE;A/AR=;&5*H,+Y_Q%!F_[7FVOMY! O.J<+./W-.R-'0P##/>5U<
M(NPS]=D[H!D'R1<3&68]5]]/F01L\5LY2LTDH7G6=1FINNV<+M\IL!O1N%ZD
M>NNRTBOH&T=T%R-WN$%54 U\,).!%57XT$R(>N>^63AYP@S-Y":#N%[:'!UC
M0O)@5?5[^TG9E:IH#R%5OJ28).F[/1*2&0L+I//.U:ZOWR5]?53GD%2AD)RB
M!RN>_I(4^GWQ44.3%Y0X8G7SG<%"5">DEK+[I%*0?!DRYLX5AVGZ-<?.$IG1
M!#W5SA+P1>ZEO?S/4LE3LNN<5+1VL8+M!FCJ&G>O26'G"OMHB>L,EY%O1V$/
M^C+51LG/FA@K.PC%5A@85Y8FL3>PL:QVB14/=U97WZ$4S16TE>C_/N37PXQJ
MV8JC4U:X<'[^QF4;OP>2KKH06)6S.UO05U%R7V[:S3.6NI>?*Y0^)OH..G;L
MN02&S":]<V-0DK.%^[IMQZE+J5?V%.?5RJ>+,E:I_5@KA'G395FXRWQ==)"[
MR4M8/B4=*Z2BZ<CJ=4%5AQZA\EI+YP%MW+&W-KW"5'3/?V5V&,7T%C:": =N
MT9)T+F_F)T@U#M:,7%S:&*;X9&#<'\MS[R*U#K-SSV2BJ]GN0ENOC4N&OID5
MO+]7*$PRL>T50YD.Z)XY ]\@ ^<7V%@5LS0_ W_#%2NI=;O'#R3Y:^,]U!<R
M$S$CJB^RBWNC3;,X'+,&K)(N>0I:/;)[*\V0EZ)!LGOQF9=:^61OL@YM<=#E
M$,,1[:ASO5\:-3E</@Z<NH**9\S*SNT.45PW:J"[+5$*+'6?!?Z79Q!^RV.V
MUV?*'2+]A-ZN]YWMC9Q=&A45R&;I,?-.W8USWL.#?EU76T5U,G"Y.^V$NV,C
MZW/TPC*R6OHV/W E!.ZJK$[2/2HI^?0];2B7WSCV\JE:>R*?LVO\S]2>/(C[
MQ;6VD9*MF-5(-2[-\)JS/VI&\K*=E+K[]L1JX]:S68@597F'ACZ=RYN"QUVM
M";E6MIE#Q?*6G\4:0],*FT6.N[OK/C05J7RO"M-2(T?N)4P?CQIM3;,SL].Y
MTQ2JD"7*\%GA4XR'/O.GU+ 8SB@VT-FXM9I'I_D)KR+F-]4X/D-R#PY]$F"*
M]V54OS+JT( PRU1RVL'@068O/FA/SNUY-6\J<46C(BI",E\^[=%"V!R3SR9]
MV+A8RZ[1QCY3R#87W"M]_\GUX@4;Z6#IB_)\N'IBC';9@,1/#E/5:X'LJ>D?
M_U5N:5Z^RVU_LQ(CJ^65*V\NE=MFD-(S-I^Z$MB=&F<KGB*0GE=O:WO_4TE@
MSP ?/1^[K'0?:5P@Q]G](QP>+]*>B5K=@<&&&^6E;VH#3_5)#W>9B^[ W+N
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M /575P+VUPS8GS@0DJ7 QRZWP6?/9$%'.8&Y \OL3KU'Y+2R;S>;?5ODBPV
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MN\^ &NM=\R5^"QJ"776N)KL<X+N95 PQ/C2L_VR3CC/5_*H'C8T)*A-;.C0
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M>J>@+4?[V/P%28X@8AY,(<%]GRG$GJ7R?N]B^S(X]AOD98ZOJ-J8'N=S)O*
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M4;ND*"[*&"#GMH+EX?U;CW/0L:=H*,YS$[*["6SSJ=7FNZ$19H8 G<GMIE"
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M+_BS_DV1W#UIQM'M/',2T6<I2DI\E6(8KE:P#LK?[WD^MV#+[59,#\:>K2D
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MT8[WQU_9<P\_V>19\VUL6IS ;&)ZPT>P8BC5!";=CLDR4^03SV]0(N0TU^P
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M/B+N6%7WY=]^A_KW$]V</X]Y;9ZEZJ;FS%=$B,G'2N[]J&^_71DC3V3>*M+
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M#2D\S7" ^O7H[DF>-V#^V?/^A^D'D_OO95 U9O'[>\J8F[$20.1K<-M\%!8
M-L8"ICF'%Y-6BA\<27R83IH"O@<M;#_" FJ_@C?)IC8"#!FV#E)Q,_PA$-)_
MSY_=TRX=;-(E9NS!-( %+*PKX@!#CP$C#;" ^&I!# :$!1 ;M$HQZ&;RK!ZR
M!@/?'2YB 9&_:I08" 4F#HYZ:M=G</Y(OLJO>CAV#P/_X@I JN<"#]Q/*LB2
MI@S*<2L/'6<T"HRY6>WF+U'\&%28[@J5EKBV M[>3<.1!,/1SMXPY56*!P3_
M!#3W-]1)9QCJ%8.S,A )Y!T<]N"D<=SBU$:;#L/6[C,<TPQ8P/L\C41(=B_%
MGB.0KXUT"II7N5!9<*:7+QX=45J4YW=7(_?K1,> E?#6M\&H_36+XL24@9AE
MO=MD-]<MH([3\(O(TL8?)4OV*3IF!0QC.LE?C8)]:IU;]Q8Y/S,0X(,N0=$F
M:'08'L^K]$^0XA;1 S/4<"YE9HC&^P7O%$%7O<V"#3_\MZ9V/@RF%0MH5/.K
M%_< M^'OBP4SX94RM)BV^ST9MQ3H$C/U8![P0U4OU>YO8@%(?Q>D<B[DMZC(
M5Y_@9"B)UXJ'!_N # YNXB><#5(3)U*W7W KO2J[F6_0<0]^;$EN5.KB9/$7
M(?J6@.96\-]-(#A:-+.[%%8$SAR)^$7-J:!X^_8]]IVNNV4)8P%#%F YI*V1
MZ0IW@JA^_D+;F><F$^5HSI+$5/7YPW"B<Q<JAV=4KO$_D2+TOTTN#2!;9LM6
M^O8?XL+C,1(W#P5W,LSOXH9G!O$8R/=W+'*XR=7?BRI?P (TA-2V\W"=E<M)
MJ*%R337XWUM/X#^0=$@\:$4T_2^?5XOI5WV3-H+*PV0HCTF\S79- CD>SJQ%
M!_^Y3%1M0'24?%5F@<CD51S?_F6>:+Y]0\P!_R$;?;*7#68U?K\N95MFW[!V
M(]J3[#R^: 6GIO,0?K C;CUQ,8/MBP COAZ#Y'=-.LK# CRB0_W/J(+P]>"+
M21T,8^"CR=Y/CZD#\5"E&]'*0F!'G!-XJZK<,^=K9QCS*CM*#>N@//KJ !\5
M8,:C,.VX6ZOGV2,3RQOWGQ;F]8!L?K8H[;6R"QOCA]HT.[7^M1!'(4MBU2>J
M3PAP66V])T?3KWP2]T?31]/F@;C!MT:1_NDQ*RSQ4BHZ@=L$^[HXKEV]CW+P
M+.!831*K0P_\@@/CP4ZEPV\?TQXF\UF<YEA&EZ5Q;QPSC8/NQT-+^)]1@9ZT
M#+EMLE:*WC+;P9-U7N(_+3M$]\A\!E5,[+>F=>$$\H/R5W.+OXOP(ISM.J'Z
M']L'.]:NARDGONXU^=E&TD_@GL4O E3S0#PB4QQGAK]I[:K%$P^JP +^-&Y]
MW/A:[6^BO/#L0FX;_:=%>6._V,[Y22?D+XW1!YV(8N /J3O_W/ZQI 5R4I42
MAWQII[  7S[8Z<*?]YTO7'%WF'P"?Y[@'H9. "_$5F,!<U$(A3T?S&QU[5S4
MNFJ7MJFER:@?@A,+$)M;QP)NM?,,4X#L#":V?NQGF";=*UQ[L!?>[%'N9H+6
M3J$@5!Z-3&=8AKM%^/-?DI@%F>F9M$6F@ONB#8O8A89X],!9 EQDIIQ_J8G7
M,2SBMOUJ4(9S:G,=MLY;1Q_1*;;QW :XP4G#TQ9'2<==A0&&Y78%*>HK\'+@
ML";5UMQ2_.[+2,2EV%>1&3ADYK^1@;..D:G9?)DQKI;%->#^I$CE2S:NR01P
M.8_UP4LSK\[:T<A:5*%XY@FNDPKWKCT?+ !JMX\%1)@4*TI1GXNWXRGBV6=&
MX%B&N_E842!4/<+ 609BA<M]5HEZZ$PEE\$J+R[I-R:C$IWE1Z%[^!>K67^3
MEYH81& R^EZ/'2>K+^ L\26)[C)X) ]N8,T2$#@6@:&IZ@G?9G_J)(IQE=<\
M6VHZRYM;W6;0VLE'\C,2>M5\F.S#:5R;I^'E%,,4/T7)'_];O-'^_'1X@O&2
M3,9AR\"UB 5H_D:':S&HWCLH=)<1K8V0^Z7=C'2\_J2.'X_U_KMF74T%SYD?
MXM(OM</-#?^(XY? #0\6>,#'4OTM 85CT3$4Y?+-M?6 EMNE>S+*(/MVSK0)
MZ_[%*A(2711=M2F$]6;[I C.P .['?AA(4['K#3,*Y#=ERG'#/[6L4G_3R7G
M@OJB_\F@XO54T0GV.(9@AX6J7=+>_V"&1_<7:)B790X+AW\WR+!\K)5/HVPX
MV:F"^J!])W9H:KBF,(+1CC[F[B>C)ZA.:J [GG\<XZ=8 A"7T*WNX#:^\;"_
M^(7BL8%2_/:./YKK[57YHKU_\X]W*/\6#^XE0OQ+9"=L^EN$;]6-7#_XM$V%
MV: \[,O$W\(M=#!0 G[_^$W:J/)O7_FKS93]5N2)K_RS&0;\\14<:E#?+]0X
M33'^\155SQ-G,#?'^T;(\2-.O7\JW']R<N/H/A8 %W;' MKXAB-_"^.WL#&N
M;1/'(N7V^M6+_+2F7QJ7YR:++^=YC%/#+M>Q<7K]9H:_]K=;X+L#C;_62135
MFNKAJ+7%B;3H)R%_G".I+,X+SC;$,_8LA&HG2YT.AG)7\(9\Q*VTR'&"L_X7
M_0;=L:V>2(2][/&)_V2>H,;W%J6H0AQ1.&/ \71L-M?^5(@O_E44O_WS+]W!
MB2Q^.^B)1.1^6^M/W3W\+9&=?_!J<OQ+[/_L[_$ZT<<V:OA+'-V>?^DS?QOI
MB4W]@[5=^=6!X)V@-_YWGWG<X +T?D,KQ'M?QFA)2N3WG&;8EH[\_V4\7@%*
MS=,V%?GR<*M;F=OE(YGGE\G9*W[^LV<QXM[2 ;J8KL**DBV-R;JYW.EWYQ<N
MB#K6'6IL),_F.;R/4Z>PN.LF3MY1-W.)M;2+;BK&*R<\\/I9QM-G3LO1&N_M
M9&U:1/2X^'L2&WW6:[@0]?E-?M[/T+P,A]D*LDRIU781S@@)4/=9W"0RSZMU
M_@!DM06VK42O+NR@.9(Q'&7YF]6[GVK-*HITC4VY+)^2B H/RU%2+6IMV1ZJ
M<_!Y7G3\4A&70NYG.3W&LG O3&?;0%1K,.D#Q94<]"C1=LO2BER*2VZ;>LTU
MZ?&]CKFD;<;@+89;WVNR6N'*V]YJJW.Y,>2(&ZF5,46:-[UNFH%-HAT*>F=E
M:9.;KI^5Z3D7O I0NK<@1B]B(J.ZZ129TI2F>"-:R_K 5U;-!D8;$HL%7)T\
M;7;$/MY/4>R39^_DW]#MH6Z49: W=$"AX7QWD2F4LZ7Q%46P&U28SE-*W0^F
M\V2 -R_<+>)KVRS,8^/Y>:]O=SVK)8JJ8_?RW;6L[5,3$RK*%!2$UXR)5"F'
MI2_UOKYCJU?A(=4US.DZ//$X>/CEH(DIR"DH;"L4R'I&S.2M^#=&)57DXSE5
M7F34@(J6B&' *P']QTM+Y\:JYL1:,#W7ZC@.\X2;A1?(=%Q*ZK?O5_?-^,[J
M#HLR^7^O; 60OHD%7UU_D,;<22XKD;I+#A]%-BB7%O2LG:6PE_.J_%+B>WLK
M)+BL V2XHK8$9>G9%16M#)D?\0P,L:?[_LJE )H4_^#@\5(KYR"Y;*E%#+\F
MG]%,T)V]O>'1D0G=G![R4N@T7<$/R6:R!6ABGC8RM&.W^!FM&F059AQC!_F<
MNXI8B*]PF_93LG @3*;_,9A8%F?=%-:6M%@1$<84L6F@?_"**4B!_&P&03IM
M<%]6!K(>]J@V^H>.H8'":>OXU8_KQ%=J>5M@M#U[:JPC#\H[N_00"T'\65S<
M#2K6$@H6W1IW@TYQR.A_"^F<M86&9Z4L@X:=?&=6-9WB>0VYU\2#;2>HQ)Z4
MR7$6Z<3J?GTQS!G;Z_$B;<B<XMI%\KG&B*4*5\NI\8_NY7O+-L"%IA<NNLW*
M K[Q]+D]"O:>HDUDT_P70P+9FX5GG=8UTN&1T8TBG?-SY:,J6MLNH?43VO&/
M/LK3CX^.MG,31%(#U6(7TJQV[\-A(I9C?=F*9NFZ,@XCU\O*7M]2I1]\%1VN
M9&G0)/)1:4#$C1-2M.G3/A#TLCLXSJFD*_?;69#0<\T%+Z\G.Q+OZ&>N[<13
M:Z]HRIV+B,^0,#1J>4;#B 6X>C]5<TBM(,F2Q*V'$\M?;NY]++Q[L]I"(.R[
MX,JIV^=ABD/PI4-[C6)KBJ5#Z:1S@?ECRER-][5JVBEM#I@ PJU,P4)K;'MJ
MU=D@BTL&\VCRMM;I%@$@<'E[T'6OM%]%V#27\1+3JU-U''8BD,U,$4$(%Q90
M6#37&[J9$D]<O3!47V_<.B/FL$>&#D2X7QJYOU<^HJ(=(8+(V<OS3+UE+V/_
M4GKSYFM*>A\;)1FELF6V+H$V2Z]^W1C9>2VC3XW4]\YOB0:2P@2ND.@F]D[O
MO8PC4U%]_#/4-1(+H,]I/5I(WZ/CI#_>R!$KG1#W\DYYN,=-$VF:R]EL2)PM
MQJT85\$UGS)^?5"K>A0+4*J5W\(-".]KV'N-;PTG1ZP,<?E%$$P+H]HM%"ZJ
M)M:T-)?<B1.T'-JQ)-^^NJGY'H*"%2NCB,)09@U-$C>P@"][&5C FU!PD"4Z
MGGN>8?@Q1FVI@G/^V33D*A;0Z8P_?5L.:H:*J4P##Z\L@Y$4K,CNPW>5?GN?
M0)\.=?P/LEWB&QEV:'NQ@ UNY<TT"*D%%H![K,4_I>Q2.5/LQ>( I?T/OKG$
MX ]YCJ?@T-F!@X1<\'LX/Q^M,?R>TOH-1TH,WSUII#R6Q11R<;BM\:=#T[
M:IM-EDHL0#)'!@LX'8\R\Y0_ 266\M@1D\D%=UJH_(:D+\=!QOV"5-)O0F<
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M2)S//7L-F-T.@?=7^_I?N_F]G[1A;!S] VULN;'WY8X2%Q.5N'*+13O/:RS
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MJ!#I53X\1:.9)BZ#.I]_BX<>IE+@W4#=G&1CH$)CYJS",,9M=P096[XB>P8
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M^/6/R9#ZL@<SD*L/$K0M[+6T:*A>W/Z:8<L86\K90?;4J/8Z%/6(7=Z=7*3
M=R&Q2R\U?IKNF9@Z?4"VSE"SU76^1LNA#Y)P(F6UK1!8BF0JL@2S73><F\=T
MMWZZ6U.V3[WDZND0?&09\;KR8-L62@J1=( A>"%ELS\N4.VGW-DH9T3>G\3P
M>5LO0HN1X0W<X&!F<T:IK5$P'^EUI-:'0,CKSC8)?*J;+J.Z;CD; J<]1)LZ
M&(?7:00XB>APAG3OUI*.ZID5ZILYY3WSNG3&NM+C4AW17+ ([1':)<.AEL3
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MGIP^@9%@_'?S9?L:T9)NYRGO^\BI=/!13L;'N<\@_YUO6W_))*?:>YP[F^H
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M2I3!<[-L6W%7R045[\:[^H_)^?T]A)B4#)*-Z51K_%)4H4/5:0(.>BSQ=V,
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M 8*$.=^ &T0:4WOT2!+_&"2B1\GS"+F&V+O8B.R#16-*MC*30=K[SE7(6%G
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MI[9;;C<7 AKW,*EJ,.F7][K:L%]XB13@=0-KZG4FI':)-A" [3M(4=ABBXT
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M?4DD\BV,-+3"G2?6AP^^":8I@VSZ-:WT:^SDBM#'$,91Y4@.!CX+%I66,$0
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MGF_>-'H8I6A/>^K4XF9IU4[..:IJRA+H]^\*^4XROZ<5LC\3$.VZN-E0C[O
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M0XW3JL&7<*71EU/A@H$L,JU+EKB8HA3OTXT@<TS\5DS&X1)X)1_7Z&KP7B
M^39K<%:J%I@UU&/XU,L1"C"&Q6589;N!PX6/^*0MWO<7@GM?6<G#6(?NP.5]
MV^1SBH-S\6X7"U.<HP"0(%=T]_ZCBP4$8>YYJM4N9EL*9AGL465HK8,HK<RQ
M? 62;:KB,9K*N2&L7BRUQ'-1DC=XM!MYGA:WI25'#WW<Q?,YM39ST8%$B@N*
M2XJZ:5.\^QT>K:J17JSG&.2?B%N8D[<-PC6"@GWN]"26%!84F9.M4Z@]'!G2
M'SW7,#$<-&R1ZK:T]27G[VFKQ\J-1BNXIJG*^I80W2OLD>Z,Q7 KU^KF>*1!
MYIRSOS<WD5CK_/VRK6JNDH%H \!&"TW;9WN?X%,%U*RY5C'3Q;N!FE2?K4VU
M!F[8R0;Z!']2*.[)SQ OR"_I6HPK,37S%NU6FTG&C5Y_8.-LC,%O$G?JFGXY
MOWHKP62F?NM9K+:/XT@>QU!@<4.=R4V%5?.P)'04DS)EG*69AI$MKTO/#&Q"
M9Q.U]E]Q))=,+F91N7!DE%T[96F3IKQ3)1FU_SB_HK@@)Z1G<4#H;LEC_0^R
MKS"!%?XV*KW0&.\W+[:W>WI>S%SJ;,KQYO.\ZP.[FE?,H-_=[3MR&KD,NC;V
M50V7Z!D@<1[2;Z9"Y.6M @9Q+!W/']*0RJR:!8*U7=WH3>GI8*,X=;?+9=9"
MHS&*/YSW/Q<:ZSCN!2,OJ-[G6'ZR?0HJ,GTF5^:9[]--YX500<I7IP:]0Y>U
MQNY/\4_8.Z_Z1O4J=C*8ZQ;F=YG1TY,V.L9_OV+A&%>2-?J:Y G6*:M34&%^
M-@SK/<BH_["(VZUM)CLRVN"F36R8<^CKGD7C>RZDIZK=#$E?M;4E/I$MYK^W
MH?S9A%CUVA!>_[93!#T7Y4R$Y620SG]T-LZI04[2OE.E1&=\H),#YO^:]+\F
M_3\UR3?'J/#>QV#RQ-O8#[(>$Z.6Q$.DQ1;M^=7J _B6W!$ [0S-:9.4^&CR
MIB6J^D@EKRQ(QQR=RCAYL1U]\/4S_<(RJ#(TD:MI$3)FW+4*N7?$4YLKGS07
MTV(?M!2?Q42#<OFOT61^.SJ*)^4JK0,4-6#1CF;_K5%<=\3BU9LN]EX*_)\?
M3@V0'31#LW;&6<*)+I ];H!VIU(+\4_VR@HJ%G2+#5Q=S+>JG$%-:V9[NWKV
M_[1SGN]L.%X;CZ+:"DKM/6O47E6K5%$U0DOM4:-$&BN"&$UIT<8JOJA=>X\:
M,6/4IFC%J-BD]MZ"^/G^GO_@>?6\>,YUG7_@7.>^[\]Y<R!-$1M4BBQO?XN)
M2WR3X")+9K#\J586=[NOCR&SH(<SG2M<HGPF+()C:S2"_YBH9[C#U6B7E^KJ
MB![I=/!8Z_)W>C$J>]RR;Z%T/O#(WMYD*PV(MPM[!2Q5_;:$%EFRU'V\H4LK
MHCB#M)@^T+=?[-[1/_W@6? /!$%>1*>E:L[&)4-C:(#8F4A;1C=K>$+R7?UG
M!M&U!3W*Q_/3:_YY:'P]#\ ZK412I+YM6AK$4MZJ-_(:J_J;=T"N:W!@)V/9
MB[)7K6T( "!Y#P!X;L2;KC7V$\0>+S0W?RQ4<CVZ H0?'"B8BR_9TJN+_=2U
MF[#AG.)HCJ0OV>Z+].XCK>1H?!74U.&\6]<1/3Z^+*/2FBRZWBTDC3^+9DCR
M(#OD!\:F'!:+!*%Q#)N^$X1?![HL47,1<*<88^)XG#Y5>P9SK(//K,?WS?.V
MFZ0E[&G.E6*"3$7S<.PV7QQ\Q,V>BNU#E1&9!@7'+15MU\-&X7.DQ/HX4^4!
ML0+VDRY -Y-\U4(LG'4+\_/Q:L=E(%W)LNGK,>TY_@SJH/6CFKN8UL[[+K')
MN;%F"4-JX=SOR#*',#=1!JU.ES;SA;[(L5)$A\TG"5FY@ T5@3F-R/P"GZ;/
M?WVU.9=OL67QARE'2YD3K"+N)^=M@EDH(E+!"3=4[S2P_0.@GU]AYO"_<^0O
M?!XD9G?,.KM,$V%7DZH=.6/;DOG72IO_H;W*!O#;1>1\B/Q*T5L:3ZN\XQSY
MO*Q3-!EKT*FN@.!+;):(H!*H]P)MKJTL!>"<>3#B4AAJ8P)A4K0:.E$P@ZNH
M8KM2WA2I'#7[W%OMGE7*_W(K1?,+7=-!Y-&22@F7;K)RE,3+>BUB?[AU4YQ/
M[#-:&49:I0\G:@ZCE],'-GF:+TJ30!NV!P*_H3N78*(VN0,T[S3)8B\!DZ,I
M4/:WMHHEAXNO18"MG5W^UKI2&6A^LOQHT !J0937*16;T,/-+%O)#IZFY^R6
M=R\*ILPL12.X?9CINNFKSJ/:8GZR5N2!?0B:(1:6.T[ H9%GZ@B.:/.OD8YQ
M+O"7$3;OB^3X+Y$RI)W/8Y9LJ46#46P!\U,D@FSW%$C3+A]PZ;2&]9\\P9;*
M43VTKC77\^B&ALQ,:M>1?*:(I&9.> ';Z<DVTC&I05@0:Z\ 4HVF2=+(\4P\
M3%5.XYA*'L$K;6[I2JOO?V/[!@-5XNL9=1RH<MAU!6[Y"1YS%S*X,,E7WQ#_
M1"H9VLNK/>L'5'B#4^L]YJ@_1 E=3[?2($EF^B!(\5G%MK(,>7Z!DRS:ZZ9E
M .5-'>@O8;K;NGJ!M2K46CK=)#E;:,(CU)3>Z%LY%X/L,LY8.#2BWJIAUC2+
M3.H->7SP7'X0+^K=W #A_/,Q)W)B%@'_=>/<-,-QQL%]4<&IN7_;Z&Y,7$<]
MT#@SSP*#P59<&"TJ1<D_R]=8.*$;O$W.[V'YI2.L#2>M(H5KFGG2LW6\P=S8
M4 N'>R?B]$MO$4*8_</( KR+">^B.**F3^*LIFUL?I:P65E!IVEA'TE,C(%Q
M?NSQ0W[%Q_T3&U< (.B[;]44D1T?^/7;R#LNYAQC7C,U$:F3;_9SR7C"N-!L
M!ON8=_H3XA#;67FNC/EE:&YSHE:\T![QS#>-0:3= W!\'^.*>HYI1)HV@&C>
MM8Z5>DI:X5R(@F.Y>_2QG>*E\XP'UB2?<XP[/V'4E8:>W]"95AR/Z=C-:2-X
M: JU-O^(#:'X.FVJJ_FT&*8UOG7*Q!I8A3DG"GZUI;V?M,CV\GSX@2W3P\1"
M&)_%LG2/\XMZEK7H!^_82J"VB^3IVS'*OG<U''AMK-3:O^!CQ"BI;U-X]AA9
MAS(8U(YW%LL'7 &>_576%'UE(_[+_8CB*=9>!SN8]!'UAK+F^ZHT"2 3:8.@
M?%]'\$7A1_AH''&Y=/UTO/U[@+PI%^ZJ^ ,/!)?%(49#/V"-)U%,Z[C?K#H,
M#>\@'95NK,HL8N&(8K6)OYG _D,PSKR<7WI8.9<I89A% 4 -N*Z>YQ[%.0QS
M1*J^="9AU;E=4<\(D76+R::Z,3&)YBAQQX3#*9786[UG=-K2Z%O<"88R$PJ%
M;Q=0$F1^S#VL14S'G7<EU:%=K<II$[E&NE.'=4<59PF;BG,$[$6,6.Q@C8U@
MY>C.X3EX>SOO#3JE*Z^^06N1CVG'%,E\!S ?#8'IU#U8:G)JH.'?._6B?Y,,
M\ KLIHJ-#_'L[2.D;!5FFVR7V451*DWO#4(,S0,Y2K0DYJN^3.L-YG0PGG\0
M3*,^2QZ0:K.>)-'FRP"4QYB!,SM;^$*&3"P'!AG(4[9)\OE^#@V_C#%(6*4W
M423:7BOL>4?+%6"\=1E1GBKJ6[:0:FG]O%^G=-G4$L*ADA@ IT2K"\L$HF"U
M58_X[5C7 J%LZ!@(S^?\ZA#"[0H'DYFO#%63MHN ^=@M:S$&ZC)\'C3"N(R)
M;=N#23$L';G$\7SEN=G13>N;3L@J]---CF=J&V.5:O-XQU?2MAI*IVI=I196
M) CWJJ%N<K,M^BQRZ\_.0!U28(>"LJ/G!KV)R!K8?6-;X)>[Y17 %K%LFE1I
M"5850"<JW(\_]]#AEY&Q%^J+H6L4!AHZJ*C)N6LWGVMW%EI!I-;#]!4=P0N?
MZ6C/QUZSTJ9MD3F+]F0T+V+NH&PFS4LH*GT-5B06S;-K]AZ&;I<[/H..+,/!
MCG:%>=_LOL6W\1\>E3L/5]?MAG\ZA&J )\3%!7G_Q,Q9/=\Z3])<[]B^J^59
MA\,HHHQ*'!/05P"E!!%3Z!QR_WO*<3<(6%N>C96"/!:?[Z9L.)/\ Z #V;S'
M$R8$L];5X>DT(/2H+.;=M(:0[B<[2D]G9D-U^]L VEJ:6R . TA+=KZ<: K$
M*\]@2_98.;V64A<9[M,H,Y3S(MS(.'&":*%-C&\2Q3R9CP:Q!Z>EC'PP_+59
M:\O24R3+NXA W\)SR:[]%;J5_@>?0:&,.G3->IW;7F"]SB39''F"O9U'K4X2
M$KI$FD\1.-Z"$U.J6%\=^*,CYWQIGL:9S,_Z^).R;* &K[HG]:=^_GH[,E ]
M37+,'9^_7D&>HZ-B;)0DA6=ZRH^O +=I<,=GSNZ3QU> TN['8SMG&*6)K'21
MFQ,O324$<72394_P;W%F4@K=L 2.]2/J1LSFG0^XE0S7 _7"6;\"PY&_.C57
M@,W;//49-X O#$@9V,*!_>&%0Z2 ()&A?.AF\Z/YOK0>\N:'/ODZS*'&M@)G
M@M]85"XAC=D%4]""(WM,]/858&P;-OLPV7X7>I@_YK;TPTUKIMKM:$!^Y+;A
M(VY.M<-!V*N']DN+\G%+%N'&8NX>8;IF1MR1KY]%W8G3X7@FVNGH/>@OQR!9
M,L!IZ7NAK6@ULMSJWH:_,$,1^7:_.I$%8:)I"B-C">/ZHUMYISW6<<0K@"YV
ML3Z,A]25,8IWX,8WX*? +G:I1P8ZO15/LM-<)RUF'EM^++*>O70_-3L(DF/2
MROQ1IU@:=S^=JJS3<Q#!%,<3FRI<SVB7R8V3GE&A84@5G-RNL:6W!J^E*AQ]
M$H>QLB,<'&2"+Z>=JM>&GU_;EE[ 9%;*?VVK2N;M1AA%-5^),&&);SQ)=^3;
M2':"/9@_$:&''10F_PL;30,H70,<\_PK5.-IXQ6@O2&S$DD#.F5\1#EH,/!R
M#WZ1R"0UW9G!E:SW71XOZ*< 5'@<ZO3'1JR9DTVKN7K$O$;J[[JOBY7S@Z]+
MT^VD#F1QM_&>J"-6$0;'A-*7V5.88:'*#('=_6G9X6.7P%=5LMC"&%<W"MA[
M@,VW0]*,L>]4Q.2"V=,BN09[.EN%."[)#\<E,&;:4N1<^[2D3%\Y$>76&$1B
M""E:461(_ZG*NYO+&B?5&*&5Y#4P(-S+K'JJ4."*CM=>!%](HN;LQ\MS6NT5
M1<3U-C)AK,@Y^&I"^LT8>O^?C;G5@YY>O\^,SIH\[]R+*V30?AEM ")-88 T
MM<R5M?^JJMHAF)4MKNFITHY96;"U'OK<!/Q\&"()J_D0"6]G?U-_'O"G8*\B
M=%)N *I.DFXBNF <,JG';$PA.O79:B&U<MXTS\CH3MKWVB:B4,/(<L+.U*ZO
M<LK(DG[]Z5N<9G#444/YUZZW.2?=[K*QW!P>],Z^:DPL\Z@9?5T-;+/S8G6)
M+AE(U$/HX/WEICUM ]-COWU5H[XEU$9-E @5DQ[JQR3>+T=<_4O(G RC"F!;
MG['1F-$_(PO)UNO4(I6L05OSUCJ'W=]_N2;!I4X<1X1<1"YIZ6BW9%Z?8S+!
M(UO;6Q*!?.2'7MJ*X*3W/3QGL7ZX BQE</2??#\;E[<\NXE918U=!>6ILD8@
MX4Y/ ROV1&5A(>8;_H<5H.SX"GCQ?XFJ5"4=2[S6'M]01<5A_3)67/8/3V5U
MDF&#TVB%2<H,__YU"O#N4(8_NJ-#*M))#3.7_E[_6SF0MSG>\'*L*35&V'3P
M1^#0#8#\10$9G/21"F1\-<NT#K1^<B_K7W1 ]'P&-J(;2CE83>H1%PID^FX+
MS>TK+4]B)_CX4.B3%)^RHE,C60KMN-\GSWDVH&Y\[3J/F^)KH IX[\6F?N$
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M":D[,UNH'52'-H,5,9?E*$T4"=(C%)_\,*Z/<?D/S05YC(H"0W"VE*)O*)_
M%<"WW$K(G DB,:?P(/C#L-Z=(Y1(0H#6.+'LM2)3PLZEM4S_H6GTN-@=PFGQ
MVA?7I%GO*F0)2LN>[\WFHUZRW=N%M9\WW66O %P@.Z.R/(A,BU3H%[S;Z_7;
MPWP5-K"4PT$-$&1'(*>UN3KQOH#-9-N0UBTGN_Z.=6HE^]1\L.1:IDNL4\KB
M\M^38=@C<CRWG?,U5[8!  I'?<7'ZQ<SR/DYPL6G8^IIS.-Y2\+%$-(4I: ,
MRRF5*H5<IGI_50^N>=NV5'E82OE Z<WNP^#8LB41W#^BZH9>S[YD_IPH,#(L
M,1?X=P5EO=VF6H\*SCAA%5/6,Z"EU(!;LSJYJ-ZO2V35Y=2[ 'S<^TAJT//J
M BN-HM."IRE8DTK,N:RT(SB1G%'AN9UHJ9/23<_0;B]%:@@F.P::5W9IT;X)
M_W?7IO>GGN5$+!B$\[L47@%PDGT-6M0[-;1-JO5+<J.KV"ZNZ M==_["ZN?0
MW&AY.Y;1IR3<<&Y.&6M]^CS+%(([LJN 0.:R/V5==GJ_]67PWD_8Y/JO/E?J
M+=<_:Q(UWCYPW.05 )Z[@A:1H,3U75.% _B^O*4M=<VRZ,G!D /71Z=6Q4-%
MX>+9%;'6BE,HR:^3LXI+9,<Z ADNB)H [0)/Z'(E/S9J\$<R:$CR:(%85,+]
M[<($3BT76<A<V-?O/7H+J]>3?)?#L.[]TB_*W:WNPO)2QRQ([%WB!=TEL.+>
M%:"WH/0*,!%Y!2"(3G 5M>WZ!;374>(U"J8^92SJO);6O(>P;?(U[/=@/NH%
MI*4<6HCPO$PP&_$^2Q^6:@E9>5&SISF4Z=,8GNY^X^<X8XO5/08[LP>(:.N+
MY@\QKR=0V/@7O^4D.$ZM#Y/+5J3:/?*VVGX()NUG\65M[!^Q[\H,@P-<Z]!>
M4[+53_FM$%^>.<!/@(I<^ZY1Y1]C7861OD&^2!@=?>AV8"4OU0GZHPF+ @O_
MO1[F%<4 X_$69$+D900()#&TDB&?!7;?W9[00HRZ&JZ+Q.&N  //K@ CODY)
MA5:T?4M?9.)-X0V)E,,LU;B\SC?K;0KQ[SIMQ:2WZ4.,X7Q\LQAQE,V,S3&Q
M/'.5R]3G.B5*Y @9[DX^;N^X?VR4]A37I, [WT#\$GBXI"NC[JPH,/,S.O2N
MI93E6%MJYON)[*^[1*?;WP];ZR,7*[_S/L/Y!,0/BV3DK%V7-=H:'R?6[A]P
M509<7S[#O?LSO@--OP.=@L#A(^7Y-7=[/YQX]99GO[+I2;O1$:*^82T1:>Y]
M'WNA"R1) OF@%F@]&UENSLY&WF,8'_<IR>DJ10C#/!5JM4T#''%T]KF2<PDS
M[]7F[]($_BK.'[MFT?=)J]01.E/(4S%B+B<3-@^KK )EZ+N_K>;<X##:OP(C
MYL;\:#ZWQ.C(9M);7C;.@6 P+S:]:(Z3A_K!:"UQLTUNMS-Z  4%ZBA%Y+5I
MHH$^@Z+R;R.]!3$XI;5,ESQK6 Z< U/;'4SO.?@ J@T/ZM+P%@12*QZ8RS^D
MU5RPI;'^N<CFO0>,T^%OY8[RU1]PWC[B@(RZ%&PE_:M3P3\M_Y,4,\V2.KF!
M3[YT1]J V^U)>N^&M,;RQY3I%EBWY_O%@UK&!:,IP35F?#4-Z2'=I8_@TWY
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M8,</S)K#R9H.!OZ#(/F]@CI ,\?S0TF^PY?WT3*U1;L8TZ1R&Z<G34XI&U!
M _TM/B=K&=@J'<)[%K2U!L7.GZ:H<*\]-\E-123?QCW9_,/K%0*DB,*Y\R3B
M7E'C8; ,?-Y"0^5'Q'213/T/%/#'I4#F1J AJVLDW!\%A$T$$#ORGEL/'GX
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M32LE>[JTIAMCF< 2M"<4]NP%+* CS8P3+SAE7E:GPS&J(D+R@0+)5BKN*0K
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MDE<_YW:!2@2Y/$@<U]2=,3R''2/%WC<7J>1Y_+8'$QQV-O?2O9"(M_/;VX\
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M-E$]"0]8B2"8-Q0!W\C@U8<U-T7/)??>&@_O@,R7I7&>8$XG^Z\SI-5NA1.
M/(YMEVJA*]IIEWU'-CQ[Q9OJU=%\0W*V\3-O1\EMA@)<.E/@K//9 -]D0H(3
MQ(+;\,2N-U='-W&CBKMK#G81=G##9YEI9!DU,TBR_=9 ^T./;P9)*\&A#BD$
MQM,NKF6P0[9 [8?W>&OCP9Y7AW&CIR2U!_2=EW)9JOJ1^1>; Z63Y8"H9B01
MH>B-N _)Z(WYRP;<,FT S<<7;?;"02L;VU)6R+.2/29G;L:EU("25AR6N1CD
MA">A-;)2%6LLVCE#$CRC^_&Z0"Q?FA.F>AZPE.AM-<'A6AW3T]-3H+5!(7F'
M8/>U:]OW^09*N-63C/3@9W0O6CN/L^"[[912** U3+ACY(JM,.-!#)&P@53^
MP/)LBEAN 'D%#G?A:K(EBT0#N-/(=;5\I.[NFZ+%IQ&NKI27+C":M*30BVYL
MOLG4B>II:7JW2?6JBK$*'CQ#%/!AKOC^>B"^[!J(D#YJE%U +T6@+,4DH.%A
MK=QC<L;91S0AK,TR%]UT81X8*(#(B\\<,K.0. 829+T6Q!",@@VL=S71(?.D
MDMX6D3L:%9]'QR;$7MI$=7F]JS:<IVN=5(YFZ-\052+.Y];&QY+"<UX0@I6G
M4*6,JHT6(&?S%AR)%42!I#M/UM;6T/:L(^"MGOB0=+C'^2(H1N8'@[UF-L8C
M:DHH3'Q"SX=ANTISH3M[=I"(W;CC/M^#MH?-F(ST1QZ4-4ZKHJ.:2!@)NS)1
MSBIB-'/4RQLZ!0=/*L#LHO!"%AX\BD<_7DO"O>G#&L#$##]S[:"53)0;_SET
M:HT&RE?Q+RFK$!@R=5#WF2)I5UV>%W@Y;I-6"__.4TC2^H1)/O:.XA)?9  +
M>NB5=N_U]SH!6'T%GC;8X'6A67(0-B5O]=4=; 2;)[N=KHJAB*TV$G9M !:V
M5\GTIFE8?3NZ0EJ5L5MY91XJZ&8CUWU';$F&?3,T]<=GBHZ/;H6&*^^NAF'[
M03\LL8.3065'"H>!2_*'B1&)X8L313>:XP5>*NZ0K2M.F,G\9=C)D^8QNR;T
MCZMS5V^383*D#3Q'K>H\W419ER:A*[+1H&0C\DS6WOC^[#2AC+GWM-89$YF+
M5&X1VB,W$NGJT"UQP9G00]X$JAS)M1 ,V^F3I/<?U1_7$-"XK=_P,&<&!*3/
M[[B^SK!-SA/XW+06[09X4*XA^8T-3;8]:/J3VUP?2,8$Q#_&A8;]7 JO\U>#
MG811K60%%1BCGW.51,.[C I<??0Q83D!HMVR%3<S/@$#&>D;,4@CD-;#6PVL
M2.RS]PRV>;#K]3&?I$<SQGXJ]Q-/(HQ:/"I$ <:P=+A6:X*D\/FB]9C=4J@L
M@>CUSW>K,=T _EF/EQ&,-BK?\LHV*]GS[ES(H[@$4EQ"EZ4["HXI*7/CZL&5
MQYW>RRH3*8:&CN:X(*M0HC?OZ>/).^D?*#!FOC;-)F?CL$]+RF9W2 QIF$D6
MJFHC>&!)69^<'7*J9_.S3N)M"NZRAX//AP%^?E%&(==V:;&Q/2]ULB!)F:Q6
MUQS^0#.)-P[R'^\IV#DFK)P1$%AZ?(F?N IJ1W,SV?CZ7O['JU00;X#,:\JM
M.FN(V[-7$X_"44 ;1_:NQ5>JWC%J7+_5])2D Q+JV.J8*H7AV;%AM2(.W9V:
M_"LJ:6H862BW4.,> M3Z%JMK8V/QX-$.O\H#$'K"?GZ;$Y>)[A$*"'>:IQQL
MLR[4FU/,61'##<[K3'J7]$#:#L_3V7'E32_3>,4^"L#8:E5/X)+87D0"&G(D
M?4X!Q!I/[OZ+1'XA<RRZG7I.4(L"AN//2O3^]*S-]>UL/(IF\6SXMYROIR%'
M#/P[H:46H(#.4-#9Q6TY HF^S?-_V@W5VGH*7TQ'/ 6S9OQ^WK^1%G/<FX!U
MQR]RG(NR_=+I-4'[I(Y/\'&C2LU'&8GO+\S0OL_<KC(6&S\HXK&C%&5D#-BD
M&"!Q',V^[%=9X;E?%;@<\6J4>V.6RM?5S,$\K:N38C7;PP1CE_2*9/T@-9>N
MK*SX,M6WH!J#3GD$UOA5\++<=;3@P.Q7_ >C#<9J;5G,G%6Q.[54"3G14S S
M2A[\':7KJZNYD+:K$*M&@CT>/>#X12T,L41.-T;YS:"FN.+(Y\ODE>ML9"NY
M]LD,5W8O]9ISGD%_1KP)[NG4!\VB34SZ\_GZH!-(>^,QLQL(6:V  M+;E57D
M-GJ3,F(S+M85U'/=P@=EAVTV+/3*2XIB[* #O!(IK>'6CTV"N>RM&S;E4R@2
M\2@5USA#Y@(Y$!PL;>T,8S<B0EV/AV3Q4<!3]#N+61R&*US]D*WXDJ^,[BFF
ML'TQ"5X'GV1V,ZRMA+F13(_*Q%!HKRVGW;Q;^$3GDZIQN]CL5"+QI]F<^M\D
M%. 3E%Y/V-957-/GFBW9+LWG(Q=?Y&">%)B0<(0];"52ZB^N?/+D;.8'0B:J
M$-)^$4^PM*T8_5@ISF>PBHZOZ[I1F9@!ZNP9QS[^;MW2,(YE-[,W83%X9:1<
MSUF4@>R3\DY^T P6?=(FYDCQ.CRHE"E9T#.PTH;M1ZK502<]S2_1*W!7@U+,
MLK?O][/J'O1IM1M0JL?L^$J8-&D;"7!G9CZHA/-+ZAC2B55.7\C;YD7^1-R<
M$93X7.B,CNB9Y7+76:+;"YA2E17IE+OHIO](,@JXCWFCF3J;^AX%Q'O>I HL
MDL]';+^&3K$LRQ5BRE.@@,; @HKYFAL.;8''&Q&]Z)+QBZ.[*M-%'>V(MZZN
MH+<H0 "D!N,D\Z'Q_K A4_8TP)]['X$OA:FE%[3R\/+#FH7KO5Z71<E&BM/K
M7X.5UB0C\G CBB?*T 43FD!%Y#M=HPP32[:E6C%N8T*+R#SE0A&\U1S&%,<8
MU1:^B<DQ#:A.)J2_]V#ARNH]?/1EU;@DA:V[35L[<TM4"B2P2_HL2VC6"+.%
MTJB]R?Q#Q5>S,(^2*1EUCSX8M#]YT7\IOGG5$U2>8\)IBD\5ZE*@3L()43KJ
MW21$A-TIV:*R IWE=K KL<Q'Z13D#C@:U/+T;4&]W )WR,]HN#W)LU" +D<)
M?83QJT\' H:4MZ79OJ2,71BOY>,8Q&N.\7JE4Y*NG1J18"%%^A"-2:<?C!\6
M\3=Q?ITN?<$8%5JSIB.S,-=TMC +?- _[J/IZE.'8#W_:*L'TH.22USJE]=<
M43UP.]/<8#V38E]I$7-7>AW-M^L'B?B4T L/R5%GG#7@Y.<JOFQ;#N]6HA$W
M7=U=*&]@>&T@'(3Q?CC;77L%6-MO[K[2D0F)MKAA63Y-0IXJ^.\?AQ+T) M1
MY3+)/W868U'3K(]V1>!Q*>B%@S#EI*%I*B7<I,Q^2@G\4R^",('5G':;P14<
MKH>MI&0?B'*9"(.YQDM]MNC?G:/7OW>;CZNCL"SW__IV@.#Z7HFD9D&-0B!3
MS.,Y@Y^,BU;FIYGDN89C>7'F2MU0 Q5#[K4&!ICAS@R.X6#FH.5&:9U:6]Q'
M E%1DJ%M@_;*KTN&5+71BM,5&AZU[X[8Z6B-IKN7+5I4J"Y+&9\2^T<*=)VW
M.XH?5Q_I!GU'+W;W39D>I.L:U= $ZU1F#&1LOTHJZAL#:4'\.W>8ORQ:BI#&
MCWIW]Y)B>""&HTX?5SBC .+9K93GUCCSK]5$%*C-<\X&I3S?5GL_4X;=R\YJ
MICFHS:C/^"(H9OHYF-KT"TV8A=4"E6&8C(J U9#!CDYQ@>+&"X[5+ ),Z3-N
MWAI![4_4I2H]_=.@IE,N?;<1?6=6FZ)RE5KAV&6E7EK/50O1PM*Z!6^SM@:2
M>C^:IQL<74F(_N80@D(1 IO)C%>OP#H66RWCL9>0QP>U^3X*>"O5X?DK4)ZG
M&-_1"V)8#U./7H+$LV$4&A6J?.3[3[\\'$7_F(^Y#O^%<V$2@[Q! 5<[!,$]
M17F6X$WLEWZ.0W8D!8*QNE'MA@N9.NH^UMX33"C@BVXS"CBE0P'=7: 6J%M\
MSZ0ZW"M^0HL"&B_']LAT]O-;CW "@WP4@%7DCP*V9%! 3"0*"#"$B>NW+CVZ
M&] S9]BR%<+PRVOI@C%TI'ZMPC.NNU?-/HZ+M@\"<2-3'Q>DLNZLK@EWCV&Y
MJ^P?+6XF Q5IT9RW\.'\-?0ALD[]%]KL1RI_@A<1VX8I%!/EM>HXT\P=$&OJ
MKQ1S8>P'U"G3_:9;92C UDOYFT851E-BH@O?\9<I@M5VB>X3-AMNY8_GFMDP
MX:+ML2).5V,1V+OS#4>:Y&K;7Q38OJOT'JDG(P6["W<C5$:-48!:;5+]KX7=
MQ_Q/=F0!,QJKAB!/NH ;,^][:;'A3[LW"$>3\KVQD,[#;I!V\;<6NL+GDU&O
MU3]1A.D\QO.=(U+<[O#>KA)B@I3P!E",).W<&%R%CMK1M=.B5X=O\GS,&XX_
M&/C)GXJXEWU$FS5Y!03JS#/GN[M+*9^9'-VP-0 5T9.M$NM4ST\$\U,/EG!1
MP&K%CZ,QKQH(P2\#J4;X!0HP2%<R4'+Z<)K)[:%Z,*I^(M[X0,F1+.@P9=0U
MI80HTR-"4PJ6<(*'W]IZ,3&(R,[MMW4Q7"='\ZFFWSPAV1&?2+]2BQ$Z-O2&
M]#1;7.ROBK*(2G%$!,I@POV&YE^[&]AV=T>1FGZALSD"H<D]'C/9(N]B&S?(
MSRR;FCAR"?/.X%P^A!;:,%^F'[^NI)+R,'WG0:F" J@Z\3/.Q>V2A2'L[T1B
M%2EH/ODJ=4(=D3C1BI(*WN^SYP0K T5F]K H,-=M7&Y+C/&B(*)6XJLO1'&&
M'1R^BVZ?DU:W/$9CM><R<XGS1<BUL@_F&Z5J:4@_K^0;N2A4':?,[-][P>T8
MM8C9P('>*G.L45%T\>&VP@G18,R<;)>+47_/VKA+([W=\J:Q=5<3;HY4%JY
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M23GB3SL32@X,3&F</;I2'U_Y3_VVR]-S,SDFE23F;ILV,.=&UNKJ85N8+)Q
M.3)4XL<GZ/_&SC!R6NP"JJHK/UI1JUZZHQ,UUYH4\*E+^F>X[)7V#IMC]]E=
M-9RT7E!+]=&WJ?ZB<T$?C4^/$'N)I6CH&_.UU"D"X-FZX?)=!)_3;*WB9IDV
M=DF70"@N+NW/Z[/\,2WGQQ<V)*)<T6+]$DW&9"/V1 >#BE_-G\69N\98GJ%]
M!<:AYBT)I(T,W;G;)>H,8>DOXFP\[#3Q;(85RI,O"P]H!TC72TN^WO;)3XYN
M.FP%5,'W@SN_ZR?[GM[]RE"YE9ZEZ> :4ZT!!I=K^]UVC;S_'0^DW40JT @@
MFR] 5_P+E1Q_?&3/+$76E#+6(FOHT\'L*K\__BMPE@J'12 ;]AM/'70"S'=_
M_V^FWE@F5*<F.;<-:\@_/#DL%'%_VV"LP;G-GAJQ'E 9<[;D?ZEM*],T(YSZ
ML6PO?GELW>L< WW7%[C9S4@O2M&IZ#.FC?DF *Y.AEI,S.P'E]>X:_(NGQ "
M:W<D_'>UG>EPIJT\C%)2!:MP2-(#0B&L9@&S PJ9ML-*MU$CCE5Y'SJ@WIYO
M:9LY8S"_746F8W'GZ[*-Y', T\9!!GNY4$NIYC/G*0?'96%&Y$/FCI$FQR:<
MSFSI\;URG<C\GDJQ?%-$01&H]4S@H7S5KR-$Y3<044]42_!"7]X]V3UK6H*@
M&B:!KWIS/3\W>Z-ERY%/Z"9J:CB$Q+A^U!6?9MI9+'38%:7-[!IXZ V\ Q.;
M]JY%_FJBQY<EWPA))IHY?&)$JQ!K&#PBU2-_\YAO@.^&L<)20^5'_'9SY<SB
M,V$\_ $:+(L]6L.7F2 W'[.8% C-+HDTK45N(X_+[&=T)__U"SJ>DW[G6"VM
MZ.DH3BDVPP0)B@2? //L;;PL5G=HHLNR\'VQW2'L=OL@#[;87Y[%U0/-])W'
M@[M&ML1C:Y5O;J<P);GP'=8)92]:'&T_5[I;\(("XP4:AGDUYMA8%25>V$(8
M_K>/84P/TM/Y9'AG>/$5/$;3OPD<Z)8&V3/&5L&]TYO%>SHV3/%=%%<M;WRA
M]5IRQ1-<I#,'#S2DEXVQO?$L-)XE)=:^#</64&-G[]O@],*$Z,US=; D1Z[K
MF-^5O0($X!.%9>GZNY4A]B[4=VU[AI/X$T;2@\1$/+]8:(6^?N5D+BI)DA5&
M45XBM1CYX6%,O:M=ATQMJ-E,N9T@!U4])0WW,J7B([GG3#>M%DUB-+O*X-N,
M[)>F:O$MJCN[M9_D;13.?,DGWPVY'@<".FX)LZ0SZ.>?>C1X@E\ULBKDFA9\
MW@PX1H5;:X+M'#Q+% B497 UNMN/3N3 ;QB%QL#X7E61MC*1F&=0+L.6&>/B
MDOLK%C/,6!'W9YZ&^X^25,C1CNC6-[_)95I)+Q@P5S]Z')$]S]QTLNDDIB'@
MAW;6=*?&BC633<Q.6_QE%O2N&1@65CU: 15HPZH.9R,5.Y(PIT?21UWJ#%0L
M)Q(02CZ<4Q6_M'I*;O2$_B1%%MK#=E+/-32X [/3'5=)ZT0!+57#*&!SXQJ)
M9$$!#PT86X1Q?E:&/ZZ^EE#:()VK/3F;#?4A:93#STC9^]0R'+;_,.*V';"'
M;"*E[1L/5T PH2%+<:[PKW9O2D/L5K^YB)E+;Y2SI@UH#I>T$B@GUIE]>&]-
M2SWJW)1U_'"#M:4GR!IM.P4%A+V?N9$9YLK2I]LG(]]\-R",]-75DF,68W[7
MHN>A^4TPO? =''PLQ=/Z+3J4FX&O Q*NCDZ7NJTM298I_&UYJVZ\;1)SX%.X
M_).F&]^;?B=!C?Z#XXAIX_2<*PZLK5)&QIQW;P)U*# \*-?-X9[I_7Q1!CL/
MU%P4Z&=D>%6=G30H1/<Z-4/9O:PV/D3\W+ZB5HO7>#!XL>88;]^1L]. ,^)L
MG54=]3[PP_K,/?1/9_1^ D9XQ&S=$G-J82*T"C2X4*K6&9\OX9RKMH>M*H]Z
M";=3U3.%.ULK/7PJG//:F?:ENDQW]K##^LB7S*04;JL$!8$#(>7[3/&SU N0
MI3!&S4;/;KPV!T57T:]-N-[N][)&)9FSMBE39Z&4'Z^QL:8_OQ0]'[0W6$A/
ME81:1Q>?QE;':@\X:AVIQ>7M$'@*O%9@/%YA ?C.UBBK;ONT]>P;)@[H#SN\
MD5!;3F&Z&/L7YMGU-AHJ*8:O?5J2#WLG4(# 0_VCK!^%RH^KE1B_XU(\,LV(
M\/+#HQ0)<.K'UQ(JE>B3EYS6$T#;]P6@-:R;<="/Y\27EY?:??[+LP(K0I.2
MW<B1>\)V5-('"]\'U3UXZB3,<ZQU:@I*U<IF[V+E-+'-M ?*"XQ=3=03._)=
MDQM,[(*^:\B1//XL1_P2[<_TAWIP]VG9J3T<%H-L. "=.HYN/8-/0A $W##U
MMEO7\!&8*.#DVLL *Z5__S'<:\?[7()W=9TD#@7@9+>!3M8S08NY,O":3C@$
M!3!3::. 2IDK9H[((KMXVMC<]E^G"B&ZA#I"3+'EM3>#"K=&.[HB<WD\TG@X
MEGIC1'=4XW7[F[2!+N(J!@6$%(FFEU]!Z=8%KL;M-Z3HD&3JP;=>T:N, AHU
M03 G4,LVC.[FTM+D8D<=R5VW I;.5[A\MJO=^/T4!#>29D0!J5P<2(02"F@?
M_A.\$S#K;PL30'609K?OEIW@$4BO\J+KLUMW(U.XX4XE1 &#\;="^62@@)7=
M 5;(3CDH5KK"\#+B7P =D3>,?/DWYK\Q_XWY;\Q_8_Z?@?F\"'";U(0%A8)6
MWMS-,'D_NC%][O1^8/O1@$/G=7J]6AW+4M%-N$CJ.0$(04'C6>$NVI6CO1[>
M"?6/2>:VM"/6D'-(?O.[G'N/)X3;>+ U9EZ>N([_&4/@EF(<UN#Z:X4;SC S
MI'<!Z' 6!<"TI^"+R.?7*.#:' 5 2.L\:K:>\H?GP,JPS]C&E?%G? KV9);?
M6=.=[)O=ZF(1!8 A2%+YDEMQ)V0N]E$ /&]U"UH?*T$M\[KHIN^?CX5,/ROV
M=F@\$2B^U6)4 6BP(@)Q#4*R1\#U*3MOKO50P.)M=;.2'Y$>\1Z_^:P'!?0-
MM/YIE3\Q*90&2\5*8$YRW%8\$@1_7"?GCUQ^7;&>O]RC^QOJWU#_AOHWU+^A
M_I\$M19T?ZY^,XB^)I+5/2-!'F?H(4=,Q$#=V_J@9KICEBG0K#J"?#S,39YO
MF&;:VR..O4+$6^:56T0[W27K3!'BEL<PV^N WW9V06L0J\;S3A3P/-.!9'<(
M2>Q-V&L"+STSUUV=IVR5&Q/\50Z7C$U] 7:_=VX[T%[JSD*#2</>&>3$)8P"
MFJ09QPYLJQ;T]X^9%EH_>!SA$ZRP=[:MF]<<(69"9WLSGA+)#@=SJLG<,QG(
M.AI-M/_2P)[PO_@ZRZBVXF[-IX46:E#<I7C1X@X%B@2*.RE2W((%M[10H%!<
MBQ?7X 0([E:@N 1W=R>$X;UK/MR9=6?6.M^._L_9^]F_Y\@^LN!8(*6"GUX"
M3?Z*WIG23/<2J/SO4J+$G.*</EKN6<%W,26_9TV7<R Q0;P7.7%#'_-4I8$.
M$B'/J_F5"31&'=&=A;/]S_H!/X1$O^\$\."N&"9%<EH:/[T6F+7X^FJ.MPJC
M\RT!YCT/5&1[6>&P5C(XPBWT!3PZCEG80I9M^M]JE"-?0\8<FN0!\,X'6W"@
M;ORD[B;MQ;7/:FVUH+Q<ZN"+5H?S,V[TIH<_Z9#E]B+%).KC*6>2&6-O(L]!
M='&KCBG62LI4XE$7OJ\<(DXYT?$@N"E6Z%A*7 %YYOQ-W+,-UHJ7BC0.FG-U
M^ Q1+9J'6N^W+7SP( 4W46>J8/TI=F,J32_KUUH^G-R/%-0_OH2MW,1R: PH
MN4=;O'B7T!+^ NL,9G$-69U.T0N.7%E]!W(=_08$H'+A% $B5F.U'/IE_J]L
M:>Q-]QP+::NY4 P'\R3(9_57_,S=)<B\D]6@#-D[/NX:(5.QZFGZ?UNM%5G:
MJ4ETM1<H#K29:U'A62-2M><!L/[5$R);#\6;MYDVHO%3]#3UNW2$7)K^,-M<
M.-A9XH^]Y;^UCMGC>,YWPW1*#-X;7$XS$][&%>KVX>DI.FE!%7\S_CP_<^A>
MB/ZH^\IMI%V4'1)AOH6\<M1\>5!SASQIT/R3G7( [>AE^G]MR-;@FJ!K&N%B
MC-SA:6XL.Q>=X.4JU/"@:=-5MGBMX<MU?&M82#QV'81QN*T6@G6\I]_ZELN-
MU)]Q ?BZFOWR5 [>"(FGT/J6L^OMT5^L;?7>I<0-A>V:17HF>HY2\5_K%!F"
MUZ2()>+>_UDF^D[V)5I.:B!6Q%_;^S%FC9C'[2V:$6/)X%6*7/-$P1G16*)0
MHB4[> ILI.M SHX*Z%H3\EFWJ9&%9O"7]<+WO5Y[5[$)(XS:XWGRX!R<N*)=
MD1]C>L"MY'>GRVR]:E[#JC01EB<\&QJGAC3G$<3D8L,2CL7HY+_(ZY>G:RO'
MDZO5'+Y74A.I/UYR?#(_[/$^W/=:RS/=H<8Y>=YH[5!SP+]1-XP9OD<>MZ\7
MCB;*>P#P0=";N/=U93G=!RN%YR.X!K91,([BG9-FQ QV.$=,_R!EXDYFX47Q
M9=PO^)5C 0K/AP5H;,<XC7ZRF72KDI6W^[SC<DS/X3O&@,7Z5C[WM,3DU+8Q
M3FT6S&:HU/KTC0@P_O/KG'>JA3KSK7FN<._$]-+KUG96N/?O2,P$G3W-(.TR
MP.<>F:<R7T.,G?>^#'_W*X9V+  %!Z8U=G$)ERLW!-^VW3VCDIRECA>I921.
MC)Q&M6L4D#%=Z-9MH*TXRD"R5JMO%*<P9U\+:O22KZ>QN #ZM_X4N3J^V473
M>I$H5<:N#9*Y]VD;EW!C' ]1,SX 8DH>I;)\MO6<UU N]Q2$HA@EGH@/6[W4
M=*N..'P%?K/71A-]#K,0R*%P^&N&N<&V'PGZGQ.G#*EWW!R4U/5J@5?Y^.@R
MJ,:=3MWN<NK7H)BE\KZ+<V9CQH7*9,K6,CSKLH<3?AOPBN<!T*&RT.Y7 8J"
M& X^ /I-)UOW7T,O#;:*= R]C<]%WH]%+3E.G-R3=)*/_/Q4H%3I-<75<I=
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MXHSA#M@\-Y]VCR*Z-0O7DM:H6P4;I$OXU.8=Y+4.CJ"QK>?<8%/?R[Z,$._
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M6HFP[)@MX[37-S5N&AA ^M<S$TWN&(0;1(75-K8W_03K<Z!*2;";+)ZLB3\
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MG%F.F[]#LM,B)1K*3,,>@ROQF8X=*#4EZI=;NA(H4#=V;P!1UU9W*C?Y V=
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M]!9-FO;YT^63PH; W^^+.?>H\(H=$84OP"+1T[NX?K4BD5N%2['7/^AWQK]
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M%BE=GXLXW%\04\8!GQ/&;S=0T(VBL,]TXD3C^7E#ED]R1/::28C9=!S6YB?
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MWF")Y0I/&09-UD523&-@C*_=#OO@?@OB=+P+<TG9?UQ-0?5&EJ(=N,;[*Y8
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M/"8AD-ST;>#/5*XU>UKM^%_JL ZRN.:?BX1ALL!! ?!S(MJVDC^B'^Z?8#M
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MDL"MTIXS9?.-CS+P:SKL4L+RRZ<F+F8-V!%>!!]EF[9;X"3-%O&L]6/6U#R
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M68WU*XG(7NKLRYSYIF3(J U/<!-/CB_^^V3] )+1;X 3^<2>-.(J9A=7F"'
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MX(SK7E7Z?L7E70^'N-I#UGB3, E<JPN?P Y%S0:/@P9K1++5?^!#5WY&T/4
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M:6F)?4HZE\A!V!+(-7O[;+: O8GQ&^!9M'QPT5_C]WXT\#ZF'6DPERKJ1'(
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MU+6>8QU?@P\D[>2JEH#?%6E3((P)]M$/@&SPFT8X67,@Q:*-2?D360#@1#Z
M>IM0TD;]'GO/U; !^EU/.3@P1A )PZ<- 54;S_)>/2*LU0T19P/HJ,A0@U0&
M15@/@#D-IA#CF4-M'[)6= IK[77[(+\9/OD<GHNB0TS6BS;A%Z95?2K6/%N7
M[WHA ?%/XH178P#+,;IH ,C.?$F4;1;L+ 3I480/E[<R',35[C61V5<I(Q:$
M46[11Y6$^JS&D5JTF);JB_=/OE0X=?'_3BO'/:,:XLUFGQ>?J/<:$9EEX0"L
MFG?M]CGL=GB32]TFM(*3@R@<+TH@\KH51]$B8\=7&B W%1Q3QL=5%(>,N@AL
M?I(Y: D[-V*W>D'8TW$ATI0<VZ=T\X^/T_,:NV[D\T36\4=G^,#B6-\ &O_I
M[$W6)S'0XBQ8^]=$>)\VG^>YSA,'R'FCZ*8(PC)+RKN(P G855R-"V9HE?E1
MT%A$219N0"5'Z+)E8@)I@[@:VE/4]5:42_4=>A9T6:[GF [4RDA,BA"@KU<&
M9+5KPM$O3;5@ 7)+T]"Q-#1"B$AO^-A;">PR(N"7B#OALZK[?^-)Y']=CC$\
M*Z4]I$B8P1,SO+3OG TM&$1BN0QBQR%MB8:^O-_VF2U74$W;ZYL423\)4709
MG4)9Z>%ZM-B,]B#BF*G%A%")':G'$GTN;3*'LS$4C&: ?FIY1R_ UD^V1RT]
MYUX+XI6*4^@Q*#OC&#=*>-+'6W;4/+?+MQX80A;I1()W!Y>Q8(D5BTEAI>AT
M1MESQ(14].><_6S_EDV[U-?$B!A#D :.D^>:99Q.<.(A@PDARU0+,J##_X<O
M>ZUXFM3X5.^%]L;H#,;Y+>@M>X7<OEKTM6BMV4191D8$PU<7S#SM7GJ)D G5
M-0I[>7 FUQ5;[]3$WDOZ@T$14._Z/61RUTYZ428%='FL-C'P8S?=I2CC9@V]
M44X)-O&E+OK20;A]2E7^NEW'4"J#2NSJ"-JSCA8G/,NSP/TJ\[U!)(J(" NH
M&/5XIGFKK!DI,3[7+<U1BK,F3?)<DPM+HT;@;H0H,KZ&8E)+4Z].T!@K_,,:
MQOMJ8"8E[$2UL?43IBV#?EKC3PSV 0OJNJ?*%/9*Q1$_,:-&PE@W=MM>4U3J
M#4.S+E'U.+-[JQ;K5BFZT];AE[0,GT^\%'.@ )!)>6$%%<;XM/3%CZ R].<[
MIV]3!UUUTWEFVXI57<Y78%X5AX,:/&<[6&'>+]]<L]DS=<QZW1MZ$93<+9#E
M)?L.Y_)>O_ZX(#=+E=BYO"X-II!+";5:(9%I:T 9E.AN:CTC<<U:6DUZEZWH
M,)MLD"M\O?P;X#?OIH_64Z7MU2$_4[X;W0QM3G.9S ?Q*2!*Q$*;4[=NSA[U
M2%)RIC,>3AC_X?WHX>BV@J*@KB[E^9Q2TVF#J@Q56",O=G7?K7E88F37%:U!
MP1910H> (_ =_^XV+XPHB"ZF2!G5N'M%?<7\2LPX:LGEZ<>!HROAI >,7]0L
M]2$%FF.%]"FU:N(]E-'BQ0V\&"!-25&GC?XK6=YO -0X-$]\PWU9:?MOP#SO
MZ 'W$>L42DYL6W#]*3$C2MCN;5=)I".)2Q]^K.*4:IJ7%[@.2S3'UI;(A%;1
M?I[8-/T/8?E#"+):O7SP&DI-#?0=")'1R)&8U;FL3Q'P\77*Q 98J:[Z?^["
M'LR)&^EIC1(3'B>SZ<S9JV;'YR?:A"EU=JM>:2797NSL//=0<EA+5H0&VW5]
M@B))Y%0GCC%JZLY)*^,[R%3PG&WT0K0/BZHA:JRG%REQ&]#QG"LA*Y'H95EI
M_7B+_A*-*>4-\?=G=JH/T^X6A;\\=Y;S4I8Q$R,/&@,S&!,<F@EOCAY5>;<[
M1QO05.XO[(GSIP>W\1-A0,8ILZ;/<^>LK<_Q7N( HHU%KQ25!;X+C@JV:T?5
MM"[L[_6["XH8S*&T8-7=)HF**#=I%W("IY2O;'>5$E?"C]4SIO$V;[.FF!Y!
M7 A'.L8VD=]6Q3'5,JD%9#$;KD@@) \VF-,>JNO!<TT& O$\.U TX[[%QM95
M%-F#*&O9ZJK B99[LOR%(>_]!B!0J5<4M)H976\!1W29K*_S#9OG5&<P/3X0
MUMWG?S!+/2%_)55&>]GX7R/3'/\/S5%1 ,J6L4:)G'*GJ5TFQFR<(FRX6G,I
MN=X%[ 3-&,N^I3&+6(Y/80!QZ^T V&^^A0V4+)[\6%-M #*7Y9%)HUO>F:O2
ME\;7I7'/_1+MB\POO?GW5>90N*[8O%B38*<1:0P)^>(PU400$]JS_J*(3\:A
MNAXXFL9\1(;(AA<XHK.3X.:?JW_YS3(T)CF4#X[#TVO42L6*?+J;V%.SMK:W
M;_+-AMY*BY9M LU7#ZQX"#$R:XSI8?&V+>#('/8EB4M-M?*ZH,OL@60NL<BO
M3XX<K?GU!-5O[PN9A5TR]^_[2X\^#D\.F8(/4E['(=Z@D7V@I)!G1+^)=J<Y
MU+F6M65IJ]T?"1C0.EF(462@PSU^<+;(@E_A$>5L34_%7QDL2R_OME?-M[]T
MIOI$ZR$V\P96>9@TM\9[4BYEIPB'B5 1\_"#*]DUG=W 6UCS'%MSG!E1.LC1
MJ*L5OPU'<5]#9\'/APGK'6+(*$4$2/[':4B]+IS&R+:E8SPGC"3YOE+F8#J]
M:%W8T)1$AC!4DAW;.Q[$;[M=&,Y@9E28,4/2Z$Q^<-,C!CC>[/!-\CN!(&O:
MTF)X<"20".2HJY0U3MK5D2D.-EYZQ1A @\@_[+2[P\[TQC!LK:H8@CY[L6>J
MLG1-J3\$FL$_L,.';?OCU'NLP"O+7^J1/M%ZE #7":>G>--C_HV%22Q7;4>N
M*(NB"!T [Y_^WS^9H[-:-2[_*"4=PZX%$SIK!202+J3!^'4.Z>2NY\WFL+A>
M2_1\T?K2]4*Y^0FAP(Y>KI:"W$2OA)TH#>8PL-F):WE89VIU]*N.2H["I["H
MU'D&^PTPA%&E\4B,'G+(]:P8XK96R3S!>R?MHM^ ]8.XVZ,GI7=#[-90O4)?
MBU!44_K^87EM!$ZQ O/8E?+7=X6$U3"!ZG'Z:#N?"0WCOKZVYC!Z ADW91E!
M7%F+0*?4MKP.LRAVU>@O.+R;NF\6_,;6TD.XGD;P%.T=8\7#(U.&RK85XN^B
M=T5X+TJC4UPGF!6L(.AK=Y!L>&^4 NMKU :+ <?B0Z3-I,TE^(?B'VDP.1'-
M&$./@8S(\4N)VBTH2?,9S<88TAH#1*R[^DW$51K"GH(%<E7C\@51[,BU*%+:
M5]*H]>2) DI%F?H7G$PPL,^#OO0X?VR!9\__K_:^,BC.-ENP"1#<@G9PN@E.
M@KL%;=R=A- $=P($"!(($@)T:"1 \,8UN =(<'>'X.X:K%DR4_?6Y+MW9V=G
M:V]]=W=^/'_>.O76.><]^KQ'^KYB7D9+TWZBD: )O-2.T= VNU.F)_\64[+8
M3,L65UKC"G!WT<;2.T$!<,P6*B3IM^T'FP_QLQCA5D?/A$FP)P2"<(-"*'6T
MS5%;A':?P8Q#8"?E;MF,1V@<#KCV7\6:0;'H-W*SEJ++CZ+K#+DSTE8]P2X#
M2Q>%G)*1/7(A/=])PV8\19<MSI@PJ-:GZR\># O]T*EV@R\A*<[*H$39@_AB
M,[2?QAOBA#*/QC@LPB$X92W490$F_B!OXLD VY*#I EN PB.K,O9E^I/N,/R
MX:8N.=1/7,,OO;7E?50L&N?(.J05>FJQ5\+#S36'#)/:7A>FO[_NY6FR<(6+
MI\2:A3$K-L]X_Q+'@+ 25[<5;H;L"UI!8+M8G_3:O'*6#%?X*8.B\1P>":4>
MV'NPEIX;\=6&37#:7  ?.T&_BB#'1G_GF:3X<,\7VE-(<LZ6FF'C,%QEJWTE
MHXB(!/U.G^+""AB/P$4/.\!!OF<M23K\4=B<1F2Y^6IY4A6+9RE7[;.^;BCN
M\?;5>NX2'9T:^RFW@" U[@W#S,L-%8[1$AYY!W56I][O0N(!@8S']#2*-#-1
MM=<PQ10<[0#2\)=?A)AJ3_,NU:.W\*VMHI+BSC4! ++M+=5?N?/,<!%#:<5\
M014OA<;U9MQXGQ,R5#BQI&3K4-_@05JL5AF?1O*>%XHVW#"*1>@JAVE93!_B
M4N4_4_KAAD$VJHSB!*NZ=EWP4H^'%S-*&JU47E1Z[4JEY =19"UUW:FH=I-5
MBIX CS&$(NIZ=P" ^:@%-^<K5\?ZIN$\R1!^05%AM&&%,ZZ2\'T<2IEN]W!4
MN!)^2#B^+5.!,%S]_08-Z8CYR"OFN%6%^O@$2_8I1ABJQ $A G6X+N)OYXM_
MLOE#AS!K*N9!_RGE/S(/Q.Z?F@?RVVP0WCPT%5!JK*R&IZ.Y26LHX8EZ/6Q)
MC?01XIQ.XMLCRB80;(+D@I-TB16E*PV7\H,U1X^"?GS\\2K\K6\:E5FQ(6L+
MQ9-5UPE2WE79AJS#\A?]/ES*%5'@2C5^CI*W\)"\-H"B^3$5\+[\&V<=SO3W
MZZ&%Z3&=Z5'!!"7']XHRY62[R]:O,H\-SK?4D8>&G+ZZXHAL9E3GWF?R%/V"
MIX57Q72<XD>$/:=]4HZYGC7R[Z]_R&BZGE#;S*HKN;)6A$+?8YH6C85NIDI)
M/@3MA3&?4>?^3RO9\%W;A"%U[TQ:&=GCB=^9"LC5"JW72/1.4#'89FK'B<[6
M/*B +Z.(O#H]*='>-E8+%>5:J3>>DBMP!(>90$/+6[GZ 4A:C?U-21)>$W.#
MTF#H9W?V]9[PI0=&J$C4^;H%*2 &0\-%0G$ >YBN@8XF_;EZFFCT;H=B;8[-
M^4/7777PVT0Y+@ 1@&J5XM<6RUVK_"K#B.)TLBM/:2A0JX4VR/ .3:X_.G[-
M#D?VI*#F4U%U-!U>_MW'3*MJ6IKV ?CZ%[ -85W5@B4*>RDY^R-3^_=>+D[<
M7@3M_KS%^^GE52Y%5;R:!LC8[S:)'[8\L$/.G=D_D[$@0/DW:V(\&ZPX/3W)
MJ@OL64Z&"F/4K@]I G&%4[W\NZX20*%OUV0_0=[W+W9T>R<"J-"E' FYU"H1
MT59@1<D%7#<FB2 OC) 3MQ&.% CHO8.E2&J/LAT%+?-U^2F?UG<D#;^F3_&F
MR2/\=N8W<TM/)-&B9U.\SXLC_[SC//YR$+D_/O,I+$DQMM9.9BX A*-W! O&
M@O*B:2J*Y?$<[OGB>OCQY8?5ER8;"+94Z-;83B%>)9Y)4BNPYKYU\@F5Z*_M
M*B3K?P6)$;4_-R90;77G&X$\NG8.UW7/$XC&E76_"-:9QNQW[KKA,3K**EW/
MZU;3!;._0.UFE*\4,\$I35!RV,/GDHJBX;I**T%V+1]E'0G0<7463U[5M@PL
M*\N0$<UDY_?"/0.[N_<H0!P#R![#H[(JKJYB"[D4G+FA]J5%(6;":HS2#JBA
MTQ:>0'<5_,+?)?,MK#?P4CT>XL;D^W@W[)3^[2W  XA\780ZGF]D)!@SJRH?
M+P>@)O$BV+(9XY6^8T-\F.ZT.=DYGO,QA&MCST7;BT!*SRHCMI!_YE??I-E?
MF57H1ZAO,W'6F2B7R_X2+82#9J';3]T*U2SLZ,+N6F_1Q%:MYK/F9\T*4(_S
MPQ,-N': '_4/PY.-U-[WM-8FW?@$-O9&&H^$P]C(6^M.VX/CODV/,QV/IO(;
M)ST1]1<\I4U^#.8?5E4S=TK,":XTPK,N.MEXG!.:+^MP^(W*TT2?C!I3O.;&
M%@H)<,3AS#2\Q)'BJ"'ZOGY1EA!;AJ6.[2]%MSZ19?'\=:#.J)31YREE2Z1!
M^F33Q^;";AN8*W YM@C]QN^9)?3EDBWESJ-TPO*D6T"/53#4,?^4-F35T.4;
M5.8C-X0DD 5L!]3W?KAH5VCQM2E@Z/Y$?#C9 LK<5W]S)&E-"MO(],8T\Y/-
ML_TS;]O@10ITC*03\,K52&S&3LA3K3RRE2K^W,Q?DTQ:8L(#\*5(*L*P@R%A
MXF/J:K5M*NIJ]F<!*%&Q7,$X+1(1^#?8$25YAK.4!7D6=O;/HQ1N_ 8JG^M@
M/V&)UZ?_1H?=",@?F6_0> !"AV&CNO$)R[O,K9TPPL_F67 =68.IY;,>F#P:
MF..NIXGGHR(+YKV(-(C43UG+Y.?O?3)(?\TEWT PE:WEG2<UA9MBWI'Q]BY=
MQB"UP5%C?0)\ZU#H/'I>@/50[DEHOAB@33B(9BGFI(S8:B;<W'MX2*O-FK>1
M''6L)I^G%MV@NL):[@*_LT-(;$O9R/!([3/=CC#V][%K#;0'%*1?AUSAZ!7L
MW$]X!GBMJM&2*N12<@J,] T?&/6\53#VAYB]!J!TE? VC3KP7<WFQ%'06T$?
ME,6'-3G?'+&R%6Q'&$H[\P981C*OF@0AN/"F[!$(FJE+31!?>X^WTSE14;==
M(O_-WO,D@!?<=> "V*TGG#>R<HHVXR;J7@7F53W<KXA["DRJXH_,F9TH^&DK
M!9,<CL,K_1RR9DW,Y-S5W+4.H"(8H$H<.( %4T*"1>K;+1JX/&TI[5M9DI9!
M>9O1)BJ\=5%"SV5(?R^<S_JMK#ZWX"#QOVSI!PD*W@#<?LH!J,N_$"=X"WA4
M:MY(*!AAXH"R,37I1Q7IASU4%?$8QT3I^(%"N)^S-W3V-'?M/1B/TG]SY+X_
M<R%\3D%T<J03(Z;?PT?MI""<G@C&SAUU+2:K6UX5H\1N(XUFY^+9SLWJ+B?W
M_1Y!%H"<;(3"]>$^QE7#2$6!6R)!A;+!+)R$Z^I#2D!:;*]UK$O$S/V,B@8B
MLC!=N@>*U0Z>+2=I."/?X YR*Z@M>V)M:B_8>FROOG_2U$[5Q.?1CABU;P4K
MKV>D#ZQYZUP)XC5^T16"PCM&4U0 :G_W-ZR>T22-([-$7Y*+X*-"=0RNPI^J
M+,,&)ZN10F%/N+A7N/I]G_EJ7;I.U^)T/JI(6(23,4J&45ATQ-<'>Y@Z>>X_
M*](IX;VR_1EF+$,YU(';^%-,%N#I:0\O;]U1%M?$< !K$LC2YO"5OUC"R8RU
M7X4-4":0NJ#-NN!81L9ZJQ]XMV_S)1R/F5L<E9>I>N\S)='F+!NO5)V3[8 :
MI"N55%B[L\7Z!5D)Y$0C4RI0)@RW+WV^!52ST4B*O+SP2\4X*&*,HLQ'W<LA
M76?&OE "06@V)K_JN>0+J'Q-.,W ,M?10@N%>XJT1#ZMQSX%>X#5,3)]5TZ/
M,5:LW;_YK2((\F\!I]L!)DKJ'\1-VCII]..>[)2\0S),;>]JW@+L;: .G(S?
MJ8I?:%V5[/OXY*+6'"W> E(ZD#\1YA+'D[> 'Z3?\5PU+"Z*S;&URTF#7H=#
M<<4&O!S/YK/5R6OB"8,A_.VIS,@'8O)% (_/IM3FKB>&ZO:??IH[YK5YGB1F
M9Z"6S\[=BWI/B9N&P138H7.6RPFN<7Z2".$AE&5<9U>OXOX^>>D]B)&F5CAE
M0)"P$+KLA#ME)A:B92#PC.T]4I\,TO-$!WHDIV9L?G[-!J<#ZH.8'<6<J>LL
MZ?!S_81U !"J=VQL72"VWA_L'_9$:+_Y/Y[=_O3INXW"84#DDJ"XKO&K'N)C
M_&M=Y^E2\75,&A(W(EAL*/+@M,]J<J,N8L>J5)J+*%W'@D8O9G<R.J(9OV;
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MQR%Y$20<7_:&W^P&=D<4^8C$@=$OHA [OK_4XNN=I0^8NE,+>XU_ ?X+\%^
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M(B7(?#D%OW#F\9K8ID(:TGN>2HGYB:0<5%-BN2D+K+4[MU-^^>WP8V7E1LM
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M4WZ/-,MHVHD&_9;-<_Y>^?6!7 "9&5[CJ"K#<ID<$7OZ+PMFC7HS<FQTAC;
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M1C-O_^W56PX45K4,E/V:QO.3Z4#[.Z7'W3$$DV[UI/UX$(/*OHHOF#XKCW.
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MM?Z(LGBZFL6LED^:%H\J7CKVF?EJ] F>M*F40-**9\R;BM<LC%-\KDP!H%>
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M;\*OX*T:ZI!":T(#;K=&Q^_>#+25?]G[@TISVK@.],7;&A=D=@)P/0'<,SZ
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MDW:5G8I]'ZK&_9]X[_0Q[LX5LBJV>=C753)[+ G"F F3!#*[M3)UZH%=?O'
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M#:Y[1^X.663UN[C8;G5-%2ZHEBS;78SZ7-*K.C7TT9-!UR(Y?0=NFS!.0^6
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MULZ],OA)R8Y8T<.?=FO^YZ5".@3*^9/=7@"Q#8\&@*CQ-3R",''Z"]8D_NB
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M^/#Q/-7W9@Y9"Z-@]J\Y7RR^B)]UM'7VLZ4D *)VG&'LN _[ QS%J?_.@B"
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MM/7#>-T.2@"=>ST [3^-MKS&*6#:^B*DJ'PR]+#WVC2,'@\D>.W,7;9S,_]
M[4WY< 6%K<JCOH8&1@CFD^""($<\@)V:7P(QST\ P76('4Y/PDN?0QPG>":F
M4E1:DWW!TR([O>;C[4K\(YPE=<N3-6O%7"ZYY*DF7MI<A-."ND>!RUH82CQ
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MK2)@9X]*.'/3K87WS/WOD@ *]6S#T@&I^[-^+@\P- 8LA[$0L[9<H_'F9>Y
MA:8OWV6OQ@0%M0'<0>R7?:7I(G-7';]W>=%EM/%SE =G)UJQ>\D1?8A"P16G
MJ>JDDAE&V RSSZ/6PY^/%@N03?_H5HI(+";W)?8!SQ0HPQTHOT\;=W[J\5W+
MGBK4&F.\VVHQ [P?$Z-M[\N.BI1_- 2#I>A6A3\:3E8U]*AY,"S3W14X97;@
M$2C&N))F0SRD1!AE4,K.PI3WB0RY=#!BV6:W#SNO.R(GHK--T"> L/(3 !6\
MV[UTRO#[^%ONBKH*3ZY'.]?U7(67Z*8N5D,N@ 5-L5;X;36Y VZZLM6 *;M'
MP?$-(F_$@0+>'D4G@% ZMNLEB.'88_B#?KGTTE!0 E>U+E[@"32II#.=4O[_
MY8^D_O_'_[</XI-O_P]02P,$%     @ [8)F6%U46@%]F0  ^K$  !,   !I
M;6<R,C0Y.3DS-3E?,3$N:G!G[+P'4%O=DBXJC&VR,1@P&6S @$DF9S#89 ,F
M@T@F!UE@<D8&3,[98'). I,SF)Q,#C*(G)/(023I\I\S\^Z<<V?JSKRJ=^N^
MJEFJUM:NW5I[?]V]5G^]:DGH/^AEP%-%6059 ,8#  #C_@5 PP'O -B/'V,]
M?H2-A86%@X.-BT]"@(^'AT]!_(R0A(:2CI:&DIJ:GI&3F?XE.P,U-8L@*_L;
M;CX^/CIF87$A'C%.7CZ>OSK!P,'!P<?#)R<@(.=Y0?V"Y[_<T+\ 1-@8F9C?
M,#%> AX086 28:"[ 73WS_D(XV\-\"\-XP'FPT>/L;!Q</'N%6J? AY@8&(^
M>(CYZ-'#A_=7?>ZO QX2/2)^P2WU^)F:"=9+!Q(>O]AL; ;IR@Y2]?$C1EY3
M1W\<7++GY!243*^865A?\_$+" H)B[Q[+R,K)Z^@J*&II:VCJP<T,[>PM+*V
ML75R=G%U<_?P#/@6&!0<$AH6%Y^0F)3\/24U)S<OOZ"PJ+BDJKJFMJZ^H;&I
MLZN[I[>O?V!P8G)J>@;V9W9N975M?6-S:WMG]_CD].S\XA)Y=?T7+@P )L:_
MMG\7%]$]K@</'V(^Q/H+%\8#M[\4B!X^>L']F%A*#<O$X=E+'C]L$NG8[,H.
M' 9>]2-24\=Q7#)&OA6FX[^@_0W9?PZ8__\K9/\/L/^):PZ CXEQ[SQ,(H D
MX/*:)><K[O]-\AIO*+KRS[P!8FF]=P(\PNN7II,N=VRY4W,^E7<4>;U3")U0
M:@2,B" P*UIM<#4R*F6=2K%M7GE:D':#C)]F=*E75D_R*45J58#)=KE>?>#6
MR%R9\WGM14>QJV%SG;Z9O>*U(,P._;VWU28VP7L24&.6+VDB:M1Y<=1:[DJB
MDUK1H[3QTU#1'LL6I_ I^7PHSP_5+ZY^US.HQK5A4?G)FIL0DXR+-;6W%W5C
MT>D=@/5KEX*C\V>*G;IA8$&GTIQ&PB=(!'^ZR9G/.\6F"1?Z#%,IA]'OK4=?
M)!/-I8YY-5H]AH,#[ ]?!EE^&\)O#MJ0&$ YR4WO&LW<!L G:P\\^4F[;=&
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M]$>[HU50O.)"%*_N)-C.E\G=[?V,@;*9?4$T!Z.0@@4%]?66]6V)ZC.;5,O
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MOS JG(BVX!\3+Q/],:7#?1^WD:U;04S3-4@FRS@SL!5UP&,;I]HOXKS7F'I
MWV:)Z*)=4-&2P1*>C/\@^4<[K_"X_"73Z]M?G@#6$AZWDV=0$EC*HIH! A9N
M5M\(LCYKWBM>CK1H5G+1OGG#(&261M8G9) Z-E9;"GEJH[8K4/P2WO^;@0>?
M#!";F=VC5,A8/JZ8IU]EF4B:7F$[D+WMYAG?:W[RC(U\=U^%%$+\MDSW5K)B
M >A3OM>=_,76KKG[XVL\]Q\WS=A,7W?B'*TC.,L7_#6JJW1$FMA2?AZ;"@8@
M7+S^H $3%K]?+M)^J'[,5HO5B+4MD?@[7;^;V)VK!PB=WGOG0@I+QNWTU7U
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MBN53G]!#VL7:>H.M<%^4'QI@X@XY>UY:$!_72$JEYOI\X#CY]I[)0I X7&@
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M:YFVX]V^_;4<;G_W7<?,(+B'OG EJ85ZQ7=T].Z,53PL<#XQ.F:*_6?0EZR
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M\6JZWQQ??V9,[YII9N#'[AJYKSY[A(0'71?TSX1IYUW*.4'A"TK=9,0]>0O
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M'/#%'VMMZF\TBJ67@B:&0Y;45D\N7V3V7]8<$_)FH!XTL:'X^(*'A:2R6O^
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M^23"-"M:9&@6=C!KI'O+Y^9,0<R/O?M10 3TP>(1_7K YF72U)K0,QRP<*G
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M590MBN!>?,5Y44ZO;;[UG6?C7VL3WNW06#,%[Y>8$][[D85.%,UOUN/]-NQ
M_F-5V4/+Z)XG01L-TPEY*DBO9 ?.B4YWST]#<4"$KEO4LNU6N%NO\KB+W A<
M_6.OU9(C\_,K;[^1DG)9MGNAD1/!]D)JK,]0<=H?JV=__P#HUL>#KV1G]1;M
M7^9J[TV67=$#A5#F.C;0UQU[+GNQN^(?9<X4*?;Q$I>&<S7CP<R*BJH: 2X9
MC_)$6B@IL+RE4H%JN?6N3+CH);>]X,^LN.4(LX<B4>[,A/@QWSK$AG[/*V A
M2)DIGG+,]7EDK#&(P66E.& ^'X%>539?>M4PEC&2-^S*19<;OA(V>_?R\\^S
M[XNAC5QJJDEKZRHU:7N7:VJC'PX_*6EX(5G1X:A?G_%BN0G?QAZDPHT#(IVG
M9?OHT5+=J1HG.+_B_-=AO1]F5-"50EOHCA'T5TY9SH^8RUT!; R/8(\O?OFB
M-6B(!3S$:VVUL]=A7L+S2=6%9^EJQP&7<8")JE((>]D;U$6&.(D9$0[H0BTB
MSHA 4OP+'"D^48M.\N$886T+'&!CA$J!4OE:,)K\?+C@M<.(6.SS^ GZ/@S,
MZ#*&-Y&;BBQ1"C+JAD5OP5!+*; [;P2-Y"5V!O) D-TK92F._LL:;R/F/]P)
MU<\)!I3V\B+T(]D?]->_T\7'2U&"KYOR>1J0S?)#8Y1^,,IOH8+>6Z,G1S!Y
MKM-UME+::YM!C?(R.S_&.4RK_T=JP*48(.P6TP,'!DQ;7)/<4EJJ%UE'%F</
M/QEC[*&K>4QGU1-=<S6CAZWY'8I2!RZ_K$0D0I0TO>*JVYI$KT2FS6X(]'&L
MK,78M-4":DKJ2@&=&N.!K(RDG$_X0XPVC+1R<VA8#Y]LRG'HFS,>_+YT9=!Q
M)FUTY/VR!/ZVDO8]VGVI!A+%-[Z/D618Q7Q0CDPBC@P/B?;)_.![*D%BOM4.
MH,.1BI8XA5. 3C_Q/V_<I5H6VRDJ42E1MEWF*I%7&.J-HCGR,6N(<NY8)TB#
MF^78*L7D;SMS5ND(>3-&+?%2;S0S#)-@!H["NE<Z*8GITM1V<$"X-K(F@KM1
MV=/Q^=$C,5\,$4/)CAQM63ZF<]T8\K&D4IF]D3R)\FMW=KCLY^XUA\NA]Q79
M$(93;^ P#A *29//?OB*#&P8G=$Z>4XB&KK:IM7@/1N^6,MTDSDC?<.FOAE4
MRR7BRNB'ZERIR,Z(!SY:PKG<SZ/%O<DA/BLO945/_#;%W$M2S62_3-AI3FCZ
MJ5U2*C^QB+Q.FMBI,:"T^(ZQA09S+TVHYF9AVU&3/^7SRS/+@-?+\@_,&]U-
M$R=)_5HZ=^,',.&S9)WQI^-YUK9'UT,]RH85'^2Y:=Z_JF!/R#5X6&+"9@;3
M'ST4M_5VWWMP[T9R=-N;:/,'A9#)7RJ.7K#@A!;AMS8W-LGGU&S*K+,,!6V(
M%/DD%591,1O?BFX]^O1&@L.!\=.1XNK[X45N!U= SZHN)B8J];NEQ%')/25^
ME1$]+&*Q^;5CD4AE(63K%-%UH,2>64?ZY?^*- NC=C]5D5VWO;0W\;U>ZA9?
MC5SSA\HP+_)P1K.U8]JEAEG#<Y<FQF-U"Y[J+Q+M\KZ%JA"E?6Z*UC1V%'<V
M(Q^4ZGYJH8WPAJ"B7=[37DJ+5S<J?/I:#M-)YHDP"G:OC]I4QB4D\W\EU'3U
MV1Y].!^=OJ+/=8-4>IU S],8[B\4"B/_=<V]:'HZ5;-UTU;4XNGR#SE. X$1
MEM,) VG:9E9D+FRIEWW;U5N+LQ5KP<\2ZY$\IN_$F8#AVB4&P?V!SZ/S),1D
M#F:X81J:>'Y^,MLP+S7+E9?IQR\AOIC*U5KOK+\A//=,=4V1[G-#UWJ1 *-B
M,?3_A)SK?,^][A[W(OIEUET15%US(O.[JAX<T&>. ^J@.,">JRR=&+8->K9?
MA(70>9!$HUQE%!&-Y4&KKP:K)+I='Q0%AF&*O\.6#TJ30H ,R_QN=[[P@^GI
MYS3BZ]I$OK7F?<\QZJ!0>K5$=GH(^:%G9)S03G9RWY09G)M:F'; -2 ])QMT
MT_]YMUC_'+3[\3#B-P/HSC+:3:B<#6>\XA"?#D ^HQR/92]Y'3C.H4$4;]4%
M$:4[RZW,0W0GCD[OL* ZP^XBX^-NY\LWU9DSU(NVKC?P87]UE;JWGN8&+F[?
MUI_@<>WUU=-^R]8<?66 =5'#MQRD$INE(<L:HP["YWG?]@=J=DXJC(2E$KT^
MV?/$,=!\X[F)JGL:7_O&9:#/2*Z'OOIPC+:[1LJA0<[Y'=EHL8_\4JWKMIE^
MA:_F4ZO?@EUF$$MC<N?-GP,G&P5+)=YM2;L?J(^L2G</LIOTUVS?=)B_P*BD
M,&1!\DMH2TNW5PU>(.FCNA"NPT;/Y9=NY<"T1C/],V MCZY16)0_.&I1]5IQ
M*(Q1M5'.2R+7#0C=6NE7;HWWTMD-.PPEN7Z,I4GZSMUJ__ICEV-KS#S=N8V)
MFO+7X</;H=QBHJ7,(\S8D5'BX<1;>K)WY^YV?FEYXX5G\NQ6:8$M4X+#0D.^
MEN@T0WL]K$M2G@2;09# +[L0&NL=/RM*0WT2N4SG $\3R=U43L(!A1A%[>5>
MAR$L 2,QBC&G<-YXTH9_VIBJZOWV_1J5#)^6U \6>Y*V,IJ@RMD'G5R9,N(\
M1[MR8^?@XXJ*^+<8P^+PNN\"TSS+FV\/'S!-3<%#!;>V4LF]KWL;>0ZE&2SY
MMA\]!XK5D$G]BLZB7/?LM[YF&ZUHN-MO9>VXZNS3@ *(,VG^+'[^E,-V8^KO
M,DV?=YGW\TL<\!X'E.:QR%+J57LL@CA^I2P0NN*!G#\/Y,8!!YRG4\V*R#(,
MC/$VJ IS$-A ,R.]<!B6M^OPBUGKQ7E%QO+Z?\FGU\,J0C]"_H=#!,OO$#C
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MSM/A-_;'/''+2\6S-TUJ9U6;.I;X50?_SCWG_]5UE1+/[XHDAS3PG)B(/9T
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MR1* A%;<0P(PK-4(K??I35CAK^Q.!'N38>YVY,0* ;BP=_ZXRE/P^9NP>90
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MVEA7I[6><M".=2>DOIK,/?AZ1S5C]MG2.QS;!FF'&,LV/>];?X(-"[;!)@@
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M?PO=^VS<[YQSS[WW_?$;[^%88["Z5E?-^57-;WZS:B&IG_0#.*IV5?4J0'8
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M<KO]?=#D5<3,4ZMS]JN9K\5&C1IFU+!S8O,7F>5=?\"Q&CYOP8'2+N\F-*B
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MS4>8WQ!+G$G 1>'+ZYJ8!+S+(OA,WV\*-:G"2V]'/R]F[U\-CA1#@7P\;E<
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M:BV)R'W7=%JN[ 8'R,SR$CU;ZT XA, D[+_)G/%WN30;[O2\&*L^?BA]A<^
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MT<%7V]D3:Z JZ'EN&[FE";/N];7F@@+7=T.-_(7O[W7P4YTY+R.QW#..II!
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MAC4SZ";1T*3%I3V[R:MDXG_JLQH]0PX2)[\)W=VTV\<#7J0B_OP>!+\G>D!
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M$S!^PT/9.O@6P3U/Q2$1.T*DN1UZT+6K285!$&XIAB.6/AS%:92SZ4YM7!L
M+"8^TI5]9OK!!TS@46X.SVNP_1,9;V<]8_GW_58'KWTB)]Y"T1@'WPQL)[#Y
M\B(B-.WE&5'T12WJ],P^^C0/7=\15 [&#]PBIGF]2@-0[_ZQQ?@PJ08P9=B8
M;Z  4Z;BUN^C&S>V)9X@&Z5Q%M'GG4/$KA:DBU!6W%':,P60)>PYV<\VW/CV
MMZ^;!C=N1H!Q!U9V5E#_[I,F01K.H M3Q&P#TO\#P=O2<96"??)[GN&4 I^I
M5M:;1;90W1G[)^*?;IL752G'^:T!&/TTF?I37/=Z4@\?J;7($^I!D^:ZL/)V
MF;<9[\CD!=[8) M4R:SX21:&'M@W:25[\R >#YI 3/R8R%T' 8I%]4CU=NG*
M$2MU-D86!SY]K6<KU@R;.*'R%T?<Y8=+G9@*008]<'U7OSY<]^:L4&0::0.9
M7QU-NSQF;K(-^3Q]8+*J1/_.H_7IA X&7A2+M+\G$] 1Y0UT5)6<Y,7%-*[K
M?NV6;5GG2'KS'B1&/%0=_[M(]+^+^_Y=W/=_M;COP:-?$!GK) ([2LM/I#R!
M4]ZI4CT$&='F*^>+_/"22XOBAWU/."<:^Q3A!RSW_E'ZH[[F]_7N#WR7G;#?
M9.>MF\4N9B7 O,!R&P,_)EDL$3>.KQNN KK^*^*\[E:QB-2()O98\,5L<=_R
M-BA!!14(70I!S OHLSR-1>!C(DXC!FB/TF5_]?1N="G0!"W\V3$V/U;?F-*9
MPF<]L U')VPZL9[4_$?&1%[X#[739IH39K:&A"W*!\ G?POGAO]4#/UG&0Q_
M^_R[P._?!7[_9PO\5*.^X]&B]QL44 KIWE)T:.XQK.C!,YUJKJKA?_P?D*PE
M,EP \QT'NT_*4 *(5,9V'#@9'BUU34^Q#K!S+LF( X(J^VA_[!)CUVA\GP*U
M&LO_];V@WS]7X"I3TF3U]^J'FN;]9SM>,V:9P9UJJ0]!%+C*&]C'Q5'S.]EB
MSU<B3_*T>-;E"=3U%RZ-TTCIYQED1JO*:"W;$#M<N'MZV=WQ0%4E>U@A"6[9
M:6?=9<S8>'9X] .&@T>4EVH)I0/:_/"/JVBRSS421  KWZ^F[:#2<]NP>'4=
MZ;A6:7MM1PYU3Z_W$,2(!VVO)R\%\CVCW-2NAHXFDO\LN.*\*.#R&)2_$,O-
M8>W>L.(>?08J> P\3P*?.) *\. *#@' 'A!1WD4(K!#1O)!F N)W?_S].]&\
M\$_9W?F_:R!<C]?#Q: %J%W/VH@J]5$T#:LR/<<'T7F[S;PB!:T*_;1G8H!(
MA=_%>.8%90RW?7@=S6L^Y;0O%4A.?4QF+5?O$.2?/X'<(TO DP N;%#NY7!%
M!F?)6[PAP ^%1S^($H@!(Z2Q"_ R#.L0FW10' 7W(>B<0F?YX\&B'R(?SH:
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M<2A=RS8:X9YA*ZUF5Q%H:PL6(<@ =%X94H;Y_ ! 1AX *]JME&04,2,O5>H
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MB!6D%>4K-UI+>??B'+&\ADR[UZ=LFG&R&(MW&,&2O#P?PR<LM.H&6[Y?S?'
M8^ADU"QBHUX52YK!KN F;;_3UZ_NV=E?V#&M]",7WK JT-B*Y^VD?<HYC&+W
MYL;H26=:+9GX+W1P&' $.5&WV*UGM WJ8J31H8;)?7,"NMK#Y1:L-UQ])3P-
M.UE2A<O?YY8]-4Y?O1C$J9MN&P3_LOG&ZK>G7MSM]:IG) @B64J+PXH:)%4\
MJ*IRSJ'SK7@QAO$Z@@*9GUGN55SF)=Y(1N>,Q:3XVE_8<"/5&#M?5$-PEE#2
MJXKV3%<#.3%MB6*+OJP2A? %COHY:9/<?,X+#WY+%V.-)E .NOM5K_UZ=H5
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MA7<;5C0U^@+'B$!O6ZI*1LCMH-@40UE*#>++:K*4P/\GC4 ?#^"N]$(W&O%
M< X12N3)DJ3ZX?7WYLM&D]?3U6\6+7BWGI#B0F8GFF6=?V%3,F%,MW&NW$T)
M10XOD T3:E;LZ3?^K>6442,$1;]8W1I^2E%!2D0T]^;7:!U_"[V@C&H$N15&
M+"LY_E(9VSBGP+8RW4U;<>R$-DYTA2G'5U),,C]=26CNWC/BR>O7EZ2(7;^N
M>Y",<]/719<&%5(6F0D4?&)KO-_*LK1S:\Z3N*=<=>+N!JFMDD/'6>OAP8:S
M]V[:,Q'KKPLEW8Y\UZE4/'GL0^=4TI&HY>U8ZW>#YLQD%>WE2AXI&?TM=2\O
MSHB;]$T$Z^_:"+FV/OL:7J_&ZJ3QY9[#<IAH\OP :3(BOCEIZ,S=81LZ0JP.
M>:E\1PG"=P2R GG&$J7:%=NC)QFR0CO)EF@U060/;9V7U<[-8G9Z%S'^).R"
M6L2Y'C[4 ^(JBT_WO.]TLDKPUB8H!U:QT$*#<0[S1*/W>Z.=$\<JONR4]$H*
M.W/G-%D[KZHK.9T)>K,DKG%G@+QV41OR?GB.0L:JQN+#*](:Q#"=T)T +J6!
M"VP>2YQV,;2[(M2+A<^%7$*UT!,V+D9K.M6Z!?YMCZ,$T7'3&I)N>(!-LR9N
MN08/)'(5HJQ!Z3G[VRS#]I:=44MT@%7#;Q+'&U?DO3>DC!KHY7(?]HSWM"<*
M$-LR3+E'GW!5YVQSL'=ENZ='EZZ=I5/B/3%,/U\=>\Z[7EQ@489]YXY%I\V<
M:KZ]]$:,9:;V/))V?5BQ/9^RO=YF6#7B<]PCBWX^[M$N[N2"D@ %HD]J75M'
MRHMKD"<<](CKWYN3")='NI_*O:6[[?/(IEX<)W0KBYBXM539U<=<,%#V4X$E
M5,ZU6;WK(8^#E+2;1%^/DLN=C+1U7)CY^W*=!#UG[\N1U2W8A2E/)[(@:.DP
MRL(/<JJGP1Y'D]0JV86C-B\]&XX':K1KO7_C/?> OY+XMQIO]'BI]3-IKHJ5
M\\$VS&^O15P*H&FN%TEC-$'Z?97WE3[O3[X +V[8O%4FV2KI,63$D%M&-8QF
MKU9SEI>WL!9I*7E3W'R&EFB3L$_3TBQ%.:U183VWYBKI'14*&STKYS+T@[7:
MV/,KG'=?]E+G*PO4X0$IXM=7")&1ZW'/*@4+N[@3VZP2@EIO%NJ]H,^N>TE^
MI;]"?D+#_>P8J:K,BF=^NE[!D1'4)R.*$IXO4<_DI#C)&=PE0C41\+MM24K*
MRKIT G7JGV;ZF1BVN[LR5!(W;5W-3/I#%0,5E09D+;J=Y'SK^+9/6B-&5+%'
M[R#(P9U7E-FWFI1>F9. ANNC*$O5T?GT;S@D:U\N/#HJ 6>$F/>BLN%VB<[2
MK4JE_%'/C1SN^7*%U ;!Z+]:<DI&]."!^';*84\W,^NNE58BM#8>J(V@3\OK
M8>W$O*#Q_.CI'MYP5=QH(^<:JJ&&P?*TAIX&#J=\=57P=1-O]^WY1M;(T#'D
M4P<^DL;THK=M%/8S[=LJ.LD+TV=<_98L;JB<5[&ZZ$KQK$;VBJ+%[09IWLN]
MTKQMHPHGK#F?:D*JE;PBVZR?.A6'<'25J]I( I/)U0H[QL\A81;.G54#L8AQ
M#Q:U? N;P_&WV5]/,C,R'Y$Z[%0@>2U>Y?@)%M^ .>5FQLJRI($9)%DAJ73C
MI2ND4>E/;%69%#8RX=[([\7*(?;<^Z@[J$5L8&6KN+/6:9>/C4S-]]&$-;V5
M=*C^]PA^NO+-4'Y^PR?$[]<SNSH364>R(D6%]7EX3HG&$>K4.:VPUU%WUN?)
M<-]F220[*L K>\50" ^08*S/Q]DNV$M,A-DZJ_57)L9O9F=4QY[L6C=@,-^I
MZ-2)LBBTH95G*WE4P\+\I AC/.;LKAZO\&!08TK:S84<A4#DSEB8:< +IESK
MDNR.ML7E?]56$#'R00M=J>P]*G8X@GA%6.=RK!3#A$82U39%U!NVZ\/HJ>?&
MF 9(H#V"%,.0[JRVW)+0,ZE"8_)JJM1$[!.54SV.H&CEKE(J&W7I*QF22P*,
MCJ184C%UWZ(0:[DLFZMAJD;4X;E.N4[UTDQ=DK+&EF1Q:87>=6<?&+-_I:T7
M%:YRE[:4ZQP7W@QS26VUYTD,/N;$ID!DYZUQKJ/R0G\M#TNEW_6/ WEOU)]#
M;@EJXXZB>+,2+3KG(YO7;^O=R*0[S:W >DK)9E9!.^:";*-T#T.%8FZ(O]Z2
M*Q.EFB[Q6THU6>#O]N]I=CL1 045O#M*2CX?UHSJ'=^R)'N8IV"X>6AVBPVV
M/N(!^NYR5 \<9KLEHG%/(6[YTB8=)O *'CAJY84'+F_@ 00<)YQNGY75(B9/
M\V5;N_@+>&@@(9'%+?9B4=!Z./JN-M^6%6+9"R?LACLY3(CSFL<#, C&% \\
M%;F,!]ZZX@%D [B,4U)_:%/ ,J3VOSF>3RF?3-?$&<<&^7V($*RZNAU6YH '
MW,E7,I"H9S.0=7*#730>F)#'G"TEQA+VXG!0=+NKWFO;"8F&%0X\\-. 1!PU
MM3]V,&=W%!:H_\?EH&.D;= 99L36"AZH]^]8J(F@&X&^D/]I" 3UOL!@:1B&
M),28;_V\VJ_!$]*/>,#XH64%HPC]?0#HG8]/ AYPG,>A(1.:B)\7@Z-E[,EW
MB'.P&-A*PGK9Q:EZ)_BXVB\#Y'_&K^(/Z\&J&=["VJ1@RQ-X() FJ=^75[ <
M=@K^\Q#HF*$I8K@4#U02H[N7?UHO\1<(*GB_B-G$3*!?P7[JW_XS?#F_+ ;Y
M&0#964?#O_'^&^^_\?X;[[_Q_AOOO_'^&^^_\?X;[[_Q_AOOO_$^I<Q0NTD_
M5?MRX)AW@K5$%T' 1*YPOM: IT_R[*V"(HT$=H>!6@E&>&U/H FOSFZ*.IN:
M_%8XXJ6:+-5Y+UG*FP3_^O;4Y]:7RX0AJN: -M?3$G1(/K+)XJUI<>3[IV-?
MGY]\O,L(F=7&4:^$Y;R(_3JXT*EEH ,9&53>>KQ!E9EZQ^^KZ6?AV<^Z:3%L
M5"WHJ'IJ?8950].D,D3T.,-U,<>M3:I BQ6FA&Z>A<)FLGE%&G8*Y0N?IXN<
M*>4"%7CO/U&?K5LM<K)7D[UO_LL-#@WY%PXSDB()RJE?RCZ/&04PW[=K.U['
MS-&5O.+Y(LG?=%0I0\;.X;1[*UW5Q]8I;;E7[[*+\ "+F'J 7BP>^.HHI";[
MP/3??8OF7]I.'JV:5%-?YEL40O<H-;W.:G_-8:;+P=X9>:KRXW Q_W)A*ZGS
M=>'R-9V[^=XBH8S.?"$N'YD^";<Z7R()-*HK3?'7'E[,M#HI^Y#ID;$:_#6\
M9B,[7QTU$IA]:B<H[G!MU*5C=)Z_246ESNN:U"3'0M *0DUFL6XD"G[:^9<N
M2P80HH_/^?+EA09A5;36W.ZF678@4_' H6N@=KTH;*74374\'>5VU>6H]P<,
M_W9D\8HY;5S5*97/DGWL@0E6HZ'>\(^1\#'">)316Y8O.B4B0:.C,$7X^/WI
M6W%RJ.9<4CL7^[SK;[%=3*U?53%$/9'8!\,TDP'K.UD[B.:8^M?+Y\,>+&\-
M$/%L#'#QU7E>*$8EQY%.U9(+-'$\YWQY=#0:%U9"SZV6:7HQ_9#7 E<K[EQU
M9'+96"#]Y>.JCO<=I+J,H/'"K7+\,4I*1@D%2<>=@B:R*UF'92VP2<3/<B8[
MB'62MVVE+J]G\*V<-(BI9&Q?VKB72J]Y)=>(U<1,NC!K0HNE '4IRT?]BGE[
MNM?'3Q\A6?*C3.)2(E7:#RUHY4/.<K]>:FZ!<6O$E6ZZ8RHL2V+2=U54K"+Z
M0JMCN8M7KM$P6$X5EA9ZA%;QJ4,GZ;UKF47RVODZE9\,>,C<=J>PM!*X [D]
MD"=YQ+-S'$Z#/#,ZXJ(H<2HI'^<QAZC^,%:.&^R>YCJ?Q#/!&N!BK'N(^#UK
M7-- =-I5@5>1[3JJ:G*94[1U4GH;ZSP**^>4!1_UKI,TB[[NCW^P'7[UR-7I
M7.&>&=>W/04ZR@J&IAIC(L_[)KTBIRJY=;7J1M\D?!AX$'Z->LYUB9@57@.-
M@6IW&U3C"#HS%PG$ U#R%@^]TVS?GD;#)&_93XC*UFD5"=^Z&?TJID-6 3I>
MA'[,LKMSZ6F_U3Q/0THE_PY$VS/.OS5 .ZO%4XF+ZOGT6W9BC$4B*O9Q+",*
M6_&\YH;\&\DXY,L-:"<JAZGG?'=RQ0ISAOE]^AL1XR03!+51E.N;$.S#GH*.
MU"G:BE-YNWC@-F=@I]JK\*QA+#)^[J;S")-2+4^2:8^@0:;\Z>'$PWY0?56#
M>8URI0E2:(T<A[&"E?4#/*!N 305(]ZGE5^@]H?X9D5=N4.M4D+D,>ZVA <L
M>H4;T6+GNBI9G&-WMBQ&!A7/>>F$O @1@ +$$\MW4Z\4+;[SW#2?%@JIS-L-
MML-1,S4_S2TJ&QL<%F_1&"@F_DHR6Q;$E8!"/+]=N\,YIS8H52J8QRE&%.TT
MGH[>'&]!5HG'E_>IC7'X#0]AA]RFB5')[M)%N^Q>0J]8#B>LD6..AN,*WKV=
MM4LR<2/C-<]A">O.MN]2D[6+.?OO*0__VG;7DQ-5E^-7X&ULV\R08>VG3L>!
M'--YI2ZGPO?&ZD;"NQ+]AE@^;\R#36_5N#H_[H]]6N>D#0UN;,PNZUG[EDL9
MC65=X.9^M=@R'5RY'C@4V9.0[9 D;))[,I%6(JM5.O2C:WU8QO"(LX&V#@?O
MH'OX:O(4\>#:>&&YX&CK@O]VH:7*1B&3OA5I30 1LY^$IJ:LF&9TV.O$JQ1.
M5W0WX\>*NR0-DRVL;1,8:/LUF*+#Q:;%=C1E9$WH1.<"V:C8'MQSSI>)J/5D
M^M Q5J+C^#K[OO'P8UKF.!]SK4$2"1(W=;&3M;G>Z[1I,XEO5E?7R=2;F[NF
MW=G&ZE'-/I-V0^]6AW0+:S[1F$XSVGH6^MN-/@B]':&-*BH=L!O&=!S]&')!
MK)&%F&I@1%L&9BR<5!W^[#['*.-]B.N8)88@VW1PM$U273@KE-_P1"[Q8)PJ
MKHC+U8'!2D7#NDGF^*L.14X1I=8[=M(7407!R%GJXIW"^HQ, ]T$4B1GPTDH
M_W$)F(\KB?,#MQR&Y&(/25MM[:NG/A\FGC3JAB,,.CO>C.&!PS+OYOC2D2/-
M:7/9_)MO\,!C5XY%G*OF;94LIW?W\$!*WYU4'F,V"T33A\"0%&)B1OII2?XQ
M];;UC$&)$J,RD5#)O)C7)QARCY0J<L4HO^N8LQ<]W^E!!JW1)RU#%>7;;VJ'
M% 5+4.\R/E>0&22-K:BHD\U "_#H:%HZ7>YA4.TZ=H'[_<F9R4>V!/,-POVE
MW,\_U7#6$+EI'D*0"S.=FS.3%!R_L'#V3;'0J3/!5S"P&N%RSA*%S[?RUY%=
MU?:O[B72#KLNSMC%2J"FNL.?A\YK3]6GI2F?JS$!&$[R2[Y,S&'T%)ZGUTOI
M$_+G@FZ/'9)OV.4D7L^VN([B"\Z0SYB/C-XIBJ?9"7]E>;VBNM=0L5#?-#7%
MS?V)#Z^66*$%IMJ/(]ON'4>"'_!W^[O]GVW)99FF+0M4E,9O@@#FY/QU2YCB
M"FE!L;CLNN;+NK,O1EA>,@+7L;* F=I=SW,K05YCLL_GM5]=RN*]8=K/7=-%
MT,+9XSM.REX;#K%L7TXH*QXN*#!9BKLJ[GV9_HXF7Y:[+"K.=^-TRIQKU\EA
M7I&&)W6"V 4RKOC\\J(N[O&R_%BQQ:\W5YH8C.\RC[81K?^[=\W_!YK="!\J
M'8U0!0N:6FEA_FGB$K_A(FP\,8I_[K!MW!&>^/P.=WD+:]J@HPZ-$X'$LC=3
M@9P;.:+HR[ VS&T\8+@;-_F*@-@KBP<C,]%*@WZR(_PA<F1M5[JWF>"I6D*
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MXNX7U8..8E$<NVS%F-T_1N8'*C\B<SCI?3W/^ 3D'\,7X%$%ACK(SII&#$>
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M*7(I?)&I[%,Q_RE%*DY^)&.O+*I!!6'?4ZZ<KEV85%_BM/E\%(9@/&-(2-;
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M^*E^(7H)RR7O%)0/7U0FSX9.0J#)L J-0NCVA1%F<*=(TCI-Y6!/4&>]TMZ
M41;:>\1\<7L7%*=4Y$2F"6C,;-PV<>L\?%G30A:X-]-+_TYCE;?8QE)RMZ6^
MH"B8DH.IQB2R8_<AZ\16#'@<UQBN]_@6M_<3T/*%?8?A1=70Z138]OUAQ/%<
M64!S][Y8P[+X!%;'U:3#R^T['E'?\$!:_03'K:@^.5B/3=P_-_0 RJO@HF@0
M2"+XR*/K>Q9]'_K#1%!V#Z^S@L@1X($[(Q_6]]"R<SO:NM,BN#=;\9C\X-D6
MJ$LO9&ZP4SKLGA^0S6<(8J#5 IT*=<)P[-J+MBZ+FV!ONTYT@&!2\EF?NR3"
MLA4WA\1I%1NN9[.,;M3:H-G"BB='%-J/X:C6J9#(_W0;O88EF]2OO@PM7_SF
M$$@G\FVSMK@-Y;Z]572_)H%\BO9<2P.-*AZ[7/$T&)<?#6NZM(Q6]^,XA!@T
MK+=AWX\:ZNU(M2 N?^\5@/.+!Q>_>S,_"PZ<P)J SH0K(P]86A,PKO(&# 12
M59%T@04Z+]J*R;="?N-W'N-!S)!@3 SK82YMD WEH7VWJ7"#1XFQ)M]@E>XG
ML]EM>0?+L+ZQL[?DAQ_+6")1B?M<F 5=F8<K[D$A\AZT+G,"NMI8YDGIL;^&
M#2ZK0G!V#\7QS=/PC>@)G-8WYAP!U_QIY,LG\LNBK+ ,T$#(PZ=@?C428G6<
M#E+U?7#<B#TQ]C;,Y\@F1=Q&]'TP'K]X JY26?F*I$\%VF,'!PT'B;!/C8>_
M ^K],P^^L>JA+Z@?NON^W?R9"'N+^HSB@6V:>W@@&]Q)SCPH7,I.R"L,_^IT
MC%)1Z\5Z)IP8S-$R&JQ#!'A*$FYRO]9C;/&J@^5S_5N%"[@5*>(VC?+H#7K1
M&&-Y4KK*3U\=X"<-S",#>N^Y),B-"RD</9Z8HKCIYH@'KKUX#>)Y40&JN!)C
M;LF_L+YKR1]3R_\^;/AXN*V\<(^S=]V*TMCSA$[M&RTW>*<<PXX?6? TVLA*
MEWDCRVIC:)&N\BZ%:^$>NK@VW]PU@RUZE2VIA//9)1:7)6<L5P7*'<[GP\TL
M;V*;%6X4XFDT4EZ7TLF">E_T(J:0[H$6&QMH")0#&N@T0M2=965O:M_7C^NT
MI#,CT#U!+5JUW..76\ =7E/5;7UR2LR\=SW(7ZU<#ZI<4FX8?,)X9=Y+W\#(
M(L>Y?F[<QEG]YEK))W5V$)"N',M;N'HW!>G)3S<GAC1?9S*SH)2&%"C-+5\_
M[CA)Q]"VXZTF;V+9O-*X)OL9$_-0=0QK=[MMH\0^8YOY#L.KQ*+%3((SWC,V
MRIT%P_)U&A&1Y0/Y=:P/'<^/ Q];<PZ]&2/ABG&J74P="IFG$%"<?/1%#LAJ
MRO'M+WG5-V>K,WC#TSDW5DI\5;KP71)M4[Z8V>VT6Y&.MH'#88LSLHGH4E-W
M.AL'QZ]*SR&-+Z(R0@0$Y^&SVK%'.MD+.D8V9X=:74?,--B]^B:Z-K*OZKC)
M55K<)51X-\MY_\T+<#.[/;TF"KFBS5++S&U!F-EP@BOEPKA4(L.5AEZF_-L<
M>MI2RA<TID(<>+<UE3T,9ERE['HZ,O4%NYJLOHX %]_M[&B$!Z8EY[ZK<O<O
M_L*8LW5]%-Z2J@7[- L>%GH+H#WO%7MOK)NP\2KP1&'ILC;[;$#6M^XD;S0D
M?:.]"9@[UF"9N6GU3^GE@=:J;>YIK=//]>NJRK?Z-632 0=E K<&'K3O?$\:
MD?>/OW57'@0S_*<JN7>1YGTT+',: B8XCM*C]/<BN;?LUY^,A.]K6C98FY/W
MRX:N?K7-OJZ=7T9K1CDGC%]"(\9>'%F,)_.4B1M?#.A-[7V#3L$IL?O@@2'H
MKK"]827[#!Y@X40>WY!/8.B[PK(5?0J<;6_F[];OZ9RF6-JWBC1#_B>! K5L
M7[\^@$(W\F;][7<C?HAK/*A\G="YJ%[F5PP'%>G!GU0D4*Y^%_"#"#\]@5N+
M!X?F-B1!]H7DUKYY>XO6+;!Z[7[?B\C_I.!@] E9PHR)LA<(O<-8MCMG_N)>
M"5^ MOM.2DU&DY*>@(?<V*0J+P<!;V!<)< XL=/[6B3 DU/D"7CB@$B35R W
M8?D>Q0NVRZLK0:_K;>HM>CW/H_-@1YS/+:L7REKD-9U@J+]:YL12"9PO3T6;
MC.<Y6^!.(=&*4R+ZJ@.!$:_MIB:<=DL:'KK=))1D&D<PHB5JBDK9XFJ:&OS.
M*7U&-97T!RE(:K8]DFBRI@PY*W__Q&?8T^".$NMGE5Q1]?I'\[NS@V_-A/L]
M\@9*H^^[FGC#7>=-@00_#J!>CA0\B1TAF-M[U?K7=U\VM%<S6K?%+*&XC\V8
M@<=2&O_HA83;X'DA)&9L>0=5CK/1U-1-WGOE1:(&N3'F@AG/SOZG#PMG_NH.
MOX,''F"F@6XT(H*S:4:1F.?+>, @!,:6_1QV2#]C0R!BA2812WXEP8\KNNN_
M^ZIY-0J&\<^%]6K!U@4UK,LEDLPUY;XN-;.]?IP4Y$H6YCV&/&5&[Q@47NS4
M2-G$ZO,R@]&XD>FP.1ZH-@;/33O'&O" >S%:(R^@*^KZ1-(M_R3:YJSP3;$<
M2C2GUOEB7'5GVQFY-?XS^K;\7;VJ$!][Q[QGQQZR5+L/VCK?.Z(Z<P&!>N,,
MPST!*8GDV3L0_CSK;:M$!:U06D,C=JXLCQ/P4VB!X?4Z>MXXVM(UN4>[GOIV
M75C.^M"QDDQW+FZ;JT4#Y6T"DEYY=J%!\DS\X$%W3 "%![!$$WB@4F?_Q-Q4
M@P?63\-QV]:HA T>"^+S5,K-"I:6O1MV$E7BTCE)/,C-8&/Y^D\#RI@MZ6[-
M>FU]1-8(*W5XX@*_[;$PN?_'WGN'1;%D?^.-J( H8P#)# I>$$24* J,J("(
MB"*"$E64*""2AC@H A)'0$#)DC,B4=(H.4B.DI/D,$,<F)F>7X/>>\6]=_?N
MOOO][O[>Y_VCGV=ZNKKJU*ES/N><JCK5JU(U3<:]6_4,?J\F%CPD"",#S=<0
MA*^8,N^FL-"RQ^6%.M51RJJ:S5;('"4^_LM8K7VMB+77*R*#^VN=.#PL26&T
MBD_J<R^L "M<[1WF^*O%"#(@ ]GXA6 (YQ#;J.:S,W#(,9WC37HB9R2H>K/5
MD>\E\HKV6?/@D3GQJZ1R:TKLR =<++Y,0"*'VT_XP9-2_:]5?1LKU3/:!L1?
M=.!D(#H<M5:/<H/_R&4&XUN,%VENEHL$1*2EQVHR6DD)6#EQ#%2(+3&MAW5X
MUI*,?4.(?J&9)(>+)"/4=GKR/%$FR<C4FQ^R7RO2/#M&1\'F,Y&N%)]JV-$8
M,4PM&KLPUACJQ9OF]VY3T?[HRA3&*1.#E6G)0 %JU7BY;@E!3P9J'V Q! \R
MH)_A(UY!@H\]U!S625JN^\MK2+]=?!*=<OG^]^Z^#SK"Y$=1O=OE3*9WX<.!
M+.SJ8EVUHI/<N,*A!S=(7R4(HU,ZMZTQ/CR?!K%^47O[3!>EFU8S.==+=4[[
M%32>:>3/<$)4%_*X"![IE+QC8I[29TR=EQ]XQ2:&0RRXMTKYVIFT":Q'U>U1
M(83OB<.BK-XBLP#'A\5)2OXR^Z8*#/7DX4(!#Y?7O64*)W%Y$]QC@0U.%)3%
MP3C)Y/=RY^\XT4DPU#F*%)>68!\(&9\MULAM;3IA:DMS#&[B_XGS =V;2NOM
MVQ_5?YRE[)C._7'#!F"?_G>FF]A^PJ0/2LK@%5L/S$S9TGJEMO9?7A24^3,D
MFB: DB=1,X$H+BW!3YCU X,@AAM4U-X/[BQ1GWXH."(HO\'A*@L9PZ1_]3M8
M_9ZD#F)2=U2?;EV$+' Z6%3E\WY>9NYE!GF"GAPDX$$>)#*@C$N=]SYARIKT
MX.ZM5W[44JFTX'X4+:JY)($,#)V%0F= !^QNP4P>NT<&4&U$PQ]OC-%$3O P
M&7CKH 3%H-9;.DB%S2?1]IB#E)GXZ[LZ.W+D5=*3C&;/N0K!9Q1)6;&HYBOE
M(!E(Q'<QCR*H\4\Z]]%_>MLM]Z!3@,OI'6]?_#I5=Y<B&:!&N&$F==I06'94
MF4N6PS9Z8[?=I2"PKGA-T&T.BM0HNK; "EXVN"QHA,'388;/LP2O%3J-OLHK
MS(UPJ;T=I\;IS&!P'V6!XFML*Y:*-3HDV6,38F3$E=&)O+_G\O)(SB1%T2&"
M][J*&VTSQ3)]SG]RWP<&D]MV0K^D)((SS\U6@3^2WCXT2W5%^V239NN\2/\%
M^-G683%%CA%Q6-*XBR09J'+FQE+Y$$];QO0C4QH90O8&<"WZ25 QC3FH>V>^
M$"7=._2Q"Q1\[W$I[S[\NA";XOY)<>M[DYBH*ROF3$1IO-%0T[X^$_%(#CN5
MHRG^Q]H_V/  3@M+7J.2NK#R3)A"@N94Z>Z"=G-!4S5<M$ERK&'L/?^7-!(?
M>7KI*>9T8<LD6D6L=42BA[ES;Z*<IFG57.\@CP5QJ=)JI88H7-!L1J350W@(
ML#0I/YF8G?_J8UXPOS/ LL&Z_?^IZQ]]OJX..0-*+0L2]GV! M6ZZ9E7N"ZB
MPZ3N*FLV&6@)ZFC^ZQFE_\-+9FSHBDSJAE'=77U3:JUIMC*=AK3AQZUGG:/]
MM>#/B92C+W*E#"I"EX-],Z2>YF2I/ZZ/*)(YAZ2D7!DO2?$"1J4/X_77RIQW
MY;2M[(]9B1A_HSIV7"_<_O%I[8C_HXQDK4L8QF*:G4WTD9R>VDRIL%^N44.Q
M_S[ 9ED=LI^TZ(^(Y=.R9,#Y(1D8V3PFN7H(OL$40P8P0F0 )T+1?T-+D'@2
M 4#^224C:3V$#'C&@HQP%]3D?6^06$\&*IJIK&4?8[ %1$HR<)%>=VU<%_P%
MC==RIH#0T$N0L"1(!@Z=9US9-G%G/0951%_,*(X6,;T@]83+Q-S DNV]G<J]
M.SX.\OU-YY2_:L-^:C6:;MIK&#5L@:<"W7DQ"Y\Q1"7X]D9=SJ7PN_U-#U!E
MHU@8:>\-U. ;%#X4F$_*8-Q.?\O?<(&R,";Z?4E^^R.!!5/N@[U:<N\K.7?N
M5F.FBC*._.]SP(^[WVX?CI!9_B5*]Q1^HWE:EY$HLS-?_70URZ6ZHR\SSQU,
M.?W$1NY62I4/N\(C=,+F018IW\_%F(Y::\X,Q PSNX*H3,AW7(\%#[Q&3&R0
M <@PA79-MT%@.A<N'M7GI+=U6L7-[R=&J&[NF'2,@(S39_@2"059P 8XUN<3
M&4!TD8$U8LN*D<=J(VO3O'36UHDBR;\>7;/9;NDUR"[IP]9!##1"XVB\W%TR
M$#4#A4Z@X49..<%@W\0:_")^_'9#J9OG?FAXYIOP'L3EC-3-DT$22<O\8P+R
MY]UWY1U=7,GO.\K>=L@G,G8@ U4F3$6$V JYIDOR'>,W&["U/!FE\IW25KI+
M'=]/G%I1)DRJUP[^2.>V#JB]0?2>,4<4;%1_;XKW=^+7S_W(&,0/#)MN@_U%
M#G$AC8$X4B$9> J5:X"KOT8]&BX&1V=D']X+NBN?))+[E0P 7P-TW=_&^_>7
M]O+6G^;!F[3S4W;\:=BWW>W-O+K=+9XL=U1N >5NE3),HZ_^T]+%=\[U:.^5
M9I>'U%<H^[,J%2Y?OJ[ 25'[BXNT=0O(ZZC:)6J2SE>MW*8!=DE;%Y5G=5%1
M/2,.=:ZMKE4+;@!3@VNS*)SU0!05TD0#YYOI8_H0YF"VAS'WU2/_+!==]LML
MJ+,=YDQ((VOX[&I73HM=D7F V4T;I].1.11PUY..%VV'DX[A9'/4-I)M#\KO
M+W/KLUF3RM)<MO[6<V'K.;.F\E#V@71G@NE<[$F+#O1#CK$A6/I=Q[.X^"9?
M*Y/ZW@8)J_7TC-#^MW2WGT4;2%!2A5:6%GA7Z^X/43:Z2: L?^]I9GMJQ_@"
M_B9[Q]DH^[=#)D_A[B!GCHI@J*B23#/_7BS-SNN[G^'7*J4Y"TO"/H%L>26M
MC[Z>(J5,C]:)[\4XU'-$KK3CSU4&#PBV2/?3"YI:T+NSIMZ17CZ8>4OT#3:4
M]RU>._J%2_FGDI+N+)Z5M":*0XP5YG#-Z@KX(Z^K=&%UEN<YT-NQ_%:Z_(A-
MR</D_AY9[(+6!S^:2)'(4S9U%)RGUL^RZ7\0.%01TK-6/4/;BX'I&@7N.SU"
M$*VF.[_7]@D5>Q+E &_*^(@6&:B.ZU>V7MYH/GELE'30K+^+^"WG\. H*#D^
M-1V)T:URM1!$3%K:SD=@.):W4I0]+='O%;N8ZS:<4'MV523")RWI(MHPHSTN
M/ @K$O^8T^'&GA'3&PGY7G*,K3Z%.^R[.G>/:#\G^9D]'ST.BB[F>X!@*J1]
MBV3@[" ,%ZEOUE,N5@0IS^I##^*ZYM8R_^\_U9(R9KB^2J41WF?^R?.8FG_X
M-)O%2;K&)-A0@)/ZWLN@Q2H8/Q2K9Y] 3-0-@B2O9Z.@'"U\8U1P2:,E+J!(
M+%G%,:MC;N-/JTQ\H#=GT!^$^JT"Q&^_<F4/RVQ_]AFWSRU<8]=HM=&.,S+N
MMS]R^6OF!HWHKC.:H_K@GU4;3JJ9NR>+:["4=(T[L0_IKN]WE"(#=R<1R[<S
MGGV(HFSBQ,(]/N:^>IKX46C/$B&K26. \6 X*N;J65L=R((8+\'R-]-@6TX*
MKTH4&K &=I&F]U440[;TL_V:SB#:?BM=[M*'ZB_'9KKX01%:SVN(YG'V<XFH
MZJVT.%*,EL&LI14/LS(NND\Q$/04O]F/JMI*DZWX )\,M&:'!()PJ0!J2J(0
M-J*LNY:TF1#;I]BTP=9/2,2OQ<X=G( _",G4RDSLPF[FL5I8"$+OV<R70&:L
MW2EAJ_JI#U*H :(AA?F?;';XHM,DV&TF_^48&5 C?G62SJUPY AJ^W3U, V;
MT_MKJIEPOHW020_LL6G,S>.H XZ0#6])2AD9T4)5A_<7)>);5CTMH-8LK:3:
MNF:TQN.]^# ]QYJ(]HKM:[JX:"U%?]#SU%2_ RB5]%VT$7IA"18?$/B4?16Q
MD&ASE+3ECPZX?..CQ:J"_:C$UGO5&VSEB5:C"+3Q-RX6-'6/3X6;;;+J"@T9
MN/1Z9;[D=YV * A8^8%=1;;*NNG?>;Q)*&&+T,UB@=:24"<Q;EMYB9Y(J*:P
M?.LM=GTKB2B.Q"PXBT#U9I@=FX"TDM0%T8?.40QW"M I:%1OFX$B1"^^@H(0
M]+*$Q[4IJ&._#A&'.$\FH?T;14]0+<>F'3+QD&K7;+:1-(\9W4P.)@.&(<P$
MMGZJK4&_(@QZG)[I/^<L-?F-.Q.@U*^RLDG::ZMO0_FM3HNHK(:V,WT0?=?-
MCC%# _$;#TJ-<;;$8/1!,M#%BUG>F1GKW'(2-=JJ4YHZM9(9+JE:"0HA?=\P
MTW@)!F7Y+_+$F\CC7PQ_QO0;D*Q9(>\_QO'NKRY\1)I3/6(#BB4[?0U,X$^:
MP-(1T#I6)5^_#61SOB=+?XMIR]?F(E5ML&C($WR71?9Q^!,0D&T3AJ^0Q,%Z
MG7@=92R=@;)[MZ8=-]STU=<KD+)/F[3_.-K%@<O?NPM);X9PT/(&2+_5X8MA
M^58+^-6MXQMR%'T@U(H0VAH.5D^[32YBH)%B^:Y5$,L5"OUFIE9BO^'E7#^B
MZIL8?4/,J*U1B\(O;^E'YS>U*OY=>:5_5]N9S9$9']%!M?PBY9!YANC0\AUF
M,]0W$=DNR@LU]AZI2RJ'NJ(>\Z,:V^5[';/$.933W7UYZN+SNC'2@J.Z'.N(
M,WI1*!V;J6KONZFNFYKM/+,YIM\$$))3D_!VJ!>,6X1/(CREG'.V>G@Q#&/U
M>P\W<<-G2UAWC.@@6GZ9^UV-A+8L1-OQ&7!M5*8@)&I9H0A2MX5?)>P,@;O?
M_ON;6K#E377 ;3+5TN(D8K31S*/0GF3XG87VD1!EF])^\ACW'S&'#'A!;][D
MLGFL>*EE:'2OO#21Q>EO3Q-25R$#+[4'218HTLZ.E$=9:2V2UX3\XF_;NYZ'
M"R$U*U<+X1]-C>MZ;WKMNW_GB]X+:>Z>2AE.5%%A;CIX"*D!=QVM8 GJRYH6
M^N*4I/7F<<K8P^N"%[OMQTOVE5(A=Q4:'83%?XX:U=BH+H>\/^PEZ4/]DBR.
M)]R%,C^T\QL 4<GT%"%83;7B#I#9:''P\F(M;3$M5WCPK4>"TN7HLI+=V<M*
MAZO+>Z3R@A+*OVIH)K1KC1$"' +LTO=L>5 CF<Z'D#S72R,7)V3E(VV%+@^8
M^'Z^IC#4"2M'N>?9L\_GVJ%B29&C<UT'[F0KA/>([SE%,X36,6F?C(;QM'#C
M/,J+-*/H/@U[KO12?[5MRY@;5RT[S?/ 9?F3:!M1$MOY]NU45]=&6ZP)2VYM
M41%-794R!<7"4VW?[W,'=5-_8>Z VGEJ0[UV $[8R"2AZHDS,X?6E%M+KV$A
ML]B!F@%U)S2'0>'Z1D2_;HJ888S7@O3E7_W#S44G_V?58$$]L3/'Y.R/!C=?
MO\.9R=XY#2JF?V0S8+VC ]D!?YLUTB=BI7&GNB=J3!M"H,>HTS<1;F'#&#3L
MUGJ4/)(1O 2'H;K/PDB'^:,S4!\QBYQX!_!3,VHR2WN7G4'_G\7=_[&D!X8E
M=6_,6 XR!/P N?[1QYSX=4611:"BO"=JYI7NQ@ZU'-0+/[9Z4B>J2^4L;TS)
MH5'*Z-JDT@YS*/XX@!J\'\=YBM-%AHES+27JBX8M$:^)&GRK,/C68HR@SD.X
MA2$2H5J=O*1_*Q\-UK5A)LIZ0=(>Q/N<A75L'A1!74 C,_MM41[K0=8F+YA/
MX"0-&&\$>G#DQJZFHM;QWB"!@6I5#8I#I \/KDW>( 4EHIK<\DD;].G\??E\
MU_C.3DTJ_UJ2WBEE$'0^"D4NE3*_%T0]-!I<&C:%8F,W!!*]U52PBF'<&3_5
M)^?X*963.-_GYMUOUI0]=.#9#8!;=;ECP_^D)N'M93)@4>H>[ ^..NW;(1_G
MW$0&%J]6DU!*9.!]5[)Z,/C3'P'.+G_*YVT3-3IO?IK(:7''1\42?5(=^3LX
MWOPKTTX402.(_5/@X>9Y42<5E>#FIQ&Q)RJP]'1C7<&H<MDI.@7O\L*P!.2C
M3%$,KI/_CC/C@%-\G$J@7 L]\_K21^F^T)%B*=Q,>:'^TX=Z" ]]+TVDFMC^
MG=V7F6HVFJG>(<]5'D"6E[^<.=6C9!Q0E.1E7BP6CKHRD ;;C8]LJ^)@];B3
ME1] ?<SV!MOK&KX*CJ@K@S]M,4Q9 J]I*I.!=\(HL<Q;F7R0,Q@8W 9U?>]@
M0Q)EA^$/4=O%G]17]W94H7/0HNU/#KJ.!3A-NI$-,<MN4>;[M-)NZVJBSV'$
M2I7N>&[LG2[XXJG;D!XQHT([?8\5B:5BR]M6(%-]\_16Y%F'$R1ZYV/F8>/\
M:N^+%2&EFUL@N*Y[O2&>&-Q'1-IG?MXXMUV!+<%=$ 90E0^NTKF2 5FO2?YZ
MZ<D_"SZ?_?$,8\<:$0D%.%V_@'(%NJZH12X,R5F!&%QXA$ACG]E>IUNA@UZ6
MVKWY_87K?[9R]/>NS-#-,V6/Q59@5NH$213\4QKKJ96#BQJ24/^TH&BF^6!N
M+/'2XW'=^6RPT!^"C<DHIC^46?0:ZZ21$7Q>O+E9Q%Y^E@R0 >[/J*[E08*
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M?C*P'2>V5].Z^I*GM_6,<E;4^OJFKSZUZX6:/N.A9_W7P-P!U-][LV6.DV/
M_Y]O\>?W;L;,GB_RUBMB"]1.W Z/VU%15(W:Y(#"(XL<]8?;NX[8CK'*O9=0
M&@D6J_!%44,X%#0R@L_Y9[W68P1=X?O?EN86R[5*]MY1N[UTNFKHB9#8DH[K
M[Y9*2N'XE<G1=%&)_C]V1:X_L,]E^'KN-T!D_>T7\/<>-"!%D,5W^B"VW+5:
MLAB'<<W>J?IL&;[68)7S#_</J.RGYO1Q;6?1X*7\'(VU]77D%_T:Y;JB)$A@
M&5<+YK7>:>.@9E[R+O-&I%U3:V'43KR")%=,;K96;O_*YW0+.ZM^_:#"J'O=
MZ@K_VJ>6&";@;(_F,TM9M&2,S 4J$L8/'N0^T=T_R=\R&;UG%<B(>)1&?91[
M)T??GJS_\].8_NE+#>'-95=\)*WZH'#-JDI*BD^ #0>0[L5+Z857-)5*+!=@
MH7W]P/V6;[[\T:![2Y'172;_ 2+_=&>(MY:C)LZMR=O:%":#3<^+Z3SX/B"C
M-\_51?EH24*I?DL&4=<(9UZ9/D3@5TQ-"*JHMVS^!:1>]Y"(AEW&*E=ZEYA7
M*@^C#QB:QDV__N5TH/O'1FI)/PDJ?\T\9SX</1DX.%^,$/?@1LOY"=4F$;L1
M)V6:+@9641TMSBX+$<]R-/6:&-E[J'<FY,#S=]1>G&S[S\*3.$@F*>]P'% (
MMX\JU>BFL;A _"?#!YHJ$_4J7#=?(@Z=YRB21>X.M!Z-\NY)2'9*0/HIP>1S
M7E7N./\Y'GTCHH#'YZ#"0J4),K,"%, ;80=:>U4Z[F.Z,GD,8POYHWXY)1P>
M5>Q4LS!(3S$GHOZ9Q<-[H5C4W"C="'%PHG-A+?E#V[CZ8HW48QHNRD3C:>=?
M\/45\AK8!Y',F- ON8K65D]UQVQMKK_UN.@SXB+5X[5.J#QK7H'R$+N.CR#J
MGDQDJ8F9'I#38^)>WH/D[_5A*<'=K.ZI7F5T,Q,IJO?E5^H8.:35_S&NT,"\
MCGKL[L''$B(4\U;JP43>@!'-^E5E..S %(&Q[MEU1WSM=$/!5Z=3-/ K*WS_
MTI377YH6XZF(Y&HK/OZVSW@C+EY@F)WJQ*P]G]]89R[28(YCT2FL_/J'>P_6
M#KZQ:.,\B;C03G$,4XEXH<.E5HKM>E8^Y35A4A^@[1SGHMPFVHJG'?DLS=OQ
MH-G:5VHYXHDD.+R4BVO?N\C*[FN[H2H6O*$4+K;'V_!E]'/.4?TS)/YRZ5.R
M#)C*!1KE!)?"<#0\XBMI9*?+<83[\#(]Q4*[>H!"IG'YJK^W+(MO]>J]G#Y3
MVRA!:06)ZJY0L_C,:1S8$FKC$^I;-H4V9DZ_&'4B2J#Q\L;3+>FP19M[X6,V
MI!1'PJ:N']DQ4*_LZUU=K2#FW^A4NW&SE)5XI1TS3(V[U9AJ8WWQ+2_R)-S]
MS6VQ9LNF6PM-(A1S*^-P6L=[Z<B0"NGC.1TGU6X_,G,L>LQ%FV-^KS<34(</
M^S*.Z/I9Q8[$XWSR8/S"&CVIIWS?.22M7YCPDUE+<*0/7N4:3<YX';^1*A*/
MK'"UXW86H5AFL'"&X]1?6"/8IC<@I/?@SFX3H%@4O#:K4%/-X^H?6'U5/<!1
M,A_OB:.Z&F Q,A.F2:N8QLPB)W0%KZ+.%1&M5RJ14?]I@*N#!U\^2LLZ=V5$
M^VSMG=BG?:]\=IREZ[M.E=&BBYC,1BZ-S,W'I]Q&^FG37LE_56U.?Z(^L)TR
M?R?.)\ !RZ]9"1['&92C/.RM_=ZFRMJ-T$Z].3R;=)2Z2K@6?IJ9S7^PE)>R
M)RGSM36,20>O<4Y*[S(^2+K$;IRWL&U"?;'[0*/0Y6JSZI<FJ?BPD<$#40>1
M9_#W01/+E)ZTK#+XF,T3L7EV.HIHF&5,J3-.%EUA[I[W#OF&J'TRE3I(;9KF
MCM<.!U-)4RFA4_(,XI4P#N/6 ;P^OZG:S,7F%7[5#Z&+7Q3/"+0_N!M1Z@)%
M8H7\C<[T)6V]QKN(YG#/1^5/=\L(52!Z^Y=V.$EPK$RV_^=P\ZGL,,;3F1G_
M-'/&&=YLFG$4$_0L9ZGZ6=A[:M9/# LYUZF\#2,I<?F>DDYZ(U&L)>GO;]\M
M-Z7=S</VU*V&DH=[0C13;VC.&.'7$_4B\3VE7$'NZ1.@,;$BQL>T<3YZ-5,E
MQD62K[<L:C_(8G+V)=8M(B\U5J?FP>VX>Z^;'CV3J9FJDOF8[FOYB4, MU:>
MBG2473UG?J#GFD%^MUSU3:*@CXOS&S:8_4H/+^4GO6;G(X/U!G<E8<,EY^JL
MEA9T>+\\H,R04Z8JW>T<I#OZT+>+^$LD;59K#[])0\PY&YDLKL#/U^.L/U(Q
M0#*K<P+O&'D<I^^:D1?=.:'@KW6):]_XO7+KN39ZBHFSJ[XXDVIL+QYUIVTV
MAR3%?=/BB5_1@VH<VVF>+F#/G*1F C)5OF596[BL4#HBU4C,@CK#U*PLY"7%
MT[5W0+4$E<1JICS44[WA*)>57CA<!Y^HTBJ0PWKGB.%HV]S87II'-CN'+*(R
MC5?M__0HVY*YN;P( X&O?3'\2/>))W0 D??*!J=9S_M*AGK(VZG$AI!VWX<B
M$?/O!^$QENDN,WN#) SDIFDXL$35@:."ILKK(0/6].J"/SV7)Y[0I4$UZPL2
M5LD 48FC*G$14R"5BQC7M6N_H879_A2.S7(\1@9D7F,6>C?CG*VZAU;;R< ;
MIXD;LD_(P$\%4#\1-VN,XB>X]MX$'ZY%R/YCXN6SDHF9\[#_1_N_E_:;2NVS
M*P[T)>\B#/*?7*B)=GG\V)[@E7^][=KG%I&.S?48]]\<TT9\UZ=5#C'L6(\2
MCE=A<&^=4,N9R?+U WTLDTG1L#W9S:7"^+/U!![YR/J;[[SY*;.//-#I'I"A
M[ U7HPL<AGN%HKRC*M8BV?([1"^N<1<7^KQHNIIT<._=QU+\4V=Y*2L<-8>5
MV2^.FG)5GV5X?FA:]Z'OR3G'RHHGICWE 4)Q; _8VJQ@U,C5B1$P"L+B[MXT
M?;&EJP<3NG=7W;IJP,/,+MR5[N!&3[$$A@UA6/#RE3T5>9$,;=;#*&%)\2Z5
MDUR[/&MK:V9JJLWX]8;7RK7-NI1Q"6]&-*WRT;=O71YWZPA"+PC540SM^.AR
M/M,0TE/6\ZV@(%ZH3GF?4:B3;W_DZN&UC.E+YR-O/WQ:[;C?1'W8XZFDTG"2
MXQV.[$>2O6/\>V,>FDN](P/B5%P25.'6F0^@.@:'\MURHVB05^:K-7,(HA4A
MZ7R)KS.#>%TE5.2O&^<_+V9/FR(#AQUOI0U^V=FZ M3O++V?_YH6-DS%A;ZA
M$RL+(&5#W$JYB$+MN;0HFB^]QANB?6ZC=V[K"_=RON-\^JE*IO(1WO5CZ0G<
M0GGOL2ZPVGS$A+GGMLV[XT>CAAT?TZS6#-F'KDQ#P#C27'K$6%W-QN,CR-JV
M4^5X01%2[^$KN@] )"P&79=*-'Q?8@Y'BC7)&Z8OJ+$'QSDF^;"95D>/E+ID
M"%: @/)!9/5%'*5N#I6BQ/X72^..7V9Z7"0GM%ND^8D7-$UI-=MFE_O%)"YJ
M:<G->%*#)YD"9P%*T4YD^36<S>M0G:AA,@ S"AUX:O+H2$#GA)'_"Z;:?A\K
M$.[8E7CC/,=%;.#'T '7$2E=W8Y'G*WW2Y1>3C4K%' *1%8,[;5HLH=Z\*]M
M#?G?OCXT<9"!&F_(G>^"3?/'9EA68Q:/3I.!E?(-KU8TCFO:9P9%I^/3_?[9
MH7OFA#@RH(HID]JE/':1#$@&@NOT]7#\YC$P&8I$-^7K _'Q;^'^,.*B,F'L
MQF]%6%]0<#8P<26=."[=1D5<0X,$^HQSM+\]MML/1?G<9*!4EJ?G+AF(A.+Z
MP?OHK<3IK0^C,]+^45D%64;: ^N_W7)<0BS5(A;\56[(EE4X?[^1_TZ*ZJL;
MC[/^ABZ&8_1:)^3_]ZMFBRI'KQ_BA'BV1 8F.S/>?T!XP!=_D2$#VA-DH"5=
M^Z&)+CY@15\5X0:_!.'8@W_+!Y'_VRZ&1N0:>$E;%RQ W=!FMXR4(@/^C.H0
M4^#M:J]0GG!5 TW\DV7]KV@B4A/5=0R\D)AT C5:U@M^$%QDD+K8EYNU*-"(
M-DU%8BH6GBR-2ZE8:P?H^<XI;W[=^BI(ZB*!9&#F5J_Y.JOD'3)PSPBS+);.
M,A]_[21-CF/&/>_,O5='F7,P0TP([(NIJ,%"R-@,DHQCDR=M0N^\C_PR,6 6
MJQMYU4>_L*X2Q[/A#=\@HM=;5,)562^''SY9C-OOD]#S:*,,OG*:#!0B@B3\
MZ/V[;]XC S?@A-AU%4R?^=L,RAEE7NS<6H7N?KR2Y$63D7T"MNMI>8&WA]A]
MZI\-X2)*G&9DG7F4;8?2#VY4*]W)G=-7R\O-[E^T>U&I70N.C")>9*"&)UQ&
M<3"71^.%N,,E^](63CGPFV!.LMGY0.& ZV#D2N;(.5;8+F3]QZY:ZOSF1YT.
M.P8_F2WR4E=$W0P/G#K/(OC6\?+A\3E)[;M=O9:K%^_NW$D&;"7ZYT(E[48$
MZ0VE:=M./AK-06M_^.!.<_3&N)QV=I"*$[[!ROEHLWJ%V#N&SEPEB7M]P\N]
M_HROJ4$N5_\I'8W\-?NH,F5*'5UM16O+7W+IUN.??.Z.^%@KA=SA(B5?QL&3
MC]-_RDZ\<K] Y7YAOGG)SOKR(W#=UA0DE58I;K>KI6W269&LP;[S\8R&W7ZW
M4%<FBA7WEE+@C/%5M4R37;/O9AYS#M,]S@<<#*C(0.:M8HJDZ7?('0Z9L*F7
MTZVU:=K[?9\<T7:7.^>ZW[(7;0],EAZ=T<CPCC.:D"_P&IA>N.[>UA L>(KW
MB9R%4DZ+HQW[F*#E2"]S>L>G -&V"R%:B\)%7N-$U"]9:?B;\FB-MD:T]<DB
M\X/IZ=U!00K#'1^'/T@5J=](Q-,2$#?RBR%IRJY8DU;T6#2SWH<K/2<T-W9]
M-WOZA&^Q[(C@@?+XF54UL1[3M2\Q7IH'CG 9FEV33]=M+;Z5:0C^DHM=\!&8
M\QXT(^R.UZ?VLF%[]1!AG;7>BJ<$Y939R$"W 1DP2K^!ZY@K_3 *WX-WN/92
M"66>)+#RR7N<('*93I'C2R/OCH&W(X+[D>B*M4*JYW%Y.:Y*1P17SKWX_/0!
M%TG+I-F_+S+HYLT27*;+7%5ZDO$IO(?L"W2>X)<*\?UON4X6(>]*'8>LV$F]
M5J+RR ),1SPD*2_Y&-&8R#S\<E^&E(6?19M7+QZ==F<2I.SP;3L>,-VC:'AD
MNNWR]"U5.F(H4(^3PZ1K(]'E9W7=<Q5-;N<:_E) N!0,&O*EI,7M]8ONDAF>
M@1V\75)NTM-1&I=&]>I=#_45#LN^"4EU08,A<YAQ#\+="GWP=(A:VW+ECF:M
MU]T[4EC=.%]25^NT(X4.8]<JI,S+\M2S^PVQ/;*V;)97'H@%"-^M8EIZ)O$I
M>O=M9%-%U^!!*Y+TS%46,V];-O#J31>#D'I0#)SDB5[.O))!JTL& LJ'$1O+
M1>"%HAY@#&1#U;RA(ME&D0&Y7.N@6N(9"%6$M@X\\#6>X=> W,F05*&W1-X-
MSA@O?JY_Z9"F__9KFP6?G G'+1!?%&)(C\&8G%CBY8W8LX/E(;'B/V"IC!X9
MX#@\N%*+>ID\S?$U'1VQX,R(W! \8*)N;YT7V;F6W]KHKE!E$\SM=$:D":^.
M.(28:+L" >9(J7=,LFJHVM6)2#HW!8EK-'F.D&NX9V+$@+AAI+M&5!4F\N$]
M4,?>:VL:Q?".*] H5"%%EWWISP8:-W@QG9#DCF?B;NYN3[N<F 3<?%'#N1;C
MY9K4V)QS#DYGM'_*_I$I>YJL%[_$??'3>K43R:)ZU]O25C29'YG/Q7S(?64:
M<%R=KRRMY3P;#Y%/F<YM4;;J71YJ:5*4V3$S03C<03\_ 6OC<3(P<<KDP='W
M;1.*WH;W[S]E5[B+G*GEB<PMD@4NVAKM6@GO#+EQ(F_IB-_E[@="_L_V&> M
MR^T-W$3<6I=?Z/#+VCQ.^]JH4#NVI-%^?3?B!5$8"IBO*;*K2.C0!^GK\JGY
MNM)Y\%G>ONXH@)TKJ;#D+LQ"=I^=;Q_GXISP+PJ=,XRF$R(#PRCW%?9K2]??
MF+<ZU$K6$L.F]-3-WI2]8\B%?,P]AI&,3T=:3W#E+]$]" RV0PSHU::'\E)2
M5>CL:Y%4N>=TK3WL!:)#JVQ<0F^5KN#,:AJ)9QCCL9Q^14 A8!I<%5RYJ=LG
M,BX\_;: :I"AZ\9Y"%I>$!EC\#&7>=HY_<W2%X]^R ^*":*8%A<\LYI,/#=L
MRE76V5H>W_N>.<JQM69<X9BYFOY89P,]19CEV]O:,WD:GUNR2M[+^S'2G:<
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MC+.LC'&<.*_"*Q[+81\L?/^;'J@&@\8^U@:C<WG(VO[B$@*<TLJZ>1L<BN0
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MFQS@\&,8!^!-8_ESM7+R,0[PI(NKOJ[;L(V>J0W'+"X$V+O6,^[X9RW)]7$
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MJT>#X! 1$1&?):8C(:&[>H'IPM7_[0_F$T!.>*H8[QHNSD7@%#D.+CD.I@$
M8?T\C?/C _SQP3F%BW<:GX"0Z,Q9[ TEYX!3.+BXI_!P3Y_&P\->=<=>!_#(
M3U-<$)#!IU1]1'#1FNKJRY!$0M8;!9^IU;HWV00?V[PB.D-#2T?/P'Z)@_,R
MEY"PB.BUZV(W;\G*R=]6N*.N<5]3ZX&VCI'QDZ<FSTS-;.WL'1R=G%V\7GO[
M^/J]\0\->Q\>$?DA*CHI.24U+3TC,ZNPJ+BDM*R\HK*NOJ&QJ;GE2VM/;U__
MP."WH>&IZ9G9N?F%Q:5E^-;W[9W=/<3^P5%<.  NSL_/W\9%CHWK%!X>+A[!
M45PXIQR/;B#'.WU! )]"1I7@D37EQ:LO":ENA"06?"9B%53;I'YLTWV&ADUH
MBAU^%-J/R/YS@;WZ/XKL5V!_QC4,$./B8,G#)0? P-X!9Y+GF7_:?VD3 #6Q
M, ?)R0\\[^\+?VA,CZ>>"+?R78BZ\/9!L3/;PZPDF5 5,S@&('HFQE(UK6\O
M7/':E"JE.:K!F;W#92=O0V63]M7#/HOYH@HR:Z:7,ZI.C#S7F1SSAM^;R@R5
MV?K'N910]VB*?:F62=$UPU6!JI8%K;Y+HG4345&67+E3#GYC0(J>Z 47YZ@S
MQ"7-.>R$$XA[)&?D2<U,>_</OF+MF=&&E+%;%8E[VA:E3:&[E_:C_1X=IJA[
M[6SQ.4%-+F7QJP@.Y*!D4LQH TU-,D8Z7R2$,5F5!]AG1VHY#(BL63M*O+@!
M<YY]F.!QJ<+*=YQ,Y>SBYW5JY50;7.6),>9W($OT3MWM,@B5F[UD]J@":;"Q
MPIF:]TPFH'&CB9[09"*E(61VAEAO /5@]0&+/_2<Q&4V])T53>3WH)LX^R'^
MBTD1UZ>U'X<8!_K<[YHE7S4/C)G2\C8NW*+H>3!!1\G3#I.JAA]H<4R=K<(
M> @XZK*SN)+1BV^OXSU#PA\MQ;]VZ=W56*!9$K4?E<R]K<"5J;TKJ:@ZL-U^
MODF8<9$W(.KR?*FH41Y8K(*X>_1&V(UE>#EQ3OIYKU&M4#>S@#;G1+ER8K19
M /)]MB%)M8QMRK*ZD[C.5]NZ65T:\!O#=&OY_GQ9C;>#'VN+S#IB(^(ZY:H&
MBML86W+6\Q-\II\[6XL_BN%@.E-C( NG1-\Q\86M0=$!^?HYR^KW HPKHWLS
M%B[+;I_YW"=A/E7#-SMB8+:[=#7V*G&%^J*#E[]C0)YE#@J4-:I-0TN$PZ65
M=1"R32\\AP%([<@(5UPT)H8+V2IC;LOX*_B?J_$/"%B ZE1J&'&*A=5$/N8:
M>/\TLV[0O?-1[XXBL\[(&H/[J): "6/R\\D#T!UCEX$8OK2#YXY=PLLF=CBU
MCX+-OFRFO]K>(#J;;,)6*%EO7.R;%/0V*-9E,#:OP"31S6A ^.R^B S%ER[C
ML)(7P([0C0"S.W=(=W7P5N[$/I[/=<Q<%1WVCH]Z;FF5][CL];FS+=_H);,(
MA<>XENO,%_DG0WN8]L.XW;*#*H3G1$K%FALMGAD:6A5W\4Z0)TBZ^V:S+)0X
MCG-^+.E!,YM%.-Q+$8%KEVNH]@8OW,IHXI6!.6_,DN=>3A>JZ2^+@AEE:"\[
MU,TWS8O[*7#7"H:$]&G:U?)M;E-*J*W0F%X4T%0_W\+ZBAN*D,< %WD@.W".
M[3S&>@::D'RG[PU7EB?IDB.T[GXIFO]NK9%Q,]I,:9BM^M;^P^GP65=VG[+4
MY=2(^GNE%4]F<]3P63=7%#-6&!S>L8IYKXK4W;A!K\M8,$@]'<_=*]1)Y%1T
M)[)>-'=!$-]I0!]).@FTK#I/#MZ$%\4HT;+2.PON\ZK5RW9<EF3?"X6KW0LS
M?S#2JUX;W(AF#J^[5/+XP2;.![(%7?Q;#P)2?3Z)TG32[>3SP<D\48RF4VTQ
M&>NGB^%U^G1ZEFU&+X/VA8VFO-?Z!^O';HC[F@2-I011C$4^O'9P2NE61GU8
M/,E&7_D %,S6,Y(X83I<"LV6VS+=>S>:Q)S3+2(M3.GD=5M)$7E]A_%)]2CE
M%SY<2];SC\M!KZ!;I_O!*W.0;8;IZD?I!F:&%"7O/^)UDFU\4O_NEI$>[%(^
M]7BY-<;E(KM_:"K#&[/.1+/ TI*T<4/%)Q;N>&6J)E_?,/*43\YJ$M1C )I\
M?R&!A8\,WJ444^[NC'"T<][-3] M36$,D ([H,L))]C(M*+4TG<-$K^]4_I$
MEJ>!ZV6HPB?J#CTG9%UIT8<G [E[7EY%ML'M,M0-J%O]^3L;5,,(T;OOFX(T
ME&6:YB4FD3@=W G%"-TIQ;.G%5MTG 5\XK7]9Y& -/6=\&NR=[)=MF]5]G-P
M,"B8]L<YQ&5],^MR/G"?%178>S;*Y.[.-6<M1;TI%S)58S._VZSF7-T_1(4O
MLQ6TWSR^NYTW_#$C*75=/-G,4EDTN@A;LQ.Z.)/\@?\I;=.0""'5UCC./OBX
M)GZ:O>Q]X8?;].R=>EY+!B^3W;A[A)0>CZB5U=0Z6XS8Y 3$*#1=KT,.4$&)
MA 4@MO;FT_Q%4;,F%Z\-J7!<NV;E$CTRY5-SNN\J[.TE>WEBC8U9W-X-K73-
M+&B]6EM)U+Q:RA1<O6K#SD'J"ER"A;HKI<9-N-XM DZY-X$B4#?@%.)U5>I9
MJ[9]63VZ/^)@@W.=5#[Q.BC<)0@V>19*Z91$(J_6UUV,H,,KOMVR3\!F(JFP
M;%X4W3$\W;B:ZLTP-+/UU6G&4L"_+NZ9JK]J?PT&:!E.I1\(L^GFA7WMV!R'
MF4^[G^%&V@;./"]8^#!1GG\58>T,\G6SSEZL?'.N7?RYG)&GML)YDU$F_V44
M^Z3B!I&Y**7.\I=+T.L7<N-98R%$'2[!AKFZ<-_Z0W#C<[[7/KWW9%Z*$?O@
M)CR:6!GP:WW_A--P+'*2(E!;3K"L!M2P\N8,$1MPG6TPT$ OW;]6:%@DWJV%
MIS6[M8;P;@3X;NS] 83I])<9)!.:\U)GFNCUE@.3@T&+*3#^TCA%B7')&&\#
M=,62#=F^*DE00FZWF-:7-^X5FJF=,F,<U\$Z T)Y2TBBMZ'MW+K3CMYL-:4J
MYY8>IB4;^=B"QNV89EWS#5/-G 8_JR$*-Y2BQ?M*:9Z\(:&W&.)RET]UP#MU
M14Z6W^H+G<UZOC62U%EC?FBXN7.O]I(A%2*[7O2YR&B3D?^4==/FH7S!BJ&T
M5K329K007,=L0'3I=.$HS_2W!N51IG>D+BXN6JG=_G'7.;-<S]?5I>C%*7T;
MDH!=1HW5&O16.=YU["QQSLO>A,KVOYM8U&KJ:A%M_KCQ^E#\Y;:$BY9CWK/-
ME6'AIAB)T&:FME=P$3H(5'EG/GNSK"$BI"8\\HW#@XHYFY7F+H8'#LE94&Z6
MBWR:RDPMT*E+99E*CAF+D44E#2+9E:)/Q\I(BCW=R53UQM.GIJ8A_I4#,0O.
M?)_'19ND'V8'(+4R$>*?2^//?0SE3!$<_2H3[4 W%N1)6A^FL>I&R0MM.)M/
MR3AK'"NZ+E%(V(*;YYY]W^!,R@*S4&]?X]3\4AW%H+X[J=8G])6*3>SLBKKH
MP6Y8M*]42!3C&>^O8B\9Z!@ONO#IH//0!;:552NX*1OY-I?6]JSK(JQ?[W0G
M:(RU/",'Q9O-X94O 89DR]NQO6[$F[](3[4KL45@UJ&6?BF+EWG',#/%2(VH
MUR7[&0:X :T#[Y,_Q@#Y;\"I+Q@(O'FKM6>@YW3U]3I/U0L5XI)>58D*P@ Z
M._D$3M8HW@2^&/;6T:LMG35:SQ:&B]P$)C/=P-/ZZIJN?5%6;T/H C*5.JOR
MG+/O]SU14W5=VPM=O*.:3L];AO3;!ODPD'I[1'[J=+2F'Z./>TGH+@W8[N0Y
MSCQKSPL +Z7 OICWK[R##WJQPU]K*E OZ[I'Q;UYUF;9(=F<:B)7M=MJ3Y]J
M=O9;N;H<&QB_6).\NM(;F8?#72$'N;-&J5C8[28J[/WZ+$GU/:E^T,U0%5L=
MORK6^QTO@#3]&Y:\EUXSI]TR[DR3X[X\$+OVM?V"W#D85\$\]#1XEB@+,MB*
M 1:%M10Q0.A>!J1RXH!3RW#2BE!AZBQCE3,_Q6PGYSOJ&^6?FG-E32<S+6HO
MZ#G%CB?+<[*V;'7(:?#K(;7N9LOT96PDZS!U)PLKQUIDN<0ZOME&!OO&"W@U
M1!N;($66=CLIMO&VVK8EY<O34->J?## M$&1HZ6"S[/9$"*Z:WPD+J7YJ3HK
M.O>;XIQB$J,<H/=<R=?)A)N=.*;Z:BD&GM9:R/*I3@N\)J=F?6<;BU1EV R_
ME K7&4_DD9C1X0.3;"S:'*!FZD'TT_U6<B.*<?GSY)_4$LEF95VT_+:YK6@6
M;[2,%;]H:;O81DIJW<O25WMILS1N.A>\6M9RDU_@+M1#< U-_:EYL[-1S/)A
MKX2RVK=M_8YRD+(L^S4-5;?10MEKRC&A<_,! 8%G955(44;%O1?+0Y_-?"$^
M5#:Z5%-7C:R;( ')#K(.V#/K*+:U;&D!D[/D7]C"!FKPBQHUU$.+:D*<="S)
M'36KL'-:15!"DC\G\$_[KV\Y%N8-I6)4!?(.130ABOP1"7!$B*XP-.-9M$/V
M1<FUCU'O'BD\O@+&O<]H."Z8E3:#K$%]!2,>N/#O\<$VO+&JS<  WKY)&,!F
M!8TP1',5@Z?(NL"+++ ][+:Q*1AQ<YOL@"#_$ 6!Y_(K%EUWMHZ;041A@,V/
MVX;K^I")LQB@414#G"631<\-'F["4/>?0>I "9 N2<C&# 8(!&WZ+H*VR0R1
M" PP([OD\*@M8 /4T/F[S>"3_F3?1)\[Q$6_7,$ $! *6]%>@Z4Q0((+!IAH
MQ@ ,6"=(]4R<T)<@*!Y)6F2DX5X=!H!K0.KJNR$5]AC C1\#4.O\9E8>=>&
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M_V&VN?^"C='0D^"@:0W1]8.8\\$_:M*/\(](5<!R#YN1+O0DKX=[_90^-MF
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M2'-=U=\!MD\PC%+" -)5(!01>$K^9$=':SC7)ZIHK4SU,TS<,?9I)@:HTTK
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M'[IIBK_!Q3Y<%:3,E7[_#DUIFL8+FW3=F!A%I@G_=9YM$N':>G-BQSWC9OI
MX%%\.NI@D"/;5/YV<??V2!2QJEY9C.-Y-/R\+7HQ7Z9Z<R=WM\(BZ^Z6X$@
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M$SN6ER^7UC3=)&?XJ9VT5) T@5.'- ,4CE*B-+;+#:5*+*WNWL>A':BL#F"
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M*VOK>>Z^]'W^2E :).&4MS<U[90XOUE;89M@KJI0/#9\:\+8I%.N6699NMF
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M )?(D#$6'\P&/^!P.#GD0KU)>#G-L"G7"Y1!A,X(+99-*D&T_2YL.M^M:E-
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MC+@O6TB]&IE6#WLD"F_CZM10LN=I_7?4]FO!GZYN+=RH*NB6M9SY4)IP/,R
MGCQ/Q#<]  '#Y8P;J>OW?%7@C& J#7*)MO_,%R[X9D,FV_X6;F_JF+R28XC*
MN%I(R *N<O 9^5Y*J)V8;4?,*@4(66??H #TB^V54L_J).P:GXK]<GNE[GT%
M"=H@4=U1BD ;6; 7R_<3K,^W/3XS<#]@,,.;RBC-UIA WTI3ZD);NUY5R18&
MMU#-;*AYQ?ZFYG%@'=3'<X]#WA2,VK@(.>:)[*=^*_$AEXKX]#.WUQ&+MC?_
MV6L;_[4.OUY4^RLC%@SR(V$!DI9B=--+F2FZYX_I[;I<P=O37QRUE3:CXW4
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MT0GD1VW7; *\A@[G-5#E9MC(?RM48.&>2W.7RZ-^977U: Z21=N1;@E3)]I
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MGJQ)WRF4Z!]K#=G M#$D(V&N)FHC8B;CM9B>05YN@H7EN<Y=MG6\8?JH_W.
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M.'B\_)C'Y0[2'M-]X6PEG5;GM^3?<C,/V/-4P>*=\D8Y/URTW]+HJ\O8<T9
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M7*[1K!?1N%-DU581T;/=*7R=(%C;R_VV&KI.+&Q#B.(4H1\FS(M]$F,#HH,
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MM3#N);+P.W9Z/UH&\(;L4V$?+\\WVWA<%A_QH;?[:/-Q;H'= =[5\[-S(]B
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M349<^C-!D!J"\G=>MF/<"-TF8_<WK<_H:]%(U?J-N9=W?\WQK."7;5ZWM']
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MIS\H>%4*6P5W('!W(_>%4\M/\>=-CZ3\'3+#VW>GD3(_X/,(B\-ZO*/VQ >
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M@DZ/B8K).!3>"9FTAAX(E07L=XBH^'*]0$QA,O69/#*@$[*4!-40CG4A]4A
M(%WY)O9U-<^D"DT;+$GIT<^O&%O]I<<F^#V]Z[+BU4>-UL8!IOC0E:VK;S"!
M:MG],IC<<8S%FX:.?*#*F[KPKS*/WXD_H"/T?9XA![ADV:#BLDY(O/#-&"&^
M6+S85X%D[>3<=M,:&7V,0"2K[36U/W]+U.Q)3N=VJINO2[L(.V'#\I]^QUM
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M=YB%W,7+"J:I+R7[\>'LC786QAG/A/9'9#%XZF;[&[WI]B.#3-22MKU\W1<
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M7RV\V<G ^'UOGNT_OK2LA;<(2+JVIT:+EAOL?*OR(0$.*?7Q<*7^D@DX46V
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MCHEX.99[5EE+X7\:5Y^\OX*]HS7><]>^'S^W&@S&SA%UVB+1:ZW@!4L-3Q*
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M&=-<FZ=BU1@1N?^^@$"649L>'\8W<X=,OSQR.B -JN1'-G39ME?"UM>OS)R
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M-  RHH^>7;UX-==)25P4$'(J307!+GK!SS9)O?V"J,W1(,+@E'B1Z'V * >
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MM!@ZP]/8>\DO]U7=%9'XW2QGQIN?LBLV@B SQQOW$)V6SJVP(4$.@?>Z=CX
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MO*<Z6C3WO_WGB?_?_LM&0QK]/U!+ P04    " #M@F98N*%T$XB?  "OR@
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M6(@DG"7<3:E\N!R)[6':52YOR",L69@@\&R8V)*'Q1-$7:R%)($$N=:<^-N
M)>^H6*7HE!P(;1,50B4^6#"M:II+;G/F0<# <[NMU)4A#'!1$(40Z1 N'T]3
M/#QY-\8S#!/\*,"#&-?6C>LJEE\Q6FBSR1IU5:.6>:/:;<?B J0J\1&C^FU\
M*,NJK4\,3V4A$3T4M=OYTFR_1%'YV4]31,2$7(HLMI]#QG+3<7?G]J^N+RQW
MUF;/RX,^-TC8+4<<:G#<>_LXHECUX*=NI@DR7*7L<&:GTX&__1FK3HC3XC'
MM!HA5MC\:4+G+!5O#'6L81;>'QJN_=*#^=Q/J->#60E*Y<-2/SRO>=O*)6#P
M[BWMKJ6:7_HUH\G4RH:&_&/YHTDYWELN6J8P)MXQ=V,;$UK]A]*7K?/ZI6'-
MXA%@I5T?DI4:'[.;PY+-4R5%/_CE[G#V>LSF[,Q44V_$30>U@X G;T+?I[8R
MQ,Y=BV.E8[LWBNNUF-9:SQN$YAY"R?B^_;XY46=?_*(AE IRN3;(]A9(?:L
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MV$D1#X[,FJ#'-4-\"(67;JR'?$?3@\/U "?!%%:>-[B=^O8L59'C=VP_$',
M;_%-#3@T-31\\L_.\0S">+@2IA<$"K\CBPHGM[]/>Z0],Q3-ONN@E_4Y@DG$
MSLD)S+GI=Q\YJGX(V\I1"YPPK:03.=_N#ZUW#'F$1A0338-N^>B/%^747S+<
MU@EZ$WC_Q@\%MK6'1M%A EW4E8C*I[+I[+3 3WRTF-J4YNE0L,&."R]$<W)
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M>$-!@<6+H04Y:N+4[6XR_$V^#@O9W)U4UK&2:*7&8)7OY3%M&[2X)5QA#4P
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M;H"^Y%D#&3#V__%26#=66)<;?2\L^#Z_>* .+:><-%-L/ 8@&,"F5$\D13#
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MZTFJ_^Y$JG(=FQ9B@-4OV.AABHW<F]I;Q__L[?^_%'\Z9JW%8S<Z1%T]BS#
MLC[$TARF>?]H]9:?T:KORL!C71M9"\(:DSD7H62J/;_$5)DE$+#C]5!\(MWQ
M-8WZY>,V,]H$4OWW?:^%\<UZ&%7LIY&WMQT"E)>V8#.F59:/O_!_%MD'8@=I
M?W0/KICXRT(>:BL^/L\YHVTC5N6<5_'=2)BSF1>90#UV6,JKJ+>3PM."+5_N
M*2TKP"]SQ>A^7%QJ-RJWG#EYA+=6Q55E;28^W?><EAU8&F06$^-LQ/<ZIN?P
M?:7\&FL!G] E-/4.#C^63_KQ-<;1]ZWC0^TP $42+K_@-UD,H-^#8^\\QBN:
MKWL!_L3MQ\;H!U<,5Z_PN$T[.!W'R_:.4&QU97T1IZ5$.B.JA#6[3B_G*:_A
M26V'!U1Z+'J9M+'$5KCIN29[X%"\SJP_C@2%/%&CXT0XL;5X2G6(CVRQ;=R\
M>BV4!WX&F\G$O: ,NW[2X5:AX9IUL!YU^5X=5AWM<, G(>*Z3)S+D]9^^_:I
M/6L[(?%U)?."6S\%SG7FJ'2<W-TK0U\5%GD'O/0HEZ\??VAG.1H"=?A>IYQ[
M6S/ J5$K=0IWXHIJA8W&A4-643_9P&8: WP^";Z3XM7*S:OZ/7I06:B&4F*4
MK.YGWP_U+;2$6XRZJO/Z$=7=S'4J=5EI"V/E/6;E^DL&/PMX%%KI-<F@__OH
M+H/,)6/N8P=BFPF*XJF,CYX%$6\WXE9=5Q,G,PH2CHZB>VMK/\#8\]BY!H5V
M3"GFD97%%H>CMG4JQ5)=]O!A63H?9V:.@14X72?7T&81Q]BJ>^7/;<T-G<:0
M1HI+[:8/.N,N9MEU513@RH>7G>)K\M22)_W'E-.LW]).L^*,R[LMR3]I7DY*
M5 ]I3W,:ZC;"%*?A'*S]OVR/9JK2RCI>W8RW?.E>NUTO'N*5*#B3M)/+XGT%
MWE5EM5! +=U[S4@;^6,PQ[9>EJNXK7Q?HZ*V*1%]="<4O'LZ3'W[UWGOO =S
M=(53S=F.;$K_[IGN9^><JT3:+&+<;Q;.XF=OR.J/)<:GV>MV;_O^3-LC,=VM
M"TF;#.I_WSO=<9K5WWOZYOCY!4-B'*11\4;:FLTKN81W=1A \05WH)@8\T;+
MROO!2NMAM00W&JY]S?$W<GE9)GHT[#QF'M7O4^K?TQ7S$*#L$XD\' 6]186?
M<@?F\K0\>6<WR]RYNW*R9_)>5HM3M,!@=2 QNG%78_AXLL*7:50U(%C>CJ*3
M]N0-J=K*1/&PK(Q=?=F(HCZ>%:34-MKZ5W&H4]S9"@EE]]>\EA[\NR=TH%#K
MX:=N[C>*"SV/I4#C0E=/*?,\O-IDRA1O0TJ)LZ+FQ9-S'_H'#+(P08:L,_)=
M&7H"A+!)$R?Q_XY+#T*&Y[">5 ;W+^$LBYJ[\5*HK34P@SS(EB]T'8T6@GV<
M,Y /[MBX)CR0K7E5>JY.L^K+CO.S,'[Q.)K85[-M,&,VNKIOS"SJD5KY:_^3
MXM[!I?@V7SF0>)_BZ+XY&B5  \K4D=SH; XR")'C&D]=YN>K,J1H.RD6/F@'
M$1@X5-AH[M!S=U^6V70CWODJ'0M>.Z#G"?B&=%<S).$<MRO2#B88B^+W.BFB
M7_6[L^VXW401MLQH>: ;WN]J6%#34$M*]E2R$5+\UUPNQ[? YN)-W/""28O]
M&;_GBX?%5-WHX&W;]K-;TS]^S2I%/O-_N#\)>"<"4;#>$1^5])TR1:;8 OWY
M!JCORR]BIKU%MN(I@9'6<*_0U=MQ.Q.*R9SA[4-X=9QAL44V7FNEM2,E>R5F
M^'B+$:+XAP5C_VO!Q'D$.2H7:/5YM68V1&MYKKL;Q8Z3GE$;BSA]-]*@[,@7
M^4A?MG[->51"NX^,VL8K=ME@IH<O]M>[P[(PR>ZO)/G_G7]+U5>D]/NME%LC
M&HE*&;C_E(*W_6.&/NQ#@:Z+0(MBK8QT ,9>[/SU/SZ__MI8'];9"\F#CK<'
M##Q>J;QNQ^I&HQLWP>=9K=E%Y#*[>P-"IH803GN0Z<4ZGFZ=%:E2]_WU9#W5
M+65VD+?CMA<\>=NK<:#(ZTR$1Y%MS>C0?TB;E[]N)6A4LRLOH<G!T=H[]^X[
MZ6Y)@NP2T4/Y3RP?S@5K9RL;9F5KKCJ/F;I&X8@2^6+/EI:IU#BF!DA; IYZ
MTX3@E<CUHWW1+T=4R552_HG9RRG6FXDRRDQ2PQQ'RZ>2@XM@(]WH/F>6D8JR
M>HDPIY]=+&E>=5J>)]X,R ;;C'/S DG#)Q-[#MSM%+9O9XT37G?R9^6Y<0(O
M"5L77?8,*Y=,+$F=^[U,/U2>"QF*<=LG-_;7T#J/CXY=AIMF:QM(-!VQ$89I
M6^RNU8ZKR[Y%BR-PJW[6&1<&$/-L):B)2M)<I+7-EWYDF(N<,JFP;AF0VR]:
MYA:>F%_&&TL/V^FS>,I_"6*PLA9M*4C4R8;D&LB];( MRTJOOY'88%38!I.;
M\*UK5<'+]6=9.QJ*&'*="AL+LI?&"Q/6Y 5]X!"96>O"?AP=8RN%P - P4^?
MRLT,CH+2CQ;K%.X.ON+7A$5-!;R8>!!%3#O/%? ^=+R.YJ7"O6]/=-_Y';)"
MF3)SF_7KECK30/T4&"![QIES%5JB9CZ8D]ZE6K&"N!O?VL_)GI'U]5O/G^<_
M^?=#ROE^X,R.%O0VZ"_3N:HH&7JLWA^XP0DC(Y77D6J:'\\6M[?ODF(CIR=?
MM[)P7PX5M-7YP*U#'<#8<$+4+LK52: AOGA"W8C73O/BL]UZF-Z@G-Q-,)\)
MX[I.W.?BP8R%0@0?']]UO4MQ#!">7K06-"HSF)UP.7\Q=*K$$:D0_2RJLR5R
MC#]REM[7B>F'#O5\O54.I*S+/;<](MBE_9Y^@JGSZV2RY^Y[HZDV2+A)M%)Y
MV,14KY&1%8]X!NG*4)IID6=D/$N4DQH+7)93HG?W5ZG'FI)1Y!S3L'GAUG3D
MC(TG5='5SR6LRS4I(58.#).-$GGM*J:C^8$L5VA[GA)^QV"D^KET[<?=B# 1
M+Y$55$NV3OC].B[L[F?WL%HZ8/.9]_.>@J C 60TNGGPB-HO%^LDF,&?P3O8
MY/B>[LYP_+F??!)C$P;X69H#[58=1=>S_:+>U-ZH<T=]W /OE$'Y3 *,*L_D
MC4F^_)ZLYN^OF$$:I7I1[ WE'Q9Y.1^$2$DE% B^P$]![I@>5G^(FEY D_<9
MRVC78[4&H>6.=KY,)<5?A(1&=\$3=6:*G)>T="X<Q3PSWRO*GH!Y?W78(_TU
MOA_"NY2Y-?\/>^\=U]2SKHLOI F*(%5JE"(H(BI56E2D2Y,.0E24%A&17H,B
M2H^ @((4 >D0E5XC'46D@W0(2&^!  %2[L+O+NK>9Y^]]SGG_N[O<^\?*Y]D
MK5F9F7?>>=[GF9DUR^H66VS_JVGS475T5>BED<<^'@3BXOL!7^=);:A*>7E-
MWU)&V?F4T?S0&1VE.:L=7"H#C''4WF17J& E]%U!4+U7U(XZJ\N2',2\!Z6$
M%X<[P]>&OK2S-,9HG7G72#26=BG;6,0/I'92Z(V.UMVRE1KMS6-E>N/%&WD@
M>SHAH1P2R@4-<5L\=(B!^?.A*@'9Z%TZVZ->K1E,3W99!E@I9BJ)_3D8<4Z\
M5I/'V]2>E<WS1U[9C5ZE5UMEK$KV?UFX@;E.!NY[HNJ365Z7;?GAEA6'*)%2
M3'=.$> AV-'M"!W4)%6OKU3F8#7'1],FAF]WHYZ.G"+-S;>[)4N4EW<3#":<
M6.#.:G >G:WM*HBK^])4CM.U[50:@L;:UJM)>6WA)CF&UUR.,RE^S*V.>JI"
M09&<QXX<\5Q<O3YN/HSOF#K74Z)N[">CUM,](V]_42WZFN\7^0E(=P:^ A2;
MWM*QD\.<4Q6U?>*31UL.T=P-YRF:<.?Q=^U2X./"SZQF:[Z_G#<?U> H^OJ4
MYQK];"\F0*"ON$V7FF"ZUM<?XL2;5/A^9LAJ^))T^O,+X:P/#IZLX=\V[9$<
M9)=?5NWN^W;7V*N/CB^5Q<H+DUCN1@;"_(]VX^:9W7O"!^*1G",G+%-%%"N@
MW97B[ 3IM=4(5&IU_^URKU3D9V76)IJ1V9T$P"E<0>.-[D22NTA)@;0&1#?)
MB'V>[K;U/4#B4[[3(^BZIB09V%V&DL(=FK#"=8S4\_X<?26'X#YUBB6O>U3-
MIZ,J]**B-ME*UH1)&JHI8-0 0V!7Q"6^F/_@F1M:F;>(UDT,X^YW4 FD)LR+
M)G:CI[VQM,2'I?MKH%Q?_&\56JY@0$[ZFV*:UHH]U2"(9@M:GQ%@P)^B(@7T
M]YV@>$1U@)&*R]G=@S_#"S,ULL: <RIL:$P^4%U6'CVKH:Q8Q3RF#E7P;^CU
M+_DR;,?5--HVW)!UPROX2OD=T7?/#Q[6U3FHL#OPEBLJNM*VS;#!*.NL\2MX
M@[U02XCD=/B=L"<N.(.874JKP1NH)[Z"DH(R)M<^P-3/KQ._M:1N*FWVF;!Y
MY;0IC[:MK:=KC8^^%F\LSY V9D%NV@OD^:D?V[>=U]?=;4LMW4"CGIFBBNO6
MSV].92L&;Z.$^P@L^?-%[YZ.KA[O:!,\5!ZUDAYE<6M!+3[V]<4X]O2<Y=N%
MKX)JJW2?=K7NMO=.^"^+;;&LF![=;YY95]0A.%<5\F1?M%C3M0^$W(.RT!M,
M:FR+YD>>.:7.Y\'ISC:N1"OW#>\R.N1N,B/%#130A_3[C+@^J+[U@B(GHAE9
M/DE0?O#L>DZDZ2'D]8N*6G4ZNNU!BD9\"ZN;1'C>D %&_1N]69]$B_J;.]WF
M'[;X=;!LB&R(OJE=.U)A\U7_1 (;=7C:W4O BL?1T.[.6CY+[3,>7/E1;]%C
MZ^D/OH 2<PJBN>QV,W;%\VC=P(L*+[-N7Z6R: @#Q_.;VO+J*=<H"+T#1M="
M!9\*A@K2<0&YN>< WIS-V:\WNN_M.D@2DZ2.U)E5SB"*ICX&[T<_1,%QQLWY
MQ?&><;:W9I43PKKA5"%DH'LY4NAF.M';)5I-()OW*PWC%66,BNZD32RK_G4]
MD\#Q!J&X-\Z.Y_C5,TZ[+,''1..PNH%O!I!#!:,W:RBI@W?N\);Y[/7C3HLH
MZD+/-6@6LSR=6T=<B#4MHM;3$ ;HA^+KN @F='1E3^(%3^Q=8<!/3[#$M)2X
M\W&L'>\YR[Y]W35A\HAUA)>A4E;O@&'>E=/;"MZF7'U"GS$#.7WS>HJ%47>=
MA,=#J51W@X"^2A'4Q:H4G=A8I P^UHG?@=W#5,G@JG7'&ZJ4Q1LRKZSF<^?=
M*YL"!T<SYX:?JQGM>\A9]!I[ 4WJ5K\-]SM6V<;<B.)H&L/7D2F:RV^,%:KS
MU][CY9*[>A]7VEZ<,4GWE2R+<A1?,;U]D?>HW^=9Z"Y3OJ7H9'^.LUR22G0_
MD__-8Q)1RY&B/?GY$SU+4R6EX6J'K>G38KW?.W]7^8Z7B\I9/EEPVULDK;SC
MWKK=3Q,R>C_-U RDBZ\3D-+R?F3@E?4O\S$=KC_-U53 5R(KN<^EA8I2/OAI
M"HJRS5\4C])X#$<<UIU\AF5;KO>J'[R@\/:KS('4YY[+R (OO\@4AB#,"*I>
M=.?5D>\:A8)W:>?+4IIKA%L2QA(G("%<'J'W,\R"1E\5)?<=W-#WN*.9WA/.
M540&#FW403>ZR0 9H- &W/D.]SN5C#.J>"#2:Z/.W7[<APY2HWR'J:1O7FL)
MP:URV"WFVML8W/O:JM []% .:R'Y8Y@J/A?OH=F_<N^^&_=EA5+FG?XOEL_B
M2-5\WD=*X/H]]TI\.,^4'#(M=,PXYOGV1J!Q=NH1ITMKC$$$<==M<R4D=4E#
M..?#KQ^]#S1.K14P>#0D0$/R@Y*+LAJ\#E[4/_Y=-UL@"F_\EI4B;'*5;LZ*
M[=%DE^0W1W;EC=@V"3_3:-U9"T/]2\>LI$"%R=((V3I2#L*UXXV4CRD[0EP(
MHCN(X*I2;LG_\#+@K<VJ?XGZ[QP\8[$@UQD(AB[&EI$>PS,*G33!/UILA&Q^
M'MY?Q-K]KSZ>^<=AYI9CYJ9_\@J7IH&&X:6G[P@@-IWH8$,,K).!.;9R>%@)
MLFE7NB2_/7-^R+=_NTS)H7C]^0,:6K"9Y/H/)5PP(17:RK2)5"&,%<^&3J!+
M"0A0^$1PD\B #+Z+6#$%1C@JN_'M'71S^C>EQ571X9:BO<BMT E$F8+?SRFK
MIE;!A&1@/R7RUMG%548GOHX5^0711Z11[#;Q@"1BCS ^I4&L^?OI=D4#2&/8
MU3^G4]L"J1IB[F@Z&1B?(0-<_O66 V-\8XHI(QXX$]#03OAMTB,N*)'HA$TG
M,3/R@1 OH$8&T 4D21\Z#YBGC^<6PGF.=3]I_>6I\3]RW 1SQ*O[>NT7&T(B
ME>&[EH1&_28W@_?3LL5G9H["S)Q.L;ABDS[OB.]E3(=CYX<SX=%DX,FSEA3<
MP2XRL+J(B# JZZMV<O3P>I"@%,WWO6_ZI$W=B0/AOF.AIW*9-19JL7+8RBYB
MR]LN*Q\R0 >)!%OA1RWZ]U>P3 I@QW]4<7=\2FMA?:462[P-ULF;C6T6O1;M
MN?KG.F6 ><:T(/Z2)\0DWFW[6;_ (+$%-HD;S%A>CQ8?_^J>O@)9A+V>WEQ<
M?NUL'COCSM42D2_F&^SJ)RC\<O7IJY"V\]8$JXR^%+R&K]M^I07V*]VG^23Q
M_N+J22E,M#%8;U>3)-!&VE.H72I[R!\FTJC^:^I>HA5H>9,?6;OD,@RI+"R9
M?#DB7703\F)-UR&Z]7;SB..AX(& A[1\);-E5L>Q->T9_>OV7!H:^E$!L46/
MSR%"XR!'\9AC B&N$0(.(OJO+%(AYJA;HN:+J\+#S=M%>TCUM.I%$C.2!VQ#
M8?4_VC!E[05^EO1(3FW?&#F[U56H:E2^&IA6-7_4V6,>BQ03) -:I?*66X]"
M.F<O\D2F>@CPS+(U@34QF$+N4LW_J$F>U2))LN;1[7CU;LW\]Y_/BQ[1[VO!
M>F?G1M"=3!H8N_;^J'T>M!RW*_H5.GD:VT(\X(K<;Q@U@I _*/%3=:+( ,*"
MX."/ KT4\L,"Z5U6SF"KPB*A<RP9B!]MJHO74G "S94$F@OL!YM>H/?YV8"-
MZC[0E@33<A+CAG_:X*B#/<=QSFX6G%[?(2A/75Q9+H2H=X<-QXE<+7@46]?1
M/N?00A"JE?ESKMP$AV0^;3&3,:'@B#'DBB)_Z(837JO:\4_Y0/&@7]!Y1*!_
ME*(%+ 7,.,5M&[EX;HDTU0V7XB"=-DMIT\5OA'LEDJPWT,<Z='T]"@5(H(;E
M1G0*:X!&1I*D3#UCFD6S:^:Z)5%2::8A&Q;<EP41''NJ"0V?8$;;(1C^Y?0]
MY/6TZ@$2"R/7?N/\<9\DHO[6% RT,70;BVZ.[\L:]9O:_2(/&C)7M!TZ>1Z+
M @V9LH??-^3)?2Q-U8D!JP0AV.T6[Z&JE8J.=*R(U/TB^T35D?HRE4DS;P_K
M:WDXSRR'?)!S">TK?'7_8<OM9M ]3\CK[BZE?#%Y8Y(\/[[.4DP&"C\1FKS9
M'@Z,\KI*W_K]\7;:YYX5U8H9OG??]_EJ"+TNE?CF=;!HDA"B?(==^5OXQ%0!
MZ-[#,$9&Z+VU526L"01[<G'RB=7I8<RWLS"#=:89P8?2+I&OO0<@6ZN/H!OS
M(,SY3X,V!G9IU<N["^]1)4@,*69B*$J&BQ1)JVS^%>+/F/$.,+KF,18-%JT-
MF-US)@_;Y.H!B[\) ?__#BW/^ZTJ\EO2A_(<&15>'7TSOZG4U]B!6O!@YH /
MFG19.P;X&^7;5S@\[&^JC_GN7=1MGUF>)-SDP73M/:PBCK)Y7>G.]C:DP#WU
MJ=[GRU1WCHZ]2,-LGHWP-#()OF[L%.R&6!([,GM]78$,")Y:WUX>C:,L9$2]
MO2,<K*#+?R9L8ET_X'B$YMF46-F>%[$#,V&QZDV#I&L+#$*WS/!IW*,<>C46
M]M;E[TPVEN_*FYD9OK9-/B+7[Y820E!!V+*-ECVI;A72:QT?T@\/7%*UWSN%
MT&9>:-%=MS6W9["V&SMA>1TS\QGSU4+LRC=*L>H,&=HWU^60WGF3*1S*&+4$
M\0^*Q5W9#_(G PO56Q5<!7A%7*<+E]\1,RQCM^5.*YOQ"0Q@UK:2RRY<V:B2
M[@TY0O=1\/4NP*"Y.UI0^X@=Y5D_QA%T1T#^??D=D4V%[NG8F-*IV8BAVN:0
MC,*;GO'F">>=G2:ULHH$'GB47WV.W)T=6"OP@Y@7]2^;^UR?2+\7=XH#WMQ0
M=*0YUW Z=O!TQIVEL)E$'2FKK:FE.!,.>8\=_>)$E_ )6\YL\Q>?[!D,NT$\
M*I%,M%@5_;PQQ5CDOERQG"QAW"Z=O]28U->Y+P/USN^O0,H\P2#L;: Q%L#4
MHRW;HWW^X/Z::.!$9D^$]".*_<^7/SX?T:G;VS.<X]88BHLI.<#4-12HYG!3
M<G^\E.I'VI=T&EH:E\*X?AJBL?+Y>?2F ^;JVCD8Q*IORAWT%Z\U5BW"6(HW
M;+/K.\1#;"Q:SC=)($=7<6*=MJ5V!WS:#ZGWVFZL%N=QYS@C+_BXNK=DJN<S
MLN"UZIXUE*&'S(WC[>_QW[8QO<[_C(?I(V7")RRR/E&<&ZYLXN=.&G#5?"3V
M2I-)'OFU8A!JZWC6:%@XQ,T6IDJO KA!:/BV=)^:P\<M@F_$#P8_\>EQ'FH$
MY#U6^ZMVUR*L)]!/?2]F28UE36EK=H^=;Y[13[F47K'%ME0+B13Q5<QJH?R"
M%:NDLG_*&\_#SE=,\5:%C?K[<FF2K=CH]#QU]6ES#4%9(\H*20I%MI9Y& M!
M(']!XQ8\ET+AV3VK>_?"3N&NJS*X)A06W$JS[U[@BNUU[W]_N#J:A^(2AT@A
MK($,,!$D,/ IZRP'SLJZNT\-[09;<I_R(-_:X9\U<4&#\KL736NT7*-*FX]H
MJ8^%T@IVTM2P!4ZB.>>4SI@A/HC'F=VJBV._'GU<D<Z@W4F/AB,",7T52TL,
M+(3B+$R$?QV'L+3]1U?_WB@%6YOO53W2P1K5[U86;K=>W^&<HO+G#Y!+$ U!
M4'H:RC,N<2LQ;NOBNQ'UC)-.N\ @28W@4''-[X,D#K7#M[^P\D8!&L=B*>3E
M^"RP6IITMO^F(WMO$X_Q=Z; ("$=G_YQPG$2.Q@P&%*F$<V1^GN&[C@3"L1$
MRF&US-%*._?01:KP?(K6$QJT!:XD9J%JSC<2S!H]RY\$IU-&"T[F&Y[,N =J
MB+!_?_B?41H;U% 6_%9UGHL?U<-)NM//\<HR/@)G;R.:,_S&+ZSTKOY76E4R
MH-17MUJXH"V;!Y$)#Y\T-UDPVQ#M49 2;9\<EG&)9D5-''NT2[^AK?1YRJ!*
M"W[GS'+OEOZ"7U[_O0+FYF9N4]*2.H=2;69185^TW(?6ME<=;QYA:4E7_;3F
M4G:Y^GQ@QV*+@VB?$JXT\@>HQ-,B+4=%U9KE_/KS)BV&146JAT.NW-.N<WE&
MM:[.2PT?2E>SIY=M..-P$">;<STT,\:DC_0L<TI8OW@YC:ASX="AZ2Y?@[P%
MT*IWX_6"!AVW[XN$<5(JS:2MC8>26B;;E<;W*"U3VH),OCSM>"A3?G':Q#)_
MN,WCS?CPQZJW<6-755HY;V=0M%^>;+NXI' Q:^A&5KR"7F[E-,_1%=G<K9"Z
MBK/H-TKM.4(</9L7)"W@>V2 >71Q.T[7FL4BS.[$"\)2Q2<;RJP>0C*\P:NG
MH/IB;G:]AD*_1,J6Y2?=3T'>SG/PL.*U[V2 (%HAF?-F?;6W.NKLINR#[_'/
MG3MX]_JNI-F/?_(M.>DZY#"T0O)FPK].TEPU]YUA$-=QY4N^%RA(H@<(]O$!
MNF3@H$I^]7 Y\X6HNKL18/B30SNE+0C4R;W@.$K3A^HW$[K4L%H&V,K./^HO
M&,'[;3(>MM]"GBBI+8X4#M5_>EXS%WI^*$7!*!84'F*D]1N"*\NUZ,AQYTZN
M[V(!9?AX+Q[(Z1NF9XI$>#@8 G1K3U_.QE>RL:^FFG>('-N[;D4=GF*9<3_/
M^TB(XI,RD]V(^A$'DSN<EC1'65U5.F[IQ?-[^"24?>V+:R2=Z/V*3+6"Y3[U
MC)FFS<0\D%B.%DTH[RRYL[:T&[8X\ $F5:1Q1N?CQX^%FD]:>)RC+(V+,EOR
M[;;E?"-*;+3?O$_*RH8^.E"1P]%49+=NMYIE(7KPFBKAQ@$>:QYAJO.\7ZGE
M=+7%T!,J1H5E)6CF?/.@:26.M?Y765^.5_2R"B>;*)E3Q!WWWC!P*!UZ]F1Y
MJN]FOSCJA :KY65/TLV[PE0HR"DR #6S:*@,]/2X>L[KP4+E36/#%]\MPB\P
M2PP,D($!#1\XAI'EC+3<TZ0CB;<_B([(#%$5B-#*ZLG9CI.! G,KF7G'^[;V
M%@6X]R9-7&%-J"::]&S8?*7R):Z+^774TQW'WU'AELT3I'JE$RPW>\VG'/J?
MOXFE?-[=# @^O9\ENT*ME0L*//,%&@M1.S<QQ2GZ>Z/]TJJ;A]4$%@U=G1B_
M;N\&+2\'U2:QC4!LV=V7&&GSSO/8SFMB'PSL$C6+7^"(B,E(=U[O!OUGR][Q
M8>++XCQQ3.:B^<[>IRC\G;Y6KAY<O  WE]"2##OS[G-G<6[5U9?3TO)WCAJ>
MX6C<94B8C[)_[G"N*?;Q]_M4IE;#+]:=E\%*%Q!/BEWA9I+2>I$\'V)S/MOH
M&DZ_Y;AWLEWNE",4BH>\S#D%@R6GK"'XYS-6->WE!RYVG\A,<,Y,N/T#60!E
M[2PNQP.4^Y_G?GP>8'[>W<UU4SJF1$S8@>I$>@E-9.]'^XRWDB\._DA[CCDZ
M+OH1^S]8?9M<.S?_^^K;K%Q[8[G^)+&G;^&\[?GIC#R!Q\G H^V\%WJT,9:^
MDEC;9QFV:S)A0H][7X<=VJAA\A9E\MSZN-OGDDFX5\.GO%"IDK#]"NB87$_Y
M;M6@ GC-/JME&S9W.+_()]1;*$6T/#(=/4U:$"!]=B4#BJ*=<V"6C5C=IV(*
M%F_/)OI)?H+/9!2^9U)HSY+7+7$<D)ER.@KSM+AJ:=RC+;/6=)J8PYKTB<,=
M<&L"O,8;B3#=6A]QNKH,K2RJFA #D_+2]0+'^HUUI8N*Y1\+D+S-E5F1!,;4
MD7=Q==,^KPS7BU@I@<@GADI0[':0V_@!R_E*QQ&YDJVT,+:2UY2^09^.";JW
MP.IS\7'=B_7V$U"F!5'!KOG38B6T>J;-^:GL4-#_4H[=*U@JYI6 E8;PU_9(
M'>3CM+8L*"ZEO^.N]*+U*$B^(XO"OIO=[BXNGRX-:3:RNL;\37%GT; :@7$4
M;6&RMV)?&QWQCFU?7KJNXTBZ^Y1-_M7+K65C*8MA!*4OC*LYNYE7V+BG>WCY
MWI'6#&2J]?!Q/:JQLZ5AJOBRB5'C3^R<J 2X5D$@WT-'*MLY+T)>;:_4LH!&
MK$!OB87H19[[1N7EIFV,>G1LLQQ#!2BDTFE/1\E303,I:3ME,F7Z&\=L /ZG
M*P_E? ;,,*AG5MS8I&D.[[[\(FTJ?W/65S&'7F\I90:<]D0WU7*7KQE7'58Z
MWIT1IZWD=E6KM>W\^7< X"7UZM<0;V9U$B\ZD2117UE#+ FJ'[$P:Y>\,WJ1
M(I:.EG,VRAQ] #']PIX,; XAB,=Z*>8E]54 UI\.MB^^5T"9<7:15#6,F+_J
MUC-P'GN(=+4*M;L*"M6W1SL/=R$V(S8EAUS(0+Y33F9_UM%'("U<+@3[$[<3
MD:J?>--^?%T>CMYL_J%2T)<NE+XE \<35W>W]F??I:SKH>M"=M"M(V5@:>%&
MF^([5..(@6+T+D4>WU$P9U&04;QS0Y/"S%]Q=RW<ZU)AHZG[+^B;#V=]SZ=;
M:MZ-JU><S;EN@J,RKLB0TBAYS_S$-B/V<ZFW7V8*1[S]_2AQO_28345M'?O>
MGDO=&F8_V&^CY(O,Z$<'[1E.94A^U%364K>C^!/#EGYM7PR\>!KWO(?I!_,^
ML)_;M2M<.KC,F!K@_PN0  ^%MA:.RNU@@CU\PN^0OMP-U=Y1V%AJVQ-A"A,R
MT"^WB:EPHO-$W.CU%<*T<^ABJ;L=Y/QS&6I&/DC?:+Y ,3W!1T1P+2HX9W@^
M4\.Z94542]A(T5T?7RHK%<Z/FCT1/TX0[?"]B''B&FS#'-+FJ)>YLF=28]^O
MT1M41G5S5I86Y,U+$ :"EAL&13WDP#&7YYV_-D(]9TG'2?"$1KC%?L%3-C!.
M0FC-[ W:9D;/SI\5Y)VVCMEL=L:;:%^B%A"Y>_HCFP 5'ZY8C\8M\U&ZJ25W
MHN+ISV.@GXGQEQDY?:&O.:/?P:)R!BYX_USKU''DE5,X/6IN!FZM[L%AW9X"
M,3/2SF.V*^,WZ)-7/O>31H;'+)2=Z:9;+M :X+F20X$\Z\QO\P]>WCNSO'Q;
M6.A$^''A@="2_Y$UE":_]I@!W1LMC>([S"OHQ9HRT@NU2Q(J8'/(]/;8=Y#>
MUV8FFK]6I4D"E7YI%4BE'4$J;;'Y6X\"/@_%$QX[H1>'8$2@#WF0#+3&II*!
M;W)@:%8I,.E%3[/XD0&K;C(P1Y/OJ4:Z6D!+JNLG [MB#G><U'**5%@-N?_>
M",-_>.CM*:!'B"JPM 1W%A,)4KO,-E1?;3"3-+L@>B74]\N-[/:],^-@ LC=
MQ+V4[(+3(C.W/H=W?- E=O1>Y]8@ Q6[H;UID38\V9_W>,C 1L<F:XIU.1E(
M1F07.(C,WFH-1[Z_@>B $CSUMT21.[-D $D_D!;I?O:J-?'I+,F+#$S5(]^-
MD(']),9-K#O?'@IP+'% -SK( !\K]Z&4/VX9 F_A"6XD=>SON +#K^V/VRWM
MH79 XHEDQ!9\_I&3^%_/9)"^5OTEY=B/FS^2VO]Z"EITGPS,QI,4H,UE<^E#
MY[;L9M%%9\%3R/U3R*6VCIVI'W]4^#14,9W1)M)C[\(&R1,L;0/!'OIA%?I'
MPDJY4WNJXC:13GMGM_]TU8[TN:9C-X7@B8AP?:&_?,Q'T@4V:(+>: 'K \-F
MR&FO$L "M P0X)EI2+N&P?27I$^U8+D@^-W]Q^FV5+;_?#T[#>G0,"@01VK]
M^;HB2+7_E"#WCP2QI!;T3PFD_IH@+RVEY/:6_D7H$IP,[&S_.&D/?>_&^*?O
M\((T)/PXF "R9*E, OT*NPG:1CG- ;*Q"M8>A1^ J?#U7UZZ[0QZ8 *2 (J#
MJ462).+6 O3/"6ZI\ WM)VA1[D7,@CX* >M(:NA%SP[_^%[X.52Q./!;X]21
MH!Q$1QE)"3VEML4.!@FE\1_%=7?57\X0MV8)E3N2M7]RYRBB.6:/TH ,I#@1
M@M%3EB6LQ/W[,=!W4M =D-JWANV/7T+W=T<I(UT%,QC[D<'5J?QB157112^^
M\8/1>>?'J@'_DF]=*E=GOE<\>!P)!A5#]I\CGQ<RTM<"TS!UR(D.+STTBN(:
M7Y9A^2H;X?)HX-'N9O[X>P+8G5-&(3@R0&_;R*#6: YIS-.V;@ C<W6"*)3?
MZY(8SYR.^W,Y)I^]WI2UDNJ[R!WA>/0K,#F @QQ4PXC@!&&L&E0)<5LCG7ZC
M-7G>[WQ/%"SP'>^,V[O>G=%S]M"'1"^Y #E(<UGV[\^841YJ1J_S>P:2Z@8@
MNV)Y,7@6,B"8#NJCPAZPTS<7%OW#RZF,&K\_LU9HC>$@A'C -L? -M$4*$RN
M0 ;#UH5&$0,^3D21R ";L#_">T\*T=I/^V0_#AKKX,Q#^@VG K- 7?%DV&J"
M#.3\6,S@%"N0+4EY>@&V3@?Z)\H>@:,T5A @ _S&@?L BB"RE\"N@Z%,>YOH
MHT4&4KG>3T)VF(LA>[068$%+<J)J^#+;6?7U[K'^1DO^3SO8VCUSJDW/NJ+Q
MJG&]];80QPUL%&3OHJ+W@!;H2=OA*9C;BR_77GN[V->:;SB7N9.(NIJSA(Y(
MV$8+B/XMT&84?LH"^S1K*A%Q$*\Z(\I?BG:HK(Q2O23,P\Q8IFN>#DI?CR;4
M+B]H6C2"Z #@Q ]"F'FI&4/C1MT4E\LMINZ/C8KN>]"M0OM*YF'\,WV+O;6E
M:POGZ+?8:O9'XFS0J/DQSJZ9/BDS0J+I,V'.,[J7:!_:4>J$;BPBPKQUAY;3
M>UT+++1**V^^LQRS6 X)F8\A2/5Y(AN';(.*W7LW+X9^/&AHVCP;A531'TD
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M?>@U7BB^$EA2XL/;.-'A+W1<JWRNX;6A]:"!Y'UQ1*U6 EE?F="PEA**VX>
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M2AMDSJK>U8]JJ;%O\'!\H/X8PZF^(/#@&R'W9E\$_(JF8[$YV'V>;ST#L[2
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M*R9"^WK<PA:'T2>GKM1\T,[8^5!]UV6^@>42]S_% WZC0!Z;OYVPA$9XO\1
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M/)%]R$_O1^AMNN$HWOC]$T=;.'8/K/C)?'L='2T#U(^7 :%8$1US9 "=0G2
M_N2KN5H_WK_S&:M&("'W=L"62O^Y30/^.Z\6^C3+*)U=6XEBP,F%BU;.R!Y3
M/[0V"X0?[4XP<;_RXH6!TYOY[M9WC>NU[FEQLIP3)HID@*XY@@SH(O#T9&#2
M2F?L/#;ZE$V_(T I2'R%QE=F@?I4N#$%=]X,,2% !K!&10V&%J@F'OTO#[KQ
M=Q$Q9$#@FS5V*TB:#)S6BO\VS.U8E)35B>TO+D8S?8.S*!AG.LY5(5\=$H8$
MHU(DT7SXQUVH<._O^?YN;9K#!3=6!"FB-EPQ)8X$/TQ>J>B1&IOIPU%;)J 2
MSCFCJ/:!H'^]I3-R=0TQ[4>KXLGBV=)<ZUAMGV=6U.',>BC1_=C929?M/9L:
MF1]&(62-?P&#KZ'.Z]1E 8=CH6Y3[=JCO$$/(!S0:1,0;)9.T9+:37[%D2C\
M,^L"B[DXQNP;(2=(W4\<1Y,?]!K@![)O_PAI/!&L^E;S:_O#Q51QL'6^3O22
M* C*Z=1^1V&R]Q*TU32UW(<E'*3KN&7K-FA$![[&8L+)0,OZC_F2$B_/<8RX
M\L(%V+;' @AZ/]X$%8M![A AVQMDH$#MIQ[DG%SQXX5.?ST#&;02(0,I76 (
M@.[V4OR_J__"59-GOG8@B+9H@23%!XPR=5:!/QO>R@@K-ZQ7BM5)K@RO-Y%F
M* Y\S7BA] WAJHLU])' <Y!:]"@]V*=[*[6,(".\'$^JBT;,M2Z.Y<U"G[%O
M;_-)W^GY?O2SY Z=X%3$/-CM4#=^[H0HB:,$5;\CM/BCI,JDH <D"7P4;>"F
MI^1L=Z'3G;CQCE'6X#>JF/(=I-7IEI\JX05MK/*[,MRTE9?]1>CY_$0.K2R?
MM6'WXQ?=-N6AD4G"LBN1"=M3[$G9==-CGIH+GD5)*(6KMAOYEEH8QF<GNU'\
M874,K$C*W$\S3>O,&;:!0^4:MS5B[@3$;@DB3@?,]V<PZ0=#E\OP Q;U+5F;
M>#[S+[EN9:-D@ HG)@'^P_'N>YCX.H8S(0=$-6::-IZG)^MZ#WW -V79=WI)
M^S-7/CXSZZ#+Q$E8;&U.<@ HCE&0AA$1NJRGZ.^%,]5X@<Q&CIU=$8'ZR'?7
MX&WM*EZXQE,-<QM?9B5W0XZW_;WIM8XS,<U7LF7GCNAH'*@:VAF>+*A]XS+%
M'=OS]JBFY+II3#CR/+P?\7/?C,YGM<$@#1CU>S.RQ 9_:W*GN4[8\"!KKQ!S
M>_GSRU^I;>[9_0N[[/TWK$<;$,=RD*XJZLY#2.&:"Z+Q^#!0&/!EX9 @N10"
M[#7V(W&V$C)3?6DU:ZCH_"=K)L$$M/"/X4X'9U;$>TG4+LT08CPVJ^'M_-9Z
M_KMOPRW\.-?P U"N,A6*A_)(_&8*J4)F7;*#D@RT!DV2@1]S-ZGT?BT$[PXR
M<"-QA\OV$1F8OK)&!GY,\W127XO(WI3Y?9#U;R1*MLRORTZD2V0?@_R8_K^V
M^NU&"Q(];0+9)-K^>37>S[][N6HB:/>6-S/>(FK'S35[I_;9Z44RP(-H341L
M@K1?3<B#K0$_1;H*%C$?NGM1M#P[;E:%=W]#.JE?&.VDDAA8M!1:XA-'-$YN
M9?$)'M10_+Z0K:/[2V,6WF!1!J?)0'U\.@%Y-G-)=T6<N'ZJUZ3:5V0TA-A$
M!FI51(QX61E30?Y[%#HM *JR;YH#8/9B?MRPB\*$)Z[H/3ISL([?4>GPMI\E
M!ZR+^M= 8DG\]?>-7I+4@K<I<J*CBZ3V2E^%;27E\+Z"TKA+!DXL,Y+J2]&[
MYTRZV#9JX@G/BJ%[]$/[P 2[:A(?0>+'*:4+D0$/?]0ZR-Q,.!>#;!>\^Y/2
M@VM'/1BJKJD':^XI/Y<(3Z:=,F=#8OQ.3MWHS.PIF'G*_C+(-DX1?XWP#7?/
MEA9T3B.JU_'2C>TE[%,5%@W)YWJJE9T<\B2/PMKI7N7WZPNHIDY% UNRL@H#
MRC?&@ZI/*XB+X:37&[<NE,/=SB.ESR-?2I !I@[-^=.Y#UU\$EFT4N+'][=]
M^]+Y]P:]<K(7XN14/HPX<.@/7_G*I/",TGE.PK12/**XQMSEWL9PG>O ]<M4
MHK)1;^FZ\#R4@<@9N+5Q:?*&1F5IB>=U+VM1[FN)G2R=4>.$S4*/^K&#?.R]
M8Q;PX.F2Z-&KH5A*X=>R9PIZ3^&V"U)SUI4<O]@LN!1:1M:&BN1K/_Z7AJ)"
M15!Z.Q_WI4@E'DH&A.AA>S0:8! 70'FCJ/_FS$_@'>1ITNRTPW</L70,BH.;
M5 X$^=J 866FA507"&99P@H-?A9!HD(79E& K9;I.[>/+..^7&":E0U2'>C6
MJ@4^)9ZZ=:@=OE7HTC$$SF&@RN05#!^^>X;C+^+O\3\E8$5#L!YA)1;:WFT-
M2L>*RBK["]/MDU9,@PNF((W?IF>[ ^0=1!^#4!!6L@AC4YE$'!L<;$"XL&C;
M>MQI^?1:?$R/^_FEPJW_^AS/=Q+(NUN?Y1!!,M@58JGR$.PCB&GE7E(4Z,Z-
MJ0RGH#^$2#?BCV7K3/LFX?V/(4MIBJ0((D2A-B%"XB,96#_AB2#5K2'F#F2J
M]GHG;OXGR^1[N8M^7^7[=Y6/YD_*YQ\LFKL@D]X[6&C=,KXNBMPE%?T9/7_^
MO<!@U1Q(W-KMOHX>=RH0<G#>?RJ3APQ$0J>UT;L-H ]%5X5.$D#C\8,E[(<0
M>6)'#+5<TGXLA$P(^GE@^T$*.V@+W4!2O?3X+J^'6[VO!5A7)<:]@\.(.3<]
M_$!.+&)2"P23>!!,5B'T^V#"CVA5VR<UL2A2I/FN=.U#W9V#H,,SEX"-T093
M'?@#2U)^8 DZC7Y"Z2RB%05&K6_7&8D)5;N__J[((<![<>\A=2D@6%X 6<^H
MTK']?AW]Z\C+K(_X#J,=8HMM/Y/'M<$H<6Z"RIR?JA9IA0B;!KVW4&+@7WIN
M\-=^.@)OJ)5$M$[M0S&H1G W"^P01WF^=4RH;WP62:M1GMWW_R.+H+<07IQ"
M+'$*D\(C:Q:J.7X_\44-RXF3A4RH[2ZP3<(XT=->[T%#W03+7&"U:,6&322I
M)4+V:!B)7+UZ)'X^&3PSJ?(UV!!6KS;>[,_C^JW!26I5'7LT$")7R4K?))0&
M/>U3#?[%+? O\JR6K>XB,!)S[V ?D9N]^^_X6_BGZKKA>/P^'E0SS U"KN72
MLV4ZL?-2'SW+&H:(66&."K!)NYN55>H,)=_#N[T0=LB+Q^X'(+V!/"P5-3YD
M@HXC1&7Z\S&W.OTH7-Z8'%8FO%A1M1_"X'G3H7]=N=),9S7J@^K8P>5 (TE'
MVL9D >S;^%!?H[LT+Q/NZ<3)^1K0F5GB;6UX7%&JJ8Q'^JJML5HF7:CB07_(
M4N0*[:-7RM^53UU74_3*[Z!9A+#X<DYF2VK!#B@VZA6]BS:ZV>+"ON2W.*<I
M0MF,GKSE:PQV'D\TJ/8B;.&UHOATE-T U[TQX'R+]$@E;6L#S>86RCTM0$$=
M/XZ) KE@?;657PH9"$TGL3B%PG"Z'.L(TNF:TE"/.SZR6PH'!C!E2'&WL +^
MX3KW]07V=->MQ9G[X<Z]][<A2?:(>D>L%BD$0](E TU&2$K$IWK\,*D<L=0U
M\*'+G>^K(I(IICF%-2.BDZ  7(C]"BEOV<Y)4 M7.F6W*Q7WBJ.!B!VZ]%ST
MG>\[/1I=I;X50WV?%VEQ+1&(^GI\ 1FXBD4(DP&NK_T$$ZS:C>Z,GIDUB@C>
MJ8>M$*A 7B0);&F5$\F"ODY8]6C$I)6X$@A<32 GI2MK$M\5#ML!PP6;U;"*
M_ ?%USY\%+98BY:$IWD>F>:>9\?@BU \_I%">]=&I+]#]_Z274P\D:6)L&^(
M/,@1]'0%?GL!@3MOU:;R;=\,TE/-$-;[8C8!!$5ZH8CGSR''CR)7?7J*T9P$
M@VY<HJ(2]-E>=S_5([/ Z2"]U&2_O!&1MW^O*AW]U698-?,>4HM,@+1P$NOP
M"R47GM )MQ432(1/ >MAK, 4(O0JV';T/])CLG\M&LHQ+6EPWZS >WS!5+NN
M?G7/4C6;D^)HC&-%D$)]%T]4X(9WH#EL+='W^I^] &MD/8D@Q$&"$9OK"!S\
MSPU#U:^@AI4WZ\[L^0X:54A$Z[AO1#YW%:+(?'SM7:THHDL!]HD,--?$A9J<
M$BQ5@)/8.9J<?EAU?U>.0X<P93\*18 /VJ7:_E9+Z"]>Z"/&2C$%^_E/D7A3
M&!MZ+EE\F@Q,@28&/ <(9\1#QW\X'S;]IZS TE[BD_HE/^[&L>/X%(R?V)FS
M"E2=:1T\>^G&7_6FCVC[;++V%%6R:&I^V0E<@AY%S&FFD':<L)DU68VR4[8(
M&AVVRX*Q]VEG87I]EKI@T$G9!$DZCL7"SP;E$K8G<XB0\FK]:P1B"L)DQMTN
MT,#@=:_0^L+58P$?#ZC!G,TAM_95PQ5#,K#=AHCP%E]:)0.",U.D^@N(.3JK
M,K5^AVW&I1'Q=7_;-DP+1B1Y"(:_DO6%X^A7FO[I=!I@HQ-3A?ZMVK87/]]?
MM]7F8IUKB4OX\(N)^\5#-E=#QD1Z4HO*U[BO1-T0^FC7]T%S-E)7!SX^EZ/S
M=:Y;_[JVXJMU$(G]P2C?&0LEKH]/:<<-8UB9JKOQTG<BI<Y\,7H'3">7;++9
M@DQA_:Q#RN8\&&7A3OE]*\X(FTE$S(;2K6YQ7UO4-V*9YEJ5Y?#]4S.-QR(:
MLA=-2 V@8GJ20P96X\#VQ'4,;I,T4HAH+4)<S74D>#]DL!PV3>AX>;L('\&V
MG-2Z9OB]X+YUN7[).TWI"49%T0HR$!2$M?@!#22II6)C@]>9JR==N])UPKWL
M\P1^PRG(;QX78_!; C5H8TJH=.GZB.X:4>"IX-F5NK5<&@V%79/B?K50]+0N
M*&X6ZT%:T$LQ[:W;A JN7'X\;N]_\.E*W\OL.+'O&KQJYC6_.!%L D*(7D3L
M[B:";8K22=W?^>6O!9;\U9VWS/\&67\O,8!%_=RX:C^Y,^HN"+;_L/O\-V>N
M9^6KC4_*&M3V\I@X-EGVZ'!T:]U:*&BN@5(3"2P+2:,E&-1!O#*D #O*=LF.
MT'%FJ0(E4:+,QW<C0UI)T2W5>3>?.W=D\Q?^6I!Y)3K$IY-=M46(N0'4Y7^Y
MT,ZD,U!F7XO<X?$1/+\=W\'#)ZR-CS\>+OJ$>FN7F1A6>?*! ?),J9(."'AP
M#".1;ANV#79/KL=[:MC:1&NIY=6@K,=#;.*"D5GTZ14SM>6%NA@G0@R4"512
M,?W)8UDN*0NNT!<[#=H]"O9Y\UC8/.E8\DSWS6L/FS/R .<6I=0^%%ZU]OC^
M2_;<R( O!(ORQ,N#73CE,DAI'R+F6@IGD$X&Y7XZS]93)/#FT& 26_^P8=G:
MM1[U_F6G#RKW;GXH]53T-U\B [^A&]OKC.F5K\%7SB'/N/_2T .\F/=8@::$
M1KG8CL<V3]4+" %1>4RJF,'IS9G:N+3@3TVC5).<+7$6$&%$O126EO1D#[4'
M<J4(XU[)%&Y[=Q88S-/*4^R69;?FPB7]!2]485X$'@66N:P1LKE,!HKH>X9[
M5UR(^T66G]\UB2BQ..B4KR"NV)3?5GE17^.PHIJ4+>DH*AB*$QY%C-,2X..U
M+(A/9_8IO4\*\>" K5I9SHA2EO*.;H+":32SPJG\MAP+SY/V&='C2]\%C3]R
M!]H&#H0NH?_I"M^:@![U++.,V_'5GJS+.*/Y](",_]KKE07=:XQ?J\Q/L?Y;
M#Y>8),"Y5L.=2">M/&T;!H8<,Z2WZ-S-%PY,?P\0.+X7^LRLKU;04T;7S\D@
M4:6O>/B>5*\T5O)ZKBWUBV39=L!U%_KH'LZ)QV'L5.@*1BM)0UKC4-"WUSE3
MX62 P<UHUDH*ZU["XFDL?E@7S@*/?L)LJ59CI/E8CDNX%/_^+LL-M6R\/Z%9
MAMNIJ-KF\ARC]68JHTI:Q2J-9R$CQQSBOKKYT,PIKD-YME#)"RA]W';ATS_(
MI&B'@B.&D648/Z6\MOKL?KYC FG,C$\K6RO 8,[O-'<#UD*M#+Y:;"=7_>#Q
MNKG:H2:![ 567#O@9&=%7=3I>RL?'\E=%7)?"K89)6L9\M7S8[N;6S-(UAK>
MQT\.8N^6%'^(2/1O5<(GROL6K2;,%KI!0ROO!X^=J- ^8LH?/J*=>5JN]?VC
M:!G<"#7@G<26.$FT863"^[>8E!J;%DZ:&5GDSI;8_VEEI%='Z"9(E2#!I7R<
M:\NC0;D=MP?.;.MQ@+B)[$[K/5LK@G_8M7EQ7*6_X";W;$E9".9%ZH)A,B-/
M)ZWRY/B!0;Q+D]Q,#?5H8]'".J=0Y*4JO16Q]0E;M/="7E0-EI3$V!"/#<J5
MW"*INX;).DY/W<(=7_./_32*?X:Q"9N<Q!1<EM3 ;1HE."H)W8WEEYV;#0>1
MJ3\[M](-9Y[\"HXXR"\:'&=(6WC,IN#OK^W4'[ER5NSMHY #5T74%RZ<MS)[
MNPAC\M4M6/Q?W7UW5)/KEGX0*8=>%*0E*J@@32DB$(HB30Q5:B@J-42:M$@+
MB( 0BJ" TJ4C)"A5(!2I(B(M@ 2E)(AT$IH! AF<LV;6[YRY=\VY]ZY9OUGS
MQ_M?5KZ]G[=\S][O]^P]!%/)28+#2QP4JZ2[JN6Y5!ZPV[PCR\93^<N^**&$
M#%J&UB] ?7V=$H3:5@??@+DU130BL/RP&0@+Y.+GI> 7.0%9V#8GGA..$2/?
M,1G8\<Z<TV0_&H#W6?N4"'9DU5'%#2OK3Q<6F"H:N57LKC3-2[WLOE<T,51;
M?HIQ'Q5LE2-1QU$4+,SA1C_B5G' :5U#9HR%E5LUP.&EG;$Y!3B0]P,-EL'?
MTP9YS;7025:4[KUR,$3 >8G^F)R&RF:"EBT94T8&W2;M1""+;: 34-TKR^4/
MYM:(PH**(G "*/+NX>A8=VJ%&YE[I_*MSE _S\\[G,=9 $M4[IEE!_H%T 1?
MH+RM]@^%R7GZ *BPSQ8F\=WZ2<JPAVK'GL= S$IW07#YAV0K3)BFE:MO\B"=
M[5H)0?8)D"5QTH(L,*PH<J;0:BVM5T LTJ=[-B?/F*ELZ%:<=H98*H<)3B[7
M&/9[!Q9SNYN]BM(R:^VZ3@8O[/F.C)<XGO09.[WOVV.SGAARK= M*#$5!B_6
MBVN%U;NZ?)7'"8:](FB(((2/=E>V0K^9UE29C]KC^RF3CWS>E2W)QP&6L?RS
MD@['*?X*<(.7F+/Z0,U-NB8I7WRC(!'K0U3&:N0O;KCM#$TM"5;T,<2IWF6]
M])D0>MGV8#HVQ'>F[T#&ZT3V>1K H+710.>*>*^8G(9ALRYCN)K.W\S77!3J
MM1&2^'[+4V\B.E2S'P"QWEM[QM>4-[THKT?N>DC?MO;BZZMH.7E[YUEV,X)K
M/%C1 XU?5A'!*K'-.J8,H=@K+-_NH-%"7>KGAD-<X;-(?EU'^>G.#6L'ZV.O
MNX+*)1:0>S@Z'$*WX\HA%VD4$P,'5W=XM=Y/(?I\[6KH$5GVQ%9)>_4<K:W<
M)W[]_";#'M(*#6F*^Y!JU2M'H./J6\Z16Q^)1?_LTB]>LA']()HQ_UY K+ZW
MS<4,%RI./U):W',6PF,@Q*A+EQHQ$SDX\KM:LF*::V$($=/Q$P_>P)K8W[CG
MFB3T'$A4G-_CJR7S=J4W3BYF%"? X7=+^]QBU<KEN4HBGX9>MLSL"I,E!:!=
M^>,)(VLUF1,W6$N_2%YX^J/D1<E1E*Z<QS'2/@6,;,\1K!Z2+DYQ\S!/=4H7
M2K2JOTILOF_)2Z !>);?+ < A4G-A7+N@6XN*?,+O.Q8S>VK2Q 7*"*S:TJ
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M'?9.AFC3 .%E-$#7K_+;CUNW+O[*?-.9T0 H3,8CS26WO_+#%UQ!@G_M'^,
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MN?*X+1?^B<:'?QX; T\"=*THZ;,0(+3OG;3,O1<?ZT9.]=UQ>B")6^['6M,
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M41$-ST'('YHB/3%8USQ$X8<,P[QG$*Y/3]](G$WR!X^R.Q <HA34;D+4-\U
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M_N[YZ5GWT!\G-O)5+DNYENZ-<3Z@@".!Y 3_99SUQG$*U:E]3H$%U>N!.<%
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MKNJ/,=).5V1CLWE*$CG_ [&:5G68/_@]&0;%>_*BIC;CQ&3.]*[* T7V:9H
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MO7S,ACXD\2!/Q8HEBF"JG=K7.(R.-$'#<-GQP?O 3==$)DM/+?\AHS.J(P+
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M=";->3Y HIG44Z2MK]RJIOG)7,?LV_@%' ?+-'F,#*W24%9X+H(.CO&RMH:
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M;,?Q,H+[S<Q ZPH2P.A&C+]!>)E#EO&7KN4-ACL('G+1A#=ZSW.&Z598N>"
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M^25+*KC4U.[04)[V9I;3]7LN 8-9\O7EZ;(/;NO_^=\8:,B9_P502P,$%
M  @ [8)F6.4 CMJQ,0  JCH  !,   !I;6<R,C0Y.3DS-3E?,3@N:G!GU7H%
M5%S+MNTFN >"NP9WUPXA6 C!)7B0!+?&K9'@%B"!!!((;@&"-B[!0W +C;N[
M6_?O<^Z7<\^[Y]YWW_A__/%VCS5&5W7MJKUJR9RK=B-^(1:!^T\5510!E'L
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M#"A=Z:_VCDMV45A-$.9#_?2JS!9IE>Z:HH[\7W8A1GU0'U<**ZT9.<N0'Y@
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M1G7Z5',:BH+2,\\V/HQ9./*O7,J@H;2T>1YJ2?N3Z%D(S!.7"0/8C_E$%1W
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MF&RQQ9">M41W389?G)5<3H(V!GL0 "H] HC3C+.$^^]"#@40P.6$_4!>M41
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M>274NO_BH#)(>PMIZQ%9&.O90ER305+I6B>@$)CEV</%()VU ;P*DK&(7D(
M2\:J2#8Z%=MZ:)YYZY3PITF^$"PW;4_U9#!,"!LXE]Y*F2?.&7T="2ZI>XMA
MG'#EQ>P%>C:Q\*=[BOG]Z2MKH?%8TB^6"Y>B'C/Q[)IS!@=A[E];I$&U'N;"
M'R0T'/$E4(U:UXR)%&ZP/W&"?24@K6CG.G^9F:\T63KCG=EML4T,4_RF[[NJ
M^E6NJOS(8DK\K.O%44_04+@_>;&]J"GWD7"J:"*F0MH1SH,Z@D>/_*ZGY!
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M]<Z\\ZU9\\W\LLX?R3DY9^^SSW[VLW?.RL/,PQ+@N8*LO"S@R5, X,GC"_"
M $@#,)X]0W^&AH&.CHZ)B8&%0X2+@XV-0T;X I^(BIR&FHJ<DI*6GIV1]A4K
M'24E$_\;UK></#P\-(R"H@)<(NS</%Q_)WF"B8F)@XU#BHM+RO62\B77_^GG
MX3>  ./) *H RI-7@*<$3U (GCQT F@>Y41[\A\/X']YGCQ%045[AHZ!B87]
M. #Z'/#T"0K*4U04-#14U,=>W\=^ "H!&N%+3LEG+]0^H;]R).+Z&I.%02=5
M^0>H/G9$SVWB%(")14Q"2D;^FH&1Z0TS#R\?OX"@D/0[&5FY]_(*&II:VCJZ
M>OJF9N86EE;6-LXNKF[N'IY>@=^"@D-"P\)CX^(3$I-^)J=DY^1"\O(+"HNJ
MJFN@M77U#8WM'9U=W3V]??WC$Y-3L.F96?CRRNK:^L;FUO;.\<GIV?G%Y=7U
MS5^]G@!0GOROS_^A7@2/>CU%145!1?^KUY.G[G\'$*"BO>1\1BBIAO[)\<4K
MKJ\81%(Q695_,.FXU8^ )DYC6,3T/,NOC_^J]A^:_><4"_B_I-G_IMA_TPL.
MP$%Y\F@\% * ..#RABG["]9_I;'\N$IP9BO_1OW>GK[.H>9=WONY0BQ0AAS4
MN3:I]L;_NXNW YY'^*&68K+"_!_6;G/=X\MJ!+"925 NY?X!@((YK9;)UN3'
M6#!F8!D)5=DK=>[@5O2 P8*W[TZ;@UAJ? _5-'WT5O;9+Q#*@>]AIM[!DR_G
M*MY+$XT(7D#("1-2=@1U(NPSI4>MBAJ3$&W5ELBA$[_9BFLC-S?[RRXG(X"O
MC"O^<X2-^Z&G:,MX5DQ8M]MIC1N0,VAEW3<\?O\UA;W;F9HN?#/$9)J:.!:)
MG.Y'?6(K&.WFZVOS*LZK:@VN3V<1?NKP= NW:'NW<-Z6O%H1%U&@ J6*(*CO
M/3S4\:,=#BOV\,..5/#&?@/YH<*J07KT]#CNO+0E_"(M[.>MY=XU7+B?9;B9
MPWO=8W(;+@MU+;9FF.GC_K AB;T9(=YB-V\P+,:D"\+,?<Z73D?:095[L!NM
MKYX]6>J71&G+2($HC:H*[SRVKW'AP#,T_#7_62[!/J?X_1S'%1(8LF1;*MM^
M<-GA-=6AY/VTM%-=F-"0$N?$E^(51-T>S]15/>4K8LP@*<K>LM87I3?E??.0
M,KUOA.SZF5AV(SR)0D9L_8V1LFA ^*-\ANZ4&;RU$] AJ4V5,=S:JPP2SI*J
MS9RWVU^UE#.%*XHTUW1$B<.[CH:3J9/S&T$[$SM\56)71GJHJ22W64WAOX^'
M%B %QG /]W?U5@Y4Y ?6SW^H/??)B=;.YKG.[\\<5"\<P+-HE7.6,;T"Z9%?
MAH =H@D39KDN]4B":=(=]>]@7'>2;;53Y[<M?%-L)E;?=!C>ZIX7!9&\$6@-
M2#<G+63/SQLSN/R6-4%7D7[68K2J$93;(<^S85B"+N'M6H:NE"37W# %,CC6
MND_H-^X/(UP@>OK68_7TKK [FMNV[@<$E,#&?RKJ%]Y1-<%Z*,*4R->8, >K
M9NQS8V10QQR61B9T<P3+'R.V,A%>([/:G08H%]5-;GNN9Q!RQX2#BQ/*(@6^
MJL7!LQN69-B=J-L"6?BT0ELC:)=5WH&E7_%]1WJ9=^!$RB;D6'0Q8F7B3)0-
M4M.4M#%%_Z$8Q)S&%3@3-QXZOJ&CHMPJR3Q7-F0[,7CF]>9'9X4D)9-N$9.J
M[MJ25\;YL[QI3(@AM)AY#L.@4W?IV9]N?_(^EB;RA?[U(I:>.PKWUPM0B$J>
ML0WWAZ+#4M'!;^WH KO=SFDF+3:P@X6;>7LVRR@/T$$?Q3.-LU?04OD)-ZX<
M+4T=ANSLAB\&\($G[I*O@*PA.%Q"@3/3*3MB9+>,$2Z1#*(.>K>B<^K-W^;3
M9]6Z<94$WASL"<5]GC5XU!6G1(S@J&4PSSNU8%]M?=[QI;O]U9 S7"6H3$0Q
MOZMX]P9R7-]HS"7 EL\I]S1# N#>Q:O$L[;P98=G4GWRT*J,6[*Q;?1.&TG:
MUAQ[L: K-F8NTMQ+1$EDNM@F-L6V/M5^IS%1^FT<@T(Y)H6VQUHX6N \:]P=
M>F, U+)]//B-X2P]+M8NMC.'9K [/7]+M[K87V$.>@")1\-FI[.[+'XLU(F!
M+*YY X&15A6@JP_WP2>@ K3J&AU\A@O' ,GYA>8BV$4_Q[.>POSOKFC3 <2@
M3T[&'/5?FD2[F0M'-UM;P)6\+"<@Y:2YBQWFQ 31P1O>M,M>N@8/@@VC5-TO
M2IYS8G23;<N,QB]$#A\ &'>7(<JZ)VY!6_0]RJ"6#V\$%^:QTK6PC0MW>+3
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M1*WOU]BFVK*D5CKX4XY0-9LO6@U[E(K2=*'KM-UR7#"46IXDGMJ7UC)256=
MVV3DA#ZKV9I<DZ?&>@<YM=+#8-V7>RF9(?8.-771KSP^O<!%!GG[VA9EYQ&J
MN5L5=O7I<8<?X64Z?L(K=;'+KYPXL#QE8UT?OIJF3',;@5AN(2E@O"W2JL?
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M)OJ%_G(7W#PJ"X9M=B!?3_!&XG6O:G@C8+972E<2V>9K02QS$>%%"?H9J8_
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MHTO=ZZ&Y">;L_'*#R5LEUX2ZO0> 5+KH/L7][OG;DCL*U_N<@HYBY4;?O.1
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MPT*(AB6,>H7GT^!UHO'J]6$GM&U^0\&5Z.X*XP0DG#HSK*%R10H]3)?D19A
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M"ITA'UK(&R"_ O16"?Z"4?UJ^3L7SQE!Z!">>P9=Q9:]ESY=.[NW16NLWS)
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M0GS_$EV&C,4^THZ943HOI#5\67Z[Q0_5S*KO-)/[*_@J#'H%4.:6JSSJF_>
M>%(=Q12%71DI-Q2\+I\T6LH2)]L$%H5N:YJ6U1]G=D:E4"?@WRM@$]'!IK4E
M?#6W?44 4\'<+D:J09EG$UD,&^G.#'7@;,[U>K41_;"+@( &D><R=0ZHS!N=
MVI1M]9E9M3M[H6F<[4*!^\#:..*#[QM]<FMA9+3M059ODA5T/$4&_#+.AP'C
M[U>;4<>"@&[JBII^@@TR'<U^J=DP%AQ9:E6N!"-92+MK;?^\4Y)]P1 LJF]Z
MQ^0 ;'XCTHXT0;I^7%:1,Z7IRI59J@-NA=I1__EM$S;-S@AMW3(V<=L/N-*
MFY]G'P9C"])ONU0,/0!6MNE^CBLE-57OIRP;HLK_)&Z9J!)L_7DCQG,:H0^
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MTL[)CLK<D]I_^'IK:=.5X'%!<3,@L4B1'0MA0WA^/*C"=?7D<DUUF9^.,F]
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M&QUA 0R-M;6P,E:C+;F7ONG:]#UWD$V7>$>G'C02OH@F8FS9!*[=B,S8ATG
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M?^7;:Q,O\WKO# >[G.RPZB,DMG=*:B;.P,]\;#,@CB>.&)KM&!( ]?E%\95
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MJ)[UCRP_ =#-Q-BG#:@PH[0,.UL=484]+*^*R#R>E+9![#_676J&"5/!K9P
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M';T&IH/G69TB+"N$9][!7(/<DP<MX#J:C80\G$=\3T;A/**IY_X(J'>D-T\
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ML<ZT)P"%7P?[G\4V?WPQ]8C2NS\#)_L]A/_PG-F>"4[X/B1E4"1!H[C7\Z:
MP\<@+B3(M(+0FV26'9NL+'/@#A\T+*]@&?>VKKEL/ULT]\T+W[=Z5G@&$C\4
M%R[_6)HVS)7F?%J@P1#)OKVX=JX:$%JF"*(J1R&%[+C&,NW8G+U+HBNS4VA
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M\&IWWS#@.-_KFH#/S?&\\HUUMDW7XL^0V+&:SEIA!!4EQ1$(8< !?;%'V2^
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MQ%'+.#[T[EKD8&W!7Q,.$&<5@ST0BXYN5D$Q;-9NMDM:ZH!VT*GAP2=1!//
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M/*#U;3KL$P=P_2,<\)^W(5JYOU*NODT!#I! E'C"S@V9Z^P(L3TCQ&&"K/W
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MPG9\C6.TO%O=7L KXY<*%C28370;A\8.<_U2"UQ(*+[$8_7+#F8I)*I=?:O
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M%FF/?(>24(1;\?A0?G^JUD:\=8<(1$T1,3(I:/+V(\(>()X>H=5Z[DM@E,!
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M]A)JYM^!70!LB7KOZ*Q-*JH*!.KCE91@R8CK72G[1V:]-O*;Y_NK^AZ%QK*
M>>8)8-E'WU\_Y+=/3/\8"89)JQV4>U+(:G<GUWTHV*'@.#1RFNMU&JW*B,/
M6TV4%:@9_ZF>0&86Y6D>A]=)!7OO*V\\*HII97@0?I-495%C)LJT):#QH2]?
MJ&A"OY[L$P<OBWM&2D9;8C)PFZ\/A6*H''687R%:57<41^G[4+Y H84.5]<>
M,?6!6LX)1?.;UN*(&#[BY A-!ZX/@L^#?C!I"L.(F>+B;G0KHFFP8V-\F/HN
M&RB$_%<&2N=Y^7#L4MWO2!+9/B6?U/7=E.XH&:I^@<K=6"79^(3N4(++8P3L
M,96;WGHAD^=D#D7/E>?S+"[C0Y:C&%^+'9II+"4YU784D2!&0 NB><7.!K+S
MKMY.>F5/6L-FZ>!Q-T[_>[H0CA[.Z&U7_;KUL:!QK3\^4[P>1Z1<K)M72B0I
MX[XD Q?"]&Q:3H5H<7/?;4>O;?'ROJ9#H_Z(_?;45D;W,U*(:8F+"$E$8$'Q
M8++91#O2$R #.YE>KU DA%AIZCQ+;P1WX,M++\V0Y..7&VUGI3[)S$WSG2HJ
MB;/?TXYAZ2$/P$W@Y-<(7PM)$ZKT8ZK2TH\ZR]R&"5Q/@%)AJD*IM.7I("T/
M#VI':)8V6!,AX%EE!2JM,@_#2N>A8=P@0S//RD)XM[K]->N@UY=U=O):H@PL
M1X_+X@;AH3W\/BWE%#8?&TB=OI!V71V?1F[ER1.@>E#MLXSV8T;U$R#69NFP
M"PX-+KA#HS&2^?6723\\E+N4PH7PPM?\%J,JB3_R[I]43,6TV/\0L2P/1M+_
M+;<G%OE[MI1AR0,QW\67SR6K3^@\QEVZR" *Q8&W).G=4@=!/X%W9KY5+4/-
M"40R[I10TJ JDU%'0IA 2F3&T:TJI!.E#-@92%Q9$0R\^]R.J%1&KLE6UG81
MXIHO5:SU"ZUHOO-YKQ1JZ0+/_K(9!LFXJS+#KSC<PSMP%/$WEB&=P%?1,$4#
M'DM^&HC,+I1 K?#DLC&)E:[.9")]QMH=F38Y7@]W.3T>') O*Q1E _;0E\V3
M5Z]-S3QQ5HIRDWI.DJ2!6*MMB]ZWW"3[0JI4W^9XK5MZ$6T;7%"* C1<R);$
M.YID0QMW)9MT4 ,)%,\O"QS*E4ID2V+-3;S*I3G'U-$5^PA,D S8RM?I]]HM
MJD637+PFY4%X-"<22T3&ZLH#,1F_T>H4T4C!'L;NR^>+$$R5HNQZI[$^\\6E
M <GW*/<JWZI.X),02:&CDZ KJ?=,N4]"Z[7.OMP !U#3Y-NG;0V5T63FG2''
M!T@R)EX"4+D:3^G:.QDV+;?Q]E>D]9K.L'GE GI)= (\*)69UC=HQ7QN:TO,
M]2G)GV:V8S:7?E,252A>(\N*9:T$!*(+N3+RE'9;=^*+ICN\-!/G_,%8E*D]
M<C/^F,C"GBEQL @[*)5/%,4+HH[JWQD4*%>[Q0&^^3ER&'5G&_0$H.HUX.JH
M?VD?*6M._$F4>4(,5;JZ3SO%-OKH9FOJ)G9ZLGA'F'@\?46F?B;SQHA WF%G
M'>=V;K'V9TUZ!7V^@V[-Q$1DO)*X^'@H]DXDK %;+WC"L$**^<.[. #^L:GJ
M('#]7,B]S)S7>312TIE.7A36"/2V&B#+)?/67*!$#VB>.D[:]+CN"0^8+=;4
M#P/!/'[P#T:NQ[:T?+(\U(EF,1\E;)*ZR [(=>0^2)]5J!LZTK? +L(O&O,.
M(<]17/ZF1TB]0WV@GO<RG>SGJ=RUV*=?SBJ\Z3^]P0=-WMPE$*X);DG*R+=6
MA8O>@=8P#K7WQZ8_F!F2I'X%/,OBB3E"DJ4GKQ4;6=,&^40U-4/"F$X&1+Q(
M*HAI1%%+F6W\3RMVR_)[8BKVF$]5A12YF%2MDR&T(L?WDN\FFS 8M,B_:%0:
MY&:EV-T0\,3V=&P'G>I^')WD: ZOB7VK&%4YSO9*!*9 K>:K'KMO#7M6)\6I
M]Y$N^6M7Y> X.%#>E;A7<3MV"N*0W/ 9-I9=K+3$M7E<S8C?69!^+<!KG.LJ
MSK&9,G&#"%Z069&1";?O!@"'MJ& =2^2$ +3&"21"M4:*,IB6Q:SBD;M!95>
MI<(G<FR]L"#F;5<")H8?RI/QPFFK]25RJN#Z =F(M?:P5Y@R1M:+G@24M&%8
M+5&7*6KK6-BME@3\I/"@P;E"OO1;R)^TI^'TVNBAY./.QS>_1>GZ?E(^ <K_
MM-<^8K&1C];DVKR^-%P/!#.4.:O\D\TG*@?T6[=-3\NTMY/;$"U6FFA+8DN:
M[3B9[7C5:.1;727ID$M''\D(HWM%NPFY@3)/=T[LH!8V)>602Y#/D<D38--:
M.NB>0\C#&;YV[B!Z MQ"%G/*N!-\7YE\;$YI/POU,'T,;J5^ @#^HFT_"[[5
M@*^MN[AS+1];X"N\31L0N% K5PODYQ$GTR6&?I9]N!'Y"D[^YS=K\0W4LZP'
M]#OVQQ>;?VB]P)F>[L2!GW$VN#@^L^<\ =:?PP6COZ=<Q7D"9&N_?P)T?H9W
M.$S(UMT@(CZ^-$+U&R_)AI.UL3_21=]*?'[S!'A7%OH$"+QMOX6L%<@SO2=V
MIV&@=$03I$<,D%LWCD:\_>!R5A?V-X71K<0]+7S(_W3,_K8U6LYZO!>_5;V>
M;V\4?[CU.\M9-_?KPMO@? )PM84_ ?QQ_'[R_-%3^S$X@_1O36S4CRO]0'Z_
MSYX &])+)H_;3X";#;@9_+G:-]#.X!*FFDK^.5;]+Y[O6I@C_. 6,OW;0O]E
M;( NL=^_V,#^S<:ZL.,1U[Z-< )[3ADN2AC,H:[W8? )<-K]! BFL O_#5\>
MK<'51W\V,/ $^/*JB^*2:=_OEOT/;2$%DH?*U5D?V.D)H 37@;?D?S3,_5\!
MWA[]I:SX'2&/T3W@S[AOM_1=EN4A/.I/ /O_/JPTHG-][ 5#Q]EL%,JWRK_&
M>7!W=6Q[V$C_P0U<[ZG_8-I\,T(IKUOE;NN;S^+Y[).CG ],(TG!>=;)F$[&
M^3J+"L.5>8$KU":-*,\#TLVPAPK_PQ2YB6XOJ'KAX.MZLP'7GNLD%GZ+5)\
M/WGS_Y.@2AV3WJG=76(DKT5$\R+\IA+\[A6%'W&,L)X XXCPK+U# #Y3^4,=
M^XGR$\"7XI[A?UBJ[1B&73L>66:A>=A>G3TF_HM-,).'>G=L>D% /OOO.J?H
M ^W'I5<W]$^ =NQ'?)__G67',&BAN_+MK7IW*<@%D^'!]L^QO0[W5&(D<%Q[
MR\+Y,OQQK8G_K""6S#5W^P;.V2P<@ZC7\7\KR$.!ZF%V=782XW<\)/Y(5^/[
M7SB'#I+WJ7O0=T7?M'#FU,]VP9VU:LIO _DL^@&]B?YOSS/ZSQA,.8J(78]&
M"XK=\,&GL!.#>UD&7 3+8+]]O8GVLV?P=JW8?V3[@IH%?O^["T-JC"__@D.A
M7Q?%1O3=*Y[H>X2_H,O^7Z"K]6XGVI3_\>4I!F+6K=3EW^3Y<#B_[Z8O#W6)
MOG\6_6<\15UW#&HBZ%W@> ,Q/6(<4R^A!%Q1]OLWCT04%VS6%+>(%$\ /+AI
M41V"!\?NJ;W$_ [[X +7[><,")K.]\ G%.[:-GW$::6@N-J"AR0\Z?LW;?#O
M;(=_0W8I)YP2+LS+OS6!.XX])]SY*9!O=:[.9N%2^,.;O/62>@E)WS^75(;^
M99KH^V$]_D< W-U[)N =1L'2_]LQNX._(MNZA*7Y%WO^KK5+5BOX?4=\];>D
M1G##ZOYMV'J&_#&VC:%F?)?C5W*3(F-'(URCPR/]J==6A**WH]PU&%OT%[Q>
M8$:^I68B>'+ISY #!OR_7$RMIW?!3X"RRB? OHT64^T%DSZRR;,P4YKX#M)9
M?V*H4:38"M&'*4660 93%-+TR^?79" ?42]-]=+:Y+2'<KOKM\%\LCC6<8K]
M@&?XKQ=><RZKU[XQ+]+/P7S'8 Z68.$J@<YO95->D9V+BC)3[M>!UAZ:#.4Z
MV3 J9=8L@DVU%^C.=1QH*D7LQS;4?C61U1JZLJ^4/,P^ ;CM>$<$3T2R1!,;
M=S9=#8*7I38!R_ E&#4*=9"J7Y=T_J^/EAD,I+'OTCP1<7\M!2_%86&A$@F4
M)H_S]+<U)I:7?DX+C5V[X4RM.@P4F51"EJ4&4'C9%02;VVWC0:V'C"&,*+%V
M9/J!EJ<O>^*<YP0N\<O9^C[?-B\E^AEQYX2K5R4KO]K<(1S?NZEZ[?]I?<^-
M<XQLZMCAZ'0&,GKR(E@]A&. @L) RR>"D*])>YY"-7*Z)>JC8$O!K_1V)'UJ
MXG[DPOK'T5JPS&:[N+A6W,]\ZGW#**;$T:]-9:-:2T:JN3U"UMITUOC?WM>N
MQ^H&D;'-,"</;NV,J,7W)OE9<W;EYYYK2?"$4[$II/%EQ<1(/'ALI5LLW;JM
MH@5WSAZ3['PPD]V)3IVHM__<R*(D(Q+58DI@<BBGOX"13')5/?"3!<2?E"ML
M?H$,L$>Q!_G\8.=.'"/:.ENX;Q^[.[%=.(2X/HPM'!>RTA'Y3PB%+#K.TP <
ME05@)'NEMBQ'^15^QS(41X'KII0.%P;\Y41]H@\EEL?7?A<W* _W!, 'I2:V
MW.A3@JQ[["Q#],63HD6^2-&[M_0>0T@1;1V]*>P&9*Z7O._$<6MA5R.9U0Z8
MI17=9!U+"G,(W8V2!K9:JSJ.V4H@3O7#"IU#",^=\]I27SS^<D])!#-R'Q=W
MNNG/4N8UU/U)GS+F%R-"HY,[.:FPSU\\[O<'F.8'2&6(S/:] K&<<??:F[QX
M"(F[9@PS[J^G'K&E;(QNAV6KIC(/S#UISG=<@@9CQ$Q_=_8M]R%0XG8@Q&HO
MZ5?43=DYN+YHMB$ZP='UG>#Z-DC<04_,.PP/=>S/M8Y8KF!<L];?(*M^=$,\
M7_O?H&Q'ZMA1(R*%6[9Y]+^=7;1=M(,EW 79U4NJ7-^4(]AB@%0[^ROIONS>
MH,=VY37J>QVNKH&,YB06D]H=;#8&:],( Q\)$(<Y%?ADW)%^KY.'SE^6*NKW
MO]+#&T;.SNNQISI/A]4NQ'ZN9X^/)Q(.Z3[?RA2$B<HK3Y7?"_)%0, L:@#^
M,<&,R@;.03?:5D%>@MG0;R*$9[I^ECJ]KR<-!F*DP+2+J)V(KYUG$Q+NL"(J
MH-X_[MI^6]NU^2#_(.>NFZH=+*6I\V3=J+(I;(BLDG_6WJS93Q/Z/CVZ1:P6
MN&;8%'+';&C1Q4R8^0KR"KPW:A2/-!,UL]CQTF. DMQC#W>I2PBH+XTT6E,=
M\/QL8+VXV>$\\"7(4=588M0YXK=F6L;K*Q[38@_PI#7APG&.U1L<).P :HY5
MT(X4PG.$^/Z<APT[8Y8XWW*C>"/8G1T4J3V:IJ'9QMDA3W> D!!G[4>;0N0N
M54/7+VEQ#VR887*O=@SL8>O ,8.K[P"VFV@_!@%0OL))Z$-VCOS5YS49+A]N
MJ/=XH3C'4V328C7?*PJ-MYA&Z]35CDZ>+)'-^95S-W%U2'$TO%37",%!.96A
MP4W[GM+9QUTO0)]/T?)8JGD6"</5\^-/?/1>RK;?Z^5_V>OC1YY",VEK8568
MOFRB7G$<&R?:P%0H.(QXGHZ5>H#P_!DJY255HW &H6!.6T6T87VT;%MJ?N8S
M_R'^C$DFV78$G3U!-5_3H*G7E&U5  17>\#^\\ RD14EO=6AX87'-JW6N].Z
M+WJSN0^Q.1]_B&FG7>OH&;&[K<P3]SDZ_=(6=]@RY2Y^2)K\-*4ON;OP\==/
M]@RZ[X3S'(=S]H*O>VUMY"U+]I.;W*^_X/@4$X9_7R:UE^*.B'AT#6/[4E\_
M_M'(IDZ9!].>^OS-^9R96A@JY4!/W%OB,;(S9T.>ARSVUL9N]45G[V92TYX[
MX;?5+SIW:C!!A<.^IACX,9R#RV\1H?3^P)$RF+FG)>NRLUT(;I<Z%X\452Z]
MAR/ZNO, &=EEF?CCRT-=5I+9K8^U202U-E:O!E5K/$N8DH=C;LT!$0#I? >K
M63Z2CQE.P+DDQ&.L[VLF8:P$$@#C=V01"#?A>*=3SW-EV5V_F&NV>Y)H"?4E
M0YOS0_(MW0:XAI\?OE$]#>JUC":VHE'P7>PTD7:SJ(]Y]C+8+J^,]+F_VQZ!
M2=]K=F5W*X<=T!;*V#1-BB_"\M99F=M>5Q*_D"VA':PKA\%^<Y7 D[O!T:GY
M5J9/^+<:.&\5-@]R59M@SB!8"^,I(;8 >R=?&,=\^-G_8F )[)F.I":S,$@=
ML KMW,(4DVZ^X$?=3)=$"R!WRU"0ISLKRO-'](Y*O] =SAYHBF@JO@4/ )4Y
MD[__%CCWYT0=.KK@GM (:JX7++X1PZUN;+"!UJ:]2,OEC'?=*98G_BY+:LZ/
MT,P9\OP35DJO7B1Y^=WOKR#8A)^1YQ3[UYJDOJ7>3Q^?(ZE^I;/U]!#8<Y,6
M1?FL7K/BK3BS[7%41B(EB1T2-@6*D]I91MX9H*:F:NS<*/$X,;%R'?Y0CZLG
M3_/QW;,1A.=VBT/%6$)(6Y<E35B)=CFKRZ.NWM)1Y@")9ZC4K*M2*KWR,?BX
MV=*O1>E4\RTMRZ^V-<RU?APJ'W[?9_>;9G]PA2<M[_4J->SMC_,C<86_9D14
M;FAVTN\1>%7R_9.SB?]_N<2?%OX/4$L#!!0    ( .V"9EAGA;'IC48! %IC
M 0 3    :6UG,C(T.3DY,S4Y7S(P+FIP9^R\=51<W;(OV@0/ 8(%AP2'1H([
M! ANP5V"0R/!'0)!@@<G6./>$+1Q@@?WQB&XNUMS^?8]>Y_OV^?*>V^\\=ZX
MY^S5H_ZIFFO.6;^NJEDUUYKK<>;Q-^"EG)2L% #A&0" \/0#/,X#) !H*"BH
M*,AHJ*BHZ.AHSU_@8[[ P'A!C(N'C4].0DE!3D)&]IJ&E?XU%3,U&1D#+R/S
M6W8N+BY*>GYA/@XA5DXNCC\Z04!'1W^!\8(($Y.(XPW9&X[_V]?C3P .VC,
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MG9I3]9C Q&GL^2L:KA7:DS]4^YMF_]<4"_Q_I-D_%/MWO>8 +Q 1GOX\1!R
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M$7-07)LV6GM$2NH%]BICI8'>@BR5A)"JD"56T>]$D>L=R10#/!5)_!!\%4G
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MYT%>/BK=]>DT)0 DRNGC<MC0H5EU</FJ3/GS&'8<*&#QV)>)G0#_(F("^KV
M(BTD3O?JE(\R/-G?.+X3FJDFOV[X7:AV=P:PFMQ^ZW3=N.U1K5,??OBAVPZ"
MO\'R3A@-?O44'J!">EE+>[RW^+! X22M0&MHG8BA@-=YV5W,\UTORK"0BA5G
M-&B#Z$X21VN7PV7RZ%2/XZ4<X^S>S<&&$RVZMQ9=><T]]*PR[ 1#K@$FY)VG
M.ZOPL>F5 PTKW\UH-<)-^)<N/^I'0%#$RD.U4JMFMEV1).8"?6 YY[ PIIO6
M','!=$Q-E!V2"6QN=BWAU<V7EXNH?CD_?$#'EWN:,*K)&HMHGL2$Q:Z#6OWB
ME=9:]5V)A<C,Y<USJGS^N]/PY?ND_)&O[LD6\U)C+)8@QQ)]M/Q$)32QR)A>
MT7R=^FO+E<+QJ#P>0X5^,&U_Y1FB&\W59HV0UDKP"5TL/@;_4[WJR%*S=DWF
M+]>>*$)M,$?.O3;Q<8%'^+1-T L7M6)%IT,YED$.M@!SU#\8YFU=GA87?7&=
M>B-"LLL+Q;)HG$"J9(X:?LC=H)^NV)$.$B+(V_6C^*()^P@?;9TD'([324FW
MS"([,>")6 &Q4'=2SEARBF]WN-E7O;KK:2AE ?:TO@JK6:31L=%UBK]TJ_>M
M>$F??5$XG#]8W&1P:Z5,'0,L*H^[F%PV0!GI;'TY:6OKLTS?E_@S=@ G40C;
MYHSRN?["==6(TG&\ 0:FP!)/W"=27(/[]0,C>]!$S0&OH0A12QW,P:2QK5Z6
M9]^@E&*E8ZM^R'GG^-+3A[A@GBL,5+ZSDHJ1DI:]H,THW"L:+.!*34!+#[FZ
MNR"0<XJ/"!^?]YU[Y?=F1G<'C&G/O+\B8_RUAP#?Y298POMX3RRY,V>S'Z6J
M1=Z1V;F;^AD1J^=F.4A ^JN/V&]&E_D92+PZ+8)9\KK/2W>7M1UU\W$?[U(=
MUF1WYT)M'0ZTC;AEY@W'2.RB6Q5T;OR$ XNCBL(EO' GNXXKN3FOATX6'P._
M930SF#R>/PF1T+A W4$VO)[_=JH-VT=D-&_4;G,2(GFQ,2FN4TYKHEW]XMBY
M5W<YIN/6Q0]?A!QMV92=J ].Y75XNY6Z:5O6[+MR)Y8_2P<NTNWAT5N0V] A
M?%I"_;@2)N/5EUE;4_%_KZ[NLMH)NV*CT*0JAUVT/2?.]!5!QIT/PY(#F@+/
MM\[+T+BECZ>#?#2R4;HNI^F YN1N_9]$%5(/?:A7/,\UFR>Y@;&NI48\.^M&
MC;E5,3:]T_?H(J5K=^0FG$25R!0[\L9)"FO1#R6),@)1LCN%0Q5GDZ%*.07I
MFHWW\8\ %BQWJ=;Z8Z/09I6<1=F("*LD;?0U.DF,WM%8W=2Z!"[_0*G)(IT7
MLC3@(\YG_AF&)\D!K$(2JU&\'Z!6L 4[^9]#@?V0V(#ER&FQ-1:*+;UCR%*:
M&=YP L.[+:N5 'C"HG:#Y+);VHV_ @$C+;==O/S6 XT3!59;P_%ZQ$J4DNJQ
M@9YOKE+&4[G5I[P%EX'X!XN>TE8\^ S<[QZVK; =C*#/S23AV/#$OH%^5UZ(
M5<=J#<5_!"!8:;62'_=KVU 8S2&5;YG:$]'#<O)6F.P@\T;E^1.%?).R^_$/
M7 )>##GUPS]SPAD _T;/$J_N?;0? =,.#H>U!B7N;2<GYM,/[O#^*:>T673[
MI]HT[^W?FU?PI,G\.)'N]E4B%T?.7.KOYYZ1171L/[C@WN'> F9?CRB>B-06
M6W_:*8.>/B/Q1&?*Y=LQP"=O*-O?=UXEN+$O+]>J'S<^=NA2Q!+&R0M?5F4A
M[RX_[7]W-'*S6@5GA'0_ L)7HD=7%7E^+L8?M#T"RC#=4E&#CM[ 2 U/D'>7
M=H-YI(K8R3"V<X*.NZ=&HK@SE$Y,[L@7O]5&8":U \BB%_<\8)$6>8MS>E=O
M$XGEL!AU>*&FX!-P6!Y,B-\T?R<.@?NA<*X\G?+B0W#?R&2D'X%EQR/@A.&:
MDZ7OEV5=IE'7.O:.QKE#:&I(XHJP!>Z8;*EA[_I[^?OB5UZ6R^!QZ 4;EE%;
MI]GQ0W*2?7#SIXR1X#72AGM,W$2N1+X65IPHJ459%EO/8$AYK.\*!@@#&VMY
MI*(?93X_+%&,)?UP&*W;=1DG+TWIV"W@HWOCJH, &Q]CW[><^V7=<T76B7T2
MQ8Q,P.D;F>N=G\]^^(AE+>TN,8VRO92RM37(2^%TSIPAOU75#F8*:TF<62+O
M29-W-Z\,7AGBNC[4OI>$C)#!*AM>-;K8I:SV7CTH>C$5:3S/ J  R$O#ZHY;
M"U>6"84OOVSPQ'LXNUL=04V]"L\>@- R8!]/@V&&4-2V9-Y-4HO/"(^BB"B)
MC_B4R52$;.&.H&G(M./S0:]*RH '8/%$,V&.-<G(90'8%C9^8R'*RDO%>02%
M55V ,4&O#*G\7UY;:",/[N+NPOQP]=U'(-ICIB>)L!IH:E=2DAM#L%\OZK#^
M;?S\&82>;LVCOW_>_R=GD+JYM=3AW5/Z_M;N_+K9;NU!WV8COW)<QR1PPO&Y
M[,B@]&]_ <M(+J R2AH;CA7Z):-)O4Q!,-%^(K:M9FO%"L2BL\OI^DLG;ON6
M/H->J>RUK.,"I6[9$OD)?7@M4-9'\5+/0  FQC0[7[=&C7U$*3?.J:6Z>64'
MO4?D%YOM35YJ?00<RXF^8C&;^GC\4/-42N)5%3PEMFJT)SY7HB]6 ]#A,YG*
M^QW?;X(RT!\!K?X9KA3 40=77WFQS%'IJIZCX61GTXVUP@V=#Q[(.=??;E?,
MX,-]]3)0)SIJU)AIKFQ5<'5XLJ(_>:MIAD#FN)*PRSWO#4$KKAYW4DR9;@/R
M2JO53,R'+"V<?&CHLO24<<OHD8,K?7V"!$NSPCOX]B\AXSNM$@_>=RVC\5J$
MF8;V1X8>ESQ^:A,BYT>(3QY/.6Y_4-'<QJ'70&?$ L4L)(*K+[KD\QMYN^)F
M;1!)S1ME#^ZZ-08GM]-]45^\S(]RJKA*=(_*N@L('QQ-:S\32<,Y+LACU1N@
M\ RK<UC;'#[\OMF"T:.K"&M8 0T)C%B"&0R:YA%#GI9>;1[0">[X'(9YW=B@
M(U4/>FSU9W8Y OZLBVJ[BQ_JA0/<^>/R^0-+W,<],?YYN[KY0W%]W@2Y^PF5
M2':JTE[YQV>=)$*&E..N"54J?B8T0_7K<3([Z2[E%7K5:1^.'R[2]7QN#I:X
M^WXNJ(=7K!CPK$D?MX(+%^W.?L> ]OF)^X1!E#8/,2RW\%>\+LEUFU#EGBW.
M%0W,$_H>0#3Z5\K^RF:CWP^H2M,^O,CEF;'=KFZFWR5XAYL=IY<:#S#>M4PT
MFZ]BJOJS[4]WOQ#48_FY15W+%OY4V!OIC+)"?-I8>[:&TKR-#]8**^3&N>TT
M=W8<1OO5*^2&0/Z3%I79UHW8 :XS7 ,:T&AY'8-$67Y!M".=E[L3VV!D2 5$
MB5Y/4MWA,,G6\GC(C>)U59KJ\6&NJ0-TN![J,>'XLT\5!<2K>#SJ@#!_[:W^
M7'FVN=BG.IWR@V\]-TY1@Y9(8ZI<VJ9/JI6Y%26V"^&H<;)*+>%TL@JZ17UB
MF,D@9_L(N0TEXO<:!WR0(2%>,TPSVZ)NR<E4+299].M]<9VFG\@H"TJR1:I?
MMAW1K(,S\,#,<);\Y!KVM#RR\7RU/[H@_=M2>!?V[D8Z)\:F86 QF:O"MZT\
MY%-,"X7VW/PCP$!9(')70#K\XA& -_,J3I#TC'RQ'LZGG0[N))C$V/.57VT-
M\[59^0U6L)2B '/;73MT3@NXY:\2.\31??G0P$;RI8G!>=*/.S3K&N5.[&1[
M\DTBI4P4S<M2T2&BCU>.%]QY)>):35-L;>+4<HZU25%[&\7;-2J2GEM9?]FW
M4N?E=;O\0%QN(9.#BKSP6X/R6I9+^?:Y[B-@N5V1[I).+=(@C9NAK.U/;.E[
MFE3Z!V06_Z/?A0.L77>Z_H.M9ZKA T_I;?S[1T!6?L7#/;Y_AVR._ZCJ-!S^
MG-]\1A@BNFGD62QI_@AXXC\"1E4GX/!PT16:,?]M1NM'@+\D6=4^!0Q\QM8\
MF5/U5*?\NX#R.,ZJ[1R_YA'0EA.MXX8-4KY)7K)1T?'_$S_F:79&3[/S7QZ3
M9FY"K2V\'SCZMTG_G?TT9[:G.8L>;><F&7R9FX";7Z4F:!K]B0W'522$!R:!
MK\Y5!EC;#YX&Y[@;D@.R_8G_"$"GBW@$B,DKW]TR;"0;7SZ-_MUW,Y\@^2^2
M/X"0_ .(PH<'?*>!']Y_1N@? O\_(?$OB/[_@4C=SC6#Y_(C)N0<3T9*/#?0
MYH(N=:&^3]: HZ#P$4 A_=]W%B%Z)5[@>T_*VQU*>$BM4W3 )$.1O?W!?A:G
M_F#L>RR,AI\EHG_J/RAM1C7=9'_V?S51$1TW^O\2"/]_:H1X3_RVJ^._013V
M!Q!&=]?_$:)_2/X2L/X9HK]$LO\\$/V_9$6YH+(=:#6:G4-6JCAG+1F>5C$7
M;*-'3FXGX<A_;;47WN2_#]%B^D>-\Y!8<H!MAN&&K^Z\( %"5!2*(),?$"1#
MT'E* __)<4QSW?ZG^OZ'Y>8_J1W_R]7_LT)T>;N9Z"K0[E"DUP<\+JIZIHB?
M"G+*I651:S Y[5_^ .6Y4D&GHL$MG-1TN*?RHK^_IG\X]^^I*RK(@PU^5PU:
MW, ?-+I^?ZY\<ZQ\M_T(B*(\#ML&G_T&7XT] DCF<J(]W>EWS]L2?7O8_G1[
MS)_OL%.1%FH*G=KQ9[J+_-]TA5TZ#M>X(FK[LT!T!6],=*M=]"@7SETK279Z
M2*F5?U]ZR.[_[WPN_P[Z'/^10/]EZ7N033C_QH)(A?R-UH+)$XS_$%@] :_\
M%&/!2$_E7<PU; K?>:#>US#YM**^^Z^BIU'1,I]BMLA3(>A+>0(I8=A*_G3;
MPK9AY!CQ5U$N'$<8#^Z#![\57=-35QEA7;GP,NIO72/\$U_Z+[#F9AIT_@NO
M_P/PXK2MP>14KL>;FRMS^OS.6-%:19)N?F'\;21!3IGZ9-O:KS71/>H=\%%%
MOEY)ZK_G:O;17W:UFJN@DRQ#+9/B,F%(Q1<$:?^,#V,Q=S65>C:OIR3G_U+S
MOO_30?R7T?T+K_^(USP+HL+$(=)E72E9UDLB/%UU%=FZ*ZY(:F2K4OPCY\L(
MMMN#HP=8::+2%5R$V7\/^L<6=6@5R>*W1=U.;]O+*S0*^I6$JZ>5_2_]B\?K
M<9C+X;G'*?SO-&<\&VCXKX3WO^SSOQ9>R:"5(;KA#5:6 P):B41C97S-?/PT
M!V>9CK>:X3]4.9%5>[.(N6K35C&R35>&Y)Z4' !:DYZJB6NYD;II\7N+DH,$
M@L'S9??TSHYF.H%]Y!T;GVEP"8\A[T_*P8XKP"&_61K7&LTSN^5U%\=[^M$)
M'ZK+.<K/7'7-F4"/\1F9PWT \4WU[32RV[C!M:719$YP3MUTK;9IK2I["^*+
M.N%C$$0M:'VJ+/Y!25KU4[A[$^A<F+>3Y-Z0;O3U%%5D%\TOJ[[A#BRT(7-K
M$<$Z&/>08<_<3)H=#YU;PW+GMT_O*,$B4[_22EL056#WI/FE++!LIRB3=ZL,
MZT89;0!,GOZY9?'Q>U>6G(/P<=JJJ!A-IA3Z77F_FH<@;M\#AXS@@ZV<@[;^
MS7-_'(>>>(IJYY6(A'&C%_:JYG8E2KQV>^';>-T\1ZOH-:L!+"M5>GVL&3\U
M-(6>B:1/\Q9X$'YH'>6Z8U'KPI/-_YIK:H[/%!""\'QH,GSS8E%@]Q'037)8
M@5G9-%'3]SMD2UGU72J7H9?K_#3^E(":'=MT__S%/=*N1K@B'"S<Z$>?NYU)
M&]]%6%4;%02>53F&CM>-<?K_J.^CN"CA!DJ4\B314MIJO]\4HJQ7XKR9].+)
M_EAB_6HZ%42M*_-E (V]QLNTDIQ=G_UX*&'Y%;U4ZC%V)<O6P*>?1V?*E(>/
M@.KQ'RJ1::U)O,X)JG508:KPT\5G/?-W@CHG=*7%NZ+;6N[ E[+S. R'A-E"
M5Y<E)-Z&.ZF/@% 'E@-74CZV0R0[VHU'0/HT0R?_'S9Y+J3A:^22V?5@:@';
M^C%FJ&.>A6G#1F"X:*/[V5M^+[A6^Y!8DZIY"W V?UITV%-;L;U$UA)K.6D7
M%0M*$]1KH[+T"U36?'(4X<"6AB_S348)%U[ ?DA%O/Y3YP[BH>J3)A.LK_R%
M-^-M3X4L'U0^[F1.@;IU7X_6$-1,<$=LX.UJ;A.48Z3YK)-1-%]L)O^8DFS1
M?FAK7$_Z>L1:BWYPH0?DFCBD"__-<Y?0\^L3W^)%Z<7/NI1,RI/D4&;F0_LY
M8LG!.,^)ZF2[+_&I_<>AH2S-DMF+1C8DPUD3O8X<= -U*K:(9([@WE1RAM,S
M(^5KMOL C61>EMI'P.>VP?.(1:4)Y2288'&0@RM#R$LQP?3+4M?5TW=+U#^.
MNS=SG9V93W?IN@MDY<),5=]]0I42R6GY^%2)56WC:NLT!^4W2>/);*3Q\?4)
M*S(E)#!7%.U,.=O-2X#C>[1NH]://4#O[>2 [HPLD_%H.<P")?%7Q30G7; Y
MLN3I5-HI2!>OREP?4B$B\[L%R%@HEP]'0YT#RMRL="TK!$/2%>=NX+5I>HQ7
MQ0G)[?A:)V<O9I>3<.)&DWX)CX*$Q]U2HD_E9>9(<C'9^*7?1%KVN$>\+@7%
MJ#TW)T*Z!/3J8V7Z-P$XM[3NB:V765V29I*:T6ZR]::D-3H@&'Y&T5%T+UL?
MW(SL6B<I:L7.K,V_)!]I"BO><9(N]%%MD;^7ICT(HAI:_MPN12QV,>)@H[[3
MW?F]_!&0K<$DJYPHLEQ<7'@=80"?A%9-W7.S5"W@XJXN?>1XT^/G(+<+"CH1
MFMN,JMA)9@=%P]P; R4N.9]_+O*Z7U16AC4JXS?1!W-K29N9UWX+40O$8J)'
M6M#=V[M-1*_) RLKCT[G-'N=SNU)'F>&N8(\BQ0](40YC=_+901E%BLQ/@6=
M#UE9)]VVQI?5?- QG)E1M&3/Q&BZ2#E\_FEG6%J(!!JJV9A\_E4[RG;M@7/2
MJH+I>"N4Y4+TF31D86\N=#Z)T+5>KP[#7HM/WY+,-'V*T77(LBLF2T>_W5U(
M=6=S4YO%\M6!TTKX.K0 P$=1XVMXD'>Y(%)IEJ:W[TU L.$VG=PH$E8^;Q.J
M4CN1F"NO'GU@WA U\P@HQ9RA].OYGC.W.'?=@TD!TCL0&%&I2AX*-'@W/!0=
MC:W.Y6OD_NFVIUC[?$A4K7J**DF>/Z@8'X+Q#:VS DG3%0X5+HQPR7A#%97=
M$JWESK^0CR(%3+FVS)Z;CQ)_H&W@Z/86;BQ5D"-XP0\<A;8HKF%RV2P)'6^D
M+2@B.>!OS!$R=;\CUH_^GCO;KN[8FN3_S5NVT483MG<F. <<7*V/Z52]ABHD
M?V@S8(6AF8<EB9^]-_O5P7[!MZ=^K@RUIN <'6,^*F,Y@DG&"98^ FJ(?^J'
M .]I5&];HY9O:SOW2/(==B^%Z>4FZ2<_?M^:.&2.=.:RJ39E196BZ*F8_K:H
M["T:E/^^M3Y<^@0H3JN#M:':9>SMK?&@UEEWZ<<^>L[@JG?G+9ABX1G6:'?&
M2\FZZKU:/*JU- ]_IK%8U[H<MN/\:TROCZIGG(/1.&+J*SEJBUC^DKQ_0;NK
M<#K,2:;!BNYNVQ?S$P3#P[0;/'/K>C!8IY7J<R:+-$'\XD7)IY^94EZ:BGF\
M)(,42-7)'YK"!=-DASHEV36_O2##>[!F0B]=5K[&O@_9J[F<AC]_!'#"MLN!
M'=]:8U<?G"7"-SUMWT039\NNLYHR\P,R'0T@IGRG3:3B^OTKDOCJK_YV;J3K
M'^=&$M54'P$QU#$W.Y055]/CD(EMUFQ)?%6BOY\60-Y8T'REMCC<;A*,T2#R
MV:+RGG8U14BC4-Z9#-.!1M4VCI ?N$#9I4G9Y2NN\['R^"$/;V'(^W6<!Z1'
MOZ.0):;BG/N[>:EL@<?MTDD-Z("U4S7*CI:0@4"A1$3\K>];8 &^@]*#ET_;
MX$:&MSI4LFWD/JJOV;QX<<FP/#BK+MO:]$VX=>JGM!17-/8A*QL1EB\*XV7E
M=%4-=ZZ'2"0>1DO57CCS%+5A[MD&.TZ[NFW!W+],%(]8AM)_"M'^''"^IZL^
M<*WT7UU^<1VJ(N9@YVERW*-W*,VSBDU?X*UQQR>O7F,(G7>X-O'-6\OU:I-W
M:'P$!-KVK6&"Y%5<RSULY.V$8AL]Z'%3 @[[4>7V7V<"4Z@S476H8B6HBW\9
M>Y$,G7!?9(2&'&VVNFB_P*HWO>HC GC%J]^CVCE;_XYB(LWJ4,'ZM/B.)I$R
MEB R[M.6W%R:9#_GNOWMJUJ(^QWKE4)5"':-_O+(1HE]SR0B\U,,AX2OG;-=
M@ST&U*:QAT#F:1B<,[&#D:(43"/1=K6D0UA\7+.!OR8*KH.6U)0RQO0JN?A8
MS3&; HMN]*_V;7>OSJP;O?7;/PJ?!WQ^V1[52T]\#\10/S%_J/BJ)SUQSL]6
M(.^:\2N%#H'O2-]\:%?W6M2@NLY.L_]TR8/X@+5@R?A%YR&O*J;-GF9C]W07
MZ!&P+W]B[9:J^W;P8Q"8O>-L(O.BQJK;Q]"_T$&-6#/^VJ?-$![2?K)OG;6;
M/+Y3+>%94 7I3B]#(/T*^+(S9&^5^E#>DMU;/&=IK=;*X2E%KCZ=YOE)_KA)
M=S*J:V(WF2.KS?H',8V6"I3\\X&>;KAHX 42[&#T$6!JPUYBU/7EJQDP^!NV
M,RQ,Y4MC]-4]I/#F.4%!V49MF^ >W%)GI<532"Q+LN1&U%)Z,<%BF"=. $X@
MWP'GJ#F1'#I_V3'&77V?%NTS<_K.\2!67[B\E#NF TA*2NO)5LMH!@V@)C;!
M(._RHQP&TV73!9=NZZ9[H>07ZNI*,=OGU;\CR*$Q3J?(.E-<F6YN7FPUFOJR
MA[WH)_<($#U=N"@9F798'S\GW;N.-93W()'4W)8AWLP]P<KFR5B!B,-'45-)
MW>)$.#BCL2_*$56.-ZI]1)(-?.TOCO)KS\SJ07&JJIT)\Q.H!<#GZI-EZ[<S
M<Q!ITB*(G?/8>1ITDBM"L(] 8RO8S+@%@5I(H_]4,"WM05IEO.8CR-W9'"OY
M10=L;OV=N0F_B7? Q+/,N>B6O&O[VW%9BYHZT#5D-54O.$E/>_GH6>=$I"6L
MQ@.T/PBC&U#W&B+8%'D]>N CZ)@M6V@SW53.EJ-#%;>3KL!Y50F&0[E%$@LZ
M?2NNX]4G*XY\,@1NYACB+- I4%9GCLXOBR^!R:FW7H0'RT^)QH4P1?A)2.;A
MV#G$OF-9+1P8,3-I9&@4PHLV%/C"X*VDRZ67UW5GE]?VE(/]F"VK4(2WMB5[
MD+XO7"!^3TG;ST!O5*7+V2JI4#9K3VT7>CN()TG"$C4;R/%]X(4E_1(4V V[
M/),:Y?YERU:0D0_3G"KOC-I VZL_1N_AU&LD+X?D>^0JZ^EAS O*7K$,:KGO
M\:8"[G8YTV-L2E)<2Y5O*[E.L-]/7SB/L=DG]?>L[O1H$LV)"W\><H3!^6 6
M$[F3;2NXC=[TRF]E\7>'H)-LNE,G!R.S/IBE]7PL")'^/[\:[6FR5##[\*[H
M<7H[DN'HS679]2)]R\TZ=-9II\6H=9O-FW>N<I/%KZ4DG='SX+N.'E,<)-;
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MT;]7[6M.-TGY';9!85)?+&E\\8YQJ]#L?-MH?9R4:9@VS5>QE-\FWA^NN^[
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MFK6OPNKZ@\VL[<RF1EO<JV.[9-!0C]Z\B9FBN)5>A287IBMJK=LR)0\9N_P
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M<1];]?9#P,TT-@O'R<4D%661M2:98N-"05O#]9\F]S54SCEQ=ZC'.)?:ZZ_
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M\0#F\K/401444>6DF\O6\I"3&1;'\5V3<*0[^.)FO Q,0I-L0SY4M72D<B0
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M);,RR-KX232'4=^"!" Y>B8H!X(T?7P7M3-4X[F<,;RTRYQXY9W55F".J3&
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MO*Z-:R:U/$MGQG03B1>E!O)"ZJ9>[R"EB:/I?34@MAB4&KMHZMQBY1S[\T.
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M?H]+D9EFAU[\#/E[>)@R=J7GAZKZ&%SZMD$Z?: TZ_[UJR&KAB<G$&G0^K>
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M__1J2/.F0;DI3#.8#%7.WCBJ45^Y3DC7C#PB;T'EAE]-SW%U?DB'*@(9;"V
M^&Z6PI$8AM:=<:(>-M ZYS!1WEF,F"IF_YWK?6>49U7/LN35$%$7;TX]3L54
M27I5-7=/XBN$85"8'# S#U$2!AFY9'.DP<]S7_0,\%H=<OJ$N1.QIR ZAHBH
M&AHFA6$#5IC@UX46W@0KCA=GZ,<AUAUQH1;9^P#NML]*S*7GP]'-W68".$[
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MWE7F$EE,YODLV7Z7/#EY[6V48>X2^9UFM$'FT3Y-GNI8*)^Q$C@+FWSR9E\
M<HTS_LNUNQV%NC-71BZMZMP!M,#]W!'#EA7FK WF$,BT!ZN&R<0CUU^PLJ&4
MN/ZN\'6((3TM8@N]R(.V=@4(Y'7VBF?& Z6&1EY=GS2+GG6;+/(&[P1[:4'?
M&UT'/*P1>^D?><0ZGJZS;?P4IAX9,.NX(J9.5G B=!38D1,8(-L+LVIJ;:J9
M=CJ*\1HD3Q-4(&Q"J'T[56YR"WT]=7EW6=R^Y%&2 77><=Q8KCDD;%,*6A\E
M59SNB0Y FCI$>!_6W1H%QD-8GJ>RLG!;TQ7F*-UWP6L(5B&?0!2SODASC3L4
M)*%Y3>?#?BN(I>'B^?,O&2\5)/V91;3G>13DG IZY(BZT%\JHPD[J?FQ&1T(
M.=+HF5?OSA$-!9D\Z$N6WC#U:B*Q3BJ[]3'+:I[QQA4!G3QOJN7>!![S+W,I
MJ$BK"FXW+MD+< N)(4D7<_X^\.*.13%%\HL90[L>P)-D4C@*T@[ZI:S,-ADT
M.[_M-+J.Z201RR@L96,]A\,OTUIKW4.;_FI_>6-9P^G1A#=KH\6(0,Z<%[>O
M*2MCF,;&4=DE5$;0J]C?HF+1SO<3#"N%6P<6=8M-JUKM_(6&K<<94$IXSSCC
M+UVZ9_8"\&_FIM#,Z/F^619HGFY!4,4#>@$H20L,"DFL.LU+>?4]TR=UDPB.
M M^H^#!CXSG%\H8T)?\! _ _U*^3KHB)-[3436<>'WO[_R;\OM%U3#=N]G@0
M%7L<A+L+@[=XH<M !0T6^\!B6S6&0ZN9K[UP7P #D2^ :ZP7 ,R] +53FJ?B
MBLR&L8G[$AJV@G.OI")5TYZ@9=D89FG:AD CK'7?=YKU&"$H^^3[E]QD1RQ6
M^I3)Y^5BG2F%X:FIJ_YW)'WJN"&*:D/.X<$TL9OT%JH\YW\B*8=:5_O$EKI[
MG%BCVD;FK)$0AYWB/](+6_KI"#L*2\.[3I[O7P"'985X5 R%VS']&KC\\KT:
M#GO/U'I!0*"Q@[^B@W\O?21XO7$%M^<M^8]0V1[[P7&[V&URUVLQ)B/>O?C,
MKY%!@GO^(G\>#-0;"$.LFH3_G-<\("P_3,=3*9FDKBE7*-36A;4ILT(J[(U'
MJA>6Y8G-U3:%Q*^)RZ0^G8EFO7,ZG/,P5DF@;GJL,QYVPF^U0^A56%^(--44
M/$G=HYXC=FUL$E')W&S,--(KZ*;-#SYKEV*\04F]? &@+4(0Q]/#XR--W2!:
MJSC>]LISYA^DSX_Q H_7D,G?_E/-[OZMQ]>5E,:>99#4O_:3S!Q%7GIT 1!?
MN=3WO./WD&,]07E3TKKORN^(]94\]^7RCYJ1H<PA2;\))O>1[9E+WO](^T#=
M4G/)\YU-6.I?_ZI4NG&^8Y?2X^X%<+57+DSXV"IYO_)WR-A2]O759<U 9 RD
M=AB65Z)7N3??-Y#^#D"LP*.X+[!!]NR?BTT@!\,WD*6JB]NI>XC8SCKEW'[0
M.-37Q7;8AK) ;>:*@:4\/^4<FY >W!X<8!], JX5W)L7VSDK''8I,<H&*[%M
MA;M%8G5DH+]%/^!^BZ\.T[#TTFX0?/K#_F:0<4OSM(9]_G&[LO)G)1#;Y[H*
MK]/G8W\"_5XFID<[R72H_K=8&K):LMH&M5U,=S[>'YL4#"4FB=I%M>0LG.GL
M.MKC;#/^QEAA.Y\\/_</;T3Z9ED<:7(;&:,#"=;5MJLW7_G-I%['.,*IFNN<
MM=&#Z_Q;01:_Y!YE[)1HNGC5% KM&Q*\J?@-GR&E>OI VZ&\ &!#J> + '-E
MO,1PT',8*M8,V$L]VB"2T&W6]#S]%--36ISW!D7"($*"3(?+RT9=6_+_SW[@
M?U9<=&P,_+^-BSS^#U:2VKP%:P%<FJU\KOF3AO$+YTLCDUQ5>2#AN5$IUA4(
M(*62.A(QU.AWY^5V*6N1=QP=0=L&YWQ7,VMFAH<99@2Z8EZS;7(BAC.RS[TZ
ML!U_ZK*EMR7L0ZR[>DSK16LXSZ51?\2BCK;X_N\28B0*)O[*BF-T5)L(R0X_
MBR_1E8P7XT;2@YC<P@]J=:'V+=#&4ZN[CIBE5W!UT(Y(RH"I"%?,W;Q*]JTC
M,R:]#/A("@X\J]:6$=)*]O_M"W;1*?=H(9>\/YY"TQRV6R/=IN1@_DN59WN;
M&X CZ,(R9G,?-YP?F7;40:Z'-F^<5=+<Z%5/"Q-*3-H.ST9JAW(^G!=:XA3O
MDB&."CPRYPWF=1:0&NHO07?%/3&Q!P6TQV0UX)"M%F@P+D^/6K"XT#(&[E)J
M2:F]I_XGSQ.W][T]@V],P>7.;Z?A!0IYM4J)&TI&D(A$4>PI%O;$>WZKV$-F
MQE1@JHQI-Q)9IK2VRBM;)M6 3&NP %+,IWDL]0]CKGG\9'/-ALN#I5\E'.:0
M,=>EX]A,^/>>EKW*T+Q M-M(C3\*R"VPT-]V@7U_%K=E\$T4N&7K&MECVU76
M%BS;$;J[UGX#;"(#_D3>3U-VZW].E9B"SWM4)5N^T=TRC/5"'I,8%&$B)U5K
M:IV[6@*F<VLG8>>_QS EZA0S5G)0=,$ I%B#/R++>R(BSH5O9U1RY]#Y$:<Z
MA4-6V'S8J,!Z;+1&4=SGD.B&"0+AMP4*W.0"[NR':F@/6%.9QA?I-B*^5R6L
M;(Y6+2T7T@V+&L"0C3@WSIA87<_K4N/WL^VC:P$*#\I-/[8;PE+T4)W+16Q;
MERL".VUE^!K<@)K48>2 W^7HT:]MD_APAJ[/2S\_;(4*9)C'M.DA=#[7US@Y
M5S@Y6L5\JLU^CX-@ 79FZGS_2OXW^;YF 6$>8Q^G?FYZLU%Z X$&Y+U(C*C,
M='"*45%(OT+J/HQY6+ZB2'U2(8P,,3+THT]!Q#[\#T>X=S[Z300___UZTRBI
M6LOLHV*)V'4L:T;\-NH1C9:H*0S-=<4W$QX_%3=?G18QW;C;BK"V<(U<GVJ[
M\5MWNREFXNV-?*\#',BK<SUA, [XV$FM2,((PX_?\O7UU0YX+N&I^NF^1,-$
MEPZ='F0[Q-)QQ/+SX*G'FU1Y%\NH+C<N(X,4Z+[%N+OT@2.\A+H.Z.E4)EO*
M#8#+8H=9TN?&Q3*U9E),6T%F6(V1.>QPB-EDKN\6-MJ]=P6U=ATKCHD3B=<3
MDDZ0G'L"7.1NH#6US,M=!;>JEHA>4X7G;)-TGW0GU63PQ0&^;RJ A;"%<2^>
M5BO+EKC1Y$1Z-POR>V=F,=T91Q#/RILYPE?,3?GR(<0#J'+W;OJU1@;=3+VT
M9[11-UKIKP)#?W*W2>YU2%:FY"[LGK@ZF'^L&,ET^$Z6L+(<,A&(-_STJE]M
M!G2RC5,Q@FC7JEYKY991\65@8$]C1<F+_"K=F189+F,F)'?K#-BP/1E5F$\L
M'JIR>U.7SL"&8+'+"-=IN\+/LS>0A/A^R"+(<"OZZ0QRU(/K+L02-0U[W/!(
MCG<V\R3,U@_)"L?!TG]?& HE]Z'^'MS[,@4M; I=8,RT7<=P1J\VS.K+VO[P
MIV7>#2,D4RY'V;[RSQK*M'F\($]4>Y:;!=DG@V5(%-,Q/=WSC4A=:H'7&BO3
M&:B!]DP$0HVZ&>HE@QV]1DLA.U=QH/]W8?)<K;=:*WKK==4A)+Z10SDP3)FY
MDJZ?K!!;HXI<WH]N-\AB$[OTP#Z&E4U7$?,X:_@6VO"]SI.5Y0OC]H$L&5#6
MWKGHDRU!E(?.,C<_"@R>'"B"UD!,<ZBY<I9.;)M&*+':UD!9A!_T65O:D/FV
M#^M"XW2)]&AX,>UZ\XC;+@L[]2K7C87R8>43PTR,=Y^"_SQL%"C&7S?9?83W
MN.U=C_OR(!+SJ75-,EN>%L5R3!?C]]WJ=,*,3L)!'YK#M_F2.3+I4C;TE#=N
MXBGL:^N:DA[82*/$E[H9Q:T6/UAH'/;7Z\JO>?MO)O+^)(83X3_NE<9& -&F
M(U,=QF>$Q8KLM#WG:GLF^^TZLS\*1/:)]P_)*O,7LW +L+;*>I0HLMVVCY/7
MESK2YK*S*/O%P>O_4E;Y5+S,#PF!Y\RAW?L,B?MP%,U$[SROA])C!*<"A?@*
M\W0:O]A))3WLX=<>YD48"&-OV]"HY5IB9L-=$@2*63S^Z>ISXG;]DZWCX/]6
MGB;A90,*<@0=_P%[ZX:J2V-@B41)6>7M-=MSZ2X8&' Y?U9[37]>:DPWP^9^
M8$ (=:Y@O?S81".@[8"M]1>V[J=ZQE48]K!N&-A.5F08N,6Z9 SY^FG'1*;*
MBXQL,10N&9 Z%2T.T+VU1T<S% [.OEMPIY\Y9=)C74O4+8BE!5+3]O58EM"@
M4"20$?Y2T*9RP56!$$3R+_-?%HVZO:Y&]LG[SO&;K=,UB"1*<:+$+6=/)\G>
MRZU(?]BYD5KV.\%&$8\@\-JEG"FQNCCL9]\KA!JPJVS.YLP1BRV"C2II#GV%
MI--A#[6%%^![.@HG9OZ]=<9FKVW.(-")C//3+YF:(=WF, "'8_[]=LW5L(CL
M8,,WY>KIXT,UA6$K9][-(*SI4&01#AT/(\=AV1J#EA2$J PUSU_RR^)(?FXZ
M)/LKIA<P[Z]B%Q.-2W?3RHIP7+7 O3%OOT\MW[23--L@D)JGWPT-=?6=NO-"
M/U@ @Q^:Y?^$;Q.&>\?JIIO%S+^/=E'X\"/GXNMW\SZO<*+^2B!5)NG75:2:
MH0P^&F3* IRXN!;47FD]_$/N##%%;0-T!M8OYW!-,[>K7MUP.*F'53AM)!>A
M:1ZQQ<R3??)9=$2E/Y='P9WV'FOK.1^,$\TJRB668Q<KZ,WL&3(DE>_;,0_#
M[X30MU0HCQ#/-=EUN<(U/IME!6<=HR@":,@QSEJN%">CUJ_H%(E]A!+['Q3,
MLT6GX3'%4IBEJZLK!35Z^*T0EI&FWP)'.A4\%7;#/=JI,@V8<3]G/$/])+M?
M(\M9.3E>KC &K&8GV#Y=/RHQ9V'8ZGA9[V_(U\5Z"K!-OE*9GZMJ2RC_1<ON
MA!W!B_%=U4QN5_PH8NO2B6C8:_WG$?4S4CB'4*\-YR;:FX ML2/3+_K].LG>
M39<9/S8K@ILPQXZ6AC;V/N6H"8FI1N[5>^S:C2/I?!3FZHO]M&%/$QE.L9[(
MD!>*%T&K&070TB+Z&Z*'3OO*>!NR)8*<O\?*&>)_W@BGZ9BJ\UC%7=V#K60D
M5*;V+1Y3A_N5-)ID9:MH[/NI:VYNKBTXYFMJ/J0E-;,EE2C4K@*OYSD98"2Z
MW>]$! JELO<(KB\DL-* 9%S!=-+? ;=[,7 (D#@!K^X='D:LRJNB5 /#2EWX
M-8.^K;[2UW9081H0*6L5C(]RT6OL+H\=,\/YL5.;&$G3_'BAKKCQ>W*?(0HE
MPY5H_*Y-^+K(J4)LT4W,E[=3<:#]OEA]&L'I;D'RJ%58A7N9G W9#YSWJ/>^
M6BU'O/T:41;MD/ MO"UM30R$1^"!G]VZ9,/'ZNB3=7'/IP F:$SYXH$GFI?M
MG<SX4(\C$:VKD'NIHQ.<CL&?(7%8L7I:\R<SLY^I[YU:V/B6!KHMP5;E)SEZ
M*]0IT%T$^(MHO)2'D_-(]3A>6."I+ JEH<:'EA\(TJF4 K4T,LY\'X\4M?MS
M)9\BY@_/EYXRV3^H]\E=8U9D-I%?J!-9?/3YP,.!OUA'9E'(L:=57ED@Z(]C
MAPQG#E<:JQF,1VE'VV?JX>IVH4Q!*F&B7)?!$..07[;KZL5SEHSY%!&3#2O-
M [R54"E^?53B)>&&YOZP3TML4E6@(M6AJKW[7ZP@_K>R.(8ADMA?D1& \RRB
MY0-/.(T'!-J:.O+[JX]<KY3E3E%@PGB&E,%?"NN8\P((S&SK/.J>D>FU+R1*
M0BT^SP,78BHK&X[ZC^.1@*&"0-BWIWM?[]GZJSVSXN@'ZZO#%X"92=!8='55
MQX[.5?]CV3'-/OK=UDTFSU/].N7=^4S'R=+D?Y[.USZ%!;P !$6[VE\ &92&
M04/M?^Y#GWT"=B(S+'I0*L %?U\!GNS!ZGPU78_X G" MQ4=,I_<35[CWSSN
MWF\\:]V@S!!>#)\(:]J1S 5MDA8'K1851:GHB"L"&WYCR7.(^(DMZ*Q>%!?5
MJ!$?R,ZMGE<UBF9W9#SMI $S&6L:H>IC.!*=2%=B&H]1TB6WT<[GH!> UTJ^
MQ0#%ZH:6OX:3A<6Z7"JS[=3:O%MSI.-@/TVA]X$1&4SKZZJIC[F\D;@'K?OX
M18YRG/]CSF&9C'#ZCFASQ4&PCDJSAW"X;OH7!8^2/]U*-BYO8I'O:#R(102J
ME&MJ-5#OM0),I,*?^^R!\1#7$HVC8Y%>2H/Y-:G[Q%2EIZV #W<D1%MDS,&^
M+X#,JPHW[TR)SAW\[5_[A)GX\0O[Q?H8S\<;1#HW*#57R/G-9Z3PDHC>Q9 _
M"8ABF4"5MR-WV;/)ZCWGLK&Y_L-GG,):_J,E*RO=%RQ,-:]$HL7&HM_:0]4Y
M?Y80RQ8?&9 0_'(B'6GZ8FE!9>XR3*G.>!.$?D07/VKC0E="3P=8[OCFJV5%
M5$_4]C./6%Y@4*_.;DFS+L)[;NZ/0J4L_B*LQK;/_N>$,#9!"N<PRXD+=7I4
M]QNQ-T=KT>;K39O3"WL1MHD1#"4,_YV=X<*"K)K_],O^=Y%:Z_7<O$3+;=@Z
MTNSS..W!%I%Y$XWURA=:Q$X1YHFR1,CI(U_J==N'DL)>GM;IGE/N 2(R&02:
MLXH2>6F%DZ+]2+O>P;[AJMTQ99]/@C+UR%G<>=TE)5WA<LF_8LA\.M_>2/0K
MI_!4E>CO0@7;@_T%H8-^=$-Y=#E$L:LH@:>"D19Q1CW:B:>PG[;9/UB[CK"9
M (V7_0I55GG 5(=H.G 6R.'D)I4A-.Y.Z\'CR>.*9D'LH"BG5Q]X32"8%;&D
M#(%$:P1OCS %[W\6N)-M&E?HK:\#&R&J-(5N2$":;*)B;\9^+=\U$6/VR=._
M_]+K&P?T?%M<F3WG3-I+^FD+^52TS8Y[XC*_G6^P$,8Z*<"%FN09X :&S%$%
M2GK_A2NXR743ET<&?<\T26KUX,T^UDEUB28=CG/QJXT*4Y&$>#C:9.8Y40'!
M?344YS.G-J5 ^)2*@ZE.<4$KQRC+( Y+[,:(<S;A[]^#)ZJ#A;K#EM<J-HCZ
M370Y'%'Y<;$N5]L%.G4/':_-,]"++AZ-QLSTQ[I[IWD@P&M^;O5A,J*^22I^
M5>;8"RK$;EA"17NTQ<[J)S/PXN*Q L>FD->?<TS?BO8,*V#=X?6OWEHQ1L_W
M1)]WG*9%2B&BE)-_$O)_*M;)6F/IF:G*H[R_O"HBF91,(.9B[\XZY_(N>FY?
M?P%,*FI>C;*-:]]^*9 (0$U]79,JA1LP1Q6/ =[(3)B7=<)05Z1UH1;.YXXL
M17!%Y@SPSE[JFD=W-I?B+)'^5;R,L(]P63ZKJ)CBV;!F(:M\MA5P<KO\Q[$"
MM"G*7>?7,_U'S";RL[=N7V?(Y=$E3Q*7A$W!P;T;$.;.]TWQ K,OC>KC0/ ?
M1Y,UAV?S-I%R$.7X"@C=Y_:B-O@NF>BNS:X>^JU KY.;X-ZC7$VIIS@&0+DO
M-!=3F?AL4G1'K/#%S^>Y8]O5&)O)8T^F+>OHC.A!].3*6(;_/*C*?ZX(O%P9
M9QW;TE\TZ(=C(HC#@3;F*BN1;MU,S +ZD(AF!0W;#-XFL$3J?]X[TI G4225
MI6;.P^"L'J!9UA0L&55>G8_)S9\A8W_R26>]JHRV63=Z+2R:..C&7<!&74]C
MOP02^AG23V::VO!GA5FE?O91@K4M'EL>_^%3Y'<$35B1[27QD1$=.+IP+_+(
MP@SD,'X3J19&?U[&8="-*#?YZ?L4](8IV]%)8Q\X5#'/A ?4-QS9;)4JA.UG
M"D^8MD8JOEDR%(AJ/\!N(";OK[=I6?3VOAVBLC51#C.+.XS)*$M2=HEN1NMS
M,3HPZ+I!<YZD2D'0_#L>V5> ::6,.NZ1N3."]-?Q\92M %/DJ_4P[4'ZAD?2
MK\4KT(870(C%&'>/ 3O)+C7/Y!',NP 3*U5>B'?3280T\]N!XIH0Y1LCV_O(
MU*)%VF:#E*_;6WV[\SY]RY=$.^"[RO-IJ2D'8OUII?J0A 9&,!T2F<7[)^:W
MW9E$=2 2]J. #RN5&YG6R+8)R8@TV.,37_0%!WN/H4^?9PGRH7[/X131K#TU
MMSR5)+*4=DWO6K-\<M\LH3URJ$R"_$4"\O>]*&AX1TM^_@C;,*S&D0[]9]^+
M=X.H2MS>EGS=*YS7UN=[ K$R1W\1OO:!U%258^+^@7)]JL<>;0PSW[:T+%1E
M>'JV-@&Y]2D A[_B@T%3TN]Q[REB14/3P9L47O+\AZ->*;.U)\Z++CAM6U.]
MO*-2[Z*\26(T4,@S:ZUS)^)2!QHJ3QVS%I7)<N>@B9-"Q'^Y'L/*FA<NIXZ:
MR(A.*)Z-3%\IZS]Y] !\ 6 MS&+=OP"Z:7U&GZH[2)0.Q@O@RY@?Q'B[U0.:
MU!$NL%MP#[0O1Q4&K[+>P/.MA\9 HM[K\EEA[Z.37 XF-N9:2-O>*K2#:9NG
M0=:ZXKK=/46FEQ2A^2U3D(<#K?KFVH;4%0XH7R2^H2_6S!-$OXZP)M9+%LT7
M%EB;*? +M3(G@I:A'R-GCF;@GN)RSU\DC_7FR^^I(T"C-F<T@__.($J6L4_E
M/BN[2B@Q5?@0G']+-9:Z#V"%",!>-B_@A6[E6"#Y?'E2@XEY]?%?;D08PY>"
M]'4#NQY> /K+%Z,R!M\A081I7C%X=K9UW$$^5$M$KF)_!"H6#OT9[4H^)++$
M'E58GOM_(\U7:HW[<A&@Y+X'0K)6_]57:-'\F8%TC"/NH%<3,G%9AF89.ZU<
M'[))Y E^7_"M@%Z+Q^G K%1)Z 5@D.GRL =915X:827I/!Q$]SVL;OV-@=RO
M$?F'@LGOIP4HYQ8B[5:(BIF\"C0]',1+%N.C0:2IOJR22?I<D]JC.VR#" ,
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MJ/O,]&N7U_/W]->AJTI> ?S(AX,T'V4W_R#^/H"5+0CK-T3P&!DHA86GN[\
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MH>L%X)?N<J)8Y)TE/5L950'.P9L&+;^S=*3(H\GJJCD15BE<63!1S-7_^;#
MLICT1 P->>J2>_2\Z76#ZA0^],!)8CSTZG%BQ5)J1Z3QVRW$V%QN+41*F!@+
M#^>O]OX170&-Q [F'\<ZNOAP#6'[UC[&DJGQNP5@Y^Q3E'K#F5;%/" ALU-0
ML312.1_((1:EI%_BJOP%@$Q#5UA*K.=6LHP=$QDU&[*><N3^%*3:7#]C5=<1
MNT*@:)_&Q4T8C%BO VYKS,\NTLIV<\Y/63#QCI.9EC,8E21*R<-ABHL=4D8
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M[59_* 9$AVTOOO?@SVT=[GWFFO8(P!(R,//!J#7LFB3.MNTI);,L.>EU_V(
MF:I_^\YHQ<Y+0\IFBQ@T$L1"C$@JXI9IMX)&Y]7QR'>74GKF6KOT3/D(+HS8
MOCPAVVW.S,.,9W6.<LFBEC>UE*]YFO*=+/;>D9FN1W-(7AZGI3R P9%CS%X
MWN $T2&O^I_7U?7'[O':GC\J=6]#NX^:_>HZV_(PAAMH/2J=GG%OOT5N39',
M_5EB>HT!/30968E^V(&'*8 @B;_W.VF7EH]L*\T?^IOIHC;G#N>YT-V@/J8A
MF?S1#Y^97@"/M/<F2X<@X8NTW<=AH,M#D\@7WP?U:PTCE"/3^S0\'9K26W"W
MZO3BD0=SBUQV!WAYN9O@4W16,]J^B)+);*M%@>U-WY )Q-"P],2[PHR3:'ZV
M9BJK-@LD?62V*A48YQJ.'A,W85T"LYM+NE?8]ZPE!NES42=HQ*(8"^Z $W8R
M"68O Z1Z!>=JBBL&&D-]*-!_S":\#V8@53'U$=8(HZ==-5,N_:G8M(^GPV6Q
M,8IS?TYJ99\<..'9R=J#$3,4M&BAOM_./>6>=E,;=\1'B%VYISZ'2Q\O8D#.
MZ,<(GZ.L#ZMRRRG.#['<9\ZLFZW@8<>##0++#(7=%GQ*;&EZ/K?4=-!GK-0H
MG57]?!MVF&.;XT.?*(UX8_6+35R )J=? 9]1@*%B0;!&S=6/)@"DI>RB#8!Q
M&+;U]V 2S E9<,++EDML<Q^XG!S(+"@@#:*BDT<&]KV!O19Z']#L^@>0+)TN
MUZ,M-*K;ZD5WU*3=[I.BN)78A!CI&ST5%T82C_"L;L""%DT#)>Y.^'NI*S.)
MOXC76J*\TOR2(YT:9A!GU*_=&G@@S##)QX:9I=S:^E5L()RL(3Q >H4F4855
M@<K1)7,6+$J]:\GIT$[X/IA5J<QGA",][/*FB$0CMEDR05=ZL:XBM\;\S#KJ
M0S!LL05[D8KI<%^*V894X6K,3Y-$)_(R0_^)1>.(]X:3;3>O^6N?)459)J0M
M_<IS(7"*4.$A Q-_9.GV0KIYAF*,QM68SS)EA);6P"UV= (+DR!0>)+=R:Q!
MIBG*!O1+A1LC1@$>T9=54[)@#,MR*\R-8.82_U<;N<*"?Q3CQ"\ /<K/+X"
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MF)_[&JDTU!EA([5/!7]/*3O( 5)+!SUAR:.Z0$KI&VWSLHG4$:KP#A=15)L
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M<^X%?E:,QIL =?UKR\-FRYNQ<(\BKW8M.+[%@Z6#6.+'BOR6@*Y&I:3-^V=
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M/4'BS#\B[C99K?-D3VA5BD9?\UWW2] 8;6:Z;'AR2'63A^$.<2]_2B?XE@_
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MQOC182R'3TL@JW#4T7U.]>WK7PYX-HY+([N(;_8BWXND0D:^Q,@R_.2YV,I
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MUFLC4JT0D<%6!@;81TGK7!U1OY>"QB>#3R,T9.CF$N($3N"I2=HB U?)KLH
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M7O@I21&Y;:,!2=I.0;6#"T4V^[>BYA?N;\ZV,\M=&%]CX3$.XA27Y5\)>Q*
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M=(6)9%T:R3S.?89C> ;IJ/3HKYT.S6V6*+-RELY# XWR*6B@3PHT$GHL6V:
MP&]"C$;8'*6ZU(,TWD$MAC9"M7["\#O:PEM3VU+;[N*%5U#]V=\82M' )8%
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M-']1GWNJN[&ZFQ/166=!AMV;#",37Q>WGA=LH('YI6E-V(PR&R[N)-MKK1"
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M67M>-J)RN+4JP:NIS4CCUQJL/W_/)XV6#.$(&AH,.K%2M5N%[I$E=RO$1NM
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MZJ.@_#'@95%U*E],*A^N3S=U&H9$#BZ+[EL6W5B&#E*6O%(6E_^+DR%UQYC
MDVG2X/Q079<"4WUP7H7"MUD.\NY(?(E.KJ#W/A3/["M3 GO.'CS A)P?)XZ]
MM]1JPH=R0F>D*6.[]HD#I\LA[,WV5'42SNO\D\RL9XOQ'HL@GM/<Z1S0U5O0
MRWPIPO[$LITA,JV6!^TA1I+AWDI=Q% :+]D'_^CF@DPGM5P1#NEK$G=MU@OU
M"3X92;32YM9D^&T.'!9DU]9;-%,":!N^1U8PQ>(7&%J8!S,'^U+3F8 :2_,]
M^5.T%%@J!C:-/]#Y:K9*#Y1;9*2-^/NWB&D3I&99C-OD5FZ.\.B2KYC<ET%:
MP<ENC631*$JI%0\^+QNKRV77M.Z#DWZB3D?UEIZZ3'AWD8P75_:,"<X/\IL%
M<!U=9DP)N$V8#$VQ=$^]V%!46678GX8! ^FIL\P<)Z%UU9 JK0S )VR ,%L!
M/;,H\K7(A];7%*J&#8>6RH*W#:E"E(4-TJWE"IEJ]^_D/D[0<J-\1YBN>8$$
MAP$>3>GK*&,CW^RNEM)U-GLE7YO]YJT*?CM%^Y^YM]-\S\HR&E (3;;43@N\
M>9AD:W<CZ&(8EA!BQ(?,X=[T;&=L>0#/RKAI7?%CXB1KNC"BXIIF+*4-*YUZ
M\1ZD%->F8;S41,37^Q.*6=U:*2'F]4V1UH81DG2[?"HW.FB#[A:UWXBQAMB:
M7O@"(7S17'^5'R!IS$B)1!!//3D](WD\S*S%G<=8Y4BE'H;%J.975!;>M6%K
M?4U[<V+A ZW=:D Q6-Q\4C>WF(ZGQ9I DA!")\.3E0J0&"H]R/PVH=MEAYMW
MIYL;T4$*F",2X1AY-K87NAB:>V-RTGX%)NN.)4;KS"&S/*Q7K\!D!?>H7;SI
M^FVW1$_S[XYH*6I8M"J.CI0QOJ:U4*>Z(9.JY/-(%^M8]8.*O;56,6O:5EBT
MPVPWQ=[ZIB"-:5[IM?!-*N8SJ^&&&&/(BU&*PQ=@7JX1QZ +TAE6PV0GZ>4M
M7?0;DDZ6MEXV(T=/T_HJIZ5UWSQ=12@DI3-Q^L0+S#8<157UCA0HR6V-T$=N
MJ5<.;FS>C-*!:*:$&\=07[FP/#.2GCA-FZ5-^RY<,\X7,QE#B9)+E=9STW%7
M6W!Q4F_%(*?1!T>G(!,O]J<O'^"8T+ F5QSAA(\5FAN:9[;V?YL VP2YD/M?
M>.WEFD;C];%!,&4$5$X^L?R<=G<UMA1,:6A"I@2^[O/O/'C"%U$>(/Y0]MOK
MY%@)^6-=V98.VHVJ]^9Q:YP*I%%7@J51'CHH<R1[P_F=ZA>@G;=6$OOC,_L2
ML]+(ZS2AR,-*9.^Q!A3\5]>_K,O>G<27FZ]>R<8LG.)^VI6TY1,-+<QB_N(=
MZ_F\GU^5CK=5KCYHSP,10=NE#3!.XQ#UL(8&V(\ZUM]H1@-6A2PH5XS37)68
M58>=X6J@D)C*>O]*?GV]PC+EH3/H!$KAUH9D&\6XFAPT,).$J@?MY!J@7N>B
M 6\H KYRH+2YYD*RL2&XA^+8#SU6*T0##]30 $SBS/U/(%,GAK9 W\9L%Y%:
MRS_#.( VYD,1!(5G)VA@?32U7[HR>U*BM&BFZ[BTYV<0*VC 1QL-') ;G.YC
M7'ZA-";O4:F"FAO"HG?-XW\&TH\&",K1P H;[&@9P[%^*)AA.O,%JJ<)RCW7
M*_0KF%04.00-]*E!MWO1@'X]0X!8O<+L68(ORJ ET>Y7.-*_B,%=C,S#/:'I
M]!X1$A8H.O\+F%_E<.#.>@B_YW?H3/N7,/\SPKPK*IB2@"U'(65W9]K 5:_>
M*R?SCSLC!0'5,W\$2EH"$[4BL[CX66TFCFJ=KNM?MN<Y14:&N=5'.SZT:[;!
M1(WIP4Z.*F\GF=/I&U^HA')4B$)09+HS!R!%Y$4)I!IH)V4)0P4"^OT.&IC+
M_691D%0PNGW,E+2FZN%M'@QM#(Q#O5E% R_;T$! ZL\S/3C)O)QAT"]X0UF'
MR%X:C!PH!<_P!M$ 5B@:()=&LE;#5L23C@FAQSF'VJR(36\T\)HD6VGS)/'\
M5P6X;!$DF2AL$(HM]%C) =KG);%#A09VU3;*E.#C9V@ !Z2<.K'_']":NEY^
MBL(73Y>N7'(=_1FAQ"RX&[-S#C#QO3$::-$HZ9<>A1PAKWC)A=I^W2W\&:/J
MKRP6FJ:$G@N $1'),!,S;_ +RJP_,:G?!0;I%<[L/("SB<%X6V&_8E7ZA<WZ
MJ #Q6@/8]S=_"?;?"C87^F6&D'FGH*$FSBK7GD) D>.A1F'#O'XP^$FQ4UJ\
M3G^(D)R2E2S&>^NVR:@;O!LK]-L:$T,82G=G!O6(&Q[AG<SS9VMY,ZG;DDR]
MU6DU2KW042PX#7)$ XF\:B3^UR1\8N] LQ7KO)6.:E#B!P@3@[6(;:]^3(4/
M\4_O/_S_*'^^8_%@:&" ."/J__H7((2W?_%XOSP"7OD]+?YOEP*7%MB:8R\"
M#02>C()UM_^P4)^( _ZGQ%."E+ZF.'M:-3*^M!@C=:,BHBNLP;"_5CW=U#6<
MI R318&*93VJI1&B#FY/T #/=T%;@\;?,B8J_XOX)](X"P%>=Z^_>VK-[D-W
M+5[EGQW=_VM^F.->K+;E//_>=/EN:6N4]E8RA&CA JN-23#66SJ@F0! Q :<
M<*,H*T,DEO=F4$@"B5D/UWD4E!,-;'_.?"9>EM+P&&,A-N=#3Y"5&$=Y(?18
M?QKCE)*ZH*<[K$4@;26#FVB@\7"W#8G2P;B:5])(;ELZ:.\F[.R83),DG[4P
M' W\!#+U;Z@.SU%QX(U\T.B [M3785R71!0:./J.L6F7)]I ^R>8%-P;EP)[
M78Y] ?8SQE]H"<2"IY/O&?P-X^(Y1NC?*)DXIP3\$C'PCWE+^>QE"?:,_@4?
MZ&=2E/\Q<S]0;?P_HU[GWU!_^%^AON('*>=+5PW#6CMRWWY=UJUP,EQ@'NCH
M(X4E?% 0_I[NR!>VP(0)?D9/H=?UB!RF,5[@?0@,#1AL(GT<^0 E?>OYF< *
M;YR1^4$NONRMF+FK?B%/4Q,G Q9ALVD'O0C* @P5&-7T 3PBR6=A.P/NYF>7
M1Z%'/][HL!3CI3Z_YK>-.G\>^Q2O6DD?4R=BR8#VU;N@ >@H\C;T5R@4V)-9
MA41HP#=B4&)%OQ8CG7446>IAV" )LNMO4'/NV#O?]P@FGP/M](_;GET^^M'Z
MP;M_W!(-Q'C_#95ZUR6MLS 'IHFLPJL88,&#T!4LI[\A##Z5L0S 2 <?/H-Q
M4@8[Z:+\FNP=%RP39\&NMDB^Q!@T\/#O7:DH&D6,LB?_G7YU >HM50U?:)/L
M:M(!MQYF;3!&"+,8OS# *-83L--[SCG*9QUVBH)ATHE?@'XB<4BIX_T5LM*O
M0F'%GEPI)/R3$/Z$%C@286_Z$V[N/V.R3ZD3_!63\G\3S'^=8/)AU\MSFTFA
M_-_X:KW8/-1EGK0L?.!AO'+G\]$G$ME_;M/9,C)?'-:H335K[M_PF;*_]U(>
MT$EI4+4-G>8GE(XQ_8+1(CM9S)9' ZVP_8$N3,#20H&]ULF^*'%L@,(XG\0H
M@V-BS-:"NHZBW+6@WX4P]BLWI4$-!!)]#EU,CT9A!Q@<&W@+_'TDV_#M<@_<
MWAR+PDB)/^9@#-11,'3YQV@_BI>(@H 3110E&OBM#3/T^.]#,4JH!?;,@8$\
MK::82WK// (D=T];/\][G8^3+"WOS5DI_("Q?K]/2/T9D#,IW)1\+PG)C08P
MVM?[F!N)AS$ F,"F$'E0@HE_[# 6H.1/R U^8A1C?-7Z#=B@C:C?9V#,T_;O
ML#1)_BEZ#KSA#QJ=23NP.DQ"(<8!VZ$[MUZG?TCVF9<&V#/[ES;0SZ/-*,Z%
MJXK9.6?S!B>KII@X;.Z#I]<N9DK4CX7(JMAXB<@).#'U%CONK?UV;M3D9A@\
MS>[X/P\]JPU8T90+TAA8'BK3Z#+8::@S/X>+!G;H-,H\67;-,N=)"+NA.652
M3O&MHF7C=^0**-)9]V6N/=FV2 E8HE)7]']&R4!?]VX\O\\45&U9]VF&!\4U
MG*\E?C-(?G:B??RRY1>ET]ILT:J))9!;K9KDW*/>6;-XR2N?6GE2@Y;)$":8
MKY]!K-_I7BEFL_X6&?VKRH.!J/>.Z;]')1<3@P\*?9 8O\NDD(_118P'73%K
M6!&C736X?!R-DDK00<$P?JFOF^^B'IF2ZK]S/%OF>_/OAU'GP:<AII'QMQ?Y
M,:693 G,>!XJB'\]QB2_S(./T$ !:*26;=Z;'-K!UR^Q[@<OZ$PC]OCIE:$"
MW^I?PSW@!'KHAP;"MD91=:,GL7ML\)EQ$$JZRP"Q;[ $::\=ONYS,>!2-\_5
M-V R?"7EK,\9C!VYEUO<-=E$>S_&\"C%VNDJ.ZY*ZY=O@L%2(T-?G]XETHC(
MUQ:]J6H<H:L578L3\+*3B%M.;D<KZX,2^/KO!VQ<K"U"-W4M.W6 <;;['[8Y
MC&J8WL9']E6'$9$=/E$A<NB)>U-*8Z3T6/8ISWD$5*AWE@!;\*[!D(W9_'U1
M=0'U+H?.&+H1ZZ@Z##,/M9](#_'W_/3$8"4W8=<6D<"+@LVAG!@=U21U,;[Q
M8C(FW1Z KMPJ'"9R0-VG\3OSD#U_-@ <@U&G7O(WV<\.$;%RGPB49!6TJ]C;
M+ZFJO$L&BW)ZX=*X! ?%L5=]R5 =(*1Y.QKJG]DA$'RM3XXUI5J*5>A3?+^L
M#&9Y5*XHP]-2WC<&W+:[?TG:2EL.N V^R8G9&Z_ RD!:^J=!K-M=(W$*^N6.
MT75O.\ 2+EV5V(7:%NF%]G?4I5R*- 8-2K>1[T9!\(.9S@93[%L-<6=)OJ)$
M&']G((_,36)(*H)]E'88P:C.3O>%DCJY5T@QYPQV:BRU$^ZXYRQ+(%>,3;'3
M+H^8LX;MA.C;GE),I4K84/MMD]2CW.?^'N_.S9'-2G<*Z2?YB,=0(CZ<PAR]
MIC'?TS[]&K@OBDK/F_27O^/3(1)85AV^&=K#\^#58J;\5T4Y8&VE -K8P%&Q
M^XCR.N=265U91%=U>;SAO.U.P>M_:8R<F>K%/@O%Q SM@[G0T048@KJPAD0*
MH=&(PNA96*8Z9O=T0 ]XY;&B,6MUKD;X&+5]]J>K_;\?!O^F<W]63+QO202P
MA5B+)'@38M14U[:Q\.16+,O9"U3Y-]5WOZ9/D%_?XTO^1(*)]2R@)PR;T/5N
M:$SA#<R^QFS)!8]R#&G\*+.Z@&Q"7#+G3X/ -O@F:\9;69JAQCBJ[ZHY*0VA
M> _VV*EE_>KIL[5]Z#2@[+8?PD+&GJ@9=V1GV-@]-:NC:\WD5]!O+;JO8,F:
M5LB!6<_;/\ZN55ZF9:NYYF<-'(87Q16QS<6#N2PAWWR$LO92[P63'=XGU7G!
M?'B0,1?47^%S*X_>BH**G\LR=*3:3E:.$C]L0+E?7X<#L\_?X[IO;VQB;!E\
M],P5AGI;OJ"V#BNM1(:.&L#G, Q>'7CF)?ES*/#K 90R'EB5O_<$L +!-UE0
MKZW.GHY*+&!E04?+DA"7/I&\-=BN'!I0ALW89J?E )F%VJ9B(B-#WHPFZXH]
MM[.$,DD-Y&7Y<?H#;[P?NI@>D?\(TMAZ;\@L;(PU);Q*CB(\*ARC=*P9C'_?
M"#\L9$H +FM&Y!C!12M%ULT>H62RQ#?I"ECC0*'&Y3<J&F'$8.6R ;8FSH=-
M%XN:9T_X)9^8BN'Q=<;>NMV>9R&USY @35!^,_[]>-I&IG'\[5P4Q<[B<J"H
MI'7:-T+1[OUVJ4=6(L7Y,']QZL OT\PT_.7SNI_?I[Y>L,$)L<=3<$-H9&]2
MWGT]Z7B6Q%%]M+IF]W*N(?8L*<23R.%ORKRD@%'RC1,T<(._]\Q+<"_OSJ!-
M<-W7^>IU526P:XN/R7$L.+"I,F1P_'.R]#97Z@P-LFF;&[J;;]6YRS$WT33J
M0-O^O#$'A;+P'%+\Z*2/2OKM+9M'#@1T;_9"-)(1*JMA=(U^+YYG+1!B_\D]
MLG?".^":**X.[K?6J75#QD6:<-8M'1/6M"6)N()M0_UL7>+\631PS0)UIVX7
MY!/5NNE$%7ZOB[WMSNQ[0STJ#^=/!$E$)O''?LV9VD'_A[VWCHMRV]O&1U))
M44(:14D!D<Y!W;1T# ZE(BW=.8342$B*@(!THTAWAX T2'>#- PPS/P&=!]A
MG[///L_S[N=YWS]^?]R?S[IO;E;=:UWK^N;4S0@82);Y0 ;\:^N)19J%!A*N
MPS8:P>QE;$%^WAL\E+: W$9#WT[MS1#?O==FIDI;M/ZIQ8B^:K7 !Z;A5$3Y
M8E?F8M:6T%MOPYIR-28UZK)@@BO-0F6#&&&@EMN>+8LZU0(D<Y.4D$%'(*)^
M^81U\,^U$EF##KHFUZECA<O P$I*_HT6A=0G.>LW97(7U'S-4^AM9=XM+P^M
M.'%?2OX?#/WFWK5(=>68T3VDL+,X@J-V_".>@P=+DS(PW<::;>Z5R3V4/.AK
MG'A_Z0?XH/^$,T\4Z#Q&$8<45)TJ@!_;EPW]&@J%?K?>WOLQ3!6Q*__#,!2H
M=C,Q)0GZX8J\4KBTP@-PCQ]W[W7&!]!W8G/]:"E8U>FX=ZCOOFB:*N'.K>U$
MSY.[KUX_4YQY!\?\L:QU15Q,<)P<;[5$X6'*</DW9J:D3S\'PX_7)W,$R&+1
MIU(!U*9[>^HTD^+@='R5GX8J"O7:+7A9LJ:"V6=H*S-JEQ^O2H)9+!RLBM>?
M":K0Q(M+[+7[][+AXR5!9;;?H4!9^3]A!(09IN<X0 ](:&9R3]#P!-($7Q%;
MRO(M0P+H\!\AJE)0_RZGFT6Q"/?@(3S:#T<"'G!?V@P_I0)F J>T@#<#+44F
M.%5FJ2'?#9U1QHJXGWO&=,5X]$U=Y-RJ$D74HTYQ7;[7#K$\P77BQ"#RY\H]
M4!DQU(?E_)WMH+ I\2%TV15'6  )N"(,W(S$$E1OF2P!NM!RR#L/<;.HDE3A
MN&Y_%"':U?&?Q%*6;7A.3%M0$[M(5A<2..O@'KVA0^\^(JLU04GRGFZ'</A1
MO/UBT 0L)W+F?1CKQ ???2OS]3'5E6V1\!LFY((#'K"'I50'&VJ3N3:S0+],
MEJ'ND"JI2#+G2'PGF'I$\[Z(]W1"0"7?5 *V27G[V-UR>$)%\+=@,025BP//
M?'E:NEW.REO!H+4TS5@_]C4W.54,<W(J%4_=6+ICD.W3B+'R3^ E,S>>8U%(
M:] IFIFAT.R^E:X<H@NR?6L,"1@:A;#,-W>-S5].'D)AS78[SI>MVPLHR K'
MS2^(5#K>8.P<WB&<W@ 71<Y(/Z:AK7BCI:6)>C[J6-FB&VVKLZ<("^6"/4DE
MZI"RB<M8O-%YYE-K+:]J+7$EO?]?1N,Y\35/[L43(@$?RR$R>S';%D$UJ\*T
M2, S6T3D*O>?9@A7-P_^H'QPF8S/FN9JGK/-QEXNR]=>+-*=0(/OCPZD=O=6
M]Y;%*+C_SO10R[)2@K]R5: K_#,YT;6E^1=B0PPZ.Y0IZ^<^(L;[@^1Q%455
MTGY6JOR[>'#*;;#8[A 7 I25N^4 ;F\WLQ'2:0%(@!8PUUZM&<Z"!(09)T&&
M"%>U(Z6"_U)(\#TG)(@.K-84,M.W1*5 NF*0 "Z=1S%%'X].X4N,Q1;L(R$G
MGU1%A2>R&GI++#484[N@=\,.=^EESGI*_(J>_^R#L.:LQNG;V.2YXQQ-Y7D!
M.9)9Q@4I?$R^/$*7*%V@^S5.D/&D60J=MC*@2Q)[U^9HL_WACK"((^<0#N4A
MQ3P/I68L;DE1A9<48^!T<JAE^Q[)4N=60W-6V;%^S0F,9'%DO\1EALU@5K6?
M6F?%&C=2BR!Z68M_9&"61J9XJ*ACYNVC>SWB=QS-8E =ECK#6V6F-)Q(<;MG
MF64R,R^5Y!-QA(:R(D.CJ\1ODA-/,3&46%9:W"0*])8W,!1@C!'L"6:-X5Y3
M&\_!V%+\M! _AN,_1,.>NLO"Q,QL-%.YH(B2<P D%[G14"@H#_%U<ANH#1EZ
MC?J>LM*>>_@VU;_BOLM9%EU_13Y(49.<IT?9>Q>%%P]1(DCUI(JT#!+@5IT6
MEH&6*@.M@M1/7G.]F;JD+NB>/'TCS]!+)$SKI;+68OZMDL21*.B,"XU&%;."
MS"X20 5;K3M:\"IV9O2E+RXWQ/C:DT6,WD=MHV-F<UOY]G/^_:N5.[J/< IL
M]X(" J_+33[WWDM3&<V]7XGS?5L?1;$X-31.A86/KY)0M.MWB&M*24VN0A.Y
M7JN+S^9JF"P'X?-?MQT*GJJ_&8'6@98YWD8[T3*M+9&]R4#-*E'63_CZ+KST
M:AD'*?'QB^N#E=KD$8&<M(_4FSJ^QU(8/Q'*M!9WOL&B')'WOOIAJ(FFU$S)
M$_47UIJ4DN L"1/E0[E$*RG_N6M)U3'W3$B?*37;'*#P<[T)9-,)MO)4H\QU
M'(9:]802%4Y9R255ZC.2V1K)4+RU;!*/X=)6:BH,F*?29*B./XFOF1-'G0'Y
MQ0BU;5A^!M P_Y"(';*Z7A-IHQ8;8=[L/$^LI#6+ B_*:#C0?L;TFR798H%<
M'V&T6P_"L=-D4->_G9!P/,)TP"P9J^7$88+6 ;[;^8.$&36A *MEGJI$MSGA
M\>L39;>-<M$#5%E9\5_ T*4+W,:TK9H7"<C9A)SX]!V!<OX\K\V3<@'ED@H9
MVMTRKL(2'<'O&[NSO8790E)F[4X[I$UCWB?/7&UGXQ-D #U)934T8YV&4^^5
M79QTF)7O9G^HP^990-SX]%K3JR>VQ4%I4MIK,$W>KR]F*?U1/('9Z)R^8%S!
MO-3^%]:HK?P 21^X*)YD1S_C26>6@Z&PX68><#HJ/:<HW]]]5/B S+Z!E2I'
MD]"[95&&^PZ+>;J8G7),P"HWR*,N=R(U-[Z$S/^[_M"=RF&&.(5+#GJ4IA5>
MWQ>;@5?I[\G>=E8/:"_@Q?@<VC=&N P29O7-77ILFODRY%$2M'G %92T5))I
MG*&3<OT^.>"I^\9@63(9XXN@6%D; ^@B$C#-NXD$[-]?Z<RX-?PY0OWI P-J
M,6HYN0^P?(DM(KL^#G50R,9-3 UWK,R^&)"1UI;Y$&]F +=R%%%KL.JTUT?^
MHR&1#-A!@[-ZXDOS/:9!2\M:M(<)UH(@RBE\@Z]?=II&4CN_W@V; [YKNW'W
M6Y,QQ35+:U/$%?8<U3 1,+2M;(LATOA#2TZ7+6F]7(5^W:((LQWM-6-!^022
MO?4YRSHFK/O.Q6Z8^FWL33OL"[DD#28)UW<O[^)F5PDI0F53):XVK[@;M@"@
MJ7JSI@K$,(9EA@%QWY3BM0/":PEC'N.2T]"!9RO@]2=:(::XPUP]&7D6$OUK
MMB%8(]H3JV@+XWI(0$B9X^2)\8ADL+!(GO9)6(NB9-Q)_U/5DCX1$VIF4WU;
MJ I8^ST)R==)V&)#N?[X0.Y$8JB":0C/90'R9L[5?O7@H+SE:KI"/K#9EZZK
M_/Q3F0?$[P52.P8]4DG7WJ'HL2KQ__QI]CMQ9\9C-OXAQTL]DY9/>O^*%ZJE
M?%;I3Y'NW+'7^3=(X=$U1K^QS<8^!R[VH.@O'3W)6D(AH"N8K6;U])[FS;,@
M9Y4&INEI-;L[LII$O<HQK*\^M!]DU;.;?.3/G VK>ER>0ESVXK?NG;K:="PZ
M'+G:&+TOF,Z]N3B@MYRD+Z5UA54Q>C]U\E;BJ=\<C WGD:F3%B=IO?>3T@,$
MG'C86>ZLL%CII&$Q-X7>%%3:3>QF+=MX+HDN-Q>C4^B5!;)_#+ :])8P#AX(
MDH$28?A6O.AC2JHT";>)'$["D0'+M)XI)G0JCH4@K2>HD>EP( $?V)Q(+LKH
MA?&U?YM,GAE6@03X@EL\=MO='@CKI[TNNVW+N_9T!XT)V\%=")2X$E-3)\!-
MF<FVNPJ*EMQ^A*= E>,"< %)T+A^!FLIZ-5%7.\VB!G.\VU=GOFRHG"G^ZHC
M6QR:(]I'PY$KH[U5BRHQ;.!!0=9ID2!^A7>B^B[V+#R\<?V7=/#><N<\O60\
M;41<-"P?]]S_Y</"9BW5PEXN^5RF-J,KH<HJ_@LQIIUAGS^AID350WDF+,H#
M!Y,XBXE"1*'.'HB;)RQDY"KI9$6:(^M4]\0K)'I]>1W:NR4?M)G5U;#=E;1B
MHP"IA?+/L765TJ<ZKKBM%'A5!99[ARLO& 4(W9];-@_&L.9BIHK3P\IYK:I)
M+^R N\! \'4OMBV7^MHV-5#G8UEE2&<1=(8OA@MN=.,:D.5@98?'=I\W52=.
M*^Y#39ZO?BU+(Q\X;6"MAAQ.EKJ\+^@0("QD1@RVZV[TNKX]%YA]:51X*##F
M,$?GCGIA:&012N#+%S[]O #!H7[@YR&X?PEP;W_R2[4.R1[A&NHSWKK3=>)6
MLOVAQI)0*PG*2H?3OD7!'4];\9OO=P,63NK8M0AXP_?XR6EP9.0,OUR+W_<9
MTO#Q*-SCUTZN)9!H6_.)HI\$FXR($<,UV7<5UK<<BO?0&],RV<M:_)\T@3^\
MXB^>2D/AKF9(P),I). 8-WTW_\F?6^8_%_J.E=3PKFFWBB+6;&='E\$\[U/"
MU'?NA!RIOG^BV7=<)>H7 TB=Q3WA4-A<VUXEW=9ZPHE[VZCLJYM;]I=*?0[O
M[X5!HK,-#YGVU".%"SVN-@S[N+CN;XZ+;2I<D[T>>)^_]=:G-6'JZ?'[:]I/
MEDE[Y$57?=ITTYQ!:C@]:7D;D-KF7 $%4QJ7G&4=CK?-42.EO9AP=2NZ$FE:
M'$JCMJ-%'LWI]_LE*+',(,-;X1'Q <9$\<8>(V-Z/L_:GD2+9%]A6WK,EZ],
MMTO->@OPR$33LE>EZ^I:4GW6S.[<_@IL(5H6Q,PL^]AG]K7,=4+N,PO^:(@Z
MG#7$]$IAK@D'GD*^:(@92?[(B_>.7!U.M^.1@!.3O=7<ZPI5 VQVK*_U72JT
M#N_33G=*9CLZ2 VYUJP+739_#+&*LP92J&[A,#.>V%_I-1N_ <2W>[VNU_#X
MH#?6U]<>*N3%N9"!0K4M\P2S+%?M'C;SV6MBW?IO=OEO#Z4]&1[5 +>8&J,]
MPM"[0H$'8"&W=1-TDV>3T92*WR<J%O _C'!QMR/*2596D1DJDX^U5#(,A8L5
MNO&UE O6%D=%W>*<(Y\]J:^6ET;?S+3%9<T.H3TI$-&5#=L6LM^Y5?#PPQ#-
MF&&J<W-JJH;)_J1!/]NM,C^!T5N+6-G+HE0]NR(M<GU3Q8;'':_;X*9J4)VN
MJ)&11A>R+G>_"-BUQ?K!P:-RQ_"UU8S#C06W3&N98X."0G$O74S8V#?F8]Y=
MHY8D+/X3UF&+2OKI$YF#];<Q<H4EY&WV\@I#@SG#2Q3R\26LQNFC]27 52\&
M]!/)&9-X=HHBEPIG(YD/;*0Q6ELG+HW.:EUUZUR/H=]YJSI,ND,J*Q0$LL'3
MA7Y-B!MO=<A[11MC<0,37SK K70"XS$V"^Y"N85$"MRF5'A2G9*,8WR\-"8T
M&G@* *1\6CXMCYV5CSIY-M.'MF@_A8_OPPGHP317^X4Y9H!K4CD&%<$#[^$1
MY-@6&)"];%R9!,GPJ<XU^^;18^F[8_+$A%R4%8C(Y1%#7UMM&F:]CWV)G@;:
M!6:ZU2*$1>K%F[I^=YOJZU)&D\88VE0)R-U$(SGS,7+SEH-ZPQWZ]+[P6)+5
MN^.$'3XI] $N VQ7)_(<)R $XQ-+TM.Z=XJ A>Q]1IP^ZW$N2 !XKV9-FWOY
MT6/>>Y0DVDEH98JBD2J/-].\D\<H@X"R)5YZS7LZDMWQD;(DU&N[-6E5C4LB
M502$DKUK1<# B5O'9I4V_DEXV72M&*^H62Q\%5/3H:Y*II>',6SP,P0)Y)R)
M*202S#(5,AJ,K^G(<]ZM=?W*OWJ((RM"*]^7E\?^<FW&U]3[G386;H+S5PT?
MIM+#.P<D%'+<\&%G*%.>BN5?N ==PI8!/^C]Y<1$X<S76TVVQ0$/$BPY<4>Q
MA@\QQXG_I$[C[B:W51)7/.>M+869FI*HJ%B8J)B4JM::EZ5:]DH2>KE)_I-A
MXD)H,FL_Z+>/'3Q%K9S2"G3H<CQM@F9H>E;2\BDY+]%^2LIGHC28F=D83X;9
M*!'C%/+6NGQTM^6X%8ZF3TP+\OBF0?!PN>N(4@AX+>NW/[A:7$P)W-V-W8$$
M%%YJ^0>A"-\ ?41T,]+P%Z-XD3C"H-*NBZ$J"\6%]+RX=*^3BQ-'SG,],!YN
MND.=R?@,JM%[75I<)?8Y#E-*YD_N<X/! P<LPW1)DN3^/?J)#^GHT.6&P7WE
MZR &$1/Q!R4Q/EH.Z0'8N2Z.SH6Q"VZ/1YZO\Z?U%GHE&78:ZA0QO:QC8.7E
MSVCKQ%@(JW0>B!M.4D?5G6?UT](A]>POB00GK>+0+_79:M)Y#X!^SQZU"]:T
MFO.LP@A]FNQX?8\[(O]@=,68Q8/E18;)B[Q*QF;&3_K47I%M=>M*[=N;XE*!
MG@0V%46/6*,$1$R'\X54GO5HOZ$IW"/^\L8V_Q:T,H\!Q3CM;N*.!"K%L'@$
M91;NIX$2M,'B-YE23P?"=H<84#C=&RN__C@C6+Y(WZ2@?TG.I>QE;O+]=_S$
MPY?7)>19^(1!13I)@=Q<DF[Z6RS$,&VG:3:9SN]SC&8IKZ8DTA.Z=X^&8F)"
MC_KMMO:J&3K?*(F3>)QJ[M"J$T_B@7.__2XKGK@].!:&M/K]T'UE2B]AY_6(
MDP!((F<T1/NF1UOELK7-E8XC8[]P[!#.KI]JN33<>U#/@PKYA"+<5XPK4RRB
M[<P'?A["5QN9. .99@6:1-^ABO>PB"T)K/[$EGU1K<7S)RKQK)C@=/V4D=C8
MU5=>5+,N<7@#Y3L;@;K;MY& 4=M<ICIY$XY,DCOM9/00Q/5\/$BWP2CB*/E7
M,5]XTZ]^G59GLRH^U<;*^O/CE(\/.8=(4(/'T11# A*R:XZ70(\SIY/&M.)]
M6>QBRJ664;*8X&;+"999S486\%=Q 3@M:T2[L^> !+CAG"]KE>HN0"P/L^TE
M%5#G[I O<(D+Q2;<E,[?@#C/-ZATX:;=!V%X@,UCWOJK9<A&5G(J;*@AE&WB
M1!UCW'J-#U!&9=.BFP]N1@)\V!(A70.3)[LLJ7YUX]?L2G?8+:JEA\DL<6N7
M0Y0V)!G(#A/&J 8JZ N0@%>K#;2[Y*AM6IUQ_B8[^EPU3.?+\_5( ->Q=TS)
M"ULD8/.]HQ["FW?R8(#V5]&&=C.UD/#P",6?JWW.EZG.YL%&?2TXX5]^BCP]
M!'&Q)Q( !$$.NI//E]_BPKN^$YB,A_8A ?5VTR%'>*.0257(/XIJ'9#ZJ&[@
MXLH&XHCX7-%Z&O+NI*Y3LT 0 I.O1$WQ@UB+XY60<^6R$)CR"#;\Y-3%Z.'Y
M<K 6QPZP5.#O_&C_X7(1L*SI0$PMY Y3 ^&,.C=0"--9<K(G>:ZLU0)G-D-'
MN)_Z0'V0/%]F__W3IO__G_9O_+2J("!6X0TS@TAS\VW_#M%GWY3:?O^\&]Q5
M$-E!\(-TG29+O7DOJIG"["8$%A+0LI"-!&CU'0X5JFM 92(E,8QES"V547*.
M.I;GWV-+2SSO&D :]4:Y5YQ 3!: );VL3>Q.L'534<(G0P]1-0IGC0_HL,X.
MSK)F74ZX8H($$%<^2!Q9V>\SRC>U3'_>D:H)"/TJ&CG^L")]=$%6TELZ:87"
M-M&$U&8D/HLA,&TCS7E@7'11NL]N57;\8>,D^+?IE&+"$G=!F[U\65CZ!]B!
M4I]>_UYQGT]0] *K)!TSL-'!6LYQBRC2LC9J!&==9'4T^?*05ZQ[L> S]5UM
M(=?A-0=:,O@5X-$&IODL[<IL/N-6<7ZR:3R=:2>A+*+S,V?6X0U:1SMA=9VF
MEUY62K(OE^Z#T,HXG[@:FZ)'L2@HIS$7 8<7]"<^28$^8_)GO'LB3RXE.DLR
M*\.KCY\$U3)(&KK$U"3T+(4.6B(CK?U!RXRX4%4#XU1YBQMS2GB8.64?-#-[
M[NN>4Z& *"]8"]#^O9,X^H+N""Y"TL7B:%=WP;0E-M<%>_VRU>SO]T'./(;'
MT9*MD177H#+@&7U,-N*(4UT.!G'$F0(^$2V"4]'2*IZ9*='X--4@!AOY#T6/
M&D,MESBQDCUJ843277#1^ M?A.[&OT_OH=JONC88L=C&ZI,7<&"EQ&40[D \
MLI(+M2-YE?Q,7$I0U70P)=UO9.;Y#+2G^T5?TE".+B@HI2]*G^]RE8QAJ$Z=
MF=.FA-7.<"?A\302T%P2=V@OY[\Y=659MK=\@TQV^OJ,M3 /QFI:UO1KSINC
M S:M)&T"VHL6C[?4KNA^,"?U>M\:\T[!1-_R.6WE[3MG&FFFU$2 7;Y:$0Q[
M9K1"RIP^5GZ8A37/0*".G#K[2PMXK \N/L-3ZHN+#X;+K-$'73.8BP>@Q<A5
M87=/;.DVX#O4V;\9-\DW>/INGU6<7?Y[U67LK3R-6J4(-$IZ89!F!LQTAJ9T
MBS=;+UN'^Y$)>9U9\LBG[W"AK&65'+)BKM&.!I8"9O(C4,W;C&P;;M7G*RZ9
MVN^BAP<@Z&HI,[E2'8[/I:ELU%+S5<B(,[7J-EZHF^@+9!9M\V@/)Z(8U9G!
MX#+K"NWP+.(WH82C8XMY70Y0/_!S"]S?X4S/D>JY6J@D+H7Y A;%R>&7UUUG
MS'\3XN#$T!J[0.NXCP10J1>]@$6S.EIO"CX17"?7G/57Z!#=0@*$_^'A=,,'
MB]@UV4>8,/7?N#AE<%B8%:XRY[,O:)A-/]R6:O%!S\Q<;:UF,AVB*/'/J:36
MT[-S,_<Q+Y):]^M0R4IS0>_OQLXTCHG,RT]_ -&_&39B-TZY3F^Y5Y=MU^DH
MV^3LX'\SIG=DQ)0REDJ2+6*Y:.;&;(A,VQ9C4Q!N T5_N?9ZU7'7#<Q 15(=
MMR5T[%F+HRYL).";-C#5N=-U8PM]AC=DEG4#;W2Y>T)B_RA&:L%1!NT^-LDN
MOP#@J!NMYZ>Y '1IRXL/@B&@=I?TQ5VQ)=::M$IC%N)0DOX]=7*LPE11Z4Q[
M!JN%UP'MKKSJ"H#E9Q&9W^0OM]AH:]_*2O)1PTE.1 <H]W_5ZK7^3J3U2>H?
M:3T_V]KAE)0JEE6\V2)_?&KWW "KQ2;/FGU'H3ZMM>WX^NH)?R(^RW_'32O?
M#0F@.TXXFIML'8">N^G3#%AS1 )J)V'P <AJ#$1P'[H%\:S9.LQ" H:X$7;K
M) /!""'.!@C^:3B/[_3_R!D1*QN#0TQ%,=$G_&R&FN;&U,>![XF^P#**MNV0
M^H\FI@+/H=M7&.6V;D._UDPH.M%&*MNCIPP(V\W07AUI,<Y>L=$:;1[UXJSM
MJLDU?"0H>;^Z%H0=.)0[XBH&D[[9U.(=*#J#"9DS#42M3G_AF]DKI.W3<E1/
MQ *.AZ%K]Z^/FDO-#E958O% L&0EB,*]Y:C>TCQKFQ41-U4022E73G_[3O+1
MDVO1C0GE DIC!VF9+ZEHXH9RU45[&#HSGFL3.-Y.N%\"*=T;YYJ53T@S&ARQ
MALD,M7NB/27RWFC-4VF9O+HFK)O:8&HVO<1]&/;L9HRPON_E%O2)LMC+9N8I
M4GFIO$O;645UY!K]\=+4JT.C=4!L\.4(6%P 6E#7?D*EU="-F<J[YC2!/%X.
MQQU46B^/N&I7Q-%)AES%NETY/TR,,/KRA&<^8B&-B,)N%YBR9 U5T?IFE IT
MC-JE[7WCJ6Q.R3OE9DSB< ]C=FPH;=8NDW>PU3\C+3)3ID\J#QQQ71/M!7]2
M&N<\GZJXE18)4^F*Q@BS40Z *27I3==GT7,.K*63Y\3P3**+DO:0R+EL%J!'
M8K3W$-TM"-98%'>1?PWO=,)TWE@G1!T4X_DGSAP[/',2Q0N5BJ]2B2.24DY5
MK/=24E-2Z,[#0FI*DN=K\3O$E\%,29X^=]CNH/U8+9W$OL3*6ZCU%J'<C?8'
M8ZZ.^!_E9[R_TQE514JPMYOG(VK[UUKOI<]$%W%B&_'/5%$):KT2"DIZT\WZ
M8N^CG[)R+T7F[5<2_2,V*J8=62<SW1%*XL\YC5)2T]"@1<_L>().JN8KS&*N
MD&IT)3.WGHB;.^(V%-,P;_T&UDG-</,:GK7GFI>X3(Z^,!NS+P09/FBPF<Z%
MJ]APE%\>/53KB]#C<+30"_D,&YJ5\IBTLN $3OJK\_E7/IGA(%[EW9F<Z_*D
M(OJM5,?ETHH)M<JC3[VN#^S2FC)2YQ0-S>KQL^;L%_O2)%/5>BJ5W!)-%4TL
M)?&ZS.4;W_,Q';D<#_7VI,JQFUB"2CY\6V8ACM0L/-)L=]FG=IN:O/:MV-Q6
M=L*IU3]A7JMS3+F.59Q;@=@[2S"2?I-G'7L?.HABI&](_$[@SMM=-V#Q%F2P
MJ$5P_(B0L:$J%G\ "V^&#A(@L]@X8T4@7/3\;<=43T5R@HD9<TH^CH*R5UA4
MV.=+1DEA'I=T%1%=M-NWM'XXKQRZ@OII/[>(8OR0^%6C:2I.30OJ"@'O5!K>
M!FX_:?X@H;/G\)OHLP._PT62W"<Z=R(>3*^6X7<6?;P$<;,A>T<!;\@ZV#T:
M^.&O'J&[HA()9#JN N*XW:>/5IRC^NF1QWRE]O9^:I*'L(,BK"9#\H,I2'WP
MWI69?O>&I[@ORKY>>::-W1!"MEH^L)^=Y!@UR&2GS9_,^?J#^C)L*&%2$\Y2
MN+4VDG-TTBN-WQ,E2WLWNG+*243$M IFB2"N'(0_R(1!U!(4RRLC7Y1R,6/Q
MK"6+2((!N^#3];RC^2D+QC6#E9\KF32V4FZ>3_7$18Q"BAKKW@/$=9U(<8"E
M*.&G 3O:&R;QK/W<BWVWRGS8UM=3Z3OT=6>>"E)\UQF<4!^_323D7(!F F9"
M;ZWF'FW J[[*^8CB>G::?09-Y&K1OU9/7+J"<^4V0.#V?A9DE,+P!,,,>!JU
M$J117@+=[C4U?FNK<C.HV>J-!+YC?B/'J^IKFP>>12(J"D6ELAGTXY0\#?>P
M17T]1 )-CDSOJ?6S76$$7'F;,)@'"H.!IC:\\W;QZ55BOL[GO? 2B#Y)_:@)
MV#T:RLEZI9AU#U";B/G['L\9I_(J*:5# E+;NC_M[B'BU",-C?'++-S-OE6\
M@>3M</:%6!RX*&(%_;NTY']V@:I1*]*MZ\3:8LZDZ=R-<6[COC!DR@+N;E*S
MUPE\[R+N6'/^\%MI@5!'3]?XHL[CO$>6?Z4BO;&%ZC[TEYG5YC36P%=8RFHF
M2/?WJ )N_003&0?^I(R79C<R242,1R53;5OPF5E#K:F49])8JC)YH1"U-UI0
M:/C39'W9!CG,UJ5T8N[HG/<";-V-J<G$D?2D<>D8*LPVJBF##7=S(NF>0=/P
M;2>N]-OBXKO*S6CR5GS<CG:2N>]@Y0U?_=9@P";1U_]5:7"IV3KQ3:#,<:^@
M/CK :J*JG/ JG"S2ACWTMF1W8\LAQ7:GC5+/X@ *)S_E/*9P#?(G&KTCF3\+
M%I;-3&>5*$PFYTU9LT$\89'G)R$ZE'O9G(W[R')_ISC^:S;7)8]OPAYNIL.W
M8<93(=2.S@*NY.Y10YMI,E*'!J+!Z:%[).T!$<\C<A[/)!VJE$TE]I48% H_
MF*X"U9>_Z]MS4?=R-=>*\]-5=(%VH,B2SNHCAJ#+=VF6<Y,]W[0+>]U1_C:W
MVU7DW'J2P &>8$0"7OFV=.AC]F'CN%WJXIF]Z=_"\]+$85J,;(B.P+O38BOW
MSI5.EX*2UK(O;$LYMC1\F]2+GM_9DBHJ2DJ/'T8]NO(5P+]0QE:67= N,B8A
M_5WGH;<G?1@$;T"<CD9"@EESO+#HZ=1 ?K_/6^(OW="V!2]I4.2#<-#,)B@@
M[^YLI?>C:A<G"65Q_VF_(J>BY2:AQIZ^N&O6FFM/E2FJ("DF@D_0$,TSHU:U
M.WJLX>LQ2:81WO]&80WXKSF$WLS7N>@0ZIO[$L!L(RU[ML8;4:ORZA^<6/"8
MC9D2,5-2B17I4LZK+5.3/ /^(U-U=,C_B;?FZ[.S$G2J:(X4.XVWP+3%B:>D
MK'@UB9_3FV95=C4TH3YQ71L)\')G-1'%Z0E^:Y8.UJKOXVY*I>650J=-13,D
M'7%;8]+1E.[!5C=J)?;1:*2D99JI FG!UEUREO@$K8WL[;?E8_%J7 ![M;<J
M"[7:]O4(W)5M D')C]ZU/&MXJ\;8[=&+8Y72;)HT_M@G+5Q&@CG0Q$3^RY1O
M?&&$,N@MH[T&2OZA(RZ,* 1,]^9JZFC52D9:<>N=^-W*VD^_F1?'5=A"K\RX
M0S!$YSVVG]M)6[^]>C2?]L[0[K+QH:%]?2*UC5:_0DF<0<J3\=N3E/=YK7'B
MGE=G;1OS5^"KA7RV"JO8^+:/&S)\M(L^!_-M@\U:A^JHS-00C#FJ-))1B/3W
MR''?E'8,5OVNV'#8SY&U@H$$M.QUG9Q8;.4<+H0YX86U]@JL?+66<RSM,JD)
M8(7GZ%/:WN2.H&!MU3_E05*XTJ=.]7_0A9_Y384<7OU^YC?%<*8)IR.)G'E2
MW36]VN8^0)TW0%L=1LNCLD -JC(9! 4P' /]\N\</XZJ4'4_XG<=O.CPR61-
MH&J-Q:60=NK$'AY)%?HCB6IB')K" S$:UFS'Q6F[ZFPGS$4_O!)FUKNY^U3?
MGSH);"C#KSX3S9UQJ0+*N8@0& _DDHK745N7[3;9E",!@47KC[3"CN4*/A9U
M3P^0-L75ITEK6F+$07<GT6!9.ZI#E0\234@5P6/&-OBO ?71H^FS8M0#YR"=
M1FZKY,30&PE88T_HK3*HC+T@N_WP/TV PBUFLH$T'+YP@=1A'8'BZPOV=,<'
M&9"2:G9(]R?4HIV<17"CZ!TC$>V)UVI_!GK[A3_Q=*)D(1 LU&HJ2(;-\$%?
M[NY^R$%OT\V[R2*^IF/F"RXN @O!I.]F@]X]U\D3^XH]6 EJ%KVWI0!U984D
M,WKL25',\P;<>,'!?<FBH7RRZ48E7UIJB!]W&YOZ,(;\]ILG5G7"1^H)^P=-
M74>DW G'<$AS)LRA)9ZAS[:*2R:\%OSAJB05/L>#9BS3(=4H\><X85S>(Q["
M%<<N,XLGN!0*)PC@K+HK^:S%=9-XGLK-#?_"42%IL_57DZ7/%1B#TZH8*DLD
MD8!PKT'4)%$E="AB9YZYU]J_D=;L^,1?_L:Z=C8]U6C0/O3 XCYD?D5^Q4T$
MF/_?=,)7VZB9H[5! K1B#RD^G;\QM1()H851HB36F/P3&X5%G1X=CDT^!)!'
M]V@AX6M54OFGR18#?HOIQ"0HZYNQOPK<\Q66OABXM_@C<"_\?. >MP&%TF 8
MM+3B'D-2J+PXFW./<?-2AU+@3J]O\VS@;+%14@*3KBPFL94X6!N#VHC5VXOY
MD%(,/0$<-3&X@%AF6_\0YA) 0,I-;G"$8Q[_5J^'1 9J_$@;&WZS&M5 (@$*
M@]TI/M_Y6%X2(Y5'%T9^=3JTWPN(,Q_)8LW.W#9,?+GICL9P3$ XB<]C[JG\
M;A"Y;,Q#ICPS7V%1%K&9Q*1RYIET?(R!+@A,_$Z^?S6%*8(RZD:\HW<YEE9X
MF2,P.I^@N*:ZIXA6\,N*IFFTAN?MQZI>^!:.V"U\-!B#C/UT)62B+QF S+$F
MX=]B%C:^5X]G:&D?2I.]IY?^),@N;\G"^*2MNN.N]A!<,LLQ0?G8/=]VB(P2
M#8O^!OK(YT<J3!FOQG2\/]WC7NNGZ_<82I7X'-;M&UPR7=7I4Q-2F)Q9'S;2
MQA'53M>*Z7OI5K$HEZ/U4$.UX(N/Q<$CO0N8[^A#$D4H]T@6]W>J<OM!1%32
MU_U4OA.(.V,W(@$TR]7\B#876>GDTB*_%[VM$C?B++&'@.]5:HKDS/H%J:CX
MK#7SVP+G:-RR>]81PK#ZD1%^DI>7@QYZS^EY[O(L,,3*I#*)],BGI(19Z&5O
MI3>Z6;3P#A8?%8QB%-G;;NN-6$L00%AF0V1"FR1U],&NP0V2PY _<S=3!_R5
M-;@="2@$PD/L:_86:CJ&W@SENW<C =LB(RAQXX?[M&HQ2O!,3;N$$CQ_*$;/
M>=FQW?D1^'')^$>(" J3E#WDN/, 6'(W%E(TVE9EGN=%3[,4V?IT^&>DD]R*
MU9!A9^\X"YW\#T[=O\VNJ]2+VCE/47V,)@2_417KAWX3R(.+B)M>[?Z^F[C^
MU"K.N9=+/R"%39M=VISRI0,M <\&CI'.39>-:\O;8^R]-UD\>^]+WOZP HET
MUEX,<<>;##.WU9X[TM [I#B<*[HWE*#=5$4.,AN/*N(K"E>O="%A->@K\Y1J
MOFXUPKG;I)H$7?PAOZ.%Q3%1D!4)./<9+PGD!0I6>HE'^XJ+JA'%&<;O45@*
M*HM:Q1S9@<)"(WVY[#*NI//<&^IZGBW0KMQ;< W*S!H0")8YB\!11(,>>>^C
M4#F48!%1/7H(:M_;PU[;0@)N49^Y7Z74[HTP):6@%51*,GLW'%CCQF:;?8"X
MF-(<DBW0VKD@ ;ZFZ@5PB;48S-&[):'WE/P*M']W'?[I(]SXXXS[6 <$N]WG
MV)-NIXVP'C]+UJC&V+][_.0QB&RPNRTP(DQ-Y?"Z^JK/EF2]!1ZL!!P.&B"=
M&RMGX0Q63L:YQY](*+#EU[ NOB?DMUD3L%NSMIK]R7$P?)SE4-G[?>U.O&EW
M-87C$UNF(MS5<0-\$+C&ZL[89NL-CJ0M'9<I5#<GL+?,DW,UF])-.!^E:]U0
MUK.V8@#FVM%>,;.E9FVL9NK9S<;-EEZ;5WVCP+Z]^I6P1""14.._Z!I&R!:.
MD+\%/,8<R@1%M?TZ!?^A=LEGZT'1S:FBFF-LQAV2%;7Y<B \CK0$"7@ZAWCN
M(2+SPY4LDJ7D'4AK7$IB:8"K+S0X>6S;5.*7ZG(SUJ8O 9(+,/ZS<(]_=ZFY
M;!QBGP:O," D<L[?Q(PIZ+5<-&"!7L/QD8"03A"B+'TGWR@OQV%K.)@29H3:
MN7-\?TM\ZCMQ!J-.Q19TJ*-)<.!@_ZH,Q96DE[W]#_S3L?-:9_38VJQHQ?DL
MN8L*8EQP&K(5&LK7NWR+CN6>]RCEL6D4L 9FMM(GU ZJRY%G+\II2!:!W7N<
M&QV/U4-,.8Z#U2L/&MVY^EU5\L=,WK+X]Z)E4G!<CH]' L Q+=-O ^U8<5U6
MY0B<S/+HKXG3Z3<PDV/G/LAV)&MRIRX\-DA.'M/47#1^ZY68H$7#&L_YP<%4
M:R126B4F0CO8EFC'4$"$.5#$>(/R$0/5T[V%(FY0#VTCJ:'FSFQO':W1-M;"
M4V!S.;5XNUGC=')UD.V];\]C=79$DS?9S8O#6II%I5)(YFE0<LJK%XX^-=/7
MN:BYVK6<RKXB3DQ;,_JBH+7!-L3*O>I/B965Q'R2PJ  L.5+%6:3:3ZRQ&O>
MLC'^%(X\H_(EO'.%0MQ5XGS<\\]9/\C,4)RPT/>FN)MP:=UXNT$:4H#X,]5B
MWKV_,'+-(P&GH?$5/T/C38=JSDM,66(H9J]R \7N(P#G?8I^7EC$2K)BKWXL
M!/!3P(O^I>BTQG<"V71X-CJ#NM[EBP;6;Q]$)Z?BW7-,V=#>&+=?D0J^1,U2
M1O(B3LU^5<= ],KQN.QK2FE9:1W9NZQ#$$.+0]J\FM4F)&#W3C[]C2Z>U83/
M-?"0@Y\&L/Z/HA_^/$M')GK2!0&*QSW#-&$;T ]<'5$XP>C&KE<XQ?3"Q5-\
M'TDD16V^YZ=[I-  *F/\#=L\62"M1W6AZ1D*[-.F_G%4)85%**)7J,6^P!L;
ML%)_VBJ0+WD)8SY3;CBFU_C+7;EZ!?+1 :Y.!]&KL(?5S-U8F59YHT_>72%J
M>M."7F'3Y#3JM_T:;WU)3LPPBO-59+\S*Y'. D/<>TH)78_5KP2R4;Q]&SLB
ME$T)6"F;"YX.V6DUAC;4!5A&;WW-Q683G+>35=IMA+QRN0/3,]BELO9V2*XK
MJ(LI34!E6G]&5"IRFJX0GC<Z#9WJ^'XW.H43_3 ZZ<."GE0"[8DXM*&!;*&-
M+0MG01TFZJ" 6UR.[M\Y+>PL-3B^Y]X>9G5M^%YBL?D3RXW%$9FB!^.T+OFS
M*-F%$P>/:#OXQK9HX8^L8827^VW'7>H0C /LKI0S^#=S+>8Y>(HZ5O 4)KVU
M(?4)!.QA,?')3MFC)N#!#W1ARU-O[CWX!N++ANE-]8\4K<7X?KJFPYUCJ%O\
M1FVGBQ8LBL7^SF*&D&3$Z/@[-VQ>X?,$+\0Q;HH"L/_E'/8(7Q13_A A]\.?
M:!@X-T./>J3M'.GT,F';B@CU-GN5S"_CS?8X+4(>5Q/UBC6$4R=51S,9"6BK
M,X7L$R@L,*'W9YQ&$@M)W=#LB@@<;W5Z6+:\.K0*YGF7;#;L4HCBKK+A0GQ[
MLWG?D0!Y$29T^7_X!;.&;OE!BVH(QT:;4AW!.QK25S^WHP.N+GXX2"0HAV[M
MP9IFL 9II771=*D?T%_CJ7FWXR.R%1PYY@AL+&_Q)YU;J:8H[X'GO.3Z>.OQ
MD1L3>L9_DH@LZV!RFQ EM^;)P8,TSM_PE,:WA%Q ]'RR"V*$ML;&[&<JOLUN
ME/S>:OXW1T#<*$2A&:YL>1@TE:'XZOINQ7*$.K1P2/'3B#&$&*Z; M8< 9M>
M8RNJ?,Z?I(^I)E9+W'45+KW%!S6[53C <5!':3Y,@8'GMC58NL*<E75@1!J3
M--_9IRU%\R@\4,VZ/KF31&?B2QN)@(RU=7C%\_ 89BX)4VS6JM^PH,PL8C_!
MZ8QOLAL_2.N1$[I$9Z(]0&.4FZR=^''&1BX)^L7:VH'\WSD'O/GKX,'S&48H
M]C;.PZC)&TSF9L<48@JL\Q&S__(2D)"[HW -I$[JG<WMP_A"!$ ,7XB1)$ZT
MTI7$F/W.AN>QF_8\WCA%M1_4?]4OQK.\O[,WD6=N5K^ _=:I>61[^"_]'(ON
M_A_%#/_00MF<10XKXHK?P?+\0V+AT_#N']'<,LS,X@#GXMA-QD9P?*RI"_Z>
M1_#,G7>J9:UXE\CA*V\#JLE,)G +H <J945&VOLAS-O#1S1)I15F$(VB$;8]
MH=+Z0$!!J*?*^*IS?)8>HK>ZM)SHI.ZN3_$):W_[LKR*NC.^0A3HA8/0F_5K
MK*PV/LNJ8_VY73)>CW2^,XZEZPETQ3O0F>B+9$9N%^E6*E^#,N5@_4/@N.#?
MF#V_<N1WC@<K/W5>)U92OO1$Y[;?.@U-Q>NUSZ?NCM$&V^_/4N[EZCM&T18Z
M.F]S%.0.SO_*Z?/+W?&>!+&EO-4/G-3#X?_ZP]W1Z_YE[DM3HO2#[B2CCL'[
MWV!@-YGU.Q:%LFAA?(OQB*().,<07"1S9.()#"(6*^6+EK-ZV\4A?%)D]2NW
MM@MH4R&@\N$;1_851._*5DKP(Z(Q 1$" 9*5>/0ML\6 D4UM1VLWVC;<PB^E
M.UPP16SC'SOV&N!VW"4Q3!*2J@XRI<.H'4D60\KDIPU ']G_2.MS#C,KBQ4.
M^?U1;Y/II/[ZXD[F(2BRBXG:]M\$4.*V\@6:2WQI1?4T5/1]"J=^93MI4[_W
M.]S9=*K=(_4@0Z/U,@OWI]\JWEB.?NH+L4@%&/6<"QB<+Z[9MD*1X_TKP:<M
M#R'D40P<4<<YE/G_E KEOY;[Z%Y2U%MB0'3GC51B"OM+9ZBDK"2%F106=:9!
MIOL37#\-=_8XYCJG[,X.NI@.*?0OTN1=VD8"?C<2.^7O\,SQK$Z>%]<'Z$X3
MC)QNY<=_FD9?=@+ZO?+2)J*OV?[M9RW3XB-3S=:,;'915R]K@?U$ FHR-O7:
MVB87_*%:4U,109=/,^TBH3>M.VHX:$IYYCG!])590T0>[QKL7SJ#*M[*$'F;
M6DG$9<E&W9'HFI;VPC+JXD\WJ)+:;BM^SF S$F/$W6M*$5X\>V,1^JIO;.=Q
M/CJ)2KQ!Z ,4.=32_]]+TW+)&)_MSEGR"N+>BY&!9S".PC^VRR\R04]57]!C
M?%I65<X;;?OHK;.@3;J/><=-.JTHBJGA_CWL#RU@WUF%*@\#4R'_EF.K>XCG
M);LAUXK?90]/:(](9CQX>=Q46<DL4L.R%U!CY,:BCP;!D^7X+//*/:F<<R?[
M1FH[)'J510L)*#>?,.QB&XS5!H8(RQK.=%UOR])8KJ\G"P*UW5C!9@P6R'M>
M[6X^AUI*ZO_(^',:4/5+HL]_FWW>+4GY3,!_@XG",R*KZ=72H-RJ;GW=L;'V
M^>;)>ROC52CQWO7Q:T8_"Z(/A=$DM!65;J&TT6ZSHW"KGZEDK? >>@.>20+F
M<,XRBS[[F74I)3$Q#B\>Q0O1626W2$/SB[I[-^C+> N<5%YVM4[X%IG6/]WL
M:D0""!P3GM1TT_=]**HI-1;.I):)=^07P7=F]$S9:B]:A#,P&R1B'@.'/6BU
M9CR$SEQS9N!V65IC(NFO=@-P5L 9HB]>(P'L^[,;9;M=#S:T4YW&A[S@3[!?
M%YFY2&_A!S(<FWC:&+TPFE6J1X_'!-!BF^E]VBQ:3Q$/M#2Y+I$:+'\IST]U
M:\/'5O;@4W]1NZQI2IU1BEYH0GT9H?=@S!KO2-S;DOWM8;<"_7LYF)J=X^V&
MW4<@PTQ'Q@;!IE6=%4&VU,YV#XHGUV]W8T>ZJFSY^;E*VDQK%+KIC&Q+V:DZ
MD=Z25FN=&RI'?W,YGP"6.RV'+5:VF5*N'FEFM+V2D=?#CHL7C._B/_7\!YL]
M!Z\ZFHSPN-\@^[CYRK_BS"XJH$&9H*@E)&#;$CQYXAU^" 7LG4W0U]XKK$ZE
MGY  F7#R4-VSV+/0TW@T--(=NI#=3,&D_/1TW<P%#VXC%**U;S%D'='Z%E$K
M\T>!"CU35?4\&@E>#45^<U7=VD]_AK^7X&666O+.06)F:MK'F;&1\)!QY.#$
M21J>[0]S0>'/,0I_\I_!.U75.K)5+4&_038_N=-#N@,LD !/K!"81@U1S=)O
M*!"O]=:6(W'U7SSJJ*"1Q'X-?UI#:EXDOEDIERT";1[4L:I/7!K.ZT*0<C1:
M'!&Q(0&;=(-R)?"WE%W'6/G;>8@P+Q:UN1SKR?.U9YO0D@B[I'Z3<W&:BC7*
MG=;^NC UA;.6_0Z&XFRWD8 G*&3$/NRS?!A\2R[%6<'/3G(0+O0LL^U:XX%B
MC@_Q'+-(MGS9Y"5(JP^*Q \E05B6LND__KO,=RQ5!W#O[Y#5< B]^KFRG#GC
MIUDD !TRNX-"Y#QC^.H(ZQ^<@4'J0K"U%GPX-VH_6E.>ITM_^/T%0%]/=>1F
M30!DSGB@9G5;]P1O:!S[G_0I:1[M25 6#Z8D3S$"XO5*1:]TC7:0 2T^2UZK
M68H_6N],KMN[3[T?'+_$K.='J:72&-^BYQ9KB)&Q(N[344TV?%Y_ZA/RNVT3
M[SP]_L-%]W<FW?LG2DPPPFO>VI7*BSIV/B9!F?W_;-[!KOJ>T_Y'%/JR5_,"
MN056;C/LLIVD334J=C&K#,C&49B4W.">\ KG)\]/#2E](>39&^F)6U$D<:63
MW3@KH$4.O=]8@+N9GWBA-D-C;N@M-/=+;G_**^X()1TA!VX<&:;,?YUEQP'5
M=<3?DV7G@MV6[<Z/\\3S1T*)7Y-_[TP8!<N KUYC>Q*2JBY?9'W[[JO IP1.
M^8E?1GZ3YMV]&L]2Z9O#)Y.S4&YS!4S*<%LB+*(7U-%NHX2JXI<\>X')@MH'
M+N!_YAFSE4(K<)57=;3><2K +7PQ@3H9CQLV(/&E9XFWO#@(M<OBOP+0$-M;
M?(VG_C^0K:9_J !^_W7['^;+S$-)UNZ3TU^WO\F/,<M=J(C= 5Z?R,PS*:$X
M^?[Y/J69U=W9CT]X7XG-AK'VNU.N4@0B.+?,0^PR>#^8&EOFX\W-X8^K@@BW
M9!5@)M7,D7E[KU?9I+_Q]-L3.;VN&/ 3&UB&X-Z%,YI-NR%(ROCNM1[G,82?
MF */]3ZA",?"[SPLQ?C&32+5ZV'$>C%VQ(K8?U#.YC/ 1A&?ZU!,DDQA6>?S
M#W/G+WC-_Z6V_45U+B@!6/NSVVTAA_QL%HBZ-G@3P#GR=/<:&N,668AJG6;1
M$>M2Z%H]Q5CV@<I#G(7OCSH8A'<7)U<G?H#L H(.TB8Z5+/Z16%>2[)A$H6A
MC"<NA NF)3#/4PS502T\9F"D%2TA9"[!*&%O#?@N.[VL,P"FU-L#98W9XO/N
M:RRY^G@D]R0T0&:].-S(PEK$5"7T]D0:&PHC67]@)!) LH@^C1]=RH>N._#;
MG-E]IP1.FG=Y"0TT) IX ?4KH))J>^#L@MRHU;)RGM:A3L<2ZT6D')+3ZFI4
M.&0\ZCJQ!'Z-_1;M*O6]$A.U<$A1NU@G )Z=E.=0J[M]TPBRMY3PI9RE=K?^
MY_SCK8Z[2/>E;UO8L6HZ6;T/DR&>74;!QC3;YL8)5@YDXVB VF9ZPZ=2.B/V
M1%,:.K.4H7+3 ,.S[T/^W4W4=."NQ MM^28XI=XN+N9*&I70_G2#;K$*X!(4
M]<$P4\R@H!PZ0V?_-J ![\A*W911;',P=-J%\7//6N\@MMM:EG2[\PZX__]A
M-?=;<6(U@"*JACN/0&8?I7+V^+.)I(M\7)[(,W!GLS\WR NRY,]Z:\09$R50
M@A.\\CC7;5 T5S!:O0<ZUFE>1"T2POT%_K5"ZVOS$C.S,6O<OTK6^%])WGCI
M+WQ+.1!_,-OI5!T_0HWRP!2U"DSAG4[XRI=<E)5C9)[6_UDX/.K"S-03R6)1
MM(]G-2$1B>OWS$Z:4@F6) YJD3$9T[<TIA"GAQY)^G]@<@GC_$QL(Z<'?186
MK1&SLS(S%1DUSP3MC-$G!D4J)\=6L*%$H@N)()" _PU#'UCF+"UFDL<U*+/1
M):8_HC0FL2+&:W7%+35QF7SH7L'1EG?_NR1#835#X7Z?;2[%3YW&(8W-SC<E
MZ(V9N$&!PV>YW/YA!<J _'(F<:WZX95Y\V=*L:A3YQ)B#U;6Q@)_82&GFV4E
MQ3C)!R5$3J'Y'8+YS@,Y^=<Z]R$$$[+[^07K9UG&1D^SC/TDXTI4]7YT\Y)T
M3RG.7# 7!92^<L:X23^0<J:BH@ SH2].8JSJ$'8+:\Z4NBJPQ>J(S$:4OL>
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M%[7.@+!T>LS(S<W5]\EBS"U.]UZ9?W<3[T.M%OI .S^:BCS*TN@:8=)>:\-
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MZ&GFCE1@^)0=)LG' 5>$0(Y?J^^PKC[72.>].T]D2\7HC^U:X"%R#HIXK0!
MH'4M<I?53-23I#6% W.[/:^']V2$SX8.V:(5)IB_61O52<2OGQ&)50IX4BKI
M<NG=_]0^J>"IJF,C][&BUV#8,9U#3,^H)RHQ=$-I79>LKFH@O:9?14=+F^?
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MX)VGKH7HBL)="XL;F6M,B'.0DO:6HK*EK'= XE+LA7-Q/]]MF Y6F4Z'3-2
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M147:>ZVDI_J0%O%]9;IH;HA_X?;("%R3/KFXEMD &X-O/S7JLM-EX*N*^9O
M06002#O!D(GV_6]7EQA=G <F(0_"^-+&0&<A4V1N;.=%+V5%>Z@Z(6G7#!)-
M,LN[,43.:Z)XV2-$)':!  \A@I] W2,O+_T5&'<C2(89LT^0]QQTB\HF!>V4
MIZE+!8A\PO*><Y# 8/*_:&BP70LH(+%Z!Z,_%!!+96!DQO"9,W3)(L,]SW#>
M=(?#O&V+*D"2I?%=NZW$HU)'KTM[$)*:!]3/FX\6W\]*$*87-!"_7S1#/&MQ
M=K[?H1G.$!5IWGT_$HN(_J'BJXIES+',@9=A</?#%K/,>^%)]-'<:K#BZU56
MCSI<CMXU+THY/9(Z&[3'>M(OLY*]^_C.V>#]IW0RQ1FK46M'W\Q?JCQ5*>^P
M?2C0OW]V9UDI:8X9#[M<TN6^Q]52WJ 'DNF1Y4KQWQ@^[#&8CCWDI9Y17&HS
M)(ZC^H9SVZ'%.YJ&3-+%*/!^1![+TS4*?=\RSH,,S465*Y\JGMN3<@"0CH69
M9M1$Z_1KVNYB55Q_YI"]A'IZCGYYTFS<B\ %%MYKP0E$$"Y1%Z:):"?\YN!V
MK<H&J.-3N^<XQK:S;U\X5- Z/$L-QHSR"'=QHZXNYJ3-;V7H-V=.5F<,<GOA
MM=V^4Y[+0RA@F1><X+;W]:Z C8'=<T78?6%32Q*&3T^D0T=Q*1CE^3)-2O2W
MT85V>+)7X8];YEG::XA5"_9/QTFP)O-[3+,^O#&)[I6_+K/Q^!KKHX?&!OG\
MEZF)93;[^%T,.MQC^.]&$"]&&(;*5E-C*49:ZGLR%93HONC/:$WY#(XFS*B0
MO YOB.<TJ*U^Q2/NP&6Y4B"2G3@E=?][1VN.8:3Y$4_Y#0<*:WU7([J&]==*
M=^,]&*-T,TI"7U9.,NMB45JSRIW6OIVM3)HL%^5LF<IN4N3N.&*O<TN2/'#N
M%%>.?QQ=HE6,'^QLE?K,,_U$,9GI;KZ_X"<9T4A)>VP,PP0\8T;2B\0=11':
MO%_@9OXO,;2%VZ=H"?B_.;W'@GIY4L.T?7OE GKN_0-Z5K$L7U3FO,-6= [2
MW9"/W:%?"[4X!UW5#>@X3N,:8UT-CZOXWC\'>\I (D[?,I]&?TUJCH6%^:-V
MQ(*;=DU8UW=[S3!IE(6'CN1A*]BX&G;-_>V$CT4&*5?2:SF$]')ETIHX8U.?
MS#(R,9AN*-'*R\EH<</:V"]<F2JZ4RTUF%6#/W%3QTO]>:0-_U;!LXJ6<Q!W
M<;A\Z667Z^(/8?=T&'$>#[X%)XI+L*E0=]2R%>8HW)%F//LFX#7T**&P+[<F
MG,%?RMF4B?'#0M0Z+"R(5&F$.GZBSBGQV9<%&K&5YA"K/7F6?&7IRWGWE03M
M[[49\]'O9&>G2-Q:>EG-DP>U8Y'EWFAL@]N%!+#N[^?VR>P]-8H>G:PJIHY"
M]HV/=[L(B%I=[^1,8+FS$/7]7K'$@YIN@MX2^]N-]"'7O)IQ&5.QQP=CZ8><
M^/1W#0?8E(3CGV1=RHDU./U&,MKU?0]F3,J<\9&?MY)KF%.[[G@I4KV%]VES
MF'!F=$&6V65"P4PR?N+8QU*S?<FIB>]TPCIE"0>;*_2QFHJP*5Z$J8.U54@5
M];5C[J7[BC(H"5H+/.*X['TG4MHH1IPADK.:.L8P$DH9%G2?_"YLR<,WTVWA
M??;G1_POB5X.[%A4O;FQ-,4Z_N;-.>A2FTBNBM*B^)+1EI,=@RQI5/L.TZ2D
MO:KWZU+B204\ 0G!HK3MM3 1FP*! ;+R?*3)D7@_\)[$^J75AW>\O<WPRL<-
MM<I+VN<E^1YFY<A1+&E>HGK=;C2O"@ (@4OPWWQ:V:H;5&AQ&/0W88S45/3>
M%2[XZ>/2./')AU^7_(2TWZ%EU7R?W:Y3UQ;>(;RS<9&E:56_'39ES7/+BGKZ
M]\8B_XB-Y:OPPP8=2^'W;V?UWP%  =QE,[P:./CKZ(Q?_[JV%,UU0D61&?G3
M^9\FD%"%:XP;A7H/&.C623THOPO36S[ZLKUDI2Q=PZR38I;U]D#-:15)F9(\
M+NZVH]QZ8Y@X_]TWFY=A(8\H2/G)OK@VR,*QS-S#?0N?19H//VKE">=?QE^Z
MU'M]8\Q'B+4IB;RRIKAZZ,[.C1R+=0OC:XVWKN!E>@GEL<Z>@P+82_4(5[QO
M5>^P(1CZGQ1_Q7WWTC I44#=+A?:EN8!O'* *IG::8AZ<!$Q,3M]LJ>W+D+C
M]%>='I4'Y;;[K.N+;_#4[<:WD22PH>S@%I6J3@]D^I_V9PVP+VL\>"&V^[35
M!PODIE8Y>^;1D$02U12K^Z#6RX+PT].0SU_HKZ/SV;,L#G1XYF1KV?J65$89
M/N9].B'!X%XZ,2[M;@K5I?& @(VW-XJW^DN.7E#.A$6V"0EAN0?-FXV'5LP#
M O775:9]#[ @1:=L9*TPDQF.<J(5UWIU8$I0RXVN!54&SJ2%H>E0]E(AV2:8
MPAO'O.&B4P.AYLD!/:\[NM\VY3A;H+N*-<"CZUT'-D^52;6@.[B%$ ^]T>0\
M/*2DF9]OFRKB E(P,+M46^(>ZX.R3%_=71N&A(7GW_"3Z)W8[L"6)$HA6U5=
M3N*H#%9!OIZ9O-LG$3,WME&X=,7A$[?2([M^AN&4/V7NX-#/U1(U": 1QN:F
MN3R):2PQ59'837V\QK2^E9WLRC7; :&E5E=U(%X*S\K[.M'65Y?+7]B5P,58
MH2U)CZ*D8FBN2X:RU8B[<UQFF#70.UY9_D@F]NT+QVH2P?!M7M]SD,[ QF3!
MYNBG/G[ES_N*(\^Q>>)FITE<8QNAV^^_S6FMZ\@O$C:7ECRY8J";^\9EKAI^
M>;W/-:K!V3UD[<;LJ[ 7 C;*_F<2ADC.IC$+3[;B.M@2\U!73ZL )\C0D8)%
MJI",J2%>TZH&TZPO1]GN?CG>E=;VS:=GS)BE_X0#_TV.JB< /&[AAU^$<>RU
M XCU'-1V:7ZMOD/])^RZ345.7DZ4+&H])'J;<+<[K%3.\=NR$;[E/;9'%;JI
M9>S0!;GB<Q#T9'!23[GB8^_+&Y.'@H'?PI(QGIFR.Q@Z&8E4OIKKEFM$J!=D
M/LYQ E^9+!UWBWQR#F*EK0VU+\'0O[]I'- 9AF.V%_K9R"0SZNF 07"'!W^T
MP +"D5)UW1Q-'#E+2JY^VZ&'Q)+M6Q,D2$^RK\M8\N4CXA9F3!K5Q(;<&,//
M( =U+:D!)7IZS8YK!,M6UKIC"I9S;ZP><4_?L6&1PA2R%.MZO')PF5>@ADWZ
M.)FNW8=?B%,A$KUQ38)>H@;WIM0DF:%:[V+_EM'#+ZR0% J7FS@[>4MS6G3D
MTE;6I[=CC*>2;1T4D5&*5>C!I.XN84GUA8T^GWOK+E&35#;"'5I6X?BM4[2E
M2M-RM=5RVY"O=T[\YJIH+":M2X7N8)\64N"LPGH&9FOV8J@>(Q_<#@%=OT77
MXL,7F!PSI<=F-DIWFL^A7!#MO9E=%AFC7T%8*^'H/F'.YA]N)_AHLJ%Q6>R1
MI+G3F=I22U<[E2E''#U!ET /#KN=L8/EG59!(BI>D4;$2ZG94:HG,;/)";K8
M#:UKPM$66G'<1-CQP:^K7(UF3P]R7@RR4S4X3,8%)AJ!P,ES/OS2*9%3RM1M
M;?.Y'[]D^FCZ9C,D^2AOLC%6?>CDC'UW<+>\Y@&!!3M[(F9IC9N(EQT,U"X@
MG%KDEMGUXD.7\^"3(&D&XE1.?O0U?H3$#ELFF^>\L$K"L9%G:7ER#JQE2XE6
M24=F 5O?#P):RNPKW)C;,RZ)OE[)"DDB!D!NR#GHX$N>0;--2C614ZY6)Z:1
MP T:H=S,: (U-%-]V*5,=N;H,=<E'U:DS9E)UD63S9-AL(VET$3\@UDWJEY)
MR^3MZ9-.!70E[T&.(*\=;E^!%<FL5<'D)P8+T'+!2^O\MM-G1#?<K<ETJZS,
MN5T=ZUD6YRO*)Z,>+@QS_ #^;]P5_,]!"YA6_RC@ =W%*/M1P*/E7\4;^5E
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MLJ*QS%J>O6P>=GS?=,4;^ L]!&!?#],'M X[E)C802%\T&7-_3""<X#X\-6
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MR.8F-[Y<R[,//4YA_F)?H&#QN2DY:D8]OP,7L_!'CK<A=*4K.=T5N_<THQQ
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MP=Q<&Z&=F628!2ISYP)%'M0U3 E->E<\-4 ,)ZG+>@ ?3WZ7\975JAHM9JE
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MGO#ZI%C21Y5CU5;.ELXF=!$+*0>6^ZDV$OT6#KS9^ZK+DMWPNM%E8IK4S'.
MW$$2$Q:4 2$=+D0-IY;;;G8:[WV9VVGJSJXH5"F\+MV"!B!)WV18PZ*G83WP
M%'63^K?.LIO;AEF2 '=32*L1L;4OZZ +OK'BH'/UAAY7[RO[,=K7LZ#]5;,+
M6XW "A9Q<#4\+.^[8:?)4^_7]5?.O' /,<.0C!#Q]_CD[LIB^TR7:NE^MK6V
M'[-HH!'8H8F4OOH;2GP.0ME,$44M 'JPJ@6)6W!"0><-P2KZ$^(>6.).N/*W
M7:0IL!&?" %(;MC^&#1ARYMQH6%^%=F9ZG:]4XM1]$W1V]8F I2>+?@H3774
MM#S)1T_)76/>5ZAC,_R+UF?(6^=R9#SJ/BX#&5KL[:5&L6JHW(H%5A>;"/G:
M8V_BZ);X'L#P",Q"KE%=9 /"K8MZ-&SC>T/_R.SJZ[4QZ:\QVRU;_0HSXH95
MF$$(# -#C%JG;QT!*=_F3GI(K>0\?)^B".J7.ZB^I^?E_EG\7=CE2QO7F,&6
M-H>RSM^D[&Z2Z."&=1,JXRO\?<XKIET74!TDB"G_6^0J! XY)MOR+4"M][$,
MH#3^IG8V6ERZX,O![)L7 -._4BS])T_O]=_ K(5-UNA5M M81X0"L_GY_FNQ
MA>8*HV,\@Y^QA;R1!BVTQ%C:3U7490T<$9[6=K'9F_PL52'(6,?LO&XTCX>
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M[;F,QD*M]ZX/>O]<#E#8QV-)OQ4W_Q2N?_< LT4U+1A5G /<3BYDW_J'[(/
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M;=JA6Q?=WQ@9T!*<GSF^Y9)V<F#EW!1$JVZI=>2X)V+42_%C;C[EOD NN?@
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M0:C*K&2VHX'MV=D5YY&]B32M#+EO:QPTN"5=GH-IA5,"4\2EN<'%APLO9'\
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MNIE"EQ[H.;<ST'ID2-ZPO*KC%1<XE/9PLB;6]_312&YM\W,,X#R ]X.F3X5
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M CTA,^/+.7>G9TK(L%?'OZ.SU--G5YD0G5;[J %>!)9JO]$I\89IBDROU*Q
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M:5EJ%1Y?&/2J1 3'R@UM4AOR5&YQ#,G4=&AQ'A;6NL2.%"QEG=$+Q9TCHS'
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M(#5&Z<X6\063110I0>XT8N44Y/P[D5B%X<@)7SA8RY(L^[@J7#&H5=V&ZC,
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MX[[U9V$?!5G !-M<;9A=,S>KP:ZJ)>M9/[2LKD8+?/S:#"V.:E@1YC"? F%
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MC!C)?2&]]5:0]+]$2:)1E$$4T_$;TP>@'7I'7YS5K\CL#LFCP&Q>Z'6YA0<
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MIZZJ0:C->XVAUOQPP]?O5I/!>527,'P*,M!3PFDG<=[H<8M.R;G5:WNGM+]
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M'U:)74-6J/;EOY4?1N+1GJSQU[+CRQ .HDXCD&+MZC$7O#Y B(.M-8*'!3T
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MN1<&!R]=ZNK_FVUC8-YW+.*W4,:'!_ KF([=MZ=Z'S!T4@!Q&GZ(<&0GLIU
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M$1#CM^3AX MX80^8[>IX"QV$Q"@@;K:/(&5I'M<93=#4\Y*JR8W;(%L3C3?
MH7+TRD[?XI?)[U4NOR[?PE(7B?J0\:2Z7+&A:) CF12S&2Q[N9'WK6VT$I,C
M=HW,SRI3F>)=V!-M4ML1OA]D3D$*9M&";<;+4SX57(X6-97]Q>]$%*->*^=T
M-NE^5'%@HAY_TI@NT.S8,GJCKHUH-GAF)W<RLDN9/#:-FNA<"4O\\W./)9>+
MR@!#^!;;]WW1?8A[GJ.?U@K;D(-._?J[L(8XG;*H)KTI.N<PE<FG5QT+&D0J
M P1.7;/W97Z6Z-=\B\[YY%!8UZSR?814BEIX."TTU'EJOFN_LDYR$8!3@7:[
MYMK2W\H:S<)!+RL!=V[IT)NC<E_'O95@1C>+]57BD][]1X@?JC5DK'5A?+_X
M(Z?.((*B>E$TK%P8FV&DN[N<E#@T<$Q;./.5NY(&<]SCBV'@*/^A%36^YG11
M=5"60CW\COX+K(H9>XP&4KI#'L[OA5>OPU"S&57?LZ$$R &>#=CZG$O>KITN
M7S;O("^Y$\XDZB6AB$-VUG4:[H#OG\L^=#V2#=!/#O=Y9@4RYGAGWKT<[_UP
MQ:3R8C3=#*F1RUN^\<MS[D.]B@^3+LFWY?)_VQE3CKAF->&8QW2_XT/L>3A<
M?/'3C&ZTL+GSZ:WKF:AO+/?4:_<O*Q)0$A$66GXB>=PHYC&DB0.;H<]?N6*O
M;"5FEG_KA*K-YIV$[9N(UUFJG66*FBOO7@KP*%C49GVMZ8Q]"[_.Y1%8*Z9E
MO,_2Q^$M9])[+<6W.SM9I8YWG45@M@&AT,PP]/!$+MAB:%=QQ6LAI;A/9*(N
M^),7_2GJARPAG25\ZPG(]<F( 9YBOJT,WU;A0&7^3);; =9GT4T#@)O_*Y'^
M7?8H^9FUP[U@P\.]X$J=NMY+__=LQ)[<%F%SSJ2LT2.D>1Z:OS48*/3/;:>%
M@&$L3&63?:810G<+PME@\:VJ$_'"]6YXU/U.VJ?\KC/D)-C%<$M?IN 51%?L
M1&;$6G_TFH9)-N#9<$?AC6@C$=QQ*:U=CSYF(F?>APQ7%MYO;?39/\REUQP^
M !5J[[K\2JM0Y_&-;/1)((P(E BOJ8M5IR_5$N0M3A(>0GV$9I5DBM@H)08U
M@C/.$5/'Q:IWV-PD7UC/2+&.C&<Q2M4R&;*1EI9320N/171&*2,,*>%LX"K\
MSB,!7.RLNH:Z;PK1J#JKNZS3; Y/651#=8-H[\57IU'OQH3RWEZ&$+#0+-P#
M&W6OY4<(3,"C>%A+FY'OX5<(A#Z+0]F-)O)TO=+C@QMNG:_H(:X*IG-O=)H9
M[YV*;W5F>=>U3VF.K?1AZKXP29WWB!IF(_PQY[8]JP,'H]=36BV?%1;9Y6XG
MS8KD5+$W36(QOK?X*.Y/G&H4&SM9YC350-L;DY078IJA>H)054!!^&PZR65&
M%2>M2XZ-=?V2*Y+=DDO;>5QO"W/:#,X.)SMF,_B,?G]Y #KOPIB'?FB@/]/9
M.G&E-.G=&,G<.DYL1=M_ TW=:B6(8U79_-C,^(KAV^GF?<T0=,:W60=)5.6'
MR$G71)=F7;O[3VBR:D/N%#_Z\F PP>B%N;:H+$0OMMW;0QB'VHNM/!;9 &EU
M5IT?.P Q[3GLEP-,UQZ@,_1^T942T/A_W;#[GW;&O..Z:V^>_16(<.Y?XA$8
M"U_]%8]PF&>';FK\*\T.HTL,1K;#V'C8>(A(%?2ZS"@!_GTA_=>E$$A0.JF4
M B>4#$Q+HJ @XRZ5%.J.OV.<%0I5%HR*0L /#_=1_W*X7Q"]!?@#K&OZ^&PU
M7* 0UW4#H]U;@ G[[%=.><H*YJ-S5/>0C/!H!/PRA-G?/L/$"N,(9G'OQ2Y@
MX>#<A-Q$=A4[93O%6%+??NR%[@O=#X1AE W0DI3<*Q8 2*#^A[MO'Z%)<4(I
M[#393Q5_#COUP,=[LAU6)[0AE(,-]A(70]IORRE=R]75UI#6+=?":(;[GFYF
MR4A])DI0C>-2F%\QSIMO]'XD&)N+[&;?%G1RTGC[^4TBS521L2HTQ'<C-U.]
MM*2<5CNBR9>U2U7G='+N4_II*0^L$:6_>C/DM(!<H7>8<BI[A"S$)(;VVT6#
MK:SU/PG."RZ*(S8'((C67_O1V>Y/^O_M9HXLT)$_5,69<FC\_?*E$Q"*^%WH
M-+<WY=#:;U$!$0S=NWT=B- )9>HW7]O @7778$_&NZ\." CYWTHG<<@^D0?K
M1, =E8?P\:K!>#O2]/^>K1P>1>PHN0"VL4EPQ1M\%M^XJP] 9@6^3XCPR<L(
M'M^X1F_A,ZWP9N%TP$M M)KF1]:VJ[5Z+$*KAC64;,TH!)>U ]?/CH'KJ=.O
M#SMWGJ&0L\%Z.G66VBFQYUX,SK%33L+@3\J( &OO<<(M'\)PEU9E#G^-$(RT
MX'IJG6G@GH43?_U>?F?)'L-<4W"#2GLMC4 [2U+:2;M[,*R-6"S293X.I<:5
M-DJ>*SNI_.+.!1)QD>ZS^Z;?A@EZ/YCM7YUSNA=0'I!#ZRQ+>*J[3%B(H:PW
M-.9%R6LNOI@"H7,R6I&VTC?V5BTD 6<)6)*E,/W [Y?*D.2[SBC)K7, 1M."
M O"7K\5; 6XL0=!6WQD'!]/L4S)<S7&/-$M$&?>W8:G49SW1/\?Q&*I97%'=
M_?G[R7>-C!""^N*P Y#;]STG+9E(V>CWML\!J']G3P:Z'+(&'DIC#(SC!KJ_
MQP)T7[FS0=S8L 3^JJOX:/.#G+Q:LE5Q=36U^&PHG#7H!A%[^;M-.SV+P=];
M>"O&:B#"<MRF/75?T=&9&(PC S[K>OH?1V"VZ,ZC0R\G>QFK80YVZN8#T!,U
MDL@P)8'9>!./?4>@/Q=2B5:2W96@_6TPP03)-"I=PKO<=+X=W48-D"5$=B#A
M !3'=WBKHIB_QS2:"T72WH=SQ9)OCS'NK7+^A#&N-4C^'%<CX1CF?6I@LRL/
MR)ZT%!3#4^8\IP7J=#6\[#F>XXO]6?%3IDM ^(+BGL3@1/L#'3./\^(GS7&[
MS'& )Y+ $ ]0K7D?3#95>Q=L4C%Q /)4K_V^?J+K +1,(UD3M 47 W3?37%)
M@&QAN] [5UT$L/S<BP9']<J_ZCG_\9@?"=]R+XI[T?KOC_]N1G34+$IORP3S
M,V:?0I4<W4ZN"KB&QOA/G(R EW_L@=8/0+LG59<39&MAVD/?ES& TG5S0N\3
M<6PA#D"GTGTJITG2#T##_&@OD,MUN&OK/RH9CS^A1O*OG1"5+/?*YHJR]%:,
M'9\,/?H/#0[GV@?0P%RV]MF/9(F-'QQ'1&3'$W%N'XRN@8XL[1 "8GF+K'($
M[A&U9<W2ZX_Y&?9KAI3X&=K_F2$!#)@AB<%R4O4G%X$0Q9 Y ]MC'9R-'Y']
M1_=WA(.\"^0-['ZU(ICY>ZO?*UEO-X+5P_Q\]9^I>M41-]^-1O^E+-*-4E"#
M#^P>&%F;&S<<@-AY8_+G,"4W XU&H8VUY8X'H"Y 84BY$V%_UC@RE[B/Q,%"
M.:B-;8)KVS&? ()IUX[MW\<"E,5M:;P?BI:9JC]32%9(1?(>5RPY<K%=<OK,
M@U^3B%_V<T3ONWWXU=3YNJ2QB\(=RFYU#X)O%?V''1V UHG_(GTA^0YA/WI8
M!/#W)$TD35R4]!BN(R+I6UU+@07$^0#Z] Q^!?&_ TN^!73]:Q3J:K3I1B-[
MM;UACS=P[]$CD&,43SZV'GC:N*3:QI,_8BA\Q%#T@_PXT9O_MJ9X8G/^5RW)
MCEJ^$$=]\<EU+?\]U-/_ZU 1'Z_>&KW=F'OWIBB% 0I=PS.R<@#BO7?$;N@1
M*H!\YWZ1#T+VNBF"?2>>6E94AJRW053#>Q-)\@F$>WL .MX,&,NU!'0[;>UA
M%UST)SY]HQ%O\_MFU1C9"G]/V5O1 U#:X"8P> &?PQ$  ZQP!WA<EQQ/GRR-
M'&2BT>CKCP3C)E@ZRF;(9N,N\R#! 2B*Y[ Y$C_& ] .X<PO3E<=B)@/\HWV
MR;VMY]3WY?OQ%4;\CZDCO3 :\R[2I\1G-1MS70O^Q^_7@%>1[!%82N(9P ?T
MN&3EN_==6<RZ>_RVR]$U)0]E1UZ30B_*K3M#[(6USG->WEG/U;$)P/@_D_Y'
M-M?#MI%RLDF'.%?FAKMZBPZ.X$B)E-&,Y!&=?Y5-KZO^738E#?^KY$$\EJ!.
MJICZ1^?_%*MZY-Z<N!)@#8_WGOR/=X.V##$_X_\SK,F]H1;_+V:6R"M!2T*"
M<8ARM5B4_,^ROB@ U3ABF+\\8.N$??2O+T_3I"MZ8#2"_5?ZIT>9_JO,YG9?
M;H7\N/$/ ?AW\0BOVB8_G@K_BL1[7?%NIS/ $5"UB7N7U31^TFFEGG/3=M_O
M6+QH3?[")@2?!+>ML53X6E2=TSK':E'!U/0UM57)>JNB-J6VQ"7DZ5D^=1(U
M$N8*8*B>NL?E%2!TK8CVW8H9\:A #M_R:L/HP/>7T[SU-B";E;O,WQB!<5[]
MHRW^!B+9R[:,D&T,"0+KFZ)? MEL.XX#@&%<)/_209SC9+=&V>U9<J_;[F!^
M>NQ3&) ##LW_JE]4E],_:D.7]R<VDFUW^H:.F!/[-WJ>/J*G*,E_TU $[761
M3'UDKV46.A+N -E<VF6N^+L6Y#Z<UY$:5*C^Z (OD9_EJG-V'-<>K#PN^9"
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M-L.%5XXX.2[MHW, .X("+[?FQBJW?Q$P.9JX8\,*LOIJ]YK!(;;C?V'[EX!
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MR*8%2*;/DQXIK:@DS=0'(4^/ YK%%W"*4HAD]XFDTI1>N9L:=F.0]@5H.&$
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MNK.__B4,48#+!"U_Z[H?@\A9804+%%[5O>[]C=$91LWUT?8K7_Q5TL&'F^R
MG2);6,N[^(E\R-U,4S5+_ A(W=L8&)E$/D*0;L>-EFI9*M4\4/^YW^RE+2@
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MJ6WWIR>:NN]1:;%9@3-GR1Z=^>QQ %EH1''E4(,SQWM]6,NXPE/V@/7K6\<
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M)6?_S'2,%! !N_1OW.&1!RCU@4^3B;X%1S'+,;.LC)OUL(:V_1Y?\%A #%4
M]Z[R^ON6=S2)6[0!?)02RQI'MR(B%/;"()"8AF5$6%2,$E,T;;JHJN*TO]&!
M=1;;*I,?QC.$::>(W70CU2W_2B8U1%J-Z9&+NN(Y:I4S-"5J=#D4H(\F$CS<
M;]SLTAY<6I&@+$>X"XM#)E<<6K[6R3U%Z0&/-J:.=&?V4TQ,N[VZ<P(/."=3
M*+F>%!GK39B\$,^]"B3FME= #%&(].I/NTF&:N^P,)8-'+!GM>5TFK*@HT]<
M-A^Z=,2^BNZPOU;DX&"\L3&M]"288B%*^T/7_?("R_8M4);]@CS95-('\GQG
M.3'-3]^B(Z/NES^U=7Y!1GT"Y]1);0A0J_42*F%9LMGD)O&B>2'^PGMO_/U)
MG.HCJ3>76KVTRFT!'T] DLFEG;_MDU&I:J,^P[^*+@=AQ$ 'Y$AS/\S;>NFR
MZWR>#&VWG=&M. K%,D]@5E>1W-:PB*F,AB8CXX6OY PG15D"RMB&*Y(>.GHQ
MM#Q8E0(;O;<<DYI.A&CFK)5B-3.X\Z"#92'=ESLDECF/=*!9D%6Z%D2"LP 8
M^,S=*GJK#W;S=JMH=O)T?&'Y"[ V8\#40'+KL_,,@O"A3DM2F)?.'^S)Y4\W
M4RZAVCRA3$_L_YI T)J0W8U;XG_W6LMHPUU8B@2I-98]6&A?[$976/ N]AX%
M$5$(Q<+-F)$=<=EB#FSUN[HX]ZE/9 PL"9PM,U<YZB(H),=I.XUV79H%7L7I
M7$>^3"QM_WPV[_,5*..A]OSKI5 : YQ@NX59%;(77G(UT(TWJ2LVF2UL/2VD
MO:^-G5JG]I9WL8]J<):6[47+@>4-49J!C)_N?-5_[<X7O3_ ^HL[_QGI3N]O
MOB8:=JYJXX42RL=PD*W8 (\^#_"5V<-,3@);4+X%*EN240YXG$.DDA[_E(-I
M8'9K106IF@=5DP:1W\#"3IKSI/9K6G"*(&UA@,"'"C; STX* Z.R5ABDHG*W
M/S Z_0$U_E(J_+^G-(PVTU1.'57X\.K7P;$J;QZ^+BXX^N'8=SD&W"PT8:L<
M9TD2-"P?GDUH"0Z=3Z#VJYJ)1/J?<$F.83A(N6:N*L)6:J4Q5.YPA_7JN!AI
M&=7)R#)2%.5X+@F39F=J>+S36+4EU[LVT8KV+M2;1Z<1R2=?%;,55Y*WP<VS
MY8D3+?JFA"]8BFB J_7KQ>DX'^P/R]$.GS5<>5Q4QD:"=:X@E_,0(MXNO((V
M.Q \3^*DXV<I0X1I"UV3Q@5S.85\&Z&]Y#R4;6BO1@LL8%=#+B+V"G+JP,(W
M39<W:3ZFR08U&<%=UM[E2HTGHVP;B$C*=4B(:V9*QLD?2]BN)T+YMK-D O*]
M@#M7'[XZ@8T<UO$7\Y>FAYJ>Y^-P1).D=?.2OK#0O"K8CA,^ARF@D".W92ZR
M(\EJ]2L;#.*P7U$VQ3@+HUY,.(6 RD'&8 %^%6#"_R&.TA??X?!WAZ$*G@6T
MU@,SVYJ[O2GJ480<"JWU\%]S*%S[<&"[JFU&'5&BCO2HV-#QU\X@JQ:5Y]=0
M=]@+Q=V*K4GD2+'/]$M%):0 +HN(5^;E< ]F$!__*/833D[0\,4MY0(Y$-A:
M>1-!94SK>?59J9#J- )&V\.O%;2(;+MD3ZE?#"=WFRI!IF^]517F/090&MM2
M #BPQ;6!GN=BE]#]]T)$[PZ%23.MBF;WV4):\KA!1MA+>-[#_T0>Q5-X_A$&
M)#;43G"!?4^VT?G5PP]=#_T] D"!HO65PTP!CKZ_=*)[9J/8HIAZ]TC*CE+"
MU^L0)%IUU<):&ZQNF\SK<62O*+)%:\PI;HWQQNA5)//#"Y,I40O.SL/Q^IWM
M]QLB:A47,8./&MB"Q$*[[NUKG=,BOYNP:"#!>FEA["5?V?1@8KDHI#L[/2!:
MN0AHE9$\)DKL?&*;UL'L3@<K5$KT2N8D1<S()';.IE$ K6FF<N[6K+":?A[X
MD0>TUNF,H[,SA,V#3#Z')*WX1N%5>;>2]_ <?MA#8]L3[7D<2#]U:UKLC0M9
M\5G@QO*5JW4^Q7LCI,^W<7<W3XM(W!B6R\Q[V1S<H(AR??B\V7[/<SH#K,:Q
MKH>#W)ZYF8IQJGYJJJ%60>Y^Q=NN0%4'-N%T;0[YK?S2PX\E'")F$#FM#UD1
M:Q*>(W>. ?>K<A!#3Y_>R(/!=-'7.LGE57OIL@?DVLOMW^(BY4+FDM:J>J$I
MY^[B2A)#6&(20V;](UA0&2GQ?A_+0BYQ24^.W)G$(:AD'\81QS#NNJ@ZQ%NE
M?T++&+6]B&S(#55F])B/7^X^<[[SOT2B%]K_/VH5V@M^[4?C%NW4KZBOR!\6
M:#-JO$\8666WJ^^E(/.ZL;J"648MM3TYNZ&B5,)9N#T2[NY,*Q73/QEIP1QN
MTEKF?9'F:HZ+LQQO6OG3;ONW[ \-//V>EQGTGM^U>/4 ,'J^BOX8X$$1T[M4
MQW'Q.K?J8,%,20GWU2=O)(>&QKOUV.7I^J.BLRKR]#XLJ(JVJ0[3YY'+H<T?
M_ \!H^R_&\@6N&I+=R)_K]19:EBP/;G%9,NS F-KR<KV4Y(:).7)8N8Y=3UB
ML :I(J [QI.>$&^5S)"@I& ;GBE$!&-7"A&*GE')%S"%@WA29?S%7;-)$8I8
M6) MJ/69"G7C0QCGJ2>*2C BB4%"#;B([%J\1D20%T-]:$S$?M<,0!'.QP"J
MUOO,Z(GMI>&-"RLXS/[7:<F#IX5>1[4,=9("YS/"T*0O$X>'Q[@0&Q;;6<PW
M-)WFJE?4.IBTR>9M^BL=^_S"$K7\.=8\M2U?^1LXF.ML]HT*S5@Y:_K'WYA\
MF@P2)NI3;XY<Q,"6[DUG)C^R8SRRG\[]T%02=D/;CT4DU\A]UJR(NE0HARNI
MRY:87!8UW&QI0*LYZFK4_ZEAG#14FRTBKSW_C08E0C9"D<M(3[Q1$-XD3N:D
M->/-EY?P4/03^D)!CSNCP*M#<!JNE#(VCV&,D1FX<S&W^]*TOX@0"[F>Q7K)
M*89*QJ3IW#3<F0_:2#G!8*$9YV&BC7(;HLAN1,+=ZBRUYWDW'[' Y/L&AV;-
ML(WE<NT>HME46.  EMAVU]"WQ8!0EO)G?.DTY;GP75S97WB\<VC+'&J*Q]_?
MPM9W?'Z/:]>7=PZ[%1L56Z8L&\GBA+3"$?EAXYDPV\^AM3VJK<XRX>(:%AH+
M(1KF'U\R+@53E+T[;\X6[6BKNY!E*=*:R1 Q$E((NPEK$^I<RV]H-"P8%@M6
M4E322WN"!8'0LLUX!L\I2XA;C7R UV#SE4]G8_7)15&/.8$(=;[OD3B_"]#H
M&8;?1>P(YE /]Y4S OM46YN^._I?&=8FQF@Q%8_D#Z%',32[BBF-'LD;78!E
M#6&6;=U.]TG2),V5Y5[]!=%W0E?98QB9B P>/B<&;-/VS*84VK[M,9(R;Y]^
MR5=:.B>*;MS'RE_)X<8&GA3<=-G*HJS,X=Y#LCY-G(&^J\L1D GO?4VW/W3M
MI"(1: EL.4F&12=: [PTLY.&,,-W;AO*(MJATC78B9H''51WG"&D6F.M5=8D
MQ.X#*0*7Q1EB6)F&Y))K8=*EUV0<V_G$AA_??EVRK+<<@1H2"#DO3U)HU?],
M9G9AGJYA16^4U1?JZ]>WKED4*$HXQ;*SJ?"4650BA1P$*:T^.=QN^ "&8&(H
M873-BP)&9M',G<EW1W= K]R1WLF*=PC9'T'+698*1F]BY(&!<ZA[LU9EU]EE
M_##W9C6M_=16E.E&F)?'ZG^-C^)=,1[\4W+55$LGA"PW_H_I.'8>$NX>L325
M+E><!4+<29UT"V6%!<>4N2ICIB,<F2G._ A 5;F%4DL;M>%'(XU03JCSXT(7
M+VQ8P"G.W6U%1]W@*BA9M;LQ"Q!0#%E'IIQ'LV[1U!P#Z@,R?'QUW'C&8CJT
MZ2ZUWP-FT'/[G,R"(S&J^R8ET9Z:5ID28$']Q$#$VN:17"Z>^S[#XYEQO;'T
M[VU#D920_2NX7<K1@_!$R5\3:E5@7NXKEP3_L;S0M$)BDE]=B*,1[Y=>AK$]
MBLNZGJCJJ2X$G"QX!\Y\.$J4=3V%:4"6CIV6C._M*DAL"\Q4^;7B^@'[E(1\
MJ^?!#>W$#!?O@<Z)NQR]5]#E+W>)9DZ]2N#5'C!P<V:/7"#5\Z(6TTFQT5]-
MFZHUF] <O,K &&]PR:^)8DG>T0>2]G*W9,;@24=.N%'U0P[G1@YVU$E/BAND
MF=:0B5OS)6LF+6-<X>[YQC ;WD(S@79M1]7^T9.O-FKPJPRJNS948/WBU6A1
M=D42J1(C50!RB 42(]0^I*]OQPOPSYI^!@<!XQGLQ ?)!0@QQF?4;8?ZX3P@
M?MOL)!6A1](P3EX!*080R(80SE__T[\^C_Z$V9O80?\-TGAM-RA;2=0W*$.2
M8KO_&* ::L+L;[=;7'*?+=%;;%3M\$:Y=U!''Z815RJ*@P\PZ=PF*A1BV;K8
MN6%+(N/7XI(XLBIBS59VV7'=[V.IM$BW&C";'YO0^JDGT_[)@@A]&_#C6Z*G
M"D6<ZHV);>&QST4KSCLZ-FT6Y?=.U0>[\1+SZ@^TC',]O>/D>M>0ICYYO';3
ML/2EX,DVCFWH!]MC .V!?-:N)_/5LXA,_[8X<0S=GBZ[*4G?#'%1"N_AIKYA
MW-<NI6+_9*&(.5=0[\%9W]9JM?,>UKIK+5WJZ MJZ"OMQE SBKD>P1;W45;Z
M VO6\5>$<YS=BKA;[E\;$3=U/]U3<L59\23=#(C.\*3+V$O0QOMQL<4-@W&^
M$PUY.BSEIQ5"Q_+29X-/K" S3LJM)@\;[F-T)Q(9 HJLAOL%J2J7-1--@W!^
MQ+BN5_.)PJ2>8N?[DWDR"\D#\QIPH$NMY)JTX$U, N0II_-T\HVABTP/4++<
MP'?W-"#0#/ZP*#"1G]H26%#-6 YB9=]Z.*BZK# =0XF2GD?]S@(J<=.29)2[
MN+]%\ITYP^M" 7^E,:?\D\;\FPB.IG7NN1D;A2DYIR$W'@J#D]O)9>1 .;B*
M=!N$6**#N:;\1I+>AY6OWE)/O)?>M<.HU,I#%-+GJ:&8E4M^7R,5:MIZ 8?=
MV#S]!1=W F3+4RQ2@L>25%(9)1C9+;PHSDZJ#^<AI$/K]!&:1-_+(/\70XK-
M[>]Y3K>B:NB97TTL&B\8LW^3,DVYA9SH/HI)/*(&>W/[Z[<:*]-@GC?[?5$L
M:VY> (J=?%?DT^.>FY-*=X RN$>F$2!!J?\@"C ?31,!3A]SERUW,_=1O 0\
M&<"4^#7_^M<Z@U,2$JA/K>XT#SQU<N!.V)H/4XF&1O%V]QB_.I7>MG@@^%!C
M[+V*CQ-S8=FU*QL5[?W$BD(1']1.93;/"8,T?.2S;#P<FB\:,XZR#152,6?L
MZ3$Y+GF&.Q2>5;S^6:=FX !6N^8;=.4+=[D/>%4NN.)BF$#G_<"J(M2W1NP!
MFYX)K$YWYG1"%S> 8K[6\^N,5>%.=6ALBMV.T<3+39>7++L2Z*21FR+HT1J?
M<;_%'3:Q("R7Z<M+? UM-[=#O:J*+-P&-(=2(.(/L)JB(D(#UQ](@"#QB[R^
ME$R#_4&BN8A2:<[[,=>Y6OK4<T0_H,Z%""3>31<^997XFG9_Z'/'NX3YJ)1+
M8\U("!+ATJU$<WM(:$LH7F"IZKX\ FD=LIWOE'@=U:,ZUIT!8@N9H68P2QZ6
M:%^ &CJB1EJ?:$H$P-@J47<%$<GD?#+MA(+%<WBX)?X[!&SFW":OE_SOG9HS
M53/56Q*$ [[^*6/\CT'$.,/8:(8(3\G,[<< =X+KNI8R:+++-Z#6MVL!FV%?
MSJYI-_*2:K(].%]0 RJ'ZJ)GQ#,!5$@?R7^R /PF:M&A.P9D.QS@_D/PO=P6
M]-?90)JCY=_3I#[Y_C1;I"X:%NR 5DPI]06E,U-O/,&((<9B(V]98>".\P_/
M2F< RP!-*D(S"JB0M]%ET>J7\?N<^ ;65CJU3SB?$0945R#D 1+ED9_T4RCL
M&].7@8.BB*-BHQY(O/\#28N3"(=X_!++!.RPYEUG#P]D^$JHMA!67,,G@5OV
M#3;94-G&SVP+M4?Q=K5Q5,)M:*[Y:D;[GD]>VG,GM1AX'?CF-N9M RH82$SW
MR49=,9NHQZE;PF D@$N1J95K<GU11UN:[5%YO$L'<'?.ID=ZIBHW^EI>XN*$
MIJW(V FNA%?3.,:0(GYEP2C^L33IA'R'/-JN9XG[%#&PI:&F%%3!(20?^T+,
M-C.2*@OIIV +03J_%M4/67.1M0L#=0F [UK<Z3"_@U&4D][)1524ZTW%9N$$
M]$NK%0:0XXXJ F706YA(%-@92R?0;+>L4<>OY:]ZQF)66\6-/ZJT6JN5(9*"
M7(GGBWI8>?HP0R$"1$][408)FHY?_OBX.47&I+'-_8F0[U]%DN>\I:=,]AA=
MG8X!:M]S"B8*V=  0HCK/\E2D,]+W[.I8BA_)%,57>TJC4B/*^>T:0;BW]=)
M/S]L I.P<?EI'I$B+%VP1NRSL[C88>?,0<&P&+IHC)K@0*VH>6Y5D5'[G'GF
MG1!-H<P%+'R#G]9(;U-@X'DT N8"/(F7E>-/ Z/++E%CR'^D9(%L0;:IY_N5
M%!4?_'<3@=1W@?;4>WOQFR[AVX2S_D(]Y%> 3EP/?^1]!Q]P])JW)55.#@FX
M$6=5(CAD]TG] T_M;!59N) R7D)VAC@@4_3]54^<3*8@.?F @VBNV["\]OWC
MB-F[W.7(*Z2;"*:%"O!B=\,X%0\((IBN]E%DS%$")>I[=Y:FVTKZ[J?K3R/'
M4CCG#3A<C*-:!ATKD<_>*DJR?=B,#GHZRN2#)G:_HKB-&U"VG*H_H3?PB&Z4
M&?6Q/PEHNQ%C4G@]\= VYLR2;&0EE-V[$1>NG\3H/&!FCJ@0+M<_)> UK$<L
MFM/$C5(YBTLK+1;-!7]^4RT 3J 3FFZ[F!KCS"NH'DF4Y3_(3A:@J_M($IQY
MK^@8H++[9D:"6Z5B<.7JRH6/8_Q,IH71$7CN8YF(7?2,:#CJ>847!LF/:*TD
M!!'L23>_'!U4[NH8US.+N_K.[?02:LDDUS-YNR4[W#D&K-&B&&3+PL!VW AV
MUG=??;_.U3?F,[,C>P_\BB6_-/GZ>PIZVZV_9C+6.P9,@H>M=^=FRN_X5'R_
M2^(=JI+&[)@\\R/IT92O4_6-P:Y)LB#SG'$ L2)?)6N6.V1]L,WB&-"V0B@S
M<Y&5X96=FQWOJ\K8 %'U#+-A^5.W^U/'PT7D&HKO_#R7_N<YAPE&KTAWBM\U
M+QC_/),X7RS4_@\S\3S+-3F'\Q]N>_I^8JN]&=\OU\;+0+,$,Q+=$$O<Q;*,
M@85+IE48CP&N0W8T^,_1JGOGCP&]',> .AB+K.1FA^272(-#Z_;)>P:^:#SV
M/?+0"U!;90AINO:5<:/88^/R,2!9\1C@C1$/JE^(\IU@2QEY%734?G0,F#H&
MG%J3.56_V5T/#FD0/MATZ,1#5/N3HWO<AQL\&VQ__?%F^2SK.]:) \G)9+6U
M?1!-"W^L'-$;>X4=Z')T"P8JJJGN(Y4S0LO=L^HI8B@Y/-7AE2+R>P)J/O;;
MM1:\WK!%R3C^WG#YG+-%94AKLN9+XK/=+BEKJ=Y4QP#Q+_A7B%^4O\5P3WMG
M6V>WHHD6ZX.;9R4;<GTG%;^7BY3:Y3ZZ-X%_>X3F%6&HRYPIS =).&NI07*S
MYQAP##BI1JB]2&A_&)+\?K<+%"YS=RS4(4LIN^HWSQ[-IQT#'G(3RGCZ$TVF
MK*)8=ZE]&V/\DE@A#((FFL> QH=K:E^O_9P)ZUJJ^*\S$R,1W4C+A&Y;'_!0
MGO+M%3L&')R5G"),AJB!]9\)F!D6>>? ?/3^[/^CK0Y) 9.2^^C\EY\A3#_L
MJ6N,#IO\,9D_)W?A5&\,.>>_&174;Z+MV_A@3?Y@LQXOYCXEU,+\M76Z-P;T
M ;N?<P0D>22Y@&=51Z=2UK+P0YR8#-];\/WQ )\/A4=W_ZOAP!H,^Z6_W2OC
MMU;J52?6WPWULP>L:\O2:^)?D3;+CBQS6A:;EA_Y*.0D;RR#@N;NXQ?;(3R*
MA]-^W,RN 1D?>J7;6K%BU-6K\.JF[[NB#/Z.DHH*RK3BFZPGQ"_47L3/Z'7&
M$2U-('^2@@NKJ.(FU^JV6M0",V1Q?4VL8=+<[L<L\!+$E*R'X-V[2_0$L?B(
M-L2F@TZ&DL.[.YG_8_()MKHX_ .@F9Q876+=!1)*J )-_.I?XK<F8<7W.T+[
M(C?YVJ<CMN?KL/@?TDY^6+ G;#7Y Q#EZQ3BE"G\=B1L.I:.P.>1FQ 64&KD
M2%VBY$EO!OGQGU\)'P$E_23_NB7J*4-Z;X)NU U-:@K($O\:=T/&KAOE 9X*
ME"5/>%\8UU'_OB[@\/5 !A76*UCX/GY*%Q_55__\_W=J^88-/#K-NH:;@\[>
MU"<A@=XV]?<1^X<^"*/R[)Z=+/]4$T[X7>:4LY%8RE61ACQV>\CBYAIE@WS^
MC^4^Q%_+I/^X#CR7ZKH:'L]AN*E.U>U#&(NQP:-U7(:0Q->8@&^>:Y#_.=5;
M?M)T0MZE,,)9%;\.BM^[WC2'W3+X+1*^J^4<T^E=DYTMTT"[]>6 Y]II7_>?
M:\N8O/:H#3;D^_T_2O[MKN]OFEI.8@H\1X=9U])>T1^._[@#TG=*V@/_&XH?
M3YQ'W<;)3_Y-D#._JCW,1^;[C&1^S@C_K21^@!^; NA,4FK=?40(L7KY3RRR
M#O:=-_F:F_]A[2S$=[Z!K?U9D2(]"7NYIY:^MA#\/[6I!>Q$@^]9]/[P",XS
M+F!^\:"#5%6J]WD+?PI;6'3,'V A_UM+>\&5?>X&9*EW5YWE#!YM\8(O 8_"
M?V^&W;Z)3*\K^(, _VC.$_WW&\7QL?XWVG<AVX-C]BN/\$3P.U63X6'W[]%
M)S9B:+<=#@3QW.;_0M7ID]Z9-L4XWRDI#_9_0%MR*N7@5]"ZB)\U'#_<[^CP
MQ^".-S72ZPJ/ 0&^OTZ[27+WEQL#_B_3_AV<'&\B,_\/<_JM>96D4U-GN'ZM
M]^BW!VF-YY5_OS?8ZSWX'_%I15Y_#*Z39N,)S0DL,S#B:A8I+U>)_&+71K]J
M>R+-F.H;+()5JO<02CA!8WPY;MWW@9 :XS,D[HG?CM%'DZ<@U:H>7["*D:Z*
M$2NG;D=Y23)8*:V,5<9$COMU.'&K<\9/2(,<4*[Y%8TP!'PWY?J;+8K%U]A_
MO6FA/,,QV/"&O'PK=9=FLH\_5/X[949[GUMS_ 1E)5"!VKN2;]>]QS0CY3E<
MBS/QR">W*WF4+OF#T@4;9HX>?;^.*S7;N;.7Y\%="^W8+LZJGX)YB(FV9OP%
M:\4D-"F[\?C']AT"N\/?E<Y'+*QG*SX=TAED74L79US,_?DE<@W2T'P[5/X[
MM2(^O_6Z[EW)K1\R.I0SR?WH??[2]]&>?2=4D[_@4#\8Q?W&=?<]>:_G?N!W
M:'OY-[1)>T"^U7R'MHQH[YRND&K]Q\R%)AJ^C0%K5OP_AT&JO98\S?H7[G(2
M<U[P[BJ,61Y)C>1#+U&M76Q ]Z&^CQM31^3!6U.4\1=VP,D%YS"0)3SO,B8]
M6OT)*?A;G)XL)L@+^'_@HHN0<PTC64@3-=_&1VLZ7W]@"_SFB=TKOA0_GX](
M</->QA>>7"MC01.U\ ='Y$2 '^/YK3$VA/#I_'R)8/)SD1_V+!Q1MYT%353Q
M L@_]U/"KY6FP7S7[?L[TYP6IIE;E$"_^RW=U:A_EV0RX^#&=_PN"F]DI7!E
M/65D^,'VG#-'M534O8$O="3LP('G R4CA!+,!+6;]?C=_P=02P,$%     @
M[8)F6(3%L!*V9P  =*0  !,   !I;6<R,C0Y.3DS-3E?,C,N:G!G[+P'5%/;
MUC:\ 1$! 5%Z50%!$9#>B:B H(!T"4U$:9'>:R@"2B\"2I4F':2&WHN(2"?T
MWFM"#1"2+YY[[WD]]S_W^\_YQGO_[[SCOV',,4BR]UYKKC77,Y]GKKV#'<7.
M I>4Y!7E 3Q\ ,##_0'8"> ^<.'\>:+SA!>(B(B(B2^07*0BNTA*>I'^\A4*
M*F8&5A9F!B:FJ^R\G%>OWV9C8N(2O7G[#K^0D! KI[BTF( 4KZ"0P(^+X!$3
M$U\DO4A'1D8G<(WIFL"??F&; ,H+^ D$U 1XUP%\2CP"2CQL&\"*ZR<AWB\O
MX.\O/'R"<X3GB2X0DY#B#JBX!.#C$1#@GR,@)#QW#O>M%^Y[X!PEX>5K_++G
MKZ@9$UVWHQ+PC4J[P':OI)E:O1_!+OC<WH^8A(:6CIZ!XP8GU\U;0L(BHF+B
M$O<?R,DK/%14TM#4TM9YJ@LV>?'2U,S<PM+!T<G9Q=7-W?]U0&#0F[?!T3'O
M8N/BWW](2,_(S/J4G9.;5UI67E$)JZJN:6EM:^_H_-+U=6!P:'@$/CHV/C>_
ML+BTO+*ZMH[<W=L_.#Q"'9_\\ L/(,#[Q^MW_:+$^85_[AS!.:(??N'AN_PX
M@/(<X37^\Y=EU8B,[:Y<%_"]0'4O*JVDF9A-4!U!_=R^GX2&76B. _G#M5\\
M^V..^?T?>?:K8__EUSAPD0 /-WD$E  (.-J3(\JB M3D_J@Y(%WALHFZ$DK3
M$95O+QKJJLL83P@K"<1]B>?J=':D4M,_ZPUS9%1^MJ9AZ.O*=.UN)KJSTCST
M)4^DDEKXYBI7P1;$8! -,HT'O\,\YIV_,\IY6Q;4-UQ5E);0SQO5&=E5)SYK
MM9&@7P1G%:A_FU,DLC$?$5!H'7I^5_&A&!_5R_B]HABED=O"M?PNV?J9B)C0
M8I-5!<M<]22MQ;=A3Q7'>9?6N0IZ(&T,9D%;KT]B!^X5MOAWB_9I9DZ4WBR/
M'<N6LV=P:>N]:*GSR#J^\$I)RX<8<\X-O?'OM=FK-!"7G-ZE>]\NB0AVY3E^
M2DX8BM6^K-^U:MZO'^WY")%QQVA+3O^(R\Y N&*K8BEA:D(EYFZK;12Y+)52
MT@*2^YSE/2/2:FGJV'37F$?(RX]/7G8F?8XLWHWR@VAGM;>/O<O,+/(+_C*
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M^\13*<XS&N4?WE$O 44=Q9^UHO/?H"2Q /N@\DD7%DAC (Q*/1]C@8]%_EC
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M];6X)".?5[,^>V51\'?:S#[[^X'Y=OFW+9EA=Y@J^1,LN4N2\H;TE!L3N;"
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M%4U7XR >)ST49''L;@Z7VQ( */K:.,49 1QS^N/)6HH^V7-/>15.K3#"U7+
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M#=\X^:\3W0E>D[;I(.>^?\NY39Q;:(+WEA@6?[C;(AM6"%SM?KOZ&ZWR"NH
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M0\U9+/VOF%@YS/-O,*# (\0[)XD+W1*8YRE5WK]<P.S!7R3G_TNPL.]<R!=
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M;\6G/\!_/OSFHZ9D??Q+I]B%KT/U@^[^)<\DN2?2_[&S@,4/AO\?4$L#!!0
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M+&4SCF!O&N7T.,F4FZ.B6+AZX]M34@M(!\.MVL&7)<-EG\>4=%4C>[R$;D"
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M" N\H((=\.CUVL\1-2ZG.UMCFN^"\>NEE]@$B*47J&!C_1CPH\@%I(A/)[#
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MI+.)^"9$G@; TNRIE&(:P*U+D9..:EKF*@B;3?I;JO0$YV*17Y (;0XT\M&
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M'(7H+._U[H"-9+YHJ:HMW(MD2]U&?=WN$"U\.]J#YO6J,:_Z5 8FT)]NW^S
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M_KRTH:&MKH[_J244#H(\CY>JCG^9RG(M]-1R+EYHXH4)JLM'3,S@<OUSR(U
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M;NK]%WR=_W];)C'J^_\!4$L#!!0    ( .V"9E@TJ8K]EID  )W=   3
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MKVXP.^;;AE%X+N":)FND]Q\X9 .)M_ 88]#C1RR1ILQ-^:7I6?"IS2%RP5O
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MCXD1LKY_6Z'R<B?'+I_5INF+&)]@E+OZ>H:I%Y5RUG#1F_Z070WS:PY@<M'
M((AQ^>229?RBLD$O.@X+Q$JBL(#!6)BLXK*FPHR*R:Z;J._QL.M0(^PIK'4<
MTS@T[)C<6>Q3:23T+5 !T5QH8#-I'::'!>[N@3QGCLYJ+YURU2@,;C(4%6SH
M_S+4?9>URVDS\:':-C\K*C[TK^[\_^V@Z/4M@BN'+YMUC>?02* K5IZ'?GBA
MIN7_S+O8"/6UV$S911##C KC?]@7_T2$YYA_X@E!SJ@Q,S4R*7*%G[MN=*^Q
M@_R:O85W'[D<[KVEH*+@?ZT.\L+4\K]J?S>;&_BR?YC+"WG\E!&:YDLMIPOM
M#!9,F"(V>9Z.4A/NXWT2V]O^/H\]9)AJ)/ !4JS[35[;S?@9#W=C0J&T*.D5
M6+RE5;9OAMZH%W?C6_<U.YBT5&_R]G[?6CWOJ'OL,#O-)X58UQ=SAU60X(A>
M&T6^PMX'\Y2_<&'X&4],+#AW8VATWO[QRCA!/MZ+O%*/*:VMC2OAPO_K(X2_
MX14S9VIW,R/TQ91HWZY7$%?0U\K/$5'&"$!>#TPN]RK(W^BS"M-Z]/$PI>+R
M]%$!!U0A.M7YJ9]/$@D^@V-ZIL=;D1C23R7@2'\]S96&\]B AY/')?)F5!!U
MS/!\^Z*Y1RWO4N*0]O9<T;@\P\,R%(V2-J727?D[-36XNPBU'W#VQ$H:)E4&
M%:G-!TQ#(=_ -BBP]MC%N,2,P!C+_6/G3)*I6+VQDN??QW:+UYL23NS9"3D[
M:V%WCB7W'%?__"ZG3S<(A4;8789EE^F4":)ZL "+)0D6^#[AM27Z1Q*%TW>A
MWB0NCS,QHT;&5\P/.?F$BWY1W2B7%\O?4>\5-T\K,$H+KHH#FT/YD;<O0;J(
MH3#28&@P9WR0KKSV8>E!3=*'K(8%3)C;E//)U>CZ+BITS$*T(5VMN9?HP,]<
MMOH:]FFMKD^>UG2V/(C 9.(H?(N:-_KJ+@(3,Z8:ZOF-IPJ8;M\9CUY@)#(+
M5!EMF5S8K)\@OA NB%.0SV:\5,O% J'Q\JD'J/ .Z?2,N!]99^58 &9N%/ 0
M>'NC5\QRZMY*U-E5PHV+H&&W(K[4 FL@>\*.8[.@1C6'9!<5'QNKT=;E&>TU
M;23"-]@G#$GSEB WMWY5+<:_-,<"C$ZK-6NUQ>R(14W)9,1^Q+& **3AMD3J
M+2SP^@O85,I^X 6T[(+L@'C"K"AME:K5KX7"T_:P+<_I?=Q&8 '9 =W%3=6,
MV\X[&0-(_.@"AWLCC?$T$/F?TAC]($O7Y8HC3"GSE)RG3#T_PV.DRYOBI\9;
M4S_JENX$E5RY_X5^IO@Y#<V+8E.'G:N.NO,G(:*Z_BOYUJP:9TEM;9I*'WG0
M&PBTRB/1-]&RIJ7J1V*'VQGTX<^G5J6DK83# WM\*P0"D>X:'H59^0[)TK$_
MW9D4M<RX\/ ,OFC4^O_"B6K1G4P+2VN/XLFY_X^'E<K/'R8]S9[X\N3:J,YE
M%LO9+LOE$>]6_PI?6WB^5.;U?S9F?5^/!(=6[C,V?\YG,]X:I"CV2;Z%9S)Q
M6/5<SBT]O6H-(XU,JB&+EE6D1WVW5\ONHDRB#GX"<KTK["<'MFPQ741!2A:W
M_5>'WXG"R!S\/U54G#O/.6KI\Z&5'^(Q?UEO\FAF'CEVD 7E7F4VXR55ER(.
M["J35)8!+X7P%(7H6&^](OMECPN]X!KP6IX3,-249Y!94%B4VDN2;*=^G]\G
MAP6DYPM-E0ZW_)5*=I+T9F1'P\4/7S.#;*Y;_$M&_0=(K;H7J<$4F\B@M%&7
MW3ZA_:7[<BH;_'V>L=<L-#J+LC7XVOAZ^^[(+I4]D=.FVH-.U?APR@_FJSG4
MR%1WES5@T/B-NB,6@A5P31UN:_'XPD+1J!!!!JF7GL,UZIO9.KD#'ET_7[WZ
MT%3#/P:=,SA+7W5V9<HM-D22J%#@Z>S@7]?0,1,_-S8;/'1_??8)UX?)M\#I
M<WI_5>75)'SSWV558Y2(;&96*W1R+=LPO3R)+I$.];.UY=#-I\7)YJ;% LP?
MDP+O(;56@X?=5E)OW)&E<]Y1^0SI!4L?">CIUHP>%36I[T;-S7:.JS[H(\KF
M:JR'KE"W%)B5+'Y&P SK*Q(_?;M]B]$?2<=2D$D*:\,05R""JEK?[AT<[.V&
M+%A8J%OD6L.8"$PW'4M3O03V/CMYR17-#HJJ[[NL"]"Q<VK7;AK^*;/#_7,P
M]"?I_%N77[/QLHJ]STH'4?]^-R@-"Z!_@OCVM]\@KEVV=*;?G8*PF<$JE,$S
MC[% %#3(##JF+I<@DEOHVO OPOBG'3JG+-50)H,/"(.PAWE7/$WE(;! .[I
M0#[^FBHXCJ0;C)PGZ@&1'<N)""S#J*QF<<:(,V J1^MYOYR:LJIB_2--T7Y;
MBGD$)7& (PMYI6UTDV"'Z3N6%F?NI'6$),9 U(K2LY;CUK8A?5R\H%MT!*%N
M4,3VF9&'SB">!/FG]4C.F&.C)ZT8_*)9!2O*X%W0$G&"AD/0ZDV13G_Q[P0G
MP7G.K[01.2$^EP=^)=*_JNZ%+5)/1'I\*RG.60\J\K,[8 S^F"Y+#F?B)GB
M=!YY.$9\?*BWF=ZQP?,K]UZ8X?&5@#*.FQ6AF7:I6ID">F:O>(U,#G>NDE3!
MMY!7H#U?^H5Y6SP;J#.28A"B&W>H7@MJ\\/1.8M!JBVO-WH=3<@5^V]N>4\8
M\-^T?3Q)*19Z6=7;#?;BL3TC:C 1G8H9E=FA&MYJ.9#R#;@<*+N\SI]9"C;
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MX =.ZCKK*1!W.T'C:C5$?U_Q!;'-_L]DSE+&4TX(RS?^LL(4@T_CE=$R=["
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M;0-*U65RA<N" ]JK24'3]5880<A3+/ Y:$.N< >STIQ52X92O_!@0</P]K!
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MK8_HBNU@[&4_@%VN+F&!JXS$F'MZ-;PNXH._FM5:)?AKC1*EH=V3OWK?_N_
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M27ADW.=ZX]S/W^.?N7=Z;LY#4P>"//*-47,]ILX5,].#N0P!=$2[ 6EO(K]
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MMV2&0]T7AP];)_$/3R";Y)W1P2829^K7FYKXJ@LD>SJ+DL_;<N78+35VT["
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M0?QX..*PP\[]!8Z +B2W=->G\ :HGC*UP7&N^++[6A I8M6W.X$$"_A60A]
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M8V;O\F"UCGF,%7K'>QLN<&>][N.R>.SGF#+&/-/VQ,D1>89VI5?TFU>(/"S
M#7&"%"^C0<=38USUE&;IT$0PD]9I@N!\K&%0]_LD:^[@DC2[>(<'I=SCMHZA
MYS0]\'&,R(1! -FCLK'=78Z+#]WE,8'7#"*2F^U%)6DO/XMWE.G\@^-:1 $[
MXE[,)+\V"+N$:%]XM<%NM:#<\F<=[QG+>[AP^DC]T.PLP'/5A$<WGL">_V%
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M<B9!$<HG>>&>,E2!O>LO2]TP?4=#4X20IT8R-Y/<>2^.UV1G@F!'_UR,CW?
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ME!"$R./&0>A.)_04$RRC%'&&!0P0;%DV2+&'B&W?6LN @!U[FX#X^_.,!L^
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MLW'B;(I3;CA,"Y=Y=F!N=)=C@4<KG1FG.*LC170/5\SGW]:,F/M2FKW:LSZ
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MW"H/[OGLS:=M?.4O^?^!'O/B%\89R'&7$IMDESC>L "-['EI/+2\.SDO)D'
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M=\F_AC,=LUEY/R>NIA_W!PC?./:PAQJRO67")4_+TDR%Z2+("O80@Z9@X K
M]A#"3Y01?EP4PV#F^W![=.CQM_I$^HA-%S];G1HEA9@/HO<>I/LM-SUX/"QP
MU&1J./XL$9*DE\"58,FL7TC$["I#[-_6B/*/"7AY-QFVG6+0G+FNWF!JJ!$G
M]7*=^>-'[F9RP!P5X&'ELR3 IB')>+/&B%"=):KN8Q9?:SKZS9#_5F%B;,[T
MIHE&37)>UYK)[-?O4Q+BQ]QU,@Z[?X6)A/CWE.1A$DC67^D/&I+:+%BOUE"7
M:5B<T:^^>I#!)44OWM:C=D36#ZV>UG):[Z5/9>9.9NRXJR1$6>+&!.DP/E(G
M*A^3MBHU->7E9!=HT757O2T=OV='0-^YP#,<%K4\XI7:53E:I3)J$[7B?:'8
M:QF?">8CR#B-J79$@R8]+]5;3TYJ?-B-=\E(AGF9R:2HQSUZ<GT<*00Z-7]M
M/!_=C:QEU6K21IR$N< 'KI/?G5'EC&#9]7/[MAH_"+!N$NC^P_45_WA<D;ZO
MUC>J%*V_ILXC?JZW^9_DZU<)GT3^OEJ9UK7TYXJ^I2(#[;E&QWB0I[5_!&#R
M;U?Q,B90-909Z,2IMN(G_L<$&1Z##"_IZWMR'*-%T]NB)L$?I^?;W-8DHK7X
MY&89O(A9*:N-,Z^\&V9Y:]GW^0\]E4/H2^(S_%=Q6D_ER!0A%2V5XR68$2LO
M\A\2_.L*-[V^;POQ=?V+[6Y?\8BVAUUSWSWD4)YQQZ5VPLM].?BM-Y;P_4?_
M)FSB:=S/DN#)N>0=U\8G(KT'$,PD$4CT"/\O5TFEZT"M[_0D"LELA$(KP)69
M-?:V%T^L;J_UBO>4T?U ,7=B@>MH RO[DGO#]"JQ:;(&HX_ORN_)K6H3PW3,
M8&^/=WH#I9S X?M'OOMY"2/DN7V?5MN6".+(_(,U'//>'4D(?*W3L-6RNR6>
M*.\>HGV1AI1C\C0(<+R0ZI?W<?0BG.R\?CM:KO?55&R7O%6IO63:$'EHGJT7
M^\O5UU[NLIE,0(NB]F2UHQ.98N.$\^#-ZO#<0"]Q5N*Z+;/3#IQD"X[-H)H,
MT_0^&=U-D4[OV#+C&_CN;TL]QHAE/V52M$<44>0]]>#J=+4T53O9H"E4*WXF
M?;E$R4IIJ1:Y8Z)=)H8%9KRA5L3VWPZG^H>^_EH1QO./*+'*GW;PQ@)V90VO
MMUE6?KR6V\EX'/%:)D Y!?U3L7!:9DG\WIUM2]E4CQ1@^$OC83N&8WQ?EL>W
MYW%SLT">_0Z-/#.1P3LJ58ENZ /S][YABNHT_C--P57D94,G;Z<;2L5L&4\R
MR?GXR-3[32]LOE76A2Y?N:AX!!_'L&?6358U\')%[^A6OEK6/K@37_A1;_B#
M%D&L''U^X0GDQ#_AV[?R^M?KUUTY0W%2Y1<.[YR+="$KP@S+XWZQ^/&ZAAQN
M1:X'"]L5BITO).1*V^<[&";&<,\9K^L+'/66>G1:4A]!*1UGE!+NQ#Z>>9MJ
MHO]-KF9IY1H:<54BDZ([(IH$7O>*^[5^(C=SG,I/H;)C0J_B$M-.2?,T']&,
MF1HW!WQZ7C+-UQJS[K*ZN-9/?_EF&9)^JW$RB'G&D6D-D>A^Z%=[?5>.SOK)
M@TB\8"*O1*;!I,)]S."XT]V^EW#"OHN@;[\U/*01H!RO(^GO4*/A3T'^[?/C
MY*/9M/7$4[-1S^E1YEW-P4G(18'P=B04WP[_DJX3U=+EGQ0JK0Z?)GV( ;4D
M_:J]3M2?4W)*X>^$!0AVS:O_=_^OT L'CV<KR[".*.:.>_8^-?22,:GY#N&$
M[>I1'8ZAW"RN[OP!7;*$".@K3U,%X9G#KH""V?P#Y^ZE;9"+MOA:T[DA%NC6
M .E."K=0?DW%I0"(;:0Z>P?CLW=T%3VL1. 5MMC\[?,;X3=PO_EPFE0)?2_+
M>I;_^[<Z6CS1)J1%QT,DW7IPBF@!--]4J92C*E(6H:2Z\P'8=N1!^XY8C\6=
M#SV:=,Z*?([,#G:JWF!X/DBR#ZD2 &F'K62\\S(NME5GK$*M1*QEWV*M2,9K
M2*=<,UL,:10K-@GD10Z\G=$8A_AXS*7Z,EUGT]8FFI':J 9\F'HZ!T":E:/I
M?0N'!@T37VB,IZ=[ZB&/;=U8PU @M=HE+,#R$U4'<QH=W>[0*7]2:PBQKU$Y
M'+Z(YN^N!N'M))ZP79_B'#T.7ZX=(\K=+<W@#=W&)WL23=(V_[W'>;IT!RX6
M1IZ>6[BC:S<SF3(6$B$VX=Q9H9E-S.7]^FJ/V9$P'G1Y=V*^.R$'];S;DL_<
M_U* \X.747WM$?H!1-B2Q6ZRI&0S2'&B'#'0LB]]0!+'"?+3]%NB:/Y2&230
M8/_ U[2S6]31B5]?P5W_Y<_%U]"A_%+3Y;RWQP,*78;G>2&[7[_53/U*[#M1
MH:HHW--E?;=)NKLQH@%X&X+ICYCW"2Q]<Y_4J=Q9IY)I<#IDC+X?[38(5= :
M#^*=,1ERL;+*VJY/+^"J,->PL:=Z7JL$1&V4M[% /F^W7/,RA;[[8"?IE;;1
M[C,V:S[WO3R>Z4RMM4 &#RQV><3GPN0KIC<6Q.'@/[M5?XQ)RO]2(1ONMM;/
M''QEBD&"Q6TVHSU8YO;B<EC8;83U G><<6;-:ZW;CGXTI[V"Z,/9C":#*JT(
MT93H%L?L;9/;15_F+%Y//L<(%('+9*+\=GLZ6)5U4 9NEQDYVS<DWV_CHWXN
M6)!P?N2Q&?0NG;Q5^690N4FJ/8C^I5ZWY.-#7\>N,J[W9T->A=L@SKM7;_+P
M'A*\2GLR3(@!D(E)2TTT74GU[Q\TIAR5MSE173%.C::%FNR*6$:4VR>)2OJC
M7 SK)O9*FL=G GE*..\?]C\Y;ATDUD3!!&I0/LM2?E[@&]/V2020,:\"[M>#
MRS3O\SW2,F4T7TJ>K)(N(MLSKIO_W!Y#@;I$:W>M\2U^QE5T\7"?OOATD7GD
M3#( !-P-*[K=\&5FVVUF;J:DW9EJ7KE"\3QBN1KZ?B8H>5E 6?[-HPF78WY1
M4O;J=^#D;M653$;6EXY6\"H+]K#62=[EL(1J\*<,B<J;C]%90Z5@D,DAF0N5
M0SHS:F!%:@#<,<7T@[,[OJ3\<M6,/.<:RYM!*"EP%$6\# VK;J'<EJQLK"%X
MC 5B?MZ-?_'AW%5R%7%_,;HZW!'9H!RW/@_S=++H4*]W_> @1O7L-G<6=QEZ
MYV,U@C)<VCS'=]:HH4Q28Z%&>\:HSU6SA_SPW!:P7DGWU_,*1S]= 5\U\F7Q
MO;W7;A=Y?RC K9.G/-)9+](CNO/B>;#4/E6@?L5(H[QLE$VV@W_70/%#QVPK
MAJ>D5!0O41R'I7I=(+IC1S"KG>&)I&;EC?36JA.8'6%2<#['$^DUC\&KQ2UL
MJ" [D5YH9>.#Y4<36=41S!J6CY-XW;<SG\O)[C_V&J+SZ;QA(3CV_[5WW4%-
M==L^" HH151J0E%0\8M4*8)4D2;21'H3(S4$I)=05*1(+X+2D5Y$1$CH(,T@
M+4"H":&%'BG14 1,+MXW\V:^;]Y[]]YY][5YWQ]KYLSLM==>9YVSUOSV.F>M
M;3M/!43M,/^V9=**$4RT1;G):G%7QQ):Y7,-MU3X!HIGLM5TD"W0 %@LZ7H$
M=P2?0NQ\Y"/P ,(VMO%>LHL)DD>ILM3,,C*"8(@,\S;,8LOUV$)5!EY^M56Q
MZJ$K73NN[P,08<I24(]4V[QA YYO"+*;TSUOM.VT;3U>)#32"ZNRHP+NSW^6
M1'&AU"8F%YZ*!HF2?%/FML+"C,:$/("V_4GJYS8#S BG\QNW6(-,,8@X3V:@
MP8B/",?NJL.8^P*V!DY+M'&TFU,^3P5T5 V_OSAB3QD=WG%V&\Q^DLG4XTNF
MK\(?!71[I^2>"[I+*HG8O+R-6 ZWRY\.+G;>W'=T#4-XG@JP"I&3HAE2)X5T
M?#=/GM ;DJX@<KU7KYC%66[%:NG)LWA0/$RET=$<@0XU/H5KQ]&W$F_./)'[
M,,83EZ"AU#JVE)$34]FYH'UY.R'\2">/R!JD\S73)RMI\:B+S$W^8E/[$]IN
M41=Y9/=NVGK-1G#4=8<[:/_JT&9L "391#5LFJ",EJ(9\]^R";/<=HLA 3M3
MOBP[<ZKV*FGV=%V/(A*S6-\2*@/QE1TVYNU>G <-!>:<2B\>FX9#Y=V/!$-/
M/MK^*@\;RRE9 "]J?145I1L!<UAEA7-QJ1- ',LM*-W:PU.OG1V;_*;FM6J(
M"!7**QJ7OQ.>LSBB/-[-\)SM88S7:?)^PLA]RICNL5'HO/6^)>59)!5PPIX*
M6"BW!8;VG!([H""H@.$^:UX86AAC]1[;-H1*EBS]D4JV+>L[?C9-VU4_:5DI
M=,?7W894P.FMCC8RD_+^>;%?W174V96P)=^5FZL@^C],ISVI@.WW1V J0.48
MYSV3I )(#T)_-]_44)WOK_R*<<I+MAY_6_P%N$MN/V5[5XH*2 U&B?UA7/,(
MW'::"A@2IP+F[K4=&?M<,-PH#[UQV#F)H1CO@=K^,,S_!^6,1PTUD65'Z"W6
M/[7_9VLOLA=.#J:WWB8?V+]]KBW67*?DA33M\XJ]P39Z>K,BBR1[%/ZKPZL=
M_\_"G6%,V=7+'+,['D;1L87)E'?'B.VQR]\#Z^SW7U/48;:4YN)C19B?A-*W
M+<9T4S;0E!=C:Q^[0=O-DOE?0-'&PQ%JM.UT@<9P7C%]C.O)N+C4%D3>H$"$
M^$NT#3UHB+[?9%Q\/81F'PYYPAA!L,BY)I/%6WDI+,S:TY^V4XW0N0K1-2SB
M%;<&JFQ\Z&'@5B O9@5.?+P:7LOPMC9"D5/?K%)($B=0IW+1T]-<XZ8<K[H%
MI1=#!2!"$4J=[C_?+OVP=?F&2J\Y;&HD8)\J.35R8MT[VWB<,[33KXL@2,!\
MB5L7?SRC_YE5[E![)%M2XW_8@5GSRSE;D\[8;V'<5;1Y"=4/8A?TG=YI5S@P
M'9+!7DEU$ U'9CLS-#W:NWC1<$5BW3+AS4\79/J\/NMJG;Y7T2J2PZN^/9F!
M'<B73EL$>!AD$V\>PDZLX-!F Y]5I"V3;O?O6.9GTIG+C0KTMK'_:"'RCLA/
MNA:S2/_=;O_T+K')3.S=<FU#K#9=#R0)6'"-ZU)#%8L_1Y_F=K2_^WVG'3C7
MDF.<Z%NF\J*7QNV#'CFU--^_RO*@GKEFWG^C"_;OO/LZ;\G![Y9^ W;J^%T<
MGX@A@ZN89_SYU=*O*]<\JKG>>=_!4K-13O0Q>%-#F66,S#L>7FBKZ<P[D^XH
M;YX(2],R?B$$ 4HJV825%&F7.5N$5#O!I,%@>)^G)R1'G)C[-H_UQ/98<94]
M??Q[*>#&A;0/RVCU#$VS0A33T_=*FY07W[L]TTQ.?._,N%C;LAT7OH4]B_*N
MDXS!7 G4#K^YL@UZU%HT4JLKIH:4.3#)AMJ? ;UZ+O TUR@><9^?P=]M]@$%
M$WD;4]"*;T);/F;-M2)4M0""M@@7)A)BCMQ<S0>B,]TW[.N4FYVJ!S%K62O;
M:.[WN=T6^A$(=Q9_)5MF%ZP(HI9F9E9O3 C'WOX)OPS9;^>26]>WV)TDPR2!
M34WUY,,']<U -WNS5U*=Q2#"\A%4[HAY7OMZZ^<9T AEH*V?[<R#TT"N'L)[
M8=K4?8GRJ74E[M8(C 82PUQ)1 G7>F[W[M-]3-9?2I:(-65;B H24]XXX\4?
MPR>-&<B"WT$C95(>?O):FR!UPY&YQ9-K,LZ.)1:JSJZYOL(&EQ(^F=+*/ET>
M;159#QRL*+' ._G),)Y^B6RU@E'.]ZP&Y+'>>-GZ!4XZK0SX<L,)^C#\'E-_
MS)4E_ <JH&DYA#_<> Q&X>_<;M-I''+CI)SK[X"(]WY>1"?52^YR#]XD=P=?
M+';".L0X[NI*=F '9^6^S<5>2EE7(3[8..*?;]+5.;P[JXK);QG<4A1Y):Z4
M1P@[!BR"A TIUG/:E=8SJSQQBX%6C_:T1Y>O"3DZ7>UKYY?E!JWD!A956?K;
M'.A'-BXVBK2FEZR+?-SAC1^(,A8WHP)8Z&W5;'Z4^^MT-N)'\"X9E\.7.I[2
MU:B\FR0?!X!,P^W-N(I)=4BIL^]KF6I(7X39LP<H?N&-?0.:DJ)72J!P*3'A
MJ:)6$864!AG"4OLF>"64";=_:J6=!X^**3%<<)>!B.4*,HY1 9%]O#\.OF=-
MC"#3TG8YDBPL5$$<VZ5:"W%/2@OR3M2(*ER>QU7J'^H1U#!+K8-!>W7W%P]6
M>)UH5Q#N^Q\IS/&D9=U3NA:J95+F/?K2U5F^G]=7A6(ZD+87FL65^-!G'4UY
M$B:7Q,Z&\9HMSA&4$ZM@D;='8.2"(K5B\^(<3^;RCGS!E)1O!%"*H;,-]U"M
MH*"SA7IJREWQ90;V,ZRW5=94^.77KI7X:]J,+/D?*2[ S7?NJ06XWPBN!B%I
M[-$WB<\9T(&54GZ<V(F8"*2"C%A<5_16Y< E?9Y0QA<T0TP0$'G#5@/G+]MI
M$IB[FXH,*U&'UW_(%AD5OUI&#^(/#"DY#C%$4QV?LE4D9TKIIV2XCR^J6"N/
M56#\4@YNCN,EQ"?8'>ZC^)5M2I>V)I+/#OS\$Q]G?.IFXO.+L;(&!=)]1"6&
M,'.21F2YKJ=)GQ;3L-GUAQ=3:AQQM+&^[&/_=LKMOXE.6NOHUHR1U\B'^QQP
MG1=3U_6'PW5@,.;L=R;CP]<-[CP3C-,X4<H%>%#[^ZE6XW%SQ&!@]\%L%*0Q
M3=L'EKE@3P/!K4*+_IWV:=:KC3!*D7TIWKQ;9.DE!':#-4.QDY[?HNT?^! R
MZ(^CJ$B$3NQ44>(M5HE9I+JCIX^H@"JB[4\08G@\81\Z1HGPH B2;4L-U2%$
M$RSYVQUO.!'Z&/#CN=/>.3@DS"!U<D74# \^. <-$< T*[O6V/:;AC)$2Z+)
M[/IJI)R$JFD@W%Q(FY0$ZJO]L+L89F-/P.FZS1K5!3^:%SVC'K7XTK>*;A%"
MFTMBCYD_A!.S WL5;VXT?E?5_'R;T+#+2RR_Z5]OLQ)I*ET)TKP4_QI71E9D
M'W0>MP%'4ZZVC;D6(^CWHA+GDN)1)QKEEUSP^FY9TV/3%CN20>H+8'ZF-0W*
M8?]#ZT?17*;>*5JHTU$M7][#*>>VV-M!?J8V=(T<KAI+S[_).:K WWQ:665Q
M4>:5-]]O:L](G3]3W!X@Y=D4/+GD3P*>QV7%'AX[+F^VYX1JXU@MS-N9: \5
M&N"<.F<G02N8=MARZ[Z4/.+6*Q!;4A9??EISFWF#/INULZ\&K]_]-OG'IN=Q
MSGLQ4#KX@=9&ZH^7]+0Y]'=[JMW/$RET(V-\FQ2PHL;"&:)3U1U368.W%U5>
M"UZ&?[L1#=C!_=3 W N_TI)M%[=HEIK95-V1T#563N*UF;@W'L3I<*EYXDZ:
M_*C)1\O9:?:TZ=J*5S>59>CQD)0M:V94! 5/ JSJ5KB4%5JLL?6.K_G.%WN!
M"5XK?D0TWRN:M5K3-'_'.TH2VZ.MET81>#W@7K(=([+)::1+D-WX- LCC>JM
MFHPPO7%I,>X$QC7YN*-=Y%Z:T31>QX5B9"/E>A;0F5C(V\7J M@I!_<':<X3
MXZ[8LCH=.$9).\&V?((K&U>;.OF3EY+,CB9O;NHQ#LB8BP8Q+RCZHG7JFQIJ
MK&D0PI6;Q<[-#4F]BQQ"<SN"BJ6TH\)5%ZHCNV %S@>;F?95?>]TEO3VZN2S
MKF#G)$Z^0BW#&%0% #0@DY%5H_W774I2LAFM12"9UPS(Q'9OTCO)  8<Q0@M
M],2?B)*B69?6P%("=BQQ<E(_YB-F'5][[D\IS:?4M?&R0+]L;.QP4?B=*-*9
MEJ,.X_V[GS6ASR\Y8>UC44L)KX'ZQ5Z#+K,Q",O#@"#W)1LT#ZZOZ(?E8\$^
M)F(37SKW " 0SX[RSSEP4O"9:])Z;\VQ *^2E'9E//&IRXWWT\WWFNHZ^#-=
M&4&MPC!/X&'F\DMI87>Z<=/P+]\(C]$]$D^5##SEA^BKAO_J@9F4VS- *N!#
M F4D\)<+_@[2CJ?L0W[ZW(CL%B/F&:JSI^?]+ZC)^+]"_UAT8T]_:W&H5S-:
M>12#<UI)>#_%>5.I8*1BK9'E=2$'](SP6U\NT8)E0<S5C.'\;/P[M1)Z40?$
MYJ^SQ7JQ$=F.Y9-]]J$P]H%W!:P7*AK,@L%I_$P*\BK1)J/+M5S=68VQ RR*
M,FF+<#[PQ_RG<@/ZGP[XR@*8IY.L+ <N7)KUR>Y/=(ORUIC44"G5[T0SQ\F
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MR]^NV-&G<=#4<ZKJB+@,RJ!&_2 MKW'+P)G "Y%FM:>E^FYFWB%R[W8+@RB
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MK<:#?$L#I?.U]>(-FV+-].>\ 8[Q^XK;H^NMS\$LC''<M--TW8U&3I$17/'
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MQ<S1A&;T(8CS2GJSYNPIE=.K!R=QOL1_/DH8_XMS'W>H?A\-]+EU0"XHX]&
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M/-I]=N"GL!_("%_#9D6F($>$K1@@74,-=,C33 <DCLKH^@+8(L6 +8C56IA
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MM'JW!MTL"3D?5L.Y+KR]&ZR!RQ RH8[L2QTWTSJWF.+H3]EUD&FU]YK(VUS
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M_\ZUEO51-3B%<R'H&E)T0$2>FM@$\K / RQ/@F=F<<YI+;UL-SETS^$:DB2
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MSGR!X_'%AWK^FR=![+-^WB=*K#)Z K(CH]%+L0W[]7NCQHQQ[QP&6.LY0+\
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MNBT>5-&.QW$2V5=<BY'_<BM'+7WR^,L7KS$L'-4PZ+!$%P8H7"KA6]ER.'#
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M$?=XHZ%Q6I>FET%I7%T;^5KVZ/_I[;S#FEJV!;ZI 9'>NQ(0E"J"].HA@)R
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MR/G'X2'<#OD,_DXG91"_[?&N4RABCMKC^TLLO5- S[$L)-;M$/1K-2F"GN5
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M@;X1'J<^7/R4PJL_&(QVGYB;8T32X;(C1?VY92(Y<D.P5"UY\$*3GPR1 "]
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M[-0LVR_3/!@CS->_U$0![$HH;76(MN'ZGR#J?UI P8.J0T97->.SF%$D\MV
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M:P%V/MXM?NR/UP71?;M+:[BX*M6!3SW^#L_C$<Q6,O]Z8>,_'?L?4$L#!!0
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MY7%YQ;%5GX#$[F6=JO@5#B P4B4Y41*&]BR[[=UD[MBAFC5%=RF@?O\TX%Q
M,U&$A?DRN%" X8Q]M#B!?-^S6^:ANO7X]_A@5Q;'K"G8O(-XCD^P7C[]<V-;
MC.0=M</#6C?)\9"HEG\D'& X/8.U3,"!O+%/$"%QJB-*:HV<0VT;GT]*!546
MS"C*J\T .1QX21"=!P>&?5KA0%7=$Q6O4UK[G9G4/GG;;.(1X)G=3\D^ZY9-
M,KQU(J$7*5/3:!FCWY@R.LIT5[M$ 0%PLO?D8+C1JMWBU""-[9(VF<(Q&"C\
M6T6^*!S (Z 3(M^<]V\OTK$VQG/8!;-%U1T*)"IPUR:38"F9$U!GX 7Q/+(X
MT)WG[7^(Z)E1:FWVDO_@&=V-'/N)$#.[IVHR2EW-7C_/.-N90TBAD3[SOO'.
MG0EJ/G-*/<]ZMJ&6O+U^&9#X:6G)L=X,Q9'>=S#QBP3IGZM,O+X6N: BV-@\
MF5IG2XQ HX!YH$.A%WKS#TIA5X()Z*<&KJ4#-E(<#%EK6"IJX-UK:*FO\@Z=
MU_DIPM9*<\!GDZ ;G;GX?&1L$L'-^*C8X_?-^[)IQO,M 8;*5/0L'QP;#ZNO
M)XLKK&%L4VVB]QWY.R)A'+.._,_W0F2=NC&#_+X,MKNN$X$Q]\-@1$>-1*?T
M34$L8:3O/G;0#3%N8-YKIX'\L1W1O,+9<[VV7^?_YL>LIVK>_/B%9S7M3P=9
M;7:P/ZUR[V>?(%DOH*MST[9<^M;#IWAY8_I5%!SPLJ@S/'OD=@R2N$"?ZSQN
M"3AXU:[>5KT9"PVZ=KP_S;Y'K?Y0)6H,+G#_" >^XO6(TGAL3^#::2\;5H<Y
M;(8%74RP1K^.EC9[@;J9<3.H CI6MAH05HUB%V5[WG#K,LJX-&^79XZ:0;'C
M+D_MOOLWF-FX(^7+OM^# W5S+D\KZA*V#@=N,CT4JFT$EW19_GR6D;!"-5QK
M=2 =.XOP1=PN)\CN(R+-X F.3]8RK1 P2;%AI.S3E@*':LZZCAHR@!X>RJ7I
M1MM6?DV==AE8(5G6P+C@P-!8?L "QV-6O3C?LC)[?.$:+6$$B:'Y1_'33:[L
MH?G/H$)%94<7A76N<OR;FKEC#VT<7[ZFEICM#\VDGYVXF['(K/?%7,X,/+ZT
MR91S?&F3*E5V<BDQU*OC-?*MI"&6]$GL.I(14(<$YQM#16$C#3RCI6.6U'9N
MX1UO\)_37W4!6:C0U^+X1@V9FV,.8#:&5LZ)UJ&P9^/\43M\:.G1)"[L13%Y
M2=87'2&JH;OSOH88MQY4+ZE4V];?Z'D5"OAL<G\1_[*0ZTF(3;BL/X$2;AYC
M/8"!FRH]?(I*(?=956)F@F'6G]PS1NCW+!OC9#4BN5\&#\J5H"8S=@/*?#64
M)EM-^!I*.&.@G#L0A9!"_7R5_Z,KAJPS"D1S(=)U]\3.PSA1UI4^7YWYMM/J
MKHC5>R*L@P;2<MJK.+<W#5KY%'>>4 DB?_99BO[>' %ZW<;9(3 )-7Z54D+6
MKJTX/N/!+O]>5IJ%:Z*&1.R1)>6\\$H"R]>E9.G8AIY3/H3O!XU)]))6UVXI
M9=+"838N>_T9*7M*OLVA2U&"@ &GN<5[<2NQFH,7)#OS$34)+=^TV3HK?6*^
MYYV\'KXTOM?ZX[*\ 4TI5[T_1H%]89$;S.*:I0>_,R*9OB8&#<V6-+5[/;.G
MMSIS!\Q6LUA$].% PK4-'#!\6IR3R.K@TZ3G\6 :-S&C$:5,0O#<A@V=!),6
M"9+SBW%N$4U9+N=0@8N#MX5, [Z=8R7')R[:YYHGA7/%49M@3%!T>(X I0UE
M3O0OR2OJA1P(^.-\!^FZP0"Z["3#[-MK1)I :-W= NXEE/[A+6=OT9H!B4^?
M@[C&@=1'A7M$PX4HK15EB%4 9ILEB_6?>>+XNB2-8+4)L4&]D7R#<W>;C;+Z
ML=+B83[7N1:1Q?SSE/<^9XARY%$ZRRKGS_P$3>[Y/#3WX0"*?18V4EN48-:I
M M'!L^I+#:- @Z9T'UW]YIF0SMKH!V1\-9WT_^[)S;]6U!JF7,M%&EKK9U@W
MFS^=IC$1&.Q7Z6!<:I<4I;^QX49O9=%_<''TLL?\11]DEL9Y)'_8O9T\/[T\
ML,16R;;=&,C3P!1'6Z6B FPZ*Y26Y)W.H[.LC@9@6G,K_1[.LZE^Y=)>^3Y[
M@J"0W ;#CER^)(*S+!_ -E')"WUU^S$O>6BB9=+5YS"J,4TYN*^X?.Q3C.JV
MC%X#J*$V=+B^,>)%X/A0'#/L35%>C.5<%=IKD<52GT*;Y3BU !,[5Z+3\"WM
MP1G:O'2IJ5.V[2"_5P,ZIL-/>"S[8<+@&2?+FPC\M".LUU>D9E']>_C&' YK
M/W8H?UQ5'$"%<OLYT\2(5!2DQJ_K)9?NMT$'N0J5@?UBDVHR^"&:[3.?^.A1
M_2SL7<LG57&;J'[DC2K_G'E?&)U47]:HAJ3X!?:F4DWE=)X@Z90@#48YQ=#T
M\#9-/.O22MQ,G\9Q@J22F4FY,K#@]B60 P"(7Y U:J:NQK@R*WB/E60_(Z9[
M$G+W;B"FM<H0F9BKI\M.GW(DW/OQC^N#J"O.GH$BY-X01T6YEZOWXH-Y-603
M9'LQ8G*"Q+J+IV06=4EN6K!BS00R;0H65T8?(9539)?/JFO+2[40OD>]E)7"
M![U?\0E2^&3)$7)%GSYN2*2BZY*Y/8=H=1S1ZF9C[_?I9L$=;" )6<,OH=!'
MH:,^]P)F9]_O;KQ74\I%+DRJ#&YJK&L(67ZI@--++(-TO>GT?MEZV3!X='7I
ML,']LHEF+P19]J.*/#U&EB2?>P1[;Q)^M:L?AUJ\><?,I]-,3ZTL9&?Q;Q'F
M]X3Q;KN/^8HUZ<.&-5[)!RLH>;N?Q9-R9<2M5@UJ_A!DM1#&- ;8&3+W&>R+
M?VY4OKM>BYH/QD^T,P%E[3&!HKG)?G=$JH!BP,-LG^.8XO:K]$E^1ZY1*<V:
MZW* 5D2*C0B* PUB<VFKIN1XVD_)R^U(+JWU9'K?S!QJ<8.8"6EO#@8XA1"<
M!:D4.T9(%'\BX01A>^LQV;=WTS?PF)W?1!(,+M--75UE"UT2+CWY)FKNSC1F
MFRC$>EJ^0+TJ)J?\]680MIIJ7LC**K[Z8KE9T:)-/,B=4&L^;-^%%8?U8[8Z
M4/0JNG"P),#Z5;IE8S/C"2TRKGD47BO)@9.V=7[J+9;F(LLW2/Y6>/W:<Y%6
MXBRE!Z+U<&*&3.QU $MADZKK?L%#1E.HQ5G=$+54^4-DY)'EP0*W;185*.U^
M7KXH#6>_6U1?_I-)H,:*$/1U^58E,L.EQML9+976_C+$N^UZIL)?IR<Y=YI)
MUW1IZV3I'HU9Q'O!"W:R1R0ZWB\]:?-J9_Z %M_Q$[K?U/ XO$92C- O^HQB
MA+*G95WH88<U<LO4G7>HU1CMY5BDV^O:EYPE^$\1K^23?YB6^+QCII+]QV>,
M<Y;XNXA6&?+QVR;G<KU^'R4R97$.YI%Y=&LXT(QA@K++3#]U-70V!O5VRS-*
M4&C2P9=7V(0NCAGF1?[<>TNDI=4X>2>0/+DJLV ^%6H\-$NHQY]2U.Q#P3\^
M%ZL5A/PF@$;[+[3 TO2)6]/3-Y;\V-H8L4UX3%Y"H;II2V;/J%S;F(!N*#[]
MPGQK)X) T[$$\7F5FLQ:!:%V\YL5Z6G6U.4%I=K  F2#?H<('<J<31>5^BE0
M*[%ER(QR76.$4[@Z$P&AU P&L%]Z?*QM7?SK(3)9+*)!V#*[B*XP.+H^KWGT
M!8U.+Y4OENT<OKI]N\ZTTEOUNJ<X%=9.?B(N]0E2H9[4'UC%ALBG TP/C9>I
M'&&_ZAX<//SRAXQY! <\S,28K_%=Q+=&6O&K>?UXU)(8_O);090)I2?!2*RI
M'(&M3G[:JX@/NG0F(;(D2#X1?OB&P?'9CKDVA$%2]H4Z/0SJM5[N!ZW=1U@H
MU+/S>O8AJ61R)A;VUC$>W-VX ZC7U&CU,EC*I]TR;/'I+EN/A!=F?/.QQ1,L
MY"G)2R3A]_':]B<YH&_2]AB?^]IQ^=#RSPG8\(4$\I\PM93 T7444^&9L:Z^
M(?.5[K8VXB5^@[=;<B9)S,#X^APVP\?P]U1=:'4R1.X_=8WV&*>NAAW[H6EN
M^>NOD0QXT<R1/HM_LJPPT)?R0 WY3?P[[%H!GSN[:Q:DYDXHZU<4G+^HO*][
MJ,4_#0?\R5RE[P(-LOM?\(EI*-5,\;:RA*^?;I*8RR\6V H[?.04HKY\G#'<
M(_A<LL,G4!F6R<<DR,;^?LJU"61(.*'\]7MCV*N -I_LOET8GW\$,YG]6G*"
MXA!37H3TOVH#;^L,1O'8JM;<"IM;VA^Y.'D0=S^EWQ%I/C;L)U#+R*])TL,_
M*E<VN(0#$"V):Z*G6L01-A[[S[ZW/XOH=-1H#IWEA .CD,[+I]H"1A#[* ,'
M+IXX15W^/[^IELR+==1H\I/&AG8^E4 \3^7/E@X<F#5^(J^=#\(2__SF"HWI
MYEKD'VK_H?8?:O^A]A]J_Z'V'VK_3U!;E=AK1 D'OKG/>_K/W<3R]>Z/+L5P
M'=DY1ZB7"['P&XHRD#K_#JJ[>RJN=3-I_CW.)OS?)TOD,GA#TB_+=(*1LL2
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M5M^VROE#YQNAM%GD<" W0!$.= G"@9Y8B(RH$!QX TN" U^<X$"PJIBXD6'
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M>5<IF575!PP7K2E<P7G!.35\X*\C<)),"+/_H[_9_CN*5K9:34/B:-;%.N.
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M>NP,.(@W]#/Q#.UI6*=MKFE.?GA?ES7ZZ\*B]H=LKR="<[?8<\%!#=W.\\"
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MU9:=R]L\GNI$[\4CZJDCK-@#!#'WM-9-1H*XEGRM53Z[^VKX>SE">JYZZ2R
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M6D7'*2 ZWQROCR7EX")E,-RV]MH/,Z8SAK-0UC B6O_H ,<C4^$P,BJ_$#3
M6E $55=BMTJ.N-R4QLP\\IXJ'K>W)ZBH9.%MJI0UQPK[HLRRPIK+X1!GH^:5
M^Z/9U $Z.Q0,N0X5I!=2L-+UA'>%<JVR',D)#]%=:<Z2MZ96>%0/[)T...LH
MBR=W=7[SQ)WWR?M,I K-]PK/Z0VD?_%HF\J,1AX6139#9A-^,T%%7C@IL:C9
M5EG?OXT6E_S@J45/O/F]"Q"L1>%+TK@@CA9S_>/<JY0F&._R)NO(R8WL\>N1
M@[+W<;OGA\6S'D!1#UM;H6/**0^W1),;]](K1^5$7$M F50>ATDT('HP<Y+\
MP'[GS54-I/+&SDF*R)5>1WUD/W^<+78;NY[3VO6Q-XU5#YP$"5;<+0;P   0
MQ5#2U8R-3XNM:A&N[Y)I"B13>ZVK)D,&_*M#!]\^?"D"JEH?8UK(8?KUL312
MV6B"289 EYW *\W)9EG2X+*41-C9H&_^2"KD3,>8NK5YPF45!3R?? ,"U>Y6
MDYRW%F9.35:")FT:33X(4*" Q+B79J\<GI=L,".Q0&/)6MW4+XB?\\NK*6 5
ML;@(;QD\5JK5,  G9CH&='#V%;9=+MQLB,'"Z?DZOL_FCVY-?HB=.8O!"XA]
M(N:5LGRJ*Y[Y"4D[^FWV_/Q),4-VJ/VZC-?,ZV]!0,#T*-6P/]XC_+&H!(&=
MHWQ?UP97=F?HF!(YETODT[Z V:VSK_6,7L):JNO81CEA777G3Q6X/H:QYSWY
M=Y#B?Q59GV\K?"/3>!@D%L+RT4SO08RBZ)/>-[*X L O:> CKD07EXRM+6%Z
MK?;D",OKE]G,D;=O%6T")\56_U=J]^^)XP/RBVO#P[7);$?*P RC>\I'R#%O
MP6\A_4V,V_'1J=19Q-(YS<=&%Y'%^MM)9U>4P:GJT-'RW,;Q?,].64'71?+;
M1 ;V HV9G:"M?=MRQ*-LM$N3GW6R<4YF(\%=MF_,#4B2C,?8U-16#6Z6MH3Q
M$.GNN&WT?]Q_LEU]%R\C4+6>*?H[A&14.M[\[3:1%<;X_VVKHX,/I[R679QQ
M?0C7&W8QT-4KL+I+O99T06;F)!',=NFLG0(-1\@Q?O*1<BY1SC->M#Y:,IGO
M( U-UJKK!ICQ5*0%,'9.=,)G+@H[KU9IA +;(+-SKY,TFZN;QI<C7T;2U^-P
MB-ZV[3BJ*&Q'LC97C8DKV,(X-YI%L5>>VV/I>;Z;I5;0HJLCM@$.-BNX^V&5
MGPY.:0VH[+E?GJN7/0E]O/9LL <PC\?;^^=Q>Q]5)3LJ\KWHL0K_MRP<-?DR
MZA=$G\S4A__ES\L8R\!252E QD)<Q1[J!^J'ZYE,($XE[WI3I5 <1&V2L]DU
MMU2%KUL8<!1IJ0RW2RB_B#6B?7;MP_"P+N+V]7.VZ0*22]LVMIB # D.@<.#
M4 2^+]85]V?!^HV1^V/YFNFFO*IWF406)HB\=<I'GM'I!",P3!D[%I@[6N]#
MPDYF*Y,?[(N]+-.+PF46GI>1/FS]L:02W#GI%G/I-@R*ZR'S#L7-X@8&W!.Z
M?,11@ ELZ9IX'@6P9A%-_G'W/<4..[E;:K)_[.:LU%5#96B&2)JQ):[R>D][
M\]\]QS _P3/]!1G)/<)5)FP1S^IBIKG?UJ;\-'S)VG>S/OKMWD<<IA6R/8UO
M5X-9C=JYC*&(3)*M'1;P++Y%$VOD$,>()9UCE+>.LPS@.>?#=2T96/"B8,?9
M8$??=SPIM+A6^F=L'[+&R9+*[C;_M([,+Q2 AP*^\[QUJ3%1 (.]':9TDNP^
MB,_0CL@] W[IR,@ #BB 9.@ P22U_1:" F9*ZRMH85(('X\7R&Y:DYN4IA2
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M<R3?0-R@@[/JY&/LNEP8*%)T$39[I:Q"7A_#G)S\/NSAN5'SYX&TO=5;CF'
MF>A P\3DDDG5Z,O'!ZX$-9[^<)J"D=YS;BF.8V';BG*7TN0]BP:CV["S1;'Z
M7:X*YIF[A.OB;_M\>-G+=+ZR>$U.!>S63L+/<CUS](VE"UX4]I *]#WH8HE:
MK8J0JN9V7/27(/VOR+AY"@8]$^!')SVHZ(EH2FVI^4UHM!C5[1<!TP"_<8*Q
M.5SH^OE0)PU%C:73E=-TWK=M8BL[IHA>@)/))%D69[&;'9.Q7=UZECLW6]]:
MBB2_J;K-+5;B(4C3D]%MW?:GR(LFEHT6;RY/MHYH_)U6A@9H(KX)OHVH[<^(
MH^VZB"4K\W>J6(?/6 @('(UK6&(ZJ&-U-&6V?SK@K*#9N<(VLYN!*;/#^,E8
M[99%79"$%O<*4?UL.\/#H<>4#LQ5%1O?B@MZ?MDR2#!8/QR;G-&F-C<J^^7*
MXM8WX+QUN+/\?5O'O=*R4-'.+8XLMEB^=U Q IYV?%*QWHVO!*)Z4R6?"XF\
MU?G5_R[[YFWA+D WYZNXZHH$?OO987^9<<BK@3KV>+N8F^]1#A)6<)Z(VF@\
MF?>NE,D%C>^^&LQUFB>^(H@E<\-L >Q'#,M[.DT(YRYLQHPIHP7S5RZUMPA>
MC?:QN=R98L81+%Y>(MG*8!_MSL[_.?JBN7M[4VW%<4)/E2D,V)#\)[/P7VYK
M==;#[8*MG5F;I_+-(\,:+_GH2/8ILDWH+AR3$UR9?A828/&1MIDDA6V"\&59
M+L([]:2.X)3(4$6@H0"4XH8FWLCV^&X,^X7J%0G1#_H"_] 3?]L20^N)<T3
M/G@G#LS\C%0:!3# ?]\\4)O[QT[9:YPT/130IXV6R-XSOPG11L7U773*+/6
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MZR26F7O405JXXF-U9=OJ>[1R"Y1#^D_PAZE9Q(-4M$@;]C359)P9BH\3J\I
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M\DR^V0?/]"P<[*AO&!X/4JH>^4WR]N]?2RZ"]PH..L@+90#G*^LI9!=C7T$
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M9Q"!F"?M<D45C*I"1$K[_? K_$6;H^A!)-<4'#J%)FJO_6/]=GYT1*)P'=_
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M(X@=E;!+0_G7F$O*HM!HS;#+KVNB;M3G1"AQ%B"N8"#4H;!& 0FKP6*,C[Z
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MD\!FO#D'WOH$P%?N[_G6XE/[WU.L_W[01>WC'V$K&48'"P#_])N0.VL6WS(
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M'ARY?3N+&P* ["?E#?#AX.0!FR8E2G%*,33B&.0>M],M@7)8=\/)VRKCZO?
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M8J(&+&:1NS@JVV <KZIU:AC/JUUH_(GT"<#D8E_6<0#- 1R"SK=&,?S^3)0
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M^G?/"&-_.9CQCT<U$-+(#9I=&M7#=%\( /*4H?.!_W.ENU0V5'%*L<":,2#
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MQ<RC7C"X'; 'C=N__2?U8TY 2^G("6W.C^.7', EP)ZJ,1VF[>MP_BFS229
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MP,;6AFO][(?U:$Q9O'QV#'(/SL%V90%,8HNDXG^ULNS_DIOTO0!P%W;S+^L
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M& KGDW(,0C[R$U]B"IVX$#:4BPGK4'W+W*R?XJAH?P=PO A5/P L7!"@0C-
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MT]FD9([$NC;^UH3;7>-ST2-USW]?5.F+97F: J^>OXZV( <LK=M'XVT*8.!
M%L<@]%4 P*JG$ <7@,7F)P0\D7+T]_G5ME#;[)@H-Q4+<1FM:/]*"/]--\6^
M^-,6LR3C.W7(D^&#;TU8PU'N2/\^5O;TMU+SH-?*-!3@BNHJXP>0R,TLU).+
M00);]GCLWL&M3#'@P\==@Q L 60=X5G8:_\(DYUKC7@B'S[RY%*+J +-P!N
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M.?UH$6*GKR4_) L+S1"NGPA22>E.7QE6)'GH!TU].O_MYQRRP>ZA<$+07Q.
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MHSL)%W_DE2'][GE*\=%3_78/ZF;TFS_!0+<HNP5M+8Z+E&GW,^:3'8C@T/.
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MRUYM"P/FT5LUVP)2TKX+QO P=Y/L'$U?0[$[ LU[M28OO6I;0H?UONLORE.
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M?YVRQ)K8R>PC,OCL&0P(8W9WI@CZ+EJ'A!,2SE@EGB+BIQCVO1\@H0\&\#U
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M@!ZM+)+$=)RRA_A? $:P\/Q_]A>,9Q(Q)F>$$YT'[V' ';[70<HFF+ASD[T
M/(L. RZ8#APE3M4&XF& =^[E]'D&4WZ[QQ9BLA=^<D'I9YS &S ,H$6%8TWC
M2*/G_R$]8!T%5@;AP[$E;>C_\*MK>,&V49 XY3"YV_L#-]0ENEB3Z9INY,
MQ;+"=X\Y0HS77_]\]>#>7_MJHL/[2W?W-YOI&@,WC4;@BB$Y"]L7'R$89,I$
M1QW*S0S8Q+$P4.TQW:-_3QD-.O9/T60"7$&*3 BVA<?RA_4DP4-(@I]1M#%U
MD1)+0/,)0X;\6T^:&7E?'K IT9I^ -ZI?GN!&9L7#]Q-Y"IR:Y[>3=M.*!J0
MY5DY4HIK'#'A,MAENBWP5N:^P G5^2C#P8SI/-Y5@8W6S_P2^4WY"Q"@42./
M/K11(GT@B28K14*WZ%WZ=(0\*DZZ J=S"CD@X&></;WYN3RQT\*UK'^\OBVZ
M4+%<I\LQ_]'0Z'+RPW;XF^]2NW9 ,NYRAB%]U'NJ3$'!C7A][827CVMC2,O1
M0+@,BB\C(U)4D&#IWKZ[V![0!L6ORPWC8 [.WLM<&&/2V%KXN'R[IVZ1\8()
M@:GH&PEE,K"2";X7+#%/\(A+;K[Z#+*E.L># =4S\,RO77] ]]=<\I^EC[>K
M>R70W#_ 0C?6*$N;]S99:W0(*T&FL_G $\E^N6DPBZ/.R8BK:5C;@#;3O=\O
MR3&)(H,! C+"<51,;BSB,9)RTJR U5B\?0>=1"V91'+G(3$A9/,J"X!S7V2<
MNWZI==1",WO]E9?UPL^N_8ZNGQ.Q[X GI@<CS"+^%X68"MCCJG"_2AU%/YLT
MBNA-%<'C^5BQP-A<9AZQ$Q#*-4[Z*9TV50PHET_]/GN=:]YX_A:^4%Z LIR,
M?P=^T(\1&/KH8VE#?3G"?'MF G+=).4O_Q9R5A['-9_D0XKP+L=?W2^*Z@>]
M"QU-0((R$G46;JY^K)F$_;,C9,>%P<U G'9Z?D7IHT,U.?RA #:(ZVOL<D*V
MP'X*E<#] 7_ID-?2+6IJB+U"SCB*9>P).7<BX2W-3X*K$[^:\X^YB]F2ODK$
M"%1<*A!A; "GA'-#XNI%U;XAN_5BFM&IU:O) I3)L@E]%:1,,KL ^1,_\O$N
M;/2=#(>WO:!B+D4P8!LGD)FR!FZS0RLACE>5P^&-B65X0UZ## /0D)*T5SG=
M0V8$9"3.IYTDTO0;R9EQO\=GW@] %+H/M)S7W6GE$3\.N_=>E'FLU#.,8[L'
MI1!\;Y;ARA?2!CDDQ8!CN9Q%AQ$0M')GD4+T_(M2R\KH70V6,# \&(^S_3XE
M/;Z;4("@ML8D)GRMK5;+;;TLI??+,OW>^[C,)6TENRX>:3EAEFKI"*[2RY*8
M];9O_Y930_!UP*)T@)69V&'PK,_G!Z?)]TR[$AF;SA]V>MF-/$IT0HRG?!X<
M48B#DD@A\VDO#JTMC?@+:.<7[#E=T.VD7T3J]7WV" [P>"C?%$X.72O05K P
M1H,^?PB :@5R:/C+,2.DKXD13^6,+J4+).=]H(YC/BY-4G)/YE[ZP7O^^DR.
M:#'J*6*632KC]-55T<]-D I&*^/HGP^_-.)E4G\8M78J#176M2!D+-WB#HU_
MO4,4T9S_# .D0-!,:1A00!B]+_1\?&\W/\K:[*]93/ZHID#DBY9:8M\J@I+A
M<4RJ6;XJY]5_Z^X[HYK<NG7?& 2D@T'I04"E=VE2@DCO2)&F5&DB-53I@AA#
M(%1!I/<>I1?I1:2&HE*D=^D@2LO)WOL[9^_]G;V_>\ZY9]P?]\<[1D9&QGC6
M7&N]\YG/G&O-=## 8Q58Z_=+GWUUI#W)YJV5&&3>AUU>.^<?NN7445DQ.E>;
MHA%_O_5:A;"K6QBV.MG@EQ3Y.G$9NWQ#6MN)RLCB+CPOEZS "C'!*&ID@8DE
M%:Z;#)9:F&SRAH#:UI,F<E\[>;&KCSYJQ+^'\T:W2M]6<N="^!_2F8EY/]G$
M-OC<#27N:'C:GQWX-;E;HEQZ]T'XC4S?@NO-$=?%17:O9, M:9ZTM,>3IX)'
MK5/]/V6VE<0HE>E7Z%QZD-SM" 1 C-*ZY]=<&EUL>1GB%52"*EMIBZ3B)*/D
MA5D6^!)T5^NV82SA9DDHN4\_K,_;78-NEI@3W1OO2+LZ_J3*MRSSTY=GX]HT
MSX)%G=E\?>@9O6874Y?C.A[<"#/$DY(=R^NBR;=..NG"Z_W9R%F)N>@U& OZ
M+V_<*^^^/+\S(7[FFHX#[J":W/^L=YR?GW-+[.* K9'S^C0/18A1V=,,/516
M+)YS0-O-?V28,I<Y'' :R0 ]\[ONF3#7-%@5W?9+$U:=?ZE&^M9NGE_?^ _I
MH6FW)FE*D1/&F[]VTE5,*IEB>-=(YSG9MT:HI3&<%Y.B,#*>-6$535WF-JQ:
MJ)H!6&!W=7.LA#\/]GE3IQV<5P)=C[X&DQ4.:.?GRB9!PH,MZGY&]D  [F=T
M.L !9-T&J2=F$1X)A?NEZ#OW,A+8V!&5"A*ZTAO)B7CF=)=*I71$Z-:P'LK&
M!P?*ZS BR0BS"6S@W6X:')O2=A//K%;I"N\H<_LA+&3C1$<^,*6XSH)07(">
MIR@3#J# !@QP>:E.$\H8A&2UT$$J>Q950=P>86'?[&.U>2_(2[(&>@(+89VL
MND@+:VR\+HRJIZR,6;M'@OLJQ\F(Z=/Q[F]+6?'H?94F.9(*WQQPBD,(<Z,
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M:DIC^H7V37V5 WHI*S8-YQ 2(X[<!3<E'IHD77CYG31&7OJ>:"']]7GG6+*
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M'7YJX@Q/LW' O%/Y0R9[@;(\5))PU<C ^*IBPT]GME#CNZ\F5%H';[VA1!G
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M0H*_C6 0$! 0$Q%3W[A!+7B7_J[@?_Q!_P3(\#%4,-]@8=P#,,DPL,@PT*T
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MX8IP@*+.O\\WLG&1DRVY9:4A"]^6^2C>X6;<'ETUA)T[ND;Z@2EG12T:@/E
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MI8KW%@ULK3(A68/SFP6*&?4@-&W1"4FW#/RU>^>@':@4-& *,C\%:?,"JC^
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M/..5[V1@(=@ERB9)PHXB52(/X6$N9N!6[@+"ES.[#\FJ9LIFT&/H@_)][GV
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M:JOXY1>A"QX4KV+MHT.(&2\$/>9_U[@C9D($K.+?_FXC-(.7G/%QE:TCU$Q
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M8L=4NM GJ&[SJ;\4_?K-3/9GIS!3OD@7C-6G'EOM*A2SUX^TPI$0?W#% M'
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ML]&:UF;7E4//-4_IE1\35(%2FVA)@5(#[_\CBSC*.[M]X 5R@##[>UJA1;3
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M\VJ#$U\[HL>1U8H ;#<?^15"*C$5&0UMBPYLR%.,$X@7Q\7I+I,VEZ[9^TC
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MN@CK@W?A0L@'!F/%R/M]$U'ULK:?SK\X*=G\-C_7EEFX?5PXP[/+SP>M' 7
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M7=J<%OYC*.;7$O.(?9;M"-PC..>MG<@EB&QT]G:3R=\MW=P6CJ%*]G6DL,=
MV<64!1MVUZ-RJWTUKZ=2)C2QC!A?8?2]\_#7RH%68YBQ0,@TU'0R2Y9U1$^
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MH(_V7K!,X#-%B?4OI<^2J$M8K',B[T<&TS#(XQ]?3RG(PYF)@@C@.D"!MX9
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MD;(^+OGDWWHS348<G/6G,&JY9^7#CO\&C L8:;! C)4&%B@A1A<<KZ,]!["
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M2NM?7E)A4(EH&ZEJ]SZ69>H#3BGONQ7JI-./*WU\#.Z[NL\\R;H#^TX4;H)
M&VY6WC%6CFEE/XFX&<* ,V>TX7_R0N;MD/DAR'XHI"/2T6>+WR4N+F:B.=_F
MKG=QR$3)RY_R=.X(S:AW>J*?%^R%U!O5,ME.R6A^OM1^V(3"3ZJ$4F(!" YH
M-=W'C2KPO^8GYZS:':::DI7-*57*:GJ(D78 ;2=#N+\LPL[NNNZ?+S3W%/12
MA66'+EL-?=W27;3<1XTGQ+PZ]X^QLV+ED19X][*1D"(MILS)X2G_JPHLP++[
MAE$<X9Z[Q&!+5\\*1/*-LZ[)DLH+')U2S@^IWGGC\?A#:TN#!$?9XHD_WCA_
M;GTPJV/=N!GWD^ZH-V3T/O BE)DZ3 DQF_J^6T>8^T<5?=0SV/937PDLP R^
M!8&?8KHJ!\?C;54-A>+P@K*53F-F9_U!")Q!+P(K_^W\[V2VLE8Z%9X"Q4S>
MGV^ 4V%@BP=TX:.$!=*+H9BK'*C1\?,TF ='HKV?O="RE'G\L^4-$BG2GY4*
M%-JW_EZ@*!&R1"*E7GLA\S.6]Q/)^]!/SR\"C?=#&I1R#13\JTD$:1PMXT%O
MUKF5?VR:Y&MZ!T"(1/E/E5;ULF(KH[Q&\M:RLBH.L,!;0<+AM3F));9.EF!M
M17&1^Q2Z#,0__^%L]Y)M6J&REKQNV;>I3Q)$DJA".[1&"\G,'S&!.HO0\JC2
MXBU!E*.NI&RD%7.43"SUX69-Z?T/*R>40[[B2$@8KZ^5VX(C=?=)>->RX/1,
MRMT7<+J0N:OT0>.UZJPZ2/ />WW=X=5!]M&CPL\17]7)4QB_O\7K4!0DRW8%
MD1X-W/8L7Y(9@(KLRARA[MXA*2+-5J'^_EUZX69*6M8@0>70GV/DWT?O&IW_
M[##V%NV?EASX2WCN[S72WP?O7.;HL4!T[@?0]@46L##<L,VM#:;[Y4GZ^LM+
MW_*W!LM,NU'RW),C]'YH!UR)YJ;,C7S<Z,3M<[2#Q<UEZ$C&%GXAS4@FR[K(
M'I=HSTT3RX2@+)ORLQ-)D]2*F@[4"UWQHRY*Z#+X["UD0H-_VT1=QZ%K6-NW
M4!/WX"=_\\&_4"N#D<+8_K[O-C_YK UB%[\K:DZ,YKCW)EQH<9N)?/OA?$/:
MPX:(:=->6]&I%H^KK+#Z?=-0X]Q R#+<" M\;1\XI+39L*&1U7.MBE&[EB6@
M_@9.GG'-Z[-<XCUG9?J;%[JC6IJO_N$R*O!KF<])":_B:Q2L'<SFQ(Y+?5(?
M+O%-7_9<KME^Q$CEB)1OFR?96QM$V[_@0SQ]55YWDUBYL<EQB?%2R7L2Y286
M@;99ZFHP+X9D;.3?R4[-8^,BZ5AE./=;AE<^'<00S6P?SMK)RC;7U#;77F7C
M>O!$OLHHER%@00=]+=N.\0HJ:NZ.B?O<A6(21[P]>E50[LV-GUX]%HR-)(#/
MTS^WO__TBA?K#;_36?#?9W\4^'QZT1QR"$G^WSK0LMI@@P4>@B\(VR_M\DN,
M.F"'5W$?,\5LO"XI]QL7FA-W3ZS<WPTL@:_@*'A)-0[6A,/6> I+=+XW([>+
ML<#$R_6SL.QR/E_>K0W<0/\[F^DOM@90Z_R!R]P]'#+FP-'R^S[O/4O#_&^A
M8+K(M>PE&;JV6YMK.R6S15L+5Y_>BSE*O^YI"44+=X9>UY!.@R&N9E=A@;C<
M!IP"8,8"&;%E2RB&Y0]N$B*<#49$9JH"]UNZ[[DS2#CDII<D?F\F:I!?W*<O
M_7!<[,#P&)T0&662]3J @&\S##C^XY_("J8B$C4W$[4GOC]X,,S^L.79@]-.
M?([ N$=WK4NYRQ%DX6Y\?)7JCNU3J0F5]P1O\*V:L>-/OA%_ 1[V9S'[@?#?
M;Z,-4#GFD6 <?$AMD$56!EY23B?3SFA(E29<ZO:5%<E!1N6(G(3O7KF%!386
MRU*3_:3TK1;XR:O#I9DL"U3#$CE<]6\TM[*0%Y\M@R(!U\K_3\=J_\)@"<A<
M] _0#@?5<4E.K2,MY.<=3(L3Q'#+-JTK%Y&.TU4J?S5HSI4]Z/9<-N<3_!9G
MKSHUXP[G%4/NB*3Q1++S6=4^T%RJTG&!LV=SJR86*((?M<O";)]@ 4EW\U6_
M2!H1.FH+@5XOARC)0M5T:*M(CR>K5EG8M &YJ5'.KN%B\*:NA87+> -_IT<"
M'",R]J"8724]]G76!V?JYZXB_>-;4<FI9:VF4GM^4(HA,'4L#?EO,C34MR"W
MP24\BV+H.#^AR\WF(SNXW3,5@XGECUX6@SCC$_J?KRA:!*$TL*U+?'],S$>^
M)66B:ETE+QPA]X7-8N6*$LWN(WJE".FG^9Z)!I"KGL)[M2\BU;28MG99]_ P
MIUB@<%-GB2/$WI<?$3SRY!O!SKA'51_/[5Y_A(/Y,8<(6; T'5*HQ=!LPK6[
M@;W@IZF*2:Y5?..S,]^DW1>#E9&0%JHI4,1<BTI)-?NN=%7[$Y+<-6"/ -83
M(&EM$3&EQ'E/:35XX/7+AL.%3QP_J@\"?//=[!+#+V?REI'7\\A(?+6@. CT
MSD;$GGJSWC<F3Q0+5-RH,Z?NV'&ZM!M$2Z1/H:Q:3[QE$I[<[:X0<GNIH<;D
MK"*,MU8'#6CB,+;UT)GRW!*W7XE/XHS:CU%9\)MKP>W@I9#WTHX9GJ^D8+<]
MLT74A"3SWGN\F1"7#C0#_[N2H;,LO3J8KJ^@J4]FW!.[!X_/GEX_'KA0:K:M
MJ3),?YVJSRJ8XD4\U(2[/P!3*?MG3$-0/;CD.:=( -M!!DZ:K$QI-$S*,(-=
MG;:).][0J:>X=\$"KAQ6 F?$/RV5"6'F.,K_J_::0G#1/6ZW (L+@0C0)/S2
M82=4X&B9@5O>*M^1S1;&GP:%,D/& @\YEKP&;(=Q][^/*OSP8^Q KH?Z,M7_
M9>>*[#3$4,>\(!4U]KVGC>J2P5\[:Q^$>/"':@BOPF645>(*+'W/F!RCF[>Z
MSG0P5[P&O",F;-=F[HT#<3M+@KB9FAVGKW1#G3IX#,.  =&DT%HKV@06H<(/
MZ/BEAS5<,!?<1-\]L\4HMA;A<\1S[U\(7IYPF)M?Q@1&'1?CGB&2D&?$^O3[
M[.W.Z$:J?2B*:E-#34;Y2=%4S@H9#^4!5?R+@P>0R>/]7U4LP1,BD')!R&NH
M<,L'M@M!Q,(JC'$YPCW?<$!;*)@VC?4"_+F\R^S82/G@\/C'@.G8K[J/X21F
MSYFF\3TFYZ0O4R'C=Z^9(6BH][7I9, ^,04OU-IZI-^?/57J!RTHI9S\*OGX
MT, V@-U-4UEP3U8./=VT?GEX/F+8^90GL## -P\.LC)KRGTPCV#ND/I57:_'
M6M.DJ:SHT[YTI;I*DL+!CT.*])8+\RB_0O %Z-G%/>B%M=>\E<!G_Y_-VT*G
MR*-E2J._DG=EU9B3X4 #UYZ^_9E>::7TQG4:H3W<)XM\7:E)ZO8Z]5O$9:IW
MV1D9^JJ_6[Z"2NW'<<FRB(*M!=&)1X[EI=>4#\G0-RQ\7J7Q'O/+T&]]CE!C
M%?0B/F36IG3!=/\8\/[UY?U_%)[=AU01?#YQHH:4EY);L3_Q$V]7.Y%1^CE[
MF7MP^<5B>H7_/+U& ,.1,AY)@1=_PF#4JX"9H&O3YA&;A">PO79$W5AFV.SH
MU>5GIBW!$[!GE$/7^V,!N,?FKV(B+R=M7P1*EBA]YC'O,JN;=X(LR#9NYK3J
M/7Q/^YW<Z\9[3'_S-EZOK$PG]:YAA>9USXI1_[$UB(W_^L#\ZAGKI>G,ZP%X
MRBC3Y'GGI&_S[I=U+](TJ\G$RQ<@GN4)IZCC4IRL5*;E6/1LU9B)LN.F.F/6
MU(S@-QT-M\P/T9XJT:5QEGZ_[C&#8X40PQ'<^S:U%GJ1-D\S-0BT%?P2T_B/
MZ-VHBQ#J7=RW5^N_*0**UNC7Z3(UYW[TY(*>_D(O4D&F[6X9S0-VY6@WJ^?7
M "N_(/T#Y.57,;]/G?4[VYAJ]]]@B=2;Q@-M7I5^'#^2(E<D"PN]!C^A:UHH
M3/%H&)R=(:IQ!JC2Q4C.3XLU?G++Z5%#'C>Q0(,GNMS4;QE$A8*US='66 VJ
M!X?6$JLN)'"\Z?SIE.8TJ!<=5/=Z+I[+A7T\A-AI*=5]N_?PV"A?NIHT.8O#
MCO2=O@).8]RU2Y3E&5FJ1UY%&GT68OUY]H1466(Y+;Y5#T>V*I)-7-JK:-VV
MRHU^KHCK_9"^,UZ7%1]UUB%=*C\_W99D<<<AN</084!6:<)0^LS"-Q^. DOL
M&WQ##:B&#?0ZTAM\QO2S'FK/B.T+_?S$F!FABT3?1_A"#LEBFN=2H<>%3F@1
M1(2)L+71Y1+XN 3L\O.PV6W-8@#)TQHS2\7(?9U?QOBW*E*(.]4UH>K:=9$D
M+$!9X9EYSZ[:12R>^[JZ-%DJM&LFYE2)>M\DR_\ZH@'D(O^-Z61 Q(&?Q/H-
MSFP,\X9<?M6YY#R]<E0OU)>-^F$A?X-]S'B-A6PB Y\X$H?UT,:7W-=1S4YK
M'8.36^0L#=GQ7Q1FBF0?=SA5'.Z;5B29PIAFOE::G;[0NN1N4:"'. N;G>H2
M\9/^Z .?0>ZT=[:34:C?-O*C1<ZT?&#J'>@GY$41SCPWKWS&*(T*E(IS7$S.
M:()\PJMZ*=U8,YGB.B"Q;=JI0#^T0X_ Z'3JM$$H<Q1T!WMB:+3[ .-83P>P
MUG 1WVD'X:?X$;YEG0B'AQ'F6Y-KC;9A$O#G)X596JMRTTN[G7,U94%;W9=X
MN9 6$:2&OP52)(+U,O$U#F75'4MRKA\\WC6S/&7$D9D;3% <S(1":>VQP!L!
M+$ DCZAN$\)?1RTA8 I*3!<RWJD4/BH$5; C* \6>"\E'7**X6Z.=J!9.-H?
M@PK/H[3.?5)ZB^:4W\SJNF'NH#R.3TKU,J V#Q9W"SRDO_J2#5\1EWS?_9)U
MZHVL-MD %O CE2GX:79=6'Q%[S#+DKR>\D7*EZO<QSMO7.8:N<.,#_;X[637
M>V0YA^@4D??W8.0-H?@[I*S?'227RMX)5KFWK1/0<Y5^G9JC>MEWTR(M*P\'
MP,<1E565==3](C[1@IFC>CU5R0P"[3[UKU^A12I&V5!>.7YI1U.!##T?'P:?
M_2RNK#TZVD_:GAK0>:"Z56/<'KC"CX=3)9?'YWIA&1GO%8@ROU)G%]'5UW9S
MN:B4B[P^%GBPC#-$W48X0^36M(0%OOOYC"J!QV5[5R.M"1O>@85V>C%?F3XC
M]\0[;>$9,>Q>./4RS'2A=FJ*&Y:_V^S8QZD<9.JB1<SP3$YW&VB.WORUI[^F
M%/Y!N13BE L=WY,RG"$Z9'TN_?ZB\!2.N;8]%6U@&YC)H==E)O;F0O*7-1AQ
MW/Y574NK;*Q*'*<:([0*8.6E-PGG<!8A,&KL7OEH0]_\%(1_BE:]20XGV#R!
M3 M>?ZA6S=ZJ?W %\AKO7K5 XH7D(;M+,Y.&@'9E6I8#0T?NAY]Y/6ERB, W
MO3ASZ:.'4[ZI=C9Y[;Q\3OEG73GJVRL%^[V6$@RB43+;BO^)J@3_@EJ8]'\&
MU/^,.HZ!76Z*(3".AR_^O<=9YWZ"N+F@&DM'4*' =Z9(0#9LN1(6BJ$:JF9N
MO#!NQ1A,DZR#3&'%+F3+,#K/U A_&L1910#B@</UY>/N%NAX\>-R!56P"50W
MR;-X65"=6S&H4 JXYG0^T XBWJ2+<9@Z<>I,M*T_.T> #->?HXR*[6+#H7=1
M45Z!*]/359";:00+/!5##<2+C3>XRD=8#@G0E1\=(3^'K/F.N4>7ZVO;<)S>
M:RE6I[6.;((O.= )Q+%=^Q4DKSWMRS5Z''JM,UQ:P<FU,^[J32?<_F+: -$>
M/P2H\0%WB@J7Z<7!7TF890,;&$+$WCN""=>NWX(PALIBM6AUVRU#DX32E^/Z
M)YLRY=&&HAMOG+EG*<5\/DN([DVNS7$C0,$[S=_\^[)^,*5"Z)V?,WW6<.8I
M^(H APC73^SS5N0QUT2LLFDZ<Y=&@M8(<8Q8O+G8341#HU='1</X#YZ8FW\_
M4?.?S:?_615[196>9=K0[>7Q^K^MY6QBLW9I^]9Z/9_MM6!)DF_6[9U')1FG
M&.D'H.TX".LS$%GSRJ,AT/8DI%B[LJ0WS+C:@@GQ]0AZ=C2&!1 F_"@M+$!,
MIHP%8.IF6.#:,$[1NGU\%5[RP_-$ H1ZYJV$/K?% J@'B6A.W*60+,A 3BG.
M]FY"6NI^0@TYZW:HH.9Q?W8%^KM^/$69PB;NQ)UEW5B@I748M#ZBCP5^N#8O
M*J%Y95@Q?B(0-)4:AG*<'.@6OY(4%<MI86DI,[JBY3;!S]C)\^]F]_O9ZVN.
MM)6S\7$3&I/G/7-X+KF@^_$O/DO;R/-"L;:IJOS@^$9V;;3"[;1^Y=&R#4%%
MGKP2<$<S\FS1\8)$ ;?C5>3*!YU6'<8E>SK'&M1S-A()KRUK,(QX'BQ847<S
M/#HI#NL=$[[4.'#UX7L^J4AU3?9G[)[$=D)6L=^3E-JGNQ U_USF+Y[S"B%:
MX[-9-2Q&?;U5LP-TC];QH^)G)^9:\R85/!R>M7/V[&GG'DC#89Y&BF/)^LA[
M0:8/Z[:HXYLZZ;PB*Q@F9"2/*#?TG-2O93D9&_ME6%+;N%^=19%>,U$SDWO^
M4:;];J,]W/3=D9;"JV=:"JP/G_*V7<-GB_N>?BVC5MUJ22Q86+U7-"/N9_-!
MS_PZ*)>R1ZS-D<(S-,*?$K'\83K0S5E0MC%DR_8C6Q^K*EAGC&%8F)^5.YV&
MMQ/0YRCV54-TA->:7CJ\8CKHGW $P517]1<[PWP5EQPI/6,U0^(<\;J8'K=
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M$9E54^FY-T1A49WPXP.Z_!'=5T]'=;,;N2&8/J8)_[Z53R?(D5*X-)P?\>K
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MQV(1CK%=4Y^J\499\:/]:TM<U ,;KBW!B&:VH:M3,];SDY$NK"31X!IQ/1E
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MZNL21MKU$)W2?0\&OL5%I)S#Z[0TDXTHQ15MA_65<(RM)08)OB05Q5EC BP
MS\100,,@&T[56. ["-/H$T]I.FSRT[]0_HQJ!LJ,@/VX-)-#EB0OD<BW/30M
M3OPDG5W-J6QAN0T[*3=M5*#DJRX4C3"G[*6TT!D]*F1X.6BX=7=;^HI"-"NY
MK*6$3N<72N<P+@ISN[D[@^@G95C ;G/(6-IL:T5"'YQY\_9380B>IYU<XX5;
MPF>F:>![S><D X+!,G$T3U9& )>AC:@H575U0M4V0_MA4>(#0G9%?"#EPEM7
MK(EQV(W!L%>W_EN4T3:Y>L,Z<^: :0BLHV(C_4K-&>8NBGMMS2[4E7/*(#4K
MIF'S^AH'&V*N<D+K$7W#/&D#AU..T>:W#61E=GE%=(=EW,JK+9=ZZ:7<(5^2
M12B9\66NZI!]\9Z4VMM^V8BV&!,2"CPCS9&B8R.:UZ6[&;55'U\LQ7MPE;R"
M+X8$[3[(K%&G8<BP'V+[)AU*<Z+'IF^F %C9T=Y-7"*1GK"MTC(Q7'D8V2DG
M>4OIWB5W5="B#'&KBN"FI*O>FN-Q::_4Q5VV%!^],0J\;J9@4U+)<#,&4C(1
MV$^>A(->[YW^^>&Z[U<" ( 4H*C0).#[_Z]HUQ+Z<Z$8"=-H?)6LO[%26DK5
ML+Z5U#<SH_S$DJ@S1MQ1Y#_)SP:IL'W!:&6>D2KKY0S3@K1,(#@N;U9!4*=_
M..!E_AUV)#B)!9;G%\T>7L;.8SQS+P^5)OFPP'H89%ZD]*M?/[1 =GW,4+^-
MG]#.^Z.D>W*)D?&<.NP!VVS"=UYOZ"-UU[$#6.N-S/!EII#?K MNP,29CCI4
MS[]]^^AE$F73&:O!K. $HW!TV/&EM2AO2!C6;ZC^T'?'WE(O&C_H2*3?KM1K
MH7>695T-Z;:7?;_OR'T_9[8GSJMK5G7ARHWC_'O'MIPE9IVRS V#1_7/A&N&
MCDU45U_OXD<4U%LDR'[_'\6;^5.3:1+'7T00F%$<D9&A(,'!'1%0;A4(A$,(
MF8B " @A9!%&"8HIA'#($59G"*"(,2NLU$ D(. @1C'(+8L!(6 "" ,%%E<2
M.2(QB5%RYUVF:FO<J_:7W2K_@7Z>3U57?_O;U;TE2;>1UGX 9@C+N)*S:=X-
M&\D@ ,4FG?*99TU %IH)2H\0"#G%DJW$<HJ^1M6%TB(M3^A8A>H)[*Y(UBN<
MY=>8,1<NMTY5X3/M:;B#?(,@0S)+]LOE@#?O2!+(A,_5_BCSN=*Y![>&*[YL
M\7IRR#'3Q@+J[P.A!&1#^Q9V"V0ML;A9(;_"&6.-F4'M9=E8U#HL^L!+CW"A
M)02"A$-N6-MS"ST3'3<[F)]P5&J. PR(BU;:=)VWDU&Z]^/.0^PEI=,D1D\@
MQN'X1)BY4@# UA(O'DL*F3,3$%_<G>KV;):C@BMBQ-J>1HP;[<[91[T4]HVE
M;?8Z@N;K-XE&P(<8.Y8ZFGN:X(7OX\QJ7ERK2XZLV&."LN >\JL)1?(>!F28
M[RBW'L=#@R1N'-K%BIUSL4-M7Y@ V4#"-+GZ>8%'B=UPJV>.R%#@ 2NOMN^=
M_(B^-K38WE(9\$,54L'I&_YC6ER3CT5;"9$/7\*J#(YH2Y)_.YL*49/4=B 0
MKP\"X\&88!R\$#X=?C3WI+;3BE9BY^+SN3W(_]&?R'N,U<=;0Y3J"A#PHS/L
M1BYZZV3Y+0O.D]I_O3HLM-;K"'4^$2(^^6,'AE,2X?Z'EUF'$<W?0%K?]8I'
MJW>  +4J 02V1(% 4:WV&VG?@E3Z@+CX/0A(3.EM[SWR._C96"9<89]O\5L#
M3DND_](TFNLNQC.]]TCT'K;%'Z;),KJZ'[L*1J0'PLF,C(2XGTX/QW)6#B*E
MK*$E[T/]%+E%@&UAJ4@8\6>9?@0[GEV#(^[(_W8F^3%.?*BXR:859Y0X$VO<
MZ>MEV@'%WKM<1T8X"\O="$-'X\GD8X\&/"Y4NI)=JA[>O:YUVV<&L94@U-9K
M"?CSR0X$+[_4[<V->5V]W?V+2Z<NG?"R<^!:EJJB5Y5O;C]N[QBG1PI060H'
MB%$[-IQ#-'JSGGX0_^+9X2DU$L_5?\6A>JX]15IV#H=%;:5TU2.%K.4NO,[Y
MMMEW5YTFU?6]+5WEP]EGS)#1!HJ_"F\B>)4 9Q(6+I;USQ[#-V%Q$Z]?Y(Y^
MM[I4>R'A-JR0?ST2P10>B>V08^H&:0)6G<?HI7[V#RLB?Q<A\'5LZM7*#WO&
M7>]?]!Y3IM0&:Z1&% 67#ICZ-6[JA&6C[DL8BH;*YAKKXZKWM9.B,JIY[)MH
MA2TOWIJ_E6>1*<1,E2U5F3!5'$H].L:5FD?S^2(O&,<(ZZIE)'.HA"(6]IYW
M <SE^Y(4AR4L"88]9X),I<6.[!NJ2GR*BT[$#JV(V2'9#;'^BRDF4;W!G3>>
M<%&>:WV"&BH?VY<:-_94;*^O5^ADN-7L>6D=I#M4'/"M+2QH^$?3+^\6(/QL
M=#F<&NB?O*T$T^:/DA@I^)%*3V%=7;C-;,2HF)^P[1Y:@BU+O\- E[KX=I1%
M_"JJ=7R-CJ&ZZ!4><8(2 M,H:YC)1P.PL^ZUR)T?HT)]U=NC&*_6[0T/ET>*
M328'S$X2;0'NWHKGVEU/QV!P;M!==)%]QD FP<!QI73(0O+SQL:#7J/D2(]
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M#.>1K![-1U=',<#^50P0P;#_:0H##/#I8( 6/C2_KX@':>$0VBPKH[;YKRK
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M.1,W?2XXJ[[Q_E$#C[#A/>AYLF4C.7N)--XZAZSPT*#G.@8HX1,@TAK=<2A
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M4NSPSFIXVH\H4<C9"?ATXA0#X)R-W,*F;*T_#7[QS0D&N'FF!E6)@A__(1_
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M!%C@W!VCD';P&;LG_#SZ"K#6GDZ2)U0SWE0?1L/<#.E<5ZG:9-Z\UP^L]FE
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M/^*20=/M]HG/:54-\[Q*>#+V/KHMK]EJ*$T&I6M"IAD.%9"L'_N\\82+ )7
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MZEF&!)]=3<<[#55H?Z7-(OR&>[[)P,7KU]+)0GT_R]5+NVU6&(QP1;F<.C1
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M]=0Y_O=-V=I=^$]_PH?Y_]\$ %!+ P04    " #M@F98SB%(-7(Y  !31P
M$@   &EM9S(R-#DY.3,U.5\U+FIP9^V\!U14RY8W?A"0+$$:D-1($"1+1D*K
M" B(B$A.5U&B@.1,(QDD" A(D"@YM(0F!\D"DD-+AB:#A";90-/]]7USWYOG
MG9EO9M[_S9JU_NL[K+U64:=JU]Z[=OUJ[ZH#N.^X18!&745-!2"X!  $^!\
M-P,H :27+Y-<)B8E(2$A(R,EIZ2GHJ2@H+Q&=Y6:GHT9S,[&S,K*P2W,R\$I
MR,7*RB=]4U#TEH2$!)A75D%&3%Y87$+L=R8$9&1DE!243%143&+76:^+_;<?
MW!> EI3@S24"0@).X!(M 2$M :X3 ./E)";XRP/\\1!<(B0BODQ"2D9.@6\
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M^GMQV15M9%SB3_9!SYU'R!FX)99X4+^K]A?-_FN*!?Y#FOU-L7_5:QJ@)"3
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MX.UU^ #;.W9\KY9S],R"R,'B/.J*HH,G*_/W27B) J%ZLG:S)8UJU,XU[H0
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MJ&C.P,18UO-3&.6GS+WLI;#) 'E$FQG+)._^1$$X1E&PLU]@^5%SK%MUMD'
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MH(BHA3.:\D>-^PL$!RE#YT.]_MG*=YU.OL&FE.O!76M)%[<>6^EA=V(OCG#
MDK')X5-AF.MMQU.*:2A"%I)G4MH3I.M36( #[EV6?$DH,NBTL_-D_6_MU<16
M*?**9XY?;O%77\8!WW#  X8<>6B_V-30LIYM@MC[5S^LT;Q8]7F\8";"D"/F
M,\X6CWTM3&(S(;;.!+HA>:3L-8$#PH<^]^& N>N'F._:RJ"X>= W7V4BC"SJ
M\F7H\">L[MBD5L2QQ(BO2-&6ED,MA;W# 9-Q[J*KXCA!OR^(R)=_5.P6M@J_
MM&SWME/W+S=E\.SK?2Q6?<D6WQ?LER%2EZ8&%JD%C0[_8V _Y)G<I<B\CWFG
M7+[%,)GPH'3_FCZWNV"3TV0#<UZAS:1^X8OZSS4-\9)R\AN).( @K@OP/9E7
MJ*M+1QN?^RAK.(KS=BJ:#PXGM(?,_#RWP@$(<]5[0*!H69T]DZ/9;<3 'E+3
M0OMSO(^=!H5:M>>T,>HB_D.2CM3WQ<W-6?V1DQ]#]E<;7EG>48>Z+N<!:LI>
ML"Y[K:Y473A\/L&#*BF9?CCBDU)*GOL[X:$[62Y[>O*F;J5V[!*COC?SM@YM
M;O5:\>P,?".G#":$/[5:P.>8H%_S:!UY"F1:Z'Y&D4@X#+0Z(KQ64]<H$+V1
M'L;AT;;.GOC-5PT=M\3F\L4[-+/ [I:6Q\VW+VQC*)XK\Q8>70Y0<![#RB_B
M@'([3+%MZ+>@EP1LE+\7_[(R_TI_\EO8OW'L7UJC1*(@!Q!K\/&R-#98(*&\
M:ID:$SM-<N$Y@,=G\I7M5JI]\,UT'-"$2=["SX^#U_4_9NUR;"!TI6P#?-R^
MC /NPG($UJ%$.*#7>!BR'=*##3*_K__1'!UU+@B[& 5#!D+HM0W9EDS68\OR
M&_>O-#HZ7NV72'(FNG]-T&F8?&.;L>LLK_OM$I6Q3O7,R5L[JWB%#J[7K"\>
M7R9IIY!+HPZ]_9#1_>"NZ)6'SC?U@'HN#H2+26Q'+.T<.O:+MT-)L1IX>DWO
M2I]4Z'2G%3C$S<S7_' $>MO]>0-W3NXA'@DRWIZ.K'?A  7&PYQOPA%\A1AT
MZWH.UM4+!1U2QFQ44>2H\T,414XW6C^R_TM?P?:-^,C8H;=8;Y%UU4Q&S)'Y
MX%O1?PX[+2(:4EF29@'B8;S/$_Z;SXZSTBDSWNOP:.XW_,;6IT+M#2SM*@J@
MZ:8/[/0F:%<,I;X^K_5X\N4LI*U\D^FV0%'?YZ\PDOUC1+B\D!,.((578RF2
MW.J<WPTX/^QPN5J=[NQUAFC,WQ/R %@(.5P' !>LU/YXAL ^:HRSWMC]_+Z.
MX\NO[:*O_!-5N\SHQN%"YIH(":I'0A#]RNC%!0FS%\XJ<[IA%2OZSY0!EPSJ
M_1Q/BSL^9+N*,TY.XK.F@]MO!&/\+6(?!8%"4+;=H^#0AMPNNTLRHDM)HJ07
M6S[Z6?K4*"A6+:;D. SO>WF NUXF:IWDPN4O0<;?BO\?@@R2"-]G^-;G=W
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MEDNW%,6"(+B%D1GP62W >+7AEQSB5(]O7R2$@,C30_,K#BAXB0/(%P#^@,O
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MW7ONG'/N>7\\^25OS7[?O9^UGK76#H<?#S\!3FNI::H!:&AHZ.KIZ@& PQ'
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M5=>\:VQJ;FEM>_^AKY\P,$C\.#0\.37]>69V;GYAD;2VOD'>W*)L[WQK%PV
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M[\RSNW^<SR<D-[ESG?NZOJ>? P4;>_</=^9R&59PV<2I79!""HCP7>2'?EP
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M<J>@@$&67,LOO 'LC1%RO!?>3K=P?'=#I(YZRZ;2I];LP*6^Q-DCK/J+INM
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ML>"+."'>-5Q*4 ;YK!X.\JB " L0HM77F YB4U)9N&B^=^9R>_VGK;.@.F6
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M!:]_">[M[?.-0DT"D_=AQE D15:*.4D]VXZBH<$WGP.%9K("2=(<%+8@OWE
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M_R)6GU.KLCAOC<68"?? [0;,P+&/5TK*L!KQ<(V4;1?!U<0<+B!9;Q(B&%+
M[PA1ND-@83PM.HMU5'%?5,*JXQ,>_^BE$"^UT6NP>R=L)HMA34Z%4!ZZ>$C0
MR+D*3Y2+NF@:?C:3Z4A\+@VA&2E6[D0"GKGS"=O!*RXHO/J>^@7_4->GCX>^
M,,QNL 4G=BGHRIP0"] $/#AEP\H'&]R')"<N8%3/@4>UXVU;_'NM 3<F*^(Q
MX,$&V:@.8E.#$WAH5=%[?L070Y),DJ<=BDZW3$D2_@=]I__U%EU8'PZ0_0_-
M"[))?977>GI,^*A=RI?3Q+--H<K7\,_1[+SA%A]DDU"9'KT"B1=S<QW)9D#V
MGHT<%6Z';$SI19T<8E!G&C.%)=9^;^@PH_V,9T*O#9Y"=H//@ O\R S"LPR)
M!%9<4S]^,M=F5P9K> _,KXN5&.SD.'WY80932R-1QQ0AJL/F^V<ZV?@E*.0)
MK/;RPZ8\*GVH2L_PL[SU'MX/A8C&>A>L=HWAU7\;BS9PO)F)MTBJH_8CNN4@
M#\S8_0FV<L8^*W$@];*CY8D_MZ.2V5,MK8_/6GY0I>C5R5V]4.+.GJ7\,)K\
MYH+@9GIT;]NA;^!B#J&I?9N_]=2?=E34=N2Q#'"AG*QE:EV[L/G1MV\Y\MO?
M9H<9P"4.EOCXN'IF?<@+U2K>G$L$8I"Q3)RC>B%I,)QGWIG5.YRM^$?EC&YK
M/Y6L'4L?.XTV*851S-%29WOR!>CH=(^\*K-W#BEH:XL;OX9Y6K_UML:\:YW-
M5N=JF2O30_-U"@B)VJVQ<!OFC_E*;V<A>77.WZ3F'>H+C7]V/1Q(I]3 ^2"K
MD:B9Z]L:W)?KY,-!Z;=FQ].O)Z-&&;-I="JGP[[A%9PF9)3JNY&L7@%J:1_U
MX8.S1\]'[3/4<S&V@EH4!@S',-#W<,5UX.SW2O8%Y>W4*9=CL(DY";C"+W\7
MXR%+]:RW;Q!"U?+6\32K,3&9A:3[0!KO3.R.O\$@1?I -5LCQG#[BV#A+:7'
MD@M/)\H?0,'2YI4#B^AGAY+))PZ\C\G=(3[B-9'!IF#T4N)C0M^QO".M.8EL
M';#ERR?(VJH;"<[QJ7WELWM,5ANE!G;HI6L1!YL,53&)HDNV&Z8^1X^:1M(:
MUQC$XWL*T0[ Q8&/.&E9N(#Z2,HDWX.P';.IC-S;Z%(C2^2"M*%;M!-@U*5D
M5>LCSL!2_88-0<%$I$ 0C]LD7UZ4"R3KY63_&M8#1?$B! (T&^$]%4\563XU
MME7+]/+W*'Q4^FY:[:FT%4G);0VZ[X*FA^BY6<=4D#?\N\V;=8R-@NS.N%K^
MA(A_<>IHA?A7R*?*GM8=_-Y8IY.U?1DE=R5Z":R85BZK]^MQO3;?,NE6^$ Z
MK6756_2&>B\>S2;+S>T3F7H!^,BB&,HSUCM($.MC($B2H\UU+?30%53!S&'*
M/0\:#&P1I0G8T)AEE!DL57(?&\P1B-V .\*P6A\/N&?G5B93<]-CF1SP2:;*
M<1N?Y9I+H= Q2)]B:(';-#UA%/FP>II:J97X<#Y1=Q]&?_L,3,];N0CGQ/DE
M.) <:)@9.M]<2T4N2NM:<T#$\U\4<G?CV*G4A</GO+[L)"VPYXI6N6NPWE5P
M,=KURVL*T4AF%>/>+6,(V9!;3,U&%;\<& H<X_-Y__0K:37H:P+?._F#TI^
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M,0O18WH\C&KM X>C_1(7(:?<B!(F:'EMRU&*D<"FCGWO0;C\HO5Q,7K'XR=
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MDF9*(T_8R:]Y(PN"-#PN.@M10W<3^JDK>['P7C-+LN1-1<LZYO2R(V\T*/L
MH'V2:^@KK6[D@Y7'COGVY)G!<]J@&?//PVV&GKV5\*(.8'=P"<B]M:WE';?!
M/<@49DC6MM[KO#N4UPS4LBZ_#SB5,[# 7X[1-%3!75;,??7F(2OYNK.!^/I4
M^+TAF'Y66>MT(2<Y44Z'%9?-ASO'Y#6XW/96H>HC[NGS6'YK >D8KU<FWZ\C
MBO7U4RS];[PYN<I+$OM8TF$IEU<FK1]7XI!OJ4*2=:#+S<=UGW_4A!5[&"W*
M3&Y(0]C7EQ1H@IU1/L.EHA/"7,#D+')SSE,$JGL]PUJ8,^<#F\X0*N.2=/0G
M*.4X=@-3*Y</MAJZ"+H6ZR#US.Y]&VA>[TVAH8)\Y$;8Z =[#2M@ROLTBS [
MXL-C_U FS4Y&BD'M5(:]XPCFJ(W:V$!;X?<#O/ULF1=7ELJ5.RUB@N6_3? J
MJ=V%2*E*P<#R:&D3Q4I\R;5.<';[U.K"MPV,UY0"A\LT5%PQ-P,6O;5K\(,?
MW3F#M^4_4+[&7'\5E$BJ]J9US2D]+%V94&BG%YC@:ANJ!HTE\9>)2KD,5VG6
M;PY$;V%Y2=R5&/T@ZR<.I?$%!BE Z_?^_UG]:2UEA-9AIE,OKM6RQ??F9]9N
MRT6HW%@RD@>5Q:M,5'F-!+B:?5.' F9H NE;@M6BSYVS5 "&O@D6HAT>]7;_
M/[#^V^G>87_D WOR#QE\O-'0%6;I:R<6#+,YXSL&M<R,*-IO87RK,<JL>"^*
MC+_#E$L)-ZDOZ6+':Z*8^U0EVSA]("WY>L"NR)SD(*3/IF'J_<WA>\L<;R+J
M] Q*###N?2EQ@1+ZHJO#^'K[?*1"%<FBIK-#Y<(!GZ._'FR51_]]49+1=N[M
MQ_]H(*G<>=!5EB,LGJ$O,=Z*#P>RIKY\KY=*]M(2<KS1U&B9M0\(""^><'M8
MT1V/I'4'K^K%@DY%&::7=\9,9%A>MI$6[L2(VEHSK'1G.5;BUPT3"(RFP'%;
M\$<CMYPO]V$?TV%%4;I<D18E!)TG%POU=)GC+42-AQ+<YZ %U)?1SN5EG8P"
MA(>SV8ZF]AHWN4KDN^Z?&#*6/<>1 #HZE09U1H75-3N:A.AG"W[*&3^473;G
MU'@-H=X#9)GV]WK?K["$:JJ(A&2M -]!O$=OUI0PKYJR_-CY9J868'5]4*#G
M2YU:?%PQKRE.9WVD=F>YY[M4?Q7=TQ^PRZ,\)D^<0[OG.1W:/G"N]E?+->A-
M)BCI?3/0RPA/46&!)'K=_HL_R:\B"@ 2//RG?ZA.E1\<6:5.;*9;MK2N6YXD
ME'B)5 CI YEQ2B(_N(YM(-T\?NJJT_7X=G_VGHP,P6^9ATDS?S $=1W3,QX>
MF_EKA97_YRD\ZTAZ66:]H[6YP0]D=_N,C)]MN$?.,<N:;3F[LPM+,-*8@[0*
MYT^(Z)@9_>2=XBHNK9*5A\ZH0%WQ(R4O555$9:DYJO_:M)#?#]5-^YYZZ7\_
M#>A?\SM_C=+^XOR$A&S;?Q*(VK%_I->#?M"R!VCX2/Y6]WPR7+T\,.TC?<>]
MHJ(CW&^OZ*:Y8:6H+U."4B,98,E+1M"-1+%4\Y"I\L_K/'*#/^NZ-J+ZP?*4
MV#?Q<HFOETP5WK&;',>'4Z9?;P2=:5YV8N[;C;%FK_=]^:K.VRC-URZLMESJ
M2;UAYD).>U-,O;%B+M'FL/^@T.F_)A. (<V#E3 >+LW_=P_L3[2<?_G!1[<O
M:A9')-]B%-'J%UKH_'WNJ<97ECB6HN9'-_]QI,#F<)%E&Z'[&=CG:]_7P;_R
M6,]8J=X0,[5BY'(W5O+SZ):5RV E0ZZ#;0-Y,YG!S).2*8>-HG'D6CSF6(*K
M>QQ=:@T#>T,:K/7+W,!+0AC"8Z^K+%&XE4;2ZS_KXG,XI$1H+<'.]DB$3&_O
M#B3.8VK.OHG@=2;EZ>70L@68U@2",/R(($T?C8!<S73T[D$ZX-.Z3]JA>SZ]
M6>P^J_7O#SR2 0XLF/N.10"R4-0VP(JK:L8QJG?/^N@+/L:RB-OUSX>9.G_<
M2X0H?IK%>Q_&(<]W5%:]<0 \Y^7IJC,<G< YYKR>-5BCTDH!]="L:[^>"+;_
MV(A,U8]TG^)*NV;^JQU>$6#[OYAJ!8YT ##<T765/A(/T! :^$?BMEKV;A<Y
M/A[OFOW3I/MF@ ]+\)_O5$9[#1_^_M_$3S7-7N. R\T^?ZK%>WX=W-AOD.H@
MR/ZGCI@T>ZC@D:A<U7ZS3P<GD!!7.D"49?A?%)#5=?A=WOZIQ^%!;,>350!/
M8?(==V,6E3>P[RN]4]]/(4_MG(<7[ZB4L;<!1X<5E]O>/WYT +'XC=_^=+=I
MGNIU='-%#K:SIRGH;1IN5*=S&7.%0&Z8($B#JJ;DZ:\:8F=:DE JZ1GW_M7A
MF]P'&;J+'W_Y<^[^"66V'Q/\@U_UX"RQ=SB0R>\?Z;N@H>/O/DL#],\3)HD#
MSUUS2(;YNW3ZSXEO7#XMQZ07S\HMP760$L17:GR@%7C@_*1)U U%Q"Q3X!?U
M<XV)I)?Q>B&I*6M]BNJJ&M/M[[Y?N:6B;NRE'WB/!,J&'[O:/.\;RM:2?\!8
M]3]6VD>9X[6*R(* C+*:>#<5YY4:XI%6!"G)U('@R8?"*C3X(O 4@ZEZY_@5
M+:_5EO"R)</;/^#(3LXG(O7R3G&A5US_REW^7R0S8M2!\%]F(1_.!"3J&5%N
MG=@'/$=I&OVX#R[*D74VD0<G/H[V6+K%X_=J;>1ZAHHW:W#&B3$]U#B-*WV>
MH=[+)\_BAOZ1>[9(!,Y9^Q,JPC^\7+?C%N/ @W_$4WV"(,H"&"IRS-03//)<
M%ZOA(&<+<(Q*. !\?[Q9C]VK%V1/_^\WDX$#R!](YF_Z9.B67)H]ZZ^S,H[\
M.OO0]B\KW#\BV</>4K<D_BLK=8CX<2I!@_'@.[6(10 ]S5_+7-C<1$%>O];1
M:1$!A\PO8RDZ6"]92/8PW9U?!7"8Q6Q[Y'#@F28!("B7GH&1_\,2'<ENDB^X
M_VCZS*\4VAF# EB)D64Z" #AM?3?K+5(MS^TM_HGZ:SIW2MH8!VUXK:QJ-%"
M&W#8@-&BU[2OA.,&9H;X-,(&9&^?9M;V#G_!CI_C2@TILHW#F. C3N&JG>Q7
M9JWD,^[4JB2LD&8\.)L?JDV5!?+4I+<$[!210_$PH=&I*JG&?[T1)>3>?DS2
MSC#2+AT*.$$XK!3YX\_I!NX<\.+62146G:>_BN_1R'@-1RW55A6 EHJA'8KH
M9VN?>[[%=.B^?: <1X7!@+=U DZU%A)3;VB8(5EM;B::[[]J.;DK8D'ZMB0#
MUNXLC+95<_$8FQ9%@P<NSMM[B$Y:;FIY?4BN?9.P9[P779U)NV9]66(ONDW!
M37!=WFYRW:I]Y2:/L+'$2OQPT7+NH*70-N2+736#^\3!19W]U*,WW3AN;T'B
M]"31=WK2H[6S?\+XEM6-ST;MBO0I7!ZCV&<W" _*GY9!CI[J+JP,'!QEAHE=
M!@H/\&ZPT7,RZ6&[S)GKA)=!Z RRG0P E)\90FIKW21N:SB /I(%/WUL_^^[
M1IBA8<"Q(3,'FO;2P20>L%+-:;8@3O 42W?#&TY5,31"^"J]5BJR&>[[XAXS
MD6VAEW<^_94ZY7\'J0C5:^K<JY@Y:D*W>N5H%5=-N79BL[.I3) MS&V\*O4;
MU*DY  68D^:1G9^IM"BWVOF44O)"U3_SP)K(T(OY%YCPPAQBJ<%+,H)'83Z"
MTYU9ZOE0M<VT^EO#@I\??.E^AJ]S$9NJ @;O TZZ?]@'*-KRBG:UT7 LSS0_
M5Z5Y)^@;7J>H)A^\;Z]" 4:N1809NXLD*1*@PGGR4>=]2 1CP].2PNZ"O]FI
M:0(L@"+]<S 5MN$G!A!2WL0<OU ?:J8C+6^=E#>2%FU]<R9]!Q,O9V3&*IAF
MR-@9\Z[FM_T@?PJ@= J:*Y-*5SV"-#"D7$4E<MBM%&M+@H0DA0.\)M-&W.]W
M?Y]6Q\\26!'.0^=T5%2NUJAMA@F=CDS6D%O+T46P%OC, G(6QA&_S(E"1.;5
M)!<1.D;5R]&S^X#5?C15HVAI:TZ[[\=GE\8RG(JE7XU!IE^;N3:<N;=$W>[9
MKV]C5/3?Z)4D+.+M.S^;OW/1-2KZ,[^%3F43W_"-C_2KLVK@: TMBQZ^*G[A
M0H^D;UX_#)IWF%LJXM<,Q6E7O?QH&VG[@("<VCUOIM;DPMA'TV@71U3]P5NY
MVON )*)?#21S']!FKYA80:_@G:"PK=.6_E@<E<>5AK/FL>_Q*]U*;]ZAEUR$
M?_IDW!UX.RN#:/YJJ5C(*#<F*Z]P7.3J#<E5O=I<$^W-*P1N[.>R</>X!P=L
MD-?M%+3ORCI@A%#>-U7UKSDN]CV?=Z?K69W,V61UR@O]QBY]$>"U@K[1"9Q8
ME+$O,RH+MZ1F-4KCUW!7#[,)_?.UC[Y@6_Z43<@U,=G=K'^8T,#I*C<D2"-'
M7=FX*W>U0J8T%34UTMBO[V/-]T$:J=RI32OF^P#YDFSN;;0I[_/)7R09W;#]
M^,-5O@]FK^I8(7SN]SN?1@PQ)8EG9ZNH %M<?!H(FCH6O^-YA$;!Z8)ZP,U?
M&7AN+N;=[JR$#O9MGNFHYN\>9I2!AU-*Z0XZOD#W=P52O];.Y!)\3O/Y%!A4
ME^1M6K9,)8L .U)5;C/^A/ Y%^IU_H-)_G]*^A &/#]0E.7(-$RL787HZ#Z%
M]Z4T!(I"[Y0 UXO3K0MOT6Q0R]I!\6"%05&?,R9O[4TS6ZS?&PBN\H%&?!<M
M%&=>EXB:D/):GFLU>F6>Z)> >[,F.OH^O_J#/^@ -=_Z5[K3#B<Y._ZW#"7U
M\LAG[<>R,K;\$Z9/T3W3<"0[O6>\(;88=5J+6"LC7--7](%.:8<7,E-D*Z*9
MHKF@'&W#""'5NE2K@!P':F3/U/Z43APMC\HF^IS^/B'IFAL^ZR"[3-++H/*Z
MF[\GN&T[O?AYJ OJ]8 GW&[.F@LH=DQ)>%BKEPO1<M:K7TY%4IDF8=T95!8Q
MR>1T-WF_5^:F5G2>W5)7>="Z28:39:,R?F>LW?DJE*)=^^&UZAXM-BM8SZ+E
M[K0+5H9%J85?2N8_5?;'I0TW8C2% MQLPNVJSX0\LE+2F)E'\KZ;$*1S+X&&
M1I<G H$$^Z1KQ26MW*?&/5"X!VVY'9]LC6=ZV@6_'\59>M]$VMABKW6#+ZN<
M>*)N:EA L6VL.+>'TZGISKE?$&6;.F.GH&+EE!RG8DF&R1>]?L#C)[]E J4V
M"2_6-:[FWWQ(K54(V%O;<QO1%$K$V7S0D\_D85X7*Z-<8J^UN+U%XJ\^'[TH
M$^2]36KQBJWKR]#;Z=KJL8Z=R+;&FW[7!N/(=X0FPS+1>O)3T>&;(R^1^J#C
MVLERFU@X[N;'.POPBS0V"G/I]<G"3GQ!A]@O/<R)&]CP%L$=CMZ=)R7,"]F#
M'9]0(DV*'W\/K!+*?U-J)QJ/?G:;JRJ>ES*!,!9+F4*"Q#923[?3QU);G21&
MXE<]WRSEEE(4AA^'$IQUT</=[]3YAC*[+/]3=")#/:,JF7WTX2_WNQ4K88@C
M^I-.\;@UP?N=1V[Q* 46^7=>K/<6>)V'C#)%32H(I"[JW\"J=\W37G/K6JJ&
MLNCH/DRP^T?B!:JSFO>&!(_(I<;+=!2_ -K]WD15DW((#?4<"5'0VDW*?VY1
M=7QYO.> /8HT*)&3??);O;OYQTP1J4AF\+W!GY4&%,^\M*?\C1,P'Q_*N('%
M+_L C*=2G>@S/]R]8[RXZ7=5W3][Z="@#>FGTEN.;>\PH<F@\#5_VK-2QTB^
MUJ1JKGR_Z0+:7*,KG&'8[,)-HYY:*C_%LY^HH,@R?Q56"%%4Y0LM7.3#*WUP
MFO7CO&)MUN6+&],:N_F]K+];E<Q%4$I^;Q';;:=I$<.?]QS<NIQ<'U#Z>.@Z
M;:X/J30^9S*CSW&DK<K7VHBF7-[QD^M#H.)<-_(89:S'MB/C8,V. J(.,('T
M-RT1[N';#-Q-DOXA[/K1XR-,OOR-N6KLDM/@];D-V:#GI[XDD@C$=&''EFW.
MPQZOK#FXM233*]WQA)X$AU0^^R9'^PV%S0;>:_*NCL\G@&-)_-3V)];FTY:\
MZ]U(:+5'2@(]#JE'D:W3JW43.NVU32*./BW(P8$M>5#1 BEKB\&47JVG.39+
M<[#NT>2WFCF_[$ZY+,&C^^'H15$WNN-W2#WX/"H?Y4A^VDOH_3U07\@/_<LM
M8?=Y+:9%9'Q?SCZ'(U[(N$ 0T<N,RU5=P,)(%'EN0H#76-K'1\Y%Y?IA4NC1
M;/+SHSV$P42#PD90H\>JJ::BO$X%-V>Y\U2$JDOL-1.%ZG'9NH+4K>2J ;37
M\@?-C0 )& L;SRXBG+HU87<Y8O1RTN[<Q *DD4W27FNG86<8M\E^K1ATT1T=
MW&!]+F0>W:G]"])&/JT#?5,.C%M#^[M5+]Q[."T'W'J]K%87.6AZ.U8@'/Z)
M[[AC2,_GGQO G]9&1AV]ZU\&[^="I_/E>@-(S.,8OWF)LJ$0".*I,X./2#U8
M8+A(9F5TO/*^@GYZ]OPX_QA7HG@P_AJ/8J)G:6.59U@J94KEW4NE.=ASBIII
MG./5(Z&>1P?-8$./6.5 &T9(H"Q7X4^1"1O"8Y_KR=SY5W[>]Y/WHXD-)&_-
M^\E3JNAK-F.=L_L;BM.6M<CHTI%HV^4UO<^IAT(GSQ=*H@NT5OK@:)?,:?6;
MT$W7R!:$+-BGN]AXFK>R6Z2,9?VXJ]TC7$_V08\I!0L];2HWWR)]\7!J*"9U
M9$D*'4B=;3]U8T[-.=8<M=9VC.;N,17$^<07-&TAV= ][J5_</9?\7U3Z\)3
MXQ_&J EC6EX:3_/*<SXFYK($Z\H@"WF>>M>'3<A5U?\0MR:=JYI3+MZA GS9
M_OOPC.H*,?XG32N/B]VXQ!+8/>B7"YJ$,R_&<\G=4\SUDIB*#A'1C)%5:&OD
M X:][V229=_$\A/!8/5IX/G-]?QC$[)!5U'CC[@WL6<+\.5$\<\<85H^&5S'
MZ,]8(ZTO\X# ^C[ZR=R.5TR#T-,/]@&O!UP.3%[T-$SE(]5PA3QD@N!&=<9^
M>QY,$]6?T7GP-;?'?CH].93$M]J[Y\9'$V?X,#)W<+7U,&/EP";TXX&A)[/Y
M?,BI.;;@$^]PP7R\7T-"$#?3C3VW.=XCU""Q]"N/FA))/Z#: 4ZL*LTX[^1:
MGC/CPT8EQ_I+"Z3M5.5Y2KVZ37'@K$ZGD![SPB21(,K(VRM=$\\P(1#X6(+[
M#H"^LXSI;1)/Q$J#12H.N0"&VV6O >6JDMX$(.#L5PLJA:T;P;@>#Z[Q[9$'
MJ"Z;9.A6[OABPO/T88VOU[_ERW[=DT]^0 PW^_YM'9NS'2*L.Q6TJF3V03XF
M?#M][(.]HFZ3T74!#@RF>]7I6UO023>;<T65[VZ2VN55/Y:T'Z=7@#19");K
MVFZC@-%&&:'"0G0Z1-POA2$1SO4N5WW.9,Q;4PNA6F+$R1<W",CU">W@F@8U
M@X1JC!W-GAI07+SR.I+;BU2W=YU":$C)ED^-C%G'IGT=]?E4B4YLM/1)*-+.
M=/4+[APV _ +)$,W]@%'/&*T[IA;MR(FF +ZM7JRG<^?K3L/MZ')+<_'/+W;
M4CJKR?/@@^+990-A_><VF%L#*:H;V4P:CT4FZU+[$]R>%E-B+%%;A3/E3!$J
MH<\:CY8YG??X,J+]^LW[XXIS2902].7.A9^[HP<2$^-[%?E$Y,K;2*]-K#;#
MJVAKS]+$Q[:I1)H3Q=E!-B!A'<M$$6]$O/WI<'":5R8;4+I[*IX:F"4(]*26
M+/LLXE;-PQ!DH4>SG;"M59!SM'#UT]DEL"+\\;@UC7S"5Q$^O>OBZZ8Q,HI;
M;V^+:ES.'AFU6D,D"U4+SQ9SV)HC'TRKI=&\*NT =@FK6-UEOX;&#^\4#C0,
M<MUMN7A'^X?G$XD%8RW%J9<76L=0K1[V((-/=J>U[+6'E51HYRF\7)-HUX][
M('(,-$"V(U"-'@VE=2QKUV\5;:5"HL)\$&3QP&JVR(>A+#\BT="M%AA<V"MU
MYGHIE=B1K-F..%];WF__SI_K"AHZ !K#-<^WV4M.06Y5B;RG9&3OQED3$IWC
MR2(M>]<'V5W[3MS8\DM'J+AH79;OG'QE$^BQ.7&QT_J=Y\!3'T1PQS[ 5AR\
M+-Y_<YOTBN9.N;:Q&?GZF1QHS(LO-#^5&&A64-&#)P>:G.R< O,66]XP*-CN
M6IX>M[ ?AEG1@]<7BI]KNCF&91Z<I9AE^+A>XY4CDVM+<$<DF$)\ON$L'A>Y
MCHUK?#0D9.LC1L^:TZC7G96%F68[FQNV+NJ1^05(1TPRO;NCOZZMNP] VX")
M/>/>O#H4I@8;M=!6FN5PI;DOB&^!2;QU*0R72MG1];:UKK7$(%WQ_,D[WERM
MLEX[I.[1Y?#L!_-;IM:2^N1GJ6N18]B0,SAN&]]Y4IZXL,BD7U^7KO?;"X,N
MG?A,>"DX>M12*,>-4ZTJ((NLIX4^,-O>+OQ3+DO5]#3'*$!B5W:%W6T"X$IP
MN:1B[@_PA5DE6_7K95A]^VFWW>NF#3]#2(:<F87Q-KS"R46OT>^09A_?6[N4
M5#TE,6]=4_&AG]BE_[%ZIG_9Q_?\Z1;%N34%'CB"Q=<F+'7^<?.)OLQNA#O!
M&*LRXVDK^ EUYU_K=LT  <"1ESY=Z6*O-C>P<#0:5+0=%$Z03HHJV KQTIWD
M^2$P-:NUTKN6*Q/S3!,=U;,;]F+5\F?>I.YU4*BL:)@!)LWQ1:=/H/4\HNL)
MDKWKT/]TQW)YNK7!<E<DPJCW+CGL>-J& FQ$\T/"8GQ_%TU1.@ 96-6H337"
MA#1N0[0SD9(H!2OZ25,#*0V$96=ZE+YWTN4,JJI:@Z52] $>>?GC$+W,Q^R=
M\!_RG<FN_K(POP^H@.FOLHD'K&=/VBLQ3WOYU1*?6,O/KNT#WA3/A32(6&CI
M]K>54_3S%3P=[#.GX:VEZ;"B#47V]MHN:NA-;;K^VR$YW1L=\PMJ*NQ81:*O
MJ,G ]#ET:YF9WH2^Z4O9.8T;2)7;FN<#TXH4W<DK/5T*J#H\)8"UK!;=6BEE
M0/WZQ>8 FS201\YS.O1&KN?W>R(G*;P.IIV)ON='UL51S@.O@NBG31TQE,]J
MB5K;I+;^DM#)!/<K2A^<RS/?"L2A6Q%]J=%W%GBO(J>\59)ODY.Y.;XH+/64
M.=P9GQBTV:S&>(BVICA?]IG0$24VYG*N6\;J!DT06^8TL^>@;^J$Q*1V:K=(
MH"R/),T0VO1J/LCZW3I_NJ'[G)E.;0T7][.Z5N]8<?&T9&JHE3IWR)"6&=2]
M8]:D<4@NN=)RT 0_7%2N(%:"<AG&">@4473LYHI'N0T3A^>D)C?#U]#?@FL=
MVW]N0WKW&+M_Z=$)V< &XMGAGI*-!!^'Y4W]U8MO'1?@R=9$K$ARQD^< ]UY
M$G'QH5TW7<+6NU=ZI._)3WYO!B06%3T\HG)Q0?,6$$0_<!(+HJA,R;K @C R
M RYK6#Z*VU2/K_V[N%I$Y%)X6?XS[?7 (AP#6E(U;VJ'V,1=[?[AWC\Y1NU?
M18<#P4WP3QX>9?^!<_,%%HA*4H8+GCA4SM(#9Y+.=^ZYWOC(I+D<_=8(@IHS
M4%[+"SW*Q,_<:-^;;77AKX>>_S["9/DU)B9K;.5.'*-]V0.MY:?L WB?^8A,
MH8/W >[PABINM@;/WI$76\<:PK=*6A7);?Y(&7&Q2)$D>VT69:Z'3ICG?@S2
MZQ%DA;!Q?*N;G!T?UPD7 ^)ZVU&:5-AXW\E@!2^(I6S-=]0^(&=7I&./:R8\
M/RD/0D7@Y.^+]N-5,\1,E_3FLL8LOZ,3%_% U8=[<VOY3'7[@!,MJ!V+79%Y
MPXX+5@W"T8T!#F)296J3=R4Z@[F7=2*4I/<N($7*"R"/@]Z,P>Y6.[0[E0U6
M:/EF4E?'5#)2K"<O&4YTXA6I5<MO=A0SPB\VCL'5_%LN0X;"5]^WX/5'I._[
M!?BQI.'BKWC>^_D<BP-S42F@>Y=XK=5Y<5M>)<^HS_4'(BJ@^%0J(^5(1OPO
M=C?#UN4"&344*"+B]3=^1*B-2%3'<7Y>% ZL.GA@U^SY3I,U?=)K^IKJM;'[
M@,97D/KT'R)\EMX-TRW[ -8$UV>[C$@(!5S7))T)W,#6&VQ9T1 _1WB-\CK5
MZWV2S,3TT>@6-BF;%LZ09R;PGX]=8)1E)5C$\ K@@1SPFSV>8S4_B&&X0NFH
MW4(Z@<N2';06/<D9-8^</-$,%/.-1')1+A$RZQAL)M>QYH'FPOXB$_  7\D=
M^5H.I#LVFW8YEU&91:X-N-4@&1PPH'3G6\^TO]J!!$+>>[WFT9V'#L0(<$->
M( TI+\).OE.R'*Y"C/-G;S JMCJOD.K]6&@.4S!-WKT]W/RHH+>Z*872715?
M,)[,+@[7C; X*4= MF4;53Z?O[<$UX/-VIB&#G 5PO0FF([OAHT6M[C,POU>
M9WTL8WI==[MI]0/\:\: &V 3N*V]K%+=/K9]BC9(O<G7MRX(V4V!I_$=X]H]
MP_<1&]_JG7PGBO>'Y\'#75K#'J?FC)0FS,)6?_>:CIJYE^&UE2C>X,,K/@J^
M3GU?L72%=_W-*)8I>.XGG0O!U>]L*J/O/@#:384\^@)7"1^$]*^NZ)914-S=
MVN[4Y\NM-X.EG41*TMTCD:)OL=LI6Y 4I'B'Q5ZSH0CM4D5,YYAC]XJ;\[-I
MKV0330;>N\@YM^5\I6OCXIVEZ'/(R\.88KY./-Z!]S@L.5T_N:8X5LE3;5*#
M?59E\*I_2/A6V<0!?&"3R9D/OTX3:;#&5;4[G;SY0@^>DR1--49D00ON=9>N
M82/PUY%\K)K206>43FU?X[7D3)I'?VBP6LE<NCL*9D5JQS38AD]>IB_#%N'9
M:+?,=-G?Q$4X#U=+.4'A9\B]'&88N ;M&&55>CE5?788>[TFNS;IRB2U3!D9
MH:2,23M_*TSN>W9NPK)O46R_J9K[ Y%4PT%)D;%)7HCE0JJ8U6&*>\1A:LJ)
M?"5B_ H?2JNXP2D%"RO=!^@BOH.%_;Z#X2GYE>(-8??5OK:U+85*L59'^Q!<
MJD^[2F3;Z_B7-6&60I)E,B]L8JI?E!N5=:=,*)!&5I^9+R*9Q,&7&KN&CU M
MN?OMY8)+TETCD=?>[@-^7-R"8*CTMP(';K\H7ZDI-^Q<&*"*C.=87FUMPV4&
MH(7!!_Q]#6&CK>P*2RUG7/OUS)A!SR<X+7;L1B)VF]OF(L3)S@I'!\:0SL5(
M;&>%.).'Q).^I^\;<5Y.&RK5F_9WN\;1BZ@@B_2KUG;<TA:+=]*AP1X2841[
MKR?/8[Y<-(T07LG2>:E)A/#)E,@OI*/?X>60<FQ@[S3/N7Z\%$7UE>R;=?Y'
MZ4\1ZY &7R#:H"12\(P*THGR8RRVCS9M5.4-(4V6=EN=Y!-Z/SK2>)ZP=XZF
M&E$S+ABO+'<,X].UC*[/S3&ICVU5P_A:F.3U\V*&;MEOUXXZU3E;?\[]$::(
M,/UQ*I/7]KU5;^S)9]]W$I3$$$UX88\JU_?6M1,<2U!FVH,2!UFP_;03!DF@
M=(VS];,^BK"16X(K!=0TNUWK6!HOD B]F>$)KQ]YB\X:U.1L2KHW![,:\SGJ
MX*)K*&S$FA,A7;Z("3-BQ6;X,B EV!A.A[*ES,+-='5J= M6GH84&##=H7(L
M[SJ,OTY2ZL2G=4GWSF,ZE$?'R]"_>)A)9YT_&7)J 9*.5!4NS+V9;/?Z4[;R
MMW8(QT3U6;$XBVGWZR)91''6'M8K$ZBMV@ET*+@-(9^[L9Y=J^O&'^Z!RDGD
M4D!,T-?SCTC;B<_!9>PY7X^\Q;[5;3F9RRM+^:4\(V^N]!VTZO)H=>T^8"'W
M;=S$4,1-R)!RXO6BLKCE[JO7#&#Z^@?;LWE\VW9HPC+9?COV:_6)B7N6(TQ.
M&DN^?#0!_]9A?HDC7Q=@!98?OUF@@&J\W:M&E=\(_0(=8Y+K6C UAE2::*%1
M@SF\N<@1S]XGC;Q;_2Y_X>&ET5-N'JV5 U5MYCK^A@5C>'ZJGM,5\6+FKDZ\
M&S5R^36IQ79,Z06V2NS:1*DN.T0"2V4EZ;W<4Q'@C1YZT] <V9UH%,)BCV%J
M=CI'=5RMW3S]S5@Y?F:/BW8[^7YE**_R=36O;=D)=,W[A8FXS@LWUK#H=<1)
M:46C46 MI+<C][29HG8X1L-((Y[O$_PX#0DZ<?'X_;4EV*:-1XF./Z.O%Y*1
M4CA0*=@6]F%N 7Z4&@"_PT9(1&TIN'/U$8I\K.F9%RY$*AZOS)UP<>A,WP<\
MWX;DD"*1KC==@Y0&]Z*GS:M18?-JRWU;'R@=6@VI-W@S*KW5EM<B3)U.>9%*
MD'H!I@C)5[L3-++V+U11)PO&0H%9>(9.3K:.VM2ZX(Y&WB12-IN0TI(8_0V;
M SZ-O&]W)5 FLJO*@RE$@7WC\K,,(3#O7,1,>93Y^ZSC91(L8V\S^N67UZ^^
MB;^_J[.L^J4\)NF-N_K1<L=>;#R>":FJCC$/:9H=QK_M=*,CBM9FMP&7V5%B
M47V;'E[-:7K2PDG9!R<Y>BTW6E/_ *$9;G-.ADW?+P;?V4WEVCQ_H"OO1_!1
M[U6/NFVT+;"4!?JE8%',2N.?]@$O2<.3(]_ 3!)[0INR\ZTC,QL')X:/$]\@
M/!T9N2,MOJU8/08W4=MDFX4+O??C2#9^L7>*[U=%]Y?S4/^>Y"G8819,5F:
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MD"8XO9NJT(FA6;@^U5U;\IL6$B:9?*5OPT@^<5FUZL*2IHIGYJ?+NIW,\5
M:F)7!WN!>F"K7-CR#:SRG=@UQEZF)E7D66USSM4B;2?JD*=IV]2Z /L(/J\A
M*D.NBE6NLNE+@@T-$7!U$+,$,Q]38L6CLX0,&QA]7W+ZDIB:T?YN0.%-F[D2
M?Z2>I?/'@<4X_:Q&Z(Q2R;S2]*2?/&UCN;I1,]A'\>Q]+Z^>1IKX /HP=+<E
M-^DR9=-=*_E&&$S9&^[:!QQ>K$V])[T/V*+"6_&,?FC2J>HY]+1![,:KLE6)
MZ>36U!VQ%+_^J+;JB9XG:3N%V;D20_4"0T\1XVTG:79)VW>/Z[HLP=9'J]G
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M1E6GZ1<=F51BE[Z*+XR=;(5L0[Z-L-#X-DR:N/GEL!TCW"9Y/?=/['%21R;
M$;G3U^'0[?M?"H,+5LNB@5==:A08LC^(;;&Y7T<L:/OO79(-/KK8ID&];LIE
M9@*8.+0_;2HV(C0?::=[E86"A)&-T;%$Y^QFGV3F(<YD^Q4GM*DM=F]Z#6M8
M<F"C>^P#AOB:*[$3([27)KO-6Z=E*3KKI>@QJ=4WXVR$_*:]?< Z]CY5+1-#
MM"TE>*+K5 ?RE79&>JI<1O7]U2_IP=T,^E^WO4W'('@:47CN77S=YT/G8-N>
M\')($E^ES2G(\6IEU^K3:EEVEX4B( <J8<*OMI#[6;G:7']EI9C4R$^;3%2-
M=^4,!1WH=Y9/JQ(EQ7_=!['H%, KA=;'!1FOAN^*K,J0>R;N]-S,8CPP8TY1
M0S?T3BF\IR&0M:=R[L3S>_H*U9A^ 5,@I\OH01!]LQ[T6K[3MSU^M'[0B2?3
MP^4)]4-.%S:PP5&F5ZU]GD5$.:+1^P#;ZO7S>R"*QC[@>YW?"+98R79]@&4?
M$(I\4+TBP;<YM[BR-)K,]-Z/?2=VP_;@.7G[U>!QZ$7Q3KS&;KS2Q/#(,A9C
MN1.\AHULW =P)!N\V#MW"$CB_WE \CLZ#BMPVGC[MM&>@N6UA8M\^%_,O7=<
M4UVW+AHKBB"O2E !B8K4B#0!I20* @("4@.A1$4I"46D"!C !DAH(DUJI-<0
M*9$B!.G26R#2):%(DX2:4,*%]RM[W]\Y9Y^[[_N=O<\?,V21]5MEKC''>IXY
MQAP/X7=Q\_0U<""],Y:WOU,)EOD&UW(]0I9/W?B-W7<_,&%+N:L)_"&,B(9E
M;-\JDNX2.3==1;IDWN$7$A1W_0Q4LE$S-C,$U1L;Z8!22]J#2)_X2TN[737F
M "@CA]5$>P <SL9]_R!.,5ZG\N5IC.I([^/N0SD9</AG=M&T/?!BPIUA^Y+O
MWRWT.\\-*/T:H*E5VGTXE/+QL<$]:25W()]%VP_>'K/$XN:/8K()&*7S'W?Z
MX)X^=WJEF/I3YBTY:_S&F=V9D[+NW$L+LWQI"?/NXQQMPC)!RX79>C0=K7V2
M<(5N\&J4@W^F>QF[8)Z8EE#D,O$U2' 2&O.B,)&V]G@_3I33Q^*M;[KO9])H
M)!NJ-^=];QJ]D\W0H*CN'PBO0[N'"VWR%]\(@0:M=T=& _-! 8M.L#3,BKAM
MTK! (S\VSJUY=?R0>[M_I@?<Y17E7"O[HG#X +FW^'>5IHM=DA2P]JJN=J+
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M_X:>FC$\WD^J[/?T)NR[@.#-?OVM_J6I7<#Q%690PXOL;\,F\93O> ?Z1E!
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M0QS.),K$X!W2:UU([,MYMOJI"X:MY"'EE.8)YVV_I=7""'V&:?X^,<FH=W5
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MK@Z'?6,)\#K:RU.!OW1Z\RT&<34 D[R?216CG0S-&+.]-U+[_U 0_3_7(G,
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M)#0$K\P($]_2DGO*@\]MPEI!1[?!'J#H3MP0D4!+#BXK"STU5&7I^)#-/F6
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MU=6H9@/UN;RP!PSULBZW;PY/:-9ZN4A,>+[CIQ)>3,?3WN@3RDP>WQK7;F5
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MPU"0SO=U#%6^(*!OCARSF_%$,"TPXQ#@0R4LU#1V[IW48.B7=G(2_4DOLOH
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M/7[8S=)&Q[/MZ1-_6@)>I/1'DW;QD@N)$78=D),X')8C-,,5D<S3R6K8=N!
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M. 3X\"R6XJ^^('RG2#:>N:DO;OKJ^U+A:XOWB=_WN-D:%:^O67Q^T8Z8SZ5
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MH=[,91N7Z;"TYY%3%C:U J?A&PA6WX^P^+@2C#;P=!AF&<ZT[-P&<+]^XC:
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M2[L+1*%=9\_IN%]9#S_=O1ZX+%PW"Q23+GNXMQ;G5<^O,>?1*K!_(2!XG&8
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MS-Z?;%@B.G YH3)6'G(MH0@8-)7X/FLIVP,S9/,UMLEH\+PUKK>"&YA<B-S
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M<^CQJ8I383F\7C];'LBVP(A3:HV+00XWEBUUN:YH0DJL)[W+.\BPX4'> F3
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M_7Z3#/E,6T0\+7_B"7>?V\K0! KE>IA5L$!CP+<&1Y+SIMXEE_25->X%+G5
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M;Z0>,TM@*2Q_=Q]1?EABCN3;Z[!/QU^IZ1;?C?:<EY]TGR''1H0_'= \?'/
M='"5A_ 1^TVIV/[U"1"I^OZX\N/\ZP\K9^QB=.U>EN[JAFHE/ALPK,/FWGKP
M\5U2S]%21/>,9^NO_MA_/[]W;U_ NQB[VT "$(9W[\IW M+(-$/VW]H;5J.K
M_[0SE-(-2>/&'_AAT_5(:&\M?_>Z\19HO$@W#W*CI8^89XW.@6<(T="KH)54
M@M)FR9<B=)YJ$_/MQ?#[T=BG9%G*_F5)TQM:/@VMP?[C"N7OR9^9.4HDVP 4
MYTOOT9UNK<;$KO3_XQUF_]^NO<XN&I6FCKO7$L_]>M-7 _]N,OW(=SXI\;'P
M[ A/XH7H7?-7T.P G%5NPH/VW-[*EW7_D<])K(S)*0:P9$7^OM\^+X<;ZM%<
M@@7+R^&&BIU_5<N3B77H8B(;:;BJNNSVRNQR>05G%07<-+PL@YU%3$7P-J/+
MXG:*Z?9Q%I \*EMCF]N L4?%\@X\9E["*^;5RNERPK>49^"JR"/Q!"(73W==
M>1(TWX2@*L>MA;'F)+<&Y.>EHEVDHHNAR?[7N!JPVT1EGXG155G+>1/$)X9(
M=>EE#W8_)5?9X]G-'_IR<PS%=R-G19[^W$-]-4(XQ RB./2H'A!\YH=/13O"
MQ?V"O?EI(P2CTF!#!\LFOD=YBQ<'Y(0VXND5,:[^2=DUXUQTVHH^B7H]/5"C
M>Y6^U9A:((19X BS%1$TR_[&9)6N&M?1<7ALVCH\0RS,WJSB!O_+.$7E\;H1
MVF.PLTY9)7P16HVN*])$]W*BT76%D&722@$0=W6.E4_Z5&*H,#5[<?^Y:G*C
MK6""TL]['/.UMTQX%<<JD O(!L>5[X-U!9ZM%"2H]S?V3^>\C(XAO;U$J[CT
M24=W^#N^8!O@L T0%3_SPFI+D]S&)1Q:%UG@] E9,7#,+[8H0\5IO5/VB8<F
M.0/S$G_K]UA=2T?>X\ ,W\<;;I?*0S34<?Y+_$')2M9Y8B^0=%"?2\%>!H_P
MQK"SZS$G[&?C["RA3FTA8TO)9!_JZ.I%U$[&!NZOORE(;-^,!U$CPN27N1.\
MHO'L]P:[_K&?3#!ZX@)V$3H$!-3VWE@1II.#[;<!;RNY9,D#"= (!G[&W[C(
M$9]^A!5?X3X6?AP5TCE0M$K:X-5V/-*++> BSMFTRG/6*I/XT-&EP7])X<##
M#G.J&/@8[PH(Q1X]@B]IY>S9X45S<"X=HLXJXE 58_"-/5D=T/IM ._@UCFN
MY/L89&./3 <T(IZM6Q3+/C>5MI.P07&#T)_Z-'SF*I"Y'#<#5V8_4!<,5&U\
MP?R9[T,G1;%O!_=8@TMFN \:?UN0.OPNM3JQT4?*]O,H;)XC0GLY,JM5JB&\
MNIHZ+,__/NU,+O9S("_F_(IEFUW2(?)M6U/Z8I->I7/.TUO[GLE3]\=5DNM[
MLA2>H1JO1$[HZNIX0N@)];/%6'IB_6Q)7%&<G9&38&YJA3<CVJ@SMF#0]X7"
M_OJ#-A^ 6H:5DUHVZ$Y[%M3@$,6\N0#1F,=Y<VHM+X,A:#H.EMGZ3%CA8JCQ
M<?@&O^+FZ@I\?G^_4ZW$1E7=5W3#!GH4WZ&$_@;F$^;",^B:)^4G?P9J;PUH
MNO97]3;@\^#6/M3^&M X ]OD,,!E.R^#OP;;"$3:ZC("OA?./OLZ'Z$A%4/K
M3<0YY65?O29.J?C=XS65_@Y3W*M73&J'A(SLBKI+^* 3%G9\I<#G*L-^X-!W
MOICO^*^!\FS-V_*3WA%)_M &X+%B/Z^ EH,Y-A*;26<=*78_2)C&3E\G3VGR
MI=$0X(#2/B<5(LZ3<*[2.E@^B1SV.U#AP\_[^0T/*V]KV2B4AO\JP.9M:CAZ
MH!R2+SODLM7@S'C=B$7H,/"@J(0'N@J^GRV3."_:*55-'H'PJ7>;;@ULM'6P
MCG]9G(%@8C$;:3,W;6-^^'(93?M* <X?*D-=W. IVRSY!Z.I_5<*LVL5;\,L
M'ITYQE&ELFRP#"4@;#,,0B>]:4 ?947]([U2N\%+7,''!!Y64^((KUIP;SS)
M),0L]2^&L<+XZ^ZG8D"MVE?_QY)7CI^O?$<2)?Q;25]L]70#6L#TMLQ%.ZG5
M'S<8=2*)#DE76.0[3U?/%$2V7]!1K[H<$'Y*O$"Z?O3HJ5[SNW3/Q?M>_J]-
M3C[IN_@Z=:X]3?6LE^$9Y;:,^WOXW6V%&=UUI>$(%;GSS>T!.GTEA[]&16Z0
M2=N XTCW8_5*(Y K\]^; CLMJ8T_P.U#3!_*94QI95@BCP8.$O2A]?#$5<$>
M"[?PDHD>51G =,)<H.#OJ5G*.;XAZ%!/E!F*2I%-IP5D_8+S+B0;^-Z0JJM)
M98W^+'I$I).CD:"NA#XQ#^5O>+M'PU+:>6/N_.MQNL/CY(4Y4FBM8[MJC.M^
MJ1)&NJ<J/H3'=V,;@ L,XG0$2JF)++^O:%:E\X==(G:KOD&E/\B;^]J28U*X
M)!Y]W'EHTV[-B2Q@]USD1![-\K%5VI&LDQAV#U.:(;EY3B\2>_S=ZAK^!?BL
M3K9U@U:'AS;B6]O3+O/C$9X*#3K=QMJNF"R''%UOL;_J/M!,W@W?'@+5309(
M3?915P_L?>81JRZ&_TBXB'A[L&T/BUS@2R-V6CI]C5 ZHHV@&(5N P3W]?9D
M?W4XLXYW4ZS_X5%!?2P6TG19:[DQ+GC=Y,GQ9=M$NH,ANO1Z_P*H60M2:],3
M37UFB'*@^WQWD:B;U-:$=CZ<E3/;,$JNN]:;TX:"T#D019TP%"3&U1F^Q)^X
M-9 WG@?_.I/]L=&Z-X*UMU:?Z:3Y<WJ0J&>Y<8,JPVKA&FT"?4^.)PUN@'SL
MENS61+#M54#6Z"V/$(A[N;0Z6(VJO3A^R+TXTJ$'VL\1#!?4B_A+G*A*)]5]
M<KQQP<J50OA.5WL;F6]LX(!A%.TW2)C.BVNW7)'3;XQJN-=4T9S?NGA<YTGZ
M@K'MQ2R9K]IE)J"<-O;#PM( #;&@PV4)3 @E2?;P1(8V8@8=!A>*:HWV2ZZA
M44D2ONG.Y'>[?AJB7*UNN4,=?DR9I\C8.R,U>C(B3,)VNU<29IBZONL6 B\]
M&Y&WZ;4Z 7G-'Q71^IM1XT=B^]88NS4/AG4V-3["0"^P]>@-"3'1B5 M:(OM
M)::NG[??*8$RN/X67T7W>.7KM.R"A^OC6[BVH#!G]$$&O7_ZQHV^AK$8%Z.?
MDJ27:ET.ZX8;9@-JWS5_/S9YZ$J(88F,'KHPF*^//N@%/Y1/U1 XSP9U^565
M1*AMGK6=;AWE)T@.]1<'1+X9A^O[*MX*T+NG1-Q=*0G9-SA W<\[;OVLTM]Z
M;)>M(1):JHT$B_;'IMPOS,Z1Y3UN0D[P/_6?W-O  \0DNNYT2=]#W==T)C%Y
M=74Z=- UEMA/;L2*%Y2V*Y'\65H9M@X_ICV*^7?U9?Y?Q+UW6%/=NB\:*XH%
M43I*5%2:@)2 TJ(BO4D-!$A$.J%(;P'\I&D$HDB1(J%WB/0>I"L(2(V @(1.
M* DU0 @G?*OL=>X]S[YK[;7/W7^,)\^<R9QSS#'>]AMYQ_L;?S$)[>*5/'@\
M'3#@/I%8CSK@$OP&C%,;1Y4O*67E/_MG@0ZKGDV;:?X'K'KU!]Z@9M*;XDM
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M=DH&/H*K+!9\9.BO%YT2B=KV*CE>C?4:@#A>]X=T6EZ;Z\UM:FL_4Z/$0L=
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MY_,;$,KZ"1OT59ZHG$L\A_O69N!]QQ0HA(1'E/R9V%;G?I#I0Q/<YR5XA>W
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M3Y G1VV<537?1&T0P]B;.P\1G^+DNQ,7J!+2([/ZR9 "_=\EA#[:[9$5&G"
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M]UP+*9GH-%;:@]0., HL9:P7?X3$RD?YQ5CJN[<@Y4F%]CN,S7>?[4&P=E+
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M'/Y*"=4)"& 9^GLUL.%4!MT_22I >?S'-O7Y4QG^D0A#3UH=RG],^B]JKN4
M\/R'*__2-'/Z'I[/$08\C_OW0]6C=P#\984G\VO6WT]R)3UD^B=#_W^Z%8(O
M:\V.5?57"<60RR?,"PZ$H.H;JLUEY=QR)PA>::W!H'5\9/;&G0]$V Y9Q6 W
MBW,+FUROYCJO^6L'VU<ZBBS1I#:"\KKO1.D <=VF\#K#0\!LEC&-:^\.LI3]
M9ER"3EZ)Q5]&]T\^*GV!KC]KA!\19%S^3RTAW>/R'ZL[)6V7QY]Z6G @GCZ/
M1X0I)R-'!9;*8YZ>R"O7?;AZPWPPZ90,ROM2G1TA&O7P7S.U]'G,0];%E==S
MGI4)"8*FO:@KR" I%1,7*&OZNJ-)UV[[O=[G^ZT)KCW2;@?6,2XFA]V!WR&R
MS\-)V S+0X!1HSH5*^9=V/MSO<+A#!V#PW270\5UMIPV<P;@JU7]+^4:.RZM
M0K#LPS=:5V"+T_P[0OA(Q.>5A/S6'E_E49\':>T#JN67Z5%J*J!".M$H^\<)
M^EO>_#>V^_PG[7B1L%3DQ%']!I%1@+J B:O:7TR\8+]>E,R/(WP2.0B(*5!3
MOP"XT!\=[WD;P"+MQY]:*N=NM#R[_LO0:U&WL,[LZ:,E!>:Z+C[0\N@YYRJ@
M.HF)P3R0_ #K0ZI/6NGH_R# 7:ZKI'J46'=R3./?V( 88A-93O<U3AE.PO_O
M+Y/L[?Y#6;C&[:!GVO@Y4D_]63R='@1V X19DNF#J%89AP)HQYQ(A/ZUN#JO
MY-$ML]*3:E^RVV73)8K;[ECY2KE3UO_!VCUVU4IEZ'=BH5\-T$J/0RDO/CS"
M6(*;?ZD?D:V_6&=WS.BH"-(_,UO]@X E@6/=PG3Y]\UY>L*TZ-QPO!.W$KVC
M_P>G>V>4;FH ;<+_<(<_7^5/"Y?)Q^+^\)SFGZ0]PL+_#:)A)MKJC[[3H^T/
M<1L7ZE80&C^SG#5?4EPHWO#$[3E&^$[O>YS 4F-CC/,JHL53""-C,]? 3LC.
M#!SB[W6':9;Y1D.6C/G=!E2F*4O)0]#;8QL&C2U:ACEXWSECK7*ZBC9_R,WP
M!,R]O$ ?1/YC,5M'>@TP6E3[_WTMP!*DD&Z3JJE75U!&NEU,_$I9,T/RNC-N
MP@'0N27>-3/*&[>F3\;&&P8J^*#3%F/GS6LAC7Q[%7N0<.3-<$?=@%/^T0%]
MF]@NUYXMDSV:69'2.25AUGF>7'W3M#W]/.[51,"4'(1GUH^\=DEQOQV+($N:
MOB=^K5>[>*TZ57-J]?0PZ#)(QW<GTDB[PBIZ1N^(D._,N( 4W1D!WO;'_3>;
M]<SQ/_W=$1\A*$]@\^DQ[>R^AXR#,;I_6XY08F$\JDUQ[R\7_,EE4)>'LP;(
MUQJJ7>3)MJ\=4KN]FWNBE!319@TO\N\-*6YTRY OF,><[ZTTV,-74M0W9F#^
M3TT6\L?RAF##6E\%V^B2N_1?=E$?UT\23>)K-XV>K=Y,U%J^T_]K.+VZJ_?U
M<%SFJRZ3;K+;MZ!((4-EE[2W1:<&-]6%>L!3+B-! 73([&)"_]AG_!0\IK_J
M)]*G].(ITJ#L(XEH:J0@7EG?SJFED06JY2HXZ]@3C0J;F'+F_96=71CYZD\M
M%XA6O:G7_87NZXVYT&^%-ZFK0FWN[)/LA87?3@T:E60]<(RPAC*/IT0J^9Z?
MY+G+"R;J;^;&3V\% [?RH =0K"6XL'_5_QKK+-LAX&KAG6=RK44K8()UUK94
M[: ,*V^M(&BQR\9;TL@&4Z2$/*;WH$BF+;M*6DN>_O1,^M"'S?TVS9Y;?'A%
MUPR7-NV/N*PH'F$DAV$MS)CV,\J/F?C:-O1J/.4/)=\QI%DI?!KJ0A4FBJYE
M@2WU/S=4*,QGZ,)\,&R%291A[ A5I;SVV0GABQ'XAX:I>Y^R6)-RB+IP?D$5
M4#J"&U13:K\LS&(@+7U\7)HGYGPB:DX4B7"Q:3.)B^YM'\9''"]-'!CI\N?T
M5YW RZ!L!IZ.P82;9PP3OP\J+1Z9\9?/X][1#T#5A09QU_75&D+&JT#\Q8]P
M-Z!WD[Q%$'!M\DEHF-0[A^1;54\$VI:[40(GK&PR$BW8W)_:J?*/"EW>:7UG
M,N_*FHA3J+0=JT$H:>M8J92CECP'!X)-:@,KKFU+O8<^')0<GM;>/Z&GOY#Y
M]$^2LK]$73&SBT>&/<DAJR<U;DD-]-9SVA1AU"(^E*MN>D6 ?]5C$"**H(]>
M-B,G(JVBUC1W1YB/_5JSN-[/E#\)(C,=L)XOA =<4\])0L0"IE7ONM?$E<Q2
M\FR99X<K#+*WE44*V9;7*E%2J(U&BNDP?!+JAS0I=9F&!K;G/-O^L>K'RMJ$
M1AG94H;IIM $2\[B:0\('E.LF>B#^4VR.<93^M/!''?#C\[G6/C;><OSH'X+
MTP1->EY<0[CHD$/86YTLU/H3QR\8!H]\XMK,N)D:M6B%?K%H@J?=#.N0?9VK
MZ_+$;B:N<"2]1HD\5*96Y39<E-+ ^H-;-7OJ=NWE9-CWX>PJJ.K,91$EA=22
MU/XMEG*ZZ894UYD:_)JK:=#H\*H-]!8G0SC439GIP^'IFWH@]%T$!S(>*^%Y
MSM@=/SV$DI(;/!"R#LO?5A9EUO*41Z'(/VD*QE74"IW^\F4:R'C<\O*-M*G\
MXI<E+)/Z PO%*MKD@R*:5&DR7@/A$^\:IFC<F9Q14VZ556*#XC^BV7BWF7H\
MKDRT(G>YK!HUOXJ[.3):>4[8GLLM[FMWC]CXIT^L'2;4)^6UCJ>A"\N>_&LQ
MK#=CTOA77X%XA1/\Z+>0_ L'2NG]2 V>H>!<G_QSIV\D*.F]C6OM5)=-.@2$
M D/=XF@R%2E::7%5=[?NK\:P2OZZ?:V-L]U4XC%*R6FPXE3H7UBGC$?CWUP?
M:+JKPC)H5GG[FW!W47I<_:0>I<'Z>2N[+JK]P_0L"K.59W[N@N%R!,_-Q/&4
M%K5R"+J%O-ZNW)$86V1+1G42 3+NBBV&IJG&*!<;/W/6[_8TR2I<^[!^XF15
MK6GHU\*K9M[2$3&5=W656&__S4^??:^\I)SYO\.$_R\H>7[ UT'+IZK]@LX!
MFVY*>P/"J'H]S7(%+HLT'3H;IHN!;KU@V<V_X\L9JPW5 MY&:M:*P[KH?C;(
M9L1A"7?=W+GVW3Z>W=:#M6!+3LY)"QCUW-:O\%=6_EO/_DR3-GM+$2L=)3&K
M<6T&R7#7<GHL5W[>\^^1!5V9 .("_TH%K'^[Y=Z2&]R"ZC1H7>[R$IJ[CX50
M?!%)KWNKL:)] ]_?*_E[M_A?&'CL"@N4,OML6_ 2+=FW!6RN]E)BOU8PHC+.
M.AMT885:;8G5IW%16]C6=#%%OV/S;LF@U(5>K[&]QRUF93K''/M.)*\J8^^0
MG]RW(32@3= >3C (H?H%]*5<U=-#@+%#H:>+P:X52)NK]&QN>JS=,?X<)Y;1
M_W;R1P$IE"%1._5TGZ+G/X2F@\(B?<I]1^':@$_J*2CT$4J:"0J :@V&EJF5
M5P!$IC3M3]LCXR1;'%9^_CA1WU?[J<Y3N5+\PX^A+B<1(]Y9R6. B IYQY$Z
MHY6X4-[I65"#]52<HS58G<$RG,L@LD_K.HG:T\*(&%JF"G)S0L?*21%FUDI"
ML6ES,@SA-A!X#+[0QU8[FM4,-?"9--Z .WN\5LCX>O@?J'"W@XG9 DG!8)##
MQU#7]<0 \?_JF@ C5\R$V5U$6R"O3T7YS]D;9-2V\ L"PQZDD^X1L8D<MDT=
MT,W/'H-S'^26K57.2*'YR9AV@6?5GE<"*SI-J49U=2YQ1N!(7]&WH+/.%<I/
M.XJ\X1?JN:6*O[[01BQ/\'P2]+9MS]\2-"B59:+H8%'S_OI,K4*S+EN1NWAO
M%U*8OC-3G)^?X3ET2&EQD%>0X(PA_R=<3TFX!5EFB8T[DY>,525YMTW/7?=M
MA*Z+7O9AF]92?I9I.5I_4.%?Q$8L %R #RWBH9S^?C'P^L#W%"#AEG1?JO@)
MC-]F5\!C[IA3ID6!GD@)"O:6A#):@$B$FR+ER%^'+%^[]*@4(2=$3R[*8E1"
MV@7S.\K[=$W!"<>E<[/A9N=,O=Q<8=*F/ V;U6:P-H?03[608]-,KROWD"(G
M7UI.U/2^AC/S#EC$7[9$0W?9";;M9VT2#:*>^\I?\+^O>;Y MNQKFZ6EDO%6
MT#6JA7G_R:0M+"-9NDVHYE.E>@>YF&'?;\.\MGWN67N="Q-5NGJ85>/&@VUL
M3AA/W#7_CFX=9OU+!P/OZBFA>37WWR\E!RH,*0;L8%T'#@&VNR(&5Y@6(3,'
MR>/L"FK4 ITBB^&0 PBSL Y;/XUW2?>KM.KD)[^@D$#AWG,Y"6)4+95\Y/FX
M;R8A3^AC1FSEX:S[81QKQ)%Y$!EP*7 OK'!?8NH0T/8U>[U%$RRS@V:BU(X9
MA"J\T)9'K'<\(F]-H-W2,I\=V\)F*K!2K20D53<"*PC3XD3_/GGD'<L@+Y4Q
M<F=IL<&,/C&,I/.6=^@&>KXG@%B)38@QNY:P^3DQL19HMA8IBFO)+IN_"E$T
M4VE3BY#A?D<7V7SU#=7$XA^.NY:$G#;V >?;NB+W A =.NT:"7/7-744*F+)
M70;O*P1BI/TVL&?LRQP@EGG?L UIH=EY[I+(VTB#<9B!OSA2K2'VT660+(WM
MU,[.V$9!()#B(CQ4>RV$O&A^%WSVMC4=Y0<)MNMEL%OZM)>__]9!YEF7LU$N
M?MMR"&"[$V4]*4!=2JD@X?Q]OC%C.NNGH3]6-\-L6LX;*K,X%-R\+3A88?MS
MXCBEY.J$L7WX/(Q('RS6IOS'C??YB/!X&=%6C4B>%<-,BV B7(L*I)2ZC++8
MNR=[8WDYX]>+K?Q^RK4DK)<MSS[K/#/WF0KW</*HLN@XG4.:2 5=D'IPK-L&
M^>0Y#AB#5J06S%L  W@7;HNZELWJO FZ8C7@DDD?$!T_+&F'$)(82A"(E]O#
M1R ]!E/DC1S%@&+Y\-.>?!\,7K/)(Y8#"X 6WY'HX:R579V^M5-+RNO#4CT^
MQ6V([SB.KW"=<(57#2 _1LK>J%H&T:ZN36Q05^FYL[CBZY_[$!32F*QH?^^K
MHB4GUJ'Z$*!W"%#?16R_KK5SHFO^Z3K2"_W<#_?%/KS('I6+GB9L%N2S;#2^
M'<:]I"@2MH>&[^+<X2GXT7(,Z=V]7X&'@"UL29#-?F7"]6^]ZGM7O;@D%\V!
MX#]:.[-,)9;OX^P,]HV4&SR<");)1A58JG\';:'8I6VEDE,A=MUC:-9R:6;E
M2BOMEL](^9H$4X0_'@VEFKRON)3B'03MIXPA^]Y\#D#,U5V#*A99NNX/;7.8
MW;767MZ]:B2HFV<5&(Z\399UZ&O7L 6M:/3C8 >?5J'&J4?]",/9<K(R%O$N
MWG-SRTQB0_$77ZG^.V'8@R1'S8!\];R\[]=+8]]TL S_]L6@Y:"2U3.[Y#^(
M<$F?Z6G(SU7S)Y3YX5HT&G9O_V8/*QG?@&0GGV@?^.6@S::XTX!8+EUFS"WN
M17\7ZTDJ5>@D@=OO--9'GA^9'\954-P)Q_*-\X234=1T"H0@T#:CV>.'.CA&
M$2),;1L;8BIEACGC+NC#%BM-(]P#R9NEFVGY4?%($<+)JV1(P2Q7R9; I"Z"
MH4V"P_';55?3H7""O[NKP\/-_/#6-YCFWB2%FS[9_@]NC;8^KU<THKSUOOK]
M)-VTUB,52<GQT:J/\6^6)B_,1]O(,L'5]PJ%LKKRUG]B[+O3NJ5;WXY/$KDW
M<IA0$%?/&)IG>B"[3L2N[7JQ;6O*J91VJ=NJ5*%^5 :?94]\):HF.U#<3*7I
M(\TC8YJU-?DL>AXF5@CM1HC!E'32?W9[+#T #6TY>-5T;27&ERQ?(&NO:D=C
M>@K K5WC+9>EYTWVV%_QU1O*JE&%TN&A99\9NL"Q;A7*(AV:YO9"\51Y\N5U
M-0-.KH:UJ<8W\_71][YK(UK+P6$;BN*S]'[O!(7A6*.'5=<KY@B?%""6 \WY
MR:,I:Y:R03:K?!1$>Z"@S[?R1@DFU'9CV:Z,VE$:H.I!JFBBA-1%&?S[X%=Y
M1AW8B*0<[;EKZ#;[6X-2NPT'B'$%(*6FXB1:-'D?WS2JG7=C6(&\/[2%;MK/
MCN9W<_^"M>4,C[CAX?-3[DF.D,32)Z[IGA"@PT"AZ+E*HL5FT>BN@%UO0523
MR6A<R:D0ZX0P)0GCH8R2T#>.S' %JA$E,Q&I%QI_S1^OQ'BY2(B7<2A#7=K6
M8CH(Y;7M^O5DZE%ECRB<:'GD]2B7X?KP#B!;L:CS)S8]MP!$PH#""$&@YE=3
M ?'>+M)>Q!XH\+JCLV#V34,14KLQ466$%]A>\Q8-="BDRN(S%H+.Y Q^UK2:
M'ZV3A8^,ST4 ^3:+>YT>IT1,&2 &AWC.L:,KE'A%MOH7@JY@ISPGA1BW-# C
M(]-Z2$Q_#? 2D@>C823$R;&=O_W3+Y%7QQ*64KB"9";_T?_D*&VP'W:<4G"J
M7_E\ZOQ$HSR(V[3[]'/EWVRU0 8JI'I Y#W,B&.G^*[R:9 AP6-JXZR>U_L]
M= XQ;C3$X>OTG?(35E8>V!@<"Q7*%=U<)!+$M8=X.'1%KP1RX0-J]ZXRCX%Y
MPI:'4'NY<R34JL/1,2!OB[5C+P$\#NKTY)$F2[1V9W>(<'-@8^M=R5&FW#D\
M7@^.""+G/?K:%"[>!Y'XVLXM)JZ;%_KA\;/5/H-0S(V/A-M:"_YK(;C[<E7J
M7(&TBBU@"_ -\Q)S1\*CKUO8SD]7S*O+JHWNJH V&YMZ41=<[O+W[WD7__*"
MU;BPN#[;."L U3P0*<%I?%44Z(;RQ,X"SU'M$K/J'^+<UV#%A1Q6D%:#8+HT
MK"P.&O)Z\ 9,:6>."B!X];)S1&,MA/P8=Q$$/'I2K?K=6;%7_OB!B>M.M4_F
M1W&G#M)=4KAK/KM^P]H*9^8;E,DAFS-RSF4@FAO9;M4.LLK]VB#"=9!@//?3
MJHBX'J5 5RIXZ%: O?(: 5M/N]#9;]+RX2<DZZ/%M):=[VZ KX%?"MEY+.-T
MRG=6-7E!(?B6H&!<8V"EE,C,;P(.BO=22*@3^HCC(UM!'47C3_!L;52UHM\B
MV#_F21--&KEP=Y).)QB9>:[!!8@I]S%F."N(\ <B7/>/+^;N7W>3G65CUS,*
MR$%M&M^R@T3HD=V+#>3CH:O1M_R6J-*DN>E6;K,,J36'37GPMG^T7=,]3&<#
MQOYQ5 1Y2&:K0N7U*/7Q$.\+3;2Y=SCM+DQ1D"&V468-I#.RJF'\]HR.COI&
M)&(JJR?^A5=["T-_GD&:Z1.-'%A4X9[L5'QK#LXN6(.NCH,IYP=Q8\[A#[YB
M7P6R+^X8Q;N>OM"$K<2QK[&YKFYB$[_;*U\D*WP0+1 HTE%+1PG-]_K\5^/^
M-KSPJ*H9D_KN(8!@&\Y7&Z4I -I,IL'Z@:S?B5#YK/5W7HF;+RH.(HI]?;[+
M8KF!GU*D*$&>MULPPK5[D+.'@#.W!^^Z<P<:[@&+D1+E];\>"U"%PH<4+GVI
MJVP%"^[+/&CU=43R\/+&2XN1]7U@/GYI'?T93C=5]_*P>17H4 N)2M'^ZDC+
MJ=;WJZWP+#^#C3.#<J@$J\5-.>&B[P$.$O>@:Q68D[\4DY6#!*>Q]=*>W,#W
MC8*;-_0DEGS+,NY[\!^D!=@WNQ*??N*9U1$,$H0O[\;G)R[L:,JOMM*>98T_
M?6O"GBNYI3^1\VA)0]$KV_GXIWG&QVP)VE\S"7^D#>I9Z0THT?&E(AWO"?Q?
MK_ULJ(;;,LV7OK!A^"3.@X<;_3U!:*$W3,9Y+H2 \R$Y[,:?VV+=LFUN +NU
MNL).6XL8ERVL5[NK\1P"?B?!13B(#3UB9KUAPLAJ_:BA?C_\/.NGF<"<<+//
MJ@$L,48,JN6Z2@!;AZ>K$?AXG^;S0OABLXXY940WTMZE H@"D [LG&)Q%8_9
MBD0O72B3'B[]O3]DQ69O%$T'E?;E2T[_;?___[W5Y?T-9RDO:@D_9$I/%]44
M?WJ*?F18OQ0M)3SZ\EHWJ,QHJE+<$M5P,;K?*_6\8FW&[HY',8[I?/G'783R
M9),P'^FI810/QWA)F_WH8N\=!>A:(?7XKVNQC;:_S?/%*Z25W,IZA#W8/G!"
M1\I)F 1T_"96,;PYC\FPX/TBV72K#?P87E?3.DJY9@KD6S3U"CREU*Y7RQS@
MXC*("G-A&QT+WCAFD/?MHYS6_54I?!.I/4/(J+$DM>K:*0L84KDR_/X[B$0^
M4C<\61TL,RQYJP>:$,E1U+-G\KN"X9V0PG3;)>@AX!+VQA".C]>YM;'(5::C
MU<;I9_Q6<:Z%Z2\2<8Z,;N[U'%*XW8)(5@7+I%F2#47X&&\?(&:#F'W6;2W?
M,,T;(D6GS\XT:'ZEQ_R_/B/BYD/OKL/Z;O4VUHL23@V^O[@\5QOM"F,B)<$D
M5-CFNOUCZYNM&$"$X?!;A0$3C%65F9G?%KFSA'F-&%+O+)D/CAH>D?W^:Z4R
M([%!'74'0C,8]/<G5PXN!#C]]1B+GB2O@7_@2^(/ <P\RF"*(Z5X3T*J5@6>
MB*LZ2$%*QFL<$TCY5##[Y.'$]?G]0\ P;OG@H\?@^^N]%0':%OIQ;S8X/4&"
M'95C%)$;SAE=*XN&(G+GKN0=_*06]#6_O,? XL032\*-JHSM<V!D*<2I1"W'
M&:6Q?MQ32A*)7&@5VVS)N0+/W&O'7)C-3!JTHMLIR+17O--YB6<BOEB78V_C
MI06F+3^7S-:013">4NB\T%_*7+A*RCF"FLBM/S3FLY"QA&QFXMTK^T.;X.4U
MWHJVQBGXHRA4+(_E_&<]UZ).=./F&[ENJ=.' )L:E]=[2XM01XS4&6!_I8?_
ME$MZJUK[*1_ICEY.7ZF-_&\_=[!O6_H]!7_NJV\9RD 4_"C?R *C!+MAV(PG
M]G1552U9*JU][I>##K?#!X?$EHCH<UQ;V#]2&&C]M:$I<C/X7R)FPMR82[]*
M#!WMD2"*-*CER1HS'?7FR3&3*F7O\XY?HA94DX M^PCN^PD9NB]E(:DMMA=J
M5YZ<8%TW+D3FU_$ND:HY!M3*$ONIW$Z,Q9;PSO)L4D/&G9.(7:->)4(LHG,[
MNF'5#\4,-=Y8\?_RV4SYRQ,9/T@8\@GEP7;UC #3(MRD-&Q)P@#KX8_XV5EO
MF;B4\?:3M'M*,1>(%=VE\QI^;E72_I9G9#S/4(</O!7"Q9:>^UUY !Z$=*1X
MGS#I[.)8\(<T!<J3]A>A9;%F%@7+GWUB4:&92"^)\Z2!>AULX!FDTO[CYB*^
M'+^],J6AN#V6&V7OX0F-#,BGV]*Z FYT@+NJ$P838!\F']_]#0G^..5[:U3^
M5^.5;E8V?] +('OCS/')U<2UFT[D C_4;]J]H*_U\P<?8->8"+RC152I0 >D
MC>6=$OY#@-T0.GA/M;8>+92BI$3V]4;HS>\/X9%G*TQ$+::KL3]F1<P>D,30
M4M?W&K_ F*(T[F]P+,A"TL<H/*)W Y<]-@O@%SVJVS'<S#\@;BS'7M['AA1!
MS;[O.TA:=J+O#.-X5%RYC[&[J),QK^DN;GNTDW#WA3\$WPYRSF>:,FN,*J^S
MWS0Q>?\(,!PCIA_R'O3Y<XS)[@.R:$OT@M^'E5,O$%ET>*-6M,7_M&:_I<'C
M$%"NE7QOZ<K*B3RL. 4B<<'A'K@![H:I:!G'7,:7MIH <^F/V;+TSWB2.?^'
M:1 SFJI?QF1I!O[RO#N[+24)44UY>PBX?E8A#'?1X2<Z8>=>/.@<)@G,LW%0
M(+W?7D8[^^$@#SA<@9/GIPTF+2$D?N>C5U1QZ;A)F@6:?N7'X$W9*3@UV&*/
M<8MU/[V^<<KB$/#& ZZ^2:$M8/]H13KNYP./7U-B@3SXH>)*RZ+%KJ-7>'1&
M;/>X]FJG#S0.A&9U1J5I\O3CS75ZI)#QO>,0<!9S&CY/NTS7G: ]_,@AH.R!
M@CE=O;B6&,%3U\%KAP#HOL2V_2$ XD*!#-D FQ3T16EBV^9_Q;VV[7#R&E]_
M+0).V4$?])GA(XX*/6-?YY QKOI3"O<IBYA).DK@2='9GJ0RXE(I,XW$1J[=
M#SJZ!S6'@./8AJ:@DQ0DG*Q31===ZNZ]0-8M'1*^D]X-]-Y',.->!@4Q77((
M:+<=_AT4$DH/DKKE+_UU6??X@TSFM#O5:"Z?]\(>N_&!][>*<V#5;)5W9P@X
M&TK)-/JZ^BL=V-9X:,;*+=?G"/_[*4QDHIG_(A_C"!%^>TD!6#T(NCRF-H=[
M358:0. C%+:U3$F-S8> JOON%X,8]VM9C;@^)9 J%C6NZ"VL-YZF^)E+=[EE
M6B;NZ4QYO]4*>7\#Z;%FMO.Z_I*DJ7BS?#5/[)?%P%M.TD8&XQ$@:]U" U-0
M=@J7ZL$-B@OVPN,)T:0'K N>&^ O8): 4HYCR$ULEN6S)0YO;%B;_K8GE\+D
M!04_>W0^_IUOWSN';M:OGLE215,>M3:=@;'=.J3M![?X.H&Q?E.1IKG9!RG@
M5<:%2/LG\[$<7>Y?#P%3YFU5!T^I!5TT?@JKL--,ZS//%;A1P-'/UK$1<6('
M*#T )V=QO<)-6!]O//-CA6Y,BH)4'S4)S^W:;4I20/%5/S2J97IMM%0;DNQ=
M@+GH-%2<,=T0\#;W(+8WT@!?4;(*9T)>C&?N^+A!@12JD BBPD$>,GX&\'-W
M>>T(A(8$IVG#$\^P[UN?W\H." ,R\2A^6Z$!.[AMNX"QGGY,8</=,2MMGHVV
M.JOHSA1>PP4Q,_$B 6>O]@C+$GV]A[4>&7T(@LOH3<4Y+0I^S"_GJ$+L"E)M
M_TE0,5T-^KK *-_=>!+Z8WD<> Q,$MS;^-V#_!C$N,NM"J<D!WTI(*Z](L]Q
M!#'N70WZ@ER%DS%Z/A":O$I_Y<RSW.]^QQ([2/@N&X48GV C-BBRX[ZL%M(@
M7K(P(-\K<F2FD5W.J];,G?\#'>6V@ED";VCDFZN_N?& K\$/LW)A6L7$UO#=
MSAI<9'%-I*80X#;BL.]8=XY#?]ZVW88CY\$ZK\HC4M'D:U'6RC)GT.9\<U"P
ML]$=GR#U.I+*E)^YRGGT&?D]"![&3 JM_& 7TG["LK^:O!LN6G.EX,3+N?(9
MUT!VBM.%Q%2[\%E8N/64J?$-0'MCK--= >#X4T'M=!S,,TMBT4+Y'I1#&L9:
M\5Z;%]Y9#61'RH:M2Y^C.QJ\@U3HK?W."Y>*^&6C/"Q!E@2=-\"3(VG13\('
M-[$Q5-O?^UBF23'&3A8\T:MA:LQ<O5U)3&39#](^>4WA:OHWV4QX5H "'.V&
M+%6P!;[4->N38YB"1-H,N*2KN-U3\=O/F8*@X]8[0>)6O[VQ/05=#R2OZ5]G
M;<(&4$#3V28W(KXM3M25G1<OX/%P?28F$E/#N7<N>^+<5^D3B672>_1PPP//
M2YK4H_T84+0%\Q?7NFR)!S"M8\.3?:TM5S)$['[MVDX/4,O01<A'T_*W)N%@
MSCG<*(7TJT>A8CUT-K\[]QV]#YJ59I]KR#6OYO(LOXDBA6^)K1J"1$.WA"+Y
MGCZ*!H!6)DEOLK:P9U/DA=##<@RWD]N5T"<688.(=D2<2J3@Y;=Z;S;17]!
MUG76F<VC4H#NK;I+; O>MC<;Q>0X"6IR8"^4<?&% &]2..'>(-LM<3]O;,SW
M%XD;K7L1C:PYO H9%ZJM](;D11;,3=I_SZ-JX/<"'B001'=/_ JJ@Z?0G4)8
MX(B4O%9@B,];VL,=\"I^'K]RE6',9B]Q9QU-X+F(H$JTTJY=.2C'K$$6^)I
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MM!R9Y3:ELC(U,P?NH#(U+;5<* XJRT5JYE:4ABL7I:FI*>561#+%+>9.<^1
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M>"*POTB^,;4:2Y$5H1^=UJ]Z'Z,D"([;[)>BX0SC,!R17Z1 JN_7(77 *-K
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M3=_6HTL:TWP;9>'$UKC.J/JN#=(S.TL&I&SG\A:WH5Y'!=W_>5N@)AQ>3]T
MO>2^[+&6(S)>]6QT+G02KE(X_6OW!IV*%$]=_VHK02THJJL!6&29.:#TMK'W
MZ-[LU]HT5PI&=:EQN+S7MO#6PMS$UC[MWI7^D845V= ]P/'8NRLM$8(;>+=N
MC_7"$I-#?$XB#F-6YP\8D4/-BO,JBP8SM17CWD\"!7DC5-UFX<>1]\QVD$';
MY%$,[T)[8WZ9T 11C$[(*%8^53(R18R0CNFGNJM4=[B.+]9E3AR:A]LSSB7:
MJ+!>>8AN;[8CEI&W'R*!CH&_)MP%#*<>\9PR&97IN%>"2&KNZ4)AX9G@1*&C
M(/$LR76:?7_4D-Y128>_C BGX6FE(7G#3"2>%C.ND1C:1\30"'5#L\\:*&_@
M?$@'FO!6[.7 J>K\BJM&&L@Z/;G>+7+#H392LNLF=@8^L,%OF0-.(_H&*7W)
M>^*^"NW= QSTB(]V$"Q0@_90@#(B0- ;- B1OC LP+P9/[H$E:,]**&_,/Q2
M@+UK71' @M&'4'&:8PG=C1E"Y$^@/=@@08)VN=M=H_< 5;W98E-5-75^ZL/6
MD8?ZJB$4PV608^B.*7S<(.0J7GS+O3T0;1#8$=S9D6V86D[R0=6Z_V0_F9WI
M44AGI[C^AL3Y8UXCC\;"FI#$D;@13>JL$GJ8N[5*^..\PHSDF._[%2URO67$
MJZ@@)F^2]_>M@JS##8;@N VNFOJ<4O>3#&Q&MP:;*\?!Q\ X][OR;C"1?(+N
M'')R#/7JX/#[)& W,8B*?FG;;?NW*(WY3$F?GE*3PAIV!S#;Z,M7&(LKG[]?
M=RNZ7H9RLBY'I?'%Z*EDIN263B'3E P]1Q-GWI#?Y5XI@$&$U?*0G(S?=!8?
MG[/8A_4\)"\+9_+AL"+:'QZL/I/&]+P[EDPQB0 3MMGW %Y@#N9CPR[9X-&5
M$Z$STCT)2^&KW,$QDCT3TP0_O]TN^($P^L"F"?CP?K_<Z9NBS=L)V]#6T6)[
MAE_G&FA=J^=(Z0N_Q\3[N^D% @M%D1N@V<D]0*-.(IIY&BS8R\TP8=O=WI'>
M<.H80M41KQ&=1\Y1=M8W$A8ZA09<U_C6?=%4[H2?>X#(@/<(UNQD\72%=!(M
M83L1'-<]%/7U\\:_J-V/1>T$%K771-]#!=#);14H!@OMQDS7R,T7)UR;B'8]
M+!\;M <X])^X70M9N*.*PI;B<^?_R/W%[ \AKX/3PN_M0)/\;NT7I+TNYQ9%
M'#(DH)(%^<B[73:2M"(K_A+W1Y50 [$SZZ=4YSMCN# :#!O:U\1,0X5U/&?/
M8CH)=+^] Y:#-*?%XM;244+K!7?K A7EAJ7YE^$!.B=FNS<-7^'"C+'+0"3R
M0#?NRN#!(1V][?=/]-,YRQ;; SWI;)2SW7$0WTA_<J[LX@73&ZL[?N2VB:\@
M)Y,I< )'5*8!1G+=^RW_B#.HV\QXMAWYEH:]23AH?[]Z[NX>8%!V\>0[NUW$
M#Z8XPU(XKJHL5O5H2>W87,_[: 4AO0S#JU6]30G8D[A(4( "E:TQ9,*!E^CG
MC0\%=9ZZWI=C?IHUY8 #+/(.X?BHK.QFLR$?/#/GHZ*V@?NR[9S6<=6#_ND,
M#<8WC>%FW$N /;M;(R%&&*V7^/@RG+&=865Y;_?@IP]I2:(E*5I\B3G0&,;3
MOSJY":_GK1A&UM#FE7^1S43H89,->P NS G&+=88?+.K;T5WWP, W7:=, VR
M6\<@O:3.4 AM$]A').T!CM$S&<8+D.#1N<<,Z4'*3L0:GI=NS<R2K:LN@)35
MZ-';#!L"4D7&]K??A/I-2!!*$VH3,2$[*+[KL0]@+G,8&@6R0Z !%T]" B 4
MFPX+AG%36TT(LC.]D-F_!W@%[1\]++)YC<E':T*SIL<KYGK 6ZI6(2<PV'\K
M]!^(#UO-1F?ZA#8)6BZL!G#YI\83G3^*D:8P_![N%R,;9&WALJ$),L9STLU)
MB5N[M$-R<X:89:@CU68<57QNNOI%C8 SK//!.\J9)/")>3$;W#$9ANG&-S2(
M(YWR< LQ%YC 4'DX>,KV%]2J6KHSD&?NN%M:TY=O>N%KEV;A!RQ@SW9:KU)O
M=?,DP:1//ZITO-$HPPN 2D_,QCW[TYGI,?GU.!Y$C\!=Q.6G>ZE<GW>2FWH?
M;/_S- 4S>/ZI/68_\?A-N@S^$J1F%]'/5)T_.#=Q7T2#_!&IT3/B[*1T"'*-
MZ;E]5.C%H\XW#?ZD-<C-&KO^\(%;AJPUTG]M=.[)-G#21F[G^L!'Q=X+MI/,
MN(75/4 NZ@O3E-I?ZM>V\TR*P(O,I$TO&]+)/S9'5_A9!-\W*I8\A:'A8V23
MF9="=^>VJVKH]FV4FC#_Z=I$)5V!<?@C.L2Y*35/.Q!&)X]S(+L"^38D7HHH
M13 7?<K#-PO\!E!UMO3-6LD\BXX1&X.>02(_G32FJCB4:WU:4((0&-]Y+$E9
M6XA3#J[$<*$'EK8H7/&='XRW#O>8MC-[%&QZS@,I-U;M$@ TT[*3.@0=QAQ"
M(HL&M$1T8U^-$"_3LH,F?WD>?1[\'$&@0VA']96V+R?=NN;65\UP%IR07+U-
MO>:9*I9]!=V%T]NZJN@H>&9)CZZP\1Z]*V6[A)C#G-AONGGXZ6K<.CY^#^"0
M>TKWTME-$.5I[[!:GWWA1Q/C=/<ZHAB:GB*Q0]HDUV+HJQ$STF.NH>E,B?WV
M\.M45Z;&HVWVM2)XT%CKYO6YYMT;6#Z;O^YIKNX+_,T2$RB.YKPFRD/5#3P[
MC5Q[F+@JJ/EI!]H+XNPK-,A0DP[D(^GPJ<EJQA<(\YEE3^M$U-AOB;]OK4-)
MK>PBQIW[$LK"^FT':PP)RT<&1Z1Y3KT+P+9465/CU3,#OJ);B>$A#B,Q&NQ;
M,%@#8YZ%"3JQXMX_+<7$Z-F>&;_/%^=?"T#,C HAC[__$M?'W4U\2 ^E;DS?
MK'AQLH#+OQAAU(!5J,5I%P@- TV0$O1?Y*A3B@,,Q#SF(/V]YUT/]:+W\-@:
M+L_9M>%;%^W$N>;A 4A>FEM2WTFXQHGUL2D?$-=C_W(7F4Y=H$&7Q:#U]& Z
MFRJ.D]P*LIV++2M^H'7NO_D.__DFJ7S_8->=$__"IUMN?^TK'+EN9GBISFX#
MCP9?]XE88/IP11/6X9$@+4+/4Z%F/BITD0//'S-V= E!^MXSE?C'CD_U(9)$
M09U,CF@YNL0DU+6-N-NEX.&*Y.5.OR<0>?* MD8.W<(P$1WEU3.3EGCN+_V0
MJ%<YB;#\;K<;O-; /FR5T792W^!U20W"6K:;^4^M1,ME85(A,>D@V':KV]>V
M^V.]Z&6_*/&OW4@+4,'H",MOUY>8\(BO=)=DS#<):]O$G;:Y5WT\WUKPQR H
M\_3LK@3ES2!%(9 PR +K8FC"2_M=Q(1=;X%IF5WNE[XEBHMHC=IT_(E3:N+1
MN:+H7\,"&^$62F_ J#'3$=8+SIRK-&W[S 1MX3+H!4O\P"K7CLIAM@G1!I']
MCWN=!1<+33>43S!>L^F<N$A8B:Q87;;T*BV!O122<H<?=T#QCXB6?V1ZSB0!
MFWE#75@?'6YNT6Q+%/QA. $NV0,$V36M>1A;;(YR/2LP&>=E\E'49)OG41\4
M*:L%HW?IXXYND6T0M>;-M0TUF= <PA4G#!LNHX5'=M+*#D<-O+SY^-P6-->"
MH?^MZL%.HRH6,Q3O_9-D@'"PQ6JZI_IP7M=')ZVC@R<T)O[.Q6=\G>8!MA*;
MG?G)]V=XIXJ6P<)#(X>"C.G07!U%Q(0&RT@EU"$E\WP,)LY,*&Q!Y7S3?S<U
M_P%MFN&H-JI%8:&35JQ'BL@&S6UHT5U0UIK]&TN)O!*=YIK'96:3^G=*OD6G
M$=&]1,Z/+V[#,]V%T?4ZI6P\@7&S.D #?S&K;]M?A\44OU:LYQY\;]V4.7Y<
M9G4E,*YMU-&H%O.!;.*D;7DF)OVRRP,S#NWQ>9/L5=O'UYR :H9Z [>GIPIS
MR_QZRO+I?]P'L\V<O*0_%FII9_3T]GY@^4M&![1XDW, 3C?<=$8^<_XZQ"+N
MHW6L8?W?VT<<\NK)27NUKRIR>!^4_P?&:,_>O=-[@'\YJ=BC7V,V_MMFX$H%
M_,305JP$'^CB3Y$$/8WNP@4XA\?R:(/;"+&9[LZ=@ #N$%8VZW8AW#R- =9C
M/LA*TVWH]!;!P"XP.;8^_O(\Z__8LIV_]<])]HT0MJE-PIK*IH\*?>:^2-/"
MCTY459JC$:5]U>F-9C72GZ!H>K#7#]*3,RN[<ZE8V1$LQ[_M]1]\8M3S;]O_
MH!P8P//?MFB-]R7"#J0' ,#AZ Y>7^R-4\9WC35:_0KF "ZK^@J/\W'ID)M&
M!>]64%P ^ZVFN"<RL/=T+PLU26P?\W1B31#3A,_NL8Y0+,$J5-]1'6IJ.S9K
M"3S'P'[Y1O6_*E^3>:"U@UV66S%]B=2/%&.]B9]U=DB?QE.$'5DWY,H3=H-Q
MS]Z5'?C!2IX5LW7T*Q%T3#7_Y<5'\R6IGNIWU',R?Y[SUT-XO8@G<O,<B&MT
MK$]O=NT]8"9;98HXIO*4,?^!5.7)Z5N/[B!$J=[YDQN1>2+;)NI(C95QLC6A
M%.B+: :YALTE%TK,6QD4TFZ2O2[N(O)4S#KY2YR%_15F*C$B@[68%)3:]][
M"Y8Y^Y2_LH2CZ;FXG6/,QQ'I<1J)N^.,^0(5\7I< W^7PNRPY82)_?YIC0C@
MJ>/#;R$PJB[24W&T":66J?PV(QFROZ%OI $K;\CSO XQIX=*[X<)RJJ-FZ&<
M!A<@*2]6G?25C4W^[$YZ:D<^]N5SBY/R5"S0L'87!WXB&=+O9,>JVIJT%\R9
M%O-5QZA<S]3I_>;I^&2NMZ_"42T)O4#/]O58XQOZ?4T$IW(K*QCF>;90Y%9Y
MIGFCM&<F[. /)7;8WYTV#X(NJOVKL(?M88X+>%'_09M\,<<7L?BAJPGS\!M(
M&5)52)@+'D"PCCED$S>68KO0HZW\N! OYI :#3<>Z+VWXUV;U)SB\L;;:8GB
MW/7&YCAUU&8U7JZRN[K3,+:-8(:/PXF9!=:^PBTZI@WO$TC&_VU1B"UBE+:T
M7V0K3=ED^+>SF*7@'W& ]TR(;L1^'&!#?@\P(?ZC>=]5%>4;QKOO+L_#70/;
M-B3/U[Z?A9\(^(RJN\DB"R9A4V*AV7VE%NVT;=7*;-BJJJ0W]QWL./O9F3<@
M6G:)_2/RNS",KEZT]"-^!#1#D.$UVE^V#B73[%(V9LQM5?E6T$V=1S^$V!_O
M)P\4W2CB%%[!1-B<MMP1TLMZP>5GKC;2X;!*,PG($-IZ@[NS#?Z*"N6":S,[
M1T\>5CXIK1N=,M_&E/4Y:FDY:VTK'CM8#CPTWTUWO:_?!G7$E^4*3C@X(+54
M[W)9&J]'U#'%T29%H9S'AZP%!?'13!9]O[4-%GO4+(J8%169N![]Q2F_([-P
M'LX15M?QJ00\RAT>;+[D!0\&!MO63T2H5EQCS)G1N/(*O ,)C2U7F[WEEYP"
M>5LRS6VO- /,+HQ<^Q:Z?(TQ_X96VHB]*^UM$F=R8![*KI#\3=L(=TRZQ)C>
M0G%8*-[B51$4(U#96!0@(K*H9\K]*8FU3,/YM7.^I=W]],<3GQS3$>!O^N/(
M*Z<=JTKVG.8DG:8IE6PSJT+UT1 _Z3ER5Z'5'_(0ZCCR_+.)X!+;3!_4=]?0
M?-PAQ< 4["*$PR?@RA7*EENC;WFJM(V)GX6+Z,JJPA>"=3P-GT;FI@44CC=O
M"R]#7Q[QW6RZU!PZNML#5]>DAVW.H[@PR2A!U;[,/8!?A>&K#>S%-0M1%E4+
M7CH$2]B=FP,?^8TNU5KGV^RI(:&#0G=J-TOK4^25"B.B23/8IZ=R1!"=S#._
M49\;U_#:9K\5X$<LB%X!PR(OSLLA3C*%WS^ ?FY4"Y]6V[>OA^>D$^BO@(F?
M6]8@K171ZU$36%2QH]$EA5ILUN*%'ZF%#@PR?2O[:Z_=,Q1/@<*XR^<KGN8M
M*ELL/(NV.>Z;E5AG'SM(?!:M3&7FQJZ,8]?.*))@9[)K'Y^=[9N":()/^KRR
M*WKEO;&.]WI5>BO(FX^J4P<,EQLLOMQ-$5O?8 L*/#OH).SGLB\Q\(?6[WO+
MNW#=_,IM>PZKY<OYGK2+Z9Q+NTZJ5<;V[#&6ZWCI@9^%LZO-Y1)A^/B.EK<J
M$T2YW2]5M[_IJ(5TPC8PX1 ^F<5'<;>_^*SC(\&2]%^(A%-2Q(78$6*$3/W=
M1-WTZ:(K]WRMC#72R,I)5'%,*G%A-TEQI=#RDQ_T!_@(-2,I)"/FF83,+-R?
M<80ZVS/^1CKR@$VJXP,I9'9B7(]+MMRRT[7/_E 9BL).PC;4PBHA<@_06].S
M#6TRHJ,+<ZD8(-)M5ID"5YC%5L+VF:X;<^9"73N=W,9?\7IHWD*"CEU^#J\#
MGQ9B&"\;#I20/9Y#>Y*UD*]VU.G=''?&?H\%@M;FZ!.U">K-TW#QZ&S99VO@
MRD,J.WRY75U6HPP))> H,.4<K2\5$H526]W]5"G*[+[>$1]3_J/*^9$"0-!^
M'O8 <5)?Z.GU7']53TWCB('W"%A>_U!+[)OP+4-*:>3A=QU?]@"P=71XH+PP
M4IY!I_01I>B9%/2B]%M;[M0 Q.A^BHZ1_9N/CTV@DN.I&HX@?3W]JC_==&BM
MLO<%^?1 TT&Z>]VT%=%,LNST+/P!4I:NP-NE#=N7N>YK;.;F ,KI<%RYO81L
MX7Z]+NU0>XQ"S=X#/)Q[HZ$+]X-\W_$*"OSCL98_31=Q+6/^"33]<Z6;VYW,
M_)G43_?54,_394&_U!>LC_K]I$N_HU'L.X.C8\XUP')@G!F)>.SFGT^WU/R,
M+3*NWOM6WL\@$:G6C=6U]E$5VU!WZA[ R)E_[IK!;^%M!9:U9#/KD!1]U"P6
MMVH??B6Y?ON5X- ;FVJ-VVX/"O]TGJ!^*]^HJ1T5"<A2L5U5Z*D.T/G2OA'!
MBX(QANGB%/35E<.RHWTU-\"B\XZH].95^U?P<XGW/2;=YU\,,KN5U-6TOE@^
M__'9&W]L\X#?/^(+%L20:D?6'TA[YY*872Z/\3U 6+25(76 NOE7/*&O *G*
M.JV,2<#0V!^"CD-&L)@3=D?W\P>J:SR0M^'+Z,+_GC1093ANZQ(NM?&#.;$K
M39&#"VWTN[X,8"TS.A;&)OMMZ/< P_BW$ ?4>L^N?D!I'JJ9-1J7R V0XMNO
M[/XMAZ 8\U<.P?P>X/5BR65P'&T*K?)WS(%<<_2)F GD)ESK(Y*M<PQ(#+ 8
M'W%FZR[2<,W@V 7?+(5(XK@Y2YPA[+U5I0+\"]F_R(WN+SJF!X:2^"$J-0[<
MG(3JWK;3Y8LV(F.[%L4!C^2]QK%+F.C4 VHO4^(UUA?A?#XU=<8.%6_*;I6!
MXS9]A+NP=^,P/%'I4J:^[S?(WSO#?C@_W$]_)R9UK_/VRM3G=O)MN5%[)L1G
MO'G26TK9^H@_Z9:TF,$)P;@I-C2,JL#)F2YQ.7WXNZWXY9P6C!8[; J'='_T
M_#,V.F!NQ2>Z[^:[^E7\H8$6%[2;2<1 4EU4VC?+AG@L*73:1+;*S=9>Y-3/
M]\NWLB6^<3OR]?:3\/P=33H29Z"M-<+$LS(YB8=3J^>KZ6]IX8/JNJ9V-BE1
MR <T^V8<=D0O]]*+OZ;'BP_X"SX6(3+:2A&JA@*(Q0(GSL]++?@;=,VQJ?*J
MD%LIM7AE*C1TN@]TX7'F*U>]'<.Q/4#]:%$M1['/F!?>7PBF*+F27E?;%>>[
MJC#$/#6+&MB&1=I.\HVV,[,,OS!-$\=_'K"UX^4TBVIF^+<P9_%!N5<=2P(:
M559JQ2>!:+@?JHFH0]P#O,MFL!-+Z%MGS3 T_'M\%G 00Y7:T:BAV_^@H,+\
MF^NN%D+[4=Q#NT)L.R!:9YVD_'Y\ _B2>UL#I4<KDNF$R@Z(5KO;7*9N.]TG
M0E7YNGLL- N.351=;FD<%ON3EI'?&0Y60ZJ?S.@HW-[ QSU<+;Z.J'A)VGY$
MLZR[FP=K">K0R41:T,3'*V<W8_3$FT[X0?N?TC-57MS9NA+(UX2DJ<L>8&A?
MFY5"2Z@'(-H"Y>@$T*7G0-4"Y?LTWE1@<*R;%?2C3VASZ/T**;C&-KE0\VCY
M5M>?OD:;,Y%K-2$14TXSJ$$\$<Q=,*0"CJ,":W=>N?ER^._+9=RJS!]O_HR7
M4%KP2X2Z_\Y']>*[\TG^\)C?=GESPKU*<D5RLW 1NY%0\O#%W,_/JPTN<^)^
MJ.*OD8F7+0=^W/S Z4\2E9Y8+^XY,"T[;;EKDXFW%0A[[54^W[^><Z$HQ+5:
M.*FA!^EH'R#H7 ]NPBN'Y?<^J9DW7VGQ $U%S.GD^-@U;8_<:9/B.,&%M-[1
M]5$:;,R6>OD"L2 *;3;C5_I6\U'Y0),^ZRDMGQ51W6GVL3^IZXN3[W,7D6@1
M>8_=A,25*/RV6/%!VBIK#AY<9UL9$UK#QRI^A!2#/IO83^&+P$?IG@W74HAQ
M:[Y!,=FYJ^4O GLTYS!L;4]>*<Q:Z[NG"I0HT<XV.\W,CSDA=89[Z+?^I</V
M_W5["@X'./7DXG3_%G7,(K <9(>Q7JBQK]QI8S%2U(0_NL@\OD-%L>]/RX#5
M*O M\P+_QK<<Y'/$V&A4!7DP*WFJ$[2&;C(4\#W_='1^A"A+#RW@F'\+?K8*
MUW^5[<SRB:7AFBT@3@(%Z%?I!'YPWTJGXG' 7 -$BOP+(^>L"PF/";]\^;\*
M[C]X?SZ<<=:HZX:5[>6,E9N+!DZ> ,T-S[6,E=/=64[.  4'=.9UU]2K(1]P
M<E_:(?<EX"?U!;05L121'/0)IV182%; 2V4GLS ;:ZX=2!BT\-HN)="3[%##
MZRK^M VW14X,")+52[U2WYUE,GXUY'TNJ'=;O7Y4(-MZ/Z7!SSZ4*8=)\!C%
M(1U=\Z_7:.,$68M=^7CGM)5"G;:E:#'M1?3"[M']!MA@ZQ[NCFIN'7KUT_,%
M=O".&KE%IJ35$,];RU7<L#+%]/>5&J)K1UEF0FGA3$];S.]=30(]-'N8LAGN
MO@P5L>A9%@@Q3F+,_@I4LV+L!S9F4\7HXQ?^RIK@I;J'-"/E>J?+U]NG,/8^
MV0?TW4N9QT-6U>]#/SJ@!+H?5F;M(GX5 ]\J]3@/GV=Z)L7!M%2Z\A[-88X?
MJ4LIM*<62,#HE]HK3V):B1$]&I;9PY=_YC(0=WX[D@-ZDF9#'ADEMAM+9YHZ
M($WSD'R)@I@+3--V:X9$TD'##RBIG8KEVU_+C&X86W7DCF$M/BQJX?7BW23*
M_YC]H%2 @154WI(]P$H;TQ3M.;Y9VF%"[D]JKO=(5K?=E0[N(Y[^,;2?VH"_
M*Q]9:A]E*?5!2:=-X&3Q];S(!"U]_Y!":NKDW?U<"I$<I&Q%%'HI>05OEBKU
MJ2(5=.^B^9K&SB+I_+!+08PKX'?=[R:4%%8BV"XT#]A:$7?G>F++PIQ,UX<B
MNY0*G&YFU74ML_=(8O&:/WN[BZHCR>KWD?3%"*V/!1&\[LOW(UXZW;R\GE9?
M-B?)8=0M6O<?8G5>K GPZG_D9H.(BVK)$L.*Q^/<=[JL.]\X,UHH!1S>R]_Q
M!G1OUVDK;;F1P@:PN=5LW0[I%#B:;IM-:57!9VK(<B>XU.C14"%JADN/5?!>
MW6=7G+\W.S$ZK^6V*P7BXWLF7]O%\3ZPD5O^UT?):_W.PF@!W,2NE.[V?(*&
M^N0JM:ZOR8;+;%H6-CM1X4*:)?:4:L5+;M+,;S@9,XY0K+3)7PH&_R1%^4_%
MR8XW&O_6&%9.\I1_*9";.7@9MB^5'GO^)7_XO7!G@/KYR'"T8\835SU [/.,
MWU+<,KN2M'IQK\_'Y9(XK]05##FN@,&P <*OD7O(X@-M 5%#GQ6QV7K#V%_/
M&%?A0!EG"[JJI9 >!Z%3.E0G,7DIJ:^0RL"AWY'S66,,+)]6LL 0/^S3&A[]
MN/S!9#Q8R'V_<,$'G@5=P]]B-I:6BAXQ*4OBL!DSE?[1871_SM:";J/!B7.&
MT;V& :WA/RMHBOSUR^R-1'H$']'MHE-.JPXO[5=VI3K=8\C<7T9I F'.9HH_
MTTN\JG/\[-UMLG0NXPG7I[O;?;2ZEE1/J[D/?JGC.3ZO1T95'EGU?:&4C76<
M@0;-P?DB!QIJ<"^V0QO8DB%5D!0OS6/;J5S()=EQ^PHG#&^010,&YU91VG3T
MW@2\K\KR/LTDUGX:DN(."\F],K 5Y57/P5<^!FW/NVOG?S23]EKGL<9HW]>K
MQ$LMX/WR@Q7'C,2A9>''6T0"69A'Y[U&77%%:K W15>BLP.EUEA)%GO&('5<
M93G5[[W-/KT]\ZW!P#_^:I9O4?L#A)?+NK/[",;D(5EI\DB)M%&8/BS[2/;S
M22W/L-YPPCFAK&[1_1271_^O]# EU@4_^.^!-B%>E\S/,B^N*:W"DL 9C\IL
M_/N>8#Q,_7WUK+AQ7.YGC9X[;&/&KY; [H0LZVWCZQ,..E\_X=N(5*9FFUUK
MY[<LP^.KN'%7^AX4+)%6?7[ =.8LQ,[I\=O[:\FK'HY("O"U[P_^WY0SB!MU
M\R0!G,%_MT+ZJ[9!:7D-'P.&6"K&KX[YD<F#Q39/KDA/HR-2A1$SF0<4DM:O
MR?_)2=;XY&'UN1L"2=9/8)XZ$;H,'=H#%,D4:7]]XL4W/DK%P7<L47$,F[AU
MV>][@!,I<N>/R$5"N^P$PSJBT!RRG\?-%K:%P'.[DKT1FUHR2-V-?_UF%A53
MJ17!V'-"$\4Y62DI#202^B-8&BEM.3/IQN^W@8\./,N 8'0JWE-N70N07E>V
MZ7K<Z]S/>WBBBGM"N7:2Q*]M?K.3$"#&=LUC=P"H&OW=7_\Q\D :/74/H%EQ
MR/WRT>K*VAI!%]NW/)FN'6@!Y/&D/GO/T#/;T-,2KZ^N)1X[5L^W=BKES"V-
MR]HEHOW;FC?IQ=WGEY+7<5A\^)#M'L!RF_QSH\=ZP&V5_>MVX^]P;5A9Z@FN
M8='")GUIA7ZD%BWP#JGDYS8YC#XZ@9NDJ.7GNR_K)[6NWE?9BG9RAHQ;]^'.
M7I)WMS:9-4K'JDJ98"UO^[9Q^4^(X)/=74!+<';BZ>K>PCNT)^NSUJ$O P]6
MO=#N9)N%WZ-SCS?XW7.;.GM,+*XYLDU<<.7[0MW3E=BICT@05=CQ6N-.E>U@
MM=/E!K?@0P 3)2]'A*"IE6D2?3M.5-<:8VV0E"UR%@^FUPO%WG@.J4#\0J#I
M47:NBO'W%59ZTA856_+Q1]%MAI'"R"B<W@V(7P7\5<DIG0!^'3?KY094:*=W
MWITZC=592SB'!ON&\H-8L?W^M?&7K@:C(Z/%]*H[<P+/-)DU7=F&9C8S<8%Q
M#72EAJ'!)KG!2A_F(E+?WK=H809[VY/W@7ER,&O,@0 R-SV/E06_ZZW,[3TP
ML0<X576T=&.E-"'VS2#Q$KUR3-5CYZVUN#A;=\V]=?WKLK@!O3\350(3WG4$
MDIE1H3V8M#0F%QU;C.80?;,13H.HKSG;K6K5'+H" *U!ZI<C3@\--45)GO'K
MTXD$'V]W?+[TE8+1^P,9/U/9-73 _#$QZ47FV[>K[Z.L--!9^<PK_)&!F^OY
MU:@)R@69$I<1PMB#.0&WJ_*D(PT)W@/PC^3SM76;:LQRI7P@#U%\V$E!+3^2
MQ0[!OSQV<"Z[WD<?ZGO' [F6/-]^*'XR/5B=/EY3RQ]R9_C+KG2>Z>RC\2<O
MM(.M;B^U$$\P%%2"!R$&I/7.UVM\W<[&')'LS539U^G=SI2C&@_]H)\O((0!
MZ0>)F@)O/3,"O$YSYC1R._VI<LC\$CMKS;(\%TH5;C&\"MA=NM7SI)N:FS B
M^:E:R8?ZB#?[%J>*>A-#M(5K;@1*^.CCXZVN(J8,^1AR<4LI0=:[THM?5<*:
ME.P;*5]7/BQ%HD-253"Z_<KOT7X;BG0")![BAU*C[2I_ARKAZG@L?XY;XCX.
MDJH=C#X5/-4S=6QJ1NX!!"0ZMWNV2/[HB$UV2!^FH\R+FC*Z"</^]C%80%>0
M8M)ODP=)UR'U-?S9917WGUYGL152G'*TZNMA8B <ML56'\A7$4+3-9N'W_:Y
M.H+PYS-.C:L-S]1'2@3R9QH6NZ/.>,X*CUCG^T%_"(<.@F0>YK8<P<[CWR:=
MJ?AP]6"LS=TO#+EX9TM_+991&7J3RV[2"1$P\)02!=9B#A4W"3CLJD,'@=Q5
M*O%*79-RKVS\J9CO6'M7?MM&_P*,0\F[ET>EIPO[T8Z7WJ^IG($4A3_%R'A1
M'!JU^]YCQG-G\((;Q^)'0$SAZ(DFU0^OT_*[#,9\$QIDV9K=LW_<MEU*)5$%
MF@V/7<<M-)X^DTK:]L7"<).18=H^^ ]@1>1UYJ\8(_%.<-R:D)WT0&L;5>&*
M<G%P%RVAWB*[9SVL]@K =1[^&7,4>:/;D9JNY,.W$I),[;,4-7R.!BIG!DA0
M2SHL>=_>$1?$&\I_D&J:696?Z?B0WYFYME4U<Q/K&34^RV$9N6W6CGQ6;$]N
M?B20Z0ML\ODYJ(_6M"E#= 9>=,Q:.7Y4P?+1<-ZEI];N-]/'@&%F\B#&1]&Y
MY?ID(?XYC3=]U;)-8D?\(YK!-KYK6#$NJOJ0U;D56F=F@'^#SH#Y%E]H J%\
M"<5.D6OF1_R=#B%'Y?_@;(N.A&;K_ J0_E/(G>0-+N(6,V>QAO2'.2FG?^0_
M<"_R.*WH@Z_K!]3[5>(N A?(/S%"&E*#03'OREM \T]7[^=Z^5H$G9D= )Z>
MV?; #(ERC^#Q@9Q#Q<_K,7HK*<KC/PLR1'XNS\*UD0K4'HMF?N@9:'DT7NC6
M#]HU$RO[W"4;OBWG&QNXN99?CUANV0;.B;[E$O!,217"ZV,*<KC0:B^^KZC3
M0DV>3.R^&ABWT6G#Y494H$;"&BO15\[L0 ,%^*3D56@J#GUOM^Y.H+B&9[RC
M'Y@_[,._(9Z#.ZR<3Q1\N$WN@_,$'MXMS/ ,7<,?(3,Y?CM^*S0/F^XFMJ;*
MQ_D,ZOPPJ2-]46]88DC38GSY#MU#J:T-*T_4.F@_W45,_D"J^V:6:@OB!->E
M*SV'X@O\/L+<O=]6:YC>D5:8Y5B..&*R[ZEL-HX*7C*WNM*\BI>--:I,CB28
MQMZL)$5?:U8TKNL)R3=N-$D-:Z1!&["+1CJF[Z,#YD]K_G)A:/IDDI+=\'J_
MF)Q63J>E%6^S3$S/^/+W'J>NHMK9P9+<\,Q;2F^C-&1@*U71J+$]0!U*YHM7
M1*HZE$SDIE8XECR(^OA]+0_,3;T'LW+0^"JW:/W'0?S^YX?L6V=L)/O>KY=9
MR:?SV-Z/>/5@&-5<A5E*2DHKV_KBMFCC]'O-,#;PNF5Q:N#U^3_^BV##1<W:
M'=(FM!%]@K"5P)&T-34_/E_RI7+_\L%?YZ<;M&V=<1;2RVR7#5**QO$'8!<@
M )V2 3"FN^K0^&C08'MZZV-B%#4*/S#^()HT:9N5M7;=BDOY2&[O RV^";&6
MNT:%EOUZ[Y-HP C@B6Z$KK7MM%C<LF?$A/5U$-?UW@(#Z:Q@J(%N>BKAHI&,
MPDHZQ3!HNC#&.5P'MI7GK/8'/H8-F-M5IU=3LW=TL\Y?F;Z.G=*W'(M\-\J_
M HGHKKE92TE?6.A\V3AFEV<MB#F\\-0R[#A;#O[7Z)MW[Q$G HX@<=3F\:%^
M*ZV/M#>S<%LDJ$<_I>I&I)L-OZ.%2?^F?.M5_O+9;N82&:VW@@H;;"B)7UF0
MR/3KC9BZB79:71:B6Q N/SG@WH@</OH!+SZ#O43Y0H,TH,5LAJQU0Q]UXIXG
MR38BRO"\BCAR7W7]A'V=T-*%N""=%3P;B2AD[4@^'/:C%E]<WQHT;DO!-A5+
MN(]4B=+\M(,/L<C2PI?FD'_A[7Z3WK[G-HZ?N3\^+B!F^LKSQ.?$G_B4TI7A
MYA[YK-.0AFHZ'BDOU>J[B4^I<IRX6^VW&&+Q"M3;DC;B%&/+Z6ZM$TP\H9]C
M$-EUF@XUE7T: E6U7W2[VGR1FEWK/C+'HZYMV#X+#T">I?H4?_NKU+..H4!7
M4^PZ+>@6[0?M(HIV0_4)[ )L@OC4ML+PHF+#+S^I@8TVVE&XG-+[@$:+M/"M
M^M'_3<*L<.^'"07MP7]EGY]<*]"< %$)74.8<5"OM=4QVPOD**0-33X+<WYY
M >$D-Q6C.J^OS4G?I)2^#?]M<&@3M$+$846PV=,:Y *D<Q]7XY]^EZDJSCLV
M8W\V\:5U/0]>457R/O7(Q@VWWTGGN%/CE;!$MFB0X1WNG=/?5P8[R^ZBKY9<
M\I&]N#CB[@V.LJZ*F/TP1D(X0$\_+:7QXM^P]GF"=52*W\C)2;_X@'D#+!UA
M1/)V5@_'!D<F%-JM9T9WO5O'P1.ZD^H'$ZZ]^%Q4YH]$-E6(0AI6!BG3XK2"
MIT4/2IBDJU*6'S(HA;/;J(:WSFX[=1#A6<4]0)0[C++)L@=L*(4^K.[TAJV%
MAL;%\KP& W4@U!%8K-CU3F-UBQSPF=G%?>EWYS:Y[I>AFT@ Q?I$ L[*\NM6
MY[153ZVQ_6TYTOG X)D:47Z*BUTGQ;HCEJ;&T69WL[,ZT-N!J9(TY/($DN(-
MDVT,+1E*1$_;>%"5^M<=I[@8.C.7DB>DU7^[/%4M>"VB#Z:A@LAU%9!F5!%/
M(@N EA3A@W("#@I,PD\-D/F"MPZ?-IQGW9K\9FTGGY&'8O_>2Q2V:,LW S&P
M/]=<!]E%7I=_#/0<F*T16,3+)=YD("Y*K;6K/B=QXFS'GP"5^D,GK2X1J,TN
MBX6!<8M]S&O%O6PCQDG5HM6I^_(0\]G1N5P=4N6>4ICC*TH$ZLB3X3#TI)52
M[MC=CRT-SEO0$7<?_@Z:C^G45X)L4'R/2X,3BGWC\E0KA&>"W&)%/#TFTGE\
M6+OYCVMKCM*K%RGWR4/;I;4.ON?/;4%%\AA \\W'LMW5#G:]?WSBY)W>@XV$
M[[7T"GL/P,"?R=5.&,ZDD_T1:P4*9M1[7Z=Y,*V5YR*"-3M3V3TZ57>J'34:
M;=8+<V9.UV/>]1UIC&IPWM3W:LSU5+DH(!:,!@4XUI+[BJH20VV-FF*\^9!I
M1E>?&/6RXT8RI]Y9>8I[I+,XGD?3\:=^M@SGD;1PJ1O_4:3^6T"/05;+IC[
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MC5E'SAM(6_5ERYE5;-(8TV%12E^01)-'49*:XC;>$2=?63>62$-&L,07K-U
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M\Z,;.J3(<^>D2)@ <GGGSCX<=^2YR,AQT[=\TYY<7/L^-T4>;WN'K/;.5*Q
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M./^B9IENT Z3[ 6Q6D4@NW67Q74K]9W0B:&WV6-:%<SZAOA\WULGD%E[U'%
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M'O_,857D)QLGCN2Z'FL*U,$WH3X<M]D>XW5R)*R]\IK8/GZ@;S<KZ $\JKS
MYE[0JE2\GWY%?O/)Q+US_^P0X8FHYN3IH_7.NO$N/X/-WP&!Q%UJ[TDM>X(9
MR3?,QV].1,*(&2$X<7%?#3#N+B8^.Y4-7WHH0[Z%CI''";V^H:X.O!<_RRZ0
M,[*;$)7/,Y'%MFG!O )6FX8P"C=A8?7;**.R*L:KIX46%FD8@LK#4"R]V@P%
M2)T<+E#TL!3<ZZ0.Y00'#.7D>=(Y95+]]ETD3SC\W\S5/^5/1UG.F.9?TCDC
M^E*4:;.B_0QZ3FD_H;/M+Q*U&C#Y-IYPEY \H#W<08ZLY<C(Q;'24./X*//D
M:_%Y^J(HOQW(>\@U!E9S/?7A753(T6U*_C+C]9G-&']\_<N&%:^ M<?O/G^^
M2\O@$X\1*A ?^5ZBGKG)ZIJKR:7^7%UF =E<+QQXWZJP=8]Z+VWXCUI3NOW?
MB339=0 >NOJ0/WO&"/87U.9/*)_7[SXJ'J@MB*P-.3/<46D@,G" [P>>P7!C
M8MA;V(46[\Z,2:W[;4'.4CX0W6Y=#C<!S7:SLCY>_"Z4D6D!QCBY(D)NT[:#
M(;,14D,;]G<-.WW38\D.+<Z,G:LK6CA*I,AGS2,,H866OX[6R^RCCI1=HR)+
MA<E!D>DOP Q'Q<BNBBML%G'T4_T7X/S&ZL$O -+IQT)'W+3#2C([%OH\JXJ(
M]K&P^;)B M)E>1=W.-B=<9U60J[(H5F=;9"/-0T7EOWU!O67DB;/?/38$_H7
M7U!\8<VGF8ZV;5<496^'GSG"B,3E;I\;"C<)4YN- DHM7.1;,0NZ1BX';:S%
MUB-]TZN+Z[;>K'7>RUZ^;'_GV6Y)DPK_\+SG6'PW&BUZK<$[[T4'+7TC9?(N
MMYUGDZ]7&/DR,OO\0A#&VX"<,9:MI A[/US5MOBLJ-FU-'HE8P1O=OEE\C&H
MIJ(4RG6^YWH-D8?61#N^IRZ:Y""G$,M%N^%+\1P.J5LK&ZW[HYNZY3B,< @W
M?#,"]HT$^OHMW*X4[0('>PB&Z@ZAN^$QLPO"5M%OIKM&C$/^@%*"&Z1VUHJ-
M3/U="BR)7E5G+UW8\(]BX2DD#9?8FU/BO#Z_4[+0B2L4$^S-1<M"W@6)F,>H
MT((A,W5:4L7%NF13)0(MO6+FZJ8]2%-E(*+N2\ NZCY=]6.;5Y[5B^X_HLY1
M7O%O(:C")E"\E,Y"GC[-U\E?^K!^3JOW]S[.#E7K,E(^+EOBGN%!LB(2U?T&
M-7$RNCP#-L+Y-Z((*&V*[YV0V>\EU(2ICJJ)R.W>)<9? )NGB_1$(ZO>LOG^
MW:?NQ#I&LXAG7\9E325F+^MSFWPMN=+?K'I7>6I_R M)>.V1M]#I2\X:*/$3
M+TY]9K.R2>-=HN-2;U&)![N"DMNK%NJ8BC@\WAA/P--Y-R*AH#T'E^0D:F3E
M6XX!TC#R[J&O)"SJ#A[(_;20X6647_K#SWMS%;+?CSAUV()(1YY$X,4C3O6=
MUEWUJ2$LM26#7:?'$5V-D]339[/T] (JS<UQR]\U?ORD.4'=W$??F6/3<!A"
M!G- @*WY_>\KDU4*T@2N>W8W.E97K-0BY/\8S5U/ 2WT-KAU_=@6).Q]LHD=
ME-?F:9IE;]PTL%CI9J+Q=-^P2/B8X9>JZH5'M46Q)HTO)S;W6X:?OPSN#^+4
M7J2=9)FVJ[3+&IW(?NYN0&R*,(JQ[^.X1GG["\!K^Q,VX'&,N*>6?@%6Y/SP
MWV45<X=J@Z#+JX=FY&;J7X A[/Y'3[Y/2X:-54C=)^2PJ$MD1>[58S2ZZEF2
M&YQ<LIS."0MY7 MJ7KZ>]#%Y,H+^3#K25#SOHRTTUDF-Q0DD[)GZ\K\/"48H
M7U21YDU3OA0; M*V_4FB=W/9MBN_U0[FWRV\;U_@0Z-^X-D88)]\P#4]]<;+
M5[B\_R1#U%3]P+A#QFI#:'W]#8[YVNBW,?\K@YO#^]@:H'IB[\+ MNXY\Y\)
MG8SL1=F%0U[?)N5/P4MA\W-[:=TE\,^E:'T5SE=_8]BI5Q'@./1?5Z5.U'SH
MKW<:#YRM/05ZG^H%PN^;*+W[M(G>8>JF+KG2\0WMF]E+9FR*N(ULS+FR@)6%
MN;-_G:T+-"0;/A"7SQ%%!JR6..9.VLVRX0<?Y_ED1-G%L4$K; 2^T"V_2W%L
M>HB%K\A+"M/5:O.<873,1 ((<:EZ"M3_"E9>>T"Z QTW3U2FWUE]-M3UOAB4
MVMXE!$J\.:AJITXM '(5N"N738P*!=_A??@RZ BS+?K:\TT-!I(BPX'9VYY.
M\RW.U:J00>4'L?HLB3?G:I#(1G[96[<3@6C;[AQ9_:'/6];:+M,&5WR0.O$$
MC,W6N>_JUB?%4?P"M04#;8#G,HA<I.QO<\:BRG]&<OF?$@WY5Y93K C>4<_?
M/14\,L]Z7RNPNTL_#Z'#&K-'Y%0]OZ, RR2CX-2Q+GR=X1<HOP"S:DT/;J:=
MC'FHOWQO(+Y;COZM$<$WHUGI;0?^!G]BI#^^,[FK:C2\0].>%QW@2W $"15<
M(;C!HM V7+;X$?V<3S=FBH8\N<W,CIX-QL\X&JOR([L>G:Q#VJ#(K]\2*=AS
MIBKGSY[<O]\EH2; K;N(W%7)>3 _H""KQD>7AOX:4RX& &U :F4T!LM6)6^E
M#>.E:Q([)*OU-;2(]97 @X&,L8U@WZ+D3=:AJ#M]\RJ;$D':3\<HA<!5J>WB
MX+N]BRPR^B):(X'&.S^7VVNP,?=]\[&SJM*&&HWC(6X3CJOQ;$8X:]; @K=P
MH7<VSKD8IVV:L783KU[-6B?>$KF$DI)+:2M2ZNR6-P<CQ@H0#_30U[RU!N9?
MAG7 BC!DB=O!P=LEK&M;V:M7Y :J<HUL"9XU86_35>X&#U6GM!/M;#:-.-RE
M#56EC?GS7\<^=:U+B36]]:%%>U3 ,<:")>Y]\S)<,R&VH%-YPN$[XO&X=392
MP59L*[=7ZX^I9YY+CDB/SH$!NB+EZPRYO2J,?S:@N" @8))Y=J-)5N92 -PB
MHO!+14T<O&H<*B"2[)P' L>QZ9U>I9/6L&!V.(5]$N\HE>P)4+ 3TK5LV<YG
M25%F8)E/D1^P7<L5M?"4/,G_.4E<?G&2#/1G$DXL9\*+"_<E-%4 TDX"QYOQ
M<#CS;.*"@4"R77H_6)2=V L4>U'2\G6?N:8V?+4;))XH*"BVX+ [-?(+<$]8
M_BS*%?))B=:CJ:+OB5-=T1SDQ1'+'?19441@P4Q54#>B$3=(IA WM0X":C)N
M7_;CS\+&COY]3)H#!5@(Q.W_21V(1MMWL2MNN$&O),%U*ST!H2*.8]K0,/G,
MC1V'V?@%B-Q"??[.UPX_2&RVN)L\TLI>-#?UWD(W9N.#T-C7@:&6+XMFEGQ<
MBT4%4ATJ9F_FH14(YD@B#J-0/X$*_K37;= $RO^>4_ OD F:H7PI*W5@U.ND
M? I@),PQFYP,/SOX;71NM.HFH4[BBZ*(O__;KT';\^XH4-XG<(IYW"+;D.?-
MG,A4!4?]9(>#^AG4^Y!&U]-':2M#JVLQ,_<L**@9?$105V_)+X#.]E;+JT.]
MRMZ\[N0]K HCH_OVLW*VPJ\JY;T.N<T$E;.&1=V*<7\N)#K_E$.N8<(_SVW\
M+RS4AHD(5A5A@#139K*:IXYZDTFLT2O%$GZ>[\+=7)2FIW*6G>4*EP.8R>ZZ
MM0=_C%P.3_[)1P9A609$L&SPO4I"WC=]?[:2:'N95?#0E<]YV?):GD HZL9F
MK$6EPX+3;')'J#(2O$BFG;%N2NUS>OMR"\6-)77LN+&WJ8&VC99580]F"PWB
M.!#&L9[J%45W-BRI<RQ#N.@_17SGS[E<D_ RY)@XG8IKBTUW5U<^AT;K*U]
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M=:6KBQL>A'JJ7+1#%,F\^GUO[8%_U!3I?YX8K.7\50^S4?,[QYU)/M_$>]9
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M_=-7![!829^"-)Y58H$@,S"N=;<_O^IUO1G+J7(UB1O3M\*6[D,>>F"=Y$^
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M06(!%N+?YG25*SKIX"ZXC$(/B?GD^N1['U!:V7(M&X*6NO&+Y8R#5@)._@4
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MM:@N-*IJ\S^$X/KD],2$=NY5ZMQGLLV&8*3^YQ=+ZA@OP-(S5)TR]EZ')XP
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MI".I"IP?;LR#L'3D[L^ \19=%Z#HB 3)#P6J/W)36SLPN^HY!S:X)<@X@ C
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MUX$"IJ6X;+,#LZ8HHI3D"/]HWO\/)43N %K((DQ@X,@:MNML0A2$X2IYKM4
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M1>"AFHE4M-FJ#>XHS!'_,I<>/5XF4:S+VNM)%T&DD>5XN[)HW% _]=BAEN(
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MOI+0(C+T.+3;]($A,=+(I9G*A"9EFDN=Q,7X1O.RRX*UI3*?OC?CW@.I;]-
M2U[HQ(1,*CB&'TD7)UD@J;GQ GF)\@#GVUI_+=X\ ^@R6+Y&R^;T";RR#%4E
MF%X'?0_=LBQQJ)-G:WG=5CQ3 TM@PYM(&*.2^3CHEZU=F>FQYT7)6_8P^N4;
MSNWFE7XVZ\'P#)(.4&K-T2NWU1SM%$E6RN"7>F'A;?3[U3'O;3J_NK975EUT
M]VJIJ1-EC-*+-*=XH8^DB&V7*NCL3]Q;NT:L1\1<V>'[7/38U?X[<H-"]KHR
MV8.VHL]!;/&.D.KZ=Y72\A]='L>@1/'DE0F!:+=DA@W!T2826R>H'N^&6Z?P
M+"X9>%L ;:$1;S"3$[3K/*>8YE';$NR6]=BRY(CU<'G6P6N2#Q18%7<A"/.(
M^++AQ08J_O&W+S6NR7=+K 9D@"D_=SF55_3JY E*YAWWN>L$&7Q$PU4VUE@\
MD$:>QF32/O#>'(UD12R^U0<:*<F0Y'QY9NFJ*CQ7KFX&'&1(S%>(B@,5(327
M62:*VN5_>A2WMT&2&T6#4BM#IOR/X"$;HB'G(SY10KV]"7E&K$Z%JFB+U<O=
M]%7/?ZX^-WK@K*\0,Y=KSQ?$(85WF:R'\#C7OL=P&0;9#G>;V*CJTXH5Q>O,
MZ4LMB85;R5CZW*_9*<1-OGB9K[7DV"XR*>^!#@_.^G*A%Q9.+?-]M8CEV<!*
M8:.R\:ZGE GC@TFQHHNMIY8=B3\"?_7TSZ_)F1N(>C5_=Q5'<WVM*)S#?!0O
MTM7(-Z7+-$_$2;UQ%<\4%.A,K]4NGE+>DGQ?4!&+Y'K_Y^6/_C^#_).F&OL2
M4IGS3GBDBJK!* S0!K/+$#W5_8KP30TW(@]>2@H1=554>'0@NEGZRG?;WR+8
M]S9S.M0ULGR8UM>F%@+,S^XW1J__F%IMO"GLE^5S,<U:"[:;+S*)#PAJ,7WB
M&QIC8<.EHN3V)D,Q9XR_NX_G&;,T)_FY2;?4$/"'\?Z*L]S;:NJRX1SMLUQJ
MP%,DQ(+[*VGNG[\T_R;@VCKO>QG.$EB1 "[Z6"1 ?E&IBTE)N%:>%^#"?'N]
MSNOM-;>S:C?X%K] CRWR]@/PL$FQ<7N0E" JQ&'3BG6PQGK8T2HB[$LSU=5R
M6:DCK2E#7DN_#Z]25&9F_,>*SX/Q+%0RC"M;9X[0>3\@$:HJ;CISMR$RU%78
M%QS^1962(ZVM0+>V4E?#_FMQ+_GPV->-SM/!!/N?*J=?_AL2D7-)K#,[M[-2
MST7$N?)2DY VHPR&ND$@5CYK]M:/#D]]ELSSBJ'E*-TA-Y2^?)X@%D^FOJ-%
M&-?F1OEE@=(D5Q\5VZWH7.-,3Z!EMF$/Y]4>4#H?&N)1P&(CUF93>JXM"JXI
M.68&8^/7_"F\D_[:X&O9$F>J]:5LNYP!N:L4ZJ=C>!&QFHN[D2/-[<7)WISQ
ML7TB$Y[>C%G6ZQ >S\'%(&N9V*$?[^31Q,:S/AH4M$R1OW!%+V= "0LH^VLV
M>4A9T[O,=']:,LYYX96R!#4 NYJD4V;6F-RY<DGVA+-$7IPV-IA)61Y .TW=
M=*IY -\:(]W46"V19(ILWGG!S$,Z-Y7E"E49VV2V=VMX)PJ>#;R16VV2@W[\
MA"W8R[,&O@L8+0N ;9N':(H(Z*<HAZ-B_<EA.NKIKP32U#BIRS3_R.Q%=:)B
M45@2RAB=QCNA 2+O(!<J6F>Q=&"Z_*'O=)+#]K!'*'V>^&(T\S3*^:SFHZ M
M^ZA57*^R/,ES((Q>&KO$24<9A_2:A6V/9[^ZLP^B#OY@HZ)X6$8J5$%X#CUE
MO..7?@&>SW7FR7=8 H4NS85S,&+UB>H]E!L1:U<"RGXTU;$2=-G4>+U1/]J/
MDT)V,=>)$0\BE066H?8LTS+! I4E4D5T5UR8X:HK\G%TA>B</I 3]0IP66B:
M,'JZQO$SV'RN;61YQVNSCQLSV%YEN3;YCTO]HV$"*;B"F,Q1[(-:(\J([KW<
MHP98HYJ$_^-'_Z*@]__WR(TOG7AE3*_RTBU[RO]< E-![VT V&F*DKS36]!"
MZ-3J*D -9G&7E#R!4J]'Q[EP=&C(Q&S[-:<$OJ&B"=_..9(DVHNTG9F\R\TG
M#&H"U+9M/$TM!(=TV<==FPU&*DI^@4>2S"GGGLL1:BYDE)_'AXWOR<P):.H_
M&I"G#B97R$KWI]/('%.5NVI?QLLWH# @1_%GE^_\3^"B ,'O6GMN2[NEBZDL
MXA'16=;C["PF\QE#;D>1=\L$$_)D_#TTO287=[KMA9YN>[>R<^8_(X\>[ K*
M=H: *=DH&=]2F9J>_M+E<X]%^#8F!:$UQ?$IXO<ICJ)"2:0L;[O%5IJH15I3
M@6XY$];NRELJ-66>(KR46E!NIGXO+_N#="2W'.=?+Q?CS+B+(A'5'H+I?_A_
M6DXE>5YJ0 +,^H\N_I%*N-Q0*H#3)_]*JNSIOUB3?!E0*BL[JY?PB$14JR82
M^8QO"6*SDZ-)\T</61" 6@-69S'Z+QX$[IU44KOS9O^'O?>.:JKK]H6C" B"
M/"J1#B*(0 2DA%Y$! 0$I"48("A(2RC20[=1#$VZ]-XA$4CH(%*E]P1#!^D@
MH2D"P@?/>\YWW_=^[[GWW.^>>Y]SQ[A__,9@;!B;M=>>:ZW?G'O.WXRS10#^
M667?1=5;2@ZW  "+OV7*Y9UNZ0EV.>?_,0K!P@C8& DG1*,!1FM:M<G_\''M
MO++JF6@LFA^0XWC6TX#3O'^H]A,](OV9NTR;JYO7!I.*/E&LS'!A?7)P;9J<
MS%"Q,3U.J':ZADAWM);I=54BZ1^DZ/_J%3'08T4(+QD],BP6AB@O'/UJTY'.
M0H_,/11'2_D,@6]1<*C>'!KXJXWOOPEE"7TP@/_T#&@KY#\7JX^_=38_E(&,
M>LI_>^&]:)8R/0WN#"B59:_BU.3B>X   ;+AS ?H]68(E&?].<0]ICNK)U!0
MJETP&&<'XX5?(2=/?TE\1!PX 3#XLU_8'NLX,)QF..8(>6L_>!RW"><:R!K>
M("ZPM*%08=J[ZLN)$,.LV+R0>IF,CORF3R(W("< & #PE([6'?4=.G)HJVP
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MJ9%9:=<%(T7GKIIP26/D1O=W*VUW*DO'2318YTTS/.;M)RMJCN(\@P7Y(N,
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MWXY[!\F&60*[7)(XXW\:O*J2)V)1T&;^KMRA"GGZV73I[#BLUHLDA<:'[93
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M:B\Y5!MLPK_.@C(^%O0COK7RD+K-$O/G/NW_M/>&OMW/5K(]/4_R&J?<Z_Q
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M/6/S24Z![L&'^ICON_TL)P",=S-Y?1'4)K-IYFPZ(.\UXESBIS1KQ00!I>F
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MCW-37YI^)\\M5!+^EH>,T2@A37YYACX4:3\!T+VY$W;S-VAIDQG%J27 =3%
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M<=S(OLAL4E:FZ''<^NFA6V2<=90<0+L%FCOUZTX 0IV_' 1X1)J/J=$$\"W
M$:@25VYBV(Q. QN/\*_H?-G#WM1WF3CT=K/4@/&?LO/';G]]"/HO! _ .VQH
MB"()T$' /<1F.KU_?@B-1 W/ED_R?(Q4"O1I.C7TL397%HA>KX-.<5 '%0\-
MW?T*Q:M;D2WQ%6>I]_79L,%O%1YLSNC#M?9&JH@5+GO+;2Q@*Z%%\O(WU0-H
M37";JZ._UX>%R\F.%W]E%!=^,R27;9KE-<Q\O9/8^,@?V#YYGU"BS(R%B.F/
M_:*-S=4@/0@G1!>5?K9$E[$YYEFG=AA4#MN-%_ [,.IIT)\.^M%9><K%?\J
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M#"V-PK<P7--'I7)U"Z(7XWNGNS\?LZZDH3F4RT_-EVGI3"RAPPIU KKV@SM
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M(:)W+=<>@/Y1*A<.LJY&=2=NJ;QO2$P2:63&1'2[BFM?;HG?XF\K_$3V_V3
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M>\U%+R2.)2EWK._LY_,N2@TY''.]<D(4$BJLAX_/=J&"O0Y@YBB$B/@/"W.
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M@8!_32XL#Y _]G,NTSX/Y=3Z?N#-%&N:7Z+;T[NFZI3X,%ZRG239F-F?>G4
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M'FDJHM,;GY-SJ"X(J;2>,013:<D1_C<(+S,0!*!B^:!CZ1XCYOD\[W/BR]>
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MBE?C[Z5X J> ?1'E((#^Q0M 4D6:,VRA[XF//T15RY?(@P=S$(N3L% KJI]
MQ94@D/L^:P;Z_E-Y>B)11D7*R_7^2Y!"Q:W;K?*+6(!SV,Y;]/J5$6I#>:DK
M%"O0W&,B)N?''+4*GLTQ#ZE>L=2]]B^5H\G[LN4%:X]3<H6F^6,!YR.\+AU"
M(=$CPU'O;MKB'?TW7Q#_+[\T3JV_IAFR*7<@\ODM-$Y)ZPQ?OX!$'YGX-M/D
M,AD+T(J1K,TLD&0U_;R$S,U<R:2,,_JV=L*'.-T%[EU HEG'*QKGJG#PNX,1
M#<<"2 2:S7^]'_J# H(4@>V72M_% N3-T6]Q $VIMPU'%\+L;ZY/8]K*,9<=
MEUB $S+K@F;LXI3U]+*Q_2L.M*U1RIAWC6<"O\Y7P;%[V S\Q>ZG-Q"5+/,!
M"T@(+0MU<\0"7DYB 0%+&"R@$C5P&6E_>0&]P,PMZ8 GTQ*+;)/T:06GY6:8
M;T+PU_V_S"CJ\SW\-/>GG"*0WT:/OKU]105P,WM,U!U)TCSJ*4!0\\4[[/44
MNR?]^1N01%N7)>==YHF"/^=0_E/W%[@"JWL_Z9(0<D  0^/RNU)I]O^&NHW_
MI*UJ(Z4T6S>5W7?+I8\<^#@V61.:9X:_'F3\FZOM,KE*TN565?'I7HC\![=7
M(2SM.7DEUI[_^N0LDY&U5C*2<5.9LO,OWGFOF]@] 9>ZY!J"+A/7?RI[V$'^
M]04UA/SS$BJC>>>N80']!EC 75Q:N6A7_VM-XG=>S##"_MT%IOT/8^P]E<?<
M>GS&I\%)8&<ZB5>6U++S!]Q2+A&UBCJ1 P_^]<4JL\WGZOW77:7EK$PH)]4Z
M7[5Z=1JWB\ZPOK)SBL]1(^:H9P$46,!G!$8.%^?#"W173QY)O3=5;]PV-M^;
MALR=_+H37.( :73&)>=3:'LR#(UY4.,Z#Q;PG@,G)J[L#OZTP'I.C 4LU^%6
MEZ43TMDRV5(C_ML8V]\D*A1 /6L@_]M\:K@LNW5H$96PP&UE.*;_M/LUB2(;
MM#7A^S^65*SQ7_,H6-_@M>=X51@E5 B_'>$N_V]64V3&HE5*_RV%2OXL!UXO
MU2TU\7[2Y+:_R2OP-WFOX[PE1T/=E,UD,2WEWPH,1#U+_TW@04ASSS[TES&;
M:6+NP;[!#DIPHBKK$%QWN!9.0LTZ^[+C4)3/U0<"]1/^8G8WIS@OQ.;BR_I/
MV'-#O.2-^R8FGB!NSE+BW]^%^R--R12TF]4MNG\6?2A>[$WM4F"X=T#VZ4JS
M9V6GC/ 8$MYOJO9[K+EE,JGL$?&-'D#$;I& T3.^8)BZ. 7^6N@BDYFIB6;K
MFG0)"V8S)6*B17MQ#$4C&:3?"5=>?<<9(H,=WW;0I'$BL*2HL='U[PJW5V N
M^_ZF\!<L8#\!Y8L)3(9@". H7$5TW3RT<5T2#IE7A43+JGC0BOC^/A9L\+A"
MF91EZ?;:IRFT727Z;CHS[FJMIF$!;[DQHG9=1H/'G-P6>9/37S?9$@RA/P97
M[#^?Q6^:_2WK*O37;)UT3++Q?7T@@H,KJV=+;QS=^/K)U7"S4L-.BG+35OI6
M9XP9/SC N)X*OW,=+4@XH14272^V1"T]8;B_V: ^]W[LWK! HKACKW#444&\
M5W(GXX["0%;J3PO'2HI;J=0R2>GJ3'';_%ZG8GF%='[&+T0;XJ7:7"MUWW=<
MXQ*"7Q9[%1B9-5H5S)H;37EG&G-+5RNVR_65K-N^CEMG^IG\00ND(@^R5EN\
M(<:LK\[;:W0B\62'(I_C]EXZ+-@:$7W4/LA;+GAC+MX;&,MP9O[@U5)L.J%V
M$$S!.\DU)_,K-&*;^MA-T&0-IY#Y@?^N\,%ACQ 9[<9A3W;[UQG\+W>\5*#!
M^!?32&6.6B(A*6(>8@%:L$;2@3K[E+*51&7LJLF5M5P9^]>WOM^2)WH/XJ2I
M9 !O\^G7E$3L)&2#Y;7>?E-H["P<#4 4@VNHOU8-%P]>^]F\3*%R@A^OH+[^
MMJS\Q66TP^4%[ ](%JT\W87\ Y*[?H?D;^A_'8'^-(NL/RWL%R1[J?V"Y"LX
M%X#^LT,/_!K\ZPF6YY\#H-OV3GO3N"KB%Y@TX3PPY3?$<-J0&DTK-B(I$MO@
M9^N];O*.K$HZ0B,UJ^ 7S@G^&R,M(K;\UD&@SEN<ST!:*OC]2FX;5>._/K-0
M"16_(.("UZ,G8E*\PYH^Z83F[?L[T-[&Q<[6D0MN+("'?5*Q1ASRFU7C)H;\
M??\7YCD%07YA7MS!'P';[X\(EO0+,O\!5\J&8>P@^52N[S]_PG7%DCQ.3TIF
MC+KCY=EVE17?@]2?&O[3F_PRNDINM5 I_0B91F&$WFJQGH.BU]>4KK<V_G6/
M9A@G4ST5$MN2?T>)S*I#=.+%@ZBNJ>Y>H&IB!*"[M_)RBK4G[X]_!1K_^DCU
MY139Q<:7V2ZXU0R';17]I)#KM.ODKQPO^(/Y07\=G$[6PJ9"RBU_A/HJN0)4
MCGLX*)@@#L"L\IDP,_/B"2$Y>OVDNIFYA=2_'JS>RM[=G7_1V'A(EK2U(4>A
MI16^^/*-:E!5)Z!EE66V#&97.=ZWUE&B0>)$1S3XYFYF,H?""G[^<R%=%F>-
M7UIPW,Q]0WQ?H*RI?*H7:L<D.2UKCLCA2F?;?*?+VU4%:.'PN>2ZHGI?H-QX
M>VZMK=1C9JI=>.,8?MU"Z&,@XN-5U;7W,LYR9/_TZQ<XRF/HO<H11-R!B@\<
M8O[BPW6E0-Z5 <;FWY'*F\4N;1';"VPOL#'&[$!71^ @@/4?N\/_TY$1GZD=
MEL<7CZ/4YKIZ@4:)_UE!5YH[=N0+3J<_-N;*40Q13I,GFK9.5M^^-S@]D%DP
M.3=I?L=7+<^1REWP,1U99Z&V78O&GU]/4U.W==.\%SD55B;E/DU7(L[:5 >H
M@:P%PD7$GQ<4&E+XX+V&+1GD5+]C]*A*M!TD9(R*^L[%4IV[.+JNJK+]T_9+
MHD\Q+$^8+^&XO(NKZYH5J=QI4T[-\#9O3@Q/P9071_PNQS="OB.B(J;BDZ^N
M/";E(&K],9VO#7&/=P0<UKPPYVVW7S::N&5V\T<JX1+=D/]1WOTRM"8D9Y2(
M$S&(<=.3T$SQ $0WO>RS-%ALMC7IF)8%L3>=+M2WP@]US"9_#S@^^4QR*/B8
MX\6(;NR901=MJ8JKK_1!"9C#I5O31=V?/0OUKJ-UDF13RE7R;2"\M_8Q.X+Z
MT#+K%'$L.A6X^7J)M5DQ DQ]AVK(M.-6,W=N.CCW8Y\R2M37F36<O_!1Z/;!
M%#T]V>F'-V2;]E-;S;(W<>GRAL"E=R,F*&'W>/5E8YB/H=-"ZE[,KG7YOE(^
M[TUM32[^A?5N*DS06"^!P8#YK<;E1R/ :<W+&_9K4?HHS;?GJ>,=>P@%(>YL
MW2"=Q\6E'Z(B%+A7D\%1)XAWAUWWWD)(J@7;7HMQ8YB*U7VLO"%-YF?X=I#C
M_<;S&S[!WA+0Q=*1#+2(S5;O ,I3Q^UE8<6W]\I//1C.O*LMDL\#6UD/^#9A
MQQL"F#?VJS1,R1M-V[TFUNM1OW3,)3<-I6OF\6W"W$UI/C\RL.MV@"U714$H
M(&%;ADK)MF"59TGT(KO0PB+^C(:RB,U)4!R]KI14^C514:^Q9B?:RW0(2GG/
M\G(:+E:H.>.XA3I!6"'8BL0U]&WR->R<JP\A44>,T42M20_4J[,2HDI4Y]JS
MUQ ("Y,3GO5&1I09D-(VFN&-P&W">2?([N4-OT->3=(BI@B]_H3G/N]X^C,,
MTF5MTLQ@I4GQ=]B208]!(A'3K5%_+,X3FR$6'%3'\BAA 0A=C%Z]H1G)KZ;R
M'\U:,U[,/=];**UY&'6V)[)NO;=-FZOYG9=6&0N0TD22>@JMPXHTP6'_F 06
M<$1NHD6].8BBS5C1@]0%9%W+C=5D2[97N/I.*Y#[SML?MP]XUC5#S?C-*6PS
M24)9)VF^T)@<.T\TMC?XBN8L[#BNM4S.-&2]ZA!,E5H+U1EFZ"P7 #.ZBV7I
MQ!FL^ZN!= ;+U4QMGKS#])RV".T251T33>MU'AA51!U3-F2 %-W=":,+DPRT
MLY\^JDV;GL=[)LN(=$Q8S-NU'.*(39PYD72;@BG(Y.&[1*PY2#MGS'DEE#$:
MQXLNOE-C6Q&2BIXM'_C#@?5$YC,G*GJM62S\.BIE@,25>F[HR[12Q]N72WY9
MC3(0!G_"X?(_?N\ Y.I*F%:6)"Z4_;3]UYQ<GZ_;%IJ3>16H(!\94(!=12+Q
MM_U_&"!91JCA44</]\@;@NV][M;+J8Q7:TA%SPC+L5@@ P[ TFJ$^1;+;8#[
MGY%Q&NK>LSP-J#+@XE?6XUW8:!4;SV@66L2;&K9'A_.B;)$AHT]1HA;J=55?
MAW=VB[)M5V+D.CN=9S^+X I'!/1R05X%9BBW:NR5[5CX%KK(;0VFN<[ 079;
M6TNE74."J@N(.@C$5",.,@]MQAVE.RPU^2J%CO&98LT$=,;77Z*L)U=V'(N/
M96CF-!IJDMP&VA=:/\X+LDN/GB:F!#K0XP.6/A=;?.=4EV7A5!MVW-M!KW97
MRNW-X$).3;*[[#TN/RZ;>)J9!B.'7N<88;65C)=3M+P/-*0BW*D)20^R\)3:
MFB]GI?QY$I%?P+%&1NK^7TS STT*KCN,A,>&RC4I Z/=$\(7]4?U!\FVC>W!
MJX=*QU7L>/Y*OB--%S\^H>]U/V'A>#[U]JFB!3U<QV)FY=X^_@[CFXUD=Q6E
MF^^<BOD1N<,Y@_!8RPF2"8KN_+[.Y=.3HL9[,AE^Y9,WY3I45_V8:6!4-96_
M/O.0+N^U$I>#2E:?)<D4Y'_)SPX/:?$KZ_*+//3?E;H$$VA%5X'. O:893^<
MWR?F,06?>'ZE<W3(3!1JZJQY=YWY>N$.RPGRKB_?2]^[]3;6E2%76^A"%4 .
M^ORU\,X?[C)B[9-+AN^$$GN @"O>] 61#5%),XQZ*XVT93P%'XO*P]2D;W''
MZ&)6-6\<'2.4AW9'-\>O)A-511&FO7C=Q,H4D;PZR5,+=EB30ZKFF#Z>#]33
M<$PM5G]\/[;D()U;T)0U$BTN$%+^T^&QA2,6('T3$@YI-9 &^93$Q=5()Z::
M?FS&H6!(,NAIV ^$/HH;5KZ9)>T-[EBT[^SQ@3=IHBY&(%O)$&'#16!0SSXN
M2U+^.D:-U%:&-E$2O*S-!;UBR9+A*2]F7ZQ$APM!QKRP@"+O84@85*%R?V(>
M!Z[Y.-<VJUXFQ:&)])"Z8'KH?F7;FNIP"-17C+?8^-0*2O[S$@_ABH@]D/^Q
M97:Y/]2V9#[0%CV$FZEY0$X2"T@,GVBHCWZ]F.]?YOGBRV6(IZX6Z'7:6]!S
M$U2?8CF2B8%D9K?Q4T40B)<J_4UZ>S:2-E($0B+/E)S3EV@I\4BK.F6.Y0->
M)4B9 #D]U2:M7B/Y5(KUJ1)(18Y0=^1*FMCKPX^T3D+0A=,"=QV=OI-7J$I:
M(J?S++39\%(-5855S9^95P^ N@VMA%0?"SGRTF\-KJEVB;Q#/PY8A@8D3%K7
ME2Z)HWW!D+W& ^JB:_FZ*I\,XJ/%!M8XV]+9.& [M>CX='Y&-+AQ/]$K$A/H
M$XHA$$>-:E$%&>1WL70D]?&OYB-MPG#%51YD7A$2+8*J;#4_8AH&[M]I;/\6
MAD/'1)G0/OXU>3AJKS79?=.$O\A50J?;]8>IH<\M^W4'2EUU^T>EPUG:!<YT
M_O"27:#T6.=J0QP*@@6PL<1B 2:0$PN3CU4@D$A,'>^4@YA;>5<'A]1>N$!6
MY9CTE&U1\N1B&RTC':P>9K3)D]K/U@ U&C%:>_2M)#C[<J25&'^:--V86=VY
MX]'$&-\@N31E[KV4[/'KCGY%0DZR5TPL*U3.JI9=-9.:)OWFIHQSJG&Y<(/L
M0"@K_U59,XGBD BS0=.6.)DH'B=B0Z/I#>'L^,3!!:_GA.W$7YMF.N[E0_'
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M/9<FU.6N<Q$ZJUX^-*]OK]G,;&] /,_F0K^ :[0:&N.[E>0+KG*?WL",QU\
MF<RP7KCF9G&:B^P<:(/E8&84>R8[IR#,O_]:4C =XS6/[V;G8 /+\XA7X7VM
M"'[X7+S+J@'!/XQE6-?UK*SL[QPC8A0@D-%G3V:<;Y2H+=@_,.'P94 [&EB]
MR@@!"F;]=U%G5=<5MFE?(*!6:6[@7OB\J3YB?&:U8821^_2EX&P^5:[;%8#9
M"<=,1+ ZBZD4LGLZ>C#4TU\QY0'']'\"#;[\#5Q[TISIA^GXE92N_\L(_540
M;U8\" 8YP5YF%B\M0DJU*P;9-N''CDM2W0/8VL%?=M!_BM#_J5)P@H5-O#GG
M?RPR&P-[>8X,R2[T8/D!8H'PWIT\^+SQ:[-T\H16_#^./' ;ITEU)^.D<W]S
MK ?+A\@+'5>6HZ%??+[1TUG L#<4^<DOS<&(^OW/1BT5E(T=AY43Y4ME&T>U
M)]*<^$.6_\ 6/U?\ARF__E;"6K7+;U,21WMIHE@6PC7?&H))]<0,IS6J!%>8
MM64[9N.I[-\G%SU;_LH0?R&^0"+9<0+:U0O&*[?/3J.U5\0+JKZ1NT=:R1OA
M/!9(%:?<UU'=SASBF=9"N&0R@VJ;O>U\OVPBSBTNL,<_592/-<TW+<7*/3Q@
M,$**[ZWX_HQ5''.KO2S<>JT[1;@<Q*]S_]OHM"0]I%B1+RQ[^,Y]?GE+CNB7
M^[3)>*>ZTPY-#/VHR 8-3P_R"MV6*T!=PQ5 :?6HT8"$3*%VK-CQM9_H;8G2
M5<!9XH#]R6=05!;'=JVLP"55BTJ1.^)<_"BRVG*WX.YG2,?VZR\#1"L[9B-P
MJ"]/T_OV,[5@F[NZH^QH5$EL7T;U'OXFY/R6,TUUI%9E1JTQL,/-EQ6Y5%-R
MB]D/>M,KX?9VC;=3^; "7*L"V: \GQVW(^^E(JL"XB*.Z3+WV'6H9P)D;[Y!
M/3ZW/!S;RBN65-U3P5DU;^M)\XGYH8E*=Y:E3AW?*#X'G(T;5Q4N^"BT%2+8
MT3X%W7C)<L-WWJH+1CMUR?W4TKZ/_"JQMYJP6@&B*,",ST^VT3_/O:;>[93_
M66Z48NF)8:%H"9R/K/HC=FI!HW%TY_ XTM'(,+R(1=8-WY]?<20Z? *I5ZO/
M=)\J:9Y)OB*2#+Q.OC5[[>%&C4,JLF\MGED<)91D(\\KM$&R%ZAG<J=+5:+Z
MY/$A9:9*CY/)-\>\C%,;5S=M$.&,:+W,];$CMFOVZU5W+E-??+POU=_BL'Y3
M/"O&9(\T/)?$SCAZZ"GWS9^CZ6H)V=8VUP<7$A&F?$-I=BQCVZL(F2:4E$;6
MVD[1U.SJ02<M&<\'XR<KG^#)T=SCE?/UM2X^DHHCVS;6*DMYM:)N9JSXP]K.
M#R)->?VV%L:V5HMUA!O5Y':GM[_./[7B\BO%1Z<=_=P5VU0L2@JWZ'2 #!8)
M8\,*@I=Q%B5^3'6QZ,K.Z^B,68VZ'F?IWT+F*NUHH0*P-A$ASGO1QCK*7W()
M EK6%5XZG6J70DWN#U]HY$RLGXBXQ=5%N6@1RQ.K9LI^S-U\8P,K))I\?@8#
M25(GLL?>\R W]][2;*'N3M]10X@@>2X4W?:8T;1V1=>JCLM4\"P5]8:3;&DM
M8KH-#O6N%=K1IL3F$(J6A?WF]5-[((U;]3R6,+F_T%I1GE+WK=^_%UQ#9[-A
MA_5T->1\$L_33$HG)#?' _S&[H%"E'?74MV*5(C/];':?\YZJV/SY%A:5+6F
M\0L%(WD"+6D6GJY5 B9 _'T+.I6LG_VU\,E#N<(/'EF94\%]<;S&(7$S$K4-
M51'+LVWHAD^]]5%($+&T)THQ&]R7KP?O&!>E5M6+?&"/3^PV7VLL:H(J<JY7
MUKM@<=>DU<$[&$W&&S2HG[=QTQVV?BCLO@7:A/8=8VC?+&A-D:\9]*;,/M0$
M"W)JERW'V"VZ:(.XLMTC=CHD*N+I?;\=$JD_G?H6Y-*^D)+ZSA.IK +N2.76
MMSU4Y'&^%#;*$IAZ;KS2VBJV>EVA--Z8Z'AX+7]2P\@W8;YPML3J$[2TG3DW
MZZN%9?G2-Y'H(L&+0@&4UEY7[MR'\1$;":0FA4 +;K, +-A7EKYM<IW?<H$0
M379G6!]* "7EQ@;*T_76'_J+U :8<TM2Z/O>W2.9+LZWRK \WNLO,.;R&8E9
M:GM?*"(NJQ1P8ZG7,%%C6?@H10XB(;R<+F=J1Z'X?O:W&/G&>,WAAPB+<+,X
M][CG\JM98?,-YUUE[M6JNYN[4!IJT'A\A]P@Y5N1@"][D1J&U6=;R%AD6F"%
M$S2^=))-37JXPYX7P.AFMF9PSN)@:(A]T3?IM7UF>&!AH??)RG%P@0%.]5KM
MP0R2 R+@5!L!*/(1!".MO95M,J$H5]":!X,0C4@[1->DH"U]M)+SH<L.[4;\
MLU.12$;VB*Q[*_A[0K$/$#[.HSLET]I;-L*H[=II+9-G(2(>=!J4YN6, .![
M8XM.T#&!KO_YB_(G@7I%]R43XNGPDJ3N2'-7AU3V/]7#V##GF^].MKK1Q$NI
M9G^)D[3/K1;_JNZF=&E-6E?NNN94WSQF6C*R/$8K5=*1M'=S2L_+<^RX/+3P
MA2T5T[4\1F 8>52JO(/6S :6>M?;SLG!0JKS9W4E>8><>@=9$D=,R/"X\.6+
M#0U+>G9RF?37%&I2+:?V'/GX^3*?&V/63B+1Q<T.8\-&YIZ(CQ5,3FIEXTN5
MC>5C[/MFJ903PSUCOTF&!%0.WH&F\B*=;=C1\C:6MQD2/I6&147SIRIF3C2M
M3P95&:<<2R8"8W>+2PN-H(G%D45" E,395%2P J)DF_?CN!PQ\N*1L*S4X>Z
MFP:/ZW/DYC/4H4;979#N+T,9#=.5S?0LMSB"38QE;F9\?#F><^]EX;JJ^V!Z
M/D(801-)QD+!-C%IP/[:KD3H34+,=*-O;"YR:=KU-.'RM70:+&I5&\0#FP=6
M(B]$(="/-!K?8P+I[OZV$CE0A'FO7SM::4S:BS(513T7=R/^Y.?H@+-JG>OC
MM]@*-VTKAMGS*;Z%LJU XP!5T@2>/AXYA30?$3(/#!_;>9F731HJ"EW/8+_'
MWX7C*CO&S*6R'TTM[X5JCA2])L?G&;LH;[8O4 5<K*<P&!KWZ"!\1"1"S)WD
M17:XG_F$5U:5B,D$S=3LD&V@!^"Y&]2!RYT[AZ?>%?7ABB&/PU8 5P#N7HRW
M<,7(M@O$=DOE0_F@5/X2TV:[U/M4 LK+]XI5QS35*EEQ*T[9T&'H\)24^B"M
M_]L/I_G5#B99GB%#Q?=FN^(UW+F[=6JJ:.C#+U*-X0U/;8_9MUCB#6R_NBW8
MT*CYO%ZV$5FF!7U/'1#KC54]-Y2*>IJQ8^.GJ]NTXB3OX,NZ9Y)-U1TT/_0S
M4%_X<;-YR^44_IAS%Z1T/?7^< ..)4-/J-WBT,%OM(@-B5_><#^BC*4SN *,
MOW?)]((9I%12:N@E_>,A>_-!>%BSQ3./JHN"RULGA<+*NOO-9<52I\QB51<#
M*0K2^=T.RJ^W_CE0DM$X?.'ZJ$M[EN$:J/KD'KD@T2M2) ?C(DK9Q(HY.\_P
MX@5JYZ&SQQ$?KQC<L#<*9,%0/S[V*FOZC(U^U$%I6G\,,O.@H:DI JU&"G7-
M6TG(T2%L-H$F-XD/9/M8O/D*!<V:Q?3&O:!2VNX>KSCT,=-JCM-I'EH9C:*P
M]S#7G?(1*[(+7#<?=3$\9IQ>UQ*326<DV]#IHTRRLG+A2%3)2CU9!8](V>6L
M)T8>6Y=,ZX&C8JL;PC)%1\<K75)LV^5*1!,_S'.6!]#V\1_BUQ8;SEO?YHU\
MX_V.-Y-D\<D/5"![JD)-%R1N*/*VMWJ3UV#JI$(P]4W#3^RV;J_3RC_$R_2=
M70'XO11S>^JQS=]JO"T*:&50+!\J'Y1W[3PJ"P)NE,-M5PTN@SY6['F8\BX2
M6&42"XA^9:[,->(+C&+%Q,];\HA5<3%\>[\=K&;P.5.L'JB7LW0+6#^UK4AX
MBP/@J%C43V1<C=K*K:V,>'S-24B1S>R.#?;^<6'\<2C,5#JSA]U*@)*/KAW@
M0^+HB5S=-8G)LJQ3]">34;O+RSO8<[M+F7_A00:YIJYAO+A8?6/$:+:INYEQ
M/+BJL2::,OAN0_2,=%9*;\TBU@6DF-3Q2,$;7=D?OA3]Q(2HT*&BM/4;6[;C
M#/7>M3UWVV[%(9[Q'5#MK-3WV77X>W')Y+,%1MVH;/>F>KI>>%:=K><->&%G
MUOUZ9>+]TX.'W'=5.BBFS@B'B@W.06.'6Q;M:&5EXM$9P:2$:^[7M<VWZ!;@
M%B1N'6?-P97A0$7#%W XN_:Y4:_J@#CMMMI:2*QBY:5;J6J!VMF64UU&+8FH
M'DIHYT[KUXVNF47C9_N&QG+9CNIO8H-&RHHN%.;5R!4]'#)GUEQQ"DQ*1D2;
M:0([T72$H^"60DF\CV105:2-%U-@<_$DQDOE_$V;5&V4600G]N 7>U<2X:$O
MYWK.>B>WNO*-\:H#%$5OO/RU>:!,QC* X<37E$F-<2%9M_'MJ36\-F.YOJE5
MWB&X: /[H+[>& ]>5'$.>2EK5?-D"QA1#TK''T_)L4+_2 (-N]S<N@)4%FU=
M8!X$J\4+I 8QU<XC)KY%VE"49M3R2'9Q7P'(XCM$_;P7P]]W);^5>T$HD\N2
MHAW?*=&9DY:MUQL7!!Z[W:O[M SH?&3KU)T+9^YR*_&R-%AQD+<?MCH;"(6O
MC==58M/RT.L4-ZFVXJTZ[ZYU>1BX+%?/JSSM1$<$9UQ&<]J8A35^7U>+>S&H
MNKBH=2RPS6?#C$YII#+IDOQ29*K<$V<5J\X>!;)\NRVW931>[3)_O2G!%%D1
M+H"$(3UFA:*]DI,)/[8GH)=ZO0N.)=# ]U> #^/G6*K.@1I-ENI6KO>+=.%3
M8D:19HF1FDAOBQS+0L248F[63?+L$O)HUVB"F4$3*/*6R8SK751X<;W1(2%7
ME.)R6[09PV<1F<K>#9/[#3[NJQ*"!IU.C*^50PLS]Y^1R1&X%BT0<)A#N/(*
MR^$9-9<,1LA7>_<L/2O[8W?2B)3M7*#\)YZ%Q$B1O<;E4*_\M<0IHOL7U@QJ
M>K<C*X'VZ5[O47MPZ;"D,L'C/:7-'<YBI0TPLD+ESG?H[7:78G#?4JL56>_7
M2#&.(=*<?*@;5F!W*]2*9A1R4E7Z<\J@D_Q)B-I]PR;I-6Z>(_"RJ#YOY$7$
M>LA"Y>R=]=)U-%-<T#5!D4R*WF<M<R#+N\&;-YQV0B)&=?=(8^?/2=CT4L?W
M21XS94;3'M/^>.ZPS7DL4-D^^?Q8TH SHTSX/[+H20\U9D( <"\8)/?QBHGJ
MI^Y17H?$0M-Y)@ZMI)Z*Q@A%+P[6M!:4^+S^?,6>3\!X(5%37-3M(-M%?0$/
MMOUB_V$A%25S)(\N&O+ZVL.\&[KOA/.*=6>[[/((Z&TC71SW:D&MA)G,5X"1
M2J$47Q)-R7>OHV?F)X._?C:-F5V3HT!#C^,_32N%:4I"#+B8, "$UF%AE#+C
MWL-2B0;;WV,A+3@G%7KQX0UZ>1&D4>[7-\!FIR;@A8UO!Y^5EU>'H)_':?]&
M].*Y(>TEX"B=I"Z$*(_7[92"/=70VB=74NUK48HL.'5Y#V[G7)C$)4*C:Y=P
MDWGA:X%NW7**Z5QP9:$7/C$?%P]]5)SU@A#>F(911:J Y3.0P!J-QMK((PW'
M#K=5US/='#AB$O*$DHO]1/ *D.]_-PZV2XE7*.]8ANG93+DWYAR:!,E^59+_
MJG7? 55:G.?(B4?"<S<[_;?W(R%D2@!)#07HOWN*@5<F&T_1-#+Y6$PCVC>V
M!<),QGR_K@$EI05Y5%/S"=Y8&Y7YJ$,,?XD-[DE"E<4MQM%7+Y@B+%);I9#B
MGM8B8N#[.3$HJ.BM1&Q6ST/H [>'>(NO8K#R5IT0#X\]>A(E0WVSRJ"7-XO[
M_!J3V'WD7<9TO#R$+8JO ,$R;5S3D.J?CEBBDMJ*2%!M?<!\W(YZM'KQ(]==
MO(L O;WB<)GZN= D2?6<GU1Q0K81VBN0,]1C>;4*[XLE+^&>;QX?(-?'- P-
M+B1N^=J7"7_G+OFZ[>;&$F"]+O%FN=X]E2FDIP+'82:YD^+E)SBN #D0[&!^
M,3JDVGAFS=><FW#<;E_,CG3-,R+2H<#=1.^-#=?P3-<&W<TB\2<^SZ%507 K
M9KH1MJ'M"V&8DP.4V+X/FM[-O>*OZHYXDA$#]SH SA[09UHY-C:S#10[\[SQ
MOCM/-)D$$]1'[B6Y^]IQN1,F[/@94]="'&Q^$B4!;S(KCG]_$L7:(XZG*FNP
MNIJU(8(\GX*&*$Y61CRXF((PLXP(G3:(H8N3>9"\&I2272UD<])0,OPU@<F-
MNHBO5CE3:P8OAPLZ(9*.@]-5BUO%QR&^/_9K)AV\J+YG^T2HS4LV7]R-%]E;
M^%X7+>E,4/OVMSPT!F%8-9HY.MM6O57PS)^_@N]3!_&-V=38TOE&@1T=B9?4
M>X&!DJLK*64WD$9IW8FK^?F=6HJ%P6VJF9") ZLK .&Z2!-%5=E^XO+9N5;$
M\FD&'5%<SP6@Y0+HUIU(-8#(F&00N[-LR#4.*Y=5_.P"[JWKY?+R,)9I/R8O
M-QX4\6=045J>F>F;VV_K;*F).[[^8L$$TZVU!O*6EX+9^DAJ[UI7GSE;7L\:
MSV,\7)NTFS->HKRLJJZ>[]QTKKP"7//X8$**W/9EFM*7$/ANVSD-_[Q3_QJ_
MP_P\;*0K[B24I#*W/3W^0T$O2KW@26JNF^?A.M?E:V/U)@33PP'9\WL:>T2J
MT4 ^H&KI: )YE -]K:RS+Y695GE]/>9]IO*B>%EE5=Q37AD--OL;/O; O(Q,
M=/UL;^?Y?2N/J3F+Q!-%3(R'QX,8+S<[%QO*1XJV?K'\)]5.+?UNQGD9.4[+
M50%/&*O'?GGTM_U[T5$+]1*("?H#7MML[2-RW(7?%D#:^*UGC/H%3L,/6(P.
M?T4=<_[G@T%'6?*[#;5#/'/E9:E;33\H>AB!,:6J:OO%=2%YRM%*QL')'O,+
M4PO-<R)C!&H$&[(G+3G0H75?WF;CN_!B:R$=':]:(QO(()C'IU'%];-.0;!D
MEXBYEP@R&Y@9N+L=D[>*HL\-9 \!C60I> &+WJB+:G.,O2U8->A"S-G<DR;<
M:7<[$40OL<8A'T?H]+#&I$J@O@YK;YA<])Y<]&C;V(*L?!62IU<E6G8C/_+9
MVE1O2#0)7I,5_9P,J-WQ&Z^3-AA?1\U='+NJ2\4#7]][,60>A[X!S,S('K=%
M[3C&4B)LQP4/@4]-TR<,J-##<A\5ON(G+KM,"//0=-EC0D;5XM4KHB<W4>2/
MW[.[BU_#'Z^'<CW/U+2K65(1RYXX"+?=,=JSZ4JP(0WP@&03?9N!\ )()\3/
M,\4T-E11ATZYF-X%O?HATLI<DV<%?8RFBWZH834SDU!Y X3-G:&@)V?5^5T8
MDUZZ(RX[4)L]1&2OF#7Z&9&DJ)/?T.MRZPOAO'636ZBMG.#TQN;Z.&W]YX*!
MITZ;<HAG&?'5;G7[%P2;5$475P"*OKMZ,[V2SS#.J@64; FFCP'2HG:'\%FZ
M-1#1SSYE0Q(Q\NL= LHVT(;K!#P5/E95&4G%IS%5,QG:-$#0[-!<957CGA ]
M04SVC&'K909"0/6+^3,ZXA8+?*&ZCV,-X@N&*;8\ CY/VLZN18#+ >;!\;E,
MK<7S(4KPBJKWSG;P([$O9D@I_7D&HG.XA+&DTFAR_QVC5\I"7UK82=_I#!*L
MG>B>>!YM3?%1S(#+61W\-9[CG8%TY+ET;!RSTY'L:8*>R8B (MM,U(6BCXL=
M.]BR_K<["PQ1($ DM'PAU*MP\"88_:/M0$7B8UMZ3RN;;+:SD.9Q9(I:93/>
MN?"WN1D<U^[!U*O5VP%DXLWP^P45*!G8Z,2^7<,^B>^B%HW\J94ST7*@M$%Y
MG8U.TA%/]E-Q<8A# ;(AI9-;<;9?;\[[*=5QU+P*@5Z02DU31465EX?FE*WS
M-WRQ/%,;,!CCEPVEH9=&QB78$ >R/6*H)D>^6U4S-?&3%S94J:S\L+K1%%_;
M.M7OE76A5-?L<^]XFRCIQ<] 96=BRO<#'O-E%\%;WJ#"/K@[]$2O)@Y\R/4;
M0;#9IK@8N!@XQIE3.)FK?&NHV:1:3/8Z1"(\)P AW!_Y@W=[)2KZ]B."OG<$
ME5I#'&/W,&YNF0]"\YYZ65G<VXZ6>EBL..?1LV$2)4_:.&EC.WKNIUZF*!T#
M]E@YJ:/.?3,'(S;2,_ X,1!7-!E+%O2O>27=!3G+*2S"5'56^,@^;2R)6+2N
MJVM4]Q?"LF9*)>Y89DZZ6*D?2U,,+5+()\HR01Y^DIUPGA;/5'QQJLS(*U.3
M+ZQ,5#CXT?/A_"V2%'A#\<C"$JD]8!#NXJQ]#O(ZU4.8P^TD _Y-;D#=,6+_
M-C-BH%"2K]YDIDYB;L'-@02QN+=^(@?WCDP@OTS6I7\V64UL,M?1Q0'Y&Y%\
M@2[*<?5-'M0O,FDYQ4R:VAH?A(Q0:*@(>R4,D*H(;9DEEZ)VA*V4?YY17<8H
MW.):R6,V[7X<<?3=W<QH7(B/! UYWR:1A>(/G%F\IONZ8X5CPR167C.?,G%I
M*%Y5);<_OU/?TJ#YHW"2C45'/E.#2*Y+3@J#+7IVQFDH,5)_M!),ABE0N[-&
M'7B&7N9GVLI@28N(:*J<&E:H<IM4*6+N-/1QJ^WH69 &:X#++9OHQJB7, =V
MV@J,OBLQR;K- =XB4K)ON%+M*J TJF_JDJ\ #,SM$[J75 +YN0]UHC1R$4(I
M$R"N^;X?KVL"T3OM:H40W@_U'1D*"EO[:2O&QE2/XH&-(<D>L<4>@5&94-=$
MCN!MZXJ-0DGE/$*]M7U^"Y(PZBY5<6ENRPOI?'?QBDNS)Q4>T2_,0C5+'D=?
MD*4HY FO">D.DC\XGNHTG8\[9_P\'B\Z>_MP2QZ^9"AI16#*5@QP6X"<=#J9
MT.[=R,Z>@J+",Z9G(=6HD1[*\1"FSX% ?P&Q%JJU^%33LN0G]=G\5:WK#IUF
M[GQ*-</>'&9O7)-X-10_6XB]5MQ0T3:*V"B[F%!*6M'UF5TTGYC<D!AOO@+<
M8EI.M;DS0!"I5A[[SNTM8[E9CB=(N'!2>9Y=;V[79CEM_L8G"O=W"HP64J6O
M?&VEY3V15/S%\]N?EAXKZI>)D2]4![/[;.?AB^9W&WB1](+&7L>%M$P=]%.H
M([T9[$3"7=+!)O=>;MDXO/T:)V\659]*8HTQ4Q[+0O)=/"[J*#$V*>BD*I%L
M^!*?SC%V5%P0@M:Q\Q'V^M(5"W?+F#C@X6@[RW1/M>%>OZ%&]F.F\=!:H4]0
MA!!10R<;"]X+#.7&9(R:V+"<O_[V^-@K]-77%'%VB?<HN-N8UEE';6W D?O^
M?C*OWQLK&%Q!2H8X5*7L@YUAZ)?8^P>2-AJC&P;,%&7UH: ]JJ.E^@Y;!,RM
MP<R1LX4-75? _4:GOGCI>;2N3V#35GCUCEDDW.-YE)V;S?4Q^J /MI4LMWO8
MMNMKY"U5U:[Q2_&54&T(::@B[D$G Y2,MB0W/3X.N?!A0)[4L<=<ST; ;-.L
M+SVL&DK979F ^7O]V<@K0""V'6*[7W%R._,:'=JOE?W\%4A97E2_ELO0PH&;
M2[Z[KB2D7D/;E18A.BX4N=E,.PL%S3#96*DV:=_-"%-D)\VD;=VT&K',S]5H
M;18HT-)2_C97H4,=ZE.8^SZZ]6XD=6DW[?G+K"-:)KRBR9V;5A(IH>[1RV_!
MY%T;TA6$OB]T/,C-:MGRCQ#*&7 09)IOHY34']I_!3 >(#.(U!V[MXOCUUL5
M/2I+?F8.N37HQ4=XI=O\W>-)!3/K6.$*>N&<<*]<@Y?M6R!0" T4/YH2OT=X
M5D-1M[)BTK1.M*E^VS'NS'P/@^72G>X,3XTKD;_+PO5ZZIV/_769%;7:.DRD
MF?N0[ ^>A^9 7AGC38?(XEO%&2%IECLP(-4F$KYB_^N;M-Q_].UT1YYI-9V8
M3DHM4_IH/,ES@^B9?=N</>*PWPFM7JEB9CA6D??=T\"0BIV8K2?LHA(]M38.
M"J-?'J'3<W.^-FX1P@^9DYS8FB<DO(DDAS7(K<I4X(7^W(*]*-U=?^SDP%2Q
MJI^E+\83\TD!09NC(&DD/\]WNT#(=63R5-V6EA?0M3-(-68($7D^,*8"(8YD
M5/J:@B=%V#3\?(\V4=CR6^L3L>Z1=V(^3WY+O36T*3G51QAU)(ZM=%Q?)P%V
MIUF.Z2E<B_.7] !OYQ-$I2*1%;=+Y(;ODB>G<\MH;:TI.EA='[&N"10'#8^1
MR]&B3.Z6-(RZR):J+">YTY;G27HP17JV)$Z07<?XM@;*(SL,46-W]%!V3"D5
MZK1LU<&OI=59 5C*A6OLSXE?/(,Y+;'PC8Z\$Y]E($&S4X>VIBYSMK 8Y'NY
MD(8N.#>,/3;4YWFF_O*YSLUUZ<+B:-JER>7GB(IMXW8QF8S:R^<'>E7-"0^&
M1]5')YE!L?Y]V%UI2WP6P_'-HVDKA9(R&4>>H:@<M.NBZXWZNJ7#+9$#]?'T
ML9V'XUUHY,WJJFNV/>O=3,"\]&M"%8%Q_]KL @43MN>2MM6WF;;V(RZ.+J!(
M[=%=GB2*TRM @UW2:&I:@(S_NN&_)+] <7;]N81-W/Q<U1XYE@]:J2/\B#1)
MQE9F</\* ,?N- K79)?:_BO<#?Z]DL5*[B_ 9?G[G%U[2YC]Y2=>M)7,+'C$
M=IN:R.?)K0=F ?+>,;K;5X"%7MC9\FQO@T4K;%]<']8T^VV(H.K/GP$#X_[5
M&0FT1[^)]'^4BIP1[=L8!'?!D88DLQ8V!\$#QZ=!MIZ^E&=$^=!_B1]'8@*^
M2G(2K(*D>;VY<4MWO3BS_ES&)OZWZ:H]KM6FPX6:U,Z"?XXK_2\N-VW_OH3@
M5@4L4)+O9/*4_CBT&;.?AJVMWD=0[RI> 4)&^BZ/KP!#*@ OG_^GV2:T1U^^
M_=%08W#_@&')SNBHT,7@FQ*KC'4?T,XNP4>PY9^C;O^O%2TDL=G+&H&V487J
M+ZA")Q!W5?I]$8J;;_7,)_>_=0?\%U)-_.\7NL1-B<]H\TSE!+8:M"](_6F8
M\S&"97<FI2B-(D/_F5F]W\!QE'MDZ8/&@4QE=[,X14UV??:N$T(\:^>>]-^N
M18NQ*9H?F!/BR_#7G,UG_=?]& NF0^=!F^$ ELYE?U@LP""CW'5#]F"D#XNQ
MV\NT+;\"2#]LWOD5< LP\O\_^K]X5!C7MBB/_3Q,)W@%>-B*SQ(.4/E/$Z-4
MM)-7VCT0E3]@"=Q(WH=N@<H.&MZOE GN6%.MA>VII=?%<?Z??$"!,ML[ZH&.
M<6C+5"FRM &BP:$Q63N<IKI*++M['];V3CBO**UZ_0IP>(,%<Z=Y3F'R"':&
M3W9Q"[R;3@(5$ P;5_O[G>*GG30TZNOJQA4D%LX@C 59LK.4<[:]- W;>,CB
M!3E5/;K?987.=KJ4U>Q$X0H 'J_K??5_DQ2$2EEW/S#68:5K7[YZ67O=XX^$
M,*D/WYX+WNNO7N(;8O%TF-+\$?=?=H#E%D?K!"32=D3C[1>*#,'H!\YU<6LD
MUP>[N'4%V+3$UPWI^\<[__1<\W_].=R"9S%D>1LM]D*64U%TY9#J[?^XD^3_
MP2L3(8()+YHU7'^D-SDE]>A+0]?^A+^JFA9&YXG40)=.08'ZLD76,%@6!H7*
M'EP!?H5K-[R R%:ZL. TL+HK0',_5K@:.>L4>2X/XSJDHCJ80_[ID5 :NB[R
MX@HP#9L=Q^T*F>+SH&-_K-:J$K##6WS>6+=/2[W:L3<"_CDV%'\_6N*2^P-Z
M/%]H$#@[16T6<]ZN/"&YK=7=A2K=J0 -=NN,-:]@5[!8>K4M&V4L;!NV,Y=[
MY#:5MG7S"O"7KBOY<%W7XKH.C#DWU+P"I)VGG9]9GM5OLZ#)?^^V?4>X4>,P
MG(?DLDNJEF$G.9K1;]#WN@63H<8?+V,@W&0U,S)<%QQ#0J#!9C0Z'C?Z7W'U
MVU^X_+E3\._M20!;>"JW-$?6)3\T)5=8,Y#<93VG'QJO[']^H.'5V9!@FFP;
MQO8)@-T9<\Y:E=P&H1;ZO)AGY;VO )>%>5> P<O!RPNA(-V_TN7;>L)Q_D2V
MUP=?WAOSM^YR4OY*">;OE!@ 5]X70O6N )&_*+125A\7YJAY;G4>]B4F*V@D
M*,BG^_(K _CS">Z]*\"6L<(?365)5&5? 61/9$]VAS=9'&"6"J=JZ9:(-%)X
M/NSWP0C#YYJI32#T9<I.#D+CB/W>L,6]=<$UQ2'7J;R%^>G$TJT*K;MQXG.*
MKU\-UQ 728;XO'+[#P6FUJA49%GUC_;- Q;)NA4I9"_"XI>W[DV6/[QU?:Z/
ME?ZS!]J_*2:/%Z3=-&(ZXM7OCT7)VTZ2F[TF&#M'25_^;<1UZ>C&@5L+"W1B
MDV:KA,"5A4(H^"] )1%:__OZJ:WOU,K^L6J#2?(E:>HT(^U-#A%ZBPY;)C1_
M;V["6V*\\I;+<6GBLN*KZ >.[*\GV$8^YPDA'-<6,L4Y)YV&'U88,LDL;?.8
M[D]W,1 [G*J?'4<QAC.LQRFMVVL/I+\_1<(HV_,&YPI7#_,)36@'VB32U*7W
MP(($-8KZYA[7_#Z^4ASP&N=BBH[G.KJ)<GX_JETNJXBZ@"SHC3+D?(7ZQO!A
M4/VW^_DNCF#GJ^-A-!0.YVNR.YD*7,Q(5YE@^I3WSHW5LHK7I4P,JJ=K/EXR
M@OQ;'619FF.P9\+Y=BZ._-@HOLMCR'Y0I7&DE3XY=B/_C#X=C0V+^(:&?WHC
MQCI02W" $ G9W^B%'08[E#:'G='O.\<9;YUWKWL-+;S2 9FMWT5 "'+RW\*V
M<)LX7,I*PG0M#YV6U8<5/G@FJ(*3<6!<5U^)#V"#^KAQ*7^6+MCTN2,L>6/-
MR]8W.J0LHHS5^56OYVU'$AS.KW^_\#U3.U]%P7[";@MIP2R,7RB]<&+@7_7A
MV@_75IDXE.#,R!KZKZ9U&RS_Y[1NK/_=M&[$<98_@[,2Y2.$%\N3\3!(EJTM
M%JQ_'/CD$M95 PL^$20*!9JRW502I"3P=YII.*!JX#P 5MGK=M4YV2N;S5P!
MJ@]A9X3ZL-FCW_.W_ZK\^*.R*Z7Y&K&^41MY_*'Y\\GLUB6NW:K?V\VI&MOD
M8\R&;S4,B ,9OT:N@:7)M7X8];_QN=[9$,Z8]S.08":RL'CI8>NL7NJ)2'GV
M9.^P2AZZ^][NMP-.MMU^0>P=DK\UUO!4NP]ZDK7O?;*(,X&A"1IKBNK&'0>W
M.&RU9IKG6(>;5X%O<-A'_0I=\R'H^14@'1Y_B1/*>PA\5D]-*N;/V.+ZT/,G
MX%X?$DB>_NP-D7CU 9H=#\T;W2BJMPTT[8F;,RQ(L[K(+Y%]W*YO=C"H.H.I
M3@\KJN\D=5S: FEF>F.YWP:^R]S5-3$?TY!_Z_S?UY?5/>D!G BNT7@C%-\.
M_!7RP;-(IZI30T8*/\5LD>9B@RE#A?QO46@NI[JG<<??5BKM-FW&#L9ECBN8
MZ[TCE9%V#&HCQ;;#3X7XXPD]&4%4-)'"'AF0S!'=%_$[ MNLVIZ\^2X^/QO?
M,N0;:!%;6(GWM#()ZB6^K2V"T NEF8?+9W[3[NU)YF?BGE,$YA1_![Z>2GY#
M/0*]'$"W=RGF6<:C'%K+UD>DM\C%K[FR(E7PNRTTD7<&]F_.W;&/R+K<>9K8
M,^SLP>/-5K#N6)=6,1DKKY6,-S5^ORJ<'<L0HULUO3QI=!NS64,@ZR>$%)/,
M,.&X7<L2B]YNGHN4V^,+SAW:V>*9]V/7#U1\[;Y"-:PBY7H\*%5$+:3YW0>
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M,N5%>.F-:JP.:&)/ SPE%_/@.E\0]ZRHWC[0$->"X?HE\0ZM+41@!\G5+Q%
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M1MZ\/7<B3+$@,;)4^4&ZCV,_PJ 1-E!\J9&P;H@?7!4_WU-^FVH^/S![:TH
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M#\4 0T#GP6!'.QR&>VV=OJQE<N&\!-RV"T!,O[R8K!Z6_.G-ER9)U'[KZ-C
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M;6+?@-*=Y]N$,5<^1DU-3;=C*B]IUPNN5!47,1V=CK4-Y[0]@UFB6ON41TI
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MQGV_]%5GHK9IQ=05=UAN!UX_76='LGR)V%M'M0LF;GF#-UT\;?:4WPV_8KG
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M2:DS?7*VGGX30U_,UF:+?L173<GPV3,_XDDV8_7 M'63$.6^U$^ZFZ1MR+6
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MT^>96X*7A#$$D9H@]H>)@C41([J/IOV51=X27,HTK]V/55N20$V^2DI8[-N
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M]G40:*]8%:!S2)'GZN=O:O,\Z%EZO'A$W3D<\R6VGNX\W<HY+V\BWAV@"+1
M)>(?NH^M-[? O4/$R^..\VK?[F+AE, 9_N%MS#G<UVVT-C<L=%=069D<9 ,B
M<^Q#0<H2 !G.8^"4)GWZ8BBKX%N]C=6ZF%]4FB CMYUS(5=XPZ>J75,O@EG/
M9,U&#,:LC%FFZM]/H[0,4G>S+<3_//B;C'!/"XAWE02A>D1_C,W!+XA&> =X
MX@JLHS+T4&]3=A!F+HQY ^6)D7H$Y=!. 3"+:@WMG'X>TD>7-5WCS^9SN2+I
M-WHD3</8/+9?LFAT:4[[6>VT6W>X[KOF@%5AW/ZSHB_[K7YK,@TVWTJW>Q[5
M7//7OH\._^HJFFOM82DVLC3$NF+CP>"9C4L;D5F9-GO2*;M4MUQS\*VJ5C*<
M?#E010H-$\/JP+4"#<I\O0'7@S?(!]X!3C7J&<AW3$F<PA7KBUL)!USF%/,V
M!*8W]WJM)D.QL-.(1+W1CXH&<V;#B>'HP3MX&*:#O"AND.84UY+\C3-T.0'[
MJ3%=8->WF^/M?1W'"Y$Q MG]TA+6Y><Y^/)'6"X#Z%S>;QB"8*.^(OO-PEAP
MJ2Z]O(/Y<,AQ#:9B0$H@1;6[=EEES207054-E-CG^(<UT0I*=*>=2*P]/=P^
M/P'"\^B'549X'5<MB3Z10"K\NO*RYMN]RA9V5ALLSQN?2X/-^?9U3B_["'^9
MMB:"U10YV\6V3AO0X+.)8>X:?")&]1H7YE0(D*WB.2 RMP0]=HZ1W58CUN&T
MCKM<)SS3XNM__-(^L"O')=3FDBX^\0?L'<^#KV_K?F&TYJV+EXWOG6)Z+%?&
M=WVWTN=#]<>(+ 5F\W[<A:WI@.U?LDR8-LC\BL7HGLP#@IKX\U*!51EA-3M.
M,O;)[N>5V[K\G2E#[6/08ZW=UKG+%+]:K$,/;]&?"3R:>WTTEY6O: ^<M_6(
M>+8+/6#M"LW@B8DS$PAC&JU?RM42G#< ;!'!W=#:4G?4PV@H?K0\9%+%;8 V
MJ>&1ZYZ &0(9[\<$OQ,6B>//9!$Z!;N--C=C41*#O$QT=1_!EZ"[Z^HA4IFR
MJ,<I;D452T84>F_0>VTL^B,54M0_+6**5DDX"X_/=7:HHN/+/V>(^-DM-Z)(
MCSIN.28A8P&CPD,- PCS%:QK5G]7-UM9M3$H_?KUH"7>TO-L5W4-%29;8J;!
MEO$^XZR0\&EOWH6I45W50P(#@0ZB"S2QGBN+1G)>Q6#Y/[_UP%IG<7+6J>S,
M\["1B'F1#;/1H16QT'*\;(B-&+O<^YF*(\-0'=MX;.JRBRE5._3V.RI^=@>%
MS@H@H:>7G]OH:YDT82AG&VXBW?<XAI)AI*R*]K1?;/05#B_)%!YR\$DF2*E(
M$$8;'EPWT K:H1UUP90'2=%AUG=G"BU] A&5+$HR:.BP$KV.#!^A69S"[(BD
M$:"U[7NL7S8@S%>,W)6@A&(717H^?-HT!W.\?/U%!]GNB08#-;D S2#&$A*Q
MZ+Z*]Q^QHG]>J\Z"'/2W$FJ/."\3[CD/U-/-S9X:PP9'YY>=\?;S^MS0MNGV
M&)P[LXFG/^@PD_U![*W;N:E. ;#OHELVPIN9619H<#9].A.Y5!*K.?1N_(N_
M&U(+AW!6:.NAHDQGE1_TYT;DP-ZGK=G$J^:N^LY4;G>JPF22AI/30N5+9HAU
MV9+!!1ZA.F-LQK)NRJM29&98.!XWA:)8FX1$)%]*G2:&JT!.PQUA]1JG7TN2
M%4>?CRS!^'1^*C(K=/8P."+B8!;Q:/&HY6(CKQ(TXT.CE!09A'?X%D]#;1HA
MG)$1BU7[N!=0&ZK5E]/3?&<'3U/PF;1=&D.JC*BJ, G#L[_K"_=\-_/=63XL
M@4V^KJP9S2NG^A+D;ADEXR1KU\S,+T1J!32)N;K2DQ1EK?Q^Y"M@"30<)FX2
M.CDYNE7C.B&U"17&&9G?". "58?P7SF?%!L]F>HNO,B3*4MR?PU<C?+&O0-H
MN#*&DEF' #2> =R 6M<\3XO"92J3/HK(Z-]D6/)?35AK@E,Y<_L?XL#\T*GR
M=9-\=%E87;8]X;O&^/ "1Q).RB4:LO$97X'3)EES]]MDFW?4FO@A%J@-T5UB
M*,VVUFF4-6-[-/7'%K4-8<86'\KN43]HGK)Z-#<&PF$3FD1DHRBX9^OEK7%<
M](Q%J/ZF]/X57U)#6?T(&S=S8S/;@EI9ZH](ML4U:H1(O$@I.&\.TL8+K"XV
M>;&JJ5\JHDW\[6RM2CH #&#'W-XO3Y@%-RU$7;L,,)WE9>AMR5H3ZH#3QA";
MBWQ,[&%JZUJZL:>>1]7VWYOG6]=,MQ(2SBGH1T^,6*G*?HXV,?Y6'/[SB4C<
M M%/'9V?T[*6]F2\;8N$LVV9VBDGRW!;0P^GB:N):7Z+NN/=[KT]B27QBU%;
M'UXPR*TV=M#1TZF)-A&WT7)(54UNX)J(B<.G[[MA<^MBV$PRIJ]I-X7!R&.3
MRBK5MR=LLMOJ]/[RI80&XFA)]LX/_0L[[09HWLQRZ-GQE]0LR/O/J#>.X>5P
MZ@?B/ L#H*$QE>0NSOB^/K3']P[5RVA4^-,[TM>PUAZ&X%@M>;V%U:&>JO*6
MX ZC:=%W-941?,\4"3@"6L/"W@L7*F. SF!!,%>]GNSZQ@8WMB/ C)1CE66N
M[:87>4F<60Q/ FCU#J##U5^?/)TO^A'\<80;?KJ;HUJS'D3\*N>\F^SM6EKB
M0RF5*KCOR>FE]N"0[<[284VAK<8;=JFBP(UGR\_]-'Y.:$9GZ&Q4Z MGQIZO
M$.),=0DS:V8Y-0XMX"JV$5I/(Z$[$[;_W_@<8=2N\17;,9BIJO+81F\P)QUL
M=^=Z/#+JQ>#7\"R3-E1B-NU4>R;$GL^WO0JDC 1&PM],0' RJ]^Z5[%+1JHZ
MP@#5N1?!ZF.F>KG#!BP^%3/GX3MB&T4J^A[)6A4?[.VY.+$_O2,.RVCP=W@,
MM.RHY=7E#?PP>A3^3.9[X;K)"0.PV[I=+FUZ0I#T^\SV)PMQEA%!(+'P<9<5
M2N5$D]RTP6E\,:&R*]U(@H9$P*Y"^2'VX<3R*+<BEVXO!]&G&,5?R]7LU$\]
M+LS,P2QB9"X6HHNRKDD(*EVVQWHV/,[=3HZW5@_L?&0AK*>S)$J)9U65@N9N
M46S*&>1;I2$E.6-5NSC\SSTHMHXXAD4UNO4G>')=L[[3S=T&CB/2B^QH>MZ*
MN^_&GW!7+%@W3@IQDF_< 61D##V#!'AF(0* GV.GK$KSNV"77;H]I;DN+8<0
MX<IMC1WNZYEM^142NSFIX;;JUL^OIC:#-O5O!S(?KM7G=Y8:S<U(HR:S[AJS
M9$Z6+Q=P.W\K6OVYK?6VG8D]]:-CCZP#T -=>..!#UW^UFCUCU'M6)!P1PS7
M[BL10S2>#YO1NH1>M^&UP3@E9]_M8GI^0MF/969"*%4==0PIQXL7#S0ZFU37
MMC ]S:)?.>6L7\&"CB;TE+$NG+9[/-]5N2:XJ,0&##B*D3A[)&M7U1)->F%*
MFWZST!%W-5)EFJ]<\CCY>;+)NCN]8_1TM=@RYM6C[C6FB/(E/0,]Q5BEX?.Y
MN3FVKX7!CW!5NZNER1.CE^"8B@.GY14L>N17%N]?ZET$JT1J55>,<Y5;UWKB
M"?201G$&&- YPVKW;TRSQ".H=2Q$$QZZN/S#;*$:-:.[<#8VAD",7H>951/9
MWB)U%<D]VICA>V>OOQMGLVA6>]K@B1UK5ES$WOMQ*.-3V8TN22P'*1HH]QMR
MH-1#$2CC/X\I]?>\;[U?"O:(^/5?SY *_#E;(J6Y?67BBS41]],!S_L@E7%_
M='S3K"BK'5WR@,=:-R:1,O";3A0/BQ67.F3]XT<_T 6+]*V>#X*PPK<V'A<,
M$W(]@@*EQ=  >2J2'3&Z&?^DZ>_-U3?/^O/AEPJSA<_:S0[RIN$JDD3XLK9(
M$J+\=49<R/IMD%&E[5/P)>_)8+,VTDJ/OK?28Y;(6_F5Z@:M'6=5?S;^3=RM
M![KGRK5CA'3UKY=>H$(YI'\(:, 8LY8JE!8E"=[^W:BK.>9:JL4H+[8>;<M+
M C1#E2K\C7B89?"5]UG>D51*$NC+TI4A^_U?BLG+GE9E@GS2[W%MBTB>MV7E
MGZ 0;#$"NKG>60IO9+TG,0EK.0IMO?ZYEAKAK.BN/9P: 922/2NV>4EDY16X
MI:L[?QE;WY:7T"[ZB>!!A:G4NTZ"L@V9M50D#Z$56R5-0^NW/X2-YB,[BL[Q
M_/FG?^4#WL.2@&?K7"K_XBBI?XKPF$6S;_MP,^Q0DRDM:=4WOBF)1/*8-&$[
MY>C%"9'JZG_23_A_J6B4WNR7?3]SD4ZF9&I][;O5KSK>5+I3%"DB'<':RIFG
M\O?YYU]='F OW'@JWP'T9RZUPCQ8[@"=YN:(:PB-X>!]IFJU/V6J7D)@B![J
M3$%:%NX]0.W^$QZ@_X6!A2?H)1X<&VLG>_L4;:8AL3/,0?P^"<RK8](UD?K-
M"[4-MMR&?T5@X2)K-'%C]B @3+&5!3Q<V*\V_ALYAR/+[F_@-<FMJN6ZW'*G
M_ZX(UG\NOY&V/8R[Y+N=@3 =&J&F7\!9ZA$\"*EFB.[PKXF3\YJD)!P1V2>_
M"DIYAOTH%FI::=V+AW5GRN@UEOO/U&XV4"8^#,J]B&HG;WJ!)5_#];90^*'(
M?S(4)E/J6JZ]R5:L9[UQ= 6]_0I3ZPTMH>C)X1W@_3Z"X$&!I/D=H$W<] Z@
M3'F!<P=8E/Y_U?]_KY:P<26?I=:NW66@Y "*1A?D__W=64/:,C #[T#W]LEN
M%8:05&MP(5AG;FD&;Y=]YE-.;NZE[]\_I>$\3]\T5M4!O1IQO1:(JGC3QW_C
M-2K$F6^MVQ1K.*L0:A-3@/'AV]5I!D[,_]83 UMZK95?9NS82.WQ*)?.BC34
MU-85TV]I=NX +Z\6]JY'(Y82.O]C><+$ORYOI:O#:VNH-,X"H1+#5]&!'$1I
MWP%&NQ$HK1<J=X#'#R-OA2"_!.\ @0#K_]MK-<-4BX=9/J46<W \$HW.0!_^
MWZ2P2!BY_KTOTK\5\>>_R7XE[W?RZHZLFN.',9O;U =34K5%=I4\B9O+"DF5
M^6:HL,U8^A+RJ2%B2;-O]N4[6>Z\+SX*-0GB%-E60Y8(72EWW XWN"%AH58Y
MM'/$;E)PFHE4K^XE>&1I6B.!@8PC!=HWT:3QQ2I)=H5#.?)4Y0A"*=?Y6M5-
M7LU3B5V_?P,\;&CI>"AP4'_$0O7FQ(T%DBMK>?A:_#G1M%?<WE MS8$P1&!F
MJQKL_<S7+G[7>82Q>)=!?_2T3NC[B_;E?:K%Q*T75VFEYCEZEY.5Q=9>.+DM
M_N6K\9?@@E8A<+\OYIA6ZH*/(O7K&D) QL8Q+\,!Y;*&R46Z5VE2,97+B283
M!&Y;=M^YD 'S]'J>BCXB>)G\I;XYE!^+EP&A(_]-5&*^EB&-69OD_DR#>((%
MWV_E<71$%N'+?+T&PH\92TC5+Z)!=FO"(E,E,MLTJ447[MR1=P!,7A7L_OAZ
MBI0[0#B8C%6SU/2QR2:#35JVI&.#=(<BS^T$<X<-O^Q7%G>J&V\MDY+B#^,?
M5#D>">'I**5D[-*",:)A3=I56JS%%_L*(U-9P;S.$3Q=#AG7L#6SB^1\>SH6
M\+CW;[)PFJ ".I>PO$^Y1!:#REE-=P#%BV34&-0QVQ_/[P#?92(6+Z![+*7P
M:DSSNJHDND\-'+!/(RDBM""E*B8?EG))TVT1^E$7]M D><6PD.S5UJOQ+OT;
MI08.RDKM-P4S/TQD;\HU,(#T)=&<'6H!E9:YPX9@T.%KX^=$,*]GO:M9MG@7
M%-4S5HCGH]4]H5-*Q,'SX77F5U"U3#X;6H+MT8(<G3Q)]3%706&FV4%/@8[4
MRK%;=*\E;MQ/'\R8C4WKI67I;2V1RR%'8"D:B)-KI7:1M*&N]5GZ4.12_W_P
M]I5Q;7W;MK14< K%O;@7=RC%I4B0( %*<0L.00H4+\%*\" MKL$3'%JTN&MP
M=XI32NGC?\Z]3^ZY]M[OWO=A?<S:V6OO/>98:XXY!Z43@^<1*?3S"'SO7(MJ
MUWB"^\50:]\?C!2=*YG>5KT?%PP58WQ=$QDUMG]YT+.N_JMD4N@4O]:"D,$W
M]O3F;.:DS O8"9E#OU^S;&U[A_Z[<\>_6M+8,RU$5+X@-V$J@>[QV"A>F?"L
M)&1-".*>GN%E2"Q_Y"HMCL!7UT&-.YF='J:_>V-5"@OB+*[WRQHZ/^D$4QEE
MN%Y>L;2=)?0H%P@_N6#I8[,TAO;4U<^D.+(V-:.L5-),<E\N!W:Y?2U>GT+B
MRPR+3!T,:/",)(5,03X4Y=&K56@.KVV;ZL?.<[19@"THGC4NQKD9=H*R[[@D
M8^D63-!]XG'>'E6Y<?F8JHK5C<S@,4-!M$_"T$RRO]V'X4+"I$SE!3J)J:B*
M"R[U@4:;>H.)G \2%#\3EANZ930'37Z/(13UJ]JA=^.48V:"G"Y$*GPK_M "
M+T0$[&9 ,WYD$IQ'N%'%620MGI^+KEJ &0COE$-,O7W!UG'J_CZ#3T>B(E0^
MQ?$%/.9_^M$\5#,6/K\F_X(<YOG 'TSR4ZI[9&.HB3,\KHST()5C4YTPX65R
M>JJ=QUY;W?X0<+KG:'H:\HYGPNGC8^;G1_YZI\VS[_MG&KVAW\[>*_H7#=50
M^W,5-#P4V':ODST-1 I%573 DZK[7"3YGPPS\M?'R5-5:/%[_!2T@/:' A-<
M$.>_FNW)-E?.K!+(K]3\8Z;*#I70FE7^^Y$R<G@I@.:?.IN0JLGD"E!N3?A6
MGL?[/A?GD+[#^DYW4-;V%Z;Q+[6H$YPAJQD(JAQ*?<@)#?1 T^AN'G6/S%$G
M 2FF*L_W!7D1=D9+V_VQ8(/ 9]D4TZ,)6!84M.W^3\7RUT8G$VD5WP4Y#P7A
M/;=#=>PQN5IDMFE_H55YBI#80G?QSK3;MB!CC15$YG34*D^>K"-DE&=>^RM.
MZ#I#^_RS=-#:Z5L1HA-Y]4M4,E:VF)\>@R:.UR>Y5QOT?&+*&I39.^.+\]?&
M&R83O7G&C" 2'3^O4D0XMAU$?OP,(7LL;ULDC$5UT3D[B-]:9_/\,@VT9?Z[
M*H!](T!QN,D!##"T:WM17U,="Y_>6AF(+I'9P=Y[2C/5S&-&/1#=\$97%KQ!
ME)+N'<E6.+$4^7249,84GXH]-[_J'WC)W^Q(D.WS3Y8OWBY=EGD9 !9_?Q89
M"'9&^R2=O_VK&?XL\C^U%3,R[OWH>4@D"!$]QNKORJR^Y8INNLYRM7IE/;&N
M]S24B5AK<QP9CI,XS=Y3X.=YGBC-"CU3=XFZPF7X!?Q,S>K+7_THT+=B0O&$
M-Z.BZ(9Y-@DO[7,$?;CX: F^,8X/U,,[6GBG=&;FL@E<W="<;A$#L9S9-=',
M.^$5<H<')"0HW]8EK;_Z4!+.,;(J7V),<L<*.3=(8^O:OW"UJJZW/GK <.<U
ML9,M,7[A;6C%.KW:,/=BY;.E@92T2EG=&WZAPH/T28 &1&6TN4H/ .OZ\=CM
MIKY+6J9O$ @07OBP@O(NVEZJ#1?7F&<?]WKQV%>P)K>EY59C$N)F[1*O&=2#
M$JJ,$A'E99QD< 1*/=5M#*);0Z;\%2V3W/3R#ST:<M/QQDSD:CH9^ZACRCB^
M,U9Y55+:PP6%% >O,.^,NH<)&P\->X@3:Y3&,RTJ63V%#-(U3D2N&_EF94MF
M!<E>C9<;OM=Z(ML4'C%Y] /E=DU_@LC^:_:0OV*Q-!FTH' /9=S:_ME:HC_K
M9"HP#VE:3F4_EX5=6!'R?[/5*C\T,*X;NZU$NOP^\CXT.>^]GHYU"WRU^^X/
M!OC5I3&:\+%.;C1?UZ3GKGBOA\Y+2GMB,5WFJ.R#2-*6N!K&)C[K=Y^4W<QL
M2QVHP(<QSXQF*8[(J?,Q/'KKC><;IU_>2N;ONF*M<X\1K\FZB^_.C,XHON&<
M2%2Z$82G\.P/'Z7J>2<9<#W]B.3RMS]&<FEQ+MN=DN"168X&ZBO?$6=YOKY<
MMZ2?/9MYU[O]>;K:T*AMV;>V>\+T;AT),UR5.VW*)2CO?9@B3JQ'2%V6L]/O
MCN\6R#!UY"7]1!SQA=[R4^#/>#U7/Z^2EI=!02Z%H6X/*S)(-->TQ9GIL@);
M2UH$]7YF3/_"MLC=<V<IJ+]KH@W7GO)R#&!<M&D@D!<9);%*-.GT*3)HC'-L
M5O<AFV;Z[I'RJO)5N'JI8U_ :IKS4#EO#SB>YD.5;HC/KJ:8/0>O]9>"Z-#H
M33]T]=3\0B_$D;9+(6U#>^"S&KSAMW)7JK%I1<:E#\.<T(-^L!A=)QQ*3^J
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M6FB]V)#(6_K&O<%80TI$] T '\<O^SYL+ZDPA:H'^3!I="]J<]POLN7DY"3
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M$>J_&\V=#WG"N@8@].E8\X'69>.*-&-U[HQ-?)U<>*$J/*MX,2]B!/!>S,L
M=J3_?M_\;7,E>],GZD4]3BW-L!K$Y/LF@H:;\3\8'>+V18L:)?;>OUY*U>/2
MG3+92&U %W(_2X*<Z(:D+VRDJ+JJ-(H,]T0.ZF< L"6U1*J$&;CN&IC=4#7@
M,L0\SH4EX]WJ60RP59;[$"A(4?^1260MYPGVQ<V83^NHL;J-[8*#J(&H@7%
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MQA <P6%.[$HP#]KIK\6L;7A2G9?%? (>1 A\-$<!8,OL?64QU,V"R8ID":,
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M,-!5R%3*_T!^:]^?S\95/PDHT"&J,94Y[-?"[1<R)5/BP.S<>O.@YP^& SJ
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M;D2I_S:!*NZK'CR)RB;=)H7#ZBPC'<+2Q/\S_IR4_\=Q*G=A_]W:-$>4;9P
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ML0G/ WYX"0>L]N%?A&Z[X=6@.*9*'6MCM;OW%WNL]O%X.(#_SY>7U5/ @7"
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MM"TU%R]>T)'BFUWKYK:[&'[S0;7*[::[UMLPAR4TCW,"]GPO@Y8$4\&.;&?
MT.8MX9M@WK0M9P?90\%15$:W9E]:P,AH;CPL(A'XQJ4&SGE+P*7?@<GPU1A*
MN8)S*\SW6.\Q5NU_C/ ^\YPS4XHJO:.FY[E<5W?P#-7K5:W*BA=R/*E9.PJ5
M]X'WEO.4G5L7"QBP>:XQR)D]S/O%SX[ZC-V!^\I<FL"F4/:H9;J;G1-_:57L
M2*D[54L.E:WLJ)IDK([#A(VCW+ROO*GJOH^SF-A$K&#6Q^YO(AI\0>=) +.
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MN/64%A=?MHL*H];4T6%^/+AX.-S-15MO.QO!%1'3?I>PZ'5P:;"RL% C%5=
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M3" C-AWI8=PR ,(2?BDS"ZM<.W?)'-\#.EA6*<2>_2ZPM7[4G,(\R.;G(LD
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MT9& HQY=!0W <O;#I)/-R\2YR6(7G'QS>QFOG)G/3=Z:>%7O#]]^C5H;0D4
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M0'IR^+7-[]4[48G*Z'O ^X/?&1^UUC"C')D *.Z WX^^^4!8_V #F6R^RO[
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M/Q5B -  2J/__]R1_]N4I"Q>0+62<?@(ZJ@LE$<<1^J%Z2" X_]4_W^KE@)
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M]L]ND&T8.PC,;I9C'MJ>]L0G+.LTX:T"EZ5C_](!/0P'D'IV[J!IO\-WCG"
MC8X:#N 5PJ.SI3,^XNT3+%D@4OS,\4[.T8_% 9!#-TB;&=(7&^(K='** [Z.
ME^-=5_$W?2AC>&89X6O*[W$ ?/8TPV>+[O]F-XOO_)21RW$OJLQ$.N18WK\+
MUJZC*0F_YC++9&7>:6Z O(U5AA% )N1QP+V#>P">H_R[97<V#K++.84#)FZ!
M3M.:K[9C%0YG#WHA+V%B*+P ERCAIR'XD/NU9*@4O 3"&Z)IRC$94*%(ITGP
M#RC$1*5>)AWFO,A' U/5OF42[0BE[#%^TN<J(HO)KL&QKFA=N3/-(Z48M040
MA=G&LXWD23NEYQM.UIKM-YF.+I6B^CN/XF=@83*"4:X+Y$G'T&*C+*S$T3Y]
MR3PUF;&7Q.T$ACJ[[?S+OIM?XS[Q9Y9J/)#G\)ZGO-ADY.SO7>@U:U)5+QV-
MY&EB[ N\5,ND35I>T&4<EC5/3;(^*1[O*_NYI- T+[1Z=,KY)2.OX%U";NIU
MS6\8$<3EG"PS,Z,/+*2W/XJ1"!J^AW._>[(8C#)@/BWS=IW;"4=O%_&KLB>_
MKU![.MN1>K4<(EA%T RSE1YHGY:FOF#H%:<S0EGZXC3'T5<0M1(30:%KM<PE
M53+Y:25K$<+6/5\&UJX;KDI7%6UJSARMZ;\(J0L\9.(<@W5&]5BB'(NYI'<:
M]6I#;'8:WP'4%L8="'L<8.VG-[J_6?G>M_GJD.%M#L-+H99@-JPN@5RB>,Z<
M,WOG_.:T]JK6H#N_3>:02>WT-2'0M;S&YR3%+ PQ)9B[U8U('GST=9>5)EUQ
M&W8L?311T95;^'AQA3NR>=%2S.)%)MO0EJ%8!T.*3A_!263?F=4-A3*A$ D7
M-<1*U\3U"T8R-7L%;BY<;*#68/GS&(EQ=P$-M1'19GL%P:*<:;'<88(X4>J&
MU6^16PZ?6UA[&L(C,,[%K:X.KD41"RZ#T7;5$1C[F-EV#28-;YE!/Z61[%@5
MYN3K92%GEZB;)P-EU2-W0>%",'S6=KYZBU ?23160I_10&_7VZ7"%JC2Z7/P
MMY'TSNSNLT,<<'@.6V8.,W<4C"N$3IYA-S16/<T4A5[[9K4\G;PHUQ2YG_;[
M/@./!.W*>I%CVXC1!L4&21A-/!!OMEH<TH"'FK5_ER/*U"[.8B+$\:+0A..
MQ[![[W# 2__:TV<62_R? F1Q0$\P'@D?D$ .[?=+J(^)IR#C/-A;@=>T%.F
M?T A6!T'DU2E5I><&E,ZF%76M[SJE_@J=-8RP366,<\1Y?E!'\OAFW@**]E0
M>9IIHEPX[=U'_*[3;423^$WMAS(*F7<?BC;%T::P%C5QUK9W$C+1/@8/W.<S
M+NVT.\X?/\G!?KSA?0NX3J]\WX=V7-;5&/\<<1[FZE"IV$W5_F8-_5&&WEKC
MJ=EOJ9="#B_ZEUAURI$-^^F/#0\(?,HX*+H\<_A90]!P;\1I_[ \(1)8\1.8
M\Y=H&S8SZY2=/LQQ#Q+;^MYB74JLD-GV_@ 2VF">4SQMSY"669(G-O_IF[%_
M;ZQ47)&%CMDH'4%&UEH:)-PM0K19F("RE(NL646V5[;WH(R%[RTU/Z(6DQ+'
M@.<!51;X)6R"M<WNFLN8X #S0<@?0='_?UC*W[2>Y8 ?!RN0"[/HPZB?=$29
M8%6[HR";DT+KYD6_WL^RMD?G%UB)VEEE:11R"1HM9HJ2^<L]Y#>/!/ L=/X2
MDOJ4M!:"8J;& ?3*&&YS?-S)$M_! 83X?Q9*"K,#)8<792WM2_)!)#/^95DB
M(2>ZX*<TI)]=1B*K\7&3,0*RIH9/\5M[(*AB9;Q0>=2G0;,X0*D,3W/[\<Q/
M<0&$ON"$YP/"(.S5*M$8'9V6U*&36U -1=.27ADG)K1?[ECG[V@+H0,O^2 8
M3T.H]V&Z,'Y4%@[@&@^$?^>$Y/GD_6]+YPA!)DCST/EAEHW)C.:2WCZNVH_M
MZV-EZSY=&65?HYJ%=UD;G[FT7/XFLFZX-;=%!3IO@4H[\#M)S2'K6@N+I=/"
M<,9*&Q#-E]UB59&!+,20T3)$O*PT#A3/?=\54EFXW_.66AZ.G W=;[ZS?M0P
MG2MQSZ/J"0YP.T$'B-4=Z2,G66O3Q&I)F_H,'<G'I?;+J>?Q3$XT%<MN=-KR
MF;7^0%+FI"A??H ++-6[FE5^UO3;-$I'!6&:<IX)U*&L'G_$5MU0XX$#K@*'
ME$+=',QC,&Q[@8-^"B/O32N#Y8KU393>J97Y4!/87M#=8<WQHE6UL7[7XIJL
MPPM4ZGRS<'_KD+VQ^QOQE#0IU2BC!YK1C7=[>C9(>HJ-[[AX]2\T?YK)8QEP
MSEU_R<09H*G"1V'"+A(=">RSLW9(:T0X3OI?QI+7?9F/=DPH^!([JJ&/K VK
MXA^T*7)@J#F2[(V!)G%@H3$NDTL,6!I409Z]]!/5L\9YN<CI=J;)V,' G@DV
M&^A0 <IB?@NLB7 9J[YIZ"Q4G?HH<T'EBQ27MV:.+$!X\);Z3FU=V/;,S2AO
M;4-KS=Y+;&'$=6("WN-MRXZ".YURK%2?'/+L)6LH7-]+G9N#*YA1M( 1KX2;
MM+W"-8QH(]^GABFP*P(NV%\[Z$L42/O]J)PXJGBC:X,_@KLF.C>^YK85\]\+
MG,\&< #//= )(1P;8[SAD PYOHI'L0EV'+!O/Z[SNYO8'+_)2'\-B;^?$2;_
M?;_PAOT];](DBOP';?#*J'8%2 PWJ2W48P2\2R#6:^+"CO!72RH>K7LLB]GH
MM&W1$QQ ABIH0X>'^4EX.SU@T"!.(7O)I:_]=MQXC,&I,W/HW,-G*M'G[9#&
M4ZTJ820YO$5W",%)@+=G2,NE=0Y6A+6Q1L1E<9^N).;:A,&1G9<P\LIQ+OH0
M+&CT.X8\'U7X]9YSV4%.J:H]\>>+CZ68#@C/-1>;R?5YCWD[<B;HK6TQ70.S
M5 0JD3"MX^-/'(O7J@H2$I;2WL+Z9G9#NI+;7-?>E<R:T6:_M:= 1<:"JH6[
M>CNO0991[UTDH6?M%;I! 'CB=I9ZK%F:4N[SI'XR^=U+\0WOE0C $46\M6$K
M7'1([HK,X@VF *5 F?8M_$K0RG$;J>9MIRL-;CT^/QT4DF"D=*9(]BG1[3DH
M\WHFV9<"Q,"+;;D/OGFJE][&:^PL7C,RDO59:-8FMQ5X2#O5SJ85-Q]S*VXH
M538T8[CDF_$'?IA2PO6. #>"=HQ036-]E!F29[EQ*L,)-4"A37$]5&F$VS=R
M-&6^()@W324/L175R\7P^,:NBM3EAK=G @& "J"K(EC$GAUZ(@J)";A2.;QE
M55L;.7D]ONLZH^1G_@G^/HP WJ 7.^$'6XQX#'][)I+OWQ0J(QRP5'0;ST<]
M<<!@B9G:KYW ]O<W8[!\D)Z#.:$3$A ^"OZO9&7TYN@KJ^_J(L<@E^87'\6:
MVEC1?NCV8P$>'185K+L<IQR-C16=KB_K@HJ*Q3,%$<O[;:QFGNIIVD]I!343
M]YEAX"$LR:2YJ7C6HH#^IO$(VW+E15V.&7A?%G*@'1R>R8XH&RL1CW<YHU#E
M5)U:N_22>(;;\RVUQ6<E1?I5*+DHI87R\*3=P7HU)<L*74(7:9<YI[<4^/Y3
M2=CMO[ED?SR'@XFCXA>I:=>D#Z/RO+R??&P(]#O-4V'FF$,:PA$O,4;8E:!C
M,<"7G7X1^I<JZ _<\-3X%5"VQZQV7B@7A-7>/KDWE6XIY]BH>FY],]X /G\1
M57GZB7#7'CB4YN\&_Z4*_F,W/LJ!O/H[6> Q[K*$'0X/68:^W*<LCN^UE$Y<
M<QA>^S]JC7H[VRV=!=^F23Z&,:6I18V^$XFL,$(OYQT<1GDZY,]$\??J/#$@
MDO"V&?]IG^6+-N1+>B%D%G(:XYHIC:H%1\MP>68KSSN</*[CNU.J2A!&G#]K
MOY7>:4$C0^>!2I%7<]90KT4[SQ".IF#DT>-F\_"(3'JD/*E584<*N-/AJ4R]
M+MKR ",BSXAA*,TD'=0;*2&7_'#6,BZYUI:IF_V'"2XV>2(OJ"$4"\\K':4%
MEZ.^+YQ,*>M;8?AWS"['%T+LUY*E7\;U,^HC!RJEINIO6X%C +/LIJ'N!=[(
M:FBU:HX7.TR LS[AF]II%HN3M:2,.*5;0UP4Y)T,ZVD];*(ZJ15@Y7EYM^O6
MT\+<IRIOJ=(B]UZW<#D8NT]'H7+:ANR,'^T_ERSO;.M=KO0?Y&2+'H-'-CE>
MCBG^NN8C]QI=4^N1KUBC<N::2]RBAPR!/+L_?;>71=?P1L.GST%EZQJY#II*
M/#2B06.& T@N*LK'IGYWQL0HE;!@,J\'![X"<K?ICI3F'QJXC&J"FO%)T#W^
M"VV9O.^13J$<!8]A'(;=HL(4,L+433';_$Z!,K_QO%TX.:37"^E\ZJMXRC_Z
M5ZOLE;L,Z55%.)]68_6:#<$7P$MY* GL)#ZAF\D/:8ODR^?\K1V_00AADO&T
M'S(A!=[G@5G"0+^Y4,3WS\K"C-*P\ ?S&9?5-'3B<ZICDHR2/*UXSU14#42D
M"1:43*UG\Y_8"0:))YB9B+I\6TQ\E]FD26RD^(P11+M_TU];%2R(-<Q^;=+O
M35\B2ML[;.<RTS"G ,0JK,N3_Q=<BKMJN-SI4D0_MY9(J14J@OE,J<Z/]X/F
M=F^X78ILK+X0C'PACH2T+2)33DDNX(!%'(!1<S6&156Q.VB&RMC,254%BSQP
M9WW,AX2:!X,S?)4QU^!$D"_]!9#9R3T<$,TA@\BOG$NMRI [I+R'7;A#PPT2
M;R-9E86C]PDV6IB'+8=D;CYZY.@K]ITD5?4%U%52YKG&HO%H\%RZ:CKU6=N:
M6LNHB#(N(X(-*GZ?0,G9%RS^4,Q%:6S6H6W+UT/BN(%)B:W]@3P'%!A*N&9Q
M2!6, Q3+)+K2',<JYCZ9J+^7/Y)@V&*S-Z1(W+9WI&K;[O^ ]LC\SMD4UB5I
M%,9J%4*X]A1/R6;2\<X^0S/D;*':."1XZ>3^^,/.P2C)Q[VL"*G.VPO4M+<7
M637":[NXZ!B-V[P1%2?OA5@U8%)E?#O8JR:&GW+ZLR?,IQ-Z.6"'+^.W>'>8
MD&_B[E6X(X8>H5RLLK_.%([N'R<?DB?(Z3RETIA[I@C8^^G'2LDQ;RK=]WL9
M?GOM0Q"HS!)%DPY[T;#U:4""=MWC;NI2*!_IJ5U:3$%LDRME?GC)VCO;25L\
MH5AVNI/_M."FEOS<>=E-C0XYCG%19X8I%*RMIL+\1@V#9X-O#]>>%<@]*>X6
MWYF"N-2R@(LHXXVIJ.2:IEO*VHT$6,CGZ@!:138(156RO(3J2N_%[8_63Q*/
M]<P(;X\?S#*#Z%#9G_F):FL='"AE><Z_HCR:3A\9\X!:+3H3L&YQ*0Y:CE6E
M/O8N?>20=<%D6^IJ:ZR\W"L"W_F%4H[KR.4J,'([+4$ZZ(O(99.#8@D(_<&4
M;^^<1OAD4PE;]'-%JW!@D6MYQPP<Z"?D/M_,XC%28'3@>&N^?,=:H[$9'N)+
MMK%&V(%EWI1@6>W$^[2%Z7JBW>XG^]"R%;"P9=  89GO(V^+4/A2DU<MMCD;
MF[3QZB^T? GZ2_0H!;V [FIC6'& (R3)6>?6 T4Z'9K?,OG/7HQ85<@+\'<V
M*/K\^#N#.-2OZKJO_B9_M^BD/N9H(L*[.R$>R_A_'5A_GPN9('>P=U@A)R3X
MU++2(,\0TB,WA:T7VJ5?@7/@,TZ%6ASP+@1\(N:C%XX)WH)O)N" B_(,O\2R
M1;DK)M6SSWE"']IYFK:2%7Y6?BVBY37S-68U>))/Y?K&BS[8-[.0@#.->+CL
M%#/9=&34@:>W2Z"KDXN/ZOU9?!\BODDY&3Z5)RYW-1]P&I*MTKCZ)/XE@\7M
M6$7)[&0*72=V*JF"_WR<UJU^EJ/4+/3D2'5)SE*CF>_#L7+]NH'M6^J,J@L(
MB*9'S9@;J>C-?4DOP=44YL,GXP9.L^>:>#A''$W41;KW+E(-R_D'\:;M^UNT
M-5 U@1<<<HVF,S]=DW^'YJA.LD'T?]"_0/H6L1R+>$:>CX',&KTEPQ(C\:AT
M^<B@:U:IJ7IXGK"G\;6EVF:WTTSUI,ZE2$DKPX48+<; XNM$<G\;W/^O!2O8
MXAX=RI><($%H0?)@OCBOME.#OMN!3*@]0R')2I-U8./&^+;>0!Q\5^/MGXU-
M'XHGSE,6/Q%GXA1(VQC2YO2"_VTL#L#'/+K?U.DW=36)\7;YKU8_M8HSPSQ$
M\H3FIAA J)T?/+]1O^0;383W91X?F[#J^ 4ARG5T:TBKT$4CO_=3-:LUOF,2
M> 2YW+!SZLL":0<?7\[$MX7QX8 DP-WM#[X3IM?1<W@UY,SR\8+;N_H( BB4
M&%1F4B@DF%/Q/G/;]/BITI#X8&*@L"UA*,H1>0G$."6745A8/5ZF]'5KPE$H
MEIP/:U6M@TI"JH,I)0XYPN".R+/X)%XI^&E(9NJ!W.C2+(V?W3R[JV94AQRS
MO[(:DN(^]>N*LT:^UB^]Y$XW(.$!(@C>4/9J1SUW/,+2W%=5>8H(HTT<=]*P
M\ '0$NTXP D'A/AJ8(>F#W<N4IPT['1+E5TMRK>GV6AX5)/EQ'3;A2E>@H*-
M-CZM]N_L&,T['PMQX%DZS!:>YY/WOQWTC9!'6)5]T)^SQV$\T+,Z_$R2]BS^
MKB,2I?V.ITN!\$"AYCZ+/A3% 6&07349?"IJKH6?"YO_NHD9:-4_'[C?4%]/
M\#:,P9N F4B>>[1X8-P-!VPY$FH.!WUHJ$F@@<QH@\N IU!*0?QUUC4#Z8R=
M4-$IP]!VGD:!]P_O8!IB7PU$"A$'-TF=*\I%6=RK4ZS3<MMY N6&W/>4L:EV
M!9&U7+3+/#_\&!$>:8W]U%B1VJ9R-2.6=#VS>_]2'JH$*71W?%]DWH)2];3
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M&X0B \)_'<>1&F$UTF7A7=3GIS;0D;/F/,7>E2%330DW.GW-?G$PLV/@^$H
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M/NCQ;",OB-*PD_%*MVIE;49#+]W5LN,@?>>J$P'UB:E9XW974JFOPN>8T2S
MGDG)E 7(3Z,B2N6EF5V:6&[7PC97@\BUMT2:TZ1,6RJ(DTZT1IB?!#A<1M&7
M*AV2H\K])$60II_Y85\OM/FEKT&>H5V-M!G\ZW<!SNIPJ:]D1,R8J^2GA,JC
MO$8[^XVJJ3JAW@_TN9#XT+036C$0(*.P8/?6Z^$8[&/-YJ7YZ*OB)5:S:-TC
M$+$?K;NK0$>#TCK/LVV_L:7$Q)G&5XHQ]+2WLJ.)" $R=\!KO'V:6N.+G(@7
M5&/8<M?Q;76T4BHO\P>Q[]6_.9SYU["3X'<??R-E;O;$ 5/B\R[@%]ZB1AI*
MIW5?X;>!2FK.XE@ RXT#WCV#K*F:?S '_^:"MN8O#5S?HZ)8-<\DM\(NI78Y
MW4Y54;M_VY.VTW90G@V&N2P!W>=SP %'&T)8P3C4?6?PFB8^W.R,6&#,W'4U
MB5G!<3.3*S,SSN0.10+M]"_N:V&6**"+)2#$ZQG(ERP8#I@MA*,:/"/P=,\>
M 3_U4\4!;PVT_DW7978S//7PEMA)#2K[P\CCC^.D3(KH^=Y3_K>_LXE>^7<8
M-?T*_._X[%MRT=_94W.!,$"67F]"#KK1D16(;JQ*2CA\LQ><9/!WW;60L/2_
MZZ#G;PX]P7YS6.:OFB?^,K,8#4:*8.]9!$.V8+ME&[;W\8#W\-]L0P[@T_5>
M9R3O:7 B#KAE?$B&3\1_>RGA^=\Z9&71 =D5\[+ MO#@$W[^PO(?=5'47^I_
M\YC/KSJPZ3:GCNK"@LRNFM16DTO?Y]:=/G+MDMTSHZ,EX8SE5"')4I!KR_W]
M0WW",EIONQ><*6=M=S]^*1OQE>EDONKO,@.=_\0 ID)YM"M'ZJ=>FS<,B;YN
MPKZI_9\["O[K4L<*?R&B6F1A@H*TUS9\9*"RJJ\/2M*\OE$";5($/$?TE<.:
ME!\LE)T7T-%X?$/JZMHB)6ML<7L%/>R?@GU[QW6=JFH-^PD4U*1#9-^\G^5V
MY*;2G0M>-[7!<'%PX=/N'4,<T#* &M=#;F(5_7FQ;5K#)<9:ZD>2%>XVY^J-
M>O$,Z\8"&,UQ$'?R'0?$@!#17G'8\&8K[ EXT>P1/:PRSBIN4\SW#?37_?WX
MJ89NO-NO^8Z!=RJQ8F-:RI5QENA/YJOL0L$'O?F11GZ.Q4TO$ZP>/[QW89P-
MJ?V;<=Q?:7U?G)"K-*C_'0GH?"4/J4M'MY]!?GE=^3?:&2ER?)8-_B%G;3A5
M<S9&^XOH"?3\AG1H]=#=';9=]B;"*9EQN$%H 2;9F0PRS@PI\\US_<3#SS6<
MQ7O5[EUVY%6UOWK&U?R<P@]Y1F+3 ZG+5X!CEQ3PRY5 @4'3 0QO ^\I&#)'
M!\>H@1"9:]#]4QP0B%<-*4HPK&5:BL\'P4Y!*PG;8M?H&"M?GM%0./(9@2(R
M;3-39E%$0CC@@CR[&/U'O,*^V9#A(RP!'BX[1I*Q8H/;Y5;/P34[\<_+-Z7P
MJ0R,CF#P'_U] 0/M^/FA[:6XG5S!_@-@G L12;* LLOK"71^TW^M;/I-SU?>
M74)$^==!ZYCX,+V@L[X&*797%JG#D3.V'G(<_LYJ>YEJ<EX%NKNCL1Z2<B%I
M !RQI3_>F7FS,CS*MEHLGLZ-8KT>;ESDCDQF->G=&@AU[[YQM[?>DEN<2EAR
MW8RZ?8?2?(U%;_ISZ1JZIN#9N*>O-#]'A.Q3_O+6_;?4F:+.H)8,)*\)DBZ3
M98R%'*5U_J*3I^"-WH5&,,KL)>1+'@PR)X4#R YDJ!54@];QWH@#R-]3H^FJ
M=S#$X'EEC& />$U['(Y@PP&A/OG$>4P<KPB6(8A&3KS9J)KC@%97+!VD[7LP
M-E3 %P<0#* ,BBU]M/ ]@:2]:KM%O(([&ZC*G.?+'DM6;6$?-C<^JO5Q,88@
MWJ=C0_T=?GZ@Z><'.*CQ0U^!KQF,_3P:Z&\T4E^HF,,!O[RA]>N'?+M^$M'T
MFA]6CO^6<PS>WQI@F8R>*<L8U,'4.+T5ED$'\@56]K/6:W@M$A/K\3'_'AY4
M#J*I[PDRR(!^U00\_TCBE P]CB6$(F!>K?LYA$-1H7'$^*%>S>[S;UJ@J"!X
MWFZDA@\,+?B4-G 5PS]S79:O=3][WFI5B HUZ<BZP%"RP-PD5BK;O%S<&E_6
MZ'26YIG78?DJEM$:M'_%8?9'%\TZA$/XX6_+P'YY->[7:W2?^AZ^:\(^'##O
M@8_9MY*;?QJ0#R_,5^)3,N.CGX34_4G(0#E/5.)BKY]-SE>CKR@'H]"Y1I6)
M7J<)3H\Y'?B\3 HV-,,*/X%3&/ZU)S^ZO9HCP1Y=K!6JZ@J2@;1Y"YV22W=C
M"6M_S"_I$GS_VB8(134[;W%[[L<RZ&U9/SJX9Q:7"?YE3S^^N+YK@69PC\,0
M.R-@68@?TY SV2-7I%JQ%PT_ST >\3:Q'9VF*D020TLQJS!3^LN!#*P6OT/:
MIA&@4W>? U/J>[*EX7]\" O=O(GC1>R%7LB:T1@8P?YC+T4#'W:S;/#(UNJ!
MGSPTZ*<)EBT-WGC5"!(1BMPVZ&X0;/*3*CG-[))0UJBL69E>[_01^AL&GT0Y
M/9U!\SS$6^N/&/[=G#^V/C+@+A"#8#6,W'P=;1".4;#Q%0YBVR2_<ONE3ZQ#
M_Q .Z&QD]-^)JK5Z(UHWL&IA^5/G:C=I^?;<*W:)IWYL8X!;\&#8DH<#6)1;
MD'86R2>=K2>ID*Z6UI]&@$K$R_6??$1M;K4(XP H#J#'IY<6R)Q?5V$53W_,
M81[DXHD$YB,*KC4BH_22]S L:^$B;?R]T[<]YY##S++VLU-^UMXGD,C/D$T8
M:KP.X]Z*^(Q/AA[<A9?Y^->!'D?%S8'ZHHZ)N;8'XK!3BT+'>#2WP"KB1=/R
M762+GD7!.&:<4>,3KSE>X16!<!XZ'Z?^&RWD9A?@QZ=(R.F!$&I\'/6CJ<[*
M+N]7B#>4R]#!7*!B[)K@QYFKF20VRFE7*'*E"1-NF/?_":\.?L(K\Z*@=27B
MO,O;=DR[)::[\%_Y#_A7J\(_^I.;YOZA197GT T0;R/H#JE>\*6NA"**9Q%-
M>(FSN$QQ !QR:G_P_6?7[(',>^.CT2TE/*8$X #T2&^ E.FQT!**RWCOJ8=S
M]*)L9?>]0[:?&W_ VXFW5R4VQ Y^!8)* _]<,?JI<A3]<YO6%=3>@J^ML1V&
M#GFGJ;+^)<$!CYT5:F<A-<?H$N)^'"M%B=!K!8YN1Q]P9S1UF/0J:+<='3F,
MX ,AGMN^@?2_@?0%RN1@&5.BP&N*Z;LI..#%GVI*/]?^A&F!,D$!4AKOG!%*
MM8UL"R+16%WX']-PU-KO23@;2M5\X-07;]QZ?^KMOPW&?MU3LW#;FH7=X=%#
MB0@UEMZ*+N9G(L$[^OC>?C>Y_J.%+/C^.Y;XD= W9_;SVUW>.?.O9]:5N!G<
M*/-ZOJ.!S S*[:A(QYN&Q*=K4JQ*2GR$!?\^59ESIV9#19H]1G>WMU#7P\,Z
M#]5<7*X'F56\X72"&P-;@J)3K"5U@ML"%Y,7OJTPFQ'88L.KC<M-;B-G4DM0
M]Q8[+O!_5;1K=EI(W[FU?O0*/7X#;^^WS:/4+6A,O<2],*(=$I,M7_+U(MZ0
M4N!3_$#96Y%A0]OD)Y).6];G%82)8\9SKC"?R_]W5.87ZC ^@(:YL3:;'Q]^
M< JMF!YXQ+&$E&> 54VQJW-'8H=87P\&%_<%!3[X$GU4(@\ A("^1GBU:IE)
M^V%#TFG<!$\F^'KK0%UVII(ZL?TB:$&NN5!V>35<YC(Z.<;V>XS;.#FK:NW_
MU\YWQL.Y=OV.(**7Z Q)"!(M>C=D;WUK$6V4%-U@(GHOB=[92!!$"6+$5D;O
MHZ2H@QEFM!DE2C CRH2)'/OYLO=^SKO?+^_SGO<\YW<^K&_KOG]KK>NZU_K_
MKW7=:]_+XL,0(-28(Q>W&#DQB 'VU#XVS;FS;A>O"[Q_]@S<_/<HRQZ=IFZU
MQ#(-V\=\VE4\6!R!RM%@U\4%>Z>+K!(2 ^;40;C.15?+98YF$:WVX:]S;@OX
M:.E%C-VRG09\@76"ZADS?TJ[35BR/XN.]R5M*@B_>5IUXAWV4 H;S2M$9T=Y
MPB#OH%E$T?O1#%IO+#<_:[%X\<56?%;OJ5I<"\4MTT5Y:E<M\KD6[M9P;E *
MX^( H4".==0RF_JC$)CCUIU@^HBC[')[G>^5W'/<+B'J_!F&AT"V?;,>Y*.V
M6?G]+SLCXV=0>8.F8LU'_?AH^?\ZV?K?13R95%7G&4H3BSG3?Z$3+/4ZC9:'
MQB]:^W2C$[S6(^1N?7Z=T&&S-261D_(I)+")^IN5ELW:&1U@3=T<E*X.A%3M
M0.JE7M]<V(+ZNLA3/-;-B;;@)W@>EY[?(OC4OEY:"HX[,H*<P>&=+=D<EG<1
ML<_]^_$=THF\P//>\CGL%A&6K5.MK1;_L$W'*V=,.MU?[?M3(-#+R5H1DVK-
MYA(](&TQ!GAL[QEYC9B1>N3 I3?S ] HW\T/"U*2&1:PK7Q4)!4,H!O,_C0(
M=ALJ89C;X<W>MHH1";-KXC;0W*-K45;^ @G<_YDH&!?N5 -9XF],N-\PV]*]
MF#)ZPS]7E[*<-9454SU40<+:$H]S\0YV)BW-C4T&5FK<54Q;N=MC?<+%REM:
M' $@?L@YS<P1(Z4%8\V2(Q##CM/Z2L_O%>Z/,04?1C%B/ /!C##PV#Y6 =A9
ME0]@'*GF_J)J?;F723K<]G+M6Q+\.>_8E/CCWWIP564E.1Y DQ"%.9)"U]T.
MAL!SD3@NLU81(7D?;I/R<N)DUHX6\&^/&?TB93J)#F^*TW#&FLB#E;VOU(.%
M@:E/[CL[H_5#@+Z./JT@MG"-Z@=VC(K+@X$YAA,>3WTX+R<*)". --_D*0;U
MCVL)H/OIMZ287HN\J:V5V&K(L\J$<@LBTG-WE5"HSP/6G-C[V(BX' ]^[_F,
M=?O #,+>WN=^S/>21!^A\VET)20E/MKET5--LYZV/M@W(5)^ *X?IXBLN_$T
M=O;HM3_=BPY.VM0]\7TM(-> K8!I/%CJP&0NN0:T2(7O!$],-B?*,])],F@1
M1D#8!BN.E/?!?T^1K-.#O^R<RY%BH+A=NB64G0.?RRP:RYT(_NEC//;#2&48
M,&2CIIR4CRA6Z"9R)7A=FY4,$)OR^5+\Z&IM=9_+8QF2&75P^(,ZC?K$<!6\
M.'V8ABO6. ]/*\G_HBKC$8_]P16%;L)'L7(2]'5B'\).7%$M!]5(!N&ZH59$
MX_VD+@MOZD(C=Z\ZV/6<T8-54'!3D$B3_,X# 9*<:1OA.+_<;KLE>>R8?J.#
M]9O8(N4[E>&(:DHCG/7>+EG/IV3[!DJ$-1VA+"J8%LKA5WR%,$VR0_C.F]XI
M/M#SV'.AC,\=MQ.8G9K\VVX8:#6-&W).-]N\X++>ZB385#_:6\VQ<1K?=BY.
ML(YMONFUX-DJEO^3^O.$_ D\S;KCN-:U9^\5UB,924$UF[UL"D"K$P]D*1NC
M0M"S#)E6): NJ X@IS,C1  EA7M7: JUZ$?!O6F\.! 4A]<AY23+RI97*T8&
MKO;VRW)+OYC>&_>;F'QH)3HD2.%9+(:23]GE\VQAK"-*<=WA9%RN#SWLM&%#
MH?B"A]F$KY3/,9C14.(RODD4R_\ O%,L.:4.!?J>"L14VX;K$16;U U;K*>P
M,"9NMB$NQBQ,)]V_/(?]OR3BXUTNQ)2?":X=_BFU=C5[K)3MJ0 N#1H-R!1$
MR8RPEU1K(CKCG\+7'KO+9NJ3WA?J_/M%:9+[/M,/P*34V5<P"%?>I?8#H-6Y
M/P9!1N%H"?7?Z4/USBE&?H>G5W$7#.@P@TR901:C'.O]0]7]!R ^G;#__=)^
MKT*]P055$AWH/93<$B31"/[.XZZ8QD5MVB%!!"80H919\4_*Y>>\:HC>0_H>
M,JI;])REA.["C-:*J!7^*)P>^;KF!5-X#=6_0,?*/P #T>K8/[0S_F3S80GI
M;KCX!9Y;RKK <[[_8/#/2=;G<=U"/P"__VQ#!_@*_3?Q4;:+EBAD2#Q83+GB
M<ST/2XTTGQ%XSNJ0>V^Z.4)./VW:>'K7:VK<P1MG@Q"TB!ES^ -/%>P)I;WJ
MV8XU5DT&$,]Z,8*(/+2?5D? 8:R2>"_ 36"6F2P?E!"UR17QK2[4OH>),'K0
MU4@*,PSAWW.%Z'\0G2FR^&LL*#:6"5-+P!^ 4H>3C>8HA%YPT'E,T'(!NN+"
MT#^'Z:^Q,*,I_$-WZ@> $8A;/J5>CH0XYOPU2N5_C866@/>?E/7^9*SI/T<I
MXY_7&Q#2^H>^X!]6P[= _[030/_?Q?^#+CHDQ&B*;&EJ%NS1TX<EBK18!MIJ
M]5L,:W,T_?4EM:>!*97NN.&7;S"V29H_ /,XFY.()RJE]#-_N:YO,?,0Z=_Y
MZN[GH"PH3]9Q:A%=J[&_+6O6C.P=A#A#[ 6U&V'>Y</U#3+*DE,)D6#3/R>)
MG)5ZNIP<7+?PA0,F_]Y)XM\H$2H]P"@AXJ*]9<D,!Y&.XF@OZ(T9B8==SS3O
M;PH;(VBH7!L38KLDK@@A"O2%,B-'!$E6^+=E<99TI0\!=P"EU/^JMMVO2'4+
M/]_5,2>$-4'GJMUP/F=Z^VB# *WFRC0Y!%]%*([.5YRL.#F1JX3#)(O4&HX/
M>13&R?J,N&76X*#AS)J#71_JRCTUA"@/Z"=S3]FJ9$T)Q/O\7PAC-9WA_+7C
MB'5R@CS%5N"&A3=KD=B+TB6N4B^_C.'VJ$35V>.X<IL%&T.A; ?=I<O";F(3
ML:#;7S5 0[S0I/(22W2X7:VM_0?QE# [[INLV%)E1TM]IX4IV ZF*C&2??CF
MRZ53M'T\AJ\J\?4+&CYAC-;1=S'*)?';1F.VX<:,91YO,49:CD;+\B[.$_2M
M]:N.87A)(4O"_5#';B@>J+N]LJ3#N&;-YI/^\#,-/59@MONMYXE5"8?$PZ]K
M9RQ(T;9@[6^VOZ9'-E,LH&_B(SS/3(AN<5^\*^FA$4^V5%?5HNV3U\,E*SR7
M6?Q-209P4Q9/3E?B(FP75C&7J<L=-W&2P;]1MQ,8%!J5%$X!B0A'HV7L/]8_
M?<_^X2#@FAG-&W-'(5_\)V964H;U.98H4/EF?GX!#J^K?'[/K[6VZ791T?&[
M>EQ)XKL \5=.AMG'JV;PQBSCRD-",U382Y4_)ILY%'"H^G?]QJ\EW)KUU>$Z
M4_Y\0)^=7UK;FPML>1=N"=>;E'7S=K4.=UA 'G!V:3CGGRC>A+E!5>=CVT:\
M)B]];QV,I",.QU4N[8S!MC!=:4S8YY9Y(I378X Z^@7YB9'7(:T$=TSAEH#@
M;R_ZT&:E<O;O5>,F '38J7-^CP*KNN_U"NO'Y34WV)/Q!PX;$ADX( 6LY-F)
M#-;]M#A.9KYZ[L'89]T%&8;!^!,J,^HV=3Z\MZ YO U)=@CP\Q$6]&B9N:_:
M&(31NX:R'G+P&^QP[,9MJJNHT;I\=<Y>\']QC:J&+&= !.EV(/VQ&:SS.Y@*
M"[X7T3&N@UJ<@.C;Z*0/T*1(RL=/#4<OOKUH,YI'."CK/*D><8RI>_G-F3M;
M#J4D&&+:IO",T&O=BPK7B-!\_?2$;:3&_F?8][OB#YD'?H,K%^+RT^*;?*X0
M4$UB1IL)BRU%AYFAE$MOR1JS< VUOJ!6L%0J9K01HB3T,3T@A<YNW_FHE*D7
M'U@55D[6G)4^/(MO[4BB,.!Z>R N]:E?]6@V#HX(/K&URKOY]))>_S5!PU'B
M4AUL>YDV7%NDH50SXP8U+=^"1.>PGHIC;GE5N-)5C\"G40/F]5*;++MVQ30?
ME?G-J#255,=2SYDFZQ3.W@L<;-7M2;-+O[Q&7U0L4U"P/W"N,H6#=/,-(;=E
M=;Y&Y)C%!7[:5A);F5:'TLQW61*.F676#HXN=2ZL%[(>:1YM6@<%'BLV.CC\
MDMG/FQ?D%PTH9>(53#I.(QRL#C[%RCI@E>;7&\^O^Q91D8VMILDW\;TL8)'R
M^N"WQ\,A(R_R @$WM)BU#'A$NDXA82D3EW9Z;L9C3+]\"]?A.!5[T'N)7\YI
MNCOL_%6$=XT'ZB0O&Y9IS.WOHD+%JL5/7=R 9Z8FO1OYB<CX W#\)K>FP4CM
MV+A13_1$D)__6"'(:DK= 2_-83^,J< HQERBH 3+OO01;->,MA1,FAZIAA1S
M3$K:19:>)MOGFH"5IVL%M<&1"L2T\1)?YH0N%98N(G!ET&/6&]V5L4D-,"<4
M5^*O'$'92. (0XV[GTUT($;S.6<[F8U.;;"Z*'TB-(XL[H>'E/!,2%6ZE]E*
M?I2>+REINRSG$/6<+.>QDL86 H4^1^>TED1%R3F-^LVL'5+"_:+8U#D[6DHN
MGO-VC4 UI%3ONN1$5!1>?F*]S$ZQ"=;8V09+YAYFO5C"4V5E_@#0"BG7PK-P
MWC8[Q1S3"KK/[_K4(7_BWJQ(CX7_AV,T_I&1\XG[B?M=MW 3NREJ]]O2:7-V
MQ>;?)Q;)<.^)E\$[D@_&^:IMY"VN^3\,C96]#;0V>6:-]#G<R5VD'C6^FO%8
MIN# 06CH1("'9%Z[A6:PLY[:\)9EGQ@='6'-(O%?H)Y%DM$0EZ;H#+S%1LA!
M=OSS%Q0R=>_7^B7-%V,! ?@.^-H2-6$YCBP*/-NJCV1H/9D:=,ZZ+(O5HEK+
M29V6)!M 7D-.?PH.&N1MJ:4>^M@?YA9&]=P+^LT=]O&.=BFS%B$0'E'KV2,6
MNV=&G-MV70)<5GPSI$S^\"[!LO@8:]A>: +GLD[BN=,WSJX6R*,A_E%=#?=I
MF84T,NR.Z5[/>RGPQC3?_8S7P##=**"/&P_;"NUI<,,Q\WL$J::BKVYF=UFA
M?:)"FMR%1&?,:*JWD(NF57:?PGPD]XH5/!XQM@DY914?27RY1\L3^C;[]W)B
M 49)P]0%<3OT)_#VV14V^R4F!R=+ZI:S(M1YR0JVCNEPT8Z48EZ,_N"K )^F
MI4K@9S$U!.3C>N 1>&8J6T_5U%BCE[Q:HY?E$AZ"M!U<@ET+\84E#&3VJ;@B
M/ 9_>F#D^]2L-_N-U0).3S@&4]9+9'P3X\U9B5OFV 'G5;(GNL([6W^M1&93
M,IE1*V]$:^"3TY?,?;W9^UB$M>8T&F\;_DMI[D>B2!)S(EDEJL(T+=^L\3)H
M8#%CY0FDF 1=*<RX0GH:YG O^!V<OH;>_F.JS9UA=N?H8 ZL^04VA> R^(+-
M%FR"'W_6[T"Z9%7$! #P1H]'A!E[@UW?;4<RH>&@*UNG 1NUC!OE3*\Y%J;?
M=U[U[,&_!6BH,J!#= !^D4J$[^@D>1LOV%J\"MO>K0^_9BJ6.Q_2%"3O(Y24
M0"P21TA"H9C_-TGAU)RN)I9@[F&9?0?C"Q@>Z,A%''F&+S$BP%$Y >5=J<<[
MU5!;R2#^3$5"7V!=2)=XW>)R\+V],_/6CC;D>HCTS=L6HQ(R!]7<J\L<F"DM
M@3!07)<%;O'I^=F W%:3[;9LR/2\)U]TNN.7U)Z>W"F2M2GZ2YV/,)&SDG%]
M[0#*BAUI$:,YL5;/.JH[_7MT!(/4,V(6@]^-#$I+#&R/<\6QL/Z6L%,L5S!_
M46+7R#^M,,HYS.18QN/W?YF][WWFDO(E4"!M#FVK WA"@PM=_L1*I$D*B'#D
M+E+%?KJF_P%(2Z="WBF?"9=VJ]XYU:T7;A+&..[?9$FK:W/:6%5HUP'<FSVL
M-88:MD]#R]BP]M?U+,@CW:[!2@.<FK23O8W^WZKRF!4J%U6H&Q?;*)$==&*4
M0H-+@BU$TX2]YK /-]/IHRG5?[[,_SGUF?U N%RQ,DJ>6)]DR7JWFHNVCY_B
M1+RG+%IYUPEWR(MZ56&W  &7V7OX.,<3A1^HO$AUSNY%UD0-5$_[5%JA%.K<
MK)+T-8T7)]XOFY6Z=FZ+76KT./:H2J%N2013'9 S>Z667@SY7I 3Y+ !30+9
MH';S&"GC!*&**;<_PES!=YZ*4;X@H&/\ZQD=C,,S?,-J)@9;T1D]5@(O-VF0
M#2(D<\^E:S,*M0]8(59!0>..%E35((K<<?')ZE(F0T3?$X1+A$O-CNJ;!H\0
MKEQAI8-:@(8NH!_F0M+Q],XW*1D,73B5S4I3V1"PI209#.O7ZY9%WVAIB1]'
MB4."4<J/S1*3E<U4Z?+^$^!;KXC2Y-:L(6I.#][%7Z^,MWWG;:"2[2QX?5AF
M,_2XWJ L6L64AV2X^D"1-SX_N 4\7G@]&^7F\'Z>6VQU<A:H9$J*"8-A3.N6
MMQ05%<?:5Z9S7[UCDHF74A8TW',O97(;Z!'HG#R29K5?^$ O4EG-5_VS<_9;
M2UT^H7J!HXP+(J!;N4::5S_SVFGD:OE6N,;G^Y4X@BO8O_#_JA5!X3LJH;2G
M)(+C76=96:+(M6:3P.B/B\=%EFDWL".MH?DOZ^T].%L,^$3GOSQ3>9FX;10Q
M=?AN/!GPM= T'LU,6)I H(,:^FMLQ]&*)X'?7-*-UW\]N*RG/I/E4<*VO]X"
MGU&0Y!U&W>)XT]ZHY_$&<(A@8#BIOUL6?4$KQMW_)T_IQL7JQ:;D@T@OHVH]
M.Y;*PULX3[+!8!NLR>.?KSRQ;9A-*F5Z&6"W3[++J(QXW=/__5>1@S#H<NJY
MY=Q&US.M::EP22+$/#9"=]6LM74JM67WR5F%/L+MD<;I_24N0@TIIOR"(1KA
M&>WN>>P#"S!\D+PDR4PV=C'@>3/%CKR;PFH4E.@4;#%4S-/8U=8STQR6B$]>
M9]ZOB&D7 BU3IB))-_81+6!<!,@*+5%?WNS:-G5T8V3BH5R;S_[(/\9F??Y^
M^WQB*+!QQU$H?RC'T;Z3S[=*YW:_5S0NT'NEQ,(QEX"P1"D(,AESPCE6"I"X
MU\EA;;\\-68Y@VGOI[^)E@@^&[3&2)6XN913J0Y7/6E!=<;?_;PO(Q!M;7DE
MZV'J+]O(.(IY70KEM1A[Q1:J'P#N+B7^\EN,10?#S"<=;@<P^4E7HO60X-6Y
M9<^"6 _.3_1\-E(\E.T/S-\+#$1KN*F[)A/K&8,-(YP>H+LT:G8**C!2&7>,
M;#C7:H&K(#DF&Z:!JNDNG9I@BWX!F40'HQ"1I*>/FO)6]A_6I75FA+M&:X2I
MXY._TIO&NWK3*AB0=6I;>H4UH[!66[&U64546ZV8:E+08"O&NM\ ^L['<<<B
MI+(E;K&5*[?H[>JW2<HN[55OG[V)02Z,RP!V*P\<UYT+J^Z5S^BB-0E+]W5L
MKA*K.+7.(?7JF-*3.> -&$=]M];LQ^42!SR4,B?"&V\(KQ:7!^L\X-C:>4GY
M.D4GCIY<]CC[MG.5AE,ZP)$ZODG]YP!MW,[QE*/"3!XGQ._&G@.BR&FY,F0\
MK1(TN.AD.P-_I7NJH8K<W964D*R2N1VW/99NH !Z_D7Z4#I%-3Y-L2$DRDF@
M(-M.<K RU=/N]9$0&AFM9GJ9]#RX?  %?NV0H[I;#-K35W[T#77T!,30%_^
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MNVO=0;5-X1H+F!WXTB&2VX W*K)!:O!L$JK "2)?V5*N*4#Y'_EPDE6\T'F
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MS1F0"\J)!V)&&$6N+_F3BPLV>6_M5>%-U=1C2RZVY.(IY*)8T*F'L!%E<2&
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M^^K/8K'7D=OI]E2O;.EQ]:%=QCH[(YT"G__*?$]-M9\+K9\[P8=;@P)UI;\
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M^7!F>O>-@C\+9-JU/L#)8$#P#H87&QU<'R/<I\):+#BFRJ[3(L]PU%U]-7B
M;<F5.[J2WC"LH0#AP&P2[E27W(%_ZSHO>GFHV(_SLDSC.E^V8S77SD,M?UB
M95^8<=?Z%PB71M[#@C6R4R"EJ78@<S'I%"2ZP3H'NK2+F <;_8,!AQM.4L3
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M!RT+9N=_E4D##O.16?@XI/&*,H=(&>)6E K):E"87F#O_Z,_GNV@LO>X5/9
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MF=T[P.:9RT8SK.4UI[@VTOB^,PU\VL-ZX4Q*KW%$VP8>#XOY'B95UBK%4SN
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M/T.Q31N)@88FN2!96)T9X>5_\>KB[\_>G0M/NB1@A<&1+EPSQH-%'"RB#]5
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M50%OBM[E;@)=KG))>C/R'CB>-9!?>J4E[RDUV/IPZ,1*$R239_9&&3D=].H
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M>S<D6V64\H]<T\4B0&5?DB7/)E51NN,<QP8?,WQ*DS=8E-'2K5&&P/HR)AR
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MF7#O 6;1,DM%:'S6Y1GPV\#25FF,]A!HH*!4&$\JWH>X?]&%[?-JF3P Y+\
MFW<"S!Y4D3A\-I^5MY=W[AR=KFBKCA;4&B:SP,-MZLH,6([K:8)X>*@XNI7L
MC;J5"9N79T^?>E9Q^Q'L=LLT^_L;7;O]NUV[<1]<NZ&%Z>O[2A>MK<-.J[&2
M"DYIFL<'X+#VR%_EDWA[=JI?N+4.5)HZ$JI6V\KL=K@63U[\_..N0."0%E#/
M^7;7>\5"9NC']MWN>'"W-[;6,6F27QIR[7.F(\KT#+<[HQCO)4%SG]:?-I9M
ML]7.MGZW,"&Q+9P(A4<HZCS<'&/D+, 'Q61W)<U2MK2=CJQ.2 LGXX[GC+E
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M'9:#63]\*@>R-U(K^)X*2 !#(HP=<Q#[V,&++SR&PTF43A? 5VECDT7;PXU
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MKZ*B=,&PR88[K\Z$\6QDPH#,#3F&< ?S>![/N#F\BDSRFJR?IE?9A4S"#\Z
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M$>S;%[O$TQ;,G'4EG<3B,^M<*&Y6&G$<C.>#7XZO0=7TFI@"6WA\8>_2I1#
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M(MA!!'GFV<<LLZ:)8LOV9A(>*M.>D>H,8%\<9,8GJ@WT"DHO8UU*KB;H <1
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MR/WIR<DTK%9&N9WU'FOPE?"=M39L^>!7)MID+^&U(L[&$7)+\7N1ADFT62-
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M[5!S4TXV^&\D')(T!^5!=G;2L^)K;*"]<YS0V+V;!^'@EP].,2M0AY(FNS1
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M"$V8-NJ)EX1F6KL)R8V.W,*)-@J?/*\OY [_%:3(HGW?SILM/W3/*O"FDQ?
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M-1\9L2E8^8Y ?.1V1-K2"H;H_,U"^:;:S6$^JSX<,9M=-KN)UTKHK-^;N]I
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MK'CJS!3S.4+"V5W^QL4M/D9D-A#\U2$,4!<ZA>#O&ON>S!XHN,G!<)JR._.
M<UA>]YN,#TJ<9=.T ^TR_J?#NJ[Z_8QN(DD'$DDKPD8*)#3-I;.O'?&)1%:<
M&<GHTE\+(V#1F=H)D1S#M'QRHR/58[$Q'74=D\3"VGFX.^/&'^EF^?78CH(/
M)$O;(*NM^DT-*+8U:"(2(IN_AVW/], UL+3\%F5R!I[LKS37::ZBY>*,4]X(
M'NVI:8)&")PT[FX$"C29!94%LVNAD<0;R$$KU)WS9V7))1H82K0I]41"V&@0
MDD*^T*E29D(VX1?&]W[K<[0Q/?WDZ=/"+O!M.LIC61W&NM<)MP.13\G;H Y?
M?(IZ0/4EHG=* 0 -TO*IQIQ N\B#(2^QT/$3GKVUSU2$77TTH7L7#B\3")S(
MRH']0>#'3/1/#U,H&EP3IZ?PWIB&QB'7*(E)X@=K<42?U3GL_C_#A:7)4>JL
M'L]>FR=H/_ #__3S/$&;)VA_&;DJJ\@$LH_H(SE&V[MI)'A'G]V"AJ ^:TP'
M#Y=0124;[#BB5%?=[RD86[L5]BA58=J4S#L]^"RL'KDWSHIU,WV,F<7''';1
MMA9"KHH3CI\78V' >OSSI1SC4!K1X5&01$%6Z/';2N5X2#I,3^-P9DW$O.0X
M';C34H&H0KX[<4&-VY!P+%8M0@V"BQ:A&<-%'J[6">8.?* L:V:5^51B?13X
M)B^% I6XMD3>,Q: 9^E_8EX?"5OEG8OJ8'*.<;YUVV(XATJJ2J+451M;CSV
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MH)H=NCT?QJ((T!4GF7_F"J 4U)]7?W)(&%@HHK$E6E:RVJ2*]:D@1=O=E(V
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M@V?)QEC":L5PR-Y3!]JJ*?>,]5L?VZZI]U?PM,/%6!9;QMMQU[5@;XBSNR#
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MT@895X2D>X6W3)C;*S8<NMMH?\><LZ,<FW!M+4?RYGS2.^Y]7RC,""73@/'
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M.-F.1M[%=;V]IB3O*_X.-YJZ?E''*98J[- IE"_:':'1P*M= ;@P#H2P%+I
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M2H=[& G\\5V8)(S?_ANHKYX_^]X!6L>R"(OM.F?.;89K>4,\8[3F%/;]P"#
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M*^%M!,@0K2IJ0KT8Z-UBG_NXJ3_"".857JZ$Q2$L$(A<0DZ!;"KM#2>QR.#
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M4N!4XM0AU@EW5 ?QLJ[7%'V,TB;\;[!G<P+B-]1?W;X-KOZN"+OMK=45O:U
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M.C$O(KO&$=#@Z2%24K8#H1W\_8Y/R=\-SVG 3_RE_RO1V_D2V6< /M?AI.+
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MIA[9$WU",DR%%LT=&M7=\W? A_)R&D&(SO;X0SSZ&X/5304E T-9E-B:MF/
M2QC,T WV171V?T9.&H1^2E(UZC<E@EJ#7G&/?1(CJ\R:R7*_)!:< JZ1H>B&
M(G/04I!;<M<7#'9T\C;UZ0"-0L)@!*6"50EQ^#:B,GI/)]0X<ON?FWQ=]+DO
M>907854T57%L#8L(COA$-9)'*PJ.$T.,]Q<PCPPLC(16 X>_R"(WA9"@NUYQ
M$KXSK68+B2C%=H=I'0&]/J7NN?!<94XU1YXA+1Y><.:*@)+6E_STZ>L+=?ZH
M:W[G>3'#?/TUKPYY,*@/,TJ0/L@B:&T"4I@0F6[\>&QB%I_D@L,JUBY7_!1<
M5*Z@&_&ZK15RXT7"^<SXR5(<X![>EU^UM%V[\U^NWKJA5>ZR.&*)T=^1,R4]
M%LIZJ8@P^JX9U7R;;E]>$-=XU6JEDT%,8Y&LLFGXO)C>H=_1HCC@L%.0D)5G
MT_J"V 3$=8ASB]W>+=<4>X8[IN\DLW]YC*?S\#1JB*K@D1LWGKC!Y51*T0J)
M/KQ/WAY-$5-CU$6:AE5Q0:*>)I=(5^;CP?+75?\3XPPOB#TV/._3US\)W;\[
MD+?'^W,6SM"I]PV=^G*&3LU\6+_ED7?UF@ ST4!&E,#RR-04:SWG<:I8#,RV
M2&0>VKUDMS1LB]':=&,@[!?#6>THH"-(?(1+2#RSMHP420@BH+%C1*.D&=A8
MATB-?2=W/%^\1/<:V_ZHN.US5'8D1(EM]2!!BA_]2%_UL[0YGLGY0J[:R#""
MQ/>9@Y</\>C"+)-RYA"7_F%[B03%_M"T!XIPP_+Z[L7KBPOD6X); K$ J7I_
MQYU3ODS\LV9N6 O:^J5H^3Q5#T5^=Z$\\&CC(<^*?!R@I]D!O ;,H]4!J*-F
M'>U)JX;P<J2=$:[61\X*WS<<NA3>N]0)*J)AZ0=72Q$!NI53-6O-&C&O?-Z:
M3ZBD-KVT%/FTT8?2_(]ZVD6# GBT&LJW@UYE$1E@!F'JA6&!*2&?87H[H9Z1
M_N2N2SNXJ!3*=/PE D-Y_B0C5'/G'.'YK_+M!KDF]L\'#V;50?VL/2Q=^NR<
MWY/K"6R3:,O>5FS8QH-&Q7''QJ2B]Y"!0%R&Y=$?/SS!U]^]R'RBD6$?/;[E
M.W7C(.4XW9'#&#9^HG"]<%\QN%QN0HX]Z1?B0O&EK=&^K%Q!R[RIPZZ@BP7;
M3+FK\17G6[JD4*-Z !P"4&HOPKBX#6$?GA3PCY&)Z[7?X]U!=WY="S:7)5R]
M:F(LL4L5 P"G9*D<$P9<6_(2BO *X95T:$VSP,B"W8#*KDU", </HA.,#U;-
M?E"#-)%]61R*&QFB)#(!189$2<9XUF+^:0X\U%D8Y%F^+'A/23I@7S;T[D6"
M9TNU]J=*Y--1A)/$1CCK<NL^\;!#!QA$]=+7)(>T10+_(Z,3+@T*39::>[>M
MSGH4F)DS?6<CBTWRC(,UIMAMEOY@=AWJHDRG>A UIYOY748\NP8?I,0?:1^]
MP-6P?-'/F;N$O)/H<WCY;6GE69:RJJM+).D9S#Q@9[,6]W&P2NI,QGP@J[Z*
M87#<^%K<T+O"^1=/H=6D::0501YLS1XM79N+4$;*QU9(:3!$X.OW*SVE,^&2
MNV$N4J^-?SG*>:(=O7UV%8!P+3&;LF_@L8$:3RH9X0%CN80X,\4ML(+37(7X
M4#PZ!AA!HT)[9:]9U[++]FDW?:YX1>F;YL)93+OZ%NP)KVRLOBAH=:.X,U\H
M#7\MJ7E#!=!U >1R;\EC,QZ46^*V1XF](ATJT)"=WPHG'O'J-^8I&(5-)U$J
M?5,V"7WW?/&L(&)8KB:*:;+K2W- *K+$HN2<*+#"9[E)-?]H#-?A:6FWZ^#N
M^,#)HXHRF>GV43%&W2:NVT;KFS2C9 P8R4:J$)*I+@%O80DYZ\H*3[L.[L:>
M?>9#12S><+MW9=L4PN_+*0"IWHLE<DIP3YF-1UU)3#NWO@+Q:9W\FEY)4_1H
MA["7Y.=LM"I&L(9H+_52TJ:=$;M)Y?HIZ(7RLV[AAV@I?%GT")9I69UQ(DA:
M:EA;*X$91@UC+N]R[Q#2-"B<22U8" &C"@318=$6AC.8"WI8.":Y]K/:YI*&
M[UGV+E79HS-18;\IIF \%?5\.!U0;=NAJ*-[Q%Y6YQA3IXF:%!O>%D(B14 &
M0>OK,0STPZ]PESNQ*=, $5,9-LI%F]FLQ\,T3K;XAV5?^@CI#T4?3ZS-F+87
MHM\VP9&@DU/\Q'5=<!"C<91GR^">#2P#HG6FMDD !4/XW4)ZD!'-1?!_R)3S
MLD,51'JD("P-\X15&V)[:4EH+;EB-,M@@PG[8?462CEALF]47WU"'#U"2()5
M!A\-98X@?9E.R,Q]>%]]ME^L*ON,B*%?0T7^J:PI-5BO>=W]3&RZ/Q6@'#2&
MI/"B'W[UY>=6^_\N[U979W_/?PUW75Q0CM;:7^GC;YX]I?3M0I4[T'\0CE-J
M)LN72\)&P+93]0%4U7)\6H+MXD=2(27:"^1\="LQ3V^ZQAF$%QNGRZH*W^UJ
M6Y;GB_CX$^/NCQ4G8W!Q*$T8OA@&(YF:5@ZW+QY\\<GRTT\>?6I,MN&)%T+-
M X#_2I*"WSR+F8JPW]E5L*=!VG XX MW [JY6ASQ*(&C9/2 R(33@_?:D.K@
MRI1\^ ZN__.)5\B.O> H4.97IO9HIIR92\P4VP\C,2=%9WO:3UCVM*UW13\S
M1=\+RT.YY1@Z\ZF\6%H*])S)C-S'<_&/;T9>1,18V*7<[8_U6;:V_S+MN^8C
M4I)^P)(L:?&&;8;"HW"KV6Y1?3$R!TJV)@BU9 O!"1-#(=>XT*TOQDU..AR(
M!&S+]Y#Y6#P/QUY8B;C;<Y*0$X2RWDYLVRLN-GY=UV]1NQ3.?4+X@ J;N'C\
M'AX[<T<?BPP"*]/!M+1FO6ZQB*V91&3E(VKO105!!9#(VU[)G(G<N=$K_"T<
M^R _; E(PW6?KK47=L5%I'"^[UB7%SG?RX8(AZKN$^*[6-<M49>21T^177C,
MR^XJ.+/UH2OZ10^KXVJK[S:G+#_G\;G;;62B)*R0?%O?WH?%MBSK0E^F\8&,
M7BH#H1BR"B5KGV?ZT%BUR[9NEK$)<%FOCYKGPQ0T&KC*3?!'=.QVPD081A:=
M*[;/"3QH@;9@R0I2=-L8/P+\-OA@IZ=BB)>CZK9-3)30: KWE@V9"7J <(<=
M/=FVO@'RD</DE\$;K%'A@-:-EN?!0E$;DPL7"S0IS^>+[BKNAXXO0P<E6A12
MPF*UG:-D2C4@YM:"' 5>/&S)\CTKTKE"$S/X=:T+ET]++NY;B2VY8]83CD;N
MI>KR2^ND,<>5GE=OKJL?CSSV%N3%;J63T"]+/53G$^E#Z92& T@396C(WFKP
M59C_P!Y3[Y6), 6T.%WZ!F[.=#!F39KC*P4<M: 'D"Y\>(8>M&G7WY!Q/19Y
M<R+T<[X>:[K45H7GOZ["OD8!F6NA."I^?/J<\;W8>ZQ *G1OI=-LRW!\/WW.
M@ERXO.2,*HYFJUJ/@%U=%II2N@*)0SBPZD-+\G)%,4N"?D00R*]F".0,@?PM
MCVR1NF"ZR'Y#-E-!@A3?+2ZJGNTIV6'<U=MB=6 U,:XHM7M"$H)B7$T>P6P,
M64.!+_L?]J=\Y3P9MGR"AR#VL#=,U[QB"#FAP_+6>)M$%"T::*,@NPS.1,<,
M3GSHN.K-!K6$J&.(A(*J(N&X,,R0.Q4<I8R+&$J6RF&7$+.8+^3@Z+'!01'5
M/JNO(]N(/[%8^1-M](=*2NPX"</$ 0@JSU!6&W!$1\'#G@?$#-KHUFFEIT3.
MU:H3%2%D5* 6'L,;*H8T\L31U^MG2?H^,<(P(@+)#Q6A1L(U^\>[J[L$ [[=
M<F%!IL-5*H!(<WE=)?2K[)%1<6@/'#-0669[E%<J4R$Y"KGV5;U=>]:JE39$
MTWL7OB_U4.C/YJ(\?D!ZY]U5&TD%5V%DCA:H3[LT&NF5PENV7H1)W99%,SNG
M'\8Y;8KBC!9V8C"(99@[JVMUN\H-LY^)WY7W;=^4W^6R+EJ)0SHF,FWN 7.A
M/'V%#8WT/_Q&A<:FA31E(D!4&L+L%#_8))$WH<BZ S,12Z&5<=VTBWAO4!U5
MC'(T!4@(4'-BVTK56$*J_I['00!6(J!6PU\Y9@:")YU1@\?2:S'8[PO_;.(:
MO\C\;T'I-%'405.?'E9<,:_"Q(=+I%G/L3W8QIPW(UB1ON%N\91:RC_TU$"&
M]HXO.L@ I+%R>K#07ZC,RZ>+IA_\/')HDOU'#&?7E)>7?"#E9O<H 0'BH/Y*
MZ)OV3WI<L.35UVWI'U6&&UNI/YVMX ?!"UW1)K@I4GCOQ$J7/,LPL#6"%4T_
M=R[R-_@ 230;H1_GGHX&,@BWOS0WD<)>O_1)4$-KLW&3P'+V]CL JD4>MDFY
M$4K2L%MBJ0/[=:$GNDN&P]0 2"S/?5,8O]F@/ISF!GJC39]>/8G;:K_)<R$T
M@]=$$R]T'MARF8=$8[C82&TR!X)-(KL@C\5.3#3RXHI&.D;Q,>4<H6Q'8B2H
MMX==/+T?CHG?Z(-E?;>KGR":W:\_K.&Y"$$2L(:(XFY#<"0EK"'< B<YG^&T
M4L;V&J./["CNERS;7GEX8B#83K'U6C>#[(W^B>L?H.I7KQ@PS/LR[*6TI&P[
M515F>W37JNZ=]X+*G*58J/$IV:\ U:V8NLE37_?, @P=8?35X(&X9RWD+\PP
MZ([O\[!W7VG7HFNVD;H"-K;T$?JBQ,+[J'HZY*YS74K:;P;E?*W34>3<6.%"
M*AVNSL$J'KZVU]#Q%D+H/9L)AB18C"N]'S)NN(#.YJ(5!-(F#[]\$"SR$121
M80N93<9E:0**UK@>D?@0.6,.,._R_)X=IKJ%%>9\\76Q(LIY,OA"_4HVS<A#
MK&N#F9(*BRJ\1OCDILN$MIO6P9Y*C'0H4L2L^S6S]5_RP*0=:$%A3?!URSI:
M_%8/)>E$2ODMM:,U<0+H_7'_VG#K4'64MH_N]&@29+_DZW4#<2\<L3R$S)8^
M,04*.S?(,%!=<]_48G-]Z*@BK@4I?(4.N?G(^(#8]E'(-?<O<&>6;X9D'%_1
M$:'$>(@4Z[-)UU_1>@\0RW%%U(#4T\5P< &K(D3R5<U\1SR!C#-0S&J"]M5.
M:(BN,OD-A_4YL5;IAHR[/):!TW,RQ-1,-!/F2T87_3,SDF(&A[M(.OYT%K>.
M119>&[$0H80[FKY$U'M82J];(G2/9($JJT:L"5.)$$EPN!ZYA[FKDJ]Z<#?R
M?;D8S!M5Y"P5XZBJETR0R0#([?$^;LL_6@7D0SS<>P:I3CW[3VAS^RE"ZY_V
MB><^ *)V!H3?CB7^>S'211L-S#B2FKO6T-4DM9A,S;]U_,;7+V<+GQQ+(JX'
M2Z+F<!.SJCCN=3U#L.^I:T%0$.\4C]-,$@Y$H1[V\D-H>A5>S/88EQBE770-
M^H.M3P\S$2NB,7N7_R.61C7",:A9QJJU^9;RPA/?81:,LNXB!4?\S#2D/;M@
M3OR"2Y8[@<IM_]JGKL@NCA$"2 *;D^/<>V21-V(W(A315'@O'G$)<_;#.VI_
MTD]WX@))9EDT+>FK1G>0QTI'PI"@7/#GBS?BUG-:P+VYGC^(J*V4<H-Q%;:K
MDCO55QPDBLRJNEP1HHG'5?X<Y6&47SAZV-[EZ=H-W!WCHX^W.5^\=MW4,1."
M(-SR JM\30G:A!,BZ="*-(_60:G"5M4Z<M>-DX K$ DK5[\C0IA#+QN<&$H"
MXOJ@T6G3P"&-] #Q:@D%;$SA*0Y]L#WOH_?WQ[><KP[^8%S4 #P?JMA*CLP5
M\ST1I^469!:(2#;29AS7L(9;_??K=J5M,J)D(60L';=&))A)"V]QP[P5+/!-
M-0?"_:[UFRW3G>"WX5&NBPJT*&*:\*/8[(GC>ZJSK)':JO1[H@UEL@NMK;=%
M5VB"/3DN7O5F KO9Y4N^(>CX\Y<7D=!YK)E-[&7IHEH\HX9+ZHFX"R>_#2-O
MT_Y)YQ_U1M@3[6Z)M^92S;Z5^\0U$INLH.=^>UR?&#()PV512,FZ-PKVX>*T
MFVD<>0&'JA#Z*<[IZ0MA0WRJH3L6MJ=JP,*,X(9VC\S1#+M\SQ/^Y8,9=CF+
M]O[^Z4[N_"6+.8@E$"04OTJ./'%:Q\M/WL>&V"T5B6+R7_SBI^K 9TH6)JU:
MSUX^8]\6Y)1K%8LA*=FZ#2NZ+ID;+3Q1+D6BLMIL\]U.%*K"V.NJB%I8P>80
M1_]Y.-6^^>'B_^,V-1QT9P;K2:\O9I@/@M<_/R5(HU%%N%'2T7E L:]85R%
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MTDJV[J/G/SS_VPNR=)_0)OKJP8.'GVH&)G=6SLFP/A8Y<V=4\MU2HY@]*D/
M$=HKI5+4Y]:8^X7 H\S4,QF:DTW=*<>+V!OZ$CT2F_F*"9#*W8(4DTAE /4M
M0G6%T? J>RQ+ZY/G+[^^^.G[3YTQ8[2ET,6-G8\FL$RD_7'8?Y9A)T>GS5XX
MHIE $=3Y-/Q6&S=]57$9GF)3=LHC^6,X&:](4K=97,0IO#"M\\R]"D:YE3NJ
M@08/?1^&'R(N&P#=N%B?N+41X534>[IX6Q!(CI8J&C$*,+G6Q. :+T^88TAF
MUD06R#VZ#Q^<[0CL$,:T??M9<P@/$F+(\\77FO:2!E)[09!S9Q%AO(O,3#>!
MK1E=%MYI".G#.%='=%L+[[7PA7[]PP5;@[T"L''H0VU<'Q_A*/9#B/JE9WWZ
MW+O[BM.^=6V"))7XO5 F*9^"N$)C3\#B<09&CQ!MW Q<%:PI ]D5&9;\UV7-
M@@_(</+F8S&%SWONCIJ#OD!?SR@D(/3P]1-&PA/3OMX$P]7@@#>&@-??G#WX
MTU>/O_KJT9^H=[A9YVMJ1J]QR5U]G>_SYCK8C97;=_U#6)2:DS/X<>]HL+42
M-;7S[67WR(_]J Z"R/;5U&03SDAD=ZEJGXS\S;<_GSUX\!A?_>GYM\]__.^O
M7[Q*O_+3M_]]%F8Y2P_$L=.0N],7!;V(U+VQ_-;T4<JI%/)R>3Z02F<G[V]%
M$PX=?AQ^_G\S"X&C:QWV-2/4_T)5]S,Q:+]KBN(_?R RNYI.87Z3"]G8X&AD
M?X=FF-)UT<=T&F:3GK+?!\_7E\4-64$V_,^^/?OBBP=_(L=G=VB#IT.FEWHX
M_E5(-C%9\Q,KB&G0B/Z[)LL=KG9B1A]NZ'_>7[[INV<73\- K\HEI;ZR#YCY
M$A0GY9OIB%@V=8L.NK%HEF F?J;'A-R_$7CF\Y<?L\SO-XBY'OKX.$X;]:&K
MLS=R*- L8F994Y(!B_T<P.MR7P#8XW(6R1;P*]^=-P_-&]7MVZ_'283X_I?D
MW>OLSUZ^_OX#VK^??KSHN_(7KYX&]^Q!&GHN) YNR_ +>@<C89A_+>*#7&[K
M9?A$CV7J03M"8J&2Q$+X:5<F/A/[CXM_'O*FX^HS^2JT!2^NT9/PA(/CA_T1
MNN"8_D8R*Z,AY.AXP^4I^):$R'^?_>G/#UP68-$+O./STP^?$\'RFI7(^<Q-
MZNA1^=(M1S8O?@0JVGGQ\W^?X=$6NW+5U#3=+.57K\FS+U"-@GH=@Q!>?OWC
M#QC&!5%/_TH^"U5,%F_.?SC/U 2N>.](R\IZ\>+'9ZQKP6W4BXM*1%]VY-1K
MXS;Y[>OBDEI)ELX%RQ??OOG^\=G_^;\?/7K\)%IZ[DZ>G-Z+,&^<YEG\T*W/
M[; ,4QO<,-HEB_U5$<9QW!=\;C[,XL@CQ>NNH))2+X)A[V]?7M=T'2RSC]A"
MOQ'S=SGA5M[B49KK^ 3[BX&>% :W/%QNN5_0RB3*8NPNV@R)-TW43W!(DXK=
M\^I?Q#G\A&B4PQQYSJ]6LG]EZZ,-I0ND_#3$-JCA$3EKIS[XR[<A.BJ;\(/V
MR>(YQ7?8'.]T\? M07)9Y!FI!])M(6Z#&,*3*2X']'?JELNREFOE8,(.2[&E
M &U9,H[F]+MY5MSPF@<3),*JCWBM_UT:!E@L"S41J>5'>BUN".Z%M7X=;(4)
MF\0''9IGH/P2#;AWZ?M7)G%&8X%F#(.='[)V>L<2APYA.IO\[*H@[W2ETNM'
M?Z>+;77<4HAZT=3T?YKZY@K]C7(T9HMG)2FIYAE.LTR/IK#ZZQ"B9&$^#U^#
M\>'U_SSU@6&B3)3L8R58-COBP$?WIZC]$2WXEP[QYI(T@CDPU)MN!8*Q]#\C
M:(-^GO;> #"3<N)=(E'9.%KLE'V;RI(-N5LLI>N:C*8Q6UEBWRCSAS\ZE-Y
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MF*6A)'GS/O]/!,T=:3%H"I)AJF%Y+@#=QJ.!!GS?]=@]$F6CF*R]\'A<:C1
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MF):FL6H_XR>9<?J/,T.[KZD,$1ZCVMVV87:(!I,,U$&D,<)U7&0HN,]'WM$
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MZ!&(?A1EW,?9Y_C,RB+XP,-+N_#\!$!QKW4F.\UWW=]6#-)(:"KNQ:U[U"$
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M2Y$IYG^NLAG$#$.BTR!]5_?$JY1R6JA\&_PS/EH+-=J%6CL7P6(!]T@E&I)
M)![/4BY<'E[6[;#<L_U \^/3,9(K8.]= _;^O +V5L#>SWED(YAF( ]+Y:@W
MG5A)@4JI^9T1/U,*]$7!(NL.?AR+GIK%_Z.N^JQ&(9/2>_F%V.$%"D QRAG
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M<8A[RY*XX&+F9I-)SH>5NS"2A+A*^*[UF9]OOA )K^ 0$ZYQ,K/7%S<ED9P
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M[!"0X+\9B0?V9Q*(%\='*9^COB$J)M Z(%*+OF;Q5=778B.T>CCOJP=6Y4!
M6:LI[L6]&1<7#@43U-JI:UQ)/!XV11ULA:]+J"$I4L0=//,HU2 N.8@2[;@9
MJIYE?Z-7[:5"O*QH31VN?%O?,DM<:^?J)E=0ZBO22Z?U.O.L=.?T,:5H8GD.
M<_;/U).EY,E[/O; !7S@W$<J4F_<X^U(EHS#L2CE9%H@^W$@86$MFD0)CL-F
M>!-V%0\1)K4&[;(G7TEFQ:1$B'O%,S G!/'9JXCXPN<)Y;V*H H-.''T*I=Z
MUX&JFA 1T.-(9;8B[P7]'G00=6L.!)C>Q7_@R#;32:6D!&FQ.2G;&XE%JQB+
M&:M*F-RJI\I9)ON,XELB#>UD1KI8LXF>"YEH&# WU?Y^6HP+3X4@^K!X#L6G
MX:2#UZUFPRR'K1/7FM' M9+E@JBTS_\L#25^EYRY8:@A5@:]N! 9CZXE91DM
M.[MWXU9[S96C>=UK9657&>_MQ>O"2\1?MC@N+:2^P\2'Q<;5+6;I=T6XSC3$
M+Y9<T_.;ST3BK#$H(Y@JM2X6CFH143;+0OF=U_&48BPZ)U*,10@+P_G09H#T
ML-537:7P^I83 )0Y,TPP+>UPLN\NEB]MI->?C6=,'023U4%0:IYPFRY<$VUU
M=-'=D0\OS^K1MAJ+W*0*ISA]>L/!GKY5 T#(GG^*)_<'&-?]P#Q83"X<_DM9
M?F[#B0&7C8^$$ZT=_"'?Q^Y,V)4G7@IJE8S5)#E?X?457N4#[#IAH=3;D=E0
MW84$91>;.0R%$,PI#;#JX[DJ^/NC)ASB.DR5P\+=^O$DK4Z6/%LCS2?J;[Z"
M.?NBVB& VWS\LMA\].*CCPL.Q_:;/WZR(7?E&5PFSWT[3)9L\$QNB'5'*(>3
MM:]'M$,4JA631O;H=TUU81/MAG1A96QR<K&2RH3T9>CQ+$3(WN4Z',JZ=^ 4
MAGFDF!VB F.UUJF*3C'9>D6Z[_A<#IY%B(ME<]?';3#IPIWFMN7SS??*/<QG
M0-CG%&63-R=Y(MMX%<NB^!,F6@-0PAVAV.*B\GXV)Q /L^$R$+*Z\"8KA)O>
M^/C;]1S&:NW <5*':\WEG#9?\ ^Y"9*=5'^4"ON7O7C]CEM%DRP#D@F)>8J4
M@O T1)DW3J2?P2E)FR=GDS<A&C-EJSQEZ3ID%96WG8KO'[@HG"%I\/1;)U*G
M<:&*JM7YE,"GUEC+[].,8"W1-Y2'E:TI%KUJRHL\/P*R.-183FU*GH-W8/[7
M7,)/M^TE7B5MB+GPZI(9:G$Q2<@LO- S!1U6]LKQB[395"7)Z7J*Z85CL>LI
MD5&&';@/QK-L;[!SPPH!A@,"G)-PV.G"^+N%H11"'TM?1I!!1()&&>2-.8O"
M.\&IL.5O":T$1&5:J9T?NHR1R^<."5TFNS!$&!SY!^\"9TMJO"*%I8@I\:P!
M\(10@$AK*;1%+%916!PWF$R>33'&-FL[[:9O9<SJ8?'.8G??@;&KATSX]KXJ
MW[1Q9I!A.?1E.#='8'L+9!,V4*,P%5R^Q3&<KN4;>FI.>J8J5K2^&=?^="S/
M"F)\UR#&/ZP@QA7$^',>F417@MDAHR(Y^$CPB#A];"5R-LGN)% 1.3(]P5C)
MFU.?4=;115'D_YUN+P.R?[^8(SCG32.WJ56[CC+Y3N4%NI$>FK34M8#\5N9G
M BAXY:SAJL4)],63%(<]<V'?:X=*68$8[<EBHT@\ZG4FR3$0K9M NOSNFF*<
M3X-GY^6#Y0I7L(]3+8TE* 1JV.0&N$3[/!4.GU,IYGX)2&\6TBB%[*9"N6:
M @LAC(Q[\3WHNQ<'\2DZ[A]@*O&UL-V" XMC]DA$H1)FW*:GO4F$1AVB<J)8
M-A?CL?^+K\GNR.G&M=(PQ<*MZ;PG>H#]0.*I69[->\W\NC/^GCUXU<W0)0NM
MN=@QL7(4K[0"[\DM:R@<C!(Q"HCGAM$=0>%VM\@OT!&],NJLRP;+AFI7E22
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M2[]SF VR0$($"[QUR="2336$,=MHN,(; >:E0 D2LEE^D6CM>/&9?N-OW;[
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MYC<=>E?#TMS=5OM12!7"O[<AMJDXLA&QB B-4E(D6KB4,J 58((?<2F;_]8
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MY'4+^3\DI132Q9R!\CRQ_EALJ <HEP$C !<Q'PE1^"G"PDRL17AJ3+'10%W
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MH@-R=*Y4AK5%4O"&3^28L:R(A'#*K96E/8_R^H J<+;FNNMCN/DMYWM"NQ;
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M2I[A>Z1UCER5)*\2I>&<QE5B=4'\X\79Z:/P7Q"L__T3[/CTZZO@Z[\J4(1
M J+6B/](],_HJ,^2S6#6[V&RWJN3GO=_G-G2MOX?.V/OK<G\*;P3RCYA(>=]
M!OMNB^UG"8$&7C$%38G**+7K65*;7,H%8^DS4*W7'PQW!II4SS38[(F$"6V2
MCHVK2FR/7HA35.)9(3+/Z"0CL!>1_!ZEWL<2_]%7$[#Z:B*'7V%Q7XMJ-DO@
MGQM$_$<]QYEY4<]0VZ!DT0O9.3"O\H7W-BB#+;YWY^LD[?AP<\:*0I+&PN7[
M:7P&N$D4@$[QOHWC GU4D?:C.$D[&$A%,41I0&#RPY:0&4,UZW!YW^WT^4+#
M!:2J'TP*>MQ+>/Q52M>_QBG=/1 [@:X^VJ#[=UQSKU&.C3/1POMS@RXADI'C
MY,#C;S@X+"NQ,G.++^K'+'V<0GGG'@1?*<4B2PJZ!E1'$:$JLTF7 #2P4YGE
M!M$[D?0GLV&W.,GGBN9U=NDZ"^U=-Z?8V+KM90%_8FY)# P3/8!VGT)WG^R=
M]%[43;W/9.;U]X*=_L$+]1)]F_V#2/YA4^L=?VQ-H8:SZ1_O[9,!&4PIU8S\
MHTW-^Z5-$8D4)F9+/F-*<V57?YO>S;DSLBR>L58Q=%G B/*],2%O.(U+9\ZU
MB8+>\*+_DH(].4V2MJ0H\,>",JHQ N2+P2M>2%1KQ!PNX32,Z8W9:^R8E[^"
M/6QJ;*SAC.OAGUX,7J*V4TTKR6^C(-%T6F'FG%/0[$9F;* /_R(5,%10 6=!
M5B-#M>1RPOKO5E63O_/AS!#A((\Y.)B1XWE.JZ+4]S#FO#90T@+. S1'$'5R
MMEE/Y3N9F)35!!OOEAW]T&'I\AQVLRN*=\( J>0#XOAK7',;'L1PK?PHJ08A
M9B/H],Q8>]VIT),OYXI\^.L_ZS>HV 97=8Y8NEAK&$X PS)6C.52J-'P#<JM
MG'&F@T_Q86V^9VFR<$N#,(Z<<\ -,QHGL;H4+UJ<VP"D)#T[LTX5L@:NPZ7$
M5]2=@>7H$B&\]L[>Z/20G2&<$M -I['B?9K$,P()R(HBQ@FM6"\7 _T U4C\
M,].@3!SQKF821E%.B,=4N03#3&HI?*&6%@R'-:F-PI^&5+U %\6UG$2"^= =
M7HIE+1^6RS1/TA33-#_3O40CZ#W&-S!J+MJ/=X[Y1-86^JS=8AV'EBM,;*V8
M878#TA_&6E6! $5Q,='L3:M-].\(Y!T&_6.]U4+KG+IE;YSU0%ZE28U>TA=$
ME1J]7*&6O.2;O_XW$6!.JRZ6(]K!BVJ&:67%-<+H.G;BN$1;+[%5$_B>ZTK(
MQ7+AK9,L+,E"*W/OG2((.J_OLBNS*@<.*OZ+1EH%E__:.R0))QA"OM'&KN"
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MF3G'<9P>SZ1M_V+W[.Y?.;C&W)8E#RDE]OOI7X"2;/D:QZ9DBJR>Z;9L4B2
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MR>%X6)B+9VV+/3)B;7OZ=5I-$O'0,0) 6(L@+ ,(ZSF$/62"I>L"L1I*ZKP
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MJE6C8;G*&7+46L0=)DBEDB J/,X<IKDSOOGR+@LE=-&L"F(#C%=8G; S^5Z
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M(DM39BE%5#(53' 2YI+*N".A*#;&TV".-=-P_J7GC[<"R]RU97&/#=\0V\V
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MF>R.[+P>]7(UU*=QRF..@=NPB WQ5XN J0VK"E"UKM:N_8.J6)P9,.DGS\%
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M>B,L9PB+S,>^90(IE:=(6"-IE@I*;_<]>,J>T=[H6Y"P&,$_\Y06,M?4<<6
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M]:&F](191F5#@3D; ^!9.F!2 (#_#(##$<::PMP7;M"BW!EH4]BP@PV[E_2
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M%,$,,2XEL3YW2M&U&U]L()D<X$P": %H]9>0O0 M+AC51&%$M7:(4\:1M'F
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MF"*1.HZI=[FG_*;;Y]+@(7"NPYWQF(!0AI02##&/*3?!560^7[A]9^[LZZT
M_F@91ZO9V0_3LAA]/0Q6\]C.PJKJB[\'JWEW;C0?^/^>F\S/S[),!RF%S"0
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M V #8 -@ V #8 -@ V #8 -@ V #8 -@ V #8 -@ V #8 -D"D&F$( E@"6
M94L8IA7L ' !< %PL0D,TPIV +@ N "XV 2&:04[ %P 7 !<; +#M((= "XV
M'BY6FR+Q"+RX09E[5O#U8O&6G[[B! SI4NM4:I#07B*>.X=DAAEBF>(B53X7
MC-Y,P##&Y8J$[Z0R#=_1,D4!]@SRGE*>X]RZ_%8"QKZ;7&5</#YOH@JK'C[]
M(($B%X.,9JO+H6@G#%_GA?O(_@ML' /X OBV$GR9M$HI29'(,X*XIQX)G%.4
M,<F4(%F64]E$]AN ;YO =]6=DYZ2W=::_+7Z;=]GJZ''0WOOTKY70S4R+E%5
M,O;)!V?<J79EPL@@H9@RT'J-B!O=HE'>['BJAZY_>N_NZ;?"+6WM+L6-->O#
M/@4@!" $( 0@!" $( 0@!" $( 0@!" $( 0@!" $( 0@!" $( 0@!" $Y,)!
M+AQ 9C<@<[/+[F9$"VH)PH2DB.<Y1H)HCC!-C:;8J]S=*KO+<I7I\"_"DFK$
MT]P@[9Q WCJ92\^=X.G-P(.C$U6ZZF ZJ29J9(O1UVO!!U5]=3GJ8&__XP^B
M#2@;B/ OY61=$0==T1( BAL%BH\+,/EW0,?FT5$'FU/E6,:BY!9Q13Q2)M>(
M>$])1KD1/FL$'2=C\\?)>!A6O=K]U[287#144)P"-@(V C8"-C:/C2JW3FB1
M(:NH1#QC&FF=9\BGN4P]Y:GC]E:^ .4JC<&MBCB&N!<"26%2E,N,IXJF6FN_
M/FP4<B"R'! 2$!(0$A"R>83TW.8R9RG"FN. =CKXUBK5B'(:W&ZOF7;L)D*J
M++4R-1:EV@14=<PBK11#3&J%L?(F]WQM",E6V(T&P!' $<"QQ>"XT?E4QN1<
MY\$DY=;08)QBBB0U!.F<!/^=$(/S6]!+.0XFJPJWD^BX$Q9NEWF*O&?8XLQC
M*T23T/NXI"HBR("+'OKQD-0*B R(O$;,= QS9;5!C&99P$RC@IMN%;*&T,RF
M5*8<W\1,S*C.\MP%=(TFKI$Y$MYRQ)Q,M? .*[*^S4Z"Q8!3. YZ!&(L,D_#
M3Q5&7W]<)3\_&OR6WDW#NQ]\W6-GO>K)74'"D^VG>BP/O7YV:WSRVV(27FON
MG?Z1<XDR9GP:QG)1C+XFH_$D/&HRCJ);1X.HB;.)+T9J9 HU#.,-?XC-3*NM
M&XMFBV^7RS9TY\@6I:M%ZFV8W/1T],X6U=E07;R-5]^=*1L/=I?RLXL9D>8I
MS;,_Q,ZIA;]8#+C^*G(C&X3K/*Y%>,+;2SD[?R3._IA77I9Z]]'J([K+-E[/
MN[-KN!!(79/\Y#(1_4Q]=;,D<Z1\6*&W:OA=753O7KVYR1L+PM="=#?5GT/<
MM8+.4U?S#JA=+&E[H6<YN[Z!-3C</?QU=S_9V]_9>@Y;-SRJY 4T06U1+</M
MERN0_3+V7XRJ3OQP_+UJ!^%V#O:/#C[M?=@^WOV0'!V''_\_>V^ZW$:2I(O^
M/T^1UG?Z3)49@IU+Y";-/6;45L,>E2@K2MUV?QV+C(7,*1")S@0H<9[^ND=$
M;EBX@B1(ALRJ2 *YQ.+ANW_^^\<O>[2%WTZ\XT_>^\.3__0^?3[^Y\D>#>TI
MJ&LO)O[+T1?OVW\>?S\Y_/+AY-=7NB-/KM9J[;TS \Q =6-RMEQ4K;V"8T')
M"T/'RPEH;-42-*_RIQ1OS:L"WS_P_]K> #LW9?-&OFGDG-7 N-HU,(G%^ME_
M606NN2B;LBBG8,Z]:>]_NP&21K\N20[R//JKU24V7! <).%57U_U77B099'?
M_[ORXKT:PQ5X0-E&/"!C<V[! ]I(B.L[<AM?6/9,((&\ZTS^:U%&VQ$^X")L
M9N>[= G"DN(W_^]?DK]</?%;8;P]V=+LDD+^/\EJ[^-,2/$?1?VW_S-$C;H;
M[=P$G&P?%G%'].58E6-5#\*J0L>J5E;N)B!VCB>Y4^-.S<JI"=VIN9\DUW;R
M+5%([R;*MZ.0/JBMODN">\^:,T\[]3Q55^=>-9=@.F, !L.0%^6BE,V;NU'D
MOOC)'YI+[4>8_2FDT6N8KJ/B%[FM+VJZMQ>&5]JUNX;D?FIAN&U!O\B%-ZV:
MYL&3\9X-M[AM:M&3[_=CI-KM!ZNX!YUO3&7>?2>>, Q9F@4D]].$T)QQ4E!.
MB0AD4*BXB)50K[X9Q-X>F(?/2'9,T#'!%\\$"TF#0 2*9,K/"8U800I>),17
M*J.Y*F0<KD$O)#R/92S@2A&EA'*5 !-,,O@S\6D>^$&!]SPB$TSR2> _8!'=
MWAZ8V[:[<9ZF[>?C4&#.K,X=PRS>6L)7O)Q*;V:U;IW;B]ZG92.%5\Z<Z\D9
M[:_):'=4_$JW]45-]\%=3WH>Y4Q@U85^XEU\4<,<0_V0X5/]U?S-/92F'R1<
MPDN&BIBSU)Z1XKEWO<;WUD#;;%#1@&5QD>8D5PR,(ZDBL(OBA&19%((MQ:GT
MTUUXE88';%>%G9,@>UE6U!.CC#B^] RW\H7RI2PK9) '">$\9(1F/O EED0D
MS;(LCQD/>"1WX>AY +Y$\^B5<Z4=NW2<TKJEIALA$^!8H'\'*[OEK-%T[,F?
M^+MT N-%GS(G,(8"(THCRH(T)? #E-)<Q83%<4QRFA<12YBOPFP7BJR&K'^'
M9^[]X,CM2'2D$Y]FKUQX. [UVK?RA7(HRM"@YJ"9YD$ *BVF<O D(7%>9$F0
M93SUUY"4[J+2/BB'HI,T<>JM\\D^1H3SO(()_H]1:=D,8YC "V2S0""C6NJ/
M:SG5N$6+:A#>G$KFE-\7?@9?JVAYG#2;4$@_C-."T$+&A :2@QXM8A*F7$A0
MLF.06_=1IN=R?OIF>+X/9^+(GN[#]G#_8<[VM^JX/=F?\6#O/!TG>DA ZR=/
M*G$)B8Y!OB8&N>N6H,]BLYW#]?$UTDIY<,-YN3S7RJDH&PX+O&@\^ Z&]*>T
M*$R2+VN=:S?!U#S'=5_T07RM7/=QU-+(IWG"(U L,S\A-$THR86?D80+ZB<T
MBD WW:E:>JR^FB,.^NF']H ?SW[OCO=)=[J_R,6N%=,P])UBZECD7N^I8Y%.
M,76NTJ=63-^?L=FIQ"(/Q<K:NV#3I;0*JI)U+7&Y*OZG]X/5-9LMO&G)#"BG
MX[4O^O@Y7NLVVYW;IYZN.[?[94;Z@LLD3!A):9H2JGQ%,LI]DJLTIV&@PKPH
M=A&(_P2R^!\HBOM:S6/U3R."=Q[%B%]6WM#^%!0[G7/SVF-E//HZL=M/U; I
MZIL:/-YC32,7#O7G.1TW)Z*<:NE42[>5+_?<;LG)C*0HN.0D$RP@-/(SDD>\
M('XJ:::21#$:[T(5_(V5,Q28Q[,/6ER6)KIPJ"5EL//NP"\LH^7)_8XW!)59
M4PQ?N@YH_([-"KJ,)FH=%&_]C YIQF%TO.;I.BI^D=OZHJ;[J&Z3<!=ND_ Y
MBLSCQ9FL$:Y-EA>80>+\)"];$W7VUM#>DC+,HR)-2)YRGU"5980E/MA;*I1!
MX(=I&D>[J-(]FO$:BP4^2//S:*;/W1_]L=MYLM;+0C5V/B+'LQS/,CXB4? P
MR1,22R: _^0182($=A1&LLBH8EF^!KQ^%Q_1X_,L.@DR5\S[B!EJKU?M_5K+
M.2N%<0M56@?FR[J&+_4G0'^D^]N%#U_^L7,B9J06"^X782Y)PK'H-@P5R3(*
M$H?F<1&D84CSM8R4W:C%]EQ^-(A1C98X.U>-)W[TLK)3G';L6->K8UV/U.&#
M*9:F7!)% T9H4*0D#X*$",ZRQ$^2C"OV,-KV_5CA-5"UZ0N#JGTN^7FO5^,^
MY+8>><XNT7IT4ND9'2\GE?9+*E$_"Z((9%&4JQ"D4A81%@6<A%$BDH)FN5([
M09=<ETKM,?YJ3O&WF@FY<P2<)'?"R7'$O=Y3QQ'WBR-&A<AC/\B(BIE/:,*
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M&89\2$+O!ZMK-G,Z^+,Z:4X:.7>J<Z>ZK7RYYW:SU@>V:1C$?D12(1+0^J*
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MX,"*BC E@F:4IGD<^L%.E/-GF%7DLCB=]N_XK>.WN\WBS/TL4%E&5!B$8 H
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M8*PB?(H9K&%KNA&B9LV-Z:QL^:_&?&!6@RJ;WLRZQ;!L*'50BC<;*.U6L^]
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M6$B"^S0@%]@.9C%PMI#LD--]/SB!BVN-?H.> [ZLC=UNH8E!>\!/+@TC-*"
M<"G^T:&?;3Y /7_49\D,:>V0>)<E0O&4C87*;5%P_D?655M],BHQU<A".BC8
MG3.]I*;^M ,Q[O!G0673I:C]U97!VQTJ$&/J'50E _4HJ9O<MKD_EZ:@Z37S
M[*\@YNIMK$%GHR\T$LP/LR6&+0$EU7_*16?9#)=_T@:X;3>::7O4.E_>6(];
MO5^_J6.O'5<I*BP@1X[6G>0>TEC3,Z(?HU-J76.=6-<:RB'C_H$582TT>(N4
M9[AU[WG#$5IM?=,P&7J<P:1@QH6U/KZV0FP,T#QHC%+UX@]6;" -6S>C#L_W
MA?&B=7%/Y06SZ M&(T'P+.WY,MA<@\XJ[<KH\N^JT27=6A9LFBA\"I+H]&SM
M3KV*^EPU<ML:Z;%UP?E--JU^$A:ZZ?+!Y6*J]]>:38?:/P74?S0#0EDLS<O?
M8[:?ECA?#>%9D8)F2+N^ RF#*_*/;C:_P;OD?MG._>!@<G#T+G38F?PGL$W2
M<BR3+NZ=].S;9,,CI8U4[B>VM+_JP!!LY6%I!<+PDQX_O]&@E-6R&0#?&OVA
M:4$[,<VE599T$=M<ER :'L%XK3$C>ES/QF2$HL)D>PI9RW'=BWU+VQ/.F^8A
M_9'0T.BNK/ UEA6&:Q5PKJSP\<H*7X?ZM=ZU;YL.MH&5C5C7 .RX,SBL$\4Z
M8DI;_SVMM&5JK.B;<,4!7@!>;[2!:W7FY"!)TJLV[39$NS\[MK%\X0H_V\ ]
M7-JDV>O=PU8I:M@Y8N?,9F FP4<],J3>4=3ERCF:C+TMSR[K:MH&7W6?B@&2
MP0T?TKG AJT*^N<\=LU5S&.6\420/,:.CRK)2,:RB*12Q6D09H7(=H/TV*;
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MLYXO@O;SSI:Y'=F].9YUZJ-L;+WI5?G8=\2N2.(HR&GDDR+.4T*CM" L9H+
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M<K2GINU [IE,E]_9)0)GXU/B>]%Y.XR=TOLM2D__E^?MMF^+3*@0(LH(IWD
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MWEWH?;_8SVW] WO9\WD?&I*\HN;/<9C$<2QCPOTX)-3')B,9%82*4,0!\*J
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M>=)\=]9C,^+Q >O>J1Y2]L"%[]_98.)>6O;2LI>6MXH,IHI73"$8%P?))WV
MGW(BBH60?+9*A!UIF8.-E4B&"&TBD167Q'L:B8Y162.T38GWTK*7EKVT[*7E
M<Y66#^_T]^*C%Q^]^.C%QTL5'YM10_@9FX Z(ADV[MW/J%^M5+EM/Z.^?Z1^
M1OV.C'H^0^/Z&<_]C/I;S*CO!W+V,^H[1::]_.J'H=XKB=X+JYYA>H;I9]3W
M+-.S3#^COF>9GF4>GF7Z&?6=;,__/LMI^RF.+[GYH0LYS>^R"V)_^9C7406J
M'9$@?HBTO"+6,4=\H,8SR95,ZFKYF#<ZQ&@<H3X$(JGW)$@3B.?)TF@M%Y8^
M>OF8'6JI^I[2OOBC%Y.]F#R^F.0B&I\L40FG15IMB%,IDL"-#%PR:879Z4E0
MUH6@!6%<541F$+*>P3E94>ZR9O!HJA>3O9CLQ>1WLNDO0#KVK;2]O.CE12\O
M>GG1M]YW(5;8M][W_0U]?\/1W-SL3&8Z./!KJT!DQ4"\>&Y)Q3SS((:R5CN0
MG()6/E11D>@,N+G)4^*R$ C)*:W*E4YY!Y+S^W-SGWTW1R\L>V'9"\M;==[G
M;)2*AB@N%)$B!>*\I80ED'O2:\]3OBHL0P*Y)(4D5%2&R&P\<5Q)4D7)F/"R
MBLSTPK(7EKVP[(7E,Q66?>=L+SYZ\=&+CUY\/&KC?6N^_65QGF>C"+^GT>>.
MR(N':,=?O]GF/"%YHH3X<X>&"EUYDKN\^N\[E8\#/\N#,^"[\>5@//K[8I0&
MHS5N_V!^YN?ED,_H+J1!\#7\#6[+WQ?3.992-I>Z #*!!QA-!FCP?\[MY_5P
M &\2SP:S#&]1PQ4'?M#VF@S.2U%FQOL,OHSF9W#R_"P/*O!-FKO!8^69G\6S
MRY/!IS,X?4_A9GFV./9U/:I&S9/A18(?^TG,@_HLPY%P8)X-HJ_/!GZ2FA\R
MO"K<!5_R9"\I'-YW9J];_8?9^LT2ZUO00G,HWNK5: Y/$0]2QX=9KO)L!LOX
M<3Z-?QO\IY_-/.S.;R/?P$(L%ZJ33S^XEJ/5"?LV1U\O4KK(U.\F&!B8Y":>
M@*Q4>. OT\]-]S:7I7N;MKOZ80$L!6P\>',ZRPW[_5!G/'Z>!^['83GY[?0<
MWN-R<(H$  3QI2$%$ C3P<7R HL+_'4?4=SBK8X>2JDB]8I32AQE%9$X!<I&
M^(M;J62,4<>\$THQ+C"N:2114DNDEQ;.49((Y90RIM*![E2AOD6I\[YJF>3]
M[ ^D;U"9L.3OJ_4 Z[=^/,[II\OVN+H]L-X*N-1G(,?JS4@+O2;0(M10<7<P
MT/+X5#AHW@%Q SZ"U0 _O2$<E[F846@=7:S$2UT($35+HSD&%T"FY7R4RWZ,
M9/6/7:.KX$6R5AE"L]%$ZNB)M=83[GAD!HP^MCLVYRYTM9+"A5T_^-G[V<>Y
M!R8L$;L/>?81%VH[7@<_XO%P%%#DFV*U^9\1PF=6MT>WT3RZ26/\NF >.Y&\
M2R2&VKO(-S\ ;^1\D"=I-#D%.=2J_>QG8[ 9D ;AV8K:_P)<"*>#T J@/. ;
M6%L\!X18O4#E!J0&QV;XO+%<9OET5,]GONQ\C4M:1&1C0^!-UJP]>!/G>"_F
MA&C$)CQKO3@_;T[&IQC\C"(V@0I%TZKY_)?/<,'AP->#>@&V47F340W[4HTF
M&<VO30E<7!CSNA[\D<O#I,%;Y*<*-AC$-=SBW21.9Q?3YH&'@^GLO@)Y1?^M
M^=^2/Y.>V2H%(@/BO +) RD[2J21B0K-O-]%TO99EFP?,16RC/":!*H2J4P,
MQD<:@MHA_Z6<?#-)C:!\OYC#FY>=_@1+M46SI,[Q55K,L%8!S,LG4;^,#BZ!
M\-8]1%>=IZ=BEY/!F[J0TDIY?\D@86'YKHKBI9F>P/J?3.<#E,&CZK(<BH;R
M_')E8\>6SG:O.\L17>.$A.W!EVAMQH9IFP/@4GA/8+F O[8>0/E@P^P'O9!]
MXS1,@=2!68%Q<O$!KMPR?\VS.&H]DH<A>S FF'/<$B.5!V)GDCB6!+%:Q2+X
M(Y+PE<&2/KEH/,-,#%@@O,HDN&P)52YSRT7E=P'D]UD3]?QG>/%?9]/S_\3M
MN6I!_-*\/;KLVX(<EXN KS0_PWN0Y"\)4BAY(@;YW5\.Y!4 H:[PR'#PWXNZ
M^*] ZD"&C1 _OQCGI0C'3]Y]>#]L^68*UF,J5D[G#!01P=:0FA/+LD(#Q9(@
M92#,*NX9LY2K'0DMC:L8-Y(D;@1(=9U($,81K5+4BG$*:G'70&D6H1!F0Y,M
M*>;Z8!I1;Z41U366!SV17;([X.@Q/,+)X-TY*/,1L-?X\BK-;"O^%=7LRLG6
M)"Z:OH/ND_&.ZQ@#J9("G>T$.%)>1%)5-L!'/$?-[T-%%_GB](JT6TFTE?=4
M7(FWRX7Z- 5C".19,8COZS?)(?B%72*NM=^T8?;][QK%T'DQ0>&E]X>H7D!L
MH[%@@&O0-ZPST -XAZ/)Q6(S-HDFRS34>?:YX*FV!G03)MSBP&)@-#RZBDBB
MP=+&),6M8Y([5OKZ!NU^7G5Z5[)@,0?SZ'_0^(&C?AK[^#?R,9Y-QT@*%W@%
M@JXQ6C_GTY3'2Q-MM#+WX4!@HL5Y.;@N9A:X"$#E^ T(EN9YO_4,)T](]2^5
MH)%H_HZ.YPB\.?0W\S@WH7;8S&D<%1=O%<.[2EY+.FTY8 3?QF(A7Z'233K^
M-B%N&.I 6N-%:BERXV+KX$Q[J>(+CR_QOC<+]31,",_C1Q,\"Y<#)6\)]:#[
MVUYX29C#P6Q4_XU4LXS<#$< 80^0Y(=@\E^ HPX73J//(R"4-+@<Y7%JR'_Y
MW>?IV,^;EUJ]/8:9=I__RH,V3'T^A=O50"?%W\&DQ8K/EL+E>H8]O#G7288O
MOCYPRE5RN&F@K6B7UJ?:)(VU7[6,]Z:,^U'B$+>@@JLW#)>#N?\;?E-,'#2.
M8*_:F,H(7K&L,#B,^!"U'S?J#[_XQFML/^C9"#[$,-<83+$SG\"CS),FGO@9
M(R.Q/0[I8MS ?K0? 5.#,0 [NW&-<AALV'BT33VC26-,M (=GW#]+/!XTQF0
MY&B^$KRI'+*BPV8U-JZW2I_A F[<?IM@FU@5O!<P"?+C1<;T57EZW&YT1)8!
ML&6T]';\U2SE 1XK]+=!!["992,R)M3:6VW!JK0<&!>SSTUT =:BT,MHB@FZ
M"W":OI;5@3>ZUP.O]MZGC17WG3.A=;)1*G"_:.+@B)DJ$*\H!9<,3.B*YTJE
MG9@!=S8(B@.7*BP I2Z"&X<-WO"9=-R"62YN$RK[?<WF[U!9;)G-%XN-D#!A
MF_8SN\XSZY#I_.>K2F"+O;ZE*1K9%N>-#3G?HJUZ,$$[<W#A1PG#J?#J8S_;
MN$YO-SV1W;3<(XPT@G)&XSF>^<EI4WFP7V7NFCDE/(G2=#IIS:,INAC%L@:Y
M]0/2S:3./^(U6Y54.@)](]';A$#16-.+5JDUYC=>=);/X&PT[,;3NC.4 BR;
MOQ;K[E__!<AX)23'^2M)HUF3.L:A#XOSR>LTJB_&_O(5?OOZPB<4)QL=DJ/F
MGFU38?,!!M%&U>7R]N54 JSR.DR_XGO@_(I5X=37&U9'W8=0[P=F=[^5_Y4\
MW:XSM57HA75;37'7OYRMVD$O_&EN.CV)KV"57OGQ%W]9X^R%3>)8[GPI==J_
M[??9W4<M%;OK<NZIG2NE</]\B*%N7IUV(-^0?&42YHFIJ1B10BKB1,6),@GL
M 2=9].D8^895"\BRN <LR]9F2.\G?V".$_.D/_EZ5/]ULHZN%&,"OIY.(IQ5
MA-\G>)*?QB4TE\&FN$"%-%OD/]VUKNYY*J@W12VM5V6I@)8N^ZXBFI_-IHO3
MLU46:ZG$:KQ.PBC!;-XDLS%U4LQRC];_>#S]4@]^*$=/%S5HGOK'5QU1-%UC
M_'YDTVJERFV-.5'7CVRRUQYRW??V1,E^VD^WX'?[:1D]+/.^U=N((JYJS_XE
MS/[Y7Z^I N[QFWO\YH?&9/FI+>3W>P=2W6A@1=\4]ZUVIB<GA\=J>'OVS6S[
M8\TI*^E3#,0%EK V,Q/GG2*<*<6U2"XH=M5?I,Y[F:0D(6N.I9R.6)<=H2YD
MZ9B16LF#_N)&8/D_1_.S'=^PWG8.ZVU7<J5$RK6.!#K N7Y8Q(%GV<WWH A@
MFPY]N>I=U,^F^U0NLGE5VJ'.NT.;\;9$G]%O7P>>>Y7T8KCMI6JB'^X8;+J=
M9I/&*.S6(BIC(6(6F@0;(O%<:)L-#R:%'<UFI9'&!Y(\KS"+BCTZ@A/FC7/!
M!1$L.Y9F.Z#8_LV/)K]-Z_I=6TWS;O*+GV&2^W!M[(ZVP]H3^.D:M:?L=Z?U
M;F8:_OCDSE:O_O ZRZKO4K-RH)JI5X<]MG&/;=P1E:JB\]1114(0EDAI _&1
M"F(D=Q6-*ALK[Z-22VW_L3W%I91Y7VUWQBZKGXZM5IE^8+W:4<SI)]&]/?CT
MC0*=-QHSVJO1'OVK1__JT;\>!OUK[Z=P:C<$R0.5?!RWMDL:S64VE"3.#9$X
M LQ:&8E4C#LC*Q[33JS^+K5='V98F#J__  J9?YFDG[Y^V)T@6;8&N[W!C5;
MA[=3/RO\JT/[+4\&RX4JU;NK51K"R?,G@+JZ4=W&40F2R6 H315AL4+;GDOB
MLS:$1YYT#IPYO@.5=%2"/';IX!-1YOU+VR,V1"$5^A@7YXMQ*39/V*,:U^6$
M%YODFI=KV'25]Y6!]]J[NRJ-P?=7(JCUB7/BVAI!S>];(\A/K!5T_>?:$SK_
M3!TL8GS\RKV^9/'8)8NZ+UF\LGJ;\9&^'/%X!2)]F74OL_HRZX>A"TZYZ&75
M'<.\/;^\1'ZY4=JCYY>;Z?:^U>#;B_N;#^N@2I]O^VZKQ_K&@INAB=)LLY.&
M.%TE(BL1B$-HFN0K[E.FP<9X-3:L@[6LX.1:HXB,B1(OI2!9B\0T8U'S=./8
M\+_-IO4MBCN^6=,AAY8?!GU\KO3>#PSK15@OPKXQL2$D*J35(,)4)M)Y@>DM
M272@VG.C?0R[6!K24FJ$)%(X^*NBBG@G#.$\,Y!>V6FGGT2$\:'DAT&1GRN]
M=[S-Z?NT=!%':X'0(IA'G%850F/VEN_+8Z->6VP;O)&*J@H$+%@<<%)QT!:(
MVNBM@(]<<I6ZJBVLB(IIM'5M!4>J((BEC!+EC.=<PJEQ![7Q4;0%&TK9-\7V
MDJO?TA<@N;RGC DN2=(X9BE&@3-J&!&)(I2<5O#O#MZLUR%D@=,:)(HO'IM6
M$"<KPTT4E"OU-)++](YZ'\\]BI4[J>>S15S"MI?9/77?D-@W)/8-B7=&-A?)
M4(GHI"EQ(C58RU:#O1N<MTQ;GD%Q[$14F+,,R]QC-!F' UGBC4J$:L^T9MQ%
MO].3_RB:1A\>G_H]]_GU1G0O'GOQ^"#B48J@C!.*:&-!U#&&XC$IXK/1CD6!
M_^_T5^<<G8J&Z,3@'"DY\38;PIWC-+%$G:^>*(3 OC%@NI>0?5#ZJ.;ZI^G<
MCP^TN/1*Z<4XO7UD9\O>]CDH)2O" \6I0* FG.&9*&XXYUK;Y'9BTE3PH WB
M0'))P=YVAM@J22*R4\%6F7KV-)$=/12BCTGWDJO?TI<@N:*SV5M*HHX:))<%
M4U@H20P7D:9D>;7;6FP,=3(;1BHG*B)- !EFI",Y>1Z5SU+JIXD4B*'I:R_Z
MJ/11JHQS71]L\NZU11]\Z8,O'0'+<R8G6FE'O/6&R%S!3])K@K,X!4TZ><V/
M87N_60N#GS=D ?P\SO@#*+4WYU/8ZO\IGQ]4>$<+^RC#7V38YYX >+V0[H5T
M+Z0?64@GQG5E',C:#)):\J2)9<(2Y:L0O*;2VNH8;D;'A+2P+S,RWV.4=C5$
M/QQ,<A^G[U%*'TY+?J<HI0>*T8.CGH+G4$4<ZY2Y(_"!(Y1* [=@GE'_H('_
MO^1CZ2HY-/J!@V??&2IK+RY[<=F+RUO%:JR43.%H H\UAA(\ !>5(I40(C.E
M?*QV9@4=-=MP/'$IAD*H7EP^#(AU)^3CQKV/AE5]1[S<)T1<O2NH[*;[/<A?
M+_*DSH,OOA[\X[Z PRUN>'2AQ%7BF6I'N*T"D8D9$K),1,? *U7Y8,-.\<9=
MT)5O$I X*)STEG!2UP6'3PZ'AA^?% 9P]!C7&SW1SFV_MA77RCHBM QHCFO0
M+TX0+6VVV2=/^<ZP'1V=RBH%$I(PV(.J8?NUA5\UE8Y1%O@.^L C;C\].:R9
MGG#[X9D'\[,\N,Q^5@\RR+ZT,T%%%")!3+'A8);KBPQ/_SF/+T\Z H]]<+S"
M?L#WZ^[YI_V [TIE7R4M<#RP(U)1H"_M-8E)ANQ#2&HW7'H;D50&0+V)<;;(
M:3G :93KMXO9['CC!YC]+N8/J)-!NU*#7QHU5M^'%I_-T &;&%"224"#EH%:
M5&AW<T<4\XE7KC+5;FCCUC3X,9[EM!CG]]5!:OR$AF(_@ !NN23#UIJJ<?'K
M48W5*=.J2-9FM,!H<MH/%WA<N[Z?*;!]2#]3X$K.JD?LOKE:[!&[][Q>/V6@
MGS)P;,+J958OLQY%9O6HZ?V4@7[*0,\O_92!KNCVOO_GVXO[1ZZSG\6S$HY.
M^7,>3_L6]^?:0=>C=1\Q7T:YJVA4CEB:(I',<.*\,R09JICD6GN_,QWY-B5O
MF[F))1>^F:2?USRX#,.W >(C%72XH>IG#_32K/M;VDNS(TJS+'RV&F08!]%%
M9':1!,T48=CZKE65<W#WJ4A[*FDFAU;27IK=PQ3NVTG:Q?WE_&(\O<R9S'+3
M"I^OI,%[[?'=LU"O-+:Z&15+NDJ<*%4I,(&3)9:I0*RR+D4?F50[)6-WZ?I8
M<MX?#>/MUD8<;6:-T+97%KWPZK?T^Q=>-$K))<@MG;/!B0*.>+@<,9F))%3F
M0NY,(;A+#\;C"2_96[I]T/<HC=/^*]SYPE]B65:O(%X,V[Q4!?%/_V YX_VF
M]WS\HK?TV?/Q?D-/B1!5XH(822V.2*7$6QU)X(P*K7(T21_#T"M:\T.C-(]M
MVBG3XWGV0<PCL,B'V;3*=0WTX\>#.L\^CV(?P'Q![-.KAJT8@*64^ZHBNE*!
M2"\E"597Q&4>@W1)4'\OO/K-K-<FYWUL&>^X:L*P!P9B^-ZIO!=<W]V6?J>"
MR\98,0Q9.@<R2PKGB(T!_O*JHIISSN*];-K'%5Q./#""[[.A\CYP>2]F>3\_
MR[->*?2 QSW@\5V1R9SB)E>9,%,)(IVFQ.+8;>N2CT)S%=W.Q-2[I/0+IQ[$
M.CB67F$/G,WO*.QP;S3W\K&7CP\C'YDURMJ*F(2(1,YF$D2PA!HG*U\97XF=
MB,%=@LF/(A]Q9*KI)60?>WZDLH*"Q^ZOH/?TZJA'%>Y1A8^AFXSAB:9HB!(^
M$YDI)S9&1X2R46GI&4WF2!.@'E8MB:'BCSK3Z=EC"O?"LA>6O;"\5>\"]39K
MG0A(/S#*P00G3DM)N&9:,AM2HD>!8']P8<F&CHE>6#X, /M!F-M.B,V->Q\3
MP?&X&+Y"6^U-8L1XE\!CKACQB2M266JT#]QPNM-9>FO\U-^R!U>B!^S=W%I]
M,FB6I:LPO2\(LO;=9(WPS2EGPP)3^W9Z#D]R.2AJ%5SBT60^'?@!L!")?A+S
M>%Q@5'&&AY\CFNT8]W/@3V<Y-T/,6B3Q_^-GLU$-NJUL^'!PL9C5"S^9#^!Z
M\$KQ;.MVY2KU8!]9W.)5CZZ1T4>I>$J$@6(FL@J:!,DMJ%A322/!/['BJJ!@
MU@NF8R15 ,]%4@E:W&5*O%!<5?"=TF974*2/^)Q;"KC^>S7?U+OO_O+K=8-/
MV%!_HUOP\6EL4/]]X6=Y4.4\1R#D:56-8B[ /4!'4R"AZ>QR4.X[ -%86IA'
MD\%/TWH^G0P'O_NZ]O%L4>?YO%Y1UH=9/A\!M9P,/NW0&>S%.9!AA.L@I+V/
M<;J8%#H%^KN8(HU].<N3+=H[]:,)' _'XF!Q(,_-FPS@RO>DR@-**#$E?3:>
M<$X%6GN*>$HSR<ZR9'T.FNW0EK*THIPS$B7G1(JDB<,:BPB&GQ6^8DF'+=IZ
MO^33LCIOV\5!1OT9%GN;G!)\0L[A?F=X 9+\)<%Q "1/GD0^K863*^,'UAAC
M5PV@IZ+N%44VI+>YN@-<WKT$>N9KD*<@7,^1(1Z&M 0X!955.)G .FR"!J>
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MVC#TI^D'?]F2SA[K^Y>__G%'U[Y+ J+#GCVE43')'.@"0XD4IB(V<TZ2",G
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M0#L9_-I6AS0N;E-<N1/\*72)E#ML"CB:2ZS2M5_R+'?.MF8>?!\:!*%5UN!
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M OZ6Z_2]QH"YY<DHSXD&#L02IP#DEABQ%-RX')+PTNYD8T!(ATPSSK%&5JR
M*36(^1BS$M9XS.%<%=1O8AG96;?1TH. \/>/^PKO4L#FEJ2Q-E\XXC6W)*H0
MA:&5S=5.Q0UH%QXD6":5+Q"0$MY?6$5H5C9EPT7"TLT'?Z%G%.MM+=,K%NV6
M#S-#ED.S]UMV;N?\DB[6[-^[JZF LQR"L#PJRJ,1)EJ#I>^,.B+1T \T!\*%
MTI7C.JJXDW6Y"\HC4-SYJ.E_ J/O[13;FT[S)(YR#_2X10/V9+"Q5@U>VN9J
M]5B/G4ML_)9/L3J^J7&%C7J*/;KYT[[4\,ZOI2D-0XZ8KH!_K^([739]D,N.
MS;CDNOD*Q'V45S@8B)37!M3!&AA-_*R@TLP:H,<11B$7]6B"0!AH!WPN)U_!
M[(AQAAV>?@T2WRCD13R#QYG/,=+^Y2R#H51R*4!@ 2V7YA&JQ1PD9E/W"L[D
M K,#7\"81E2<%JLJ-4>6ZVT=%V'M"WB.QT!L&%^"N(450:^D<_K]5H1Y'Y2]
M;B ;P3Z7M%O!^"WY/01CF6-KWK+#/4US<U!#KBOE<%ER=+//\"T"987QJ#X#
M:VX9!]^XR@8]=VZ_OQL%?W.)7!S_7F=TG#-+VKUNLN[ 7I.$401\^_/)J&J[
MZ]>Y^/H;VF&I&4X&'^"CA6^*S.<%]6MY^K9R*I^7//ORAI?#08%5PDS^&*[5
M0AU/UYFQ<H'5\R&44Y$I* [ VL8\1[W 3KZF8?]JSF/GQ&';A]$FAF&-)@W2
MZA*-]W+PUY./)TO(@5;HQ.G%94&/Q0^:J@%8P%S0DQ>-T721\;%&DPH#0"WZ
MP=B/SO%)\!+SL]$LD>;ARZV6 +W;50=7$=5@=7]MH)"WEW+]8G51TQNIZLFR
M_+_HW2GFKDMY!%;M#QL_&5[>S_?>%I'H0.SBVA2%"^Z+C[M:?W7\N?\Z.E^<
MHV(NOL_:ZX:M\[.9;Q>C-)PL)G^;3+\<A)S8MBM6^@$(:Q1'N"'P='%Z.BGH
MIDU2%/BJ4"U:-PTU%&"[$H.;[GF*'="*.G^3^.L!J*0\PP W)D<O<MGNLI]H
M@A6L5GCW'!>;S>EK:(!RN^4:K2'P6A0Q.+RU?]8H?S>"!]Q<Y&\\/AJ# 8\>
M-X#BVPM\!MLPR9_S!M<T&5^X2\H5V%F#L?]2+Y"\2H!E/@>KK1#U5?S ;SY&
M5W3SC2(1/?KR]X:^;/>A+]\,>OD*<?3HRP?1EP\']*XCV4-C6Y3B.KE$E%.>
M2"42<29CT7=D.<E(LZ?'".A]Q&(Q-$% 6_X"4A;G]LUS'\O;W'.'L;QU0=Z'
M5:7=Q]4LA,UE;&V#0;.<?:"O<V[0'ZCT064WV_?Q ESH:QTC=<*^QYC%^U6Q
MFALNRY@V$TLC+&CR@WC6]'.7:23G;3NM![<#['?_0 !A&81>M%(0*G'6FZ@X
ML2%%8F-@S#'KG=Z!'U8Q2^>")9:"P 0IZ4DP<$X 20I78#&FZGH)V-)'^:)0
MQY_N\VZ;9V+JD8R^DK-1 JIZ]>O_8XQ1JJ@@O$H"'E@Z8HT/A$NIM<PR66&?
MAC+8"=TP';;^>0([%MU=ALATA7&;"N=ZBW$[@YW6QHU'=;UHZTBGBWF)-*!7
MMBX WQR;LX07@*\6X[:(U!>ONIF#C2[3"GEPZ3'GKZ.Z>'I-M7B-7D?!1&B*
M9K.'"]9-1?E!U/*MFO&3 2;7,=!QBO5,B$18'K?!(,1.@>:WIM>WB4C",?#-
M:)K*U6HTLM,R9N)C;&[8/N0:RJ$M3H?76H$Z-(X[^+LE. ^N.KSE!J!A>?O2
MOS"?37U;@87+AJWX+3 B*.=A$SNIQB6R<#:J]]%,,[-AO9[MZERMH-]9UOU]
M+-^-^7-S!;HQ0>I:PVC=O/&-0_NH:0=M@W>[X4%DDW7/C!PV?3/-;G]HFUP.
M=1FL8>V+:&Q:GI;3$8 %NU:A%41*.AM'#!9:@6JVQ%64$YTBT\[I[/).284.
MV04'!YE*!R*-"R147A-CP/IPC*J<=BJT/F6<X^5GEXWQ\;$HB'=%>VQ5-36:
MXW9H=6+HA!M2[;I4SG3KSBX@F0E<%L7)2N>-X/"ZB??.BZI$N!>X9.=J;K,
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MB/7>B/3K"6Z4TS(::1^RU0TG0;2C'">GP\YA\R09N..T@AM&2:22BE@=#.@
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MN_,,)'K2J4G#[00DU)FK05F-ZW$#L;CAQZRG(\W FCB=E IB!!#'STG G4
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M;S/3< 2L9AE0#_3_WXMTBL*A*^'<O7VK+5EM4YJ1[OE2VLTY\9>O%[F8?)^
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MHZ\QWV.'#WI2K\IK,QU-[6#3NJR_RN+!H0I-T[/FDJQ?PD] 0F']?*9Y>_A
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MM+*ESQ_0F";$4XV1%]$ .%F,7$P<!>$!GA)S5+NGJ-<= #1"SC0I,6O%47T
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MI/02OV\1!%EZ(]]8O7^ R*O>9HGW5S?Y^6_+4J^T3-[>T5X!K )8NZC:<GJ
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M&CVQFBMD4M;<O4M(&T414]P202WW;&^U35J.?S]\$T%036* BU[5=9S6_[D
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M537V%4K:6)G]\13%OY/6=$B":BACS0]P!N8RO$[,RPW&WOS$(%\ZR*9>>WX
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MDW&B=*#O&[7?1NUB]&G;K&&S%&W>N<WR;MTQ>13=!Q'YYC'P_H5=\L )#LB
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M$.ICW?R=3[865*S* %T9J&PZVJFEQX\\@+AUGX:&X@X]'1_:>AXMU,08\.G
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M(<W41ZDF/JK7PF.A3!2QDYZO.%AY;27*#@3&,TH!M.55&(19DU.]8-G0:/R
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M=4!A01MAGH[IHAWM!OG>LP7OC7Y>_2R;9"6!-N564I\A1M^*<U6&'>/HV0-
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MHA%NME'XC/7 LC&22*%Y"!SX58.WX\S2Q$6A\C#EQE.XL8:R1EX.Z)#C.&>
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M1?C8@,AL)7C,:(!U'"7_N,6/(/I]P>0Z<+9/1(?P!\F5*B%KXF29Q_0.1QN
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MJ]GBTO:GAN\+);),]HQ8U^A2S$@&%U;V;U/C84YR0FF00)C5<F1@ --0:4"
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M8T)B4( F_>&>S>.W2B1B.C8+"C ]Y;)"/;,A+]<TYA%.EH'G?UY781$G--1
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M/-&7$YKL6/W,,.WD'F7?S50% 3B?W<,_R1E]%Z90NEK/M >\<C88SC*A]E!
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M ^/ELXY[2I)#E)[5ZRHUKA4BC+)@:]H-D6419&"M5?H<U=AH=#YR>3S;,*
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M!?6Z!A4^<+( AVK:]3Z.5Y(<\R.[6PT+ANCC6>(,J E_=)U?B.=9;9AY:Y6
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M7.G("S;T0AC[B  *FV"9)LO(L$!5@Z:4P$U 3>GM3H52$) IK'>F,4XVC@4
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M,A<9O3#10HH:*CPL]&J/_@MYR4WPWNO ?/KITY^/'1ZV\W2:#]50Y^(8'#Y
M/-$+PO0EP&0%IEO ?..FP2)^9V4VLK]\4>&:CP0"\4E(:YS_)"S^<,!4TX]1
MH"H<^^BL>4YY"=5*[R %Z*?^YXN,L_AT1*N7D'\Z*+[_%)CIJH.C78+6].'
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MK*YH?1]G-#[F:8<)0*$;? 1"_%$);8LQW !\N/R!-$AU4(\1U20G@;K/H,\
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M.:NH)!N1QU?JS])^&"? IU':Q'ZQU#W$U5:.* 8>T6L TD:4 ;&5ZP/*;9S
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MF77IDB9\$BZKUNO;K(<3YR-_^04/92$%C5IQ;=31"1#E_."]MT7J9 U-?=P
M+"_C_@1'"J(;O^Y\3&H__?3QCQ\U3LI&'9T L4B*0/EV$@F+UUV$PEZ@39P4
M15A0BC<(I9G<?-AC."?0H<C:1>XAS2*:$FHJ9!0M3J]<-NPQH'6J?!GC1<EL
MB;4?G=@]IE\68IZ(WIG%0<A.HS9M?.?1K.];604+&A4#36W>S+[*3%2-T\N#
MF4'A95>968RZ.7%4%:$ZW)EZA)(E;8=VX!3L7S"/ W<.BY]OF+>#O/9UM513
M6R?V6WCP("Q'492CWLJ)Q0OIZ8!#*Q5H5;-XS;W< $XJ.E$J0@)DP;\/<ZG@
MQZ9AUSL,8_^&+;/G-_3%2WY#&=!++&2@KI4-N@]E_;5D#->!!ZS ::T^E;(V
M3AS?>_2MD#8>DCC"']<T_'657)*UWD9BBP!+DKL0*=TR>@WH!$JX1,&21:O%
M-&E#)T#0; *E'09IP=J.X03@Y2@FD_PE^AY. )4;/8G2C:6G 8<8&3S*QDZ
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M[8!DT,T)\&I^$4KKK)%7A;*W$\ ^(A^A+2FC:/Y2MN[L!*CMTV:TZ^D$D%R
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MR,.(@A0>!O>FL<_ :[Q'&9D%)63'#5;8T&/@]5UO4?**B?7G)/Z6O0%VO.@
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MB=(&Z\W]!D;R31R&\;=5U(QC1<O!BZ05". ^KK=1D.'']V'_$@9K/CUWTFY
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M*'Y-O-T;AC*4Q$/KVP[KU=ZT9/1:780T^86^K35'_ LO)'+_&T+9'<O]K0E
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MK8K&*!67K.GA%AC-Z6@:NPV<_P@J!7O)&M[A*_2.PGA'(HSH(:@^X28][)'
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MN%<3XI8(;T29+Q/^X&GQYB7+9<KH[?0"^BQ2%("OC$C.GT6,<Z*UF4A9G$7
MR)/MPCW6':$"-*QC7;'9!'C7/IK-PIQ@D^^\/*)=+C9?[FU<KC)?O"&^;;%V
MO/<'3C/K@DCR2^Y@D[UW9W+/<L! WO+*78K7**)5??;+.!&O\'[)6]B<:;%_
M_,%?T*KM0C7-I*#U?\=;R,IG#&;):G_Z2^E'QT)2^^>]!;BQP3K1J%JX+W D
M++9]K%^'"Z_0H-3)/;,"L<49^ MS+\G8!=)FD_ 7;(XEXP)NTVG !?P49/0_
MOOD84-/6\PZ 'SFI4UL,M[M@Y*3\B]<K=_\3HAG?Y//K-&$.HR*(:6SFN^U
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MGGJ*WM[S^?J%P$KAU&*I;A]W>GJ?ZKP@['&?7 ?;* _BAD@2*6QU1PC6E=J
M C%-^>:%9!7I"!L[8F7\-CV(.+4&X[9U:3X7FR*FWGXV,[*MMAB]$]F]?_*,
MEOH@ULU\O0R^Q$:UT2B.F4K*3>XF]T0O?B1H=1O@A,COK('J#5I'H?"A*(V.
M@ [_VH=^$ *3>^P=>%KF$70(Z7$CHH<P-R5FE?^9WB1"J__^38Z9F5]]F"8Y
M^LIO8^85_>_?9.AMTQ!!W8#J/B(9)?GO5M%F'T\-XE@01A6&X'HER1LQ+TG
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M#HGGA)HMMTYNBN> C-D-QSYO_@=4/N'ERG@.@"7;49!(I =.51^@??\?4G6
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M3K![$J/</X^Q/&@^"4C^'F^G1L8_XYX7IY\$&IC6JWZ4?Q)08)JULDR!26"
M:<ZJ4Q0F 0.F%2M)=_#L9N,38E>A%P$YP[/ZEP&[L0GSKJ-@LKTEZB2;*+L!
MJ/$E6H>K7>L;K8)?)F/9SF':L\TBV+'("IU.5L=RZ?WQ\IK]'4+LT8V0FO,W
M01Z0#SJ$61C0V<(V@99>M.$TM)TG^T7V[^HEB3X0SHA@ND^2]*.JHKB)R&^+
M+T?H=@4!LYC3)5>U# 8 0:0A+TUT64MQJ_@I2-[X%S&[WQYU6C^),MT4&^'$
MVM\?'S'!5?'#=S 7T?V%0,$FUMXK_3[6[Z.%[TD:IV^[2C_-B!FMO)BFZ./.
M:"E>LV@5!7CW'%!S@]7#E<A8<7MW)!PF\AALR)^Z;*/1$=HV,-=^<-2=E=WL
M7D#=+^;2*\F'[Z>Z4K!(R7DQCX+X9Q03ZSE-4&U.<XUNC6Z36*G/842=M[=)
MCC Y2&=(<D5:T>.XID7P)3<M6M_;?V[K@ZB(3$.IB)K:GE'Q&I=*"V5+TC*C
MZ7:S#74?<F<E:6Z]M@Q.TGSQ'N!-\!"'LJ(RO(;6[0(:!N[J=[XUP&UI>3Y/
MP76PC7*RW8,D>&,_\; 08R1K;GEF"X0)Z3GY%1KUBG*!MX#7S#9&Z)]%A-%J
MF1)16/V&F+4EK:$IV'):6<ND,;0;>"-8AS_)"934=[5,&_.($%>3R9J[OW-(
M/<8T);F*:HO,-'%[EQ7)V5I7V%X7&$OKB_,:6^<,OBMGGK\CS)!;!%&W1(5)
M3V]O*.JZS?E5JHT\TY[?+S!!RH:_^X3@$F1.:WN?04.A=6W)W!G=W' \+#W!
M1':!R38HWE]E$OA6ZVN/'2<U:"*5E\%[;NV:RA8 GM#(XW)=(KWG6B/G7./:
MC,KO#1H.+:FO](:WK"H-O[/_D&@XHD5"WE\\!BC!08#X(4H&/'(Q( -& S0/
M*@:HI:Y^N*J)2"/JX/F53?-CF4[<XX1 D1Z^Q$$53Q%0F=#M8(RG1 ZSN(2Q
M(,@H@%$6W%,IY%N]4\A.:?#NA, 0UN7B1@@A$W[\_2,Y]'A^U]MXNXABN">$
M@V"G2*/%D,D_WG[I^(<\KP5@O#>X47O/*P 8@R!+&/#\WO^0P*)1]H'G%0$&
M\(HDN\'S:@!#F$62*>%Y 8 A:(B2+GR_^S]@F^BE>GAV%_,Z33X0V>QD;1<8
MK1%9WE5I62?E?^E)#.&,UE@BIU.(-S2OXR#+JO- ;_VZC\)SVP*XB\EF=+5C
M\].[<=GOX2XS"V-J<#(?)^&;1\(@AT^:FT6:D6XZBNT$8HKGHL#A>Z!U64;:
MWME2T )H\W4#2LE5#'Y;=YNA)VZ>$,W@0>R+YVT<B9+]='HZ(ZLI<J072C@-
M[6?M$ZMN]ETH]*59_%I=STL&N;_FLR]9WN0>V<4X8?M)>.W*6*IJ=',G7-%F
MF^( [THA\_P>8)3=9UF!1,_0R7K8OF9"%W1&F);]<47+(*:)8E<K^TRA8VFN
M*H[*$WB]LI([5\H^4-B!' WFF.VOU5^#N* 5T]AZZ[&&L/<T.N#;<!V@[.I.
MU1[XM]QI\R+/\B!9D=.\2.G*NC@FI-R=4GW%:>C6?BMEVTV!"7YER< 2UI)G
MJ-N;U2"M^><9A:0IYR:-I4&G46J#]XZRI[/%6^ T1&B5W>%T0^$.6#U#X70%
MJV4ZBN7E>4E6*(O>$N:HT5P891] YZ''-&\<:0[<_T3],-^T#T>*8>"([UF1
MOZ<X^I?0O)+U@$"&H4F@T].AA&AN#LT%4G0"0HSA,FEV=D;<3?01K5"RRAK\
M=!UD[P)RA,TM2^?'@LI3<N1D7%!;]&A%/<W%Z_^B,*?QIVUUZ./):L,1)IK_
M75HP\[ E6&FB8V\7:'>;\.;Z 8^GZ.T]SQZ";8;FR3Q!?T<!GB7E+3ER#.'-
M?=A QZ>&6'QILAI/3'\<=]J?\O@5?=2!7NA$21:4X;.]-^IJ=VA2)1C//@.\
M*G7\?4(V1U'>#J41JN5[D)0UF+._DGV#5O=):4G_#5$ R!XB%!-H?I#QV;,)
M=T&$F3P3F15@YG?R2[1,\R"&LAZ=R4PD8QNJZ*]I[XEG:5/;1[[2*[ ^:)O2
ME-'36 :]O;WJ+XV_\N_W<Z*=GE^7&1A^.&1 2_WDD,$9D-DH#'8WN440R80,
MA0:?Z&\6G6CH"8$AOERB%[($#876%59IZ+Z5DV4J:SS!1G:==2IP_+C:JGDM
M7!4+;N+$VWN0+VP=0P?KA*PA8S25*I8P%F0X;*IC:>C_A$ 0W5!3)A= OJQV
M+/M=FMG@.4!#=XK8MWY"@,B-5W6N!>2;:S9Y0YZ@<4(HB"MD\%([/+^C9W:F
M'9$A<D(X226&.L'$\PN-VAQCG)9R0L (6$2=Y.+Y#<\1+C)5@HSG=SN'Z]EF
MHH;G=SJ'@'!<(_2(5SH-!*D\>\?W^YP#@3@N8QSSW69M0,390KX_T*R$8%!:
MDN]O,YNA(DUV\OU%9CTH!F93^?Y.LS5P.,E9OC_;K&^B@LF2F@9SB,:OJ[2L
M20"&9%C+,[0F(1^2*6V<#G;2I4":=<HRA#_0JH:FP1EW*=Y[;9)9,LO"\C?0
MBFR^*+M4#CG[RB%4[M+<#LF5]78;"-=ZJAJ$^Q,#8W_"ZW=%3O91S?$B1C(>
M!VZ"<R92I8<U2U:+.$AH"7'Y([=3_-0%N&$_-;JLA>SZ?V5+E6$@\M.-$*"B
M"("ZI^VG;/<.LOVF+!4B12Z;XW)"S-B6%# 8,,KT=-3"A483\.UF&Z<[A%J9
M3Y0EC(@R&O*2[0XVV7"J++*.KH<,P41A"%V[ 30T6JFH7+O.Z) ^2$-Z IPL
MT=D)<IYD06N\6C.AX=7.]=,P8SQ/"ST*ED-,+,\3!UWA:F;R>>:\8G2\]D"%
M6*]VL']:Y:*R,# $?];@[:'I_1HYOKN:)3KN $L>$,%!<OF9+M_3(B-Z;OE)
M8-F1#^JH"0T#1A^((24_.PX8Y>*@/'FGD_N-)5GB5A/G$S60   JU [52NW$
MG-D'4=I4 !-[AIF#MI6@ZN>< =@RU4I[6%H34MS^&-K W)4X9!C;M7,//IK&
M.>Z0V\*;MK*/?SNN.M/>?A$BZ)N=K4R'^R3'49)%X215:$Q^&D21S*83H)ZU
MN J>JI^WO%*>S)T5DQHX"V_A;DB:4E]-!&C_=_R#K*/05:4J[?^.>XNA?)F7
M3]DC3<6A^6REJXT)VN;W]$VCQS3_.\J?4)B^)1+HION]TX.P%%'$JJP^HNU$
MI7N// G_MOA>HL^RK-C42G6+:%Y>?:_A*>C5CSO>[WH;YK;GI!3$Q,=Z^3P/
M5"G<]T,<;: 1N42-IP2.Y\%J77KSDV)9G-R,Y/,)< ^3RY/YZ$X=[I&Q6@T?
M'V0$AZ2*V0GO\;;Z250D&V(8V(GE@X7$KLS3=/A"Q@S&MCM"/B>DK)SC*E8C
M5[SGA;.F@5[#6>]Y/2F8+&L<$?"\9!/,5> $"CPO"P4,9W%TP?,B4]/@/&%(
MPO-Z5I[A+8A?>%Y'"YAPT8]KG$2:]G.QV01X5]VFJC38+,P)I?GNDJY]2=?V
M,5W[DNKA.!GI!TXSZWM/\DLP']XVR5,;,)"WO$(LF#6*Z+VH_3).Q"N\7_(6
MMFKEJ6B=5"KU?\=;R,JJ8;-D55MPRY1^="PDM7_>6X ;&JSC;JKEU )'PGH\
MQ_IUN/ *+2@=CYX5B"W.P%^8>[Y^%TB;3<)?L#E*V07<IM. "_AH+>1 =(^<
MU*DMAEL].G)2;A>CY]+JT_UJ;#\\(>JW))]?ITF.@S O@GB)\.:[; 6./!-O
M83?>^R(,1,G[@"9X:HMDSJA'7J0A$_16FS2(/<H=4?'O>0NA>J_/WMXP>@MR
M=!2(A\_GU):@P6P@ED!C/I<[1Y<[1SX$N8^;J>1MOO*DP;%+TBX/Z0'QM$L*
M[@0LRXW17=)%I\LS;P:C+NFB$^"L'PN\9)%.:VO(/9R7G-(AZ-L,)%X22J=8
M <,8H^^OP@)=!>/@H^\OL<+4!F-CDKZ_!.O5JCA5W<=\E';"53EVE-+W)W!A
M+H7-R*7O#_%ZM4*#PI:^/]L+4\E(8I:^/^,+$_ 1$4[?'Q;V:D%TXITG>.>P
M]S5%)<F0Z\N'6M=X9S'[<?(7?8RY?5&77N'->HPTI,ZHP:\ N)9HAR2]*XHV
M?\L9=/<)V4QDKY#]3D7%0S59R9L8LA[NWFLI8:Y>(^^M0K6M!11I=H:V1M+G
M0.1]3H<4]P^=T <]B5GP3G3J#?I <;JELZR81OIBATY/9V3]0 DYH\1D;K/5
MABCKC!Q0:/U9'<+T^GJ;L#21=N9G+UG5:) SF094MYM VS<70:H;(4.I<3HY
M @_KZF302&K58=8PHC3XZH2J--L$Y&1J.&O9/DU8M"P+SY,FC4'1M$L\<U:4
M,"R#+Y2!?+QV3G0SF4CR]I!FV76 \8Y,C54/4SD9='HZ,W+%DY.Y %2]')^N
M"!=5=0GSG>)]2TD']T14._J*;/AU)'KW4=3:_?3WD&H<;CG-'985(K*8B%<J
MBN/_*7"4K:*0RB#ID4_5"]!Z*)]2E78Y%4+<.T[NR3$=$S7W1&R;I*A/(O=/
MSU)&4_4"M#Y&@A>(T!TGM48SE>"AUCI8]3/ O]*JI'F!NU,3MW,&*L$$97D4
M7J=%DN.=E*WY;2W#^/)K8\DBE(D?YQ6T= <E6B.,T8K.*LL0==I\79-_1WG+
M_JI/3"*0#4<!:)<:FZ2V>8A_*"U1I,5J(\P.+'\GC7B,9=+=\LS[&-U5&*FG
MK=W7]@O5[S2NG]TG\T]R[,W>H^W5CD6NW].8'-6SOY#_J)^L-A[$)>,G9%-R
MEH'7PKVZO/T*-E'"EG^!B%5"925A;6:D$'D^"T-<".MNFHX"GEQYF-5T%&_C
M0P;.DJ9G2^F,@.S_U([>:+I<^NYAOEL#,B8:[L^!K"+TD7@.A^H8TKZNK?!3
M@,;"(*XD\^>IM\G)195LP'%B,26Y4Z@-BL+G AJ/@9M&GT-.>K.8PC#M)CGZ
MHXA6#(^3>&O4T.B0>. \!\+$W! X\TX. <DCM"+WH>?5A ;:X,8N2<]K!5D_
MU7K_$.<0.6KD/O6\YM$0?/2=M)X7*AH"S@!OL.?UA(8+G8,;V?.B/N-=1'HN
M:L\K[TP,DV&V,IC$PN?B-4/_+&C>Z <M40,RN[ SR=Z"=7.-1,W=Y4RU9R2]
M/\AK"F;BY*<D62NBUI"F+\U;$;=W2D*TB@*\>PY8M6*JSQ5KP&_OCH3#1.CI
M<;Y>XB#)@E!YLT^CHS.B%C@-$5IE=T3+T**P01*B.2YG?/O/@F@  5$:'2TG
M"505:LDO9+,WC%A84YS:(VD-91_+,TVY;=WQ25EC(:OXN%YQ=CU*Q"&R+I9Y
MXRZ-X_1SGLS7:T1K&HOY0M#R"+Q*S"S]:9H-X&T.@<HD:D5"N=:')S$,221'
M89S((&@8 J>!@]1$:"&AH8Q!0Z)16<=@;^BH<=_AT#:_]HXDF<7@.QJJ(X%$
M;/@ @?XU><F9M(N!0+IX'MPRDA-2,\YW(,PEA,@@@XS$)%N#:X!X'O&TI#$D
M=CL +VGO,,?0(;; YG>WM%\6D56_38H-*J-*#Q'=ZLX*6+$0\F.:A 7&%-O7
MC%4$%1PAA<W=9>[G[PAWIR68/;^M*6.$01P6<3"%_WQ?C^ Z3;(TCE:TC,E5
M$%.5\/R.R+R_<3BE,2'N1N=OY,_/SW_?;^;OO__]+_N=G-%:A72TWT9D-ORM
M7*)XW8:[*<.N@XP&F^E_J+W[078P#0.420IDQU;%'0]6RB>K4<NDLE*RN:#X
M(0I>HSBJXC/-\&?;+=<$H=''4U(E*SP+0YJ3E!$3ABJR?4M_Z"R9F$M;F[W]
M(:G%<5*&]) XO4UWG6XV:<+:>B=DE&*US(.D^^T9$07&7<EO\.G4DS"'V#H*
M,E3WV7E(KUC2+'!*J,QW"Z+DJ65+^9KE9CTBKRC4VYL+7&4O<K:G!T0.L0&6
M:+--<8!W99/:_IEMJ/*<Y3F.7@NVH9?I(FCQ]7>O )%;"C371Z)\/"!5O(4%
M1Q!_2%,8#0(Q[">M>IOVD*ZT"*+5?7(=;*,\B!NFA4\T*ZT*(I:WA,XJV8R(
MM@9+=[?J+_#I'2*F>:W\H5@BG%J;]XF2,5^_D$6F/7PB47/CAF&QH5-#)0_3
MRJ\8O5.WVT=5[9 F:A+C:KY>!E^G!\ 3S:E,T.HVP/2%GZP!R U:1V%T6/0_
MF-%\3(?DM=2/UV[C;*J:+BXN"7I]G9&F*T$[5"F[02!(/7<0TY1O 4Y#=UM6
MX CD[UU^8\?R1BIH7-;$U-QXD+9:W__&EX#=9LXF+/6I<><NZP&@>!O?6\8/
MB<D[N4R#EKC%N*1(NS@DA./Q$LR_W]+9M =XK;A$F8_C4HV)O%0B329H?QK!
M<!#22TV&LI\[AM)P(O$Y2]W1I3Q3NXI$\DW9$PC[]=PD&JS7[>-2CIFY0$32
MS6@4A^^@J1T>7 HU.O93@SK)/T?,#3K<K67LEAV>H[HK<O+ISRB)-L6&?5EG
ME;Z0W\-4%-($HIBJV3;/9M4-W.] LHH$PGQ$;-B#F/\#(O("">BI5_*FX&:*
M2ON2U2<\0PTMPN1?(6E:FET^@3.>(SAA*A\BS2.80HC9,/*=VG]F5A^XZ?MY
M^#9EOJYO4K<[3 +%8M.<6N%8T!C5[CG+N;'$3:3>?YC-US3P<A>GGV!,'SJA
M3C3H"64YCFCUPRI:U/Z@T9+8XW%!2S 1(W&;9D'\ Z?%EM;ZHMR7D&4KB!F_
MK6X<<./$)Y>O[1K0]MBPE:\+K#@!T:--X1(RGN0]\A:_"\[<K49>J8P&_\"0
M< <O#+UE?EWR.6&$PT2OT#IM/?)Y^Y7C@$BB* GPCEU*I0J<]"0_2G[AK2X[
MQA-HI&5:&P'ED/OB9/YHA7F; @J>] A5D<B]OO-;\$0>9L_53^)7?GU:4@E?
M]JF^3SX(>U-*RZ8'AO>(8)3+N5?X3(='/'QDX<:5"_ZXB[1VO.():Y_H-=KS
M+'ZAUEX^D*VW\R?:-9!/,$<0%]QGQ:;Y16<P*O=5!P1Q>_<.KOY.$;FT&BW=
M3[LKP463WK=S>>*369"B Z"DCT/Q(3(+!7M?T-S=QN5IANYF;;6!\*ICVSJ5
MB-E^:V?35UI17#)4O=RFC)F*?44GK]PZK<06MC-@V'J<A)MNRD[/R.7TN2,F
M2/26E#'%<->HN$1XD?VKHFOUOT4ITNI?6:28?2&[HNS!:=D2CI0S9A]!Q+)H
M"*BT)-4A^;N/GD_'"D.(.KIFV#W8H]U%4%'6OY8@[.%62!]O<XME_M'F  YJ
M\_UOA*+Q\'Y:FAZ8 W5BP"] [ "")9W3 J<?$:'[:O>2H=5]LC\'SLA>^Q#6
M;N#+:A_4]IAX\ +A*"4@A9@FJ]R@\K_[*/'M5\A>M'HBRWZ[7J.0ZQ(NOYFO
MFZWGR7%#Y?ZLEX!-RY.RDDWKK+!E.@L)7!@)+W-Y%<00@'(7)4$2"D%AA4\K
M1.;KNL1I51+8?^HU)=<-(CHRC-B/>&5,.Q=<)ESG#ZZ6!0SO"B\/#M]VET*V
M[/%HO$_PMP 3,SV__4(XC+*3X I-&<.J2U^1';:B)CFQQ]O2QH/23F"E#7=?
M^H/K,+YBFGNVH>?:?P75$;CYX"6BGSTA=L=LF7;N8OE4BP@LVW$7R!]<[0GU
M_:,S:U[1.G^AT)3L=T&$64+LP74R7U>*+AM: 0L0# ,X@G$ /4^= OV:;- 7
M,LP!]X1"1*01,?X.6/S17YMO,!CM*_D9PZ;YW/;9 =*I3K7$P>J0(/9?Y[=;
M^C5.FF]LGR8:/2-NOB;[9!,5F]I11SEDGO!.D*VBW?YZ[89+5]75XY,_4OX(
MHH3ZVN=)Z>.-2@XJRYQ\.P#QW5"Z'BVX8TA[/_*C.X"?$2R/+N8-/F?9O)IG
M/@EG8$,(^' 7 ,#$H$DDB=M73R+Q!G#^F+=.^(M+I,$ T%92<I+56TG> )9?
M#Q<%XUK3E+5T!GH[BL:%M=4$SA;@!VCTN)_;UV4M4TFLA4^1K(N[<L2"< F7
M!$%CRSMSN+.]OW<'CP6"LP0.7R5[\?LY(TGAN.62(^\#8G6:SE?EDC0:N[RE
MH?2<<@G1Z B(*+X'5),P;F= Q/&]F9K$<3O#(J[GFM0GK=MU0K5DZCZ4*R;#
MT0 MF%F%/_W^[FZ"*5Q]7+H4G2#E2A\JSNX5[$\"/?DWL[:?J2\5[^9K'N]5
MA66!Y%!W,^MOT&O>R*XOMQ<U5+.<6*P1_TE@^1B'XL$_,%G>EX1P;4P'I0M>
MW@1OW@KR(7]S"M2:'-(<#79U@:%(=&MJFPX#E6!=9A^"@N;88* 1<[06]<+N
M/FJ"_;?DS](K%\2E9JN:KV;YH0TY4-/:H42C,VX'IC+8M/>3/2# DW+\TGS<
MSO[<Z#!"X% 104HV3.FN(I3[*ABO/;"ZDOHDZ?<'4*+#@"Y%)Y@RMH[==-ZP
MVDM9:A_00A+-]RH.+GQZ0.SWAR5<=5[WZJ0Q\MLS$\$GH6I*N6"1R=\QJOS4
M3>^ ^MJ<Z=66RW-O=@BI.-6,E+(3A)>$1C(?7X_:&AZF&*^\C+5W^/!>3^<+
M6*)9^0K>(46R;"FMZ-5[/=X#$:V%P#XU9[.-TQU"56R0U\F?RW1&E+.*AMTG
M?_VYX&7,YT3\K%&6,2*>$?Z(POX:>W"?PFB-RQ?ZQ#WZ5R?@F!3NG_,4Q8:,
MY"8G&F32WUTRI5HP<I=!W<_=F[@\B<<E@M=R&BZ22B4A[\AZ.7Z\UG#7*CK!
MM RK!QP/Y_G--DW*\D/L*WK AV45[J?%U1*MP&S9RA]S3TK:7P,<T4W<I\P#
M<TY*V?,[.5DM$=[T20-9R:]'3.\9MOI[]R6<57/E-'0V:0Z'<^?<;^<P#;7/
MNMPY<QJ"5@@67_0%HS<F>MNVT?>1+,/R$\4?Z&>:Y.]>N8./@<_?R3%A^9GZ
MI;F.! N12,@GK\6Q@+E+"^Q3L9"CX1)]()^\/<? 9;;.$>Z!\Q\PC<AS?MA8
MJC-'$=P;#CP >Z4XBNYZ%#_(+97=>(+9.%Z07*JQT12S8?P@F(G@\0338< 3
MW%$\HZANCP7SE-AX2>QP5*1W"<JLV+L4-UK .@<>^37' 3]W0_[(\BCTZ?0(
M']7J<0C8^9^7MP-=P7C8=+9@VH_H$PS[76(+A7I \'JL&?IZ1/D-6B.,:5$/
MH'JLGB"96ID%+DC;[+7S+E&UMQ2<B[;[%)D&N8UF3Y3"^?HE0PP#'ZG?KU^#
M+-TE?_2<Y%;&JI32@WE->EP'&.^(//H,\,I+CM?=V_R=X=$+ KI;G -0HZ51
MRCET*,;L=WJYI)QU'*>?-#[G)3<,V/_DCVOR[RAO[?TZ0<U'/ABW)=IUE#T(
M*XU;^_JS*O>0KCO^0%EY10D709Q)R@B?!#I=(ZAL=AULH[R\N\Q/UFP_Z>1!
MF,TJGS3+@A%<JH>=,W[=L%:"D@>!MZ$\<["9^\63#4-J,,D6&Y$MH6F84@Z3
M5OX2WR=YD+Q%KW%Y+&I><>+5WH?C)Y,9R+V:DIRF<"8NNXPG:.Q\\C*31$ "
MMXOE/'3-HW]KG@8=G<.N.!&HF*?3"PXYLC.['FF2$2"0J7=$59&J-0H$<L5G
M4+W5Y/2$0Y;J@*E'HF(4".3V#Y$&#.JX_J2]HZ'V<@X:?CH%:';LDZI$HZ$@
M+_F 4][0Y3?_J:E9@7N:TUAW7C\XBZPIF9J-IP9:>J;2 %S6'WP0]9 ,U RG
M[AM4NP-6(+4[NVJS\CP%U5U.80]_(DPJ2H2T/^=!CHA(>R![)#Y/"*J4!C'Q
M@%.+A'1R,SWZK=V5E=-:K6XM.7DGU\2H]I*,)D5?UZ2)]XB,*&$O\(KO"85I
M$A+SB/UD7^4M4[I@!<%[=X>(D CB?0OZA-8RK9.J#JE4L+1D^?!7](%:\^:E
M@/7<SORN;<06"&\":B[<1/2U(D0._5YE; R#1]Z[C=#>9>!E-'MZ?"K9T6I1
M,U,>$20\"O-.C]:/*,XCLNG"9G;,+Q[DADPLAUY^?;HIMYE/(=[I^>6:O?9X
MGYBD&GD0))X>N/K%H?*CY(WERW<WG@<AYNF1:EFT#=-J:"3Z-%&:Y97]N+<G
M6XV'OA!_I$ILQO!PGY_5&L"RGV^X$=OW^0T>"]C"J0U4@T54#@::>+7U.1@*
MY="@@6D;FH-!: WC8&LW[<)A&[HQ N@%,[+T!J^GR:^ ADMNWPW&1SHL:$#$
M9MQ@,(1#@@9"::D-QD,ULK:WM/J6_M]KD*'RX__S.T+IGX/M-DK6*?VH^B!)
MTIR-P#ZC'Z&8/;KT;]%J[+/%_Y8$&[)8P_N7BTW7,_KS)DU07EU-7I+/?_-O
M6?&:Y1&!BFH2G!;;NFEER;._R9!1NEJR@58%KB*V212SVG;__9L<TVH\ 1D)
M!R$QJ]=!G*&Z\VL04UE%>J+76L+S,3J$2&_)G#:4GI<,K8OX@2QZQG\R9<F>
M/45?^57,7E(NT;(Q4HG;*L>_I7]E?\[KKXX"G@2F]@K73W#>)ZRJ3[Q[.A28
MKN$PZ>$/NSP6FU>$YVN6.D*-X1Q'(5EILJC/Q>O_$EFQ3)_0MB 6<G# PK17
M$X^,]8&S_G5*YUV5)4<6,2I_@!9)Z:^^JGV3UC?ZD6M2*[4>O-&=_!41X;Y?
M1^Y7W3V[+1NY)D.0%E:>XOB+9M0%W+HMT6:;8B(YJ'3-=^RI=/J$/5K=%/0I
MP07[P7(+LB]?MFER^T56*\I0\R7Y$@QKP\';S%W2V*2NT^0#X8R%2\N_<YKU
MM,#5D6!/XWT2T7/NHGB-HW!.#[X$#1%J5H:&A^#\:YWBU7,844?0+;6+MI@L
M>_8344&_%X**5EW)L4HW091,3!O[MTS#H<\\37X&61:$[P4Y ^8=JB0-0!(T
MYL7UOAUL.H(_ILULM8I*CW1=_6R^IJ8*,63+A.)-]?H6T7KT]!>%+'DPR(.&
MAAPY"!BTPH9KB \7)06C=S)]8MY3*V>1$J&UZQT+U.W &OTOOU(_4)&_IR5#
MM^6 Z%N00N"9C(>RV?>VSJF4]#Z5NDV@61^09%/F*XC>(5N-J%.RV?8GSS:I
MZG8@R:L<$(N '*N79%6(1F+1)N:N8S<@%D&T.IBW>JW!""&ER&9'Z]7S-@CW
M KCU47?1B.D4C* D2H@@IW[4$3*E,IB#F.RL-XS8MX3K[E+J7YXGM='7V8EF
MG4#R*GV?(8O>$L:"+8G2$:O*=B#)NXZ)07@X]LPQNZF2M3T?E?%/789$XFRH
M*[FI*<<, >^,P&-:-5N#7F1BT3(+!F$V=8'%HVH%UMZIWDG9)Q3W*),T $L4
MVQ^+RK4H8D1I&Y"L.'LCTWPC0G*1YF7@_6=$]A$YF>Y?Q-F?272:@E'Z6B>/
M6N[-BYRJY%7ICZI\DPVC3M$.J.MR\,79DN[!W2WS@+:Y9'Y4+T]=A)Z[%)=/
M0E'7).W-GH&JG\IL[6M:G:"][4</ U(RL-G6,18:N:SE6<81>M)V(,GK>%@G
M<=O:=-C"/D&]9$L:ERSP[BH(?T6KGV2VN]*9=U<DJZ[+0[,U2,:9Y<MW5$ZV
MWN6]$]4S36Q8L;='>>>P44. !.4)$8:GNB(EID 5TIMMJ%/WX#40MP##YVJC
MP22<]8@^V5>#8F&-SO#.9/*GL>5QT$,K,,NN%&^\G)/[)(R+%:T!-@O+\$7U
M'G5='&5?-F,/R.AAP""FWB@ZSV=7TE"C)1234H/NOC'(]OF,96W,\7Q;SC+H
M&5)#>H)4!M?!YA5'JS<DB7[*VX D2Z_XC.#LQ&T+A:O5!Z7ZZ,][@;GC'> U
M 2.WE)0N44(@O-]L<?K!\? (OP;)L8\H)U(U1&C%+N'7MB;WM$%-3N;B8%(F
MJS-P]E$?.V/YPP@TL;+2Q#2I<!_RBIKVC:0)E+VM8=)^ILOWM,B"9+7\)-_L
MR >E@4IL$^KH^T!,!?4='T-Z@MPHFC56>[)=UMAS!M!S?0WJ"I(%FCFIAQSB
M,G3V$&PS-$_F"7N[<98D$77KD/7D);0:=+;O-[816FXK<-W,=+_ST=NTE.=P
MFIN<TWPC]HL<DCG-FA37TW5]6&]XFTKA7*MI64S5L!/(+5TG'@E=K_P\)65S
MD,2:7O<L:3;M!332)4][\2J_Y7#]J5]9MW*'J.Y-:7<$&VPW*S\J.')+^T"Q
MSM07Z]C)BNI3E-&'P;/W-%ZU7>O2)O[HX(?@-<7T5BOUC]:9E()$2[VV,#=X
MJ6:^F6DE=7/ Q%YI)<_H- 5)Y%\"C*,L34H[N$44]RN01#0=-F5,BB8Q'_)=
M.$%_C=8@2:7G$WIMM#1OGU!>X+T6X7\'U.RQYMP[*\]>'5P2RR'^UR!Y^2Z(
M,"TN0H0+3:A@W_XMRM]?DO25OM5 1[U/B'KLU'*E_R1&(5G2JR"+LGU0XG#S
MDGM=8^_[//[O^L-@>F%^AIZU"[3JT?S![RFH,@U_!DGPQKY\6+0WJ;0)R(U:
M7F)]*;U_S$.>I!]5Z9)-1#4.Y\ZK1G.0Q%:VG)&)JVX-DM3Z6L4=.6Y1RX?-
MF![ R+JQN\J-$)I.T^8VC<B';VA,10![5XW*^Z=EO0TV<4F=#I,>37I')S?9
M(%?H/9%<:##K ];M4I$AS]OB9^]H]H'B=E$'Q9Z+[;;\+(@/JSA?7P?9^UV<
M?MXG1$"7E5/W]9O*>RT"]YRU\<"R3UG]+KM/YI\)$6GOT?9JUY1Q?R'_X=^P
M,.\(]42F#@26B;W#@HB<OC!CB-6%H/FZ/CBV;I:(O@5CHJK%P_#"N?J!%WY_
MH)Q_NT'XC2PE^<7/_)VZ9(-DQRKYB2HZF/0 *_-JFZYQ2>RO:8ZZ)E_O:WAF
M'KLV/*/N=/K'56/&G<Q-93N0=KK.G0MY&'',"" A4=Q2\>L&RA*%[TD:IV^[
MJAB.P+VG;@>2/+Y73"!9-1N#%:IWT1<Y3%'CEY-V)/@2C.U@F&M$Y2?5[+3-
M37#0'*I637I7Y!/7:[8DQLI\W=U3AUW'_[9%!9!\J=9KG[5NVY<<I>\?TPL:
MM0I0)6,,&0/LQKP.<)+F"T+')GB(P^Z5#NZ73L5I6>0Y(ZNQ"?[O_P=02P,$
M%     @ [8)F6"F7'XWB1   -0L" !    !P97!G+65X,3!?,3DN:'1M[7UI
M<]M6EO;W^15X>Z:GI"J*(2DN6C)=)=M*XB[']BLKD\DG%@A<BHA!@(U%$N?7
MSUGN!A"D)"XFK+ _="P2!"[N<M;G/.?'238-__%OSH\3X?KP7^?'+,A"\8_K
M_SEIMYKM\Q]_X+_ABA_D)3^.8G_NI-D\%/_UMZF;W 71A>/F6?S_@NDL3C(W
MRBYGKN\'T=V%<S9[O/P;W=</[O6/@NAD(H*[27;1:IZ?!A%<\N,/< %=.%.7
MC>,H.TF#_Q47[=8LN^1'G63Q[*)U2=^-W6D0SB]N@ZE(G8_BP;F)IVZD+AS%
M619/X=I,/&8G;AC<11<)/A2?AK]7S_'B,$XN_KU%_[M\F 29.$EGKB<N9HDX
M>4C<&3_N@8<\BD/_TAI;!\:V<C@PEH? SR87XR [\>!*$>$8KO_GE_=OWM\Z
M<I[Q%C +L^(<R'<)Q1CGJM4[_?OE\FGI-MN]IP93FAOY=R(7H]?O_=V>+P^&
M*I(M3UAWW0G[]?.'3W_\>OWQUKGZ^>;Z&O^U;-Z63U*[.7CA'%GS@>M0GHWE
M[[_9Z_[GO[?[K<OG;8SSCERV(/+AUQ?]YEEOL&JKX%[:9*MTX/?]OS\U-<_=
M*)L=I-M)D#K7TUD8SZ?PB7-UEPA!_SKZSW]_[+3:WJ7^B#_P+X\=^,W4]84S
M$MF#$)'S6<Q^AO^\C[RF<Y1-A*-^^S:>SMQHKG_9<-S(=WYUD[GS1F03YYWX
M("*7/H1[BO%8>%EP+QPW=?[I1CE>U^ZI97SA[-R+) L\-Y1SG.8S.(UFRLZ:
MK6[+^E][S1G,)FN.;PNKUW ZK4ZW..77>A+?N9G0,]]<^S!TSU8=AJ?'ONHH
MM.&!=3D*O_]R?7-]]:7AX&S*C>OX(@T2^'D6.X).B3./<]JO^%_^%K\<"?F]
M\)W1O'"+.*(_(Q@ Z(-I2K^&Q_I!%L11BO_,W"""'TY$(H)H_95:+;8V6ZDZ
M":V/GWYO.+>X7#]]NKEN.$&$DY@&ODA<G%,G'M.43_,L=T/X[AZ$3)3QS+M*
MG*5ROJT%P.]C^&7BW,4Q_WGOAKD["D7Q";Q)$N&)8);1=6D^'@=>(")OCH^'
M5_<F*-/P&; A7.]K%#^$PK\3/O]XYH)X@M>E\:# &\=A&#^D%Z7EMVT_:P,,
MFOT6[  _2&>A.[\8A^)Q8;'_S-,L&,_5S-%%)VD&#[ZD)3R!Y9FF%R,W%2&\
M_^(&T//?;_;[@[VM_J#9:?=ZG6Z[V^MUNYT!&EKJQ8,(AWY"[[_B??_VC[8^
M5]:,\OW;K5;YAI=_<P+_O_[V.!P*K1R'+W]=FC!?>#%OFXL<SFI"]]^&$:Q'
MMC\-9(05NB#&$5FR:]%EZ17E5ONT.>CU;,'5>LE&?D)HM<'H-V.'9YV>GNYM
M'Y\VSUOM[N#LK#-HG78&QF&04]%Z^:X^<H_7V=;N<(BZ: C_ UDT]%A5#=.)
M&X9RQP]!P=5LP]_"D/>XU9U;2ZO35%79!/S%"GM@EB=I#NH(S88,S6]C<\,Z
MP'\]\/Y1(4@M5C3HE/60!5&.U^7PKQ"T#V@;(ZE0\>#Z!A'\PD?]Z'JP)+X;
M><)Y",#P)@V4Q/=!2C8(:BEX7,&0Q-DVYJ/S1YPG]B/T;=1[/03\WNKW;D8?
M-=0]G*EP(QQR-H&OYJ7;3=TY_M@:==F,2GB:4=W"-[!H-!5C^!P_2(2;@N9/
M\]&?,%L\MT(:7#21]D1O16KUS\]72"WV$=<57.!HG[9?N>0:K26Y1L/A+$[)
M=!["^@_]'*THD&.P.:3\2D5R7S/)]5D.F;;L.QKR/@79'UI.X5R1]8FG!7QX
ML&]#.')Y!"8A#?:+\!*1H2,NQ9$ZCV3TTCTF+MR")- L?A )F]F\+GAG/-GC
M))[RF<6#B?\=H?P1J9<$(^NL3P(Q=JX?A9>3P/N$-C58X\68PO6GHEB2P_#%
M?0SRD03+.(</'N+D*\D;)2O$&*1%EBKA,,I36-Y4N@7CL1LD:=5;DF"+XLP1
MT9U[)TB<HD B1\'<!&5T0"_MYPD^MRSBB@*MX8A'3Z#WD,*_<"[2<(ZQX$F<
MP/*2U'Y(X(:H#"(6XOX]27#T)^ AQ<L3@?> Y[@T=<7W>*' .S@7+Q1FG36=
M"S2\1)2Z6IPE(D3E-YRZ&>BNM&XNQUMKO+0K;WB\SJ\\WN_=$1GLS!'I],]?
MN3Y?VQ-!$3%,W1"4#.OQ9!A$(/C<T'Q5LW/P!L;E?*$A[UF/)XZ<*P?GRN%I
M-$[(S U\M)DI7(7N ^B%_^AV>@T8F#,#_347;B)O5'D#RZ"&RX/8#SQ0-?<!
MC$[JLS>QF_AHGBM]HP4$_#$-0"YH;<27+F0(%G]@*7ATNNR1@1[D/(%R!>Y
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M'6ZV]OB>MK4V@/2XJK?X0O9.R60KG*NH$S"\L7MO8=."RU?M,-ROZ3#<H\-
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ML\OQ@88"92HY,D.<R)PC*"G[O1+%V= A>G6BHS@+O/*911G"S)MC].!=QYO
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MM1ST<!F+(@&=@/ %J%6 '5R+*0'C#7(+.2?$G#PE;LW2U&!IPE%Q!24* 0+
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MDEO?PAZ9.5R'$/:V*D\1"Q&7$SZU?G<[VJ'O@K_[Z6C'?XO\+U!+ P04
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M182T55<>D-NDH;FLCDM2$\)-(5B7A;6NPX19;:JDULZ9FP\_$AW>J?EYEUI
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M              "  >G6 @!I;6<R,C0Y.3DS-3E?,3$N:G!G4$L! A0#%
M  @ [8)F6#LQ=Y()DP  HL0  !,              ( !EW # &EM9S(R-#DY
M.3,U.5\Q,BYJ<&=02P$"% ,4    " #M@F988:HC?KR2  "KZ   $P
M        @ '1 P0 :6UG,C(T.3DY,S4Y7S$S+FIP9U!+ 0(4 Q0    ( .V"
M9ECD_GIT'(\  !K?   3              "  ;Z6! !I;6<R,C0Y.3DS-3E?
M,30N:G!G4$L! A0#%     @ [8)F6&2X!2:/9P  H(   !,
M ( !"R8% &EM9S(R-#DY.3,U.5\Q-2YJ<&=02P$"% ,4    " #M@F98N*%T
M$XB?  "OR@  $P              @ '+C04 :6UG,C(T.3DY,S4Y7S$V+FIP
M9U!+ 0(4 Q0    ( .V"9EA8'[?ZS3,  "H^   3              "  80M
M!@!I;6<R,C0Y.3DS-3E?,3<N:G!G4$L! A0#%     @ [8)F6.4 CMJQ,0
MJCH  !,              ( !@F$& &EM9S(R-#DY.3,U.5\Q."YJ<&=02P$"
M% ,4    " #M@F98<>1P1^':  #\(@$ $P              @ %DDP8 :6UG
M,C(T.3DY,S4Y7S$Y+FIP9U!+ 0(4 Q0    ( .V"9EAUK-?\B6\  !]X   2
M              "  79N!P!I;6<R,C0Y.3DS-3E?,BYJ<&=02P$"% ,4
M" #M@F989X6QZ8U& 0!:8P$ $P              @ $OW@< :6UG,C(T.3DY
M,S4Y7S(P+FIP9U!+ 0(4 Q0    ( .V"9EA#IY62Y?T   M< 0 3
M      "  >TD"0!I;6<R,C0Y.3DS-3E?,C$N:G!G4$L! A0#%     @ [8)F
M6/;F/%<9Q@  E?H  !,              ( ! R,* &EM9S(R-#DY.3,U.5\R
M,BYJ<&=02P$"% ,4    " #M@F98A,6P$K9G  !TI   $P
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M,C0Y.3DS-3E?,C<N:G!G4$L! A0#%     @ [8)F6#3)E^V(90  3X4  !,
M             ( !,18- &EM9S(R-#DY.3,U.5\R."YJ<&=02P$"% ,4
M" #M@F985"BLKJ!\  ";K   $P              @ 'J>PT :6UG,C(T.3DY
M,S4Y7S(Y+FIP9U!+ 0(4 Q0    ( .V"9EB-L] ,G%T  'UZ   2
M      "  ;OX#0!I;6<R,C0Y.3DS-3E?,RYJ<&=02P$"% ,4    " #M@F98
M*Q\6V]%[  "XB   $P              @ &'5@X :6UG,C(T.3DY,S4Y7S,P
M+FIP9U!+ 0(4 Q0    ( .V"9EC]440C_8L  #Z^   3              "
M 8G2#@!I;6<R,C0Y.3DS-3E?,S$N:G!G4$L! A0#%     @ [8)F6-S S./[
MA0  J)P  !(              ( !MUX/ &EM9S(R-#DY.3,U.5\T+FIP9U!+
M 0(4 Q0    ( .V"9EC.(4@U<CD  %-'   2              "  >+D#P!I
M;6<R,C0Y.3DS-3E?-2YJ<&=02P$"% ,4    " #M@F98=/CFEUJ& P#EL 0
M$@              @ &$'A  :6UG,C(T.3DY,S4Y7S8N:G!G4$L! A0#%
M  @ [8)F6*S "D/U"P$ F4D! !(              ( !#J43 &EM9S(R-#DY
M.3,U.5\W+FIP9U!+ 0(4 Q0    ( .V"9EB^&PG+)'H  ,J3   2
M      "  3.Q% !I;6<R,C0Y.3DS-3E?."YJ<&=02P$"% ,4    " #M@F98
MS&/^).Y;  !7BP  $@              @ &'*Q4 :6UG,C(T.3DY,S4Y7SDN
M:G!G4$L! A0#%     @ [8)F6'L3U$LP=@0 B>DJ !$              ( !
MI8<5 '!E<&<M,C R,S$R,S$N:'1M4$L! A0#%     @ [8)F6!.'=?DK2 $
M=)43 !$              ( !!/X9 '!E<&<M,C R,S$R,S$N>'-D4$L! A0#
M%     @ [8)F6"F7'XWB1   -0L" !               ( !7D8; '!E<&<M
M97@Q,%\Q.2YH=&U02P$"% ,4    " #M@F98VT_7X6<"  #W!P  #P
M        @ %NBQL <&5P9RUE>#(S7S$N:'1M4$L! A0#%     @ [8)F6$1I
MJ%F0"   H#\   \              ( ! HX; '!E<&<M97@S,5\Q+FAT;5!+
M 0(4 Q0    ( .V"9E@>:+Z'C0@  $P^   /              "  ;^6&P!P
M97!G+65X,S%?,BYH=&U02P$"% ,4    " #M@F98#=#I(1\%  #+(@  #P
M            @ %YGQL <&5P9RUE>#,R7S$N:'1M4$L! A0#%     @ [8)F
M6'HQ+G@G!0  ZB(   \              ( !Q:0; '!E<&<M97@S,E\R+FAT
M;5!+ 0(4 Q0    ( .V"9ECMI3W4Q14  -VB   -              "  1FJ
E&P!P97!G+65X.3<N:'1M4$L%!@     I "D /@H   G &P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>pepg-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pepg="http://pepgen.com/20231231"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pepg-20231231.xsd" xlink:type="simple"/>
    <context id="C_de36be0e-422a-44fa-b610-cce5387a9700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:ServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:CarnotPharmaLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e714e23e-c60b-4649-bcf1-f9525f905459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:TechnologyLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-31</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="C_3a41894a-8ad8-4c44-9399-b1722da555e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fa6a276c-2e4d-4050-a264-a051017ad010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d1b4f98a-2717-48fb-ae1c-8c5f9097d55f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="C_896cd8db-b4db-45ff-915a-26b26be0959d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pepg:StockRestrictionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_bd645434-03f7-4e7a-9254-fc4113a4fc17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ed06b17b-3586-4df6-a87e-12566f6bab76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d8e10c34-dfed-494a-8b1a-5d7203d659eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pepg:UsTreasuryBackedMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_220d4a87-56e9-4b2f-88b9-0f2f98c86ac0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pepg:LaboratoryAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7ff7e6d1-9dc6-4e1d-af82-7945a62662d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pepg:HarrisonLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6b88145a-4875-4cd0-a443-e63d1611c62d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9fc357d1-aca9-4939-8508-2e6b6c2e1aef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9444a584-901b-44fb-95ce-d2000dc58dd6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a903df65-a661-4f64-9e9c-45d340ce2506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pepg:AtTheMarketEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="C_6da8e9ac-df70-4c39-a066-f43de00ad6c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2a6bbe33-4c45-482c-ac03-94f727c30255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pepg:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_56d10337-c99d-4729-a0be-2f97270f71c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_48802948-74ba-4e4c-bd84-6de3c161ffbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pepg:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c12cd4a1-d2bb-4e7d-be33-635f490062b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:ServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:RaCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_16414ef5-2d6c-482f-bb76-768259311b2c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pepg:StockRestrictionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cc8621bc-02a4-40ab-b23b-4c8af4926152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b1cd4d63-b40b-4d86-834f-9218d8c92734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pepg:TwoThousandTwentyTwoEquityIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a02d2713-9447-4f0e-94e0-cac5b3c390f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_efb79f6f-7f45-4f73-8424-9da26d4e839d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cab43832-788b-441d-b9a4-b33219debd4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pepg:StockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d913f63c-8af0-45d4-9fb8-34b4620d0aa9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pepg:HarrisonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0686ad9d-2e32-4f08-a030-a696dc15aec5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pepg:TwoThousandTwentyTwoEquityIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_74f25be0-4a88-4a9d-915a-d6fbbd72d532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a65d95cd-5bc9-4e3d-baa3-39ba00afc7f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f5fe547c-69eb-4ca8-ab02-fd92fb002da6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c3ab2e29-df24-48f1-bf82-ebac3d3a83b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:TechnologyLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_9262d869-15f9-481b-9005-cda8096e70c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
        </entity>
        <period>
            <instant>2024-03-01</instant>
        </period>
    </context>
    <context id="C_ace6a7aa-5e97-4501-8932-98392f77ce72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e0c2b471-faa6-4641-8385-0e58de723dee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:ServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:CarnotPharmaLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d3eca86e-4d27-4894-81cf-8b20a08cff1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9b497aad-3cba-4deb-9dd2-e0a9d56f3614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:TechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_37a6b7a6-092b-457c-bee8-fde979f4e845">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_e5fff44b-bbb8-4123-aa83-3f024c4f13f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pepg:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_76920238-6f16-4c2c-b840-91aee4e50447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:TechnologyLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c802d06c-99b8-4fc0-8210-d04f7dc4782d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a065b967-ade2-4903-9ca0-ebd7ce31343d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_580f0221-c422-43d6-9cb9-c47b83af1d6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pepg:HarrisonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0917bb69-33a3-4140-b895-0b204ca96986">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7fb2ae36-5ee1-44d5-910b-7802e0cbbbc7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:ServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:CarnotPharmaLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8318feed-c68a-4d65-a6b4-50a029944a36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pepg:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_098c1eb1-fac5-4644-b049-d1ecd9083a38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pepg:TenantImprovementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_abeb202e-1d0f-4fd4-950d-779ee59e02dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_eb8cf3d7-367c-4f24-aa0c-6cc587368dd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ae4f1a1a-7f76-43a6-b05d-f7cb7ac0bb50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
        </entity>
        <period>
            <instant>2020-11-24</instant>
        </period>
    </context>
    <context id="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c24a5f2f-a1e3-4f88-98c5-79645a25bbbf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5ce499b8-803d-4c0a-b7dc-bd9d43f1ccdf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
        </entity>
        <period>
            <startDate>2022-04-29</startDate>
            <endDate>2022-04-29</endDate>
        </period>
    </context>
    <context id="C_9cb04199-144a-4871-b5ab-87a87eb6a48d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pepg:StockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_42e30e60-16d0-4ac2-909d-87e5b27fbd3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_8f9f5a3b-bb7f-443b-98eb-04f3e2b9c50d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pepg:StockRestrictionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b4470897-58c2-4502-9300-1a8a6d7d7faf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:TechnologyLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_030a5a87-1169-4748-9cd4-a4a73f0d0618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:TechnologyLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2f09d803-162d-4289-ba95-128a23f2de31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pepg:StockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_620ef023-203d-4a5a-845f-4edc70fd7788">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="C_c59812be-057a-482f-bae8-fa2c033d1afd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e7e9bfb4-48e5-4056-bafa-50d040cb558e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pepg:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-09</startDate>
            <endDate>2024-02-09</endDate>
        </period>
    </context>
    <context id="C_59392f99-502b-454a-8db2-aeb447f458ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:TechnologyLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-31</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="C_1b8a0d2c-51ea-4fba-866a-5ab866ff3776">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:TechnologyLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f58e97f2-94c9-4dc7-ac7d-e3f44208d56a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pepg:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_887c0bf2-95aa-4fe1-afb6-f5b7822e931f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a035c4f4-0bbe-47a2-a989-557b4c88dd4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_111dcd21-eeba-473b-9067-9dc4b9836ccf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pepg:UsTreasuryBackedMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a76bcc79-0abb-40aa-b47b-a2d80c882380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pepg:UsTreasuryBackedMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f91c8a3a-fd8f-4f54-b410-a52327d04868">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pepg:SharesSalesAgreementAndFollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-09</startDate>
            <endDate>2024-02-09</endDate>
        </period>
    </context>
    <context id="C_b89ce0c5-83ee-4433-97d2-dc32416736cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_298b30ab-8f35-409c-81dc-e0ab49287a93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-24</instant>
        </period>
    </context>
    <context id="C_f589bb63-125f-4e69-a1dc-e5029e610005">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pepg:UsTreasuryBackedMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ddcf7e0e-5706-4523-945c-daec00947c1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fe73f47a-1a8a-4c3f-bc3a-56c5282d62d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_dc45efd8-3a91-4f49-a118-89ede6cb57a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:TechnologyLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:OxfordScienceEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_740f6998-3da5-4c11-9020-117389e3b4ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-04</instant>
        </period>
    </context>
    <context id="C_23a4b3c2-3578-4710-8ebf-43d479465cfb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ff132215-5434-4c88-b5f1-c47dfe048266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="C_f814e08d-65a5-4cb9-880c-4b1766772c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:ServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:CarnotPharmaLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e9bca87a-c16a-42e1-91d3-d72a8f122225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pepg:ClassAAndClassBCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pepg:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-24</instant>
        </period>
    </context>
    <context id="C_5bca00da-1c31-464f-a7f2-5cd7315f851e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-16</startDate>
            <endDate>2022-05-16</endDate>
        </period>
    </context>
    <context id="C_d4800734-4394-4f05-a937-22e162de9696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6eb59534-d6e4-4470-9e92-dc335995eadd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pepg:NewtonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0eec95c7-6d1e-4442-a8e7-29920d1d09af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9e4cd814-3cb3-4300-b818-efc911437b4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pepg:UndesignatedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_240e4da2-412b-4131-b975-ff30d06f0d88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c4ecf543-b902-40c7-b9ae-990d6d5dc573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pepg:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pepg:SeriesBStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="C_063bd5cf-7893-460d-a103-34991df7eaa2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pepg:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_479f1274-d273-4c6d-b379-65dc65120fec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-04</startDate>
            <endDate>2022-05-04</endDate>
        </period>
    </context>
    <context id="C_15495aa7-f537-415e-97da-a0992d3b9cb6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0cb40be6-2cf0-473a-a7d2-976e96f36428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">pepg:UkTaxAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_369017c2-22f5-42b3-85de-349e0de7ffa4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="C_452249ff-841b-462f-a646-241176965c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pepg:TwoThousandTwentyTwoEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3ed7174f-94bd-4691-abc3-6e866114de8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pepg:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ba1eafbf-79c8-4ea9-b601-011eeea8dba7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e00b2f45-4b2c-4c07-b7e3-9f43f7606c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_24eafb5a-baba-449c-8e96-c46f37a25e6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:ServicesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:RaCapitalManagementLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4665c752-93dc-481c-88bb-900dcc8ff971">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pepg:UsTreasuryBackedMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_30c84240-eef7-4c05-8cf3-d66492402ca5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:TechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6aa00088-cf17-4c43-988e-abab7676b8a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8dfabb69-ba07-4d32-a14c-6d3c76995bf3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_77094e71-f93f-47be-9749-eda2c5ae4461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_be762841-9478-40d4-a7e8-487a90f06ec8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pepg:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6c95e5db-bd37-4cf6-b968-bd6049101b26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_48600fa6-eba6-438a-9b5f-dff15a734745">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pepg:HarrisonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_585c525a-f403-4998-a8ec-14fc01861152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pepg:StockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c0719f76-c7a1-4758-8910-36fbdccb7a19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pepg:StockRestrictionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="C_1b696bc0-9c03-4cef-975e-0195f8d44c1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9262d127-7f2e-41a9-86ad-3e2211e86b50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pepg:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pepg:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-24</startDate>
            <endDate>2020-11-24</endDate>
        </period>
    </context>
    <context id="C_2d325b41-5448-4a9d-a322-34100e9ca687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6da82c22-e37a-42bc-980f-059274a23288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_941e7577-cf0a-4629-9509-58cf297868bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pepg:HarrisonLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-28</startDate>
            <endDate>2022-12-28</endDate>
        </period>
    </context>
    <context id="C_30fabfc5-c97f-4da0-9e33-dae485ef6dee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_36f077db-3490-4321-ac37-fd742c52e7c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d7f2ab9a-431e-4fa5-8e9c-4fbda0da11cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pepg:AuthorizedForFutureStockAwardsOrOptionGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ce675452-0281-4938-89df-5ecb187847bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pepg:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pepg:SeriesBStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="C_d2b7323c-10fa-445b-aaed-2945a4bc04a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pepg:AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_09aa4d44-be62-4c19-89e9-09be49174654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pepg:SeriesA2PreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f4a43b6a-4e2b-469c-a21b-5b9a3de9dfc0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e8c98aaa-dcdb-45ee-9cad-d9b7440c3550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pepg:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-24</instant>
        </period>
    </context>
    <context id="C_2fed675d-4772-487a-92d4-4d992856e675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-04</instant>
        </period>
    </context>
    <context id="C_85e7bad8-943c-4a0e-ad95-12e210a9becd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:TechnologyLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_472ca393-199b-4e03-9b1a-59688620fedb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pepg:CambridgeMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6be9b902-7f6b-479b-bfa6-7743f9105ed0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pepg:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pepg:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-24</instant>
        </period>
    </context>
    <context id="C_99f0f78d-bedd-484e-bfa2-ac51788e3369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pepg:AuthorizedForFutureStockAwardsOrOptionGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cce7a15c-5959-4b95-821c-ff224707de79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d198184c-cc7e-4c68-a75d-06a166129ca1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_83c51675-48f0-45b3-8010-597a2244a8c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pepg:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_084747ab-da2f-409a-8832-1a799b9b3b81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">pepg:SeriesA2PreferredStockWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4d0b0ba5-3b8a-4068-b299-799ed4f36e53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ad331ffb-3ca8-41af-9e8c-a5d2e3f07401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pepg:TechnologyLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pepg:OxfordScienceEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4284776a-c9e1-4a96-bba1-46cb3d689de2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_79b1260c-c408-4a48-8c54-3595577f6b00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pepg:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-24</instant>
        </period>
    </context>
    <context id="C_79566393-e152-4220-b13f-d5411f25b12a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pepg:AuthorizedForFutureIssuanceUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_18a316cc-fb97-4041-99e0-a3525fa31567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">pepg:HarrisonLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e1609515-c590-4eef-875c-348138380b4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001835597</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pepg:SharesSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <unit id="U_EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="U_Vote">
        <measure>pepg:Vote</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_GBP">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Segment">
        <measure>pepg:Segment</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Stockholder">
        <measure>pepg:Stockholder</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_0f24035f-4dc0-4b99-b2f1-f911e6a219c0">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_059c4de9-7310-475c-9025-ab308539e75e">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_0ec7a155-894a-4a3e-b2c1-5b0559562c05">0001835597</dei:EntityCentralIndexKey>
    <us-gaap:PreferredStockValue
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      id="F_0d70d773-c0e8-4741-991d-30b53e69f2b9"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      id="F_103f5d8d-8f9e-4d7e-a3c7-dd555847280a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      id="F_0e60f457-09a0-4d36-973d-dc52a1d8e6c2">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      id="F_82e8c746-990f-4d25-9100-51e93f9ca429">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_5ce499b8-803d-4c0a-b7dc-bd9d43f1ccdf"
      decimals="INF"
      id="F_11100503-2fd3-4c49-87ab-244664e4d838"
      unitRef="U_pure">0.982</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_e22f8158-0d4d-48fd-8bce-c12baf35c603">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_18a0601a-fcd3-48c6-b129-27187c5af6b7">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_d0ef6b71-4bf2-4518-997c-c08d9ec7c53e">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_cc16d6a1-c3fa-4bdd-8de3-b89685950296">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_fe5b54d5-16ac-4369-9a4c-96a4eb54114c">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_0503dc94-8fea-4bac-94c0-73ee77c2c9cd">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_87a0825f-ba7e-4a13-978d-75405d665a1c">001-41374</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_014e4562-7d1b-4bf9-9e66-13f2c35b40e0">PEPGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_a41aa5cc-5c1c-4124-9868-30f4dd7beafb">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_4ef73132-b11d-4417-913b-efae7e42503b">85-3819886</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_88a48cc3-bdce-471c-922b-f11ae0ee7008">321 Harrison Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_0b95432a-261b-4aa1-9472-cb1c650b5e9a">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_d48ab339-0c21-4754-84b3-8db15bb9e731">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_ad3f89df-3769-40ba-bb7a-e91604532939">02118</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_75095398-7977-4577-91bd-b336b60fd18b">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_e2a5c51b-e4d9-447f-b57f-52b5ac1d47ae">797-0979</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_e06cf49f-18bc-49b7-9dc1-cb14dfa22cc3">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_093c68ea-0c10-4e90-ae4c-386acb22f2c1">PEPG</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_d2d70e6d-73fc-4329-bf7c-85265ca3b808">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_0ec5a3b6-e453-4224-91de-d407dd438995">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_969065d1-da0f-4e80-bf30-7e61685e0ddb">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_a843bca2-19d7-42b0-a3fe-e5d0e2277eb4">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_059908e7-491d-40a9-a34a-3e6178825da7">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_97efa1c3-360b-47e4-ad87-a5ae76e2ea20">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_44f7e075-bd77-46f9-8bce-f788480d89f2">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_ddf3d04f-32f2-4219-be7a-f4f57de12c20">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_c45a61bd-8f22-4648-8c2f-35b3fa29295c">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_5b2c6132-9399-4acf-9c43-6a200dcde57f">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_55f6606e-ca38-431b-a9d9-a9a44d07f180">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_c0cc3f36-be6b-4625-8b5c-f6df783d77fc">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_42e30e60-16d0-4ac2-909d-87e5b27fbd3e"
      decimals="-5"
      id="F_0f265073-8bc8-4b6d-8dd2-77c465111532"
      unitRef="U_USD">97700000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_9262d869-15f9-481b-9005-cda8096e70c3"
      decimals="INF"
      id="F_194b0c13-bc22-4ccf-a4a9-4867c7bfc842"
      unitRef="U_shares">32354495</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_6d6b40f6-8682-49a8-8758-19a73502e250">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;"&gt;Portions of the registrant&#x2019;s Definitive Proxy Statement relating to its 2024 Annual Meeting of Stockholders to be filed hereafter are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_f79dc2bf-6f22-4293-98a4-a8a96246e865">185</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_f7f7d3ce-72d7-48af-808f-77186ba65297">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_4f4a75e9-1ca6-41dc-8838-2abf4ae6806f">Phoenix, AZ, USA</dei:AuditorLocation>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_6aa00088-cf17-4c43-988e-abab7676b8a0"
      id="F_69ed245d-75cd-4897-848a-e5fe9924d191">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_6aa00088-cf17-4c43-988e-abab7676b8a0"
      id="F_135a0917-494e-4388-8d2c-d650a2b104fe">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_6aa00088-cf17-4c43-988e-abab7676b8a0"
      id="F_5110f7c3-ebe2-4cfd-be86-7e28d588d87d">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_6aa00088-cf17-4c43-988e-abab7676b8a0"
      id="F_c4ff1a5a-ac63-4c7e-9f33-1c0607850d7a">false</ecd:NonRule10b51ArrTrmntdFlag>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_5fb3fa18-38e7-4caa-8e5a-a7f812d23808"
      unitRef="U_USD">80774000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_aa2a3bdb-d224-4c27-98d0-7a589d70c65b"
      unitRef="U_USD">181752000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_007461dc-e9bf-46e4-833d-4f5c16db53c9"
      unitRef="U_USD">29633000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_dedefbe3-a8ef-42f8-896c-b936397982e3"
      unitRef="U_USD">2271000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_b64d4e56-24cf-4131-8dcd-abdb80b9f1d2"
      unitRef="U_USD">4331000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_26a4cf99-11ca-4649-a758-229ba7f71d74"
      unitRef="U_USD">112678000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_3b5b91c4-6357-4331-8f29-c7d8c4e2bff5"
      unitRef="U_USD">186083000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_0e003a75-c6cf-485e-87db-600c96d833d9"
      unitRef="U_USD">4764000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_aded7590-5088-4b37-8fc3-218937f2900b"
      unitRef="U_USD">3335000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_7a3b375d-5d97-459b-8d57-e631395c5393"
      unitRef="U_USD">23620000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_100b9ad0-e352-4843-bb95-399252b8aaf1"
      unitRef="U_USD">26549000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_ab12be16-a4ad-4aed-ac9e-5338b459d918"
      unitRef="U_USD">1990000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_3e876dae-8eb0-483a-a1d1-68f805c7c649"
      unitRef="U_USD">1473000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_6af30fdf-faf7-4de5-a4d0-5e30a9b94934"
      unitRef="U_USD">143052000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_efff4dde-cad4-4e7e-82f4-e55a13026167"
      unitRef="U_USD">217440000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_0b4ed28c-11ed-4daa-8c93-057b34def909"
      unitRef="U_USD">1005000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_097d878d-5131-49a0-9259-48fcf831f3e4"
      unitRef="U_USD">1362000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_84fde079-2bfa-4d77-b754-24fca5aa9dbc"
      unitRef="U_USD">13522000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_b056f4f6-6cca-4586-857b-f6fda944b121"
      unitRef="U_USD">11913000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_00c37a73-e2dd-4e01-a591-28f06e027ecf"
      unitRef="U_USD">3004000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_4fe3fc7e-d37d-462f-a043-ae1085d122f3"
      unitRef="U_USD">5553000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_367c896d-dde4-4245-9ee9-e9a3afe4338e"
      unitRef="U_USD">17531000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_c8265082-c77e-4cc6-9605-7b200eb2e1a8"
      unitRef="U_USD">18828000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_f4eb5678-2320-4402-91d3-38bb83136304"
      unitRef="U_USD">17100000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_0e5dbc91-8320-4d1f-8a6a-2995875a4769"
      unitRef="U_USD">18981000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_c0bcd5a3-2163-4ecf-acfc-fd7e0e1ac9c9"
      unitRef="U_USD">34631000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_6ae19ea7-5fe0-44f6-9192-8eb1f582a6eb"
      unitRef="U_USD">37809000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="INF"
      id="F_af6203f0-9ec8-4b0a-847a-c0c32cbe3aee"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="INF"
      id="F_c6553d22-293a-4417-8593-21a20ccf2cff"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="INF"
      id="F_0baf930b-0078-4143-8078-3b91dd498568"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="INF"
      id="F_c3954a80-b912-48c8-bb4a-145e8e0d9e17"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="INF"
      id="F_b13658b0-fc00-4ca1-a633-a2471e84a4f1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="INF"
      id="F_535dc419-fb9b-4ad7-8c7f-5b03f14aa18c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="INF"
      id="F_1426abf0-ceca-4447-b6d8-14227ba06466"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="INF"
      id="F_f98f8bea-09af-4d0d-8acf-22827206d560"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="INF"
      id="F_8b648f7c-26f5-40ca-86f7-50aee85f1b3d"
      unitRef="U_shares">23823241</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="INF"
      id="F_2bb839a2-bb4e-411d-ad1c-9a155cf03d8a"
      unitRef="U_shares">23823241</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="INF"
      id="F_ab6fe3d3-c3c4-428e-ba0a-993b35f06d82"
      unitRef="U_shares">23713196</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="INF"
      id="F_2c2bda19-543c-41b3-982d-699f70388707"
      unitRef="U_shares">23713196</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_9aa5cb63-8902-46b6-b9c8-c8f9b29052d7"
      unitRef="U_USD">2000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_3ee33a4c-39c3-45db-8530-d6d172066fac"
      unitRef="U_USD">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_f2da41d3-6e91-43b6-addb-c7c2c52473d9"
      unitRef="U_USD">289867000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_13cc7409-d24e-4363-9967-65ea6fbeb931"
      unitRef="U_USD">282566000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_97459db8-41df-4256-8b18-f68e569de05c"
      unitRef="U_USD">34000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_ab4355f7-4142-45e4-8569-03924cc06275"
      unitRef="U_USD">-81000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_022a7048-5689-4400-bdcf-3d50f8b8b898"
      unitRef="U_USD">-181482000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_a9d917f0-7912-4fd4-8234-e672e09d4049"
      unitRef="U_USD">-102856000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_79bb0dbd-0ca7-4e35-9f00-2805065db2b5"
      unitRef="U_USD">108421000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_3d3addbe-f9d9-4227-b9da-208283c6c456"
      unitRef="U_USD">179631000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_09ad027f-380f-44c4-9a71-3e1105d9cbff"
      unitRef="U_USD">143052000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_5733c431-a7f2-4079-9ebb-3d6e19897f31"
      unitRef="U_USD">217440000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_04dc78ce-89fa-422b-adfc-7abef9197e4d"
      unitRef="U_USD">68126000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_dcc25330-fcc9-449e-94b2-8518aea4749a"
      unitRef="U_USD">54077000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_f87df946-6811-436c-b699-3ac981785d32"
      unitRef="U_USD">16640000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_a3b19c6c-3d14-41d8-b0b3-890b9492b053"
      unitRef="U_USD">14224000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_edb486bc-89eb-4ac3-b024-15f2f3f065b9"
      unitRef="U_USD">84766000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_0fd14957-ca81-405f-9c0c-8faf0e8e158d"
      unitRef="U_USD">68301000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_1962a512-dc59-4344-8617-b06a46f6e118"
      unitRef="U_USD">-84766000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_353aa263-2d06-48db-8300-9c04960ff52f"
      unitRef="U_USD">-68301000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_adfc8d43-086f-4e38-aa75-8dc9265822ff"
      unitRef="U_USD">6400000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_0bc45c77-95e5-415c-a0cc-0e4826873e89"
      unitRef="U_USD">2793000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_625c7a6c-0c72-4aac-aa5c-187a1f53b6eb"
      unitRef="U_USD">-187000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_156dfb8e-184a-4024-9368-406bc63a720a"
      unitRef="U_USD">110000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_77261c15-f332-4b05-b2d7-d325e8fa13ca"
      unitRef="U_USD">6213000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_6cfb22a7-1f22-46f3-a34c-843a3e1ed0e2"
      unitRef="U_USD">2903000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_c1fc3412-9757-4d69-bee9-5b4101af0d2a"
      unitRef="U_USD">-78553000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_ebf164ff-c255-4589-b692-4aa9f13d3299"
      unitRef="U_USD">-65398000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_cb81aa85-81ba-40c6-8c81-05790b530da7"
      unitRef="U_USD">73000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_44368a02-94a0-4fc4-8de3-1c3c11f2c3ea"
      unitRef="U_USD">3706000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_6a807111-03ca-4db0-a3b1-2645afddd9c9"
      unitRef="U_USD">-78626000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_27931617-4bbc-410e-acae-8aee46bd11fc"
      unitRef="U_USD">-69104000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="2"
      id="F_71a19b6f-e3ba-48fa-b9d8-8c4b1dcbb60d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.3</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="2"
      id="F_9b9f69f7-6be9-4d71-b31f-5e109f34f956"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.3</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="2"
      id="F_96495e4f-e4a5-4ba0-b1f8-496730d4eca2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-4.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="2"
      id="F_c49c18c0-e043-4dc3-965b-f50d62ca749c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-4.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="0"
      id="F_68e1dc74-3411-4a2a-9cef-124528907ca2"
      unitRef="U_shares">23796000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="0"
      id="F_fa8eee00-9035-494f-b911-9202699b7edf"
      unitRef="U_shares">23796000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="0"
      id="F_5248125c-0bfa-4aeb-9583-8316c6c8b873"
      unitRef="U_shares">15639728</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="0"
      id="F_4a461a2d-7c04-4f77-b193-119a1afa21ab"
      unitRef="U_shares">15639728</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_91081160-7b58-4a80-b1ed-f4778ed3f513"
      unitRef="U_USD">-78626000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_5a5d6339-5450-4679-92ad-b9fde708b6a8"
      unitRef="U_USD">-69104000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_9c17c08e-8d48-4c45-b791-30b4034040ca"
      unitRef="U_USD">104000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_263b497e-3682-4291-978d-2c4685ceb662"
      unitRef="U_USD">-98000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_87aae7c4-4af1-4931-bbcb-68b5158a2043"
      unitRef="U_USD">11000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_62ca795d-296c-449d-b43d-3dcbd2f5813d"
      unitRef="U_USD">-78511000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_2a8ddf99-4019-417b-bd98-51ba5bedd5fa"
      unitRef="U_USD">-69202000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_f58e97f2-94c9-4dc7-ac7d-e3f44208d56a"
      decimals="INF"
      id="F_09722c04-48c8-466a-a34d-31fd6249eeb0"
      unitRef="U_shares">1372970</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_f58e97f2-94c9-4dc7-ac7d-e3f44208d56a"
      decimals="-3"
      id="F_c2ff7342-d237-48d0-a3d9-8aa5b2e68c01"
      unitRef="U_USD">8454000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_063bd5cf-7893-460d-a103-34991df7eaa2"
      decimals="INF"
      id="F_88ede50f-2f04-4372-9488-98dbc6114492"
      unitRef="U_shares">3939069</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_063bd5cf-7893-460d-a103-34991df7eaa2"
      decimals="-3"
      id="F_4832b1a0-2bbe-4234-9d73-4105cefab706"
      unitRef="U_USD">44639000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_48802948-74ba-4e4c-bd84-6de3c161ffbd"
      decimals="INF"
      id="F_989f6651-2d91-4d4e-9472-5c39d4397d93"
      unitRef="U_shares">7234766</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_48802948-74ba-4e4c-bd84-6de3c161ffbd"
      decimals="-3"
      id="F_a24b6518-4ebf-4ced-8267-34cf6a80e241"
      unitRef="U_USD">112083000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_9fc357d1-aca9-4939-8508-2e6b6c2e1aef"
      decimals="INF"
      id="F_91f5ac71-5155-48ee-aee4-253db55e94ee"
      unitRef="U_shares">963588</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_6da8e9ac-df70-4c39-a066-f43de00ad6c8"
      decimals="-3"
      id="F_8785bc8e-8a8f-4196-a99f-adb4c79c5b3e"
      unitRef="U_USD">1653000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c802d06c-99b8-4fc0-8210-d04f7dc4782d"
      decimals="-3"
      id="F_be6b0874-750d-4904-88df-3ff6a79ef0c7"
      unitRef="U_USD">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a02d2713-9447-4f0e-94e0-cac5b3c390f0"
      decimals="-3"
      id="F_251a2b60-8f6e-4fa3-9521-ed2c8acd0d7e"
      unitRef="U_USD">-33752000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1b696bc0-9c03-4cef-975e-0195f8d44c1a"
      decimals="-3"
      id="F_3c0ad6b9-bbec-427b-8456-5dc6374f192a"
      unitRef="U_USD">-32082000</us-gaap:StockholdersEquity>
    <pepg:TemporaryEquityStockIssuedDuringPeriodSharesStockUponExerciseOfWarrants
      contextRef="C_e5fff44b-bbb8-4123-aa83-3f024c4f13f7"
      decimals="INF"
      id="F_ceed9cb8-3034-4cff-bbe5-85e402fe7f24"
      unitRef="U_shares">35529</pepg:TemporaryEquityStockIssuedDuringPeriodSharesStockUponExerciseOfWarrants>
    <pepg:TemporaryEquityStockIssuedDuringPeriodValueStockUponExerciseOfWarrants
      contextRef="C_e5fff44b-bbb8-4123-aa83-3f024c4f13f7"
      decimals="-3"
      id="F_3e088cc8-6ff2-434e-81d1-d1cc6ea27e08"
      unitRef="U_USD">574000</pepg:TemporaryEquityStockIssuedDuringPeriodValueStockUponExerciseOfWarrants>
    <pepg:TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering
      contextRef="C_be762841-9478-40d4-a7e8-487a90f06ec8"
      decimals="INF"
      id="F_01900440-488a-4b2d-a46c-73b45da21d3a"
      unitRef="U_shares">-1372970</pepg:TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering>
    <pepg:TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering
      contextRef="C_be762841-9478-40d4-a7e8-487a90f06ec8"
      decimals="-3"
      id="F_b49aabf8-84ea-4b0b-884c-216ffd028cb3"
      unitRef="U_USD">-8454000</pepg:TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering>
    <pepg:TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering
      contextRef="C_e5fff44b-bbb8-4123-aa83-3f024c4f13f7"
      decimals="INF"
      id="F_9eac9a9a-cc27-430c-9b74-ccea8b719a54"
      unitRef="U_shares">-3974598</pepg:TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering>
    <pepg:TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering
      contextRef="C_e5fff44b-bbb8-4123-aa83-3f024c4f13f7"
      decimals="-3"
      id="F_952022bd-39a3-4044-8209-9c83eb5abdd0"
      unitRef="U_USD">-45213000</pepg:TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering>
    <pepg:TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering
      contextRef="C_8318feed-c68a-4d65-a6b4-50a029944a36"
      decimals="INF"
      id="F_d256bda9-b6e3-4f14-bd97-372e85329c1f"
      unitRef="U_shares">-7234766</pepg:TemporaryEquitySharesConversionOfConvertiblePreferredStockUponInitialPublicOffering>
    <pepg:TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering
      contextRef="C_8318feed-c68a-4d65-a6b4-50a029944a36"
      decimals="-3"
      id="F_afe50dbc-ee15-416d-853b-2721d8c925f8"
      unitRef="U_USD">-112083000</pepg:TemporaryEquityConversionOfConvertiblePreferredStockUponInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_9444a584-901b-44fb-95ce-d2000dc58dd6"
      decimals="INF"
      id="F_fbd5b467-8d24-4c59-afb8-689bab989ada"
      unitRef="U_shares">12359856</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_9444a584-901b-44fb-95ce-d2000dc58dd6"
      decimals="-3"
      id="F_e4de4332-9e8a-44d9-8de6-6a9e22f811d0"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_e00b2f45-4b2c-4c07-b7e3-9f43f7606c50"
      decimals="-3"
      id="F_92038386-1f6f-40e9-b16f-44a7abd71bed"
      unitRef="U_USD">165751000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_c3c62f48-f248-4210-aa60-70d0e0efad5f"
      unitRef="U_USD">165752000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_9444a584-901b-44fb-95ce-d2000dc58dd6"
      decimals="-3"
      id="F_d7d5549a-e2d2-4baa-b0f5-d414eaf6df92"
      unitRef="U_USD">12684000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_9444a584-901b-44fb-95ce-d2000dc58dd6"
      decimals="INF"
      id="F_9bcda1fc-ff86-40e0-8c1b-106ea0179f39"
      unitRef="U_shares">10238951</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_9444a584-901b-44fb-95ce-d2000dc58dd6"
      decimals="-3"
      id="F_e97ecda5-e4a5-4fae-b5fb-2740277f8210"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_e00b2f45-4b2c-4c07-b7e3-9f43f7606c50"
      decimals="-3"
      id="F_09835c4a-9b21-4216-ab43-df66f69d3960"
      unitRef="U_USD">110182000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_bf640e31-50b0-4808-8bd9-626efd8f28b3"
      unitRef="U_USD">110183000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_9444a584-901b-44fb-95ce-d2000dc58dd6"
      decimals="INF"
      id="F_bbcc7517-ddc3-40bd-b8ac-248ec440b2ba"
      unitRef="U_shares">69529</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_9444a584-901b-44fb-95ce-d2000dc58dd6"
      decimals="INF"
      id="F_2df2dc92-9df3-4a27-b4eb-82c41630a99c"
      unitRef="U_shares">81272</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_e00b2f45-4b2c-4c07-b7e3-9f43f7606c50"
      decimals="-3"
      id="F_3d6fe948-2c19-440e-b15e-163e856c6cb4"
      unitRef="U_USD">217000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_86e6dc59-f8d7-4232-9fac-49fbcbd0505c"
      unitRef="U_USD">217000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_e00b2f45-4b2c-4c07-b7e3-9f43f7606c50"
      decimals="-3"
      id="F_40ab7d3a-b8bc-4f6d-83e4-c7cc13d93003"
      unitRef="U_USD">4763000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_c4d61872-87bb-4248-978b-8ab429a8a399"
      unitRef="U_USD">4763000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_ba1eafbf-79c8-4ea9-b601-011eeea8dba7"
      decimals="-3"
      id="F_6b92a337-b60e-409e-a87a-f44fae31ad5f"
      unitRef="U_USD">-98000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_455696d5-7963-42e4-8cc8-55639fb04a6e"
      unitRef="U_USD">-98000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_cc8621bc-02a4-40ab-b23b-4c8af4926152"
      decimals="-3"
      id="F_171cc944-dd22-4ee2-804f-6397b7af564d"
      unitRef="U_USD">-69104000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_218f7b9a-f1b0-4d46-abb2-4154444ce315"
      unitRef="U_USD">-69104000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_3a41894a-8ad8-4c44-9399-b1722da555e7"
      decimals="INF"
      id="F_2ffc733e-f74d-4f26-9c58-c7a25c73b9d4"
      unitRef="U_shares">23713196</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_3a41894a-8ad8-4c44-9399-b1722da555e7"
      decimals="-3"
      id="F_154f369e-203d-4970-a9f4-8d069612b281"
      unitRef="U_USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c59812be-057a-482f-bae8-fa2c033d1afd"
      decimals="-3"
      id="F_f1395f24-c710-4667-90af-898699b0cea5"
      unitRef="U_USD">282566000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a065b967-ade2-4903-9ca0-ebd7ce31343d"
      decimals="-3"
      id="F_64b9822f-da52-46b2-ae6e-1cf1dfb352df"
      unitRef="U_USD">-81000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_15495aa7-f537-415e-97da-a0992d3b9cb6"
      decimals="-3"
      id="F_2012fd46-6130-43d1-8dc2-c5f39e7deb3d"
      unitRef="U_USD">-102856000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_84a6ca9e-19a2-4686-8293-c201af4d21e4"
      unitRef="U_USD">179631000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_ace6a7aa-5e97-4501-8932-98392f77ce72"
      decimals="INF"
      id="F_2af936c4-9607-4bb9-a588-5d66c0c6fde6"
      unitRef="U_shares">9694</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_a035c4f4-0bbe-47a2-a989-557b4c88dd4e"
      decimals="-3"
      id="F_7dcf88e5-1361-4ab0-b7a0-9f6cfcdd17fb"
      unitRef="U_USD">40000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_f269a52c-d03c-4e65-af2b-11cfacb5f8e9"
      unitRef="U_USD">40000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_ace6a7aa-5e97-4501-8932-98392f77ce72"
      decimals="INF"
      id="F_82f5fec3-8a3b-4b40-8735-fcccf5c53ee0"
      unitRef="U_shares">100351</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_a035c4f4-0bbe-47a2-a989-557b4c88dd4e"
      decimals="-3"
      id="F_4c5495b8-6e06-4796-9aa2-0fb96928b207"
      unitRef="U_USD">213000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_e3790b9d-f266-4219-95fb-a04fbbb55fae"
      unitRef="U_USD">213000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_a035c4f4-0bbe-47a2-a989-557b4c88dd4e"
      decimals="-3"
      id="F_f7ca102a-a2dd-41ee-a2f4-0c3fd5996824"
      unitRef="U_USD">7048000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_96dfb0d6-2709-454f-9c1f-0e2159dbcfc9"
      unitRef="U_USD">7048000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_ed06b17b-3586-4df6-a87e-12566f6bab76"
      decimals="-3"
      id="F_78de7753-7714-4eaf-b900-dd39299fe3bc"
      unitRef="U_USD">11000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_52cb2f60-cb5c-4ca7-9e26-739bc36633f7"
      unitRef="U_USD">11000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_ed06b17b-3586-4df6-a87e-12566f6bab76"
      decimals="-3"
      id="F_1eac2848-b226-4ac3-9673-32b7ba0b2985"
      unitRef="U_USD">104000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_7006f713-35b7-4524-9b2c-ada5d042d60b"
      unitRef="U_USD">104000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_cce7a15c-5959-4b95-821c-ff224707de79"
      decimals="-3"
      id="F_9e5dea5c-8bf9-47ee-9603-36a485af7832"
      unitRef="U_USD">-78626000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_39daaa92-8761-4f2f-8072-6393a8166729"
      unitRef="U_USD">-78626000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_37a6b7a6-092b-457c-bee8-fde979f4e845"
      decimals="INF"
      id="F_761b82d1-0115-4770-81b4-025cb20fa7eb"
      unitRef="U_shares">23823241</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_37a6b7a6-092b-457c-bee8-fde979f4e845"
      decimals="-3"
      id="F_b212a709-35bd-4a1f-ac7b-1ff21624c8f6"
      unitRef="U_USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c24a5f2f-a1e3-4f88-98c5-79645a25bbbf"
      decimals="-3"
      id="F_a7de8b86-da29-463b-bb76-f5795f245e4d"
      unitRef="U_USD">289867000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a65d95cd-5bc9-4e3d-baa3-39ba00afc7f4"
      decimals="-3"
      id="F_f4d79735-0b40-4fb0-8a5b-242761fb3be3"
      unitRef="U_USD">34000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_240e4da2-412b-4131-b975-ff30d06f0d88"
      decimals="-3"
      id="F_cc74b73b-4dc2-4602-92c1-b71c7b11c073"
      unitRef="U_USD">-181482000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_e304adbc-3266-46ca-a1da-dc126d529540"
      unitRef="U_USD">108421000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_9222a781-9076-49ac-b4c4-d1e1bf5b5fdf"
      unitRef="U_USD">-78626000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_be411d1f-8f09-43ab-bcb6-0ff849fbe526"
      unitRef="U_USD">-69104000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_41a85b79-9fa7-4ef3-bd56-8832526c4e07"
      unitRef="U_USD">1184000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_88be1916-cc2a-4803-ba63-788895ac1c3e"
      unitRef="U_USD">493000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_3734a177-34af-49f5-a555-949b3a6a0f28"
      unitRef="U_USD">7048000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_4a526cc7-4911-4881-9c66-59b86188c700"
      unitRef="U_USD">4763000</us-gaap:ShareBasedCompensation>
    <pepg:AmortizationAndInterestAccretionRelatedToOperatingLeases
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_2de0257b-4be5-41ec-94d5-27cde1775c66"
      unitRef="U_USD">-334000</pepg:AmortizationAndInterestAccretionRelatedToOperatingLeases>
    <pepg:AmortizationOfPremiumAndDiscountsOnMarketableSecuritiesNet
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_30496c3e-b806-4764-9d08-6cd406433e17"
      unitRef="U_USD">-220000</pepg:AmortizationOfPremiumAndDiscountsOnMarketableSecuritiesNet>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_0dce626a-7477-4f0f-84c0-9f79421f29bb"
      unitRef="U_USD">-58000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_43edbcec-8da1-4308-93cb-07e48f66fa45"
      unitRef="U_USD">-134000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_ee293b76-97c0-4f88-a60b-0f2e11027753"
      unitRef="U_USD">-26000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_4dbc2696-5ead-4293-ad21-f23eb84fa89f"
      unitRef="U_USD">-4183000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_edc0b29e-6c7b-422f-8846-5495b172249b"
      unitRef="U_USD">-2038000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_bafa77ce-f41a-41b7-9116-dca860668cfa"
      unitRef="U_USD">1784000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_408133b7-39f2-4183-a31c-236d6b489ff8"
      unitRef="U_USD">-369000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_3bd95018-f5a0-46ae-bb6d-e4823954c453"
      unitRef="U_USD">-1407000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_aae62784-e255-4c1d-9ea5-7913f83cd86f"
      unitRef="U_USD">1422000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_0aedf8ab-9e3e-45f0-83e6-013d4ba42690"
      unitRef="U_USD">5531000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_e049c95f-2a9c-43ed-9da2-dbd206b35ed6"
      unitRef="U_USD">-1166000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_e3945967-ed3d-4d6b-a3fb-3a0f95b10706"
      unitRef="U_USD">-2016000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_f55fab2a-227d-4e8f-8ff2-0182f6014a2d"
      unitRef="U_USD">-68997000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_6aa4b57f-08df-4911-9080-5d01eca2f160"
      unitRef="U_USD">-59265000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_6987c41a-b05d-4d64-97ca-22f8bcdf3ae1"
      unitRef="U_USD">2599000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_c22debf6-2e37-4dac-8bd7-5cd31448cfcc"
      unitRef="U_USD">3755000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_305edf21-2e80-477f-b9c5-815fa034f67c"
      unitRef="U_USD">29404000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_4ce8a8dd-eb64-4d6f-8739-e31f2a7ce5d4"
      unitRef="U_USD">-32003000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_6168a072-86ba-4c08-987b-c51c19e53c4b"
      unitRef="U_USD">-3755000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_4ae44f3f-e5e0-4938-8b13-59f637a01f7d"
      unitRef="U_USD">114267000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <pepg:PaymentOfOfferingCosts
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_c1a337e5-cc3c-45e5-bea8-934d429b1216"
      unitRef="U_USD">442000</pepg:PaymentOfOfferingCosts>
    <pepg:PaymentOfOfferingCosts
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_3f0b1cf5-0e95-476e-8a42-aed041efcd5f"
      unitRef="U_USD">2697000</pepg:PaymentOfOfferingCosts>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_28221503-7dd6-4731-ab6b-1fa24cad66fa"
      unitRef="U_USD">406000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_1c4bcd11-3b42-4153-a2b9-d6eb5ea9b255"
      unitRef="U_USD">253000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_2b59e62f-6e13-436d-952c-8ab6fd7b2a0c"
      unitRef="U_USD">217000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_b6c192c7-7c71-4555-ac73-b42facbc6968"
      unitRef="U_USD">-189000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_aa6d4571-4aec-4910-a0e5-bc2f7c9eac79"
      unitRef="U_USD">112193000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_a5f08ecf-9952-4036-96b2-644678c69554"
      unitRef="U_USD">286000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_b8f88b28-fdf0-45cf-9852-f4bdd11dc076"
      unitRef="U_USD">-316000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_97464cab-4a71-4b5f-aaef-e24fc35893d5"
      unitRef="U_USD">-100903000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_0dd526cd-1c58-4b69-a540-97941a4adeae"
      unitRef="U_USD">48857000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_a1db823b-2b89-47cf-9f71-c07cc62dddbe"
      unitRef="U_USD">183225000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_1b696bc0-9c03-4cef-975e-0195f8d44c1a"
      decimals="-3"
      id="F_ed10ac15-d9dd-4434-8367-5e82641f5d64"
      unitRef="U_USD">134368000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_f3b145bc-27a4-4a79-b614-de4366052e54"
      unitRef="U_USD">82322000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_63a61b4a-de44-40f1-baa1-9130f77dce13"
      unitRef="U_USD">183225000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_973e1de5-93d5-4c15-9785-bae668a8333f"
      unitRef="U_USD">80774000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_e6c4d886-1465-4855-906c-70b727c6d8f6"
      unitRef="U_USD">181752000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_7633b09d-4953-4434-9f35-65a962d0c788"
      unitRef="U_USD">1548000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_1509dc39-6498-463e-8ef3-3f1742c24fc5"
      unitRef="U_USD">1473000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_1e6ba3f1-046c-41cd-bb27-d48447952018"
      unitRef="U_USD">82322000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_69081f88-f212-46d4-931c-03c5f44aa51b"
      unitRef="U_USD">183225000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <pepg:PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_81e86b6c-26dc-4df0-a7cc-9038e75ac62d"
      unitRef="U_USD">14000</pepg:PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses>
    <pepg:PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_d7cb52d9-a6e8-4694-88e8-31335c523601"
      unitRef="U_USD">363000</pepg:PropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_b8da6c8e-7963-425d-ba5c-e40ee0fddcbb"
      unitRef="U_USD">2702000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_7807cb92-c5bc-4233-a2b2-4cdb041e9a12"
      unitRef="U_USD">26549000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_b550aaa6-b3b0-43be-80d9-e2a4c707431c">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1. Nature of Business and Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;PepGen Inc. (PepGen or the Company), is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The Company's principal offices are located in Boston, Massachusetts.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company was initially formed as PepGen Limited on January 25, 2018, in the United Kingdom, or the U.K. On November 9, 2020, PepGen Limited completed a corporate reorganization, or the Reorganization. As part of the Reorganization, PepGen Limited formed PepGen Inc., a Delaware corporation with nominal assets and liabilities, for the purpose of consummating the Reorganization. In connection with the Reorganization, the existing stockholders of PepGen Limited exchanged each of its classes of shares of PepGen Limited for the same number and class of common stock of PepGen Inc. on a one-to-one basis. The newly issued stock of PepGen Inc. had substantially identical rights to the exchanged shares of PepGen Limited. As a result of the exchange, PepGen Inc. became the sole stockholder of PepGen Limited. Upon the completion of the Reorganization on November 23, 2020, the historical financial statements of PepGen Limited became the historical financial statements of PepGen Inc. as the Reorganization was deemed to be between entities under common control.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Initial Public Offering and Follow-On Offerings&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On May 10, 2022, the Company closed its initial public offering, or IPO, in which the Company sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;108.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. In connection with the IPO, the Company granted the underwriters a 30-day option to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,350,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; additional shares of common stock. On May 16, 2022, the underwriters exercised the option in part and the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,238,951&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock for gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. From the IPO and option exercise by the underwriters, the Company received approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in gross proceeds and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;110.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in net proceeds, after deducting underwriting discounts and offering expenses payable by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Immediately prior to consummation of the IPO, all &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,546,805&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; outstanding shares of the Company&#x2019;s redeemable convertible preferred stock, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,529&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; preferred stock warrants that were exercised on May 4, 2022 (see Note 3), converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,359,856&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On February 5, 2024, the Company sold shares under its At-the-Market Equity Offering Sales Agreement, or Sales Agreement, with Stifel, Nicolaus &amp;amp; Company, Incorporated dated as of August 8, 2023, resulting in net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. On February 9, 2024, the Company sold shares in a follow-on offering, referred to as the Follow-on Offering, pursuant to an underwriting agreement with Leerink Partners LLC dated as of February 6, 2024, resulting in net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million after deducting underwriting fees of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Net proceeds from sales under the Sales Agreement and Follow-on Offering, after deducting underwriters' fees and before deducting costs of the offerings, were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Since inception, the Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations. The Company&#x2019;s primary uses of cash and cash equivalents to date have been to fund research and development activities, business planning, establishing and maintaining the Company&#x2019;s intellectual property portfolio, hiring personnel, leasing premises and associated capital expenditures, raising capital, and providing general and administrative support for these operations. As of December 31, 2023, the Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;181.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. To date, the Company has funded operations primarily through private placements of convertible preferred stock and its IPO. As of December 31, 2023, the Company had cash, cash equivalents, and marketable securities of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;110.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, excluding net proceeds from the Sales Agreement and Follow-On Offering. Based on its current operating plans, the Company believes that its cash, cash equivalents, and marketable securities as of December 31, 2023, as well as proceeds from the Sales Agreement and Follow-On Offering (see Note 12) will be sufficient to fund its currently planned operations for at least the next 12 months from the filing of these consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As the Company continues to pursue its business plan to successfully develop and obtain regulatory approval for the Company&#x2019;s product candidates, it expects to finance its operations through the sale of equity, debt financings or other capital resources, which could include income from collaborations, strategic partnerships or marketing, distribution, licensing or other strategic arrangements with third parties, or from grants. However, there can be no assurance that any additional financing or strategic transactions will be available to the Company on acceptable terms, if at all. If events or circumstances occur such that the Company&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;does not obtain additional funding, it may need to delay, reduce or eliminate its product development or future commercialization efforts, which could have a material adverse effect on the Company&#x2019;s business, results of operations or financial condition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. The consolidated financial statements include the accounts of PepGen Inc. (a U.S. corporation) and its wholly owned subsidiaries PepGen Limited (a U.K. corporation) and PepGen Securities Corp. (a U.S. corporation). All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Reclassifications&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Certain amounts disclosed in the prior period financial statements have been reclassified from their original presentation to conform to the current period presentation. The reclassification had no effect on net income, earnings per share, retained earnings, cash flows or total assets.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_d1b4f98a-2717-48fb-ae1c-8c5f9097d55f"
      decimals="INF"
      id="F_0ff5b85a-3010-4f82-aa3b-07d206633d93"
      unitRef="U_shares">9000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_620ef023-203d-4a5a-845f-4edc70fd7788"
      decimals="INF"
      id="F_390343bc-dca4-441b-af85-50e90e3231ca"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_d1b4f98a-2717-48fb-ae1c-8c5f9097d55f"
      decimals="-5"
      id="F_97344f0d-4628-4bc7-960e-bd7abf0d098e"
      unitRef="U_USD">108000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_ff132215-5434-4c88-b5f1-c47dfe048266"
      decimals="INF"
      id="F_c5620c06-9173-44d6-9c50-e337c6e6adba"
      unitRef="U_shares">1350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_5bca00da-1c31-464f-a7f2-5cd7315f851e"
      decimals="INF"
      id="F_f88acaf3-3c0f-4588-b59a-51369d7295fd"
      unitRef="U_shares">1238951</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_5bca00da-1c31-464f-a7f2-5cd7315f851e"
      decimals="-5"
      id="F_1046314d-d96c-4b3a-b503-a77e1eb30f8e"
      unitRef="U_USD">14900000</us-gaap:ProceedsFromStockOptionsExercised>
    <pepg:ProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-5"
      id="F_d470d703-3826-4873-ad5b-a5f643dc933e"
      unitRef="U_USD">122900000</pepg:ProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised>
    <pepg:NetProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-5"
      id="F_7214dcf2-f24e-42fb-9836-301a0a96950f"
      unitRef="U_USD">110200000</pepg:NetProceedsFromIssuanceInitialPublicOfferingAndStockOptionsExercised>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_2fed675d-4772-487a-92d4-4d992856e675"
      decimals="INF"
      id="F_440b8b98-eff6-4dc5-9f56-da118eedb851"
      unitRef="U_shares">12546805</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_740f6998-3da5-4c11-9020-117389e3b4ab"
      decimals="INF"
      id="F_3cb6ebf2-4910-4c87-a6a0-f6b6d911d9ab"
      unitRef="U_shares">35529</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_740f6998-3da5-4c11-9020-117389e3b4ab"
      decimals="INF"
      id="F_da1a3f56-0298-45a7-801c-70f1db1fe990"
      unitRef="U_shares">12359856</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_a903df65-a661-4f64-9e9c-45d340ce2506"
      decimals="-5"
      id="F_06a4d228-e85d-445b-93f3-4409ca002157"
      unitRef="U_USD">9900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_e7e9bfb4-48e5-4056-bafa-50d040cb558e"
      decimals="-5"
      id="F_f883901b-17ac-422d-a451-825fd34de35a"
      unitRef="U_USD">76900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_e7e9bfb4-48e5-4056-bafa-50d040cb558e"
      decimals="-5"
      id="F_77631167-315d-43ac-b748-5d014723420d"
      unitRef="U_USD">3200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_f91c8a3a-fd8f-4f54-b410-a52327d04868"
      decimals="-5"
      id="F_7272b92f-2540-4a1f-a87a-62a96395d4e2"
      unitRef="U_USD">86800000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-5"
      id="F_1fdb468a-7de5-4545-9747-6bb2cfdf60df"
      unitRef="U_USD">-181500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-5"
      id="F_4dcdd752-721c-47fa-894b-f36da2222c6e"
      unitRef="U_USD">110400000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_93b2f0e1-af8d-410f-a03d-7d6c68c5a43c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management bases its estimates and judgments on historical experience, knowledge of current conditions, and beliefs of what could occur in the future, given the available information. On an ongoing basis, management evaluates such estimates and assumptions for continued reasonableness. In particular, management makes estimates with respect to accruals for research and development activities, for the valuation of intellectual property, for the fair value of common stock and convertible preferred stock warrants and stock-based compensation expense. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation. Actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, or the CODM. The Company&#x2019;s CODM is its chief executive officer who reviews financial information together with certain operating metrics principally to make decisions about how to allocate resources and to measure the Company&#x2019;s performance. The Company has determined that it operates as a single reportable segment. The Company&#x2019;s CODM evaluates financial information on a consolidated basis. As the Company operates as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; operating segment, all required segment financial information is presented in the consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Foreign Currency Remeasurement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s reporting currency is the U.S. Dollar. The functional currency of PepGen Limited is the British Pound. The assets and liabilities of PepGen Limited are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the cumulative translation adjustment, a component of accumulated other comprehensive loss in stockholders&#x2019; equity (deficit).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and money market accounts. As of December 31, 2023, the Company&#x2019;s cash, cash equivalents, and marketable securities were held by four financial institutions in the U.S. and one financial institution in the U.K. At times, the Company&#x2019;s deposits held in the U.S. and U.K. may exceed the respective insured limits of the Federal Depository Insurance Corporation and Financial Services Compensation Scheme.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates fair value. As of December 31, 2023 and 2022, cash and cash equivalents consisted primarily of checking and money market funds composed of U.S. government obligations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company classifies all cash whose use is limited by contractual provisions as restricted cash. Restricted cash arises from the requirement for the Company to maintain cash of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as collateral under a lease agreement. As of December 31, 2023 and 2022, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of restricted cash was recorded in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_0e60f457-09a0-4d36-973d-dc52a1d8e6c2;"&gt;&lt;span style="-sec-ix-hidden:F_82e8c746-990f-4d25-9100-51e93f9ca429;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; on the consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s marketable securities consist of U.S. treasury notes which are classified as available-for-sale and are reported at fair value. Unrealized gains and losses on available-for-sale debt securities are reported as a component of accumulated other comprehensive loss in stockholders&#x2019; equity (deficit). Realized gains and losses are based on the specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company evaluates its marketable securities with unrealized losses for other-than-temporary impairment. When assessing marketable securities for other-than-temporary declines in value, the Company considers such factors as, among other things, how significant the decline in value is as a percentage of the original cost, how long the market value of the investment has been less than its original cost, the Company&#x2019;s ability and intent to retain the investment for a period of time sufficient to allow for any anticipated recovery in fair value, and market conditions in general. If any adjustment to fair value reflects a decline in the value of the investment that the Company considers to be &#x201c;other than temporary,&#x201d; the Company reduces the investment to fair value through a charge to the statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1: Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2: Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3: Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For certain financial instruments, including cash and cash equivalents, prepaid expenses, accounts payable, as well as certain accrued liabilities, the recorded amount approximates estimated fair value due to their relatively short maturity period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful lives of the respective assets. Maintenance and repairs that do not improve or extend the life of the assets are expensed when incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The estimated useful lives of the Company&#x2019;s property and equipment are as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
          &lt;td style="width:17.824%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory and computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Company capitalizes within other long-term assets certain legal, accounting, and other third-party fees that are directly related to the Company&#x2019;s in-process equity financings, until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds received as a result of the offering. Should a planned equity financing be abandoned, terminated, or significantly delayed, the deferred offering costs are immediately written off to operating&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;expenses. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, deferred offering costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million were recorded within other assets on the consolidated balance sheets. Subsequent to the completion of the IPO in May 2022, deferred offering costs totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million were recorded within stockholders&#x2019; equity (deficit) as a reduction of additional paid-in-capital generated from the IPO.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Effective &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ASU 2016-02, Leases (Topic 842), or ASC 842. Under ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances presented in the arrangement, including whether the Company controls the use of identified assets. The Company classifies leases with a term greater than one year as either operating or finance leases at the lease commencement date and records a right-of-use assets and current and non-current lease liabilities, as applicable on the balance sheet. The Company has elected not to recognize on the balance sheet leases with terms of one year or less, but payments are recognized as expense on a straight-line basis over the lease term. If a lease includes options to extend the lease term, the Company does not assume the option will be exercised in its initial lease term assessment unless there is reasonable certainty that the Company will renew based on an assessment of economic factors present as of the lease commencement date. The Company monitors its plans to renew its material lease each reporting period. If a lease includes provisions for leasehold improvements for which the Company has an obligation to pay, the Company determines if the improvements should be considered lessor or lessee assets. If the improvements are considered lessor assets, the Company records the payments in the calculation of the lease liability and corresponding right-of-use asset.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Lease liabilities and the corresponding right-of-use assets are recorded based on the present value of lease payments over the remaining lease term. The present value of future lease payments are discounted using the interest rate implicit in lease contracts if that rate is readily determinable; otherwise the Company utilizes information available at the commencement of the lease to calculate the incremental borrowing rate, or IBR, which reflects the fixed rate at which the Company could borrow on a collateralized basis over a similar term, the amount of the lease payments in a similar economic environment. In order to determine the appropriate incremental borrowing rate, the Company used available third-party information, including comparable company collateralized borrowing information. After lease commencement and the establishment of a right-to-use asset and operating lease liability, lease expense is recorded on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company enters into contracts that contain both lease and non-lease components. Non-lease components include costs that do not provide a right-to-use a leased asset but instead provide a service, such as maintenance costs. The Company has elected to account for the lease and non-lease components together as a single component for all classes of underlying assets. Variable costs associated with the lease, such as maintenance and utilities, are not included in the measurement of right-to-use assets and lease liabilities but rather are expensed when the events determining the amount of variable consideration to be paid have occurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. The recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset or asset group to the estimated undiscounted future cash flows expected to be generated by the asset or asset group.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If the carrying amount of an asset or asset group exceeds its estimated undiscounted future cash flows, an impairment charge is recognized as the amount by which the carrying amount of the asset or asset group exceeds the estimated discounted future cash flows of the asset or asset group. There have been &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; such impairments of long-lived assets for the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Commitment and Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes a liability with regard to loss contingencies when it believes it is probable a liability has been incurred, and the amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount the Company accrues the minimum amount in the range. The Company has not recorded any such liabilities as of December 31, 2023 and 2022 that were material to the consolidated financial statements&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Company recorded convertible preferred stock at fair value on the dates of issuance, net of issuance costs. Upon the occurrence of certain events that are outside the Company&#x2019;s control, including a deemed liquidation event, holders of the convertible preferred stock could cause redemption for cash. Therefore, convertible preferred stock was classified outside of stockholders&#x2019; deficit on the consolidated balance sheets as events triggering the liquidation preferences are not solely within the Company&#x2019;s control. No accretion was recognized as the contingent events that could give rise to redemption were not deemed probable. Upon completion of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;IPO, all preferred stock was converted to common stock and as such &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; amounts were issued or outstanding as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Preferred Stock Warrants&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company classified warrants to purchase its Series A-2 convertible preferred stock as a liability on the consolidated balance sheets as these warrants were freestanding financial instruments that could have required the Company to transfer assets upon exercise.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development costs consist of salaries, benefits, and other personnel-related costs, including stock-based compensation, laboratory supplies, process development costs, fees paid to other entities to conduct certain research and development activities on the Company&#x2019;s behalf, including contract manufacturing organizations and contract research organizations, and allocated facility and other related costs. Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized as prepaid expenses until the related goods are delivered or services are performed. During the year-ended December 31, 2022, the Company received &#xa3;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million) relating to its 2021 U.K. research and development tax credit for research and development activities undertaken by its U.K. subsidiary. As of December 31, 2023 and 2022, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; research and development tax credits were recorded in other receivables on the consolidated balance sheets, respectively.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers under the service agreements. The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The historical accrual estimates made by the Company have not been materially different from the actual costs.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Compensation-Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, or ASC 718. ASC 718 requires all stock-based payments to employees, non-employees and directors, to be recognized as expense in the consolidated statements of operations based on their grant date fair values. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model, or Black-Scholes, for stock option grants to employees, non-employees and directors. The fair value of the Company&#x2019;s common stock is used to determine the fair value of restricted stock awards.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s stock-based compensation awards are generally subject to service-based vesting conditions. Compensation expense related to awards to employees, non-employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Black-Scholes requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends.  The Company determines the expected volatility using the historical volatility of a peer group of comparable publicly traded companies with product candidates in similar stages of development to the Company&#x2019;s product candidates. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term for stock options granted to employees, non-employees and directors whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prior to the Company&#x2019;s IPO, there was no public market for its common stock, and consequently, the estimated fair value of its common stock was determined by the board of directors as of the date of each stock option grant, with input from management, considering third-party valuations of its common stock as well as its board of directors&#x2019; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent third-party valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#x2019; Accounting and Valuation Guide, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Valuation of Privately-Held-Company Equity Securities Issued as Compensation &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, or Practice Aid. The Practice Aid identifies various available methods for allocating the enterprise value across classes of series of capital stock in determining the fair value of the Company&#x2019;s common stock at each valuation date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Subsequent to the Company&#x2019;s IPO, the fair value of the common stock underlying the stock-based awards is the closing price of the Company&#x2019;s common stock on the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#x2019;s payroll costs are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts or existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company records a valuation allowance to reduce deferred tax assets to an amount for which realization is more likely than not.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained upon examination by the tax authorities, based on the merits of the position. The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; interest or penalties charged in relation to the unrecognized tax benefits.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Comprehensive loss is composed of two components &#x2014; net loss and other comprehensive loss. Other comprehensive loss refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders&#x2019; equity but are excluded from net loss. The Company&#x2019;s other comprehensive loss consists of foreign currency translation adjustments and unrealized gains and losses on available-for-sale marketable debt securities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is anti-dilutive. The Company&#x2019;s potentially dilutive securities include unvested common stock under the Company&#x2019;s equity incentive plan which have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,233,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,341,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,233,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,341,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Company is an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act, or JOBS Act, and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company may take advantage of these exemptions until the Company is no longer an &#x201c;emerging growth company.&#x201d; Section 107 of the JOBS Act provides that an &#x201c;emerging growth company&#x201d; can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards and as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of the IPO or such earlier time that it is no longer an &#x201c;emerging growth company.&#x201d; As a result of the Company having elected the extended&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;transition &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act, 2016-13 and ASU 2019-11 are effective for the Company for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB or other standard-setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#x201c;emerging growth company&#x201d; as defined in the JOBS Act of 2012 and has elected not to &#x201c;opt out&#x201d; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and non-public companies, the Company can adopt the new or revised standard at the time non-public companies adopt the new or revised standard and can do so until such time that the Company either (i) irrevocably elects to &#x201c;opt out&#x201d; of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for non-public companies. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Effective January 1, 2022, the Company adopted ASC 842. Upon commencement of the Company's lease in December 2022, the Company recognized lease liabilities totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and right-of-use assets totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, or ASU 2016-13. The standard changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today&#x2019;s &#x201c;incurred loss&#x201d; approach with an &#x201c;expected loss&#x201d; model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard&#x2019;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The effective date of this update is for fiscal years beginning after December 15, 2022, and interim periods therein. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ASU 2016-13 effective &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740), or ASU 2019-12. The standard simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and also improves consistent application by clarifying and amending existing guidance. The standard is effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ASU 2019-12 effective &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures, or ASU 2023-07, to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 on a prospective basis. Early adoption and retrospective application is permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, or ASU 2023-07, which requires public entities to disclose information about their reportable segments&#x2019; significant expenses on an interim and annual basis. ASU 2023-07 is effective for the Company beginning the year ended May 31, 2025. The Company is currently evaluating the impact of this ASU 2023-07 on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_a768a06b-78b2-4a7f-9985-3a5531bb2cb3">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management bases its estimates and judgments on historical experience, knowledge of current conditions, and beliefs of what could occur in the future, given the available information. On an ongoing basis, management evaluates such estimates and assumptions for continued reasonableness. In particular, management makes estimates with respect to accruals for research and development activities, for the valuation of intellectual property, for the fair value of common stock and convertible preferred stock warrants and stock-based compensation expense. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation. Actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_8a4ea5ff-daed-4eef-b21a-2e8146995529">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, or the CODM. The Company&#x2019;s CODM is its chief executive officer who reviews financial information together with certain operating metrics principally to make decisions about how to allocate resources and to measure the Company&#x2019;s performance. The Company has determined that it operates as a single reportable segment. The Company&#x2019;s CODM evaluates financial information on a consolidated basis. As the Company operates as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; operating segment, all required segment financial information is presented in the consolidated financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="INF"
      id="F_cdb6cdfb-fe20-449a-b96b-cf8efe7b6192"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_a6741793-e7ce-433d-85b7-bd25d38775da">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Foreign Currency Remeasurement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s reporting currency is the U.S. Dollar. The functional currency of PepGen Limited is the British Pound. The assets and liabilities of PepGen Limited are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the cumulative translation adjustment, a component of accumulated other comprehensive loss in stockholders&#x2019; equity (deficit).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_80907b71-1f9c-47b3-aedb-91d39480cd4b">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and money market accounts. As of December 31, 2023, the Company&#x2019;s cash, cash equivalents, and marketable securities were held by four financial institutions in the U.S. and one financial institution in the U.K. At times, the Company&#x2019;s deposits held in the U.S. and U.K. may exceed the respective insured limits of the Federal Depository Insurance Corporation and Financial Services Compensation Scheme.&lt;/span&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_9f2bed1d-6da0-47c0-b3cc-c6bcf37a93db">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates fair value. As of December 31, 2023 and 2022, cash and cash equivalents consisted primarily of checking and money market funds composed of U.S. government obligations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_abf7a75b-9af0-4d87-92ab-eab4430e32e9">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company classifies all cash whose use is limited by contractual provisions as restricted cash. Restricted cash arises from the requirement for the Company to maintain cash of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as collateral under a lease agreement. As of December 31, 2023 and 2022, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of restricted cash was recorded in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_0e60f457-09a0-4d36-973d-dc52a1d8e6c2;"&gt;&lt;span style="-sec-ix-hidden:F_82e8c746-990f-4d25-9100-51e93f9ca429;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; on the consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-5"
      id="F_61b28f6c-dc6a-43a9-b6e2-e279eb576302"
      unitRef="U_USD">1500000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-5"
      id="F_abcafa4d-c0ad-4a4b-b6ce-c96ddd780b03"
      unitRef="U_USD">1500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-5"
      id="F_d06d491b-759e-4909-b394-ee97cd840c95"
      unitRef="U_USD">1500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_197fcdd4-38ba-494e-a165-f6915cfb4526">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s marketable securities consist of U.S. treasury notes which are classified as available-for-sale and are reported at fair value. Unrealized gains and losses on available-for-sale debt securities are reported as a component of accumulated other comprehensive loss in stockholders&#x2019; equity (deficit). Realized gains and losses are based on the specific identification method and are included as a component of other income (expense), net in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company evaluates its marketable securities with unrealized losses for other-than-temporary impairment. When assessing marketable securities for other-than-temporary declines in value, the Company considers such factors as, among other things, how significant the decline in value is as a percentage of the original cost, how long the market value of the investment has been less than its original cost, the Company&#x2019;s ability and intent to retain the investment for a period of time sufficient to allow for any anticipated recovery in fair value, and market conditions in general. If any adjustment to fair value reflects a decline in the value of the investment that the Company considers to be &#x201c;other than temporary,&#x201d; the Company reduces the investment to fair value through a charge to the statement of operations and comprehensive loss. No such adjustments were necessary during the periods presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_00555125-44db-4539-be2d-da37bea2eaa6">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Certain assets and liabilities of the Company are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1: Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2: Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.491405046981553%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3: Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For certain financial instruments, including cash and cash equivalents, prepaid expenses, accounts payable, as well as certain accrued liabilities, the recorded amount approximates estimated fair value due to their relatively short maturity period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_5c996abe-5506-4c78-9c3e-71f761cfa0df">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful lives of the respective assets. Maintenance and repairs that do not improve or extend the life of the assets are expensed when incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The estimated useful lives of the Company&#x2019;s property and equipment are as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
          &lt;td style="width:17.824%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory and computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <pepg:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_7be8d0c9-2340-4254-bde1-65e0015519db">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The estimated useful lives of the Company&#x2019;s property and equipment are as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
          &lt;td style="width:17.824%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory and computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</pepg:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_220d4a87-56e9-4b2f-88b9-0f2f98c86ac0"
      id="F_f0864a44-4b82-44bc-a5a9-15acd947f88f">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_2d325b41-5448-4a9d-a322-34100e9ca687"
      id="F_7c8acd75-4f4b-4720-899d-998dbc7329d1">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_227f086b-8491-47c8-898f-46568f5d3006">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Company capitalizes within other long-term assets certain legal, accounting, and other third-party fees that are directly related to the Company&#x2019;s in-process equity financings, until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds received as a result of the offering. Should a planned equity financing be abandoned, terminated, or significantly delayed, the deferred offering costs are immediately written off to operating&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;expenses. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, deferred offering costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million were recorded within other assets on the consolidated balance sheets. Subsequent to the completion of the IPO in May 2022, deferred offering costs totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million were recorded within stockholders&#x2019; equity (deficit) as a reduction of additional paid-in-capital generated from the IPO.&lt;/span&gt;&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="C_8dfabb69-ba07-4d32-a14c-6d3c76995bf3"
      decimals="-5"
      id="F_796ff137-04ff-47f9-bcde-b86b49b6df26"
      unitRef="U_USD">400000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-5"
      id="F_f82386dc-9e6b-46cd-b603-d340683cf56a"
      unitRef="U_USD">4100000</us-gaap:DeferredOfferingCosts>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_6b417dba-c43b-433d-9e71-fbb70590aa47">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Effective &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ASU 2016-02, Leases (Topic 842), or ASC 842. Under ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances presented in the arrangement, including whether the Company controls the use of identified assets. The Company classifies leases with a term greater than one year as either operating or finance leases at the lease commencement date and records a right-of-use assets and current and non-current lease liabilities, as applicable on the balance sheet. The Company has elected not to recognize on the balance sheet leases with terms of one year or less, but payments are recognized as expense on a straight-line basis over the lease term. If a lease includes options to extend the lease term, the Company does not assume the option will be exercised in its initial lease term assessment unless there is reasonable certainty that the Company will renew based on an assessment of economic factors present as of the lease commencement date. The Company monitors its plans to renew its material lease each reporting period. If a lease includes provisions for leasehold improvements for which the Company has an obligation to pay, the Company determines if the improvements should be considered lessor or lessee assets. If the improvements are considered lessor assets, the Company records the payments in the calculation of the lease liability and corresponding right-of-use asset.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Lease liabilities and the corresponding right-of-use assets are recorded based on the present value of lease payments over the remaining lease term. The present value of future lease payments are discounted using the interest rate implicit in lease contracts if that rate is readily determinable; otherwise the Company utilizes information available at the commencement of the lease to calculate the incremental borrowing rate, or IBR, which reflects the fixed rate at which the Company could borrow on a collateralized basis over a similar term, the amount of the lease payments in a similar economic environment. In order to determine the appropriate incremental borrowing rate, the Company used available third-party information, including comparable company collateralized borrowing information. After lease commencement and the establishment of a right-to-use asset and operating lease liability, lease expense is recorded on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company enters into contracts that contain both lease and non-lease components. Non-lease components include costs that do not provide a right-to-use a leased asset but instead provide a service, such as maintenance costs. The Company has elected to account for the lease and non-lease components together as a single component for all classes of underlying assets. Variable costs associated with the lease, such as maintenance and utilities, are not included in the measurement of right-to-use assets and lease liabilities but rather are expensed when the events determining the amount of variable consideration to be paid have occurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_4d0b0ba5-3b8a-4068-b299-799ed4f36e53"
      id="F_ffab2137-f2e6-4bde-aa5c-8d9fda57d076">2022-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_4d0b0ba5-3b8a-4068-b299-799ed4f36e53"
      id="F_22564d2e-9950-4f90-9c71-7b1c975f76e5">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_ee4bea4a-313b-40e8-8b8e-fc3e46bf9e13">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. The recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset or asset group to the estimated undiscounted future cash flows expected to be generated by the asset or asset group.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If the carrying amount of an asset or asset group exceeds its estimated undiscounted future cash flows, an impairment charge is recognized as the amount by which the carrying amount of the asset or asset group exceeds the estimated discounted future cash flows of the asset or asset group. There have been &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; such impairments of long-lived assets for the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="INF"
      id="F_15e1c58c-f1b0-4e50-8440-f484d25cf729"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="INF"
      id="F_2e910111-7b16-4169-8de6-b3acd514662f"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_39ae7e18-8fd9-42b4-8209-e193e94ef1da">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Commitment and Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes a liability with regard to loss contingencies when it believes it is probable a liability has been incurred, and the amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount the Company accrues the minimum amount in the range. The Company has not recorded any such liabilities as of December 31, 2023 and 2022 that were material to the consolidated financial statements&lt;/span&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:PreferredStockTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_ae531f62-118c-4d8a-9e8e-7886b25ebfc7">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Company recorded convertible preferred stock at fair value on the dates of issuance, net of issuance costs. Upon the occurrence of certain events that are outside the Company&#x2019;s control, including a deemed liquidation event, holders of the convertible preferred stock could cause redemption for cash. Therefore, convertible preferred stock was classified outside of stockholders&#x2019; deficit on the consolidated balance sheets as events triggering the liquidation preferences are not solely within the Company&#x2019;s control. No accretion was recognized as the contingent events that could give rise to redemption were not deemed probable. Upon completion of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;IPO, all preferred stock was converted to common stock and as such &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; amounts were issued or outstanding as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:PreferredStockTextBlock>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="INF"
      id="F_3d3f0c5b-81b5-40e1-92ed-a9e296f15127"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="INF"
      id="F_d322073d-bea7-46b1-9b5f-1040d7be8a09"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="INF"
      id="F_d4894129-c795-4de1-aa17-54b4332c4c59"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="INF"
      id="F_4199d7d1-d428-4c9e-9df7-49741ee52ebc"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <pepg:PreferredStockWarrantsPolicyTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_3affdff0-c2ba-4e5b-ac95-293b2794f98b">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Preferred Stock Warrants&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company classified warrants to purchase its Series A-2 convertible preferred stock as a liability on the consolidated balance sheets as these warrants were freestanding financial instruments that could have required the Company to transfer assets upon exercise.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;</pepg:PreferredStockWarrantsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_909b2c2c-f2fc-42ca-b053-1d1eb121516a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Research and Development&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development costs consist of salaries, benefits, and other personnel-related costs, including stock-based compensation, laboratory supplies, process development costs, fees paid to other entities to conduct certain research and development activities on the Company&#x2019;s behalf, including contract manufacturing organizations and contract research organizations, and allocated facility and other related costs. Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized as prepaid expenses until the related goods are delivered or services are performed. During the year-ended December 31, 2022, the Company received &#xa3;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million) relating to its 2021 U.K. research and development tax credit for research and development activities undertaken by its U.K. subsidiary. As of December 31, 2023 and 2022, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; research and development tax credits were recorded in other receivables on the consolidated balance sheets, respectively.&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers under the service agreements. The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The historical accrual estimates made by the Company have not been materially different from the actual costs.&lt;/span&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_4284776a-c9e1-4a96-bba1-46cb3d689de2"
      decimals="-5"
      id="F_29f15c09-b0fc-484b-ac08-2c5fd64edd37"
      unitRef="U_GBP">3400000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_f4a43b6a-4e2b-469c-a21b-5b9a3de9dfc0"
      decimals="-5"
      id="F_2440153c-e6ad-4b6d-a1e1-264a4b8ac775"
      unitRef="U_USD">4100000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="0"
      id="F_2ac48ddd-b0db-479f-a921-26c1a6dde75f"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="0"
      id="F_80e0cda1-ecd1-48e3-9206-d7becc49d019"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_c0253ae8-e895-4a8f-81be-aed276c65830">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Compensation-Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, or ASC 718. ASC 718 requires all stock-based payments to employees, non-employees and directors, to be recognized as expense in the consolidated statements of operations based on their grant date fair values. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model, or Black-Scholes, for stock option grants to employees, non-employees and directors. The fair value of the Company&#x2019;s common stock is used to determine the fair value of restricted stock awards.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s stock-based compensation awards are generally subject to service-based vesting conditions. Compensation expense related to awards to employees, non-employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Black-Scholes requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends.  The Company determines the expected volatility using the historical volatility of a peer group of comparable publicly traded companies with product candidates in similar stages of development to the Company&#x2019;s product candidates. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term for stock options granted to employees, non-employees and directors whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prior to the Company&#x2019;s IPO, there was no public market for its common stock, and consequently, the estimated fair value of its common stock was determined by the board of directors as of the date of each stock option grant, with input from management, considering third-party valuations of its common stock as well as its board of directors&#x2019; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent third-party valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#x2019; Accounting and Valuation Guide, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Valuation of Privately-Held-Company Equity Securities Issued as Compensation &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, or Practice Aid. The Practice Aid identifies various available methods for allocating the enterprise value across classes of series of capital stock in determining the fair value of the Company&#x2019;s common stock at each valuation date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Subsequent to the Company&#x2019;s IPO, the fair value of the common stock underlying the stock-based awards is the closing price of the Company&#x2019;s common stock on the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#x2019;s payroll costs are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_5c5a8c6d-956b-4f68-8a83-7ef57128bd89">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.133%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts or existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company records a valuation allowance to reduce deferred tax assets to an amount for which realization is more likely than not.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.133%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes the tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained upon examination by the tax authorities, based on the merits of the position. The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; interest or penalties charged in relation to the unrecognized tax benefits.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="INF"
      id="F_12625635-baf8-44a8-8a53-6ae91d2b48c8"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="INF"
      id="F_65319430-b597-437b-a5ad-2feea0aa0e0e"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense>
    <pepg:ComprehensiveLossPolicyTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_bb931870-610e-4b4b-80c3-3d2ef4bb19f4">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Comprehensive loss is composed of two components &#x2014; net loss and other comprehensive loss. Other comprehensive loss refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders&#x2019; equity but are excluded from net loss. The Company&#x2019;s other comprehensive loss consists of foreign currency translation adjustments and unrealized gains and losses on available-for-sale marketable debt securities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</pepg:ComprehensiveLossPolicyTextBlock>
    <pepg:NetLossPerSharePolicyTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_011ed5fa-324c-42c2-85f8-8723355592b7">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration of potential dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares plus the potential dilutive effects of potential dilutive securities outstanding during the period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Potential dilutive securities are excluded from diluted earnings or loss per share if the effect of such inclusion is anti-dilutive. The Company&#x2019;s potentially dilutive securities include unvested common stock under the Company&#x2019;s equity incentive plan which have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,233,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,341,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,233,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,341,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</pepg:NetLossPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_601cf422-f937-4294-a969-6d0340114949">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their inclusion would be anti-dilutive:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
          &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
          &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,233,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,341,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,233,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,341,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2f09d803-162d-4289-ba95-128a23f2de31"
      decimals="0"
      id="F_1552c5a4-e8b7-4188-912d-30792e35ef19"
      unitRef="U_shares">4233203</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_9cb04199-144a-4871-b5ab-87a87eb6a48d"
      decimals="0"
      id="F_33bd0337-412c-4834-b046-7c6a9b775c05"
      unitRef="U_shares">3341834</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="0"
      id="F_f43b30b0-6ac0-46fb-b592-e2ba4b939a96"
      unitRef="U_shares">4233203</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="0"
      id="F_80bf527a-faac-4e63-bb11-2d0dff23c2c3"
      unitRef="U_shares">3341834</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <pepg:EmergingGrowthCompanyStatusPolicyTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_7fb3f7bb-426f-43f9-856b-55b59bcd7fd0">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Company is an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act, or JOBS Act, and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company may take advantage of these exemptions until the Company is no longer an &#x201c;emerging growth company.&#x201d; Section 107 of the JOBS Act provides that an &#x201c;emerging growth company&#x201d; can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards and as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of the IPO or such earlier time that it is no longer an &#x201c;emerging growth company.&#x201d; As a result of the Company having elected the extended&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;transition &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act, 2016-13 and ASU 2019-11 are effective for the Company for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years.&lt;/span&gt;&lt;/p&gt;</pepg:EmergingGrowthCompanyStatusPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_766d6532-1806-4ada-b7ce-d611d032fcbb">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB or other standard-setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#x201c;emerging growth company&#x201d; as defined in the JOBS Act of 2012 and has elected not to &#x201c;opt out&#x201d; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and non-public companies, the Company can adopt the new or revised standard at the time non-public companies adopt the new or revised standard and can do so until such time that the Company either (i) irrevocably elects to &#x201c;opt out&#x201d; of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for non-public companies. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial statements and disclosures.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Effective January 1, 2022, the Company adopted ASC 842. Upon commencement of the Company's lease in December 2022, the Company recognized lease liabilities totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and right-of-use assets totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, or ASU 2016-13. The standard changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today&#x2019;s &#x201c;incurred loss&#x201d; approach with an &#x201c;expected loss&#x201d; model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard&#x2019;s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The effective date of this update is for fiscal years beginning after December 15, 2022, and interim periods therein. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ASU 2016-13 effective &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740), or ASU 2019-12. The standard simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and also improves consistent application by clarifying and amending existing guidance. The standard is effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ASU 2019-12 effective &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvement to Income Tax Disclosures, or ASU 2023-07, to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 on a prospective basis. Early adoption and retrospective application is permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, or ASU 2023-07, which requires public entities to disclose information about their reportable segments&#x2019; significant expenses on an interim and annual basis. ASU 2023-07 is effective for the Company beginning the year ended May 31, 2025. The Company is currently evaluating the impact of this ASU 2023-07 on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-5"
      id="F_a70d7749-86da-453a-a732-0eec38c5e62c"
      unitRef="U_USD">24500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-5"
      id="F_f8fb1620-2a29-4627-8db5-11d31a8ab86a"
      unitRef="U_USD">26500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_23a4b3c2-3578-4710-8ebf-43d479465cfb"
      id="F_2adc4213-7d03-4b40-affc-324ffbe311e7">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_23a4b3c2-3578-4710-8ebf-43d479465cfb"
      id="F_d278a7b5-872d-4a7c-a801-4cc0abb4c602">2023-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_23a4b3c2-3578-4710-8ebf-43d479465cfb"
      id="F_647543fc-1d1f-4a4d-ba04-609ea6db298f">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_fa6a276c-2e4d-4050-a264-a051017ad010"
      id="F_13962768-5bf3-4eec-a396-cc8be46a2839">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_fa6a276c-2e4d-4050-a264-a051017ad010"
      id="F_08690fb9-366e-4046-a575-14efa8ec0d8b">2023-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_fa6a276c-2e4d-4050-a264-a051017ad010"
      id="F_164618f5-53f9-419d-b8fe-fae852a33871">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_e64ddd38-c491-413b-a5f8-d5bc3600821b">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3. Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth marketable securities for the year ended December 31, 2023 (in thousands). The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t hold any marketable securities during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.700000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury-backed money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table set forth the fair value of the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicates the level within the fair value hierarchy utilized to determine such values (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash Equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury-backed money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64,397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64,397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable Securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;106,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;106,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury-backed money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Money market funds are highly liquid investments that are valued based on quoted market prices in active markets, which represent a Level 1 measurement within the fair value hierarchy. These money market funds are classified on the balance sheet under cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Preferred Stock Warrant Liability&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the November 24, 2020 Stock Purchase Agreement (see Note 9), the Company granted warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,529&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Series A-2 convertible preferred stock at a price per share equal to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.42&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and with a term ending upon the earlier of an underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, the consummation of a Deemed Liquidation Event, as such term is defined in the Company&#x2019;s Restated Certificate of Incorporation, or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. As the warrants were for preferred stock, which did not qualify for equity classification, the warrants were recorded as a liability and were required to be remeasured to fair value at each reporting date. The warrants were exercised on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;May 4, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, just prior to the completion of the IPO, for proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Immediately prior to the consummation of the IPO, the warrants were converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,901&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company's common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As there are several inputs that are not observable in the market, the warrant valuation represented a Level 3 measurement within the fair value hierarchy. The Company&#x2019;s valuation of the preferred stock warrants utilized the Black-Scholes option-pricing model, which incorporates assumptions and estimates to value the preferred stock warrants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The quantitative elements associated with the Company&#x2019;s Level 3 inputs impacting the fair value measurement of the preferred stock warrant liability included the fair value per share of the underlying Series A-2 convertible preferred stock, the remaining contractual term of the warrants, risk-free interest rate, expected dividend yield and expected volatility of the price of the underlying preferred stock. The most significant assumption in the Black-Scholes option-pricing model impacting the fair value of the preferred stock warrants was the fair value of the Company&#x2019;s Series A-2 convertible preferred stock as of each remeasurement date. The Company determined the fair value per share of the underlying preferred stock by taking into consideration its most recent sales of its convertible preferred stock. The Company historically had been a private company and lacked company-specific historical and implied volatility information of its stock. Therefore, it estimated its expected stock volatility based on the historical volatility of publicly traded peer companies for a term equal to the remaining contractual term of the warrants. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining contractual term of the warrants. The Company had estimated a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% dividend yield based on the expected dividend yield and the fact that the Company has never paid or declared dividends.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognized changes in the fair value of the warrant liability as a component of other income (expense) in its consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the Level 3 warrant liability through exercise in the second quarter of 2022 was as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Series A-2 Preferred&lt;br/&gt;Stock Warrant Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercise of preferred stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_14aa4fda-6e23-4d89-9852-c1c7a420bc5c">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table sets forth marketable securities for the year ended December 31, 2023 (in thousands). The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t hold any marketable securities during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:36.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.700000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.84%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury-backed money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="INF"
      id="F_874bbcb9-d95c-400d-a3c9-2b9623e59e96"
      unitRef="U_USD">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_111dcd21-eeba-473b-9067-9dc4b9836ccf"
      decimals="-3"
      id="F_c9851112-cfef-405f-84e2-262b425144e1"
      unitRef="U_USD">29622000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_111dcd21-eeba-473b-9067-9dc4b9836ccf"
      decimals="-3"
      id="F_fd4890b7-6aa2-43a5-84de-171e11135932"
      unitRef="U_USD">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_111dcd21-eeba-473b-9067-9dc4b9836ccf"
      decimals="-3"
      id="F_6d3f304c-bd30-4b4c-8ec6-aaa80d59f970"
      unitRef="U_USD">29633000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_371be5d6-590c-4e20-b482-541e33e8a6fb"
      unitRef="U_USD">29622000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_760d8176-91c9-44b9-a4da-f7e1a70ef617"
      unitRef="U_USD">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_11a53c69-e4dc-45a1-8a80-33677d9e60bf"
      unitRef="U_USD">29633000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_f6e6fac3-5e93-4fd5-b060-dfa46f86415f">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table set forth the fair value of the Company&#x2019;s financial assets measured at fair value on a recurring basis and indicates the level within the fair value hierarchy utilized to determine such values (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash Equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury-backed money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64,397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;64,397&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable Securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;106,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;106,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Treasury-backed money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_4665c752-93dc-481c-88bb-900dcc8ff971"
      decimals="-3"
      id="F_9a87d0b2-376f-4c19-89b9-072843fbf5f2"
      unitRef="U_USD">64397000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_d8e10c34-dfed-494a-8b1a-5d7203d659eb"
      decimals="-3"
      id="F_759f6ab8-f85e-4cb5-9c92-da357cdc140e"
      unitRef="U_USD">64397000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_ddcf7e0e-5706-4523-945c-daec00947c1e"
      decimals="-3"
      id="F_ccd320ba-a545-42bb-a010-30d19895acbc"
      unitRef="U_USD">11980000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_887c0bf2-95aa-4fe1-afb6-f5b7822e931f"
      decimals="-3"
      id="F_2357866b-e28a-46e3-92e3-c66948a61f70"
      unitRef="U_USD">11980000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_ddcf7e0e-5706-4523-945c-daec00947c1e"
      decimals="-3"
      id="F_526555e5-c052-407e-984d-4d2d51f0f1c8"
      unitRef="U_USD">29633000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_887c0bf2-95aa-4fe1-afb6-f5b7822e931f"
      decimals="-3"
      id="F_07707d48-3c03-49cc-b68d-267b7abbef39"
      unitRef="U_USD">29633000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_fe73f47a-1a8a-4c3f-bc3a-56c5282d62d9"
      decimals="-3"
      id="F_20145002-5d23-47cf-bed5-d643a0a97caa"
      unitRef="U_USD">106010000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_eb8cf3d7-367c-4f24-aa0c-6cc587368dd2"
      decimals="-3"
      id="F_0df2f15c-882a-44ab-88ed-51bbdae853ba"
      unitRef="U_USD">106010000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a76bcc79-0abb-40aa-b47b-a2d80c882380"
      decimals="-3"
      id="F_a6c5b069-4ff0-482f-8919-ab07a14254d5"
      unitRef="U_USD">18645000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f589bb63-125f-4e69-a1dc-e5029e610005"
      decimals="-3"
      id="F_a23c7ad8-5ded-4867-95dc-b274b2414837"
      unitRef="U_USD">18645000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_30fabfc5-c97f-4da0-9e33-dae485ef6dee"
      decimals="-3"
      id="F_e97e16b9-b2fb-4f1d-ba28-f1a1abace658"
      unitRef="U_USD">18645000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_bd645434-03f7-4e7a-9254-fc4113a4fc17"
      decimals="-3"
      id="F_0ee755c7-5235-43db-9a80-1d4854a6a2de"
      unitRef="U_USD">18645000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_79b1260c-c408-4a48-8c54-3595577f6b00"
      decimals="0"
      id="F_fc0a5200-901f-484d-8c4d-28454ccc6cee"
      unitRef="U_shares">35529</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_79b1260c-c408-4a48-8c54-3595577f6b00"
      decimals="2"
      id="F_ba3d8857-0e76-46ca-888a-292c17f03139"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.42</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_ae4f1a1a-7f76-43a6-b05d-f7cb7ac0bb50"
      id="F_14a18fdb-4b7c-4c17-8c90-474d0361aaaa">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_c0a19928-745a-4714-91d3-865c92c17c50">2022-05-04</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_479f1274-d273-4c6d-b379-65dc65120fec"
      decimals="-5"
      id="F_3c126462-81e5-46c8-b44b-1852a118025a"
      unitRef="U_USD">400000</us-gaap:ProceedsFromWarrantExercises>
    <pepg:ClassOfWarrantsOrRightsNumberOfSharesConvertedToCommonStock
      contextRef="C_479f1274-d273-4c6d-b379-65dc65120fec"
      decimals="0"
      id="F_7a926ccb-fd56-4930-9a3c-ff8bfd52ec62"
      unitRef="U_shares">34901</pepg:ClassOfWarrantsOrRightsNumberOfSharesConvertedToCommonStock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_298b30ab-8f35-409c-81dc-e0ab49287a93"
      decimals="1"
      id="F_6d8c45c8-0d25-47fb-a500-468bff2ef5d0"
      unitRef="U_pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_daf7da48-07f1-4345-93f2-57d81d941cad">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the Level 3 warrant liability through exercise in the second quarter of 2022 was as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.58%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.88%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.54%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Series A-2 Preferred&lt;br/&gt;Stock Warrant Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;226&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercise of preferred stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_09aa4d44-be62-4c19-89e9-09be49174654"
      decimals="-3"
      id="F_de54adcb-9b1d-4b7e-9a95-2155263d9b51"
      unitRef="U_USD">226000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_084747ab-da2f-409a-8832-1a799b9b3b81"
      decimals="-3"
      id="F_4775cc6c-5e56-4e36-b8bc-a2368e72b7db"
      unitRef="U_USD">-58000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <pepg:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExerciseOfPreferredStockWarrants
      contextRef="C_084747ab-da2f-409a-8832-1a799b9b3b81"
      decimals="-3"
      id="F_5c9a0905-bb38-448b-ac03-7429f0c5e784"
      unitRef="U_USD">-168000</pepg:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityExerciseOfPreferredStockWarrants>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_47624e70-d227-4ad8-884c-4512974f2cd1">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4. Property and Equipment, Net&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The cost and accumulated depreciation of property and equipment were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,821&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;171&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Construction in process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,764&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Depreciation expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_14b700df-1cff-4024-ae67-2c2d6eb2192e">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The cost and accumulated depreciation of property and equipment were as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,821&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Computer and office equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;171&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Construction in process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,764&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6b88145a-4875-4cd0-a443-e63d1611c62d"
      decimals="-3"
      id="F_30e8e947-96fd-4f3b-9f35-daf2ade0b8cc"
      unitRef="U_USD">4821000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_d4800734-4394-4f05-a937-22e162de9696"
      decimals="-3"
      id="F_bbd03486-965e-49a3-ae64-6b06a276acbd"
      unitRef="U_USD">2424000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_83c51675-48f0-45b3-8010-597a2244a8c3"
      decimals="-3"
      id="F_30c03ffb-145c-4cf2-ae00-4a831459d9f5"
      unitRef="U_USD">1446000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_2a6bbe33-4c45-482c-ac03-94f727c30255"
      decimals="-3"
      id="F_aa011324-d676-4cc3-91d1-3d0da4865d0d"
      unitRef="U_USD">171000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_d198184c-cc7e-4c68-a75d-06a166129ca1"
      decimals="-3"
      id="F_63d70448-0dd2-46fb-8610-b9a81682ec30"
      unitRef="U_USD">69000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0eec95c7-6d1e-4442-a8e7-29920d1d09af"
      decimals="-3"
      id="F_43b57935-678e-411b-86d5-ae7691c391c3"
      unitRef="U_USD">1129000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_6aeb554f-2b05-40c7-972e-527222668d95"
      unitRef="U_USD">6336000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_6c98ea80-c6c6-408b-8354-723c0dd82f2e"
      unitRef="U_USD">3724000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_97ed0f69-a8a7-4ef9-a4a6-287a30d6da62"
      unitRef="U_USD">1572000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_d126f790-4e69-42d6-8138-5afbba60488f"
      unitRef="U_USD">389000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_3b90a0d4-fc1d-4e29-90a9-00470001a10a"
      unitRef="U_USD">4764000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_9844159a-8a7e-4438-9c55-f333e155acfb"
      unitRef="U_USD">3335000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-5"
      id="F_25d2e069-28fb-4d17-be4d-6cb2f5fab8b5"
      unitRef="U_USD">1200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-5"
      id="F_68f26589-364b-4c96-9793-648e8eada024"
      unitRef="U_USD">500000</us-gaap:DepreciationDepletionAndAmortization>
    <pepg:AccruedLiabilitiesCurrentDisclosureTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_55eafd63-2159-4506-b6a6-cd4beabbd58f">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5. Accrued Expenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Employee-related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,440&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Taxes payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</pepg:AccruedLiabilitiesCurrentDisclosureTextBlock>
    <pepg:ScheduleOfAccruedLiabilitiesCurrentTableTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_8d1fc47d-2181-4d5e-9729-51ad2f9f7f0a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Employee-related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,440&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Taxes payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</pepg:ScheduleOfAccruedLiabilitiesCurrentTableTextBlock>
    <pepg:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_029f0c59-80dc-4172-9a97-d70514266aa1"
      unitRef="U_USD">9521000</pepg:AccruedResearchAndDevelopmentExpensesCurrent>
    <pepg:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_e3ae8672-2426-4e9c-b615-1d82f65feeb9"
      unitRef="U_USD">4840000</pepg:AccruedResearchAndDevelopmentExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_d51d6fd2-55f5-41d8-815b-8589dcac1454"
      unitRef="U_USD">2368000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_0c4424f5-6ee7-4829-aace-7e13d35e234d"
      unitRef="U_USD">2440000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_53bc5d23-7408-4f00-a86c-b210365ec7d6"
      unitRef="U_USD">2574000</us-gaap:TaxesPayableCurrent>
    <pepg:AccruedProfessionalServicesCurrent
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_08002aff-6f5b-4a44-b86f-9e2cb49d30a5"
      unitRef="U_USD">715000</pepg:AccruedProfessionalServicesCurrent>
    <pepg:AccruedProfessionalServicesCurrent
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_8ccf1829-9944-4399-8cb9-8a5f062221c6"
      unitRef="U_USD">932000</pepg:AccruedProfessionalServicesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_99527efe-17f3-4960-8e33-89dac3625c90"
      unitRef="U_USD">918000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_9187588f-7d59-498e-b3b8-0794faf7af35"
      unitRef="U_USD">1127000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_772d0dc7-53ae-4e02-8cc9-358c564a10d7"
      unitRef="U_USD">13522000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_d0a8e66d-677f-4461-9644-2616418bdd0b"
      unitRef="U_USD">11913000</us-gaap:AccruedLiabilitiesCurrent>
    <pepg:LeasesDisclosureTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_3686a7d1-7a9d-49f1-ad25-f8076ab27209">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6. Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2021, the Company entered into a non-cancellable operating lease agreement, or the Harrison Lease, pursuant to which the Company leases &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,668&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet of office and laboratory space located in Boston, Massachusetts, or the Premises. The Harrison Lease commenced for accounting purposes when the Company gained access to the Premises on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 29, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, or the Lease Commencement Date. The Harrison Lease has a term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;nine years and two months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; from the Lease Commencement Date. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s obligation for the payment of base rent for the Premises began in May 2023, and is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million per month, increasing up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million per month during the term of the Lease.  &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has one &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;option to extend&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; the term of the Harrison Lease, for a period of an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. Due to the timing of the Lease Commencement Date at the end of 2022, there was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; fixed lease rent expense associated with the Harrison Lease in 2022. At December 31, 2023, the Harrison Lease was the only lease for which the Company recorded a lease liability and corresponding right-of-use asset.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The landlord completed significant leasehold improvements to the Premises, a portion of which the Company was obligated to pay per the terms of the Harrison Lease. The Company paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the improvements prior to lease commencement in 2022, and paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the improvements in 2023, for total payments to the landlord for improvements of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company determined that the landlord is the accounting owner of the improvements, and payments by the Company for the improvements are included in the calculation of the right-of-use asset and lease liability.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During 2022 and the first quarter of 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the Company leased office space in Cambridge, Massachusetts, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the terms of which were month-to-month, with a 30-day written &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;notice of cancellation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company terminated this lease in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company also leased laboratory space at the University of Massachusetts, Mount Ida Campus in Newton, Massachusetts, with an &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;initial &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;lease term from February 1, 2022 to January 31, 2023, which the Company extended until March 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Company also leased space at Innovation Building, University of Oxford in Oxford, U.K. The Company terminated its lease in Oxford in July 2022. All of these leases had initial terms of under &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; months and are considered short-term lease costs and are not recognized on the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Summary of Lease Costs&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of lease cost under ASC 842 for the leases were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fixed lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Supplemental disclosure of cash flow information under ASC 842 for the leases was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,  2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating cash payments for operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash payments for operating leases during 2023 related to tenant improvements of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in rent payments in line with the Harrison Lease. Additionally, the Company made payments on variable lease costs throughout the year of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. These payments related to parking, management fees, and other costs associated with maintaining our office and lab space.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The remaining lease term for the Harrison Lease is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years, and the discount rate is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future minimum lease payments under the non-cancelable operating lease consisted of the following as of December 31, 2023:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,079&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Present value of lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Included in the consolidated balance sheet (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liability, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</pepg:LeasesDisclosureTextBlock>
    <pepg:LeasedSpace
      contextRef="C_18a316cc-fb97-4041-99e0-a3525fa31567"
      decimals="INF"
      id="F_c564f2dd-18e6-4fb6-b428-977f47424083"
      unitRef="U_sqft">31668</pepg:LeasedSpace>
    <pepg:OperatingLeaseCommencementDate
      contextRef="C_580f0221-c422-43d6-9cb9-c47b83af1d6b"
      id="F_d154ae7a-2203-4465-a00e-e981d8aeb613">2022-12-29</pepg:OperatingLeaseCommencementDate>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_18a316cc-fb97-4041-99e0-a3525fa31567"
      id="F_3709f856-b689-41de-918d-afdb97d52a3b">P9Y2M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_d913f63c-8af0-45d4-9fb8-34b4620d0aa9"
      id="F_829b0913-5657-4d43-8f2e-d6a056fa4691">The Company&#x2019;s obligation for the payment of base rent for the Premises began in May 2023, and is $0.2 million per month, increasing up to $0.3 million per month during the term of the Lease.  The Company has one option to extend the term of the Harrison Lease, for a period of an additional five years</us-gaap:LesseeOperatingLeaseDescription>
    <pepg:OperatingLeaseMonthlyRentExpense
      contextRef="C_580f0221-c422-43d6-9cb9-c47b83af1d6b"
      decimals="-5"
      id="F_eb1e8615-2282-4dd1-a9fd-752cc43b0229"
      unitRef="U_USD">200000</pepg:OperatingLeaseMonthlyRentExpense>
    <pepg:OperatingLeaseIncreaseInMonthlyRentExpense
      contextRef="C_580f0221-c422-43d6-9cb9-c47b83af1d6b"
      decimals="-5"
      id="F_7d7cd6a7-7a15-4a72-a0a9-435931e6052c"
      unitRef="U_USD">300000</pepg:OperatingLeaseIncreaseInMonthlyRentExpense>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_d913f63c-8af0-45d4-9fb8-34b4620d0aa9"
      id="F_13ecc270-525d-4ac0-9a90-4269613b3329">The Company has one option to extend the term of the Harrison Lease, for a period of an additional five years</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_d913f63c-8af0-45d4-9fb8-34b4620d0aa9"
      id="F_0120af5a-6df8-4600-8eb4-b1ad31f105d7">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <pepg:OperatingLeasePeriodOfExtension
      contextRef="C_580f0221-c422-43d6-9cb9-c47b83af1d6b"
      id="F_c6ba1324-b926-4c36-9e76-064ac46ce8bd">P5Y</pepg:OperatingLeasePeriodOfExtension>
    <pepg:FixedLeaseRentExpense
      contextRef="C_d913f63c-8af0-45d4-9fb8-34b4620d0aa9"
      decimals="INF"
      id="F_7fa9440a-3f3e-496f-8520-2fdb4c4cd5c8"
      unitRef="U_USD">0</pepg:FixedLeaseRentExpense>
    <us-gaap:OperatingLeaseCost
      contextRef="C_941e7577-cf0a-4629-9509-58cf297868bf"
      decimals="-5"
      id="F_f770acb4-1671-453f-92c6-981783e38291"
      unitRef="U_USD">2000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_7ff7e6d1-9dc6-4e1d-af82-7945a62662d8"
      decimals="-5"
      id="F_5428dfd4-1138-4f3c-82d7-658903dc1ab6"
      unitRef="U_USD">3400000</us-gaap:OperatingLeaseCost>
    <pepg:AggregateOperatingLeaseCost
      contextRef="C_7ff7e6d1-9dc6-4e1d-af82-7945a62662d8"
      decimals="-5"
      id="F_307a4ce0-97c4-42a8-94e8-e5a36919c03d"
      unitRef="U_USD">5400000</pepg:AggregateOperatingLeaseCost>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_472ca393-199b-4e03-9b1a-59688620fedb"
      id="F_12dd1eba-fd6e-4960-a7de-a275db7f8648">the Company leased office space in Cambridge, Massachusetts, the terms of which were month-to-month, with a 30-day written notice of cancellation</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LesseeOperatingLeaseOptionToTerminate
      contextRef="C_472ca393-199b-4e03-9b1a-59688620fedb"
      id="F_9415d8cd-dfe7-4123-ab9b-b9784b14423f">the terms of which were month-to-month, with a 30-day written notice of cancellation</us-gaap:LesseeOperatingLeaseOptionToTerminate>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate
      contextRef="C_472ca393-199b-4e03-9b1a-59688620fedb"
      id="F_1d26b7f6-a074-45be-9b07-9931003fd7ee">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_6eb59534-d6e4-4470-9e92-dc335995eadd"
      id="F_a739867e-2708-4f44-be71-72b03d29b339">The Company terminated this lease in January 2023. The Company also leased laboratory space at the University of Massachusetts, Mount Ida Campus in Newton, Massachusetts, with an initial lease term from February 1, 2022 to January 31, 2023, which the Company extended until March 2023</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate
      contextRef="C_472ca393-199b-4e03-9b1a-59688620fedb"
      id="F_d54e3924-9222-41b4-b021-39379285e1c9">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_3ed7174f-94bd-4691-abc3-6e866114de8b"
      id="F_b3cc2d1f-5c13-496d-9d30-4dc929bda7a6">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_8e0783a8-6bef-41f2-ae8d-dad17e9b195b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of lease cost under ASC 842 for the leases were as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fixed lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_82c7a957-2174-458f-bb11-c55581cb9862"
      unitRef="U_USD">3799000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_840d416e-7c89-4b8b-b08a-48cbec82b37b"
      unitRef="U_USD">993000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_1748466e-2c91-4484-902e-6505f7fea8a7"
      unitRef="U_USD">188000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_a9887893-d115-4460-9ccd-4be0e9697f75"
      unitRef="U_USD">1294000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_0aaed132-f336-4ffd-8e2f-73554b72a79a"
      unitRef="U_USD">4980000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_575c7083-553e-47f3-8d24-5ae29ba0e278"
      unitRef="U_USD">1294000</us-gaap:LeaseCost>
    <pepg:SupplementalDisclosureOfCashFlowInformationRelatedToLeasesTableTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_a4530757-f6d0-4087-8a19-a24c81c97d2c">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Supplemental disclosure of cash flow information under ASC 842 for the leases was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,  2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating cash payments for operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</pepg:SupplementalDisclosureOfCashFlowInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_aee636a0-32ca-48e2-b789-6d2bed8ac368"
      unitRef="U_USD">5299000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseCost
      contextRef="C_098c1eb1-fac5-4644-b049-d1ecd9083a38"
      decimals="-5"
      id="F_4b56cfb0-215d-4d5e-8550-535d89c2404c"
      unitRef="U_USD">3400000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_d913f63c-8af0-45d4-9fb8-34b4620d0aa9"
      decimals="-5"
      id="F_135a7b7e-403d-4e1a-bf63-a10f8723ef50"
      unitRef="U_USD">1900000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-5"
      id="F_d901221f-576f-4007-8550-569b7fa723bb"
      unitRef="U_USD">1000000</us-gaap:VariableLeaseCost>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="C_48600fa6-eba6-438a-9b5f-dff15a734745"
      id="F_e287c816-9028-46b7-95d9-ab42ca28c3a4">P8Y4M24D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_48600fa6-eba6-438a-9b5f-dff15a734745"
      decimals="3"
      id="F_94744cf2-a39e-408b-9c85-6f11bd986d3f"
      unitRef="U_pure">0.08</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_9a0b84ae-ef90-4834-9877-123ae194a53f">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Future minimum lease payments under the non-cancelable operating lease consisted of the following as of December 31, 2023:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,094&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,079&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Present value of lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Included in the consolidated balance sheet (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liability, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_53703d61-e48a-41b6-9581-926bab766b07"
      unitRef="U_USD">3004000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_aa8d323a-5ba6-4cb9-9cd3-8dfdc0edee07"
      unitRef="U_USD">3094000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_a5a9d3b2-506b-4c53-a533-e2d2af52e990"
      unitRef="U_USD">3187000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_e8361e51-d53c-4898-9bd6-ec767a8ed5a6"
      unitRef="U_USD">3282000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_11117963-db4b-43fd-960d-2c33532a848b"
      unitRef="U_USD">3381000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_0ccbceaf-1f7a-47f1-a1d5-673efa7ab3e5"
      unitRef="U_USD">12079000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_7aa2e2ba-2844-4221-b4ce-639c482c026c"
      unitRef="U_USD">28027000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_7342d9e9-e745-4e5e-8b60-b435a47d541f"
      unitRef="U_USD">7923000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_12d18867-4a18-4f50-9287-182ca3aaac89"
      unitRef="U_USD">20104000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_fa1485df-2ac0-45ff-b8c4-64d52aaab26d"
      unitRef="U_USD">3004000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_524c42b4-f1db-44cb-b3c9-ac48a5437ad4"
      unitRef="U_USD">17100000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_9cb42b6c-29a6-46c6-9131-56d3ea1394c6"
      unitRef="U_USD">20104000</us-gaap:OperatingLeaseLiability>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_972ad9fe-9bad-430a-8fea-4c9a051e4ed2">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7. Related Party Transactions&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Technology License Agreement with Oxford University Innovation Limited&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In March 2018, the Company, Oxford University Innovation Limited, or OUI, and the Medical Research Council of United Kingdom Research and Innovation, or MRC (or collectively the Licensors), entered into a license of technology agreement, or the License Agreement, which was subsequently amended in December 2018 and further amended and restated in November 2020. The Licensors and affiliates held shares of Series A-1 and Series A-2 preferred stock, Series B preferred stock and Class A common stock. The License Agreement provides the Company with an exclusive world-wide license to licensed data and technology owned by OUI and MRC in respect of CPP for treatment of Duchenne muscular dystrophy, spinal muscular atrophy, and other conditions. The License Agreement provides the Company with the rights to grant and authorize sublicenses to make, use, sell, and import products and otherwise exploit the patent rights.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As consideration for the license, the Company made an initial upfront payment in 2018, as well as a Restatement Completion Fee and a License Data Fee in 2020 totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company could be required to make milestone payments to the Licensors upon achievement of certain patent and commercial milestones related to the patents and commercialization of certain of the Company&#x2019;s product candidates. The aggregate potential milestone payments are $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company also agreed to pay the Licensors low single digit royalties on net sales of any licensed products that are commercialized by the Company in excess of a threshold amount between &#xa3;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &#xa3;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of December 31, 2023), subject to certain adjustments. The term of the License Agreement continues until the later of (i) the date on which all the patents and patent applications covered thereunder have been abandoned or allowed to lapse or expired or been rejected or revoked or (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years from the date of the original agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Upon completion of the IPO, the Company became obligated to pay OUI an exit fee between &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the value determined in an acquisition or initial public offering, not to exceed &#xa3;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of the IPO date). The exit fee due to OUI, based on the proceeds of the IPO, was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which was paid during the second quarter of 2022 and included in research and development expense on the consolidated statement of operations. One member of the Company&#x2019;s board of directors is also employed by Oxford Science Enterprises, which is an affiliate by OUI.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Additionally, the Company paid office space rent to OUI. For the years ended December 31, 2023 and 2022, total rent payments were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. The Company paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during the years ended December 31, 2023 and 2022 to Oxford Science Enterprises as compensation for their board seat. As of December 31, 2023 and 2022, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was due to OUI by the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Services Agreement with RA Capital Management, L.P.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2020, the Company entered into an agreement, or the Services Agreement, with Carnot Pharma, LLC, or Carnot, under which Carnot provided research and other services to the Company. Carnot is an entity controlled by RA Capital Management, L.P. Entities affiliated with RA Capital Management, L.P. purchased shares of Series A-2 convertible preferred stock in the Company&#x2019;s preferred stock financing in November 2020 and May and July 2021. In addition, entities affiliated with RA Capital Management, L.P. purchased shares of the Company&#x2019;s Series B convertible preferred stock in the Company&#x2019;s preferred stock financing in July 2021. Two members of the Company&#x2019;s board of directors are also affiliated with RA Capital Management, L.P.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the terms of the Services Agreement, the Company compensated Carnot on a fully burdened cost basis for personal time devoted to Company projects. In addition, the Company reimbursed Carnot on a costs basis for any subcontractor costs incurred. The Company paid Carnot on a quarterly basis, in arrears, for services performed and costs incurred. The Services Agreement was terminated in April 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Expenses incurred by the Company under the Services Agreement with Carnot for the year ended December 31, 2023 and 2022, totaled &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. Additionally, the Company paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million during the years ended December 31, 2023 and 2022 to RA Capital Management, L.P. as compensation for their board seat. As of December 31, 2023 and 2022, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was due to Carnot by the Company for services rendered under the Services Agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <pepg:AdditionalPaymentsOfRestatementCompletionFeeAndLicenseDataFee
      contextRef="C_9b497aad-3cba-4deb-9dd2-e0a9d56f3614"
      decimals="-5"
      id="F_a536bd46-6791-4d59-9204-944ff412e9d6"
      unitRef="U_USD">100000</pepg:AdditionalPaymentsOfRestatementCompletionFeeAndLicenseDataFee>
    <pepg:AggregatePotentialMilestonePayments
      contextRef="C_9b497aad-3cba-4deb-9dd2-e0a9d56f3614"
      decimals="-5"
      id="F_27b985f3-3951-487f-93ef-e8c67a541333"
      unitRef="U_USD">100000</pepg:AggregatePotentialMilestonePayments>
    <pepg:SublicenseesThresholdAmount
      contextRef="C_30c84240-eef7-4c05-8cf3-d66492402ca5"
      decimals="-6"
      id="F_094c276b-63df-4069-be54-508d51ad0222"
      unitRef="U_GBP">20000000</pepg:SublicenseesThresholdAmount>
    <pepg:SublicenseesThresholdAmount
      contextRef="C_85e7bad8-943c-4a0e-ad95-12e210a9becd"
      decimals="-6"
      id="F_27302211-c2b1-40fd-8c90-e9a2b2ef349a"
      unitRef="U_GBP">30000000</pepg:SublicenseesThresholdAmount>
    <pepg:SublicenseesThresholdAmount
      contextRef="C_85e7bad8-943c-4a0e-ad95-12e210a9becd"
      decimals="-5"
      id="F_e7969a41-4624-4ad1-9d62-5cdd4ad8f704"
      unitRef="U_USD">25500000</pepg:SublicenseesThresholdAmount>
    <pepg:SublicenseesThresholdAmount
      contextRef="C_30c84240-eef7-4c05-8cf3-d66492402ca5"
      decimals="-5"
      id="F_403c455b-0415-4ba1-9008-7e3d331f357f"
      unitRef="U_USD">38200000</pepg:SublicenseesThresholdAmount>
    <pepg:TermOfLicenseAgreement
      contextRef="C_9b497aad-3cba-4deb-9dd2-e0a9d56f3614"
      id="F_f6fa1998-d2d1-4bb3-9eb5-b5c01f6efaae">P20Y</pepg:TermOfLicenseAgreement>
    <pepg:PercentageOfExitFee
      contextRef="C_59392f99-502b-454a-8db2-aeb447f458ec"
      decimals="INF"
      id="F_8fee6fad-7b1e-474b-8217-ea0b5e81c83b"
      unitRef="U_pure">0.005</pepg:PercentageOfExitFee>
    <pepg:PercentageOfExitFee
      contextRef="C_e714e23e-c60b-4649-bcf1-f9525f905459"
      decimals="INF"
      id="F_aca340ce-9ff3-4b6a-8b06-c23796946b2a"
      unitRef="U_pure">0.02</pepg:PercentageOfExitFee>
    <pepg:RequiredToPayExitFeeAmount
      contextRef="C_e714e23e-c60b-4649-bcf1-f9525f905459"
      decimals="-6"
      id="F_8fa495d0-91af-4e81-b72d-6ff14bb2209e"
      unitRef="U_EUR">5000000</pepg:RequiredToPayExitFeeAmount>
    <pepg:RequiredToPayExitFeeAmount
      contextRef="C_e714e23e-c60b-4649-bcf1-f9525f905459"
      decimals="-5"
      id="F_00c51419-7b70-437f-8e22-d3bd76499c19"
      unitRef="U_USD">6200000</pepg:RequiredToPayExitFeeAmount>
    <pepg:RequiredToPayExitFeeAmount
      contextRef="C_c3ab2e29-df24-48f1-bf82-ebac3d3a83b1"
      decimals="-5"
      id="F_e83dca53-9782-4e9d-95b1-ebb448688c0b"
      unitRef="U_USD">1400000</pepg:RequiredToPayExitFeeAmount>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="C_76920238-6f16-4c2c-b840-91aee4e50447"
      decimals="INF"
      id="F_1a8db0b3-0fe6-47a2-96fa-5f486482ebc7"
      unitRef="U_USD">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="C_1b8a0d2c-51ea-4fba-866a-5ab866ff3776"
      decimals="-5"
      id="F_d7d82dbb-399f-4257-b4b8-e39d80fead1a"
      unitRef="U_USD">200000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <pepg:RelatedPartyTransactionsOtherCostsPaid
      contextRef="C_dc45efd8-3a91-4f49-a118-89ede6cb57a1"
      decimals="-5"
      id="F_eee0870e-c368-4a0c-b949-06f5c6970095"
      unitRef="U_USD">100000</pepg:RelatedPartyTransactionsOtherCostsPaid>
    <pepg:RelatedPartyTransactionsOtherCostsPaid
      contextRef="C_ad331ffb-3ca8-41af-9e8c-a5d2e3f07401"
      decimals="-5"
      id="F_41350681-4ab7-4877-ae94-63cf513a8361"
      unitRef="U_USD">100000</pepg:RelatedPartyTransactionsOtherCostsPaid>
    <pepg:RentPayableToRelatedParties
      contextRef="C_b4470897-58c2-4502-9300-1a8a6d7d7faf"
      decimals="INF"
      id="F_5afbbd4e-5ec4-49bc-b3c8-b00d1350de8c"
      unitRef="U_USD">0</pepg:RentPayableToRelatedParties>
    <pepg:RentPayableToRelatedParties
      contextRef="C_030a5a87-1169-4748-9cd4-a4a73f0d0618"
      decimals="INF"
      id="F_bc168918-e03f-448e-a123-f816dd89ec2c"
      unitRef="U_USD">0</pepg:RentPayableToRelatedParties>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="C_f814e08d-65a5-4cb9-880c-4b1766772c26"
      decimals="INF"
      id="F_9963e971-11fc-4b05-aaf0-aeb6c0a71fe1"
      unitRef="U_USD">0</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="C_7fb2ae36-5ee1-44d5-910b-7802e0cbbbc7"
      decimals="-5"
      id="F_883f8948-5810-4419-88a3-529402b77b6e"
      unitRef="U_USD">100000</us-gaap:OperatingCostsAndExpenses>
    <pepg:RelatedPartyTransactionsOtherCostsPaid
      contextRef="C_24eafb5a-baba-449c-8e96-c46f37a25e6c"
      decimals="-5"
      id="F_0cbe2ef1-751b-4854-baee-aaa10deae51a"
      unitRef="U_USD">100000</pepg:RelatedPartyTransactionsOtherCostsPaid>
    <pepg:RelatedPartyTransactionsOtherCostsPaid
      contextRef="C_c12cd4a1-d2bb-4e7d-be33-635f490062b1"
      decimals="-5"
      id="F_ded85f89-696c-46d9-bcb3-c467e7996151"
      unitRef="U_USD">100000</pepg:RelatedPartyTransactionsOtherCostsPaid>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_de36be0e-422a-44fa-b610-cce5387a9700"
      decimals="INF"
      id="F_282d75a2-6bae-437b-bed1-80efeebd3a48"
      unitRef="U_USD">0</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_e0c2b471-faa6-4641-8385-0e58de723dee"
      decimals="INF"
      id="F_b3a9dbf3-dd6a-4d39-a628-c5bc370f8efb"
      unitRef="U_USD">0</us-gaap:AccountsPayableCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_737c87b2-a109-41fc-b0eb-2356f926c5cc">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;8. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Legal proceedings&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is not party to any litigation and does not have contingency reserves established for any litigation liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to the agreements, the Company agrees to indemnify, hold harmless, and to reimburse the indemnified party for losses suffered or incurred by the indemnified party, including in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third-party with respect to the Company&#x2019;s products. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company&#x2019;s request in such capacities. The Company&#x2019;s maximum exposure under these arrangements is unknown as of December 31, 2023. The Company does not anticipate recognizing any significant losses relating to these arrangements. The term of these indemnification agreements is generally perpetual any time after execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements may be unlimited. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_95526d9d-595a-453d-97e2-93c1ed4c0ea0">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;9. Convertible Preferred Stock and Stockholders&#x2019; Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:5.133%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On April 29, 2022, the Company filed a charter amendment to affect a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_11100503-2fd3-4c49-87ab-244664e4d838;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.018&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for 1 reverse stock split&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of its issued and outstanding shares of common stock, which resulted in a proportional adjustment to the existing conversion ratios for each series of the Company&#x2019;s preferred stock. Accordingly, all share and per share amounts for all periods presented in the accompanying consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse stock split and adjustment of the preferred stock conversion ratios.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Series A-1 Convertible Preferred Stock and Series A-2 Convertible Preferred Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the November 24, 2020 Stock Purchase Agreement, the Company agreed to issue an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,939,069&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Series A-2 convertible preferred stock to new and existing investors at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.42&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, in three closings, and elected to convert &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,348,693&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of outstanding Class A and Class B common stock into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,372,970&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Series A-1 convertible preferred stock. A total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,033,117&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Class A common stock held by certain founding investors and employees were not modified and continued to exist as Class A common stock. The Series A-1 and Series A-2 convertible preferred stock was converted to common stock immediately prior to the consummation of the IPO in May 2022 (see Note 1).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Series B Convertible Preferred Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In July 2021 the Company entered into the Series B Stock Purchase Agreement, whereby the Company agreed to issue and sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,234,766&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Series B convertible stock to new and existing investors at a per share price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.55&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share for aggregate gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;112.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Series B convertible preferred stock was converted to common stock immediately prior to the consummation of the Company's IPO in May 2022 (see Note 1).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the Third Amended and Restated Certificate of Incorporation, dated May 10, 2022, the Company has the authority to issue a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;500,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock (par value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share) and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of undesignated preferred stock (par value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share). In connection with the IPO, the Company re-designated all shares of Class A common stock as shares of common stock. Each share of common stock has the right to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; cash dividends have been declared by the board of directors during the year ended December 31, 2023 and December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has reserved the following shares of common stock for issuance, as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,233,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,341,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Authorized for future stock awards or option grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,091,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;901,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Authorized for future issuance under employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;216,306&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;226,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,540,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,469,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Shares of Common Stock Subject to Repurchase&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2020, in connection with the Series A-2 convertible preferred stock financing, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; founding stockholders entered into Stock Restriction Agreements, or Restriction Agreements, whereby &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;139,057&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares that were previously vested and not subject to repurchase became restricted and subject to repurchase. The repurchase rights lapsed as to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% on the one-year anniversary of the Restriction Agreements and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% on the second anniversary of the Restriction Agreements. Shares subject to repurchase by the Company are not deemed, for accounting purposes, to be outstanding until those shares vest and therefore are not included in the shares outstanding on the consolidated balance sheet.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the vesting restrictions placed on these previously vested shares, the Company was required to determine the measurement date fair value of the shares, which was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.37&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share or $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in aggregate. The measurement date fair value of the restricted stock was recognized as stock-based compensation expense over the vesting period. As of December 31, 2023 and 2022, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares were subject to repurchase by the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_5ce499b8-803d-4c0a-b7dc-bd9d43f1ccdf"
      id="F_e453c843-0440-43f2-8bdc-8cb11918a963">1.018 for 1 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_6be9b902-7f6b-479b-bfa6-7743f9105ed0"
      decimals="INF"
      id="F_b3dd6e79-74fa-4c48-9f02-6dc16996e9ec"
      unitRef="U_shares">3939069</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_6be9b902-7f6b-479b-bfa6-7743f9105ed0"
      decimals="INF"
      id="F_e3d9ddd1-46e3-4d3a-9a8b-1c5a9d622b59"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.42</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_e9bca87a-c16a-42e1-91d3-d72a8f122225"
      decimals="INF"
      id="F_1363b465-b0a2-4619-9f91-f43844f168c6"
      unitRef="U_shares">1348693</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_9262d127-7f2e-41a9-86ad-3e2211e86b50"
      decimals="INF"
      id="F_51260d16-3b85-48d8-bf22-895e6f4b8938"
      unitRef="U_shares">1372970</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_e8c98aaa-dcdb-45ee-9cad-d9b7440c3550"
      decimals="INF"
      id="F_de4780a8-c918-4a31-8474-1d12272ea5a9"
      unitRef="U_shares">1033117</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_ce675452-0281-4938-89df-5ecb187847bf"
      decimals="INF"
      id="F_44c7f1fa-e79e-4b60-95df-896ac29e565c"
      unitRef="U_shares">7234766</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_ce675452-0281-4938-89df-5ecb187847bf"
      decimals="INF"
      id="F_7a28197d-0260-4b7d-8e83-b8391ef988d0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.55</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="C_c4ecf543-b902-40c7-b9ae-990d6d5dc573"
      decimals="-5"
      id="F_388a0d95-4c14-4233-af14-efd53f1f8950"
      unitRef="U_USD">112500000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="INF"
      id="F_44681358-9113-4eac-95df-af83a3adc61d"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="4"
      id="F_5584d775-9dde-4c94-b243-d94e5ac7cd5c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_9e4cd814-3cb3-4300-b818-efc911437b4a"
      decimals="INF"
      id="F_3d901513-a384-49c0-b566-9c467f091e26"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_9e4cd814-3cb3-4300-b818-efc911437b4a"
      decimals="4"
      id="F_8dc87438-897b-4d9a-9b01-3a8524a8e3f7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <pepg:NumberOfCommonStockVote
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="INF"
      id="F_30279cd5-24db-4ac5-9ce6-e4aceb8397bb"
      unitRef="U_Vote">1</pepg:NumberOfCommonStockVote>
    <us-gaap:DividendsCommonStockCash
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="INF"
      id="F_e1150500-b7db-47a9-bba5-728318447128"
      unitRef="U_USD">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="INF"
      id="F_29239234-1005-4362-b9e2-5d20cb51ad99"
      unitRef="U_USD">0</us-gaap:DividendsCommonStockCash>
    <pepg:ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_27ba53a3-13ac-447a-ba02-10bd80cc6bc4">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has reserved the following shares of common stock for issuance, as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,233,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,341,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Authorized for future stock awards or option grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,091,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;901,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Authorized for future issuance under employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;216,306&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;226,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,540,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,469,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</pepg:ScheduleOfCommonStockSharesReservedForIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_cab43832-788b-441d-b9a4-b33219debd4f"
      decimals="INF"
      id="F_42f42e76-7fe4-446d-98ef-83d8e671b562"
      unitRef="U_shares">4233203</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_585c525a-f403-4998-a8ec-14fc01861152"
      decimals="INF"
      id="F_21800f5f-128d-4227-b12e-859020e94eb3"
      unitRef="U_shares">3341834</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_99f0f78d-bedd-484e-bfa2-ac51788e3369"
      decimals="INF"
      id="F_f167bf53-c5fa-4f53-80c4-203abea0fc9d"
      unitRef="U_shares">1091187</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_d7f2ab9a-431e-4fa5-8e9c-4fbda0da11cc"
      decimals="INF"
      id="F_aa2615d0-f471-4356-a3bf-1f19b382de9a"
      unitRef="U_shares">901462</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_79566393-e152-4220-b13f-d5411f25b12a"
      decimals="INF"
      id="F_437d042f-4109-4635-ab30-df684c0f1808"
      unitRef="U_shares">216306</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_d2b7323c-10fa-445b-aaed-2945a4bc04a2"
      decimals="INF"
      id="F_659fd800-ee9d-4f0c-909f-7122946c09d6"
      unitRef="U_shares">226000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="INF"
      id="F_63b96317-5865-425a-aeb3-5cf38f943151"
      unitRef="U_shares">5540696</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="INF"
      id="F_f77e2128-0ee1-4298-997a-b6ead5cf170b"
      unitRef="U_shares">4469296</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <pepg:NumberOfFoundingStockholdersEntered
      contextRef="C_c0719f76-c7a1-4758-8910-36fbdccb7a19"
      decimals="INF"
      id="F_d4b2920f-fac4-4545-86b7-de774425d511"
      unitRef="U_Stockholder">2</pepg:NumberOfFoundingStockholdersEntered>
    <pepg:NumberOfSharesRestrictedAndSubjectToRepurchase
      contextRef="C_896cd8db-b4db-45ff-915a-26b26be0959d"
      decimals="INF"
      id="F_77c426c5-0c46-4729-89b1-64fbc493b944"
      unitRef="U_shares">139057</pepg:NumberOfSharesRestrictedAndSubjectToRepurchase>
    <pepg:PercentageOfRepurchaseRightsLapseOnOneYearAnniversary
      contextRef="C_c0719f76-c7a1-4758-8910-36fbdccb7a19"
      decimals="2"
      id="F_4d36d18f-92bb-4074-81ed-ac5627ebe7c7"
      unitRef="U_pure">0.50</pepg:PercentageOfRepurchaseRightsLapseOnOneYearAnniversary>
    <pepg:PercentageOfRepurchaseRightsLapseOnSecondAnniversary
      contextRef="C_c0719f76-c7a1-4758-8910-36fbdccb7a19"
      decimals="2"
      id="F_6a209067-8bc4-4d5c-a7aa-ff7ad4648bbf"
      unitRef="U_pure">0.50</pepg:PercentageOfRepurchaseRightsLapseOnSecondAnniversary>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_896cd8db-b4db-45ff-915a-26b26be0959d"
      decimals="2"
      id="F_3a32e90f-6ee1-498c-8175-03c8273b1a7c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_896cd8db-b4db-45ff-915a-26b26be0959d"
      decimals="-5"
      id="F_0a9c0080-c8f0-464b-9c32-0c98ba30418d"
      unitRef="U_USD">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <pepg:SharesOfRestrictedStockSubjectToRepurchase
      contextRef="C_16414ef5-2d6c-482f-bb76-768259311b2c"
      decimals="INF"
      id="F_cb3e69a3-9e32-41e9-9f79-712f375f8e60"
      unitRef="U_shares">0</pepg:SharesOfRestrictedStockSubjectToRepurchase>
    <pepg:SharesOfRestrictedStockSubjectToRepurchase
      contextRef="C_8f9f5a3b-bb7f-443b-98eb-04f3e2b9c50d"
      decimals="INF"
      id="F_40f358df-8b4f-464f-943f-ac770a758b4b"
      unitRef="U_shares">0</pepg:SharesOfRestrictedStockSubjectToRepurchase>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_afd69b93-74aa-451a-8e6d-0b275d938e9c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10. Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company maintains three equity compensation plans; the 2020 Stock Plan, or the 2020 Plan, the 2022 Stock Option Incentive Plan, or the 2022 Plan, and the 2022 Employee Stock Purchase Plan, or the ESPP. As of the Company's IPO in May 2022, the Company's board of directors determined that no further awards would be made from the 2020 plan. The number of shares of common stock that may be issued under the 2022 Plan is subject to increase by the number of shares under any outstanding stock options forfeited and not exercised under the 2020 Plan. Additionally, the number of shares reserved for issuance under the 2022 Plan automatically increases on the first day of each fiscal year in an amount equal to the lower of (1) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the shares of common stock outstanding on such date and (2) an amount determined by the Company&#x2019;s board of directors. The 2022 Plan allows the board of directors to grant incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock units, unrestricted stock awards, cash-based awards, and dividend equivalent rights to the Company&#x2019;s officers, employees, directors and other key persons. As of December 31, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,091,187&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares remained available for grant under the 2022 Plan and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;216,306&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares remained available for grant under the ESPP.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock Option Valuation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In determining the fair value of the stock options granted, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;The Company&#x2019;s expected term represents the period that the Company&#x2019;s stock-based awards are expected to be outstanding. For stock options with service-based vesting periods, the expected term of the Company&#x2019;s stock options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;The Company has historically been a private company and lacks significant company-specific historical and implied volatility information. The expected volatility is estimated based the average historical volatilities for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, stage in the life cycle and area of specialty. The Company will continue to apply this process until enough historical information regarding the volatility of its own stock price becomes available.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Expected Dividend Yield&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#x2014;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of stock options was estimated using the following weighted average assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate %&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility %&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.05&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock Option Activity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock option activity under the 2020 Plan and 2022 Plan, are as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.11%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.942%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(In Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(In Thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,341,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,421,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100,351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Canceled/Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;430,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,233,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested and exercisable as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,477,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested and expected to vest as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,233,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The aggregate intrinsic value of stock options is calculated as the difference between the exercise prices of the stock options and the fair value of the Company's common stock for those stock options that had exercises prices lower than the fair value of the Company's common stock. The total intrinsic value of the stock options exercised during the years ended December 31, 2023 and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. The intrinsic value is the difference between the estimated fair value of the Company&#x2019;s common stock at the time of exercise and the exercise price of the stock option. During the years ended December 31, 2023 and 2022, the total proceeds to the Company from stock option exercises was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted-average grant date fair value of stock options granted during the years ended December 31, 2023 and 2022 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.56&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.66&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense recognized for stock option grants included in the accompanying consolidated statements of operations and comprehensive loss is as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,068&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,233,203&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; vested and unvested stock options outstanding as of December 31, 2023. As of December 31, 2023, total unrecognized compensation expense related to stock options was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. This amount is expected to be recognized over a weighted average period of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.49 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <pepg:CommonStockOutstandingPercentage
      contextRef="C_b1cd4d63-b40b-4d86-834f-9218d8c92734"
      decimals="2"
      id="F_12619112-7348-45a0-9346-2062571e9152"
      unitRef="U_pure">0.05</pepg:CommonStockOutstandingPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0686ad9d-2e32-4f08-a030-a696dc15aec5"
      decimals="INF"
      id="F_8ae649ab-583e-4a58-b157-b366bff5c62e"
      unitRef="U_shares">1091187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_452249ff-841b-462f-a646-241176965c50"
      decimals="INF"
      id="F_1afdee70-a8ad-4400-96ed-2836b0a50b6a"
      unitRef="U_shares">216306</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="2"
      id="F_442ca51e-742c-4bfd-be39-a0ea9d0a9245"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_8fb7a5ef-d7fd-4900-9975-9dbedf859b1f">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of stock options was estimated using the following weighted average assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.343%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate %&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility %&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.05&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="4"
      id="F_06de1448-aa73-41b1-b967-ca50fe442b72"
      unitRef="U_pure">0.0419</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="4"
      id="F_9261349f-4cb0-4a55-9705-6d53ec8d568c"
      unitRef="U_pure">0.0295</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="4"
      id="F_34e2b803-4528-44c0-ac08-f977c1b68c65"
      unitRef="U_pure">0.6513</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="4"
      id="F_c9471a86-548d-4155-9b43-c4dd4140075e"
      unitRef="U_pure">0.7168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_8b4afdb2-e98e-47c1-88db-9fbd2b915d53">P6Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      id="F_cc9bdc07-4e79-4c32-83b9-e03047829428">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_9dfc082d-eac7-4104-a019-d404065cb2fa">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock option activity under the 2020 Plan and 2022 Plan, are as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.11%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.942%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(In Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(In Thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,341,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,421,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100,351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Canceled/Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;430,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,233,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested and exercisable as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,477,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested and expected to vest as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,233,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="INF"
      id="F_46fbc827-0f81-45da-8a1d-b2a80d28bdbc"
      unitRef="U_shares">3341834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="2"
      id="F_b1af84df-8e40-4cba-a6bd-f698d98bd6a2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      id="F_163aee20-e2ff-4d59-8340-bc28c90641e6">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_927d0617-71dc-4264-9e1c-4f1769ca2928"
      unitRef="U_USD">12877000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="INF"
      id="F_3902ed29-0570-42d2-afa3-f5825823567a"
      unitRef="U_shares">1421936</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="2"
      id="F_6ad39aed-2813-4ed1-918d-15e7417819be"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.7</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="INF"
      id="F_868ab850-deb5-45f8-b717-a37397e8676f"
      unitRef="U_shares">100351</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="2"
      id="F_5157fdcb-a557-4a61-9699-e81ce1804855"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="INF"
      id="F_37038635-2928-47a1-bd37-293f72931ae5"
      unitRef="U_shares">430216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="2"
      id="F_dabfd917-6d7e-4107-8b7e-e75008d047c8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="INF"
      id="F_7d3515b7-6a6f-4ca7-9546-decf4678a274"
      unitRef="U_shares">4233203</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="2"
      id="F_7f5b57bc-2e57-4c36-878c-7c96a59126ed"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_43deff4a-40ed-43d6-af7b-f68c47dc094b">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_246ee5ca-5b91-4c1d-80c6-4e8e7fe0a48a"
      unitRef="U_USD">2147000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="INF"
      id="F_96f7f044-b40e-477a-9184-cd7469dd9ac7"
      unitRef="U_shares">1477013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="2"
      id="F_c36b763b-f22c-411d-9db6-08520265e50b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_28e5f65f-2614-4bc7-8905-0a4bed293b46">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_d040ae9b-2807-4821-8a6d-c36fdd47eae0"
      unitRef="U_USD">1427000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="INF"
      id="F_cf426203-7d15-4c0d-bd1d-cf41a33cd510"
      unitRef="U_shares">4233203</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="2"
      id="F_6ec0d763-99d8-4ab6-9cfa-64bb4aa63419"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_80df22da-5885-4e95-a6c2-a0f2588eab42">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_4c56ffd8-0a49-4515-911f-41db5ab32d95"
      unitRef="U_USD">2147000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_74f25be0-4a88-4a9d-915a-d6fbbd72d532"
      decimals="-5"
      id="F_9d10e18e-87f4-405e-8599-ed8700a8e354"
      unitRef="U_USD">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_b89ce0c5-83ee-4433-97d2-dc32416736cf"
      decimals="-5"
      id="F_6cfceb3b-6d07-44f3-a96e-3d177e6decac"
      unitRef="U_USD">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_74f25be0-4a88-4a9d-915a-d6fbbd72d532"
      decimals="-5"
      id="F_1635e8ff-222c-43ef-91a9-5fea276895a2"
      unitRef="U_USD">200000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_b89ce0c5-83ee-4433-97d2-dc32416736cf"
      decimals="-5"
      id="F_138c8633-13a2-4aea-bd2b-5bd6f05af41a"
      unitRef="U_USD">200000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_74f25be0-4a88-4a9d-915a-d6fbbd72d532"
      decimals="2"
      id="F_0c6e604e-35cc-4e47-aa98-ed19c5faac56"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_b89ce0c5-83ee-4433-97d2-dc32416736cf"
      decimals="2"
      id="F_ba458dd5-0203-4454-8434-409ffd496a45"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_e204b202-7e90-43b3-87c4-bbb7b07c245a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense recognized for stock option grants included in the accompanying consolidated statements of operations and comprehensive loss is as follows (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,068&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0917bb69-33a3-4140-b895-0b204ca96986"
      decimals="-3"
      id="F_e084d7ed-5c40-46bb-98e0-e0fd25f21415"
      unitRef="U_USD">2966000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_abeb202e-1d0f-4fd4-950d-779ee59e02dd"
      decimals="-3"
      id="F_83de3c80-d765-4766-be9f-449e13c45011"
      unitRef="U_USD">1695000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d3eca86e-4d27-4894-81cf-8b20a08cff1a"
      decimals="-3"
      id="F_168d1745-7add-4078-a243-8cca4f9387af"
      unitRef="U_USD">4082000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f5fe547c-69eb-4ca8-ab02-fd92fb002da6"
      decimals="-3"
      id="F_a585af6a-0774-45e5-a8e8-7bbf5c6bd3f7"
      unitRef="U_USD">3068000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_8f73aedc-6fc3-47be-bf23-80581b44f24d"
      unitRef="U_USD">7048000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_485c15c0-0455-4a1b-a8a6-82094aa65c03"
      unitRef="U_USD">4763000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="INF"
      id="F_9d207a04-0107-49f7-a585-b4535c479442"
      unitRef="U_shares">4233203</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-5"
      id="F_80b7066d-df88-4460-8ad3-9b53586a55ee"
      unitRef="U_USD">20200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_eb1230c9-ef75-47c2-9abc-a5ce7a182db2">P2Y5M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_6b115b5a-ee3c-4499-84fa-1b61168fae68">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;11. Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s loss before income taxes for the years ended December 31, 2023 and 2022 were generated in the following jurisdictions (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.76%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.880000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Worldwide&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78,553&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The foreign income for the year-ended December 31, 2022 was due to the transfer of intellectual property, or IP, from PepGen Limited to the parent company, PepGen Inc., in an arm&#x2019;s length transaction at fair value pursuant to an asset transfer agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of net deferred income taxes consisted of the following as of December 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.76%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.880000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized Section 174 R&amp;amp;D Costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Intangible asset amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,879&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use-Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fixed Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of income tax expense were as follows for the years ended December 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.748%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.759%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.057%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.759%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.677000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current expense:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;U.S. Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total current expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred expense:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;U.S. Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations is summarized for the years ended December 31, 2023 and 2022, as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.892%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.259%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.234000000000002%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.259%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.356%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State tax (net of federal benefit)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;GILTI Inclusion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.K. R&amp;amp;D credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign rate differential&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income tax expense (benefit)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s income tax expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the year ended December 31, 2023 and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the year ended December 31, 2022. The income tax expense for the year ended December 31, 2023 was state taxes on interest income generated from the Company's cash equivalents and marketable securities. The income tax expense for the year ended December 31, 2022 was due to the IP transfer noted in the paragraph below.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 1, 2022, or the Transfer Date, the Company&#x2019;s wholly owned subsidiary, PepGen Limited, transferred all IP assets to the parent company, PepGen Inc., in an arm&#x2019;s length transaction at fair value pursuant to an asset transfer agreement. The fair value of the IP assets was a non-recurring fair value measurement. The Company engaged valuation specialists to calculate the IP value, and the IP value was measured using the historical cost method. The historical cost method estimated the fair value of the IP assets using the historical cost base of the IP assets and the expected market return as of the Transfer Date. The significant assumption inherent in estimating the fair value using the historical cost method was the expected market return. The Company utilized a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% expected market return, which a third-party investor may expect as a return on their investment, and which is based on studies of venture capital investment returns. The Company calculated the fair value of the IP assets by computing the present value of the historical cost base using the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% expected market return. The expected market return assumption used in the estimation of the IP assets represents a Level 3 input of the fair value hierarchy (see Note 3).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has federal net operating losses, or NOLs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and federal research and development, or R&amp;amp;D, credits of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of December 31, 2023, before consideration of limitations under Section 382 of the Internal Revenue Code, or Section 382, as further described below. The R&amp;amp;D credits will expire beginning in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2041&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.  The Company has state NOLs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and state R&amp;amp;D credits of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million which begin expiring in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2042&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The future utilization of the Company&#x2019;s state NOLs and federal and state R&amp;amp;D credits to offset future taxable income may be subject to a substantial annual limitation as a result of changes in ownership by stockholders that hold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% or more of the Company&#x2019;s common stock. An assessment of such ownership changes under Section 382 was not completed through December 31, 2023. To the extent that an assessment is completed in the future, the Company&#x2019;s ability to utilize tax attributes could be restricted on a year-by-year basis and certain attributes could expire before they are utilized. The Company will examine the impact of any potential ownership changes in the future.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is subject to taxation in the U.S. and the U.K. The Company&#x2019;s federal and state returns since inception are subject to examination due to the carryover of NOLs. The Company has not been, nor is it currently, under examination by any tax authorities. The U.K. tax returns from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2018&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and forward are subject to examination by the U.K. tax authorities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the reconciliation of the beginning and ending amount of total unrecognized tax benefits for each of the periods indicated:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.34%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at beginning of the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase related to current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Decrease related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Currency translation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at the end of the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company does not expect the amount of unrecognized tax benefits to change significantly in the next twelve months. The Company&#x2019;s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. It had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; accrual for interest or penalties on its consolidated balance sheets at December 31, 2023 or 2022. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; interest and/or penalties were recognized in 2023 or 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_58145a35-4038-4670-9aa2-3158aee4ab6b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s loss before income taxes for the years ended December 31, 2023 and 2022 were generated in the following jurisdictions (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.76%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.880000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;96,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,383&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Worldwide&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78,553&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;65,398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_ae6e914c-334b-42ce-a0d5-59810a2921de"
      unitRef="U_USD">-78195000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_6f080439-d05a-4e44-b672-64e6b87fb443"
      unitRef="U_USD">-96781000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_e073fbeb-6b24-43ed-89f3-a3608061da90"
      unitRef="U_USD">-358000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_7b9f08f7-f153-46fa-b2c8-07a81d99c7d3"
      unitRef="U_USD">31383000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_abe75cd3-1b8b-4a30-8956-ad7dc3243a75"
      unitRef="U_USD">-78553000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_fbe5e30c-a753-4972-8d21-029a00995d42"
      unitRef="U_USD">-65398000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_dee150b0-b3f6-445d-a507-4d0bb9910963">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of net deferred income taxes consisted of the following as of December 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.76%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:7.880000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,038&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;523&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized Section 174 R&amp;amp;D Costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Intangible asset amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,879&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right-of-use-Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fixed Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_abaeccce-49a0-4a7b-a5eb-f76e8178a21c"
      unitRef="U_USD">8038000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_b3e62500-18fd-45a6-95eb-313f08a2c772"
      unitRef="U_USD">474000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_8e1dbdd7-c503-41ec-bb72-27b9ee448ad3"
      unitRef="U_USD">4547000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_c245fcf0-3a7d-41fd-9949-98e8d5398be9"
      unitRef="U_USD">1287000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_afd29507-c210-4d75-90c5-14fbac4eb2e7"
      unitRef="U_USD">577000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_2cc3a092-b750-4a29-9cae-bf8dc2ab520f"
      unitRef="U_USD">523000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <pepg:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_434ca816-6701-4be0-8aaa-ef60655be084"
      unitRef="U_USD">29470000</pepg:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <pepg:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_3811c280-c5e9-4ca0-bef4-d5ce95f3b28b"
      unitRef="U_USD">11818000</pepg:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_5c60d87c-0f23-489d-82ed-d10bd9a7f36f"
      unitRef="U_USD">2510000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_4b318fd7-b85f-4897-9e55-b45c53953bc4"
      unitRef="U_USD">1081000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <pepg:DeferredTaxAssetsRightOfUseLiability
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_4a082464-4afe-43f3-8843-92359d122d86"
      unitRef="U_USD">5485000</pepg:DeferredTaxAssetsRightOfUseLiability>
    <pepg:DeferredTaxAssetsRightOfUseLiability
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_a6e4e470-6adf-4126-980e-472053a68775"
      unitRef="U_USD">5760000</pepg:DeferredTaxAssetsRightOfUseLiability>
    <pepg:DeferredTaxAssetsIntangibleAssetAmortization
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_8559ed18-d763-441e-87a4-aa8a1781f652"
      unitRef="U_USD">7425000</pepg:DeferredTaxAssetsIntangibleAssetAmortization>
    <pepg:DeferredTaxAssetsIntangibleAssetAmortization
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_37804b13-417a-4dcf-bd13-a5db5e807e7a"
      unitRef="U_USD">6879000</pepg:DeferredTaxAssetsIntangibleAssetAmortization>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_d6e1f8ff-4b1d-48c7-a7f1-2fc0ab896329"
      unitRef="U_USD">21000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_8fde5448-ecd8-4349-bb00-61c0075c743c"
      unitRef="U_USD">58073000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_8bdcfa55-1b8b-4277-bbb6-b8e3216818b3"
      unitRef="U_USD">27822000</us-gaap:DeferredTaxAssetsGross>
    <pepg:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_6155311c-df2f-426e-9916-d35135f01228"
      unitRef="U_USD">6444000</pepg:DeferredTaxLiabilitiesRightOfUseAsset>
    <pepg:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_8f4289dc-e6f8-4d5c-92ce-ef6cb106c86c"
      unitRef="U_USD">6233000</pepg:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_a68bf275-9272-4986-ba00-69da4bb855ec"
      unitRef="U_USD">1474000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_d0e5470d-4369-4671-83f6-75cdd618b993"
      unitRef="U_USD">45000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_a24e9bff-543d-49fb-b3e2-ee0c26497a14"
      unitRef="U_USD">2000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_d1feba35-b123-448c-ae16-8025f5b087bb"
      unitRef="U_USD">7918000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_20130f32-ad37-4232-aa7a-c9306ccd9eb9"
      unitRef="U_USD">6280000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_a88fc20b-dfd2-46c8-82da-f73285f13247"
      unitRef="U_USD">50155000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_903078de-9b07-49a3-bdf2-acd10d8eaf79"
      unitRef="U_USD">21542000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_276c93fe-f0fa-4df7-b0e6-06af0c061c87"
      unitRef="U_USD">50155000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_207ad11c-d309-48bb-b59b-31354845cc00"
      unitRef="U_USD">21542000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_3146437b-859d-45ce-bdb6-40f612836651">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The components of income tax expense were as follows for the years ended December 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.748%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.759%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:17.057%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.759%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.677000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current expense:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;U.S. Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total current expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred expense:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;U.S. Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,706&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_39eacbb8-1549-49ce-8b70-8e2a2e5cbdf8"
      unitRef="U_USD">73000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_a3b749c8-e064-46a9-94ab-350370b7a73f"
      unitRef="U_USD">23000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_e71c26c1-3aa3-4db6-8adb-95e82a933ac1"
      unitRef="U_USD">3683000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_a0fb94be-3055-4acc-a0e2-c3590beaaf07"
      unitRef="U_USD">73000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_9159a38a-c773-4c8f-a404-750826df21bf"
      unitRef="U_USD">3706000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_1f59b544-81ec-45d7-9c2c-ce3f6a80e7e4"
      unitRef="U_USD">73000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_43b18d9f-ddb6-495d-8a8f-6c614c0c6e54"
      unitRef="U_USD">3706000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_8dc8f141-488c-496c-9ca4-03200b51063a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations is summarized for the years ended December 31, 2023 and 2022, as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.892%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.259%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.234000000000002%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.259%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.356%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State tax (net of federal benefit)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;GILTI Inclusion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.K. R&amp;amp;D credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign rate differential&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;23.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Income tax expense (benefit)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="3"
      id="F_13b7c1bf-0b5b-40f4-8de8-a67470829cc9"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="3"
      id="F_0527d328-6e5b-4904-b2b8-38983ffe6f11"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="3"
      id="F_e67eaef6-63c5-4d81-898b-61e918e5f9bb"
      unitRef="U_pure">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="3"
      id="F_d8e2ed1b-66bf-4db5-b119-c7b1fd139a1c"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <pepg:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="3"
      id="F_339bf87a-c7bc-4e2f-86f5-b9343cecab38"
      unitRef="U_pure">-0.004</pepg:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <pepg:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="3"
      id="F_63b0fb03-7235-4371-8f58-8e6a763d04c9"
      unitRef="U_pure">-0.001</pepg:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="3"
      id="F_e245922a-1a2e-42ae-a48a-0f59d85d4af4"
      unitRef="U_pure">0.032</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="3"
      id="F_06e288f6-921d-4166-9d8d-809d0685c03c"
      unitRef="U_pure">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="3"
      id="F_52be8d6b-238b-4022-ad22-26be75740133"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="3"
      id="F_913d3970-e879-4731-b5ff-09009dfb9133"
      unitRef="U_pure">0.089</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent>
    <pepg:EffectiveIncomeTaxRateReconciliationUkRDCredit
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="3"
      id="F_65c8c430-6c08-4cec-904d-d334fdd1e8ed"
      unitRef="U_pure">0</pepg:EffectiveIncomeTaxRateReconciliationUkRDCredit>
    <pepg:EffectiveIncomeTaxRateReconciliationUkRDCredit
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="3"
      id="F_ad91b5f1-2f9f-462a-847a-6fab265b1bf0"
      unitRef="U_pure">0</pepg:EffectiveIncomeTaxRateReconciliationUkRDCredit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="3"
      id="F_986caebd-8eca-4714-a71c-7bf6b4b95eb4"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="3"
      id="F_1ea7421f-3671-4b88-9106-956c8e7ea8de"
      unitRef="U_pure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="3"
      id="F_2ec1a847-9f4f-4cbf-8972-374a152a4c3b"
      unitRef="U_pure">-0.239</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="3"
      id="F_42af1697-cbc2-4834-8ded-d3facafd9008"
      unitRef="U_pure">-0.234</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="3"
      id="F_25fbbc6a-5935-4f4a-878c-ef74dc7b334c"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="3"
      id="F_65f6270e-9b70-4b0e-96fa-4770fe9d235b"
      unitRef="U_pure">0.05</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="3"
      id="F_75a44165-3805-4ac8-92ad-7a2337a86fbf"
      unitRef="U_pure">-0.008</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="3"
      id="F_8bd0880a-1fca-4cc3-9e8b-5b0c22280749"
      unitRef="U_pure">-0.058</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-5"
      id="F_7d950eb6-9a33-42d2-a07f-304120e54721"
      unitRef="U_USD">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-5"
      id="F_f97ef4c4-9dea-4315-98dc-99211f6c271b"
      unitRef="U_USD">3700000</us-gaap:IncomeTaxExpenseBenefit>
    <pepg:ExpectedMarketReturn
      contextRef="C_369017c2-22f5-42b3-85de-349e0de7ffa4"
      decimals="2"
      id="F_19fffd9d-610f-4d78-b09e-40538920c2fd"
      unitRef="U_pure">0.40</pepg:ExpectedMarketReturn>
    <pepg:ExpectedMarketReturn
      contextRef="C_369017c2-22f5-42b3-85de-349e0de7ffa4"
      decimals="2"
      id="F_3007e2e2-7638-474d-98f5-d472a4b2187f"
      unitRef="U_pure">0.40</pepg:ExpectedMarketReturn>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_36f077db-3490-4321-ac37-fd742c52e7c4"
      decimals="-5"
      id="F_417f3ad5-9eb6-44e5-bba7-170895cb38f0"
      unitRef="U_USD">23400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_36f077db-3490-4321-ac37-fd742c52e7c4"
      decimals="-5"
      id="F_8c885e2e-f7b7-4430-89f8-3dc47b6947be"
      unitRef="U_USD">4900000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <pepg:ResearchAndDevelopmentCreditsExpirationYear
      contextRef="C_56d10337-c99d-4729-a0be-2f97270f71c5"
      id="F_d725b462-192e-45d2-8845-5af173f1e3f7">2041</pepg:ResearchAndDevelopmentCreditsExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_6da82c22-e37a-42bc-980f-059274a23288"
      decimals="-5"
      id="F_f7cc2173-fada-4b49-8894-fb259d2461d0"
      unitRef="U_USD">36600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_6da82c22-e37a-42bc-980f-059274a23288"
      decimals="-5"
      id="F_de25bc81-8ecd-4485-8c15-6384fb192f3e"
      unitRef="U_USD">1300000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <pepg:OperatingLossCarryForwardsExpirationYear
      contextRef="C_efb79f6f-7f45-4f73-8424-9da26d4e839d"
      id="F_6edc8c75-8729-46a0-aeb9-71b73f6ad90f">2042</pepg:OperatingLossCarryForwardsExpirationYear>
    <pepg:ChangesInOwnershipByStockholdersHoldingPercentage
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="2"
      id="F_a8a5ed95-1dcd-4ea9-b639-a4262fee5560"
      unitRef="U_pure">0.05</pepg:ChangesInOwnershipByStockholdersHoldingPercentage>
    <us-gaap:OpenTaxYear
      contextRef="C_0cb40be6-2cf0-473a-a7d2-976e96f36428"
      id="F_3062ccf9-2ebd-48c3-88e3-8f9f10106df3">2018</us-gaap:OpenTaxYear>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_06551429-2517-4a14-83c5-276f8c6a9fa2">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the reconciliation of the beginning and ending amount of total unrecognized tax benefits for each of the periods indicated:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.44%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.34%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.82%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at beginning of the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase related to current year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Increase related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Decrease related to prior year tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Currency translation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Balance at the end of the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_50100a32-7b46-4bb6-9376-17db92214cb5"
      unitRef="U_USD">673000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_e0d9c7df-b85e-4ae8-97ec-12771cd9c94f"
      unitRef="U_USD">751000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="-3"
      id="F_f2a2fc2d-b9a4-4a8c-975a-975bea2a556e"
      unitRef="U_USD">40000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="-3"
      id="F_0eb08e66-5b50-44b9-9a96-a0d8cccc2d26"
      unitRef="U_USD">78000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromForeignCurrencyTranslation>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="-3"
      id="F_fce87866-ba3e-4321-894c-3a4299a21570"
      unitRef="U_USD">713000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="-3"
      id="F_f47a796b-7a58-4df0-a43c-b4e38f227908"
      unitRef="U_USD">673000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_032b677e-9240-4c97-8fd4-3e95b8fe0a15"
      decimals="INF"
      id="F_a30b25a8-eb0f-4619-b36f-da8a8e2e95be"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_77094e71-f93f-47be-9749-eda2c5ae4461"
      decimals="INF"
      id="F_cad40be5-2a65-463e-b7f2-5aa2a9897dbf"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      decimals="INF"
      id="F_c2bb95f0-9249-4ac0-a90d-3cd37254b47d"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="C_6c95e5db-bd37-4cf6-b968-bd6049101b26"
      decimals="INF"
      id="F_4942e0c9-d04e-44cd-89ec-5b44242d7aa8"
      unitRef="U_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_dad9c7a1-fc4f-42fe-b9e8-059e2823fad9"
      id="F_6607fe81-fce3-4d27-bca1-04d49df407ee">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12. Subsequent Events&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On February 5, 2024, the Company sold shares under the Sales Agreement, resulting in net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. On February 9, 2024, the Company sold shares in the Follow-on Offering, resulting in net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million after deducting underwriters' fees of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Net proceeds from sales under the Sales Agreement and Follow-on Offering, after deducting underwriters' fees and before deducting costs of the offerings, were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_e1609515-c590-4eef-875c-348138380b4c"
      decimals="-5"
      id="F_ba507625-9db1-4931-b774-5f16bfec2e8f"
      unitRef="U_USD">9900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_e7e9bfb4-48e5-4056-bafa-50d040cb558e"
      decimals="-5"
      id="F_4d914a0e-b1d8-4c06-af38-32e7204b70cb"
      unitRef="U_USD">76900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_e7e9bfb4-48e5-4056-bafa-50d040cb558e"
      decimals="-5"
      id="F_4bb9b6da-4eea-41e1-adc9-3dcd07263c59"
      unitRef="U_USD">3200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_f91c8a3a-fd8f-4f54-b410-a52327d04868"
      decimals="-5"
      id="F_8ee47895-fdde-413d-95b4-3ba63a9dc2e4"
      unitRef="U_USD">86800000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
